{
    "5e6157cb1af46fc13000000e_1": [
        {
            "start_logit": 9.8828125,
            "end_logit": 9.6953125,
            "text": "Rett syndrome",
            "probability": 1.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -1.376953125,
            "text": "Ret",
            "probability": 1.5556812286376953e-05
        },
        {
            "start_logit": -1.4990234375,
            "end_logit": 9.6953125,
            "text": "syndrome",
            "probability": 1.138448715209961e-05
        },
        {
            "start_logit": -6.48828125,
            "end_logit": 9.6953125,
            "text": "t syndrome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -7.5625,
            "text": "Rett",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -7.9140625,
            "text": "Rett syndrome.",
            "probability": 0.0
        },
        {
            "start_logit": -7.74609375,
            "end_logit": 9.6953125,
            "text": "with Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -7.796875,
            "end_logit": 9.6953125,
            "text": "methyl-CpG-binding protein-2 gene (MECP2) are commonly associated with Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -7.875,
            "end_logit": 9.6953125,
            "text": "commonly associated with Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -7.87890625,
            "end_logit": 9.6953125,
            "text": "Mutations in the methyl-CpG-binding protein-2 gene (MECP2) are commonly associated with Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -7.8984375,
            "end_logit": 9.6953125,
            "text": "are commonly associated with Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -7.953125,
            "end_logit": 9.6953125,
            "text": "associated with Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -7.9609375,
            "end_logit": 9.6953125,
            "text": "MECP2) are commonly associated with Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -7.96875,
            "end_logit": 9.6953125,
            "text": "the methyl-CpG-binding protein-2 gene (MECP2) are commonly associated with Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -7.9765625,
            "end_logit": 9.6953125,
            "text": "binding protein-2 gene (MECP2) are commonly associated with Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -7.9765625,
            "end_logit": 9.6953125,
            "text": "-CpG-binding protein-2 gene (MECP2) are commonly associated with Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -7.984375,
            "end_logit": 9.6953125,
            "text": "CpG-binding protein-2 gene (MECP2) are commonly associated with Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -7.98828125,
            "end_logit": 9.6953125,
            "text": "in the methyl-CpG-binding protein-2 gene (MECP2) are commonly associated with Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -7.9921875,
            "end_logit": 9.6953125,
            "text": "gene (MECP2) are commonly associated with Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -7.74609375,
            "end_logit": -1.376953125,
            "text": "with Ret",
            "probability": 0.0
        }
    ],
    "5e6157cb1af46fc13000000e_2": [
        {
            "start_logit": 9.8125,
            "end_logit": 9.65625,
            "text": "Rett syndrome",
            "probability": 1.0
        },
        {
            "start_logit": 9.8125,
            "end_logit": -1.5458984375,
            "text": "Ret",
            "probability": 1.3649463653564453e-05
        },
        {
            "start_logit": -1.5986328125,
            "end_logit": 9.65625,
            "text": "syndrome",
            "probability": 1.1026859283447266e-05
        },
        {
            "start_logit": -6.69140625,
            "end_logit": 9.65625,
            "text": "t syndrome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8125,
            "end_logit": -7.7265625,
            "text": "Rett",
            "probability": 0.0
        },
        {
            "start_logit": 9.8125,
            "end_logit": -8.0625,
            "text": "Rett syndrome (RS) is",
            "probability": 0.0
        },
        {
            "start_logit": 9.8125,
            "end_logit": -8.15625,
            "text": "Rett syndrome (RS) is a debilitating neurological disorder affecting",
            "probability": 0.0
        },
        {
            "start_logit": 9.8125,
            "end_logit": -8.1796875,
            "text": "Rett syndrome (RS) is a",
            "probability": 0.0
        },
        {
            "start_logit": 9.8125,
            "end_logit": -8.2109375,
            "text": "Rett syndrome (RS) is a debilitating neurological disorder",
            "probability": 0.0
        },
        {
            "start_logit": 9.8125,
            "end_logit": -8.21875,
            "text": "Rett syndrome (RS) is a debilitating neurological disorder affecting mostly girls with heterozygous mutations in the gene encoding the methyl-CpG-binding protein MeCP2 on",
            "probability": 0.0
        },
        {
            "start_logit": 9.8125,
            "end_logit": -8.21875,
            "text": "Rett syndrome (RS) is a debilitating neurological disorder affecting mostly girls with",
            "probability": 0.0
        },
        {
            "start_logit": 9.8125,
            "end_logit": -8.2421875,
            "text": "Rett syndrome (",
            "probability": 0.0
        },
        {
            "start_logit": -1.5986328125,
            "end_logit": -8.0625,
            "text": "syndrome (RS) is",
            "probability": 0.0
        },
        {
            "start_logit": -1.5986328125,
            "end_logit": -8.15625,
            "text": "syndrome (RS) is a debilitating neurological disorder affecting",
            "probability": 0.0
        },
        {
            "start_logit": -1.5986328125,
            "end_logit": -8.1796875,
            "text": "syndrome (RS) is a",
            "probability": 0.0
        },
        {
            "start_logit": -1.5986328125,
            "end_logit": -8.2109375,
            "text": "syndrome (RS) is a debilitating neurological disorder",
            "probability": 0.0
        },
        {
            "start_logit": -1.5986328125,
            "end_logit": -8.21875,
            "text": "syndrome (RS) is a debilitating neurological disorder affecting mostly girls with heterozygous mutations in the gene encoding the methyl-CpG-binding protein MeCP2 on",
            "probability": 0.0
        },
        {
            "start_logit": -1.5986328125,
            "end_logit": -8.21875,
            "text": "syndrome (RS) is a debilitating neurological disorder affecting mostly girls with",
            "probability": 0.0
        },
        {
            "start_logit": -1.5986328125,
            "end_logit": -8.2421875,
            "text": "syndrome (",
            "probability": 0.0
        },
        {
            "start_logit": -6.69140625,
            "end_logit": -7.7265625,
            "text": "t",
            "probability": 0.0
        }
    ],
    "5e6157cb1af46fc13000000e_3": [
        {
            "start_logit": 9.890625,
            "end_logit": 9.6796875,
            "text": "Rett syndrome",
            "probability": 1.0
        },
        {
            "start_logit": 9.890625,
            "end_logit": -1.3515625,
            "text": "Ret",
            "probability": 1.633167266845703e-05
        },
        {
            "start_logit": -1.5234375,
            "end_logit": 9.6796875,
            "text": "syndrome",
            "probability": 1.1146068572998047e-05
        },
        {
            "start_logit": -5.98046875,
            "end_logit": 9.6796875,
            "text": "t syndrome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.23046875,
            "end_logit": 9.6796875,
            "text": "disorder Rett syndrome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.890625,
            "end_logit": -7.62890625,
            "text": "Rett",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.69140625,
            "end_logit": 9.6796875,
            "text": "neurodevelopmental disorder Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": 9.890625,
            "end_logit": -8.0546875,
            "text": "Rett syndrome (RTT).",
            "probability": 0.0
        },
        {
            "start_logit": -7.8515625,
            "end_logit": 9.6796875,
            "text": "Mutations in the MECP2 gene cause the neurodevelopmental disorder Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -7.87890625,
            "end_logit": 9.6796875,
            "text": "the neurodevelopmental disorder Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -7.90234375,
            "end_logit": 9.6796875,
            "text": "gene cause the neurodevelopmental disorder Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -7.921875,
            "end_logit": 9.6796875,
            "text": "MECP2 gene cause the neurodevelopmental disorder Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -7.95703125,
            "end_logit": 9.6796875,
            "text": "cause the neurodevelopmental disorder Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -7.98046875,
            "end_logit": 9.6796875,
            "text": "the MECP2 gene cause the neurodevelopmental disorder Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -7.99609375,
            "end_logit": 9.6796875,
            "text": "P2 gene cause the neurodevelopmental disorder Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -7.23046875,
            "end_logit": -1.3515625,
            "text": "disorder Ret",
            "probability": 0.0
        },
        {
            "start_logit": -7.69140625,
            "end_logit": -1.3515625,
            "text": "neurodevelopmental disorder Ret",
            "probability": 0.0
        },
        {
            "start_logit": -7.8515625,
            "end_logit": -1.3515625,
            "text": "Mutations in the MECP2 gene cause the neurodevelopmental disorder Ret",
            "probability": 0.0
        },
        {
            "start_logit": -7.87890625,
            "end_logit": -1.3515625,
            "text": "the neurodevelopmental disorder Ret",
            "probability": 0.0
        },
        {
            "start_logit": -7.90234375,
            "end_logit": -1.3515625,
            "text": "gene cause the neurodevelopmental disorder Ret",
            "probability": 0.0
        }
    ],
    "5e6157cb1af46fc13000000e_4": [
        {
            "start_logit": 9.8828125,
            "end_logit": 9.6796875,
            "text": "Rett syndrome",
            "probability": 1.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -1.388671875,
            "text": "Ret",
            "probability": 1.5556812286376953e-05
        },
        {
            "start_logit": -1.53515625,
            "end_logit": 9.6796875,
            "text": "syndrome",
            "probability": 1.0967254638671875e-05
        },
        {
            "start_logit": -6.34765625,
            "end_logit": 9.6796875,
            "text": "t syndrome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -7.61328125,
            "text": "Rett syndrome is",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -7.74609375,
            "text": "Rett",
            "probability": 0.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -7.7890625,
            "text": "Rett syndrome is a severe neurodevelopmental disorder mainly caused by mutations in the transcriptional regulator MeCP2.",
            "probability": 0.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -7.94140625,
            "text": "Rett syndrome is a",
            "probability": 0.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -8.03125,
            "text": "Rett syndrome is a severe neurodevelopmental disorder",
            "probability": 0.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -8.0546875,
            "text": "Rett syndrome is a severe neurodevelopmental disorder mainly",
            "probability": 0.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -8.171875,
            "text": "Rett syndrome is a severe neurodevelopmental disorder mainly caused",
            "probability": 0.0
        },
        {
            "start_logit": -1.53515625,
            "end_logit": -7.61328125,
            "text": "syndrome is",
            "probability": 0.0
        },
        {
            "start_logit": -1.53515625,
            "end_logit": -7.7890625,
            "text": "syndrome is a severe neurodevelopmental disorder mainly caused by mutations in the transcriptional regulator MeCP2.",
            "probability": 0.0
        },
        {
            "start_logit": -1.53515625,
            "end_logit": -7.94140625,
            "text": "syndrome is a",
            "probability": 0.0
        },
        {
            "start_logit": -1.53515625,
            "end_logit": -8.03125,
            "text": "syndrome is a severe neurodevelopmental disorder",
            "probability": 0.0
        },
        {
            "start_logit": -1.53515625,
            "end_logit": -8.0546875,
            "text": "syndrome is a severe neurodevelopmental disorder mainly",
            "probability": 0.0
        },
        {
            "start_logit": -1.53515625,
            "end_logit": -8.171875,
            "text": "syndrome is a severe neurodevelopmental disorder mainly caused",
            "probability": 0.0
        },
        {
            "start_logit": -6.34765625,
            "end_logit": -7.61328125,
            "text": "t syndrome is",
            "probability": 0.0
        },
        {
            "start_logit": -6.34765625,
            "end_logit": -7.74609375,
            "text": "t",
            "probability": 0.0
        },
        {
            "start_logit": -6.34765625,
            "end_logit": -7.7890625,
            "text": "t syndrome is a severe neurodevelopmental disorder mainly caused by mutations in the transcriptional regulator MeCP2.",
            "probability": 0.0
        }
    ],
    "5e6157cb1af46fc13000000e_5": [
        {
            "start_logit": 9.890625,
            "end_logit": 9.6796875,
            "text": "Rett syndrome",
            "probability": 1.0
        },
        {
            "start_logit": 9.890625,
            "end_logit": -1.353515625,
            "text": "Ret",
            "probability": 1.633167266845703e-05
        },
        {
            "start_logit": -1.5390625,
            "end_logit": 9.6796875,
            "text": "syndrome",
            "probability": 1.0967254638671875e-05
        },
        {
            "start_logit": -6.07421875,
            "end_logit": 9.6796875,
            "text": "t syndrome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.890625,
            "end_logit": -7.7734375,
            "text": "Rett",
            "probability": 0.0
        },
        {
            "start_logit": 9.890625,
            "end_logit": -7.8203125,
            "text": "Rett syndrome,",
            "probability": 0.0
        },
        {
            "start_logit": 9.890625,
            "end_logit": -7.98828125,
            "text": "Rett syndrome, a progressive neurodevelopmental disorder.",
            "probability": 0.0
        },
        {
            "start_logit": 9.890625,
            "end_logit": -8.015625,
            "text": "Rett syndrome, a",
            "probability": 0.0
        },
        {
            "start_logit": -7.8515625,
            "end_logit": 9.6796875,
            "text": "cause Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -7.91796875,
            "end_logit": 9.6796875,
            "text": "Mutations in the MeCP2 gene cause Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -7.9453125,
            "end_logit": 9.6796875,
            "text": "gene cause Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -7.9609375,
            "end_logit": 9.6796875,
            "text": "MeCP2 gene cause Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -8.0234375,
            "end_logit": 9.6796875,
            "text": "P2 gene cause Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -8.0234375,
            "end_logit": 9.6796875,
            "text": "the MeCP2 gene cause Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -8.0703125,
            "end_logit": 9.6796875,
            "text": "in the MeCP2 gene cause Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -7.8515625,
            "end_logit": -1.353515625,
            "text": "cause Ret",
            "probability": 0.0
        },
        {
            "start_logit": -7.91796875,
            "end_logit": -1.353515625,
            "text": "Mutations in the MeCP2 gene cause Ret",
            "probability": 0.0
        },
        {
            "start_logit": -7.9453125,
            "end_logit": -1.353515625,
            "text": "gene cause Ret",
            "probability": 0.0
        },
        {
            "start_logit": -7.9609375,
            "end_logit": -1.353515625,
            "text": "MeCP2 gene cause Ret",
            "probability": 0.0
        },
        {
            "start_logit": -1.5390625,
            "end_logit": -7.8203125,
            "text": "syndrome,",
            "probability": 0.0
        }
    ],
    "5e6157cb1af46fc13000000e_6": [
        {
            "start_logit": 9.859375,
            "end_logit": 9.6796875,
            "text": "Rett syndrome",
            "probability": 1.0
        },
        {
            "start_logit": 9.859375,
            "end_logit": -1.4365234375,
            "text": "Ret",
            "probability": 1.4960765838623047e-05
        },
        {
            "start_logit": -1.5283203125,
            "end_logit": 9.6796875,
            "text": "syndrome",
            "probability": 1.138448715209961e-05
        },
        {
            "start_logit": -6.32421875,
            "end_logit": 9.6796875,
            "text": "t syndrome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.859375,
            "end_logit": -7.74609375,
            "text": "Rett",
            "probability": 0.0
        },
        {
            "start_logit": 9.859375,
            "end_logit": -7.78125,
            "text": "Rett syndrome (RTT) is",
            "probability": 0.0
        },
        {
            "start_logit": 9.859375,
            "end_logit": -7.84375,
            "text": "Rett syndrome (RTT) is a debilitating neurological disorder caused by mutations in the gene encoding the transcription factor Methyl CpG Binding Protein 2 (MECP2).",
            "probability": 0.0
        },
        {
            "start_logit": 9.859375,
            "end_logit": -8.0625,
            "text": "Rett syndrome (RTT) is a",
            "probability": 0.0
        },
        {
            "start_logit": 9.859375,
            "end_logit": -8.15625,
            "text": "Rett syndrome (RTT) is a debilitating neurological disorder",
            "probability": 0.0
        },
        {
            "start_logit": 9.859375,
            "end_logit": -8.1796875,
            "text": "Rett syndrome (RTT) is a debilitating neurological disorder caused by mutations in the gene encoding the transcription factor Methyl CpG Binding Protein 2 (",
            "probability": 0.0
        },
        {
            "start_logit": -1.5283203125,
            "end_logit": -7.78125,
            "text": "syndrome (RTT) is",
            "probability": 0.0
        },
        {
            "start_logit": -1.5283203125,
            "end_logit": -7.84375,
            "text": "syndrome (RTT) is a debilitating neurological disorder caused by mutations in the gene encoding the transcription factor Methyl CpG Binding Protein 2 (MECP2).",
            "probability": 0.0
        },
        {
            "start_logit": -1.5283203125,
            "end_logit": -8.0625,
            "text": "syndrome (RTT) is a",
            "probability": 0.0
        },
        {
            "start_logit": -1.5283203125,
            "end_logit": -8.15625,
            "text": "syndrome (RTT) is a debilitating neurological disorder",
            "probability": 0.0
        },
        {
            "start_logit": -1.5283203125,
            "end_logit": -8.1796875,
            "text": "syndrome (RTT) is a debilitating neurological disorder caused by mutations in the gene encoding the transcription factor Methyl CpG Binding Protein 2 (",
            "probability": 0.0
        },
        {
            "start_logit": -6.32421875,
            "end_logit": -7.74609375,
            "text": "t",
            "probability": 0.0
        },
        {
            "start_logit": -6.32421875,
            "end_logit": -7.78125,
            "text": "t syndrome (RTT) is",
            "probability": 0.0
        },
        {
            "start_logit": -6.32421875,
            "end_logit": -7.84375,
            "text": "t syndrome (RTT) is a debilitating neurological disorder caused by mutations in the gene encoding the transcription factor Methyl CpG Binding Protein 2 (MECP2).",
            "probability": 0.0
        },
        {
            "start_logit": -6.32421875,
            "end_logit": -8.0625,
            "text": "t syndrome (RTT) is a",
            "probability": 0.0
        },
        {
            "start_logit": -6.32421875,
            "end_logit": -8.15625,
            "text": "t syndrome (RTT) is a debilitating neurological disorder",
            "probability": 0.0
        }
    ],
    "5e6157cb1af46fc13000000e_7": [
        {
            "start_logit": 9.90625,
            "end_logit": 9.703125,
            "text": "Rett syndrome",
            "probability": 1.0
        },
        {
            "start_logit": 9.90625,
            "end_logit": -1.306640625,
            "text": "Ret",
            "probability": 1.6570091247558594e-05
        },
        {
            "start_logit": -1.462890625,
            "end_logit": 9.703125,
            "text": "syndrome",
            "probability": 1.1563301086425781e-05
        },
        {
            "start_logit": -6.19140625,
            "end_logit": 9.703125,
            "text": "t syndrome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.90625,
            "end_logit": -7.66796875,
            "text": "Rett",
            "probability": 0.0
        },
        {
            "start_logit": 9.90625,
            "end_logit": -7.94921875,
            "text": "Rett syndrome (RTT) is",
            "probability": 0.0
        },
        {
            "start_logit": 9.90625,
            "end_logit": -8.0078125,
            "text": "Rett syndrome (RTT) is associated with mutations in the transcriptional repressor gene MeCP2.",
            "probability": 0.0
        },
        {
            "start_logit": 9.90625,
            "end_logit": -8.1484375,
            "text": "Rett syndrome (RTT) is associated with",
            "probability": 0.0
        },
        {
            "start_logit": 9.90625,
            "end_logit": -8.1640625,
            "text": "Rett syndrome (RTT) is associated",
            "probability": 0.0
        },
        {
            "start_logit": 9.90625,
            "end_logit": -8.171875,
            "text": "Rett syndrome (RTT) is associated with mutations in the transcriptional repressor",
            "probability": 0.0
        },
        {
            "start_logit": 9.90625,
            "end_logit": -8.1796875,
            "text": "Rett syndrome (RTT) is associated with mutations in the transcriptional",
            "probability": 0.0
        },
        {
            "start_logit": 9.90625,
            "end_logit": -8.1796875,
            "text": "Rett syndrome (RTT) is associated with mutations in the transcriptional repressor gene",
            "probability": 0.0
        },
        {
            "start_logit": -1.462890625,
            "end_logit": -7.94921875,
            "text": "syndrome (RTT) is",
            "probability": 0.0
        },
        {
            "start_logit": -1.462890625,
            "end_logit": -8.0078125,
            "text": "syndrome (RTT) is associated with mutations in the transcriptional repressor gene MeCP2.",
            "probability": 0.0
        },
        {
            "start_logit": -1.462890625,
            "end_logit": -8.1484375,
            "text": "syndrome (RTT) is associated with",
            "probability": 0.0
        },
        {
            "start_logit": -1.462890625,
            "end_logit": -8.1640625,
            "text": "syndrome (RTT) is associated",
            "probability": 0.0
        },
        {
            "start_logit": -1.462890625,
            "end_logit": -8.171875,
            "text": "syndrome (RTT) is associated with mutations in the transcriptional repressor",
            "probability": 0.0
        },
        {
            "start_logit": -1.462890625,
            "end_logit": -8.1796875,
            "text": "syndrome (RTT) is associated with mutations in the transcriptional",
            "probability": 0.0
        },
        {
            "start_logit": -1.462890625,
            "end_logit": -8.1796875,
            "text": "syndrome (RTT) is associated with mutations in the transcriptional repressor gene",
            "probability": 0.0
        },
        {
            "start_logit": -6.19140625,
            "end_logit": -7.66796875,
            "text": "t",
            "probability": 0.0
        }
    ],
    "5e6157cb1af46fc13000000e_8": [
        {
            "start_logit": 9.890625,
            "end_logit": 9.6796875,
            "text": "Rett syndrome",
            "probability": 1.0
        },
        {
            "start_logit": 9.890625,
            "end_logit": -1.353515625,
            "text": "Ret",
            "probability": 1.633167266845703e-05
        },
        {
            "start_logit": -1.5390625,
            "end_logit": 9.6796875,
            "text": "syndrome",
            "probability": 1.0967254638671875e-05
        },
        {
            "start_logit": -6.07421875,
            "end_logit": 9.6796875,
            "text": "t syndrome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.890625,
            "end_logit": -7.7734375,
            "text": "Rett",
            "probability": 0.0
        },
        {
            "start_logit": 9.890625,
            "end_logit": -7.8203125,
            "text": "Rett syndrome,",
            "probability": 0.0
        },
        {
            "start_logit": 9.890625,
            "end_logit": -7.98828125,
            "text": "Rett syndrome, a progressive neurodevelopmental disorder.",
            "probability": 0.0
        },
        {
            "start_logit": 9.890625,
            "end_logit": -8.015625,
            "text": "Rett syndrome, a",
            "probability": 0.0
        },
        {
            "start_logit": -7.8515625,
            "end_logit": 9.6796875,
            "text": "cause Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -7.91796875,
            "end_logit": 9.6796875,
            "text": "Mutations in the MeCP2 gene cause Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -7.9453125,
            "end_logit": 9.6796875,
            "text": "gene cause Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -7.9609375,
            "end_logit": 9.6796875,
            "text": "MeCP2 gene cause Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -8.0234375,
            "end_logit": 9.6796875,
            "text": "P2 gene cause Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -8.0234375,
            "end_logit": 9.6796875,
            "text": "the MeCP2 gene cause Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -8.0703125,
            "end_logit": 9.6796875,
            "text": "in the MeCP2 gene cause Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -7.8515625,
            "end_logit": -1.353515625,
            "text": "cause Ret",
            "probability": 0.0
        },
        {
            "start_logit": -7.91796875,
            "end_logit": -1.353515625,
            "text": "Mutations in the MeCP2 gene cause Ret",
            "probability": 0.0
        },
        {
            "start_logit": -7.9453125,
            "end_logit": -1.353515625,
            "text": "gene cause Ret",
            "probability": 0.0
        },
        {
            "start_logit": -7.9609375,
            "end_logit": -1.353515625,
            "text": "MeCP2 gene cause Ret",
            "probability": 0.0
        },
        {
            "start_logit": -1.5390625,
            "end_logit": -7.8203125,
            "text": "syndrome,",
            "probability": 0.0
        }
    ],
    "5e6157cb1af46fc13000000e_9": [
        {
            "start_logit": 9.875,
            "end_logit": 9.6796875,
            "text": "Rett syndrome",
            "probability": 1.0
        },
        {
            "start_logit": 9.875,
            "end_logit": -1.4072265625,
            "text": "Ret",
            "probability": 1.519918441772461e-05
        },
        {
            "start_logit": -1.5419921875,
            "end_logit": 9.6796875,
            "text": "syndrome",
            "probability": 1.0967254638671875e-05
        },
        {
            "start_logit": -6.44921875,
            "end_logit": 9.6796875,
            "text": "t syndrome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.73046875,
            "end_logit": 9.6796875,
            "text": "in Rett syndrome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.875,
            "end_logit": -7.7265625,
            "text": "Rett",
            "probability": 0.0
        },
        {
            "start_logit": 9.875,
            "end_logit": -7.875,
            "text": "Rett syndrome.",
            "probability": 0.0
        },
        {
            "start_logit": -7.69140625,
            "end_logit": 9.6796875,
            "text": "Methyl-CpG-binding protein 2 (MECP2) mutation type is associated with disease severity in Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -7.74609375,
            "end_logit": 9.6796875,
            "text": "disease severity in Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -7.9296875,
            "end_logit": 9.6796875,
            "text": "mutation type is associated with disease severity in Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -7.9453125,
            "end_logit": 9.6796875,
            "text": "-CpG-binding protein 2 (MECP2) mutation type is associated with disease severity in Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -7.9453125,
            "end_logit": 9.6796875,
            "text": "severity in Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -7.97265625,
            "end_logit": 9.6796875,
            "text": "type is associated with disease severity in Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -7.9765625,
            "end_logit": 9.6796875,
            "text": "CpG-binding protein 2 (MECP2) mutation type is associated with disease severity in Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -7.98046875,
            "end_logit": 9.6796875,
            "text": "binding protein 2 (MECP2) mutation type is associated with disease severity in Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -7.98046875,
            "end_logit": 9.6796875,
            "text": "with disease severity in Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -7.98828125,
            "end_logit": 9.6796875,
            "text": "is associated with disease severity in Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -7.9921875,
            "end_logit": 9.6796875,
            "text": "(MECP2) mutation type is associated with disease severity in Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -7.99609375,
            "end_logit": 9.6796875,
            "text": "protein 2 (MECP2) mutation type is associated with disease severity in Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -6.73046875,
            "end_logit": -1.4072265625,
            "text": "in Ret",
            "probability": 0.0
        }
    ],
    "5e6157cb1af46fc13000000e_10": [
        {
            "start_logit": 9.8203125,
            "end_logit": 9.671875,
            "text": "Rett syndrome",
            "probability": 1.0
        },
        {
            "start_logit": 9.8203125,
            "end_logit": -1.509765625,
            "text": "Ret",
            "probability": 1.3828277587890625e-05
        },
        {
            "start_logit": -1.537109375,
            "end_logit": 9.671875,
            "text": "syndrome",
            "probability": 1.1563301086425781e-05
        },
        {
            "start_logit": -6.5546875,
            "end_logit": 9.671875,
            "text": "t syndrome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8203125,
            "end_logit": -7.6640625,
            "text": "Rett",
            "probability": 0.0
        },
        {
            "start_logit": 9.8203125,
            "end_logit": -8.1796875,
            "text": "Rett syndrome (RTT), the second",
            "probability": 0.0
        },
        {
            "start_logit": 9.8203125,
            "end_logit": -8.1953125,
            "text": "Rett syndrome (RTT), the second most",
            "probability": 0.0
        },
        {
            "start_logit": 9.8203125,
            "end_logit": -8.21875,
            "text": "Rett syndrome (RTT), the second most common cause of mental retardation in",
            "probability": 0.0
        },
        {
            "start_logit": -1.537109375,
            "end_logit": -8.1796875,
            "text": "syndrome (RTT), the second",
            "probability": 0.0
        },
        {
            "start_logit": -1.537109375,
            "end_logit": -8.1953125,
            "text": "syndrome (RTT), the second most",
            "probability": 0.0
        },
        {
            "start_logit": -1.537109375,
            "end_logit": -8.21875,
            "text": "syndrome (RTT), the second most common cause of mental retardation in",
            "probability": 0.0
        },
        {
            "start_logit": -1.537109375,
            "end_logit": -8.2265625,
            "text": "syndrome (RTT), the second most common cause of mental retardation in females, has been associated with mutations in MeCP2, the archetypical member of the methyl-CpG binding domain",
            "probability": 0.0
        },
        {
            "start_logit": -1.537109375,
            "end_logit": -8.2421875,
            "text": "syndrome (RTT), the second most common cause of mental retardation in females, has been associated with mutations in MeCP2, the archetypical member of the methyl-CpG binding domain (",
            "probability": 0.0
        },
        {
            "start_logit": -6.5546875,
            "end_logit": -7.6640625,
            "text": "t",
            "probability": 0.0
        },
        {
            "start_logit": -6.5546875,
            "end_logit": -8.1796875,
            "text": "t syndrome (RTT), the second",
            "probability": 0.0
        },
        {
            "start_logit": -6.5546875,
            "end_logit": -8.1953125,
            "text": "t syndrome (RTT), the second most",
            "probability": 0.0
        },
        {
            "start_logit": -6.5546875,
            "end_logit": -8.21875,
            "text": "t syndrome (RTT), the second most common cause of mental retardation in",
            "probability": 0.0
        },
        {
            "start_logit": -6.5546875,
            "end_logit": -8.2265625,
            "text": "t syndrome (RTT), the second most common cause of mental retardation in females, has been associated with mutations in MeCP2, the archetypical member of the methyl-CpG binding domain",
            "probability": 0.0
        },
        {
            "start_logit": -6.90625,
            "end_logit": -7.8984375,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.87890625,
            "end_logit": -7.8984375,
            "text": "methyl-CpG binding domain (MBD) family of proteins.",
            "probability": 0.0
        }
    ],
    "5e6157cb1af46fc13000000e_11": [
        {
            "start_logit": 9.8515625,
            "end_logit": 9.6796875,
            "text": "Rett syndrome",
            "probability": 1.0
        },
        {
            "start_logit": 9.8515625,
            "end_logit": -1.4462890625,
            "text": "Ret",
            "probability": 1.4722347259521484e-05
        },
        {
            "start_logit": -1.541015625,
            "end_logit": 9.6796875,
            "text": "syndrome",
            "probability": 1.1324882507324219e-05
        },
        {
            "start_logit": -6.44921875,
            "end_logit": 9.6796875,
            "text": "t syndrome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8515625,
            "end_logit": -7.765625,
            "text": "Rett",
            "probability": 0.0
        },
        {
            "start_logit": 9.8515625,
            "end_logit": -7.828125,
            "text": "Rett syndrome (RTT) is a severe neurodevelopmental disease caused by mutations in methyl-CpG-binding protein 2 (MECP2), which encodes a transcriptional modulator of many genes including BDNF.",
            "probability": 0.0
        },
        {
            "start_logit": 9.8515625,
            "end_logit": -7.9765625,
            "text": "Rett syndrome (RTT) is",
            "probability": 0.0
        },
        {
            "start_logit": 9.8515625,
            "end_logit": -8.1015625,
            "text": "Rett syndrome (RTT) is a",
            "probability": 0.0
        },
        {
            "start_logit": 9.8515625,
            "end_logit": -8.15625,
            "text": "Rett syndrome (RTT) is a severe neurodevelopmental disease caused by mutations in methyl-CpG-binding protein 2 (",
            "probability": 0.0
        },
        {
            "start_logit": 9.8515625,
            "end_logit": -8.1953125,
            "text": "Rett syndrome (RTT) is a severe neurodevelopmental disease caused by mutations in methyl-CpG-binding protein 2",
            "probability": 0.0
        },
        {
            "start_logit": 9.8515625,
            "end_logit": -8.203125,
            "text": "Rett syndrome (RTT) is a severe neurodevelopmental disease caused by mutations in methyl-CpG-binding protein 2 (MECP2), which encodes a",
            "probability": 0.0
        },
        {
            "start_logit": -1.541015625,
            "end_logit": -7.828125,
            "text": "syndrome (RTT) is a severe neurodevelopmental disease caused by mutations in methyl-CpG-binding protein 2 (MECP2), which encodes a transcriptional modulator of many genes including BDNF.",
            "probability": 0.0
        },
        {
            "start_logit": -1.541015625,
            "end_logit": -7.9765625,
            "text": "syndrome (RTT) is",
            "probability": 0.0
        },
        {
            "start_logit": -1.541015625,
            "end_logit": -8.1015625,
            "text": "syndrome (RTT) is a",
            "probability": 0.0
        },
        {
            "start_logit": -1.541015625,
            "end_logit": -8.15625,
            "text": "syndrome (RTT) is a severe neurodevelopmental disease caused by mutations in methyl-CpG-binding protein 2 (",
            "probability": 0.0
        },
        {
            "start_logit": -1.541015625,
            "end_logit": -8.1953125,
            "text": "syndrome (RTT) is a severe neurodevelopmental disease caused by mutations in methyl-CpG-binding protein 2",
            "probability": 0.0
        },
        {
            "start_logit": -1.541015625,
            "end_logit": -8.203125,
            "text": "syndrome (RTT) is a severe neurodevelopmental disease caused by mutations in methyl-CpG-binding protein 2 (MECP2), which encodes a",
            "probability": 0.0
        },
        {
            "start_logit": -6.44921875,
            "end_logit": -7.765625,
            "text": "t",
            "probability": 0.0
        },
        {
            "start_logit": -6.44921875,
            "end_logit": -7.828125,
            "text": "t syndrome (RTT) is a severe neurodevelopmental disease caused by mutations in methyl-CpG-binding protein 2 (MECP2), which encodes a transcriptional modulator of many genes including BDNF.",
            "probability": 0.0
        },
        {
            "start_logit": -6.44921875,
            "end_logit": -7.9765625,
            "text": "t syndrome (RTT) is",
            "probability": 0.0
        }
    ],
    "5e6157cb1af46fc13000000e_12": [
        {
            "start_logit": 9.8828125,
            "end_logit": 9.6875,
            "text": "Rett syndrome",
            "probability": 1.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -1.357421875,
            "text": "Ret",
            "probability": 1.6033649444580078e-05
        },
        {
            "start_logit": -1.49609375,
            "end_logit": 9.6875,
            "text": "syndrome",
            "probability": 1.150369644165039e-05
        },
        {
            "start_logit": -6.0078125,
            "end_logit": 9.6875,
            "text": "t syndrome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -7.71484375,
            "text": "Rett",
            "probability": 0.0
        },
        {
            "start_logit": -7.84375,
            "end_logit": 9.6875,
            "text": "BACKGROUND  Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -8.0546875,
            "text": "Rett syndrome (RTT) is caused by mutations in the transcriptional repressor methyl CpG-binding protein 2 (MECP2).",
            "probability": 0.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -8.1015625,
            "text": "Rett syndrome (RTT) is",
            "probability": 0.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -8.203125,
            "text": "Rett syndrome (RTT) is caused by mutations in the transcriptional repressor methyl CpG-binding protein 2 (",
            "probability": 0.0
        },
        {
            "start_logit": -7.84375,
            "end_logit": -1.357421875,
            "text": "BACKGROUND  Ret",
            "probability": 0.0
        },
        {
            "start_logit": -1.49609375,
            "end_logit": -8.0546875,
            "text": "syndrome (RTT) is caused by mutations in the transcriptional repressor methyl CpG-binding protein 2 (MECP2).",
            "probability": 0.0
        },
        {
            "start_logit": -1.49609375,
            "end_logit": -8.1015625,
            "text": "syndrome (RTT) is",
            "probability": 0.0
        },
        {
            "start_logit": -1.49609375,
            "end_logit": -8.203125,
            "text": "syndrome (RTT) is caused by mutations in the transcriptional repressor methyl CpG-binding protein 2 (",
            "probability": 0.0
        },
        {
            "start_logit": -6.0078125,
            "end_logit": -7.71484375,
            "text": "t",
            "probability": 0.0
        },
        {
            "start_logit": -6.0078125,
            "end_logit": -8.0546875,
            "text": "t syndrome (RTT) is caused by mutations in the transcriptional repressor methyl CpG-binding protein 2 (MECP2).",
            "probability": 0.0
        },
        {
            "start_logit": -6.0078125,
            "end_logit": -8.1015625,
            "text": "t syndrome (RTT) is",
            "probability": 0.0
        },
        {
            "start_logit": -6.0078125,
            "end_logit": -8.203125,
            "text": "t syndrome (RTT) is caused by mutations in the transcriptional repressor methyl CpG-binding protein 2 (",
            "probability": 0.0
        },
        {
            "start_logit": -6.9453125,
            "end_logit": -8.0546875,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.84375,
            "end_logit": -7.71484375,
            "text": "BACKGROUND  Rett",
            "probability": 0.0
        },
        {
            "start_logit": -7.828125,
            "end_logit": -8.0546875,
            "text": "T) is caused by mutations in the transcriptional repressor methyl CpG-binding protein 2 (MECP2).",
            "probability": 0.0
        }
    ],
    "5e6157cb1af46fc13000000e_13": [
        {
            "start_logit": 9.90625,
            "end_logit": 9.6953125,
            "text": "Rett syndrome",
            "probability": 1.0
        },
        {
            "start_logit": 9.90625,
            "end_logit": -1.3193359375,
            "text": "Ret",
            "probability": 1.6570091247558594e-05
        },
        {
            "start_logit": -1.470703125,
            "end_logit": 9.6953125,
            "text": "syndrome",
            "probability": 1.1563301086425781e-05
        },
        {
            "start_logit": -5.87890625,
            "end_logit": 9.6953125,
            "text": "t syndrome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.1484375,
            "end_logit": 9.6953125,
            "text": "disorder Rett syndrome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.90625,
            "end_logit": -7.76953125,
            "text": "Rett",
            "probability": 0.0
        },
        {
            "start_logit": -7.671875,
            "end_logit": 9.6953125,
            "text": "neurodevelopmental disorder Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": 9.90625,
            "end_logit": -8.0390625,
            "text": "Rett syndrome (RTT).",
            "probability": 0.0
        },
        {
            "start_logit": -7.84765625,
            "end_logit": 9.6953125,
            "text": "Mutations in MECP2 cause the neurodevelopmental disorder Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -7.87109375,
            "end_logit": 9.6953125,
            "text": "the neurodevelopmental disorder Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -7.921875,
            "end_logit": 9.6953125,
            "text": "cause the neurodevelopmental disorder Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -7.93359375,
            "end_logit": 9.6953125,
            "text": "MECP2 cause the neurodevelopmental disorder Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -7.96875,
            "end_logit": 9.6953125,
            "text": "in MECP2 cause the neurodevelopmental disorder Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -7.984375,
            "end_logit": 9.6953125,
            "text": "P2 cause the neurodevelopmental disorder Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -7.1484375,
            "end_logit": -1.3193359375,
            "text": "disorder Ret",
            "probability": 0.0
        },
        {
            "start_logit": -7.671875,
            "end_logit": -1.3193359375,
            "text": "neurodevelopmental disorder Ret",
            "probability": 0.0
        },
        {
            "start_logit": -7.84765625,
            "end_logit": -1.3193359375,
            "text": "Mutations in MECP2 cause the neurodevelopmental disorder Ret",
            "probability": 0.0
        },
        {
            "start_logit": -7.87109375,
            "end_logit": -1.3193359375,
            "text": "the neurodevelopmental disorder Ret",
            "probability": 0.0
        },
        {
            "start_logit": -7.921875,
            "end_logit": -1.3193359375,
            "text": "cause the neurodevelopmental disorder Ret",
            "probability": 0.0
        },
        {
            "start_logit": -7.93359375,
            "end_logit": -1.3193359375,
            "text": "MECP2 cause the neurodevelopmental disorder Ret",
            "probability": 0.0
        }
    ],
    "5e6157cb1af46fc13000000e_14": [
        {
            "start_logit": 9.859375,
            "end_logit": 9.671875,
            "text": "Rett syndrome",
            "probability": 1.0
        },
        {
            "start_logit": 9.859375,
            "end_logit": -1.4482421875,
            "text": "Ret",
            "probability": 1.4841556549072266e-05
        },
        {
            "start_logit": -1.5654296875,
            "end_logit": 9.671875,
            "text": "syndrome",
            "probability": 1.0967254638671875e-05
        },
        {
            "start_logit": -6.453125,
            "end_logit": 9.671875,
            "text": "t syndrome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.859375,
            "end_logit": -7.55078125,
            "text": "Rett",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.859375,
            "end_logit": -7.87109375,
            "text": "Rett syndrome , an autism spectrum disorder mainly affecting young females .",
            "probability": 0.0
        },
        {
            "start_logit": -7.76953125,
            "end_logit": 9.671875,
            "text": "of Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": 9.859375,
            "end_logit": -8.015625,
            "text": "Rett syndrome ,",
            "probability": 0.0
        },
        {
            "start_logit": -7.85546875,
            "end_logit": 9.671875,
            "text": "methyl-CpG-binding protein MECP2 are the major cause of Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": 9.859375,
            "end_logit": -8.0703125,
            "text": "Rett syndrome , an autism spectrum disorder",
            "probability": 0.0
        },
        {
            "start_logit": -7.91796875,
            "end_logit": 9.671875,
            "text": "Mutations in the gene encoding the methyl-CpG-binding protein MECP2 are the major cause of Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": 9.859375,
            "end_logit": -8.1171875,
            "text": "Rett syndrome , an autism spectrum disorder mainly",
            "probability": 0.0
        },
        {
            "start_logit": 9.859375,
            "end_logit": -8.1171875,
            "text": "Rett syndrome , an",
            "probability": 0.0
        },
        {
            "start_logit": -7.95703125,
            "end_logit": 9.671875,
            "text": "gene encoding the methyl-CpG-binding protein MECP2 are the major cause of Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -7.98828125,
            "end_logit": 9.671875,
            "text": "CpG-binding protein MECP2 are the major cause of Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -7.99609375,
            "end_logit": 9.671875,
            "text": "major cause of Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": 9.859375,
            "end_logit": -8.1875,
            "text": "Rett syndrome , an autism spectrum disorder mainly affecting",
            "probability": 0.0
        },
        {
            "start_logit": -8.0078125,
            "end_logit": 9.671875,
            "text": "cause of Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -8.0078125,
            "end_logit": 9.671875,
            "text": "protein MECP2 are the major cause of Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -8.0078125,
            "end_logit": 9.671875,
            "text": "encoding the methyl-CpG-binding protein MECP2 are the major cause of Rett syndrome",
            "probability": 0.0
        }
    ],
    "5e6157cb1af46fc13000000e_15": [
        {
            "start_logit": 9.8671875,
            "end_logit": 9.671875,
            "text": "Rett syndrome",
            "probability": 1.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -1.3955078125,
            "text": "Ret",
            "probability": 1.5676021575927734e-05
        },
        {
            "start_logit": -1.5537109375,
            "end_logit": 9.671875,
            "text": "syndrome",
            "probability": 1.1026859283447266e-05
        },
        {
            "start_logit": -6.390625,
            "end_logit": 9.671875,
            "text": "t syndrome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -7.76171875,
            "text": "Rett syndrome ( RTT ) is a severe neurodevelopmental disorder with features of autism that results from mutation of the gene encoding the transcriptional repressor methyl-CpG binding protein ( MECP2) .",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -7.765625,
            "text": "Rett",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.0390625,
            "text": "Rett syndrome ( RTT ) is a severe neurodevelopmental disorder with",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.109375,
            "text": "Rett syndrome ( RTT ) is",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.171875,
            "text": "Rett syndrome ( RTT ) is a severe neurodevelopmental disorder with features",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.1875,
            "text": "Rett syndrome ( RTT ) is a",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.2109375,
            "text": "Rett syndrome ( RTT ) is a severe neurodevelopmental disorder with features of autism that results from mutation of the gene encoding the transcriptional repressor methyl-CpG binding protein (",
            "probability": 0.0
        },
        {
            "start_logit": -1.5537109375,
            "end_logit": -7.76171875,
            "text": "syndrome ( RTT ) is a severe neurodevelopmental disorder with features of autism that results from mutation of the gene encoding the transcriptional repressor methyl-CpG binding protein ( MECP2) .",
            "probability": 0.0
        },
        {
            "start_logit": -1.5537109375,
            "end_logit": -8.0390625,
            "text": "syndrome ( RTT ) is a severe neurodevelopmental disorder with",
            "probability": 0.0
        },
        {
            "start_logit": -1.5537109375,
            "end_logit": -8.109375,
            "text": "syndrome ( RTT ) is",
            "probability": 0.0
        },
        {
            "start_logit": -1.5537109375,
            "end_logit": -8.171875,
            "text": "syndrome ( RTT ) is a severe neurodevelopmental disorder with features",
            "probability": 0.0
        },
        {
            "start_logit": -1.5537109375,
            "end_logit": -8.1875,
            "text": "syndrome ( RTT ) is a",
            "probability": 0.0
        },
        {
            "start_logit": -1.5537109375,
            "end_logit": -8.2109375,
            "text": "syndrome ( RTT ) is a severe neurodevelopmental disorder with features of autism that results from mutation of the gene encoding the transcriptional repressor methyl-CpG binding protein (",
            "probability": 0.0
        },
        {
            "start_logit": -6.390625,
            "end_logit": -7.76171875,
            "text": "t syndrome ( RTT ) is a severe neurodevelopmental disorder with features of autism that results from mutation of the gene encoding the transcriptional repressor methyl-CpG binding protein ( MECP2) .",
            "probability": 0.0
        },
        {
            "start_logit": -6.390625,
            "end_logit": -7.765625,
            "text": "t",
            "probability": 0.0
        },
        {
            "start_logit": -6.390625,
            "end_logit": -8.0390625,
            "text": "t syndrome ( RTT ) is a severe neurodevelopmental disorder with",
            "probability": 0.0
        }
    ],
    "5e6157cb1af46fc13000000e_16": [
        {
            "start_logit": 9.8828125,
            "end_logit": 9.671875,
            "text": "Rett syndrome",
            "probability": 1.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -1.3642578125,
            "text": "Ret",
            "probability": 1.5914440155029297e-05
        },
        {
            "start_logit": -1.55078125,
            "end_logit": 9.671875,
            "text": "syndrome",
            "probability": 1.0788440704345703e-05
        },
        {
            "start_logit": -6.265625,
            "end_logit": 9.671875,
            "text": "t syndrome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -7.734375,
            "text": "Rett",
            "probability": 0.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -7.76953125,
            "text": "Rett syndrome (RTT) is an X-linked neurodevelopmental disorder due to mutations affecting the neural transcription factor MeCP2.",
            "probability": 0.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -7.8125,
            "text": "Rett syndrome (RTT) is",
            "probability": 0.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -8.0703125,
            "text": "Rett syndrome (RTT) is an X",
            "probability": 0.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -8.1328125,
            "text": "Rett syndrome (RTT) is an",
            "probability": 0.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -8.1484375,
            "text": "Rett syndrome (RTT) is an X-linked neurodevelopmental disorder",
            "probability": 0.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -8.1640625,
            "text": "Rett syndrome (RTT) is an X-linked neurodevelopmental disorder due",
            "probability": 0.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -8.1640625,
            "text": "Rett syndrome (RTT) is an X-linked neurodevelopmental disorder due to",
            "probability": 0.0
        },
        {
            "start_logit": -1.55078125,
            "end_logit": -7.76953125,
            "text": "syndrome (RTT) is an X-linked neurodevelopmental disorder due to mutations affecting the neural transcription factor MeCP2.",
            "probability": 0.0
        },
        {
            "start_logit": -1.55078125,
            "end_logit": -7.8125,
            "text": "syndrome (RTT) is",
            "probability": 0.0
        },
        {
            "start_logit": -1.55078125,
            "end_logit": -8.0703125,
            "text": "syndrome (RTT) is an X",
            "probability": 0.0
        },
        {
            "start_logit": -1.55078125,
            "end_logit": -8.1328125,
            "text": "syndrome (RTT) is an",
            "probability": 0.0
        },
        {
            "start_logit": -1.55078125,
            "end_logit": -8.1484375,
            "text": "syndrome (RTT) is an X-linked neurodevelopmental disorder",
            "probability": 0.0
        },
        {
            "start_logit": -1.55078125,
            "end_logit": -8.1640625,
            "text": "syndrome (RTT) is an X-linked neurodevelopmental disorder due",
            "probability": 0.0
        },
        {
            "start_logit": -1.55078125,
            "end_logit": -8.1640625,
            "text": "syndrome (RTT) is an X-linked neurodevelopmental disorder due to",
            "probability": 0.0
        },
        {
            "start_logit": -6.265625,
            "end_logit": -7.734375,
            "text": "t",
            "probability": 0.0
        }
    ],
    "5e6157cb1af46fc13000000e_17": [
        {
            "start_logit": 9.875,
            "end_logit": 9.6875,
            "text": "Rett syndrome",
            "probability": 1.0
        },
        {
            "start_logit": 9.875,
            "end_logit": -1.3837890625,
            "text": "Ret",
            "probability": 1.5556812286376953e-05
        },
        {
            "start_logit": -1.5009765625,
            "end_logit": 9.6875,
            "text": "syndrome",
            "probability": 1.150369644165039e-05
        },
        {
            "start_logit": -6.1484375,
            "end_logit": 9.6875,
            "text": "t syndrome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.90234375,
            "end_logit": 9.6875,
            "text": "as Rett syndrome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.875,
            "end_logit": -7.5546875,
            "text": "Rett syndrome (RTT).",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.41796875,
            "end_logit": 9.6875,
            "text": "known as Rett syndrome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5625,
            "end_logit": 9.6875,
            "text": "disorder known as Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": 9.875,
            "end_logit": -7.765625,
            "text": "Rett",
            "probability": 0.0
        },
        {
            "start_logit": -7.7421875,
            "end_logit": 9.6875,
            "text": "methyl-CpG-binding-protein 2 (MeCP2) cause a delayed-onset neurodevelopmental disorder known as Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -7.7734375,
            "end_logit": 9.6875,
            "text": "a delayed-onset neurodevelopmental disorder known as Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -7.78515625,
            "end_logit": 9.6875,
            "text": "neurodevelopmental disorder known as Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -7.83203125,
            "end_logit": 9.6875,
            "text": "Mutations in the transcription factor methyl-CpG-binding-protein 2 (MeCP2) cause a delayed-onset neurodevelopmental disorder known as Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -7.89453125,
            "end_logit": 9.6875,
            "text": "factor methyl-CpG-binding-protein 2 (MeCP2) cause a delayed-onset neurodevelopmental disorder known as Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -7.91015625,
            "end_logit": 9.6875,
            "text": "delayed-onset neurodevelopmental disorder known as Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -7.9375,
            "end_logit": 9.6875,
            "text": "-onset neurodevelopmental disorder known as Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -7.9453125,
            "end_logit": 9.6875,
            "text": "onset neurodevelopmental disorder known as Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -7.9453125,
            "end_logit": 9.6875,
            "text": "cause a delayed-onset neurodevelopmental disorder known as Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -7.9453125,
            "end_logit": 9.6875,
            "text": "transcription factor methyl-CpG-binding-protein 2 (MeCP2) cause a delayed-onset neurodevelopmental disorder known as Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": 9.875,
            "end_logit": -8.140625,
            "text": "Rett syndrome (",
            "probability": 0.0
        }
    ],
    "5e6157cb1af46fc13000000e_18": [
        {
            "start_logit": 9.8515625,
            "end_logit": 9.6640625,
            "text": "Rett syndrome",
            "probability": 1.0
        },
        {
            "start_logit": 9.8515625,
            "end_logit": -1.44921875,
            "text": "Ret",
            "probability": 1.4960765838623047e-05
        },
        {
            "start_logit": -1.58984375,
            "end_logit": 9.6640625,
            "text": "syndrome",
            "probability": 1.0788440704345703e-05
        },
        {
            "start_logit": -6.42578125,
            "end_logit": 9.6640625,
            "text": "t syndrome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8515625,
            "end_logit": -7.54296875,
            "text": "Rett syndrome is",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8515625,
            "end_logit": -7.734375,
            "text": "Rett",
            "probability": 0.0
        },
        {
            "start_logit": 9.8515625,
            "end_logit": -7.8046875,
            "text": "Rett syndrome is a neurodevelopmental disorder caused by loss-of-function mutations in the gene encoding the transcription factor methyl-CpG-binding protein 2 (MeCP2).",
            "probability": 0.0
        },
        {
            "start_logit": 9.8515625,
            "end_logit": -7.95703125,
            "text": "Rett syndrome is a",
            "probability": 0.0
        },
        {
            "start_logit": 9.8515625,
            "end_logit": -8.09375,
            "text": "Rett syndrome is a neurodevelopmental disorder",
            "probability": 0.0
        },
        {
            "start_logit": 9.8515625,
            "end_logit": -8.1796875,
            "text": "Rett syndrome is a neurodevelopmental disorder caused",
            "probability": 0.0
        },
        {
            "start_logit": 9.8515625,
            "end_logit": -8.1875,
            "text": "Rett syndrome is a neurodevelopmental disorder caused by loss-of-function mutations in the gene encoding the transcription factor methyl-CpG-binding protein 2 (",
            "probability": 0.0
        },
        {
            "start_logit": -1.58984375,
            "end_logit": -7.54296875,
            "text": "syndrome is",
            "probability": 0.0
        },
        {
            "start_logit": -1.58984375,
            "end_logit": -7.8046875,
            "text": "syndrome is a neurodevelopmental disorder caused by loss-of-function mutations in the gene encoding the transcription factor methyl-CpG-binding protein 2 (MeCP2).",
            "probability": 0.0
        },
        {
            "start_logit": -1.58984375,
            "end_logit": -7.95703125,
            "text": "syndrome is a",
            "probability": 0.0
        },
        {
            "start_logit": -1.58984375,
            "end_logit": -8.09375,
            "text": "syndrome is a neurodevelopmental disorder",
            "probability": 0.0
        },
        {
            "start_logit": -1.58984375,
            "end_logit": -8.1796875,
            "text": "syndrome is a neurodevelopmental disorder caused",
            "probability": 0.0
        },
        {
            "start_logit": -1.58984375,
            "end_logit": -8.1875,
            "text": "syndrome is a neurodevelopmental disorder caused by loss-of-function mutations in the gene encoding the transcription factor methyl-CpG-binding protein 2 (",
            "probability": 0.0
        },
        {
            "start_logit": -6.42578125,
            "end_logit": -7.54296875,
            "text": "t syndrome is",
            "probability": 0.0
        },
        {
            "start_logit": -6.42578125,
            "end_logit": -7.734375,
            "text": "t",
            "probability": 0.0
        },
        {
            "start_logit": -6.42578125,
            "end_logit": -7.8046875,
            "text": "t syndrome is a neurodevelopmental disorder caused by loss-of-function mutations in the gene encoding the transcription factor methyl-CpG-binding protein 2 (MeCP2).",
            "probability": 0.0
        }
    ],
    "5e6157cb1af46fc13000000e_19": [
        {
            "start_logit": 9.8671875,
            "end_logit": 9.671875,
            "text": "Rett syndrome",
            "probability": 1.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -1.423828125,
            "text": "Ret",
            "probability": 1.531839370727539e-05
        },
        {
            "start_logit": -1.5625,
            "end_logit": 9.671875,
            "text": "syndrome",
            "probability": 1.0967254638671875e-05
        },
        {
            "start_logit": -6.265625,
            "end_logit": 9.671875,
            "text": "t syndrome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -7.71484375,
            "text": "Rett",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -7.98828125,
            "text": "Rett syndrome is a monogenic disease due to de novo mutations in either MECP2 or CDKL5 genes.",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.125,
            "text": "Rett syndrome is",
            "probability": 0.0
        },
        {
            "start_logit": -1.5625,
            "end_logit": -7.98828125,
            "text": "syndrome is a monogenic disease due to de novo mutations in either MECP2 or CDKL5 genes.",
            "probability": 0.0
        },
        {
            "start_logit": -1.5625,
            "end_logit": -8.125,
            "text": "syndrome is",
            "probability": 0.0
        },
        {
            "start_logit": -6.265625,
            "end_logit": -7.71484375,
            "text": "t",
            "probability": 0.0
        },
        {
            "start_logit": -6.265625,
            "end_logit": -7.98828125,
            "text": "t syndrome is a monogenic disease due to de novo mutations in either MECP2 or CDKL5 genes.",
            "probability": 0.0
        },
        {
            "start_logit": -6.265625,
            "end_logit": -8.125,
            "text": "t syndrome is",
            "probability": 0.0
        },
        {
            "start_logit": -6.875,
            "end_logit": -7.98828125,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.83203125,
            "end_logit": -7.98828125,
            "text": "disease due to de novo mutations in either MECP2 or CDKL5 genes.",
            "probability": 0.0
        },
        {
            "start_logit": -7.93359375,
            "end_logit": -7.98828125,
            "text": "genic disease due to de novo mutations in either MECP2 or CDKL5 genes.",
            "probability": 0.0
        },
        {
            "start_logit": -7.9453125,
            "end_logit": -7.98828125,
            "text": "monogenic disease due to de novo mutations in either MECP2 or CDKL5 genes.",
            "probability": 0.0
        },
        {
            "start_logit": -7.96875,
            "end_logit": -7.98828125,
            "text": "genes.",
            "probability": 0.0
        },
        {
            "start_logit": -7.97265625,
            "end_logit": -7.98828125,
            "text": "MECP2 or CDKL5 genes.",
            "probability": 0.0
        },
        {
            "start_logit": -8.0078125,
            "end_logit": -7.98828125,
            "text": "L5 genes.",
            "probability": 0.0
        },
        {
            "start_logit": -8.015625,
            "end_logit": -7.98828125,
            "text": "P2 or CDKL5 genes.",
            "probability": 0.0
        }
    ],
    "58b6bd2622d300530900000c_1": [
        {
            "start_logit": 8.5859375,
            "end_logit": 8.59375,
            "text": "apoE2 isoform",
            "probability": 0.9541015625
        },
        {
            "start_logit": 5.55078125,
            "end_logit": 8.59375,
            "text": "ApoE2 polymorphism is well known for its relationship to type III hyperlipoproteinemia, and the common apoE2 isoform",
            "probability": 0.04534912109375
        },
        {
            "start_logit": 8.5859375,
            "end_logit": -3.02734375,
            "text": "apoE",
            "probability": 8.52346420288086e-06
        },
        {
            "start_logit": -3.091796875,
            "end_logit": 8.59375,
            "text": "isoform",
            "probability": 8.046627044677734e-06
        },
        {
            "start_logit": 5.55078125,
            "end_logit": -0.1458740234375,
            "text": "ApoE2",
            "probability": 7.271766662597656e-06
        },
        {
            "start_logit": 8.5859375,
            "end_logit": -5.97265625,
            "text": "apoE2",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 5.55078125,
            "end_logit": -3.02734375,
            "text": "ApoE2 polymorphism is well known for its relationship to type III hyperlipoproteinemia, and the common apoE",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.5859375,
            "end_logit": -6.31640625,
            "text": "apoE2 isoform is encoded by the R158C allele.",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -6.4921875,
            "end_logit": 8.59375,
            "text": "common apoE2 isoform",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.3828125,
            "end_logit": 8.59375,
            "text": "the common apoE2 isoform",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.56640625,
            "end_logit": 8.59375,
            "text": "2 isoform",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.8046875,
            "end_logit": 8.59375,
            "text": "type III hyperlipoproteinemia, and the common apoE2 isoform",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.5859375,
            "end_logit": -7.83203125,
            "text": "apoE2 isoform is encoded by the R158C allele",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.5859375,
            "end_logit": -7.921875,
            "text": "apoE2 isoform is encoded by the R158",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.94140625,
            "end_logit": 8.59375,
            "text": "to type III hyperlipoproteinemia, and the common apoE2 isoform",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.5859375,
            "end_logit": -7.9453125,
            "text": "apoE2 isoform is",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.97265625,
            "end_logit": 8.59375,
            "text": "relationship to type III hyperlipoproteinemia, and the common apoE2 isoform",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.5859375,
            "end_logit": -7.98046875,
            "text": "apoE2 isoform is encoded by the R1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.078125,
            "end_logit": 8.59375,
            "text": "and the common apoE2 isoform",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1015625,
            "end_logit": 8.59375,
            "text": "hyperlipoproteinemia, and the common apoE2 isoform",
            "probability": 5.960464477539063e-08
        }
    ],
    "58b6bd2622d300530900000c_2": [
        {
            "start_logit": 8.5859375,
            "end_logit": 8.59375,
            "text": "apoE2 isoform",
            "probability": 0.9541015625
        },
        {
            "start_logit": 5.55078125,
            "end_logit": 8.59375,
            "text": "ApoE2 polymorphism is well known for its relationship to type III hyperlipoproteinemia, and the common apoE2 isoform",
            "probability": 0.04534912109375
        },
        {
            "start_logit": 8.5859375,
            "end_logit": -3.02734375,
            "text": "apoE",
            "probability": 8.52346420288086e-06
        },
        {
            "start_logit": -3.091796875,
            "end_logit": 8.59375,
            "text": "isoform",
            "probability": 8.046627044677734e-06
        },
        {
            "start_logit": 5.55078125,
            "end_logit": -0.1458740234375,
            "text": "ApoE2",
            "probability": 7.271766662597656e-06
        },
        {
            "start_logit": 8.5859375,
            "end_logit": -5.97265625,
            "text": "apoE2",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 5.55078125,
            "end_logit": -3.02734375,
            "text": "ApoE2 polymorphism is well known for its relationship to type III hyperlipoproteinemia, and the common apoE",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.5859375,
            "end_logit": -6.31640625,
            "text": "apoE2 isoform is encoded by the R158C allele.",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -6.4921875,
            "end_logit": 8.59375,
            "text": "common apoE2 isoform",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.3828125,
            "end_logit": 8.59375,
            "text": "the common apoE2 isoform",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.56640625,
            "end_logit": 8.59375,
            "text": "2 isoform",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.8046875,
            "end_logit": 8.59375,
            "text": "type III hyperlipoproteinemia, and the common apoE2 isoform",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.5859375,
            "end_logit": -7.83203125,
            "text": "apoE2 isoform is encoded by the R158C allele",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.5859375,
            "end_logit": -7.921875,
            "text": "apoE2 isoform is encoded by the R158",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.94140625,
            "end_logit": 8.59375,
            "text": "to type III hyperlipoproteinemia, and the common apoE2 isoform",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.5859375,
            "end_logit": -7.9453125,
            "text": "apoE2 isoform is",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.97265625,
            "end_logit": 8.59375,
            "text": "relationship to type III hyperlipoproteinemia, and the common apoE2 isoform",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.5859375,
            "end_logit": -7.98046875,
            "text": "apoE2 isoform is encoded by the R1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.078125,
            "end_logit": 8.59375,
            "text": "and the common apoE2 isoform",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1015625,
            "end_logit": 8.59375,
            "text": "hyperlipoproteinemia, and the common apoE2 isoform",
            "probability": 5.960464477539063e-08
        }
    ],
    "54db62a3034aea571d000001_1": [
        {
            "start_logit": 7.93359375,
            "end_logit": 8.09375,
            "text": "SERCA",
            "probability": 1.0
        },
        {
            "start_logit": 7.93359375,
            "end_logit": -7.51171875,
            "text": "SERCA)",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.7109375,
            "end_logit": 8.09375,
            "text": "sarcoplasmic reticulum (SR) calcium pump (SERCA",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.8671875,
            "end_logit": 8.09375,
            "text": "(SERCA",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.078125,
            "end_logit": 8.09375,
            "text": "SR) calcium pump (SERCA",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.09375,
            "end_logit": 8.09375,
            "text": "calcium pump (SERCA",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.125,
            "end_logit": 8.09375,
            "text": ") calcium pump (SERCA",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.7109375,
            "end_logit": -7.51171875,
            "text": "sarcoplasmic reticulum (SR) calcium pump (SERCA)",
            "probability": 0.0
        },
        {
            "start_logit": -7.8671875,
            "end_logit": -7.51171875,
            "text": "(SERCA)",
            "probability": 0.0
        },
        {
            "start_logit": -8.078125,
            "end_logit": -7.51171875,
            "text": "SR) calcium pump (SERCA)",
            "probability": 0.0
        },
        {
            "start_logit": -8.09375,
            "end_logit": -7.51171875,
            "text": "calcium pump (SERCA)",
            "probability": 0.0
        },
        {
            "start_logit": -7.7109375,
            "end_logit": -7.91015625,
            "text": "sarcoplasmic reticulum (SR) calcium pump",
            "probability": 0.0
        },
        {
            "start_logit": -8.125,
            "end_logit": -7.51171875,
            "text": ") calcium pump (SERCA)",
            "probability": 0.0
        },
        {
            "start_logit": -7.7109375,
            "end_logit": -8.0390625,
            "text": "sarcoplasmic reticulum",
            "probability": 0.0
        },
        {
            "start_logit": -7.7109375,
            "end_logit": -8.0859375,
            "text": "sarcoplasmic reticulum (",
            "probability": 0.0
        },
        {
            "start_logit": -8.078125,
            "end_logit": -7.91015625,
            "text": "SR) calcium pump",
            "probability": 0.0
        },
        {
            "start_logit": -8.09375,
            "end_logit": -7.91015625,
            "text": "calcium pump",
            "probability": 0.0
        },
        {
            "start_logit": -8.125,
            "end_logit": -7.91015625,
            "text": ") calcium pump",
            "probability": 0.0
        }
    ],
    "54db62a3034aea571d000001_2": [
        {
            "start_logit": 7.41796875,
            "end_logit": 8.203125,
            "text": "SERCA",
            "probability": 1.0
        },
        {
            "start_logit": -6.9921875,
            "end_logit": 8.203125,
            "text": "the sarco/endoplasmic reticulum Ca(2+)-ATPase (SERCA",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -7.1640625,
            "end_logit": 8.203125,
            "text": "sarco/endoplasmic reticulum Ca(2+)-ATPase (SERCA",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -7.29296875,
            "end_logit": 8.203125,
            "text": "Ca(2+)-ATPase (SERCA",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 7.41796875,
            "end_logit": -6.515625,
            "text": "SERCA)",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -7.76171875,
            "end_logit": 8.203125,
            "text": "(2+)-ATPase (SERCA",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.93359375,
            "end_logit": 8.203125,
            "text": "(SERCA",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.9921875,
            "end_logit": 8.203125,
            "text": "-ATPase (SERCA",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -8.015625,
            "end_logit": 8.203125,
            "text": "2+)-ATPase (SERCA",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -8.046875,
            "end_logit": 8.203125,
            "text": "reticulum Ca(2+)-ATPase (SERCA",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -8.0546875,
            "end_logit": 8.203125,
            "text": "+)-ATPase (SERCA",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -8.15625,
            "end_logit": 8.203125,
            "text": ")-ATPase (SERCA",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.9921875,
            "end_logit": -3.904296875,
            "text": "the sarco/endoplasmic reticulum Ca(2+)-ATPase",
            "probability": 0.0
        },
        {
            "start_logit": -7.1640625,
            "end_logit": -3.904296875,
            "text": "sarco/endoplasmic reticulum Ca(2+)-ATPase",
            "probability": 0.0
        },
        {
            "start_logit": -7.29296875,
            "end_logit": -3.904296875,
            "text": "Ca(2+)-ATPase",
            "probability": 0.0
        },
        {
            "start_logit": -7.76171875,
            "end_logit": -3.904296875,
            "text": "(2+)-ATPase",
            "probability": 0.0
        },
        {
            "start_logit": -7.9921875,
            "end_logit": -3.904296875,
            "text": "-ATPase",
            "probability": 0.0
        },
        {
            "start_logit": -8.015625,
            "end_logit": -3.904296875,
            "text": "2+)-ATPase",
            "probability": 0.0
        },
        {
            "start_logit": -8.046875,
            "end_logit": -3.904296875,
            "text": "reticulum Ca(2+)-ATPase",
            "probability": 0.0
        },
        {
            "start_logit": -8.0546875,
            "end_logit": -3.904296875,
            "text": "+)-ATPase",
            "probability": 0.0
        }
    ],
    "54db62a3034aea571d000001_3": [
        {
            "start_logit": 7.4296875,
            "end_logit": 4.55859375,
            "text": "SERCA",
            "probability": 0.9990234375
        },
        {
            "start_logit": 7.4296875,
            "end_logit": -2.55078125,
            "text": "SERCA, an endoplasmic reticulum (ER) calcium pump, is solely responsible for transporting cytosolic calcium into the ER lumen.",
            "probability": 0.0008196830749511719
        },
        {
            "start_logit": 7.4296875,
            "end_logit": -5.5546875,
            "text": "SERCA, an endoplasmic reticulum (ER) calcium pump, is solely responsible for transporting cytosolic calcium into the ER",
            "probability": 4.0650367736816406e-05
        },
        {
            "start_logit": 7.4296875,
            "end_logit": -7.08984375,
            "text": "SERCA, an endoplasmic reticulum (ER",
            "probability": 8.821487426757812e-06
        },
        {
            "start_logit": 7.4296875,
            "end_logit": -7.2890625,
            "text": "SERCA, an endoplasmic reticulum (ER) calcium pump, is solely responsible for transporting cytosolic calcium into",
            "probability": 7.212162017822266e-06
        },
        {
            "start_logit": 7.4296875,
            "end_logit": -7.609375,
            "text": "SERCA, an endoplasmic reticulum (ER) calcium pump, is solely responsible for transporting cytosolic calcium into the",
            "probability": 5.185604095458984e-06
        },
        {
            "start_logit": 7.4296875,
            "end_logit": -7.6953125,
            "text": "SERCA, an endoplasmic reticulum (ER) calcium pump, is solely responsible",
            "probability": 4.76837158203125e-06
        },
        {
            "start_logit": 7.4296875,
            "end_logit": -7.72265625,
            "text": "SERCA, an endoplasmic reticulum (ER) calcium pump,",
            "probability": 4.649162292480469e-06
        },
        {
            "start_logit": 7.4296875,
            "end_logit": -7.73046875,
            "text": "SERCA, an endoplasmic reticulum (ER) calcium pump, is solely responsible for transporting cytosolic calcium into the ER lumen",
            "probability": 4.649162292480469e-06
        },
        {
            "start_logit": 7.4296875,
            "end_logit": -7.8046875,
            "text": "SERCA, an endoplasmic reticulum (ER) calcium pump, is",
            "probability": 4.291534423828125e-06
        },
        {
            "start_logit": 7.4296875,
            "end_logit": -7.87109375,
            "text": "SERCA,",
            "probability": 4.0531158447265625e-06
        },
        {
            "start_logit": 7.4296875,
            "end_logit": -7.93359375,
            "text": "SERCA, an endoplasmic reticulum (ER) calcium pump, is solely",
            "probability": 3.814697265625e-06
        },
        {
            "start_logit": 7.4296875,
            "end_logit": -7.98046875,
            "text": "SERCA, an endoplasmic reticulum",
            "probability": 3.635883331298828e-06
        },
        {
            "start_logit": -4.62890625,
            "end_logit": -2.55078125,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.046875,
            "end_logit": -2.55078125,
            "text": "an endoplasmic reticulum (ER) calcium pump, is solely responsible for transporting cytosolic calcium into the ER lumen.",
            "probability": 0.0
        },
        {
            "start_logit": -7.05859375,
            "end_logit": -2.55078125,
            "text": "transporting cytosolic calcium into the ER lumen.",
            "probability": 0.0
        },
        {
            "start_logit": -7.42578125,
            "end_logit": -2.55078125,
            "text": "endoplasmic reticulum (ER) calcium pump, is solely responsible for transporting cytosolic calcium into the ER lumen.",
            "probability": 0.0
        },
        {
            "start_logit": -7.55078125,
            "end_logit": -2.55078125,
            "text": "calcium into the ER lumen.",
            "probability": 0.0
        },
        {
            "start_logit": -7.65234375,
            "end_logit": -2.55078125,
            "text": "ER lumen.",
            "probability": 0.0
        },
        {
            "start_logit": -7.65625,
            "end_logit": -2.55078125,
            "text": "cytosolic calcium into the ER lumen.",
            "probability": 0.0
        }
    ],
    "54db62a3034aea571d000001_4": [
        {
            "start_logit": 4.796875,
            "end_logit": 6.67578125,
            "text": "SERCA",
            "probability": 1.0
        },
        {
            "start_logit": -3.294921875,
            "end_logit": 6.67578125,
            "text": "Sarcoplasmic reticulum Ca(2+)-ATPase (SERCA",
            "probability": 0.0003077983856201172
        },
        {
            "start_logit": -6.8359375,
            "end_logit": 6.67578125,
            "text": "Ca(2+)-ATPase (SERCA",
            "probability": 8.940696716308594e-06
        },
        {
            "start_logit": 4.796875,
            "end_logit": -5.0390625,
            "text": "SERCA) is the pump crucial for calcium homeostasis and its impairment results in pathologies such as myopathy, heart failure or diabetes.",
            "probability": 8.225440979003906e-06
        },
        {
            "start_logit": -6.9453125,
            "end_logit": 6.67578125,
            "text": "(SERCA",
            "probability": 7.987022399902344e-06
        },
        {
            "start_logit": -7.34375,
            "end_logit": 6.67578125,
            "text": "reticulum Ca(2+)-ATPase (SERCA",
            "probability": 5.364418029785156e-06
        },
        {
            "start_logit": 4.796875,
            "end_logit": -5.76953125,
            "text": "SERCA)",
            "probability": 3.993511199951172e-06
        },
        {
            "start_logit": -7.69140625,
            "end_logit": 6.67578125,
            "text": "(2+)-ATPase (SERCA",
            "probability": 3.814697265625e-06
        },
        {
            "start_logit": -7.89453125,
            "end_logit": 6.67578125,
            "text": "-ATPase (SERCA",
            "probability": 3.0994415283203125e-06
        },
        {
            "start_logit": -8.1171875,
            "end_logit": 6.67578125,
            "text": "+)-ATPase (SERCA",
            "probability": 2.5033950805664062e-06
        },
        {
            "start_logit": -8.125,
            "end_logit": 6.67578125,
            "text": "2+)-ATPase (SERCA",
            "probability": 2.4437904357910156e-06
        },
        {
            "start_logit": 4.796875,
            "end_logit": -7.53515625,
            "text": "SERCA) is the pump crucial for calcium homeostasis and",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 4.796875,
            "end_logit": -7.59375,
            "text": "SERCA) is",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 4.796875,
            "end_logit": -7.76171875,
            "text": "SERCA) is the pump crucial",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 4.796875,
            "end_logit": -7.85546875,
            "text": "SERCA) is the pump crucial for calcium homeostasis and its impairment results in pathologies such",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 4.796875,
            "end_logit": -7.8671875,
            "text": "SERCA) is the",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 4.796875,
            "end_logit": -7.90625,
            "text": "SERCA) is the pump crucial for calcium homeostasis and its impairment results in pathologies such as myopathy, heart failure or",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 4.796875,
            "end_logit": -7.921875,
            "text": "SERCA) is the pump crucial for calcium homeostasis and its impairment results in pathologies such as myopathy, heart",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 4.796875,
            "end_logit": -7.94921875,
            "text": "SERCA) is the pump crucial for calcium homeostasis and its impairment results",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 4.796875,
            "end_logit": -7.9765625,
            "text": "SERCA) is the pump crucial for calcium homeostasis",
            "probability": 4.172325134277344e-07
        }
    ],
    "54db62a3034aea571d000001_5": [
        {
            "start_logit": 6.07421875,
            "end_logit": 7.59765625,
            "text": "SERCA",
            "probability": 1.0
        },
        {
            "start_logit": 6.07421875,
            "end_logit": -4.06640625,
            "text": "SERCA enzymes).",
            "probability": 8.58306884765625e-06
        },
        {
            "start_logit": -6.28515625,
            "end_logit": 7.59765625,
            "text": "Calcium is actively accumulated in the endoplasmic reticulum by Sarco/Endoplasmic Reticulum Calcium transport ATPases (SERCA",
            "probability": 4.291534423828125e-06
        },
        {
            "start_logit": -6.82421875,
            "end_logit": 7.59765625,
            "text": "Sarco/Endoplasmic Reticulum Calcium transport ATPases (SERCA",
            "probability": 2.5033950805664062e-06
        },
        {
            "start_logit": -7.41015625,
            "end_logit": 7.59765625,
            "text": "by Sarco/Endoplasmic Reticulum Calcium transport ATPases (SERCA",
            "probability": 1.3709068298339844e-06
        },
        {
            "start_logit": -7.6328125,
            "end_logit": 7.59765625,
            "text": "Calcium transport ATPases (SERCA",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": 6.07421875,
            "end_logit": -6.28515625,
            "text": "SERCA enzymes",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": -7.80859375,
            "end_logit": 7.59765625,
            "text": "in the endoplasmic reticulum by Sarco/Endoplasmic Reticulum Calcium transport ATPases (SERCA",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": -7.8359375,
            "end_logit": 7.59765625,
            "text": "/Endoplasmic Reticulum Calcium transport ATPases (SERCA",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": -7.90234375,
            "end_logit": 7.59765625,
            "text": "Endoplasmic Reticulum Calcium transport ATPases (SERCA",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": -7.90234375,
            "end_logit": 7.59765625,
            "text": "actively accumulated in the endoplasmic reticulum by Sarco/Endoplasmic Reticulum Calcium transport ATPases (SERCA",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": -7.9453125,
            "end_logit": 7.59765625,
            "text": "Reticulum Calcium transport ATPases (SERCA",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": -7.9453125,
            "end_logit": 7.59765625,
            "text": "(SERCA",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": -7.9921875,
            "end_logit": 7.59765625,
            "text": "o/Endoplasmic Reticulum Calcium transport ATPases (SERCA",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": -8.015625,
            "end_logit": 7.59765625,
            "text": "the endoplasmic reticulum by Sarco/Endoplasmic Reticulum Calcium transport ATPases (SERCA",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": -8.0625,
            "end_logit": 7.59765625,
            "text": "endoplasmic reticulum by Sarco/Endoplasmic Reticulum Calcium transport ATPases (SERCA",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -8.109375,
            "end_logit": 7.59765625,
            "text": "accumulated in the endoplasmic reticulum by Sarco/Endoplasmic Reticulum Calcium transport ATPases (SERCA",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 6.07421875,
            "end_logit": -7.4296875,
            "text": "SERCA enzymes)",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -5.25,
            "end_logit": -4.06640625,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -6.28515625,
            "end_logit": -4.06640625,
            "text": "Calcium is actively accumulated in the endoplasmic reticulum by Sarco/Endoplasmic Reticulum Calcium transport ATPases (SERCA enzymes).",
            "probability": 0.0
        }
    ],
    "54db62a3034aea571d000001_6": [
        {
            "start_logit": 8.140625,
            "end_logit": 8.1484375,
            "text": "SERCA",
            "probability": 1.0
        },
        {
            "start_logit": 8.140625,
            "end_logit": -7.5078125,
            "text": "SERCA)",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.58984375,
            "end_logit": 8.1484375,
            "text": "sarco(endo)plasmic reticulum calcium pump (SERCA",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.86328125,
            "end_logit": 8.1484375,
            "text": "(SERCA",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.078125,
            "end_logit": 8.1484375,
            "text": "calcium pump (SERCA",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.109375,
            "end_logit": 8.1484375,
            "text": "(endo)plasmic reticulum calcium pump (SERCA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1171875,
            "end_logit": 8.1484375,
            "text": "plasmic reticulum calcium pump (SERCA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.140625,
            "end_logit": 8.1484375,
            "text": "reticulum calcium pump (SERCA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.58984375,
            "end_logit": -7.5078125,
            "text": "sarco(endo)plasmic reticulum calcium pump (SERCA)",
            "probability": 0.0
        },
        {
            "start_logit": -7.86328125,
            "end_logit": -7.5078125,
            "text": "(SERCA)",
            "probability": 0.0
        },
        {
            "start_logit": -7.58984375,
            "end_logit": -7.98828125,
            "text": "sarco(endo)plasmic reticulum calcium pump",
            "probability": 0.0
        },
        {
            "start_logit": -8.078125,
            "end_logit": -7.5078125,
            "text": "calcium pump (SERCA)",
            "probability": 0.0
        },
        {
            "start_logit": -8.109375,
            "end_logit": -7.5078125,
            "text": "(endo)plasmic reticulum calcium pump (SERCA)",
            "probability": 0.0
        },
        {
            "start_logit": -8.1171875,
            "end_logit": -7.5078125,
            "text": "plasmic reticulum calcium pump (SERCA)",
            "probability": 0.0
        },
        {
            "start_logit": -8.140625,
            "end_logit": -7.5078125,
            "text": "reticulum calcium pump (SERCA)",
            "probability": 0.0
        },
        {
            "start_logit": -8.078125,
            "end_logit": -7.98828125,
            "text": "calcium pump",
            "probability": 0.0
        },
        {
            "start_logit": -8.109375,
            "end_logit": -7.98828125,
            "text": "(endo)plasmic reticulum calcium pump",
            "probability": 0.0
        },
        {
            "start_logit": -8.1171875,
            "end_logit": -7.98828125,
            "text": "plasmic reticulum calcium pump",
            "probability": 0.0
        },
        {
            "start_logit": -8.140625,
            "end_logit": -7.98828125,
            "text": "reticulum calcium pump",
            "probability": 0.0
        }
    ],
    "54db62a3034aea571d000001_7": [
        {
            "start_logit": 9.984375,
            "end_logit": 4.52734375,
            "text": "SERCA",
            "probability": 0.966796875
        },
        {
            "start_logit": 9.984375,
            "end_logit": 1.1552734375,
            "text": "SERCA is a membrane protein that belongs to the family of P-type ion translocating ATPases and pumps free cytosolic calcium into intracellular stores.",
            "probability": 0.0330810546875
        },
        {
            "start_logit": 9.984375,
            "end_logit": -4.3984375,
            "text": "SERCA is",
            "probability": 0.00012803077697753906
        },
        {
            "start_logit": 9.984375,
            "end_logit": -5.1484375,
            "text": "SERCA is a membrane protein that belongs to the family of P-type ion translocating ATPases and",
            "probability": 6.0439109802246094e-05
        },
        {
            "start_logit": 9.984375,
            "end_logit": -7.234375,
            "text": "SERCA is a",
            "probability": 7.510185241699219e-06
        },
        {
            "start_logit": 9.984375,
            "end_logit": -7.3515625,
            "text": "SERCA is a membrane protein that belongs to the family of P-type ion translocating ATPases",
            "probability": 6.67572021484375e-06
        },
        {
            "start_logit": 9.984375,
            "end_logit": -7.5703125,
            "text": "SERCA is a membrane protein that belongs to the family of P-type ion translocating ATPases and pumps",
            "probability": 5.364418029785156e-06
        },
        {
            "start_logit": 9.984375,
            "end_logit": -7.58984375,
            "text": "SERCA is a membrane protein that belongs to the family of P-type ion translocating ATPases and pumps free cytosolic calcium into intracellular stores",
            "probability": 5.245208740234375e-06
        },
        {
            "start_logit": 9.984375,
            "end_logit": -7.6796875,
            "text": "SERCA is a membrane protein that",
            "probability": 4.76837158203125e-06
        },
        {
            "start_logit": 9.984375,
            "end_logit": -7.68359375,
            "text": "SERCA is a membrane protein that belongs to the family",
            "probability": 4.76837158203125e-06
        },
        {
            "start_logit": 9.984375,
            "end_logit": -7.77734375,
            "text": "SERCA is a membrane protein that belongs to the family of P-type ion translocating ATPases and pumps free cytosolic calcium into intracellular",
            "probability": 4.351139068603516e-06
        },
        {
            "start_logit": 9.984375,
            "end_logit": -7.80859375,
            "text": "SERCA is a membrane protein that belongs to the family of P",
            "probability": 4.231929779052734e-06
        },
        {
            "start_logit": 9.984375,
            "end_logit": -7.8515625,
            "text": "SERCA is a membrane protein that belongs",
            "probability": 4.0531158447265625e-06
        },
        {
            "start_logit": 9.984375,
            "end_logit": -7.875,
            "text": "SERCA is a membrane protein that belongs to the family of P-type ion translocating ATPases and pumps free cytosolic calcium into",
            "probability": 3.993511199951172e-06
        },
        {
            "start_logit": 9.984375,
            "end_logit": -7.8828125,
            "text": "SERCA is a membrane protein that belongs to the family of P-type ion translocating ATPases and pumps free cytosolic calcium",
            "probability": 3.933906555175781e-06
        },
        {
            "start_logit": -2.564453125,
            "end_logit": 1.1552734375,
            "text": ".",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.08984375,
            "end_logit": 1.1552734375,
            "text": "of P-type ion translocating ATPases and pumps free cytosolic calcium into intracellular stores.",
            "probability": 0.0
        },
        {
            "start_logit": -7.23828125,
            "end_logit": 1.1552734375,
            "text": "family of P-type ion translocating ATPases and pumps free cytosolic calcium into intracellular stores.",
            "probability": 0.0
        },
        {
            "start_logit": -7.25,
            "end_logit": 1.1552734375,
            "text": "type ion translocating ATPases and pumps free cytosolic calcium into intracellular stores.",
            "probability": 0.0
        },
        {
            "start_logit": -7.34375,
            "end_logit": 1.1552734375,
            "text": "membrane protein that belongs to the family of P-type ion translocating ATPases and pumps free cytosolic calcium into intracellular stores.",
            "probability": 0.0
        }
    ],
    "54db62a3034aea571d000001_8": [
        {
            "start_logit": 7.4375,
            "end_logit": 8.0625,
            "text": "SERCA",
            "probability": 1.0
        },
        {
            "start_logit": 7.4375,
            "end_logit": -1.353515625,
            "text": "SERCA genes were identified-SERCA1, SERCA2, and SERCA3. SERCA is mainly represented by the SERCA2a",
            "probability": 8.153915405273438e-05
        },
        {
            "start_logit": 7.4375,
            "end_logit": -4.01953125,
            "text": "SERCA genes were identified-SERCA",
            "probability": 5.662441253662109e-06
        },
        {
            "start_logit": 7.4375,
            "end_logit": -4.49609375,
            "text": "SERCA genes were identified-SERCA1, SERCA2, and SERCA3. SERCA is mainly represented by the SERCA2a isoform in the heart",
            "probability": 3.516674041748047e-06
        },
        {
            "start_logit": 7.4375,
            "end_logit": -5.0546875,
            "text": "SERCA genes were identified-SERCA1, SERCA2, and SERCA3.",
            "probability": 2.0265579223632812e-06
        },
        {
            "start_logit": 7.4375,
            "end_logit": -5.0546875,
            "text": "SERCA genes were identified-SERCA1, SERCA2, and SERCA3. SERCA is mainly represented by the SERCA2a isoform in the heart.",
            "probability": 2.0265579223632812e-06
        },
        {
            "start_logit": 7.4375,
            "end_logit": -5.58203125,
            "text": "SERCA genes were identified-SERCA1",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": 7.4375,
            "end_logit": -6.31640625,
            "text": "SERCA genes were identified-SERCA1, SERCA2, and SERCA3. SERCA",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 7.4375,
            "end_logit": -6.421875,
            "text": "SERCA genes were identified-SERCA1, SERCA2, and SERCA3. SERCA is mainly represented by the SERCA",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 7.4375,
            "end_logit": -6.625,
            "text": "SERCA genes were identified-SERCA1, SERCA2, and SERCA3. SERCA is mainly represented by the SERCA2a isoform in",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 7.4375,
            "end_logit": -6.796875,
            "text": "SERCA genes were identified-SERCA1, SERCA2",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 1.98046875,
            "end_logit": -1.353515625,
            "text": "SERCA1, SERCA2, and SERCA3. SERCA is mainly represented by the SERCA2a",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.4375,
            "end_logit": -6.96875,
            "text": "SERCA genes were identified-SERCA1, SERCA",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.4375,
            "end_logit": -7.125,
            "text": "SERCA genes",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.4375,
            "end_logit": -7.1953125,
            "text": "SERCA genes were identified-SERCA1, SERCA2, and SERCA3. SERCA is mainly represented by the SERCA2a isoform",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.4375,
            "end_logit": -7.24609375,
            "text": "SERCA genes were identified-SERCA1, SERCA2, and SERCA3. SERCA is",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.4375,
            "end_logit": -7.48046875,
            "text": "SERCA genes were identified-SERCA1, SERCA2, and SERCA3",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -0.225341796875,
            "end_logit": -1.353515625,
            "text": "SERCA2a",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 1.98046875,
            "end_logit": -4.01953125,
            "text": "SERCA",
            "probability": 0.0
        },
        {
            "start_logit": 1.98046875,
            "end_logit": -4.49609375,
            "text": "SERCA1, SERCA2, and SERCA3. SERCA is mainly represented by the SERCA2a isoform in the heart",
            "probability": 0.0
        }
    ],
    "54db62a3034aea571d000001_9": [
        {
            "start_logit": 9.328125,
            "end_logit": 4.109375,
            "text": "The sarcoplasmic reticulum Ca\ufffdz ATPase",
            "probability": 0.7890625
        },
        {
            "start_logit": 9.328125,
            "end_logit": 2.591796875,
            "text": "The sarcoplasmic reticulum Ca\ufffdz ATPase (SERCA",
            "probability": 0.17333984375
        },
        {
            "start_logit": 9.328125,
            "end_logit": 0.919921875,
            "text": "The sarcoplasmic reticulum Ca\ufffdz ATPase (SERCA) is a membrane-bound pump that utilizes ATP to drive calcium ions from the myocyte cytosol against the higher calcium concentration in the sarcoplasmic reticulum.",
            "probability": 0.032562255859375
        },
        {
            "start_logit": 9.328125,
            "end_logit": -1.42578125,
            "text": "The sarcoplasmic reticulum Ca\ufffdz ATPase (SERCA)",
            "probability": 0.0031108856201171875
        },
        {
            "start_logit": 9.328125,
            "end_logit": -2.04296875,
            "text": "The",
            "probability": 0.0016794204711914062
        },
        {
            "start_logit": 9.328125,
            "end_logit": -3.318359375,
            "text": "The sarcoplasmic reticulum Ca\ufffdz ATPase (SERCA) is",
            "probability": 0.0004680156707763672
        },
        {
            "start_logit": 9.328125,
            "end_logit": -6.3984375,
            "text": "The sarcoplasmic reticulum Ca\ufffdz ATPase (SERCA) is a",
            "probability": 2.1517276763916016e-05
        },
        {
            "start_logit": 9.328125,
            "end_logit": -6.76171875,
            "text": "The sarcoplasmic reticulum Ca\ufffdz ATPase (SERCA) is a membrane-bound pump",
            "probability": 1.4960765838623047e-05
        },
        {
            "start_logit": 9.328125,
            "end_logit": -6.76953125,
            "text": "The sarcoplasmic reticulum Ca\ufffdz ATPase (SERCA) is a membrane",
            "probability": 1.4960765838623047e-05
        },
        {
            "start_logit": 9.328125,
            "end_logit": -6.9453125,
            "text": "The sarcoplasmic reticulum Ca\ufffdz ATPase (SERCA) is a membrane-bound pump that",
            "probability": 1.245737075805664e-05
        },
        {
            "start_logit": 9.328125,
            "end_logit": -7.02734375,
            "text": "The sarcoplasmic reticulum Ca\ufffdz ATPase (SERCA) is a membrane-bound pump that utilizes ATP to",
            "probability": 1.1444091796875e-05
        },
        {
            "start_logit": 9.328125,
            "end_logit": -7.19921875,
            "text": "The sarcoplasmic reticulum",
            "probability": 9.655952453613281e-06
        },
        {
            "start_logit": 9.328125,
            "end_logit": -7.24609375,
            "text": "The sarcoplasmic reticulum Ca\ufffdz ATPase (SERCA) is a membrane-bound pump that utilizes ATP to drive calcium ions from the myocyte cytosol against the",
            "probability": 9.238719940185547e-06
        },
        {
            "start_logit": 9.328125,
            "end_logit": -7.42578125,
            "text": "The sarcoplasmic reticulum Ca\ufffdz ATPase (SERCA) is a membrane-bound",
            "probability": 7.748603820800781e-06
        },
        {
            "start_logit": 9.328125,
            "end_logit": -7.4453125,
            "text": "The sarcoplasmic reticulum Ca\ufffdz ATPase (SERCA) is a membrane-bound pump that utilizes ATP",
            "probability": 7.569789886474609e-06
        },
        {
            "start_logit": 9.328125,
            "end_logit": -7.48046875,
            "text": "The sarcoplasmic reticulum Ca\ufffdz ATPase (SERCA) is a membrane-bound pump that utilizes ATP to drive calcium ions from the myocyte cytosol against the higher calcium concentration in the sarcoplasmic reticulum",
            "probability": 7.271766662597656e-06
        },
        {
            "start_logit": 9.328125,
            "end_logit": -7.5078125,
            "text": "The sarcoplasmic reticulum Ca",
            "probability": 7.092952728271484e-06
        },
        {
            "start_logit": 9.328125,
            "end_logit": -7.51171875,
            "text": "The sarcoplasmic reticulum Ca\ufffdz ATPase (SERCA) is a membrane-bound pump that utilizes ATP to drive calcium ions from the",
            "probability": 7.033348083496094e-06
        },
        {
            "start_logit": -1.7177734375,
            "end_logit": 2.591796875,
            "text": "SERCA",
            "probability": 2.8014183044433594e-06
        },
        {
            "start_logit": -1.7177734375,
            "end_logit": 0.919921875,
            "text": "SERCA) is a membrane-bound pump that utilizes ATP to drive calcium ions from the myocyte cytosol against the higher calcium concentration in the sarcoplasmic reticulum.",
            "probability": 5.364418029785156e-07
        }
    ],
    "550739cf3b8a5dc045000002_1": [
        {
            "start_logit": 9.5234375,
            "end_logit": 8.5703125,
            "text": "AAUAAA",
            "probability": 0.998046875
        },
        {
            "start_logit": 9.5234375,
            "end_logit": 2.34765625,
            "text": "AAUAAA hexamer",
            "probability": 0.001987457275390625
        },
        {
            "start_logit": 9.5234375,
            "end_logit": -2.1640625,
            "text": "AA",
            "probability": 2.1696090698242188e-05
        },
        {
            "start_logit": -3.43359375,
            "end_logit": 8.5703125,
            "text": "AA",
            "probability": 2.384185791015625e-06
        },
        {
            "start_logit": 9.5234375,
            "end_logit": -6.515625,
            "text": "AAUAAA hexa",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -5.86328125,
            "end_logit": 8.5703125,
            "text": "UAAA",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.5234375,
            "end_logit": -7.390625,
            "text": "AAUA",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.22265625,
            "end_logit": 8.5703125,
            "text": "The most canonical AAUAAA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.50390625,
            "end_logit": 8.5703125,
            "text": "canonical AAUAAA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.73828125,
            "end_logit": 8.5703125,
            "text": "most canonical AAUAAA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -3.43359375,
            "end_logit": 2.34765625,
            "text": "AA hexamer",
            "probability": 0.0
        },
        {
            "start_logit": -5.86328125,
            "end_logit": 2.34765625,
            "text": "UAAA hexamer",
            "probability": 0.0
        },
        {
            "start_logit": -7.22265625,
            "end_logit": 2.34765625,
            "text": "The most canonical AAUAAA hexamer",
            "probability": 0.0
        },
        {
            "start_logit": -7.34765625,
            "end_logit": 2.34765625,
            "text": "mer",
            "probability": 0.0
        },
        {
            "start_logit": -7.50390625,
            "end_logit": 2.34765625,
            "text": "canonical AAUAAA hexamer",
            "probability": 0.0
        },
        {
            "start_logit": -7.73828125,
            "end_logit": 2.34765625,
            "text": "most canonical AAUAAA hexamer",
            "probability": 0.0
        },
        {
            "start_logit": -7.94921875,
            "end_logit": 2.34765625,
            "text": "hexamer",
            "probability": 0.0
        },
        {
            "start_logit": -7.22265625,
            "end_logit": -2.1640625,
            "text": "The most canonical AA",
            "probability": 0.0
        },
        {
            "start_logit": -7.50390625,
            "end_logit": -2.1640625,
            "text": "canonical AA",
            "probability": 0.0
        },
        {
            "start_logit": -7.73828125,
            "end_logit": -2.1640625,
            "text": "most canonical AA",
            "probability": 0.0
        }
    ],
    "550739cf3b8a5dc045000002_2": [
        {
            "start_logit": 8.6953125,
            "end_logit": 9.21875,
            "text": "AAUAAA",
            "probability": 1.0
        },
        {
            "start_logit": -2.529296875,
            "end_logit": 9.21875,
            "text": "AA",
            "probability": 1.341104507446289e-05
        },
        {
            "start_logit": 8.6953125,
            "end_logit": -3.28125,
            "text": "AA",
            "probability": 3.7550926208496094e-06
        },
        {
            "start_logit": -5.83984375,
            "end_logit": 9.21875,
            "text": "UAAA",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -7.1015625,
            "end_logit": 9.21875,
            "text": "polyadenylation signal AAUAAA",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.5703125,
            "end_logit": 9.21875,
            "text": "signal AAUAAA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.98828125,
            "end_logit": 9.21875,
            "text": "ylation signal AAUAAA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.6953125,
            "end_logit": -7.73828125,
            "text": "AAUA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.1015625,
            "end_logit": -3.28125,
            "text": "polyadenylation signal AA",
            "probability": 0.0
        },
        {
            "start_logit": -7.5703125,
            "end_logit": -3.28125,
            "text": "signal AA",
            "probability": 0.0
        },
        {
            "start_logit": -7.98828125,
            "end_logit": -3.28125,
            "text": "ylation signal AA",
            "probability": 0.0
        },
        {
            "start_logit": -5.83984375,
            "end_logit": -7.73828125,
            "text": "UA",
            "probability": 0.0
        },
        {
            "start_logit": -7.1015625,
            "end_logit": -7.73828125,
            "text": "polyadenylation signal AAUA",
            "probability": 0.0
        },
        {
            "start_logit": -7.5703125,
            "end_logit": -7.73828125,
            "text": "signal AAUA",
            "probability": 0.0
        },
        {
            "start_logit": -7.98828125,
            "end_logit": -7.73828125,
            "text": "ylation signal AAUA",
            "probability": 0.0
        }
    ],
    "550739cf3b8a5dc045000002_3": [
        {
            "start_logit": 8.6953125,
            "end_logit": 9.21875,
            "text": "AAUAAA",
            "probability": 1.0
        },
        {
            "start_logit": -2.529296875,
            "end_logit": 9.21875,
            "text": "AA",
            "probability": 1.341104507446289e-05
        },
        {
            "start_logit": 8.6953125,
            "end_logit": -3.28125,
            "text": "AA",
            "probability": 3.7550926208496094e-06
        },
        {
            "start_logit": -5.83984375,
            "end_logit": 9.21875,
            "text": "UAAA",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -7.1015625,
            "end_logit": 9.21875,
            "text": "polyadenylation signal AAUAAA",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.5703125,
            "end_logit": 9.21875,
            "text": "signal AAUAAA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.98828125,
            "end_logit": 9.21875,
            "text": "ylation signal AAUAAA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.6953125,
            "end_logit": -7.73828125,
            "text": "AAUA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.1015625,
            "end_logit": -3.28125,
            "text": "polyadenylation signal AA",
            "probability": 0.0
        },
        {
            "start_logit": -7.5703125,
            "end_logit": -3.28125,
            "text": "signal AA",
            "probability": 0.0
        },
        {
            "start_logit": -7.98828125,
            "end_logit": -3.28125,
            "text": "ylation signal AA",
            "probability": 0.0
        },
        {
            "start_logit": -5.83984375,
            "end_logit": -7.73828125,
            "text": "UA",
            "probability": 0.0
        },
        {
            "start_logit": -7.1015625,
            "end_logit": -7.73828125,
            "text": "polyadenylation signal AAUA",
            "probability": 0.0
        },
        {
            "start_logit": -7.5703125,
            "end_logit": -7.73828125,
            "text": "signal AAUA",
            "probability": 0.0
        },
        {
            "start_logit": -7.98828125,
            "end_logit": -7.73828125,
            "text": "ylation signal AAUA",
            "probability": 0.0
        }
    ],
    "550739cf3b8a5dc045000002_4": [
        {
            "start_logit": 9.875,
            "end_logit": 9.6796875,
            "text": "AAUAAA",
            "probability": 1.0
        },
        {
            "start_logit": 9.875,
            "end_logit": -1.3515625,
            "text": "AA",
            "probability": 1.6033649444580078e-05
        },
        {
            "start_logit": -1.423828125,
            "end_logit": 9.6796875,
            "text": "AA",
            "probability": 1.233816146850586e-05
        },
        {
            "start_logit": -5.328125,
            "end_logit": 9.6796875,
            "text": "UAAA",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.875,
            "end_logit": -6.5546875,
            "text": "AAUAAA) nearby the 3' end of pre-mRNA is required for poly(A) synthesis.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.875,
            "end_logit": -6.85546875,
            "text": "AAUAAA) nearby the 3' end",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.875,
            "end_logit": -7.23828125,
            "text": "AAUAAA) nearby the 3",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.875,
            "end_logit": -7.33984375,
            "text": "AAUAAA) nearby the 3' end of pre",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.875,
            "end_logit": -7.39453125,
            "text": "AAUAAA) nearby the 3' end of pre-mRNA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.875,
            "end_logit": -7.4375,
            "text": "AAUA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.875,
            "end_logit": -7.5078125,
            "text": "AAUAAA)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.875,
            "end_logit": -7.70703125,
            "text": "AAUAAA) nearby the 3'",
            "probability": 0.0
        },
        {
            "start_logit": 9.875,
            "end_logit": -7.79296875,
            "text": "AAUAAA) nearby the 3' end of",
            "probability": 0.0
        },
        {
            "start_logit": -7.6484375,
            "end_logit": 9.6796875,
            "text": "A polyadenylation signal (AAUAAA",
            "probability": 0.0
        },
        {
            "start_logit": -7.6796875,
            "end_logit": 9.6796875,
            "text": "polyadenylation signal (AAUAAA",
            "probability": 0.0
        },
        {
            "start_logit": -7.6875,
            "end_logit": 9.6796875,
            "text": "(AAUAAA",
            "probability": 0.0
        },
        {
            "start_logit": 9.875,
            "end_logit": -8.0234375,
            "text": "AAUAAA) nearby the 3' end of pre-",
            "probability": 0.0
        },
        {
            "start_logit": 9.875,
            "end_logit": -8.0625,
            "text": "AAUAAA) nearby the 3' end of pre-mRNA is",
            "probability": 0.0
        },
        {
            "start_logit": -1.423828125,
            "end_logit": -6.5546875,
            "text": "AA) nearby the 3' end of pre-mRNA is required for poly(A) synthesis.",
            "probability": 0.0
        },
        {
            "start_logit": -1.423828125,
            "end_logit": -6.85546875,
            "text": "AA) nearby the 3' end",
            "probability": 0.0
        }
    ],
    "5e764647c6a8763d23000016_1": [
        {
            "start_logit": -2.203125,
            "end_logit": 0.278564453125,
            "text": "cholera vaccine CVD 103-HgR",
            "probability": 0.79541015625
        },
        {
            "start_logit": -4.59375,
            "end_logit": 0.278564453125,
            "text": "CVD 103-HgR",
            "probability": 0.07281494140625
        },
        {
            "start_logit": -2.203125,
            "end_logit": -2.720703125,
            "text": "cholera",
            "probability": 0.039764404296875
        },
        {
            "start_logit": -2.203125,
            "end_logit": -2.802734375,
            "text": "cholera vaccine CVD 103-HgR (Orochol, Mutachol), the first genetically modified organism (GMO) used as vaccine, was in its time (launched 1993",
            "probability": 0.0364990234375
        },
        {
            "start_logit": -2.283203125,
            "end_logit": -2.802734375,
            "text": "1993",
            "probability": 0.03375244140625
        },
        {
            "start_logit": -7.2578125,
            "end_logit": 0.278564453125,
            "text": "HgR",
            "probability": 0.00507354736328125
        },
        {
            "start_logit": -7.65625,
            "end_logit": 0.278564453125,
            "text": "The oral live cholera vaccine CVD 103-HgR",
            "probability": 0.0034084320068359375
        },
        {
            "start_logit": -4.59375,
            "end_logit": -2.802734375,
            "text": "CVD 103-HgR (Orochol, Mutachol), the first genetically modified organism (GMO) used as vaccine, was in its time (launched 1993",
            "probability": 0.0033416748046875
        },
        {
            "start_logit": -7.6796875,
            "end_logit": 0.278564453125,
            "text": "-HgR",
            "probability": 0.003330230712890625
        },
        {
            "start_logit": -8.046875,
            "end_logit": 0.278564453125,
            "text": "live cholera vaccine CVD 103-HgR",
            "probability": 0.0023059844970703125
        },
        {
            "start_logit": -2.283203125,
            "end_logit": -7.03515625,
            "text": "1993, Switzerland) the ideal cholera vaccine: single-dose, protective efficacy of 80-100%",
            "probability": 0.0004892349243164062
        },
        {
            "start_logit": -6.60546875,
            "end_logit": -2.802734375,
            "text": "launched 1993",
            "probability": 0.0004489421844482422
        },
        {
            "start_logit": -2.203125,
            "end_logit": -7.234375,
            "text": "cholera vaccine CVD 103-HgR (Orochol, Mutachol",
            "probability": 0.00043487548828125
        },
        {
            "start_logit": -2.203125,
            "end_logit": -7.265625,
            "text": "cholera vaccine CVD 103-HgR (Orochol, Mutachol)",
            "probability": 0.0004215240478515625
        },
        {
            "start_logit": -2.203125,
            "end_logit": -7.30859375,
            "text": "cholera vaccine CVD 103",
            "probability": 0.00040221214294433594
        },
        {
            "start_logit": -2.203125,
            "end_logit": -7.30859375,
            "text": "cholera vaccine CVD 103-HgR (Orochol",
            "probability": 0.00040221214294433594
        },
        {
            "start_logit": -2.203125,
            "end_logit": -7.3984375,
            "text": "cholera vaccine",
            "probability": 0.00036907196044921875
        },
        {
            "start_logit": -2.283203125,
            "end_logit": -7.453125,
            "text": "1993, Switzerland) the ideal cholera vaccine: single-dose, protective efficacy of 80",
            "probability": 0.00032329559326171875
        },
        {
            "start_logit": -2.283203125,
            "end_logit": -7.52734375,
            "text": "1993, Switzerland) the ideal cholera vaccine: single-dose, protective efficacy of 80-100",
            "probability": 0.0002989768981933594
        },
        {
            "start_logit": -2.203125,
            "end_logit": -7.63671875,
            "text": "cholera vaccine CVD 103-HgR (Orochol, Mutachol), the first genetically modified organism (GMO) used as vaccine, was in its time (launched 1993, Switzerland",
            "probability": 0.00028967857360839844
        }
    ],
    "5319a7d2b166e2b806000029_1": [
        {
            "start_logit": 6.10546875,
            "end_logit": 4.76953125,
            "text": "hsc70-interacting protein (CHIP)",
            "probability": 0.9990234375
        },
        {
            "start_logit": 6.10546875,
            "end_logit": -2.603515625,
            "text": "hsc70-interacting protein (CHIP) can",
            "probability": 0.0006260871887207031
        },
        {
            "start_logit": 6.10546875,
            "end_logit": -4.1015625,
            "text": "hsc70-interacting protein",
            "probability": 0.00013971328735351562
        },
        {
            "start_logit": 6.10546875,
            "end_logit": -4.5078125,
            "text": "hsc70-interacting protein (CHIP) can remodel mature aryl hydrocarbon receptor (AhR) complexes and mediate ubiquitination of both the AhR and the 90 kDa heat-shock protein (hsp90) in",
            "probability": 9.304285049438477e-05
        },
        {
            "start_logit": -3.33203125,
            "end_logit": 4.76953125,
            "text": "Carboxyl terminus of hsc70-interacting protein (CHIP)",
            "probability": 7.963180541992188e-05
        },
        {
            "start_logit": 6.10546875,
            "end_logit": -5.265625,
            "text": "hsc70-interacting protein (CHIP) can remodel mature aryl hydrocarbon receptor (AhR) complexes and",
            "probability": 4.392862319946289e-05
        },
        {
            "start_logit": 6.10546875,
            "end_logit": -5.61328125,
            "text": "hsc",
            "probability": 3.0875205993652344e-05
        },
        {
            "start_logit": 6.10546875,
            "end_logit": -6.25390625,
            "text": "hsc70-interacting protein (CHIP) can remodel mature aryl hydrocarbon receptor (AhR) complexes and mediate ubiquitination of both the AhR and the 90 kDa heat-shock protein (hsp90) in vitro",
            "probability": 1.633167266845703e-05
        },
        {
            "start_logit": 6.10546875,
            "end_logit": -6.59765625,
            "text": "hsc70-interacting protein (CHIP",
            "probability": 1.1563301086425781e-05
        },
        {
            "start_logit": 6.10546875,
            "end_logit": -6.828125,
            "text": "hsc70",
            "probability": 9.238719940185547e-06
        },
        {
            "start_logit": 6.10546875,
            "end_logit": -7.29296875,
            "text": "hsc70-interacting protein (",
            "probability": 5.781650543212891e-06
        },
        {
            "start_logit": -5.96875,
            "end_logit": 4.76953125,
            "text": ")",
            "probability": 5.662441253662109e-06
        },
        {
            "start_logit": 6.10546875,
            "end_logit": -7.34765625,
            "text": "hsc70-interacting protein (CHIP) can remodel mature aryl hydrocarbon receptor (AhR)",
            "probability": 5.4836273193359375e-06
        },
        {
            "start_logit": -6.09765625,
            "end_logit": 4.76953125,
            "text": "CHIP)",
            "probability": 5.0067901611328125e-06
        },
        {
            "start_logit": 6.10546875,
            "end_logit": -7.48828125,
            "text": "hsc70-interacting",
            "probability": 4.76837158203125e-06
        },
        {
            "start_logit": 6.10546875,
            "end_logit": -7.6015625,
            "text": "hsc70-interacting protein (CHIP) can remodel mature aryl hydrocarbon receptor (AhR) complexes and mediate ubiquitination of both",
            "probability": 4.231929779052734e-06
        },
        {
            "start_logit": 6.10546875,
            "end_logit": -7.609375,
            "text": "hsc70-interacting protein (CHIP) can remodel mature aryl hydrocarbon receptor (AhR) complexes and mediate ubiquitination of both the AhR and the 90 kDa heat-shock protein (hsp90)",
            "probability": 4.231929779052734e-06
        },
        {
            "start_logit": 6.10546875,
            "end_logit": -7.65234375,
            "text": "hsc70-",
            "probability": 4.0531158447265625e-06
        },
        {
            "start_logit": 6.10546875,
            "end_logit": -7.66015625,
            "text": "hsc70-interacting protein (CHIP) can remodel mature aryl hydrocarbon receptor (",
            "probability": 3.993511199951172e-06
        },
        {
            "start_logit": -6.3515625,
            "end_logit": 4.76953125,
            "text": "of hsc70-interacting protein (CHIP)",
            "probability": 3.933906555175781e-06
        }
    ],
    "5313058de3eabad02100000e_1": [
        {
            "start_logit": 8.8203125,
            "end_logit": 8.578125,
            "text": "lumbosacral transitional vertebrae",
            "probability": 1.0
        },
        {
            "start_logit": 8.8203125,
            "end_logit": -2.23046875,
            "text": "lumbosacral",
            "probability": 2.014636993408203e-05
        },
        {
            "start_logit": -3.044921875,
            "end_logit": 8.578125,
            "text": "vertebrae",
            "probability": 6.973743438720703e-06
        },
        {
            "start_logit": -5.265625,
            "end_logit": 8.578125,
            "text": "transitional vertebrae",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": -6.6015625,
            "end_logit": 8.578125,
            "text": "lumbago in lumbosacral transitional vertebrae",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.15625,
            "end_logit": 8.578125,
            "text": "in lumbosacral transitional vertebrae",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.8203125,
            "end_logit": -7.53515625,
            "text": "lumbosacral transitional vertebrae, is an important cause of low back pain in young patients.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.59375,
            "end_logit": 8.578125,
            "text": "form of lumbago in lumbosacral transitional vertebrae",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.64453125,
            "end_logit": 8.578125,
            "text": "of lumbago in lumbosacral transitional vertebrae",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.8203125,
            "end_logit": -7.90625,
            "text": "lumbosacral transitional vertebrae,",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.8203125,
            "end_logit": -8.046875,
            "text": "lumbosacral transitional",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.8203125,
            "end_logit": -8.109375,
            "text": "lumbosacral transitional vertebrae, is an important cause of low back pain in",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.87890625,
            "end_logit": 8.578125,
            "text": "Bertolotti's syndrome (BS), a form of lumbago in lumbosacral transitional vertebrae",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.90625,
            "end_logit": 8.578125,
            "text": "a form of lumbago in lumbosacral transitional vertebrae",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.9765625,
            "end_logit": 8.578125,
            "text": ", a form of lumbago in lumbosacral transitional vertebrae",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.98046875,
            "end_logit": 8.578125,
            "text": "(BS), a form of lumbago in lumbosacral transitional vertebrae",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.99609375,
            "end_logit": 8.578125,
            "text": "tolotti's syndrome (BS), a form of lumbago in lumbosacral transitional vertebrae",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.015625,
            "end_logit": 8.578125,
            "text": "BS), a form of lumbago in lumbosacral transitional vertebrae",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.015625,
            "end_logit": 8.578125,
            "text": "), a form of lumbago in lumbosacral transitional vertebrae",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.6015625,
            "end_logit": -2.23046875,
            "text": "lumbago in lumbosacral",
            "probability": 0.0
        }
    ],
    "5313058de3eabad02100000e_2": [
        {
            "start_logit": 8.0078125,
            "end_logit": 8.234375,
            "text": "lumbosacral",
            "probability": 1.0
        },
        {
            "start_logit": -7.80859375,
            "end_logit": 8.234375,
            "text": "Patients with Bertolotti's syndrome have characteristic lumbosacral",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.8359375,
            "end_logit": 8.234375,
            "text": "with Bertolotti's syndrome have characteristic lumbosacral",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.87890625,
            "end_logit": 8.234375,
            "text": "characteristic lumbosacral",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.89453125,
            "end_logit": 8.234375,
            "text": "Bertolotti's syndrome have characteristic lumbosacral",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.921875,
            "end_logit": 8.234375,
            "text": "tolotti's syndrome have characteristic lumbosacral",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.96875,
            "end_logit": 8.234375,
            "text": "syndrome have characteristic lumbosacral",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.98046875,
            "end_logit": 8.234375,
            "text": "s syndrome have characteristic lumbosacral",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.98046875,
            "end_logit": 8.234375,
            "text": "lotti's syndrome have characteristic lumbosacral",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.9921875,
            "end_logit": 8.234375,
            "text": "'s syndrome have characteristic lumbosacral",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.9921875,
            "end_logit": 8.234375,
            "text": "have characteristic lumbosacral",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.99609375,
            "end_logit": 8.234375,
            "text": "ti's syndrome have characteristic lumbosacral",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.0078125,
            "end_logit": -7.82421875,
            "text": "lumbosacral anomalies and often have severe sciatica.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.0078125,
            "end_logit": -7.95703125,
            "text": "lumbosacral anomalies",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.95703125,
            "end_logit": -7.82421875,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.80859375,
            "end_logit": -7.82421875,
            "text": "Patients with Bertolotti's syndrome have characteristic lumbosacral anomalies and often have severe sciatica.",
            "probability": 0.0
        },
        {
            "start_logit": -7.8359375,
            "end_logit": -7.82421875,
            "text": "with Bertolotti's syndrome have characteristic lumbosacral anomalies and often have severe sciatica.",
            "probability": 0.0
        },
        {
            "start_logit": -7.87890625,
            "end_logit": -7.82421875,
            "text": "characteristic lumbosacral anomalies and often have severe sciatica.",
            "probability": 0.0
        },
        {
            "start_logit": -7.89453125,
            "end_logit": -7.82421875,
            "text": "Bertolotti's syndrome have characteristic lumbosacral anomalies and often have severe sciatica.",
            "probability": 0.0
        },
        {
            "start_logit": -7.921875,
            "end_logit": -7.82421875,
            "text": "tolotti's syndrome have characteristic lumbosacral anomalies and often have severe sciatica.",
            "probability": 0.0
        }
    ],
    "5313058de3eabad02100000e_3": [
        {
            "start_logit": 9.6875,
            "end_logit": 9.5703125,
            "text": "lumbosacral junction",
            "probability": 1.0
        },
        {
            "start_logit": -1.67578125,
            "end_logit": 9.5703125,
            "text": "junction",
            "probability": 1.1682510375976562e-05
        },
        {
            "start_logit": 9.6875,
            "end_logit": -1.8359375,
            "text": "lumbosacral",
            "probability": 1.1205673217773438e-05
        },
        {
            "start_logit": 9.6875,
            "end_logit": -2.6640625,
            "text": "lumbosacral junction pseudarticulation",
            "probability": 4.887580871582031e-06
        },
        {
            "start_logit": 9.6875,
            "end_logit": -6.9140625,
            "text": "lumbosacral junction pseud",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.6875,
            "end_logit": -7.83984375,
            "text": "lumbosacral junction pseudartic",
            "probability": 0.0
        },
        {
            "start_logit": -7.88671875,
            "end_logit": 9.5703125,
            "text": "Radiofrequency sensory ablation as a treatment for symptomatic unilateral lumbosacral junction",
            "probability": 0.0
        },
        {
            "start_logit": -7.91015625,
            "end_logit": 9.5703125,
            "text": "unilateral lumbosacral junction",
            "probability": 0.0
        },
        {
            "start_logit": 9.6875,
            "end_logit": -8.03125,
            "text": "lumbosacral junction pseudarticulation (Bertolotti's syndrome): a case report.",
            "probability": 0.0
        },
        {
            "start_logit": -7.9140625,
            "end_logit": 9.5703125,
            "text": "symptomatic unilateral lumbosacral junction",
            "probability": 0.0
        },
        {
            "start_logit": -7.94140625,
            "end_logit": 9.5703125,
            "text": "treatment for symptomatic unilateral lumbosacral junction",
            "probability": 0.0
        },
        {
            "start_logit": -7.94921875,
            "end_logit": 9.5703125,
            "text": "for symptomatic unilateral lumbosacral junction",
            "probability": 0.0
        },
        {
            "start_logit": -7.96484375,
            "end_logit": 9.5703125,
            "text": "sensory ablation as a treatment for symptomatic unilateral lumbosacral junction",
            "probability": 0.0
        },
        {
            "start_logit": -1.67578125,
            "end_logit": -2.6640625,
            "text": "junction pseudarticulation",
            "probability": 0.0
        },
        {
            "start_logit": -1.67578125,
            "end_logit": -6.9140625,
            "text": "junction pseud",
            "probability": 0.0
        },
        {
            "start_logit": -6.8203125,
            "end_logit": -2.6640625,
            "text": "pseudarticulation",
            "probability": 0.0
        },
        {
            "start_logit": -1.67578125,
            "end_logit": -7.83984375,
            "text": "junction pseudartic",
            "probability": 0.0
        },
        {
            "start_logit": -1.67578125,
            "end_logit": -8.03125,
            "text": "junction pseudarticulation (Bertolotti's syndrome): a case report.",
            "probability": 0.0
        },
        {
            "start_logit": -7.88671875,
            "end_logit": -1.8359375,
            "text": "Radiofrequency sensory ablation as a treatment for symptomatic unilateral lumbosacral",
            "probability": 0.0
        },
        {
            "start_logit": -7.91015625,
            "end_logit": -1.8359375,
            "text": "unilateral lumbosacral",
            "probability": 0.0
        }
    ],
    "5313058de3eabad02100000e_4": [
        {
            "start_logit": 3.09375,
            "end_logit": 5.32421875,
            "text": "spine",
            "probability": 1.0
        },
        {
            "start_logit": -6.3046875,
            "end_logit": 5.32421875,
            "text": ". The association of that variant with low back pain and the change in the biomechanical properties of the lumbar spine",
            "probability": 8.219480514526367e-05
        },
        {
            "start_logit": -6.51171875,
            "end_logit": 5.32421875,
            "text": "lumbar spine",
            "probability": 6.711483001708984e-05
        },
        {
            "start_logit": -1.2783203125,
            "end_logit": -0.2369384765625,
            "text": "fifth lumbar vertebra",
            "probability": 4.83393669128418e-05
        },
        {
            "start_logit": -7.28125,
            "end_logit": 5.32421875,
            "text": "enlarged transverse process can form a joint or fusion with the sacrum or ilium. The association of that variant with low back pain and the change in the biomechanical properties of the lumbar spine",
            "probability": 3.11732292175293e-05
        },
        {
            "start_logit": -7.4296875,
            "end_logit": 5.32421875,
            "text": "transverse process can form a joint or fusion with the sacrum or ilium. The association of that variant with low back pain and the change in the biomechanical properties of the lumbar spine",
            "probability": 2.6702880859375e-05
        },
        {
            "start_logit": -7.625,
            "end_logit": 5.32421875,
            "text": "the lumbar spine",
            "probability": 2.2113323211669922e-05
        },
        {
            "start_logit": -7.8359375,
            "end_logit": 5.32421875,
            "text": "an enlarged transverse process can form a joint or fusion with the sacrum or ilium. The association of that variant with low back pain and the change in the biomechanical properties of the lumbar spine",
            "probability": 1.7762184143066406e-05
        },
        {
            "start_logit": 3.09375,
            "end_logit": -6.68359375,
            "text": "spine is called Bertolotti's syndrome.",
            "probability": 6.020069122314453e-06
        },
        {
            "start_logit": -3.578125,
            "end_logit": -0.2369384765625,
            "text": "Lumbosacral transitional vertebra is an anatomical variation of the fifth lumbar vertebra",
            "probability": 4.887580871582031e-06
        },
        {
            "start_logit": -5.5234375,
            "end_logit": -0.2369384765625,
            "text": "the fifth lumbar vertebra",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -6.4296875,
            "end_logit": -0.2369384765625,
            "text": "lumbar vertebra",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.11328125,
            "end_logit": -0.2369384765625,
            "text": "vertebra",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.58984375,
            "end_logit": -0.2369384765625,
            "text": "transitional vertebra is an anatomical variation of the fifth lumbar vertebra",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.625,
            "end_logit": -0.2369384765625,
            "text": "variation of the fifth lumbar vertebra",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.2783203125,
            "end_logit": -6.68359375,
            "text": "fifth lumbar vertebra in which an enlarged transverse process can form a joint or fusion with the sacrum or ilium.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.7890625,
            "end_logit": -0.2369384765625,
            "text": "of the fifth lumbar vertebra",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.796875,
            "end_logit": -0.2369384765625,
            "text": "anatomical variation of the fifth lumbar vertebra",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.2783203125,
            "end_logit": -7.3203125,
            "text": "fifth lumbar vertebra in which an enlarged transverse process can",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.2783203125,
            "end_logit": -7.453125,
            "text": "fifth lumbar",
            "probability": 5.960464477539063e-08
        }
    ],
    "5313058de3eabad02100000e_5": [
        {
            "start_logit": 6.734375,
            "end_logit": 6.37890625,
            "text": "lumbosacral vertebrae",
            "probability": 1.0
        },
        {
            "start_logit": 6.734375,
            "end_logit": -4.85546875,
            "text": "lumbosacral",
            "probability": 1.3232231140136719e-05
        },
        {
            "start_logit": -4.96484375,
            "end_logit": 6.37890625,
            "text": "vertebrae",
            "probability": 8.344650268554688e-06
        },
        {
            "start_logit": -5.1171875,
            "end_logit": 6.37890625,
            "text": "Transitional lumbosacral vertebrae",
            "probability": 7.212162017822266e-06
        },
        {
            "start_logit": 6.734375,
            "end_logit": -7.76171875,
            "text": "lumbosacral vertebrae and",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 6.734375,
            "end_logit": -7.7890625,
            "text": "lumbosacral vertebrae and low back pain: diagnostic pitfalls and management of Bertolotti's syndrome.",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 6.734375,
            "end_logit": -7.98046875,
            "text": "lumbosacral vertebrae and low back pain",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 6.734375,
            "end_logit": -8.0234375,
            "text": "lumbosacral vertebrae and low back",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -5.1171875,
            "end_logit": -4.85546875,
            "text": "Transitional lumbosacral",
            "probability": 0.0
        },
        {
            "start_logit": -4.96484375,
            "end_logit": -7.76171875,
            "text": "vertebrae and",
            "probability": 0.0
        },
        {
            "start_logit": -4.96484375,
            "end_logit": -7.7890625,
            "text": "vertebrae and low back pain: diagnostic pitfalls and management of Bertolotti's syndrome.",
            "probability": 0.0
        },
        {
            "start_logit": -5.1171875,
            "end_logit": -7.76171875,
            "text": "Transitional lumbosacral vertebrae and",
            "probability": 0.0
        },
        {
            "start_logit": -5.1171875,
            "end_logit": -7.7890625,
            "text": "Transitional lumbosacral vertebrae and low back pain: diagnostic pitfalls and management of Bertolotti's syndrome.",
            "probability": 0.0
        },
        {
            "start_logit": -4.96484375,
            "end_logit": -7.98046875,
            "text": "vertebrae and low back pain",
            "probability": 0.0
        },
        {
            "start_logit": -4.96484375,
            "end_logit": -8.0234375,
            "text": "vertebrae and low back",
            "probability": 0.0
        },
        {
            "start_logit": -5.1171875,
            "end_logit": -7.98046875,
            "text": "Transitional lumbosacral vertebrae and low back pain",
            "probability": 0.0
        },
        {
            "start_logit": -5.1171875,
            "end_logit": -8.0234375,
            "text": "Transitional lumbosacral vertebrae and low back",
            "probability": 0.0
        },
        {
            "start_logit": -6.73046875,
            "end_logit": -7.7890625,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.66796875,
            "end_logit": -7.7890625,
            "text": "low back pain: diagnostic pitfalls and management of Bertolotti's syndrome.",
            "probability": 0.0
        },
        {
            "start_logit": -7.66796875,
            "end_logit": -7.98046875,
            "text": "low back pain",
            "probability": 0.0
        }
    ],
    "5313058de3eabad02100000e_6": [
        {
            "start_logit": 9.5078125,
            "end_logit": 9.421875,
            "text": "facet joint",
            "probability": 1.0
        },
        {
            "start_logit": -1.9873046875,
            "end_logit": 9.421875,
            "text": "joint",
            "probability": 1.0132789611816406e-05
        },
        {
            "start_logit": 9.5078125,
            "end_logit": -2.1875,
            "text": "facet",
            "probability": 9.000301361083984e-06
        },
        {
            "start_logit": 9.5078125,
            "end_logit": -5.41015625,
            "text": "facet joint contralateral to a unilateral anomalous lumbosacral",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.5546875,
            "end_logit": 9.421875,
            "text": "the facet joint",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6796875,
            "end_logit": 9.421875,
            "text": "Case report of surgically treated mechanical low back pain from the facet joint",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.84375,
            "end_logit": 9.421875,
            "text": "of surgically treated mechanical low back pain from the facet joint",
            "probability": 0.0
        },
        {
            "start_logit": 9.5078125,
            "end_logit": -7.9375,
            "text": "facet joint contralateral to a unilateral anomalous lumbosacral articulation (Bertolotti's syndrome).",
            "probability": 0.0
        },
        {
            "start_logit": -7.890625,
            "end_logit": 9.421875,
            "text": "surgically treated mechanical low back pain from the facet joint",
            "probability": 0.0
        },
        {
            "start_logit": 9.5078125,
            "end_logit": -8.0234375,
            "text": "facet joint contralateral",
            "probability": 0.0
        },
        {
            "start_logit": -7.94140625,
            "end_logit": 9.421875,
            "text": "low back pain from the facet joint",
            "probability": 0.0
        },
        {
            "start_logit": -7.9453125,
            "end_logit": 9.421875,
            "text": "from the facet joint",
            "probability": 0.0
        },
        {
            "start_logit": 9.5078125,
            "end_logit": -8.0390625,
            "text": "facet joint contralateral to a unilateral anomalous lumbosacral articulation",
            "probability": 0.0
        },
        {
            "start_logit": -7.984375,
            "end_logit": 9.421875,
            "text": "mechanical low back pain from the facet joint",
            "probability": 0.0
        },
        {
            "start_logit": -1.9873046875,
            "end_logit": -5.41015625,
            "text": "joint contralateral to a unilateral anomalous lumbosacral",
            "probability": 0.0
        },
        {
            "start_logit": -7.5546875,
            "end_logit": -2.1875,
            "text": "the facet",
            "probability": 0.0
        },
        {
            "start_logit": -7.6796875,
            "end_logit": -2.1875,
            "text": "Case report of surgically treated mechanical low back pain from the facet",
            "probability": 0.0
        },
        {
            "start_logit": -1.9873046875,
            "end_logit": -7.9375,
            "text": "joint contralateral to a unilateral anomalous lumbosacral articulation (Bertolotti's syndrome).",
            "probability": 0.0
        },
        {
            "start_logit": -1.9873046875,
            "end_logit": -8.0234375,
            "text": "joint contralateral",
            "probability": 0.0
        },
        {
            "start_logit": -1.9873046875,
            "end_logit": -8.0390625,
            "text": "joint contralateral to a unilateral anomalous lumbosacral articulation",
            "probability": 0.0
        }
    ],
    "5313058de3eabad02100000e_7": [
        {
            "start_logit": 9.171875,
            "end_logit": 9.21875,
            "text": "facet joint",
            "probability": 1.0
        },
        {
            "start_logit": -2.333984375,
            "end_logit": 9.21875,
            "text": "joint",
            "probability": 1.0073184967041016e-05
        },
        {
            "start_logit": 9.171875,
            "end_logit": -2.759765625,
            "text": "facet",
            "probability": 6.318092346191406e-06
        },
        {
            "start_logit": -4.97265625,
            "end_logit": 9.21875,
            "text": "L6-S1 facet joint",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -6.79296875,
            "end_logit": 9.21875,
            "text": "S1 facet joint",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.171875,
            "end_logit": -7.01171875,
            "text": "facet joint contralateral to an anomalous lumbosacral articulation.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.50390625,
            "end_logit": 9.21875,
            "text": "symptomatic L6-S1 facet joint",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.171875,
            "end_logit": -7.46875,
            "text": "facet joint contralateral",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.171875,
            "end_logit": -7.5078125,
            "text": "facet joint contralateral to an anomalous lumbosacral",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.171875,
            "end_logit": -7.640625,
            "text": "facet joint contralateral to an anomalous lumbosacral articulation",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.73828125,
            "end_logit": 9.21875,
            "text": "-S1 facet joint",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.796875,
            "end_logit": 9.21875,
            "text": "a symptomatic L6-S1 facet joint",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.83984375,
            "end_logit": 9.21875,
            "text": "Repeated fluoroscopically guided injections implicated a symptomatic L6-S1 facet joint",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.171875,
            "end_logit": -7.93359375,
            "text": "facet joint contralateral to",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0390625,
            "end_logit": 9.21875,
            "text": "fluoroscopically guided injections implicated a symptomatic L6-S1 facet joint",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0625,
            "end_logit": 9.21875,
            "text": "injections implicated a symptomatic L6-S1 facet joint",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0703125,
            "end_logit": 9.21875,
            "text": "guided injections implicated a symptomatic L6-S1 facet joint",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.109375,
            "end_logit": 9.21875,
            "text": "implicated a symptomatic L6-S1 facet joint",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -4.97265625,
            "end_logit": -2.759765625,
            "text": "L6-S1 facet",
            "probability": 0.0
        },
        {
            "start_logit": -2.333984375,
            "end_logit": -7.01171875,
            "text": "joint contralateral to an anomalous lumbosacral articulation.",
            "probability": 0.0
        }
    ],
    "5313058de3eabad02100000e_8": [
        {
            "start_logit": 9.140625,
            "end_logit": 8.3125,
            "text": "lumbosacral transitional vertebrae",
            "probability": 1.0
        },
        {
            "start_logit": 9.140625,
            "end_logit": -1.740234375,
            "text": "lumbosacral",
            "probability": 4.297494888305664e-05
        },
        {
            "start_logit": -3.41015625,
            "end_logit": 8.3125,
            "text": "vertebrae",
            "probability": 3.5762786865234375e-06
        },
        {
            "start_logit": -5.7421875,
            "end_logit": 8.3125,
            "text": "transitional vertebrae",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -6.34765625,
            "end_logit": 8.3125,
            "text": "with lumbosacral transitional vertebrae",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.140625,
            "end_logit": -7.2421875,
            "text": "lumbosacral transitional vertebrae.",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.140625,
            "end_logit": -8.03125,
            "text": "lumbosacral transitional",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.3046875,
            "end_logit": 8.3125,
            "text": "back pain with lumbosacral transitional vertebrae",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.3671875,
            "end_logit": 8.3125,
            "text": "association of back pain with lumbosacral transitional vertebrae",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6640625,
            "end_logit": 8.3125,
            "text": "of back pain with lumbosacral transitional vertebrae",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6953125,
            "end_logit": 8.3125,
            "text": "Bertolotti's syndrome refers to the association of back pain with lumbosacral transitional vertebrae",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.7890625,
            "end_logit": 8.3125,
            "text": "pain with lumbosacral transitional vertebrae",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.8359375,
            "end_logit": 8.3125,
            "text": "the association of back pain with lumbosacral transitional vertebrae",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.8671875,
            "end_logit": 8.3125,
            "text": "tolotti's syndrome refers to the association of back pain with lumbosacral transitional vertebrae",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.91796875,
            "end_logit": 8.3125,
            "text": "syndrome refers to the association of back pain with lumbosacral transitional vertebrae",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.9296875,
            "end_logit": 8.3125,
            "text": "lotti's syndrome refers to the association of back pain with lumbosacral transitional vertebrae",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.9453125,
            "end_logit": 8.3125,
            "text": "refers to the association of back pain with lumbosacral transitional vertebrae",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.9453125,
            "end_logit": 8.3125,
            "text": "ti's syndrome refers to the association of back pain with lumbosacral transitional vertebrae",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.97265625,
            "end_logit": 8.3125,
            "text": "'s syndrome refers to the association of back pain with lumbosacral transitional vertebrae",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.34765625,
            "end_logit": -1.740234375,
            "text": "with lumbosacral",
            "probability": 0.0
        }
    ],
    "554140ad182542114d000003_1": [
        {
            "start_logit": 9.8359375,
            "end_logit": 9.65625,
            "text": "mpMoRFsDB",
            "probability": 1.0
        },
        {
            "start_logit": 9.8359375,
            "end_logit": -1.5078125,
            "text": "mpM",
            "probability": 1.4066696166992188e-05
        },
        {
            "start_logit": -1.60546875,
            "end_logit": 9.65625,
            "text": "DB",
            "probability": 1.0609626770019531e-05
        },
        {
            "start_logit": -5.453125,
            "end_logit": 9.65625,
            "text": "oRFsDB",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.8359375,
            "end_logit": -6.390625,
            "text": "mpMoRFs",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.3671875,
            "end_logit": 9.65625,
            "text": "FsDB",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.8359375,
            "end_logit": -7.640625,
            "text": "mpMoR",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8359375,
            "end_logit": -7.9921875,
            "text": "mpMoRFsDB:",
            "probability": 0.0
        },
        {
            "start_logit": 9.8359375,
            "end_logit": -8.1171875,
            "text": "mpMoRFsDB: a",
            "probability": 0.0
        },
        {
            "start_logit": 9.8359375,
            "end_logit": -8.1796875,
            "text": "mpMoRFsDB: a database of molecular recognition features in membrane proteins",
            "probability": 0.0
        },
        {
            "start_logit": -1.60546875,
            "end_logit": -7.9921875,
            "text": "DB:",
            "probability": 0.0
        },
        {
            "start_logit": -1.60546875,
            "end_logit": -8.1171875,
            "text": "DB: a",
            "probability": 0.0
        },
        {
            "start_logit": -1.60546875,
            "end_logit": -8.1796875,
            "text": "DB: a database of molecular recognition features in membrane proteins",
            "probability": 0.0
        },
        {
            "start_logit": -5.453125,
            "end_logit": -6.390625,
            "text": "oRFs",
            "probability": 0.0
        },
        {
            "start_logit": -6.3671875,
            "end_logit": -6.390625,
            "text": "Fs",
            "probability": 0.0
        },
        {
            "start_logit": -5.453125,
            "end_logit": -7.640625,
            "text": "oR",
            "probability": 0.0
        },
        {
            "start_logit": -5.453125,
            "end_logit": -7.9921875,
            "text": "oRFsDB:",
            "probability": 0.0
        },
        {
            "start_logit": -5.453125,
            "end_logit": -8.1171875,
            "text": "oRFsDB: a",
            "probability": 0.0
        },
        {
            "start_logit": -5.453125,
            "end_logit": -8.1796875,
            "text": "oRFsDB: a database of molecular recognition features in membrane proteins",
            "probability": 0.0
        },
        {
            "start_logit": -6.3671875,
            "end_logit": -7.9921875,
            "text": "FsDB:",
            "probability": 0.0
        }
    ],
    "554140ad182542114d000003_2": [
        {
            "start_logit": 9.765625,
            "end_logit": 9.6171875,
            "text": "mpMoRFsDB",
            "probability": 1.0
        },
        {
            "start_logit": 9.765625,
            "end_logit": -1.685546875,
            "text": "mpM",
            "probability": 1.239776611328125e-05
        },
        {
            "start_logit": -1.697265625,
            "end_logit": 9.6171875,
            "text": "DB",
            "probability": 1.0609626770019531e-05
        },
        {
            "start_logit": -5.49609375,
            "end_logit": 9.6171875,
            "text": "oRFsDB",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.765625,
            "end_logit": -6.32421875,
            "text": "mpMoRFs",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.56640625,
            "end_logit": 9.6171875,
            "text": "FsDB",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.765625,
            "end_logit": -6.88671875,
            "text": "mpMoRFsDB provides valuable information related to disorder-based protein-protein interactions",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.765625,
            "end_logit": -7.6640625,
            "text": "mpMoRFsDB provides",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.765625,
            "end_logit": -7.7421875,
            "text": "mpMoR",
            "probability": 0.0
        },
        {
            "start_logit": 9.765625,
            "end_logit": -7.8984375,
            "text": "mpMoRFsDB provides valuable information related to disorder-based protein-protein interactions in",
            "probability": 0.0
        },
        {
            "start_logit": 9.765625,
            "end_logit": -7.9453125,
            "text": "mpMoRFsDB provides valuable information related to disorder",
            "probability": 0.0
        },
        {
            "start_logit": 9.765625,
            "end_logit": -7.9453125,
            "text": "mpMoRFsDB provides valuable information related to disorder-based protein-",
            "probability": 0.0
        },
        {
            "start_logit": 9.765625,
            "end_logit": -7.953125,
            "text": "mpMoRFsDB provides valuable information related to disorder-",
            "probability": 0.0
        },
        {
            "start_logit": 9.765625,
            "end_logit": -7.98046875,
            "text": "mpMoRFsDB provides valuable information related to disorder-based protein-protein",
            "probability": 0.0
        },
        {
            "start_logit": 9.765625,
            "end_logit": -8.0078125,
            "text": "mpMoRFsDB provides valuable information related",
            "probability": 0.0
        },
        {
            "start_logit": 9.765625,
            "end_logit": -8.046875,
            "text": "mpMoRFsDB provides valuable",
            "probability": 0.0
        },
        {
            "start_logit": 9.765625,
            "end_logit": -8.0703125,
            "text": "mpMoRFsDB provides valuable information related to disorder-based",
            "probability": 0.0
        },
        {
            "start_logit": 9.765625,
            "end_logit": -8.09375,
            "text": "mpMoRFsDB provides valuable information related to disorder-based protein-protein interactions in membrane proteins",
            "probability": 0.0
        },
        {
            "start_logit": 9.765625,
            "end_logit": -8.125,
            "text": "mpMoRFsDB provides valuable information related to disorder-based protein-protein interactions in membrane",
            "probability": 0.0
        },
        {
            "start_logit": -1.697265625,
            "end_logit": -6.88671875,
            "text": "DB provides valuable information related to disorder-based protein-protein interactions",
            "probability": 0.0
        }
    ],
    "554140ad182542114d000003_3": [
        {
            "start_logit": 9.875,
            "end_logit": 9.6875,
            "text": "mpMoRFsDB",
            "probability": 1.0
        },
        {
            "start_logit": 9.875,
            "end_logit": -1.41015625,
            "text": "mpM",
            "probability": 1.519918441772461e-05
        },
        {
            "start_logit": -1.529296875,
            "end_logit": 9.6875,
            "text": "DB",
            "probability": 1.1146068572998047e-05
        },
        {
            "start_logit": -5.46875,
            "end_logit": 9.6875,
            "text": "oRFsDB",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.875,
            "end_logit": -6.51953125,
            "text": "mpMoRFs",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.41796875,
            "end_logit": 9.6875,
            "text": "FsDB",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.875,
            "end_logit": -7.66015625,
            "text": "mpMoR",
            "probability": 0.0
        },
        {
            "start_logit": 9.875,
            "end_logit": -7.953125,
            "text": "mpMoRFsDB:",
            "probability": 0.0
        },
        {
            "start_logit": 9.875,
            "end_logit": -7.9765625,
            "text": "mpMoRFsDB: a database of molecular recognition features in membrane proteins.",
            "probability": 0.0
        },
        {
            "start_logit": 9.875,
            "end_logit": -8.109375,
            "text": "mpMoRFsDB: a",
            "probability": 0.0
        },
        {
            "start_logit": -1.529296875,
            "end_logit": -7.953125,
            "text": "DB:",
            "probability": 0.0
        },
        {
            "start_logit": -1.529296875,
            "end_logit": -7.9765625,
            "text": "DB: a database of molecular recognition features in membrane proteins.",
            "probability": 0.0
        },
        {
            "start_logit": -1.529296875,
            "end_logit": -8.109375,
            "text": "DB: a",
            "probability": 0.0
        },
        {
            "start_logit": -5.46875,
            "end_logit": -6.51953125,
            "text": "oRFs",
            "probability": 0.0
        },
        {
            "start_logit": -6.41796875,
            "end_logit": -6.51953125,
            "text": "Fs",
            "probability": 0.0
        },
        {
            "start_logit": -5.46875,
            "end_logit": -7.66015625,
            "text": "oR",
            "probability": 0.0
        },
        {
            "start_logit": -5.46875,
            "end_logit": -7.953125,
            "text": "oRFsDB:",
            "probability": 0.0
        },
        {
            "start_logit": -5.46875,
            "end_logit": -7.9765625,
            "text": "oRFsDB: a database of molecular recognition features in membrane proteins.",
            "probability": 0.0
        },
        {
            "start_logit": -5.46875,
            "end_logit": -8.109375,
            "text": "oRFsDB: a",
            "probability": 0.0
        },
        {
            "start_logit": -6.41796875,
            "end_logit": -7.953125,
            "text": "FsDB:",
            "probability": 0.0
        }
    ],
    "5c632542e842deac6700000d_1": [
        {
            "start_logit": 9.390625,
            "end_logit": 9.78125,
            "text": "magnetic resonance imaging",
            "probability": 1.0
        },
        {
            "start_logit": -1.1181640625,
            "end_logit": 9.78125,
            "text": "imaging",
            "probability": 2.7298927307128906e-05
        },
        {
            "start_logit": 9.390625,
            "end_logit": -2.43359375,
            "text": "magnetic",
            "probability": 4.947185516357422e-06
        },
        {
            "start_logit": -6.44921875,
            "end_logit": 9.78125,
            "text": "of magnetic resonance imaging",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.46875,
            "end_logit": 9.78125,
            "text": "resonance imaging",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.56640625,
            "end_logit": 9.78125,
            "text": ". CVG-ID is now a less reported and possibly under-recognized syndrome. Here, we report a patient with CVG-ID that was diagnosed using the novel approach of magnetic resonance imaging",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.5703125,
            "end_logit": 9.78125,
            "text": ". Here, we report a patient with CVG-ID that was diagnosed using the novel approach of magnetic resonance imaging",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.1796875,
            "end_logit": 9.78125,
            "text": "novel approach of magnetic resonance imaging",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.390625,
            "end_logit": -6.8046875,
            "text": "magnetic resonance imaging and we conduct a systematic review of all patients reported in the last 60 years, discussing the core clinical features of this syndrome.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.390625,
            "end_logit": -7.2109375,
            "text": "magnetic resonance",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.390625,
            "end_logit": -7.36328125,
            "text": "magnetic resonance imaging and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.87109375,
            "end_logit": 9.78125,
            "text": "Here, we report a patient with CVG-ID that was diagnosed using the novel approach of magnetic resonance imaging",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.390625,
            "end_logit": -7.84765625,
            "text": "magnetic resonance imaging and we",
            "probability": 0.0
        },
        {
            "start_logit": -1.1181640625,
            "end_logit": -6.8046875,
            "text": "imaging and we conduct a systematic review of all patients reported in the last 60 years, discussing the core clinical features of this syndrome.",
            "probability": 0.0
        },
        {
            "start_logit": -1.1181640625,
            "end_logit": -7.36328125,
            "text": "imaging and",
            "probability": 0.0
        },
        {
            "start_logit": -6.44921875,
            "end_logit": -2.43359375,
            "text": "of magnetic",
            "probability": 0.0
        },
        {
            "start_logit": -1.1181640625,
            "end_logit": -7.84765625,
            "text": "imaging and we",
            "probability": 0.0
        },
        {
            "start_logit": -6.56640625,
            "end_logit": -2.43359375,
            "text": ". CVG-ID is now a less reported and possibly under-recognized syndrome. Here, we report a patient with CVG-ID that was diagnosed using the novel approach of magnetic",
            "probability": 0.0
        },
        {
            "start_logit": -6.5703125,
            "end_logit": -2.43359375,
            "text": ". Here, we report a patient with CVG-ID that was diagnosed using the novel approach of magnetic",
            "probability": 0.0
        },
        {
            "start_logit": -7.1796875,
            "end_logit": -2.43359375,
            "text": "novel approach of magnetic",
            "probability": 0.0
        }
    ],
    "5c632542e842deac6700000d_2": [
        {
            "start_logit": 9.515625,
            "end_logit": 9.7578125,
            "text": "magnetic resonance imaging",
            "probability": 1.0
        },
        {
            "start_logit": -1.2119140625,
            "end_logit": 9.7578125,
            "text": "imaging",
            "probability": 2.1755695343017578e-05
        },
        {
            "start_logit": 9.515625,
            "end_logit": -2.189453125,
            "text": "magnetic",
            "probability": 6.4373016357421875e-06
        },
        {
            "start_logit": -6.91796875,
            "end_logit": 9.7578125,
            "text": "resonance imaging",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.0390625,
            "end_logit": 9.7578125,
            "text": "of magnetic resonance imaging",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.515625,
            "end_logit": -7.13671875,
            "text": "magnetic resonance",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.515625,
            "end_logit": -7.34765625,
            "text": "magnetic resonance imaging and we conduct a systematic review of all patients reported in the last 60 years, discussing the core clinical features of this syndrome.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.765625,
            "end_logit": 9.7578125,
            "text": "novel approach of magnetic resonance imaging",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.90234375,
            "end_logit": 9.7578125,
            "text": "patient with CVG-ID that was diagnosed using the novel approach of magnetic resonance imaging",
            "probability": 0.0
        },
        {
            "start_logit": -7.921875,
            "end_logit": 9.7578125,
            "text": ", we report a patient with CVG-ID that was diagnosed using the novel approach of magnetic resonance imaging",
            "probability": 0.0
        },
        {
            "start_logit": -7.93359375,
            "end_logit": 9.7578125,
            "text": "a patient with CVG-ID that was diagnosed using the novel approach of magnetic resonance imaging",
            "probability": 0.0
        },
        {
            "start_logit": -7.95703125,
            "end_logit": 9.7578125,
            "text": "Here, we report a patient with CVG-ID that was diagnosed using the novel approach of magnetic resonance imaging",
            "probability": 0.0
        },
        {
            "start_logit": 9.515625,
            "end_logit": -7.78515625,
            "text": "magnetic resonance imaging and",
            "probability": 0.0
        },
        {
            "start_logit": 9.515625,
            "end_logit": -8.015625,
            "text": "magnetic resonance imaging and we",
            "probability": 0.0
        },
        {
            "start_logit": 9.515625,
            "end_logit": -8.125,
            "text": "magnetic resonance imaging and we conduct a systematic review of all patients reported in the last 60 years",
            "probability": 0.0
        },
        {
            "start_logit": 9.515625,
            "end_logit": -8.1328125,
            "text": "magnetic resonance imaging and we conduct a systematic review of all patients reported in the last",
            "probability": 0.0
        },
        {
            "start_logit": 9.515625,
            "end_logit": -8.1328125,
            "text": "magnetic resonance imaging and we conduct a systematic review of all patients reported in the last 60",
            "probability": 0.0
        },
        {
            "start_logit": -1.2119140625,
            "end_logit": -7.34765625,
            "text": "imaging and we conduct a systematic review of all patients reported in the last 60 years, discussing the core clinical features of this syndrome.",
            "probability": 0.0
        },
        {
            "start_logit": -1.2119140625,
            "end_logit": -7.78515625,
            "text": "imaging and",
            "probability": 0.0
        },
        {
            "start_logit": -1.2119140625,
            "end_logit": -8.015625,
            "text": "imaging and we",
            "probability": 0.0
        }
    ],
    "587e3129c32c812009000002_1": [
        {
            "start_logit": 9.8046875,
            "end_logit": 9.6875,
            "text": "traseR",
            "probability": 1.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -1.5869140625,
            "text": "tra",
            "probability": 1.2636184692382812e-05
        },
        {
            "start_logit": -1.5234375,
            "end_logit": 9.6875,
            "text": "R",
            "probability": 1.1920928955078125e-05
        },
        {
            "start_logit": -5.97265625,
            "end_logit": 9.6875,
            "text": "seR",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -6.7578125,
            "text": "trase",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -8.015625,
            "text": "traseR: an",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -8.0859375,
            "text": "traseR:",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -8.1171875,
            "text": "traseR: an R package for performing trait-associated SNP enrichment analysis in genomic intervals",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -8.1171875,
            "text": "traseR: an R package",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -8.1328125,
            "text": "traseR: an R package for",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -8.2109375,
            "text": "traseR: an R package for performing trait-associated SNP enrichment analysis in genomic",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -8.2109375,
            "text": "traseR: an R",
            "probability": 0.0
        },
        {
            "start_logit": -1.5234375,
            "end_logit": -8.015625,
            "text": "R: an",
            "probability": 0.0
        },
        {
            "start_logit": -1.5234375,
            "end_logit": -8.0859375,
            "text": "R:",
            "probability": 0.0
        },
        {
            "start_logit": -1.5234375,
            "end_logit": -8.1171875,
            "text": "R: an R package for performing trait-associated SNP enrichment analysis in genomic intervals",
            "probability": 0.0
        },
        {
            "start_logit": -1.5234375,
            "end_logit": -8.1171875,
            "text": "R: an R package",
            "probability": 0.0
        },
        {
            "start_logit": -1.5234375,
            "end_logit": -8.1328125,
            "text": "R: an R package for",
            "probability": 0.0
        },
        {
            "start_logit": -1.5234375,
            "end_logit": -8.2109375,
            "text": "R: an R package for performing trait-associated SNP enrichment analysis in genomic",
            "probability": 0.0
        },
        {
            "start_logit": -1.5234375,
            "end_logit": -8.2109375,
            "text": "R: an R",
            "probability": 0.0
        },
        {
            "start_logit": -5.97265625,
            "end_logit": -6.7578125,
            "text": "se",
            "probability": 0.0
        }
    ],
    "587e3129c32c812009000002_2": [
        {
            "start_logit": 9.75,
            "end_logit": 9.6484375,
            "text": "traseR",
            "probability": 1.0
        },
        {
            "start_logit": 9.75,
            "end_logit": -1.7255859375,
            "text": "tra",
            "probability": 1.138448715209961e-05
        },
        {
            "start_logit": -1.634765625,
            "end_logit": 9.6484375,
            "text": "R",
            "probability": 1.1324882507324219e-05
        },
        {
            "start_logit": -6.57421875,
            "end_logit": 9.6484375,
            "text": "seR",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.75,
            "end_logit": -6.79296875,
            "text": "trase",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.53125,
            "end_logit": 9.6484375,
            "text": "present traseR",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.796875,
            "end_logit": 9.6484375,
            "text": "Here, we present traseR",
            "probability": 0.0
        },
        {
            "start_logit": -7.8046875,
            "end_logit": 9.6484375,
            "text": "we present traseR",
            "probability": 0.0
        },
        {
            "start_logit": 9.75,
            "end_logit": -7.96875,
            "text": "traseR,",
            "probability": 0.0
        },
        {
            "start_logit": 9.75,
            "end_logit": -8.125,
            "text": "traseR, an easy-to-use R Bioconductor package that",
            "probability": 0.0
        },
        {
            "start_logit": 9.75,
            "end_logit": -8.15625,
            "text": "traseR, an easy-to-use R Bioconductor package that performs enrichment analyses of trait-associated SNPs in",
            "probability": 0.0
        },
        {
            "start_logit": 9.75,
            "end_logit": -8.171875,
            "text": "traseR, an easy-to-use R Bioconductor package that performs enrichment analyses of trait-associated SNPs in arbitrary genomic intervals with",
            "probability": 0.0
        },
        {
            "start_logit": 9.75,
            "end_logit": -8.171875,
            "text": "traseR, an easy-to-use",
            "probability": 0.0
        },
        {
            "start_logit": 9.75,
            "end_logit": -8.1875,
            "text": "traseR, an easy-to",
            "probability": 0.0
        },
        {
            "start_logit": 9.75,
            "end_logit": -8.1875,
            "text": "traseR, an easy-to-use R Bioconductor package that performs enrichment analyses of trait-associated SNPs in arbitrary",
            "probability": 0.0
        },
        {
            "start_logit": 9.75,
            "end_logit": -8.203125,
            "text": "traseR, an easy-to-use R Bioconductor package that performs enrichment analyses of trait-associated SNPs in arbitrary genomic intervals with flexible options, including testing method, type of background and",
            "probability": 0.0
        },
        {
            "start_logit": 9.75,
            "end_logit": -8.203125,
            "text": "traseR, an easy-to-use R Bioconductor package that performs enrichment analyses of trait-associated SNPs in arbitrary genomic intervals",
            "probability": 0.0
        },
        {
            "start_logit": 9.75,
            "end_logit": -8.2109375,
            "text": "traseR, an easy-to-",
            "probability": 0.0
        },
        {
            "start_logit": 9.75,
            "end_logit": -8.21875,
            "text": "traseR, an easy-to-use R Bioconductor package that performs enrichment analyses of trait-associated SNPs in arbitrary genomic",
            "probability": 0.0
        },
        {
            "start_logit": 9.75,
            "end_logit": -8.2265625,
            "text": "traseR, an easy-to-use R Bioconductor package that performs enrichment analyses of trait-associated SNPs in arbitrary genomic intervals with flexible options, including testing method, type of",
            "probability": 0.0
        }
    ],
    "587e3129c32c812009000002_3": [
        {
            "start_logit": 9.7421875,
            "end_logit": 9.6640625,
            "text": "traseR",
            "probability": 1.0
        },
        {
            "start_logit": -1.5966796875,
            "end_logit": 9.6640625,
            "text": "R",
            "probability": 1.1920928955078125e-05
        },
        {
            "start_logit": 9.7421875,
            "end_logit": -1.7333984375,
            "text": "tra",
            "probability": 1.1205673217773438e-05
        },
        {
            "start_logit": -6.38671875,
            "end_logit": 9.6640625,
            "text": "seR",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.7421875,
            "end_logit": -6.83984375,
            "text": "trase",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.75,
            "end_logit": 9.6640625,
            "text": "present traseR",
            "probability": 0.0
        },
        {
            "start_logit": 9.7421875,
            "end_logit": -7.93359375,
            "text": "traseR,",
            "probability": 0.0
        },
        {
            "start_logit": -7.87890625,
            "end_logit": 9.6640625,
            "text": "we present traseR",
            "probability": 0.0
        },
        {
            "start_logit": 9.7421875,
            "end_logit": -8.140625,
            "text": "traseR, an easy-to-use R Bioconductor package that",
            "probability": 0.0
        },
        {
            "start_logit": 9.7421875,
            "end_logit": -8.15625,
            "text": "traseR, an easy-to-use",
            "probability": 0.0
        },
        {
            "start_logit": 9.7421875,
            "end_logit": -8.1640625,
            "text": "traseR, an easy-to-use R Bioconductor package that performs enrichment analyses of trait-associated SNPs in",
            "probability": 0.0
        },
        {
            "start_logit": 9.7421875,
            "end_logit": -8.1796875,
            "text": "traseR, an easy-to-use R Bioconductor package that performs enrichment analyses of trait-associated SNPs in arbitrary genomic intervals with",
            "probability": 0.0
        },
        {
            "start_logit": 9.7421875,
            "end_logit": -8.1875,
            "text": "traseR, an easy-to-use R Bioconductor package that performs enrichment analyses of trait-associated SNPs in arbitrary genomic intervals with flexible options, including testing method, type of background and",
            "probability": 0.0
        },
        {
            "start_logit": 9.7421875,
            "end_logit": -8.1953125,
            "text": "traseR, an easy-to",
            "probability": 0.0
        },
        {
            "start_logit": 9.7421875,
            "end_logit": -8.203125,
            "text": "traseR, an easy-to-",
            "probability": 0.0
        },
        {
            "start_logit": 9.7421875,
            "end_logit": -8.2109375,
            "text": "traseR, an",
            "probability": 0.0
        },
        {
            "start_logit": 9.7421875,
            "end_logit": -8.2109375,
            "text": "traseR, an easy-to-use R Bioconductor package that performs enrichment analyses of trait-associated SNPs in arbitrary genomic intervals",
            "probability": 0.0
        },
        {
            "start_logit": 9.7421875,
            "end_logit": -8.2109375,
            "text": "traseR, an easy-to-use R Bioconductor package that performs enrichment analyses of trait-associated SNPs in arbitrary",
            "probability": 0.0
        },
        {
            "start_logit": 9.7421875,
            "end_logit": -8.21875,
            "text": "traseR, an easy-to-use R Bioconductor package that performs enrichment analyses of trait-associated SNPs in arbitrary genomic intervals with flexible options, including testing method, type of",
            "probability": 0.0
        },
        {
            "start_logit": 9.7421875,
            "end_logit": -8.2265625,
            "text": "traseR, an easy-to-use R Bioconductor package that performs enrichment analyses of trait-associated SNPs in arbitrary genomic intervals with flexible options, including testing method,",
            "probability": 0.0
        }
    ],
    "587e3129c32c812009000002_4": [
        {
            "start_logit": 9.796875,
            "end_logit": 9.65625,
            "text": "traseR",
            "probability": 1.0
        },
        {
            "start_logit": 9.796875,
            "end_logit": -1.6123046875,
            "text": "tra",
            "probability": 1.2814998626708984e-05
        },
        {
            "start_logit": -1.607421875,
            "end_logit": 9.65625,
            "text": "R",
            "probability": 1.1146068572998047e-05
        },
        {
            "start_logit": -6.390625,
            "end_logit": 9.65625,
            "text": "seR",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.796875,
            "end_logit": -6.83203125,
            "text": "trase",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.50390625,
            "end_logit": 9.65625,
            "text": "present traseR",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.80859375,
            "end_logit": 9.65625,
            "text": "Here, we present traseR",
            "probability": 0.0
        },
        {
            "start_logit": 9.796875,
            "end_logit": -7.9609375,
            "text": "traseR,",
            "probability": 0.0
        },
        {
            "start_logit": -7.82421875,
            "end_logit": 9.65625,
            "text": "we present traseR",
            "probability": 0.0
        },
        {
            "start_logit": 9.796875,
            "end_logit": -8.09375,
            "text": "traseR, an easy-to-use R Bioconductor package that",
            "probability": 0.0
        },
        {
            "start_logit": 9.796875,
            "end_logit": -8.09375,
            "text": "traseR, an easy-to-use",
            "probability": 0.0
        },
        {
            "start_logit": 9.796875,
            "end_logit": -8.1015625,
            "text": "traseR, an easy-to-use R Bioconductor package that performs enrichment analyses of trait-associated SNPs in arbitrary genomic intervals with",
            "probability": 0.0
        },
        {
            "start_logit": 9.796875,
            "end_logit": -8.1015625,
            "text": "traseR, an easy-to-use R Bioconductor package that performs enrichment analyses of trait-associated SNPs in",
            "probability": 0.0
        },
        {
            "start_logit": 9.796875,
            "end_logit": -8.109375,
            "text": "traseR, an easy-to-use R Bioconductor package that performs enrichment analyses of trait-associated SNPs in arbitrary genomic intervals with flexible options, including testing method, type of background and",
            "probability": 0.0
        },
        {
            "start_logit": 9.796875,
            "end_logit": -8.1328125,
            "text": "traseR, an easy-to-use R Bioconductor package that performs enrichment analyses of trait-associated SNPs in arbitrary genomic intervals with flexible options, including testing method, type of",
            "probability": 0.0
        },
        {
            "start_logit": 9.796875,
            "end_logit": -8.140625,
            "text": "traseR, an easy-to",
            "probability": 0.0
        },
        {
            "start_logit": 9.796875,
            "end_logit": -8.140625,
            "text": "traseR, an easy-to-use R Bioconductor package that performs enrichment analyses of trait-associated SNPs in arbitrary",
            "probability": 0.0
        },
        {
            "start_logit": 9.796875,
            "end_logit": -8.171875,
            "text": "traseR, an easy-to-",
            "probability": 0.0
        },
        {
            "start_logit": -7.50390625,
            "end_logit": -1.6123046875,
            "text": "present tra",
            "probability": 0.0
        },
        {
            "start_logit": -7.80859375,
            "end_logit": -1.6123046875,
            "text": "Here, we present tra",
            "probability": 0.0
        }
    ],
    "587e3129c32c812009000002_5": [
        {
            "start_logit": 9.8671875,
            "end_logit": 9.7109375,
            "text": "traseR",
            "probability": 1.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -1.4267578125,
            "text": "tra",
            "probability": 1.4483928680419922e-05
        },
        {
            "start_logit": -1.4658203125,
            "end_logit": 9.7109375,
            "text": "R",
            "probability": 1.1920928955078125e-05
        },
        {
            "start_logit": -5.640625,
            "end_logit": 9.7109375,
            "text": "seR",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -7.02734375,
            "text": "trase",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -7.9765625,
            "text": "traseR:",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.015625,
            "text": "traseR: an",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.0390625,
            "text": "traseR: an R package for performing trait-associated SNP enrichment analysis in genomic intervals.",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.1328125,
            "text": "traseR: an R package",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.15625,
            "text": "traseR: an R package for",
            "probability": 0.0
        },
        {
            "start_logit": -1.4658203125,
            "end_logit": -7.9765625,
            "text": "R:",
            "probability": 0.0
        },
        {
            "start_logit": -1.4658203125,
            "end_logit": -8.015625,
            "text": "R: an",
            "probability": 0.0
        },
        {
            "start_logit": -1.4658203125,
            "end_logit": -8.0390625,
            "text": "R: an R package for performing trait-associated SNP enrichment analysis in genomic intervals.",
            "probability": 0.0
        },
        {
            "start_logit": -1.4658203125,
            "end_logit": -8.1328125,
            "text": "R: an R package",
            "probability": 0.0
        },
        {
            "start_logit": -1.4658203125,
            "end_logit": -8.15625,
            "text": "R: an R package for",
            "probability": 0.0
        },
        {
            "start_logit": -5.640625,
            "end_logit": -7.02734375,
            "text": "se",
            "probability": 0.0
        },
        {
            "start_logit": -5.640625,
            "end_logit": -7.9765625,
            "text": "seR:",
            "probability": 0.0
        },
        {
            "start_logit": -5.640625,
            "end_logit": -8.015625,
            "text": "seR: an",
            "probability": 0.0
        },
        {
            "start_logit": -5.640625,
            "end_logit": -8.0390625,
            "text": "seR: an R package for performing trait-associated SNP enrichment analysis in genomic intervals.",
            "probability": 0.0
        },
        {
            "start_logit": -5.640625,
            "end_logit": -8.1328125,
            "text": "seR: an R package",
            "probability": 0.0
        }
    ],
    "587e3129c32c812009000002_6": [
        {
            "start_logit": 9.8671875,
            "end_logit": 9.7109375,
            "text": "traseR",
            "probability": 1.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -1.4267578125,
            "text": "tra",
            "probability": 1.4483928680419922e-05
        },
        {
            "start_logit": -1.4658203125,
            "end_logit": 9.7109375,
            "text": "R",
            "probability": 1.1920928955078125e-05
        },
        {
            "start_logit": -5.640625,
            "end_logit": 9.7109375,
            "text": "seR",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -7.02734375,
            "text": "trase",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -7.9765625,
            "text": "traseR:",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.015625,
            "text": "traseR: an",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.0390625,
            "text": "traseR: an R package for performing trait-associated SNP enrichment analysis in genomic intervals.",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.1328125,
            "text": "traseR: an R package",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.15625,
            "text": "traseR: an R package for",
            "probability": 0.0
        },
        {
            "start_logit": -1.4658203125,
            "end_logit": -7.9765625,
            "text": "R:",
            "probability": 0.0
        },
        {
            "start_logit": -1.4658203125,
            "end_logit": -8.015625,
            "text": "R: an",
            "probability": 0.0
        },
        {
            "start_logit": -1.4658203125,
            "end_logit": -8.0390625,
            "text": "R: an R package for performing trait-associated SNP enrichment analysis in genomic intervals.",
            "probability": 0.0
        },
        {
            "start_logit": -1.4658203125,
            "end_logit": -8.1328125,
            "text": "R: an R package",
            "probability": 0.0
        },
        {
            "start_logit": -1.4658203125,
            "end_logit": -8.15625,
            "text": "R: an R package for",
            "probability": 0.0
        },
        {
            "start_logit": -5.640625,
            "end_logit": -7.02734375,
            "text": "se",
            "probability": 0.0
        },
        {
            "start_logit": -5.640625,
            "end_logit": -7.9765625,
            "text": "seR:",
            "probability": 0.0
        },
        {
            "start_logit": -5.640625,
            "end_logit": -8.015625,
            "text": "seR: an",
            "probability": 0.0
        },
        {
            "start_logit": -5.640625,
            "end_logit": -8.0390625,
            "text": "seR: an R package for performing trait-associated SNP enrichment analysis in genomic intervals.",
            "probability": 0.0
        },
        {
            "start_logit": -5.640625,
            "end_logit": -8.1328125,
            "text": "seR: an R package",
            "probability": 0.0
        }
    ],
    "587e3129c32c812009000002_7": [
        {
            "start_logit": 9.796875,
            "end_logit": 9.65625,
            "text": "traseR",
            "probability": 1.0
        },
        {
            "start_logit": 9.796875,
            "end_logit": -1.6123046875,
            "text": "tra",
            "probability": 1.2814998626708984e-05
        },
        {
            "start_logit": -1.607421875,
            "end_logit": 9.65625,
            "text": "R",
            "probability": 1.1146068572998047e-05
        },
        {
            "start_logit": -6.390625,
            "end_logit": 9.65625,
            "text": "seR",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.796875,
            "end_logit": -6.83203125,
            "text": "trase",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.50390625,
            "end_logit": 9.65625,
            "text": "present traseR",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.80859375,
            "end_logit": 9.65625,
            "text": "Here, we present traseR",
            "probability": 0.0
        },
        {
            "start_logit": 9.796875,
            "end_logit": -7.9609375,
            "text": "traseR,",
            "probability": 0.0
        },
        {
            "start_logit": -7.82421875,
            "end_logit": 9.65625,
            "text": "we present traseR",
            "probability": 0.0
        },
        {
            "start_logit": 9.796875,
            "end_logit": -8.09375,
            "text": "traseR, an easy-to-use R Bioconductor package that",
            "probability": 0.0
        },
        {
            "start_logit": 9.796875,
            "end_logit": -8.09375,
            "text": "traseR, an easy-to-use",
            "probability": 0.0
        },
        {
            "start_logit": 9.796875,
            "end_logit": -8.1015625,
            "text": "traseR, an easy-to-use R Bioconductor package that performs enrichment analyses of trait-associated SNPs in arbitrary genomic intervals with",
            "probability": 0.0
        },
        {
            "start_logit": 9.796875,
            "end_logit": -8.1015625,
            "text": "traseR, an easy-to-use R Bioconductor package that performs enrichment analyses of trait-associated SNPs in",
            "probability": 0.0
        },
        {
            "start_logit": 9.796875,
            "end_logit": -8.109375,
            "text": "traseR, an easy-to-use R Bioconductor package that performs enrichment analyses of trait-associated SNPs in arbitrary genomic intervals with flexible options, including testing method, type of background and",
            "probability": 0.0
        },
        {
            "start_logit": 9.796875,
            "end_logit": -8.1328125,
            "text": "traseR, an easy-to-use R Bioconductor package that performs enrichment analyses of trait-associated SNPs in arbitrary genomic intervals with flexible options, including testing method, type of",
            "probability": 0.0
        },
        {
            "start_logit": 9.796875,
            "end_logit": -8.140625,
            "text": "traseR, an easy-to",
            "probability": 0.0
        },
        {
            "start_logit": 9.796875,
            "end_logit": -8.140625,
            "text": "traseR, an easy-to-use R Bioconductor package that performs enrichment analyses of trait-associated SNPs in arbitrary",
            "probability": 0.0
        },
        {
            "start_logit": 9.796875,
            "end_logit": -8.171875,
            "text": "traseR, an easy-to-",
            "probability": 0.0
        },
        {
            "start_logit": -7.50390625,
            "end_logit": -1.6123046875,
            "text": "present tra",
            "probability": 0.0
        },
        {
            "start_logit": -7.80859375,
            "end_logit": -1.6123046875,
            "text": "Here, we present tra",
            "probability": 0.0
        }
    ],
    "587e3129c32c812009000002_8": [
        {
            "start_logit": 9.796875,
            "end_logit": 9.6953125,
            "text": "traseR",
            "probability": 1.0
        },
        {
            "start_logit": 9.796875,
            "end_logit": -1.5810546875,
            "text": "tra",
            "probability": 1.2636184692382812e-05
        },
        {
            "start_logit": -1.509765625,
            "end_logit": 9.6953125,
            "text": "R",
            "probability": 1.2218952178955078e-05
        },
        {
            "start_logit": -5.99609375,
            "end_logit": 9.6953125,
            "text": "seR",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.796875,
            "end_logit": -6.6640625,
            "text": "trase",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.796875,
            "end_logit": -7.8359375,
            "text": "traseR R package preloaded with up-to-date collection of trait-associated SNPs are freely available in Bioconductor zhaohui.qin@emory.",
            "probability": 0.0
        },
        {
            "start_logit": -7.7734375,
            "end_logit": 9.6953125,
            "text": "The traseR",
            "probability": 0.0
        },
        {
            "start_logit": 9.796875,
            "end_logit": -7.91015625,
            "text": "traseR R package preloaded with up-to-date collection of trait-associated SNPs are freely available in Bioconductor zhaohui.qin@emory",
            "probability": 0.0
        },
        {
            "start_logit": 9.796875,
            "end_logit": -7.99609375,
            "text": "traseR R package preloaded with up-to-date collection of trait-associated SNPs are freely available in Bioconductor zhaohui.qin@emory.edu",
            "probability": 0.0
        },
        {
            "start_logit": 9.796875,
            "end_logit": -8.1328125,
            "text": "traseR R package",
            "probability": 0.0
        },
        {
            "start_logit": 9.796875,
            "end_logit": -8.1484375,
            "text": "traseR R package preloaded with up-to-date collection of trait-associated SNPs are freely available in Bioconductor zhaohui.qin@emo",
            "probability": 0.0
        },
        {
            "start_logit": 9.796875,
            "end_logit": -8.1796875,
            "text": "traseR R package preloaded with up-to-date collection of trait-associated SNPs are freely available in Bioconductor zhaohui.qin",
            "probability": 0.0
        },
        {
            "start_logit": 9.796875,
            "end_logit": -8.1875,
            "text": "traseR R package preloaded with up-to",
            "probability": 0.0
        },
        {
            "start_logit": 9.796875,
            "end_logit": -8.203125,
            "text": "traseR R package preloaded with up-to-date collection of trait-associated SNPs are freely available",
            "probability": 0.0
        },
        {
            "start_logit": 9.796875,
            "end_logit": -8.2109375,
            "text": "traseR R",
            "probability": 0.0
        },
        {
            "start_logit": 9.796875,
            "end_logit": -8.2265625,
            "text": "traseR R package preloaded with up-to-date collection of trait-associated SNPs are freely available in Bioconductor zhaohui.",
            "probability": 0.0
        },
        {
            "start_logit": -1.509765625,
            "end_logit": -7.8359375,
            "text": "R R package preloaded with up-to-date collection of trait-associated SNPs are freely available in Bioconductor zhaohui.qin@emory.",
            "probability": 0.0
        },
        {
            "start_logit": -7.7734375,
            "end_logit": -1.5810546875,
            "text": "The tra",
            "probability": 0.0
        },
        {
            "start_logit": -1.509765625,
            "end_logit": -7.91015625,
            "text": "R R package preloaded with up-to-date collection of trait-associated SNPs are freely available in Bioconductor zhaohui.qin@emory",
            "probability": 0.0
        },
        {
            "start_logit": -1.509765625,
            "end_logit": -7.99609375,
            "text": "R R package preloaded with up-to-date collection of trait-associated SNPs are freely available in Bioconductor zhaohui.qin@emory.edu",
            "probability": 0.0
        }
    ],
    "587e1bfdfc7e8dd84f000002_1": [
        {
            "start_logit": 9.8515625,
            "end_logit": 9.7265625,
            "text": "GBshape",
            "probability": 1.0
        },
        {
            "start_logit": 9.8515625,
            "end_logit": -1.4580078125,
            "text": "GBs",
            "probability": 1.3828277587890625e-05
        },
        {
            "start_logit": -1.4248046875,
            "end_logit": 9.7265625,
            "text": "e",
            "probability": 1.2695789337158203e-05
        },
        {
            "start_logit": -5.8046875,
            "end_logit": 9.7265625,
            "text": "hape",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.8515625,
            "end_logit": -7.03125,
            "text": "GBshap",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8515625,
            "end_logit": -7.96875,
            "text": "GBshape:",
            "probability": 0.0
        },
        {
            "start_logit": 9.8515625,
            "end_logit": -8.2109375,
            "text": "GBshape: a",
            "probability": 0.0
        },
        {
            "start_logit": -1.4248046875,
            "end_logit": -7.96875,
            "text": "e:",
            "probability": 0.0
        },
        {
            "start_logit": -1.4248046875,
            "end_logit": -8.2109375,
            "text": "e: a",
            "probability": 0.0
        },
        {
            "start_logit": -5.8046875,
            "end_logit": -7.03125,
            "text": "hap",
            "probability": 0.0
        },
        {
            "start_logit": -5.8046875,
            "end_logit": -7.96875,
            "text": "hape:",
            "probability": 0.0
        },
        {
            "start_logit": -5.8046875,
            "end_logit": -8.2109375,
            "text": "hape: a",
            "probability": 0.0
        }
    ],
    "587e1bfdfc7e8dd84f000002_2": [
        {
            "start_logit": 9.4609375,
            "end_logit": 9.796875,
            "text": "GBshape",
            "probability": 1.0
        },
        {
            "start_logit": -1.162109375,
            "end_logit": 9.796875,
            "text": "e",
            "probability": 2.4497509002685547e-05
        },
        {
            "start_logit": 9.4609375,
            "end_logit": -2.162109375,
            "text": "GBs",
            "probability": 6.4373016357421875e-06
        },
        {
            "start_logit": -5.20703125,
            "end_logit": 9.796875,
            "text": "hape",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -7.14453125,
            "end_logit": 9.796875,
            "text": "Our Genome Browser for DNA shape annotations (GBshape",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.4609375,
            "end_logit": -6.83203125,
            "text": "GBshape; freely available at http://rohslab.cmb.usc.edu",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.4609375,
            "end_logit": -6.984375,
            "text": "GBshap",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.39453125,
            "end_logit": 9.796875,
            "text": "(GBshape",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.48046875,
            "end_logit": 9.796875,
            "text": "Genome Browser for DNA shape annotations (GBshape",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.4609375,
            "end_logit": -7.34375,
            "text": "GBshape; freely available at http://rohslab.cmb.usc.edu/GBshape/",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.4609375,
            "end_logit": -7.375,
            "text": "GBshape; freely available at http://rohslab.cmb.us",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.4609375,
            "end_logit": -7.5703125,
            "text": "GBshape; freely available at http://rohslab.cmb.usc",
            "probability": 0.0
        },
        {
            "start_logit": 9.4609375,
            "end_logit": -7.58984375,
            "text": "GBshape; freely available at http://rohslab.cmb.usc.",
            "probability": 0.0
        },
        {
            "start_logit": 9.4609375,
            "end_logit": -7.60546875,
            "text": "GBshape; freely available at http://rohslab.cmb.",
            "probability": 0.0
        },
        {
            "start_logit": 9.4609375,
            "end_logit": -7.703125,
            "text": "GBshape; freely available at http://rohslab.cmb.usc.edu/",
            "probability": 0.0
        },
        {
            "start_logit": 9.4609375,
            "end_logit": -7.71484375,
            "text": "GBshape; freely available at http://rohslab.cmb",
            "probability": 0.0
        },
        {
            "start_logit": 9.4609375,
            "end_logit": -7.7578125,
            "text": "GBshape; freely available at http://rohslab",
            "probability": 0.0
        },
        {
            "start_logit": 9.4609375,
            "end_logit": -7.80859375,
            "text": "GBshape; freely available at http://rohslab.",
            "probability": 0.0
        },
        {
            "start_logit": 9.4609375,
            "end_logit": -7.83984375,
            "text": "GBshape; freely available at http://rohslab.cmb.usc.edu/GBshape",
            "probability": 0.0
        },
        {
            "start_logit": -1.162109375,
            "end_logit": -6.83203125,
            "text": "e; freely available at http://rohslab.cmb.usc.edu",
            "probability": 0.0
        }
    ],
    "587e1bfdfc7e8dd84f000002_3": [
        {
            "start_logit": 9.8828125,
            "end_logit": 9.7421875,
            "text": "GBshape",
            "probability": 1.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -1.384765625,
            "text": "GBs",
            "probability": 1.4722347259521484e-05
        },
        {
            "start_logit": -1.3818359375,
            "end_logit": 9.7421875,
            "text": "e",
            "probability": 1.2814998626708984e-05
        },
        {
            "start_logit": -5.65625,
            "end_logit": 9.7421875,
            "text": "hape",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -7.3125,
            "text": "GBshap",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -7.89453125,
            "text": "GBshape:",
            "probability": 0.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -8.15625,
            "text": "GBshape: a genome browser database for DNA shape annotations.",
            "probability": 0.0
        },
        {
            "start_logit": -1.3818359375,
            "end_logit": -7.89453125,
            "text": "e:",
            "probability": 0.0
        },
        {
            "start_logit": -1.3818359375,
            "end_logit": -8.15625,
            "text": "e: a genome browser database for DNA shape annotations.",
            "probability": 0.0
        },
        {
            "start_logit": -5.65625,
            "end_logit": -7.3125,
            "text": "hap",
            "probability": 0.0
        },
        {
            "start_logit": -5.65625,
            "end_logit": -7.89453125,
            "text": "hape:",
            "probability": 0.0
        },
        {
            "start_logit": -5.65625,
            "end_logit": -8.15625,
            "text": "hape: a genome browser database for DNA shape annotations.",
            "probability": 0.0
        },
        {
            "start_logit": -6.859375,
            "end_logit": -8.15625,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.88671875,
            "end_logit": -8.15625,
            "text": "genome browser database for DNA shape annotations.",
            "probability": 0.0
        },
        {
            "start_logit": -7.921875,
            "end_logit": -8.15625,
            "text": "DNA shape annotations.",
            "probability": 0.0
        },
        {
            "start_logit": -7.97265625,
            "end_logit": -8.15625,
            "text": "shape annotations.",
            "probability": 0.0
        },
        {
            "start_logit": -7.99609375,
            "end_logit": -8.15625,
            "text": "browser database for DNA shape annotations.",
            "probability": 0.0
        },
        {
            "start_logit": -8.0234375,
            "end_logit": -8.15625,
            "text": "database for DNA shape annotations.",
            "probability": 0.0
        },
        {
            "start_logit": -8.03125,
            "end_logit": -8.15625,
            "text": "annotations.",
            "probability": 0.0
        },
        {
            "start_logit": -8.0546875,
            "end_logit": -8.15625,
            "text": "for DNA shape annotations.",
            "probability": 0.0
        }
    ],
    "587e1bfdfc7e8dd84f000002_4": [
        {
            "start_logit": 9.8125,
            "end_logit": 9.7109375,
            "text": "GBshape",
            "probability": 1.0
        },
        {
            "start_logit": 9.8125,
            "end_logit": -1.556640625,
            "text": "GBs",
            "probability": 1.2695789337158203e-05
        },
        {
            "start_logit": -1.4560546875,
            "end_logit": 9.7109375,
            "text": "e",
            "probability": 1.2695789337158203e-05
        },
        {
            "start_logit": -5.92578125,
            "end_logit": 9.7109375,
            "text": "hape",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.8125,
            "end_logit": -7.51953125,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as a function of genomic position at nucleotide resolution.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8125,
            "end_logit": -7.5625,
            "text": "GBshap",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8125,
            "end_logit": -7.8828125,
            "text": "GBshape can",
            "probability": 0.0
        },
        {
            "start_logit": 9.8125,
            "end_logit": -7.90234375,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as a function of genomic position at",
            "probability": 0.0
        },
        {
            "start_logit": 9.8125,
            "end_logit": -7.953125,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as a",
            "probability": 0.0
        },
        {
            "start_logit": 9.8125,
            "end_logit": -7.97265625,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in",
            "probability": 0.0
        },
        {
            "start_logit": 9.8125,
            "end_logit": -7.99609375,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format,",
            "probability": 0.0
        },
        {
            "start_logit": 9.8125,
            "end_logit": -8.0078125,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as",
            "probability": 0.0
        },
        {
            "start_logit": 9.8125,
            "end_logit": -8.0234375,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and",
            "probability": 0.0
        },
        {
            "start_logit": 9.8125,
            "end_logit": -8.0234375,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as a function",
            "probability": 0.0
        },
        {
            "start_logit": 9.8125,
            "end_logit": -8.03125,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as a function of genomic position at nucleotide resolution",
            "probability": 0.0
        },
        {
            "start_logit": 9.8125,
            "end_logit": -8.0546875,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as a function of",
            "probability": 0.0
        },
        {
            "start_logit": 9.8125,
            "end_logit": -8.0859375,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as a function of genomic position",
            "probability": 0.0
        },
        {
            "start_logit": 9.8125,
            "end_logit": -8.1015625,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format",
            "probability": 0.0
        },
        {
            "start_logit": 9.8125,
            "end_logit": -8.1015625,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as a function of genomic position at nucleotide",
            "probability": 0.0
        },
        {
            "start_logit": 9.8125,
            "end_logit": -8.1015625,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a",
            "probability": 0.0
        }
    ],
    "587e1bfdfc7e8dd84f000002_5": [
        {
            "start_logit": 9.40625,
            "end_logit": 9.7734375,
            "text": "GBshape",
            "probability": 1.0
        },
        {
            "start_logit": -1.25,
            "end_logit": 9.7734375,
            "text": "e",
            "probability": 2.3365020751953125e-05
        },
        {
            "start_logit": 9.40625,
            "end_logit": -2.279296875,
            "text": "GBs",
            "probability": 5.781650543212891e-06
        },
        {
            "start_logit": -5.734375,
            "end_logit": 9.7734375,
            "text": "hape",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.40625,
            "end_logit": -6.32421875,
            "text": "GBshape; freely available at http://rohslab.cmb.usc.edu",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.02734375,
            "end_logit": 9.7734375,
            "text": "Our Genome Browser for DNA shape annotations (GBshape",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.40625,
            "end_logit": -6.83203125,
            "text": "GBshape; freely available at http://rohslab.cmb.usc.edu/GBshape/",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.39453125,
            "end_logit": 9.7734375,
            "text": "(GBshape",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5234375,
            "end_logit": 9.7734375,
            "text": "Genome Browser for DNA shape annotations (GBshape",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.40625,
            "end_logit": -7.1796875,
            "text": "GBshape; freely available at http://rohslab.cmb.us",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.40625,
            "end_logit": -7.24609375,
            "text": "GBshape; freely available at http://rohslab",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.40625,
            "end_logit": -7.30859375,
            "text": "GBshape; freely available at http://rohslab.cmb.usc",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.40625,
            "end_logit": -7.40625,
            "text": "GBshap",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.40625,
            "end_logit": -7.4296875,
            "text": "GBshape; freely available at http://rohslab.cmb.usc.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.40625,
            "end_logit": -7.49609375,
            "text": "GBshape; freely available at http://rohslab.cmb.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.40625,
            "end_logit": -7.5,
            "text": "GBshape; freely available at http://rohslab.cmb",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.40625,
            "end_logit": -7.55078125,
            "text": "GBshape; freely available at http://rohslab.cmb.usc.edu/",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.40625,
            "end_logit": -7.5703125,
            "text": "GBshape;",
            "probability": 0.0
        },
        {
            "start_logit": 9.40625,
            "end_logit": -7.6328125,
            "text": "GBshape; freely available at http://rohslab.cmb.usc.edu/GBshape",
            "probability": 0.0
        },
        {
            "start_logit": 9.40625,
            "end_logit": -7.65625,
            "text": "GBshape; freely available at http://rohslab.",
            "probability": 0.0
        }
    ],
    "587e1bfdfc7e8dd84f000002_6": [
        {
            "start_logit": 9.8125,
            "end_logit": 9.7109375,
            "text": "GBshape",
            "probability": 1.0
        },
        {
            "start_logit": 9.8125,
            "end_logit": -1.556640625,
            "text": "GBs",
            "probability": 1.2695789337158203e-05
        },
        {
            "start_logit": -1.4560546875,
            "end_logit": 9.7109375,
            "text": "e",
            "probability": 1.2695789337158203e-05
        },
        {
            "start_logit": -5.92578125,
            "end_logit": 9.7109375,
            "text": "hape",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.8125,
            "end_logit": -7.51953125,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as a function of genomic position at nucleotide resolution.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8125,
            "end_logit": -7.5625,
            "text": "GBshap",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8125,
            "end_logit": -7.8828125,
            "text": "GBshape can",
            "probability": 0.0
        },
        {
            "start_logit": 9.8125,
            "end_logit": -7.90234375,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as a function of genomic position at",
            "probability": 0.0
        },
        {
            "start_logit": 9.8125,
            "end_logit": -7.953125,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as a",
            "probability": 0.0
        },
        {
            "start_logit": 9.8125,
            "end_logit": -7.97265625,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in",
            "probability": 0.0
        },
        {
            "start_logit": 9.8125,
            "end_logit": -7.99609375,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format,",
            "probability": 0.0
        },
        {
            "start_logit": 9.8125,
            "end_logit": -8.0078125,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as",
            "probability": 0.0
        },
        {
            "start_logit": 9.8125,
            "end_logit": -8.0234375,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and",
            "probability": 0.0
        },
        {
            "start_logit": 9.8125,
            "end_logit": -8.0234375,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as a function",
            "probability": 0.0
        },
        {
            "start_logit": 9.8125,
            "end_logit": -8.03125,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as a function of genomic position at nucleotide resolution",
            "probability": 0.0
        },
        {
            "start_logit": 9.8125,
            "end_logit": -8.0546875,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as a function of",
            "probability": 0.0
        },
        {
            "start_logit": 9.8125,
            "end_logit": -8.0859375,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as a function of genomic position",
            "probability": 0.0
        },
        {
            "start_logit": 9.8125,
            "end_logit": -8.1015625,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format",
            "probability": 0.0
        },
        {
            "start_logit": 9.8125,
            "end_logit": -8.1015625,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as a function of genomic position at nucleotide",
            "probability": 0.0
        },
        {
            "start_logit": 9.8125,
            "end_logit": -8.1015625,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a",
            "probability": 0.0
        }
    ],
    "587e1bfdfc7e8dd84f000002_7": [
        {
            "start_logit": 9.8125,
            "end_logit": 9.7109375,
            "text": "GBshape",
            "probability": 1.0
        },
        {
            "start_logit": 9.8125,
            "end_logit": -1.556640625,
            "text": "GBs",
            "probability": 1.2695789337158203e-05
        },
        {
            "start_logit": -1.4560546875,
            "end_logit": 9.7109375,
            "text": "e",
            "probability": 1.2695789337158203e-05
        },
        {
            "start_logit": -5.92578125,
            "end_logit": 9.7109375,
            "text": "hape",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.8125,
            "end_logit": -7.51953125,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as a function of genomic position at nucleotide resolution.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8125,
            "end_logit": -7.5625,
            "text": "GBshap",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8125,
            "end_logit": -7.8828125,
            "text": "GBshape can",
            "probability": 0.0
        },
        {
            "start_logit": 9.8125,
            "end_logit": -7.90234375,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as a function of genomic position at",
            "probability": 0.0
        },
        {
            "start_logit": 9.8125,
            "end_logit": -7.953125,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as a",
            "probability": 0.0
        },
        {
            "start_logit": 9.8125,
            "end_logit": -7.97265625,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in",
            "probability": 0.0
        },
        {
            "start_logit": 9.8125,
            "end_logit": -7.99609375,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format,",
            "probability": 0.0
        },
        {
            "start_logit": 9.8125,
            "end_logit": -8.0078125,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as",
            "probability": 0.0
        },
        {
            "start_logit": 9.8125,
            "end_logit": -8.0234375,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and",
            "probability": 0.0
        },
        {
            "start_logit": 9.8125,
            "end_logit": -8.0234375,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as a function",
            "probability": 0.0
        },
        {
            "start_logit": 9.8125,
            "end_logit": -8.03125,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as a function of genomic position at nucleotide resolution",
            "probability": 0.0
        },
        {
            "start_logit": 9.8125,
            "end_logit": -8.0546875,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as a function of",
            "probability": 0.0
        },
        {
            "start_logit": 9.8125,
            "end_logit": -8.0859375,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as a function of genomic position",
            "probability": 0.0
        },
        {
            "start_logit": 9.8125,
            "end_logit": -8.1015625,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format",
            "probability": 0.0
        },
        {
            "start_logit": 9.8125,
            "end_logit": -8.1015625,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as a function of genomic position at nucleotide",
            "probability": 0.0
        },
        {
            "start_logit": 9.8125,
            "end_logit": -8.1015625,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a",
            "probability": 0.0
        }
    ],
    "587e1bfdfc7e8dd84f000002_8": [
        {
            "start_logit": 9.8828125,
            "end_logit": 9.7421875,
            "text": "GBshape",
            "probability": 1.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -1.384765625,
            "text": "GBs",
            "probability": 1.4722347259521484e-05
        },
        {
            "start_logit": -1.3818359375,
            "end_logit": 9.7421875,
            "text": "e",
            "probability": 1.2814998626708984e-05
        },
        {
            "start_logit": -5.65625,
            "end_logit": 9.7421875,
            "text": "hape",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -7.3125,
            "text": "GBshap",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -7.89453125,
            "text": "GBshape:",
            "probability": 0.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -8.15625,
            "text": "GBshape: a genome browser database for DNA shape annotations.",
            "probability": 0.0
        },
        {
            "start_logit": -1.3818359375,
            "end_logit": -7.89453125,
            "text": "e:",
            "probability": 0.0
        },
        {
            "start_logit": -1.3818359375,
            "end_logit": -8.15625,
            "text": "e: a genome browser database for DNA shape annotations.",
            "probability": 0.0
        },
        {
            "start_logit": -5.65625,
            "end_logit": -7.3125,
            "text": "hap",
            "probability": 0.0
        },
        {
            "start_logit": -5.65625,
            "end_logit": -7.89453125,
            "text": "hape:",
            "probability": 0.0
        },
        {
            "start_logit": -5.65625,
            "end_logit": -8.15625,
            "text": "hape: a genome browser database for DNA shape annotations.",
            "probability": 0.0
        },
        {
            "start_logit": -6.859375,
            "end_logit": -8.15625,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.88671875,
            "end_logit": -8.15625,
            "text": "genome browser database for DNA shape annotations.",
            "probability": 0.0
        },
        {
            "start_logit": -7.921875,
            "end_logit": -8.15625,
            "text": "DNA shape annotations.",
            "probability": 0.0
        },
        {
            "start_logit": -7.97265625,
            "end_logit": -8.15625,
            "text": "shape annotations.",
            "probability": 0.0
        },
        {
            "start_logit": -7.99609375,
            "end_logit": -8.15625,
            "text": "browser database for DNA shape annotations.",
            "probability": 0.0
        },
        {
            "start_logit": -8.0234375,
            "end_logit": -8.15625,
            "text": "database for DNA shape annotations.",
            "probability": 0.0
        },
        {
            "start_logit": -8.03125,
            "end_logit": -8.15625,
            "text": "annotations.",
            "probability": 0.0
        },
        {
            "start_logit": -8.0546875,
            "end_logit": -8.15625,
            "text": "for DNA shape annotations.",
            "probability": 0.0
        }
    ],
    "587e1bfdfc7e8dd84f000002_9": [
        {
            "start_logit": 9.40625,
            "end_logit": 9.7734375,
            "text": "GBshape",
            "probability": 1.0
        },
        {
            "start_logit": -1.25,
            "end_logit": 9.7734375,
            "text": "e",
            "probability": 2.3365020751953125e-05
        },
        {
            "start_logit": 9.40625,
            "end_logit": -2.279296875,
            "text": "GBs",
            "probability": 5.781650543212891e-06
        },
        {
            "start_logit": -5.734375,
            "end_logit": 9.7734375,
            "text": "hape",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.40625,
            "end_logit": -6.32421875,
            "text": "GBshape; freely available at http://rohslab.cmb.usc.edu",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.02734375,
            "end_logit": 9.7734375,
            "text": "Our Genome Browser for DNA shape annotations (GBshape",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.40625,
            "end_logit": -6.83203125,
            "text": "GBshape; freely available at http://rohslab.cmb.usc.edu/GBshape/",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.39453125,
            "end_logit": 9.7734375,
            "text": "(GBshape",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5234375,
            "end_logit": 9.7734375,
            "text": "Genome Browser for DNA shape annotations (GBshape",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.40625,
            "end_logit": -7.1796875,
            "text": "GBshape; freely available at http://rohslab.cmb.us",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.40625,
            "end_logit": -7.24609375,
            "text": "GBshape; freely available at http://rohslab",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.40625,
            "end_logit": -7.30859375,
            "text": "GBshape; freely available at http://rohslab.cmb.usc",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.40625,
            "end_logit": -7.40625,
            "text": "GBshap",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.40625,
            "end_logit": -7.4296875,
            "text": "GBshape; freely available at http://rohslab.cmb.usc.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.40625,
            "end_logit": -7.49609375,
            "text": "GBshape; freely available at http://rohslab.cmb.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.40625,
            "end_logit": -7.5,
            "text": "GBshape; freely available at http://rohslab.cmb",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.40625,
            "end_logit": -7.55078125,
            "text": "GBshape; freely available at http://rohslab.cmb.usc.edu/",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.40625,
            "end_logit": -7.5703125,
            "text": "GBshape;",
            "probability": 0.0
        },
        {
            "start_logit": 9.40625,
            "end_logit": -7.6328125,
            "text": "GBshape; freely available at http://rohslab.cmb.usc.edu/GBshape",
            "probability": 0.0
        },
        {
            "start_logit": 9.40625,
            "end_logit": -7.65625,
            "text": "GBshape; freely available at http://rohslab.",
            "probability": 0.0
        }
    ],
    "53262cdcd6d3ac6a34000003_1": [
        {
            "start_logit": 7.98046875,
            "end_logit": 4.5234375,
            "text": "epidural blood patch.",
            "probability": 0.97412109375
        },
        {
            "start_logit": 7.98046875,
            "end_logit": 0.8203125,
            "text": "epidural blood patch",
            "probability": 0.024017333984375
        },
        {
            "start_logit": 7.98046875,
            "end_logit": -2.431640625,
            "text": "epidural",
            "probability": 0.0009312629699707031
        },
        {
            "start_logit": 0.0081329345703125,
            "end_logit": 4.5234375,
            "text": ".",
            "probability": 0.00033736228942871094
        },
        {
            "start_logit": -2.560546875,
            "end_logit": 4.5234375,
            "text": "CSF leak using an epidural blood patch.",
            "probability": 2.580881118774414e-05
        },
        {
            "start_logit": 7.98046875,
            "end_logit": -6.21875,
            "text": "epidural blood",
            "probability": 2.1219253540039062e-05
        },
        {
            "start_logit": -4.875,
            "end_logit": 4.5234375,
            "text": "she was treated for CSF leak using an epidural blood patch.",
            "probability": 2.562999725341797e-06
        },
        {
            "start_logit": -2.560546875,
            "end_logit": 0.8203125,
            "text": "CSF leak using an epidural blood patch",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -6.734375,
            "end_logit": 4.5234375,
            "text": "treated for CSF leak using an epidural blood patch.",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -6.9453125,
            "end_logit": 4.5234375,
            "text": "blood patch.",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -6.94921875,
            "end_logit": 4.5234375,
            "text": "an epidural blood patch.",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -6.95703125,
            "end_logit": 4.5234375,
            "text": "for CSF leak using an epidural blood patch.",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.2265625,
            "end_logit": 4.5234375,
            "text": "was treated for CSF leak using an epidural blood patch.",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.39453125,
            "end_logit": 4.5234375,
            "text": "using an epidural blood patch.",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.96484375,
            "end_logit": 4.5234375,
            "text": "patch.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -4.875,
            "end_logit": 0.8203125,
            "text": "she was treated for CSF leak using an epidural blood patch",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.560546875,
            "end_logit": -2.431640625,
            "text": "CSF leak using an epidural",
            "probability": 0.0
        },
        {
            "start_logit": -6.734375,
            "end_logit": 0.8203125,
            "text": "treated for CSF leak using an epidural blood patch",
            "probability": 0.0
        },
        {
            "start_logit": -6.9453125,
            "end_logit": 0.8203125,
            "text": "blood patch",
            "probability": 0.0
        },
        {
            "start_logit": -6.94921875,
            "end_logit": 0.8203125,
            "text": "an epidural blood patch",
            "probability": 0.0
        }
    ],
    "53262cdcd6d3ac6a34000003_2": [
        {
            "start_logit": 8.8984375,
            "end_logit": 9.03125,
            "text": "epidural blood patch",
            "probability": 1.0
        },
        {
            "start_logit": -2.646484375,
            "end_logit": 9.03125,
            "text": "patch",
            "probability": 9.59634780883789e-06
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -2.705078125,
            "text": "epidural",
            "probability": 7.927417755126953e-06
        },
        {
            "start_logit": -3.28515625,
            "end_logit": 9.03125,
            "text": "invasive measures with epidural blood patch",
            "probability": 5.066394805908203e-06
        },
        {
            "start_logit": -5.7421875,
            "end_logit": 9.03125,
            "text": "blood patch",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -6.65234375,
            "text": "epidural blood patch providing",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -7.484375,
            "text": "epidural blood patch providing the",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -7.54296875,
            "text": "epidural blood patch providing the cornerstone of the invasive measures",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -7.66015625,
            "text": "epidural blood patch providing the cornerstone",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -7.75,
            "text": "epidural blood patch providing the cornerstone of the invasive",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -7.76171875,
            "text": "epidural blood patch providing the cornerstone of",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -7.78125,
            "text": "epidural blood patch providing the cornerstone of the",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1015625,
            "end_logit": 9.03125,
            "text": "measures with epidural blood patch",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -3.28515625,
            "end_logit": -2.705078125,
            "text": "invasive measures with epidural",
            "probability": 0.0
        },
        {
            "start_logit": -3.28515625,
            "end_logit": -5.875,
            "text": "invasive measures",
            "probability": 0.0
        },
        {
            "start_logit": -2.646484375,
            "end_logit": -6.65234375,
            "text": "patch providing",
            "probability": 0.0
        },
        {
            "start_logit": -3.28515625,
            "end_logit": -6.1328125,
            "text": "invasive",
            "probability": 0.0
        },
        {
            "start_logit": -3.28515625,
            "end_logit": -6.65234375,
            "text": "invasive measures with epidural blood patch providing",
            "probability": 0.0
        },
        {
            "start_logit": -2.646484375,
            "end_logit": -7.484375,
            "text": "patch providing the",
            "probability": 0.0
        },
        {
            "start_logit": -2.646484375,
            "end_logit": -7.54296875,
            "text": "patch providing the cornerstone of the invasive measures",
            "probability": 0.0
        }
    ],
    "53262cdcd6d3ac6a34000003_3": [
        {
            "start_logit": 8.609375,
            "end_logit": 8.53125,
            "text": "epidural blood patch",
            "probability": 1.0
        },
        {
            "start_logit": 8.609375,
            "end_logit": -2.814453125,
            "text": "epidural",
            "probability": 1.1861324310302734e-05
        },
        {
            "start_logit": -3.125,
            "end_logit": 8.53125,
            "text": "patch",
            "probability": 7.987022399902344e-06
        },
        {
            "start_logit": -4.28125,
            "end_logit": 8.53125,
            "text": "blood patch",
            "probability": 2.5033950805664062e-06
        },
        {
            "start_logit": 8.609375,
            "end_logit": -7.34765625,
            "text": "epidural blood",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.609375,
            "end_logit": -7.375,
            "text": "epidural blood patch should",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.4609375,
            "end_logit": 8.53125,
            "text": ", epidural blood patch",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.609375,
            "end_logit": -7.6875,
            "text": "epidural blood patch should be",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.609375,
            "end_logit": -7.703125,
            "text": "epidural blood patch should be performed",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.88671875,
            "end_logit": 8.53125,
            "text": ", age < 50 years, postpartum, large-gauge needle puncture, epidural blood patch",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.91015625,
            "end_logit": 8.53125,
            "text": ", large-gauge needle puncture, epidural blood patch",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.96484375,
            "end_logit": 8.53125,
            "text": "needle puncture, epidural blood patch",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.96875,
            "end_logit": 8.53125,
            "text": "In high-risk patients , for example, age < 50 years, postpartum, large-gauge needle puncture, epidural blood patch",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.98828125,
            "end_logit": 8.53125,
            "text": "puncture, epidural blood patch",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.046875,
            "end_logit": 8.53125,
            "text": "for example, age < 50 years, postpartum, large-gauge needle puncture, epidural blood patch",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.078125,
            "end_logit": 8.53125,
            "text": "postpartum, large-gauge needle puncture, epidural blood patch",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.078125,
            "end_logit": 8.53125,
            "text": "risk patients , for example, age < 50 years, postpartum, large-gauge needle puncture, epidural blood patch",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.078125,
            "end_logit": 8.53125,
            "text": "example, age < 50 years, postpartum, large-gauge needle puncture, epidural blood patch",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0859375,
            "end_logit": 8.53125,
            "text": ", postpartum, large-gauge needle puncture, epidural blood patch",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1015625,
            "end_logit": 8.53125,
            "text": "gauge needle puncture, epidural blood patch",
            "probability": 5.960464477539063e-08
        }
    ],
    "53262cdcd6d3ac6a34000003_4": [
        {
            "start_logit": 9.1875,
            "end_logit": 6.984375,
            "text": "acupuncture",
            "probability": 1.0
        },
        {
            "start_logit": 9.1875,
            "end_logit": -4.21875,
            "text": "acupuncture rather than an epidural blood patch.",
            "probability": 1.3649463653564453e-05
        },
        {
            "start_logit": 9.1875,
            "end_logit": -7.1796875,
            "text": "acupuncture rather",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 9.1875,
            "end_logit": -7.78515625,
            "text": "acupuncture rather than",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 9.1875,
            "end_logit": -7.8828125,
            "text": "acupuncture rather than an epidural blood patch",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -6.91015625,
            "end_logit": 6.984375,
            "text": "using acupuncture",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.2890625,
            "end_logit": 6.984375,
            "text": "Both parturients were successfully managed using acupuncture",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.46484375,
            "end_logit": 6.984375,
            "text": "successfully managed using acupuncture",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.68359375,
            "end_logit": 6.984375,
            "text": "managed using acupuncture",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.890625,
            "end_logit": 6.984375,
            "text": "parturients were successfully managed using acupuncture",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.95703125,
            "end_logit": 6.984375,
            "text": "were successfully managed using acupuncture",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0078125,
            "end_logit": 6.984375,
            "text": "ients were successfully managed using acupuncture",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.046875,
            "end_logit": 6.984375,
            "text": "urients were successfully managed using acupuncture",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -4.9375,
            "end_logit": -4.21875,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -6.91015625,
            "end_logit": -4.21875,
            "text": "using acupuncture rather than an epidural blood patch.",
            "probability": 0.0
        },
        {
            "start_logit": -7.2890625,
            "end_logit": -4.21875,
            "text": "Both parturients were successfully managed using acupuncture rather than an epidural blood patch.",
            "probability": 0.0
        },
        {
            "start_logit": -7.46484375,
            "end_logit": -4.21875,
            "text": "successfully managed using acupuncture rather than an epidural blood patch.",
            "probability": 0.0
        },
        {
            "start_logit": -7.484375,
            "end_logit": -4.21875,
            "text": "epidural blood patch.",
            "probability": 0.0
        },
        {
            "start_logit": -7.51171875,
            "end_logit": -4.21875,
            "text": "blood patch.",
            "probability": 0.0
        },
        {
            "start_logit": -7.68359375,
            "end_logit": -4.21875,
            "text": "managed using acupuncture rather than an epidural blood patch.",
            "probability": 0.0
        }
    ],
    "53262cdcd6d3ac6a34000003_5": [
        {
            "start_logit": 2.046875,
            "end_logit": -0.2666015625,
            "text": "epidural blood patch.",
            "probability": 0.70361328125
        },
        {
            "start_logit": 2.046875,
            "end_logit": -1.2900390625,
            "text": "epidural blood patch",
            "probability": 0.2529296875
        },
        {
            "start_logit": -1.48046875,
            "end_logit": -0.2666015625,
            "text": "LP shunt placement alleviated by an epidural blood patch.",
            "probability": 0.0206756591796875
        },
        {
            "start_logit": -1.48046875,
            "end_logit": -1.2900390625,
            "text": "LP shunt placement alleviated by an epidural blood patch",
            "probability": 0.0074310302734375
        },
        {
            "start_logit": -3.05859375,
            "end_logit": -0.2666015625,
            "text": ".",
            "probability": 0.004268646240234375
        },
        {
            "start_logit": -3.533203125,
            "end_logit": -0.2666015625,
            "text": "blood patch.",
            "probability": 0.0026493072509765625
        },
        {
            "start_logit": 2.046875,
            "end_logit": -6.45703125,
            "text": "epidural",
            "probability": 0.0014400482177734375
        },
        {
            "start_logit": -1.48046875,
            "end_logit": -2.96875,
            "text": "LP shunt",
            "probability": 0.0013856887817382812
        },
        {
            "start_logit": -1.48046875,
            "end_logit": -2.990234375,
            "text": "LP shunt placement",
            "probability": 0.0013580322265625
        },
        {
            "start_logit": -4.41015625,
            "end_logit": -0.2666015625,
            "text": "after LP shunt placement alleviated by an epidural blood patch.",
            "probability": 0.0011043548583984375
        },
        {
            "start_logit": -3.533203125,
            "end_logit": -1.2900390625,
            "text": "blood patch",
            "probability": 0.0009522438049316406
        },
        {
            "start_logit": -5.15625,
            "end_logit": -0.2666015625,
            "text": "shunt placement alleviated by an epidural blood patch.",
            "probability": 0.0005240440368652344
        },
        {
            "start_logit": -4.41015625,
            "end_logit": -1.2900390625,
            "text": "after LP shunt placement alleviated by an epidural blood patch",
            "probability": 0.00039696693420410156
        },
        {
            "start_logit": 2.046875,
            "end_logit": -7.828125,
            "text": "epidural blood",
            "probability": 0.0003657341003417969
        },
        {
            "start_logit": -5.15625,
            "end_logit": -1.2900390625,
            "text": "shunt placement alleviated by an epidural blood patch",
            "probability": 0.0001882314682006836
        },
        {
            "start_logit": -1.48046875,
            "end_logit": -5.3359375,
            "text": "LP shunt placement alleviated",
            "probability": 0.0001304149627685547
        },
        {
            "start_logit": -4.41015625,
            "end_logit": -2.96875,
            "text": "after LP shunt",
            "probability": 7.426738739013672e-05
        },
        {
            "start_logit": -4.41015625,
            "end_logit": -2.990234375,
            "text": "after LP shunt placement",
            "probability": 7.259845733642578e-05
        },
        {
            "start_logit": -7.1484375,
            "end_logit": -0.2666015625,
            "text": "placement alleviated by an epidural blood patch.",
            "probability": 7.146596908569336e-05
        },
        {
            "start_logit": -7.4765625,
            "end_logit": -0.2666015625,
            "text": "case, a 17-yr-old girl had symptoms of a low-pressure headache after LP shunt placement alleviated by an epidural blood patch.",
            "probability": 5.14984130859375e-05
        }
    ],
    "53262cdcd6d3ac6a34000003_6": [
        {
            "start_logit": 8.2578125,
            "end_logit": 9.1640625,
            "text": "epidural blood patch",
            "probability": 1.0
        },
        {
            "start_logit": -2.3046875,
            "end_logit": 9.1640625,
            "text": "patch",
            "probability": 2.586841583251953e-05
        },
        {
            "start_logit": 8.2578125,
            "end_logit": -3.6953125,
            "text": "epidural",
            "probability": 2.6226043701171875e-06
        },
        {
            "start_logit": -6.18359375,
            "end_logit": 9.1640625,
            "text": "blood patch",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 8.2578125,
            "end_logit": -6.59765625,
            "text": "epidural blood",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.68359375,
            "end_logit": 9.1640625,
            "text": "offered early (within 24-48 h of dural puncture) epidural blood patch",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.91796875,
            "end_logit": 9.1640625,
            "text": "patients should be offered early (within 24-48 h of dural puncture) epidural blood patch",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.98046875,
            "end_logit": 9.1640625,
            "text": "early (within 24-48 h of dural puncture) epidural blood patch",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.015625,
            "end_logit": 9.1640625,
            "text": ") epidural blood patch",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.125,
            "end_logit": 9.1640625,
            "text": ", large-gauge-needle puncture), patients should be offered early (within 24-48 h of dural puncture) epidural blood patch",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.15625,
            "end_logit": 9.1640625,
            "text": "(within 24-48 h of dural puncture) epidural blood patch",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.15625,
            "end_logit": 9.1640625,
            "text": "), patients should be offered early (within 24-48 h of dural puncture) epidural blood patch",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.15625,
            "end_logit": 9.1640625,
            "text": ", patients should be offered early (within 24-48 h of dural puncture) epidural blood patch",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1796875,
            "end_logit": 9.1640625,
            "text": "-needle puncture), patients should be offered early (within 24-48 h of dural puncture) epidural blood patch",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1875,
            "end_logit": 9.1640625,
            "text": "puncture), patients should be offered early (within 24-48 h of dural puncture) epidural blood patch",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1875,
            "end_logit": 9.1640625,
            "text": "needle puncture), patients should be offered early (within 24-48 h of dural puncture) epidural blood patch",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.68359375,
            "end_logit": -3.6953125,
            "text": "offered early (within 24-48 h of dural puncture) epidural",
            "probability": 0.0
        },
        {
            "start_logit": -7.91796875,
            "end_logit": -3.6953125,
            "text": "patients should be offered early (within 24-48 h of dural puncture) epidural",
            "probability": 0.0
        },
        {
            "start_logit": -7.98046875,
            "end_logit": -3.6953125,
            "text": "early (within 24-48 h of dural puncture) epidural",
            "probability": 0.0
        },
        {
            "start_logit": -8.015625,
            "end_logit": -3.6953125,
            "text": ") epidural",
            "probability": 0.0
        }
    ],
    "5c5b268986df2b9174000019_1": [
        {
            "start_logit": 9.453125,
            "end_logit": 9.4921875,
            "text": "DSMNC",
            "probability": 1.0
        },
        {
            "start_logit": -1.91015625,
            "end_logit": 9.4921875,
            "text": "NC",
            "probability": 1.1682510375976562e-05
        },
        {
            "start_logit": 9.453125,
            "end_logit": -2.345703125,
            "text": "DSM",
            "probability": 7.271766662597656e-06
        },
        {
            "start_logit": 9.453125,
            "end_logit": -7.92578125,
            "text": "DSMNC:",
            "probability": 0.0
        },
        {
            "start_logit": -1.91015625,
            "end_logit": -7.92578125,
            "text": "NC:",
            "probability": 0.0
        }
    ],
    "5c5b268986df2b9174000019_2": [
        {
            "start_logit": 9.5703125,
            "end_logit": 9.3515625,
            "text": "DSMNC",
            "probability": 1.0
        },
        {
            "start_logit": 9.5703125,
            "end_logit": -0.85693359375,
            "text": "DSMNC: a database of somatic mutations in normal cells (http://dsmnc.big.ac.cn",
            "probability": 3.6776065826416016e-05
        },
        {
            "start_logit": 9.5703125,
            "end_logit": -1.6611328125,
            "text": "DSM",
            "probability": 1.6450881958007812e-05
        },
        {
            "start_logit": -1.6298828125,
            "end_logit": 9.3515625,
            "text": "NC",
            "probability": 1.3649463653564453e-05
        },
        {
            "start_logit": 9.5703125,
            "end_logit": -4.92578125,
            "text": "DSMNC: a database of somatic mutations in normal cells (http://dsmnc.big.ac",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -6.2421875,
            "end_logit": 9.3515625,
            "text": ". Here, we established DSMNC",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.578125,
            "end_logit": 9.3515625,
            "text": "established DSMNC",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.5703125,
            "end_logit": -7.1484375,
            "text": "DSMNC: a database of somatic mutations in normal cells (http://dsmnc.big.ac.cn/",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.5703125,
            "end_logit": -7.19140625,
            "text": "DSMNC: a database of somatic mutations in normal cells (http:/",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.5703125,
            "end_logit": -7.22265625,
            "text": "DSMNC: a database of somatic mutations in normal cells (http://dsmnc.big",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.5703125,
            "end_logit": -7.38671875,
            "text": "DSMNC: a database of somatic mutations in normal cells (http://dsmnc",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.5703125,
            "end_logit": -7.3984375,
            "text": "DSMNC: a database of somatic mutations in normal cells (http://dsmnc.big.ac.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.6298828125,
            "end_logit": -0.85693359375,
            "text": "NC: a database of somatic mutations in normal cells (http://dsmnc.big.ac.cn",
            "probability": 0.0
        },
        {
            "start_logit": -4.86328125,
            "end_logit": -0.85693359375,
            "text": "http://dsmnc.big.ac.cn",
            "probability": 0.0
        },
        {
            "start_logit": -1.6298828125,
            "end_logit": -4.92578125,
            "text": "NC: a database of somatic mutations in normal cells (http://dsmnc.big.ac",
            "probability": 0.0
        },
        {
            "start_logit": -6.2421875,
            "end_logit": -0.85693359375,
            "text": ". Here, we established DSMNC: a database of somatic mutations in normal cells (http://dsmnc.big.ac.cn",
            "probability": 0.0
        },
        {
            "start_logit": -6.578125,
            "end_logit": -0.85693359375,
            "text": "established DSMNC: a database of somatic mutations in normal cells (http://dsmnc.big.ac.cn",
            "probability": 0.0
        },
        {
            "start_logit": -6.91796875,
            "end_logit": -0.85693359375,
            "text": "database of somatic mutations in normal cells (http://dsmnc.big.ac.cn",
            "probability": 0.0
        },
        {
            "start_logit": -6.9375,
            "end_logit": -0.85693359375,
            "text": "cn",
            "probability": 0.0
        },
        {
            "start_logit": -6.2421875,
            "end_logit": -1.6611328125,
            "text": ". Here, we established DSM",
            "probability": 0.0
        }
    ],
    "5c5b268986df2b9174000019_3": [
        {
            "start_logit": 9.515625,
            "end_logit": 9.3515625,
            "text": "DSMNC",
            "probability": 1.0
        },
        {
            "start_logit": 9.515625,
            "end_logit": -2.17578125,
            "text": "DSM",
            "probability": 9.834766387939453e-06
        },
        {
            "start_logit": -2.091796875,
            "end_logit": 9.3515625,
            "text": "NC",
            "probability": 9.000301361083984e-06
        },
        {
            "start_logit": 9.515625,
            "end_logit": -4.96875,
            "text": "DSMNC: a database of somatic mutations in normal cells (http://dsmnc.big.ac.cn",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 9.515625,
            "end_logit": -7.05859375,
            "text": "DSMNC: a database of somatic mutations in normal cells (http://dsmnc.big.ac",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.515625,
            "end_logit": -7.359375,
            "text": "DSMNC: a database of somatic mutations in normal cells (http://dsmnc.big.ac.cn/",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.515625,
            "end_logit": -7.515625,
            "text": "DSMNC: a database of somatic mutations in normal cells (http://dsmnc.big.ac.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.515625,
            "end_logit": -7.6328125,
            "text": "DSMNC: a database of somatic mutations in normal cells (http://dsmnc.big.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.515625,
            "end_logit": -7.64453125,
            "text": "DSMNC: a database of somatic mutations in normal cells (http://dsmnc",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.515625,
            "end_logit": -7.734375,
            "text": "DSMNC: a database of somatic mutations in normal cells (http://dsmnc.big",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.515625,
            "end_logit": -7.80078125,
            "text": "DSMNC: a database of somatic mutations in normal cells (http://dsmnc.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.515625,
            "end_logit": -7.8125,
            "text": "DSMNC: a database of somatic mutations in normal cells (http:/",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.65234375,
            "end_logit": 9.3515625,
            "text": "established DSMNC",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.515625,
            "end_logit": -7.98046875,
            "text": "DSMNC:",
            "probability": 0.0
        },
        {
            "start_logit": 9.515625,
            "end_logit": -7.9921875,
            "text": "DSMNC: a database of somatic mutations in normal cells (http://dsmnc.big.ac.cn/), which provides most comprehensive catalogue of somatic SNVs in",
            "probability": 0.0
        },
        {
            "start_logit": -7.84765625,
            "end_logit": 9.3515625,
            "text": "Here, we established DSMNC",
            "probability": 0.0
        },
        {
            "start_logit": -7.84765625,
            "end_logit": 9.3515625,
            "text": "we established DSMNC",
            "probability": 0.0
        },
        {
            "start_logit": 9.515625,
            "end_logit": -8.015625,
            "text": "DSMNC: a database of somatic mutations in normal cells (http://dsmnc.big.ac.cn/), which provides most comprehensive catalogue of somatic SNVs in single cells",
            "probability": 0.0
        },
        {
            "start_logit": 9.515625,
            "end_logit": -8.0546875,
            "text": "DSMNC: a database of somatic mutations in normal cells (http://dsmnc.big.ac.cn/)",
            "probability": 0.0
        },
        {
            "start_logit": -2.091796875,
            "end_logit": -4.96875,
            "text": "NC: a database of somatic mutations in normal cells (http://dsmnc.big.ac.cn",
            "probability": 0.0
        }
    ],
    "5c5b268986df2b9174000019_4": [
        {
            "start_logit": 9.5,
            "end_logit": 9.5078125,
            "text": "DSMNC",
            "probability": 1.0
        },
        {
            "start_logit": -1.826171875,
            "end_logit": 9.5078125,
            "text": "NC",
            "probability": 1.2099742889404297e-05
        },
        {
            "start_logit": 9.5,
            "end_logit": -2.228515625,
            "text": "DSM",
            "probability": 8.046627044677734e-06
        },
        {
            "start_logit": 9.5,
            "end_logit": -7.7109375,
            "text": "DSMNC: a database of somatic mutations in normal cells.Numerous non-inherited somatic mutations, distinct from those of germ-line origin, occur in somatic cells during DNA replication per cell-division.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.5,
            "end_logit": -7.7109375,
            "text": "DSMNC: a database of somatic mutations in normal cells.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.5,
            "end_logit": -7.89453125,
            "text": "DSMNC:",
            "probability": 0.0
        },
        {
            "start_logit": 9.5,
            "end_logit": -7.9375,
            "text": "DSMNC: a database of somatic mutations in normal cells.Numerous non-inherited somatic mutations, distinct from those of germ-line origin",
            "probability": 0.0
        },
        {
            "start_logit": 9.5,
            "end_logit": -7.95703125,
            "text": "DSMNC: a database of somatic mutations in normal cells.Numerous non-inherited somatic mutations, distinct from those of germ-line origin, occur in somatic cells during",
            "probability": 0.0
        },
        {
            "start_logit": 9.5,
            "end_logit": -7.98046875,
            "text": "DSMNC: a database of somatic mutations in normal cells.Numerous non-inherited somatic mutations, distinct from those of germ-line",
            "probability": 0.0
        },
        {
            "start_logit": 9.5,
            "end_logit": -7.984375,
            "text": "DSMNC: a database of somatic mutations in normal cells.Numerous non-inherited somatic mutations, distinct from those of germ-line origin, occur in somatic cells during DNA replication per",
            "probability": 0.0
        },
        {
            "start_logit": 9.5,
            "end_logit": -8.0078125,
            "text": "DSMNC: a database of somatic mutations in normal cells.Numerous non-inherited somatic mutations, distinct from those of germ-line origin, occur in somatic cells during DNA replication",
            "probability": 0.0
        },
        {
            "start_logit": 9.5,
            "end_logit": -8.0234375,
            "text": "DSMNC: a database of somatic mutations in normal cells.Numerous non-inherited somatic mutations, distinct from those of germ-line origin, occur in somatic cells during DNA replication per cell-division",
            "probability": 0.0
        },
        {
            "start_logit": 9.5,
            "end_logit": -8.046875,
            "text": "DSMNC: a database of somatic mutations in normal cells.Numerous non-inherited somatic mutations, distinct from those",
            "probability": 0.0
        },
        {
            "start_logit": 9.5,
            "end_logit": -8.1015625,
            "text": "DSMNC: a database of somatic mutations in normal cells.Numerous non-inherited somatic mutations, distinct from those of germ",
            "probability": 0.0
        },
        {
            "start_logit": 9.5,
            "end_logit": -8.1171875,
            "text": "DSMNC: a database of somatic mutations in normal cells.Numerous non-inherited somatic mutations, distinct from those of",
            "probability": 0.0
        },
        {
            "start_logit": 9.5,
            "end_logit": -8.1171875,
            "text": "DSMNC: a database of somatic mutations in normal cells.Numerous non-inherited somatic mutations, distinct from those of germ-line origin, occur",
            "probability": 0.0
        },
        {
            "start_logit": 9.5,
            "end_logit": -8.140625,
            "text": "DSMNC: a database of somatic mutations in normal cells.Numerous non-inherited somatic mutations, distinct from those of germ-",
            "probability": 0.0
        },
        {
            "start_logit": -1.826171875,
            "end_logit": -7.7109375,
            "text": "NC: a database of somatic mutations in normal cells.Numerous non-inherited somatic mutations, distinct from those of germ-line origin, occur in somatic cells during DNA replication per cell-division.",
            "probability": 0.0
        },
        {
            "start_logit": -1.826171875,
            "end_logit": -7.7109375,
            "text": "NC: a database of somatic mutations in normal cells.",
            "probability": 0.0
        },
        {
            "start_logit": -1.826171875,
            "end_logit": -7.89453125,
            "text": "NC:",
            "probability": 0.0
        }
    ],
    "5c5b268986df2b9174000019_5": [
        {
            "start_logit": 9.515625,
            "end_logit": 9.3515625,
            "text": "DSMNC",
            "probability": 1.0
        },
        {
            "start_logit": 9.515625,
            "end_logit": -2.17578125,
            "text": "DSM",
            "probability": 9.834766387939453e-06
        },
        {
            "start_logit": -2.091796875,
            "end_logit": 9.3515625,
            "text": "NC",
            "probability": 9.000301361083984e-06
        },
        {
            "start_logit": 9.515625,
            "end_logit": -4.96875,
            "text": "DSMNC: a database of somatic mutations in normal cells (http://dsmnc.big.ac.cn",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 9.515625,
            "end_logit": -7.05859375,
            "text": "DSMNC: a database of somatic mutations in normal cells (http://dsmnc.big.ac",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.515625,
            "end_logit": -7.359375,
            "text": "DSMNC: a database of somatic mutations in normal cells (http://dsmnc.big.ac.cn/",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.515625,
            "end_logit": -7.515625,
            "text": "DSMNC: a database of somatic mutations in normal cells (http://dsmnc.big.ac.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.515625,
            "end_logit": -7.6328125,
            "text": "DSMNC: a database of somatic mutations in normal cells (http://dsmnc.big.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.515625,
            "end_logit": -7.64453125,
            "text": "DSMNC: a database of somatic mutations in normal cells (http://dsmnc",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.515625,
            "end_logit": -7.734375,
            "text": "DSMNC: a database of somatic mutations in normal cells (http://dsmnc.big",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.515625,
            "end_logit": -7.80078125,
            "text": "DSMNC: a database of somatic mutations in normal cells (http://dsmnc.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.515625,
            "end_logit": -7.8125,
            "text": "DSMNC: a database of somatic mutations in normal cells (http:/",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.65234375,
            "end_logit": 9.3515625,
            "text": "established DSMNC",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.515625,
            "end_logit": -7.98046875,
            "text": "DSMNC:",
            "probability": 0.0
        },
        {
            "start_logit": 9.515625,
            "end_logit": -7.9921875,
            "text": "DSMNC: a database of somatic mutations in normal cells (http://dsmnc.big.ac.cn/), which provides most comprehensive catalogue of somatic SNVs in",
            "probability": 0.0
        },
        {
            "start_logit": -7.84765625,
            "end_logit": 9.3515625,
            "text": "Here, we established DSMNC",
            "probability": 0.0
        },
        {
            "start_logit": -7.84765625,
            "end_logit": 9.3515625,
            "text": "we established DSMNC",
            "probability": 0.0
        },
        {
            "start_logit": 9.515625,
            "end_logit": -8.015625,
            "text": "DSMNC: a database of somatic mutations in normal cells (http://dsmnc.big.ac.cn/), which provides most comprehensive catalogue of somatic SNVs in single cells",
            "probability": 0.0
        },
        {
            "start_logit": 9.515625,
            "end_logit": -8.0546875,
            "text": "DSMNC: a database of somatic mutations in normal cells (http://dsmnc.big.ac.cn/)",
            "probability": 0.0
        },
        {
            "start_logit": -2.091796875,
            "end_logit": -4.96875,
            "text": "NC: a database of somatic mutations in normal cells (http://dsmnc.big.ac.cn",
            "probability": 0.0
        }
    ],
    "5a690487b750ff445500001f_1": [
        {
            "start_logit": 8.875,
            "end_logit": 1.9130859375,
            "text": "Epstein-Barr virus",
            "probability": 0.93408203125
        },
        {
            "start_logit": 8.875,
            "end_logit": -0.87548828125,
            "text": "Epstein-Barr virus (EBV",
            "probability": 0.057464599609375
        },
        {
            "start_logit": 8.875,
            "end_logit": -3.23828125,
            "text": "Epstein",
            "probability": 0.005405426025390625
        },
        {
            "start_logit": 8.875,
            "end_logit": -4.39453125,
            "text": "Epstein-Barr virus (EBV)",
            "probability": 0.00170135498046875
        },
        {
            "start_logit": 8.875,
            "end_logit": -5.578125,
            "text": "Epstein-Barr virus (EBV) is a highly prevalent virus, transmitted via saliva, which often causes asymptomatic infection in children but frequently results in infectious mononucleosis in adolescents.",
            "probability": 0.0005207061767578125
        },
        {
            "start_logit": 8.875,
            "end_logit": -6.265625,
            "text": "Epstein-Barr",
            "probability": 0.0002620220184326172
        },
        {
            "start_logit": 8.875,
            "end_logit": -7.515625,
            "text": "Epstein-",
            "probability": 7.50422477722168e-05
        },
        {
            "start_logit": -2.2265625,
            "end_logit": -0.87548828125,
            "text": "EBV",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": -7.8203125,
            "end_logit": 1.9130859375,
            "text": "-Barr virus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.109375,
            "end_logit": 1.9130859375,
            "text": "Barr virus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.2265625,
            "end_logit": -4.39453125,
            "text": "EBV)",
            "probability": 0.0
        },
        {
            "start_logit": -2.2265625,
            "end_logit": -5.578125,
            "text": "EBV) is a highly prevalent virus, transmitted via saliva, which often causes asymptomatic infection in children but frequently results in infectious mononucleosis in adolescents.",
            "probability": 0.0
        },
        {
            "start_logit": -7.8125,
            "end_logit": -0.87548828125,
            "text": "(EBV",
            "probability": 0.0
        },
        {
            "start_logit": -7.8203125,
            "end_logit": -0.87548828125,
            "text": "-Barr virus (EBV",
            "probability": 0.0
        },
        {
            "start_logit": -8.109375,
            "end_logit": -0.87548828125,
            "text": "Barr virus (EBV",
            "probability": 0.0
        },
        {
            "start_logit": -6.04296875,
            "end_logit": -5.578125,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -6.04296875,
            "end_logit": -5.578125,
            "text": ". Heterophile antibody tests, including the Monospot test, are red cell or latex agglutination assays, which detect antired cell antibodies produced as part of a polyclonal antibody response occurring during EBV infection.",
            "probability": 0.0
        },
        {
            "start_logit": -6.04296875,
            "end_logit": -5.578125,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.8125,
            "end_logit": -4.39453125,
            "text": "(EBV)",
            "probability": 0.0
        },
        {
            "start_logit": -7.8203125,
            "end_logit": -4.39453125,
            "text": "-Barr virus (EBV)",
            "probability": 0.0
        }
    ],
    "5a690487b750ff445500001f_2": [
        {
            "start_logit": 7.7109375,
            "end_logit": 7.9609375,
            "text": "cytomegalovirus",
            "probability": 1.0
        },
        {
            "start_logit": -0.71875,
            "end_logit": 7.9609375,
            "text": "Epstein-Barr virus viral capsid antibody IgM/IgG and Epstein-Barr virus DNA by polymerase chain reaction to be negative; however, interestingly her cytomegalovirus",
            "probability": 0.00021827220916748047
        },
        {
            "start_logit": -0.71875,
            "end_logit": 2.890625,
            "text": "Epstein-Barr virus",
            "probability": 1.3709068298339844e-06
        },
        {
            "start_logit": -6.015625,
            "end_logit": 7.9609375,
            "text": "positive monospot test result. Further investigation showed the Epstein-Barr virus viral capsid antibody IgM/IgG and Epstein-Barr virus DNA by polymerase chain reaction to be negative; however, interestingly her cytomegalovirus",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": -6.515625,
            "end_logit": 7.9609375,
            "text": ". Further investigation showed the Epstein-Barr virus viral capsid antibody IgM/IgG and Epstein-Barr virus DNA by polymerase chain reaction to be negative; however, interestingly her cytomegalovirus",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 7.7109375,
            "end_logit": -6.96875,
            "text": "cytomegalovirus (CMV) IgM and IgG were positive, suggesting that her mononucleosis-like syndrome was due to acute CMV infection.",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.7109375,
            "end_logit": -7.02734375,
            "text": "cytomegalovirus (CMV",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.59375,
            "end_logit": 7.9609375,
            "text": "Barr virus viral capsid antibody IgM/IgG and Epstein-Barr virus DNA by polymerase chain reaction to be negative; however, interestingly her cytomegalovirus",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.796875,
            "end_logit": 7.9609375,
            "text": "Epstein-Barr virus DNA by polymerase chain reaction to be negative; however, interestingly her cytomegalovirus",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.7109375,
            "end_logit": -7.59375,
            "text": "cytomegalovirus (CMV)",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.8671875,
            "end_logit": 7.9609375,
            "text": "her cytomegalovirus",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.88671875,
            "end_logit": 7.9609375,
            "text": "virus viral capsid antibody IgM/IgG and Epstein-Barr virus DNA by polymerase chain reaction to be negative; however, interestingly her cytomegalovirus",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.7109375,
            "end_logit": -7.6484375,
            "text": "cytomegalovirus (CMV) IgM and IgG were positive, suggesting that her mononucleosis-like syndrome was due to acute CMV infection",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.90625,
            "end_logit": 7.9609375,
            "text": "a positive monospot test result. Further investigation showed the Epstein-Barr virus viral capsid antibody IgM/IgG and Epstein-Barr virus DNA by polymerase chain reaction to be negative; however, interestingly her cytomegalovirus",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.7109375,
            "end_logit": -7.8515625,
            "text": "cytomegalovirus (CMV) IgM and IgG were positive",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.015625,
            "end_logit": 2.890625,
            "text": "positive monospot test result. Further investigation showed the Epstein-Barr virus",
            "probability": 0.0
        },
        {
            "start_logit": -6.515625,
            "end_logit": 2.890625,
            "text": ". Initial investigations revealed atypical lymphocytosis, thrombocytopenia, elevated liver enzymes, and a positive monospot test result. Further investigation showed the Epstein-Barr virus",
            "probability": 0.0
        },
        {
            "start_logit": -6.515625,
            "end_logit": 2.890625,
            "text": ". Further investigation showed the Epstein-Barr virus",
            "probability": 0.0
        },
        {
            "start_logit": -7.59375,
            "end_logit": 2.890625,
            "text": "Barr virus",
            "probability": 0.0
        },
        {
            "start_logit": -7.88671875,
            "end_logit": 2.890625,
            "text": "virus",
            "probability": 0.0
        }
    ],
    "5a690487b750ff445500001f_3": [
        {
            "start_logit": 9.6484375,
            "end_logit": 6.70703125,
            "text": "Epstein-Barr virus infection",
            "probability": 0.97607421875
        },
        {
            "start_logit": 5.0546875,
            "end_logit": 6.70703125,
            "text": "infectious mononucleosis complicated by spontaneous splenic rupture secondary to Epstein-Barr virus infection",
            "probability": 0.0098724365234375
        },
        {
            "start_logit": 5.0546875,
            "end_logit": 6.5,
            "text": "infectious mononucleosis",
            "probability": 0.00799560546875
        },
        {
            "start_logit": 9.6484375,
            "end_logit": 1.615234375,
            "text": "Epstein-Barr virus",
            "probability": 0.00598907470703125
        },
        {
            "start_logit": 9.6484375,
            "end_logit": -1.8876953125,
            "text": "Epstein",
            "probability": 0.00018084049224853516
        },
        {
            "start_logit": 5.0546875,
            "end_logit": 1.615234375,
            "text": "infectious mononucleosis complicated by spontaneous splenic rupture secondary to Epstein-Barr virus",
            "probability": 6.0558319091796875e-05
        },
        {
            "start_logit": 9.6484375,
            "end_logit": -5.74609375,
            "text": "Epstein-Barr virus infection.",
            "probability": 3.814697265625e-06
        },
        {
            "start_logit": 9.6484375,
            "end_logit": -6.0703125,
            "text": "Epstein-Barr",
            "probability": 2.7418136596679688e-06
        },
        {
            "start_logit": 5.0546875,
            "end_logit": -1.8876953125,
            "text": "infectious mononucleosis complicated by spontaneous splenic rupture secondary to Epstein",
            "probability": 1.7881393432617188e-06
        },
        {
            "start_logit": -4.53515625,
            "end_logit": 6.70703125,
            "text": "infection",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 9.6484375,
            "end_logit": -7.48828125,
            "text": "Epstein-",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -5.62890625,
            "end_logit": 6.70703125,
            "text": "osis complicated by spontaneous splenic rupture secondary to Epstein-Barr virus infection",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -5.76953125,
            "end_logit": 6.70703125,
            "text": ". He was taken to theatre for urgent splenectomy. The unifying diagnosis was infectious mononucleosis complicated by spontaneous splenic rupture secondary to Epstein-Barr virus infection",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -5.76953125,
            "end_logit": 6.70703125,
            "text": ". The unifying diagnosis was infectious mononucleosis complicated by spontaneous splenic rupture secondary to Epstein-Barr virus infection",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -5.62890625,
            "end_logit": 6.5,
            "text": "osis",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -5.76953125,
            "end_logit": 6.5,
            "text": ". This had likely caused referred pain through diaphragmatic irritation. He was taken to theatre for urgent splenectomy. The unifying diagnosis was infectious mononucleosis",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -5.76953125,
            "end_logit": 6.5,
            "text": ". He was taken to theatre for urgent splenectomy. The unifying diagnosis was infectious mononucleosis",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -5.76953125,
            "end_logit": 6.5,
            "text": ". The unifying diagnosis was infectious mononucleosis",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.33203125,
            "end_logit": 6.70703125,
            "text": "Barr virus infection",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.34765625,
            "end_logit": 6.70703125,
            "text": "to Epstein-Barr virus infection",
            "probability": 5.960464477539063e-08
        }
    ],
    "5a690487b750ff445500001f_4": [
        {
            "start_logit": 9.2890625,
            "end_logit": 5.5546875,
            "text": "Epstein-Barr virus (EBV) is almost ubiquitous in humans and generally occurs at two ages: infantile, which is usually asymptomatic and associated with poorer socioeconomic conditions, and adolescent, which causes infectious mononucleosis",
            "probability": 0.77294921875
        },
        {
            "start_logit": 9.2890625,
            "end_logit": 3.736328125,
            "text": "Epstein-Barr virus (EBV)",
            "probability": 0.125244140625
        },
        {
            "start_logit": 9.2890625,
            "end_logit": 3.349609375,
            "text": "Epstein-Barr virus",
            "probability": 0.08538818359375
        },
        {
            "start_logit": 5.44140625,
            "end_logit": 5.5546875,
            "text": "infectious mononucleosis",
            "probability": 0.01654052734375
        },
        {
            "start_logit": 9.2890625,
            "end_logit": -2.623046875,
            "text": "Epstein",
            "probability": 0.0002167224884033203
        },
        {
            "start_logit": 9.2890625,
            "end_logit": -6.2109375,
            "text": "Epstein-Barr virus (EBV) is almost ubiquitous in humans and generally occurs at two ages: infantile, which is usually asymptomatic and associated with poorer socioeconomic conditions, and adolescent, which causes infectious",
            "probability": 5.9604644775390625e-06
        },
        {
            "start_logit": 9.2890625,
            "end_logit": -6.50390625,
            "text": "Epstein-Barr",
            "probability": 4.470348358154297e-06
        },
        {
            "start_logit": 9.2890625,
            "end_logit": -6.57421875,
            "text": "Epstein-Barr virus (EBV",
            "probability": 4.172325134277344e-06
        },
        {
            "start_logit": 9.2890625,
            "end_logit": -7.390625,
            "text": "Epstein-Barr virus (EBV) is almost ubiquitous in humans and generally occurs at two ages: infantile, which is usually asymptomatic and associated with poorer socioeconomic conditions, and adolescent, which causes infectious mononucle",
            "probability": 1.8477439880371094e-06
        },
        {
            "start_logit": 9.2890625,
            "end_logit": -7.62109375,
            "text": "Epstein-",
            "probability": 1.4901161193847656e-06
        },
        {
            "start_logit": -6.265625,
            "end_logit": 5.5546875,
            "text": "osis",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 5.44140625,
            "end_logit": -6.2109375,
            "text": "infectious",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.42578125,
            "end_logit": 5.5546875,
            "text": "EBV) is almost ubiquitous in humans and generally occurs at two ages: infantile, which is usually asymptomatic and associated with poorer socioeconomic conditions, and adolescent, which causes infectious mononucleosis",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 5.44140625,
            "end_logit": -6.45703125,
            "text": "infectious mononucleosis (IM) in ~25% cases. The determinants of whether the infection causes IM remain uncertain. We aimed to evaluate seasonality and temporal trends in IM.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 5.44140625,
            "end_logit": -6.45703125,
            "text": "infectious mononucleosis (IM) in ~25% cases. The determinants of whether the infection causes IM remain uncertain.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 5.44140625,
            "end_logit": -6.45703125,
            "text": "infectious mononucleosis (IM) in ~25% cases.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.828125,
            "end_logit": 5.5546875,
            "text": ") is almost ubiquitous in humans and generally occurs at two ages: infantile, which is usually asymptomatic and associated with poorer socioeconomic conditions, and adolescent, which causes infectious mononucleosis",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.4453125,
            "end_logit": 5.5546875,
            "text": "Barr virus (EBV) is almost ubiquitous in humans and generally occurs at two ages: infantile, which is usually asymptomatic and associated with poorer socioeconomic conditions, and adolescent, which causes infectious mononucleosis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 5.44140625,
            "end_logit": -7.390625,
            "text": "infectious mononucle",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 5.44140625,
            "end_logit": -7.4453125,
            "text": "infectious mononucleosis (IM) in",
            "probability": 5.960464477539063e-08
        }
    ],
    "5a690487b750ff445500001f_5": [
        {
            "start_logit": 9.8984375,
            "end_logit": 9.7265625,
            "text": "Epstein-Barr virus",
            "probability": 1.0
        },
        {
            "start_logit": 9.8984375,
            "end_logit": -1.25,
            "text": "Epstein",
            "probability": 1.710653305053711e-05
        },
        {
            "start_logit": -1.3974609375,
            "end_logit": 9.7265625,
            "text": "virus",
            "probability": 1.239776611328125e-05
        },
        {
            "start_logit": 9.8984375,
            "end_logit": -6.59375,
            "text": "Epstein-Barr",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.55859375,
            "end_logit": 9.7265625,
            "text": "Barr virus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.88671875,
            "end_logit": 9.7265625,
            "text": "-Barr virus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8984375,
            "end_logit": -7.74609375,
            "text": "Epstein-Barr virus viral load (EBV-VL) in peripheral blood, neutrophil/lymphocyte/monocyte counts, C-reactive protein values, and monospot test].",
            "probability": 0.0
        },
        {
            "start_logit": 9.8984375,
            "end_logit": -7.859375,
            "text": "Epstein-",
            "probability": 0.0
        },
        {
            "start_logit": 9.8984375,
            "end_logit": -7.87109375,
            "text": "Epstein-Barr virus viral load",
            "probability": 0.0
        },
        {
            "start_logit": 9.8984375,
            "end_logit": -7.9921875,
            "text": "Epstein-Barr virus viral",
            "probability": 0.0
        },
        {
            "start_logit": 9.8984375,
            "end_logit": -8.0234375,
            "text": "Epstein-Barr virus viral load (EBV-VL)",
            "probability": 0.0
        },
        {
            "start_logit": 9.8984375,
            "end_logit": -8.03125,
            "text": "Epstein-Barr virus viral load (EBV-",
            "probability": 0.0
        },
        {
            "start_logit": 9.8984375,
            "end_logit": -8.046875,
            "text": "Epstein-Barr virus viral load (EBV-VL",
            "probability": 0.0
        },
        {
            "start_logit": 9.8984375,
            "end_logit": -8.0546875,
            "text": "Epstein-Barr virus viral load (EBV-VL) in",
            "probability": 0.0
        },
        {
            "start_logit": 9.8984375,
            "end_logit": -8.0625,
            "text": "Epstein-Barr virus viral load (EBV-VL) in peripheral blood",
            "probability": 0.0
        },
        {
            "start_logit": -7.8984375,
            "end_logit": 9.7265625,
            "text": "measurement of Epstein-Barr virus",
            "probability": 0.0
        },
        {
            "start_logit": 9.8984375,
            "end_logit": -8.09375,
            "text": "Epstein-Barr virus viral load (EBV-VL) in peripheral",
            "probability": 0.0
        },
        {
            "start_logit": 9.8984375,
            "end_logit": -8.09375,
            "text": "Epstein-Barr virus viral load (EBV-VL) in peripheral blood, neutrophil/lymphocyte/monocyte counts",
            "probability": 0.0
        },
        {
            "start_logit": 9.8984375,
            "end_logit": -8.1015625,
            "text": "Epstein-Barr virus viral load (",
            "probability": 0.0
        },
        {
            "start_logit": 9.8984375,
            "end_logit": -8.1015625,
            "text": "Epstein-Barr virus viral load (EBV-VL) in peripheral blood, neutrophil/lymphocyte/",
            "probability": 0.0
        }
    ],
    "5a690487b750ff445500001f_6": [
        {
            "start_logit": 9.6796875,
            "end_logit": 9.6875,
            "text": "Epstein-Barr virus",
            "probability": 1.0
        },
        {
            "start_logit": -1.5224609375,
            "end_logit": 9.6875,
            "text": "virus",
            "probability": 1.3530254364013672e-05
        },
        {
            "start_logit": 9.6796875,
            "end_logit": -1.86328125,
            "text": "Epstein",
            "probability": 9.5367431640625e-06
        },
        {
            "start_logit": 9.6796875,
            "end_logit": -3.7734375,
            "text": "Epstein-Barr virus-related infectious mononucleosis",
            "probability": 1.430511474609375e-06
        },
        {
            "start_logit": 9.6796875,
            "end_logit": -6.69140625,
            "text": "Epstein-Barr",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.7265625,
            "end_logit": 9.6875,
            "text": ". The boy subsequently recovered in one week with total disappearance of his rash. Epstein-Barr virus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.7265625,
            "end_logit": 9.6875,
            "text": ". Epstein-Barr virus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.7890625,
            "end_logit": 9.6875,
            "text": "Barr virus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.16015625,
            "end_logit": 9.6875,
            "text": "-Barr virus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.6796875,
            "end_logit": -7.4375,
            "text": "Epstein-Barr virus-related infectious mononucleosis was considered the most likely diagnosis for our patient.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.6796875,
            "end_logit": -7.59765625,
            "text": "Epstein-Barr virus-related infectious mononucle",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.90625,
            "end_logit": 9.6875,
            "text": "The boy subsequently recovered in one week with total disappearance of his rash. Epstein-Barr virus",
            "probability": 0.0
        },
        {
            "start_logit": 9.6796875,
            "end_logit": -7.95703125,
            "text": "Epstein-Barr virus-",
            "probability": 0.0
        },
        {
            "start_logit": 9.6796875,
            "end_logit": -7.97265625,
            "text": "Epstein-Barr virus-related infectious mononucleosis was",
            "probability": 0.0
        },
        {
            "start_logit": -8.0234375,
            "end_logit": 9.6875,
            "text": "his rash. Epstein-Barr virus",
            "probability": 0.0
        },
        {
            "start_logit": 9.6796875,
            "end_logit": -8.0390625,
            "text": "Epstein-Barr virus-related",
            "probability": 0.0
        },
        {
            "start_logit": 9.6796875,
            "end_logit": -8.046875,
            "text": "Epstein-",
            "probability": 0.0
        },
        {
            "start_logit": -8.0546875,
            "end_logit": 9.6875,
            "text": "Investigations revealed lymphocytosis and activated atypical lymphocytes in the peripheral smear, and positive monospot test. The boy subsequently recovered in one week with total disappearance of his rash. Epstein-Barr virus",
            "probability": 0.0
        },
        {
            "start_logit": 9.6796875,
            "end_logit": -8.0703125,
            "text": "Epstein-Barr virus-related infectious mononucleosis was considered",
            "probability": 0.0
        },
        {
            "start_logit": 9.6796875,
            "end_logit": -8.09375,
            "text": "Epstein-Barr virus-related infectious mononucleosis was considered the",
            "probability": 0.0
        }
    ],
    "5a690487b750ff445500001f_7": [
        {
            "start_logit": 7.71484375,
            "end_logit": 7.38671875,
            "text": "Epstein-Barr virus",
            "probability": 1.0
        },
        {
            "start_logit": 7.71484375,
            "end_logit": -3.146484375,
            "text": "Epstein-Barr virus (EBV",
            "probability": 2.6702880859375e-05
        },
        {
            "start_logit": 7.71484375,
            "end_logit": -4.453125,
            "text": "Epstein",
            "probability": 7.212162017822266e-06
        },
        {
            "start_logit": 7.71484375,
            "end_logit": -4.55859375,
            "text": "Epstein-Barr virus (EBV) by the Monospot slide test to diagnose acute infectious mononucleosis",
            "probability": 6.496906280517578e-06
        },
        {
            "start_logit": -4.62109375,
            "end_logit": 7.38671875,
            "text": "virus",
            "probability": 4.410743713378906e-06
        },
        {
            "start_logit": 7.71484375,
            "end_logit": -5.0390625,
            "text": "Epstein-Barr virus (EBV)",
            "probability": 4.0531158447265625e-06
        },
        {
            "start_logit": 7.71484375,
            "end_logit": -5.125,
            "text": "Epstein-Barr virus (EBV) by the Monospot slide test to diagnose acute infectious mononucleosis and tested for anti-CMV (IgM) by ELISA technique for the diagnosis of acute Cytomegalovirus",
            "probability": 3.6954879760742188e-06
        },
        {
            "start_logit": 7.71484375,
            "end_logit": -6.22265625,
            "text": "Epstein-Barr",
            "probability": 1.2516975402832031e-06
        },
        {
            "start_logit": -6.42578125,
            "end_logit": 7.38671875,
            "text": "against Epstein-Barr virus",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -6.49609375,
            "end_logit": 7.38671875,
            "text": "Hepatitis A (HAV) and Hepatitis B (HBV) were subsequently tested for IGM Heterophil antibodies against Epstein-Barr virus",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 7.71484375,
            "end_logit": -6.9453125,
            "text": "Epstein-Barr virus (",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 7.71484375,
            "end_logit": -7.1953125,
            "text": "Epstein-Barr virus (EBV) by the Monospot slide test to diagnose acute infectious mononucleosis and tested for anti-CMV (IgM) by ELISA technique for the diagnosis of acute Cytomegalovirus (CMV",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 7.71484375,
            "end_logit": -7.203125,
            "text": "Epstein-Barr virus (EBV) by the Monospot slide test to diagnose acute infectious mononucleosis and",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 7.71484375,
            "end_logit": -7.3515625,
            "text": "Epstein-Barr virus (EBV) by the Monospot slide test to diagnose acute infectious mononucleosis and tested for anti-CMV (IgM) by ELISA technique",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 7.71484375,
            "end_logit": -7.4140625,
            "text": "Epstein-Barr virus (EBV) by",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.71484375,
            "end_logit": -7.51953125,
            "text": "Epstein-Barr virus (EBV) by the Monospot slide test to diagnose acute infectious mononucleosis and tested for anti-CMV",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.71484375,
            "end_logit": -7.52734375,
            "text": "Epstein-Barr virus (EBV) by the Monospot slide test to diagnose acute infectious mononucleosis and tested",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.4453125,
            "end_logit": 7.38671875,
            "text": "Barr virus",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.44921875,
            "end_logit": 7.38671875,
            "text": "-Barr virus",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.9375,
            "end_logit": 7.38671875,
            "text": "for IGM Heterophil antibodies against Epstein-Barr virus",
            "probability": 1.7881393432617188e-07
        }
    ],
    "5a690487b750ff445500001f_8": [
        {
            "start_logit": 9.8828125,
            "end_logit": 9.6484375,
            "text": "Epstein-Barr virus",
            "probability": 1.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -1.3408203125,
            "text": "Epstein",
            "probability": 1.6808509826660156e-05
        },
        {
            "start_logit": -1.6259765625,
            "end_logit": 9.6484375,
            "text": "virus",
            "probability": 1.0073184967041016e-05
        },
        {
            "start_logit": -6.3671875,
            "end_logit": 9.6484375,
            "text": "Barr virus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.5,
            "end_logit": 9.6484375,
            "text": "-Barr virus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -6.7890625,
            "text": "Epstein-Barr",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -7.2890625,
            "text": "Epstein-Barr virus.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.12890625,
            "end_logit": 9.6484375,
            "text": "for Epstein-Barr virus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.7109375,
            "end_logit": 9.6484375,
            "text": "positive Monospot test and immunoglobulin G for Epstein-Barr virus",
            "probability": 0.0
        },
        {
            "start_logit": -7.84765625,
            "end_logit": 9.6484375,
            "text": "His septic screen was negative, but he had a positive Monospot test and immunoglobulin G for Epstein-Barr virus",
            "probability": 0.0
        },
        {
            "start_logit": -7.85546875,
            "end_logit": 9.6484375,
            "text": "he had a positive Monospot test and immunoglobulin G for Epstein-Barr virus",
            "probability": 0.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -8.109375,
            "text": "Epstein-",
            "probability": 0.0
        },
        {
            "start_logit": -7.89453125,
            "end_logit": 9.6484375,
            "text": "a positive Monospot test and immunoglobulin G for Epstein-Barr virus",
            "probability": 0.0
        },
        {
            "start_logit": -7.8984375,
            "end_logit": 9.6484375,
            "text": ", but he had a positive Monospot test and immunoglobulin G for Epstein-Barr virus",
            "probability": 0.0
        },
        {
            "start_logit": -7.953125,
            "end_logit": 9.6484375,
            "text": "had a positive Monospot test and immunoglobulin G for Epstein-Barr virus",
            "probability": 0.0
        },
        {
            "start_logit": -7.953125,
            "end_logit": 9.6484375,
            "text": "and immunoglobulin G for Epstein-Barr virus",
            "probability": 0.0
        },
        {
            "start_logit": -8.015625,
            "end_logit": 9.6484375,
            "text": "Monospot test and immunoglobulin G for Epstein-Barr virus",
            "probability": 0.0
        },
        {
            "start_logit": -8.0234375,
            "end_logit": 9.6484375,
            "text": "but he had a positive Monospot test and immunoglobulin G for Epstein-Barr virus",
            "probability": 0.0
        },
        {
            "start_logit": -8.0625,
            "end_logit": 9.6484375,
            "text": "test and immunoglobulin G for Epstein-Barr virus",
            "probability": 0.0
        },
        {
            "start_logit": -8.0703125,
            "end_logit": 9.6484375,
            "text": "immunoglobulin G for Epstein-Barr virus",
            "probability": 0.0
        }
    ],
    "5c89623bf9c2ba6b28000004_1": [
        {
            "start_logit": -4.92578125,
            "end_logit": -3.521484375,
            "text": "(c.19G>A, p.Val7Met",
            "probability": 0.253662109375
        },
        {
            "start_logit": -4.8671875,
            "end_logit": -4.38671875,
            "text": ".",
            "probability": 0.11346435546875
        },
        {
            "start_logit": -5.75,
            "end_logit": -3.521484375,
            "text": "novel homozygous missense mutation in exon 2 (c.19G>A, p.Val7Met",
            "probability": 0.11083984375
        },
        {
            "start_logit": -4.92578125,
            "end_logit": -4.38671875,
            "text": "(c.19G>A, p.Val7Met) of CFL2 was identified in both siblings.",
            "probability": 0.10662841796875
        },
        {
            "start_logit": -6.18359375,
            "end_logit": -3.521484375,
            "text": "Val7Met",
            "probability": 0.07208251953125
        },
        {
            "start_logit": -5.75,
            "end_logit": -4.38671875,
            "text": "novel homozygous missense mutation in exon 2 (c.19G>A, p.Val7Met) of CFL2 was identified in both siblings.",
            "probability": 0.04656982421875
        },
        {
            "start_logit": -6.6328125,
            "end_logit": -3.521484375,
            "text": "missense mutation in exon 2 (c.19G>A, p.Val7Met",
            "probability": 0.04583740234375
        },
        {
            "start_logit": -6.7578125,
            "end_logit": -3.521484375,
            "text": "a novel homozygous missense mutation in exon 2 (c.19G>A, p.Val7Met",
            "probability": 0.040435791015625
        },
        {
            "start_logit": -6.18359375,
            "end_logit": -4.38671875,
            "text": "Val7Met) of CFL2 was identified in both siblings.",
            "probability": 0.030303955078125
        },
        {
            "start_logit": -7.3046875,
            "end_logit": -3.521484375,
            "text": "nemaline myopathy, we performed sequence analysis of the gene and a novel homozygous missense mutation in exon 2 (c.19G>A, p.Val7Met",
            "probability": 0.023406982421875
        },
        {
            "start_logit": -7.34375,
            "end_logit": -3.521484375,
            "text": "mutation in exon 2 (c.19G>A, p.Val7Met",
            "probability": 0.02252197265625
        },
        {
            "start_logit": -6.6328125,
            "end_logit": -4.38671875,
            "text": "missense mutation in exon 2 (c.19G>A, p.Val7Met) of CFL2 was identified in both siblings.",
            "probability": 0.0194244384765625
        },
        {
            "start_logit": -7.53125,
            "end_logit": -3.521484375,
            "text": "with nemaline myopathy, we performed sequence analysis of the gene and a novel homozygous missense mutation in exon 2 (c.19G>A, p.Val7Met",
            "probability": 0.0186767578125
        },
        {
            "start_logit": -7.55078125,
            "end_logit": -3.521484375,
            "text": "homozygous missense mutation in exon 2 (c.19G>A, p.Val7Met",
            "probability": 0.0183868408203125
        },
        {
            "start_logit": -6.6953125,
            "end_logit": -4.38671875,
            "text": "of CFL2 was identified in both siblings.",
            "probability": 0.01824951171875
        },
        {
            "start_logit": -6.7578125,
            "end_logit": -4.38671875,
            "text": "a novel homozygous missense mutation in exon 2 (c.19G>A, p.Val7Met) of CFL2 was identified in both siblings.",
            "probability": 0.017120361328125
        },
        {
            "start_logit": -7.0703125,
            "end_logit": -4.38671875,
            "text": "CFL2 was identified in both siblings.",
            "probability": 0.01253509521484375
        },
        {
            "start_logit": -7.19140625,
            "end_logit": -4.38671875,
            "text": "both siblings.",
            "probability": 0.0110626220703125
        },
        {
            "start_logit": -4.92578125,
            "end_logit": -6.8125,
            "text": "(c.19G>A, p.Val7",
            "probability": 0.00946044921875
        },
        {
            "start_logit": -7.34375,
            "end_logit": -4.38671875,
            "text": "mutation in exon 2 (c.19G>A, p.Val7Met) of CFL2 was identified in both siblings.",
            "probability": 0.00946044921875
        }
    ],
    "56c85ed65795f9a73e000012_1": [
        {
            "start_logit": 6.4453125,
            "end_logit": 0.9384765625,
            "text": "inhibits",
            "probability": 0.98291015625
        },
        {
            "start_logit": 6.4453125,
            "end_logit": -3.23046875,
            "text": "inhibits TCR-mediated signal transduction, cellular proliferation, cytokine production, and in vivo T-cell responses.",
            "probability": 0.0152130126953125
        },
        {
            "start_logit": 6.4453125,
            "end_logit": -7.0625,
            "text": "inhibits TCR-",
            "probability": 0.00032973289489746094
        },
        {
            "start_logit": 6.4453125,
            "end_logit": -7.6484375,
            "text": "inhibits TCR-mediated signal transduction, cellular proliferation",
            "probability": 0.00018346309661865234
        },
        {
            "start_logit": 6.4453125,
            "end_logit": -7.671875,
            "text": "inhibits TCR-mediated signal transduction",
            "probability": 0.000179290771484375
        },
        {
            "start_logit": 6.4453125,
            "end_logit": -7.7265625,
            "text": "inhibits TCR-mediated signal transduction, cellular proliferation, cytokine",
            "probability": 0.0001697540283203125
        },
        {
            "start_logit": 6.4453125,
            "end_logit": -7.73046875,
            "text": "inhibits TCR-mediated signal transduction,",
            "probability": 0.00016832351684570312
        },
        {
            "start_logit": 6.4453125,
            "end_logit": -7.73828125,
            "text": "inhibits TCR-mediated signal transduction, cellular proliferation, cytokine production",
            "probability": 0.00016832351684570312
        },
        {
            "start_logit": 6.4453125,
            "end_logit": -7.83203125,
            "text": "inhibits TCR-mediated signal transduction, cellular proliferation, cytokine production, and",
            "probability": 0.0001533031463623047
        },
        {
            "start_logit": 6.4453125,
            "end_logit": -7.8359375,
            "text": "inhibits TCR-mediated",
            "probability": 0.00015211105346679688
        },
        {
            "start_logit": 6.4453125,
            "end_logit": -7.92578125,
            "text": "inhibits TCR-mediated signal transduction, cellular proliferation,",
            "probability": 0.00013959407806396484
        },
        {
            "start_logit": 6.4453125,
            "end_logit": -7.94140625,
            "text": "inhibits TCR-mediated signal transduction, cellular proliferation, cytokine production, and in vivo T-cell responses",
            "probability": 0.00013744831085205078
        },
        {
            "start_logit": -6.28515625,
            "end_logit": 0.9384765625,
            "text": "that dasatinib inhibits",
            "probability": 2.86102294921875e-06
        },
        {
            "start_logit": -6.7421875,
            "end_logit": 0.9384765625,
            "text": "we show that dasatinib inhibits",
            "probability": 1.7881393432617188e-06
        },
        {
            "start_logit": -6.91796875,
            "end_logit": 0.9384765625,
            "text": "Herein, we show that dasatinib inhibits",
            "probability": 1.5497207641601562e-06
        },
        {
            "start_logit": -7.26953125,
            "end_logit": 0.9384765625,
            "text": ", we show that dasatinib inhibits",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": -7.34765625,
            "end_logit": 0.9384765625,
            "text": "dasatinib inhibits",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": -7.6328125,
            "end_logit": 0.9384765625,
            "text": "show that dasatinib inhibits",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": -7.83203125,
            "end_logit": 0.9384765625,
            "text": "atinib inhibits",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -4.984375,
            "end_logit": -3.23046875,
            "text": ".",
            "probability": 1.7881393432617188e-07
        }
    ],
    "56c85ed65795f9a73e000012_2": [
        {
            "start_logit": 3.74609375,
            "end_logit": 1.759765625,
            "text": "inhibits",
            "probability": 0.9990234375
        },
        {
            "start_logit": 3.74609375,
            "end_logit": -7.38671875,
            "text": "inhibits TCR-",
            "probability": 0.00010627508163452148
        },
        {
            "start_logit": 3.74609375,
            "end_logit": -7.62109375,
            "text": "inhibits TCR-mediated signal transduction, cellular proliferation, cytokine production",
            "probability": 8.410215377807617e-05
        },
        {
            "start_logit": 3.74609375,
            "end_logit": -7.6484375,
            "text": "inhibits TCR-mediated signal transduction, cellular proliferation",
            "probability": 8.213520050048828e-05
        },
        {
            "start_logit": 3.74609375,
            "end_logit": -7.6875,
            "text": "inhibits TCR-mediated signal transduction",
            "probability": 7.838010787963867e-05
        },
        {
            "start_logit": 3.74609375,
            "end_logit": -7.74609375,
            "text": "inhibits TCR-mediated signal transduction, cellular proliferation, cytokine",
            "probability": 7.420778274536133e-05
        },
        {
            "start_logit": 3.74609375,
            "end_logit": -7.78515625,
            "text": "inhibits TCR",
            "probability": 7.134675979614258e-05
        },
        {
            "start_logit": 3.74609375,
            "end_logit": -7.828125,
            "text": "inhibits TCR-mediated signal transduction,",
            "probability": 6.80685043334961e-05
        },
        {
            "start_logit": 3.74609375,
            "end_logit": -7.87109375,
            "text": "inhibits TCR-mediated signal transduction, cellular proliferation, cytokine production, and",
            "probability": 6.55055046081543e-05
        },
        {
            "start_logit": 3.74609375,
            "end_logit": -7.9140625,
            "text": "inhibits TCR-mediated signal transduction, cellular proliferation, cytokine production, and in vivo T-cell responses",
            "probability": 6.29425048828125e-05
        },
        {
            "start_logit": 3.74609375,
            "end_logit": -7.921875,
            "text": "inhibits TCR-mediated",
            "probability": 6.198883056640625e-05
        },
        {
            "start_logit": 3.74609375,
            "end_logit": -7.9609375,
            "text": "inhibits TCR-mediated signal transduction, cellular proliferation,",
            "probability": 6.008148193359375e-05
        },
        {
            "start_logit": 3.74609375,
            "end_logit": -7.97265625,
            "text": "inhibits TCR-mediated signal transduction, cellular proliferation, cytokine production, and in vivo T-",
            "probability": 5.91278076171875e-05
        },
        {
            "start_logit": 3.74609375,
            "end_logit": -7.984375,
            "text": "inhibits TCR-mediated signal transduction, cellular proliferation, cytokine production, and in vivo T",
            "probability": 5.823373794555664e-05
        },
        {
            "start_logit": 3.74609375,
            "end_logit": -7.98828125,
            "text": "inhibits TCR-mediated signal transduction, cellular proliferation, cytokine production, and in",
            "probability": 5.823373794555664e-05
        },
        {
            "start_logit": -6.2578125,
            "end_logit": 1.759765625,
            "text": "that dasatinib inhibits",
            "probability": 4.500150680541992e-05
        },
        {
            "start_logit": -6.95703125,
            "end_logit": 1.759765625,
            "text": "we show that dasatinib inhibits",
            "probability": 2.2470951080322266e-05
        },
        {
            "start_logit": -7.234375,
            "end_logit": 1.759765625,
            "text": "Herein, we show that dasatinib inhibits",
            "probability": 1.6987323760986328e-05
        },
        {
            "start_logit": -7.39453125,
            "end_logit": 1.759765625,
            "text": ", we show that dasatinib inhibits",
            "probability": 1.4483928680419922e-05
        },
        {
            "start_logit": -7.5703125,
            "end_logit": 1.759765625,
            "text": "dasatinib inhibits",
            "probability": 1.2099742889404297e-05
        }
    ],
    "56c85ed65795f9a73e000012_3": [
        {
            "start_logit": -2.98828125,
            "end_logit": -6.98828125,
            "text": "protein tyrosine kinase",
            "probability": 0.1676025390625
        },
        {
            "start_logit": -2.98828125,
            "end_logit": -7.02734375,
            "text": "protein tyrosine kinase inhibitor, inhibits",
            "probability": 0.1612548828125
        },
        {
            "start_logit": -2.98828125,
            "end_logit": -7.0625,
            "text": "protein tyrosine kinase inhibitor",
            "probability": 0.15625
        },
        {
            "start_logit": -2.98828125,
            "end_logit": -7.21875,
            "text": "protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation",
            "probability": 0.1336669921875
        },
        {
            "start_logit": -2.98828125,
            "end_logit": -7.76171875,
            "text": "protein tyrosine kinase inhibitor, inhibits T-cell activation and",
            "probability": 0.07733154296875
        },
        {
            "start_logit": -2.98828125,
            "end_logit": -7.90625,
            "text": "protein tyrosine kinase inhibitor,",
            "probability": 0.06719970703125
        },
        {
            "start_logit": -4.83984375,
            "end_logit": -6.98828125,
            "text": "molecule protein tyrosine kinase",
            "probability": 0.0263214111328125
        },
        {
            "start_logit": -4.83984375,
            "end_logit": -7.02734375,
            "text": "molecule protein tyrosine kinase inhibitor, inhibits",
            "probability": 0.0253143310546875
        },
        {
            "start_logit": -4.83984375,
            "end_logit": -7.0625,
            "text": "molecule protein tyrosine kinase inhibitor",
            "probability": 0.0243377685546875
        },
        {
            "start_logit": -4.83984375,
            "end_logit": -7.21875,
            "text": "molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation",
            "probability": 0.0208282470703125
        },
        {
            "start_logit": -5.09765625,
            "end_logit": -7.02734375,
            "text": "inhibits",
            "probability": 0.019561767578125
        },
        {
            "start_logit": -5.09765625,
            "end_logit": -7.21875,
            "text": "inhibits T-cell activation and proliferation",
            "probability": 0.0162200927734375
        },
        {
            "start_logit": -5.37109375,
            "end_logit": -7.02734375,
            "text": "inhibitor, inhibits",
            "probability": 0.0148773193359375
        },
        {
            "start_logit": -5.37109375,
            "end_logit": -7.0625,
            "text": "inhibitor",
            "probability": 0.01430511474609375
        },
        {
            "start_logit": -5.53125,
            "end_logit": -6.98828125,
            "text": "small-molecule protein tyrosine kinase",
            "probability": 0.0132293701171875
        },
        {
            "start_logit": -5.53125,
            "end_logit": -7.02734375,
            "text": "small-molecule protein tyrosine kinase inhibitor, inhibits",
            "probability": 0.01262664794921875
        },
        {
            "start_logit": -5.37109375,
            "end_logit": -7.21875,
            "text": "inhibitor, inhibits T-cell activation and proliferation",
            "probability": 0.012237548828125
        },
        {
            "start_logit": -5.53125,
            "end_logit": -7.0625,
            "text": "small-molecule protein tyrosine kinase inhibitor",
            "probability": 0.012237548828125
        },
        {
            "start_logit": -4.83984375,
            "end_logit": -7.76171875,
            "text": "molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and",
            "probability": 0.01214599609375
        },
        {
            "start_logit": -5.6171875,
            "end_logit": -6.98828125,
            "text": "tyrosine kinase",
            "probability": 0.012054443359375
        }
    ],
    "56c85ed65795f9a73e000012_4": [
        {
            "start_logit": -0.77880859375,
            "end_logit": 2.2265625,
            "text": "protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation.",
            "probability": 0.455810546875
        },
        {
            "start_logit": -1.2646484375,
            "end_logit": 2.2265625,
            "text": "inhibits T-cell activation and proliferation.",
            "probability": 0.28076171875
        },
        {
            "start_logit": -1.611328125,
            "end_logit": 2.2265625,
            "text": ".",
            "probability": 0.1983642578125
        },
        {
            "start_logit": -3.93359375,
            "end_logit": 2.2265625,
            "text": "molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation.",
            "probability": 0.0194549560546875
        },
        {
            "start_logit": -4.28125,
            "end_logit": 2.2265625,
            "text": "Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation.",
            "probability": 0.01374053955078125
        },
        {
            "start_logit": -4.65234375,
            "end_logit": 2.2265625,
            "text": "small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation.",
            "probability": 0.00948333740234375
        },
        {
            "start_logit": -5.13671875,
            "end_logit": 2.2265625,
            "text": "tyrosine kinase inhibitor, inhibits T-cell activation and proliferation.",
            "probability": 0.005828857421875
        },
        {
            "start_logit": -5.15234375,
            "end_logit": 2.2265625,
            "text": "inhibitor, inhibits T-cell activation and proliferation.",
            "probability": 0.005741119384765625
        },
        {
            "start_logit": -5.98046875,
            "end_logit": 2.2265625,
            "text": "kinase inhibitor, inhibits T-cell activation and proliferation.",
            "probability": 0.0025081634521484375
        },
        {
            "start_logit": -6.24609375,
            "end_logit": 2.2265625,
            "text": "a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation.",
            "probability": 0.0019216537475585938
        },
        {
            "start_logit": -6.62890625,
            "end_logit": 2.2265625,
            "text": "T-cell activation and proliferation.",
            "probability": 0.0013113021850585938
        },
        {
            "start_logit": -6.74609375,
            "end_logit": 2.2265625,
            "text": "activation and proliferation.",
            "probability": 0.0011663436889648438
        },
        {
            "start_logit": -6.7734375,
            "end_logit": 2.2265625,
            "text": ", inhibits T-cell activation and proliferation.",
            "probability": 0.0011396408081054688
        },
        {
            "start_logit": -6.85546875,
            "end_logit": 2.2265625,
            "text": ", a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation.",
            "probability": 0.00104522705078125
        },
        {
            "start_logit": -7.21875,
            "end_logit": 2.2265625,
            "text": "atinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation.",
            "probability": 0.0007295608520507812
        },
        {
            "start_logit": -7.578125,
            "end_logit": 2.2265625,
            "text": "cell activation and proliferation.",
            "probability": 0.0005097389221191406
        },
        {
            "start_logit": -7.79296875,
            "end_logit": 2.2265625,
            "text": "and proliferation.",
            "probability": 0.0004093647003173828
        },
        {
            "start_logit": -0.77880859375,
            "end_logit": -6.53515625,
            "text": "protein tyrosine kinase inhibitor",
            "probability": 7.170438766479492e-05
        },
        {
            "start_logit": -0.77880859375,
            "end_logit": -6.66796875,
            "text": "protein tyrosine kinase inhibitor, inhibits",
            "probability": 6.276369094848633e-05
        },
        {
            "start_logit": -0.77880859375,
            "end_logit": -6.9375,
            "text": "protein tyrosine kinase",
            "probability": 4.774332046508789e-05
        }
    ],
    "56c85ed65795f9a73e000012_5": [
        {
            "start_logit": -1.119140625,
            "end_logit": 3.072265625,
            "text": ".",
            "probability": 0.759765625
        },
        {
            "start_logit": -3.2109375,
            "end_logit": 3.072265625,
            "text": "inhibits the proliferation and function of CD4+CD25+ regulatory T cells.",
            "probability": 0.09381103515625
        },
        {
            "start_logit": -4.1875,
            "end_logit": 3.072265625,
            "text": "CD4+CD25+ regulatory T cells.",
            "probability": 0.03533935546875
        },
        {
            "start_logit": -4.6953125,
            "end_logit": 3.072265625,
            "text": "Dasatinib inhibits the proliferation and function of CD4+CD25+ regulatory T cells.",
            "probability": 0.0212554931640625
        },
        {
            "start_logit": -3.2109375,
            "end_logit": 1.49609375,
            "text": "inhibits the proliferation and function of CD4+CD25+ regulatory T cells",
            "probability": 0.0193939208984375
        },
        {
            "start_logit": -4.87890625,
            "end_logit": 3.072265625,
            "text": "of CD4+CD25+ regulatory T cells.",
            "probability": 0.0176849365234375
        },
        {
            "start_logit": -5.16015625,
            "end_logit": 3.072265625,
            "text": "regulatory T cells.",
            "probability": 0.01337432861328125
        },
        {
            "start_logit": -4.1875,
            "end_logit": 1.49609375,
            "text": "CD4+CD25+ regulatory T cells",
            "probability": 0.00730133056640625
        },
        {
            "start_logit": -6.26953125,
            "end_logit": 3.072265625,
            "text": "CD25+ regulatory T cells.",
            "probability": 0.004413604736328125
        },
        {
            "start_logit": -4.6953125,
            "end_logit": 1.49609375,
            "text": "Dasatinib inhibits the proliferation and function of CD4+CD25+ regulatory T cells",
            "probability": 0.00439453125
        },
        {
            "start_logit": -6.33203125,
            "end_logit": 3.072265625,
            "text": "+CD25+ regulatory T cells.",
            "probability": 0.00414276123046875
        },
        {
            "start_logit": -4.87890625,
            "end_logit": 1.49609375,
            "text": "of CD4+CD25+ regulatory T cells",
            "probability": 0.0036563873291015625
        },
        {
            "start_logit": -6.71875,
            "end_logit": 3.072265625,
            "text": "T cells.",
            "probability": 0.0028057098388671875
        },
        {
            "start_logit": -5.16015625,
            "end_logit": 1.49609375,
            "text": "regulatory T cells",
            "probability": 0.0027618408203125
        },
        {
            "start_logit": -6.859375,
            "end_logit": 3.072265625,
            "text": "function of CD4+CD25+ regulatory T cells.",
            "probability": 0.002437591552734375
        },
        {
            "start_logit": -7.12109375,
            "end_logit": 3.072265625,
            "text": "proliferation and function of CD4+CD25+ regulatory T cells.",
            "probability": 0.0018835067749023438
        },
        {
            "start_logit": -7.16796875,
            "end_logit": 3.072265625,
            "text": "+ regulatory T cells.",
            "probability": 0.001796722412109375
        },
        {
            "start_logit": -7.453125,
            "end_logit": 3.072265625,
            "text": "and function of CD4+CD25+ regulatory T cells.",
            "probability": 0.0013456344604492188
        },
        {
            "start_logit": -7.48828125,
            "end_logit": 3.072265625,
            "text": "the proliferation and function of CD4+CD25+ regulatory T cells.",
            "probability": 0.0013036727905273438
        },
        {
            "start_logit": -7.671875,
            "end_logit": 3.072265625,
            "text": "atinib inhibits the proliferation and function of CD4+CD25+ regulatory T cells.",
            "probability": 0.0010814666748046875
        }
    ],
    "58f4b25e70f9fc6f0f000011_1": [
        {
            "start_logit": 7.234375,
            "end_logit": 7.21484375,
            "text": "Liver",
            "probability": 1.0
        },
        {
            "start_logit": 7.234375,
            "end_logit": -6.171875,
            "text": "Liver Injury Network.",
            "probability": 1.5497207641601562e-06
        },
        {
            "start_logit": -6.24609375,
            "end_logit": 7.21484375,
            "text": "transplant of 10% or higher has been validated in several large national registries, including the ongoing, prospective U.S. Drug-Induced Liver",
            "probability": 1.3709068298339844e-06
        },
        {
            "start_logit": 7.234375,
            "end_logit": -7.265625,
            "text": "Liver Injury",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -7.5390625,
            "end_logit": 7.21484375,
            "text": ", prospective U.S. Drug-Induced Liver",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.546875,
            "end_logit": 7.21484375,
            "text": ". Drug-Induced Liver",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.66796875,
            "end_logit": 7.21484375,
            "text": "prospective U.S. Drug-Induced Liver",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.80078125,
            "end_logit": 7.21484375,
            "text": "Drug-Induced Liver",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.8046875,
            "end_logit": 7.21484375,
            "text": "need for transplant of 10% or higher has been validated in several large national registries, including the ongoing, prospective U.S. Drug-Induced Liver",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.234375,
            "end_logit": -7.84765625,
            "text": "Liver Injury Network",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.828125,
            "end_logit": 7.21484375,
            "text": "case-fatality rate or need for transplant of 10% or higher has been validated in several large national registries, including the ongoing, prospective U.S. Drug-Induced Liver",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.86328125,
            "end_logit": 7.21484375,
            "text": "induced hepatocellular jaundice causing a case-fatality rate or need for transplant of 10% or higher has been validated in several large national registries, including the ongoing, prospective U.S. Drug-Induced Liver",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.8671875,
            "end_logit": 7.21484375,
            "text": "hepatocellular jaundice causing a case-fatality rate or need for transplant of 10% or higher has been validated in several large national registries, including the ongoing, prospective U.S. Drug-Induced Liver",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.8984375,
            "end_logit": 7.21484375,
            "text": "for transplant of 10% or higher has been validated in several large national registries, including the ongoing, prospective U.S. Drug-Induced Liver",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.9296875,
            "end_logit": 7.21484375,
            "text": "ongoing, prospective U.S. Drug-Induced Liver",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.0546875,
            "end_logit": -6.171875,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -6.24609375,
            "end_logit": -6.171875,
            "text": "transplant of 10% or higher has been validated in several large national registries, including the ongoing, prospective U.S. Drug-Induced Liver Injury Network.",
            "probability": 0.0
        },
        {
            "start_logit": -6.24609375,
            "end_logit": -7.265625,
            "text": "transplant of 10% or higher has been validated in several large national registries, including the ongoing, prospective U.S. Drug-Induced Liver Injury",
            "probability": 0.0
        },
        {
            "start_logit": -7.5390625,
            "end_logit": -6.171875,
            "text": ", prospective U.S. Drug-Induced Liver Injury Network.",
            "probability": 0.0
        },
        {
            "start_logit": -7.546875,
            "end_logit": -6.171875,
            "text": ". Drug-Induced Liver Injury Network.",
            "probability": 0.0
        }
    ],
    "58f4b25e70f9fc6f0f000011_2": [
        {
            "start_logit": 7.96875,
            "end_logit": 8.3828125,
            "text": "liver",
            "probability": 1.0
        },
        {
            "start_logit": -7.84765625,
            "end_logit": 8.3828125,
            "text": "with liver",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.96875,
            "end_logit": -7.6171875,
            "text": "liver injury patterns were found to affect potential severity as measured by Hy's Law criteria.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.03125,
            "end_logit": 8.3828125,
            "text": "No additional alleles outside those associated with liver",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.0546875,
            "end_logit": 8.3828125,
            "text": "associated with liver",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.0625,
            "end_logit": 8.3828125,
            "text": "alleles outside those associated with liver",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.96875,
            "end_logit": -8.015625,
            "text": "liver injury patterns were found to affect potential severity as",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.96875,
            "end_logit": -8.0390625,
            "text": "liver injury patterns",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.96875,
            "end_logit": -8.0390625,
            "text": "liver injury patterns were found",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.96875,
            "end_logit": -8.0625,
            "text": "liver injury patterns were found to",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.96875,
            "end_logit": -8.078125,
            "text": "liver injury",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.96875,
            "end_logit": -8.0859375,
            "text": "liver injury patterns were",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.75390625,
            "end_logit": -7.6171875,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.84765625,
            "end_logit": -7.6171875,
            "text": "with liver injury patterns were found to affect potential severity as measured by Hy's Law criteria.",
            "probability": 0.0
        },
        {
            "start_logit": -7.87109375,
            "end_logit": -7.6171875,
            "text": "severity as measured by Hy's Law criteria.",
            "probability": 0.0
        },
        {
            "start_logit": -7.9375,
            "end_logit": -7.6171875,
            "text": "criteria.",
            "probability": 0.0
        },
        {
            "start_logit": -8.0078125,
            "end_logit": -7.6171875,
            "text": "potential severity as measured by Hy's Law criteria.",
            "probability": 0.0
        },
        {
            "start_logit": -8.015625,
            "end_logit": -7.6171875,
            "text": "injury patterns were found to affect potential severity as measured by Hy's Law criteria.",
            "probability": 0.0
        },
        {
            "start_logit": -8.03125,
            "end_logit": -7.6171875,
            "text": "Law criteria.",
            "probability": 0.0
        },
        {
            "start_logit": -8.03125,
            "end_logit": -7.6171875,
            "text": "No additional alleles outside those associated with liver injury patterns were found to affect potential severity as measured by Hy's Law criteria.",
            "probability": 0.0
        }
    ],
    "58f4b25e70f9fc6f0f000011_3": [
        {
            "start_logit": 8.125,
            "end_logit": 8.09375,
            "text": "liver",
            "probability": 1.0
        },
        {
            "start_logit": -6.453125,
            "end_logit": 8.09375,
            "text": ".We conducted a retrospective cohort study of 15,353 Kaiser Permanente Northern California members diagnosed with DILI from 2004 through 2010, liver",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.125,
            "end_logit": -6.70703125,
            "text": "liver aminotransferase levels above the upper limit of normal, and no pre-existing liver disease.",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.125,
            "end_logit": -7.671875,
            "text": "liver aminotransferase levels above the upper limit of normal, and no pre-existing liver",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.125,
            "end_logit": -7.85546875,
            "text": "liver aminotransferase levels above the upper limit of normal",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.84375,
            "end_logit": 8.09375,
            "text": "DILI from 2004 through 2010, liver",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.125,
            "end_logit": -7.8828125,
            "text": "liver aminotransferase levels above the upper limit",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.125,
            "end_logit": -7.88671875,
            "text": "liver aminotransferase levels above the upper limit of",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.875,
            "end_logit": 8.09375,
            "text": "We conducted a retrospective cohort study of 15,353 Kaiser Permanente Northern California members diagnosed with DILI from 2004 through 2010, liver",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.9296875,
            "end_logit": 8.09375,
            "text": ", liver",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.953125,
            "end_logit": 8.09375,
            "text": "model in a separate sample.We conducted a retrospective cohort study of 15,353 Kaiser Permanente Northern California members diagnosed with DILI from 2004 through 2010, liver",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.96484375,
            "end_logit": 8.09375,
            "text": "of 15,353 Kaiser Permanente Northern California members diagnosed with DILI from 2004 through 2010, liver",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.453125,
            "end_logit": -6.70703125,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -6.453125,
            "end_logit": -6.70703125,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.53515625,
            "end_logit": -6.70703125,
            "text": "liver disease.",
            "probability": 0.0
        },
        {
            "start_logit": -7.54296875,
            "end_logit": -6.70703125,
            "text": "DILI based on levels of alanine aminotransferase or aspartate aminotransferase and total bilirubin, and validated the model in a separate sample.",
            "probability": 0.0
        },
        {
            "start_logit": -7.5625,
            "end_logit": -6.70703125,
            "text": "severity of DILI based on levels of alanine aminotransferase or aspartate aminotransferase and total bilirubin, and validated the model in a separate sample.",
            "probability": 0.0
        },
        {
            "start_logit": -6.453125,
            "end_logit": -7.85546875,
            "text": ".We conducted a retrospective cohort study of 15,353 Kaiser Permanente Northern California members diagnosed with DILI from 2004 through 2010, liver aminotransferase levels above the upper limit of normal",
            "probability": 0.0
        },
        {
            "start_logit": -6.453125,
            "end_logit": -7.875,
            "text": ".We conducted a retrospective cohort study of 15",
            "probability": 0.0
        },
        {
            "start_logit": -6.453125,
            "end_logit": -7.8828125,
            "text": ".We conducted a retrospective cohort study of 15,353 Kaiser Permanente Northern California members diagnosed with DILI from 2004 through 2010, liver aminotransferase levels above the upper limit",
            "probability": 0.0
        }
    ],
    "58f4b25e70f9fc6f0f000011_4": [
        {
            "start_logit": 8.5234375,
            "end_logit": 7.8203125,
            "text": "Liver",
            "probability": 1.0
        },
        {
            "start_logit": 8.5234375,
            "end_logit": -6.55078125,
            "text": "Liver Failure",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 8.5234375,
            "end_logit": -7.80859375,
            "text": "Liver Failure in Patients With Drug-Induced Liver Injury: Evaluation of Hy's Law and a New Prognostic Model.",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.5234375,
            "end_logit": -7.96484375,
            "text": "Liver Failure in Patients With Drug-Induced Liver Injury",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.5234375,
            "end_logit": -7.96875,
            "text": "Liver Failure in",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.5234375,
            "end_logit": -8.0546875,
            "text": "Liver Failure in Patients With Drug-",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.5234375,
            "end_logit": -8.078125,
            "text": "Liver Failure in Patients With Drug-Induced Liver Injury:",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.5234375,
            "end_logit": -8.0859375,
            "text": "Liver Failure in Patients With",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.5234375,
            "end_logit": -8.09375,
            "text": "Liver Failure in Patients With Drug-Induced Liver",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.56640625,
            "end_logit": 7.8203125,
            "text": "Risk of Acute Liver",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.59765625,
            "end_logit": 7.8203125,
            "text": "Acute Liver",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.56640625,
            "end_logit": -6.55078125,
            "text": "Risk of Acute Liver Failure",
            "probability": 0.0
        },
        {
            "start_logit": -7.59765625,
            "end_logit": -6.55078125,
            "text": "Acute Liver Failure",
            "probability": 0.0
        },
        {
            "start_logit": -6.80078125,
            "end_logit": -7.80859375,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.56640625,
            "end_logit": -7.80859375,
            "text": "Risk of Acute Liver Failure in Patients With Drug-Induced Liver Injury: Evaluation of Hy's Law and a New Prognostic Model.",
            "probability": 0.0
        },
        {
            "start_logit": -7.59765625,
            "end_logit": -7.80859375,
            "text": "Acute Liver Failure in Patients With Drug-Induced Liver Injury: Evaluation of Hy's Law and a New Prognostic Model.",
            "probability": 0.0
        },
        {
            "start_logit": -7.56640625,
            "end_logit": -7.96484375,
            "text": "Risk of Acute Liver Failure in Patients With Drug-Induced Liver Injury",
            "probability": 0.0
        },
        {
            "start_logit": -7.56640625,
            "end_logit": -7.96875,
            "text": "Risk of Acute Liver Failure in",
            "probability": 0.0
        },
        {
            "start_logit": -7.59765625,
            "end_logit": -7.96484375,
            "text": "Acute Liver Failure in Patients With Drug-Induced Liver Injury",
            "probability": 0.0
        },
        {
            "start_logit": -7.59765625,
            "end_logit": -7.96875,
            "text": "Acute Liver Failure in",
            "probability": 0.0
        }
    ],
    "58f4b25e70f9fc6f0f000011_5": [
        {
            "start_logit": 8.203125,
            "end_logit": 8.078125,
            "text": "liver",
            "probability": 1.0
        },
        {
            "start_logit": 8.203125,
            "end_logit": -7.37890625,
            "text": "liver injury (DILI) with jaundice indicates a serious reaction, is used widely to determine risk for acute liver failure (ALF).",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.40234375,
            "end_logit": 8.078125,
            "text": "that hepatocellular drug-induced liver",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.58203125,
            "end_logit": 8.078125,
            "text": "states that hepatocellular drug-induced liver",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.203125,
            "end_logit": -7.9765625,
            "text": "liver injury (DILI)",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.87109375,
            "end_logit": 8.078125,
            "text": "Law, which states that hepatocellular drug-induced liver",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.875,
            "end_logit": 8.078125,
            "text": "Hy's Law, which states that hepatocellular drug-induced liver",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.875,
            "end_logit": 8.078125,
            "text": "drug-induced liver",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.87890625,
            "end_logit": 8.078125,
            "text": "which states that hepatocellular drug-induced liver",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.203125,
            "end_logit": -8.0078125,
            "text": "liver injury",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.203125,
            "end_logit": -8.015625,
            "text": "liver injury (DILI) with jaundice indicates a serious reaction, is used widely to determine risk for acute liver failure",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.203125,
            "end_logit": -8.0234375,
            "text": "liver injury (DILI) with jaundice indicates a serious reaction,",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.203125,
            "end_logit": -8.03125,
            "text": "liver injury (DILI) with jaundice indicates a serious reaction, is used widely to determine risk for acute liver",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.203125,
            "end_logit": -8.0390625,
            "text": "liver injury (DILI) with",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.203125,
            "end_logit": -8.046875,
            "text": "liver injury (DILI) with jaundice indicates a",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.203125,
            "end_logit": -8.0546875,
            "text": "liver injury (DILI",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.203125,
            "end_logit": -8.0546875,
            "text": "liver injury (DILI) with jaundice indicates",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.93359375,
            "end_logit": 8.078125,
            "text": ", which states that hepatocellular drug-induced liver",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.203125,
            "end_logit": -8.0625,
            "text": "liver injury (DILI) with jaundice indicates a serious reaction, is used widely to determine risk for acute liver failure (ALF",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.94140625,
            "end_logit": 8.078125,
            "text": "induced liver",
            "probability": 1.1920928955078125e-07
        }
    ],
    "58f4b25e70f9fc6f0f000011_6": [
        {
            "start_logit": 7.6171875,
            "end_logit": 8.4609375,
            "text": "liver",
            "probability": 1.0
        },
        {
            "start_logit": -7.4765625,
            "end_logit": 8.4609375,
            "text": "identify drug-induced liver",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.75,
            "end_logit": 8.4609375,
            "text": "drug-induced liver",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.796875,
            "end_logit": 8.4609375,
            "text": "method used to identify drug-induced liver",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.8046875,
            "end_logit": 8.4609375,
            "text": "induced liver",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.828125,
            "end_logit": 8.4609375,
            "text": "to identify drug-induced liver",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.87890625,
            "end_logit": 8.4609375,
            "text": "Hy's law is a method used to identify drug-induced liver",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.9140625,
            "end_logit": 8.4609375,
            "text": "used to identify drug-induced liver",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.96484375,
            "end_logit": 8.4609375,
            "text": "law is a method used to identify drug-induced liver",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -8.046875,
            "end_logit": 8.4609375,
            "text": "a method used to identify drug-induced liver",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -8.0703125,
            "end_logit": 8.4609375,
            "text": "s law is a method used to identify drug-induced liver",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -8.0859375,
            "end_logit": 8.4609375,
            "text": "is a method used to identify drug-induced liver",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.6171875,
            "end_logit": -7.859375,
            "text": "liver injury",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.6171875,
            "end_logit": -7.95703125,
            "text": "liver injury (DILI)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.4765625,
            "end_logit": -7.859375,
            "text": "identify drug-induced liver injury",
            "probability": 0.0
        },
        {
            "start_logit": -7.4765625,
            "end_logit": -7.95703125,
            "text": "identify drug-induced liver injury (DILI)",
            "probability": 0.0
        },
        {
            "start_logit": -7.75,
            "end_logit": -7.859375,
            "text": "drug-induced liver injury",
            "probability": 0.0
        },
        {
            "start_logit": -7.796875,
            "end_logit": -7.859375,
            "text": "method used to identify drug-induced liver injury",
            "probability": 0.0
        },
        {
            "start_logit": -7.8046875,
            "end_logit": -7.859375,
            "text": "induced liver injury",
            "probability": 0.0
        },
        {
            "start_logit": -7.828125,
            "end_logit": -7.859375,
            "text": "to identify drug-induced liver injury",
            "probability": 0.0
        }
    ],
    "58f4b25e70f9fc6f0f000011_7": [
        {
            "start_logit": 8.0234375,
            "end_logit": 8.3046875,
            "text": "liver",
            "probability": 1.0
        },
        {
            "start_logit": -7.91015625,
            "end_logit": 8.3046875,
            "text": "Potential severe liver",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.96875,
            "end_logit": 8.3046875,
            "text": "severe liver",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.0234375,
            "end_logit": -8.109375,
            "text": "liver injury is identified in clinical trials by ALT>3 \u00d7 upper limits of normal (ULN",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.0234375,
            "end_logit": -8.109375,
            "text": "liver injury is identified in clinical trials by ALT>3 \u00d7 upper limits of normal (ULN) and total bilirubin>2 \u00d7 ULN",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.0234375,
            "end_logit": -8.109375,
            "text": "liver injury is identified in clinical trials by ALT>3 \u00d7 upper limits of normal (ULN) and total bilirubin>2 \u00d7 ULN, and termed 'Hy's Law' by",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.0234375,
            "end_logit": -8.1171875,
            "text": "liver injury is identified in clinical trials by ALT>3 \u00d7 upper limits of",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.0234375,
            "end_logit": -8.1171875,
            "text": "liver injury is identified in clinical trials by ALT>3 \u00d7 upper limits of normal",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.0234375,
            "end_logit": -8.1328125,
            "text": "liver injury is identified in clinical trials by ALT>3 \u00d7 upper limits of normal (ULN) and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.0234375,
            "end_logit": -8.15625,
            "text": "liver injury is identified in clinical trials by ALT>3 \u00d7 upper limits of normal (ULN) and total bilirubin>2 \u00d7 UL",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.0234375,
            "end_logit": -8.1640625,
            "text": "liver injury is identified in clinical trials by ALT>3 \u00d7 upper limits of normal (ULN) and total bilirubin>2 \u00d7",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.0234375,
            "end_logit": -8.1640625,
            "text": "liver injury is identified in clinical trials by ALT>3 \u00d7 upper limits of normal (ULN) and total bilirubin>2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.0234375,
            "end_logit": -8.1640625,
            "text": "liver injury is identified in clinical trials by ALT>3 \u00d7 upper limits of normal (ULN) and total",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.7421875,
            "end_logit": -7.58203125,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.828125,
            "end_logit": -7.58203125,
            "text": "'Hy's Law' by the US FDA.",
            "probability": 0.0
        },
        {
            "start_logit": -7.87890625,
            "end_logit": -7.58203125,
            "text": "termed 'Hy's Law' by the US FDA.",
            "probability": 0.0
        },
        {
            "start_logit": -7.890625,
            "end_logit": -7.58203125,
            "text": "clinical trials by ALT>3 \u00d7 upper limits of normal (ULN) and total bilirubin>2 \u00d7 ULN, and termed 'Hy's Law' by the US FDA.",
            "probability": 0.0
        },
        {
            "start_logit": -7.9609375,
            "end_logit": -7.58203125,
            "text": "(ULN) and total bilirubin>2 \u00d7 ULN, and termed 'Hy's Law' by the US FDA.",
            "probability": 0.0
        },
        {
            "start_logit": -7.984375,
            "end_logit": -7.58203125,
            "text": "in clinical trials by ALT>3 \u00d7 upper limits of normal (ULN) and total bilirubin>2 \u00d7 ULN, and termed 'Hy's Law' by the US FDA.",
            "probability": 0.0
        },
        {
            "start_logit": -7.9921875,
            "end_logit": -7.58203125,
            "text": ") and total bilirubin>2 \u00d7 ULN, and termed 'Hy's Law' by the US FDA.",
            "probability": 0.0
        }
    ],
    "58f4b25e70f9fc6f0f000011_8": [
        {
            "start_logit": 7.98046875,
            "end_logit": 8.3359375,
            "text": "liver",
            "probability": 1.0
        },
        {
            "start_logit": -7.71484375,
            "end_logit": 8.3359375,
            "text": "Severe liver",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.98046875,
            "end_logit": -7.9765625,
            "text": "liver injury is identified by the liver chemistry threshold of alanine aminotransferase (ALT",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.98046875,
            "end_logit": -7.99609375,
            "text": "liver injury is identified by the liver chemistry threshold of alanine aminotransferase",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.98046875,
            "end_logit": -8.015625,
            "text": "liver injury is identified by the liver chemistry threshold of alanine aminotransferase (ALT)>3\u00d7 upper limit of normal (ULN) and bilirubin>2\u00d7 ULN",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.98046875,
            "end_logit": -8.0234375,
            "text": "liver injury is identified by the liver chemistry threshold of alanine aminotransferase (ALT)>3\u00d7 upper limit of normal (ULN",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.98046875,
            "end_logit": -8.0234375,
            "text": "liver injury is identified by the liver chemistry threshold of alanine aminotransferase (ALT)>3\u00d7 upper limit of normal (ULN) and bilirubin>2\u00d7 UL",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.98046875,
            "end_logit": -8.0234375,
            "text": "liver injury",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.98046875,
            "end_logit": -8.0234375,
            "text": "liver injury is identified by the liver chemistry threshold of alanine aminotransferase (ALT)>3\u00d7 upper limit of normal",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.98046875,
            "end_logit": -8.0625,
            "text": "liver injury is identified by the liver chemistry threshold of alanine aminotransferase (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.98046875,
            "end_logit": -8.0703125,
            "text": "liver injury is identified by the liver",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.98046875,
            "end_logit": -8.0703125,
            "text": "liver injury is identified by the liver chemistry threshold of alanine aminotransferase (ALT)>3\u00d7 upper limit of normal (ULN) and bilirubin>",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.98046875,
            "end_logit": -8.078125,
            "text": "liver injury is identified by the liver chemistry threshold of alanine aminotransferase (ALT)>3\u00d7 upper limit of normal (ULN) and bilirubin>2\u00d7",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.98046875,
            "end_logit": -8.0859375,
            "text": "liver injury is identified by the liver chemistry threshold of alanine aminotransferase (ALT)>3\u00d7 upper limit of normal (ULN) and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.98046875,
            "end_logit": -8.09375,
            "text": "liver injury is identified by the liver chemistry threshold of alanine aminotransferase (ALT)>3\u00d7 upper limit of normal (ULN) and bilirubin>2\u00d7 ULN,",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.98046875,
            "end_logit": -8.1015625,
            "text": "liver injury is identified by the liver chemistry threshold of alanine aminotransferase (ALT)>3\u00d7 upper limit of normal (UL",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.69140625,
            "end_logit": -7.421875,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.58984375,
            "end_logit": -7.421875,
            "text": "liver chemistry threshold of alanine aminotransferase (ALT)>3\u00d7 upper limit of normal (ULN) and bilirubin>2\u00d7 ULN, termed Hy's law by the Food and Drug Administration.",
            "probability": 0.0
        },
        {
            "start_logit": -7.921875,
            "end_logit": -7.421875,
            "text": "the Food and Drug Administration.",
            "probability": 0.0
        },
        {
            "start_logit": -7.58984375,
            "end_logit": -7.7734375,
            "text": "liver chemistry threshold of alanine aminotransferase (ALT)>3\u00d7 upper limit of normal (ULN) and bilirubin>2\u00d7 ULN, termed Hy's law by the Food and Drug Administration",
            "probability": 0.0
        }
    ],
    "5a7237672dc08e987e000008_1": [
        {
            "start_logit": 8.359375,
            "end_logit": 7.9609375,
            "text": "dabigatran",
            "probability": 1.0
        },
        {
            "start_logit": 8.359375,
            "end_logit": -7.5703125,
            "text": "dabigatran.",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.68359375,
            "end_logit": 7.9609375,
            "text": ", dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.93359375,
            "end_logit": 7.9609375,
            "text": "DOACs i.e., dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.99609375,
            "end_logit": 7.9609375,
            "text": ", idarucizumab for one of the DOACs i.e., dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.046875,
            "end_logit": 7.9609375,
            "text": "one of the DOACs i.e., dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0546875,
            "end_logit": 7.9609375,
            "text": "Food and Drug Administration (FDA), idarucizumab for one of the DOACs i.e., dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0703125,
            "end_logit": 7.9609375,
            "text": "So far only one reversal agent has been approved by the Food and Drug Administration (FDA), idarucizumab for one of the DOACs i.e., dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.09375,
            "end_logit": 7.9609375,
            "text": "), idarucizumab for one of the DOACs i.e., dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.09375,
            "end_logit": 7.9609375,
            "text": "one reversal agent has been approved by the Food and Drug Administration (FDA), idarucizumab for one of the DOACs i.e., dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.09375,
            "end_logit": 7.9609375,
            "text": "agent has been approved by the Food and Drug Administration (FDA), idarucizumab for one of the DOACs i.e., dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1015625,
            "end_logit": 7.9609375,
            "text": "idarucizumab for one of the DOACs i.e., dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1015625,
            "end_logit": 7.9609375,
            "text": "FDA), idarucizumab for one of the DOACs i.e., dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1171875,
            "end_logit": 7.9609375,
            "text": "ACs i.e., dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1171875,
            "end_logit": 7.9609375,
            "text": "Drug Administration (FDA), idarucizumab for one of the DOACs i.e., dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1171875,
            "end_logit": 7.9609375,
            "text": "reversal agent has been approved by the Food and Drug Administration (FDA), idarucizumab for one of the DOACs i.e., dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.80078125,
            "end_logit": -7.5703125,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.68359375,
            "end_logit": -7.5703125,
            "text": ", dabigatran.",
            "probability": 0.0
        },
        {
            "start_logit": -7.93359375,
            "end_logit": -7.5703125,
            "text": "DOACs i.e., dabigatran.",
            "probability": 0.0
        },
        {
            "start_logit": -7.99609375,
            "end_logit": -7.5703125,
            "text": ", idarucizumab for one of the DOACs i.e., dabigatran.",
            "probability": 0.0
        }
    ],
    "5a7237672dc08e987e000008_2": [
        {
            "start_logit": 3.94140625,
            "end_logit": 2.71484375,
            "text": "anticoagulants",
            "probability": 0.998046875
        },
        {
            "start_logit": 3.94140625,
            "end_logit": -4.90625,
            "text": "anticoagulants such as apixaban, rivaroxaban, or dabigatran may be preferred to vitamin K",
            "probability": 0.0004892349243164062
        },
        {
            "start_logit": 3.94140625,
            "end_logit": -5.15234375,
            "text": "anticoagulants such as apixaban, rivaroxaban, or dabigatran may",
            "probability": 0.00038242340087890625
        },
        {
            "start_logit": 3.94140625,
            "end_logit": -6.43359375,
            "text": "anticoagulants such as apixaban, rivaroxaban, or dabigatran",
            "probability": 0.0001062154769897461
        },
        {
            "start_logit": 3.94140625,
            "end_logit": -6.7578125,
            "text": "anticoagulants such as apixaban, rivaroxaban, or dabigatran may be preferred to vitamin K antagonists",
            "probability": 7.706880569458008e-05
        },
        {
            "start_logit": 3.94140625,
            "end_logit": -7.19140625,
            "text": "anticoagulants such as apixaban, rivaroxaban, or dabigatran may be",
            "probability": 4.976987838745117e-05
        },
        {
            "start_logit": 3.94140625,
            "end_logit": -7.22265625,
            "text": "anticoagulants such as apixaban, rivaroxaban, or dabigatran may be preferred to vitamin K antagonists in",
            "probability": 4.8220157623291016e-05
        },
        {
            "start_logit": 3.94140625,
            "end_logit": -7.296875,
            "text": "anticoagulants such",
            "probability": 4.464387893676758e-05
        },
        {
            "start_logit": 3.94140625,
            "end_logit": -7.33203125,
            "text": "anticoagulants such as apixaban, rivaroxaban, or dabigatran may be preferred to vitamin K antagonists in patients without cancer or renal failure, more so after the development of reversal agents such",
            "probability": 4.3272972106933594e-05
        },
        {
            "start_logit": 3.94140625,
            "end_logit": -7.578125,
            "text": "anticoagulants such as apixaban, rivaroxaban, or dabigatran may be preferred",
            "probability": 3.36766242980957e-05
        },
        {
            "start_logit": 3.94140625,
            "end_logit": -7.62109375,
            "text": "anticoagulants such as apixaban, rivaroxaban, or dabigatran may be preferred to vitamin K antagonists in patients without cancer or renal failure, more so after",
            "probability": 3.236532211303711e-05
        },
        {
            "start_logit": 3.94140625,
            "end_logit": -7.64453125,
            "text": "anticoagulants such as apixaban, rivaroxaban, or dabigatran may be preferred to vitamin K antagonists in patients without cancer or renal failure, more so",
            "probability": 3.165006637573242e-05
        },
        {
            "start_logit": 3.94140625,
            "end_logit": -7.66015625,
            "text": "anticoagulants such as apixaban, rivaroxaban",
            "probability": 3.1113624572753906e-05
        },
        {
            "start_logit": 3.94140625,
            "end_logit": -7.6796875,
            "text": "anticoagulants such as apixaban, rivaroxaban, or dabigatran may be preferred to vitamin K antagonists in patients without cancer or renal failure,",
            "probability": 3.063678741455078e-05
        },
        {
            "start_logit": 3.94140625,
            "end_logit": -7.6875,
            "text": "anticoagulants such as apixaban, rivaroxaban, or dabigatran may be preferred to vitamin K antagonists in patients",
            "probability": 3.0159950256347656e-05
        },
        {
            "start_logit": 3.94140625,
            "end_logit": -7.69140625,
            "text": "anticoagulants such as apixaban, rivaroxaban, or dabigatran may be preferred to vitamin K antagonists in patients without",
            "probability": 3.0159950256347656e-05
        },
        {
            "start_logit": -7.21484375,
            "end_logit": 2.71484375,
            "text": "oral anticoagulants",
            "probability": 1.430511474609375e-05
        },
        {
            "start_logit": -7.45703125,
            "end_logit": 2.71484375,
            "text": "New oral anticoagulants",
            "probability": 1.1205673217773438e-05
        },
        {
            "start_logit": -0.9765625,
            "end_logit": -3.87890625,
            "text": "vitamin K antagonists in patients without cancer or renal failure, more so after the development of reversal agents such as idarucizumab and andexanet alfa.",
            "probability": 9.953975677490234e-06
        },
        {
            "start_logit": -0.9765625,
            "end_logit": -4.90625,
            "text": "vitamin K",
            "probability": 3.5762786865234375e-06
        }
    ],
    "5a7237672dc08e987e000008_3": [
        {
            "start_logit": 8.0078125,
            "end_logit": 8.390625,
            "text": "dabigatran",
            "probability": 1.0
        },
        {
            "start_logit": -7.875,
            "end_logit": 8.390625,
            "text": "Idarucizumab resulted in immediate, complete and sustained reversal of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.91796875,
            "end_logit": 8.390625,
            "text": "of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.98828125,
            "end_logit": 8.390625,
            "text": "rucizumab resulted in immediate, complete and sustained reversal of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.0078125,
            "end_logit": 8.390625,
            "text": "izumab resulted in immediate, complete and sustained reversal of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.0078125,
            "end_logit": 8.390625,
            "text": "immediate, complete and sustained reversal of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.015625,
            "end_logit": 8.390625,
            "text": "reversal of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.03125,
            "end_logit": 8.390625,
            "text": "complete and sustained reversal of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.0390625,
            "end_logit": 8.390625,
            "text": "in immediate, complete and sustained reversal of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.0625,
            "end_logit": 8.390625,
            "text": ", complete and sustained reversal of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.0078125,
            "end_logit": -7.84765625,
            "text": "dabigatran anticoagulant activity, and was safe and well tolerated in middle-aged, elderly and renally impaired volunteers.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.0078125,
            "end_logit": -7.98046875,
            "text": "dabigatran anticoagulant",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.0078125,
            "end_logit": -8.0390625,
            "text": "dabigatran anticoagulant activity",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.0078125,
            "end_logit": -8.1796875,
            "text": "dabigatran anticoagulant activity, and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.94921875,
            "end_logit": -7.84765625,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.875,
            "end_logit": -7.84765625,
            "text": "Idarucizumab resulted in immediate, complete and sustained reversal of dabigatran anticoagulant activity, and was safe and well tolerated in middle-aged, elderly and renally impaired volunteers.",
            "probability": 0.0
        },
        {
            "start_logit": -7.91796875,
            "end_logit": -7.84765625,
            "text": "of dabigatran anticoagulant activity, and was safe and well tolerated in middle-aged, elderly and renally impaired volunteers.",
            "probability": 0.0
        },
        {
            "start_logit": -7.98828125,
            "end_logit": -7.84765625,
            "text": "rucizumab resulted in immediate, complete and sustained reversal of dabigatran anticoagulant activity, and was safe and well tolerated in middle-aged, elderly and renally impaired volunteers.",
            "probability": 0.0
        },
        {
            "start_logit": -7.875,
            "end_logit": -7.98046875,
            "text": "Idarucizumab resulted in immediate, complete and sustained reversal of dabigatran anticoagulant",
            "probability": 0.0
        },
        {
            "start_logit": -8.0078125,
            "end_logit": -7.84765625,
            "text": "izumab resulted in immediate, complete and sustained reversal of dabigatran anticoagulant activity, and was safe and well tolerated in middle-aged, elderly and renally impaired volunteers.",
            "probability": 0.0
        }
    ],
    "5a7237672dc08e987e000008_4": [
        {
            "start_logit": 8.2109375,
            "end_logit": 8.1796875,
            "text": "Dabigatran",
            "probability": 1.0
        },
        {
            "start_logit": 8.2109375,
            "end_logit": -7.7734375,
            "text": "Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.7578125,
            "end_logit": 8.1796875,
            "text": "Reversal of Dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.2109375,
            "end_logit": -7.9375,
            "text": "Dabigatran Anticoagulant Activity",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.2109375,
            "end_logit": -7.953125,
            "text": "Dabigatran Anticoagulant",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.921875,
            "end_logit": 8.1796875,
            "text": "of Dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.98046875,
            "end_logit": 8.1796875,
            "text": "Mediated Reversal of Dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.2109375,
            "end_logit": -8.0390625,
            "text": "Dabigatran Anticoagulant Activity in",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.0078125,
            "end_logit": 8.1796875,
            "text": "Idarucizumab-Mediated Reversal of Dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.0234375,
            "end_logit": 8.1796875,
            "text": "Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.2109375,
            "end_logit": -8.0703125,
            "text": "Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0859375,
            "end_logit": 8.1796875,
            "text": "Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1171875,
            "end_logit": 8.1796875,
            "text": "rucizumab-Mediated Reversal of Dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.2109375,
            "end_logit": -8.1640625,
            "text": "Dabigatran Anticoagulant Activity in a Randomized, Double-Blind",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.0390625,
            "end_logit": -7.7734375,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.63671875,
            "end_logit": -7.7734375,
            "text": "Phase Ib Study.",
            "probability": 0.0
        },
        {
            "start_logit": -7.7578125,
            "end_logit": -7.7734375,
            "text": "Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study.",
            "probability": 0.0
        },
        {
            "start_logit": -7.8203125,
            "end_logit": -7.7734375,
            "text": "Study.",
            "probability": 0.0
        },
        {
            "start_logit": -7.7578125,
            "end_logit": -7.9375,
            "text": "Reversal of Dabigatran Anticoagulant Activity",
            "probability": 0.0
        },
        {
            "start_logit": -7.921875,
            "end_logit": -7.7734375,
            "text": "of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study.",
            "probability": 0.0
        }
    ],
    "5a7237672dc08e987e000008_5": [
        {
            "start_logit": 8.0078125,
            "end_logit": 8.3125,
            "text": "dabigatran",
            "probability": 1.0
        },
        {
            "start_logit": -7.48828125,
            "end_logit": 8.3125,
            "text": "reversal of dabigatran",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.73046875,
            "end_logit": 8.3125,
            "text": "of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.81640625,
            "end_logit": 8.3125,
            "text": "the reversal of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.875,
            "end_logit": 8.3125,
            "text": "We also discuss reversal strategies, both specific and nonspecific, for each drug, including the preferential use of idarucizumab for the reversal of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.94921875,
            "end_logit": 8.3125,
            "text": "drug, including the preferential use of idarucizumab for the reversal of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.98046875,
            "end_logit": 8.3125,
            "text": "use of idarucizumab for the reversal of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.98828125,
            "end_logit": 8.3125,
            "text": "the preferential use of idarucizumab for the reversal of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.0078125,
            "end_logit": 8.3125,
            "text": "idarucizumab for the reversal of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.015625,
            "end_logit": 8.3125,
            "text": "reversal strategies, both specific and nonspecific, for each drug, including the preferential use of idarucizumab for the reversal of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.0234375,
            "end_logit": 8.3125,
            "text": "both specific and nonspecific, for each drug, including the preferential use of idarucizumab for the reversal of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.03125,
            "end_logit": 8.3125,
            "text": "discuss reversal strategies, both specific and nonspecific, for each drug, including the preferential use of idarucizumab for the reversal of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.0078125,
            "end_logit": -7.734375,
            "text": "dabigatran and two agents, andexanet and ciraparantag, currently under development for the reversal of rivaroxaban, apixaban, and edoxaban.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.0078125,
            "end_logit": -8.0234375,
            "text": "dabigatran and two agents, andexanet and ciraparantag, currently",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.0078125,
            "end_logit": -8.0234375,
            "text": "dabigatran and two agents, andexanet and ciraparantag, currently under development for the reversal of rivaroxaban",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.0078125,
            "end_logit": -8.046875,
            "text": "dabigatran and two agents, andexanet and ciraparantag, currently under",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.0078125,
            "end_logit": -8.078125,
            "text": "dabigatran and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.0078125,
            "end_logit": -8.0859375,
            "text": "dabigatran and two agents, andexanet and ciraparantag, currently under development for the reversal",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.0078125,
            "end_logit": -8.1015625,
            "text": "dabigatran and two agents, andexanet and ciraparantag, currently under development",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.0078125,
            "end_logit": -8.109375,
            "text": "dabigatran and two agents, andexanet and ciraparantag, currently under development for the reversal of rivaroxaban,",
            "probability": 5.960464477539063e-08
        }
    ],
    "5a7237672dc08e987e000008_6": [
        {
            "start_logit": 8.3203125,
            "end_logit": 8.0625,
            "text": "dabigatran",
            "probability": 1.0
        },
        {
            "start_logit": -6.4609375,
            "end_logit": 8.0625,
            "text": "of dabigatran",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.3203125,
            "end_logit": -7.55859375,
            "text": "dabigatran.",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.421875,
            "end_logit": 8.0625,
            "text": "urgent reversal of the anticoagulant effects of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.5234375,
            "end_logit": 8.0625,
            "text": "anticoagulant effects of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.8359375,
            "end_logit": 8.0625,
            "text": "Idarucizumab is a targeted reversal agent that is approved for the urgent reversal of the anticoagulant effects of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.859375,
            "end_logit": 8.0625,
            "text": "reversal of the anticoagulant effects of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.86328125,
            "end_logit": 8.0625,
            "text": "the urgent reversal of the anticoagulant effects of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.8984375,
            "end_logit": 8.0625,
            "text": "targeted reversal agent that is approved for the urgent reversal of the anticoagulant effects of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.9140625,
            "end_logit": 8.0625,
            "text": "effects of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.9375,
            "end_logit": 8.0625,
            "text": "is approved for the urgent reversal of the anticoagulant effects of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.9453125,
            "end_logit": 8.0625,
            "text": "rucizumab is a targeted reversal agent that is approved for the urgent reversal of the anticoagulant effects of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.953125,
            "end_logit": 8.0625,
            "text": "approved for the urgent reversal of the anticoagulant effects of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.96875,
            "end_logit": 8.0625,
            "text": "izumab is a targeted reversal agent that is approved for the urgent reversal of the anticoagulant effects of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0078125,
            "end_logit": 8.0625,
            "text": "for the urgent reversal of the anticoagulant effects of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.015625,
            "end_logit": 8.0625,
            "text": "agent that is approved for the urgent reversal of the anticoagulant effects of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.015625,
            "end_logit": 8.0625,
            "text": "the anticoagulant effects of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.4609375,
            "end_logit": -7.55859375,
            "text": "of dabigatran.",
            "probability": 0.0
        },
        {
            "start_logit": -6.88671875,
            "end_logit": -7.55859375,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.421875,
            "end_logit": -7.55859375,
            "text": "urgent reversal of the anticoagulant effects of dabigatran.",
            "probability": 0.0
        }
    ],
    "5a7237672dc08e987e000008_7": [
        {
            "start_logit": 8.3046875,
            "end_logit": 8.09375,
            "text": "dabigatran",
            "probability": 1.0
        },
        {
            "start_logit": -7.17578125,
            "end_logit": 8.09375,
            "text": "with dabigatran",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.3046875,
            "end_logit": -7.5625,
            "text": "dabigatran.",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.37109375,
            "end_logit": 8.09375,
            "text": "associated with dabigatran",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.71484375,
            "end_logit": 8.09375,
            "text": "bleeding associated with dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.83203125,
            "end_logit": 8.09375,
            "text": "treatment of bleeding associated with dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.86328125,
            "end_logit": 8.09375,
            "text": "CONCLUSIONS: The initial data suggest a definite role for idarucizumab in treatment of bleeding associated with dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.91796875,
            "end_logit": 8.09375,
            "text": "initial data suggest a definite role for idarucizumab in treatment of bleeding associated with dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.93359375,
            "end_logit": 8.09375,
            "text": "data suggest a definite role for idarucizumab in treatment of bleeding associated with dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.9453125,
            "end_logit": 8.09375,
            "text": "of bleeding associated with dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.96875,
            "end_logit": 8.09375,
            "text": "The initial data suggest a definite role for idarucizumab in treatment of bleeding associated with dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.98828125,
            "end_logit": 8.09375,
            "text": "idarucizumab in treatment of bleeding associated with dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0234375,
            "end_logit": 8.09375,
            "text": "in treatment of bleeding associated with dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0625,
            "end_logit": 8.09375,
            "text": "rucizumab in treatment of bleeding associated with dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0625,
            "end_logit": 8.09375,
            "text": "role for idarucizumab in treatment of bleeding associated with dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.078125,
            "end_logit": 8.09375,
            "text": "definite role for idarucizumab in treatment of bleeding associated with dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0859375,
            "end_logit": 8.09375,
            "text": "for idarucizumab in treatment of bleeding associated with dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.8046875,
            "end_logit": -7.5625,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.17578125,
            "end_logit": -7.5625,
            "text": "with dabigatran.",
            "probability": 0.0
        },
        {
            "start_logit": -7.37109375,
            "end_logit": -7.5625,
            "text": "associated with dabigatran.",
            "probability": 0.0
        }
    ],
    "5a7237672dc08e987e000008_8": [
        {
            "start_logit": 8.015625,
            "end_logit": 8.328125,
            "text": "dabigatran",
            "probability": 1.0
        },
        {
            "start_logit": -6.47265625,
            "end_logit": 8.328125,
            "text": "anticoagulant activity of dabigatran",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -6.99609375,
            "end_logit": 8.328125,
            "text": "of dabigatran",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.015625,
            "end_logit": -6.8984375,
            "text": "dabigatran as assessed by routine and specific coagulation assays (aPTT from to 75 to 26 s, PT from 26 to 11 s and diluted thrombin time from 92 to 27 s).",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.015625,
            "end_logit": -7.40625,
            "text": "dabigatran as assessed by routine and specific coagulation assays (aPTT from to 75 to 26 s, PT from 26 to 11 s and diluted thrombin time",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.8046875,
            "end_logit": 8.328125,
            "text": "The administration of 5 g of intravenous idarucizumab promptly and completely reversed the anticoagulant activity of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.85546875,
            "end_logit": 8.328125,
            "text": "completely reversed the anticoagulant activity of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.875,
            "end_logit": 8.328125,
            "text": "the anticoagulant activity of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.015625,
            "end_logit": -7.60546875,
            "text": "dabigatran as assessed by routine and specific coagulation assays (aPTT from to 75 to 26 s, PT from 26 to 11 s and diluted thrombin time from 92 to 27 s",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.921875,
            "end_logit": 8.328125,
            "text": "administration of 5 g of intravenous idarucizumab promptly and completely reversed the anticoagulant activity of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.95703125,
            "end_logit": 8.328125,
            "text": "promptly and completely reversed the anticoagulant activity of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.015625,
            "end_logit": -7.6484375,
            "text": "dabigatran as assessed by routine and specific coagulation assays (aPTT from to 75 to 26 s, PT from 26 to 11 s and diluted thrombin time from 92 to",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.96484375,
            "end_logit": 8.328125,
            "text": "reversed the anticoagulant activity of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.98046875,
            "end_logit": 8.328125,
            "text": "idarucizumab promptly and completely reversed the anticoagulant activity of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.99609375,
            "end_logit": 8.328125,
            "text": "5 g of intravenous idarucizumab promptly and completely reversed the anticoagulant activity of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.0703125,
            "end_logit": 8.328125,
            "text": "intravenous idarucizumab promptly and completely reversed the anticoagulant activity of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.0703125,
            "end_logit": 8.328125,
            "text": "rucizumab promptly and completely reversed the anticoagulant activity of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.015625,
            "end_logit": -7.77734375,
            "text": "dabigatran as assessed by routine and specific coagulation assays (aPTT from to 75 to 26 s, PT from 26 to 11 s and diluted thrombin time from 92",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.015625,
            "end_logit": -7.8046875,
            "text": "dabigatran as",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.015625,
            "end_logit": -7.921875,
            "text": "dabigatran as assessed by routine and specific coagulation assays (aPTT from to 75 to 26 s",
            "probability": 5.960464477539063e-08
        }
    ],
    "5a7237672dc08e987e000008_9": [
        {
            "start_logit": 8.3125,
            "end_logit": 8.0703125,
            "text": "dabigatran",
            "probability": 1.0
        },
        {
            "start_logit": 8.3125,
            "end_logit": -7.75390625,
            "text": "dabigatran with high affinity, is in development as a specific antidote for dabigatran.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.3125,
            "end_logit": -7.96484375,
            "text": "dabigatran with",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.3125,
            "end_logit": -8.1328125,
            "text": "dabigatran with high affinity, is in development as a specific antidote",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.921875,
            "end_logit": 8.0703125,
            "text": "binds dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.9609375,
            "end_logit": 8.0703125,
            "text": "Idarucizumab, a monoclonal antibody fragment that binds dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.9765625,
            "end_logit": 8.0703125,
            "text": ", a monoclonal antibody fragment that binds dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0234375,
            "end_logit": 8.0703125,
            "text": "that binds dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0234375,
            "end_logit": 8.0703125,
            "text": "a monoclonal antibody fragment that binds dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0625,
            "end_logit": 8.0703125,
            "text": "monoclonal antibody fragment that binds dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.93359375,
            "end_logit": -7.75390625,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.73828125,
            "end_logit": -7.75390625,
            "text": "antidote for dabigatran.",
            "probability": 0.0
        },
        {
            "start_logit": -7.90234375,
            "end_logit": -7.75390625,
            "text": "a specific antidote for dabigatran.",
            "probability": 0.0
        },
        {
            "start_logit": -7.9140625,
            "end_logit": -7.75390625,
            "text": "specific antidote for dabigatran.",
            "probability": 0.0
        },
        {
            "start_logit": -7.921875,
            "end_logit": -7.75390625,
            "text": "binds dabigatran with high affinity, is in development as a specific antidote for dabigatran.",
            "probability": 0.0
        },
        {
            "start_logit": -7.9296875,
            "end_logit": -7.75390625,
            "text": "development as a specific antidote for dabigatran.",
            "probability": 0.0
        },
        {
            "start_logit": -7.9609375,
            "end_logit": -7.75390625,
            "text": "Idarucizumab, a monoclonal antibody fragment that binds dabigatran with high affinity, is in development as a specific antidote for dabigatran.",
            "probability": 0.0
        },
        {
            "start_logit": -7.9765625,
            "end_logit": -7.75390625,
            "text": ", is in development as a specific antidote for dabigatran.",
            "probability": 0.0
        },
        {
            "start_logit": -7.9765625,
            "end_logit": -7.75390625,
            "text": ", a monoclonal antibody fragment that binds dabigatran with high affinity, is in development as a specific antidote for dabigatran.",
            "probability": 0.0
        },
        {
            "start_logit": -8.0078125,
            "end_logit": -7.75390625,
            "text": "in development as a specific antidote for dabigatran.",
            "probability": 0.0
        }
    ],
    "5a7237672dc08e987e000008_10": [
        {
            "start_logit": 8.34375,
            "end_logit": 8.0703125,
            "text": "dabigatran",
            "probability": 1.0
        },
        {
            "start_logit": -7.5546875,
            "end_logit": 8.0703125,
            "text": "antidote to dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.34375,
            "end_logit": -7.87109375,
            "text": "dabigatran.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.78125,
            "end_logit": 8.0703125,
            "text": "A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.8828125,
            "end_logit": 8.0703125,
            "text": "study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.91015625,
            "end_logit": 8.0703125,
            "text": "specific antidote to dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.91796875,
            "end_logit": 8.0703125,
            "text": "to dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.921875,
            "end_logit": 8.0703125,
            "text": "a specific antidote to dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.98828125,
            "end_logit": 8.0703125,
            "text": "idarucizumab, a specific antidote to dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.9921875,
            "end_logit": 8.0703125,
            "text": "randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.015625,
            "end_logit": 8.0703125,
            "text": "safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0234375,
            "end_logit": 8.0703125,
            "text": ", a specific antidote to dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.03125,
            "end_logit": 8.0703125,
            "text": "the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0390625,
            "end_logit": 8.0703125,
            "text": "ote to dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0546875,
            "end_logit": 8.0703125,
            "text": "in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0546875,
            "end_logit": 8.0703125,
            "text": "of idarucizumab, a specific antidote to dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.99609375,
            "end_logit": -7.87109375,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.5546875,
            "end_logit": -7.87109375,
            "text": "antidote to dabigatran.",
            "probability": 0.0
        },
        {
            "start_logit": -7.78125,
            "end_logit": -7.87109375,
            "text": "A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran.",
            "probability": 0.0
        },
        {
            "start_logit": -7.8828125,
            "end_logit": -7.87109375,
            "text": "study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran.",
            "probability": 0.0
        }
    ],
    "5a7237672dc08e987e000008_11": [
        {
            "start_logit": 7.984375,
            "end_logit": 8.390625,
            "text": "dabigatran",
            "probability": 1.0
        },
        {
            "start_logit": -5.09765625,
            "end_logit": 8.390625,
            "text": "anticoagulant activity of dabigatran",
            "probability": 2.086162567138672e-06
        },
        {
            "start_logit": -6.703125,
            "end_logit": 8.390625,
            "text": "of dabigatran",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -7.859375,
            "end_logit": 8.390625,
            "text": "reversal agent for the anticoagulant activity of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.9140625,
            "end_logit": 8.390625,
            "text": "specific reversal agent for the anticoagulant activity of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.9296875,
            "end_logit": 8.390625,
            "text": "To evaluate the role of idarucizumab, a humanized monoclonal antibody fragment, as a specific reversal agent for the anticoagulant activity of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.9453125,
            "end_logit": 8.390625,
            "text": "the anticoagulant activity of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.984375,
            "end_logit": 8.390625,
            "text": "agent for the anticoagulant activity of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.015625,
            "end_logit": 8.390625,
            "text": ", as a specific reversal agent for the anticoagulant activity of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.0234375,
            "end_logit": 8.390625,
            "text": "for the anticoagulant activity of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.046875,
            "end_logit": 8.390625,
            "text": "activity of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.046875,
            "end_logit": 8.390625,
            "text": "idarucizumab, a humanized monoclonal antibody fragment, as a specific reversal agent for the anticoagulant activity of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.984375,
            "end_logit": -7.7265625,
            "text": "dabigatran and to review the pharmacology, pharmacokinetic properties, efficacy, and safety of this agent.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.984375,
            "end_logit": -8.109375,
            "text": "dabigatran and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -5.09765625,
            "end_logit": -6.7890625,
            "text": "anticoagulant",
            "probability": 0.0
        },
        {
            "start_logit": -5.09765625,
            "end_logit": -7.7265625,
            "text": "anticoagulant activity of dabigatran and to review the pharmacology, pharmacokinetic properties, efficacy, and safety of this agent.",
            "probability": 0.0
        },
        {
            "start_logit": -5.09765625,
            "end_logit": -7.8828125,
            "text": "anticoagulant activity",
            "probability": 0.0
        },
        {
            "start_logit": -5.09765625,
            "end_logit": -8.109375,
            "text": "anticoagulant activity of dabigatran and",
            "probability": 0.0
        },
        {
            "start_logit": -6.703125,
            "end_logit": -7.7265625,
            "text": "of dabigatran and to review the pharmacology, pharmacokinetic properties, efficacy, and safety of this agent.",
            "probability": 0.0
        },
        {
            "start_logit": -7.859375,
            "end_logit": -6.7890625,
            "text": "reversal agent for the anticoagulant",
            "probability": 0.0
        }
    ],
    "5a7237672dc08e987e000008_12": [
        {
            "start_logit": 9.7578125,
            "end_logit": 8.3671875,
            "text": "Dabigatran etexilate",
            "probability": 1.0
        },
        {
            "start_logit": 9.7578125,
            "end_logit": -1.5673828125,
            "text": "Dabigatran",
            "probability": 4.83393669128418e-05
        },
        {
            "start_logit": -3.6796875,
            "end_logit": 8.3671875,
            "text": "te",
            "probability": 1.430511474609375e-06
        },
        {
            "start_logit": 9.7578125,
            "end_logit": -6.21875,
            "text": "Dabigatran etexilate is an oral thrombin inhibitor that can be reversed by idarucizumab.",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 9.7578125,
            "end_logit": -6.78515625,
            "text": "Dabigatran etexilate is an oral thrombin",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.7578125,
            "end_logit": -7.18359375,
            "text": "Dabigatran etex",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.7578125,
            "end_logit": -7.20703125,
            "text": "Dabigatran etexila",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.7578125,
            "end_logit": -7.3046875,
            "text": "Dabigatran etexilate is an oral thrombin inhibitor",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.7578125,
            "end_logit": -7.33203125,
            "text": "Dabigatran et",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.7578125,
            "end_logit": -7.64453125,
            "text": "Dabigatran etexilate is",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.7578125,
            "end_logit": -7.87109375,
            "text": "Dabigatran etexilate is an oral thrombin inhibitor that",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.7578125,
            "end_logit": -7.97265625,
            "text": "Dabigatran etexilate is an oral thrombin inhibitor that can",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.7578125,
            "end_logit": -7.99609375,
            "text": "Dabigatran etexilate is an",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.53125,
            "end_logit": 8.3671875,
            "text": "etexilate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.703125,
            "end_logit": 8.3671875,
            "text": "exilate",
            "probability": 0.0
        },
        {
            "start_logit": -7.75390625,
            "end_logit": 8.3671875,
            "text": "ilate",
            "probability": 0.0
        },
        {
            "start_logit": -3.6796875,
            "end_logit": -6.21875,
            "text": "te is an oral thrombin inhibitor that can be reversed by idarucizumab.",
            "probability": 0.0
        },
        {
            "start_logit": -3.6796875,
            "end_logit": -6.78515625,
            "text": "te is an oral thrombin",
            "probability": 0.0
        },
        {
            "start_logit": -3.6796875,
            "end_logit": -7.3046875,
            "text": "te is an oral thrombin inhibitor",
            "probability": 0.0
        },
        {
            "start_logit": -3.6796875,
            "end_logit": -7.64453125,
            "text": "te is",
            "probability": 0.0
        }
    ],
    "5a7237672dc08e987e000008_13": [
        {
            "start_logit": 8.1875,
            "end_logit": 8.2421875,
            "text": "dabigatran",
            "probability": 1.0
        },
        {
            "start_logit": -7.4921875,
            "end_logit": 8.2421875,
            "text": "to dabigatran",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.5625,
            "end_logit": 8.2421875,
            "text": "In ICH related to dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.1875,
            "end_logit": -7.79296875,
            "text": "dabigatran, anticoagulation can be rapidly reversed with idarucizumab.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.9765625,
            "end_logit": 8.2421875,
            "text": "ICH related to dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.0546875,
            "end_logit": 8.2421875,
            "text": "related to dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.1875,
            "end_logit": -8.0703125,
            "text": "dabigatran, anticoagulation can",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.1875,
            "end_logit": -8.1328125,
            "text": "dabigatran, anticoagulation",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.8046875,
            "end_logit": -7.79296875,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.4921875,
            "end_logit": -7.79296875,
            "text": "to dabigatran, anticoagulation can be rapidly reversed with idarucizumab.",
            "probability": 0.0
        },
        {
            "start_logit": -7.5625,
            "end_logit": -7.79296875,
            "text": "In ICH related to dabigatran, anticoagulation can be rapidly reversed with idarucizumab.",
            "probability": 0.0
        },
        {
            "start_logit": -7.4921875,
            "end_logit": -8.0703125,
            "text": "to dabigatran, anticoagulation can",
            "probability": 0.0
        },
        {
            "start_logit": -7.80078125,
            "end_logit": -7.79296875,
            "text": "rapidly reversed with idarucizumab.",
            "probability": 0.0
        },
        {
            "start_logit": -7.4921875,
            "end_logit": -8.1328125,
            "text": "to dabigatran, anticoagulation",
            "probability": 0.0
        },
        {
            "start_logit": -7.5625,
            "end_logit": -8.0703125,
            "text": "In ICH related to dabigatran, anticoagulation can",
            "probability": 0.0
        },
        {
            "start_logit": -7.5625,
            "end_logit": -8.1328125,
            "text": "In ICH related to dabigatran, anticoagulation",
            "probability": 0.0
        },
        {
            "start_logit": -7.94921875,
            "end_logit": -7.79296875,
            "text": ", anticoagulation can be rapidly reversed with idarucizumab.",
            "probability": 0.0
        },
        {
            "start_logit": -7.953125,
            "end_logit": -7.79296875,
            "text": "anticoagulation can be rapidly reversed with idarucizumab.",
            "probability": 0.0
        },
        {
            "start_logit": -7.97265625,
            "end_logit": -7.79296875,
            "text": "idarucizumab.",
            "probability": 0.0
        },
        {
            "start_logit": -7.9765625,
            "end_logit": -7.79296875,
            "text": "ICH related to dabigatran, anticoagulation can be rapidly reversed with idarucizumab.",
            "probability": 0.0
        }
    ],
    "5a7237672dc08e987e000008_14": [
        {
            "start_logit": 10.0234375,
            "end_logit": 9.4921875,
            "text": "dabigatran etexilate",
            "probability": 1.0
        },
        {
            "start_logit": 10.0234375,
            "end_logit": -0.9326171875,
            "text": "dabigatran",
            "probability": 2.9802322387695312e-05
        },
        {
            "start_logit": -1.97265625,
            "end_logit": 9.4921875,
            "text": "te",
            "probability": 6.139278411865234e-06
        },
        {
            "start_logit": -6.82421875,
            "end_logit": 9.4921875,
            "text": "etexilate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.0234375,
            "end_logit": -7.359375,
            "text": "dabigatran etexila",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.0234375,
            "end_logit": -7.37890625,
            "text": "dabigatran et",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.91796875,
            "end_logit": 9.4921875,
            "text": "exilate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.0234375,
            "end_logit": -7.46875,
            "text": "dabigatran etex",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.046875,
            "end_logit": 9.4921875,
            "text": "ilate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.0234375,
            "end_logit": -7.7109375,
            "text": "dabigatran etexilate.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.8828125,
            "end_logit": 9.4921875,
            "text": "for dabigatran etexilate",
            "probability": 0.0
        },
        {
            "start_logit": -7.91015625,
            "end_logit": 9.4921875,
            "text": "Idarucizumab is a reversal agent for dabigatran etexilate",
            "probability": 0.0
        },
        {
            "start_logit": -7.98046875,
            "end_logit": 9.4921875,
            "text": "reversal agent for dabigatran etexilate",
            "probability": 0.0
        },
        {
            "start_logit": -7.99609375,
            "end_logit": 9.4921875,
            "text": "rucizumab is a reversal agent for dabigatran etexilate",
            "probability": 0.0
        },
        {
            "start_logit": -8.0078125,
            "end_logit": 9.4921875,
            "text": "a reversal agent for dabigatran etexilate",
            "probability": 0.0
        },
        {
            "start_logit": -8.0234375,
            "end_logit": 9.4921875,
            "text": "izumab is a reversal agent for dabigatran etexilate",
            "probability": 0.0
        },
        {
            "start_logit": -8.0390625,
            "end_logit": 9.4921875,
            "text": "agent for dabigatran etexilate",
            "probability": 0.0
        },
        {
            "start_logit": -8.078125,
            "end_logit": 9.4921875,
            "text": "is a reversal agent for dabigatran etexilate",
            "probability": 0.0
        },
        {
            "start_logit": -7.8828125,
            "end_logit": -0.9326171875,
            "text": "for dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -7.91015625,
            "end_logit": -0.9326171875,
            "text": "Idarucizumab is a reversal agent for dabigatran",
            "probability": 0.0
        }
    ],
    "5a7237672dc08e987e000008_15": [
        {
            "start_logit": 8.140625,
            "end_logit": 8.28125,
            "text": "dabigatran",
            "probability": 1.0
        },
        {
            "start_logit": -7.234375,
            "end_logit": 8.28125,
            "text": "of dabigatran",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.140625,
            "end_logit": -7.515625,
            "text": "dabigatran within minutes.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.91796875,
            "end_logit": 8.28125,
            "text": "Idarucizumab completely reversed the anticoagulant effect of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.140625,
            "end_logit": -7.81640625,
            "text": "dabigatran within",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.98828125,
            "end_logit": 8.28125,
            "text": "the anticoagulant effect of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.9921875,
            "end_logit": 8.28125,
            "text": "anticoagulant effect of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.046875,
            "end_logit": 8.28125,
            "text": "rucizumab completely reversed the anticoagulant effect of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.0625,
            "end_logit": 8.28125,
            "text": "effect of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.0703125,
            "end_logit": 8.28125,
            "text": "izumab completely reversed the anticoagulant effect of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.140625,
            "end_logit": -7.94921875,
            "text": "dabigatran within minutes",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.109375,
            "end_logit": 8.28125,
            "text": "reversed the anticoagulant effect of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.15625,
            "end_logit": 8.28125,
            "text": "completely reversed the anticoagulant effect of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.81640625,
            "end_logit": -7.515625,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.234375,
            "end_logit": -7.515625,
            "text": "of dabigatran within minutes.",
            "probability": 0.0
        },
        {
            "start_logit": -7.234375,
            "end_logit": -7.81640625,
            "text": "of dabigatran within",
            "probability": 0.0
        },
        {
            "start_logit": -7.234375,
            "end_logit": -7.94921875,
            "text": "of dabigatran within minutes",
            "probability": 0.0
        },
        {
            "start_logit": -7.91796875,
            "end_logit": -7.515625,
            "text": "Idarucizumab completely reversed the anticoagulant effect of dabigatran within minutes.",
            "probability": 0.0
        },
        {
            "start_logit": -7.98828125,
            "end_logit": -7.515625,
            "text": "the anticoagulant effect of dabigatran within minutes.",
            "probability": 0.0
        },
        {
            "start_logit": -7.9921875,
            "end_logit": -7.515625,
            "text": "anticoagulant effect of dabigatran within minutes.",
            "probability": 0.0
        }
    ],
    "5a7237672dc08e987e000008_16": [
        {
            "start_logit": 9.7578125,
            "end_logit": 8.3671875,
            "text": "Dabigatran etexilate",
            "probability": 1.0
        },
        {
            "start_logit": 9.7578125,
            "end_logit": -1.5673828125,
            "text": "Dabigatran",
            "probability": 4.83393669128418e-05
        },
        {
            "start_logit": -3.6796875,
            "end_logit": 8.3671875,
            "text": "te",
            "probability": 1.430511474609375e-06
        },
        {
            "start_logit": 9.7578125,
            "end_logit": -6.21875,
            "text": "Dabigatran etexilate is an oral thrombin inhibitor that can be reversed by idarucizumab.",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 9.7578125,
            "end_logit": -6.78515625,
            "text": "Dabigatran etexilate is an oral thrombin",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.7578125,
            "end_logit": -7.18359375,
            "text": "Dabigatran etex",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.7578125,
            "end_logit": -7.20703125,
            "text": "Dabigatran etexila",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.7578125,
            "end_logit": -7.3046875,
            "text": "Dabigatran etexilate is an oral thrombin inhibitor",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.7578125,
            "end_logit": -7.33203125,
            "text": "Dabigatran et",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.7578125,
            "end_logit": -7.64453125,
            "text": "Dabigatran etexilate is",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.7578125,
            "end_logit": -7.87109375,
            "text": "Dabigatran etexilate is an oral thrombin inhibitor that",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.7578125,
            "end_logit": -7.97265625,
            "text": "Dabigatran etexilate is an oral thrombin inhibitor that can",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.7578125,
            "end_logit": -7.99609375,
            "text": "Dabigatran etexilate is an",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.53125,
            "end_logit": 8.3671875,
            "text": "etexilate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.703125,
            "end_logit": 8.3671875,
            "text": "exilate",
            "probability": 0.0
        },
        {
            "start_logit": -7.75390625,
            "end_logit": 8.3671875,
            "text": "ilate",
            "probability": 0.0
        },
        {
            "start_logit": -3.6796875,
            "end_logit": -6.21875,
            "text": "te is an oral thrombin inhibitor that can be reversed by idarucizumab.",
            "probability": 0.0
        },
        {
            "start_logit": -3.6796875,
            "end_logit": -6.78515625,
            "text": "te is an oral thrombin",
            "probability": 0.0
        },
        {
            "start_logit": -3.6796875,
            "end_logit": -7.3046875,
            "text": "te is an oral thrombin inhibitor",
            "probability": 0.0
        },
        {
            "start_logit": -3.6796875,
            "end_logit": -7.64453125,
            "text": "te is",
            "probability": 0.0
        }
    ],
    "5a7237672dc08e987e000008_17": [
        {
            "start_logit": 10.0546875,
            "end_logit": 9.484375,
            "text": "dabigatran etexilate",
            "probability": 1.0
        },
        {
            "start_logit": 10.0546875,
            "end_logit": -0.81298828125,
            "text": "dabigatran",
            "probability": 3.3974647521972656e-05
        },
        {
            "start_logit": -1.9970703125,
            "end_logit": 9.484375,
            "text": "te",
            "probability": 5.841255187988281e-06
        },
        {
            "start_logit": 10.0546875,
            "end_logit": -7.37109375,
            "text": "dabigatran etexila",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.82421875,
            "end_logit": 9.484375,
            "text": "etexilate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.0546875,
            "end_logit": -7.43359375,
            "text": "dabigatran etex",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.0546875,
            "end_logit": -7.5,
            "text": "dabigatran et",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.0546875,
            "end_logit": -7.6875,
            "text": "dabigatran etexilate.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.17578125,
            "end_logit": 9.484375,
            "text": "exilate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.29296875,
            "end_logit": 9.484375,
            "text": "ilate",
            "probability": 0.0
        },
        {
            "start_logit": -7.87109375,
            "end_logit": 9.484375,
            "text": "for dabigatran etexilate",
            "probability": 0.0
        },
        {
            "start_logit": -7.8984375,
            "end_logit": 9.484375,
            "text": "INTRODUCTION Idarucizumab is a reversal agent for dabigatran etexilate",
            "probability": 0.0
        },
        {
            "start_logit": -7.98828125,
            "end_logit": 9.484375,
            "text": "reversal agent for dabigatran etexilate",
            "probability": 0.0
        },
        {
            "start_logit": -8.0625,
            "end_logit": 9.484375,
            "text": "Idarucizumab is a reversal agent for dabigatran etexilate",
            "probability": 0.0
        },
        {
            "start_logit": -8.0859375,
            "end_logit": 9.484375,
            "text": "agent for dabigatran etexilate",
            "probability": 0.0
        },
        {
            "start_logit": -8.1171875,
            "end_logit": 9.484375,
            "text": "rucizumab is a reversal agent for dabigatran etexilate",
            "probability": 0.0
        },
        {
            "start_logit": -8.1171875,
            "end_logit": 9.484375,
            "text": "a reversal agent for dabigatran etexilate",
            "probability": 0.0
        },
        {
            "start_logit": -8.1328125,
            "end_logit": 9.484375,
            "text": "izumab is a reversal agent for dabigatran etexilate",
            "probability": 0.0
        },
        {
            "start_logit": -7.87109375,
            "end_logit": -0.81298828125,
            "text": "for dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -7.8984375,
            "end_logit": -0.81298828125,
            "text": "INTRODUCTION Idarucizumab is a reversal agent for dabigatran",
            "probability": 0.0
        }
    ],
    "5a7237672dc08e987e000008_18": [
        {
            "start_logit": 8.2578125,
            "end_logit": 8.1328125,
            "text": "dabigatran",
            "probability": 1.0
        },
        {
            "start_logit": -6.58203125,
            "end_logit": 8.1328125,
            "text": "of dabigatran",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.0703125,
            "end_logit": 8.1328125,
            "text": "anticoagulant effects of dabigatran",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.2578125,
            "end_logit": -7.5546875,
            "text": "dabigatran.",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.80078125,
            "end_logit": 8.1328125,
            "text": "effects of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.85546875,
            "end_logit": 8.1328125,
            "text": "Idarucizumab is a humanized monoclonal antibody fragment for reversal of the anticoagulant effects of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.8671875,
            "end_logit": 8.1328125,
            "text": "reversal of the anticoagulant effects of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.8828125,
            "end_logit": 8.1328125,
            "text": "for reversal of the anticoagulant effects of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.89453125,
            "end_logit": 8.1328125,
            "text": "the anticoagulant effects of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.984375,
            "end_logit": 8.1328125,
            "text": "of the anticoagulant effects of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.984375,
            "end_logit": 8.1328125,
            "text": "rucizumab is a humanized monoclonal antibody fragment for reversal of the anticoagulant effects of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.99609375,
            "end_logit": 8.1328125,
            "text": "izumab is a humanized monoclonal antibody fragment for reversal of the anticoagulant effects of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0234375,
            "end_logit": 8.1328125,
            "text": "is a humanized monoclonal antibody fragment for reversal of the anticoagulant effects of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.03125,
            "end_logit": 8.1328125,
            "text": "a humanized monoclonal antibody fragment for reversal of the anticoagulant effects of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0546875,
            "end_logit": 8.1328125,
            "text": "humanized monoclonal antibody fragment for reversal of the anticoagulant effects of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0625,
            "end_logit": 8.1328125,
            "text": "monoclonal antibody fragment for reversal of the anticoagulant effects of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0859375,
            "end_logit": 8.1328125,
            "text": "antibody fragment for reversal of the anticoagulant effects of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.58203125,
            "end_logit": -7.5546875,
            "text": "of dabigatran.",
            "probability": 0.0
        },
        {
            "start_logit": -6.91015625,
            "end_logit": -7.5546875,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.0703125,
            "end_logit": -7.5546875,
            "text": "anticoagulant effects of dabigatran.",
            "probability": 0.0
        }
    ],
    "5a7237672dc08e987e000008_19": [
        {
            "start_logit": 8.2265625,
            "end_logit": 8.171875,
            "text": "dabigatran",
            "probability": 1.0
        },
        {
            "start_logit": -7.7265625,
            "end_logit": 8.171875,
            "text": "to dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.8984375,
            "end_logit": 8.171875,
            "text": "Idarucizumab is a monoclonal antibody fragment specifically targeted to dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.0234375,
            "end_logit": 8.171875,
            "text": "rucizumab is a monoclonal antibody fragment specifically targeted to dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0234375,
            "end_logit": 8.171875,
            "text": "izumab is a monoclonal antibody fragment specifically targeted to dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.2265625,
            "end_logit": -8.09375,
            "text": "dabigatran.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0546875,
            "end_logit": 8.171875,
            "text": "is a monoclonal antibody fragment specifically targeted to dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0546875,
            "end_logit": 8.171875,
            "text": "a monoclonal antibody fragment specifically targeted to dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0703125,
            "end_logit": 8.171875,
            "text": "monoclonal antibody fragment specifically targeted to dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.109375,
            "end_logit": 8.171875,
            "text": "antibody fragment specifically targeted to dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1171875,
            "end_logit": 8.171875,
            "text": "targeted to dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1328125,
            "end_logit": 8.171875,
            "text": "specifically targeted to dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1484375,
            "end_logit": 8.171875,
            "text": "fragment specifically targeted to dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.0,
            "end_logit": -8.09375,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.7265625,
            "end_logit": -8.09375,
            "text": "to dabigatran.",
            "probability": 0.0
        },
        {
            "start_logit": -7.8984375,
            "end_logit": -8.09375,
            "text": "Idarucizumab is a monoclonal antibody fragment specifically targeted to dabigatran.",
            "probability": 0.0
        },
        {
            "start_logit": -8.0234375,
            "end_logit": -8.09375,
            "text": "rucizumab is a monoclonal antibody fragment specifically targeted to dabigatran.",
            "probability": 0.0
        },
        {
            "start_logit": -8.0234375,
            "end_logit": -8.09375,
            "text": "izumab is a monoclonal antibody fragment specifically targeted to dabigatran.",
            "probability": 0.0
        },
        {
            "start_logit": -8.0546875,
            "end_logit": -8.09375,
            "text": "is a monoclonal antibody fragment specifically targeted to dabigatran.",
            "probability": 0.0
        },
        {
            "start_logit": -8.0546875,
            "end_logit": -8.09375,
            "text": "a monoclonal antibody fragment specifically targeted to dabigatran.",
            "probability": 0.0
        }
    ],
    "5a7237672dc08e987e000008_20": [
        {
            "start_logit": 8.2265625,
            "end_logit": 8.171875,
            "text": "dabigatran",
            "probability": 1.0
        },
        {
            "start_logit": -7.7265625,
            "end_logit": 8.171875,
            "text": "to dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.8984375,
            "end_logit": 8.171875,
            "text": "Idarucizumab is a monoclonal antibody fragment specifically targeted to dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.0234375,
            "end_logit": 8.171875,
            "text": "rucizumab is a monoclonal antibody fragment specifically targeted to dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0234375,
            "end_logit": 8.171875,
            "text": "izumab is a monoclonal antibody fragment specifically targeted to dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.2265625,
            "end_logit": -8.09375,
            "text": "dabigatran.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0546875,
            "end_logit": 8.171875,
            "text": "is a monoclonal antibody fragment specifically targeted to dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0546875,
            "end_logit": 8.171875,
            "text": "a monoclonal antibody fragment specifically targeted to dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0703125,
            "end_logit": 8.171875,
            "text": "monoclonal antibody fragment specifically targeted to dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.109375,
            "end_logit": 8.171875,
            "text": "antibody fragment specifically targeted to dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1171875,
            "end_logit": 8.171875,
            "text": "targeted to dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1328125,
            "end_logit": 8.171875,
            "text": "specifically targeted to dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1484375,
            "end_logit": 8.171875,
            "text": "fragment specifically targeted to dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.0,
            "end_logit": -8.09375,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.7265625,
            "end_logit": -8.09375,
            "text": "to dabigatran.",
            "probability": 0.0
        },
        {
            "start_logit": -7.8984375,
            "end_logit": -8.09375,
            "text": "Idarucizumab is a monoclonal antibody fragment specifically targeted to dabigatran.",
            "probability": 0.0
        },
        {
            "start_logit": -8.0234375,
            "end_logit": -8.09375,
            "text": "rucizumab is a monoclonal antibody fragment specifically targeted to dabigatran.",
            "probability": 0.0
        },
        {
            "start_logit": -8.0234375,
            "end_logit": -8.09375,
            "text": "izumab is a monoclonal antibody fragment specifically targeted to dabigatran.",
            "probability": 0.0
        },
        {
            "start_logit": -8.0546875,
            "end_logit": -8.09375,
            "text": "is a monoclonal antibody fragment specifically targeted to dabigatran.",
            "probability": 0.0
        },
        {
            "start_logit": -8.0546875,
            "end_logit": -8.09375,
            "text": "a monoclonal antibody fragment specifically targeted to dabigatran.",
            "probability": 0.0
        }
    ],
    "5a7237672dc08e987e000008_21": [
        {
            "start_logit": 9.984375,
            "end_logit": 9.484375,
            "text": "dabigatran etexilate",
            "probability": 1.0
        },
        {
            "start_logit": 9.984375,
            "end_logit": -1.025390625,
            "text": "dabigatran",
            "probability": 2.7298927307128906e-05
        },
        {
            "start_logit": -1.970703125,
            "end_logit": 9.484375,
            "text": "te",
            "probability": 6.4373016357421875e-06
        },
        {
            "start_logit": 9.984375,
            "end_logit": -7.078125,
            "text": "dabigatran etexila",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.6796875,
            "end_logit": 9.484375,
            "text": "etexilate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.984375,
            "end_logit": -7.28515625,
            "text": "dabigatran et",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.984375,
            "end_logit": -7.359375,
            "text": "dabigatran etex",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.8671875,
            "end_logit": 9.484375,
            "text": "exilate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.984375,
            "end_logit": -7.7265625,
            "text": "dabigatran etexilate and neutralizes its activity.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.25,
            "end_logit": 9.484375,
            "text": "ilate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.984375,
            "end_logit": -8.0703125,
            "text": "dabigatran etexilate and",
            "probability": 0.0
        },
        {
            "start_logit": -7.79296875,
            "end_logit": 9.484375,
            "text": "binds dabigatran etexilate",
            "probability": 0.0
        },
        {
            "start_logit": -7.91015625,
            "end_logit": 9.484375,
            "text": ", directly binds dabigatran etexilate",
            "probability": 0.0
        },
        {
            "start_logit": -7.94140625,
            "end_logit": 9.484375,
            "text": "Idarucizumab, a monoclonal antibody fragment, directly binds dabigatran etexilate",
            "probability": 0.0
        },
        {
            "start_logit": -7.984375,
            "end_logit": 9.484375,
            "text": ", a monoclonal antibody fragment, directly binds dabigatran etexilate",
            "probability": 0.0
        },
        {
            "start_logit": -8.015625,
            "end_logit": 9.484375,
            "text": "izumab, a monoclonal antibody fragment, directly binds dabigatran etexilate",
            "probability": 0.0
        },
        {
            "start_logit": -8.0234375,
            "end_logit": 9.484375,
            "text": "monoclonal antibody fragment, directly binds dabigatran etexilate",
            "probability": 0.0
        },
        {
            "start_logit": -8.0234375,
            "end_logit": 9.484375,
            "text": "a monoclonal antibody fragment, directly binds dabigatran etexilate",
            "probability": 0.0
        },
        {
            "start_logit": -8.03125,
            "end_logit": 9.484375,
            "text": "directly binds dabigatran etexilate",
            "probability": 0.0
        },
        {
            "start_logit": -8.03125,
            "end_logit": 9.484375,
            "text": "rucizumab, a monoclonal antibody fragment, directly binds dabigatran etexilate",
            "probability": 0.0
        }
    ],
    "5a7237672dc08e987e000008_22": [
        {
            "start_logit": 8.5546875,
            "end_logit": 7.81640625,
            "text": "dabigatran",
            "probability": 1.0
        },
        {
            "start_logit": 8.5546875,
            "end_logit": -7.984375,
            "text": "dabigatran with high affinity.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.5546875,
            "end_logit": -8.0625,
            "text": "dabigatran with",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.87890625,
            "end_logit": 7.81640625,
            "text": "Idarucizumab is an antibody fragment that binds dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.94140625,
            "end_logit": 7.81640625,
            "text": "binds dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.98046875,
            "end_logit": 7.81640625,
            "text": "an antibody fragment that binds dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.9921875,
            "end_logit": 7.81640625,
            "text": "that binds dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.015625,
            "end_logit": 7.81640625,
            "text": "izumab is an antibody fragment that binds dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.015625,
            "end_logit": 7.81640625,
            "text": "is an antibody fragment that binds dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0234375,
            "end_logit": 7.81640625,
            "text": "rucizumab is an antibody fragment that binds dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0625,
            "end_logit": 7.81640625,
            "text": "antibody fragment that binds dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.125,
            "end_logit": 7.81640625,
            "text": "fragment that binds dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.01171875,
            "end_logit": -7.984375,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.87890625,
            "end_logit": -7.984375,
            "text": "Idarucizumab is an antibody fragment that binds dabigatran with high affinity.",
            "probability": 0.0
        },
        {
            "start_logit": -7.94140625,
            "end_logit": -7.984375,
            "text": "binds dabigatran with high affinity.",
            "probability": 0.0
        },
        {
            "start_logit": -7.87890625,
            "end_logit": -8.0625,
            "text": "Idarucizumab is an antibody fragment that binds dabigatran with",
            "probability": 0.0
        },
        {
            "start_logit": -7.98046875,
            "end_logit": -7.984375,
            "text": "an antibody fragment that binds dabigatran with high affinity.",
            "probability": 0.0
        },
        {
            "start_logit": -7.9921875,
            "end_logit": -7.984375,
            "text": "that binds dabigatran with high affinity.",
            "probability": 0.0
        },
        {
            "start_logit": -7.94140625,
            "end_logit": -8.0625,
            "text": "binds dabigatran with",
            "probability": 0.0
        },
        {
            "start_logit": -8.015625,
            "end_logit": -7.984375,
            "text": "izumab is an antibody fragment that binds dabigatran with high affinity.",
            "probability": 0.0
        }
    ],
    "5a7237672dc08e987e000008_23": [
        {
            "start_logit": 9.96875,
            "end_logit": 9.296875,
            "text": "dabigatran etexilate",
            "probability": 1.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -1.08984375,
            "text": "dabigatran",
            "probability": 3.069639205932617e-05
        },
        {
            "start_logit": -2.359375,
            "end_logit": 9.296875,
            "text": "te",
            "probability": 4.410743713378906e-06
        },
        {
            "start_logit": 9.96875,
            "end_logit": -7.29296875,
            "text": "dabigatran etexila",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.96875,
            "end_logit": -7.34765625,
            "text": "dabigatran etex",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.859375,
            "end_logit": 9.296875,
            "text": "etexilate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.96875,
            "end_logit": -7.5625,
            "text": "dabigatran et",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.96875,
            "end_logit": -7.60546875,
            "text": "dabigatran etexilate using idarucizumab was safe and successful with no recombinant tissue plasminogen activator interactions.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.25390625,
            "end_logit": 9.296875,
            "text": "exilate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.3359375,
            "end_logit": 9.296875,
            "text": "ilate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.0234375,
            "text": "dabigatran etexilate using idarucizumab was safe and successful with no recombinant tissue plasminogen activator",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.0625,
            "text": "dabigatran etexilate using idarucizumab was safe and successful with no recombinant tissue plasminogen",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.1328125,
            "text": "dabigatran etexilate using idarucizumab was safe and successful with no recombinant tissue plasminogen activator interactions",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.1640625,
            "text": "dabigatran etexilate using idarucizumab was",
            "probability": 0.0
        },
        {
            "start_logit": -7.64453125,
            "end_logit": 9.296875,
            "text": "CONCLUSION Reversal of dabigatran etexilate",
            "probability": 0.0
        },
        {
            "start_logit": -7.95703125,
            "end_logit": 9.296875,
            "text": "of dabigatran etexilate",
            "probability": 0.0
        },
        {
            "start_logit": -8.0234375,
            "end_logit": 9.296875,
            "text": "Reversal of dabigatran etexilate",
            "probability": 0.0
        },
        {
            "start_logit": -7.64453125,
            "end_logit": -1.08984375,
            "text": "CONCLUSION Reversal of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -7.95703125,
            "end_logit": -1.08984375,
            "text": "of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -8.0234375,
            "end_logit": -1.08984375,
            "text": "Reversal of dabigatran",
            "probability": 0.0
        }
    ],
    "5a7237672dc08e987e000008_24": [
        {
            "start_logit": 8.46875,
            "end_logit": 7.9296875,
            "text": "dabigatran",
            "probability": 1.0
        },
        {
            "start_logit": 8.46875,
            "end_logit": -7.70703125,
            "text": "dabigatran.",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.6796875,
            "end_logit": 7.9296875,
            "text": "to dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.91796875,
            "end_logit": 7.9296875,
            "text": "RESULTS Idarucizumab represents a novel treatment option as it is the only humanized, monoclonal antibody fragment that specifically binds to dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.9765625,
            "end_logit": 7.9296875,
            "text": ", monoclonal antibody fragment that specifically binds to dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.98046875,
            "end_logit": 7.9296875,
            "text": "treatment option as it is the only humanized, monoclonal antibody fragment that specifically binds to dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0078125,
            "end_logit": 7.9296875,
            "text": "novel treatment option as it is the only humanized, monoclonal antibody fragment that specifically binds to dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0390625,
            "end_logit": 7.9296875,
            "text": "Idarucizumab represents a novel treatment option as it is the only humanized, monoclonal antibody fragment that specifically binds to dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0703125,
            "end_logit": 7.9296875,
            "text": "binds to dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0703125,
            "end_logit": 7.9296875,
            "text": "that specifically binds to dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.09375,
            "end_logit": 7.9296875,
            "text": "rucizumab represents a novel treatment option as it is the only humanized, monoclonal antibody fragment that specifically binds to dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1015625,
            "end_logit": 7.9296875,
            "text": "the only humanized, monoclonal antibody fragment that specifically binds to dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.109375,
            "end_logit": 7.9296875,
            "text": "only humanized, monoclonal antibody fragment that specifically binds to dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.109375,
            "end_logit": 7.9296875,
            "text": "it is the only humanized, monoclonal antibody fragment that specifically binds to dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.109375,
            "end_logit": 7.9296875,
            "text": "izumab represents a novel treatment option as it is the only humanized, monoclonal antibody fragment that specifically binds to dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.125,
            "end_logit": 7.9296875,
            "text": "specifically binds to dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.125,
            "end_logit": 7.9296875,
            "text": "option as it is the only humanized, monoclonal antibody fragment that specifically binds to dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.98828125,
            "end_logit": -7.70703125,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.6796875,
            "end_logit": -7.70703125,
            "text": "to dabigatran.",
            "probability": 0.0
        },
        {
            "start_logit": -7.91796875,
            "end_logit": -7.70703125,
            "text": "RESULTS Idarucizumab represents a novel treatment option as it is the only humanized, monoclonal antibody fragment that specifically binds to dabigatran.",
            "probability": 0.0
        }
    ],
    "5a7237672dc08e987e000008_25": [
        {
            "start_logit": 8.03125,
            "end_logit": 8.3359375,
            "text": "dabigatran",
            "probability": 1.0
        },
        {
            "start_logit": -6.62109375,
            "end_logit": 8.3359375,
            "text": "anticoagulant effects of dabigatran",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -7.265625,
            "end_logit": 8.3359375,
            "text": "of dabigatran",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.484375,
            "end_logit": 8.3359375,
            "text": "rapid (minutes) reversal of anticoagulant effects of dabigatran",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.703125,
            "end_logit": 8.3359375,
            "text": "In 2015, the humanized monoclonal antibody fragment idarucizumab was approved for rapid (minutes) reversal of anticoagulant effects of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.75390625,
            "end_logit": 8.3359375,
            "text": "effects of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.8046875,
            "end_logit": 8.3359375,
            "text": "reversal of anticoagulant effects of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.03125,
            "end_logit": -7.578125,
            "text": "dabigatran.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.8828125,
            "end_logit": 8.3359375,
            "text": ", the humanized monoclonal antibody fragment idarucizumab was approved for rapid (minutes) reversal of anticoagulant effects of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.8984375,
            "end_logit": 8.3359375,
            "text": "2015, the humanized monoclonal antibody fragment idarucizumab was approved for rapid (minutes) reversal of anticoagulant effects of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.921875,
            "end_logit": 8.3359375,
            "text": "of anticoagulant effects of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.92578125,
            "end_logit": 8.3359375,
            "text": "approved for rapid (minutes) reversal of anticoagulant effects of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.953125,
            "end_logit": 8.3359375,
            "text": "the humanized monoclonal antibody fragment idarucizumab was approved for rapid (minutes) reversal of anticoagulant effects of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.9609375,
            "end_logit": 8.3359375,
            "text": ") reversal of anticoagulant effects of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.96484375,
            "end_logit": 8.3359375,
            "text": "was approved for rapid (minutes) reversal of anticoagulant effects of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.98046875,
            "end_logit": 8.3359375,
            "text": "idarucizumab was approved for rapid (minutes) reversal of anticoagulant effects of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.98828125,
            "end_logit": 8.3359375,
            "text": "rucizumab was approved for rapid (minutes) reversal of anticoagulant effects of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.62109375,
            "end_logit": -7.578125,
            "text": "anticoagulant effects of dabigatran.",
            "probability": 0.0
        },
        {
            "start_logit": -6.85546875,
            "end_logit": -7.578125,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -6.62109375,
            "end_logit": -8.0859375,
            "text": "anticoagulant effects",
            "probability": 0.0
        }
    ],
    "5a7237672dc08e987e000008_26": [
        {
            "start_logit": 8.3984375,
            "end_logit": 7.9921875,
            "text": "dabigatran",
            "probability": 1.0
        },
        {
            "start_logit": -7.0546875,
            "end_logit": 7.9921875,
            "text": ", dabigatran",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.3984375,
            "end_logit": -7.609375,
            "text": "dabigatran, which was recently approved for use in the USA.",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.33984375,
            "end_logit": 7.9921875,
            "text": "thrombin inhibitor, dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.5078125,
            "end_logit": 7.9921875,
            "text": "direct thrombin inhibitor, dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.3984375,
            "end_logit": -8.015625,
            "text": "dabigatran, which",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.3984375,
            "end_logit": -8.0546875,
            "text": "dabigatran,",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.3984375,
            "end_logit": -8.125,
            "text": "dabigatran, which was recently",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.84375,
            "end_logit": 7.9921875,
            "text": "antidote targeted to reverse the direct thrombin inhibitor, dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.875,
            "end_logit": 7.9921875,
            "text": "reverse the direct thrombin inhibitor, dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.8828125,
            "end_logit": 7.9921875,
            "text": "Idarucizumab is a specific antidote targeted to reverse the direct thrombin inhibitor, dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.94140625,
            "end_logit": 7.9921875,
            "text": "the direct thrombin inhibitor, dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.9765625,
            "end_logit": 7.9921875,
            "text": "ote targeted to reverse the direct thrombin inhibitor, dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.99609375,
            "end_logit": 7.9921875,
            "text": "rucizumab is a specific antidote targeted to reverse the direct thrombin inhibitor, dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.015625,
            "end_logit": 7.9921875,
            "text": "izumab is a specific antidote targeted to reverse the direct thrombin inhibitor, dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.046875,
            "end_logit": 7.9921875,
            "text": "specific antidote targeted to reverse the direct thrombin inhibitor, dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.8984375,
            "end_logit": -7.609375,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.0546875,
            "end_logit": -7.609375,
            "text": ", dabigatran, which was recently approved for use in the USA.",
            "probability": 0.0
        },
        {
            "start_logit": -7.33984375,
            "end_logit": -7.609375,
            "text": "thrombin inhibitor, dabigatran, which was recently approved for use in the USA.",
            "probability": 0.0
        },
        {
            "start_logit": -7.33984375,
            "end_logit": -7.67578125,
            "text": "thrombin",
            "probability": 0.0
        }
    ],
    "5a7237672dc08e987e000008_27": [
        {
            "start_logit": 8.3359375,
            "end_logit": 8.0390625,
            "text": "dabigatran",
            "probability": 1.0
        },
        {
            "start_logit": 8.3359375,
            "end_logit": -7.83984375,
            "text": "dabigatran, is the first specific antidote for a NOAC to be approved, but real-world experience is limited.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.3359375,
            "end_logit": -7.94140625,
            "text": "dabigatran, is the first specific antidote for a NOAC to",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.3359375,
            "end_logit": -8.0625,
            "text": "dabigatran, is the first specific antidote for a NOAC",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.88671875,
            "end_logit": 8.0390625,
            "text": "targeting dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.3359375,
            "end_logit": -8.1953125,
            "text": "dabigatran, is the first specific antidote for a NOAC to be approved, but real-world experience is limited",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.9140625,
            "end_logit": 8.0390625,
            "text": "Idarucizumab, an antibody fragment targeting dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.92578125,
            "end_logit": 8.0390625,
            "text": ", an antibody fragment targeting dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.93359375,
            "end_logit": 8.0390625,
            "text": "an antibody fragment targeting dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0078125,
            "end_logit": 8.0390625,
            "text": "antibody fragment targeting dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.015625,
            "end_logit": 8.0390625,
            "text": "izumab, an antibody fragment targeting dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0234375,
            "end_logit": 8.0390625,
            "text": "rucizumab, an antibody fragment targeting dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.01171875,
            "end_logit": -7.83984375,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.88671875,
            "end_logit": -7.83984375,
            "text": "targeting dabigatran, is the first specific antidote for a NOAC to be approved, but real-world experience is limited.",
            "probability": 0.0
        },
        {
            "start_logit": -7.9140625,
            "end_logit": -7.83984375,
            "text": "Idarucizumab, an antibody fragment targeting dabigatran, is the first specific antidote for a NOAC to be approved, but real-world experience is limited.",
            "probability": 0.0
        },
        {
            "start_logit": -7.92578125,
            "end_logit": -7.83984375,
            "text": ", an antibody fragment targeting dabigatran, is the first specific antidote for a NOAC to be approved, but real-world experience is limited.",
            "probability": 0.0
        },
        {
            "start_logit": -7.9296875,
            "end_logit": -7.83984375,
            "text": "first specific antidote for a NOAC to be approved, but real-world experience is limited.",
            "probability": 0.0
        },
        {
            "start_logit": -7.93359375,
            "end_logit": -7.83984375,
            "text": "an antibody fragment targeting dabigatran, is the first specific antidote for a NOAC to be approved, but real-world experience is limited.",
            "probability": 0.0
        },
        {
            "start_logit": -7.96484375,
            "end_logit": -7.83984375,
            "text": "world experience is limited.",
            "probability": 0.0
        },
        {
            "start_logit": -7.96875,
            "end_logit": -7.83984375,
            "text": "the first specific antidote for a NOAC to be approved, but real-world experience is limited.",
            "probability": 0.0
        }
    ],
    "5a7237672dc08e987e000008_28": [
        {
            "start_logit": 8.2578125,
            "end_logit": 8.1171875,
            "text": "dabigatran",
            "probability": 1.0
        },
        {
            "start_logit": 8.2578125,
            "end_logit": -6.59375,
            "text": "dabigatran, and reversed the effects of the drug on coagulation variables.",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.2578125,
            "end_logit": -7.7421875,
            "text": "dabigatran, and reversed the effects of the drug on coagulation variables",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.63671875,
            "end_logit": 8.1171875,
            "text": "of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.86328125,
            "end_logit": 8.1171875,
            "text": "Idarucizumab neutralised plasma concentrations of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.2578125,
            "end_logit": -8.0078125,
            "text": "dabigatran, and reversed the effects of the drug on",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.2578125,
            "end_logit": -8.109375,
            "text": "dabigatran, and reversed the effects of the drug on coagulation",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.2578125,
            "end_logit": -8.125,
            "text": "dabigatran,",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.9921875,
            "end_logit": 8.1171875,
            "text": "neutralised plasma concentrations of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0078125,
            "end_logit": 8.1171875,
            "text": "izumab neutralised plasma concentrations of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0078125,
            "end_logit": 8.1171875,
            "text": "plasma concentrations of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0234375,
            "end_logit": 8.1171875,
            "text": "rucizumab neutralised plasma concentrations of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.22265625,
            "end_logit": -6.59375,
            "text": "effects of the drug on coagulation variables.",
            "probability": 0.0
        },
        {
            "start_logit": -6.5703125,
            "end_logit": -6.59375,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -6.22265625,
            "end_logit": -7.7421875,
            "text": "effects of the drug on coagulation variables",
            "probability": 0.0
        },
        {
            "start_logit": -7.6328125,
            "end_logit": -6.59375,
            "text": "reversed the effects of the drug on coagulation variables.",
            "probability": 0.0
        },
        {
            "start_logit": -6.22265625,
            "end_logit": -8.0078125,
            "text": "effects of the drug on",
            "probability": 0.0
        },
        {
            "start_logit": -7.63671875,
            "end_logit": -6.59375,
            "text": "of dabigatran, and reversed the effects of the drug on coagulation variables.",
            "probability": 0.0
        },
        {
            "start_logit": -7.71484375,
            "end_logit": -6.59375,
            "text": "the effects of the drug on coagulation variables.",
            "probability": 0.0
        },
        {
            "start_logit": -6.22265625,
            "end_logit": -8.109375,
            "text": "effects of the drug on coagulation",
            "probability": 0.0
        }
    ],
    "5a7237672dc08e987e000008_29": [
        {
            "start_logit": 8.25,
            "end_logit": 8.1484375,
            "text": "dabigatran",
            "probability": 1.0
        },
        {
            "start_logit": -6.2578125,
            "end_logit": 8.1484375,
            "text": "anticoagulant effects of dabigatran",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -6.8359375,
            "end_logit": 8.1484375,
            "text": "of dabigatran",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.25,
            "end_logit": -7.6796875,
            "text": "dabigatran.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.62890625,
            "end_logit": 8.1484375,
            "text": "reverse the anticoagulant effects of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.7421875,
            "end_logit": 8.1484375,
            "text": "the anticoagulant effects of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.765625,
            "end_logit": 8.1484375,
            "text": "Idarucizumab, an antibody fragment, was developed to reverse the anticoagulant effects of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.79296875,
            "end_logit": 8.1484375,
            "text": "to reverse the anticoagulant effects of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.81640625,
            "end_logit": 8.1484375,
            "text": "developed to reverse the anticoagulant effects of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.82421875,
            "end_logit": 8.1484375,
            "text": "effects of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.8671875,
            "end_logit": 8.1484375,
            "text": ", was developed to reverse the anticoagulant effects of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.87109375,
            "end_logit": 8.1484375,
            "text": "was developed to reverse the anticoagulant effects of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.91015625,
            "end_logit": 8.1484375,
            "text": "an antibody fragment, was developed to reverse the anticoagulant effects of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.92578125,
            "end_logit": 8.1484375,
            "text": "rucizumab, an antibody fragment, was developed to reverse the anticoagulant effects of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.93359375,
            "end_logit": 8.1484375,
            "text": ", an antibody fragment, was developed to reverse the anticoagulant effects of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.95703125,
            "end_logit": 8.1484375,
            "text": "antibody fragment, was developed to reverse the anticoagulant effects of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.9609375,
            "end_logit": 8.1484375,
            "text": "izumab, an antibody fragment, was developed to reverse the anticoagulant effects of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.2578125,
            "end_logit": -7.6796875,
            "text": "anticoagulant effects of dabigatran.",
            "probability": 0.0
        },
        {
            "start_logit": -6.2578125,
            "end_logit": -7.96484375,
            "text": "anticoagulant effects",
            "probability": 0.0
        },
        {
            "start_logit": -6.8359375,
            "end_logit": -7.6796875,
            "text": "of dabigatran.",
            "probability": 0.0
        }
    ],
    "5a7237672dc08e987e000008_30": [
        {
            "start_logit": 8.1640625,
            "end_logit": 8.1953125,
            "text": "dabigatran",
            "probability": 1.0
        },
        {
            "start_logit": 8.1640625,
            "end_logit": -7.015625,
            "text": "dabigatran and, unlike PCCs, was not associated with over-correction of thrombin generation.",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.45703125,
            "end_logit": 8.1953125,
            "text": "of dabigatran",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.1640625,
            "end_logit": -7.703125,
            "text": "dabigatran and",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.84765625,
            "end_logit": 8.1953125,
            "text": "effects of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.1640625,
            "end_logit": -7.8359375,
            "text": "dabigatran and, unlike PCCs, was not associated with over-correction of thrombin generation",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.1640625,
            "end_logit": -7.9921875,
            "text": "dabigatran and, unlike PCCs, was not associated",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.0234375,
            "end_logit": 8.1953125,
            "text": "Idarucizumab also reversed the effects of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.1640625,
            "end_logit": -7.99609375,
            "text": "dabigatran and, unlike PCCs, was not",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.1640625,
            "end_logit": -8.015625,
            "text": "dabigatran and, unlike PCCs, was not associated with over-correction of thrombin",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.1640625,
            "end_logit": -8.03125,
            "text": "dabigatran and, unlike PCCs, was not associated with over",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.0703125,
            "end_logit": 8.1953125,
            "text": "the effects of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.1640625,
            "end_logit": -8.046875,
            "text": "dabigatran and, unlike PCCs, was not associated with",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.1640625,
            "end_logit": -8.0546875,
            "text": "dabigatran and, unlike",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.1640625,
            "end_logit": -8.078125,
            "text": "dabigatran and, unlike PCCs, was",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.109375,
            "end_logit": 8.1953125,
            "text": "rucizumab also reversed the effects of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.125,
            "end_logit": 8.1953125,
            "text": "izumab also reversed the effects of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1640625,
            "end_logit": 8.1953125,
            "text": "reversed the effects of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.703125,
            "end_logit": -7.015625,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.45703125,
            "end_logit": -7.015625,
            "text": "of dabigatran and, unlike PCCs, was not associated with over-correction of thrombin generation.",
            "probability": 0.0
        }
    ],
    "5a7237672dc08e987e000008_31": [
        {
            "start_logit": 9.859375,
            "end_logit": 9.3671875,
            "text": "Dabigatran etexilate",
            "probability": 1.0
        },
        {
            "start_logit": 9.859375,
            "end_logit": -1.357421875,
            "text": "Dabigatran",
            "probability": 2.2113323211669922e-05
        },
        {
            "start_logit": -2.142578125,
            "end_logit": 9.3671875,
            "text": "te",
            "probability": 6.198883056640625e-06
        },
        {
            "start_logit": 9.859375,
            "end_logit": -6.8828125,
            "text": "Dabigatran etexila",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.859375,
            "end_logit": -7.38671875,
            "text": "Dabigatran et",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.92578125,
            "end_logit": 9.3671875,
            "text": "exilate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.859375,
            "end_logit": -7.44140625,
            "text": "Dabigatran etexilate (DE) dose-dependently prolonged diluted thrombin time and tail-vein bleeding time, which were reversed by idarucizumab.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.859375,
            "end_logit": -7.45703125,
            "text": "Dabigatran etex",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.15234375,
            "end_logit": 9.3671875,
            "text": "etexilate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.2421875,
            "end_logit": 9.3671875,
            "text": "ilate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.859375,
            "end_logit": -7.77734375,
            "text": "Dabigatran etexilate (DE) dose-dependently prolonged diluted thrombin time",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.859375,
            "end_logit": -7.8359375,
            "text": "Dabigatran etexilate (DE) dose-dependently",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.859375,
            "end_logit": -7.94140625,
            "text": "Dabigatran etexilate (DE) dose-dependently prolonged diluted thrombin time and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.859375,
            "end_logit": -8.0859375,
            "text": "Dabigatran etexilate (DE) dose-",
            "probability": 0.0
        },
        {
            "start_logit": 9.859375,
            "end_logit": -8.0859375,
            "text": "Dabigatran etexilate (DE) dose-dependently prolonged",
            "probability": 0.0
        },
        {
            "start_logit": 9.859375,
            "end_logit": -8.1171875,
            "text": "Dabigatran etexilate (DE) dose-dependently prolonged diluted thrombin",
            "probability": 0.0
        },
        {
            "start_logit": 9.859375,
            "end_logit": -8.15625,
            "text": "Dabigatran etexilate (DE) dose-dependently prolonged diluted thrombin time and tail-vein bleeding time, which",
            "probability": 0.0
        },
        {
            "start_logit": 9.859375,
            "end_logit": -8.1640625,
            "text": "Dabigatran etexilate (DE) dose-dependently prolonged diluted thrombin time and tail-vein bleeding time",
            "probability": 0.0
        },
        {
            "start_logit": 9.859375,
            "end_logit": -8.1640625,
            "text": "Dabigatran etexilate (",
            "probability": 0.0
        },
        {
            "start_logit": 9.859375,
            "end_logit": -8.1796875,
            "text": "Dabigatran etexilate (DE) dose-dependently prolonged diluted thrombin time and tail-vein bleeding time, which were",
            "probability": 0.0
        }
    ],
    "5a7237672dc08e987e000008_32": [
        {
            "start_logit": 7.97265625,
            "end_logit": 8.40625,
            "text": "dabigatran",
            "probability": 1.0
        },
        {
            "start_logit": -7.7734375,
            "end_logit": 8.40625,
            "text": "In this article, we discuss the evidence addressing idarucizumab safety, tolerability and its efficacy for reversing effect of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.8203125,
            "end_logit": 8.40625,
            "text": "article, we discuss the evidence addressing idarucizumab safety, tolerability and its efficacy for reversing effect of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.8359375,
            "end_logit": 8.40625,
            "text": "effect of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.90625,
            "end_logit": 8.40625,
            "text": "this article, we discuss the evidence addressing idarucizumab safety, tolerability and its efficacy for reversing effect of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.921875,
            "end_logit": 8.40625,
            "text": "reversing effect of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.93359375,
            "end_logit": 8.40625,
            "text": "we discuss the evidence addressing idarucizumab safety, tolerability and its efficacy for reversing effect of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.953125,
            "end_logit": 8.40625,
            "text": "its efficacy for reversing effect of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.953125,
            "end_logit": 8.40625,
            "text": "of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.0078125,
            "end_logit": 8.40625,
            "text": "evidence addressing idarucizumab safety, tolerability and its efficacy for reversing effect of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.015625,
            "end_logit": 8.40625,
            "text": "idarucizumab safety, tolerability and its efficacy for reversing effect of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.015625,
            "end_logit": 8.40625,
            "text": ", we discuss the evidence addressing idarucizumab safety, tolerability and its efficacy for reversing effect of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.015625,
            "end_logit": 8.40625,
            "text": "the evidence addressing idarucizumab safety, tolerability and its efficacy for reversing effect of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.0234375,
            "end_logit": 8.40625,
            "text": "efficacy for reversing effect of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.97265625,
            "end_logit": -7.734375,
            "text": "dabigatran.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.82421875,
            "end_logit": -7.734375,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.7734375,
            "end_logit": -7.734375,
            "text": "In this article, we discuss the evidence addressing idarucizumab safety, tolerability and its efficacy for reversing effect of dabigatran.",
            "probability": 0.0
        },
        {
            "start_logit": -7.8203125,
            "end_logit": -7.734375,
            "text": "article, we discuss the evidence addressing idarucizumab safety, tolerability and its efficacy for reversing effect of dabigatran.",
            "probability": 0.0
        },
        {
            "start_logit": -7.8359375,
            "end_logit": -7.734375,
            "text": "effect of dabigatran.",
            "probability": 0.0
        },
        {
            "start_logit": -7.90625,
            "end_logit": -7.734375,
            "text": "this article, we discuss the evidence addressing idarucizumab safety, tolerability and its efficacy for reversing effect of dabigatran.",
            "probability": 0.0
        }
    ],
    "5a7237672dc08e987e000008_33": [
        {
            "start_logit": 8.3671875,
            "end_logit": 8.0625,
            "text": "dabigatran",
            "probability": 1.0
        },
        {
            "start_logit": 8.3671875,
            "end_logit": -7.80859375,
            "text": "dabigatran.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.56640625,
            "end_logit": 8.0625,
            "text": "potential reversal agent for dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.74609375,
            "end_logit": 8.0625,
            "text": "for dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.9140625,
            "end_logit": 8.0625,
            "text": "Food and Drug Administration approval of idarucizumab, a potential reversal agent for dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.95703125,
            "end_logit": 8.0625,
            "text": "The Food and Drug Administration approval of idarucizumab, a potential reversal agent for dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.96875,
            "end_logit": 8.0625,
            "text": "agent for dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.9765625,
            "end_logit": 8.0625,
            "text": "reversal agent for dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.98046875,
            "end_logit": 8.0625,
            "text": "idarucizumab, a potential reversal agent for dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.9921875,
            "end_logit": 8.0625,
            "text": "recent The Food and Drug Administration approval of idarucizumab, a potential reversal agent for dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.015625,
            "end_logit": 8.0625,
            "text": "a potential reversal agent for dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0234375,
            "end_logit": 8.0625,
            "text": "approval of idarucizumab, a potential reversal agent for dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.046875,
            "end_logit": 8.0625,
            "text": ", a potential reversal agent for dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0546875,
            "end_logit": 8.0625,
            "text": "Drug Administration approval of idarucizumab, a potential reversal agent for dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0703125,
            "end_logit": 8.0625,
            "text": "the recent The Food and Drug Administration approval of idarucizumab, a potential reversal agent for dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.078125,
            "end_logit": 8.0625,
            "text": "of idarucizumab, a potential reversal agent for dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.078125,
            "end_logit": 8.0625,
            "text": "rucizumab, a potential reversal agent for dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.96875,
            "end_logit": -7.80859375,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.56640625,
            "end_logit": -7.80859375,
            "text": "potential reversal agent for dabigatran.",
            "probability": 0.0
        },
        {
            "start_logit": -7.74609375,
            "end_logit": -7.80859375,
            "text": "for dabigatran.",
            "probability": 0.0
        }
    ],
    "56c1d856ef6e394741000032_1": [
        {
            "start_logit": 9.890625,
            "end_logit": 9.4453125,
            "text": "lectin complement pathway",
            "probability": 1.0
        },
        {
            "start_logit": 9.890625,
            "end_logit": -1.177734375,
            "text": "lectin",
            "probability": 2.4139881134033203e-05
        },
        {
            "start_logit": -2.021484375,
            "end_logit": 9.4453125,
            "text": "pathway",
            "probability": 6.616115570068359e-06
        },
        {
            "start_logit": -5.52734375,
            "end_logit": 9.4453125,
            "text": "complement pathway",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.890625,
            "end_logit": -7.0546875,
            "text": "lectin complement pathway and SLE.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.890625,
            "end_logit": -7.453125,
            "text": "lectin complement",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.1796875,
            "end_logit": 9.4453125,
            "text": "the lectin complement pathway",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.890625,
            "end_logit": -7.89453125,
            "text": "lectin complement pathway and",
            "probability": 0.0
        },
        {
            "start_logit": -7.625,
            "end_logit": 9.4453125,
            "text": "part of the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -7.78515625,
            "end_logit": 9.4453125,
            "text": "This study aims to investigate whether an association exists between the ficolins that are part of the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -7.8359375,
            "end_logit": 9.4453125,
            "text": "of the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -7.875,
            "end_logit": 9.4453125,
            "text": "study aims to investigate whether an association exists between the ficolins that are part of the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -7.9453125,
            "end_logit": 9.4453125,
            "text": "ficolins that are part of the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -8.0078125,
            "end_logit": 9.4453125,
            "text": "are part of the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -8.0078125,
            "end_logit": 9.4453125,
            "text": "association exists between the ficolins that are part of the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -8.015625,
            "end_logit": 9.4453125,
            "text": "the ficolins that are part of the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -8.1171875,
            "end_logit": 9.4453125,
            "text": "olins that are part of the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -8.140625,
            "end_logit": 9.4453125,
            "text": "between the ficolins that are part of the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -8.1484375,
            "end_logit": 9.4453125,
            "text": "aims to investigate whether an association exists between the ficolins that are part of the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -7.1796875,
            "end_logit": -1.177734375,
            "text": "the lectin",
            "probability": 0.0
        }
    ],
    "56c1d856ef6e394741000032_2": [
        {
            "start_logit": 9.859375,
            "end_logit": 9.4765625,
            "text": "lectin complement pathway",
            "probability": 1.0
        },
        {
            "start_logit": 9.859375,
            "end_logit": -1.2919921875,
            "text": "lectin",
            "probability": 2.092123031616211e-05
        },
        {
            "start_logit": -1.931640625,
            "end_logit": 9.4765625,
            "text": "pathway",
            "probability": 7.510185241699219e-06
        },
        {
            "start_logit": -6.01953125,
            "end_logit": 9.4765625,
            "text": "complement pathway",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.859375,
            "end_logit": -7.5390625,
            "text": "lectin complement",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.859375,
            "end_logit": -7.77734375,
            "text": "lectin complement pathway (LCP), in subarachnoid hemorrhage (SAH) pathology and outcome.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.53125,
            "end_logit": 9.4765625,
            "text": "the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -7.734375,
            "end_logit": 9.4765625,
            "text": "OBJECTIVES: To assess the involvement of ficolin-3, the main initiator of the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": 9.859375,
            "end_logit": -8.140625,
            "text": "lectin complement pathway (LCP), in",
            "probability": 0.0
        },
        {
            "start_logit": 9.859375,
            "end_logit": -8.171875,
            "text": "lectin complement pathway (LCP), in subarachnoid hemorrhage (SAH) pathology and outcome",
            "probability": 0.0
        },
        {
            "start_logit": 9.859375,
            "end_logit": -8.171875,
            "text": "lectin complement pathway (LCP), in subarachnoid hemorrhage (SAH) pathology and",
            "probability": 0.0
        },
        {
            "start_logit": 9.859375,
            "end_logit": -8.1796875,
            "text": "lectin complement pathway (LCP), in subarachnoid hemorrhage (SAH)",
            "probability": 0.0
        },
        {
            "start_logit": 9.859375,
            "end_logit": -8.1796875,
            "text": "lectin complement pathway (LCP), in subarachnoid hemorrhage",
            "probability": 0.0
        },
        {
            "start_logit": -7.96875,
            "end_logit": 9.4765625,
            "text": "initiator of the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -7.98828125,
            "end_logit": 9.4765625,
            "text": "the main initiator of the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -7.99609375,
            "end_logit": 9.4765625,
            "text": "main initiator of the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -8.03125,
            "end_logit": 9.4765625,
            "text": "involvement of ficolin-3, the main initiator of the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -8.046875,
            "end_logit": 9.4765625,
            "text": "ficolin-3, the main initiator of the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -8.0625,
            "end_logit": 9.4765625,
            "text": "To assess the involvement of ficolin-3, the main initiator of the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -7.53125,
            "end_logit": -1.2919921875,
            "text": "the lectin",
            "probability": 0.0
        }
    ],
    "56c1d856ef6e394741000032_3": [
        {
            "start_logit": 9.78125,
            "end_logit": 9.375,
            "text": "lectin complement pathway",
            "probability": 1.0
        },
        {
            "start_logit": 9.78125,
            "end_logit": -1.4072265625,
            "text": "lectin",
            "probability": 2.0802021026611328e-05
        },
        {
            "start_logit": -2.11328125,
            "end_logit": 9.375,
            "text": "pathway",
            "probability": 6.854534149169922e-06
        },
        {
            "start_logit": -6.2578125,
            "end_logit": 9.375,
            "text": "complement pathway",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.78125,
            "end_logit": -7.44140625,
            "text": "lectin complement",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.78125,
            "end_logit": -7.55859375,
            "text": "lectin complement pathway activation in",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.78125,
            "end_logit": -7.58984375,
            "text": "lectin complement pathway activation in patients with subarachnoid hemorrhage.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.78125,
            "end_logit": -8.0546875,
            "text": "lectin complement pathway activation",
            "probability": 0.0
        },
        {
            "start_logit": 9.78125,
            "end_logit": -8.0703125,
            "text": "lectin complement pathway activation in patients with subarachnoid hemorrhage",
            "probability": 0.0
        },
        {
            "start_logit": 9.78125,
            "end_logit": -8.1328125,
            "text": "lectin complement pathway activation in patients",
            "probability": 0.0
        },
        {
            "start_logit": -7.7265625,
            "end_logit": 9.375,
            "text": "Ficolin-3-mediated lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -7.875,
            "end_logit": 9.375,
            "text": "mediated lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -7.953125,
            "end_logit": 9.375,
            "text": "olin-3-mediated lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -8.015625,
            "end_logit": 9.375,
            "text": "3-mediated lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -8.046875,
            "end_logit": 9.375,
            "text": "-mediated lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -8.0546875,
            "end_logit": 9.375,
            "text": "-3-mediated lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -7.7265625,
            "end_logit": -1.4072265625,
            "text": "Ficolin-3-mediated lectin",
            "probability": 0.0
        },
        {
            "start_logit": -7.875,
            "end_logit": -1.4072265625,
            "text": "mediated lectin",
            "probability": 0.0
        },
        {
            "start_logit": -7.953125,
            "end_logit": -1.4072265625,
            "text": "olin-3-mediated lectin",
            "probability": 0.0
        },
        {
            "start_logit": -8.015625,
            "end_logit": -1.4072265625,
            "text": "3-mediated lectin",
            "probability": 0.0
        }
    ],
    "56c1d856ef6e394741000032_4": [
        {
            "start_logit": 9.5703125,
            "end_logit": 8.828125,
            "text": "lectin complement pathway",
            "probability": 1.0
        },
        {
            "start_logit": 9.5703125,
            "end_logit": -1.7236328125,
            "text": "lectin",
            "probability": 2.586841583251953e-05
        },
        {
            "start_logit": -2.98046875,
            "end_logit": 8.828125,
            "text": "pathway",
            "probability": 3.516674041748047e-06
        },
        {
            "start_logit": 9.5703125,
            "end_logit": -6.34765625,
            "text": "lectin complement",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.5703125,
            "end_logit": -6.87109375,
            "text": "lectin complement pathway initiators.",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.2109375,
            "end_logit": 8.828125,
            "text": "complement activating potential and is the only collagenase proteolytic resistant molecule among the lectin complement pathway",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.96484375,
            "end_logit": 8.828125,
            "text": "complement pathway",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.5703125,
            "end_logit": -8.015625,
            "text": "lectin complement pathway initiator",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.69921875,
            "end_logit": 8.828125,
            "text": "the lectin complement pathway",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.921875,
            "end_logit": 8.828125,
            "text": "Ficolin-3 has a high complement activating potential and is the only collagenase proteolytic resistant molecule among the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -7.94140625,
            "end_logit": 8.828125,
            "text": "high complement activating potential and is the only collagenase proteolytic resistant molecule among the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -7.9765625,
            "end_logit": 8.828125,
            "text": "among the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -7.984375,
            "end_logit": 8.828125,
            "text": "potential and is the only collagenase proteolytic resistant molecule among the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -7.99609375,
            "end_logit": 8.828125,
            "text": ", Ficolin-3 has a high complement activating potential and is the only collagenase proteolytic resistant molecule among the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -8.0078125,
            "end_logit": 8.828125,
            "text": "the only collagenase proteolytic resistant molecule among the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -8.03125,
            "end_logit": 8.828125,
            "text": "only collagenase proteolytic resistant molecule among the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -8.03125,
            "end_logit": 8.828125,
            "text": "3 has a high complement activating potential and is the only collagenase proteolytic resistant molecule among the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -8.0703125,
            "end_logit": 8.828125,
            "text": "molecule among the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -8.0703125,
            "end_logit": 8.828125,
            "text": "olin-3 has a high complement activating potential and is the only collagenase proteolytic resistant molecule among the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -8.09375,
            "end_logit": 8.828125,
            "text": "-3 has a high complement activating potential and is the only collagenase proteolytic resistant molecule among the lectin complement pathway",
            "probability": 0.0
        }
    ],
    "56c1d856ef6e394741000032_5": [
        {
            "start_logit": 9.453125,
            "end_logit": 8.8125,
            "text": "lectin complement pathway",
            "probability": 1.0
        },
        {
            "start_logit": 9.453125,
            "end_logit": -2.052734375,
            "text": "lectin",
            "probability": 1.9073486328125e-05
        },
        {
            "start_logit": -2.96875,
            "end_logit": 8.8125,
            "text": "pathway",
            "probability": 4.0531158447265625e-06
        },
        {
            "start_logit": 9.453125,
            "end_logit": -5.91796875,
            "text": "lectin complement",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -6.05078125,
            "end_logit": 8.8125,
            "text": "the lectin complement pathway",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.453125,
            "end_logit": -7.45703125,
            "text": "lectin complement pathway.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.91796875,
            "end_logit": 8.8125,
            "text": "complement pathway",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.265625,
            "end_logit": 8.8125,
            "text": "in the lectin complement pathway",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.75,
            "end_logit": 8.8125,
            "text": "Ficolin-3 (Hakata antigen or H-ficolin) is a soluble pattern recognition molecule in the lectin complement pathway",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.8515625,
            "end_logit": 8.8125,
            "text": "molecule in the lectin complement pathway",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.875,
            "end_logit": 8.8125,
            "text": "pattern recognition molecule in the lectin complement pathway",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.89453125,
            "end_logit": 8.8125,
            "text": "ficolin) is a soluble pattern recognition molecule in the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -7.90234375,
            "end_logit": 8.8125,
            "text": ") is a soluble pattern recognition molecule in the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -7.95703125,
            "end_logit": 8.8125,
            "text": "H-ficolin) is a soluble pattern recognition molecule in the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -7.96484375,
            "end_logit": 8.8125,
            "text": "antigen or H-ficolin) is a soluble pattern recognition molecule in the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -7.96875,
            "end_logit": 8.8125,
            "text": "-ficolin) is a soluble pattern recognition molecule in the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -7.984375,
            "end_logit": 8.8125,
            "text": "(Hakata antigen or H-ficolin) is a soluble pattern recognition molecule in the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -7.984375,
            "end_logit": 8.8125,
            "text": "olin-3 (Hakata antigen or H-ficolin) is a soluble pattern recognition molecule in the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -7.98828125,
            "end_logit": 8.8125,
            "text": "recognition molecule in the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -6.05078125,
            "end_logit": -2.052734375,
            "text": "the lectin",
            "probability": 0.0
        }
    ],
    "56c1d856ef6e394741000032_6": [
        {
            "start_logit": 9.3984375,
            "end_logit": 9.3203125,
            "text": "lectin complement pathway",
            "probability": 1.0
        },
        {
            "start_logit": 9.3984375,
            "end_logit": -2.171875,
            "text": "lectin",
            "probability": 1.0192394256591797e-05
        },
        {
            "start_logit": -2.177734375,
            "end_logit": 9.3203125,
            "text": "pathway",
            "probability": 9.357929229736328e-06
        },
        {
            "start_logit": -5.93359375,
            "end_logit": 9.3203125,
            "text": "complement pathway",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.3984375,
            "end_logit": -7.12109375,
            "text": "lectin complement pathway and form complexes with serine proteases named MASP-1, -2 and -3 and two nonenzymatic proteins. MASP-2 is the main initiator of lectin pathway",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3984375,
            "end_logit": -7.22265625,
            "text": "lectin complement pathway and form complexes with serine proteases named MASP-1, -2 and -3 and two nonenzymatic proteins.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.23046875,
            "end_logit": 9.3203125,
            "text": "the lectin complement pathway",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3984375,
            "end_logit": -7.55859375,
            "text": "lectin complement",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3984375,
            "end_logit": -7.88671875,
            "text": "lectin complement pathway and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.84765625,
            "end_logit": 9.3203125,
            "text": "Ficolin-1, -2 and -3 are recognition molecules in the lectin complement pathway",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3984375,
            "end_logit": -7.95703125,
            "text": "lectin complement pathway and form complexes with serine proteases named MASP",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.8984375,
            "end_logit": 9.3203125,
            "text": "molecules in the lectin complement pathway",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3984375,
            "end_logit": -7.98046875,
            "text": "lectin complement pathway and form complexes with serine proteases named MASP-1, -2 and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3984375,
            "end_logit": -7.984375,
            "text": "lectin complement pathway and form complexes with serine proteases named",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3984375,
            "end_logit": -7.9921875,
            "text": "lectin complement pathway and form complexes with serine proteases named MASP-1, -2 and -3 and two nonenzymatic proteins. MASP-2 is the main initiator of lectin pathway activation",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3984375,
            "end_logit": -8.0078125,
            "text": "lectin complement pathway and form complexes with serine proteases named MASP-1, -2 and -3 and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3984375,
            "end_logit": -8.015625,
            "text": "lectin complement pathway and form complexes with serine proteases",
            "probability": 0.0
        },
        {
            "start_logit": 9.3984375,
            "end_logit": -8.015625,
            "text": "lectin complement pathway and form complexes with serine proteases named MASP-1, -2 and -3 and two nonenzymatic proteins. MASP",
            "probability": 0.0
        },
        {
            "start_logit": 9.3984375,
            "end_logit": -8.0234375,
            "text": "lectin complement pathway and form complexes with serine proteases named MASP-1, -2",
            "probability": 0.0
        },
        {
            "start_logit": 9.3984375,
            "end_logit": -8.03125,
            "text": "lectin complement pathway and form complexes with serine proteases named MASP-1",
            "probability": 0.0
        }
    ],
    "5a7639419e632bc066000005_1": [
        {
            "start_logit": 9.8671875,
            "end_logit": 9.7578125,
            "text": "DeepLoc",
            "probability": 1.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -1.421875,
            "text": "Deep",
            "probability": 1.3947486877441406e-05
        },
        {
            "start_logit": -1.3173828125,
            "end_logit": 9.7578125,
            "text": "c",
            "probability": 1.3828277587890625e-05
        },
        {
            "start_logit": -5.9765625,
            "end_logit": 9.7578125,
            "text": "Loc",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -6.94140625,
            "text": "DeepLo",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -7.9765625,
            "text": "DeepLoc: prediction of protein subcellular localization using deep learning.",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.078125,
            "text": "DeepLoc: prediction of protein subcellular localization using",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.0859375,
            "text": "DeepLoc: prediction of protein subcellular localization",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.1328125,
            "text": "DeepLoc:",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.1796875,
            "text": "DeepLoc: prediction of protein subcellular",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.203125,
            "text": "DeepLoc: prediction of protein subcellular localization using deep learning",
            "probability": 0.0
        },
        {
            "start_logit": -1.3173828125,
            "end_logit": -7.9765625,
            "text": "c: prediction of protein subcellular localization using deep learning.",
            "probability": 0.0
        },
        {
            "start_logit": -1.3173828125,
            "end_logit": -8.078125,
            "text": "c: prediction of protein subcellular localization using",
            "probability": 0.0
        },
        {
            "start_logit": -1.3173828125,
            "end_logit": -8.0859375,
            "text": "c: prediction of protein subcellular localization",
            "probability": 0.0
        },
        {
            "start_logit": -1.3173828125,
            "end_logit": -8.1328125,
            "text": "c:",
            "probability": 0.0
        },
        {
            "start_logit": -1.3173828125,
            "end_logit": -8.1796875,
            "text": "c: prediction of protein subcellular",
            "probability": 0.0
        },
        {
            "start_logit": -1.3173828125,
            "end_logit": -8.203125,
            "text": "c: prediction of protein subcellular localization using deep learning",
            "probability": 0.0
        },
        {
            "start_logit": -5.9765625,
            "end_logit": -6.94140625,
            "text": "Lo",
            "probability": 0.0
        },
        {
            "start_logit": -5.9765625,
            "end_logit": -7.9765625,
            "text": "Loc: prediction of protein subcellular localization using deep learning.",
            "probability": 0.0
        },
        {
            "start_logit": -5.9765625,
            "end_logit": -8.078125,
            "text": "Loc: prediction of protein subcellular localization using",
            "probability": 0.0
        }
    ],
    "5a7639419e632bc066000005_2": [
        {
            "start_logit": 9.8671875,
            "end_logit": 9.7578125,
            "text": "DeepLoc",
            "probability": 1.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -1.421875,
            "text": "Deep",
            "probability": 1.3947486877441406e-05
        },
        {
            "start_logit": -1.3173828125,
            "end_logit": 9.7578125,
            "text": "c",
            "probability": 1.3828277587890625e-05
        },
        {
            "start_logit": -5.9765625,
            "end_logit": 9.7578125,
            "text": "Loc",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -6.94140625,
            "text": "DeepLo",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -7.9765625,
            "text": "DeepLoc: prediction of protein subcellular localization using deep learning.",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.078125,
            "text": "DeepLoc: prediction of protein subcellular localization using",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.0859375,
            "text": "DeepLoc: prediction of protein subcellular localization",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.1328125,
            "text": "DeepLoc:",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.1796875,
            "text": "DeepLoc: prediction of protein subcellular",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.203125,
            "text": "DeepLoc: prediction of protein subcellular localization using deep learning",
            "probability": 0.0
        },
        {
            "start_logit": -1.3173828125,
            "end_logit": -7.9765625,
            "text": "c: prediction of protein subcellular localization using deep learning.",
            "probability": 0.0
        },
        {
            "start_logit": -1.3173828125,
            "end_logit": -8.078125,
            "text": "c: prediction of protein subcellular localization using",
            "probability": 0.0
        },
        {
            "start_logit": -1.3173828125,
            "end_logit": -8.0859375,
            "text": "c: prediction of protein subcellular localization",
            "probability": 0.0
        },
        {
            "start_logit": -1.3173828125,
            "end_logit": -8.1328125,
            "text": "c:",
            "probability": 0.0
        },
        {
            "start_logit": -1.3173828125,
            "end_logit": -8.1796875,
            "text": "c: prediction of protein subcellular",
            "probability": 0.0
        },
        {
            "start_logit": -1.3173828125,
            "end_logit": -8.203125,
            "text": "c: prediction of protein subcellular localization using deep learning",
            "probability": 0.0
        },
        {
            "start_logit": -5.9765625,
            "end_logit": -6.94140625,
            "text": "Lo",
            "probability": 0.0
        },
        {
            "start_logit": -5.9765625,
            "end_logit": -7.9765625,
            "text": "Loc: prediction of protein subcellular localization using deep learning.",
            "probability": 0.0
        },
        {
            "start_logit": -5.9765625,
            "end_logit": -8.078125,
            "text": "Loc: prediction of protein subcellular localization using",
            "probability": 0.0
        }
    ],
    "54e0d7471388e8454a000015_1": [
        {
            "start_logit": 9.9140625,
            "end_logit": 9.796875,
            "text": "interleukin-17A",
            "probability": 1.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -1.275390625,
            "text": "interleukin",
            "probability": 1.5437602996826172e-05
        },
        {
            "start_logit": -1.1875,
            "end_logit": 9.796875,
            "text": "17A",
            "probability": 1.4960765838623047e-05
        },
        {
            "start_logit": -6.16015625,
            "end_logit": 9.796875,
            "text": "-17A",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -7.96875,
            "text": "interleukin-",
            "probability": 0.0
        },
        {
            "start_logit": -7.9296875,
            "end_logit": 9.796875,
            "text": "-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -7.94140625,
            "end_logit": 9.796875,
            "text": "anti-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -7.95703125,
            "end_logit": 9.796875,
            "text": "human anti-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -7.9609375,
            "end_logit": 9.796875,
            "text": "fully human anti-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.0859375,
            "text": "interleukin-17A monoclonal antibody.",
            "probability": 0.0
        },
        {
            "start_logit": -7.97265625,
            "end_logit": 9.796875,
            "text": "Secukinumab is a fully human anti-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -8.0390625,
            "end_logit": 9.796875,
            "text": "ukinumab is a fully human anti-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -8.0390625,
            "end_logit": 9.796875,
            "text": "inumab is a fully human anti-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -8.046875,
            "end_logit": 9.796875,
            "text": "ab is a fully human anti-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -8.0546875,
            "end_logit": 9.796875,
            "text": "BACKGROUND: Secukinumab is a fully human anti-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -8.09375,
            "end_logit": 9.796875,
            "text": "a fully human anti-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -8.1015625,
            "end_logit": 9.796875,
            "text": "is a fully human anti-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -7.9296875,
            "end_logit": -1.275390625,
            "text": "-interleukin",
            "probability": 0.0
        },
        {
            "start_logit": -7.94140625,
            "end_logit": -1.275390625,
            "text": "anti-interleukin",
            "probability": 0.0
        },
        {
            "start_logit": -7.95703125,
            "end_logit": -1.275390625,
            "text": "human anti-interleukin",
            "probability": 0.0
        }
    ],
    "54e0d7471388e8454a000015_2": [
        {
            "start_logit": 9.890625,
            "end_logit": 9.7890625,
            "text": "interleukin-17A",
            "probability": 1.0
        },
        {
            "start_logit": -1.2099609375,
            "end_logit": 9.7890625,
            "text": "17A",
            "probability": 1.4960765838623047e-05
        },
        {
            "start_logit": 9.890625,
            "end_logit": -1.3564453125,
            "text": "interleukin",
            "probability": 1.430511474609375e-05
        },
        {
            "start_logit": -6.35546875,
            "end_logit": 9.7890625,
            "text": "-17A",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.765625,
            "end_logit": 9.7890625,
            "text": "human anti-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": 9.890625,
            "end_logit": -7.90234375,
            "text": "interleukin-",
            "probability": 0.0
        },
        {
            "start_logit": -7.83203125,
            "end_logit": 9.7890625,
            "text": "fully human anti-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -7.83203125,
            "end_logit": 9.7890625,
            "text": "anti-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": 9.890625,
            "end_logit": -7.95703125,
            "text": "interleukin-17A monoclonal antibody, demonstrated efficacy and safety in moderate-to-severe plaque psoriasis when administered via subcutaneous injection.",
            "probability": 0.0
        },
        {
            "start_logit": -7.859375,
            "end_logit": 9.7890625,
            "text": "-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -7.96484375,
            "end_logit": 9.7890625,
            "text": "Secukinumab, a fully human anti-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -7.96484375,
            "end_logit": 9.7890625,
            "text": "a fully human anti-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -7.99609375,
            "end_logit": 9.7890625,
            "text": "BACKGROUND: Secukinumab, a fully human anti-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -8.015625,
            "end_logit": 9.7890625,
            "text": ", a fully human anti-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -8.0234375,
            "end_logit": 9.7890625,
            "text": "ukinumab, a fully human anti-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": 9.890625,
            "end_logit": -8.1328125,
            "text": "interleukin-17A monoclonal antibody, demonstrated efficacy and safety in moderate-to-severe plaque psoriasis when",
            "probability": 0.0
        },
        {
            "start_logit": -7.765625,
            "end_logit": -1.3564453125,
            "text": "human anti-interleukin",
            "probability": 0.0
        },
        {
            "start_logit": -1.2099609375,
            "end_logit": -7.95703125,
            "text": "17A monoclonal antibody, demonstrated efficacy and safety in moderate-to-severe plaque psoriasis when administered via subcutaneous injection.",
            "probability": 0.0
        },
        {
            "start_logit": -7.83203125,
            "end_logit": -1.3564453125,
            "text": "fully human anti-interleukin",
            "probability": 0.0
        },
        {
            "start_logit": -7.83203125,
            "end_logit": -1.3564453125,
            "text": "anti-interleukin",
            "probability": 0.0
        }
    ],
    "54e0d7471388e8454a000015_3": [
        {
            "start_logit": 9.9140625,
            "end_logit": 9.796875,
            "text": "interleukin-17A",
            "probability": 1.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -1.294921875,
            "text": "interleukin",
            "probability": 1.5079975128173828e-05
        },
        {
            "start_logit": -1.19921875,
            "end_logit": 9.796875,
            "text": "17A",
            "probability": 1.4722347259521484e-05
        },
        {
            "start_logit": -6.2109375,
            "end_logit": 9.796875,
            "text": "-17A",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.75,
            "end_logit": 9.796875,
            "text": "human anti-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -7.953125,
            "text": "interleukin-17A monoclonal antibody, in patients with moderate-to-severe plaque psoriasis.",
            "probability": 0.0
        },
        {
            "start_logit": -7.8359375,
            "end_logit": 9.796875,
            "text": "anti-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -7.83984375,
            "end_logit": 9.796875,
            "text": "-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -7.9609375,
            "text": "interleukin-",
            "probability": 0.0
        },
        {
            "start_logit": -7.8671875,
            "end_logit": 9.796875,
            "text": "fully human anti-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -7.9765625,
            "end_logit": 9.796875,
            "text": "secukinumab, a fully human anti-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -7.9921875,
            "end_logit": 9.796875,
            "text": "a fully human anti-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -8.03125,
            "end_logit": 9.796875,
            "text": "ukinumab, a fully human anti-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.15625,
            "text": "interleukin-17A monoclonal antibody, in",
            "probability": 0.0
        },
        {
            "start_logit": -8.0390625,
            "end_logit": 9.796875,
            "text": ", a fully human anti-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -8.046875,
            "end_logit": 9.796875,
            "text": "We evaluated secukinumab, a fully human anti-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.171875,
            "text": "interleukin-17A monoclonal antibody, in patients with moderate-to",
            "probability": 0.0
        },
        {
            "start_logit": -8.0703125,
            "end_logit": 9.796875,
            "text": "ab, a fully human anti-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -7.75,
            "end_logit": -1.294921875,
            "text": "human anti-interleukin",
            "probability": 0.0
        },
        {
            "start_logit": -7.8359375,
            "end_logit": -1.294921875,
            "text": "anti-interleukin",
            "probability": 0.0
        }
    ],
    "54e0d7471388e8454a000015_4": [
        {
            "start_logit": 9.8515625,
            "end_logit": 9.7734375,
            "text": "interleukin-17A",
            "probability": 1.0
        },
        {
            "start_logit": -1.2802734375,
            "end_logit": 9.7734375,
            "text": "17A",
            "probability": 1.4603137969970703e-05
        },
        {
            "start_logit": 9.8515625,
            "end_logit": -1.4375,
            "text": "interleukin",
            "probability": 1.3530254364013672e-05
        },
        {
            "start_logit": -6.3515625,
            "end_logit": 9.7734375,
            "text": "-17A",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.8515625,
            "end_logit": -7.984375,
            "text": "interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial.",
            "probability": 0.0
        },
        {
            "start_logit": 9.8515625,
            "end_logit": -8.015625,
            "text": "interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis",
            "probability": 0.0
        },
        {
            "start_logit": 9.8515625,
            "end_logit": -8.015625,
            "text": "interleukin-",
            "probability": 0.0
        },
        {
            "start_logit": -7.97265625,
            "end_logit": 9.7734375,
            "text": "Anti-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -8.0234375,
            "end_logit": 9.7734375,
            "text": "-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": 9.8515625,
            "end_logit": -8.1328125,
            "text": "interleukin-17A monoclonal antibody secukinumab in",
            "probability": 0.0
        },
        {
            "start_logit": 9.8515625,
            "end_logit": -8.1796875,
            "text": "interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis:",
            "probability": 0.0
        },
        {
            "start_logit": -1.2802734375,
            "end_logit": -7.984375,
            "text": "17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial.",
            "probability": 0.0
        },
        {
            "start_logit": -1.2802734375,
            "end_logit": -8.015625,
            "text": "17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis",
            "probability": 0.0
        },
        {
            "start_logit": -7.97265625,
            "end_logit": -1.4375,
            "text": "Anti-interleukin",
            "probability": 0.0
        },
        {
            "start_logit": -1.2802734375,
            "end_logit": -8.1328125,
            "text": "17A monoclonal antibody secukinumab in",
            "probability": 0.0
        },
        {
            "start_logit": -1.2802734375,
            "end_logit": -8.1796875,
            "text": "17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis:",
            "probability": 0.0
        },
        {
            "start_logit": -8.0234375,
            "end_logit": -1.4375,
            "text": "-interleukin",
            "probability": 0.0
        },
        {
            "start_logit": -6.3515625,
            "end_logit": -7.984375,
            "text": "-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial.",
            "probability": 0.0
        },
        {
            "start_logit": -6.3515625,
            "end_logit": -8.015625,
            "text": "-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis",
            "probability": 0.0
        },
        {
            "start_logit": -6.3515625,
            "end_logit": -8.015625,
            "text": "-",
            "probability": 0.0
        }
    ],
    "54e0d7471388e8454a000015_5": [
        {
            "start_logit": 9.921875,
            "end_logit": 9.7578125,
            "text": "interleukin-17A",
            "probability": 1.0
        },
        {
            "start_logit": 9.921875,
            "end_logit": -1.2587890625,
            "text": "interleukin",
            "probability": 1.633167266845703e-05
        },
        {
            "start_logit": -1.29296875,
            "end_logit": 9.7578125,
            "text": "17A",
            "probability": 1.341104507446289e-05
        },
        {
            "start_logit": -6.23828125,
            "end_logit": 9.7578125,
            "text": "-17A",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.921875,
            "end_logit": -7.96875,
            "text": "interleukin-",
            "probability": 0.0
        },
        {
            "start_logit": -7.80859375,
            "end_logit": 9.7578125,
            "text": "human anti-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -7.84765625,
            "end_logit": 9.7578125,
            "text": "-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -7.87109375,
            "end_logit": 9.7578125,
            "text": "anti-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -7.87890625,
            "end_logit": 9.7578125,
            "text": "fully human anti-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": 9.921875,
            "end_logit": -8.125,
            "text": "interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis",
            "probability": 0.0
        },
        {
            "start_logit": -7.96484375,
            "end_logit": 9.7578125,
            "text": "secukinumab, a fully human anti-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": 9.921875,
            "end_logit": -8.1796875,
            "text": "interleukin-17A monoclonal antibody, in",
            "probability": 0.0
        },
        {
            "start_logit": 9.921875,
            "end_logit": -8.1875,
            "text": "interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind",
            "probability": 0.0
        },
        {
            "start_logit": 9.921875,
            "end_logit": -8.203125,
            "text": "interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled",
            "probability": 0.0
        },
        {
            "start_logit": 9.921875,
            "end_logit": -8.203125,
            "text": "interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-",
            "probability": 0.0
        },
        {
            "start_logit": 9.921875,
            "end_logit": -8.2109375,
            "text": "interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24",
            "probability": 0.0
        },
        {
            "start_logit": 9.921875,
            "end_logit": -8.2109375,
            "text": "interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo",
            "probability": 0.0
        },
        {
            "start_logit": -7.80859375,
            "end_logit": -1.2587890625,
            "text": "human anti-interleukin",
            "probability": 0.0
        },
        {
            "start_logit": -7.84765625,
            "end_logit": -1.2587890625,
            "text": "-interleukin",
            "probability": 0.0
        },
        {
            "start_logit": -7.87109375,
            "end_logit": -1.2587890625,
            "text": "anti-interleukin",
            "probability": 0.0
        }
    ],
    "54e0d7471388e8454a000015_6": [
        {
            "start_logit": 9.7890625,
            "end_logit": 9.6484375,
            "text": "interleukin-17A",
            "probability": 1.0
        },
        {
            "start_logit": 9.7890625,
            "end_logit": -1.6015625,
            "text": "interleukin",
            "probability": 1.2993812561035156e-05
        },
        {
            "start_logit": -1.6181640625,
            "end_logit": 9.6484375,
            "text": "17A",
            "probability": 1.1146068572998047e-05
        },
        {
            "start_logit": -6.69140625,
            "end_logit": 9.6484375,
            "text": "-17A",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.7890625,
            "end_logit": -7.86328125,
            "text": "interleukin-",
            "probability": 0.0
        },
        {
            "start_logit": -7.8203125,
            "end_logit": 9.6484375,
            "text": "targeted interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": 9.7890625,
            "end_logit": -7.98046875,
            "text": "interleukin-17A blockade, in patients with noninfectious uveitis.",
            "probability": 0.0
        },
        {
            "start_logit": -7.9296875,
            "end_logit": 9.6484375,
            "text": "PURPOSE: To determine the efficacy and safety of different doses of secukinumab, a fully human monoclonal antibody for targeted interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -7.9375,
            "end_logit": 9.6484375,
            "text": "fully human monoclonal antibody for targeted interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -7.97265625,
            "end_logit": 9.6484375,
            "text": "for targeted interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -7.984375,
            "end_logit": 9.6484375,
            "text": "human monoclonal antibody for targeted interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -7.99609375,
            "end_logit": 9.6484375,
            "text": "a fully human monoclonal antibody for targeted interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -8.0234375,
            "end_logit": 9.6484375,
            "text": "antibody for targeted interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -8.03125,
            "end_logit": 9.6484375,
            "text": "monoclonal antibody for targeted interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -8.046875,
            "end_logit": 9.6484375,
            "text": "secukinumab, a fully human monoclonal antibody for targeted interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": 9.7890625,
            "end_logit": -8.1953125,
            "text": "interleukin-17A blockade, in",
            "probability": 0.0
        },
        {
            "start_logit": -8.0546875,
            "end_logit": 9.6484375,
            "text": "To determine the efficacy and safety of different doses of secukinumab, a fully human monoclonal antibody for targeted interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -8.0625,
            "end_logit": 9.6484375,
            "text": ", a fully human monoclonal antibody for targeted interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -7.8203125,
            "end_logit": -1.6015625,
            "text": "targeted interleukin",
            "probability": 0.0
        },
        {
            "start_logit": -7.9296875,
            "end_logit": -1.6015625,
            "text": "PURPOSE: To determine the efficacy and safety of different doses of secukinumab, a fully human monoclonal antibody for targeted interleukin",
            "probability": 0.0
        }
    ],
    "54e0d7471388e8454a000015_7": [
        {
            "start_logit": 9.8671875,
            "end_logit": 9.765625,
            "text": "interleukin-17A",
            "probability": 1.0
        },
        {
            "start_logit": -1.28515625,
            "end_logit": 9.765625,
            "text": "17A",
            "probability": 1.4483928680419922e-05
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -1.4072265625,
            "text": "interleukin",
            "probability": 1.4185905456542969e-05
        },
        {
            "start_logit": -6.34765625,
            "end_logit": 9.765625,
            "text": "-17A",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -7.9609375,
            "text": "interleukin-",
            "probability": 0.0
        },
        {
            "start_logit": -8.0390625,
            "end_logit": 9.765625,
            "text": "the interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.1484375,
            "text": "interleukin-17A-blocking antibody secukinumab does not interfere with the efficacy of influenza and meningococcal vaccinations in",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.171875,
            "text": "interleukin-17A-blocking antibody secukinumab does",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.2109375,
            "text": "interleukin-17A-blocking antibody secukinumab does not interfere",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.2109375,
            "text": "interleukin-17A-blocking antibody secukinumab does not interfere with the efficacy of influenza",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.2109375,
            "text": "interleukin-17A-blocking antibody secukinumab does not interfere with the efficacy of influenza and meningococcal vaccinations in healthy subjects: results of an open-label",
            "probability": 0.0
        },
        {
            "start_logit": -1.28515625,
            "end_logit": -7.921875,
            "text": "17A-blocking antibody secukinumab does not interfere with the efficacy of influenza and meningococcal vaccinations in healthy subjects: results of an open-label, parallel-group, randomized single-center study.",
            "probability": 0.0
        },
        {
            "start_logit": -1.28515625,
            "end_logit": -8.1484375,
            "text": "17A-blocking antibody secukinumab does not interfere with the efficacy of influenza and meningococcal vaccinations in",
            "probability": 0.0
        },
        {
            "start_logit": -8.0390625,
            "end_logit": -1.4072265625,
            "text": "the interleukin",
            "probability": 0.0
        },
        {
            "start_logit": -1.28515625,
            "end_logit": -8.171875,
            "text": "17A-blocking antibody secukinumab does",
            "probability": 0.0
        },
        {
            "start_logit": -1.28515625,
            "end_logit": -8.2109375,
            "text": "17A-blocking antibody secukinumab does not interfere",
            "probability": 0.0
        },
        {
            "start_logit": -1.28515625,
            "end_logit": -8.2109375,
            "text": "17A-blocking antibody secukinumab does not interfere with the efficacy of influenza",
            "probability": 0.0
        },
        {
            "start_logit": -1.28515625,
            "end_logit": -8.2109375,
            "text": "17A-blocking antibody secukinumab does not interfere with the efficacy of influenza and meningococcal vaccinations in healthy subjects: results of an open-label",
            "probability": 0.0
        },
        {
            "start_logit": -6.34765625,
            "end_logit": -7.9609375,
            "text": "-",
            "probability": 0.0
        },
        {
            "start_logit": -6.34765625,
            "end_logit": -8.1484375,
            "text": "-17A-blocking antibody secukinumab does not interfere with the efficacy of influenza and meningococcal vaccinations in",
            "probability": 0.0
        }
    ],
    "54e0d7471388e8454a000015_8": [
        {
            "start_logit": 9.921875,
            "end_logit": 9.8125,
            "text": "interleukin-17A",
            "probability": 1.0
        },
        {
            "start_logit": -1.12890625,
            "end_logit": 9.8125,
            "text": "17A",
            "probability": 1.5914440155029297e-05
        },
        {
            "start_logit": 9.921875,
            "end_logit": -1.2568359375,
            "text": "interleukin",
            "probability": 1.5556812286376953e-05
        },
        {
            "start_logit": -6.546875,
            "end_logit": 9.8125,
            "text": "-17A",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.921875,
            "end_logit": -7.703125,
            "text": "interleukin-",
            "probability": 0.0
        },
        {
            "start_logit": 9.921875,
            "end_logit": -7.88671875,
            "text": "interleukin-17A (IL-17A) monoclonal antibody (MAb) secukinumab.",
            "probability": 0.0
        },
        {
            "start_logit": 9.921875,
            "end_logit": -7.98046875,
            "text": "interleukin-17A (",
            "probability": 0.0
        },
        {
            "start_logit": -7.90234375,
            "end_logit": 9.8125,
            "text": "Our objective was to evaluate the efficacy of influenza and meningococcal vaccinations in healthy subjects exposed to the anti-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": 9.921875,
            "end_logit": -8.0234375,
            "text": "interleukin-17A (IL-17A",
            "probability": 0.0
        },
        {
            "start_logit": 9.921875,
            "end_logit": -8.0703125,
            "text": "interleukin-17A (IL",
            "probability": 0.0
        },
        {
            "start_logit": -7.9609375,
            "end_logit": 9.8125,
            "text": "-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -7.96484375,
            "end_logit": 9.8125,
            "text": "anti-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": 9.921875,
            "end_logit": -8.1015625,
            "text": "interleukin-17A (IL-",
            "probability": 0.0
        },
        {
            "start_logit": -7.99609375,
            "end_logit": 9.8125,
            "text": "the anti-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -8.0390625,
            "end_logit": 9.8125,
            "text": "objective was to evaluate the efficacy of influenza and meningococcal vaccinations in healthy subjects exposed to the anti-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": 9.921875,
            "end_logit": -8.1640625,
            "text": "interleukin-17A (IL-17A)",
            "probability": 0.0
        },
        {
            "start_logit": 9.921875,
            "end_logit": -8.1796875,
            "text": "interleukin-17A (IL-17A) monoclonal antibody (MAb",
            "probability": 0.0
        },
        {
            "start_logit": -8.0703125,
            "end_logit": 9.8125,
            "text": "exposed to the anti-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -8.0859375,
            "end_logit": 9.8125,
            "text": "subjects exposed to the anti-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -8.09375,
            "end_logit": 9.8125,
            "text": "influenza and meningococcal vaccinations in healthy subjects exposed to the anti-interleukin-17A",
            "probability": 0.0
        }
    ],
    "58b6978822d300530900000a_1": [
        {
            "start_logit": 9.71875,
            "end_logit": 9.65625,
            "text": "Alzheimer's disease",
            "probability": 1.0
        },
        {
            "start_logit": -1.5673828125,
            "end_logit": 9.65625,
            "text": "disease",
            "probability": 1.2516975402832031e-05
        },
        {
            "start_logit": 9.71875,
            "end_logit": -1.734375,
            "text": "Alzheimer",
            "probability": 1.1324882507324219e-05
        },
        {
            "start_logit": -6.4453125,
            "end_logit": 9.65625,
            "text": "'s disease",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.71875,
            "end_logit": -6.765625,
            "text": "Alzheimer's",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.05859375,
            "end_logit": 9.65625,
            "text": "s disease",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.71875,
            "end_logit": -7.4375,
            "text": "Alzheimer'",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.71875,
            "end_logit": -7.48046875,
            "text": "Alzheimer's disease mouse model.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.78515625,
            "end_logit": 9.65625,
            "text": "in this paper offers new insight into cognitive dysfunctions of the Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -7.80078125,
            "end_logit": 9.65625,
            "text": "the Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -7.8125,
            "end_logit": 9.65625,
            "text": "this paper offers new insight into cognitive dysfunctions of the Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -7.85546875,
            "end_logit": 9.65625,
            "text": "The novel approach to study the transgenic mice cognitive abilities presented in this paper offers new insight into cognitive dysfunctions of the Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -7.8984375,
            "end_logit": 9.65625,
            "text": "paper offers new insight into cognitive dysfunctions of the Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -7.9453125,
            "end_logit": 9.65625,
            "text": "novel approach to study the transgenic mice cognitive abilities presented in this paper offers new insight into cognitive dysfunctions of the Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -7.953125,
            "end_logit": 9.65625,
            "text": "of the Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -7.9609375,
            "end_logit": 9.65625,
            "text": "cognitive dysfunctions of the Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -7.98046875,
            "end_logit": 9.65625,
            "text": "approach to study the transgenic mice cognitive abilities presented in this paper offers new insight into cognitive dysfunctions of the Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -7.984375,
            "end_logit": 9.65625,
            "text": "the transgenic mice cognitive abilities presented in this paper offers new insight into cognitive dysfunctions of the Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -7.98828125,
            "end_logit": 9.65625,
            "text": "presented in this paper offers new insight into cognitive dysfunctions of the Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -8.015625,
            "end_logit": 9.65625,
            "text": "insight into cognitive dysfunctions of the Alzheimer's disease",
            "probability": 0.0
        }
    ],
    "58b6978822d300530900000a_2": [
        {
            "start_logit": 9.0,
            "end_logit": 7.1328125,
            "text": "Alzheimer's disease",
            "probability": 1.0
        },
        {
            "start_logit": 9.0,
            "end_logit": -2.974609375,
            "text": "Alzheimer",
            "probability": 4.100799560546875e-05
        },
        {
            "start_logit": 9.0,
            "end_logit": -6.4296875,
            "text": "Alzheimer's disease (AD) is the massive loss of synapses that occurs at an early clinical stage of the disease.",
            "probability": 1.3113021850585938e-06
        },
        {
            "start_logit": -4.94921875,
            "end_logit": 7.1328125,
            "text": "disease",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": 9.0,
            "end_logit": -7.06640625,
            "text": "Alzheimer's",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 9.0,
            "end_logit": -7.35546875,
            "text": "Alzheimer'",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 9.0,
            "end_logit": -7.4921875,
            "text": "Alzheimer's disease (AD)",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -7.17578125,
            "end_logit": 7.1328125,
            "text": "'s disease",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.20703125,
            "end_logit": 7.1328125,
            "text": "of Alzheimer's disease",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.57421875,
            "end_logit": 7.1328125,
            "text": "s disease",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.634765625,
            "end_logit": -1.9609375,
            "text": "Swedish mutation",
            "probability": 0.0
        },
        {
            "start_logit": -5.078125,
            "end_logit": -1.9609375,
            "text": "mutation",
            "probability": 0.0
        },
        {
            "start_logit": -5.35546875,
            "end_logit": -1.9609375,
            "text": "the Swedish mutation",
            "probability": 0.0
        },
        {
            "start_logit": -6.28515625,
            "end_logit": -1.9609375,
            "text": "carrying the Swedish mutation",
            "probability": 0.0
        },
        {
            "start_logit": -6.33203125,
            "end_logit": -1.9609375,
            "text": "34% in the basal dendrites proximal to the soma of CA1 pyramidal neurons in 5.5-month-old Tg2576 mice, carrying the Swedish mutation",
            "probability": 0.0
        },
        {
            "start_logit": -2.634765625,
            "end_logit": -6.4296875,
            "text": "Swedish mutation, compared with wild-type littermates.",
            "probability": 0.0
        },
        {
            "start_logit": -2.634765625,
            "end_logit": -6.4296875,
            "text": "Swedish mutation, compared with wild-type littermates. A similar reduction of 42% was confirmed in the same region of 8-month-old APP/Lo mice, carrying the London mutation.",
            "probability": 0.0
        },
        {
            "start_logit": -2.634765625,
            "end_logit": -6.63671875,
            "text": "Swedish mutation, compared with wild-type littermates. A similar reduction of 42%",
            "probability": 0.0
        },
        {
            "start_logit": -2.634765625,
            "end_logit": -6.8203125,
            "text": "Swedish",
            "probability": 0.0
        },
        {
            "start_logit": -7.20703125,
            "end_logit": -2.974609375,
            "text": "of Alzheimer",
            "probability": 0.0
        }
    ],
    "58b6978822d300530900000a_3": [
        {
            "start_logit": 9.796875,
            "end_logit": 9.671875,
            "text": "Alzheimer's disease",
            "probability": 1.0
        },
        {
            "start_logit": 9.796875,
            "end_logit": -1.5693359375,
            "text": "Alzheimer",
            "probability": 1.3113021850585938e-05
        },
        {
            "start_logit": -1.541015625,
            "end_logit": 9.671875,
            "text": "disease",
            "probability": 1.1920928955078125e-05
        },
        {
            "start_logit": -5.74609375,
            "end_logit": 9.671875,
            "text": "Val717Ile) associated with early shifting abilities and behavioral changes in two Italian families with early-onset Alzheimer's disease",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.3203125,
            "end_logit": 9.671875,
            "text": "'s disease",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.578125,
            "end_logit": 9.671875,
            "text": "s disease",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.796875,
            "end_logit": -7.26953125,
            "text": "Alzheimer's",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.1640625,
            "end_logit": 9.671875,
            "text": "with early-onset Alzheimer's disease",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.27734375,
            "end_logit": 9.671875,
            "text": "onset Alzheimer's disease",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.796875,
            "end_logit": -7.48046875,
            "text": "Alzheimer'",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.796875,
            "end_logit": -7.56640625,
            "text": "Alzheimer's disease.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.49609375,
            "end_logit": 9.671875,
            "text": "(Val717Ile) associated with early shifting abilities and behavioral changes in two Italian families with early-onset Alzheimer's disease",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6171875,
            "end_logit": 9.671875,
            "text": "APP mutation (Val717Ile) associated with early shifting abilities and behavioral changes in two Italian families with early-onset Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -7.765625,
            "end_logit": 9.671875,
            "text": "-onset Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -7.765625,
            "end_logit": 9.671875,
            "text": "early-onset Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -7.796875,
            "end_logit": 9.671875,
            "text": "two Italian families with early-onset Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -7.8046875,
            "end_logit": 9.671875,
            "text": "The London APP mutation (Val717Ile) associated with early shifting abilities and behavioral changes in two Italian families with early-onset Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -7.8515625,
            "end_logit": 9.671875,
            "text": "London APP mutation (Val717Ile) associated with early shifting abilities and behavioral changes in two Italian families with early-onset Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -7.859375,
            "end_logit": 9.671875,
            "text": ") associated with early shifting abilities and behavioral changes in two Italian families with early-onset Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -7.89453125,
            "end_logit": 9.671875,
            "text": "families with early-onset Alzheimer's disease",
            "probability": 0.0
        }
    ],
    "58b6978822d300530900000a_4": [
        {
            "start_logit": 8.65625,
            "end_logit": 7.7265625,
            "text": "AD",
            "probability": 1.0
        },
        {
            "start_logit": 8.65625,
            "end_logit": -7.484375,
            "text": "AD in 3 out of 7 siblings and it is also present in a fourth sibling who has only shown signs of executive dysfunction so far.",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.65625,
            "end_logit": -7.828125,
            "text": "AD in",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.65625,
            "end_logit": -7.8828125,
            "text": "AD in 3 out",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.65625,
            "end_logit": -7.96875,
            "text": "AD in 3 out of 7 siblings and it is also present in a fourth sibling who has only shown signs of executive dysfunction so far. Two subjects of the other family with AD",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.65625,
            "end_logit": -8.0859375,
            "text": "AD in 3 out of 7 siblings and it is also present in a fourth sibling who has only shown signs of executive dysfunction so",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.65625,
            "end_logit": -8.09375,
            "text": "AD in 3 out of 7 siblings and",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.65625,
            "end_logit": -8.109375,
            "text": "AD in 3 out of",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.65625,
            "end_logit": -8.125,
            "text": "AD in 3 out of 7 siblings and it is also",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.66015625,
            "end_logit": 7.7265625,
            "text": ", this mutation was responsible for AD",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.69140625,
            "end_logit": 7.7265625,
            "text": "for AD",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.69921875,
            "end_logit": 7.7265625,
            "text": "this mutation was responsible for AD",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.7109375,
            "end_logit": 7.7265625,
            "text": "mutation was responsible for AD",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.72265625,
            "end_logit": 7.7265625,
            "text": "In 1 family, this mutation was responsible for AD",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.83984375,
            "end_logit": 7.7265625,
            "text": "1 family, this mutation was responsible for AD",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.921875,
            "end_logit": 7.7265625,
            "text": "family, this mutation was responsible for AD",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.96875,
            "end_logit": 7.7265625,
            "text": "responsible for AD",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.671875,
            "end_logit": -7.484375,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -6.671875,
            "end_logit": -7.484375,
            "text": ". Two subjects of the other family with AD diagnosis were carriers of the same mutation.",
            "probability": 0.0
        },
        {
            "start_logit": -6.671875,
            "end_logit": -7.484375,
            "text": ".",
            "probability": 0.0
        }
    ],
    "58b6978822d300530900000a_5": [
        {
            "start_logit": 8.375,
            "end_logit": 8.0234375,
            "text": "AD",
            "probability": 1.0
        },
        {
            "start_logit": 8.375,
            "end_logit": -7.453125,
            "text": "AD patient is extracellular amyloid plaques formed by accumulated beta-amyloid protein (Abeta), a metabolic product of amyloid precursor protein (APP).",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.375,
            "end_logit": -8.1171875,
            "text": "AD patient is extracellular amyloid plaques",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.82421875,
            "end_logit": 8.0234375,
            "text": "of an AD",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.671875,
            "end_logit": -7.26171875,
            "text": ". These mutants facilitate Abeta production. The \"Swedish\" mutations (APP(SW)) and the \"London\" mutation (APP(LON",
            "probability": 0.0
        },
        {
            "start_logit": -6.671875,
            "end_logit": -7.375,
            "text": ". These mutants facilitate Abeta production. The \"Swedish\" mutations (APP(SW)) and the \"London\" mutation (APP",
            "probability": 0.0
        },
        {
            "start_logit": -6.671875,
            "end_logit": -7.44921875,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -6.671875,
            "end_logit": -7.453125,
            "text": ". These mutants facilitate Abeta production. The \"Swedish\" mutations (APP(SW)) and the \"London\" mutation (APP(LON)) are examples of these mutants.",
            "probability": 0.0
        },
        {
            "start_logit": -6.67578125,
            "end_logit": -7.453125,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -6.67578125,
            "end_logit": -7.453125,
            "text": ". Studies have revealed a strong genetic linkage in the early-onset familial form (<60 years old) of AD.",
            "probability": 0.0
        },
        {
            "start_logit": -6.67578125,
            "end_logit": -7.44921875,
            "text": ". For example, some mutant APPs are transmitted dominantly and are segregated with inheritance of early onset AD.",
            "probability": 0.0
        },
        {
            "start_logit": -6.67578125,
            "end_logit": -7.453125,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -6.67578125,
            "end_logit": -7.453125,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.125,
            "end_logit": -7.26171875,
            "text": "APP(LON",
            "probability": 0.0
        },
        {
            "start_logit": -7.125,
            "end_logit": -7.375,
            "text": "APP",
            "probability": 0.0
        },
        {
            "start_logit": -7.2578125,
            "end_logit": -7.26171875,
            "text": "(APP(LON",
            "probability": 0.0
        },
        {
            "start_logit": -6.67578125,
            "end_logit": -7.8984375,
            "text": ". Studies have revealed a strong genetic linkage in the early-onset familial form (<60 years old) of AD",
            "probability": 0.0
        },
        {
            "start_logit": -7.125,
            "end_logit": -7.453125,
            "text": "APP(LON)) are examples of these mutants.",
            "probability": 0.0
        },
        {
            "start_logit": -7.2578125,
            "end_logit": -7.375,
            "text": "(APP",
            "probability": 0.0
        },
        {
            "start_logit": -6.671875,
            "end_logit": -7.96484375,
            "text": ". These mutants facilitate Abeta production. The \"Swedish\" mutations (APP(SW)) and the \"London\" mutation (APP(LON)",
            "probability": 0.0
        }
    ],
    "58b6978822d300530900000a_6": [
        {
            "start_logit": 7.8828125,
            "end_logit": 7.1875,
            "text": "AD",
            "probability": 1.0
        },
        {
            "start_logit": 7.8828125,
            "end_logit": -6.421875,
            "text": "AD development.",
            "probability": 1.2516975402832031e-06
        },
        {
            "start_logit": 7.8828125,
            "end_logit": -7.671875,
            "text": "AD development",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.21875,
            "end_logit": 7.1875,
            "text": "in AD",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.55078125,
            "end_logit": 7.1875,
            "text": "this study may be useful in both in vivo and in vitro studies to investigate the pathophysiological role of APP(SW) and APP(LON) in AD",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.58203125,
            "end_logit": 7.1875,
            "text": "of APP(SW) and APP(LON) in AD",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.7265625,
            "end_logit": 7.1875,
            "text": "APP(SW) and APP(LON) in AD",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.73828125,
            "end_logit": 7.1875,
            "text": "both in vivo and in vitro studies to investigate the pathophysiological role of APP(SW) and APP(LON) in AD",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.74609375,
            "end_logit": 7.1875,
            "text": "study may be useful in both in vivo and in vitro studies to investigate the pathophysiological role of APP(SW) and APP(LON) in AD",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.75,
            "end_logit": 7.1875,
            "text": "studies to investigate the pathophysiological role of APP(SW) and APP(LON) in AD",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.76953125,
            "end_logit": 7.1875,
            "text": "in vitro studies to investigate the pathophysiological role of APP(SW) and APP(LON) in AD",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.78125,
            "end_logit": 7.1875,
            "text": "the pathophysiological role of APP(SW) and APP(LON) in AD",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.80078125,
            "end_logit": 7.1875,
            "text": "in vivo and in vitro studies to investigate the pathophysiological role of APP(SW) and APP(LON) in AD",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.8359375,
            "end_logit": 7.1875,
            "text": "and APP(LON) in AD",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.1953125,
            "end_logit": -6.421875,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -6.421875,
            "end_logit": -6.60546875,
            "text": "APP",
            "probability": 0.0
        },
        {
            "start_logit": -7.21875,
            "end_logit": -6.421875,
            "text": "in AD development.",
            "probability": 0.0
        },
        {
            "start_logit": -7.55078125,
            "end_logit": -6.421875,
            "text": "this study may be useful in both in vivo and in vitro studies to investigate the pathophysiological role of APP(SW) and APP(LON) in AD development.",
            "probability": 0.0
        },
        {
            "start_logit": -6.421875,
            "end_logit": -7.578125,
            "text": "APP(SW) and APP(LON) as identified in this study may",
            "probability": 0.0
        },
        {
            "start_logit": -7.58203125,
            "end_logit": -6.421875,
            "text": "of APP(SW) and APP(LON) in AD development.",
            "probability": 0.0
        }
    ],
    "58b6978822d300530900000a_7": [
        {
            "start_logit": 9.7890625,
            "end_logit": 9.65625,
            "text": "Alzheimer's disease",
            "probability": 1.0
        },
        {
            "start_logit": 9.7890625,
            "end_logit": -1.595703125,
            "text": "Alzheimer",
            "probability": 1.3113021850585938e-05
        },
        {
            "start_logit": -1.5625,
            "end_logit": 9.65625,
            "text": "disease",
            "probability": 1.1861324310302734e-05
        },
        {
            "start_logit": -6.53515625,
            "end_logit": 9.65625,
            "text": "s disease",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.80859375,
            "end_logit": 9.65625,
            "text": "'s disease",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.7890625,
            "end_logit": -7.1015625,
            "text": "Alzheimer'",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.7890625,
            "end_logit": -7.1015625,
            "text": "Alzheimer's",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.2265625,
            "end_logit": 9.65625,
            "text": "familial Alzheimer's disease",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.7890625,
            "end_logit": -7.4140625,
            "text": "Alzheimer's disease using two reporter alleles encoding the Photinus and Renilla luciferase genes and carrying mutant and wild-type allelic sequences in their 3'-untranslated regions.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5625,
            "end_logit": 9.65625,
            "text": "to familial Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": 9.7890625,
            "end_logit": -7.8203125,
            "text": "Alzheimer's disease using",
            "probability": 0.0
        },
        {
            "start_logit": -7.86328125,
            "end_logit": 9.65625,
            "text": "amyloid precursor protein (APP) variants related to familial Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -7.94140625,
            "end_logit": 9.65625,
            "text": "variants related to familial Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": 9.7890625,
            "end_logit": -8.1015625,
            "text": "Alzheimer's disease using two reporter alleles encoding the Photinus and Renilla luciferase genes and",
            "probability": 0.0
        },
        {
            "start_logit": -7.96875,
            "end_logit": 9.65625,
            "text": "type amyloid precursor protein (APP) variants related to familial Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -7.97265625,
            "end_logit": 9.65625,
            "text": "Here, we show ASP-RNAi against the Swedish- and London-type amyloid precursor protein (APP) variants related to familial Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -7.99609375,
            "end_logit": 9.65625,
            "text": "APP) variants related to familial Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -7.99609375,
            "end_logit": 9.65625,
            "text": "we show ASP-RNAi against the Swedish- and London-type amyloid precursor protein (APP) variants related to familial Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": 9.7890625,
            "end_logit": -8.1328125,
            "text": "Alzheimer's disease using two reporter alleles encoding the Photinus and Ren",
            "probability": 0.0
        },
        {
            "start_logit": 9.7890625,
            "end_logit": -8.140625,
            "text": "Alzheimer's disease using two reporter alleles encoding the Photinus and Renilla luciferase",
            "probability": 0.0
        }
    ],
    "58b6978822d300530900000a_8": [
        {
            "start_logit": 9.859375,
            "end_logit": 9.6328125,
            "text": "Alzheimer's disease",
            "probability": 1.0
        },
        {
            "start_logit": 9.859375,
            "end_logit": -1.431640625,
            "text": "Alzheimer",
            "probability": 1.5556812286376953e-05
        },
        {
            "start_logit": -1.603515625,
            "end_logit": 9.6328125,
            "text": "disease",
            "probability": 1.043081283569336e-05
        },
        {
            "start_logit": -6.50390625,
            "end_logit": 9.6328125,
            "text": "'s disease",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.5859375,
            "end_logit": 9.6328125,
            "text": "s disease",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.859375,
            "end_logit": -6.9296875,
            "text": "Alzheimer's disease (V642I",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.82421875,
            "end_logit": 9.6328125,
            "text": "with Alzheimer's disease",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.859375,
            "end_logit": -7.078125,
            "text": "Alzheimer's",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.859375,
            "end_logit": -7.2578125,
            "text": "Alzheimer'",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.859375,
            "end_logit": -7.66796875,
            "text": "Alzheimer's disease (V64",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.44140625,
            "end_logit": 9.6328125,
            "text": "mutation associated with Alzheimer's disease",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6015625,
            "end_logit": 9.6328125,
            "text": "a mutation associated with Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": 9.859375,
            "end_logit": -7.83984375,
            "text": "Alzheimer's disease (V642",
            "probability": 0.0
        },
        {
            "start_logit": -7.640625,
            "end_logit": 9.6328125,
            "text": "associated with Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -7.6796875,
            "end_logit": 9.6328125,
            "text": "bearing a mutation associated with Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": 9.859375,
            "end_logit": -7.91796875,
            "text": "Alzheimer's disease (V",
            "probability": 0.0
        },
        {
            "start_logit": -7.88671875,
            "end_logit": 9.6328125,
            "text": ") bearing a mutation associated with Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": 9.859375,
            "end_logit": -8.1171875,
            "text": "Alzheimer's disease (V642I, so-called London mutation, hereafter APPLd2) and wild-type controls were studied at age periods (3 and 10 months",
            "probability": 0.0
        },
        {
            "start_logit": 9.859375,
            "end_logit": -8.1328125,
            "text": "Alzheimer's disease (V642I, so-called London mutation, hereafter APPLd2) and",
            "probability": 0.0
        },
        {
            "start_logit": 9.859375,
            "end_logit": -8.1328125,
            "text": "Alzheimer's disease (V642I, so-called London mutation, hereafter APPLd2) and wild-type controls were",
            "probability": 0.0
        }
    ],
    "58b6978822d300530900000a_9": [
        {
            "start_logit": 9.734375,
            "end_logit": 9.5859375,
            "text": "Alzheimer's disease",
            "probability": 1.0
        },
        {
            "start_logit": 9.734375,
            "end_logit": -1.7158203125,
            "text": "Alzheimer",
            "probability": 1.239776611328125e-05
        },
        {
            "start_logit": -1.7099609375,
            "end_logit": 9.5859375,
            "text": "disease",
            "probability": 1.0788440704345703e-05
        },
        {
            "start_logit": -6.375,
            "end_logit": 9.5859375,
            "text": "'s disease",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.734375,
            "end_logit": -6.96484375,
            "text": "Alzheimer's",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.734375,
            "end_logit": -7.22265625,
            "text": "Alzheimer's disease genes: the amyloid precursor protein genes with Swedish or London mutations.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.1015625,
            "end_logit": 9.5859375,
            "text": "s disease",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.734375,
            "end_logit": -7.58203125,
            "text": "Alzheimer'",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.734375,
            "end_logit": -7.96875,
            "text": "Alzheimer's disease genes: the amyloid precursor protein genes with Swedish",
            "probability": 0.0
        },
        {
            "start_logit": 9.734375,
            "end_logit": -7.9921875,
            "text": "Alzheimer's disease genes: the amyloid precursor protein genes with Swedish or London mutations",
            "probability": 0.0
        },
        {
            "start_logit": 9.734375,
            "end_logit": -7.99609375,
            "text": "Alzheimer's disease genes: the amyloid precursor protein genes with Swedish or",
            "probability": 0.0
        },
        {
            "start_logit": 9.734375,
            "end_logit": -8.0390625,
            "text": "Alzheimer's disease genes: the amyloid precursor protein",
            "probability": 0.0
        },
        {
            "start_logit": -7.890625,
            "end_logit": 9.5859375,
            "text": "Allele-specific silencing of Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": 9.734375,
            "end_logit": -8.09375,
            "text": "Alzheimer's disease genes: the amyloid precursor",
            "probability": 0.0
        },
        {
            "start_logit": -7.95703125,
            "end_logit": 9.5859375,
            "text": "of Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": 9.734375,
            "end_logit": -8.109375,
            "text": "Alzheimer's disease genes:",
            "probability": 0.0
        },
        {
            "start_logit": -8.09375,
            "end_logit": 9.5859375,
            "text": "specific silencing of Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -1.7099609375,
            "end_logit": -7.22265625,
            "text": "disease genes: the amyloid precursor protein genes with Swedish or London mutations.",
            "probability": 0.0
        },
        {
            "start_logit": -7.890625,
            "end_logit": -1.7158203125,
            "text": "Allele-specific silencing of Alzheimer",
            "probability": 0.0
        },
        {
            "start_logit": -7.95703125,
            "end_logit": -1.7158203125,
            "text": "of Alzheimer",
            "probability": 0.0
        }
    ],
    "58b6978822d300530900000a_10": [
        {
            "start_logit": 8.578125,
            "end_logit": 4.90234375,
            "text": "Alzheimers disease",
            "probability": 1.0
        },
        {
            "start_logit": 8.578125,
            "end_logit": -3.505859375,
            "text": "Alzheimer",
            "probability": 0.00022172927856445312
        },
        {
            "start_logit": 8.578125,
            "end_logit": -4.14453125,
            "text": "Alzheimers disease (AD",
            "probability": 0.00011777877807617188
        },
        {
            "start_logit": 8.578125,
            "end_logit": -5.20703125,
            "text": "Alzheimers disease (AD)",
            "probability": 4.07099723815918e-05
        },
        {
            "start_logit": 8.578125,
            "end_logit": -6.8671875,
            "text": "Alzheimers disease (AD).",
            "probability": 7.68899917602539e-06
        },
        {
            "start_logit": 8.578125,
            "end_logit": -6.8671875,
            "text": "Alzheimers disease (AD).We describe 2 Italian families showing the missense mutation in exon 17 of the amyloid precursor protein gene on chromosome 21 (Val717Ile), known as London mutation.",
            "probability": 7.68899917602539e-06
        },
        {
            "start_logit": 8.578125,
            "end_logit": -7.0,
            "text": "Alzheimers",
            "probability": 6.735324859619141e-06
        },
        {
            "start_logit": 8.578125,
            "end_logit": -7.24609375,
            "text": "Alzheimers disease (AD).We describe 2 Italian families showing the missense mutation in exon 17 of the amyloid precursor protein gene on chromosome 21 (Val717",
            "probability": 5.245208740234375e-06
        },
        {
            "start_logit": 8.578125,
            "end_logit": -7.54296875,
            "text": "Alzheimers disease (AD).We describe 2 Italian families showing the missense mutation in exon 17 of the amyloid precursor protein gene on chromosome 21 (Val717Ile",
            "probability": 3.933906555175781e-06
        },
        {
            "start_logit": 8.578125,
            "end_logit": -7.640625,
            "text": "Alzheimers disease (AD).We describe 2 Italian families showing the missense mutation in exon 17 of the amyloid precursor protein gene on chromosome 21 (Val71",
            "probability": 3.5762786865234375e-06
        },
        {
            "start_logit": 8.578125,
            "end_logit": -7.65625,
            "text": "Alzheimers disease (AD).We describe 2 Italian families showing the missense mutation in exon 17",
            "probability": 3.516674041748047e-06
        },
        {
            "start_logit": 8.578125,
            "end_logit": -7.890625,
            "text": "Alzheimers disease (AD).We describe 2 Italian families showing the missense mutation in exon 17 of the amyloid precursor protein gene",
            "probability": 2.7418136596679688e-06
        },
        {
            "start_logit": -6.88671875,
            "end_logit": 4.90234375,
            "text": "disease",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.5390625,
            "end_logit": 4.90234375,
            "text": "of Alzheimers disease",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.66015625,
            "end_logit": 4.90234375,
            "text": "Mutations in the amyloid precursor protein gene were the first to be recognized as a cause of Alzheimers disease",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.76953125,
            "end_logit": 4.90234375,
            "text": "s disease",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -4.7734375,
            "end_logit": -4.14453125,
            "text": "AD",
            "probability": 0.0
        },
        {
            "start_logit": -4.7734375,
            "end_logit": -5.20703125,
            "text": "AD)",
            "probability": 0.0
        },
        {
            "start_logit": -6.88671875,
            "end_logit": -4.14453125,
            "text": "disease (AD",
            "probability": 0.0
        },
        {
            "start_logit": -7.5390625,
            "end_logit": -3.505859375,
            "text": "of Alzheimer",
            "probability": 0.0
        }
    ],
    "58b6978822d300530900000a_11": [
        {
            "start_logit": 9.03125,
            "end_logit": 9.265625,
            "text": "Alzheimers disease",
            "probability": 1.0
        },
        {
            "start_logit": -2.2265625,
            "end_logit": 9.265625,
            "text": "disease",
            "probability": 1.2934207916259766e-05
        },
        {
            "start_logit": 9.03125,
            "end_logit": -2.984375,
            "text": "Alzheimer",
            "probability": 4.76837158203125e-06
        },
        {
            "start_logit": -4.8828125,
            "end_logit": 9.265625,
            "text": "Val717Ile) associated with early shifting abilities and behavioral changes in two Italian families with early-onset Alzheimers disease",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": 9.03125,
            "end_logit": -6.53515625,
            "text": "Alzheimers",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.4921875,
            "end_logit": 9.265625,
            "text": "(Val717Ile) associated with early shifting abilities and behavioral changes in two Italian families with early-onset Alzheimers disease",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.55078125,
            "end_logit": 9.265625,
            "text": "s disease",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5546875,
            "end_logit": 9.265625,
            "text": "with early-onset Alzheimers disease",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.609375,
            "end_logit": 9.265625,
            "text": "onset Alzheimers disease",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.828125,
            "end_logit": 9.265625,
            "text": "APP mutation (Val717Ile) associated with early shifting abilities and behavioral changes in two Italian families with early-onset Alzheimers disease",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.8828125,
            "end_logit": 9.265625,
            "text": "London APP mutation (Val717Ile) associated with early shifting abilities and behavioral changes in two Italian families with early-onset Alzheimers disease",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.8984375,
            "end_logit": 9.265625,
            "text": "-onset Alzheimers disease",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.91015625,
            "end_logit": 9.265625,
            "text": "The London APP mutation (Val717Ile) associated with early shifting abilities and behavioral changes in two Italian families with early-onset Alzheimers disease",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.92578125,
            "end_logit": 9.265625,
            "text": "early-onset Alzheimers disease",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.96875,
            "end_logit": 9.265625,
            "text": "two Italian families with early-onset Alzheimers disease",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.015625,
            "end_logit": 9.265625,
            "text": "mutation (Val717Ile) associated with early shifting abilities and behavioral changes in two Italian families with early-onset Alzheimers disease",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.03125,
            "end_logit": 9.265625,
            "text": "families with early-onset Alzheimers disease",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0625,
            "end_logit": 9.265625,
            "text": ") associated with early shifting abilities and behavioral changes in two Italian families with early-onset Alzheimers disease",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.078125,
            "end_logit": 9.265625,
            "text": "behavioral changes in two Italian families with early-onset Alzheimers disease",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -4.8828125,
            "end_logit": -2.984375,
            "text": "Val717Ile) associated with early shifting abilities and behavioral changes in two Italian families with early-onset Alzheimer",
            "probability": 0.0
        }
    ],
    "58b6978822d300530900000a_12": [
        {
            "start_logit": 9.734375,
            "end_logit": 9.5859375,
            "text": "Alzheimer's disease",
            "probability": 1.0
        },
        {
            "start_logit": 9.734375,
            "end_logit": -1.7158203125,
            "text": "Alzheimer",
            "probability": 1.239776611328125e-05
        },
        {
            "start_logit": -1.7099609375,
            "end_logit": 9.5859375,
            "text": "disease",
            "probability": 1.0788440704345703e-05
        },
        {
            "start_logit": -6.375,
            "end_logit": 9.5859375,
            "text": "'s disease",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.734375,
            "end_logit": -6.96484375,
            "text": "Alzheimer's",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.734375,
            "end_logit": -7.22265625,
            "text": "Alzheimer's disease genes: the amyloid precursor protein genes with Swedish or London mutations.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.1015625,
            "end_logit": 9.5859375,
            "text": "s disease",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.734375,
            "end_logit": -7.58203125,
            "text": "Alzheimer'",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.734375,
            "end_logit": -7.96875,
            "text": "Alzheimer's disease genes: the amyloid precursor protein genes with Swedish",
            "probability": 0.0
        },
        {
            "start_logit": 9.734375,
            "end_logit": -7.9921875,
            "text": "Alzheimer's disease genes: the amyloid precursor protein genes with Swedish or London mutations",
            "probability": 0.0
        },
        {
            "start_logit": 9.734375,
            "end_logit": -7.99609375,
            "text": "Alzheimer's disease genes: the amyloid precursor protein genes with Swedish or",
            "probability": 0.0
        },
        {
            "start_logit": 9.734375,
            "end_logit": -8.0390625,
            "text": "Alzheimer's disease genes: the amyloid precursor protein",
            "probability": 0.0
        },
        {
            "start_logit": -7.890625,
            "end_logit": 9.5859375,
            "text": "Allele-specific silencing of Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": 9.734375,
            "end_logit": -8.09375,
            "text": "Alzheimer's disease genes: the amyloid precursor",
            "probability": 0.0
        },
        {
            "start_logit": -7.95703125,
            "end_logit": 9.5859375,
            "text": "of Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": 9.734375,
            "end_logit": -8.109375,
            "text": "Alzheimer's disease genes:",
            "probability": 0.0
        },
        {
            "start_logit": -8.09375,
            "end_logit": 9.5859375,
            "text": "specific silencing of Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -1.7099609375,
            "end_logit": -7.22265625,
            "text": "disease genes: the amyloid precursor protein genes with Swedish or London mutations.",
            "probability": 0.0
        },
        {
            "start_logit": -7.890625,
            "end_logit": -1.7158203125,
            "text": "Allele-specific silencing of Alzheimer",
            "probability": 0.0
        },
        {
            "start_logit": -7.95703125,
            "end_logit": -1.7158203125,
            "text": "of Alzheimer",
            "probability": 0.0
        }
    ],
    "58b6978822d300530900000a_13": [
        {
            "start_logit": 9.796875,
            "end_logit": 9.671875,
            "text": "Alzheimer's disease",
            "probability": 1.0
        },
        {
            "start_logit": 9.796875,
            "end_logit": -1.5693359375,
            "text": "Alzheimer",
            "probability": 1.3113021850585938e-05
        },
        {
            "start_logit": -1.541015625,
            "end_logit": 9.671875,
            "text": "disease",
            "probability": 1.1920928955078125e-05
        },
        {
            "start_logit": -5.74609375,
            "end_logit": 9.671875,
            "text": "Val717Ile) associated with early shifting abilities and behavioral changes in two Italian families with early-onset Alzheimer's disease",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.3203125,
            "end_logit": 9.671875,
            "text": "'s disease",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.578125,
            "end_logit": 9.671875,
            "text": "s disease",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.796875,
            "end_logit": -7.26953125,
            "text": "Alzheimer's",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.1640625,
            "end_logit": 9.671875,
            "text": "with early-onset Alzheimer's disease",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.27734375,
            "end_logit": 9.671875,
            "text": "onset Alzheimer's disease",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.796875,
            "end_logit": -7.48046875,
            "text": "Alzheimer'",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.796875,
            "end_logit": -7.56640625,
            "text": "Alzheimer's disease.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.49609375,
            "end_logit": 9.671875,
            "text": "(Val717Ile) associated with early shifting abilities and behavioral changes in two Italian families with early-onset Alzheimer's disease",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6171875,
            "end_logit": 9.671875,
            "text": "APP mutation (Val717Ile) associated with early shifting abilities and behavioral changes in two Italian families with early-onset Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -7.765625,
            "end_logit": 9.671875,
            "text": "-onset Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -7.765625,
            "end_logit": 9.671875,
            "text": "early-onset Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -7.796875,
            "end_logit": 9.671875,
            "text": "two Italian families with early-onset Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -7.8046875,
            "end_logit": 9.671875,
            "text": "The London APP mutation (Val717Ile) associated with early shifting abilities and behavioral changes in two Italian families with early-onset Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -7.8515625,
            "end_logit": 9.671875,
            "text": "London APP mutation (Val717Ile) associated with early shifting abilities and behavioral changes in two Italian families with early-onset Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -7.859375,
            "end_logit": 9.671875,
            "text": ") associated with early shifting abilities and behavioral changes in two Italian families with early-onset Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -7.89453125,
            "end_logit": 9.671875,
            "text": "families with early-onset Alzheimer's disease",
            "probability": 0.0
        }
    ],
    "52fe58f82059c6d71c00007a_1": [
        {
            "start_logit": 3.42578125,
            "end_logit": 2.689453125,
            "text": "multiple origins.",
            "probability": 0.986328125
        },
        {
            "start_logit": -1.1044921875,
            "end_logit": 2.689453125,
            "text": ".",
            "probability": 0.0106201171875
        },
        {
            "start_logit": -3.453125,
            "end_logit": 2.689453125,
            "text": "Bacteria and some archaea replicate from single origins, whereas most archaea and all eukaryotes replicate using multiple origins.",
            "probability": 0.0010118484497070312
        },
        {
            "start_logit": -4.2890625,
            "end_logit": 2.689453125,
            "text": "single origins, whereas most archaea and all eukaryotes replicate using multiple origins.",
            "probability": 0.00043845176696777344
        },
        {
            "start_logit": 3.42578125,
            "end_logit": -5.13671875,
            "text": "multiple",
            "probability": 0.000392913818359375
        },
        {
            "start_logit": 3.42578125,
            "end_logit": -5.91015625,
            "text": "multiple origins",
            "probability": 0.00018131732940673828
        },
        {
            "start_logit": -5.31640625,
            "end_logit": 2.689453125,
            "text": "from single origins, whereas most archaea and all eukaryotes replicate using multiple origins.",
            "probability": 0.0001575946807861328
        },
        {
            "start_logit": -5.63671875,
            "end_logit": 2.689453125,
            "text": "using multiple origins.",
            "probability": 0.00011438131332397461
        },
        {
            "start_logit": -6.5703125,
            "end_logit": 2.689453125,
            "text": "replicate from single origins, whereas most archaea and all eukaryotes replicate using multiple origins.",
            "probability": 4.482269287109375e-05
        },
        {
            "start_logit": -7.0234375,
            "end_logit": 2.689453125,
            "text": "replicate using multiple origins.",
            "probability": 2.8431415557861328e-05
        },
        {
            "start_logit": -7.06640625,
            "end_logit": 2.689453125,
            "text": ", whereas most archaea and all eukaryotes replicate using multiple origins.",
            "probability": 2.7418136596679688e-05
        },
        {
            "start_logit": -7.1015625,
            "end_logit": 2.689453125,
            "text": "origins, whereas most archaea and all eukaryotes replicate using multiple origins.",
            "probability": 2.6345252990722656e-05
        },
        {
            "start_logit": -7.26953125,
            "end_logit": 2.689453125,
            "text": "whereas most archaea and all eukaryotes replicate using multiple origins.",
            "probability": 2.2351741790771484e-05
        },
        {
            "start_logit": -7.3203125,
            "end_logit": 2.689453125,
            "text": "archaea replicate from single origins, whereas most archaea and all eukaryotes replicate using multiple origins.",
            "probability": 2.1159648895263672e-05
        },
        {
            "start_logit": -7.609375,
            "end_logit": 2.689453125,
            "text": "most archaea and all eukaryotes replicate using multiple origins.",
            "probability": 1.5795230865478516e-05
        },
        {
            "start_logit": -7.61328125,
            "end_logit": 2.689453125,
            "text": "origins.",
            "probability": 1.5795230865478516e-05
        },
        {
            "start_logit": -3.453125,
            "end_logit": -1.5078125,
            "text": "Bacteria",
            "probability": 1.52587890625e-05
        },
        {
            "start_logit": -7.828125,
            "end_logit": 2.689453125,
            "text": "some archaea replicate from single origins, whereas most archaea and all eukaryotes replicate using multiple origins.",
            "probability": 1.2755393981933594e-05
        },
        {
            "start_logit": -7.8828125,
            "end_logit": 2.689453125,
            "text": "eukaryotes replicate using multiple origins.",
            "probability": 1.2040138244628906e-05
        },
        {
            "start_logit": -3.453125,
            "end_logit": -5.13671875,
            "text": "Bacteria and some archaea replicate from single origins, whereas most archaea and all eukaryotes replicate using multiple",
            "probability": 4.172325134277344e-07
        }
    ],
    "52fe58f82059c6d71c00007a_2": [
        {
            "start_logit": 6.60546875,
            "end_logit": -0.03753662109375,
            "text": "multiple",
            "probability": 0.98095703125
        },
        {
            "start_logit": 6.60546875,
            "end_logit": -4.7265625,
            "text": "multiple DNA replication",
            "probability": 0.009033203125
        },
        {
            "start_logit": 6.60546875,
            "end_logit": -5.76953125,
            "text": "multiple DNA replication origins are",
            "probability": 0.0031833648681640625
        },
        {
            "start_logit": 6.60546875,
            "end_logit": -6.51171875,
            "text": "multiple DNA replication origins",
            "probability": 0.0015153884887695312
        },
        {
            "start_logit": 6.60546875,
            "end_logit": -6.859375,
            "text": "multiple DNA replication origins are a hallmark of Eukaryotes and some Archaea",
            "probability": 0.0010700225830078125
        },
        {
            "start_logit": 6.60546875,
            "end_logit": -6.88671875,
            "text": "multiple DNA replication origins are a",
            "probability": 0.0010423660278320312
        },
        {
            "start_logit": 6.60546875,
            "end_logit": -7.0625,
            "text": "multiple DNA replication origins are a hallmark of Eukaryotes and",
            "probability": 0.000873565673828125
        },
        {
            "start_logit": 6.60546875,
            "end_logit": -7.49609375,
            "text": "multiple DNA replication origins are a hallmark of Eukaryotes",
            "probability": 0.0005664825439453125
        },
        {
            "start_logit": 6.60546875,
            "end_logit": -7.5,
            "text": "multiple DNA replication origins are a hallmark of Eukaryotes and some",
            "probability": 0.0005640983581542969
        },
        {
            "start_logit": 6.60546875,
            "end_logit": -7.640625,
            "text": "multiple DNA replication origins are a hallmark",
            "probability": 0.0004901885986328125
        },
        {
            "start_logit": 6.60546875,
            "end_logit": -7.6484375,
            "text": "multiple DNA replication origins are a hallmark of",
            "probability": 0.0004863739013671875
        },
        {
            "start_logit": -6.7109375,
            "end_logit": -4.7265625,
            "text": "DNA replication",
            "probability": 0.0
        },
        {
            "start_logit": -6.7109375,
            "end_logit": -5.76953125,
            "text": "DNA replication origins are",
            "probability": 0.0
        },
        {
            "start_logit": -6.7109375,
            "end_logit": -6.51171875,
            "text": "DNA replication origins",
            "probability": 0.0
        },
        {
            "start_logit": -6.7109375,
            "end_logit": -6.859375,
            "text": "DNA replication origins are a hallmark of Eukaryotes and some Archaea",
            "probability": 0.0
        },
        {
            "start_logit": -6.7109375,
            "end_logit": -6.88671875,
            "text": "DNA replication origins are a",
            "probability": 0.0
        },
        {
            "start_logit": -6.7109375,
            "end_logit": -7.0625,
            "text": "DNA replication origins are a hallmark of Eukaryotes and",
            "probability": 0.0
        },
        {
            "start_logit": -6.7109375,
            "end_logit": -7.49609375,
            "text": "DNA replication origins are a hallmark of Eukaryotes",
            "probability": 0.0
        },
        {
            "start_logit": -6.7109375,
            "end_logit": -7.5,
            "text": "DNA replication origins are a hallmark of Eukaryotes and some",
            "probability": 0.0
        },
        {
            "start_logit": -6.7109375,
            "end_logit": -7.640625,
            "text": "DNA replication origins are a hallmark",
            "probability": 0.0
        }
    ],
    "52fe58f82059c6d71c00007a_3": [
        {
            "start_logit": -3.986328125,
            "end_logit": -4.2265625,
            "text": "Multiple orc/cdc6-associated replication origins were",
            "probability": 0.323486328125
        },
        {
            "start_logit": -3.986328125,
            "end_logit": -5.2265625,
            "text": "Multiple orc/cdc6-associated replication origins were predicted in all",
            "probability": 0.1190185546875
        },
        {
            "start_logit": -3.986328125,
            "end_logit": -5.46484375,
            "text": "Multiple orc/cdc6-associated replication origins were predicted in all of the analyzed haloarchaeal genome",
            "probability": 0.09344482421875
        },
        {
            "start_logit": -3.986328125,
            "end_logit": -5.50390625,
            "text": "Multiple orc/cdc6-associated replication origins were predicted in",
            "probability": 0.08978271484375
        },
        {
            "start_logit": -5.44140625,
            "end_logit": -4.2265625,
            "text": "orc/cdc6-associated replication origins were",
            "probability": 0.0750732421875
        },
        {
            "start_logit": -3.986328125,
            "end_logit": -6.38671875,
            "text": "Multiple orc/cdc6-associated replication origins were predicted",
            "probability": 0.037139892578125
        },
        {
            "start_logit": -6.14453125,
            "end_logit": -4.2265625,
            "text": "associated replication origins were",
            "probability": 0.037139892578125
        },
        {
            "start_logit": -5.44140625,
            "end_logit": -5.2265625,
            "text": "orc/cdc6-associated replication origins were predicted in all",
            "probability": 0.0276031494140625
        },
        {
            "start_logit": -5.44140625,
            "end_logit": -5.46484375,
            "text": "orc/cdc6-associated replication origins were predicted in all of the analyzed haloarchaeal genome",
            "probability": 0.0218353271484375
        },
        {
            "start_logit": -5.44140625,
            "end_logit": -5.50390625,
            "text": "orc/cdc6-associated replication origins were predicted in",
            "probability": 0.0210113525390625
        },
        {
            "start_logit": -3.986328125,
            "end_logit": -7.03125,
            "text": "Multiple orc/cdc6",
            "probability": 0.0195770263671875
        },
        {
            "start_logit": -3.986328125,
            "end_logit": -7.0390625,
            "text": "Multiple orc/cdc6-associated replication origins",
            "probability": 0.0194244384765625
        },
        {
            "start_logit": -3.986328125,
            "end_logit": -7.14453125,
            "text": "Multiple orc/cdc6-associated replication origins were predicted in all of the",
            "probability": 0.0174102783203125
        },
        {
            "start_logit": -3.986328125,
            "end_logit": -7.28125,
            "text": "Multiple orc/cdc6-associated replication origins were predicted in all of the analyzed haloarch",
            "probability": 0.01525115966796875
        },
        {
            "start_logit": -3.986328125,
            "end_logit": -7.3046875,
            "text": "Multiple orc/cdc6-associated replication origins were predicted in all of the analyzed haloarchaea",
            "probability": 0.014892578125
        },
        {
            "start_logit": -3.986328125,
            "end_logit": -7.34765625,
            "text": "Multiple",
            "probability": 0.01421356201171875
        },
        {
            "start_logit": -6.14453125,
            "end_logit": -5.2265625,
            "text": "associated replication origins were predicted in all",
            "probability": 0.013671875
        },
        {
            "start_logit": -3.986328125,
            "end_logit": -7.40234375,
            "text": "Multiple orc/cdc6-associated replication origins were predicted in all of the analyzed haloarchaeal",
            "probability": 0.01345062255859375
        },
        {
            "start_logit": -3.986328125,
            "end_logit": -7.40625,
            "text": "Multiple orc/cdc6-associated replication origins were predicted in all of",
            "probability": 0.01345062255859375
        },
        {
            "start_logit": -3.986328125,
            "end_logit": -7.4296875,
            "text": "Multiple orc/cdc6-associated replication origins were predicted in all of the analyzed halo",
            "probability": 0.01314544677734375
        }
    ],
    "52fe58f82059c6d71c00007a_4": [
        {
            "start_logit": 2.7421875,
            "end_logit": -4.13671875,
            "text": "multiple",
            "probability": 0.5283203125
        },
        {
            "start_logit": 2.7421875,
            "end_logit": -5.09765625,
            "text": "multiple replication origins serve purposes other than simply shortening the time required for replication",
            "probability": 0.2021484375
        },
        {
            "start_logit": 2.7421875,
            "end_logit": -6.3515625,
            "text": "multiple replication",
            "probability": 0.057708740234375
        },
        {
            "start_logit": 2.7421875,
            "end_logit": -6.5,
            "text": "multiple replication origins serve",
            "probability": 0.04974365234375
        },
        {
            "start_logit": -2.0703125,
            "end_logit": -1.83984375,
            "text": "Sulfolobus chromosome implies",
            "probability": 0.042694091796875
        },
        {
            "start_logit": 2.7421875,
            "end_logit": -6.98046875,
            "text": "multiple replication origins",
            "probability": 0.0307464599609375
        },
        {
            "start_logit": 2.7421875,
            "end_logit": -7.328125,
            "text": "multiple replication origins serve purposes other",
            "probability": 0.0217132568359375
        },
        {
            "start_logit": 2.7421875,
            "end_logit": -7.44921875,
            "text": "multiple replication origins serve purposes other than",
            "probability": 0.019256591796875
        },
        {
            "start_logit": 2.7421875,
            "end_logit": -7.65234375,
            "text": "multiple replication origins serve purposes other than simply shortening the time required for",
            "probability": 0.0157012939453125
        },
        {
            "start_logit": 2.7421875,
            "end_logit": -7.80078125,
            "text": "multiple replication origins serve purposes other than simply shortening the time required",
            "probability": 0.01354217529296875
        },
        {
            "start_logit": -2.0703125,
            "end_logit": -3.517578125,
            "text": "Sulfolobus chromosome",
            "probability": 0.00798797607421875
        },
        {
            "start_logit": -2.0703125,
            "end_logit": -4.13671875,
            "text": "Sulfolobus chromosome implies that the multiple",
            "probability": 0.004291534423828125
        },
        {
            "start_logit": -5.0859375,
            "end_logit": -1.83984375,
            "text": "the Sulfolobus chromosome implies",
            "probability": 0.0020923614501953125
        },
        {
            "start_logit": -2.0703125,
            "end_logit": -5.09765625,
            "text": "Sulfolobus chromosome implies that the multiple replication origins serve purposes other than simply shortening the time required for replication",
            "probability": 0.0016431808471679688
        },
        {
            "start_logit": -2.0703125,
            "end_logit": -6.27734375,
            "text": "Sulfolobus",
            "probability": 0.0005068778991699219
        },
        {
            "start_logit": -2.0703125,
            "end_logit": -6.3515625,
            "text": "Sulfolobus chromosome implies that the multiple replication",
            "probability": 0.00046896934509277344
        },
        {
            "start_logit": -6.64453125,
            "end_logit": -1.83984375,
            "text": "bus chromosome implies",
            "probability": 0.00044035911560058594
        },
        {
            "start_logit": -2.0703125,
            "end_logit": -6.5,
            "text": "Sulfolobus chromosome implies that the multiple replication origins serve",
            "probability": 0.00040411949157714844
        },
        {
            "start_logit": -5.0859375,
            "end_logit": -3.517578125,
            "text": "the Sulfolobus chromosome",
            "probability": 0.0003917217254638672
        },
        {
            "start_logit": -7.09765625,
            "end_logit": -1.83984375,
            "text": "lobus chromosome implies",
            "probability": 0.0002799034118652344
        }
    ],
    "52fe58f82059c6d71c00007a_5": [
        {
            "start_logit": 7.28125,
            "end_logit": 0.54052734375,
            "text": "multiple replication origin paradigm has also been demonstrated within the archaeal domain of life",
            "probability": 0.94970703125
        },
        {
            "start_logit": 7.28125,
            "end_logit": -2.8828125,
            "text": "multiple",
            "probability": 0.0310211181640625
        },
        {
            "start_logit": 7.28125,
            "end_logit": -4.37109375,
            "text": "multiple replication origin",
            "probability": 0.006999969482421875
        },
        {
            "start_logit": 7.28125,
            "end_logit": -5.0,
            "text": "multiple replication origin paradigm",
            "probability": 0.0037326812744140625
        },
        {
            "start_logit": 7.28125,
            "end_logit": -5.89453125,
            "text": "multiple replication origin paradigm has",
            "probability": 0.0015268325805664062
        },
        {
            "start_logit": 7.28125,
            "end_logit": -5.9375,
            "text": "multiple replication",
            "probability": 0.0014619827270507812
        },
        {
            "start_logit": 7.28125,
            "end_logit": -5.94921875,
            "text": "multiple replication origin paradigm has also been demonstrated within",
            "probability": 0.0014448165893554688
        },
        {
            "start_logit": 7.28125,
            "end_logit": -6.0078125,
            "text": "multiple replication origin paradigm has also been demonstrated",
            "probability": 0.0013628005981445312
        },
        {
            "start_logit": 7.28125,
            "end_logit": -6.01953125,
            "text": "multiple replication origin paradigm has also been",
            "probability": 0.0013475418090820312
        },
        {
            "start_logit": 7.28125,
            "end_logit": -6.8828125,
            "text": "multiple replication origin paradigm has also been demonstrated within the",
            "probability": 0.0005679130554199219
        },
        {
            "start_logit": 7.28125,
            "end_logit": -7.296875,
            "text": "multiple replication origin paradigm has also been demonstrated within the archaeal domain",
            "probability": 0.00037550926208496094
        },
        {
            "start_logit": 7.28125,
            "end_logit": -7.41796875,
            "text": "multiple replication origin paradigm has also",
            "probability": 0.0003325939178466797
        },
        {
            "start_logit": 7.28125,
            "end_logit": -7.609375,
            "text": "multiple replication origin paradigm has also been demonstrated within the archaeal domain of",
            "probability": 0.000274658203125
        },
        {
            "start_logit": -4.0546875,
            "end_logit": 0.54052734375,
            "text": "the multiple replication origin paradigm has also been demonstrated within the archaeal domain of life",
            "probability": 1.1324882507324219e-05
        },
        {
            "start_logit": -6.3046875,
            "end_logit": 0.54052734375,
            "text": "life",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": -7.39453125,
            "end_logit": 0.54052734375,
            "text": "paradigm has also been demonstrated within the archaeal domain of life",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -4.0546875,
            "end_logit": -2.8828125,
            "text": "the multiple",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -7.5390625,
            "end_logit": 0.54052734375,
            "text": "demonstrated within the archaeal domain of life",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.859375,
            "end_logit": 0.54052734375,
            "text": "archaeal domain of life",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.97265625,
            "end_logit": 0.54052734375,
            "text": "domain of life",
            "probability": 2.384185791015625e-07
        }
    ],
    "52fe58f82059c6d71c00007a_6": [
        {
            "start_logit": 2.78515625,
            "end_logit": -3.36328125,
            "text": "multiple",
            "probability": 0.66552734375
        },
        {
            "start_logit": 2.78515625,
            "end_logit": -5.703125,
            "text": "multiple chromosome replication",
            "probability": 0.0640869140625
        },
        {
            "start_logit": 2.78515625,
            "end_logit": -5.90234375,
            "text": "multiple chromosome replication origins in",
            "probability": 0.052520751953125
        },
        {
            "start_logit": 2.78515625,
            "end_logit": -6.21875,
            "text": "multiple chromosome",
            "probability": 0.03826904296875
        },
        {
            "start_logit": 2.78515625,
            "end_logit": -6.39453125,
            "text": "multiple chromosome replication origins in Sulfolobus species has added yet another eukaryotic trait to the archaea",
            "probability": 0.0321044921875
        },
        {
            "start_logit": 2.78515625,
            "end_logit": -6.6015625,
            "text": "multiple chromosome replication origins in Sulfolobus species has",
            "probability": 0.0261077880859375
        },
        {
            "start_logit": 2.78515625,
            "end_logit": -6.97265625,
            "text": "multiple chromosome replication origins in Sulfolobus",
            "probability": 0.01800537109375
        },
        {
            "start_logit": 2.78515625,
            "end_logit": -7.0234375,
            "text": "multiple chromosome replication origins in Sulfolobus species",
            "probability": 0.017120361328125
        },
        {
            "start_logit": 2.78515625,
            "end_logit": -7.16796875,
            "text": "multiple chromosome replication origins",
            "probability": 0.0148162841796875
        },
        {
            "start_logit": 2.78515625,
            "end_logit": -7.41015625,
            "text": "multiple chromosome replication origins in Sulfolobus species has added yet",
            "probability": 0.011627197265625
        },
        {
            "start_logit": 2.78515625,
            "end_logit": -7.44140625,
            "text": "multiple chromosome replication origins in Sulfolobus species has added",
            "probability": 0.01126861572265625
        },
        {
            "start_logit": 2.78515625,
            "end_logit": -7.48046875,
            "text": "multiple chromosome replication origins in Sulfolobus species has added yet another",
            "probability": 0.01084136962890625
        },
        {
            "start_logit": 2.78515625,
            "end_logit": -7.49609375,
            "text": "multiple chromosome replication origins in Sulfolobus species has added yet another eukaryotic",
            "probability": 0.01067352294921875
        },
        {
            "start_logit": 2.78515625,
            "end_logit": -7.62109375,
            "text": "multiple chromosome replication origins in Sulfolobus species has added yet another eukaryotic trait to",
            "probability": 0.0094146728515625
        },
        {
            "start_logit": 2.78515625,
            "end_logit": -7.671875,
            "text": "multiple chromosome replication origins in Sulfolobu",
            "probability": 0.00894927978515625
        },
        {
            "start_logit": 2.78515625,
            "end_logit": -7.67578125,
            "text": "multiple chromosome replication origins in Sulfolobus species has added yet another eukaryotic trait",
            "probability": 0.0089111328125
        },
        {
            "start_logit": -6.40625,
            "end_logit": -5.703125,
            "text": "chromosome replication",
            "probability": 6.556510925292969e-06
        },
        {
            "start_logit": -6.40625,
            "end_logit": -5.90234375,
            "text": "chromosome replication origins in",
            "probability": 5.304813385009766e-06
        },
        {
            "start_logit": -6.40625,
            "end_logit": -6.21875,
            "text": "chromosome",
            "probability": 3.874301910400391e-06
        },
        {
            "start_logit": -6.40625,
            "end_logit": -6.39453125,
            "text": "chromosome replication origins in Sulfolobus species has added yet another eukaryotic trait to the archaea",
            "probability": 3.2782554626464844e-06
        }
    ],
    "52fe58f82059c6d71c00007a_7": [
        {
            "start_logit": 3.51953125,
            "end_logit": -0.74609375,
            "text": "multiple replication origins of the archaeon Sulfolobus solfataricus",
            "probability": 0.90478515625
        },
        {
            "start_logit": 3.51953125,
            "end_logit": -3.384765625,
            "text": "multiple replication origins",
            "probability": 0.06463623046875
        },
        {
            "start_logit": 3.51953125,
            "end_logit": -5.58203125,
            "text": "multiple",
            "probability": 0.007183074951171875
        },
        {
            "start_logit": 3.51953125,
            "end_logit": -6.12109375,
            "text": "multiple replication origins of",
            "probability": 0.00418853759765625
        },
        {
            "start_logit": 3.51953125,
            "end_logit": -6.1640625,
            "text": "multiple replication origins of the archaeon Sulfolobus solfataricus are suggested by the analysis based on the Z curve method",
            "probability": 0.0040130615234375
        },
        {
            "start_logit": 3.51953125,
            "end_logit": -6.66015625,
            "text": "multiple replication origins of the archaeon Sulfolobus solfataricus are",
            "probability": 0.0024433135986328125
        },
        {
            "start_logit": 3.51953125,
            "end_logit": -6.828125,
            "text": "multiple replication origins of the archaeon Sulfolobus solfataricus are suggested by the analysis based on the Z curve",
            "probability": 0.0020656585693359375
        },
        {
            "start_logit": 3.51953125,
            "end_logit": -6.875,
            "text": "multiple replication",
            "probability": 0.0019702911376953125
        },
        {
            "start_logit": -2.94921875,
            "end_logit": -0.74609375,
            "text": "Sulfolobus solfataricus",
            "probability": 0.00140380859375
        },
        {
            "start_logit": 3.51953125,
            "end_logit": -7.28125,
            "text": "multiple replication origins of the",
            "probability": 0.0013132095336914062
        },
        {
            "start_logit": 3.51953125,
            "end_logit": -7.3125,
            "text": "multiple replication origins of the archaeon Sulfolobus solfataricus are suggested",
            "probability": 0.0012722015380859375
        },
        {
            "start_logit": 3.51953125,
            "end_logit": -7.48828125,
            "text": "multiple replication origins of the archaeon Sulfolobus solfataric",
            "probability": 0.0010671615600585938
        },
        {
            "start_logit": 3.51953125,
            "end_logit": -7.52734375,
            "text": "multiple replication origins of the archaeon Sulfolobus solfataricus are suggested by",
            "probability": 0.001026153564453125
        },
        {
            "start_logit": 3.51953125,
            "end_logit": -7.57421875,
            "text": "multiple replication origins of the archaeon Sulfolobus solfata",
            "probability": 0.0009794235229492188
        },
        {
            "start_logit": 3.51953125,
            "end_logit": -7.640625,
            "text": "multiple replication origins of the archae",
            "probability": 0.0009169578552246094
        },
        {
            "start_logit": 3.51953125,
            "end_logit": -7.671875,
            "text": "multiple replication origins of the archaeon Sulfolobus solfa",
            "probability": 0.0008883476257324219
        },
        {
            "start_logit": -6.58203125,
            "end_logit": -0.74609375,
            "text": "potential multiple replication origins of the archaeon Sulfolobus solfataricus",
            "probability": 3.707408905029297e-05
        },
        {
            "start_logit": -6.6484375,
            "end_logit": -0.74609375,
            "text": "bus solfataricus",
            "probability": 3.457069396972656e-05
        },
        {
            "start_logit": -6.97265625,
            "end_logit": -0.74609375,
            "text": "s solfataricus",
            "probability": 2.5153160095214844e-05
        },
        {
            "start_logit": -7.109375,
            "end_logit": -0.74609375,
            "text": "lobus solfataricus",
            "probability": 2.199411392211914e-05
        }
    ],
    "52fe58f82059c6d71c00007a_8": [
        {
            "start_logit": 8.96875,
            "end_logit": 2.345703125,
            "text": "multiple replication origins have been observed in archaea, considerably less is known about their evolutionary processes.",
            "probability": 0.9716796875
        },
        {
            "start_logit": 8.96875,
            "end_logit": -1.2412109375,
            "text": "multiple",
            "probability": 0.02691650390625
        },
        {
            "start_logit": 8.96875,
            "end_logit": -5.9609375,
            "text": "multiple replication origins",
            "probability": 0.00024020671844482422
        },
        {
            "start_logit": 8.96875,
            "end_logit": -5.9921875,
            "text": "multiple replication origins have been observed",
            "probability": 0.00023293495178222656
        },
        {
            "start_logit": 8.96875,
            "end_logit": -6.078125,
            "text": "multiple replication origins have been",
            "probability": 0.00021374225616455078
        },
        {
            "start_logit": 8.96875,
            "end_logit": -6.14453125,
            "text": "multiple replication origins have",
            "probability": 0.0002008676528930664
        },
        {
            "start_logit": 8.96875,
            "end_logit": -6.93359375,
            "text": "multiple replication origins have been observed in archaea, considerably less is known",
            "probability": 9.053945541381836e-05
        },
        {
            "start_logit": 8.96875,
            "end_logit": -6.9375,
            "text": "multiple replication",
            "probability": 9.053945541381836e-05
        },
        {
            "start_logit": 8.96875,
            "end_logit": -7.0703125,
            "text": "multiple replication origins have been observed in archaea",
            "probability": 7.921457290649414e-05
        },
        {
            "start_logit": 8.96875,
            "end_logit": -7.0859375,
            "text": "multiple replication origins have been observed in archaea, considerably less is known about their",
            "probability": 7.802248001098633e-05
        },
        {
            "start_logit": 8.96875,
            "end_logit": -7.14453125,
            "text": "multiple replication origins have been observed in archaea, considerably less is known about their evolutionary",
            "probability": 7.390975952148438e-05
        },
        {
            "start_logit": 8.96875,
            "end_logit": -7.1875,
            "text": "multiple replication origins have been observed in",
            "probability": 7.045269012451172e-05
        },
        {
            "start_logit": 8.96875,
            "end_logit": -7.41015625,
            "text": "multiple replication origins have been observed in archaea,",
            "probability": 5.6624412536621094e-05
        },
        {
            "start_logit": 8.96875,
            "end_logit": -7.4375,
            "text": "multiple replication origins have been observed in archaea, considerably less is known about",
            "probability": 5.4895877838134766e-05
        },
        {
            "start_logit": 8.96875,
            "end_logit": -7.4609375,
            "text": "multiple replication origins have been observed in archaea, considerably",
            "probability": 5.364418029785156e-05
        },
        {
            "start_logit": 8.96875,
            "end_logit": -7.62890625,
            "text": "multiple replication origins have been observed in archaea, considerably less is known about their evolutionary processes",
            "probability": 4.553794860839844e-05
        },
        {
            "start_logit": -1.3359375,
            "end_logit": 2.345703125,
            "text": ".",
            "probability": 3.254413604736328e-05
        },
        {
            "start_logit": -7.296875,
            "end_logit": 2.345703125,
            "text": "replication origins have been observed in archaea, considerably less is known about their evolutionary processes.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.3203125,
            "end_logit": 2.345703125,
            "text": "While multiple replication origins have been observed in archaea, considerably less is known about their evolutionary processes.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.515625,
            "end_logit": 2.345703125,
            "text": "considerably less is known about their evolutionary processes.",
            "probability": 5.960464477539063e-08
        }
    ],
    "52fe58f82059c6d71c00007a_9": [
        {
            "start_logit": -3.330078125,
            "end_logit": -3.36328125,
            "text": "multiple orc/cdc6-associated replication origins in",
            "probability": 0.5146484375
        },
        {
            "start_logit": -3.330078125,
            "end_logit": -4.30078125,
            "text": "multiple",
            "probability": 0.20166015625
        },
        {
            "start_logit": -3.330078125,
            "end_logit": -5.60546875,
            "text": "multiple orc/cdc6-associated replication origins in haloarchaeal genomes",
            "probability": 0.0546875
        },
        {
            "start_logit": -6.328125,
            "end_logit": -3.36328125,
            "text": "associated replication origins in",
            "probability": 0.0258331298828125
        },
        {
            "start_logit": -3.330078125,
            "end_logit": -6.59765625,
            "text": "multiple orc/cdc6-associated replication origins",
            "probability": 0.0202789306640625
        },
        {
            "start_logit": -3.330078125,
            "end_logit": -6.6171875,
            "text": "multiple orc/cdc6-associated replication origins in haloarch",
            "probability": 0.0199737548828125
        },
        {
            "start_logit": -3.330078125,
            "end_logit": -6.66796875,
            "text": "multiple orc/cdc6-associated replication origins in haloarchaea",
            "probability": 0.0189056396484375
        },
        {
            "start_logit": -6.72265625,
            "end_logit": -3.36328125,
            "text": "orc/cdc6-associated replication origins in",
            "probability": 0.0173492431640625
        },
        {
            "start_logit": -3.330078125,
            "end_logit": -6.77734375,
            "text": "multiple orc/cdc6-associated replication origins in halo",
            "probability": 0.016937255859375
        },
        {
            "start_logit": -6.7734375,
            "end_logit": -3.36328125,
            "text": "replication origins in",
            "probability": 0.01641845703125
        },
        {
            "start_logit": -3.330078125,
            "end_logit": -6.8515625,
            "text": "multiple orc/cdc6",
            "probability": 0.0157928466796875
        },
        {
            "start_logit": -3.330078125,
            "end_logit": -6.94140625,
            "text": "multiple orc/cdc6-",
            "probability": 0.014373779296875
        },
        {
            "start_logit": -7.07421875,
            "end_logit": -3.36328125,
            "text": "in",
            "probability": 0.01219940185546875
        },
        {
            "start_logit": -3.330078125,
            "end_logit": -7.12109375,
            "text": "multiple orc/cdc6-associated replication origins in haloarchaeal",
            "probability": 0.0120086669921875
        },
        {
            "start_logit": -7.51953125,
            "end_logit": -3.36328125,
            "text": "origins in",
            "probability": 0.00782012939453125
        },
        {
            "start_logit": -3.330078125,
            "end_logit": -7.57421875,
            "text": "multiple orc/cdc",
            "probability": 0.00763702392578125
        },
        {
            "start_logit": -3.330078125,
            "end_logit": -7.59765625,
            "text": "multiple orc",
            "probability": 0.007457733154296875
        },
        {
            "start_logit": -3.330078125,
            "end_logit": -7.7265625,
            "text": "multiple orc/",
            "probability": 0.00658416748046875
        },
        {
            "start_logit": -8.03125,
            "end_logit": -3.36328125,
            "text": "c/cdc6-associated replication origins in",
            "probability": 0.00470733642578125
        },
        {
            "start_logit": -8.0859375,
            "end_logit": -3.36328125,
            "text": "cdc6-associated replication origins in",
            "probability": 0.00441741943359375
        }
    ],
    "5fe31317a43ad31278000044_1": [
        {
            "start_logit": -1.9921875,
            "end_logit": -3.53125,
            "text": "pro-inflammatory cytokines",
            "probability": 0.55078125
        },
        {
            "start_logit": -1.9921875,
            "end_logit": -5.01171875,
            "text": "pro-inflammatory cytokines (IL-1\u03b2, IL-6 and IL-8).",
            "probability": 0.1253662109375
        },
        {
            "start_logit": -3.75390625,
            "end_logit": -3.53125,
            "text": "adipose tissue biopsies to study the relationship of MAP3K8 expression with markers of obesity and expression of pro-inflammatory cytokines",
            "probability": 0.0946044921875
        },
        {
            "start_logit": -1.9921875,
            "end_logit": -5.84375,
            "text": "pro",
            "probability": 0.054534912109375
        },
        {
            "start_logit": -4.484375,
            "end_logit": -3.53125,
            "text": "cytokines",
            "probability": 0.045562744140625
        },
        {
            "start_logit": -3.75390625,
            "end_logit": -5.01171875,
            "text": "adipose tissue biopsies to study the relationship of MAP3K8 expression with markers of obesity and expression of pro-inflammatory cytokines (IL-1\u03b2, IL-6 and IL-8).",
            "probability": 0.0215301513671875
        },
        {
            "start_logit": -1.9921875,
            "end_logit": -7.28515625,
            "text": "pro-inflammatory cytokines (IL-1\u03b2, IL-6 and IL-8",
            "probability": 0.012847900390625
        },
        {
            "start_logit": -3.75390625,
            "end_logit": -5.5625,
            "text": "adipose",
            "probability": 0.01245880126953125
        },
        {
            "start_logit": -1.9921875,
            "end_logit": -7.390625,
            "text": "pro-inflammatory cytokines (IL-1\u03b2",
            "probability": 0.01161956787109375
        },
        {
            "start_logit": -4.484375,
            "end_logit": -5.01171875,
            "text": "cytokines (IL-1\u03b2, IL-6 and IL-8).",
            "probability": 0.0103302001953125
        },
        {
            "start_logit": -1.9921875,
            "end_logit": -7.54296875,
            "text": "pro-inflammatory cytokines (IL-1\u03b2, IL-6 and IL-8)",
            "probability": 0.010009765625
        },
        {
            "start_logit": -3.75390625,
            "end_logit": -5.84375,
            "text": "adipose tissue biopsies to study the relationship of MAP3K8 expression with markers of obesity and expression of pro",
            "probability": 0.00940704345703125
        },
        {
            "start_logit": -1.9921875,
            "end_logit": -7.73828125,
            "text": "pro-inflammatory cytokines (",
            "probability": 0.00817108154296875
        },
        {
            "start_logit": -1.9921875,
            "end_logit": -7.80078125,
            "text": "pro-inflammatory cytokines (IL-1\u03b2, IL-6 and IL",
            "probability": 0.0076751708984375
        },
        {
            "start_logit": -1.9921875,
            "end_logit": -7.81640625,
            "text": "pro-inflammatory cytokines (IL-",
            "probability": 0.007556915283203125
        },
        {
            "start_logit": -3.75390625,
            "end_logit": -6.203125,
            "text": "adipose tissue",
            "probability": 0.006565093994140625
        },
        {
            "start_logit": -5.57421875,
            "end_logit": -5.01171875,
            "text": ".",
            "probability": 0.00348663330078125
        },
        {
            "start_logit": -7.265625,
            "end_logit": -3.53125,
            "text": "inflammatory cytokines",
            "probability": 0.0028247833251953125
        },
        {
            "start_logit": -7.3359375,
            "end_logit": -3.53125,
            "text": "of pro-inflammatory cytokines",
            "probability": 0.00263214111328125
        },
        {
            "start_logit": -3.75390625,
            "end_logit": -7.28515625,
            "text": "adipose tissue biopsies to study the relationship of MAP3K8 expression with markers of obesity and expression of pro-inflammatory cytokines (IL-1\u03b2, IL-6 and IL-8",
            "probability": 0.002216339111328125
        }
    ],
    "5fe31317a43ad31278000044_2": [
        {
            "start_logit": 7.2578125,
            "end_logit": 8.328125,
            "text": "IL-1\u03b2",
            "probability": 0.9970703125
        },
        {
            "start_logit": 1.2392578125,
            "end_logit": 8.328125,
            "text": "adipose tissue inflammation, specifically for IL-1\u03b2",
            "probability": 0.0024318695068359375
        },
        {
            "start_logit": -3.54296875,
            "end_logit": 8.328125,
            "text": "1\u03b2",
            "probability": 2.0384788513183594e-05
        },
        {
            "start_logit": 7.2578125,
            "end_logit": -4.38671875,
            "text": "IL",
            "probability": 2.9802322387695312e-06
        },
        {
            "start_logit": -6.59375,
            "end_logit": 8.328125,
            "text": "Together, the data in both human and mouse show that MAP3K8 is involved in local adipose tissue inflammation, specifically for IL-1\u03b2",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": -6.83203125,
            "end_logit": 8.328125,
            "text": "data in both human and mouse show that MAP3K8 is involved in local adipose tissue inflammation, specifically for IL-1\u03b2",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 1.2392578125,
            "end_logit": 0.11798095703125,
            "text": "adipose tissue",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -7.0625,
            "end_logit": 8.328125,
            "text": "-1\u03b2",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -7.1015625,
            "end_logit": 8.328125,
            "text": "inflammation, specifically for IL-1\u03b2",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -7.17578125,
            "end_logit": 8.328125,
            "text": "tissue inflammation, specifically for IL-1\u03b2",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -7.3046875,
            "end_logit": 8.328125,
            "text": "the data in both human and mouse show that MAP3K8 is involved in local adipose tissue inflammation, specifically for IL-1\u03b2",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -7.4921875,
            "end_logit": 8.328125,
            "text": "MAP3K8 is involved in local adipose tissue inflammation, specifically for IL-1\u03b2",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -7.6328125,
            "end_logit": 8.328125,
            "text": "for IL-1\u03b2",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.6796875,
            "end_logit": 8.328125,
            "text": "local adipose tissue inflammation, specifically for IL-1\u03b2",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.75,
            "end_logit": 8.328125,
            "text": "that MAP3K8 is involved in local adipose tissue inflammation, specifically for IL-1\u03b2",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.2578125,
            "end_logit": -6.703125,
            "text": "IL-1\u03b2 and its responsive cytokines IL-6 and IL-8, but does not seem to have systemic effects on insulin resistance.",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.78515625,
            "end_logit": 8.328125,
            "text": "both human and mouse show that MAP3K8 is involved in local adipose tissue inflammation, specifically for IL-1\u03b2",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.796875,
            "end_logit": 8.328125,
            "text": ", the data in both human and mouse show that MAP3K8 is involved in local adipose tissue inflammation, specifically for IL-1\u03b2",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.8125,
            "end_logit": 8.328125,
            "text": "3K8 is involved in local adipose tissue inflammation, specifically for IL-1\u03b2",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.2578125,
            "end_logit": -7.30078125,
            "text": "IL-1\u03b2 and",
            "probability": 1.7881393432617188e-07
        }
    ],
    "5fe31317a43ad31278000044_3": [
        {
            "start_logit": 7.9140625,
            "end_logit": -2.12890625,
            "text": "tumor progression locus 2 (Tpl2, also known as Map3k8/Cot) is a potent inflammatory mediator that drives the production of TNF\u03b1",
            "probability": 0.6015625
        },
        {
            "start_logit": 7.9140625,
            "end_logit": -3.4140625,
            "text": "tumor progression locus 2",
            "probability": 0.1663818359375
        },
        {
            "start_logit": 7.9140625,
            "end_logit": -3.703125,
            "text": "tumor",
            "probability": 0.1246337890625
        },
        {
            "start_logit": 7.9140625,
            "end_logit": -4.51953125,
            "text": "tumor progression locus 2 (Tpl2, also known as Map3k8/Cot) is a potent inflammatory mediator that drives the production of TNF\u03b1, IL-1\u03b2, and IFN\u03b3.",
            "probability": 0.055084228515625
        },
        {
            "start_logit": 7.9140625,
            "end_logit": -6.140625,
            "text": "tumor progression locus",
            "probability": 0.01088714599609375
        },
        {
            "start_logit": 7.9140625,
            "end_logit": -6.265625,
            "text": "tumor progression",
            "probability": 0.009613037109375
        },
        {
            "start_logit": 7.9140625,
            "end_logit": -6.6484375,
            "text": "tumor progression locus 2 (",
            "probability": 0.00655364990234375
        },
        {
            "start_logit": 7.9140625,
            "end_logit": -7.42578125,
            "text": "tumor progression locus 2 (Tpl2, also known as Map3k8/Cot) is a potent inflammatory mediator that drives the production of TNF\u03b1, IL-1\u03b2",
            "probability": 0.00301361083984375
        },
        {
            "start_logit": 7.9140625,
            "end_logit": -7.58203125,
            "text": "tumor progression locus 2 (Tpl2, also known as Map3k8/Cot) is a potent inflammatory mediator that drives the production of TNF\u03b1, IL-1\u03b2, and",
            "probability": 0.0025768280029296875
        },
        {
            "start_logit": 7.9140625,
            "end_logit": -7.6015625,
            "text": "tumor progression locus 2 (Tpl2, also known as Map3k8/Cot) is a potent inflammatory mediator that drives the production of TNF\u03b1, IL-1\u03b2, and IFN\u03b3",
            "probability": 0.0025272369384765625
        },
        {
            "start_logit": 7.9140625,
            "end_logit": -7.61328125,
            "text": "tumor progression locus 2 (Tpl2, also known as Map3k8/Cot) is a potent inflammatory mediator that drives the production",
            "probability": 0.0024967193603515625
        },
        {
            "start_logit": 7.9140625,
            "end_logit": -7.69921875,
            "text": "tumor progression locus 2 (Tpl2, also known as Map3k8/Cot) is a potent inflammatory mediator that drives the production of TNF\u03b1, IL",
            "probability": 0.0022907257080078125
        },
        {
            "start_logit": 7.9140625,
            "end_logit": -7.72265625,
            "text": "tumor progression locus 2 (Tpl2, also known as Map3k8/Cot) is a potent inflammatory mediator that drives the production of TNF\u03b1, IL-",
            "probability": 0.002239227294921875
        },
        {
            "start_logit": 7.9140625,
            "end_logit": -7.765625,
            "text": "tumor progression locus 2 (Tpl2,",
            "probability": 0.00214385986328125
        },
        {
            "start_logit": 7.9140625,
            "end_logit": -7.7890625,
            "text": "tumor progression locus 2 (Tpl2, also known as Map3k8/Cot) is a potent inflammatory mediator that drives the production of TNF\u03b1, IL-1\u03b2, and IFN",
            "probability": 0.0020961761474609375
        },
        {
            "start_logit": 7.9140625,
            "end_logit": -7.8515625,
            "text": "tumor progression locus 2 (Tpl2, also known as Map3k8/Cot) is a",
            "probability": 0.0019683837890625
        },
        {
            "start_logit": 7.9140625,
            "end_logit": -7.859375,
            "text": "tumor progression locus 2 (Tpl2, also known",
            "probability": 0.001953125
        },
        {
            "start_logit": 7.9140625,
            "end_logit": -7.92578125,
            "text": "tumor progression locus 2 (Tpl2, also known as Map3k8/Cot",
            "probability": 0.001827239990234375
        },
        {
            "start_logit": -1.9384765625,
            "end_logit": -2.12890625,
            "text": "of TNF\u03b1",
            "probability": 3.170967102050781e-05
        },
        {
            "start_logit": -3.361328125,
            "end_logit": -2.12890625,
            "text": "production of TNF\u03b1",
            "probability": 7.62939453125e-06
        }
    ],
    "5fe31317a43ad31278000044_4": [
        {
            "start_logit": 7.82421875,
            "end_logit": -1.548828125,
            "text": "tumor progression locus 2 (Tpl2, also known as Map3k8/Cot) is a potent inflammatory mediator that drives the production of TNF\u03b1",
            "probability": 0.72265625
        },
        {
            "start_logit": 7.82421875,
            "end_logit": -3.6171875,
            "text": "tumor progression locus 2 (Tpl2, also known as Map3k8/Cot) is a potent inflammatory mediator that drives the production of TNF\u03b1, IL-1\u03b2, and IFN\u03b3.",
            "probability": 0.09149169921875
        },
        {
            "start_logit": 7.82421875,
            "end_logit": -3.7265625,
            "text": "tumor",
            "probability": 0.08203125
        },
        {
            "start_logit": 7.82421875,
            "end_logit": -3.916015625,
            "text": "tumor progression locus 2",
            "probability": 0.06787109375
        },
        {
            "start_logit": 7.82421875,
            "end_logit": -6.1953125,
            "text": "tumor progression locus",
            "probability": 0.006946563720703125
        },
        {
            "start_logit": 7.82421875,
            "end_logit": -6.31640625,
            "text": "tumor progression",
            "probability": 0.006153106689453125
        },
        {
            "start_logit": 7.82421875,
            "end_logit": -6.45703125,
            "text": "tumor progression locus 2 (",
            "probability": 0.00534820556640625
        },
        {
            "start_logit": 7.82421875,
            "end_logit": -7.375,
            "text": "tumor progression locus 2 (Tpl2, also known as Map3k8/Cot) is a potent inflammatory mediator that drives the production",
            "probability": 0.0021343231201171875
        },
        {
            "start_logit": 7.82421875,
            "end_logit": -7.38671875,
            "text": "tumor progression locus 2 (Tpl2, also known as Map3k8/Cot) is a potent inflammatory mediator that drives the production of TNF\u03b1, IL-1\u03b2",
            "probability": 0.002109527587890625
        },
        {
            "start_logit": 7.82421875,
            "end_logit": -7.46875,
            "text": "tumor progression locus 2 (Tpl2, also known as Map3k8/Cot) is a potent inflammatory mediator that drives the production of TNF\u03b1, IL-1\u03b2, and",
            "probability": 0.0019445419311523438
        },
        {
            "start_logit": 7.82421875,
            "end_logit": -7.55859375,
            "text": "tumor progression locus 2 (Tpl2, also known as Map3k8/Cot) is a potent inflammatory mediator that drives the production of TNF\u03b1, IL-1\u03b2, and IFN\u03b3",
            "probability": 0.0017766952514648438
        },
        {
            "start_logit": 7.82421875,
            "end_logit": -7.65625,
            "text": "tumor progression locus 2 (Tpl2, also known as Map3k8/Cot) is a potent inflammatory mediator that drives the production of TNF\u03b1, IL",
            "probability": 0.0016117095947265625
        },
        {
            "start_logit": 7.82421875,
            "end_logit": -7.69140625,
            "text": "tumor progression locus 2 (Tpl2, also known as Map3k8/Cot) is a potent inflammatory mediator that drives the production of TNF\u03b1, IL-",
            "probability": 0.001556396484375
        },
        {
            "start_logit": 7.82421875,
            "end_logit": -7.7109375,
            "text": "tumor progression locus 2 (Tpl2,",
            "probability": 0.00152587890625
        },
        {
            "start_logit": 7.82421875,
            "end_logit": -7.7265625,
            "text": "tumor progression locus 2 (Tpl2, also known as Map3k8/Cot) is a potent inflammatory mediator that drives the production of TNF\u03b1, IL-1\u03b2, and IFN",
            "probability": 0.0015020370483398438
        },
        {
            "start_logit": 7.82421875,
            "end_logit": -7.73046875,
            "text": "tumor progression locus 2 (Tpl2, also known",
            "probability": 0.0014972686767578125
        },
        {
            "start_logit": 7.82421875,
            "end_logit": -7.8359375,
            "text": "tumor progression locus 2 (Tpl2, also known as Map3k8/Cot) is a",
            "probability": 0.001346588134765625
        },
        {
            "start_logit": -0.90478515625,
            "end_logit": -1.548828125,
            "text": "of TNF\u03b1",
            "probability": 0.00011724233627319336
        },
        {
            "start_logit": -1.8701171875,
            "end_logit": -1.548828125,
            "text": "production of TNF\u03b1",
            "probability": 4.482269287109375e-05
        },
        {
            "start_logit": -0.90478515625,
            "end_logit": -3.6171875,
            "text": "of TNF\u03b1, IL-1\u03b2, and IFN\u03b3.",
            "probability": 1.4781951904296875e-05
        }
    ],
    "5fe31317a43ad31278000044_5": [
        {
            "start_logit": 9.234375,
            "end_logit": 9.21875,
            "text": "IL-1\u03b2",
            "probability": 1.0
        },
        {
            "start_logit": -2.529296875,
            "end_logit": 9.21875,
            "text": "1\u03b2",
            "probability": 7.748603820800781e-06
        },
        {
            "start_logit": 9.234375,
            "end_logit": -2.583984375,
            "text": "IL",
            "probability": 7.450580596923828e-06
        },
        {
            "start_logit": -6.54296875,
            "end_logit": 9.21875,
            "text": "-1\u03b2",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.234375,
            "end_logit": -7.3515625,
            "text": "IL-1\u03b2 reporter activity.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6015625,
            "end_logit": 9.21875,
            "text": "exchange protein directly activated by cAMP) and TPL2 (tumor progression locus 2, MAP3K8) and found that inhibitors for EPAC and TPL2 reduced AR agonist-induced IL-1\u03b2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.765625,
            "end_logit": 9.21875,
            "text": "protein directly activated by cAMP) and TPL2 (tumor progression locus 2, MAP3K8) and found that inhibitors for EPAC and TPL2 reduced AR agonist-induced IL-1\u03b2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.8203125,
            "end_logit": 9.21875,
            "text": "for EPAC and TPL2 reduced AR agonist-induced IL-1\u03b2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.9140625,
            "end_logit": 9.21875,
            "text": "induced IL-1\u03b2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.9453125,
            "end_logit": 9.21875,
            "text": "directly activated by cAMP) and TPL2 (tumor progression locus 2, MAP3K8) and found that inhibitors for EPAC and TPL2 reduced AR agonist-induced IL-1\u03b2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.96875,
            "end_logit": 9.21875,
            "text": "tumor progression locus 2, MAP3K8) and found that inhibitors for EPAC and TPL2 reduced AR agonist-induced IL-1\u03b2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.97265625,
            "end_logit": 9.21875,
            "text": "inhibitors for EPAC and TPL2 reduced AR agonist-induced IL-1\u03b2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.98046875,
            "end_logit": 9.21875,
            "text": "that inhibitors for EPAC and TPL2 reduced AR agonist-induced IL-1\u03b2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0078125,
            "end_logit": 9.21875,
            "text": "EPAC and TPL2 reduced AR agonist-induced IL-1\u03b2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.015625,
            "end_logit": 9.21875,
            "text": "found that inhibitors for EPAC and TPL2 reduced AR agonist-induced IL-1\u03b2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.234375,
            "end_logit": -8.0390625,
            "text": "IL-",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.234375,
            "end_logit": -8.0703125,
            "text": "IL-1\u03b2 reporter activity",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.234375,
            "end_logit": -8.0859375,
            "text": "IL-1\u03b2 reporter",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.529296875,
            "end_logit": -7.3515625,
            "text": "1\u03b2 reporter activity.",
            "probability": 0.0
        },
        {
            "start_logit": -7.6015625,
            "end_logit": -2.583984375,
            "text": "exchange protein directly activated by cAMP) and TPL2 (tumor progression locus 2, MAP3K8) and found that inhibitors for EPAC and TPL2 reduced AR agonist-induced IL",
            "probability": 0.0
        }
    ],
    "5fe31317a43ad31278000044_6": [
        {
            "start_logit": -0.498291015625,
            "end_logit": -2.537109375,
            "text": "TNF",
            "probability": 0.69921875
        },
        {
            "start_logit": -0.498291015625,
            "end_logit": -4.0546875,
            "text": "TNF -\u03b1, in human adipose tissue were associated with higher expression of MAP3K8.",
            "probability": 0.153076171875
        },
        {
            "start_logit": -0.498291015625,
            "end_logit": -4.73828125,
            "text": "TNF -\u03b1",
            "probability": 0.0772705078125
        },
        {
            "start_logit": -0.498291015625,
            "end_logit": -6.62109375,
            "text": "TNF -\u03b1, in human adipose tissue",
            "probability": 0.011749267578125
        },
        {
            "start_logit": -0.498291015625,
            "end_logit": -6.6875,
            "text": "TNF -\u03b1, in human adipose",
            "probability": 0.0110015869140625
        },
        {
            "start_logit": -0.498291015625,
            "end_logit": -6.73046875,
            "text": "TNF -\u03b1, in human adipose tissue were",
            "probability": 0.01053619384765625
        },
        {
            "start_logit": -4.765625,
            "end_logit": -2.537109375,
            "text": "IL-1\u03b2, IL-6 and IL-8, but not TNF",
            "probability": 0.0097808837890625
        },
        {
            "start_logit": -0.498291015625,
            "end_logit": -7.34375,
            "text": "TNF -\u03b1, in",
            "probability": 0.005702972412109375
        },
        {
            "start_logit": -0.498291015625,
            "end_logit": -7.4453125,
            "text": "TNF -",
            "probability": 0.005153656005859375
        },
        {
            "start_logit": -0.498291015625,
            "end_logit": -7.76953125,
            "text": "TNF -\u03b1,",
            "probability": 0.0037441253662109375
        },
        {
            "start_logit": -0.498291015625,
            "end_logit": -7.8515625,
            "text": "TNF -\u03b1, in human adipose tissue were associated with higher expression",
            "probability": 0.0034332275390625
        },
        {
            "start_logit": -4.765625,
            "end_logit": -4.0546875,
            "text": "IL-1\u03b2, IL-6 and IL-8, but not TNF -\u03b1, in human adipose tissue were associated with higher expression of MAP3K8.",
            "probability": 0.0021495819091796875
        },
        {
            "start_logit": -5.1328125,
            "end_logit": -4.0546875,
            "text": ".",
            "probability": 0.0014886856079101562
        },
        {
            "start_logit": -6.6875,
            "end_logit": -2.537109375,
            "text": "but not TNF",
            "probability": 0.0014314651489257812
        },
        {
            "start_logit": -4.765625,
            "end_logit": -4.73828125,
            "text": "IL-1\u03b2, IL-6 and IL-8, but not TNF -\u03b1",
            "probability": 0.0010890960693359375
        },
        {
            "start_logit": -7.3671875,
            "end_logit": -2.537109375,
            "text": "not TNF",
            "probability": 0.0007257461547851562
        },
        {
            "start_logit": -7.42578125,
            "end_logit": -2.537109375,
            "text": ", but not TNF",
            "probability": 0.0006871223449707031
        },
        {
            "start_logit": -7.4375,
            "end_logit": -2.537109375,
            "text": "of IL-1\u03b2, IL-6 and IL-8, but not TNF",
            "probability": 0.0006761550903320312
        },
        {
            "start_logit": -7.77734375,
            "end_logit": -2.537109375,
            "text": "and IL-8, but not TNF",
            "probability": 0.0004832744598388672
        },
        {
            "start_logit": -7.7890625,
            "end_logit": -2.537109375,
            "text": "high mRNA expression levels of IL-1\u03b2, IL-6 and IL-8, but not TNF",
            "probability": 0.00047588348388671875
        }
    ],
    "5fe31317a43ad31278000044_7": [
        {
            "start_logit": 8.875,
            "end_logit": 6.72265625,
            "text": "CXCL1",
            "probability": 0.99609375
        },
        {
            "start_logit": 8.875,
            "end_logit": 1.2021484375,
            "text": "CXCL1 in adipose tissue",
            "probability": 0.004009246826171875
        },
        {
            "start_logit": 8.875,
            "end_logit": -2.32421875,
            "text": "CXCL",
            "probability": 0.00011730194091796875
        },
        {
            "start_logit": 8.875,
            "end_logit": -4.01953125,
            "text": "CXCL1 in adipose tissue in response to the HFD as compared to WT animals.",
            "probability": 2.1696090698242188e-05
        },
        {
            "start_logit": 8.875,
            "end_logit": -6.953125,
            "text": "CXCL1 in adipose tissue in response to the HFD as compared",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": 8.875,
            "end_logit": -7.18359375,
            "text": "CXCL1 in adipose tissue in response to the HFD as",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": 8.875,
            "end_logit": -7.23046875,
            "text": "CXCL1 in adipose",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": -5.109375,
            "end_logit": 6.72265625,
            "text": "1",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": 8.875,
            "end_logit": -7.265625,
            "text": "CXCL1 in adipose tissue in response to the HFD as compared to",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": 8.875,
            "end_logit": -7.3984375,
            "text": "CXCL1 in adipose tissue in",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 8.875,
            "end_logit": -7.5234375,
            "text": "CXCL1 in adipose tissue in response to the HFD",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 8.875,
            "end_logit": -7.625,
            "text": "CXCL1 in adipose tissue in response to",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -6.7578125,
            "end_logit": 6.72265625,
            "text": "IL-1\u03b2, IL-6 and CXCL1",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.14453125,
            "end_logit": 6.72265625,
            "text": "of IL-1\u03b2, IL-6 and CXCL1",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.671875,
            "end_logit": 6.72265625,
            "text": "and CXCL1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.8671875,
            "end_logit": 6.72265625,
            "text": "lower mRNA expression levels of IL-1\u03b2, IL-6 and CXCL1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.92578125,
            "end_logit": 6.72265625,
            "text": "MAP3K8 had similar bodyweight gain as WT mice, yet displayed lower mRNA expression levels of IL-1\u03b2, IL-6 and CXCL1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0390625,
            "end_logit": 6.72265625,
            "text": "displayed lower mRNA expression levels of IL-1\u03b2, IL-6 and CXCL1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.078125,
            "end_logit": 6.72265625,
            "text": "mRNA expression levels of IL-1\u03b2, IL-6 and CXCL1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.078125,
            "end_logit": 6.72265625,
            "text": "lacking MAP3K8 had similar bodyweight gain as WT mice, yet displayed lower mRNA expression levels of IL-1\u03b2, IL-6 and CXCL1",
            "probability": 5.960464477539063e-08
        }
    ],
    "621ebb733a8413c65300005c_1": [
        {
            "start_logit": 9.046875,
            "end_logit": -0.5126953125,
            "text": "antivirals against virus",
            "probability": 0.68798828125
        },
        {
            "start_logit": 9.046875,
            "end_logit": -1.322265625,
            "text": "antiviral",
            "probability": 0.307861328125
        },
        {
            "start_logit": 9.046875,
            "end_logit": -6.2109375,
            "text": "antivirals against",
            "probability": 0.0023136138916015625
        },
        {
            "start_logit": 9.046875,
            "end_logit": -6.60546875,
            "text": "antivirals",
            "probability": 0.0015592575073242188
        },
        {
            "start_logit": -0.463623046875,
            "end_logit": -0.5126953125,
            "text": "SARS-CoV-2. There are reports about the uses of Remdesivir and Favipiravir as existing antivirals against virus",
            "probability": 5.1081180572509766e-05
        },
        {
            "start_logit": -0.463623046875,
            "end_logit": -1.322265625,
            "text": "SARS-CoV-2. There are reports about the uses of Remdesivir and Favipiravir as existing antiviral",
            "probability": 2.2709369659423828e-05
        },
        {
            "start_logit": -0.463623046875,
            "end_logit": -1.5810546875,
            "text": "SARS-CoV-2.",
            "probability": 1.7523765563964844e-05
        },
        {
            "start_logit": -3.8828125,
            "end_logit": -0.5126953125,
            "text": ". There are reports about the uses of Remdesivir and Favipiravir as existing antivirals against virus",
            "probability": 1.6689300537109375e-06
        },
        {
            "start_logit": -3.8828125,
            "end_logit": -1.322265625,
            "text": ". There are reports about the uses of Remdesivir and Favipiravir as existing antiviral",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -3.8828125,
            "end_logit": -1.5810546875,
            "text": ".",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -0.463623046875,
            "end_logit": -5.89453125,
            "text": "SARS",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -0.463623046875,
            "end_logit": -5.953125,
            "text": "SARS-CoV",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -0.463623046875,
            "end_logit": -6.03515625,
            "text": "SARS-CoV-2",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -0.463623046875,
            "end_logit": -6.2109375,
            "text": "SARS-CoV-2. There are reports about the uses of Remdesivir and Favipiravir as existing antivirals against",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -0.463623046875,
            "end_logit": -6.60546875,
            "text": "SARS-CoV-2. There are reports about the uses of Remdesivir and Favipiravir as existing antivirals",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.84765625,
            "end_logit": -0.5126953125,
            "text": "against SARS-CoV-2. There are reports about the uses of Remdesivir and Favipiravir as existing antivirals against virus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -0.463623046875,
            "end_logit": -7.26953125,
            "text": "SARS-CoV-2. There are reports about the uses of Remdesivir and Favipiravir as",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -0.463623046875,
            "end_logit": -7.28125,
            "text": "SARS-",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.3125,
            "end_logit": -0.5126953125,
            "text": "race for drugs to be effective against SARS-CoV-2. There are reports about the uses of Remdesivir and Favipiravir as existing antivirals against virus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -0.463623046875,
            "end_logit": -7.484375,
            "text": "SARS-CoV-",
            "probability": 5.960464477539063e-08
        }
    ],
    "621ebb733a8413c65300005c_2": [
        {
            "start_logit": 8.328125,
            "end_logit": 7.53125,
            "text": "COVID-19",
            "probability": 1.0
        },
        {
            "start_logit": 8.328125,
            "end_logit": -3.8671875,
            "text": "COV",
            "probability": 1.1205673217773438e-05
        },
        {
            "start_logit": 8.328125,
            "end_logit": -4.66015625,
            "text": "COVID-",
            "probability": 5.066394805908203e-06
        },
        {
            "start_logit": 8.328125,
            "end_logit": -5.27734375,
            "text": "COVID",
            "probability": 2.7418136596679688e-06
        },
        {
            "start_logit": -4.484375,
            "end_logit": 7.53125,
            "text": "19",
            "probability": 2.7418136596679688e-06
        },
        {
            "start_logit": -6.6328125,
            "end_logit": 7.53125,
            "text": "treat COVID-19",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.328125,
            "end_logit": -7.53125,
            "text": "COVID-19 (lopinavir",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.328125,
            "end_logit": -7.546875,
            "text": "COVID-19 (",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.328125,
            "end_logit": -7.73828125,
            "text": "COVID-19 (lopinavir, ritonavir, ivermectin, remdesivir and favipiravir)",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.328125,
            "end_logit": -7.74609375,
            "text": "COVID-19 (lopinavir, ritonavir",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.328125,
            "end_logit": -7.80078125,
            "text": "COVID-19 (lopinavir, ritonavir, ivermectin, remdesivir",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.328125,
            "end_logit": -7.8203125,
            "text": "COVID-19 (lopinavir, ritonavir, ivermectin, remdesivir and",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.328125,
            "end_logit": -7.828125,
            "text": "COVID-19 (lopinavir, ritonavir, ivermectin",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.328125,
            "end_logit": -7.8359375,
            "text": "COVID-19 (lo",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.328125,
            "end_logit": -7.859375,
            "text": "COVID-19 (lopin",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.328125,
            "end_logit": -7.8671875,
            "text": "COVID-19 (lopinavir, ritonavir, ivermectin, remdesivir and favipiravir),",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.328125,
            "end_logit": -7.89453125,
            "text": "COVID-19 (lopinavir,",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.86328125,
            "end_logit": 7.53125,
            "text": "to treat COVID-19",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.015625,
            "end_logit": 7.53125,
            "text": "key repurposed drugs advocated to treat COVID-19",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.140625,
            "end_logit": 7.53125,
            "text": "repurposed drugs advocated to treat COVID-19",
            "probability": 5.960464477539063e-08
        }
    ],
    "621ebb733a8413c65300005c_3": [
        {
            "start_logit": 9.6796875,
            "end_logit": 9.5,
            "text": "COVID-19",
            "probability": 1.0
        },
        {
            "start_logit": 9.6796875,
            "end_logit": -1.8701171875,
            "text": "COV",
            "probability": 1.150369644165039e-05
        },
        {
            "start_logit": -1.99609375,
            "end_logit": 9.5,
            "text": "19",
            "probability": 8.404254913330078e-06
        },
        {
            "start_logit": 9.6796875,
            "end_logit": -6.6796875,
            "text": "COVID-",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.109375,
            "end_logit": 9.5,
            "text": "ID-19",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.6796875,
            "end_logit": -7.37890625,
            "text": "COVID",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.3671875,
            "end_logit": 9.5,
            "text": "treat COVID-19",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.6796875,
            "end_logit": -7.77734375,
            "text": "COVID-19 patients",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.69921875,
            "end_logit": 9.5,
            "text": "-19",
            "probability": 0.0
        },
        {
            "start_logit": -7.70703125,
            "end_logit": 9.5,
            "text": ": To compare the efficacy and safety of favipiravir and umifenovir (Arbidol) to treat COVID-19",
            "probability": 0.0
        },
        {
            "start_logit": -7.98828125,
            "end_logit": 9.5,
            "text": "To compare the efficacy and safety of favipiravir and umifenovir (Arbidol) to treat COVID-19",
            "probability": 0.0
        },
        {
            "start_logit": -8.015625,
            "end_logit": 9.5,
            "text": "Arbidol) to treat COVID-19",
            "probability": 0.0
        },
        {
            "start_logit": -8.03125,
            "end_logit": 9.5,
            "text": ") to treat COVID-19",
            "probability": 0.0
        },
        {
            "start_logit": -8.0703125,
            "end_logit": 9.5,
            "text": "idol) to treat COVID-19",
            "probability": 0.0
        },
        {
            "start_logit": -8.078125,
            "end_logit": 9.5,
            "text": "to treat COVID-19",
            "probability": 0.0
        },
        {
            "start_logit": -8.1015625,
            "end_logit": 9.5,
            "text": "favipiravir and umifenovir (Arbidol) to treat COVID-19",
            "probability": 0.0
        },
        {
            "start_logit": -8.125,
            "end_logit": 9.5,
            "text": "compare the efficacy and safety of favipiravir and umifenovir (Arbidol) to treat COVID-19",
            "probability": 0.0
        },
        {
            "start_logit": -8.1328125,
            "end_logit": 9.5,
            "text": "vir (Arbidol) to treat COVID-19",
            "probability": 0.0
        },
        {
            "start_logit": -8.140625,
            "end_logit": 9.5,
            "text": "(Arbidol) to treat COVID-19",
            "probability": 0.0
        },
        {
            "start_logit": -8.1484375,
            "end_logit": 9.5,
            "text": "vir and umifenovir (Arbidol) to treat COVID-19",
            "probability": 0.0
        }
    ],
    "621ebb733a8413c65300005c_4": [
        {
            "start_logit": 9.75,
            "end_logit": 9.65625,
            "text": "COVID-19",
            "probability": 1.0
        },
        {
            "start_logit": -1.568359375,
            "end_logit": 9.65625,
            "text": "19",
            "probability": 1.2099742889404297e-05
        },
        {
            "start_logit": 9.75,
            "end_logit": -1.705078125,
            "text": "COV",
            "probability": 1.1682510375976562e-05
        },
        {
            "start_logit": 9.75,
            "end_logit": -6.5546875,
            "text": "COVID-",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.9375,
            "end_logit": 9.65625,
            "text": "ID-19",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.75,
            "end_logit": -7.1953125,
            "text": "COVID",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.33984375,
            "end_logit": 9.65625,
            "text": "possible COVID-19",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.75,
            "end_logit": -7.58984375,
            "text": "COVID-19 treatments",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.7421875,
            "end_logit": 9.65625,
            "text": "-19",
            "probability": 0.0
        },
        {
            "start_logit": -7.953125,
            "end_logit": 9.65625,
            "text": "considered possible COVID-19",
            "probability": 0.0
        },
        {
            "start_logit": -8.015625,
            "end_logit": 9.65625,
            "text": "Favipiravir (FPV) and hydroxychloroquine (HCQ) are considered possible COVID-19",
            "probability": 0.0
        },
        {
            "start_logit": -8.09375,
            "end_logit": 9.65625,
            "text": ") and hydroxychloroquine (HCQ) are considered possible COVID-19",
            "probability": 0.0
        },
        {
            "start_logit": -8.109375,
            "end_logit": 9.65625,
            "text": "hydroxychloroquine (HCQ) are considered possible COVID-19",
            "probability": 0.0
        },
        {
            "start_logit": -8.1171875,
            "end_logit": 9.65625,
            "text": "ipiravir (FPV) and hydroxychloroquine (HCQ) are considered possible COVID-19",
            "probability": 0.0
        },
        {
            "start_logit": -8.140625,
            "end_logit": 9.65625,
            "text": ") are considered possible COVID-19",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": 9.65625,
            "text": "oquine (HCQ) are considered possible COVID-19",
            "probability": 0.0
        },
        {
            "start_logit": -8.1796875,
            "end_logit": 9.65625,
            "text": "iravir (FPV) and hydroxychloroquine (HCQ) are considered possible COVID-19",
            "probability": 0.0
        },
        {
            "start_logit": -8.1796875,
            "end_logit": 9.65625,
            "text": "V) and hydroxychloroquine (HCQ) are considered possible COVID-19",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": 9.65625,
            "text": "vir (FPV) and hydroxychloroquine (HCQ) are considered possible COVID-19",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 9.65625,
            "text": "FPV) and hydroxychloroquine (HCQ) are considered possible COVID-19",
            "probability": 0.0
        }
    ],
    "621ebb733a8413c65300005c_5": [
        {
            "start_logit": 9.1796875,
            "end_logit": 8.9453125,
            "text": "COVID-19",
            "probability": 1.0
        },
        {
            "start_logit": 9.1796875,
            "end_logit": -2.697265625,
            "text": "COV",
            "probability": 8.821487426757812e-06
        },
        {
            "start_logit": -2.951171875,
            "end_logit": 8.9453125,
            "text": "19",
            "probability": 5.364418029785156e-06
        },
        {
            "start_logit": -3.611328125,
            "end_logit": 8.9453125,
            "text": "treatment of COVID-19",
            "probability": 2.8014183044433594e-06
        },
        {
            "start_logit": 9.1796875,
            "end_logit": -4.2265625,
            "text": "COVID-19 in many countries.",
            "probability": 1.9073486328125e-06
        },
        {
            "start_logit": -6.140625,
            "end_logit": 8.9453125,
            "text": "Favipiravir (FVP) has been used for treatment of COVID-19",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.23828125,
            "end_logit": 8.9453125,
            "text": "of COVID-19",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.1796875,
            "end_logit": -6.70703125,
            "text": "COVID-19 in",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.1796875,
            "end_logit": -6.7578125,
            "text": "COVID-",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.9375,
            "end_logit": 8.9453125,
            "text": "ID-19",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1796875,
            "end_logit": -7.3203125,
            "text": "COVID",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.390625,
            "end_logit": 8.9453125,
            "text": "for treatment of COVID-19",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1796875,
            "end_logit": -7.78125,
            "text": "COVID-19 in many countries",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1796875,
            "end_logit": -7.8203125,
            "text": "COVID-19 in many",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.60546875,
            "end_logit": 8.9453125,
            "text": "-19",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.66796875,
            "end_logit": 8.9453125,
            "text": "been used for treatment of COVID-19",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.75390625,
            "end_logit": 8.9453125,
            "text": "used for treatment of COVID-19",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.828125,
            "end_logit": 8.9453125,
            "text": "ipiravir (FVP) has been used for treatment of COVID-19",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.859375,
            "end_logit": 8.9453125,
            "text": "FVP) has been used for treatment of COVID-19",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.8671875,
            "end_logit": 8.9453125,
            "text": "iravir (FVP) has been used for treatment of COVID-19",
            "probability": 5.960464477539063e-08
        }
    ],
    "621ebb733a8413c65300005c_6": [
        {
            "start_logit": 9.7265625,
            "end_logit": 9.703125,
            "text": "COVID-19 infection",
            "probability": 1.0
        },
        {
            "start_logit": -1.34375,
            "end_logit": 9.703125,
            "text": "infection",
            "probability": 1.5437602996826172e-05
        },
        {
            "start_logit": 9.7265625,
            "end_logit": -1.7607421875,
            "text": "COV",
            "probability": 1.043081283569336e-05
        },
        {
            "start_logit": -3.494140625,
            "end_logit": 9.703125,
            "text": "severe COVID-19 infection",
            "probability": 1.7881393432617188e-06
        },
        {
            "start_logit": 9.7265625,
            "end_logit": -6.08984375,
            "text": "COVID-19 infection.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.7265625,
            "end_logit": -6.48828125,
            "text": "COVID-19",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.94140625,
            "end_logit": 9.703125,
            "text": "ID-19 infection",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.96484375,
            "end_logit": 9.703125,
            "text": "with severe COVID-19 infection",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.7265625,
            "end_logit": -7.2421875,
            "text": "COVID-",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.453125,
            "end_logit": 9.703125,
            "text": "-19 infection",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.7265625,
            "end_logit": -7.6171875,
            "text": "COVID",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.61328125,
            "end_logit": 9.703125,
            "text": "patients with severe COVID-19 infection",
            "probability": 0.0
        },
        {
            "start_logit": -7.76953125,
            "end_logit": 9.703125,
            "text": "treating patients with severe COVID-19 infection",
            "probability": 0.0
        },
        {
            "start_logit": -7.81640625,
            "end_logit": 9.703125,
            "text": "19 infection",
            "probability": 0.0
        },
        {
            "start_logit": -7.92578125,
            "end_logit": 9.703125,
            "text": "To assess the efficacy of Favipiravir compared to the standard therapy in treating patients with severe COVID-19 infection",
            "probability": 0.0
        },
        {
            "start_logit": -8.015625,
            "end_logit": 9.703125,
            "text": "therapy in treating patients with severe COVID-19 infection",
            "probability": 0.0
        },
        {
            "start_logit": -8.0625,
            "end_logit": 9.703125,
            "text": "Favipiravir compared to the standard therapy in treating patients with severe COVID-19 infection",
            "probability": 0.0
        },
        {
            "start_logit": -8.078125,
            "end_logit": 9.703125,
            "text": "efficacy of Favipiravir compared to the standard therapy in treating patients with severe COVID-19 infection",
            "probability": 0.0
        },
        {
            "start_logit": -8.1171875,
            "end_logit": 9.703125,
            "text": "vir compared to the standard therapy in treating patients with severe COVID-19 infection",
            "probability": 0.0
        },
        {
            "start_logit": -8.1171875,
            "end_logit": 9.703125,
            "text": "standard therapy in treating patients with severe COVID-19 infection",
            "probability": 0.0
        }
    ],
    "621ebb733a8413c65300005c_7": [
        {
            "start_logit": 7.71875,
            "end_logit": 9.2265625,
            "text": "COVID-19 infections",
            "probability": 1.0
        },
        {
            "start_logit": -2.19140625,
            "end_logit": 9.2265625,
            "text": "infections",
            "probability": 4.988908767700195e-05
        },
        {
            "start_logit": -4.66015625,
            "end_logit": 9.2265625,
            "text": "severe COVID-19 infections",
            "probability": 4.231929779052734e-06
        },
        {
            "start_logit": -5.21484375,
            "end_logit": 9.2265625,
            "text": "with severe COVID-19 infections",
            "probability": 2.4437904357910156e-06
        },
        {
            "start_logit": 7.71875,
            "end_logit": -4.44140625,
            "text": "COV",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": -6.90234375,
            "end_logit": 9.2265625,
            "text": "ID-19 infections",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -7.046875,
            "end_logit": 9.2265625,
            "text": "in patients with severe COVID-19 infections",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 7.71875,
            "end_logit": -5.578125,
            "text": "COVID-19",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.25390625,
            "end_logit": 9.2265625,
            "text": "patients with severe COVID-19 infections",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.67578125,
            "end_logit": 9.2265625,
            "text": "-19 infections",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.7265625,
            "end_logit": 9.2265625,
            "text": "Favipiravir versus standard of care in patients with severe COVID-19 infections",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.8671875,
            "end_logit": 9.2265625,
            "text": "care in patients with severe COVID-19 infections",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.95703125,
            "end_logit": 9.2265625,
            "text": "ipiravir versus standard of care in patients with severe COVID-19 infections",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.96484375,
            "end_logit": 9.2265625,
            "text": "iravir versus standard of care in patients with severe COVID-19 infections",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.98828125,
            "end_logit": 9.2265625,
            "text": "vir versus standard of care in patients with severe COVID-19 infections",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.99609375,
            "end_logit": 9.2265625,
            "text": "standard of care in patients with severe COVID-19 infections",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -8.0859375,
            "end_logit": 9.2265625,
            "text": "of care in patients with severe COVID-19 infections",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.1015625,
            "end_logit": 9.2265625,
            "text": "versus standard of care in patients with severe COVID-19 infections",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.71875,
            "end_logit": -6.70703125,
            "text": "COVID-",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.71875,
            "end_logit": -7.40625,
            "text": "COVID",
            "probability": 5.960464477539063e-08
        }
    ],
    "621ebb733a8413c65300005c_8": [
        {
            "start_logit": 6.5390625,
            "end_logit": 7.22265625,
            "text": "COVID-19",
            "probability": 1.0
        },
        {
            "start_logit": -3.103515625,
            "end_logit": 7.22265625,
            "text": "of COVID-19",
            "probability": 6.455183029174805e-05
        },
        {
            "start_logit": -4.0546875,
            "end_logit": 7.22265625,
            "text": "treatment of COVID-19",
            "probability": 2.5093555450439453e-05
        },
        {
            "start_logit": -5.19140625,
            "end_logit": 7.22265625,
            "text": "19",
            "probability": 7.987022399902344e-06
        },
        {
            "start_logit": 6.5390625,
            "end_logit": -5.46875,
            "text": "COVID-19.",
            "probability": 3.039836883544922e-06
        },
        {
            "start_logit": 6.5390625,
            "end_logit": -5.62109375,
            "text": "COV",
            "probability": 2.6226043701171875e-06
        },
        {
            "start_logit": 6.5390625,
            "end_logit": -6.2734375,
            "text": "COVID-",
            "probability": 1.3709068298339844e-06
        },
        {
            "start_logit": -7.13671875,
            "end_logit": 7.22265625,
            "text": "the treatment of COVID-19",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": -7.40625,
            "end_logit": 7.22265625,
            "text": "ID-19",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": -7.7109375,
            "end_logit": 7.22265625,
            "text": "in the treatment of COVID-19",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 6.5390625,
            "end_logit": -7.04296875,
            "text": "COVID",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -7.73828125,
            "end_logit": 7.22265625,
            "text": "Molnupiravir/Favipiravir in the treatment of COVID-19",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -7.93359375,
            "end_logit": 7.22265625,
            "text": "-19",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -8.1015625,
            "end_logit": 7.22265625,
            "text": "Favipiravir in the treatment of COVID-19",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -8.1171875,
            "end_logit": 7.22265625,
            "text": "/Favipiravir in the treatment of COVID-19",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -8.125,
            "end_logit": 7.22265625,
            "text": "vir in the treatment of COVID-19",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -8.1484375,
            "end_logit": 7.22265625,
            "text": "nupiravir/Favipiravir in the treatment of COVID-19",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -8.1953125,
            "end_logit": 7.22265625,
            "text": "piravir/Favipiravir in the treatment of COVID-19",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -8.203125,
            "end_logit": 7.22265625,
            "text": "avir/Favipiravir in the treatment of COVID-19",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -3.103515625,
            "end_logit": -5.46875,
            "text": "of COVID-19.",
            "probability": 0.0
        }
    ],
    "621ebb733a8413c65300005c_9": [
        {
            "start_logit": 9.9453125,
            "end_logit": 7.40234375,
            "text": "influenza infections",
            "probability": 1.0
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -0.67333984375,
            "text": "influenza",
            "probability": 0.00031256675720214844
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -4.13671875,
            "text": "influenza infections, has been suggested to be effective against SARS-CoV-2, although this is not yet fully validated.",
            "probability": 9.834766387939453e-06
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -6.82421875,
            "text": "influenza infections, has been suggested to be effective against SARS-CoV",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -4.33203125,
            "end_logit": 7.40234375,
            "text": "infections",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -6.99609375,
            "text": "influenza infections, has been suggested to be effective against SARS-CoV-2",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -7.23828125,
            "text": "influenza infections, has been suggested to be effective against SARS",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -7.390625,
            "text": "influenza infections, has",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -7.421875,
            "text": "influenza infections,",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -7.4375,
            "text": "influenza infections, has been",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -7.546875,
            "text": "influenza infections, has been suggested to be effective against SARS-CoV-",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -7.578125,
            "text": "influenza infections, has been suggested to be effective against SARS-CoV-2,",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -7.58984375,
            "text": "influenza infections, has been suggested",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -7.62109375,
            "text": "influenza infections, has been suggested to",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -7.796875,
            "text": "influenza infections, has been suggested to be effective against SARS-CoV-2, although",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -7.828125,
            "text": "influenza infections, has been suggested to be effective against SARS-CoV-2, although this is not",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -7.84375,
            "text": "influenza infections, has been suggested to be effective against SARS-CoV-2, although this is not yet",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -5.30078125,
            "end_logit": 7.40234375,
            "text": "treatment of new and re-emerging influenza infections",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -7.84765625,
            "text": "influenza infections, has been suggested to be",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.8046875,
            "end_logit": 7.40234375,
            "text": "of new and re-emerging influenza infections",
            "probability": 5.960464477539063e-08
        }
    ],
    "621ebb733a8413c65300005c_10": [
        {
            "start_logit": 9.2578125,
            "end_logit": 8.9765625,
            "text": "COVID-19",
            "probability": 1.0
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -2.642578125,
            "text": "COV",
            "probability": 9.000301361083984e-06
        },
        {
            "start_logit": -2.853515625,
            "end_logit": 8.9765625,
            "text": "19",
            "probability": 5.4836273193359375e-06
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -3.966796875,
            "text": "COVID-19 patients",
            "probability": 2.384185791015625e-06
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -4.09375,
            "text": "COVID-19 patients treated with hydroxychloroquine, favipiravir, and hydroxychloroquine plus favipiravir.",
            "probability": 2.086162567138672e-06
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -5.80859375,
            "text": "COVID-",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -6.7265625,
            "text": "COVID",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -7.11328125,
            "text": "COVID-19 patients treated",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.28125,
            "end_logit": 8.9765625,
            "text": "ID-19",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -7.62890625,
            "text": "COVID-19 patients treated with",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -7.640625,
            "text": "COVID-19 patients treated with hydroxychloroquine",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -7.703125,
            "text": "COVID-19 patients treated with hydroxychloroquine,",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -7.81640625,
            "text": "COVID-19 patients treated with hydroxychlor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.55078125,
            "end_logit": 8.9765625,
            "text": "moderate COVID-19",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5859375,
            "end_logit": 8.9765625,
            "text": "ICU admission rates of mild/moderate COVID-19",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.828125,
            "end_logit": 8.9765625,
            "text": "Comparing ICU admission rates of mild/moderate COVID-19",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.046875,
            "end_logit": 8.9765625,
            "text": "mild/moderate COVID-19",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.171875,
            "end_logit": 8.9765625,
            "text": "-19",
            "probability": 0.0
        },
        {
            "start_logit": -2.853515625,
            "end_logit": -3.966796875,
            "text": "19 patients",
            "probability": 0.0
        },
        {
            "start_logit": -2.853515625,
            "end_logit": -4.09375,
            "text": "19 patients treated with hydroxychloroquine, favipiravir, and hydroxychloroquine plus favipiravir.",
            "probability": 0.0
        }
    ],
    "621ebb733a8413c65300005c_11": [
        {
            "start_logit": 9.71875,
            "end_logit": -1.521484375,
            "text": "influenza",
            "probability": 0.69775390625
        },
        {
            "start_logit": 9.71875,
            "end_logit": -2.599609375,
            "text": "influenza A/California/04/2009 (H1N1) virus infections",
            "probability": 0.2374267578125
        },
        {
            "start_logit": 9.71875,
            "end_logit": -4.58984375,
            "text": "influenza A",
            "probability": 0.032501220703125
        },
        {
            "start_logit": 9.71875,
            "end_logit": -6.30078125,
            "text": "influenza A/California/04/2009 (H1N1) virus",
            "probability": 0.005870819091796875
        },
        {
            "start_logit": 9.71875,
            "end_logit": -6.3203125,
            "text": "influenza A/California/04/2009 (H1N1) virus infections in mice.",
            "probability": 0.005756378173828125
        },
        {
            "start_logit": 9.71875,
            "end_logit": -6.5703125,
            "text": "influenza A/California/04/2009 (H1N1) virus infections in",
            "probability": 0.004482269287109375
        },
        {
            "start_logit": 9.71875,
            "end_logit": -7.03125,
            "text": "influenza A/California/04/2009 (H1N1",
            "probability": 0.0028285980224609375
        },
        {
            "start_logit": 9.71875,
            "end_logit": -7.4921875,
            "text": "influenza A/",
            "probability": 0.0017843246459960938
        },
        {
            "start_logit": 9.71875,
            "end_logit": -7.53125,
            "text": "influenza A/California/04/2009 (H1N1) virus infections in mice",
            "probability": 0.0017147064208984375
        },
        {
            "start_logit": 9.71875,
            "end_logit": -7.5625,
            "text": "influenza A/California/04/2009",
            "probability": 0.0016632080078125
        },
        {
            "start_logit": 9.71875,
            "end_logit": -7.59765625,
            "text": "influenza A/California/04/",
            "probability": 0.001605987548828125
        },
        {
            "start_logit": 9.71875,
            "end_logit": -7.625,
            "text": "influenza A/California/",
            "probability": 0.0015621185302734375
        },
        {
            "start_logit": 9.71875,
            "end_logit": -7.6640625,
            "text": "influenza A/California/04/2009 (H1N1)",
            "probability": 0.0015020370483398438
        },
        {
            "start_logit": 9.71875,
            "end_logit": -7.70703125,
            "text": "influenza A/California/04",
            "probability": 0.0014390945434570312
        },
        {
            "start_logit": 9.71875,
            "end_logit": -7.78125,
            "text": "influenza A/California",
            "probability": 0.0013360977172851562
        },
        {
            "start_logit": 9.71875,
            "end_logit": -7.9140625,
            "text": "influenza A/California/04/2009 (",
            "probability": 0.0011701583862304688
        },
        {
            "start_logit": -6.69140625,
            "end_logit": -1.521484375,
            "text": "treatment of pandemic influenza",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.1015625,
            "end_logit": -1.521484375,
            "text": "pandemic influenza",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.18359375,
            "end_logit": -1.521484375,
            "text": "of pandemic influenza",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.69140625,
            "end_logit": -2.599609375,
            "text": "treatment of pandemic influenza A/California/04/2009 (H1N1) virus infections",
            "probability": 0.0
        }
    ],
    "621ebb733a8413c65300005c_12": [
        {
            "start_logit": 9.109375,
            "end_logit": 8.71875,
            "text": "COVID-19",
            "probability": 1.0
        },
        {
            "start_logit": 9.109375,
            "end_logit": -2.908203125,
            "text": "COV",
            "probability": 8.940696716308594e-06
        },
        {
            "start_logit": -3.369140625,
            "end_logit": 8.71875,
            "text": "19",
            "probability": 3.814697265625e-06
        },
        {
            "start_logit": 9.109375,
            "end_logit": -5.76171875,
            "text": "COVID-19.",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -5.74609375,
            "end_logit": 8.71875,
            "text": "with COVID-19",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 9.109375,
            "end_logit": -6.59765625,
            "text": "COVID-",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.109375,
            "end_logit": -7.1875,
            "text": "COVID",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.234375,
            "end_logit": 8.71875,
            "text": "ID-19",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.30078125,
            "end_logit": 8.71875,
            "text": "treating patients with COVID-19",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.77734375,
            "end_logit": 8.71875,
            "text": "-19",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.7890625,
            "end_logit": 8.71875,
            "text": "patients with COVID-19",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.88671875,
            "end_logit": 8.71875,
            "text": "BACKGROUND: Favipiravir possesses high utility for treating patients with COVID-19",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.96484375,
            "end_logit": 8.71875,
            "text": "Favipiravir possesses high utility for treating patients with COVID-19",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0703125,
            "end_logit": 8.71875,
            "text": "for treating patients with COVID-19",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.109375,
            "end_logit": 8.71875,
            "text": "high utility for treating patients with COVID-19",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.171875,
            "end_logit": 8.71875,
            "text": "ipiravir possesses high utility for treating patients with COVID-19",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1875,
            "end_logit": 8.71875,
            "text": "vir possesses high utility for treating patients with COVID-19",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1875,
            "end_logit": 8.71875,
            "text": ": Favipiravir possesses high utility for treating patients with COVID-19",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1953125,
            "end_logit": 8.71875,
            "text": "utility for treating patients with COVID-19",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.203125,
            "end_logit": 8.71875,
            "text": "iravir possesses high utility for treating patients with COVID-19",
            "probability": 5.960464477539063e-08
        }
    ],
    "621ebb733a8413c65300005c_13": [
        {
            "start_logit": 9.7734375,
            "end_logit": 1.576171875,
            "text": "influenza viruses",
            "probability": 0.94482421875
        },
        {
            "start_logit": 9.7734375,
            "end_logit": -1.3359375,
            "text": "influenza",
            "probability": 0.05126953125
        },
        {
            "start_logit": 9.7734375,
            "end_logit": -4.34375,
            "text": "influenza viruses, including A(H1N1)pdm09, A(H5N1) and the recently emerged A(H7N9) avian virus.",
            "probability": 0.0025310516357421875
        },
        {
            "start_logit": 9.7734375,
            "end_logit": -7.31640625,
            "text": "influenza viruses, including A(H1N1)pdm09, A(H5N1",
            "probability": 0.00013005733489990234
        },
        {
            "start_logit": 9.7734375,
            "end_logit": -7.48046875,
            "text": "influenza viruses,",
            "probability": 0.00010949373245239258
        },
        {
            "start_logit": 9.7734375,
            "end_logit": -7.625,
            "text": "influenza viruses, including A(H1N1",
            "probability": 9.512901306152344e-05
        },
        {
            "start_logit": 9.7734375,
            "end_logit": -7.65625,
            "text": "influenza viruses, including",
            "probability": 9.22083854675293e-05
        },
        {
            "start_logit": 9.7734375,
            "end_logit": -7.74609375,
            "text": "influenza viruses, including A",
            "probability": 8.392333984375e-05
        },
        {
            "start_logit": 9.7734375,
            "end_logit": -7.7734375,
            "text": "influenza viruses, including A(H1N1)pdm09, A(H5N1) and",
            "probability": 8.20159912109375e-05
        },
        {
            "start_logit": 9.7734375,
            "end_logit": -7.8125,
            "text": "influenza viruses, including A(H1N1)pdm09, A(H5N1) and the",
            "probability": 7.88569450378418e-05
        },
        {
            "start_logit": 9.7734375,
            "end_logit": -7.81640625,
            "text": "influenza viruses, including A(H1N1)pdm09, A(H5N1) and the recently emerged A(H7N9) avian virus",
            "probability": 7.88569450378418e-05
        },
        {
            "start_logit": 9.7734375,
            "end_logit": -7.84765625,
            "text": "influenza viruses, including A(H1N1)pdm09, A",
            "probability": 7.647275924682617e-05
        },
        {
            "start_logit": 9.7734375,
            "end_logit": -7.8515625,
            "text": "influenza viruses, including A(H1N1)pdm09, A(H5N1) and the recently emerged A(H7",
            "probability": 7.581710815429688e-05
        },
        {
            "start_logit": 9.7734375,
            "end_logit": -7.85546875,
            "text": "influenza viruses, including A(H1N1)pdm09, A(H5N1) and the recently",
            "probability": 7.528066635131836e-05
        },
        {
            "start_logit": 9.7734375,
            "end_logit": -7.87890625,
            "text": "influenza viruses, including A(H1N1)pdm09",
            "probability": 7.408857345581055e-05
        },
        {
            "start_logit": 9.7734375,
            "end_logit": -7.88671875,
            "text": "influenza viruses, including A(H1N1)pdm09, A(H5N1) and the recently emerged A(H7N9",
            "probability": 7.295608520507812e-05
        },
        {
            "start_logit": 9.7734375,
            "end_logit": -7.890625,
            "text": "influenza viruses, including A(H1N1)pdm09, A(H5N1) and the recently emerged",
            "probability": 7.295608520507812e-05
        },
        {
            "start_logit": 9.7734375,
            "end_logit": -7.890625,
            "text": "influenza viruses, including A(H1N1)pdm09, A(H5N1) and the recently emerged A",
            "probability": 7.295608520507812e-05
        },
        {
            "start_logit": -6.75390625,
            "end_logit": 1.576171875,
            "text": "of influenza viruses",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.2890625,
            "end_logit": 1.576171875,
            "text": "against a broad range of influenza viruses",
            "probability": 5.960464477539063e-08
        }
    ],
    "621ebb733a8413c65300005c_14": [
        {
            "start_logit": 9.609375,
            "end_logit": 9.296875,
            "text": "influenza virus infections",
            "probability": 1.0
        },
        {
            "start_logit": 9.609375,
            "end_logit": -1.8994140625,
            "text": "influenza",
            "probability": 1.3709068298339844e-05
        },
        {
            "start_logit": -2.248046875,
            "end_logit": 9.296875,
            "text": "infections",
            "probability": 7.092952728271484e-06
        },
        {
            "start_logit": 9.609375,
            "end_logit": -5.5703125,
            "text": "influenza virus infections and has shown promise against other highly pathogenic RNA viruses including CCHFV with demonstrated efficacy in the type I interferon deficient mouse model.",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -6.3515625,
            "end_logit": 9.296875,
            "text": "treatment of influenza virus infections",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.609375,
            "end_logit": -6.6875,
            "text": "influenza virus infections and has shown promise against other highly pathogenic RNA viruses including CCHFV with demonstrated efficacy in the type I interferon",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.609375,
            "end_logit": -6.8671875,
            "text": "influenza virus infections and",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.609375,
            "end_logit": -6.87109375,
            "text": "influenza virus",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.609375,
            "end_logit": -7.01171875,
            "text": "influenza virus infections and has shown promise against other highly pathogenic RNA viruses including CCHFV",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.875,
            "end_logit": 9.296875,
            "text": "of influenza virus infections",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.609375,
            "end_logit": -7.44140625,
            "text": "influenza virus infections and has shown promise against other highly pathogenic RNA viruses including CCHFV with",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.609375,
            "end_logit": -7.5703125,
            "text": "influenza virus infections and has shown promise against other highly pathogenic RNA viruses including CCH",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.609375,
            "end_logit": -7.59375,
            "text": "influenza virus infections and has shown",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.609375,
            "end_logit": -7.59765625,
            "text": "influenza virus infections and has shown promise against other highly pathogenic RNA viruses including CCHFV with demonstrated efficacy in the type I interferon deficient",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.609375,
            "end_logit": -7.625,
            "text": "influenza virus infections and has shown promise against other highly pathogenic RNA viruses including",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.609375,
            "end_logit": -7.62890625,
            "text": "influenza virus infections and has",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.609375,
            "end_logit": -7.7578125,
            "text": "influenza virus infections and has shown promise against other",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.453125,
            "end_logit": 9.296875,
            "text": "virus infections",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.609375,
            "end_logit": -7.7734375,
            "text": "influenza virus infections and has shown promise against other highly pathogenic RNA viruses including CCHFV with demonstrated efficacy in",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.609375,
            "end_logit": -7.82421875,
            "text": "influenza virus infections and has shown promise against other highly pathogenic RNA viruses including CCHFV with demonstrated",
            "probability": 5.960464477539063e-08
        }
    ],
    "621ebb733a8413c65300005c_15": [
        {
            "start_logit": 8.21875,
            "end_logit": 1.791015625,
            "text": "antiviral drug, is being used for COVID-19",
            "probability": 0.623046875
        },
        {
            "start_logit": 8.21875,
            "end_logit": 1.029296875,
            "text": "antiviral",
            "probability": 0.2919921875
        },
        {
            "start_logit": 6.2109375,
            "end_logit": 1.791015625,
            "text": "COVID-19",
            "probability": 0.0836181640625
        },
        {
            "start_logit": 8.21875,
            "end_logit": -5.37890625,
            "text": "antiviral drug, is being used for COVID-19 treatment, and we currently have limited information regarding its efficacy and safety.",
            "probability": 0.0004801750183105469
        },
        {
            "start_logit": 8.21875,
            "end_logit": -5.62109375,
            "text": "antiviral drug, is being used for COV",
            "probability": 0.0003769397735595703
        },
        {
            "start_logit": 8.21875,
            "end_logit": -6.17578125,
            "text": "antiviral drug, is being used for COVID-",
            "probability": 0.00021636486053466797
        },
        {
            "start_logit": 8.21875,
            "end_logit": -6.89453125,
            "text": "antiviral drug, is being used for COVID",
            "probability": 0.00010508298873901367
        },
        {
            "start_logit": 6.2109375,
            "end_logit": -5.37890625,
            "text": "COVID-19 treatment, and we currently have limited information regarding its efficacy and safety.",
            "probability": 6.473064422607422e-05
        },
        {
            "start_logit": 8.21875,
            "end_logit": -7.49609375,
            "text": "antiviral drug, is being used for COVID-19 treatment",
            "probability": 5.805492401123047e-05
        },
        {
            "start_logit": 6.2109375,
            "end_logit": -5.62109375,
            "text": "COV",
            "probability": 5.042552947998047e-05
        },
        {
            "start_logit": 8.21875,
            "end_logit": -7.67578125,
            "text": "antiviral drug, is being used for COVID-19 treatment,",
            "probability": 4.8100948333740234e-05
        },
        {
            "start_logit": 8.21875,
            "end_logit": -7.87109375,
            "text": "antiviral drug, is being used for COVID-19 treatment, and",
            "probability": 3.987550735473633e-05
        },
        {
            "start_logit": 8.21875,
            "end_logit": -7.8828125,
            "text": "antiviral drug, is",
            "probability": 3.921985626220703e-05
        },
        {
            "start_logit": 8.21875,
            "end_logit": -7.91015625,
            "text": "antiviral drug, is being used for COVID-19 treatment, and we currently have limited information regarding",
            "probability": 3.802776336669922e-05
        },
        {
            "start_logit": 8.21875,
            "end_logit": -7.91796875,
            "text": "antiviral drug, is being",
            "probability": 3.802776336669922e-05
        },
        {
            "start_logit": 6.2109375,
            "end_logit": -6.17578125,
            "text": "COVID-",
            "probability": 2.9206275939941406e-05
        },
        {
            "start_logit": 6.2109375,
            "end_logit": -6.89453125,
            "text": "COVID",
            "probability": 1.424551010131836e-05
        },
        {
            "start_logit": 6.2109375,
            "end_logit": -7.49609375,
            "text": "COVID-19 treatment",
            "probability": 7.748603820800781e-06
        },
        {
            "start_logit": 6.2109375,
            "end_logit": -7.67578125,
            "text": "COVID-19 treatment,",
            "probability": 6.496906280517578e-06
        },
        {
            "start_logit": 6.2109375,
            "end_logit": -7.87109375,
            "text": "COVID-19 treatment, and",
            "probability": 5.304813385009766e-06
        }
    ],
    "621ebb733a8413c65300005c_16": [
        {
            "start_logit": 8.859375,
            "end_logit": 7.4375,
            "text": "influenza",
            "probability": 1.0
        },
        {
            "start_logit": 8.859375,
            "end_logit": -6.9140625,
            "text": "influenza in Japan in 2014 and has shown potent in vitro activity against severe acute respiratory syndrome coronavirus-2.",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 8.859375,
            "end_logit": -7.40234375,
            "text": "influenza in Japan in 2014 and has shown potent in vitro activity against severe acute respiratory syndrome coronavirus",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.859375,
            "end_logit": -7.62109375,
            "text": "influenza in Japan in 2014 and has shown potent in vitro activity against severe acute respiratory syndrome coronavirus-2",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.859375,
            "end_logit": -7.72265625,
            "text": "influenza in",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.859375,
            "end_logit": -7.7265625,
            "text": "influenza in Japan",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.859375,
            "end_logit": -7.7890625,
            "text": "influenza in Japan in 2014 and has shown potent in vitro activity against severe acute respiratory",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.859375,
            "end_logit": -7.8125,
            "text": "influenza in Japan in 2014 and has shown potent in vitro activity against severe acute respiratory syndrome coronavirus-",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.859375,
            "end_logit": -7.828125,
            "text": "influenza in Japan in 2014 and",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.859375,
            "end_logit": -7.890625,
            "text": "influenza in Japan in 2014 and has shown",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.859375,
            "end_logit": -7.9296875,
            "text": "influenza in Japan in 2014 and has",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.859375,
            "end_logit": -7.9609375,
            "text": "influenza in Japan in 2014",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.859375,
            "end_logit": -7.9765625,
            "text": "influenza in Japan in 2014 and has shown potent in vitro activity against severe acute respiratory syndrome",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.859375,
            "end_logit": -7.9921875,
            "text": "influenza in Japan in",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.734375,
            "end_logit": 7.4375,
            "text": "drug that was approved for new and reemerging pandemic influenza",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.82421875,
            "end_logit": 7.4375,
            "text": "pandemic influenza",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.84375,
            "end_logit": 7.4375,
            "text": "Favipiravir is one such oral drug that was approved for new and reemerging pandemic influenza",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.84375,
            "end_logit": 7.4375,
            "text": "approved for new and reemerging pandemic influenza",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.90234375,
            "end_logit": 7.4375,
            "text": "was approved for new and reemerging pandemic influenza",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.95703125,
            "end_logit": 7.4375,
            "text": "oral drug that was approved for new and reemerging pandemic influenza",
            "probability": 5.960464477539063e-08
        }
    ],
    "621ebb733a8413c65300005c_17": [
        {
            "start_logit": 5.11328125,
            "end_logit": 2.7421875,
            "text": "influenza",
            "probability": 0.68115234375
        },
        {
            "start_logit": 5.11328125,
            "end_logit": 1.8564453125,
            "text": "influenza and Ebola, which has shown some promise in early trials for treatment of COVID-19.",
            "probability": 0.28076171875
        },
        {
            "start_logit": 2.951171875,
            "end_logit": 1.8564453125,
            "text": "COVID-19.",
            "probability": 0.032379150390625
        },
        {
            "start_logit": 5.11328125,
            "end_logit": -2.931640625,
            "text": "influenza and Ebola, which has shown some promise in early trials for treatment of COVID-19",
            "probability": 0.0023441314697265625
        },
        {
            "start_logit": -1.2666015625,
            "end_logit": 2.7421875,
            "text": "antiviral previously indicated for influenza",
            "probability": 0.001155853271484375
        },
        {
            "start_logit": -1.2666015625,
            "end_logit": 1.8564453125,
            "text": "antiviral previously indicated for influenza and Ebola, which has shown some promise in early trials for treatment of COVID-19.",
            "probability": 0.0004763603210449219
        },
        {
            "start_logit": -2.32421875,
            "end_logit": 2.7421875,
            "text": "Favipiravir is an antiviral previously indicated for influenza",
            "probability": 0.0004012584686279297
        },
        {
            "start_logit": 2.951171875,
            "end_logit": -2.931640625,
            "text": "COVID-19",
            "probability": 0.0002694129943847656
        },
        {
            "start_logit": -1.8857421875,
            "end_logit": 1.8564453125,
            "text": ".",
            "probability": 0.0002570152282714844
        },
        {
            "start_logit": -2.32421875,
            "end_logit": 1.8564453125,
            "text": "Favipiravir is an antiviral previously indicated for influenza and Ebola, which has shown some promise in early trials for treatment of COVID-19.",
            "probability": 0.0001659393310546875
        },
        {
            "start_logit": 5.11328125,
            "end_logit": -5.59765625,
            "text": "influenza and Ebola,",
            "probability": 0.00016200542449951172
        },
        {
            "start_logit": 5.11328125,
            "end_logit": -6.546875,
            "text": "influenza and Ebola, which",
            "probability": 6.300210952758789e-05
        },
        {
            "start_logit": 5.11328125,
            "end_logit": -6.65625,
            "text": "influenza and",
            "probability": 5.644559860229492e-05
        },
        {
            "start_logit": 5.11328125,
            "end_logit": -6.98046875,
            "text": "influenza and Ebola",
            "probability": 4.094839096069336e-05
        },
        {
            "start_logit": 5.11328125,
            "end_logit": -7.1796875,
            "text": "influenza and Ebola, which has shown some promise in early trials for treatment of COV",
            "probability": 3.343820571899414e-05
        },
        {
            "start_logit": 5.11328125,
            "end_logit": -7.2734375,
            "text": "influenza and Ebola, which has shown some promise in early trials for treatment of COVID",
            "probability": 3.045797348022461e-05
        },
        {
            "start_logit": 5.11328125,
            "end_logit": -7.3046875,
            "text": "influenza and Ebola, which has shown some promise in early trials for treatment of COVID-",
            "probability": 2.950429916381836e-05
        },
        {
            "start_logit": 5.11328125,
            "end_logit": -7.31640625,
            "text": "influenza and Ebola, which has",
            "probability": 2.9087066650390625e-05
        },
        {
            "start_logit": 5.11328125,
            "end_logit": -7.48828125,
            "text": "influenza and Ebola, which has shown some",
            "probability": 2.4497509002685547e-05
        },
        {
            "start_logit": 5.11328125,
            "end_logit": -7.4921875,
            "text": "influenza and Ebola, which has shown",
            "probability": 2.4497509002685547e-05
        }
    ],
    "621ebb733a8413c65300005c_18": [
        {
            "start_logit": 9.7421875,
            "end_logit": 9.59375,
            "text": "Ebola virus infection",
            "probability": 1.0
        },
        {
            "start_logit": 9.7421875,
            "end_logit": -1.62109375,
            "text": "Ebola",
            "probability": 1.341104507446289e-05
        },
        {
            "start_logit": -1.76171875,
            "end_logit": 9.59375,
            "text": "infection",
            "probability": 9.953975677490234e-06
        },
        {
            "start_logit": 9.7421875,
            "end_logit": -6.046875,
            "text": "Ebola virus infection.",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.46484375,
            "end_logit": 9.59375,
            "text": "treating Ebola virus infection",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.7578125,
            "end_logit": 9.59375,
            "text": "virus infection",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.23828125,
            "end_logit": 9.59375,
            "text": "influenza, now has been demonstrated to have a curative effect in treating Ebola virus infection",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.7421875,
            "end_logit": -7.55859375,
            "text": "Ebola virus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.47265625,
            "end_logit": 9.59375,
            "text": "now has been demonstrated to have a curative effect in treating Ebola virus infection",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.69140625,
            "end_logit": 9.59375,
            "text": "treatment of influenza, now has been demonstrated to have a curative effect in treating Ebola virus infection",
            "probability": 0.0
        },
        {
            "start_logit": -7.72265625,
            "end_logit": 9.59375,
            "text": "in treating Ebola virus infection",
            "probability": 0.0
        },
        {
            "start_logit": -7.796875,
            "end_logit": 9.59375,
            "text": "antiviral drug which was mainly used for the treatment of influenza, now has been demonstrated to have a curative effect in treating Ebola virus infection",
            "probability": 0.0
        },
        {
            "start_logit": -7.8046875,
            "end_logit": 9.59375,
            "text": "been demonstrated to have a curative effect in treating Ebola virus infection",
            "probability": 0.0
        },
        {
            "start_logit": -7.8125,
            "end_logit": 9.59375,
            "text": "novel antiviral drug which was mainly used for the treatment of influenza, now has been demonstrated to have a curative effect in treating Ebola virus infection",
            "probability": 0.0
        },
        {
            "start_logit": -7.875,
            "end_logit": 9.59375,
            "text": "of influenza, now has been demonstrated to have a curative effect in treating Ebola virus infection",
            "probability": 0.0
        },
        {
            "start_logit": -7.890625,
            "end_logit": 9.59375,
            "text": "drug which was mainly used for the treatment of influenza, now has been demonstrated to have a curative effect in treating Ebola virus infection",
            "probability": 0.0
        },
        {
            "start_logit": -7.91015625,
            "end_logit": 9.59375,
            "text": "demonstrated to have a curative effect in treating Ebola virus infection",
            "probability": 0.0
        },
        {
            "start_logit": -7.94921875,
            "end_logit": 9.59375,
            "text": "used for the treatment of influenza, now has been demonstrated to have a curative effect in treating Ebola virus infection",
            "probability": 0.0
        },
        {
            "start_logit": -7.94921875,
            "end_logit": 9.59375,
            "text": "the treatment of influenza, now has been demonstrated to have a curative effect in treating Ebola virus infection",
            "probability": 0.0
        },
        {
            "start_logit": -1.76171875,
            "end_logit": -6.046875,
            "text": "infection.",
            "probability": 0.0
        }
    ],
    "621ebb733a8413c65300005c_19": [
        {
            "start_logit": 9.5,
            "end_logit": 9.2734375,
            "text": "influenza virus",
            "probability": 1.0
        },
        {
            "start_logit": 9.5,
            "end_logit": -2.17578125,
            "text": "influenza",
            "probability": 1.0609626770019531e-05
        },
        {
            "start_logit": -2.3359375,
            "end_logit": 9.2734375,
            "text": "virus",
            "probability": 7.212162017822266e-06
        },
        {
            "start_logit": -4.1328125,
            "end_logit": 9.2734375,
            "text": "infections with the influenza virus",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": 9.5,
            "end_logit": -4.38671875,
            "text": "influenza virus] inhibits in vitro murine norovirus",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": -6.76171875,
            "end_logit": 9.2734375,
            "text": "treatment of infections with the influenza virus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.5,
            "end_logit": -7.32421875,
            "text": "influenza virus] inhibits in vitro murine norovirus replication",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.28515625,
            "end_logit": 9.2734375,
            "text": "of infections with the influenza virus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.5,
            "end_logit": -7.56640625,
            "text": "influenza virus]",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.54296875,
            "end_logit": 9.2734375,
            "text": "the treatment of infections with the influenza virus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.56640625,
            "end_logit": 9.2734375,
            "text": "drug in advanced clinical development for the treatment of infections with the influenza virus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.63671875,
            "end_logit": 9.2734375,
            "text": "demonstrate that Favipiravir [T-705, a drug in advanced clinical development for the treatment of infections with the influenza virus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.640625,
            "end_logit": 9.2734375,
            "text": "that Favipiravir [T-705, a drug in advanced clinical development for the treatment of infections with the influenza virus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6953125,
            "end_logit": 9.2734375,
            "text": "clinical development for the treatment of infections with the influenza virus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.74609375,
            "end_logit": 9.2734375,
            "text": "development for the treatment of infections with the influenza virus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.75,
            "end_logit": 9.2734375,
            "text": "advanced clinical development for the treatment of infections with the influenza virus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.7734375,
            "end_logit": 9.2734375,
            "text": "for the treatment of infections with the influenza virus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.81640625,
            "end_logit": 9.2734375,
            "text": "Favipiravir [T-705, a drug in advanced clinical development for the treatment of infections with the influenza virus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -4.1328125,
            "end_logit": -2.17578125,
            "text": "infections with the influenza",
            "probability": 0.0
        },
        {
            "start_logit": -2.3359375,
            "end_logit": -4.38671875,
            "text": "virus] inhibits in vitro murine norovirus",
            "probability": 0.0
        }
    ],
    "621ebb733a8413c65300005c_20": [
        {
            "start_logit": 8.5625,
            "end_logit": 9.203125,
            "text": "COVID-19",
            "probability": 1.0
        },
        {
            "start_logit": -2.54296875,
            "end_logit": 9.203125,
            "text": "19",
            "probability": 1.4960765838623047e-05
        },
        {
            "start_logit": 8.5625,
            "end_logit": -3.52734375,
            "text": "COV",
            "probability": 2.9206275939941406e-06
        },
        {
            "start_logit": -6.47265625,
            "end_logit": 9.203125,
            "text": "with COVID-19",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.1875,
            "end_logit": 9.203125,
            "text": "ID-19",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.5625,
            "end_logit": -6.74609375,
            "text": "COVID-",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.55078125,
            "end_logit": 9.203125,
            "text": "for patients with COVID-19",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.57421875,
            "end_logit": 9.203125,
            "text": "patients with COVID-19",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.6328125,
            "end_logit": 9.203125,
            "text": "-19",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.8828125,
            "end_logit": 9.203125,
            "text": "treatment option for patients with COVID-19",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.88671875,
            "end_logit": 9.203125,
            "text": "Lopinavir/Ritonavir plus Favipiravir might be a treatment option for patients with COVID-19",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.5625,
            "end_logit": -7.2734375,
            "text": "COVID",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.9296875,
            "end_logit": 9.203125,
            "text": "combination therapy of Lopinavir/Ritonavir plus Favipiravir might be a treatment option for patients with COVID-19",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.953125,
            "end_logit": 9.203125,
            "text": "The combination therapy of Lopinavir/Ritonavir plus Favipiravir might be a treatment option for patients with COVID-19",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0078125,
            "end_logit": 9.203125,
            "text": "pinavir/Ritonavir plus Favipiravir might be a treatment option for patients with COVID-19",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0390625,
            "end_logit": 9.203125,
            "text": "therapy of Lopinavir/Ritonavir plus Favipiravir might be a treatment option for patients with COVID-19",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0859375,
            "end_logit": 9.203125,
            "text": "option for patients with COVID-19",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1015625,
            "end_logit": 9.203125,
            "text": "of Lopinavir/Ritonavir plus Favipiravir might be a treatment option for patients with COVID-19",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1328125,
            "end_logit": 9.203125,
            "text": "plus Favipiravir might be a treatment option for patients with COVID-19",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.140625,
            "end_logit": 9.203125,
            "text": "Favipiravir might be a treatment option for patients with COVID-19",
            "probability": 5.960464477539063e-08
        }
    ],
    "621ebb733a8413c65300005c_21": [
        {
            "start_logit": 9.5390625,
            "end_logit": 9.3515625,
            "text": "COVID-19",
            "probability": 1.0
        },
        {
            "start_logit": 9.5390625,
            "end_logit": -2.169921875,
            "text": "COV",
            "probability": 9.894371032714844e-06
        },
        {
            "start_logit": -2.216796875,
            "end_logit": 9.3515625,
            "text": "19",
            "probability": 7.808208465576172e-06
        },
        {
            "start_logit": 9.5390625,
            "end_logit": -5.24609375,
            "text": "COVID-19.",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 9.5390625,
            "end_logit": -6.56640625,
            "text": "COVID-19. Recent",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.5390625,
            "end_logit": -6.61328125,
            "text": "COVID-",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.5390625,
            "end_logit": -7.2109375,
            "text": "COVID",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.03515625,
            "end_logit": 9.3515625,
            "text": "vir, Favipiravir and Ribavirin might be a safer therapeutic option for COVID-19",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.0703125,
            "end_logit": 9.3515625,
            "text": "ID-19",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.109375,
            "end_logit": 9.3515625,
            "text": "for COVID-19",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.69921875,
            "end_logit": 9.3515625,
            "text": "-19",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.8984375,
            "end_logit": 9.3515625,
            "text": "safer therapeutic option for COVID-19",
            "probability": 0.0
        },
        {
            "start_logit": -7.8984375,
            "end_logit": 9.3515625,
            "text": "therapeutic option for COVID-19",
            "probability": 0.0
        },
        {
            "start_logit": -8.0546875,
            "end_logit": 9.3515625,
            "text": ", Favipiravir and Ribavirin might be a safer therapeutic option for COVID-19",
            "probability": 0.0
        },
        {
            "start_logit": -8.0703125,
            "end_logit": 9.3515625,
            "text": "Favipiravir and Ribavirin might be a safer therapeutic option for COVID-19",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": 9.3515625,
            "text": "and Ribavirin might be a safer therapeutic option for COVID-19",
            "probability": 0.0
        },
        {
            "start_logit": -8.1796875,
            "end_logit": 9.3515625,
            "text": "Ribavirin might be a safer therapeutic option for COVID-19",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 9.3515625,
            "text": "option for COVID-19",
            "probability": 0.0
        },
        {
            "start_logit": -8.2421875,
            "end_logit": 9.3515625,
            "text": "ipiravir and Ribavirin might be a safer therapeutic option for COVID-19",
            "probability": 0.0
        },
        {
            "start_logit": -2.216796875,
            "end_logit": -5.24609375,
            "text": "19.",
            "probability": 0.0
        }
    ],
    "621ebb733a8413c65300005c_22": [
        {
            "start_logit": 9.0859375,
            "end_logit": 9.109375,
            "text": "Covid-19",
            "probability": 1.0
        },
        {
            "start_logit": -2.6953125,
            "end_logit": 9.109375,
            "text": "19",
            "probability": 7.68899917602539e-06
        },
        {
            "start_logit": 9.0859375,
            "end_logit": -2.955078125,
            "text": "Cov",
            "probability": 5.841255187988281e-06
        },
        {
            "start_logit": -6.3125,
            "end_logit": 9.109375,
            "text": "of Covid-19",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.0859375,
            "end_logit": -6.50390625,
            "text": "Covid-",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.0859375,
            "end_logit": -6.6640625,
            "text": "Covid-19: A Retrospective Study.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.140625,
            "end_logit": 9.109375,
            "text": "id-19",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0859375,
            "end_logit": -7.26953125,
            "text": "Covid",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.48046875,
            "end_logit": 9.109375,
            "text": "Management of Covid-19",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.87890625,
            "end_logit": 9.109375,
            "text": "-19",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0859375,
            "end_logit": -7.8671875,
            "text": "Covid-19:",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.9453125,
            "end_logit": 9.109375,
            "text": "Hydroxychloroquine for Management of Covid-19",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.98046875,
            "end_logit": 9.109375,
            "text": "Effectiveness and Safety of Favipiravir Compared to Hydroxychloroquine for Management of Covid-19",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.03125,
            "end_logit": 9.109375,
            "text": "Favipiravir Compared to Hydroxychloroquine for Management of Covid-19",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.03125,
            "end_logit": 9.109375,
            "text": "for Management of Covid-19",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0859375,
            "end_logit": 9.109375,
            "text": "Safety of Favipiravir Compared to Hydroxychloroquine for Management of Covid-19",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1484375,
            "end_logit": 9.109375,
            "text": "vir Compared to Hydroxychloroquine for Management of Covid-19",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.15625,
            "end_logit": 9.109375,
            "text": "of Favipiravir Compared to Hydroxychloroquine for Management of Covid-19",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.3125,
            "end_logit": -2.955078125,
            "text": "of Cov",
            "probability": 0.0
        },
        {
            "start_logit": -2.6953125,
            "end_logit": -6.6640625,
            "text": "19: A Retrospective Study.",
            "probability": 0.0
        }
    ],
    "621ebb733a8413c65300005c_23": [
        {
            "start_logit": 10.1875,
            "end_logit": 4.0,
            "text": "influenza",
            "probability": 0.69091796875
        },
        {
            "start_logit": 10.1875,
            "end_logit": 3.193359375,
            "text": "influenza infec",
            "probability": 0.30908203125
        },
        {
            "start_logit": 10.1875,
            "end_logit": -7.6171875,
            "text": "influenza inf",
            "probability": 6.198883056640625e-06
        },
        {
            "start_logit": -6.44921875,
            "end_logit": 4.0,
            "text": "of influenza",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.95703125,
            "end_logit": 4.0,
            "text": "treatment of influenza",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.44921875,
            "end_logit": 3.193359375,
            "text": "of influenza infec",
            "probability": 0.0
        },
        {
            "start_logit": -7.7578125,
            "end_logit": 4.0,
            "text": "the treatment of influenza",
            "probability": 0.0
        },
        {
            "start_logit": -6.95703125,
            "end_logit": 3.193359375,
            "text": "treatment of influenza infec",
            "probability": 0.0
        },
        {
            "start_logit": -7.8046875,
            "end_logit": 4.0,
            "text": "AIM: Favipiravir and oseltamivir are antiviral compounds used for the treatment of influenza",
            "probability": 0.0
        },
        {
            "start_logit": -7.890625,
            "end_logit": 4.0,
            "text": "Favipiravir and oseltamivir are antiviral compounds used for the treatment of influenza",
            "probability": 0.0
        },
        {
            "start_logit": -7.953125,
            "end_logit": 4.0,
            "text": "antiviral compounds used for the treatment of influenza",
            "probability": 0.0
        },
        {
            "start_logit": -7.98828125,
            "end_logit": 4.0,
            "text": "are antiviral compounds used for the treatment of influenza",
            "probability": 0.0
        },
        {
            "start_logit": -7.98828125,
            "end_logit": 4.0,
            "text": "vir are antiviral compounds used for the treatment of influenza",
            "probability": 0.0
        },
        {
            "start_logit": -8.0078125,
            "end_logit": 4.0,
            "text": "compounds used for the treatment of influenza",
            "probability": 0.0
        },
        {
            "start_logit": -8.0078125,
            "end_logit": 4.0,
            "text": "ipiravir and oseltamivir are antiviral compounds used for the treatment of influenza",
            "probability": 0.0
        },
        {
            "start_logit": -8.015625,
            "end_logit": 4.0,
            "text": "vir and oseltamivir are antiviral compounds used for the treatment of influenza",
            "probability": 0.0
        },
        {
            "start_logit": -8.015625,
            "end_logit": 4.0,
            "text": "used for the treatment of influenza",
            "probability": 0.0
        },
        {
            "start_logit": -7.21875,
            "end_logit": 3.193359375,
            "text": "ec",
            "probability": 0.0
        },
        {
            "start_logit": -8.0234375,
            "end_logit": 4.0,
            "text": ": Favipiravir and oseltamivir are antiviral compounds used for the treatment of influenza",
            "probability": 0.0
        },
        {
            "start_logit": -8.03125,
            "end_logit": 4.0,
            "text": "iravir and oseltamivir are antiviral compounds used for the treatment of influenza",
            "probability": 0.0
        }
    ],
    "621ebb733a8413c65300005c_24": [
        {
            "start_logit": 9.6640625,
            "end_logit": 9.5,
            "text": "coronavirus disease",
            "probability": 1.0
        },
        {
            "start_logit": 9.6640625,
            "end_logit": -1.91796875,
            "text": "coronavirus",
            "probability": 1.1146068572998047e-05
        },
        {
            "start_logit": -1.95703125,
            "end_logit": 9.5,
            "text": "disease",
            "probability": 9.059906005859375e-06
        },
        {
            "start_logit": 9.6640625,
            "end_logit": -6.1015625,
            "text": "coronavirus disease 2019",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.48828125,
            "end_logit": 9.5,
            "text": "managing coronavirus disease",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.6640625,
            "end_logit": -7.99609375,
            "text": "coronavirus disease 2019 (COVID-19)",
            "probability": 0.0
        },
        {
            "start_logit": -8.0078125,
            "end_logit": 9.5,
            "text": "Favipiravir is a promising treatment candidate for managing coronavirus disease",
            "probability": 0.0
        },
        {
            "start_logit": -8.03125,
            "end_logit": 9.5,
            "text": "treatment candidate for managing coronavirus disease",
            "probability": 0.0
        },
        {
            "start_logit": -8.0546875,
            "end_logit": 9.5,
            "text": "promising treatment candidate for managing coronavirus disease",
            "probability": 0.0
        },
        {
            "start_logit": -8.078125,
            "end_logit": 9.5,
            "text": "WHAT IS KNOWN AND OBJECTIVE: Favipiravir is a promising treatment candidate for managing coronavirus disease",
            "probability": 0.0
        },
        {
            "start_logit": -8.09375,
            "end_logit": 9.5,
            "text": "IS KNOWN AND OBJECTIVE: Favipiravir is a promising treatment candidate for managing coronavirus disease",
            "probability": 0.0
        },
        {
            "start_logit": -8.109375,
            "end_logit": 9.5,
            "text": "vir is a promising treatment candidate for managing coronavirus disease",
            "probability": 0.0
        },
        {
            "start_logit": -8.109375,
            "end_logit": 9.5,
            "text": "ipiravir is a promising treatment candidate for managing coronavirus disease",
            "probability": 0.0
        },
        {
            "start_logit": -8.1328125,
            "end_logit": 9.5,
            "text": "iravir is a promising treatment candidate for managing coronavirus disease",
            "probability": 0.0
        },
        {
            "start_logit": -8.1484375,
            "end_logit": 9.5,
            "text": ": Favipiravir is a promising treatment candidate for managing coronavirus disease",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": 9.5,
            "text": "KNOWN AND OBJECTIVE: Favipiravir is a promising treatment candidate for managing coronavirus disease",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": 9.5,
            "text": "for managing coronavirus disease",
            "probability": 0.0
        },
        {
            "start_logit": -1.95703125,
            "end_logit": -6.1015625,
            "text": "disease 2019",
            "probability": 0.0
        },
        {
            "start_logit": -7.48828125,
            "end_logit": -1.91796875,
            "text": "managing coronavirus",
            "probability": 0.0
        },
        {
            "start_logit": -8.0078125,
            "end_logit": -1.91796875,
            "text": "Favipiravir is a promising treatment candidate for managing coronavirus",
            "probability": 0.0
        }
    ],
    "621ebb733a8413c65300005c_25": [
        {
            "start_logit": 8.40625,
            "end_logit": 7.9296875,
            "text": "influenza",
            "probability": 1.0
        },
        {
            "start_logit": 8.40625,
            "end_logit": -6.30078125,
            "text": "influenza, the next pandemic influenza strain, and other severe RNA virus infections for which standard treatments are not available.",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 8.40625,
            "end_logit": -6.9921875,
            "text": "influenza, the next pandemic influenza",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -6.6484375,
            "end_logit": 7.9296875,
            "text": "severe influenza",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.40625,
            "end_logit": -7.3359375,
            "text": "influenza, the next pandemic influenza strain, and other severe RNA virus infections",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.40625,
            "end_logit": -7.46484375,
            "text": "influenza, the next pandemic influenza strain, and other severe RNA virus infections for which standard treatments are not available",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.40625,
            "end_logit": -7.59765625,
            "text": "influenza, the next pandemic influenza strain, and other severe RNA virus infections for which standard treatments are",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.40625,
            "end_logit": -7.61328125,
            "text": "influenza, the next pandemic influenza strain, and other severe RNA virus infections for",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.40625,
            "end_logit": -7.66796875,
            "text": "influenza, the next pandemic influenza strain, and",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.40625,
            "end_logit": -7.72265625,
            "text": "influenza,",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.40625,
            "end_logit": -7.7265625,
            "text": "influenza, the",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.40625,
            "end_logit": -7.734375,
            "text": "influenza, the next pandemic influenza strain, and other severe RNA virus infections for which standard treatments are not",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.40625,
            "end_logit": -7.8203125,
            "text": "influenza, the next pandemic influenza strain, and other",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.40625,
            "end_logit": -7.9140625,
            "text": "influenza, the next pandemic influenza strain, and other severe RNA virus infections for which standard",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.44140625,
            "end_logit": 7.9296875,
            "text": "Favipiravir is expected to be an important therapeutic agent for severe influenza",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.40625,
            "end_logit": -7.92578125,
            "text": "influenza, the next pandemic influenza strain, and other severe RNA virus infections for which standard treatments",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.671875,
            "end_logit": 7.9296875,
            "text": "therapeutic agent for severe influenza",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.7890625,
            "end_logit": 7.9296875,
            "text": "agent for severe influenza",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.82421875,
            "end_logit": 7.9296875,
            "text": "ipiravir is expected to be an important therapeutic agent for severe influenza",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.86328125,
            "end_logit": 7.9296875,
            "text": "vir is expected to be an important therapeutic agent for severe influenza",
            "probability": 5.960464477539063e-08
        }
    ],
    "621ebb733a8413c65300005c_26": [
        {
            "start_logit": 9.8828125,
            "end_logit": 9.6953125,
            "text": "influenza virus infections",
            "probability": 1.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -1.3447265625,
            "text": "influenza",
            "probability": 1.6033649444580078e-05
        },
        {
            "start_logit": -1.4423828125,
            "end_logit": 9.6953125,
            "text": "infections",
            "probability": 1.2040138244628906e-05
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -6.84765625,
            "text": "influenza virus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.86328125,
            "end_logit": 9.6953125,
            "text": "virus infections",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.0,
            "end_logit": 9.6953125,
            "text": "treat pandemic influenza virus infections",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.21875,
            "end_logit": 9.6953125,
            "text": "pandemic influenza virus infections",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -7.5859375,
            "text": "influenza virus infections.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.55859375,
            "end_logit": 9.6953125,
            "text": "antiviral drug that has been approved in 2014 in Japan to treat pandemic influenza virus infections",
            "probability": 0.0
        },
        {
            "start_logit": -7.73046875,
            "end_logit": 9.6953125,
            "text": "also known as T-705, is an antiviral drug that has been approved in 2014 in Japan to treat pandemic influenza virus infections",
            "probability": 0.0
        },
        {
            "start_logit": -7.75390625,
            "end_logit": 9.6953125,
            "text": "Favipiravir, also known as T-705, is an antiviral drug that has been approved in 2014 in Japan to treat pandemic influenza virus infections",
            "probability": 0.0
        },
        {
            "start_logit": -7.7578125,
            "end_logit": 9.6953125,
            "text": "drug that has been approved in 2014 in Japan to treat pandemic influenza virus infections",
            "probability": 0.0
        },
        {
            "start_logit": -7.8203125,
            "end_logit": 9.6953125,
            "text": "to treat pandemic influenza virus infections",
            "probability": 0.0
        },
        {
            "start_logit": -7.8671875,
            "end_logit": 9.6953125,
            "text": ", also known as T-705, is an antiviral drug that has been approved in 2014 in Japan to treat pandemic influenza virus infections",
            "probability": 0.0
        },
        {
            "start_logit": -7.8671875,
            "end_logit": 9.6953125,
            "text": ", is an antiviral drug that has been approved in 2014 in Japan to treat pandemic influenza virus infections",
            "probability": 0.0
        },
        {
            "start_logit": -7.87890625,
            "end_logit": 9.6953125,
            "text": "known as T-705, is an antiviral drug that has been approved in 2014 in Japan to treat pandemic influenza virus infections",
            "probability": 0.0
        },
        {
            "start_logit": -7.88671875,
            "end_logit": 9.6953125,
            "text": "is an antiviral drug that has been approved in 2014 in Japan to treat pandemic influenza virus infections",
            "probability": 0.0
        },
        {
            "start_logit": -7.88671875,
            "end_logit": 9.6953125,
            "text": "ipiravir, also known as T-705, is an antiviral drug that has been approved in 2014 in Japan to treat pandemic influenza virus infections",
            "probability": 0.0
        },
        {
            "start_logit": -7.90234375,
            "end_logit": 9.6953125,
            "text": "5, is an antiviral drug that has been approved in 2014 in Japan to treat pandemic influenza virus infections",
            "probability": 0.0
        },
        {
            "start_logit": -7.0,
            "end_logit": -1.3447265625,
            "text": "treat pandemic influenza",
            "probability": 0.0
        }
    ],
    "621ebb733a8413c65300005c_27": [
        {
            "start_logit": 8.7265625,
            "end_logit": 7.640625,
            "text": "influenza",
            "probability": 1.0
        },
        {
            "start_logit": 8.7265625,
            "end_logit": -7.72265625,
            "text": "influenza strains; and several phase 2 and 3 clinical trials are ongoing in the United States and Europe.",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.7265625,
            "end_logit": -7.91015625,
            "text": "influenza strains; and",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.7265625,
            "end_logit": -7.94140625,
            "text": "influenza strains; and several phase 2 and 3 clinical trials are",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.7265625,
            "end_logit": -8.0234375,
            "text": "influenza strains; and several phase 2 and 3 clinical trials are ongoing",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.7265625,
            "end_logit": -8.03125,
            "text": "influenza strains; and several phase 2 and 3 clinical trials are ongoing in the United States",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.7265625,
            "end_logit": -8.0390625,
            "text": "influenza strains",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.7265625,
            "end_logit": -8.0703125,
            "text": "influenza strains; and several phase 2 and 3 clinical trials are ongoing in the",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.7265625,
            "end_logit": -8.0859375,
            "text": "influenza strains; and several phase 2 and 3 clinical trials are ongoing in the United States and Europe",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.7265625,
            "end_logit": -8.0859375,
            "text": "influenza strains; and several phase 2 and 3 clinical trials are ongoing in",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.7265625,
            "end_logit": -8.09375,
            "text": "influenza strains;",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.7265625,
            "end_logit": -8.1015625,
            "text": "influenza strains; and several phase 2 and 3 clinical trials are ongoing in the United States and",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.7265625,
            "end_logit": -8.109375,
            "text": "influenza strains; and several",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.7265625,
            "end_logit": -8.109375,
            "text": "influenza strains; and several phase 2 and 3 clinical trials",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.81640625,
            "end_logit": 7.640625,
            "text": "Favipiravir (T-705) is a purine analogue antiviral approved for use in Japan against emerging influenza",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.81640625,
            "end_logit": 7.640625,
            "text": "emerging influenza",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.84375,
            "end_logit": 7.640625,
            "text": "purine analogue antiviral approved for use in Japan against emerging influenza",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.890625,
            "end_logit": 7.640625,
            "text": "use in Japan against emerging influenza",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.90234375,
            "end_logit": 7.640625,
            "text": "ipiravir (T-705) is a purine analogue antiviral approved for use in Japan against emerging influenza",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.953125,
            "end_logit": 7.640625,
            "text": "iravir (T-705) is a purine analogue antiviral approved for use in Japan against emerging influenza",
            "probability": 5.960464477539063e-08
        }
    ],
    "621ebb733a8413c65300005c_28": [
        {
            "start_logit": 8.5859375,
            "end_logit": 7.73046875,
            "text": "influenza",
            "probability": 1.0
        },
        {
            "start_logit": 8.5859375,
            "end_logit": -6.51953125,
            "text": "influenza and many other RNA viral diseases for which there are no approved therapies.",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 8.5859375,
            "end_logit": -6.81640625,
            "text": "influenza and many other RNA viral diseases",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.5859375,
            "end_logit": -7.140625,
            "text": "influenza and many other RNA viral diseases for which there are no approved",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.5859375,
            "end_logit": -7.328125,
            "text": "influenza and",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.5859375,
            "end_logit": -7.375,
            "text": "influenza and many other RNA viral diseases for which there are no",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.5859375,
            "end_logit": -7.53125,
            "text": "influenza and many other RNA viral diseases for which there are",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.5859375,
            "end_logit": -7.578125,
            "text": "influenza and many other RNA viral diseases for which there",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.5859375,
            "end_logit": -7.59765625,
            "text": "influenza and many other RNA viral diseases for",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.5859375,
            "end_logit": -7.64453125,
            "text": "influenza and many other RNA viral diseases for which",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.5859375,
            "end_logit": -7.7265625,
            "text": "influenza and many other RNA viral",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.5859375,
            "end_logit": -7.74609375,
            "text": "influenza and many",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.5859375,
            "end_logit": -7.75390625,
            "text": "influenza and many other RNA viral diseases for which there are no approved therapies",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.5859375,
            "end_logit": -7.76171875,
            "text": "influenza and many other",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.55078125,
            "end_logit": 7.73046875,
            "text": "for influenza",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.62890625,
            "end_logit": 7.73046875,
            "text": "antiviral activity, favipiravir is a promising drug candidate for influenza",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.7109375,
            "end_logit": 7.73046875,
            "text": "drug candidate for influenza",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.8515625,
            "end_logit": 7.73046875,
            "text": "promising drug candidate for influenza",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.9140625,
            "end_logit": 7.73046875,
            "text": ", favipiravir is a promising drug candidate for influenza",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.92578125,
            "end_logit": 7.73046875,
            "text": "favipiravir is a promising drug candidate for influenza",
            "probability": 5.960464477539063e-08
        }
    ],
    "5e48bf5ed14c9f295d000019_1": [
        {
            "start_logit": 8.8671875,
            "end_logit": 9.4921875,
            "text": "Nonconvulsive Status Epilepticus",
            "probability": 0.91748046875
        },
        {
            "start_logit": 6.453125,
            "end_logit": 9.4921875,
            "text": "Status Epilepticus",
            "probability": 0.08209228515625
        },
        {
            "start_logit": -2.02734375,
            "end_logit": 9.4921875,
            "text": "Epilepticus",
            "probability": 1.710653305053711e-05
        },
        {
            "start_logit": 8.8671875,
            "end_logit": -3.212890625,
            "text": "Noncon",
            "probability": 2.8014183044433594e-06
        },
        {
            "start_logit": 8.8671875,
            "end_logit": -5.7578125,
            "text": "Nonconvulsive Status",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.34765625,
            "end_logit": 9.4921875,
            "text": "vulsive Status Epilepticus",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.5,
            "end_logit": 9.4921875,
            "text": "With Nonconvulsive Status Epilepticus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.70703125,
            "end_logit": 9.4921875,
            "text": "Reevaluation of the Critically Ill Patients With Nonconvulsive Status Epilepticus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.8671875,
            "end_logit": -7.2265625,
            "text": "Nonconvulsive Status Epilepticus by Using Salzburg Consensus Criteria.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.890625,
            "end_logit": 9.4921875,
            "text": "ulsive Status Epilepticus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.9140625,
            "end_logit": 9.4921875,
            "text": "Patients With Nonconvulsive Status Epilepticus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.921875,
            "end_logit": 9.4921875,
            "text": "Critically Ill Patients With Nonconvulsive Status Epilepticus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1015625,
            "end_logit": 9.4921875,
            "text": "Ill Patients With Nonconvulsive Status Epilepticus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.8671875,
            "end_logit": -7.8359375,
            "text": "Nonconvulsive Status Epilepticus by",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.8671875,
            "end_logit": -7.86328125,
            "text": "Nonconv",
            "probability": 0.0
        },
        {
            "start_logit": 8.8671875,
            "end_logit": -7.921875,
            "text": "Nonconvulsive",
            "probability": 0.0
        },
        {
            "start_logit": 6.453125,
            "end_logit": -5.7578125,
            "text": "Status",
            "probability": 0.0
        },
        {
            "start_logit": 6.453125,
            "end_logit": -7.2265625,
            "text": "Status Epilepticus by Using Salzburg Consensus Criteria.",
            "probability": 0.0
        },
        {
            "start_logit": 6.453125,
            "end_logit": -7.8359375,
            "text": "Status Epilepticus by",
            "probability": 0.0
        },
        {
            "start_logit": -2.02734375,
            "end_logit": -7.2265625,
            "text": "Epilepticus by Using Salzburg Consensus Criteria.",
            "probability": 0.0
        }
    ],
    "5e48bf5ed14c9f295d000019_2": [
        {
            "start_logit": 5.39453125,
            "end_logit": 9.40625,
            "text": "status epilepticus",
            "probability": 0.998046875
        },
        {
            "start_logit": -0.9267578125,
            "end_logit": 9.40625,
            "text": "nonconvulsive status epilepticus",
            "probability": 0.0017957687377929688
        },
        {
            "start_logit": -2.126953125,
            "end_logit": 9.40625,
            "text": "epilepticus",
            "probability": 0.0005435943603515625
        },
        {
            "start_logit": -6.08984375,
            "end_logit": 9.40625,
            "text": "with nonconvulsive status epilepticus",
            "probability": 1.0311603546142578e-05
        },
        {
            "start_logit": -7.734375,
            "end_logit": 9.40625,
            "text": "vulsive status epilepticus",
            "probability": 1.9669532775878906e-06
        },
        {
            "start_logit": -7.9453125,
            "end_logit": 9.40625,
            "text": "OBJECTIVE: We aimed to assess the usefulness of the Salzburg Consensus Criteria (SCC) for determining the prognosis of critically ill patients with nonconvulsive status epilepticus",
            "probability": 1.6093254089355469e-06
        },
        {
            "start_logit": -7.98046875,
            "end_logit": 9.40625,
            "text": "prognosis of critically ill patients with nonconvulsive status epilepticus",
            "probability": 1.5497207641601562e-06
        },
        {
            "start_logit": -8.0078125,
            "end_logit": 9.40625,
            "text": "patients with nonconvulsive status epilepticus",
            "probability": 1.4901161193847656e-06
        },
        {
            "start_logit": -8.0234375,
            "end_logit": 9.40625,
            "text": "Salzburg Consensus Criteria (SCC) for determining the prognosis of critically ill patients with nonconvulsive status epilepticus",
            "probability": 1.4901161193847656e-06
        },
        {
            "start_logit": -8.0390625,
            "end_logit": 9.40625,
            "text": "determining the prognosis of critically ill patients with nonconvulsive status epilepticus",
            "probability": 1.4901161193847656e-06
        },
        {
            "start_logit": -8.0546875,
            "end_logit": 9.40625,
            "text": "We aimed to assess the usefulness of the Salzburg Consensus Criteria (SCC) for determining the prognosis of critically ill patients with nonconvulsive status epilepticus",
            "probability": 1.430511474609375e-06
        },
        {
            "start_logit": -8.0625,
            "end_logit": 9.40625,
            "text": "the Salzburg Consensus Criteria (SCC) for determining the prognosis of critically ill patients with nonconvulsive status epilepticus",
            "probability": 1.430511474609375e-06
        },
        {
            "start_logit": -8.0859375,
            "end_logit": 9.40625,
            "text": "SCC) for determining the prognosis of critically ill patients with nonconvulsive status epilepticus",
            "probability": 1.430511474609375e-06
        },
        {
            "start_logit": -8.1015625,
            "end_logit": 9.40625,
            "text": "Consensus Criteria (SCC) for determining the prognosis of critically ill patients with nonconvulsive status epilepticus",
            "probability": 1.3709068298339844e-06
        },
        {
            "start_logit": -8.1171875,
            "end_logit": 9.40625,
            "text": "the prognosis of critically ill patients with nonconvulsive status epilepticus",
            "probability": 1.3709068298339844e-06
        },
        {
            "start_logit": -8.1171875,
            "end_logit": 9.40625,
            "text": ") for determining the prognosis of critically ill patients with nonconvulsive status epilepticus",
            "probability": 1.3709068298339844e-06
        },
        {
            "start_logit": 5.39453125,
            "end_logit": -6.5625,
            "text": "status",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 5.39453125,
            "end_logit": -7.40625,
            "text": "status epilepticus (NCSE).",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 5.39453125,
            "end_logit": -7.875,
            "text": "status epilepticus (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 5.39453125,
            "end_logit": -7.94140625,
            "text": "status epilepticus (NCSE",
            "probability": 0.0
        }
    ],
    "5e48bf5ed14c9f295d000019_3": [
        {
            "start_logit": 9.703125,
            "end_logit": 9.6328125,
            "text": "Nonconvulsive Status Epilepticus",
            "probability": 1.0
        },
        {
            "start_logit": -1.6875,
            "end_logit": 9.6328125,
            "text": "Epilepticus",
            "probability": 1.1205673217773438e-05
        },
        {
            "start_logit": 9.703125,
            "end_logit": -1.818359375,
            "text": "Noncon",
            "probability": 1.055002212524414e-05
        },
        {
            "start_logit": -2.458984375,
            "end_logit": 9.6328125,
            "text": "Status Epilepticus",
            "probability": 5.185604095458984e-06
        },
        {
            "start_logit": 9.703125,
            "end_logit": -7.30078125,
            "text": "Nonconv",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.703125,
            "end_logit": -7.73046875,
            "text": "Nonconvulsive",
            "probability": 0.0
        },
        {
            "start_logit": 9.703125,
            "end_logit": -7.796875,
            "text": "Nonconvulsive Status Epilepticus: Validating the Salzburg Criteria Against an Expert EEG Examiner.",
            "probability": 0.0
        },
        {
            "start_logit": 9.703125,
            "end_logit": -7.90234375,
            "text": "Nonconvulsive Status Epilepticus: Validating the Salzburg Criteria Against",
            "probability": 0.0
        },
        {
            "start_logit": 9.703125,
            "end_logit": -8.015625,
            "text": "Nonconvulsive Status Epilepticus:",
            "probability": 0.0
        },
        {
            "start_logit": 9.703125,
            "end_logit": -8.03125,
            "text": "Nonconvulsive Status Epilepticus: Validating the Salzburg Criteria Against an",
            "probability": 0.0
        },
        {
            "start_logit": 9.703125,
            "end_logit": -8.1015625,
            "text": "Nonconvulsive Status",
            "probability": 0.0
        },
        {
            "start_logit": 9.703125,
            "end_logit": -8.140625,
            "text": "Nonconvulsive Status Epilepticus: Validating the Salzburg Criteria Against an Expert EEG Examiner",
            "probability": 0.0
        },
        {
            "start_logit": -8.1015625,
            "end_logit": 9.6328125,
            "text": "ulsive Status Epilepticus",
            "probability": 0.0
        },
        {
            "start_logit": -1.6875,
            "end_logit": -7.796875,
            "text": "Epilepticus: Validating the Salzburg Criteria Against an Expert EEG Examiner.",
            "probability": 0.0
        },
        {
            "start_logit": -1.6875,
            "end_logit": -7.90234375,
            "text": "Epilepticus: Validating the Salzburg Criteria Against",
            "probability": 0.0
        },
        {
            "start_logit": -1.6875,
            "end_logit": -8.015625,
            "text": "Epilepticus:",
            "probability": 0.0
        },
        {
            "start_logit": -1.6875,
            "end_logit": -8.03125,
            "text": "Epilepticus: Validating the Salzburg Criteria Against an",
            "probability": 0.0
        },
        {
            "start_logit": -1.6875,
            "end_logit": -8.140625,
            "text": "Epilepticus: Validating the Salzburg Criteria Against an Expert EEG Examiner",
            "probability": 0.0
        },
        {
            "start_logit": -2.458984375,
            "end_logit": -7.796875,
            "text": "Status Epilepticus: Validating the Salzburg Criteria Against an Expert EEG Examiner.",
            "probability": 0.0
        },
        {
            "start_logit": -2.458984375,
            "end_logit": -7.90234375,
            "text": "Status Epilepticus: Validating the Salzburg Criteria Against",
            "probability": 0.0
        }
    ],
    "5e48bf5ed14c9f295d000019_4": [
        {
            "start_logit": 9.1953125,
            "end_logit": 9.6484375,
            "text": "nonconvulsive status epilepticus",
            "probability": 1.0
        },
        {
            "start_logit": -1.58984375,
            "end_logit": 9.6484375,
            "text": "epilepticus",
            "probability": 2.0802021026611328e-05
        },
        {
            "start_logit": -1.763671875,
            "end_logit": 9.6484375,
            "text": "status epilepticus",
            "probability": 1.7344951629638672e-05
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -2.6796875,
            "text": "noncon",
            "probability": 4.410743713378906e-06
        },
        {
            "start_logit": -6.9296875,
            "end_logit": 9.6484375,
            "text": "vulsive status epilepticus",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.16796875,
            "end_logit": 9.6484375,
            "text": "ulsive status epilepticus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.59375,
            "end_logit": 9.6484375,
            "text": "for nonconvulsive status epilepticus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.8828125,
            "end_logit": 9.6484375,
            "text": "To improve the diagnostic accuracy of electroencephalography (EEG) criteria for nonconvulsive status epilepticus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -7.4921875,
            "text": "nonconvulsive status epilepticus (NCSE), external validation of the recently proposed Salzburg criteria is paramount.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.98046875,
            "end_logit": 9.6484375,
            "text": "diagnostic accuracy of electroencephalography (EEG) criteria for nonconvulsive status epilepticus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0078125,
            "end_logit": 9.6484375,
            "text": ") criteria for nonconvulsive status epilepticus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -7.6796875,
            "text": "nonconvulsive",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -7.81640625,
            "text": "nonconv",
            "probability": 0.0
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -8.0234375,
            "text": "nonconvulsive status epilepticus (NCSE), external validation",
            "probability": 0.0
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -8.109375,
            "text": "nonconvulsive status epilepticus (NCSE), external validation of the recently proposed Salzburg criteria is paramount",
            "probability": 0.0
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -8.109375,
            "text": "nonconvulsive status epilepticus (NCSE), external validation of",
            "probability": 0.0
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -8.109375,
            "text": "nonconvulsive status epilepticus (NCSE)",
            "probability": 0.0
        },
        {
            "start_logit": -1.58984375,
            "end_logit": -7.4921875,
            "text": "epilepticus (NCSE), external validation of the recently proposed Salzburg criteria is paramount.",
            "probability": 0.0
        },
        {
            "start_logit": -1.763671875,
            "end_logit": -7.4921875,
            "text": "status epilepticus (NCSE), external validation of the recently proposed Salzburg criteria is paramount.",
            "probability": 0.0
        },
        {
            "start_logit": -1.58984375,
            "end_logit": -8.0234375,
            "text": "epilepticus (NCSE), external validation",
            "probability": 0.0
        }
    ],
    "5e48bf5ed14c9f295d000019_5": [
        {
            "start_logit": 9.1953125,
            "end_logit": 9.6484375,
            "text": "nonconvulsive status epilepticus",
            "probability": 1.0
        },
        {
            "start_logit": -1.58984375,
            "end_logit": 9.6484375,
            "text": "epilepticus",
            "probability": 2.0802021026611328e-05
        },
        {
            "start_logit": -1.763671875,
            "end_logit": 9.6484375,
            "text": "status epilepticus",
            "probability": 1.7344951629638672e-05
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -2.6796875,
            "text": "noncon",
            "probability": 4.410743713378906e-06
        },
        {
            "start_logit": -6.9296875,
            "end_logit": 9.6484375,
            "text": "vulsive status epilepticus",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.16796875,
            "end_logit": 9.6484375,
            "text": "ulsive status epilepticus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.59375,
            "end_logit": 9.6484375,
            "text": "for nonconvulsive status epilepticus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.8828125,
            "end_logit": 9.6484375,
            "text": "To improve the diagnostic accuracy of electroencephalography (EEG) criteria for nonconvulsive status epilepticus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -7.4921875,
            "text": "nonconvulsive status epilepticus (NCSE), external validation of the recently proposed Salzburg criteria is paramount.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.98046875,
            "end_logit": 9.6484375,
            "text": "diagnostic accuracy of electroencephalography (EEG) criteria for nonconvulsive status epilepticus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0078125,
            "end_logit": 9.6484375,
            "text": ") criteria for nonconvulsive status epilepticus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -7.6796875,
            "text": "nonconvulsive",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -7.81640625,
            "text": "nonconv",
            "probability": 0.0
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -8.0234375,
            "text": "nonconvulsive status epilepticus (NCSE), external validation",
            "probability": 0.0
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -8.109375,
            "text": "nonconvulsive status epilepticus (NCSE), external validation of the recently proposed Salzburg criteria is paramount",
            "probability": 0.0
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -8.109375,
            "text": "nonconvulsive status epilepticus (NCSE), external validation of",
            "probability": 0.0
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -8.109375,
            "text": "nonconvulsive status epilepticus (NCSE)",
            "probability": 0.0
        },
        {
            "start_logit": -1.58984375,
            "end_logit": -7.4921875,
            "text": "epilepticus (NCSE), external validation of the recently proposed Salzburg criteria is paramount.",
            "probability": 0.0
        },
        {
            "start_logit": -1.763671875,
            "end_logit": -7.4921875,
            "text": "status epilepticus (NCSE), external validation of the recently proposed Salzburg criteria is paramount.",
            "probability": 0.0
        },
        {
            "start_logit": -1.58984375,
            "end_logit": -8.0234375,
            "text": "epilepticus (NCSE), external validation",
            "probability": 0.0
        }
    ],
    "623e02e0f0baec9a1b000005_1": [
        {
            "start_logit": 9.609375,
            "end_logit": 3.287109375,
            "text": "ER retention sequence",
            "probability": 0.85986328125
        },
        {
            "start_logit": 9.609375,
            "end_logit": 1.4697265625,
            "text": "ER",
            "probability": 0.1392822265625
        },
        {
            "start_logit": 9.609375,
            "end_logit": -4.1953125,
            "text": "ER retention sequence (",
            "probability": 0.0004830360412597656
        },
        {
            "start_logit": 9.609375,
            "end_logit": -6.078125,
            "text": "ER retention sequence (KDEL)",
            "probability": 7.349252700805664e-05
        },
        {
            "start_logit": 9.609375,
            "end_logit": -7.66015625,
            "text": "ER retention",
            "probability": 1.5079975128173828e-05
        },
        {
            "start_logit": -6.06640625,
            "end_logit": 3.287109375,
            "text": "sequence",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.30078125,
            "end_logit": 3.287109375,
            "text": "retention sequence",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.06640625,
            "end_logit": -4.1953125,
            "text": "sequence (",
            "probability": 0.0
        },
        {
            "start_logit": -6.30078125,
            "end_logit": -4.1953125,
            "text": "retention sequence (",
            "probability": 0.0
        },
        {
            "start_logit": -6.06640625,
            "end_logit": -6.078125,
            "text": "sequence (KDEL)",
            "probability": 0.0
        },
        {
            "start_logit": -6.30078125,
            "end_logit": -6.078125,
            "text": "retention sequence (KDEL)",
            "probability": 0.0
        },
        {
            "start_logit": -7.3125,
            "end_logit": -6.078125,
            "text": "KDEL)",
            "probability": 0.0
        },
        {
            "start_logit": -6.30078125,
            "end_logit": -7.66015625,
            "text": "retention",
            "probability": 0.0
        },
        {
            "start_logit": -7.8984375,
            "end_logit": -6.078125,
            "text": "EL)",
            "probability": 0.0
        }
    ],
    "53617eeb7d100faa0900000a_1": [
        {
            "start_logit": 8.3828125,
            "end_logit": 7.92578125,
            "text": "Anorexia Athletica",
            "probability": 1.0
        },
        {
            "start_logit": 8.3828125,
            "end_logit": -3.66796875,
            "text": "Anorexia",
            "probability": 9.238719940185547e-06
        },
        {
            "start_logit": 8.3828125,
            "end_logit": -4.29296875,
            "text": "Anorexia Athletica.",
            "probability": 4.947185516357422e-06
        },
        {
            "start_logit": -4.16796875,
            "end_logit": 7.92578125,
            "text": "a",
            "probability": 3.516674041748047e-06
        },
        {
            "start_logit": -5.265625,
            "end_logit": 7.92578125,
            "text": "Athletica",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": 8.3828125,
            "end_logit": -7.01953125,
            "text": "Anorexia Athletic",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.8828125,
            "end_logit": 7.92578125,
            "text": "developing Anorexia Athletica",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.734375,
            "end_logit": 7.92578125,
            "text": "Elite Rhythmic Gymnasts (RGs) constitute a unique metabolic model and they are prone to developing Anorexia Athletica",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.76171875,
            "end_logit": 7.92578125,
            "text": "to developing Anorexia Athletica",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.8515625,
            "end_logit": 7.92578125,
            "text": "metabolic model and they are prone to developing Anorexia Athletica",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.87890625,
            "end_logit": 7.92578125,
            "text": "Rhythmic Gymnasts (RGs) constitute a unique metabolic model and they are prone to developing Anorexia Athletica",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.015625,
            "end_logit": 7.92578125,
            "text": "model and they are prone to developing Anorexia Athletica",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0234375,
            "end_logit": 7.92578125,
            "text": "unique metabolic model and they are prone to developing Anorexia Athletica",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0390625,
            "end_logit": 7.92578125,
            "text": "prone to developing Anorexia Athletica",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.125,
            "end_logit": 7.92578125,
            "text": "and they are prone to developing Anorexia Athletica",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1640625,
            "end_logit": 7.92578125,
            "text": "Gymnasts (RGs) constitute a unique metabolic model and they are prone to developing Anorexia Athletica",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1953125,
            "end_logit": 7.92578125,
            "text": "are prone to developing Anorexia Athletica",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.203125,
            "end_logit": 7.92578125,
            "text": "they are prone to developing Anorexia Athletica",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -4.16796875,
            "end_logit": -4.29296875,
            "text": "a.",
            "probability": 0.0
        },
        {
            "start_logit": -5.13671875,
            "end_logit": -4.29296875,
            "text": ".",
            "probability": 0.0
        }
    ],
    "53617eeb7d100faa0900000a_2": [
        {
            "start_logit": 6.90234375,
            "end_logit": 7.93359375,
            "text": "anorexia athletica",
            "probability": 1.0
        },
        {
            "start_logit": -4.28125,
            "end_logit": 7.93359375,
            "text": "a",
            "probability": 1.3828277587890625e-05
        },
        {
            "start_logit": 6.90234375,
            "end_logit": -4.8203125,
            "text": "anorexia athletica (AA",
            "probability": 2.9206275939941406e-06
        },
        {
            "start_logit": -5.87890625,
            "end_logit": 7.93359375,
            "text": "athletica",
            "probability": 2.8014183044433594e-06
        },
        {
            "start_logit": 6.90234375,
            "end_logit": -5.2890625,
            "text": "anorexia",
            "probability": 1.7881393432617188e-06
        },
        {
            "start_logit": -7.11328125,
            "end_logit": 7.93359375,
            "text": "with anorexia athletica",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": 6.90234375,
            "end_logit": -6.09375,
            "text": "anorexia athletica (",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": -8.1328125,
            "end_logit": 7.93359375,
            "text": "gymnasts with anorexia athletica",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -8.1875,
            "end_logit": 7.93359375,
            "text": "studied 13 female juvenile elite gymnasts with anorexia athletica",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -8.203125,
            "end_logit": 7.93359375,
            "text": "female juvenile elite gymnasts with anorexia athletica",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 7.93359375,
            "text": "nasts with anorexia athletica",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -8.21875,
            "end_logit": 7.93359375,
            "text": "We studied 13 female juvenile elite gymnasts with anorexia athletica",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -8.2734375,
            "end_logit": 7.93359375,
            "text": "ts with anorexia athletica",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 6.90234375,
            "end_logit": -7.33984375,
            "text": "anorexia athletic",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -4.28125,
            "end_logit": -4.8203125,
            "text": "a (AA",
            "probability": 0.0
        },
        {
            "start_logit": -4.28125,
            "end_logit": -6.09375,
            "text": "a (",
            "probability": 0.0
        },
        {
            "start_logit": -5.87890625,
            "end_logit": -4.8203125,
            "text": "athletica (AA",
            "probability": 0.0
        },
        {
            "start_logit": -7.11328125,
            "end_logit": -4.8203125,
            "text": "with anorexia athletica (AA",
            "probability": 0.0
        },
        {
            "start_logit": -5.87890625,
            "end_logit": -6.09375,
            "text": "athletica (",
            "probability": 0.0
        },
        {
            "start_logit": -7.11328125,
            "end_logit": -5.2890625,
            "text": "with anorexia",
            "probability": 0.0
        }
    ],
    "5c900b9eecadf2e73f000004_1": [
        {
            "start_logit": 9.8671875,
            "end_logit": 9.5625,
            "text": "Alnylam Pharmaceuticals",
            "probability": 1.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -1.330078125,
            "text": "Al",
            "probability": 1.8477439880371094e-05
        },
        {
            "start_logit": -1.599609375,
            "end_logit": 9.5625,
            "text": "Pharmaceuticals",
            "probability": 1.0371208190917969e-05
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -6.015625,
            "text": "Alnyl",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -6.3359375,
            "text": "Alnylam",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -6.8828125,
            "text": "Aln",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.875,
            "end_logit": 9.5625,
            "text": "am Pharmaceuticals",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.36328125,
            "end_logit": 9.5625,
            "text": "ylam Pharmaceuticals",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.41796875,
            "end_logit": 9.5625,
            "text": "nylam Pharmaceuticals",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.640625,
            "end_logit": 9.5625,
            "text": "by Alnylam Pharmaceuticals",
            "probability": 0.0
        },
        {
            "start_logit": -7.73828125,
            "end_logit": 9.5625,
            "text": "Patisiran has been developed by Alnylam Pharmaceuticals",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.125,
            "text": "Alnylam Pharmaceuticals;",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.15625,
            "text": "Alnylam Pharmaceuticals; it was recently approved in the USA for the treatment of the polyneuropathy of hereditary TTR",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.15625,
            "text": "Alnylam Pharmaceuticals; it was recently approved in the USA for the treatment of the polyneuropathy of hereditary TTR-mediated amyloidosis (hATTR) in",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.15625,
            "text": "Alnylam Pharmaceuticals; it was recently approved in the USA for the treatment of the polyneuropathy of hereditary TTR-mediated amyloidosis",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.171875,
            "text": "Alnylam Pharmaceuticals; it was recently approved in the USA for the treatment of the polyneuropathy of hereditary TTR-mediated amyloidosis (hATTR)",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.1953125,
            "text": "Alnylam Pharmaceuticals; it was recently approved in the USA for the treatment of the polyneuropathy of hereditary TTR-mediated amyloidosis (hATTR) in adults and",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.1953125,
            "text": "Alnylam Pharmaceuticals; it was recently approved in the USA",
            "probability": 0.0
        },
        {
            "start_logit": -7.890625,
            "end_logit": 9.5625,
            "text": "developed by Alnylam Pharmaceuticals",
            "probability": 0.0
        },
        {
            "start_logit": -7.9453125,
            "end_logit": 9.5625,
            "text": "been developed by Alnylam Pharmaceuticals",
            "probability": 0.0
        }
    ],
    "58c27b7102b8c60953000021_1": [
        {
            "start_logit": 9.4609375,
            "end_logit": 9.7109375,
            "text": "Enhancer Sharing",
            "probability": 1.0
        },
        {
            "start_logit": -1.2861328125,
            "end_logit": 9.7109375,
            "text": "Sharing",
            "probability": 2.1457672119140625e-05
        },
        {
            "start_logit": 9.4609375,
            "end_logit": -2.2890625,
            "text": "Enhancer",
            "probability": 6.139278411865234e-06
        },
        {
            "start_logit": 9.4609375,
            "end_logit": -7.7578125,
            "text": "Enhancer Sharing Promotes",
            "probability": 0.0
        },
        {
            "start_logit": 9.4609375,
            "end_logit": -7.77734375,
            "text": "Enhancer Sharing Promotes Neighborhoods of Transcriptional Regulation Across",
            "probability": 0.0
        },
        {
            "start_logit": 9.4609375,
            "end_logit": -8.140625,
            "text": "Enhancer Sharing Promotes Neighborhoods of Transcriptional Regulation",
            "probability": 0.0
        },
        {
            "start_logit": 9.4609375,
            "end_logit": -8.15625,
            "text": "Enhancer Sharing Promotes Neighborhoods of",
            "probability": 0.0
        },
        {
            "start_logit": -1.2861328125,
            "end_logit": -7.7578125,
            "text": "Sharing Promotes",
            "probability": 0.0
        },
        {
            "start_logit": -1.2861328125,
            "end_logit": -7.77734375,
            "text": "Sharing Promotes Neighborhoods of Transcriptional Regulation Across",
            "probability": 0.0
        },
        {
            "start_logit": -1.2861328125,
            "end_logit": -8.140625,
            "text": "Sharing Promotes Neighborhoods of Transcriptional Regulation",
            "probability": 0.0
        },
        {
            "start_logit": -1.2861328125,
            "end_logit": -8.15625,
            "text": "Sharing Promotes Neighborhoods of",
            "probability": 0.0
        },
        {
            "start_logit": -8.0625,
            "end_logit": -7.77734375,
            "text": "Neighborhoods of Transcriptional Regulation Across",
            "probability": 0.0
        },
        {
            "start_logit": -8.109375,
            "end_logit": -7.77734375,
            "text": "Transcriptional Regulation Across",
            "probability": 0.0
        },
        {
            "start_logit": -8.0625,
            "end_logit": -8.140625,
            "text": "Neighborhoods of Transcriptional Regulation",
            "probability": 0.0
        },
        {
            "start_logit": -8.0625,
            "end_logit": -8.15625,
            "text": "Neighborhoods of",
            "probability": 0.0
        },
        {
            "start_logit": -8.109375,
            "end_logit": -8.140625,
            "text": "Transcriptional Regulation",
            "probability": 0.0
        }
    ],
    "58c27b7102b8c60953000021_2": [
        {
            "start_logit": 9.765625,
            "end_logit": 6.44921875,
            "text": "enhancer sharing",
            "probability": 0.9990234375
        },
        {
            "start_logit": 9.765625,
            "end_logit": -1.0673828125,
            "text": "enhancer",
            "probability": 0.0005397796630859375
        },
        {
            "start_logit": 9.765625,
            "end_logit": -6.8046875,
            "text": "enhancer sharing is commonplace among eukaryotes, and that EP distance is an important layer of information in gene regulation.",
            "probability": 1.7285346984863281e-06
        },
        {
            "start_logit": 9.765625,
            "end_logit": -6.9453125,
            "text": "enhancer sharing is commonplace among eukaryotes, and that EP distance",
            "probability": 1.4901161193847656e-06
        },
        {
            "start_logit": 9.765625,
            "end_logit": -7.7578125,
            "text": "enhancer sharing is commonplace among eukaryotes, and",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 9.765625,
            "end_logit": -7.77734375,
            "text": "enhancer sharing is commonplace among eukaryotes, and that EP distance is",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 9.765625,
            "end_logit": -7.8125,
            "text": "enhancer sharing is",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 9.765625,
            "end_logit": -7.828125,
            "text": "enhancer sharing is commonplace among eukaryotes, and that EP distance is an",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 9.765625,
            "end_logit": -7.8828125,
            "text": "enhancer sharing is commonplace among eukaryotes, and that EP distance is an important",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 9.765625,
            "end_logit": -7.9921875,
            "text": "enhancer sharing is commonplace among eukaryotes,",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -5.02734375,
            "end_logit": 6.44921875,
            "text": "sharing",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.4296875,
            "end_logit": 6.44921875,
            "text": "We propose that enhancer sharing",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.52734375,
            "end_logit": 6.44921875,
            "text": "that enhancer sharing",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0390625,
            "end_logit": 6.44921875,
            "text": "propose that enhancer sharing",
            "probability": 0.0
        },
        {
            "start_logit": -7.4296875,
            "end_logit": -1.0673828125,
            "text": "We propose that enhancer",
            "probability": 0.0
        },
        {
            "start_logit": -7.52734375,
            "end_logit": -1.0673828125,
            "text": "that enhancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.0390625,
            "end_logit": -1.0673828125,
            "text": "propose that enhancer",
            "probability": 0.0
        },
        {
            "start_logit": -5.02734375,
            "end_logit": -6.8046875,
            "text": "sharing is commonplace among eukaryotes, and that EP distance is an important layer of information in gene regulation.",
            "probability": 0.0
        },
        {
            "start_logit": -5.02734375,
            "end_logit": -6.9453125,
            "text": "sharing is commonplace among eukaryotes, and that EP distance",
            "probability": 0.0
        },
        {
            "start_logit": -5.02734375,
            "end_logit": -7.7578125,
            "text": "sharing is commonplace among eukaryotes, and",
            "probability": 0.0
        }
    ],
    "58c27b7102b8c60953000021_3": [
        {
            "start_logit": 9.5703125,
            "end_logit": 9.7265625,
            "text": "Enhancer Sharing",
            "probability": 1.0
        },
        {
            "start_logit": -1.2216796875,
            "end_logit": 9.7265625,
            "text": "Sharing",
            "probability": 2.0623207092285156e-05
        },
        {
            "start_logit": 9.5703125,
            "end_logit": -2.0703125,
            "text": "Enhancer",
            "probability": 7.510185241699219e-06
        },
        {
            "start_logit": 9.5703125,
            "end_logit": -7.74609375,
            "text": "Enhancer Sharing Promotes",
            "probability": 0.0
        },
        {
            "start_logit": 9.5703125,
            "end_logit": -7.77734375,
            "text": "Enhancer Sharing Promotes Neighborhoods of Transcriptional Regulation Across",
            "probability": 0.0
        },
        {
            "start_logit": 9.5703125,
            "end_logit": -7.87109375,
            "text": "Enhancer Sharing Promotes Neighborhoods of Transcriptional Regulation Across Eukaryotes.",
            "probability": 0.0
        },
        {
            "start_logit": -1.2216796875,
            "end_logit": -7.74609375,
            "text": "Sharing Promotes",
            "probability": 0.0
        },
        {
            "start_logit": -1.2216796875,
            "end_logit": -7.77734375,
            "text": "Sharing Promotes Neighborhoods of Transcriptional Regulation Across",
            "probability": 0.0
        },
        {
            "start_logit": -1.2216796875,
            "end_logit": -7.87109375,
            "text": "Sharing Promotes Neighborhoods of Transcriptional Regulation Across Eukaryotes.",
            "probability": 0.0
        },
        {
            "start_logit": -6.68359375,
            "end_logit": -7.87109375,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.99609375,
            "end_logit": -7.77734375,
            "text": "Neighborhoods of Transcriptional Regulation Across",
            "probability": 0.0
        },
        {
            "start_logit": -8.078125,
            "end_logit": -7.77734375,
            "text": "Transcriptional Regulation Across",
            "probability": 0.0
        },
        {
            "start_logit": -7.99609375,
            "end_logit": -7.87109375,
            "text": "Neighborhoods of Transcriptional Regulation Across Eukaryotes.",
            "probability": 0.0
        },
        {
            "start_logit": -8.140625,
            "end_logit": -7.77734375,
            "text": "of Transcriptional Regulation Across",
            "probability": 0.0
        },
        {
            "start_logit": -8.1484375,
            "end_logit": -7.77734375,
            "text": "Regulation Across",
            "probability": 0.0
        },
        {
            "start_logit": -8.078125,
            "end_logit": -7.87109375,
            "text": "Transcriptional Regulation Across Eukaryotes.",
            "probability": 0.0
        },
        {
            "start_logit": -8.140625,
            "end_logit": -7.87109375,
            "text": "Eukaryotes.",
            "probability": 0.0
        },
        {
            "start_logit": -8.140625,
            "end_logit": -7.87109375,
            "text": "of Transcriptional Regulation Across Eukaryotes.",
            "probability": 0.0
        },
        {
            "start_logit": -8.1484375,
            "end_logit": -7.87109375,
            "text": "Regulation Across Eukaryotes.",
            "probability": 0.0
        }
    ],
    "5c8973f3d558e5f232000007_1": [
        {
            "start_logit": 8.6328125,
            "end_logit": 9.234375,
            "text": "Alipogene tiparvovec",
            "probability": 1.0
        },
        {
            "start_logit": -2.349609375,
            "end_logit": 9.234375,
            "text": "c",
            "probability": 1.6808509826660156e-05
        },
        {
            "start_logit": 8.6328125,
            "end_logit": -3.337890625,
            "text": "Ali",
            "probability": 3.4570693969726562e-06
        },
        {
            "start_logit": -4.55859375,
            "end_logit": 9.234375,
            "text": "tiparvovec",
            "probability": 1.8477439880371094e-06
        },
        {
            "start_logit": 8.6328125,
            "end_logit": -5.37890625,
            "text": "Alipogene tiparvovec (Glybera",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.6328125,
            "end_logit": -5.77734375,
            "text": "Alipogene tiparvovec (Glybera\u00ae",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.77734375,
            "end_logit": 9.234375,
            "text": "vovec",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.82421875,
            "end_logit": 9.234375,
            "text": "vec",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.6328125,
            "end_logit": -6.3671875,
            "text": "Alipogene tiparvovec (Glyber",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.05078125,
            "end_logit": 9.234375,
            "text": "gene tiparvovec",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.6328125,
            "end_logit": -6.51953125,
            "text": "Alipo",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.1328125,
            "end_logit": 9.234375,
            "text": "arvovec",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.6328125,
            "end_logit": -7.04296875,
            "text": "Alipogene",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.6328125,
            "end_logit": -7.0546875,
            "text": "Alipogene tiparvove",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.6328125,
            "end_logit": -7.3984375,
            "text": "Alipogene tiparvovec (Glybera\u00ae)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.6328125,
            "end_logit": -7.62109375,
            "text": "Alipogene tiparvo",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.6328125,
            "end_logit": -7.66015625,
            "text": "Alipogene tiparvovec (Glybera\u00ae) is the first gene therapy to receive Marketing Authorization in the European Union; GENIALL",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.6328125,
            "end_logit": -7.70703125,
            "text": "Alipogene tipar",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.6328125,
            "end_logit": -7.79296875,
            "text": "Alipogene tiparvovec (Gly",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.6328125,
            "end_logit": -7.84765625,
            "text": "Alipogene tiparvovec (Glybera\u00ae) is the first gene therapy to receive Marketing Authorization in the European Union; GENIAL",
            "probability": 5.960464477539063e-08
        }
    ],
    "5c929094ecadf2e73f000019_1": [
        {
            "start_logit": 8.3515625,
            "end_logit": 5.7265625,
            "text": "Senescent cells undergo dramatic alterations to their chromatin landscape that affect genome accessibility and their transcriptional program.",
            "probability": 0.9970703125
        },
        {
            "start_logit": 1.3291015625,
            "end_logit": 5.7265625,
            "text": "changes in chromatin composition that can lead to the activation of retrotransposons.",
            "probability": 0.0008883476257324219
        },
        {
            "start_logit": 0.88134765625,
            "end_logit": 5.7265625,
            "text": ".",
            "probability": 0.0005693435668945312
        },
        {
            "start_logit": 0.88134765625,
            "end_logit": 5.7265625,
            "text": ". These include the loss of DNA-nuclear lamina interactions, the distension of centromeres, and changes in chromatin composition that can lead to the activation of retrotransposons.",
            "probability": 0.0005693435668945312
        },
        {
            "start_logit": 0.88134765625,
            "end_logit": 5.7265625,
            "text": ".",
            "probability": 0.0005693435668945312
        },
        {
            "start_logit": 8.3515625,
            "end_logit": -1.9755859375,
            "text": "Senescent",
            "probability": 0.00044989585876464844
        },
        {
            "start_logit": -0.71826171875,
            "end_logit": 5.7265625,
            "text": "activation of retrotransposons.",
            "probability": 0.00011467933654785156
        },
        {
            "start_logit": 8.3515625,
            "end_logit": -4.96484375,
            "text": "Senescent cells",
            "probability": 2.276897430419922e-05
        },
        {
            "start_logit": 8.3515625,
            "end_logit": -5.19921875,
            "text": "Senescent cells undergo",
            "probability": 1.800060272216797e-05
        },
        {
            "start_logit": 8.3515625,
            "end_logit": -5.984375,
            "text": "Senescent cells undergo dramatic alterations to their chromatin landscape that",
            "probability": 8.225440979003906e-06
        },
        {
            "start_logit": 8.3515625,
            "end_logit": -6.22265625,
            "text": "Senescent cells undergo dramatic alterations",
            "probability": 6.4373016357421875e-06
        },
        {
            "start_logit": -3.859375,
            "end_logit": 5.7265625,
            "text": "can lead to the activation of retrotransposons.",
            "probability": 4.947185516357422e-06
        },
        {
            "start_logit": 8.3515625,
            "end_logit": -6.49609375,
            "text": "Senescent cells undergo dramatic",
            "probability": 4.947185516357422e-06
        },
        {
            "start_logit": 8.3515625,
            "end_logit": -6.66796875,
            "text": "Senescent cells undergo dramatic alterations to their chromatin landscape",
            "probability": 4.172325134277344e-06
        },
        {
            "start_logit": 8.3515625,
            "end_logit": -6.70703125,
            "text": "Senescent cells undergo dramatic alterations to",
            "probability": 3.993511199951172e-06
        },
        {
            "start_logit": 8.3515625,
            "end_logit": -6.8828125,
            "text": "Senescent cells undergo dramatic alterations to their chromatin landscape that affect genome accessibility and their transcriptional program. These include the loss of DNA-nuclear lamina interactions, the distension of centromeres",
            "probability": 3.337860107421875e-06
        },
        {
            "start_logit": 8.3515625,
            "end_logit": -6.9140625,
            "text": "Senescent cells undergo dramatic alterations to their",
            "probability": 3.2186508178710938e-06
        },
        {
            "start_logit": 8.3515625,
            "end_logit": -6.92578125,
            "text": "Senescent cells undergo dramatic alterations to their chromatin landscape that affect genome accessibility and their transcriptional program. These include the loss of DNA-nuclear lamina interactions, the distension of centromeres,",
            "probability": 3.159046173095703e-06
        },
        {
            "start_logit": 8.3515625,
            "end_logit": -6.97265625,
            "text": "Senescent cells undergo dramatic alterations to their chromatin",
            "probability": 3.039836883544922e-06
        },
        {
            "start_logit": 8.3515625,
            "end_logit": -6.99609375,
            "text": "Senescent cells undergo dramatic alterations to their chromatin landscape that affect genome accessibility",
            "probability": 2.9802322387695312e-06
        }
    ],
    "5fe3130da43ad3127800003f_1": [
        {
            "start_logit": -2.357421875,
            "end_logit": 8.671875,
            "text": "joints",
            "probability": 0.464599609375
        },
        {
            "start_logit": -2.509765625,
            "end_logit": 8.671875,
            "text": "28 joints",
            "probability": 0.400390625
        },
        {
            "start_logit": -4.28125,
            "end_logit": 8.671875,
            "text": "Disease activity score in 28 joints",
            "probability": 0.0679931640625
        },
        {
            "start_logit": -4.3515625,
            "end_logit": 8.671875,
            "text": "in 28 joints",
            "probability": 0.0633544921875
        },
        {
            "start_logit": -7.7578125,
            "end_logit": 8.671875,
            "text": "score in 28 joints",
            "probability": 0.002101898193359375
        },
        {
            "start_logit": -8.03125,
            "end_logit": 8.671875,
            "text": "activity score in 28 joints",
            "probability": 0.001598358154296875
        },
        {
            "start_logit": -2.357421875,
            "end_logit": -4.57421875,
            "text": "joints (",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": -2.509765625,
            "end_logit": -4.57421875,
            "text": "28 joints (",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -4.28125,
            "end_logit": -4.57421875,
            "text": "Disease activity score in 28 joints (",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -4.3515625,
            "end_logit": -4.57421875,
            "text": "in 28 joints (",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -2.357421875,
            "end_logit": -7.61328125,
            "text": "joints (DAS28",
            "probability": 0.0
        },
        {
            "start_logit": -2.357421875,
            "end_logit": -7.65234375,
            "text": "joints (DAS28)",
            "probability": 0.0
        },
        {
            "start_logit": -2.357421875,
            "end_logit": -7.703125,
            "text": "joints (DAS",
            "probability": 0.0
        },
        {
            "start_logit": -2.509765625,
            "end_logit": -7.61328125,
            "text": "28 joints (DAS28",
            "probability": 0.0
        },
        {
            "start_logit": -2.509765625,
            "end_logit": -7.65234375,
            "text": "28 joints (DAS28)",
            "probability": 0.0
        },
        {
            "start_logit": -2.509765625,
            "end_logit": -7.703125,
            "text": "28 joints (DAS",
            "probability": 0.0
        },
        {
            "start_logit": -4.28125,
            "end_logit": -7.61328125,
            "text": "Disease activity score in 28 joints (DAS28",
            "probability": 0.0
        },
        {
            "start_logit": -4.28125,
            "end_logit": -7.65234375,
            "text": "Disease activity score in 28 joints (DAS28)",
            "probability": 0.0
        },
        {
            "start_logit": -4.3515625,
            "end_logit": -7.61328125,
            "text": "in 28 joints (DAS28",
            "probability": 0.0
        },
        {
            "start_logit": -4.28125,
            "end_logit": -7.703125,
            "text": "Disease activity score in 28 joints (DAS",
            "probability": 0.0
        }
    ],
    "5fe3130da43ad3127800003f_2": [
        {
            "start_logit": -5.15625,
            "end_logit": 4.6328125,
            "text": "28 joints",
            "probability": 0.3447265625
        },
        {
            "start_logit": -5.26171875,
            "end_logit": 4.6328125,
            "text": "joints",
            "probability": 0.310302734375
        },
        {
            "start_logit": -6.28515625,
            "end_logit": 4.6328125,
            "text": "in 28 joints",
            "probability": 0.11151123046875
        },
        {
            "start_logit": -7.5625,
            "end_logit": 4.6328125,
            "text": "Disease Activity Score in 28 joints",
            "probability": 0.0310821533203125
        },
        {
            "start_logit": -7.6640625,
            "end_logit": 4.6328125,
            "text": "study to evaluate the current therapy with infliximab, the level of disease activity (Disease Activity Score in 28 joints",
            "probability": 0.028076171875
        },
        {
            "start_logit": -7.87109375,
            "end_logit": 4.6328125,
            "text": "(Disease Activity Score in 28 joints",
            "probability": 0.0228271484375
        },
        {
            "start_logit": -7.984375,
            "end_logit": 4.6328125,
            "text": "treating rheumatologists were asked to complete a questionnaire designed specifically for the present study to evaluate the current therapy with infliximab, the level of disease activity (Disease Activity Score in 28 joints",
            "probability": 0.0203857421875
        },
        {
            "start_logit": -7.9921875,
            "end_logit": 4.6328125,
            "text": "present study to evaluate the current therapy with infliximab, the level of disease activity (Disease Activity Score in 28 joints",
            "probability": 0.0202178955078125
        },
        {
            "start_logit": -8.0078125,
            "end_logit": 4.6328125,
            "text": "level of disease activity (Disease Activity Score in 28 joints",
            "probability": 0.0199127197265625
        },
        {
            "start_logit": -8.0703125,
            "end_logit": 4.6328125,
            "text": "the level of disease activity (Disease Activity Score in 28 joints",
            "probability": 0.018707275390625
        },
        {
            "start_logit": -8.0859375,
            "end_logit": 4.6328125,
            "text": "rheumatologists were asked to complete a questionnaire designed specifically for the present study to evaluate the current therapy with infliximab, the level of disease activity (Disease Activity Score in 28 joints",
            "probability": 0.0184173583984375
        },
        {
            "start_logit": -8.09375,
            "end_logit": 4.6328125,
            "text": "questionnaire designed specifically for the present study to evaluate the current therapy with infliximab, the level of disease activity (Disease Activity Score in 28 joints",
            "probability": 0.018280029296875
        },
        {
            "start_logit": -8.109375,
            "end_logit": 4.6328125,
            "text": "with infliximab, the level of disease activity (Disease Activity Score in 28 joints",
            "probability": 0.0179901123046875
        },
        {
            "start_logit": -8.140625,
            "end_logit": 4.6328125,
            "text": "Score in 28 joints",
            "probability": 0.0174407958984375
        },
        {
            "start_logit": -5.15625,
            "end_logit": -6.69140625,
            "text": "28 joints [",
            "probability": 4.172325134277344e-06
        },
        {
            "start_logit": -5.26171875,
            "end_logit": -6.69140625,
            "text": "joints [",
            "probability": 3.7550926208496094e-06
        },
        {
            "start_logit": -5.15625,
            "end_logit": -7.65625,
            "text": "28 joints [DAS28]",
            "probability": 1.6093254089355469e-06
        },
        {
            "start_logit": -5.15625,
            "end_logit": -7.67578125,
            "text": "28 joints [DAS28])",
            "probability": 1.5497207641601562e-06
        },
        {
            "start_logit": -5.15625,
            "end_logit": -7.6953125,
            "text": "28 joints [DAS28",
            "probability": 1.5497207641601562e-06
        },
        {
            "start_logit": -5.15625,
            "end_logit": -7.75390625,
            "text": "28 joints [DAS28]) and",
            "probability": 1.430511474609375e-06
        }
    ],
    "5fe3130da43ad3127800003f_3": [
        {
            "start_logit": -0.7041015625,
            "end_logit": 8.5859375,
            "text": "Disease Activity Score in 28 Joints",
            "probability": 0.8447265625
        },
        {
            "start_logit": -2.6953125,
            "end_logit": 8.5859375,
            "text": "Joints",
            "probability": 0.11517333984375
        },
        {
            "start_logit": -4.1640625,
            "end_logit": 8.5859375,
            "text": "28 Joints",
            "probability": 0.0265350341796875
        },
        {
            "start_logit": -4.984375,
            "end_logit": 8.5859375,
            "text": "in 28 Joints",
            "probability": 0.01168060302734375
        },
        {
            "start_logit": -7.73828125,
            "end_logit": 8.5859375,
            "text": "Score in 28 Joints",
            "probability": 0.000743865966796875
        },
        {
            "start_logit": -7.87890625,
            "end_logit": 8.5859375,
            "text": "Activity Score in 28 Joints",
            "probability": 0.0006461143493652344
        },
        {
            "start_logit": -7.99609375,
            "end_logit": 8.5859375,
            "text": "BACKGROUND: Disease Activity Score in 28 Joints",
            "probability": 0.0005750656127929688
        },
        {
            "start_logit": -0.7041015625,
            "end_logit": -5.1484375,
            "text": "Disease Activity Score in 28 Joints (DAS28) is a scoring system to evaluate disease activity and treatment response in rheumatoid arthritis (RA).",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": -0.7041015625,
            "end_logit": -5.359375,
            "text": "Disease Activity Score in 28 Joints (",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": -2.6953125,
            "end_logit": -5.1484375,
            "text": "Joints (DAS28) is a scoring system to evaluate disease activity and treatment response in rheumatoid arthritis (RA).",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -2.6953125,
            "end_logit": -5.359375,
            "text": "Joints (",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -0.7041015625,
            "end_logit": -7.42578125,
            "text": "Disease Activity Score in 28 Joints (DAS28) is",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -0.7041015625,
            "end_logit": -7.56640625,
            "text": "Disease Activity Score in 28 Joints (DAS28) is a scoring system to evaluate disease activity and treatment response in rheumatoid arthritis",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -0.7041015625,
            "end_logit": -7.6953125,
            "text": "Disease Activity Score in 28 Joints (DAS28) is a scoring system to evaluate disease activity and treatment response in rheumatoid arthritis (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -0.7041015625,
            "end_logit": -7.7109375,
            "text": "Disease Activity Score in 28 Joints (DAS28) is a scoring system to evaluate disease activity and treatment response in rheumatoid arthritis (RA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -0.7041015625,
            "end_logit": -7.73046875,
            "text": "Disease Activity Score in 28 Joints (DAS28",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -0.7041015625,
            "end_logit": -7.73046875,
            "text": "Disease Activity Score in 28 Joints (DAS28) is a",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -0.7041015625,
            "end_logit": -7.7890625,
            "text": "Disease Activity Score in 28 Joints (DAS28) is a scoring system to evaluate disease activity and treatment response in rheumatoid arthritis (RA)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -0.7041015625,
            "end_logit": -7.84375,
            "text": "Disease Activity Score in 28 Joints (DAS28) is a scoring system to evaluate disease activity and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -0.7041015625,
            "end_logit": -7.8828125,
            "text": "Disease Activity Score in 28 Joints (DAS28) is a scoring system to evaluate disease activity and treatment response in",
            "probability": 5.960464477539063e-08
        }
    ],
    "5fe3130da43ad3127800003f_4": [
        {
            "start_logit": -5.1796875,
            "end_logit": 5.1171875,
            "text": "joints",
            "probability": 0.326904296875
        },
        {
            "start_logit": -5.4765625,
            "end_logit": 5.1171875,
            "text": "Disease Activity Score in 28 joints",
            "probability": 0.242919921875
        },
        {
            "start_logit": -5.8515625,
            "end_logit": 5.1171875,
            "text": "28 joints",
            "probability": 0.1669921875
        },
        {
            "start_logit": -6.67578125,
            "end_logit": 5.1171875,
            "text": "in 28 joints",
            "probability": 0.0732421875
        },
        {
            "start_logit": -7.26953125,
            "end_logit": 5.1171875,
            "text": "a Disease Activity Score in 28 joints",
            "probability": 0.040435791015625
        },
        {
            "start_logit": -7.88671875,
            "end_logit": 5.1171875,
            "text": "rheumatoid arthritis (RA) as defined by a Disease Activity Score in 28 joints",
            "probability": 0.0218048095703125
        },
        {
            "start_logit": -7.9296875,
            "end_logit": 5.1171875,
            "text": "OBJECTIVE: Antirheumatic treatment is frequently not appropriately modified, according to American College of Rheumatology guidelines, in patients with active rheumatoid arthritis (RA) as defined by a Disease Activity Score in 28 joints",
            "probability": 0.0208892822265625
        },
        {
            "start_logit": -7.984375,
            "end_logit": 5.1171875,
            "text": ", according to American College of Rheumatology guidelines, in patients with active rheumatoid arthritis (RA) as defined by a Disease Activity Score in 28 joints",
            "probability": 0.0197906494140625
        },
        {
            "start_logit": -8.03125,
            "end_logit": 5.1171875,
            "text": "Score in 28 joints",
            "probability": 0.0188751220703125
        },
        {
            "start_logit": -8.078125,
            "end_logit": 5.1171875,
            "text": "by a Disease Activity Score in 28 joints",
            "probability": 0.0180206298828125
        },
        {
            "start_logit": -8.1171875,
            "end_logit": 5.1171875,
            "text": "in patients with active rheumatoid arthritis (RA) as defined by a Disease Activity Score in 28 joints",
            "probability": 0.017333984375
        },
        {
            "start_logit": -8.171875,
            "end_logit": 5.1171875,
            "text": ": Antirheumatic treatment is frequently not appropriately modified, according to American College of Rheumatology guidelines, in patients with active rheumatoid arthritis (RA) as defined by a Disease Activity Score in 28 joints",
            "probability": 0.0164031982421875
        },
        {
            "start_logit": -8.171875,
            "end_logit": 5.1171875,
            "text": ", in patients with active rheumatoid arthritis (RA) as defined by a Disease Activity Score in 28 joints",
            "probability": 0.0164031982421875
        },
        {
            "start_logit": -5.1796875,
            "end_logit": -6.59375,
            "text": "joints (DAS28) score greater",
            "probability": 2.682209014892578e-06
        },
        {
            "start_logit": -5.1796875,
            "end_logit": -6.8515625,
            "text": "joints (",
            "probability": 2.086162567138672e-06
        },
        {
            "start_logit": -5.4765625,
            "end_logit": -6.59375,
            "text": "Disease Activity Score in 28 joints (DAS28) score greater",
            "probability": 1.9669532775878906e-06
        },
        {
            "start_logit": -5.1796875,
            "end_logit": -7.10546875,
            "text": "joints (DAS28",
            "probability": 1.6093254089355469e-06
        },
        {
            "start_logit": -5.4765625,
            "end_logit": -6.8515625,
            "text": "Disease Activity Score in 28 joints (",
            "probability": 1.5497207641601562e-06
        },
        {
            "start_logit": -5.1796875,
            "end_logit": -7.2265625,
            "text": "joints (DAS28)",
            "probability": 1.430511474609375e-06
        },
        {
            "start_logit": -5.8515625,
            "end_logit": -6.59375,
            "text": "28 joints (DAS28) score greater",
            "probability": 1.3709068298339844e-06
        }
    ],
    "5fe3130da43ad3127800003f_5": [
        {
            "start_logit": -1.3408203125,
            "end_logit": 9.4609375,
            "text": "joints",
            "probability": 0.669921875
        },
        {
            "start_logit": -2.138671875,
            "end_logit": 9.4609375,
            "text": "28 joints",
            "probability": 0.302001953125
        },
        {
            "start_logit": -5.12109375,
            "end_logit": 9.4609375,
            "text": "on 28 joints",
            "probability": 0.0153350830078125
        },
        {
            "start_logit": -6.24609375,
            "end_logit": 9.4609375,
            "text": "based on 28 joints",
            "probability": 0.004978179931640625
        },
        {
            "start_logit": -6.90234375,
            "end_logit": 9.4609375,
            "text": "Disease Activity Score based on 28 joints",
            "probability": 0.002582550048828125
        },
        {
            "start_logit": -7.5078125,
            "end_logit": 9.4609375,
            "text": "The Disease Activity Score based on 28 joints",
            "probability": 0.0014095306396484375
        },
        {
            "start_logit": -7.83984375,
            "end_logit": 9.4609375,
            "text": "OBJECTIVE: The Disease Activity Score based on 28 joints",
            "probability": 0.0010118484497070312
        },
        {
            "start_logit": -8.046875,
            "end_logit": 9.4609375,
            "text": "Score based on 28 joints",
            "probability": 0.0008225440979003906
        },
        {
            "start_logit": -8.203125,
            "end_logit": 9.4609375,
            "text": "Activity Score based on 28 joints",
            "probability": 0.0007038116455078125
        },
        {
            "start_logit": -8.203125,
            "end_logit": 9.4609375,
            "text": ": The Disease Activity Score based on 28 joints",
            "probability": 0.0007038116455078125
        },
        {
            "start_logit": -1.3408203125,
            "end_logit": -6.9921875,
            "text": "joints (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.3408203125,
            "end_logit": -7.453125,
            "text": "joints (DAS28) has",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.3408203125,
            "end_logit": -7.51171875,
            "text": "joints (DAS28) has been increasingly used in clinical practice and research studies of rheumatoid arthr",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.3408203125,
            "end_logit": -7.59765625,
            "text": "joints (DAS28",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.3408203125,
            "end_logit": -7.640625,
            "text": "joints (DAS28) has been increasingly used in clinical practice and research studies of rheumatoid arth",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.3408203125,
            "end_logit": -7.67578125,
            "text": "joints (DAS28) has been",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.3408203125,
            "end_logit": -7.7265625,
            "text": "joints (DAS28) has been increasingly",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.3408203125,
            "end_logit": -7.78515625,
            "text": "joints (DAS28) has been increasingly used in",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.138671875,
            "end_logit": -6.9921875,
            "text": "28 joints (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.3408203125,
            "end_logit": -7.8203125,
            "text": "joints (DAS28) has been increasingly used in clinical practice",
            "probability": 5.960464477539063e-08
        }
    ],
    "5fe3130da43ad3127800003f_6": [
        {
            "start_logit": -1.3369140625,
            "end_logit": 9.46875,
            "text": "joints",
            "probability": 0.69921875
        },
        {
            "start_logit": -2.2890625,
            "end_logit": 9.46875,
            "text": "28 joints",
            "probability": 0.26953125
        },
        {
            "start_logit": -5.0625,
            "end_logit": 9.46875,
            "text": "on 28 joints",
            "probability": 0.016845703125
        },
        {
            "start_logit": -5.96484375,
            "end_logit": 9.46875,
            "text": "based on 28 joints",
            "probability": 0.006832122802734375
        },
        {
            "start_logit": -6.96484375,
            "end_logit": 9.46875,
            "text": "Disease Activity Score based on 28 joints",
            "probability": 0.002513885498046875
        },
        {
            "start_logit": -7.484375,
            "end_logit": 9.46875,
            "text": "The Disease Activity Score based on 28 joints",
            "probability": 0.0014944076538085938
        },
        {
            "start_logit": -7.83203125,
            "end_logit": 9.46875,
            "text": "OBJECTIVE: The Disease Activity Score based on 28 joints",
            "probability": 0.0010557174682617188
        },
        {
            "start_logit": -8.0546875,
            "end_logit": 9.46875,
            "text": "Score based on 28 joints",
            "probability": 0.0008449554443359375
        },
        {
            "start_logit": -8.1875,
            "end_logit": 9.46875,
            "text": "Activity Score based on 28 joints",
            "probability": 0.0007395744323730469
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 9.46875,
            "text": ": The Disease Activity Score based on 28 joints",
            "probability": 0.0007224082946777344
        },
        {
            "start_logit": -1.3369140625,
            "end_logit": -6.9921875,
            "text": "joints (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.3369140625,
            "end_logit": -7.47265625,
            "text": "joints (DAS28) has",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.3369140625,
            "end_logit": -7.4921875,
            "text": "joints (DAS28) has been widely used in clinical practice and research studies of rheumatoid arthr",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.3369140625,
            "end_logit": -7.57421875,
            "text": "joints (DAS28",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.3369140625,
            "end_logit": -7.64453125,
            "text": "joints (DAS28) has been widely used in clinical practice and research studies of rheumatoid arth",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.3369140625,
            "end_logit": -7.73046875,
            "text": "joints (DAS28) has been",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.3369140625,
            "end_logit": -7.78515625,
            "text": "joints (DAS28) has been widely used in",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.3369140625,
            "end_logit": -7.8359375,
            "text": "joints (DAS28) has been widely used in clinical practice",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.3369140625,
            "end_logit": -7.8359375,
            "text": "joints (DAS28) has been widely",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.3369140625,
            "end_logit": -7.84375,
            "text": "joints (DAS28) has been widely used",
            "probability": 5.960464477539063e-08
        }
    ],
    "5fe3130da43ad3127800003f_7": [
        {
            "start_logit": -3.03125,
            "end_logit": 8.2421875,
            "text": "joints",
            "probability": 0.53759765625
        },
        {
            "start_logit": -4.01953125,
            "end_logit": 8.2421875,
            "text": "28 joints",
            "probability": 0.2001953125
        },
        {
            "start_logit": -4.23046875,
            "end_logit": 8.2421875,
            "text": "Disease Activity Score in 28 joints",
            "probability": 0.162109375
        },
        {
            "start_logit": -4.91796875,
            "end_logit": 8.2421875,
            "text": "in 28 joints",
            "probability": 0.08154296875
        },
        {
            "start_logit": -7.0078125,
            "end_logit": 8.2421875,
            "text": "The Disease Activity Score in 28 joints",
            "probability": 0.0100860595703125
        },
        {
            "start_logit": -7.87890625,
            "end_logit": 8.2421875,
            "text": "OBJECTIVE: The Disease Activity Score in 28 joints",
            "probability": 0.00421905517578125
        },
        {
            "start_logit": -7.92578125,
            "end_logit": 8.2421875,
            "text": "Score in 28 joints",
            "probability": 0.0040283203125
        },
        {
            "start_logit": -3.03125,
            "end_logit": -6.6484375,
            "text": "joints (",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -3.03125,
            "end_logit": -6.65234375,
            "text": "joints (DAS28), used to assess disease activity in rheumatoid arthritis",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -4.01953125,
            "end_logit": -6.6484375,
            "text": "28 joints (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -4.01953125,
            "end_logit": -6.65234375,
            "text": "28 joints (DAS28), used to assess disease activity in rheumatoid arthritis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -3.03125,
            "end_logit": -7.69921875,
            "text": "joints (DAS28",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -3.03125,
            "end_logit": -7.765625,
            "text": "joints (DAS28), used to assess disease activity",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -3.03125,
            "end_logit": -7.8203125,
            "text": "joints (DAS28), used to assess disease activity in rheumatoid arthritis (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -4.23046875,
            "end_logit": -6.6484375,
            "text": "Disease Activity Score in 28 joints (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -3.03125,
            "end_logit": -7.8515625,
            "text": "joints (DAS28), used to assess disease activity in rheumatoid arthritis (RA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -3.03125,
            "end_logit": -7.8515625,
            "text": "joints (DAS28), used to assess disease activity in rheumatoid",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -4.23046875,
            "end_logit": -6.65234375,
            "text": "Disease Activity Score in 28 joints (DAS28), used to assess disease activity in rheumatoid arthritis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -3.03125,
            "end_logit": -7.85546875,
            "text": "joints (DAS28), used to assess disease activity in rheumatoid arthritis (RA), is a composite score comprising clinical, biochemical, and patient self-report",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -3.03125,
            "end_logit": -7.8671875,
            "text": "joints (DAS",
            "probability": 5.960464477539063e-08
        }
    ],
    "5fe3130da43ad3127800003f_8": [
        {
            "start_logit": -0.388427734375,
            "end_logit": 6.3984375,
            "text": "component Disease Activity Score in 28 joints",
            "probability": 0.9560546875
        },
        {
            "start_logit": -4.4765625,
            "end_logit": 6.3984375,
            "text": "joint synovitis, i.e., the 2-component Disease Activity Score in 28 joints",
            "probability": 0.0160064697265625
        },
        {
            "start_logit": -4.50390625,
            "end_logit": 6.3984375,
            "text": "joints",
            "probability": 0.0155792236328125
        },
        {
            "start_logit": -6.3125,
            "end_logit": 6.3984375,
            "text": "2-component Disease Activity Score in 28 joints",
            "probability": 0.0025539398193359375
        },
        {
            "start_logit": -6.375,
            "end_logit": 6.3984375,
            "text": "the 2-component Disease Activity Score in 28 joints",
            "probability": 0.0023975372314453125
        },
        {
            "start_logit": -6.4453125,
            "end_logit": 6.3984375,
            "text": "Disease Activity Score in 28 joints",
            "probability": 0.00223541259765625
        },
        {
            "start_logit": -7.3828125,
            "end_logit": 6.3984375,
            "text": "reflects joint synovitis, i.e., the 2-component Disease Activity Score in 28 joints",
            "probability": 0.0008754730224609375
        },
        {
            "start_logit": -7.47265625,
            "end_logit": 6.3984375,
            "text": ", the 2-component Disease Activity Score in 28 joints",
            "probability": 0.0008001327514648438
        },
        {
            "start_logit": -7.51171875,
            "end_logit": 6.3984375,
            "text": "in 28 joints",
            "probability": 0.0007696151733398438
        },
        {
            "start_logit": -7.56640625,
            "end_logit": 6.3984375,
            "text": "better reflects joint synovitis, i.e., the 2-component Disease Activity Score in 28 joints",
            "probability": 0.000728607177734375
        },
        {
            "start_logit": -7.83203125,
            "end_logit": 6.3984375,
            "text": "reweighted disease activity score that better reflects joint synovitis, i.e., the 2-component Disease Activity Score in 28 joints",
            "probability": 0.0005583763122558594
        },
        {
            "start_logit": -7.87890625,
            "end_logit": 6.3984375,
            "text": "OBJECTIVE: To determine whether using a reweighted disease activity score that better reflects joint synovitis, i.e., the 2-component Disease Activity Score in 28 joints",
            "probability": 0.0005331039428710938
        },
        {
            "start_logit": -7.88671875,
            "end_logit": 6.3984375,
            "text": "28 joints",
            "probability": 0.0005288124084472656
        },
        {
            "start_logit": -7.8984375,
            "end_logit": 6.3984375,
            "text": "using a reweighted disease activity score that better reflects joint synovitis, i.e., the 2-component Disease Activity Score in 28 joints",
            "probability": 0.000522613525390625
        },
        {
            "start_logit": -0.388427734375,
            "end_logit": -5.96875,
            "text": "component",
            "probability": 4.0531158447265625e-06
        },
        {
            "start_logit": -0.388427734375,
            "end_logit": -6.34765625,
            "text": "component Disease Activity Score in 28 joints (",
            "probability": 2.8014183044433594e-06
        },
        {
            "start_logit": -0.388427734375,
            "end_logit": -6.5234375,
            "text": "component Disease Activity Score in 28 joints (DAS28",
            "probability": 2.3245811462402344e-06
        },
        {
            "start_logit": -0.388427734375,
            "end_logit": -7.3515625,
            "text": "component Disease Activity Score in 28 joints (DAS28) (based on swollen joint count and",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": -0.388427734375,
            "end_logit": -7.47265625,
            "text": "component Disease Activity Score in 28 joints (DAS28) (based on swollen joint count",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": -0.388427734375,
            "end_logit": -7.50390625,
            "text": "component Disease Activity Score in 28 joints (DAS",
            "probability": 8.344650268554688e-07
        }
    ],
    "5fe3130da43ad3127800003f_9": [
        {
            "start_logit": -2.30859375,
            "end_logit": 8.8125,
            "text": "joints",
            "probability": 0.634765625
        },
        {
            "start_logit": -3.109375,
            "end_logit": 8.8125,
            "text": "28 joints",
            "probability": 0.284912109375
        },
        {
            "start_logit": -4.625,
            "end_logit": 8.8125,
            "text": "in 28 joints",
            "probability": 0.0626220703125
        },
        {
            "start_logit": -6.671875,
            "end_logit": 8.8125,
            "text": "Disease Activity Score in 28 joints",
            "probability": 0.008087158203125
        },
        {
            "start_logit": -7.4453125,
            "end_logit": 8.8125,
            "text": "The Disease Activity Score in 28 joints",
            "probability": 0.0037326812744140625
        },
        {
            "start_logit": -7.84765625,
            "end_logit": 8.8125,
            "text": "OBJECTIVE: The Disease Activity Score in 28 joints",
            "probability": 0.00249481201171875
        },
        {
            "start_logit": -8.1640625,
            "end_logit": 8.8125,
            "text": "Score in 28 joints",
            "probability": 0.0018186569213867188
        },
        {
            "start_logit": -8.25,
            "end_logit": 8.8125,
            "text": ": The Disease Activity Score in 28 joints",
            "probability": 0.0016689300537109375
        },
        {
            "start_logit": -2.30859375,
            "end_logit": -7.01171875,
            "text": "joints (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.30859375,
            "end_logit": -7.68359375,
            "text": "joints (DAS28) is",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.30859375,
            "end_logit": -7.75390625,
            "text": "joints (DAS28",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.30859375,
            "end_logit": -7.78125,
            "text": "joints (DAS28) is a",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -3.109375,
            "end_logit": -7.01171875,
            "text": "28 joints (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.30859375,
            "end_logit": -7.86328125,
            "text": "joints (DAS28) is a key measure in clinical practice",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.30859375,
            "end_logit": -7.90234375,
            "text": "joints (DAS",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -3.109375,
            "end_logit": -7.68359375,
            "text": "28 joints (DAS28) is",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -3.109375,
            "end_logit": -7.75390625,
            "text": "28 joints (DAS28",
            "probability": 0.0
        },
        {
            "start_logit": -3.109375,
            "end_logit": -7.78125,
            "text": "28 joints (DAS28) is a",
            "probability": 0.0
        },
        {
            "start_logit": -3.109375,
            "end_logit": -7.86328125,
            "text": "28 joints (DAS28) is a key measure in clinical practice",
            "probability": 0.0
        },
        {
            "start_logit": -3.109375,
            "end_logit": -7.90234375,
            "text": "28 joints (DAS",
            "probability": 0.0
        }
    ],
    "5fe3130da43ad3127800003f_10": [
        {
            "start_logit": -2.77734375,
            "end_logit": 8.4375,
            "text": "Joints",
            "probability": 0.61865234375
        },
        {
            "start_logit": -3.712890625,
            "end_logit": 8.4375,
            "text": "28 Joints",
            "probability": 0.2431640625
        },
        {
            "start_logit": -4.83203125,
            "end_logit": 8.4375,
            "text": "in 28 Joints",
            "probability": 0.07928466796875
        },
        {
            "start_logit": -5.3671875,
            "end_logit": 8.4375,
            "text": "Disease Activity Score in 28 Joints",
            "probability": 0.046417236328125
        },
        {
            "start_logit": -7.9765625,
            "end_logit": 8.4375,
            "text": "BACKGROUND: Disease Activity Score in 28 Joints",
            "probability": 0.0034160614013671875
        },
        {
            "start_logit": -8.046875,
            "end_logit": 8.4375,
            "text": "Score in 28 Joints",
            "probability": 0.0031833648681640625
        },
        {
            "start_logit": -8.125,
            "end_logit": 8.4375,
            "text": "Activity Score in 28 Joints",
            "probability": 0.0029449462890625
        },
        {
            "start_logit": -8.203125,
            "end_logit": 8.4375,
            "text": ": Disease Activity Score in 28 Joints",
            "probability": 0.00272369384765625
        },
        {
            "start_logit": -2.77734375,
            "end_logit": -6.02734375,
            "text": "Joints (DAS28) is a scoring system to evaluate disease activity and treatment response in rheumatoid arth",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -2.77734375,
            "end_logit": -6.9609375,
            "text": "Joints (",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -3.712890625,
            "end_logit": -6.02734375,
            "text": "28 Joints (DAS28) is a scoring system to evaluate disease activity and treatment response in rheumatoid arth",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -2.77734375,
            "end_logit": -7.20703125,
            "text": "Joints (DAS28) is",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -2.77734375,
            "end_logit": -7.3828125,
            "text": "Joints (DAS28) is a scoring system to evaluate disease activity and treatment response in rheumatoid",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.77734375,
            "end_logit": -7.73046875,
            "text": "Joints (DAS28) is a",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.77734375,
            "end_logit": -7.74609375,
            "text": "Joints (DAS28) is a scoring system to evaluate disease activity and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.77734375,
            "end_logit": -7.75390625,
            "text": "Joints (DAS28",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -3.712890625,
            "end_logit": -6.9609375,
            "text": "28 Joints (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.77734375,
            "end_logit": -7.921875,
            "text": "Joints (DAS28)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.77734375,
            "end_logit": -7.9296875,
            "text": "Joints (DAS28) is a scoring system to evaluate disease activity",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.77734375,
            "end_logit": -7.9296875,
            "text": "Joints (DAS28) is a scoring system to evaluate disease activity and treatment",
            "probability": 5.960464477539063e-08
        }
    ],
    "5fe3130da43ad3127800003f_11": [
        {
            "start_logit": -4.76953125,
            "end_logit": 6.0546875,
            "text": "joints",
            "probability": 0.416259765625
        },
        {
            "start_logit": -4.80859375,
            "end_logit": 6.0546875,
            "text": "28 joints",
            "probability": 0.400390625
        },
        {
            "start_logit": -6.3515625,
            "end_logit": 6.0546875,
            "text": "in 28 joints",
            "probability": 0.0855712890625
        },
        {
            "start_logit": -6.625,
            "end_logit": 6.0546875,
            "text": "Disease Activity Score in 28 joints",
            "probability": 0.0650634765625
        },
        {
            "start_logit": -7.95703125,
            "end_logit": 6.0546875,
            "text": "Comparison of Disease Activity Score in 28 joints",
            "probability": 0.017181396484375
        },
        {
            "start_logit": -8.0859375,
            "end_logit": 6.0546875,
            "text": "Score in 28 joints",
            "probability": 0.015106201171875
        },
        {
            "start_logit": -4.796875,
            "end_logit": -4.06640625,
            "text": ".",
            "probability": 1.6450881958007812e-05
        },
        {
            "start_logit": -4.76953125,
            "end_logit": -5.94140625,
            "text": "joints with ESR",
            "probability": 2.562999725341797e-06
        },
        {
            "start_logit": -4.80859375,
            "end_logit": -5.94140625,
            "text": "28 joints with ESR",
            "probability": 2.5033950805664062e-06
        },
        {
            "start_logit": -7.26171875,
            "end_logit": -4.06640625,
            "text": "rheumatoid arthritis at initial presentation.",
            "probability": 1.3709068298339844e-06
        },
        {
            "start_logit": -4.76953125,
            "end_logit": -6.97265625,
            "text": "joints with",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": -4.80859375,
            "end_logit": -6.97265625,
            "text": "28 joints with",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": -4.76953125,
            "end_logit": -7.1953125,
            "text": "joints with ESR (",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -4.76953125,
            "end_logit": -7.2109375,
            "text": "joints with ESR (DAS28",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -4.80859375,
            "end_logit": -7.1953125,
            "text": "28 joints with ESR (",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -4.80859375,
            "end_logit": -7.2109375,
            "text": "28 joints with ESR (DAS28",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -7.9609375,
            "end_logit": -4.06640625,
            "text": "assessing disease activity in patients with rheumatoid arthritis at initial presentation.",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -7.96875,
            "end_logit": -4.06640625,
            "text": "Health Assessment Questionnaire Disability Index (HAQ-DI) & Routine Assessment of Patient Index Data with 3 measures (RAPID3) for assessing disease activity in patients with rheumatoid arthritis at initial presentation.",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -4.76953125,
            "end_logit": -7.39453125,
            "text": "joints with ESR (DAS28)",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -4.76953125,
            "end_logit": -7.41015625,
            "text": "joints with ESR (DAS28), Clinical Disease Activity Index (CDAI)",
            "probability": 5.960464477539062e-07
        }
    ],
    "5fe3130da43ad3127800003f_12": [
        {
            "start_logit": -5.10546875,
            "end_logit": 5.07421875,
            "text": "joints",
            "probability": 0.5166015625
        },
        {
            "start_logit": -6.4296875,
            "end_logit": 5.07421875,
            "text": "Disease Activity Score in 28 joints",
            "probability": 0.137451171875
        },
        {
            "start_logit": -7.265625,
            "end_logit": 5.07421875,
            "text": "the Disease Activity Score in 28 joints",
            "probability": 0.0595703125
        },
        {
            "start_logit": -7.77734375,
            "end_logit": 5.07421875,
            "text": "28 joints",
            "probability": 0.035736083984375
        },
        {
            "start_logit": -7.86328125,
            "end_logit": 5.07421875,
            "text": "Clinical Disease Activity Index (CDAI) scores, and the Disease Activity Score in 28 joints",
            "probability": 0.03277587890625
        },
        {
            "start_logit": -7.87890625,
            "end_logit": 5.07421875,
            "text": "in 28 joints",
            "probability": 0.032257080078125
        },
        {
            "start_logit": -7.953125,
            "end_logit": 5.07421875,
            "text": "Disease Activity Index (CDAI) scores, and the Disease Activity Score in 28 joints",
            "probability": 0.0299530029296875
        },
        {
            "start_logit": -8.03125,
            "end_logit": 5.07421875,
            "text": "METHODS: Simplified Disease Activity Index (SDAI) scores, Clinical Disease Activity Index (CDAI) scores, and the Disease Activity Score in 28 joints",
            "probability": 0.0277099609375
        },
        {
            "start_logit": -8.0625,
            "end_logit": 5.07421875,
            "text": "Disease Activity Index (SDAI) scores, Clinical Disease Activity Index (CDAI) scores, and the Disease Activity Score in 28 joints",
            "probability": 0.02685546875
        },
        {
            "start_logit": -8.09375,
            "end_logit": 5.07421875,
            "text": ", and the Disease Activity Score in 28 joints",
            "probability": 0.026031494140625
        },
        {
            "start_logit": -8.109375,
            "end_logit": 5.07421875,
            "text": ", Clinical Disease Activity Index (CDAI) scores, and the Disease Activity Score in 28 joints",
            "probability": 0.0256195068359375
        },
        {
            "start_logit": -8.1171875,
            "end_logit": 5.07421875,
            "text": "and the Disease Activity Score in 28 joints",
            "probability": 0.025421142578125
        },
        {
            "start_logit": -8.171875,
            "end_logit": 5.07421875,
            "text": "Simplified Disease Activity Index (SDAI) scores, Clinical Disease Activity Index (CDAI) scores, and the Disease Activity Score in 28 joints",
            "probability": 0.024078369140625
        },
        {
            "start_logit": -5.10546875,
            "end_logit": -6.375,
            "text": "joints (DAS28) were calculated using data from tocilizumab trials in patients with RA in whom disease had remained active despite treatment with disease-modifying antirheumatic drugs.",
            "probability": 5.4836273193359375e-06
        },
        {
            "start_logit": -5.10546875,
            "end_logit": -7.07421875,
            "text": "joints (",
            "probability": 2.7418136596679688e-06
        },
        {
            "start_logit": -5.10546875,
            "end_logit": -7.3125,
            "text": "joints (DAS28) were calculated using data from tocilizumab trials in patients with RA",
            "probability": 2.1457672119140625e-06
        },
        {
            "start_logit": -5.10546875,
            "end_logit": -7.31640625,
            "text": "joints (DAS28",
            "probability": 2.1457672119140625e-06
        },
        {
            "start_logit": -5.10546875,
            "end_logit": -7.48828125,
            "text": "joints (DAS",
            "probability": 1.7881393432617188e-06
        },
        {
            "start_logit": -5.10546875,
            "end_logit": -7.50390625,
            "text": "joints (DAS28) were calculated using data from tocilizumab trials in patients with RA in",
            "probability": 1.7881393432617188e-06
        },
        {
            "start_logit": -6.26171875,
            "end_logit": -6.375,
            "text": ".",
            "probability": 1.7285346984863281e-06
        }
    ],
    "5fe3130da43ad3127800003f_13": [
        {
            "start_logit": -2.080078125,
            "end_logit": 8.71875,
            "text": "Disease activity score in 28 joints",
            "probability": 0.5
        },
        {
            "start_logit": -2.3359375,
            "end_logit": 8.71875,
            "text": "joints",
            "probability": 0.386474609375
        },
        {
            "start_logit": -3.68359375,
            "end_logit": 8.71875,
            "text": "28 joints",
            "probability": 0.10040283203125
        },
        {
            "start_logit": -5.9609375,
            "end_logit": 8.71875,
            "text": "in 28 joints",
            "probability": 0.0102996826171875
        },
        {
            "start_logit": -7.7890625,
            "end_logit": 8.71875,
            "text": "score in 28 joints",
            "probability": 0.0016546249389648438
        },
        {
            "start_logit": -8.0546875,
            "end_logit": 8.71875,
            "text": "activity score in 28 joints",
            "probability": 0.0012683868408203125
        },
        {
            "start_logit": -2.080078125,
            "end_logit": -5.7265625,
            "text": "Disease activity score in 28 joints (",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -2.3359375,
            "end_logit": -5.7265625,
            "text": "joints (",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -3.68359375,
            "end_logit": -5.7265625,
            "text": "28 joints (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.080078125,
            "end_logit": -7.390625,
            "text": "Disease activity score in 28 joints (DAS28",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.080078125,
            "end_logit": -7.390625,
            "text": "Disease activity score in 28 joints (DAS28)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.080078125,
            "end_logit": -7.53125,
            "text": "Disease activity score in 28 joints (DAS28)-remission has not been included among American College of Rheumatology/European League Against Rheumatism definitions, because of its association with significant residual disease activity,",
            "probability": 0.0
        },
        {
            "start_logit": -2.080078125,
            "end_logit": -7.60546875,
            "text": "Disease activity score in 28 joints (DAS28)-remission has not been included among American College of Rheumatology/European League Against Rheumatism definitions, because",
            "probability": 0.0
        },
        {
            "start_logit": -2.080078125,
            "end_logit": -7.625,
            "text": "Disease activity score in 28 joints (DAS28)-remission has not been included among American College of Rheumatology/European League Against Rheumatism definitions,",
            "probability": 0.0
        },
        {
            "start_logit": -2.080078125,
            "end_logit": -7.64453125,
            "text": "Disease activity score in 28 joints (DAS28)-remission has not been included among",
            "probability": 0.0
        },
        {
            "start_logit": -2.3359375,
            "end_logit": -7.390625,
            "text": "joints (DAS28",
            "probability": 0.0
        },
        {
            "start_logit": -2.3359375,
            "end_logit": -7.390625,
            "text": "joints (DAS28)",
            "probability": 0.0
        },
        {
            "start_logit": -2.080078125,
            "end_logit": -7.66796875,
            "text": "Disease activity score in 28 joints (DAS28)-remission has not been included among American College of Rheumatology/European League Against Rheumatism definitions, because of",
            "probability": 0.0
        },
        {
            "start_logit": -2.080078125,
            "end_logit": -7.734375,
            "text": "Disease activity score in 28 joints (DAS28)-remission has not",
            "probability": 0.0
        },
        {
            "start_logit": -2.080078125,
            "end_logit": -7.73828125,
            "text": "Disease activity score in 28 joints (DAS",
            "probability": 0.0
        }
    ],
    "5fe3130da43ad3127800003f_14": [
        {
            "start_logit": -4.671875,
            "end_logit": 3.623046875,
            "text": "with C-reactive protein",
            "probability": 0.45751953125
        },
        {
            "start_logit": -6.04296875,
            "end_logit": 3.623046875,
            "text": "C-reactive protein",
            "probability": 0.11614990234375
        },
        {
            "start_logit": -6.45703125,
            "end_logit": 3.623046875,
            "text": "joints with C-reactive protein",
            "probability": 0.07672119140625
        },
        {
            "start_logit": -6.828125,
            "end_logit": 3.623046875,
            "text": "28 joints with C-reactive protein",
            "probability": 0.052978515625
        },
        {
            "start_logit": -6.8671875,
            "end_logit": 3.623046875,
            "text": "protein",
            "probability": 0.050933837890625
        },
        {
            "start_logit": -6.45703125,
            "end_logit": 3.044921875,
            "text": "joints",
            "probability": 0.043060302734375
        },
        {
            "start_logit": -6.828125,
            "end_logit": 3.044921875,
            "text": "28 joints",
            "probability": 0.0297088623046875
        },
        {
            "start_logit": -7.7109375,
            "end_logit": 3.623046875,
            "text": "reactive protein",
            "probability": 0.0219573974609375
        },
        {
            "start_logit": -7.9140625,
            "end_logit": 3.623046875,
            "text": "Disease Activity Score of 28 joints with C-reactive protein",
            "probability": 0.017913818359375
        },
        {
            "start_logit": -7.98046875,
            "end_logit": 3.623046875,
            "text": "of 28 joints with C-reactive protein",
            "probability": 0.016693115234375
        },
        {
            "start_logit": -8.0546875,
            "end_logit": 3.623046875,
            "text": "in low or moderate Disease Activity Score of 28 joints with C-reactive protein",
            "probability": 0.01557159423828125
        },
        {
            "start_logit": -8.09375,
            "end_logit": 3.623046875,
            "text": "METHOD: All patients were na\u00efve to biological disease-modifying anti-rheumatic drugs (bDMARDs) and in low or moderate Disease Activity Score of 28 joints with C-reactive protein",
            "probability": 0.0149688720703125
        },
        {
            "start_logit": -8.109375,
            "end_logit": 3.623046875,
            "text": "moderate Disease Activity Score of 28 joints with C-reactive protein",
            "probability": 0.01473236083984375
        },
        {
            "start_logit": -8.21875,
            "end_logit": 3.623046875,
            "text": "All patients were na\u00efve to biological disease-modifying anti-rheumatic drugs (bDMARDs) and in low or moderate Disease Activity Score of 28 joints with C-reactive protein",
            "probability": 0.01320648193359375
        },
        {
            "start_logit": -8.234375,
            "end_logit": 3.623046875,
            "text": "Score of 28 joints with C-reactive protein",
            "probability": 0.01300811767578125
        },
        {
            "start_logit": -7.9140625,
            "end_logit": 3.044921875,
            "text": "Disease Activity Score of 28 joints",
            "probability": 0.01004791259765625
        },
        {
            "start_logit": -7.98046875,
            "end_logit": 3.044921875,
            "text": "of 28 joints",
            "probability": 0.009368896484375
        },
        {
            "start_logit": -8.0546875,
            "end_logit": 3.044921875,
            "text": "in low or moderate Disease Activity Score of 28 joints",
            "probability": 0.00873565673828125
        },
        {
            "start_logit": -8.09375,
            "end_logit": 3.044921875,
            "text": "METHOD: All patients were na\u00efve to biological disease-modifying anti-rheumatic drugs (bDMARDs) and in low or moderate Disease Activity Score of 28 joints",
            "probability": 0.00839996337890625
        },
        {
            "start_logit": -8.109375,
            "end_logit": 3.044921875,
            "text": "moderate Disease Activity Score of 28 joints",
            "probability": 0.0082550048828125
        }
    ],
    "5fe3130da43ad3127800003f_15": [
        {
            "start_logit": -2.912109375,
            "end_logit": 8.328125,
            "text": "Joints",
            "probability": 0.58740234375
        },
        {
            "start_logit": -3.767578125,
            "end_logit": 8.328125,
            "text": "28 Joints",
            "probability": 0.250732421875
        },
        {
            "start_logit": -4.8828125,
            "end_logit": 8.328125,
            "text": "in 28 Joints",
            "probability": 0.08203125
        },
        {
            "start_logit": -5.1015625,
            "end_logit": 8.328125,
            "text": "Disease Activity Score in 28 Joints",
            "probability": 0.06591796875
        },
        {
            "start_logit": -7.984375,
            "end_logit": 8.328125,
            "text": "BACKGROUND: Disease Activity Score in 28 Joints",
            "probability": 0.003688812255859375
        },
        {
            "start_logit": -8.015625,
            "end_logit": 8.328125,
            "text": "Score in 28 Joints",
            "probability": 0.0035762786865234375
        },
        {
            "start_logit": -8.09375,
            "end_logit": 8.328125,
            "text": "Activity Score in 28 Joints",
            "probability": 0.003307342529296875
        },
        {
            "start_logit": -8.1953125,
            "end_logit": 8.328125,
            "text": ": Disease Activity Score in 28 Joints",
            "probability": 0.002986907958984375
        },
        {
            "start_logit": -2.912109375,
            "end_logit": -4.76171875,
            "text": "Joints (DAS28) is a scoring system to evaluate disease activity and treatment response in rheumatoid art",
            "probability": 1.2516975402832031e-06
        },
        {
            "start_logit": -3.767578125,
            "end_logit": -4.76171875,
            "text": "28 Joints (DAS28) is a scoring system to evaluate disease activity and treatment response in rheumatoid art",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -4.8828125,
            "end_logit": -4.76171875,
            "text": "in 28 Joints (DAS28) is a scoring system to evaluate disease activity and treatment response in rheumatoid art",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -2.912109375,
            "end_logit": -6.91796875,
            "text": "Joints (",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -5.1015625,
            "end_logit": -4.76171875,
            "text": "Disease Activity Score in 28 Joints (DAS28) is a scoring system to evaluate disease activity and treatment response in rheumatoid art",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -2.912109375,
            "end_logit": -7.265625,
            "text": "Joints (DAS28) is",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -2.912109375,
            "end_logit": -7.76171875,
            "text": "Joints (DAS28) is a",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.912109375,
            "end_logit": -7.765625,
            "text": "Joints (DAS28",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -3.767578125,
            "end_logit": -6.91796875,
            "text": "28 Joints (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.912109375,
            "end_logit": -7.7890625,
            "text": "Joints (DAS28) is a scoring system to evaluate disease activity and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.912109375,
            "end_logit": -7.8984375,
            "text": "Joints (DAS28) is a scoring system to evaluate disease activity and treatment response in rheumatoid",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.912109375,
            "end_logit": -7.921875,
            "text": "Joints (DAS28) is a scoring system to evaluate disease activity",
            "probability": 5.960464477539063e-08
        }
    ],
    "5fe3130da43ad3127800003f_16": [
        {
            "start_logit": -2.1171875,
            "end_logit": 8.9609375,
            "text": "joints",
            "probability": 0.677734375
        },
        {
            "start_logit": -3.1484375,
            "end_logit": 8.9609375,
            "text": "28 joints",
            "probability": 0.2415771484375
        },
        {
            "start_logit": -4.4453125,
            "end_logit": 8.9609375,
            "text": "in 28 joints",
            "probability": 0.0660400390625
        },
        {
            "start_logit": -6.6953125,
            "end_logit": 8.9609375,
            "text": "Disease Activity Score in 28 joints",
            "probability": 0.00696563720703125
        },
        {
            "start_logit": -7.6015625,
            "end_logit": 8.9609375,
            "text": "The Disease Activity Score in 28 joints",
            "probability": 0.0028133392333984375
        },
        {
            "start_logit": -7.87890625,
            "end_logit": 8.9609375,
            "text": "OBJECTIVE: The Disease Activity Score in 28 joints",
            "probability": 0.002132415771484375
        },
        {
            "start_logit": -8.171875,
            "end_logit": 8.9609375,
            "text": "Score in 28 joints",
            "probability": 0.0015897750854492188
        },
        {
            "start_logit": -8.234375,
            "end_logit": 8.9609375,
            "text": ": The Disease Activity Score in 28 joints",
            "probability": 0.0014944076538085938
        },
        {
            "start_logit": -2.1171875,
            "end_logit": -6.9921875,
            "text": "joints (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.1171875,
            "end_logit": -7.72265625,
            "text": "joints (DAS28) is",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.1171875,
            "end_logit": -7.7734375,
            "text": "joints (DAS28",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.1171875,
            "end_logit": -7.8359375,
            "text": "joints (DAS28) is a",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.1171875,
            "end_logit": -7.90625,
            "text": "joints (DAS28) is a key measure in clinical practice",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.1171875,
            "end_logit": -7.91796875,
            "text": "joints (DAS",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -3.1484375,
            "end_logit": -6.9921875,
            "text": "28 joints (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -3.1484375,
            "end_logit": -7.72265625,
            "text": "28 joints (DAS28) is",
            "probability": 0.0
        },
        {
            "start_logit": -3.1484375,
            "end_logit": -7.7734375,
            "text": "28 joints (DAS28",
            "probability": 0.0
        },
        {
            "start_logit": -3.1484375,
            "end_logit": -7.8359375,
            "text": "28 joints (DAS28) is a",
            "probability": 0.0
        },
        {
            "start_logit": -3.1484375,
            "end_logit": -7.90625,
            "text": "28 joints (DAS28) is a key measure in clinical practice",
            "probability": 0.0
        },
        {
            "start_logit": -3.1484375,
            "end_logit": -7.91796875,
            "text": "28 joints (DAS",
            "probability": 0.0
        }
    ],
    "5fe3130da43ad3127800003f_17": [
        {
            "start_logit": -2.0078125,
            "end_logit": 9.0,
            "text": "joints",
            "probability": 0.70703125
        },
        {
            "start_logit": -3.0546875,
            "end_logit": 9.0,
            "text": "28 joints",
            "probability": 0.248291015625
        },
        {
            "start_logit": -5.08984375,
            "end_logit": 9.0,
            "text": "including 28 joints",
            "probability": 0.032440185546875
        },
        {
            "start_logit": -6.55078125,
            "end_logit": 9.0,
            "text": "Disease Activity Score including 28 joints",
            "probability": 0.007526397705078125
        },
        {
            "start_logit": -7.65234375,
            "end_logit": 9.0,
            "text": "The Disease Activity Score including 28 joints",
            "probability": 0.0025005340576171875
        },
        {
            "start_logit": -7.84375,
            "end_logit": 9.0,
            "text": "OBJECTIVE: The Disease Activity Score including 28 joints",
            "probability": 0.0020656585693359375
        },
        {
            "start_logit": -2.0078125,
            "end_logit": -2.556640625,
            "text": "joints (DAS28) and the Clinical Disease Activity Index (CDAI) were developed in order to provide a quantifiable measure of rheumatoid arthritis",
            "probability": 6.794929504394531e-06
        },
        {
            "start_logit": -3.0546875,
            "end_logit": -2.556640625,
            "text": "28 joints (DAS28) and the Clinical Disease Activity Index (CDAI) were developed in order to provide a quantifiable measure of rheumatoid arthritis",
            "probability": 2.384185791015625e-06
        },
        {
            "start_logit": -5.08984375,
            "end_logit": -2.556640625,
            "text": "including 28 joints (DAS28) and the Clinical Disease Activity Index (CDAI) were developed in order to provide a quantifiable measure of rheumatoid arthritis",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -2.0078125,
            "end_logit": -7.00390625,
            "text": "joints (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.55078125,
            "end_logit": -2.556640625,
            "text": "Disease Activity Score including 28 joints (DAS28) and the Clinical Disease Activity Index (CDAI) were developed in order to provide a quantifiable measure of rheumatoid arthritis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.0078125,
            "end_logit": -7.359375,
            "text": "joints (DAS28) and the Clinical Disease Activity Index (CDAI) were developed in order to provide a quantifiable measure of rheumatoid arthritis (RA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.94921875,
            "end_logit": -2.556640625,
            "text": "rheumatoid arthritis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.0078125,
            "end_logit": -7.546875,
            "text": "joints (DAS28) and the Clinical Disease Activity Index (CDAI) were",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.0078125,
            "end_logit": -7.70703125,
            "text": "joints (DAS28",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.0078125,
            "end_logit": -7.734375,
            "text": "joints (DAS28)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.0078125,
            "end_logit": -7.76171875,
            "text": "joints (DAS28) and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.0078125,
            "end_logit": -7.7890625,
            "text": "joints (DAS28) and the Clinical Disease Activity Index",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.0078125,
            "end_logit": -7.8046875,
            "text": "joints (DAS28) and the Clinical Disease Activity",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.0078125,
            "end_logit": -7.86328125,
            "text": "joints (DAS28) and the Clinical Disease Activity Index (CDAI) were developed in order to provide a quantifiable measure of rheumatoid arthritis (",
            "probability": 5.960464477539063e-08
        }
    ],
    "5fe3130da43ad3127800003f_18": [
        {
            "start_logit": -1.376953125,
            "end_logit": 9.4375,
            "text": "joints",
            "probability": 0.69775390625
        },
        {
            "start_logit": -2.3125,
            "end_logit": 9.4375,
            "text": "28 joints",
            "probability": 0.273193359375
        },
        {
            "start_logit": -5.125,
            "end_logit": 9.4375,
            "text": "on 28 joints",
            "probability": 0.0164031982421875
        },
        {
            "start_logit": -6.3125,
            "end_logit": 9.4375,
            "text": "based on 28 joints",
            "probability": 0.005001068115234375
        },
        {
            "start_logit": -6.78125,
            "end_logit": 9.4375,
            "text": "Disease Activity Score based on 28 joints",
            "probability": 0.003131866455078125
        },
        {
            "start_logit": -7.48046875,
            "end_logit": 9.4375,
            "text": "The Disease Activity Score based on 28 joints",
            "probability": 0.0015554428100585938
        },
        {
            "start_logit": -7.84375,
            "end_logit": 9.4375,
            "text": "OBJECTIVE: The Disease Activity Score based on 28 joints",
            "probability": 0.0010824203491210938
        },
        {
            "start_logit": -8.0234375,
            "end_logit": 9.4375,
            "text": "Score based on 28 joints",
            "probability": 0.000904083251953125
        },
        {
            "start_logit": -8.171875,
            "end_logit": 9.4375,
            "text": "Activity Score based on 28 joints",
            "probability": 0.0007796287536621094
        },
        {
            "start_logit": -8.1953125,
            "end_logit": 9.4375,
            "text": ": The Disease Activity Score based on 28 joints",
            "probability": 0.0007610321044921875
        },
        {
            "start_logit": -1.376953125,
            "end_logit": -5.09765625,
            "text": "joints (DAS28) has been increasingly used in clinical practice and research studies of rheumatoid arth",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -2.3125,
            "end_logit": -5.09765625,
            "text": "28 joints (DAS28) has been increasingly used in clinical practice and research studies of rheumatoid arth",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -1.376953125,
            "end_logit": -6.9453125,
            "text": "joints (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.376953125,
            "end_logit": -7.22265625,
            "text": "joints (DAS28) has",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.376953125,
            "end_logit": -7.60546875,
            "text": "joints (DAS28) has been",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.376953125,
            "end_logit": -7.61328125,
            "text": "joints (DAS28",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.376953125,
            "end_logit": -7.6796875,
            "text": "joints (DAS28) has been increasingly",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.376953125,
            "end_logit": -7.72265625,
            "text": "joints (DAS28) has been increasingly used in",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.376953125,
            "end_logit": -7.7734375,
            "text": "joints (DAS28) has been increasingly used in clinical practice and research studies of rheumatoid",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.376953125,
            "end_logit": -7.7890625,
            "text": "joints (DAS28) has been increasingly used in clinical practice and",
            "probability": 5.960464477539063e-08
        }
    ],
    "5fe3130da43ad3127800003f_19": [
        {
            "start_logit": -1.689453125,
            "end_logit": 8.9921875,
            "text": "joints",
            "probability": 0.7607421875
        },
        {
            "start_logit": -3.171875,
            "end_logit": 8.9921875,
            "text": "28 joints",
            "probability": 0.1724853515625
        },
        {
            "start_logit": -4.26171875,
            "end_logit": 8.9921875,
            "text": "including 28 joints",
            "probability": 0.0579833984375
        },
        {
            "start_logit": -7.70703125,
            "end_logit": 8.9921875,
            "text": "Disease Activity Score including 28 joints",
            "probability": 0.0018482208251953125
        },
        {
            "start_logit": -7.73046875,
            "end_logit": 8.9921875,
            "text": "the Disease Activity Score including 28 joints",
            "probability": 0.0018062591552734375
        },
        {
            "start_logit": -7.9140625,
            "end_logit": 8.9921875,
            "text": "Disease activity assessment of rheumatoid arthritis in daily practice: validity, internal consistency, reliability and congruency of the Disease Activity Score including 28 joints",
            "probability": 0.00150299072265625
        },
        {
            "start_logit": -8.1171875,
            "end_logit": 8.9921875,
            "text": "of the Disease Activity Score including 28 joints",
            "probability": 0.0012264251708984375
        },
        {
            "start_logit": -8.1328125,
            "end_logit": 8.9921875,
            "text": "rheumatoid arthritis in daily practice: validity, internal consistency, reliability and congruency of the Disease Activity Score including 28 joints",
            "probability": 0.0012083053588867188
        },
        {
            "start_logit": -8.1953125,
            "end_logit": 8.9921875,
            "text": "congruency of the Disease Activity Score including 28 joints",
            "probability": 0.0011348724365234375
        },
        {
            "start_logit": -1.689453125,
            "end_logit": -6.23828125,
            "text": "joints (",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -1.689453125,
            "end_logit": -6.46875,
            "text": "joints (DAS28) compared with the Clinical Disease Activity Index (CDAI).",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -1.689453125,
            "end_logit": -7.4609375,
            "text": "joints (DAS28) compared",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.689453125,
            "end_logit": -7.57421875,
            "text": "joints (DAS28) compared with the Clinical Disease Activity Index",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.689453125,
            "end_logit": -7.64453125,
            "text": "joints (DAS28) compared with the Clinical Disease Activity",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.689453125,
            "end_logit": -7.64453125,
            "text": "joints (DAS28) compared with",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.689453125,
            "end_logit": -7.703125,
            "text": "joints (DAS28)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.689453125,
            "end_logit": -7.70703125,
            "text": "joints (DAS28",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -3.171875,
            "end_logit": -6.23828125,
            "text": "28 joints (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.689453125,
            "end_logit": -7.73828125,
            "text": "joints (DAS28) compared with the Clinical Disease Activity Index (CDAI",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.689453125,
            "end_logit": -7.7578125,
            "text": "joints (DAS28) compared with the Clinical Disease Activity Index (",
            "probability": 5.960464477539063e-08
        }
    ],
    "5fe3130da43ad3127800003f_20": [
        {
            "start_logit": -4.46875,
            "end_logit": 6.515625,
            "text": "joints",
            "probability": 0.5732421875
        },
        {
            "start_logit": -5.375,
            "end_logit": 6.515625,
            "text": "28 joints",
            "probability": 0.2315673828125
        },
        {
            "start_logit": -6.23046875,
            "end_logit": 6.515625,
            "text": "Disease Activity Score in 28 joints",
            "probability": 0.098388671875
        },
        {
            "start_logit": -6.65234375,
            "end_logit": 6.515625,
            "text": "in 28 joints",
            "probability": 0.06451416015625
        },
        {
            "start_logit": -8.03125,
            "end_logit": 6.515625,
            "text": "Score in 28 joints",
            "probability": 0.0162506103515625
        },
        {
            "start_logit": -8.0546875,
            "end_logit": 6.515625,
            "text": "OBJECTIVES: Disease Activity Score in 28 joints",
            "probability": 0.0158843994140625
        },
        {
            "start_logit": -2.087890625,
            "end_logit": -5.25390625,
            "text": "DAS28",
            "probability": 4.786252975463867e-05
        },
        {
            "start_logit": -2.087890625,
            "end_logit": -6.95703125,
            "text": "DAS28-CRP) is used instead of erythrocyte sedimentation rate",
            "probability": 8.702278137207031e-06
        },
        {
            "start_logit": -2.087890625,
            "end_logit": -7.03515625,
            "text": "DAS28-CRP",
            "probability": 8.046627044677734e-06
        },
        {
            "start_logit": -2.087890625,
            "end_logit": -7.0703125,
            "text": "DAS28-CRP) is used instead of erythrocyte sedimentation rate (DAS28-ESR) to assess rheumatoid arthritis",
            "probability": 7.808208465576172e-06
        },
        {
            "start_logit": -2.087890625,
            "end_logit": -7.11328125,
            "text": "DAS28-CRP) is",
            "probability": 7.450580596923828e-06
        },
        {
            "start_logit": -2.087890625,
            "end_logit": -7.171875,
            "text": "DAS28-CRP) is used instead",
            "probability": 7.092952728271484e-06
        },
        {
            "start_logit": -2.087890625,
            "end_logit": -7.3828125,
            "text": "DAS28-CRP) is used",
            "probability": 5.7220458984375e-06
        },
        {
            "start_logit": -2.087890625,
            "end_logit": -7.4296875,
            "text": "DAS28-CRP) is used instead of erythrocyte sedimentation rate (DAS28",
            "probability": 5.4836273193359375e-06
        },
        {
            "start_logit": -2.087890625,
            "end_logit": -7.4375,
            "text": "DAS28-",
            "probability": 5.424022674560547e-06
        },
        {
            "start_logit": -2.087890625,
            "end_logit": -7.53515625,
            "text": "DAS28-CRP) is used instead of erythrocyte sedimentation",
            "probability": 4.887580871582031e-06
        },
        {
            "start_logit": -2.087890625,
            "end_logit": -7.5859375,
            "text": "DAS28-CRP) is used instead of erythrocyte sedimentation rate (",
            "probability": 4.708766937255859e-06
        },
        {
            "start_logit": -4.46875,
            "end_logit": -5.25390625,
            "text": "joints calculated with C-reactive protein (DAS28",
            "probability": 4.410743713378906e-06
        },
        {
            "start_logit": -2.087890625,
            "end_logit": -7.64453125,
            "text": "DAS28-CRP) is used instead of",
            "probability": 4.351139068603516e-06
        },
        {
            "start_logit": -2.087890625,
            "end_logit": -7.64453125,
            "text": "DAS28-CRP)",
            "probability": 4.351139068603516e-06
        }
    ],
    "5fe3130da43ad3127800003f_21": [
        {
            "start_logit": -4.41015625,
            "end_logit": 6.0234375,
            "text": "joints",
            "probability": 0.3837890625
        },
        {
            "start_logit": -4.75,
            "end_logit": 6.0234375,
            "text": "Disease Activity Score in 28 joints",
            "probability": 0.273193359375
        },
        {
            "start_logit": -5.30859375,
            "end_logit": 6.0234375,
            "text": "28 joints",
            "probability": 0.15625
        },
        {
            "start_logit": -5.6953125,
            "end_logit": 6.0234375,
            "text": "in 28 joints",
            "probability": 0.10614013671875
        },
        {
            "start_logit": -6.734375,
            "end_logit": 6.0234375,
            "text": "the Disease Activity Score in 28 joints",
            "probability": 0.03753662109375
        },
        {
            "start_logit": -7.57421875,
            "end_logit": 6.0234375,
            "text": "use of the Disease Activity Score in 28 joints",
            "probability": 0.0162200927734375
        },
        {
            "start_logit": -7.734375,
            "end_logit": 6.0234375,
            "text": "OBJECTIVE: To optimize use of the Disease Activity Score in 28 joints",
            "probability": 0.013824462890625
        },
        {
            "start_logit": -7.78125,
            "end_logit": 6.0234375,
            "text": "optimize use of the Disease Activity Score in 28 joints",
            "probability": 0.01319122314453125
        },
        {
            "start_logit": -4.41015625,
            "end_logit": -4.3828125,
            "text": "joints (DAS28) in early rheumatoid arthritis (RA) by adding the \"squeeze test\" of forefeet.",
            "probability": 1.1622905731201172e-05
        },
        {
            "start_logit": -4.75,
            "end_logit": -4.3828125,
            "text": "Disease Activity Score in 28 joints (DAS28) in early rheumatoid arthritis (RA) by adding the \"squeeze test\" of forefeet.",
            "probability": 8.225440979003906e-06
        },
        {
            "start_logit": -4.99609375,
            "end_logit": -4.3828125,
            "text": ".",
            "probability": 6.496906280517578e-06
        },
        {
            "start_logit": -4.41015625,
            "end_logit": -5.19921875,
            "text": "joints (",
            "probability": 5.125999450683594e-06
        },
        {
            "start_logit": -5.30859375,
            "end_logit": -4.3828125,
            "text": "28 joints (DAS28) in early rheumatoid arthritis (RA) by adding the \"squeeze test\" of forefeet.",
            "probability": 4.76837158203125e-06
        },
        {
            "start_logit": -4.75,
            "end_logit": -5.19921875,
            "text": "Disease Activity Score in 28 joints (",
            "probability": 3.635883331298828e-06
        },
        {
            "start_logit": -5.6953125,
            "end_logit": -4.3828125,
            "text": "in 28 joints (DAS28) in early rheumatoid arthritis (RA) by adding the \"squeeze test\" of forefeet.",
            "probability": 3.2186508178710938e-06
        },
        {
            "start_logit": -5.30859375,
            "end_logit": -5.19921875,
            "text": "28 joints (",
            "probability": 2.086162567138672e-06
        },
        {
            "start_logit": -4.41015625,
            "end_logit": -6.28125,
            "text": "joints (DAS28) in early rheumatoid arthritis",
            "probability": 1.7881393432617188e-06
        },
        {
            "start_logit": -5.6953125,
            "end_logit": -5.19921875,
            "text": "in 28 joints (",
            "probability": 1.430511474609375e-06
        },
        {
            "start_logit": -4.75,
            "end_logit": -6.28125,
            "text": "Disease Activity Score in 28 joints (DAS28) in early rheumatoid arthritis",
            "probability": 1.2516975402832031e-06
        },
        {
            "start_logit": -6.734375,
            "end_logit": -4.3828125,
            "text": "the Disease Activity Score in 28 joints (DAS28) in early rheumatoid arthritis (RA) by adding the \"squeeze test\" of forefeet.",
            "probability": 1.1324882507324219e-06
        }
    ],
    "5710a592cf1c32585100002a_1": [
        {
            "start_logit": 0.45751953125,
            "end_logit": 4.91015625,
            "text": ".",
            "probability": 0.91748046875
        },
        {
            "start_logit": -2.767578125,
            "end_logit": 4.91015625,
            "text": "anthrax toxins and extracellular capsular layer.",
            "probability": 0.0364990234375
        },
        {
            "start_logit": -3.49609375,
            "end_logit": 4.91015625,
            "text": "elevated temperature (37\u00b0C) and bicarbonate/CO2 concentrations, with increased expression of virulence factors that include the anthrax toxins and extracellular capsular layer.",
            "probability": 0.017608642578125
        },
        {
            "start_logit": -4.09765625,
            "end_logit": 4.91015625,
            "text": "Bacillus anthracis responds to host cues, and particularly to elevated temperature (37\u00b0C) and bicarbonate/CO2 concentrations, with increased expression of virulence factors that include the anthrax toxins and extracellular capsular layer.",
            "probability": 0.00965118408203125
        },
        {
            "start_logit": -4.953125,
            "end_logit": 4.91015625,
            "text": "bicarbonate/CO2 concentrations, with increased expression of virulence factors that include the anthrax toxins and extracellular capsular layer.",
            "probability": 0.004100799560546875
        },
        {
            "start_logit": -5.18359375,
            "end_logit": 4.91015625,
            "text": "the anthrax toxins and extracellular capsular layer.",
            "probability": 0.0032596588134765625
        },
        {
            "start_logit": -5.84375,
            "end_logit": 4.91015625,
            "text": "toxins and extracellular capsular layer.",
            "probability": 0.0016832351684570312
        },
        {
            "start_logit": -5.9140625,
            "end_logit": 4.91015625,
            "text": "anthracis responds to host cues, and particularly to elevated temperature (37\u00b0C) and bicarbonate/CO2 concentrations, with increased expression of virulence factors that include the anthrax toxins and extracellular capsular layer.",
            "probability": 0.0015687942504882812
        },
        {
            "start_logit": -5.9296875,
            "end_logit": 4.91015625,
            "text": "is responds to host cues, and particularly to elevated temperature (37\u00b0C) and bicarbonate/CO2 concentrations, with increased expression of virulence factors that include the anthrax toxins and extracellular capsular layer.",
            "probability": 0.001544952392578125
        },
        {
            "start_logit": -6.12109375,
            "end_logit": 4.91015625,
            "text": ", Bacillus anthracis responds to host cues, and particularly to elevated temperature (37\u00b0C) and bicarbonate/CO2 concentrations, with increased expression of virulence factors that include the anthrax toxins and extracellular capsular layer.",
            "probability": 0.0012760162353515625
        },
        {
            "start_logit": -6.23046875,
            "end_logit": 4.91015625,
            "text": "virulence factors that include the anthrax toxins and extracellular capsular layer.",
            "probability": 0.0011434555053710938
        },
        {
            "start_logit": -6.3515625,
            "end_logit": 4.91015625,
            "text": "to host cues, and particularly to elevated temperature (37\u00b0C) and bicarbonate/CO2 concentrations, with increased expression of virulence factors that include the anthrax toxins and extracellular capsular layer.",
            "probability": 0.0010137557983398438
        },
        {
            "start_logit": -6.4140625,
            "end_logit": 4.91015625,
            "text": "temperature (37\u00b0C) and bicarbonate/CO2 concentrations, with increased expression of virulence factors that include the anthrax toxins and extracellular capsular layer.",
            "probability": 0.0009522438049316406
        },
        {
            "start_logit": -6.44921875,
            "end_logit": 4.91015625,
            "text": "include the anthrax toxins and extracellular capsular layer.",
            "probability": 0.0009188652038574219
        },
        {
            "start_logit": -6.53515625,
            "end_logit": 4.91015625,
            "text": "host cues, and particularly to elevated temperature (37\u00b0C) and bicarbonate/CO2 concentrations, with increased expression of virulence factors that include the anthrax toxins and extracellular capsular layer.",
            "probability": 0.000843048095703125
        },
        {
            "start_logit": -6.609375,
            "end_logit": 4.91015625,
            "text": "expression of virulence factors that include the anthrax toxins and extracellular capsular layer.",
            "probability": 0.0007829666137695312
        },
        {
            "start_logit": -3.49609375,
            "end_logit": -4.1796875,
            "text": "elevated temperature (37\u00b0C) and bicarbonate/CO2",
            "probability": 1.9669532775878906e-06
        },
        {
            "start_logit": -4.09765625,
            "end_logit": -4.1796875,
            "text": "Bacillus anthracis responds to host cues, and particularly to elevated temperature (37\u00b0C) and bicarbonate/CO2",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": -3.49609375,
            "end_logit": -5.2578125,
            "text": "elevated temperature (37\u00b0C) and bicarbonate/CO2 concentrations, with",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -3.49609375,
            "end_logit": -5.296875,
            "text": "elevated temperature (37\u00b0C) and bicarbonate/CO2 concentrations,",
            "probability": 6.556510925292969e-07
        }
    ],
    "5710a592cf1c32585100002a_2": [
        {
            "start_logit": 9.875,
            "end_logit": 9.7578125,
            "text": "CO(2) /bicarbonate",
            "probability": 1.0
        },
        {
            "start_logit": -1.009765625,
            "end_logit": 9.7578125,
            "text": "bicarbonate",
            "probability": 1.895427703857422e-05
        },
        {
            "start_logit": 9.875,
            "end_logit": -1.28515625,
            "text": "CO",
            "probability": 1.621246337890625e-05
        },
        {
            "start_logit": -6.69921875,
            "end_logit": 9.7578125,
            "text": "/bicarbonate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.109375,
            "end_logit": 9.7578125,
            "text": "2) /bicarbonate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.875,
            "end_logit": -7.2578125,
            "text": "CO(2) /bicarbonate exhibited increased AtxA dimer/monomer ratios and increased AtxA activity",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.875,
            "end_logit": -7.5,
            "text": "CO(2) /bicarbonate exhibited",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.390625,
            "end_logit": 9.7578125,
            "text": "(2) /bicarbonate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.875,
            "end_logit": -7.59765625,
            "text": "CO(2) /bicarbonate exhibited increased AtxA dimer/monomer ratios and increased AtxA activity, relative to cultures grown without added CO(2) /bicarbonate, suggesting",
            "probability": 0.0
        },
        {
            "start_logit": 9.875,
            "end_logit": -7.60546875,
            "text": "CO(2) /bicarbonate exhibited increased AtxA dimer/monomer ratios and increased AtxA activity, relative to",
            "probability": 0.0
        },
        {
            "start_logit": 9.875,
            "end_logit": -7.609375,
            "text": "CO(2)",
            "probability": 0.0
        },
        {
            "start_logit": 9.875,
            "end_logit": -7.64453125,
            "text": "CO(2) /bicarbonate exhibited increased AtxA dimer/monomer ratios and increased AtxA activity,",
            "probability": 0.0
        },
        {
            "start_logit": 9.875,
            "end_logit": -7.671875,
            "text": "CO(2) /bicarbonate exhibited increased AtxA dimer/monomer ratios and",
            "probability": 0.0
        },
        {
            "start_logit": 9.875,
            "end_logit": -7.6796875,
            "text": "CO(2) /bicarbonate exhibited increased AtxA dimer/monomer ratios and increased AtxA activity, relative to cultures grown without",
            "probability": 0.0
        },
        {
            "start_logit": -7.59375,
            "end_logit": 9.7578125,
            "text": "elevated CO(2) /bicarbonate",
            "probability": 0.0
        },
        {
            "start_logit": -7.875,
            "end_logit": 9.7578125,
            "text": ") /bicarbonate",
            "probability": 0.0
        },
        {
            "start_logit": -8.0859375,
            "end_logit": 9.7578125,
            "text": "cultures grown with elevated CO(2) /bicarbonate",
            "probability": 0.0
        },
        {
            "start_logit": -1.009765625,
            "end_logit": -7.203125,
            "text": "bicarbonate exhibited increased AtxA dimer/monomer ratios and increased AtxA activity, relative to cultures grown without added CO(2) /bicarbonate, suggesting that this host-associated signal enhances AtxA function by",
            "probability": 0.0
        },
        {
            "start_logit": -1.009765625,
            "end_logit": -7.2578125,
            "text": "bicarbonate exhibited increased AtxA dimer/monomer ratios and increased AtxA activity",
            "probability": 0.0
        },
        {
            "start_logit": -1.009765625,
            "end_logit": -7.5,
            "text": "bicarbonate exhibited",
            "probability": 0.0
        }
    ],
    "5710a592cf1c32585100002a_3": [
        {
            "start_logit": 7.62109375,
            "end_logit": 8.671875,
            "text": "CO2",
            "probability": 1.0
        },
        {
            "start_logit": -7.16796875,
            "end_logit": 8.671875,
            "text": "by CO2",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.92578125,
            "end_logit": 8.671875,
            "text": "Bacillus anthracis virulence genes is triggered by CO2",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.9296875,
            "end_logit": 8.671875,
            "text": "Transcription of the major Bacillus anthracis virulence genes is triggered by CO2",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.9609375,
            "end_logit": 8.671875,
            "text": "virulence genes is triggered by CO2",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -8.046875,
            "end_logit": 8.671875,
            "text": "major Bacillus anthracis virulence genes is triggered by CO2",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -8.046875,
            "end_logit": 8.671875,
            "text": "anthracis virulence genes is triggered by CO2",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -8.0625,
            "end_logit": 8.671875,
            "text": "is virulence genes is triggered by CO2",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -8.09375,
            "end_logit": 8.671875,
            "text": "triggered by CO2",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -8.109375,
            "end_logit": 8.671875,
            "text": "genes is triggered by CO2",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.109375,
            "end_logit": 8.671875,
            "text": "the major Bacillus anthracis virulence genes is triggered by CO2",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.1640625,
            "end_logit": 8.671875,
            "text": "of the major Bacillus anthracis virulence genes is triggered by CO2",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.62109375,
            "end_logit": -7.32421875,
            "text": "CO2, a signal mimicking the host environment.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.62109375,
            "end_logit": -7.87109375,
            "text": "CO2,",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.62109375,
            "end_logit": -7.8828125,
            "text": "CO2, a",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.62109375,
            "end_logit": -8.1015625,
            "text": "CO2, a signal mimicking the host environment",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.62109375,
            "end_logit": -8.109375,
            "text": "CO2, a signal mimicking",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.82421875,
            "end_logit": -7.32421875,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.16796875,
            "end_logit": -7.32421875,
            "text": "by CO2, a signal mimicking the host environment.",
            "probability": 0.0
        },
        {
            "start_logit": -7.16796875,
            "end_logit": -7.87109375,
            "text": "by CO2,",
            "probability": 0.0
        }
    ],
    "5710a592cf1c32585100002a_4": [
        {
            "start_logit": 7.48046875,
            "end_logit": 8.75,
            "text": "CO2",
            "probability": 1.0
        },
        {
            "start_logit": -7.51171875,
            "end_logit": 8.75,
            "text": "of CO2",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.6640625,
            "end_logit": 8.75,
            "text": "presence of CO2",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.93359375,
            "end_logit": 8.75,
            "text": "in presence of CO2",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -8.046875,
            "end_logit": 8.75,
            "text": "in vitro in presence of CO2",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -8.0703125,
            "end_logit": 8.75,
            "text": ", in vitro in presence of CO2",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.48046875,
            "end_logit": -7.2421875,
            "text": "CO2 and in vivo, AtxA is part of the sap and eag regulatory network.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.48046875,
            "end_logit": -7.6953125,
            "text": "CO2 and in vivo, AtxA is part of the sap and eag",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.48046875,
            "end_logit": -7.921875,
            "text": "CO2 and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.48046875,
            "end_logit": -7.93359375,
            "text": "CO2 and in vivo, AtxA is part of the sap and eag regulatory",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.48046875,
            "end_logit": -7.98046875,
            "text": "CO2 and in vivo, AtxA is part",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.48046875,
            "end_logit": -7.9921875,
            "text": "CO2 and in vivo, AtxA is part of the sap and eag regulatory network",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.48046875,
            "end_logit": -8.03125,
            "text": "CO2 and in vivo, AtxA is part of",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.48046875,
            "end_logit": -8.078125,
            "text": "CO2 and in vivo",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.7421875,
            "end_logit": -7.2421875,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.51171875,
            "end_logit": -7.2421875,
            "text": "of CO2 and in vivo, AtxA is part of the sap and eag regulatory network.",
            "probability": 0.0
        },
        {
            "start_logit": -7.6640625,
            "end_logit": -7.2421875,
            "text": "presence of CO2 and in vivo, AtxA is part of the sap and eag regulatory network.",
            "probability": 0.0
        },
        {
            "start_logit": -7.71875,
            "end_logit": -7.2421875,
            "text": "eag regulatory network.",
            "probability": 0.0
        },
        {
            "start_logit": -7.8125,
            "end_logit": -7.2421875,
            "text": "sap and eag regulatory network.",
            "probability": 0.0
        },
        {
            "start_logit": -7.91796875,
            "end_logit": -7.2421875,
            "text": "and eag regulatory network.",
            "probability": 0.0
        }
    ],
    "5710a592cf1c32585100002a_5": [
        {
            "start_logit": 9.0078125,
            "end_logit": 6.28515625,
            "text": "CO2",
            "probability": 0.9697265625
        },
        {
            "start_logit": 4.90234375,
            "end_logit": 6.28515625,
            "text": "anthrax toxin activator gene (atxA) expression in Bacillus anthracis: temperature, not CO2",
            "probability": 0.0159149169921875
        },
        {
            "start_logit": 9.0078125,
            "end_logit": 2.072265625,
            "text": "CO2/bicarbonate",
            "probability": 0.01427459716796875
        },
        {
            "start_logit": 4.90234375,
            "end_logit": 2.072265625,
            "text": "anthrax toxin activator gene (atxA) expression in Bacillus anthracis: temperature, not CO2/bicarbonate",
            "probability": 0.00023615360260009766
        },
        {
            "start_logit": 9.0078125,
            "end_logit": -5.5625,
            "text": "CO2/bicarbonate, affects AtxA synthesis.",
            "probability": 6.9141387939453125e-06
        },
        {
            "start_logit": 9.0078125,
            "end_logit": -7.35546875,
            "text": "CO2/bicarbonate, affects AtxA synthesis",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": 9.0078125,
            "end_logit": -7.73046875,
            "text": "CO2/bicarbonate, affects",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": 9.0078125,
            "end_logit": -7.76171875,
            "text": "CO2/bicarbonate,",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": -5.62109375,
            "end_logit": 6.28515625,
            "text": "temperature, not CO2",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 4.90234375,
            "end_logit": -5.24609375,
            "text": "anthrax toxin activator gene (atxA) expression in Bacillus anthracis: temperature",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 4.90234375,
            "end_logit": -5.30078125,
            "text": "anthrax toxin activator",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 4.90234375,
            "end_logit": -5.5625,
            "text": "anthrax toxin activator gene (atxA) expression in Bacillus anthracis: temperature, not CO2/bicarbonate, affects AtxA synthesis.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.453125,
            "end_logit": 6.28515625,
            "text": "not CO2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 4.90234375,
            "end_logit": -6.19140625,
            "text": "anthrax toxin activator gene",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 4.90234375,
            "end_logit": -6.26953125,
            "text": "anthr",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 4.90234375,
            "end_logit": -6.44140625,
            "text": "anthrax toxin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.8984375,
            "end_logit": 6.28515625,
            "text": "ax toxin activator gene (atxA) expression in Bacillus anthracis: temperature, not CO2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.92578125,
            "end_logit": 6.28515625,
            "text": "toxin activator gene (atxA) expression in Bacillus anthracis: temperature, not CO2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.125,
            "end_logit": 6.28515625,
            "text": "of anthrax toxin activator gene (atxA) expression in Bacillus anthracis: temperature, not CO2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 4.90234375,
            "end_logit": -7.0859375,
            "text": "anthrax toxin activator gene (atxA) expression",
            "probability": 0.0
        }
    ],
    "5710a592cf1c32585100002a_6": [
        {
            "start_logit": 7.6015625,
            "end_logit": 7.38671875,
            "text": "CO2",
            "probability": 0.9970703125
        },
        {
            "start_logit": 7.6015625,
            "end_logit": 0.9873046875,
            "text": "CO2/bicarbonate",
            "probability": 0.001659393310546875
        },
        {
            "start_logit": 7.6015625,
            "end_logit": 0.25390625,
            "text": "CO2/bicarbonate and temperature.",
            "probability": 0.0007991790771484375
        },
        {
            "start_logit": -0.90478515625,
            "end_logit": 7.38671875,
            "text": "toxin genes (pag, lef, and cya) is enhanced by two physiologically significant signals: elevated CO2",
            "probability": 0.0002028942108154297
        },
        {
            "start_logit": -5.89453125,
            "end_logit": 7.38671875,
            "text": "elevated CO2",
            "probability": 1.3709068298339844e-06
        },
        {
            "start_logit": 7.6015625,
            "end_logit": -6.7109375,
            "text": "CO2/bicarbonate and temperature",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": -6.76953125,
            "end_logit": 7.38671875,
            "text": "expression of the toxin genes (pag, lef, and cya) is enhanced by two physiologically significant signals: elevated CO2",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -7.1328125,
            "end_logit": 7.38671875,
            "text": "In atxA+ strains, expression of the toxin genes (pag, lef, and cya) is enhanced by two physiologically significant signals: elevated CO2",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -7.13671875,
            "end_logit": 7.38671875,
            "text": "the toxin genes (pag, lef, and cya) is enhanced by two physiologically significant signals: elevated CO2",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -7.2421875,
            "end_logit": 7.38671875,
            "text": "atxA+ strains, expression of the toxin genes (pag, lef, and cya) is enhanced by two physiologically significant signals: elevated CO2",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.2578125,
            "end_logit": 7.38671875,
            "text": "enhanced by two physiologically significant signals: elevated CO2",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.2890625,
            "end_logit": 7.38671875,
            "text": ", expression of the toxin genes (pag, lef, and cya) is enhanced by two physiologically significant signals: elevated CO2",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.2890625,
            "end_logit": 7.38671875,
            "text": "by two physiologically significant signals: elevated CO2",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -0.90478515625,
            "end_logit": 0.9873046875,
            "text": "toxin genes (pag, lef, and cya) is enhanced by two physiologically significant signals: elevated CO2/bicarbonate",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.421875,
            "end_logit": 7.38671875,
            "text": "lef, and cya) is enhanced by two physiologically significant signals: elevated CO2",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.6015625,
            "end_logit": -7.6484375,
            "text": "CO2/bicarbonate and",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.4765625,
            "end_logit": 7.38671875,
            "text": "pag, lef, and cya) is enhanced by two physiologically significant signals: elevated CO2",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.484375,
            "end_logit": 7.38671875,
            "text": ", and cya) is enhanced by two physiologically significant signals: elevated CO2",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -0.90478515625,
            "end_logit": 0.25390625,
            "text": "toxin genes (pag, lef, and cya) is enhanced by two physiologically significant signals: elevated CO2/bicarbonate and temperature.",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -0.90478515625,
            "end_logit": -0.9150390625,
            "text": "toxin",
            "probability": 5.960464477539063e-08
        }
    ],
    "5710a592cf1c32585100002a_7": [
        {
            "start_logit": 10.0859375,
            "end_logit": 9.84375,
            "text": "CO2/bicarbonate",
            "probability": 1.0
        },
        {
            "start_logit": 10.0859375,
            "end_logit": -0.5615234375,
            "text": "CO2",
            "probability": 2.9981136322021484e-05
        },
        {
            "start_logit": -0.8037109375,
            "end_logit": 9.84375,
            "text": "bicarbonate",
            "probability": 1.8477439880371094e-05
        },
        {
            "start_logit": 10.0859375,
            "end_logit": -5.76953125,
            "text": "CO2/bicarbonate levels.",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.5390625,
            "end_logit": 9.84375,
            "text": "/bicarbonate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.0859375,
            "end_logit": -7.03515625,
            "text": "CO2/bicarbonate levels. However, the steady-state level of atxA mRNA in cells grown in elevated CO2/bicarbonate at 37 degrees C is five- to sixfold higher than",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.0859375,
            "end_logit": -7.08203125,
            "text": "CO2/bicarbonate levels. However, the steady-state level of atxA mRNA in cells grown in elevated CO2/bicarbonate at 37 degrees C is five- to sixfold higher than that observed",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.0859375,
            "end_logit": -7.1953125,
            "text": "CO2/bicarbonate levels. However, the steady-state level of atxA mRNA in cells grown in elevated CO2/bicarbonate at 37 degrees C is five",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.0859375,
            "end_logit": -7.23046875,
            "text": "CO2/bicarbonate levels. However, the steady-state level of atxA mRNA in cells grown in elevated CO2/bicarbonate at 37 degrees C is five- to sixfold higher than that",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.0859375,
            "end_logit": -7.2890625,
            "text": "CO2/bicarbonate levels. However, the steady-state level of atxA mRNA in cells grown in elevated CO2/bicarbonate at 37 degrees C is five- to sixfold higher",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.0859375,
            "end_logit": -7.328125,
            "text": "CO2/bicarbonate levels. However, the steady-state level of atxA mRNA in cells grown in elevated CO2/bicarbonate at 37 degrees C is five- to sixfold",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.0859375,
            "end_logit": -7.40234375,
            "text": "CO2/bicarbonate levels. However, the steady-state level of atxA mRNA in cells grown in elevated CO2/bicarbonate at",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.0859375,
            "end_logit": -7.4921875,
            "text": "CO2/bicarbonate levels. However, the steady-state level of atxA mRNA in cells grown in elevated CO2/bicarbonate at 37 degrees C is five- to",
            "probability": 0.0
        },
        {
            "start_logit": 10.0859375,
            "end_logit": -7.5078125,
            "text": "CO2/bicarbonate levels. However, the steady-state level of atxA mRNA in",
            "probability": 0.0
        },
        {
            "start_logit": 10.0859375,
            "end_logit": -7.54296875,
            "text": "CO2/bicarbonate levels. However",
            "probability": 0.0
        },
        {
            "start_logit": 10.0859375,
            "end_logit": -7.56640625,
            "text": "CO2/bicarbonate levels. However, the steady-state level of atxA mRNA in cells grown in elevated CO2/bicarbonate at 37 degrees C is five- to sixfold higher than that observed in",
            "probability": 0.0
        },
        {
            "start_logit": -7.375,
            "end_logit": 9.84375,
            "text": "Our data indicate that atxA expression is not influenced by CO2/bicarbonate",
            "probability": 0.0
        },
        {
            "start_logit": 10.0859375,
            "end_logit": -7.63671875,
            "text": "CO2/bicarbonate levels. However, the steady-state level of atxA mRNA",
            "probability": 0.0
        },
        {
            "start_logit": -7.83203125,
            "end_logit": 9.84375,
            "text": "by CO2/bicarbonate",
            "probability": 0.0
        },
        {
            "start_logit": -7.875,
            "end_logit": 9.84375,
            "text": "data indicate that atxA expression is not influenced by CO2/bicarbonate",
            "probability": 0.0
        }
    ],
    "5710a592cf1c32585100002a_8": [
        {
            "start_logit": 4.43359375,
            "end_logit": 9.53125,
            "text": "CO2",
            "probability": 1.0
        },
        {
            "start_logit": -6.75390625,
            "end_logit": 9.53125,
            "text": "viewed as a regulon, in which transcription of all three genes is activated in trans by the same regulatory gene, atxA, in response to the same signal, CO2",
            "probability": 1.3828277587890625e-05
        },
        {
            "start_logit": -7.0625,
            "end_logit": 9.53125,
            "text": "response to the same signal, CO2",
            "probability": 1.0132789611816406e-05
        },
        {
            "start_logit": -7.2734375,
            "end_logit": 9.53125,
            "text": ", CO2",
            "probability": 8.225440979003906e-06
        },
        {
            "start_logit": -7.42578125,
            "end_logit": 9.53125,
            "text": "be viewed as a regulon, in which transcription of all three genes is activated in trans by the same regulatory gene, atxA, in response to the same signal, CO2",
            "probability": 7.092952728271484e-06
        },
        {
            "start_logit": -7.453125,
            "end_logit": 9.53125,
            "text": "regulon, in which transcription of all three genes is activated in trans by the same regulatory gene, atxA, in response to the same signal, CO2",
            "probability": 6.854534149169922e-06
        },
        {
            "start_logit": -7.47265625,
            "end_logit": 9.53125,
            "text": "in response to the same signal, CO2",
            "probability": 6.735324859619141e-06
        },
        {
            "start_logit": -7.50390625,
            "end_logit": 9.53125,
            "text": ", can be viewed as a regulon, in which transcription of all three genes is activated in trans by the same regulatory gene, atxA, in response to the same signal, CO2",
            "probability": 6.556510925292969e-06
        },
        {
            "start_logit": -7.5546875,
            "end_logit": 9.53125,
            "text": "which transcription of all three genes is activated in trans by the same regulatory gene, atxA, in response to the same signal, CO2",
            "probability": 6.198883056640625e-06
        },
        {
            "start_logit": -7.578125,
            "end_logit": 9.53125,
            "text": ", atxA, in response to the same signal, CO2",
            "probability": 6.020069122314453e-06
        },
        {
            "start_logit": -7.62109375,
            "end_logit": 9.53125,
            "text": "in which transcription of all three genes is activated in trans by the same regulatory gene, atxA, in response to the same signal, CO2",
            "probability": 5.781650543212891e-06
        },
        {
            "start_logit": -7.6640625,
            "end_logit": 9.53125,
            "text": "on, in which transcription of all three genes is activated in trans by the same regulatory gene, atxA, in response to the same signal, CO2",
            "probability": 5.543231964111328e-06
        },
        {
            "start_logit": -6.75390625,
            "end_logit": -7.30078125,
            "text": "viewed as a regulon, in which transcription of all three genes",
            "probability": 0.0
        },
        {
            "start_logit": -6.75390625,
            "end_logit": -7.34765625,
            "text": "viewed as a regulon, in",
            "probability": 0.0
        },
        {
            "start_logit": -6.75390625,
            "end_logit": -7.43359375,
            "text": "viewed as a regulon, in which transcription of all three genes is activated in trans by the same regulatory gene, atxA, in response to the same signal",
            "probability": 0.0
        },
        {
            "start_logit": -6.75390625,
            "end_logit": -7.48046875,
            "text": "viewed as a regulon,",
            "probability": 0.0
        },
        {
            "start_logit": -6.75390625,
            "end_logit": -7.51171875,
            "text": "viewed as a regulon, in which transcription of all three",
            "probability": 0.0
        },
        {
            "start_logit": -6.75390625,
            "end_logit": -7.58984375,
            "text": "viewed as a regulon, in which transcription",
            "probability": 0.0
        },
        {
            "start_logit": -6.75390625,
            "end_logit": -7.65234375,
            "text": "viewed as a regulon, in which transcription of all three genes is activated in trans by the same regulatory gene, atxA, in response to the same signal,",
            "probability": 0.0
        },
        {
            "start_logit": -6.75390625,
            "end_logit": -7.6640625,
            "text": "viewed as a regulon, in which transcription of all three genes is activated in trans by the same regulatory gene",
            "probability": 0.0
        }
    ],
    "5710a592cf1c32585100002a_9": [
        {
            "start_logit": 5.96875,
            "end_logit": 9.25,
            "text": "CO2",
            "probability": 1.0
        },
        {
            "start_logit": 5.96875,
            "end_logit": -1.361328125,
            "text": "CO2 and the toxin",
            "probability": 2.467632293701172e-05
        },
        {
            "start_logit": -5.78125,
            "end_logit": 9.25,
            "text": "elevated CO2",
            "probability": 7.867813110351562e-06
        },
        {
            "start_logit": 5.96875,
            "end_logit": -3.1640625,
            "text": "CO2 and the toxin gene regulator, atxA.",
            "probability": 4.0531158447265625e-06
        },
        {
            "start_logit": -6.61328125,
            "end_logit": 9.25,
            "text": "Comparison of the resulting protein patterns indicated that synthesis of non-toxin proteins is influenced by growth in elevated CO2",
            "probability": 3.4570693969726562e-06
        },
        {
            "start_logit": -7.06640625,
            "end_logit": 9.25,
            "text": "in elevated CO2",
            "probability": 2.205371856689453e-06
        },
        {
            "start_logit": -7.60546875,
            "end_logit": 9.25,
            "text": "protein patterns indicated that synthesis of non-toxin proteins is influenced by growth in elevated CO2",
            "probability": 1.2516975402832031e-06
        },
        {
            "start_logit": -7.6484375,
            "end_logit": 9.25,
            "text": "resulting protein patterns indicated that synthesis of non-toxin proteins is influenced by growth in elevated CO2",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": -7.69921875,
            "end_logit": 9.25,
            "text": "the resulting protein patterns indicated that synthesis of non-toxin proteins is influenced by growth in elevated CO2",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": -7.79296875,
            "end_logit": 9.25,
            "text": "by growth in elevated CO2",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": -7.8203125,
            "end_logit": 9.25,
            "text": "toxin proteins is influenced by growth in elevated CO2",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": -7.8359375,
            "end_logit": 9.25,
            "text": "that synthesis of non-toxin proteins is influenced by growth in elevated CO2",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": -7.90625,
            "end_logit": 9.25,
            "text": "of non-toxin proteins is influenced by growth in elevated CO2",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": -7.92578125,
            "end_logit": 9.25,
            "text": "-toxin proteins is influenced by growth in elevated CO2",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": 5.96875,
            "end_logit": -7.33203125,
            "text": "CO2 and the toxin gene regulator",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 5.96875,
            "end_logit": -7.69921875,
            "text": "CO2 and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 5.96875,
            "end_logit": -7.70703125,
            "text": "CO2 and the toxin gene",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 5.96875,
            "end_logit": -7.8984375,
            "text": "CO2 and the toxin gene regulator,",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 5.96875,
            "end_logit": -7.93359375,
            "text": "CO2 and the toxin gene regulator, atxA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.74609375,
            "end_logit": -1.361328125,
            "text": "toxin",
            "probability": 0.0
        }
    ],
    "5710a592cf1c32585100002a_10": [
        {
            "start_logit": 9.09375,
            "end_logit": 8.1796875,
            "text": "acpA",
            "probability": 1.0
        },
        {
            "start_logit": 9.09375,
            "end_logit": -1.2412109375,
            "text": "acpA, and activation appeared to be stimulated by bicarbonate",
            "probability": 8.028745651245117e-05
        },
        {
            "start_logit": 9.09375,
            "end_logit": -2.38671875,
            "text": "acpA, and activation appeared to be stimulated by bicarbonate.",
            "probability": 2.5451183319091797e-05
        },
        {
            "start_logit": 9.09375,
            "end_logit": -2.82421875,
            "text": "acp",
            "probability": 1.6450881958007812e-05
        },
        {
            "start_logit": -3.345703125,
            "end_logit": 8.1796875,
            "text": "Transcription initiated from P1 and P2 was activated by both atxA and acpA",
            "probability": 3.933906555175781e-06
        },
        {
            "start_logit": -3.93359375,
            "end_logit": 8.1796875,
            "text": "A",
            "probability": 2.205371856689453e-06
        },
        {
            "start_logit": -5.66015625,
            "end_logit": 8.1796875,
            "text": "both atxA and acpA",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 9.09375,
            "end_logit": -7.35546875,
            "text": "acpA, and activation appeared",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.09375,
            "end_logit": -7.5625,
            "text": "acpA, and activation appeared to",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.09375,
            "end_logit": -7.66015625,
            "text": "acpA,",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.83203125,
            "end_logit": 8.1796875,
            "text": "and acpA",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.09375,
            "end_logit": -7.8046875,
            "text": "acpA, and activation",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.09375,
            "end_logit": -7.859375,
            "text": "acpA, and",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.9609375,
            "end_logit": 8.1796875,
            "text": "by both atxA and acpA",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.09375,
            "end_logit": -7.88671875,
            "text": "acpA, and activation appeared to be",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.13671875,
            "end_logit": 8.1796875,
            "text": "from P1 and P2 was activated by both atxA and acpA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.35546875,
            "end_logit": 8.1796875,
            "text": "activated by both atxA and acpA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.40234375,
            "end_logit": 8.1796875,
            "text": "atxA and acpA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.75,
            "end_logit": 8.1796875,
            "text": "and P2 was activated by both atxA and acpA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.7890625,
            "end_logit": 8.1796875,
            "text": "was activated by both atxA and acpA",
            "probability": 5.960464477539063e-08
        }
    ],
    "5710a592cf1c32585100002a_11": [
        {
            "start_logit": 7.0859375,
            "end_logit": 9.0,
            "text": "CO2",
            "probability": 1.0
        },
        {
            "start_logit": -6.83203125,
            "end_logit": 9.0,
            "text": "to CO2",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": -7.703125,
            "end_logit": 9.0,
            "text": "Transcriptome analysis identifies Bacillus anthracis genes that respond to CO2",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.828125,
            "end_logit": 9.0,
            "text": "respond to CO2",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.90625,
            "end_logit": 9.0,
            "text": "genes that respond to CO2",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.9296875,
            "end_logit": 9.0,
            "text": "analysis identifies Bacillus anthracis genes that respond to CO2",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.953125,
            "end_logit": 9.0,
            "text": "Bacillus anthracis genes that respond to CO2",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.96875,
            "end_logit": 9.0,
            "text": "identifies Bacillus anthracis genes that respond to CO2",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -8.0078125,
            "end_logit": 9.0,
            "text": "anthracis genes that respond to CO2",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -8.015625,
            "end_logit": 9.0,
            "text": "is genes that respond to CO2",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -8.1015625,
            "end_logit": 9.0,
            "text": "that respond to CO2",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.0859375,
            "end_logit": -7.703125,
            "text": "CO2 through an AtxA-dependent mechanism",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.0859375,
            "end_logit": -7.76953125,
            "text": "CO2 through",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.0859375,
            "end_logit": -8.109375,
            "text": "CO2 through an AtxA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.0859375,
            "end_logit": -8.140625,
            "text": "CO2 through an AtxA-",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.83203125,
            "end_logit": -7.703125,
            "text": "to CO2 through an AtxA-dependent mechanism",
            "probability": 0.0
        },
        {
            "start_logit": -6.83203125,
            "end_logit": -7.76953125,
            "text": "to CO2 through",
            "probability": 0.0
        },
        {
            "start_logit": -6.83203125,
            "end_logit": -8.109375,
            "text": "to CO2 through an AtxA",
            "probability": 0.0
        },
        {
            "start_logit": -6.83203125,
            "end_logit": -8.140625,
            "text": "to CO2 through an AtxA-",
            "probability": 0.0
        },
        {
            "start_logit": -7.703125,
            "end_logit": -7.703125,
            "text": "Transcriptome analysis identifies Bacillus anthracis genes that respond to CO2 through an AtxA-dependent mechanism",
            "probability": 0.0
        }
    ],
    "5710a592cf1c32585100002a_12": [
        {
            "start_logit": 9.09375,
            "end_logit": 8.1796875,
            "text": "acpA",
            "probability": 1.0
        },
        {
            "start_logit": 9.09375,
            "end_logit": -1.2412109375,
            "text": "acpA, and activation appeared to be stimulated by bicarbonate",
            "probability": 8.028745651245117e-05
        },
        {
            "start_logit": 9.09375,
            "end_logit": -2.38671875,
            "text": "acpA, and activation appeared to be stimulated by bicarbonate.",
            "probability": 2.5451183319091797e-05
        },
        {
            "start_logit": 9.09375,
            "end_logit": -2.82421875,
            "text": "acp",
            "probability": 1.6450881958007812e-05
        },
        {
            "start_logit": -3.345703125,
            "end_logit": 8.1796875,
            "text": "Transcription initiated from P1 and P2 was activated by both atxA and acpA",
            "probability": 3.933906555175781e-06
        },
        {
            "start_logit": -3.93359375,
            "end_logit": 8.1796875,
            "text": "A",
            "probability": 2.205371856689453e-06
        },
        {
            "start_logit": -5.66015625,
            "end_logit": 8.1796875,
            "text": "both atxA and acpA",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 9.09375,
            "end_logit": -7.35546875,
            "text": "acpA, and activation appeared",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.09375,
            "end_logit": -7.5625,
            "text": "acpA, and activation appeared to",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.09375,
            "end_logit": -7.66015625,
            "text": "acpA,",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.83203125,
            "end_logit": 8.1796875,
            "text": "and acpA",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.09375,
            "end_logit": -7.8046875,
            "text": "acpA, and activation",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.09375,
            "end_logit": -7.859375,
            "text": "acpA, and",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.9609375,
            "end_logit": 8.1796875,
            "text": "by both atxA and acpA",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.09375,
            "end_logit": -7.88671875,
            "text": "acpA, and activation appeared to be",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.13671875,
            "end_logit": 8.1796875,
            "text": "from P1 and P2 was activated by both atxA and acpA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.35546875,
            "end_logit": 8.1796875,
            "text": "activated by both atxA and acpA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.40234375,
            "end_logit": 8.1796875,
            "text": "atxA and acpA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.75,
            "end_logit": 8.1796875,
            "text": "and P2 was activated by both atxA and acpA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.7890625,
            "end_logit": 8.1796875,
            "text": "was activated by both atxA and acpA",
            "probability": 5.960464477539063e-08
        }
    ],
    "5710a592cf1c32585100002a_13": [
        {
            "start_logit": 7.515625,
            "end_logit": 8.7265625,
            "text": "CO2",
            "probability": 1.0
        },
        {
            "start_logit": -6.7421875,
            "end_logit": 8.7265625,
            "text": "to CO2",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -7.71484375,
            "end_logit": 8.7265625,
            "text": "Transcriptome analysis identifies Bacillus anthracis genes that respond to CO2",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.77734375,
            "end_logit": 8.7265625,
            "text": "respond to CO2",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.859375,
            "end_logit": 8.7265625,
            "text": "genes that respond to CO2",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.9609375,
            "end_logit": 8.7265625,
            "text": "Bacillus anthracis genes that respond to CO2",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.97265625,
            "end_logit": 8.7265625,
            "text": "analysis identifies Bacillus anthracis genes that respond to CO2",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.98828125,
            "end_logit": 8.7265625,
            "text": "identifies Bacillus anthracis genes that respond to CO2",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.99609375,
            "end_logit": 8.7265625,
            "text": "anthracis genes that respond to CO2",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -8.015625,
            "end_logit": 8.7265625,
            "text": "is genes that respond to CO2",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -8.046875,
            "end_logit": 8.7265625,
            "text": "that respond to CO2",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.515625,
            "end_logit": -6.9765625,
            "text": "CO2 through an AtxA-dependent mechanism.",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.515625,
            "end_logit": -7.8828125,
            "text": "CO2 through",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.515625,
            "end_logit": -8.0625,
            "text": "CO2 through an AtxA-dependent mechanism",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.515625,
            "end_logit": -8.1171875,
            "text": "CO2 through an AtxA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.7421875,
            "end_logit": -6.9765625,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -6.7421875,
            "end_logit": -6.9765625,
            "text": "to CO2 through an AtxA-dependent mechanism.",
            "probability": 0.0
        },
        {
            "start_logit": -6.7421875,
            "end_logit": -7.8828125,
            "text": "to CO2 through",
            "probability": 0.0
        },
        {
            "start_logit": -7.71484375,
            "end_logit": -6.9765625,
            "text": "Transcriptome analysis identifies Bacillus anthracis genes that respond to CO2 through an AtxA-dependent mechanism.",
            "probability": 0.0
        },
        {
            "start_logit": -7.77734375,
            "end_logit": -6.9765625,
            "text": "respond to CO2 through an AtxA-dependent mechanism.",
            "probability": 0.0
        }
    ],
    "5710a592cf1c32585100002a_14": [
        {
            "start_logit": 6.79296875,
            "end_logit": 9.046875,
            "text": "CO2",
            "probability": 1.0
        },
        {
            "start_logit": 6.79296875,
            "end_logit": -1.025390625,
            "text": "CO2.",
            "probability": 4.1961669921875e-05
        },
        {
            "start_logit": -5.5703125,
            "end_logit": 9.046875,
            "text": "toxin genes by B. anthracis is enhanced during growth under elevated levels of CO2",
            "probability": 4.231929779052734e-06
        },
        {
            "start_logit": -7.0625,
            "end_logit": 9.046875,
            "text": "Expression of the toxin genes by B. anthracis is enhanced during growth under elevated levels of CO2",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": -7.078125,
            "end_logit": 9.046875,
            "text": "B. anthracis is enhanced during growth under elevated levels of CO2",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": -7.20703125,
            "end_logit": 9.046875,
            "text": "the toxin genes by B. anthracis is enhanced during growth under elevated levels of CO2",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": -7.27734375,
            "end_logit": 9.046875,
            "text": "under elevated levels of CO2",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": -7.4140625,
            "end_logit": 9.046875,
            "text": "of CO2",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -7.41796875,
            "end_logit": 9.046875,
            "text": "during growth under elevated levels of CO2",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -7.4296875,
            "end_logit": 9.046875,
            "text": "elevated levels of CO2",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -7.52734375,
            "end_logit": 9.046875,
            "text": "by B. anthracis is enhanced during growth under elevated levels of CO2",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -7.546875,
            "end_logit": 9.046875,
            "text": "anthracis is enhanced during growth under elevated levels of CO2",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -7.625,
            "end_logit": 9.046875,
            "text": "levels of CO2",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -7.65625,
            "end_logit": 9.046875,
            "text": "enhanced during growth under elevated levels of CO2",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -7.8671875,
            "end_logit": 9.046875,
            "text": "growth under elevated levels of CO2",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -7.9375,
            "end_logit": 9.046875,
            "text": "of the toxin genes by B. anthracis is enhanced during growth under elevated levels of CO2",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -7.96484375,
            "end_logit": 9.046875,
            "text": ". anthracis is enhanced during growth under elevated levels of CO2",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -3.423828125,
            "end_logit": -1.025390625,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -5.5703125,
            "end_logit": -1.025390625,
            "text": "toxin genes by B. anthracis is enhanced during growth under elevated levels of CO2.",
            "probability": 0.0
        },
        {
            "start_logit": -7.0625,
            "end_logit": -1.025390625,
            "text": "Expression of the toxin genes by B. anthracis is enhanced during growth under elevated levels of CO2.",
            "probability": 0.0
        }
    ],
    "5710a592cf1c32585100002a_15": [
        {
            "start_logit": 7.5234375,
            "end_logit": 8.7265625,
            "text": "CO2",
            "probability": 1.0
        },
        {
            "start_logit": 7.5234375,
            "end_logit": -6.4921875,
            "text": "CO2 effect is observed only in the presence of another pXO1 gene, atxA, which encodes a transactivator of anthrax toxin synthesis.",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.8828125,
            "end_logit": 8.7265625,
            "text": "This CO2",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.5234375,
            "end_logit": -6.72265625,
            "text": "CO2 effect is observed only in the presence of another pXO1",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.5234375,
            "end_logit": -7.5546875,
            "text": "CO2 effect is observed only in the presence of another pX",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.5234375,
            "end_logit": -7.765625,
            "text": "CO2 effect is observed only in the presence of another pXO1 gene, atxA, which encodes a transactivator of anthrax toxin synthesis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.5234375,
            "end_logit": -7.84375,
            "text": "CO2 effect",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.5234375,
            "end_logit": -7.875,
            "text": "CO2 effect is observed",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.5234375,
            "end_logit": -7.88671875,
            "text": "CO2 effect is observed only in the presence of another pXO1 gene, atxA, which",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.5234375,
            "end_logit": -7.93359375,
            "text": "CO2 effect is observed only in the presence",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.5234375,
            "end_logit": -7.93359375,
            "text": "CO2 effect is",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.5234375,
            "end_logit": -7.94921875,
            "text": "CO2 effect is observed only in the presence of another pXO1 gene, atxA, which encodes a transactivator of anthrax toxin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.5234375,
            "end_logit": -7.953125,
            "text": "CO2 effect is observed only",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.5234375,
            "end_logit": -7.9609375,
            "text": "CO2 effect is observed only in the presence of another pXO1 gene, atxA, which encodes a transactivator",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.5234375,
            "end_logit": -7.99609375,
            "text": "CO2 effect is observed only in the presence of another pXO1 gene",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.5234375,
            "end_logit": -8.0234375,
            "text": "CO2 effect is observed only in",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.5234375,
            "end_logit": -8.0546875,
            "text": "CO2 effect is observed only in the",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.5234375,
            "end_logit": -8.0703125,
            "text": "CO2 effect is observed only in the presence of",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.5234375,
            "end_logit": -8.078125,
            "text": "CO2 effect is observed only in the presence of another pXO1 gene, atxA,",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.56640625,
            "end_logit": -6.4921875,
            "text": "pXO1 gene, atxA, which encodes a transactivator of anthrax toxin synthesis.",
            "probability": 0.0
        }
    ],
    "5710a592cf1c32585100002a_16": [
        {
            "start_logit": 7.4296875,
            "end_logit": 8.8046875,
            "text": "CO2",
            "probability": 1.0
        },
        {
            "start_logit": -6.87109375,
            "end_logit": 8.8046875,
            "text": "Here we show that transcription of atxA does not appear to differ in cells grown in 5% CO2",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 7.4296875,
            "end_logit": -5.65234375,
            "text": "CO2 compared with cells grown in air.",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -7.3984375,
            "end_logit": 8.8046875,
            "text": "5% CO2",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.40234375,
            "end_logit": 8.8046875,
            "text": "we show that transcription of atxA does not appear to differ in cells grown in 5% CO2",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.5625,
            "end_logit": 8.8046875,
            "text": "% CO2",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.56640625,
            "end_logit": 8.8046875,
            "text": "in 5% CO2",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.66796875,
            "end_logit": 8.8046875,
            "text": "of atxA does not appear to differ in cells grown in 5% CO2",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.7109375,
            "end_logit": 8.8046875,
            "text": "transcription of atxA does not appear to differ in cells grown in 5% CO2",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.73046875,
            "end_logit": 8.8046875,
            "text": "that transcription of atxA does not appear to differ in cells grown in 5% CO2",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.73828125,
            "end_logit": 8.8046875,
            "text": "in cells grown in 5% CO2",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.796875,
            "end_logit": 8.8046875,
            "text": "atxA does not appear to differ in cells grown in 5% CO2",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.90234375,
            "end_logit": 8.8046875,
            "text": "xA does not appear to differ in cells grown in 5% CO2",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -8.0390625,
            "end_logit": 8.8046875,
            "text": "show that transcription of atxA does not appear to differ in cells grown in 5% CO2",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.4296875,
            "end_logit": -7.5625,
            "text": "CO2 compared",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.4296875,
            "end_logit": -7.8828125,
            "text": "CO2 compared with",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.4296875,
            "end_logit": -7.9375,
            "text": "CO2 compared with cells grown in air",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.12109375,
            "end_logit": -5.65234375,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -6.87109375,
            "end_logit": -5.65234375,
            "text": "Here we show that transcription of atxA does not appear to differ in cells grown in 5% CO2 compared with cells grown in air.",
            "probability": 0.0
        },
        {
            "start_logit": -7.3984375,
            "end_logit": -5.65234375,
            "text": "5% CO2 compared with cells grown in air.",
            "probability": 0.0
        }
    ],
    "5710a592cf1c32585100002a_17": [
        {
            "start_logit": 9.1875,
            "end_logit": 8.078125,
            "text": "acpA",
            "probability": 1.0
        },
        {
            "start_logit": 9.1875,
            "end_logit": -1.2412109375,
            "text": "acpA, and activation appeared to be stimulated by bicarbonate",
            "probability": 8.958578109741211e-05
        },
        {
            "start_logit": 9.1875,
            "end_logit": -2.677734375,
            "text": "acp",
            "probability": 2.1278858184814453e-05
        },
        {
            "start_logit": 9.1875,
            "end_logit": -3.310546875,
            "text": "acpA, and activation appeared to be stimulated by bicarbonate.",
            "probability": 1.1324882507324219e-05
        },
        {
            "start_logit": 9.1875,
            "end_logit": -4.8359375,
            "text": "acpA, and activation appeared to be stimulated by bicarbonate. Deletion analysis of the upstream region of the cap promoter revealed",
            "probability": 2.4437904357910156e-06
        },
        {
            "start_logit": -3.994140625,
            "end_logit": 8.078125,
            "text": "A",
            "probability": 1.9073486328125e-06
        },
        {
            "start_logit": -5.26953125,
            "end_logit": 8.078125,
            "text": "both atxA and acpA",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 9.1875,
            "end_logit": -6.62890625,
            "text": "acpA, and activation appeared to be stimulated by bicarbonate. Deletion analysis of the upstream region of the cap promoter revealed that activation by both atxA and acpA required",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 9.1875,
            "end_logit": -6.94140625,
            "text": "acpA, and activation appeared to be stimulated by bicarbonate. Deletion analysis of the upstream region of the cap promoter revealed that activation by both atxA and acpA required a DNA segment of 70",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.1875,
            "end_logit": -7.26171875,
            "text": "acpA, and activation appeared to be stimulated by bicarbonate. Deletion analysis of the upstream region of the cap promoter revealed that activation by both atxA and acpA required a DNA segment of 70 bp",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.1875,
            "end_logit": -7.296875,
            "text": "acpA, and activation appeared to be stimulated by bicarbonate. Deletion analysis of the upstream region of the cap promoter revealed that activation",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.27734375,
            "end_logit": 8.078125,
            "text": "Transcription initiated from P1 and P2 was activated by both atxA and acpA",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.1875,
            "end_logit": -7.390625,
            "text": "acpA, and activation appeared to be stimulated by bicarbonate. Deletion analysis of the upstream region of the cap promoter revealed that activation by both atxA and acpA required a",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.1875,
            "end_logit": -7.43359375,
            "text": "acpA, and activation appeared to be stimulated by bicarbonate. Deletion analysis",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.37890625,
            "end_logit": 8.078125,
            "text": "and acpA",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.1875,
            "end_logit": -7.5,
            "text": "acpA, and activation appeared to be stimulated by bicarbonate. Deletion analysis of the upstream region of the cap promoter revealed that activation by both atxA and acpA required a DNA segment",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.1875,
            "end_logit": -7.5234375,
            "text": "acpA, and activation appeared to be stimulated by bicarbonate. Deletion analysis of the upstream region of the cap promoter",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.95703125,
            "end_logit": 8.078125,
            "text": "by both atxA and acpA",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -0.96875,
            "end_logit": -1.2412109375,
            "text": "bicarbonate",
            "probability": 0.0
        },
        {
            "start_logit": -0.96875,
            "end_logit": -3.30859375,
            "text": "bicarbonate. Deletion analysis of the upstream region of the cap promoter revealed that activation by both atxA and acpA required a DNA segment of 70 bp extending upstream of the P1 site.",
            "probability": 0.0
        }
    ],
    "5710a592cf1c32585100002a_18": [
        {
            "start_logit": 6.56640625,
            "end_logit": 5.98828125,
            "text": "acpA",
            "probability": 0.998046875
        },
        {
            "start_logit": 0.32568359375,
            "end_logit": 5.98828125,
            "text": "both atxA and acpA",
            "probability": 0.001941680908203125
        },
        {
            "start_logit": 6.56640625,
            "end_logit": -3.5078125,
            "text": "acpA, and activation appeared to be stimulated by bicarbonate",
            "probability": 7.474422454833984e-05
        },
        {
            "start_logit": 6.56640625,
            "end_logit": -5.0390625,
            "text": "acpA, and activation appeared to be stimulated by bicarbonate.",
            "probability": 1.615285873413086e-05
        },
        {
            "start_logit": 6.56640625,
            "end_logit": -5.1015625,
            "text": "acp",
            "probability": 1.519918441772461e-05
        },
        {
            "start_logit": -5.078125,
            "end_logit": 5.98828125,
            "text": "activated by both atxA and acpA",
            "probability": 8.821487426757812e-06
        },
        {
            "start_logit": -5.546875,
            "end_logit": 5.98828125,
            "text": ". Transcription initiated from P1 and P2 was activated by both atxA and acpA",
            "probability": 5.4836273193359375e-06
        },
        {
            "start_logit": -5.8828125,
            "end_logit": 5.98828125,
            "text": "A",
            "probability": 3.933906555175781e-06
        },
        {
            "start_logit": -6.24609375,
            "end_logit": 5.98828125,
            "text": "and acpA",
            "probability": 2.7418136596679688e-06
        },
        {
            "start_logit": 6.56640625,
            "end_logit": -7.18359375,
            "text": "acpA, and activation appeared",
            "probability": 1.9073486328125e-06
        },
        {
            "start_logit": -6.640625,
            "end_logit": 5.98828125,
            "text": "by both atxA and acpA",
            "probability": 1.8477439880371094e-06
        },
        {
            "start_logit": 6.56640625,
            "end_logit": -7.30859375,
            "text": "acpA, and activation appeared to",
            "probability": 1.6689300537109375e-06
        },
        {
            "start_logit": 6.56640625,
            "end_logit": -7.421875,
            "text": "acpA,",
            "probability": 1.4901161193847656e-06
        },
        {
            "start_logit": -6.97265625,
            "end_logit": 5.98828125,
            "text": "Transcription initiated from P1 and P2 was activated by both atxA and acpA",
            "probability": 1.3113021850585938e-06
        },
        {
            "start_logit": 6.56640625,
            "end_logit": -7.65625,
            "text": "acpA, and activation",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": 6.56640625,
            "end_logit": -7.6875,
            "text": "acpA, and",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": -7.36328125,
            "end_logit": 5.98828125,
            "text": "atxA and acpA",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": -7.70703125,
            "end_logit": 5.98828125,
            "text": "was activated by both atxA and acpA",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -7.9453125,
            "end_logit": 5.98828125,
            "text": ", located at positions 731 bp and 625 bp, respectively, upstream of the translation-initiation codon of capB. Transcription initiated from P1 and P2 was activated by both atxA and acpA",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 0.32568359375,
            "end_logit": -3.5078125,
            "text": "both atxA and acpA, and activation appeared to be stimulated by bicarbonate",
            "probability": 1.1920928955078125e-07
        }
    ],
    "5710a592cf1c32585100002a_19": [
        {
            "start_logit": 9.09375,
            "end_logit": 8.1796875,
            "text": "acpA",
            "probability": 1.0
        },
        {
            "start_logit": 9.09375,
            "end_logit": -1.2412109375,
            "text": "acpA, and activation appeared to be stimulated by bicarbonate",
            "probability": 8.028745651245117e-05
        },
        {
            "start_logit": 9.09375,
            "end_logit": -2.38671875,
            "text": "acpA, and activation appeared to be stimulated by bicarbonate.",
            "probability": 2.5451183319091797e-05
        },
        {
            "start_logit": 9.09375,
            "end_logit": -2.82421875,
            "text": "acp",
            "probability": 1.6450881958007812e-05
        },
        {
            "start_logit": -3.345703125,
            "end_logit": 8.1796875,
            "text": "Transcription initiated from P1 and P2 was activated by both atxA and acpA",
            "probability": 3.933906555175781e-06
        },
        {
            "start_logit": -3.93359375,
            "end_logit": 8.1796875,
            "text": "A",
            "probability": 2.205371856689453e-06
        },
        {
            "start_logit": -5.66015625,
            "end_logit": 8.1796875,
            "text": "both atxA and acpA",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 9.09375,
            "end_logit": -7.35546875,
            "text": "acpA, and activation appeared",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.09375,
            "end_logit": -7.5625,
            "text": "acpA, and activation appeared to",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.09375,
            "end_logit": -7.66015625,
            "text": "acpA,",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.83203125,
            "end_logit": 8.1796875,
            "text": "and acpA",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.09375,
            "end_logit": -7.8046875,
            "text": "acpA, and activation",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.09375,
            "end_logit": -7.859375,
            "text": "acpA, and",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.9609375,
            "end_logit": 8.1796875,
            "text": "by both atxA and acpA",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.09375,
            "end_logit": -7.88671875,
            "text": "acpA, and activation appeared to be",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.13671875,
            "end_logit": 8.1796875,
            "text": "from P1 and P2 was activated by both atxA and acpA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.35546875,
            "end_logit": 8.1796875,
            "text": "activated by both atxA and acpA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.40234375,
            "end_logit": 8.1796875,
            "text": "atxA and acpA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.75,
            "end_logit": 8.1796875,
            "text": "and P2 was activated by both atxA and acpA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.7890625,
            "end_logit": 8.1796875,
            "text": "was activated by both atxA and acpA",
            "probability": 5.960464477539063e-08
        }
    ],
    "5710a592cf1c32585100002a_20": [
        {
            "start_logit": 9.0078125,
            "end_logit": 6.28515625,
            "text": "CO2",
            "probability": 0.9697265625
        },
        {
            "start_logit": 4.90234375,
            "end_logit": 6.28515625,
            "text": "anthrax toxin activator gene (atxA) expression in Bacillus anthracis: temperature, not CO2",
            "probability": 0.0159149169921875
        },
        {
            "start_logit": 9.0078125,
            "end_logit": 2.072265625,
            "text": "CO2/bicarbonate",
            "probability": 0.01427459716796875
        },
        {
            "start_logit": 4.90234375,
            "end_logit": 2.072265625,
            "text": "anthrax toxin activator gene (atxA) expression in Bacillus anthracis: temperature, not CO2/bicarbonate",
            "probability": 0.00023615360260009766
        },
        {
            "start_logit": 9.0078125,
            "end_logit": -5.5625,
            "text": "CO2/bicarbonate, affects AtxA synthesis.",
            "probability": 6.9141387939453125e-06
        },
        {
            "start_logit": 9.0078125,
            "end_logit": -7.35546875,
            "text": "CO2/bicarbonate, affects AtxA synthesis",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": 9.0078125,
            "end_logit": -7.73046875,
            "text": "CO2/bicarbonate, affects",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": 9.0078125,
            "end_logit": -7.76171875,
            "text": "CO2/bicarbonate,",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": -5.62109375,
            "end_logit": 6.28515625,
            "text": "temperature, not CO2",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 4.90234375,
            "end_logit": -5.24609375,
            "text": "anthrax toxin activator gene (atxA) expression in Bacillus anthracis: temperature",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 4.90234375,
            "end_logit": -5.30078125,
            "text": "anthrax toxin activator",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 4.90234375,
            "end_logit": -5.5625,
            "text": "anthrax toxin activator gene (atxA) expression in Bacillus anthracis: temperature, not CO2/bicarbonate, affects AtxA synthesis.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.453125,
            "end_logit": 6.28515625,
            "text": "not CO2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 4.90234375,
            "end_logit": -6.19140625,
            "text": "anthrax toxin activator gene",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 4.90234375,
            "end_logit": -6.26953125,
            "text": "anthr",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 4.90234375,
            "end_logit": -6.44140625,
            "text": "anthrax toxin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.8984375,
            "end_logit": 6.28515625,
            "text": "ax toxin activator gene (atxA) expression in Bacillus anthracis: temperature, not CO2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.92578125,
            "end_logit": 6.28515625,
            "text": "toxin activator gene (atxA) expression in Bacillus anthracis: temperature, not CO2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.125,
            "end_logit": 6.28515625,
            "text": "of anthrax toxin activator gene (atxA) expression in Bacillus anthracis: temperature, not CO2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 4.90234375,
            "end_logit": -7.0859375,
            "text": "anthrax toxin activator gene (atxA) expression",
            "probability": 0.0
        }
    ],
    "5a87ea1861bb38fb2400000d_1": [
        {
            "start_logit": 9.7265625,
            "end_logit": 9.2890625,
            "text": "circularized oligodeoxynucleotides",
            "probability": 1.0
        },
        {
            "start_logit": 9.7265625,
            "end_logit": -1.71484375,
            "text": "circular",
            "probability": 1.6689300537109375e-05
        },
        {
            "start_logit": -2.06640625,
            "end_logit": 9.2890625,
            "text": "otides",
            "probability": 7.510185241699219e-06
        },
        {
            "start_logit": 9.7265625,
            "end_logit": -6.25390625,
            "text": "circularized oligodeoxynucleotides (",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.7265625,
            "end_logit": -6.85546875,
            "text": "circularized oligodeoxynucleotides (coligos)",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.7265625,
            "end_logit": -7.1796875,
            "text": "circularized oligodeoxynucleotides (coligos",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.7265625,
            "end_logit": -7.23046875,
            "text": "circularized oligodeoxynucle",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.890625,
            "end_logit": 9.2890625,
            "text": "ized oligodeoxynucleotides",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.0625,
            "end_logit": 9.2890625,
            "text": "oligodeoxynucleotides",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.7265625,
            "end_logit": -7.5546875,
            "text": "circularized oligodeox",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.1171875,
            "end_logit": 9.2890625,
            "text": "ynucleotides",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.7265625,
            "end_logit": -7.5859375,
            "text": "circularized",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.06640625,
            "end_logit": -6.25390625,
            "text": "otides (",
            "probability": 0.0
        },
        {
            "start_logit": -2.06640625,
            "end_logit": -6.85546875,
            "text": "otides (coligos)",
            "probability": 0.0
        },
        {
            "start_logit": -2.06640625,
            "end_logit": -7.1796875,
            "text": "otides (coligos",
            "probability": 0.0
        },
        {
            "start_logit": -6.890625,
            "end_logit": -6.25390625,
            "text": "ized oligodeoxynucleotides (",
            "probability": 0.0
        },
        {
            "start_logit": -7.0625,
            "end_logit": -6.25390625,
            "text": "oligodeoxynucleotides (",
            "probability": 0.0
        },
        {
            "start_logit": -7.1171875,
            "end_logit": -6.25390625,
            "text": "ynucleotides (",
            "probability": 0.0
        },
        {
            "start_logit": -6.890625,
            "end_logit": -6.85546875,
            "text": "ized oligodeoxynucleotides (coligos)",
            "probability": 0.0
        },
        {
            "start_logit": -7.0625,
            "end_logit": -6.85546875,
            "text": "oligodeoxynucleotides (coligos)",
            "probability": 0.0
        }
    ],
    "530cf4e0c8a0b4a00c000006_1": [
        {
            "start_logit": 9.4765625,
            "end_logit": 9.328125,
            "text": "hypertrophic cardiomyopathy",
            "probability": 1.0
        },
        {
            "start_logit": 9.4765625,
            "end_logit": -2.3203125,
            "text": "hypertrophic",
            "probability": 8.64267349243164e-06
        },
        {
            "start_logit": -2.34765625,
            "end_logit": 9.328125,
            "text": "cardiomyopathy",
            "probability": 7.271766662597656e-06
        },
        {
            "start_logit": 9.4765625,
            "end_logit": -7.484375,
            "text": "hypertrophic cardiomyopathy (30 %",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.4765625,
            "end_logit": -7.6796875,
            "text": "hypertrophic cardiomyopathy (30 %), followed by coronary artery anomalies (9 %), and myocarditis (9 %).",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.4765625,
            "end_logit": -7.76171875,
            "text": "hypertrophic cardiomyopathy (30",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.4765625,
            "end_logit": -7.921875,
            "text": "hypertrophic cardiomyopathy (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.4765625,
            "end_logit": -7.9375,
            "text": "hypertrophic cardiomyopathy (30 %), followed by coronary artery anomalies (9 %), and myocarditis (9 %",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.4765625,
            "end_logit": -7.95703125,
            "text": "hypertrophic cardiomyopathy (30 %), followed by coronary artery anomalies (9 %",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.4765625,
            "end_logit": -7.98828125,
            "text": "hypertrophic cardiomyopathy (30 %), followed",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.4765625,
            "end_logit": -7.9921875,
            "text": "hypertrophic cardiomyopathy (30 %), followed by",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.4765625,
            "end_logit": -8.0625,
            "text": "hypertrophic cardiomyopathy (30 %), followed by coronary artery anomalies (9 %), and myocarditis (9",
            "probability": 0.0
        },
        {
            "start_logit": 9.4765625,
            "end_logit": -8.0703125,
            "text": "hypertrophic cardiomyopathy (30 %), followed by coronary artery anomalies (9 %), and myocarditis (",
            "probability": 0.0
        },
        {
            "start_logit": 9.4765625,
            "end_logit": -8.0859375,
            "text": "hypertrophic cardiomyopathy (30 %)",
            "probability": 0.0
        },
        {
            "start_logit": -7.9453125,
            "end_logit": 9.328125,
            "text": "death was hypertrophic cardiomyopathy",
            "probability": 0.0
        },
        {
            "start_logit": 9.4765625,
            "end_logit": -8.1015625,
            "text": "hypertrophic cardiomyopathy (30 %), followed by coronary artery anomalies (9 %)",
            "probability": 0.0
        },
        {
            "start_logit": 9.4765625,
            "end_logit": -8.1015625,
            "text": "hypertrophic cardiomyopathy (30 %), followed by coronary artery anomalies",
            "probability": 0.0
        },
        {
            "start_logit": 9.4765625,
            "end_logit": -8.109375,
            "text": "hypertrophic cardiomyopathy (30 %), followed by coronary artery anomalies (9 %), and myocarditis",
            "probability": 0.0
        },
        {
            "start_logit": 9.4765625,
            "end_logit": -8.1171875,
            "text": "hypertrophic cardiomyopathy (30 %), followed by coronary artery anomalies (",
            "probability": 0.0
        },
        {
            "start_logit": -7.98828125,
            "end_logit": 9.328125,
            "text": "The most common cause of death was hypertrophic cardiomyopathy",
            "probability": 0.0
        }
    ],
    "530cf4e0c8a0b4a00c000006_2": [
        {
            "start_logit": 9.3828125,
            "end_logit": 9.1875,
            "text": "hypertrophic cardiomyopathy",
            "probability": 1.0
        },
        {
            "start_logit": 9.3828125,
            "end_logit": -2.490234375,
            "text": "hypertrophic",
            "probability": 8.52346420288086e-06
        },
        {
            "start_logit": -2.5859375,
            "end_logit": 9.1875,
            "text": "cardiomyopathy",
            "probability": 6.377696990966797e-06
        },
        {
            "start_logit": 9.3828125,
            "end_logit": -7.17578125,
            "text": "hypertrophic cardiomyopathy (HCM",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3828125,
            "end_logit": -7.46875,
            "text": "hypertrophic cardiomyopathy (HCM), is a genetic disorder responsible for more than a third of cases and is manageable.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3828125,
            "end_logit": -7.84375,
            "text": "hypertrophic cardiomyopathy (HCM)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.796875,
            "end_logit": 9.1875,
            "text": ", hypertrophic cardiomyopathy",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3828125,
            "end_logit": -7.99609375,
            "text": "hypertrophic cardiomyopathy (HCM),",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3828125,
            "end_logit": -8.109375,
            "text": "hypertrophic cardiomyopathy (HCM), is a genetic disorder responsible for more than a third of cases and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3828125,
            "end_logit": -8.1171875,
            "text": "hypertrophic cardiomyopathy (HCM), is a genetic disorder responsible for more than a third",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.9296875,
            "end_logit": 9.1875,
            "text": "The most common cause of this, hypertrophic cardiomyopathy",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3828125,
            "end_logit": -8.1328125,
            "text": "hypertrophic cardiomyopathy (HCM), is a genetic disorder responsible",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3828125,
            "end_logit": -8.1328125,
            "text": "hypertrophic cardiomyopathy (HCM), is a genetic disorder responsible for more than a",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.5859375,
            "end_logit": -7.17578125,
            "text": "cardiomyopathy (HCM",
            "probability": 0.0
        },
        {
            "start_logit": -2.5859375,
            "end_logit": -7.46875,
            "text": "cardiomyopathy (HCM), is a genetic disorder responsible for more than a third of cases and is manageable.",
            "probability": 0.0
        },
        {
            "start_logit": -7.796875,
            "end_logit": -2.490234375,
            "text": ", hypertrophic",
            "probability": 0.0
        },
        {
            "start_logit": -7.9296875,
            "end_logit": -2.490234375,
            "text": "The most common cause of this, hypertrophic",
            "probability": 0.0
        },
        {
            "start_logit": -2.5859375,
            "end_logit": -7.84375,
            "text": "cardiomyopathy (HCM)",
            "probability": 0.0
        },
        {
            "start_logit": -2.5859375,
            "end_logit": -7.99609375,
            "text": "cardiomyopathy (HCM),",
            "probability": 0.0
        },
        {
            "start_logit": -2.5859375,
            "end_logit": -8.109375,
            "text": "cardiomyopathy (HCM), is a genetic disorder responsible for more than a third of cases and",
            "probability": 0.0
        }
    ],
    "530cf4e0c8a0b4a00c000006_3": [
        {
            "start_logit": 9.25,
            "end_logit": 8.7421875,
            "text": "Hypertrophic cardiomyopathy",
            "probability": 1.0
        },
        {
            "start_logit": 9.25,
            "end_logit": -2.74609375,
            "text": "Hypertrophic",
            "probability": 1.0132789611816406e-05
        },
        {
            "start_logit": -3.359375,
            "end_logit": 8.7421875,
            "text": "cardiomyopathy",
            "probability": 3.337860107421875e-06
        },
        {
            "start_logit": 9.25,
            "end_logit": -6.08984375,
            "text": "Hypertrophic cardiomyopathy (HCM",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 9.25,
            "end_logit": -7.6171875,
            "text": "Hypertrophic cardiomyopathy (HCM)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.25,
            "end_logit": -7.87109375,
            "text": "Hypertrophic cardiomyopathy (HCM) is the most common cause of sudden cardiac death (SCD) in young people, including trained athletes.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.25,
            "end_logit": -7.9375,
            "text": "Hypertrophic cardiomyopathy (HCM) is",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.25,
            "end_logit": -7.9921875,
            "text": "Hypertrophic cardiomyopathy (HCM) is the most common cause of sudden cardiac death (SCD) in",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.25,
            "end_logit": -8.03125,
            "text": "Hypertrophic cardiomyopathy (HCM) is the most common cause of sudden cardiac death",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.25,
            "end_logit": -8.0625,
            "text": "Hypertrophic cardiomyopathy (HCM) is the most common cause of sudden cardiac death (SCD) in young",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.25,
            "end_logit": -8.0625,
            "text": "Hypertrophic cardiomyopathy (HCM) is the most common cause",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.25,
            "end_logit": -8.0625,
            "text": "Hypertrophic cardiomyopathy (HCM) is the most common",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.25,
            "end_logit": -8.0625,
            "text": "Hypertrophic cardiomyopathy (HCM) is the most common cause of sudden cardiac death (SCD) in young people, including trained athletes",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.25,
            "end_logit": -8.0703125,
            "text": "Hypertrophic cardiomyopathy (HCM) is the most common cause of",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.25,
            "end_logit": -8.0703125,
            "text": "Hypertrophic cardiomyopathy (HCM) is the most common cause of sudden cardiac",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.25,
            "end_logit": -8.078125,
            "text": "Hypertrophic cardiomyopathy (HCM) is the most common cause of sudden cardiac death (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.25,
            "end_logit": -8.078125,
            "text": "Hypertrophic cardiomyopathy (HCM) is the most common cause of sudden cardiac death (SCD",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.25,
            "end_logit": -8.1015625,
            "text": "Hypertrophic cardiomyopathy (HCM) is the most common cause of sudden cardiac death (SCD) in young people, including",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -3.359375,
            "end_logit": -6.08984375,
            "text": "cardiomyopathy (HCM",
            "probability": 0.0
        },
        {
            "start_logit": -3.359375,
            "end_logit": -7.6171875,
            "text": "cardiomyopathy (HCM)",
            "probability": 0.0
        }
    ],
    "530cf4e0c8a0b4a00c000006_4": [
        {
            "start_logit": 9.2578125,
            "end_logit": 8.6875,
            "text": "Hypertrophic cardiomyopathy",
            "probability": 1.0
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -2.732421875,
            "text": "Hypertrophic",
            "probability": 1.1026859283447266e-05
        },
        {
            "start_logit": -3.44921875,
            "end_logit": 8.6875,
            "text": "cardiomyopathy",
            "probability": 3.039836883544922e-06
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -6.2734375,
            "text": "Hypertrophic cardiomyopathy (HCM",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -7.6640625,
            "text": "Hypertrophic cardiomyopathy (HCM) is regarded as the most common cause of sudden cardiac death in young people (including trained athletes).",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -7.79296875,
            "text": "Hypertrophic cardiomyopathy (HCM)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -7.8515625,
            "text": "Hypertrophic cardiomyopathy (HCM) is regarded as",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -8.0390625,
            "text": "Hypertrophic cardiomyopathy (HCM) is regarded as the",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -8.0390625,
            "text": "Hypertrophic cardiomyopathy (HCM) is regarded as the most common cause of sudden cardiac death in",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -8.0546875,
            "text": "Hypertrophic cardiomyopathy (HCM) is regarded as the most common",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -8.0546875,
            "text": "Hypertrophic cardiomyopathy (HCM) is regarded as the most common cause of sudden cardiac death in young people (including trained athletes)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -8.0546875,
            "text": "Hypertrophic cardiomyopathy (HCM) is regarded as the most",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -8.078125,
            "text": "Hypertrophic cardiomyopathy (HCM) is regarded as the most common cause",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -8.0859375,
            "text": "Hypertrophic cardiomyopathy (HCM) is regarded as the most common cause of sudden cardiac death in young",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -8.0859375,
            "text": "Hypertrophic cardiomyopathy (HCM) is regarded as the most common cause of sudden cardiac death in young people (including trained athletes",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -8.09375,
            "text": "Hypertrophic cardiomyopathy (HCM) is regarded as the most common cause of",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -8.109375,
            "text": "Hypertrophic cardiomyopathy (HCM) is",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -3.44921875,
            "end_logit": -6.2734375,
            "text": "cardiomyopathy (HCM",
            "probability": 0.0
        },
        {
            "start_logit": -3.44921875,
            "end_logit": -7.6640625,
            "text": "cardiomyopathy (HCM) is regarded as the most common cause of sudden cardiac death in young people (including trained athletes).",
            "probability": 0.0
        },
        {
            "start_logit": -3.44921875,
            "end_logit": -7.79296875,
            "text": "cardiomyopathy (HCM)",
            "probability": 0.0
        }
    ],
    "530cf4e0c8a0b4a00c000006_5": [
        {
            "start_logit": 9.28125,
            "end_logit": 8.78125,
            "text": "Hypertrophic cardiomyopathy",
            "probability": 1.0
        },
        {
            "start_logit": 9.28125,
            "end_logit": -2.697265625,
            "text": "Hypertrophic",
            "probability": 1.0371208190917969e-05
        },
        {
            "start_logit": -3.29296875,
            "end_logit": 8.78125,
            "text": "cardiomyopathy",
            "probability": 3.4570693969726562e-06
        },
        {
            "start_logit": 9.28125,
            "end_logit": -6.15625,
            "text": "Hypertrophic cardiomyopathy (HCM",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.28125,
            "end_logit": -7.73828125,
            "text": "Hypertrophic cardiomyopathy (HCM)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.28125,
            "end_logit": -7.9140625,
            "text": "Hypertrophic cardiomyopathy (HCM) is the most common cause of sudden cardiac death in young people, including trained athletes.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.28125,
            "end_logit": -7.94140625,
            "text": "Hypertrophic cardiomyopathy (HCM) is",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.28125,
            "end_logit": -8.0234375,
            "text": "Hypertrophic cardiomyopathy (HCM) is the most common cause of sudden cardiac death in",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.28125,
            "end_logit": -8.078125,
            "text": "Hypertrophic cardiomyopathy (HCM) is the most common cause of sudden cardiac death in young people, including trained athletes",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.28125,
            "end_logit": -8.078125,
            "text": "Hypertrophic cardiomyopathy (HCM) is the most common",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.28125,
            "end_logit": -8.0859375,
            "text": "Hypertrophic cardiomyopathy (HCM) is the most common cause of sudden cardiac death in young",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.28125,
            "end_logit": -8.09375,
            "text": "Hypertrophic cardiomyopathy (HCM) is the most common cause",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.28125,
            "end_logit": -8.09375,
            "text": "Hypertrophic cardiomyopathy (HCM) is the most common cause of",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.28125,
            "end_logit": -8.1015625,
            "text": "Hypertrophic cardiomyopathy (HCM) is the most common cause of sudden cardiac death",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.28125,
            "end_logit": -8.109375,
            "text": "Hypertrophic cardiomyopathy (HCM) is the most common cause of sudden cardiac death in young people, including",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.28125,
            "end_logit": -8.109375,
            "text": "Hypertrophic cardiomyopathy (HCM) is the most common cause of sudden cardiac",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.28125,
            "end_logit": -8.1171875,
            "text": "Hypertrophic cardiomyopathy (HCM) is the most",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -3.29296875,
            "end_logit": -6.15625,
            "text": "cardiomyopathy (HCM",
            "probability": 0.0
        },
        {
            "start_logit": -3.29296875,
            "end_logit": -7.73828125,
            "text": "cardiomyopathy (HCM)",
            "probability": 0.0
        },
        {
            "start_logit": -3.29296875,
            "end_logit": -7.9140625,
            "text": "cardiomyopathy (HCM) is the most common cause of sudden cardiac death in young people, including trained athletes.",
            "probability": 0.0
        }
    ],
    "530cf4e0c8a0b4a00c000006_6": [
        {
            "start_logit": 9.5234375,
            "end_logit": 9.359375,
            "text": "Hypertrophic cardiomyopathy",
            "probability": 1.0
        },
        {
            "start_logit": 9.5234375,
            "end_logit": -2.216796875,
            "text": "Hypertrophic",
            "probability": 9.417533874511719e-06
        },
        {
            "start_logit": -2.30078125,
            "end_logit": 9.359375,
            "text": "cardiomyopathy",
            "probability": 7.3909759521484375e-06
        },
        {
            "start_logit": 9.5234375,
            "end_logit": -7.96875,
            "text": "Hypertrophic cardiomyopathy is regarded as the most common cause of sudden cardiac death in young people (including trained athletes).",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.5234375,
            "end_logit": -8.046875,
            "text": "Hypertrophic cardiomyopathy is regarded as",
            "probability": 0.0
        },
        {
            "start_logit": 9.5234375,
            "end_logit": -8.1171875,
            "text": "Hypertrophic cardiomyopathy is regarded as the most common cause of sudden cardiac death in",
            "probability": 0.0
        },
        {
            "start_logit": 9.5234375,
            "end_logit": -8.1328125,
            "text": "Hypertrophic cardiomyopathy is",
            "probability": 0.0
        },
        {
            "start_logit": 9.5234375,
            "end_logit": -8.1484375,
            "text": "Hypertrophic cardiomyopathy is regarded as the most common cause of sudden cardiac death in young people (including trained athletes)",
            "probability": 0.0
        },
        {
            "start_logit": 9.5234375,
            "end_logit": -8.1484375,
            "text": "Hypertrophic cardiomyopathy is regarded as the most common",
            "probability": 0.0
        },
        {
            "start_logit": 9.5234375,
            "end_logit": -8.15625,
            "text": "Hypertrophic cardiomyopathy is regarded as the most common cause",
            "probability": 0.0
        },
        {
            "start_logit": 9.5234375,
            "end_logit": -8.1640625,
            "text": "Hypertrophic cardiomyopathy is regarded as the most",
            "probability": 0.0
        },
        {
            "start_logit": -2.30078125,
            "end_logit": -7.96875,
            "text": "cardiomyopathy is regarded as the most common cause of sudden cardiac death in young people (including trained athletes).",
            "probability": 0.0
        },
        {
            "start_logit": -2.30078125,
            "end_logit": -8.046875,
            "text": "cardiomyopathy is regarded as",
            "probability": 0.0
        },
        {
            "start_logit": -2.30078125,
            "end_logit": -8.1171875,
            "text": "cardiomyopathy is regarded as the most common cause of sudden cardiac death in",
            "probability": 0.0
        },
        {
            "start_logit": -2.30078125,
            "end_logit": -8.1328125,
            "text": "cardiomyopathy is",
            "probability": 0.0
        },
        {
            "start_logit": -2.30078125,
            "end_logit": -8.1484375,
            "text": "cardiomyopathy is regarded as the most common cause of sudden cardiac death in young people (including trained athletes)",
            "probability": 0.0
        },
        {
            "start_logit": -2.30078125,
            "end_logit": -8.1484375,
            "text": "cardiomyopathy is regarded as the most common",
            "probability": 0.0
        },
        {
            "start_logit": -2.30078125,
            "end_logit": -8.15625,
            "text": "cardiomyopathy is regarded as the most common cause",
            "probability": 0.0
        },
        {
            "start_logit": -2.30078125,
            "end_logit": -8.1640625,
            "text": "cardiomyopathy is regarded as the most",
            "probability": 0.0
        },
        {
            "start_logit": -6.79296875,
            "end_logit": -7.96875,
            "text": ".",
            "probability": 0.0
        }
    ],
    "530cf4e0c8a0b4a00c000006_7": [
        {
            "start_logit": 9.5859375,
            "end_logit": 9.4140625,
            "text": "hypertrophic cardiomyopathy",
            "probability": 1.0
        },
        {
            "start_logit": 9.5859375,
            "end_logit": -2.072265625,
            "text": "hypertrophic",
            "probability": 1.0311603546142578e-05
        },
        {
            "start_logit": -2.158203125,
            "end_logit": 9.4140625,
            "text": "cardiomyopathy",
            "probability": 7.927417755126953e-06
        },
        {
            "start_logit": -7.984375,
            "end_logit": 9.4140625,
            "text": "The most common cause of sudden cardiac death in athletes is hypertrophic cardiomyopathy",
            "probability": 0.0
        },
        {
            "start_logit": -8.03125,
            "end_logit": 9.4140625,
            "text": "is hypertrophic cardiomyopathy",
            "probability": 0.0
        },
        {
            "start_logit": -8.078125,
            "end_logit": 9.4140625,
            "text": "sudden cardiac death in athletes is hypertrophic cardiomyopathy",
            "probability": 0.0
        },
        {
            "start_logit": -8.140625,
            "end_logit": 9.4140625,
            "text": "most common cause of sudden cardiac death in athletes is hypertrophic cardiomyopathy",
            "probability": 0.0
        },
        {
            "start_logit": -8.1484375,
            "end_logit": 9.4140625,
            "text": "cause of sudden cardiac death in athletes is hypertrophic cardiomyopathy",
            "probability": 0.0
        },
        {
            "start_logit": -8.15625,
            "end_logit": 9.4140625,
            "text": "athletes is hypertrophic cardiomyopathy",
            "probability": 0.0
        },
        {
            "start_logit": -8.15625,
            "end_logit": 9.4140625,
            "text": "in athletes is hypertrophic cardiomyopathy",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": 9.4140625,
            "text": "death in athletes is hypertrophic cardiomyopathy",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": 9.4140625,
            "text": "cardiac death in athletes is hypertrophic cardiomyopathy",
            "probability": 0.0
        },
        {
            "start_logit": -8.171875,
            "end_logit": 9.4140625,
            "text": "of sudden cardiac death in athletes is hypertrophic cardiomyopathy",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": 9.4140625,
            "text": "common cause of sudden cardiac death in athletes is hypertrophic cardiomyopathy",
            "probability": 0.0
        },
        {
            "start_logit": -7.984375,
            "end_logit": -2.072265625,
            "text": "The most common cause of sudden cardiac death in athletes is hypertrophic",
            "probability": 0.0
        },
        {
            "start_logit": -8.03125,
            "end_logit": -2.072265625,
            "text": "is hypertrophic",
            "probability": 0.0
        },
        {
            "start_logit": -8.078125,
            "end_logit": -2.072265625,
            "text": "sudden cardiac death in athletes is hypertrophic",
            "probability": 0.0
        },
        {
            "start_logit": -8.140625,
            "end_logit": -2.072265625,
            "text": "most common cause of sudden cardiac death in athletes is hypertrophic",
            "probability": 0.0
        },
        {
            "start_logit": -8.1484375,
            "end_logit": -2.072265625,
            "text": "cause of sudden cardiac death in athletes is hypertrophic",
            "probability": 0.0
        },
        {
            "start_logit": -8.15625,
            "end_logit": -2.072265625,
            "text": "athletes is hypertrophic",
            "probability": 0.0
        }
    ],
    "530cf4e0c8a0b4a00c000006_8": [
        {
            "start_logit": 9.0234375,
            "end_logit": 8.1953125,
            "text": "Hypertrophic cardiomyopathy",
            "probability": 1.0
        },
        {
            "start_logit": 9.0234375,
            "end_logit": -3.130859375,
            "text": "Hypertrophic",
            "probability": 1.2040138244628906e-05
        },
        {
            "start_logit": 9.0234375,
            "end_logit": -3.91015625,
            "text": "Hypertrophic cardiomyopathy (HCM",
            "probability": 5.4836273193359375e-06
        },
        {
            "start_logit": -4.09375,
            "end_logit": 8.1953125,
            "text": "cardiomyopathy",
            "probability": 2.0265579223632812e-06
        },
        {
            "start_logit": 9.0234375,
            "end_logit": -6.453125,
            "text": "Hypertrophic cardiomyopathy (HCM)",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 9.0234375,
            "end_logit": -7.05078125,
            "text": "Hypertrophic cardiomyopathy (HCM) is one of the most common inherited primary cardiac disorders and the most common cause of sudden cardiac death in young athletes.",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.0234375,
            "end_logit": -7.4609375,
            "text": "Hypertrophic cardiomyopathy (HCM) is one of the most common inherited primary cardiac disorders",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.0234375,
            "end_logit": -7.64453125,
            "text": "Hypertrophic cardiomyopathy (HCM) is",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0234375,
            "end_logit": -7.71484375,
            "text": "Hypertrophic cardiomyopathy (HCM) is one of the most common inherited primary cardiac disorders and",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0234375,
            "end_logit": -7.78125,
            "text": "Hypertrophic cardiomyopathy (HCM) is one",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0234375,
            "end_logit": -7.80078125,
            "text": "Hypertrophic cardiomyopathy (HCM) is one of",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0234375,
            "end_logit": -7.8125,
            "text": "Hypertrophic cardiomyopathy (HCM) is one of the",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0234375,
            "end_logit": -7.84765625,
            "text": "Hypertrophic cardiomyopathy (HCM) is one of the most",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0234375,
            "end_logit": -7.9765625,
            "text": "Hypertrophic cardiomyopathy (HCM) is one of the most common inherited primary cardiac",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0234375,
            "end_logit": -7.984375,
            "text": "Hypertrophic cardiomyopathy (HCM) is one of the most common inherited primary cardiac disorders and the",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0234375,
            "end_logit": -7.99609375,
            "text": "Hypertrophic cardiomyopathy (HCM) is one of the most common inherited primary cardiac disorders and the most",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0234375,
            "end_logit": -8.0078125,
            "text": "Hypertrophic cardiomyopathy (HCM) is one of the most common inherited primary cardiac disorders and the most common cause of sudden cardiac death in young athletes",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0234375,
            "end_logit": -8.0078125,
            "text": "Hypertrophic cardiomyopathy (HCM) is one of the most common inherited primary cardiac disorders and the most common cause of sudden cardiac death in",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0234375,
            "end_logit": -8.0234375,
            "text": "Hypertrophic cardiomyopathy (HCM) is one of the most common inherited primary cardiac disorders and the most common cause of sudden cardiac death in young",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -4.09375,
            "end_logit": -3.91015625,
            "text": "cardiomyopathy (HCM",
            "probability": 0.0
        }
    ],
    "530cf4e0c8a0b4a00c000006_9": [
        {
            "start_logit": 9.25,
            "end_logit": 9.09375,
            "text": "hypertrophic cardiomyopathy",
            "probability": 1.0
        },
        {
            "start_logit": 9.25,
            "end_logit": -2.74609375,
            "text": "hypertrophic",
            "probability": 7.212162017822266e-06
        },
        {
            "start_logit": -2.796875,
            "end_logit": 9.09375,
            "text": "cardiomyopathy",
            "probability": 5.841255187988281e-06
        },
        {
            "start_logit": 9.25,
            "end_logit": -6.1015625,
            "text": "hypertrophic cardiomyopathy (HCM",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.76953125,
            "end_logit": 9.09375,
            "text": "disorder hypertrophic cardiomyopathy",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.25,
            "end_logit": -7.5546875,
            "text": "hypertrophic cardiomyopathy (HCM)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.25,
            "end_logit": -7.92578125,
            "text": "hypertrophic cardiomyopathy (HCM).",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.25,
            "end_logit": -7.98046875,
            "text": "hypertrophic cardiomyopathy (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.98046875,
            "end_logit": 9.09375,
            "text": "competitive athletes, is the inherited disorder hypertrophic cardiomyopathy",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.98046875,
            "end_logit": 9.09375,
            "text": "the inherited disorder hypertrophic cardiomyopathy",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0078125,
            "end_logit": 9.09375,
            "text": "The most common cause of sudden cardiac death in individuals aged less than 35 years, including competitive athletes, is the inherited disorder hypertrophic cardiomyopathy",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0234375,
            "end_logit": 9.09375,
            "text": ", including competitive athletes, is the inherited disorder hypertrophic cardiomyopathy",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0390625,
            "end_logit": 9.09375,
            "text": "inherited disorder hypertrophic cardiomyopathy",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0390625,
            "end_logit": 9.09375,
            "text": ", is the inherited disorder hypertrophic cardiomyopathy",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.046875,
            "end_logit": 9.09375,
            "text": "individuals aged less than 35 years, including competitive athletes, is the inherited disorder hypertrophic cardiomyopathy",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0546875,
            "end_logit": 9.09375,
            "text": "sudden cardiac death in individuals aged less than 35 years, including competitive athletes, is the inherited disorder hypertrophic cardiomyopathy",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0859375,
            "end_logit": 9.09375,
            "text": "is the inherited disorder hypertrophic cardiomyopathy",
            "probability": 0.0
        },
        {
            "start_logit": -2.796875,
            "end_logit": -6.1015625,
            "text": "cardiomyopathy (HCM",
            "probability": 0.0
        },
        {
            "start_logit": -6.76953125,
            "end_logit": -2.74609375,
            "text": "disorder hypertrophic",
            "probability": 0.0
        },
        {
            "start_logit": -2.796875,
            "end_logit": -7.5546875,
            "text": "cardiomyopathy (HCM)",
            "probability": 0.0
        }
    ],
    "530cf4e0c8a0b4a00c000006_10": [
        {
            "start_logit": 9.3828125,
            "end_logit": 9.0546875,
            "text": "Hypertrophic cardiomyopathy",
            "probability": 1.0
        },
        {
            "start_logit": 9.3828125,
            "end_logit": -2.501953125,
            "text": "Hypertrophic",
            "probability": 9.59634780883789e-06
        },
        {
            "start_logit": -2.85546875,
            "end_logit": 9.0546875,
            "text": "cardiomyopathy",
            "probability": 4.887580871582031e-06
        },
        {
            "start_logit": 9.3828125,
            "end_logit": -6.7890625,
            "text": "Hypertrophic cardiomyopathy (HCM",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.3828125,
            "end_logit": -7.87109375,
            "text": "Hypertrophic cardiomyopathy (HCM) is the most common cause of death in the young, particularly in young competitive athletes.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3828125,
            "end_logit": -7.8828125,
            "text": "Hypertrophic cardiomyopathy (HCM)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3828125,
            "end_logit": -8.03125,
            "text": "Hypertrophic cardiomyopathy (HCM) is the most common cause of death in the",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3828125,
            "end_logit": -8.03125,
            "text": "Hypertrophic cardiomyopathy (HCM) is",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3828125,
            "end_logit": -8.0390625,
            "text": "Hypertrophic cardiomyopathy (HCM) is the most common cause of death in the young, particularly",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3828125,
            "end_logit": -8.0390625,
            "text": "Hypertrophic cardiomyopathy (HCM) is the most common cause of death in",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3828125,
            "end_logit": -8.078125,
            "text": "Hypertrophic cardiomyopathy (HCM) is the most common cause of death in the young, particularly in",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3828125,
            "end_logit": -8.078125,
            "text": "Hypertrophic cardiomyopathy (HCM) is the most common cause of death in the young",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3828125,
            "end_logit": -8.1015625,
            "text": "Hypertrophic cardiomyopathy (HCM) is the most common",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3828125,
            "end_logit": -8.109375,
            "text": "Hypertrophic cardiomyopathy (HCM) is the most common cause of death in the young, particularly in young competitive athletes",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3828125,
            "end_logit": -8.109375,
            "text": "Hypertrophic cardiomyopathy (HCM) is the most common cause of",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3828125,
            "end_logit": -8.125,
            "text": "Hypertrophic cardiomyopathy (HCM) is the",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3828125,
            "end_logit": -8.125,
            "text": "Hypertrophic cardiomyopathy (HCM) is the most common cause",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.85546875,
            "end_logit": -6.7890625,
            "text": "cardiomyopathy (HCM",
            "probability": 0.0
        },
        {
            "start_logit": -2.85546875,
            "end_logit": -7.87109375,
            "text": "cardiomyopathy (HCM) is the most common cause of death in the young, particularly in young competitive athletes.",
            "probability": 0.0
        },
        {
            "start_logit": -2.85546875,
            "end_logit": -7.8828125,
            "text": "cardiomyopathy (HCM)",
            "probability": 0.0
        }
    ],
    "530cf4e0c8a0b4a00c000006_11": [
        {
            "start_logit": 9.53125,
            "end_logit": 9.359375,
            "text": "Hypertrophic cardiomyopathy",
            "probability": 1.0
        },
        {
            "start_logit": 9.53125,
            "end_logit": -2.205078125,
            "text": "Hypertrophic",
            "probability": 9.5367431640625e-06
        },
        {
            "start_logit": -2.275390625,
            "end_logit": 9.359375,
            "text": "cardiomyopathy",
            "probability": 7.450580596923828e-06
        },
        {
            "start_logit": 9.53125,
            "end_logit": -7.8828125,
            "text": "Hypertrophic cardiomyopathy (HC) is probably the most common cause of sudden cardiac death in youthful athletes, and this diagnosis has represented a contraindication to continued participation in competitive sports.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.53125,
            "end_logit": -8.109375,
            "text": "Hypertrophic cardiomyopathy (HC) is probably the most common cause of sudden cardiac death in youthful athletes, and this diagnosis has represented a",
            "probability": 0.0
        },
        {
            "start_logit": 9.53125,
            "end_logit": -8.125,
            "text": "Hypertrophic cardiomyopathy (HC) is probably the most common cause of sudden cardiac death in",
            "probability": 0.0
        },
        {
            "start_logit": 9.53125,
            "end_logit": -8.1328125,
            "text": "Hypertrophic cardiomyopathy (HC) is probably the most common",
            "probability": 0.0
        },
        {
            "start_logit": 9.53125,
            "end_logit": -8.140625,
            "text": "Hypertrophic cardiomyopathy (HC) is probably the most common cause",
            "probability": 0.0
        },
        {
            "start_logit": 9.53125,
            "end_logit": -8.15625,
            "text": "Hypertrophic cardiomyopathy (HC) is probably the most common cause of sudden cardiac death in youthful athletes, and this diagnosis has represented",
            "probability": 0.0
        },
        {
            "start_logit": 9.53125,
            "end_logit": -8.171875,
            "text": "Hypertrophic cardiomyopathy (HC) is",
            "probability": 0.0
        },
        {
            "start_logit": 9.53125,
            "end_logit": -8.171875,
            "text": "Hypertrophic cardiomyopathy (HC) is probably the most common cause of sudden cardiac death in youthful athletes, and this diagnosis has represented a contraindication to",
            "probability": 0.0
        },
        {
            "start_logit": 9.53125,
            "end_logit": -8.171875,
            "text": "Hypertrophic cardiomyopathy (HC) is probably the most common cause of sudden cardiac death in youthful athletes, and this diagnosis has represented a contraindication",
            "probability": 0.0
        },
        {
            "start_logit": 9.53125,
            "end_logit": -8.1875,
            "text": "Hypertrophic cardiomyopathy (HC) is probably the most common cause of",
            "probability": 0.0
        },
        {
            "start_logit": -2.275390625,
            "end_logit": -7.8828125,
            "text": "cardiomyopathy (HC) is probably the most common cause of sudden cardiac death in youthful athletes, and this diagnosis has represented a contraindication to continued participation in competitive sports.",
            "probability": 0.0
        },
        {
            "start_logit": -2.275390625,
            "end_logit": -8.109375,
            "text": "cardiomyopathy (HC) is probably the most common cause of sudden cardiac death in youthful athletes, and this diagnosis has represented a",
            "probability": 0.0
        },
        {
            "start_logit": -2.275390625,
            "end_logit": -8.125,
            "text": "cardiomyopathy (HC) is probably the most common cause of sudden cardiac death in",
            "probability": 0.0
        },
        {
            "start_logit": -2.275390625,
            "end_logit": -8.1328125,
            "text": "cardiomyopathy (HC) is probably the most common",
            "probability": 0.0
        },
        {
            "start_logit": -2.275390625,
            "end_logit": -8.140625,
            "text": "cardiomyopathy (HC) is probably the most common cause",
            "probability": 0.0
        },
        {
            "start_logit": -2.275390625,
            "end_logit": -8.15625,
            "text": "cardiomyopathy (HC) is probably the most common cause of sudden cardiac death in youthful athletes, and this diagnosis has represented",
            "probability": 0.0
        },
        {
            "start_logit": -2.275390625,
            "end_logit": -8.171875,
            "text": "cardiomyopathy (HC) is",
            "probability": 0.0
        }
    ],
    "5e4601293f54159529000002_1": [
        {
            "start_logit": 9.59375,
            "end_logit": 9.609375,
            "text": "multiple sclerosis",
            "probability": 1.0
        },
        {
            "start_logit": -1.720703125,
            "end_logit": 9.609375,
            "text": "sclerosis",
            "probability": 1.2218952178955078e-05
        },
        {
            "start_logit": 9.59375,
            "end_logit": -2.05078125,
            "text": "multiple",
            "probability": 8.64267349243164e-06
        },
        {
            "start_logit": 9.59375,
            "end_logit": -7.85546875,
            "text": "multiple sclerosis with",
            "probability": 0.0
        },
        {
            "start_logit": -8.0625,
            "end_logit": 9.609375,
            "text": "for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": 9.59375,
            "end_logit": -8.0625,
            "text": "multiple sclerosis with a",
            "probability": 0.0
        },
        {
            "start_logit": -8.078125,
            "end_logit": 9.609375,
            "text": "Diagnostic performance of central vein sign for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.1015625,
            "end_logit": 9.609375,
            "text": "central vein sign for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.171875,
            "end_logit": 9.609375,
            "text": "of central vein sign for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.171875,
            "end_logit": 9.609375,
            "text": "vein sign for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": 9.609375,
            "text": "performance of central vein sign for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.1953125,
            "end_logit": 9.609375,
            "text": "sign for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -1.720703125,
            "end_logit": -7.85546875,
            "text": "sclerosis with",
            "probability": 0.0
        },
        {
            "start_logit": -1.720703125,
            "end_logit": -8.0625,
            "text": "sclerosis with a",
            "probability": 0.0
        },
        {
            "start_logit": -8.0625,
            "end_logit": -2.05078125,
            "text": "for multiple",
            "probability": 0.0
        },
        {
            "start_logit": -8.078125,
            "end_logit": -2.05078125,
            "text": "Diagnostic performance of central vein sign for multiple",
            "probability": 0.0
        },
        {
            "start_logit": -8.1015625,
            "end_logit": -2.05078125,
            "text": "central vein sign for multiple",
            "probability": 0.0
        },
        {
            "start_logit": -8.171875,
            "end_logit": -2.05078125,
            "text": "of central vein sign for multiple",
            "probability": 0.0
        },
        {
            "start_logit": -8.171875,
            "end_logit": -2.05078125,
            "text": "vein sign for multiple",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": -2.05078125,
            "text": "performance of central vein sign for multiple",
            "probability": 0.0
        }
    ],
    "5e4601293f54159529000002_2": [
        {
            "start_logit": 9.6015625,
            "end_logit": 9.5234375,
            "text": "multiple sclerosis",
            "probability": 1.0
        },
        {
            "start_logit": -1.91796875,
            "end_logit": 9.5234375,
            "text": "sclerosis",
            "probability": 9.953975677490234e-06
        },
        {
            "start_logit": 9.6015625,
            "end_logit": -2.0390625,
            "text": "multiple",
            "probability": 9.5367431640625e-06
        },
        {
            "start_logit": -7.8203125,
            "end_logit": 9.5234375,
            "text": "for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": 9.6015625,
            "end_logit": -8.046875,
            "text": "multiple sclerosis (MS).",
            "probability": 0.0
        },
        {
            "start_logit": -7.99609375,
            "end_logit": 9.5234375,
            "text": "BACKGROUND: Detection of a \"central vein sign\" (CVS) on FLAIR* magnetic resonance imaging (MRI) is highly specific and sensitive for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.0078125,
            "end_logit": 9.5234375,
            "text": "\"central vein sign\" (CVS) on FLAIR* magnetic resonance imaging (MRI) is highly specific and sensitive for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.0078125,
            "end_logit": 9.5234375,
            "text": "magnetic resonance imaging (MRI) is highly specific and sensitive for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": 9.6015625,
            "end_logit": -8.09375,
            "text": "multiple sclerosis (",
            "probability": 0.0
        },
        {
            "start_logit": -8.0390625,
            "end_logit": 9.5234375,
            "text": "central vein sign\" (CVS) on FLAIR* magnetic resonance imaging (MRI) is highly specific and sensitive for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.0546875,
            "end_logit": 9.5234375,
            "text": "CVS) on FLAIR* magnetic resonance imaging (MRI) is highly specific and sensitive for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.0625,
            "end_logit": 9.5234375,
            "text": "(CVS) on FLAIR* magnetic resonance imaging (MRI) is highly specific and sensitive for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.0703125,
            "end_logit": 9.5234375,
            "text": "Detection of a \"central vein sign\" (CVS) on FLAIR* magnetic resonance imaging (MRI) is highly specific and sensitive for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.0703125,
            "end_logit": 9.5234375,
            "text": "* magnetic resonance imaging (MRI) is highly specific and sensitive for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.09375,
            "end_logit": 9.5234375,
            "text": ") is highly specific and sensitive for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -7.8203125,
            "end_logit": -2.0390625,
            "text": "for multiple",
            "probability": 0.0
        },
        {
            "start_logit": -1.91796875,
            "end_logit": -8.046875,
            "text": "sclerosis (MS).",
            "probability": 0.0
        },
        {
            "start_logit": -1.91796875,
            "end_logit": -8.09375,
            "text": "sclerosis (",
            "probability": 0.0
        },
        {
            "start_logit": -7.99609375,
            "end_logit": -2.0390625,
            "text": "BACKGROUND: Detection of a \"central vein sign\" (CVS) on FLAIR* magnetic resonance imaging (MRI) is highly specific and sensitive for multiple",
            "probability": 0.0
        },
        {
            "start_logit": -8.0078125,
            "end_logit": -2.0390625,
            "text": "\"central vein sign\" (CVS) on FLAIR* magnetic resonance imaging (MRI) is highly specific and sensitive for multiple",
            "probability": 0.0
        }
    ],
    "5e4601293f54159529000002_3": [
        {
            "start_logit": 9.6328125,
            "end_logit": 9.5625,
            "text": "Multiple Sclerosis",
            "probability": 1.0
        },
        {
            "start_logit": -1.83203125,
            "end_logit": 9.5625,
            "text": "Sclerosis",
            "probability": 1.0609626770019531e-05
        },
        {
            "start_logit": 9.6328125,
            "end_logit": -1.9619140625,
            "text": "Multiple",
            "probability": 9.953975677490234e-06
        },
        {
            "start_logit": 9.6328125,
            "end_logit": -7.59375,
            "text": "Multiple Sclerosis from",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.6328125,
            "end_logit": -7.73828125,
            "text": "Multiple Sclerosis from central nervous system inflammatory vasculopathies.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.6328125,
            "end_logit": -7.8828125,
            "text": "Multiple Sclerosis from central nervous system inflammatory vascul",
            "probability": 0.0
        },
        {
            "start_logit": 9.6328125,
            "end_logit": -7.93359375,
            "text": "Multiple Sclerosis from central nervous system inflammatory vasculopathies",
            "probability": 0.0
        },
        {
            "start_logit": 9.6328125,
            "end_logit": -7.96484375,
            "text": "Multiple Sclerosis from central nervous system",
            "probability": 0.0
        },
        {
            "start_logit": 9.6328125,
            "end_logit": -7.99609375,
            "text": "Multiple Sclerosis from central nervous",
            "probability": 0.0
        },
        {
            "start_logit": -7.96484375,
            "end_logit": 9.5625,
            "text": "Central vein sign differentiates Multiple Sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": 9.6328125,
            "end_logit": -8.046875,
            "text": "Multiple Sclerosis from central nervous system inflammatory",
            "probability": 0.0
        },
        {
            "start_logit": -8.015625,
            "end_logit": 9.5625,
            "text": "differentiates Multiple Sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.078125,
            "end_logit": 9.5625,
            "text": "s Multiple Sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.140625,
            "end_logit": 9.5625,
            "text": "vein sign differentiates Multiple Sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.15625,
            "end_logit": 9.5625,
            "text": "sign differentiates Multiple Sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -1.83203125,
            "end_logit": -7.59375,
            "text": "Sclerosis from",
            "probability": 0.0
        },
        {
            "start_logit": -1.83203125,
            "end_logit": -7.73828125,
            "text": "Sclerosis from central nervous system inflammatory vasculopathies.",
            "probability": 0.0
        },
        {
            "start_logit": -1.83203125,
            "end_logit": -7.8828125,
            "text": "Sclerosis from central nervous system inflammatory vascul",
            "probability": 0.0
        },
        {
            "start_logit": -1.83203125,
            "end_logit": -7.93359375,
            "text": "Sclerosis from central nervous system inflammatory vasculopathies",
            "probability": 0.0
        },
        {
            "start_logit": -1.83203125,
            "end_logit": -7.96484375,
            "text": "Sclerosis from central nervous system",
            "probability": 0.0
        }
    ],
    "5e4601293f54159529000002_4": [
        {
            "start_logit": 9.609375,
            "end_logit": 9.46875,
            "text": "multiple sclerosis",
            "probability": 1.0
        },
        {
            "start_logit": 9.609375,
            "end_logit": -2.029296875,
            "text": "multiple",
            "probability": 1.0132789611816406e-05
        },
        {
            "start_logit": -2.0390625,
            "end_logit": 9.46875,
            "text": "sclerosis",
            "probability": 8.761882781982422e-06
        },
        {
            "start_logit": 9.609375,
            "end_logit": -7.69140625,
            "text": "multiple sclerosis (MS) and neuromyelitis optica",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.609375,
            "end_logit": -7.7109375,
            "text": "multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD).",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.609375,
            "end_logit": -7.8359375,
            "text": "multiple sclerosis (MS) and neuromyelitis optica spectrum disorder",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.609375,
            "end_logit": -7.8359375,
            "text": "multiple sclerosis (MS) and neuromyelitis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.609375,
            "end_logit": -7.85546875,
            "text": "multiple sclerosis (MS) and neuromyelitis optic",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.609375,
            "end_logit": -7.8984375,
            "text": "multiple sclerosis (MS) and",
            "probability": 0.0
        },
        {
            "start_logit": 9.609375,
            "end_logit": -7.91796875,
            "text": "multiple sclerosis (MS) and neuromyelitis optica spectrum",
            "probability": 0.0
        },
        {
            "start_logit": 9.609375,
            "end_logit": -7.9921875,
            "text": "multiple sclerosis (MS) and neuromyel",
            "probability": 0.0
        },
        {
            "start_logit": 9.609375,
            "end_logit": -8.015625,
            "text": "multiple sclerosis (MS) and neurom",
            "probability": 0.0
        },
        {
            "start_logit": -7.91015625,
            "end_logit": 9.46875,
            "text": "between multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.03125,
            "end_logit": 9.46875,
            "text": "OBJECTIVE: To assess the value of the central vein sign (CVS) on a clinical 3T scanner to distinguish between multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.0390625,
            "end_logit": 9.46875,
            "text": "central vein sign (CVS) on a clinical 3T scanner to distinguish between multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.0703125,
            "end_logit": 9.46875,
            "text": "distinguish between multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.0703125,
            "end_logit": 9.46875,
            "text": "the central vein sign (CVS) on a clinical 3T scanner to distinguish between multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.140625,
            "end_logit": 9.46875,
            "text": "CVS) on a clinical 3T scanner to distinguish between multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.15625,
            "end_logit": 9.46875,
            "text": "To assess the value of the central vein sign (CVS) on a clinical 3T scanner to distinguish between multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": 9.46875,
            "text": "3T scanner to distinguish between multiple sclerosis",
            "probability": 0.0
        }
    ],
    "5e4601293f54159529000002_5": [
        {
            "start_logit": 9.5625,
            "end_logit": 9.5625,
            "text": "Multiple Sclerosis",
            "probability": 1.0
        },
        {
            "start_logit": -1.837890625,
            "end_logit": 9.5625,
            "text": "Sclerosis",
            "probability": 1.1205673217773438e-05
        },
        {
            "start_logit": 9.5625,
            "end_logit": -2.115234375,
            "text": "Multiple",
            "probability": 8.463859558105469e-06
        },
        {
            "start_logit": -7.625,
            "end_logit": 9.5625,
            "text": "in Multiple Sclerosis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.046875,
            "end_logit": 9.5625,
            "text": "Evaluation of the Central Vein Sign as a Diagnostic Imaging Biomarker in Multiple Sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.1328125,
            "end_logit": 9.5625,
            "text": "Central Vein Sign as a Diagnostic Imaging Biomarker in Multiple Sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.15625,
            "end_logit": 9.5625,
            "text": "Diagnostic Imaging Biomarker in Multiple Sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.171875,
            "end_logit": 9.5625,
            "text": "the Central Vein Sign as a Diagnostic Imaging Biomarker in Multiple Sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.1796875,
            "end_logit": 9.5625,
            "text": "Imaging Biomarker in Multiple Sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -7.625,
            "end_logit": -2.115234375,
            "text": "in Multiple",
            "probability": 0.0
        },
        {
            "start_logit": -8.046875,
            "end_logit": -2.115234375,
            "text": "Evaluation of the Central Vein Sign as a Diagnostic Imaging Biomarker in Multiple",
            "probability": 0.0
        },
        {
            "start_logit": -8.1328125,
            "end_logit": -2.115234375,
            "text": "Central Vein Sign as a Diagnostic Imaging Biomarker in Multiple",
            "probability": 0.0
        },
        {
            "start_logit": -8.15625,
            "end_logit": -2.115234375,
            "text": "Diagnostic Imaging Biomarker in Multiple",
            "probability": 0.0
        },
        {
            "start_logit": -8.171875,
            "end_logit": -2.115234375,
            "text": "the Central Vein Sign as a Diagnostic Imaging Biomarker in Multiple",
            "probability": 0.0
        },
        {
            "start_logit": -8.1796875,
            "end_logit": -2.115234375,
            "text": "Imaging Biomarker in Multiple",
            "probability": 0.0
        },
        {
            "start_logit": -8.046875,
            "end_logit": -7.9765625,
            "text": "Evaluation of the Central Vein Sign as",
            "probability": 0.0
        },
        {
            "start_logit": -8.1328125,
            "end_logit": -7.9765625,
            "text": "Central Vein Sign as",
            "probability": 0.0
        },
        {
            "start_logit": -8.171875,
            "end_logit": -7.9765625,
            "text": "the Central Vein Sign as",
            "probability": 0.0
        }
    ],
    "5e4601293f54159529000002_6": [
        {
            "start_logit": 9.6171875,
            "end_logit": 9.5546875,
            "text": "multiple sclerosis",
            "probability": 1.0
        },
        {
            "start_logit": -1.8359375,
            "end_logit": 9.5546875,
            "text": "sclerosis",
            "probability": 1.0609626770019531e-05
        },
        {
            "start_logit": 9.6171875,
            "end_logit": -1.9833984375,
            "text": "multiple",
            "probability": 9.715557098388672e-06
        },
        {
            "start_logit": 9.6171875,
            "end_logit": -7.8046875,
            "text": "multiple sclerosis (MS) and not MS, mainly based on findings from ultrahigh-field magnetic resonance imaging (MRI) studies.",
            "probability": 0.0
        },
        {
            "start_logit": 9.6171875,
            "end_logit": -8.0078125,
            "text": "multiple sclerosis (MS) and not MS, mainly based on findings from ultrahigh-field magnetic resonance imaging (",
            "probability": 0.0
        },
        {
            "start_logit": -7.9609375,
            "end_logit": 9.5546875,
            "text": "Importance  The central vein sign has been proposed as a specific imaging biomarker for distinguishing between multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": 9.6171875,
            "end_logit": -8.03125,
            "text": "multiple sclerosis (MS) and not MS, mainly based on findings from ultrahigh-field magnetic resonance",
            "probability": 0.0
        },
        {
            "start_logit": 9.6171875,
            "end_logit": -8.03125,
            "text": "multiple sclerosis (MS) and not MS, mainly based on findings from ultrahigh-field magnetic resonance imaging",
            "probability": 0.0
        },
        {
            "start_logit": -7.9921875,
            "end_logit": 9.5546875,
            "text": "central vein sign has been proposed as a specific imaging biomarker for distinguishing between multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -7.99609375,
            "end_logit": 9.5546875,
            "text": "between multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.0546875,
            "end_logit": 9.5546875,
            "text": "imaging biomarker for distinguishing between multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.0625,
            "end_logit": 9.5546875,
            "text": "The central vein sign has been proposed as a specific imaging biomarker for distinguishing between multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.1015625,
            "end_logit": 9.5546875,
            "text": "biomarker for distinguishing between multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.1015625,
            "end_logit": 9.5546875,
            "text": "distinguishing between multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.1171875,
            "end_logit": 9.5546875,
            "text": "specific imaging biomarker for distinguishing between multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -1.8359375,
            "end_logit": -7.8046875,
            "text": "sclerosis (MS) and not MS, mainly based on findings from ultrahigh-field magnetic resonance imaging (MRI) studies.",
            "probability": 0.0
        },
        {
            "start_logit": -1.8359375,
            "end_logit": -8.0078125,
            "text": "sclerosis (MS) and not MS, mainly based on findings from ultrahigh-field magnetic resonance imaging (",
            "probability": 0.0
        },
        {
            "start_logit": -1.8359375,
            "end_logit": -8.03125,
            "text": "sclerosis (MS) and not MS, mainly based on findings from ultrahigh-field magnetic resonance",
            "probability": 0.0
        },
        {
            "start_logit": -1.8359375,
            "end_logit": -8.03125,
            "text": "sclerosis (MS) and not MS, mainly based on findings from ultrahigh-field magnetic resonance imaging",
            "probability": 0.0
        },
        {
            "start_logit": -7.9609375,
            "end_logit": -1.9833984375,
            "text": "Importance  The central vein sign has been proposed as a specific imaging biomarker for distinguishing between multiple",
            "probability": 0.0
        }
    ],
    "5e4601293f54159529000002_7": [
        {
            "start_logit": 9.6484375,
            "end_logit": 9.6171875,
            "text": "multiple sclerosis",
            "probability": 1.0
        },
        {
            "start_logit": -1.701171875,
            "end_logit": 9.6171875,
            "text": "sclerosis",
            "probability": 1.1742115020751953e-05
        },
        {
            "start_logit": 9.6484375,
            "end_logit": -1.9208984375,
            "text": "multiple",
            "probability": 9.715557098388672e-06
        },
        {
            "start_logit": -8.0234375,
            "end_logit": 9.6171875,
            "text": "BACKGROUND AND PURPOSE  The central vein sign is a promising MR imaging diagnostic biomarker for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.0703125,
            "end_logit": 9.6171875,
            "text": "for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.078125,
            "end_logit": 9.6171875,
            "text": "MR imaging diagnostic biomarker for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.1015625,
            "end_logit": 9.6171875,
            "text": "PURPOSE  The central vein sign is a promising MR imaging diagnostic biomarker for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.109375,
            "end_logit": 9.6171875,
            "text": "central vein sign is a promising MR imaging diagnostic biomarker for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": 9.6171875,
            "text": "The central vein sign is a promising MR imaging diagnostic biomarker for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.1796875,
            "end_logit": 9.6171875,
            "text": "promising MR imaging diagnostic biomarker for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": 9.6171875,
            "text": "diagnostic biomarker for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 9.6171875,
            "text": "imaging diagnostic biomarker for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 9.6171875,
            "text": "vein sign is a promising MR imaging diagnostic biomarker for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 9.6171875,
            "text": "biomarker for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.0234375,
            "end_logit": -1.9208984375,
            "text": "BACKGROUND AND PURPOSE  The central vein sign is a promising MR imaging diagnostic biomarker for multiple",
            "probability": 0.0
        },
        {
            "start_logit": -8.0703125,
            "end_logit": -1.9208984375,
            "text": "for multiple",
            "probability": 0.0
        },
        {
            "start_logit": -8.078125,
            "end_logit": -1.9208984375,
            "text": "MR imaging diagnostic biomarker for multiple",
            "probability": 0.0
        },
        {
            "start_logit": -8.1015625,
            "end_logit": -1.9208984375,
            "text": "PURPOSE  The central vein sign is a promising MR imaging diagnostic biomarker for multiple",
            "probability": 0.0
        },
        {
            "start_logit": -8.109375,
            "end_logit": -1.9208984375,
            "text": "central vein sign is a promising MR imaging diagnostic biomarker for multiple",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": -1.9208984375,
            "text": "The central vein sign is a promising MR imaging diagnostic biomarker for multiple",
            "probability": 0.0
        }
    ],
    "5e4601293f54159529000002_8": [
        {
            "start_logit": 9.6484375,
            "end_logit": 9.6171875,
            "text": "multiple sclerosis",
            "probability": 1.0
        },
        {
            "start_logit": -1.701171875,
            "end_logit": 9.6171875,
            "text": "sclerosis",
            "probability": 1.1742115020751953e-05
        },
        {
            "start_logit": 9.6484375,
            "end_logit": -1.9208984375,
            "text": "multiple",
            "probability": 9.715557098388672e-06
        },
        {
            "start_logit": -8.0234375,
            "end_logit": 9.6171875,
            "text": "BACKGROUND AND PURPOSE The central vein sign is a promising MR imaging diagnostic biomarker for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.0703125,
            "end_logit": 9.6171875,
            "text": "for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.078125,
            "end_logit": 9.6171875,
            "text": "MR imaging diagnostic biomarker for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.1015625,
            "end_logit": 9.6171875,
            "text": "PURPOSE The central vein sign is a promising MR imaging diagnostic biomarker for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.109375,
            "end_logit": 9.6171875,
            "text": "central vein sign is a promising MR imaging diagnostic biomarker for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": 9.6171875,
            "text": "The central vein sign is a promising MR imaging diagnostic biomarker for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.1796875,
            "end_logit": 9.6171875,
            "text": "promising MR imaging diagnostic biomarker for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": 9.6171875,
            "text": "diagnostic biomarker for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 9.6171875,
            "text": "imaging diagnostic biomarker for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 9.6171875,
            "text": "vein sign is a promising MR imaging diagnostic biomarker for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 9.6171875,
            "text": "biomarker for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.0234375,
            "end_logit": -1.9208984375,
            "text": "BACKGROUND AND PURPOSE The central vein sign is a promising MR imaging diagnostic biomarker for multiple",
            "probability": 0.0
        },
        {
            "start_logit": -8.0703125,
            "end_logit": -1.9208984375,
            "text": "for multiple",
            "probability": 0.0
        },
        {
            "start_logit": -8.078125,
            "end_logit": -1.9208984375,
            "text": "MR imaging diagnostic biomarker for multiple",
            "probability": 0.0
        },
        {
            "start_logit": -8.1015625,
            "end_logit": -1.9208984375,
            "text": "PURPOSE The central vein sign is a promising MR imaging diagnostic biomarker for multiple",
            "probability": 0.0
        },
        {
            "start_logit": -8.109375,
            "end_logit": -1.9208984375,
            "text": "central vein sign is a promising MR imaging diagnostic biomarker for multiple",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": -1.9208984375,
            "text": "The central vein sign is a promising MR imaging diagnostic biomarker for multiple",
            "probability": 0.0
        }
    ],
    "5e4601293f54159529000002_9": [
        {
            "start_logit": 9.609375,
            "end_logit": 9.578125,
            "text": "Multiple Sclerosis",
            "probability": 1.0
        },
        {
            "start_logit": -1.7880859375,
            "end_logit": 9.578125,
            "text": "Sclerosis",
            "probability": 1.1205673217773438e-05
        },
        {
            "start_logit": 9.609375,
            "end_logit": -1.9970703125,
            "text": "Multiple",
            "probability": 9.357929229736328e-06
        },
        {
            "start_logit": 9.609375,
            "end_logit": -7.58984375,
            "text": "Multiple Sclerosis Lesions Is Present Irrespective of the T2* Sequence at 3 T.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.609375,
            "end_logit": -7.94140625,
            "text": "Multiple Sclerosis Lesions Is Present Irrespective of the T2* Sequence at 3 T. BACKGROUND AND PURPOSE Previous T2*-weighted magnetic resonance imaging (",
            "probability": 0.0
        },
        {
            "start_logit": 9.609375,
            "end_logit": -7.953125,
            "text": "Multiple Sclerosis Lesions Is Present Irrespective",
            "probability": 0.0
        },
        {
            "start_logit": 9.609375,
            "end_logit": -7.96875,
            "text": "Multiple Sclerosis Lesions Is Present Irrespective of the T2* Sequence at",
            "probability": 0.0
        },
        {
            "start_logit": 9.609375,
            "end_logit": -7.984375,
            "text": "Multiple Sclerosis Lesions Is Present Irrespective of",
            "probability": 0.0
        },
        {
            "start_logit": 9.609375,
            "end_logit": -8.015625,
            "text": "Multiple Sclerosis Lesions Is Present Irrespective of the T2* Sequence at 3 T. BACKGROUND AND PURPOSE Previous T2*-weighted magnetic resonance imaging (MRI) studies have used white matter lesion",
            "probability": 0.0
        },
        {
            "start_logit": 9.609375,
            "end_logit": -8.0234375,
            "text": "Multiple Sclerosis Lesions Is Present Irrespective of the T2* Sequence at 3 T. BACKGROUND AND PURPOSE Previous T2*-weighted magnetic resonance imaging (MRI) studies have used white matter",
            "probability": 0.0
        },
        {
            "start_logit": 9.609375,
            "end_logit": -8.0234375,
            "text": "Multiple Sclerosis Lesions Is Present Irrespective of the T2* Sequence at 3 T. BACKGROUND AND PURPOSE Previous T2*-weighted magnetic resonance",
            "probability": 0.0
        },
        {
            "start_logit": 9.609375,
            "end_logit": -8.03125,
            "text": "Multiple Sclerosis Lesions",
            "probability": 0.0
        },
        {
            "start_logit": -8.0234375,
            "end_logit": 9.578125,
            "text": "The Central Vein Sign in Multiple Sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.046875,
            "end_logit": 9.578125,
            "text": "in Multiple Sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.0625,
            "end_logit": 9.578125,
            "text": "Central Vein Sign in Multiple Sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -1.7880859375,
            "end_logit": -7.58984375,
            "text": "Sclerosis Lesions Is Present Irrespective of the T2* Sequence at 3 T.",
            "probability": 0.0
        },
        {
            "start_logit": -1.7880859375,
            "end_logit": -7.94140625,
            "text": "Sclerosis Lesions Is Present Irrespective of the T2* Sequence at 3 T. BACKGROUND AND PURPOSE Previous T2*-weighted magnetic resonance imaging (",
            "probability": 0.0
        },
        {
            "start_logit": -1.7880859375,
            "end_logit": -7.953125,
            "text": "Sclerosis Lesions Is Present Irrespective",
            "probability": 0.0
        },
        {
            "start_logit": -1.7880859375,
            "end_logit": -7.96875,
            "text": "Sclerosis Lesions Is Present Irrespective of the T2* Sequence at",
            "probability": 0.0
        },
        {
            "start_logit": -1.7880859375,
            "end_logit": -7.984375,
            "text": "Sclerosis Lesions Is Present Irrespective of",
            "probability": 0.0
        }
    ],
    "5c8fe7cb0101eac87000000c_1": [
        {
            "start_logit": 9.5234375,
            "end_logit": 8.4140625,
            "text": "Runt related factor-2",
            "probability": 1.0
        },
        {
            "start_logit": 9.5234375,
            "end_logit": -2.18359375,
            "text": "Run",
            "probability": 2.5093555450439453e-05
        },
        {
            "start_logit": -3.365234375,
            "end_logit": 8.4140625,
            "text": "2",
            "probability": 2.5033950805664062e-06
        },
        {
            "start_logit": 9.5234375,
            "end_logit": -6.46484375,
            "text": "Runt related factor-2 (",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 9.5234375,
            "end_logit": -6.63671875,
            "text": "Runt related factor",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.5234375,
            "end_logit": -7.1640625,
            "text": "Runt related",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.5234375,
            "end_logit": -7.23828125,
            "text": "Runt",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.5234375,
            "end_logit": -7.2421875,
            "text": "Runt related factor-2 (Runx2)",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.5234375,
            "end_logit": -7.8828125,
            "text": "Runt related factor-",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.5234375,
            "end_logit": -8.0078125,
            "text": "Runt related factor-2 (Runx2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.72265625,
            "end_logit": 8.4140625,
            "text": "t related factor-2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.8203125,
            "end_logit": 8.4140625,
            "text": "-2",
            "probability": 0.0
        },
        {
            "start_logit": -7.89453125,
            "end_logit": 8.4140625,
            "text": "related factor-2",
            "probability": 0.0
        },
        {
            "start_logit": -8.03125,
            "end_logit": 8.4140625,
            "text": "factor-2",
            "probability": 0.0
        },
        {
            "start_logit": -3.365234375,
            "end_logit": -6.46484375,
            "text": "2 (",
            "probability": 0.0
        },
        {
            "start_logit": -3.365234375,
            "end_logit": -7.2421875,
            "text": "2 (Runx2)",
            "probability": 0.0
        },
        {
            "start_logit": -3.365234375,
            "end_logit": -8.0078125,
            "text": "2 (Runx2",
            "probability": 0.0
        },
        {
            "start_logit": -7.72265625,
            "end_logit": -6.46484375,
            "text": "t related factor-2 (",
            "probability": 0.0
        },
        {
            "start_logit": -7.8203125,
            "end_logit": -6.46484375,
            "text": "-2 (",
            "probability": 0.0
        },
        {
            "start_logit": -7.72265625,
            "end_logit": -6.63671875,
            "text": "t related factor",
            "probability": 0.0
        }
    ],
    "55032efde9bde69634000035_1": [
        {
            "start_logit": 9.7421875,
            "end_logit": 9.5546875,
            "text": "calcitonin gene-related peptide receptor",
            "probability": 1.0
        },
        {
            "start_logit": 9.7421875,
            "end_logit": -1.7353515625,
            "text": "calcitonin",
            "probability": 1.2516975402832031e-05
        },
        {
            "start_logit": -1.73046875,
            "end_logit": 9.5546875,
            "text": "receptor",
            "probability": 1.043081283569336e-05
        },
        {
            "start_logit": 9.7421875,
            "end_logit": -6.1171875,
            "text": "calcitonin gene-related peptide",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.7421875,
            "end_logit": -7.07421875,
            "text": "calcitonin gene-related",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.0,
            "end_logit": 9.5546875,
            "text": "gene-related peptide receptor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.7421875,
            "end_logit": -7.32421875,
            "text": "calcitonin gene-related peptide receptor occupancy by telcagepant in",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.7421875,
            "end_logit": -7.3359375,
            "text": "calcitonin gene",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.7421875,
            "end_logit": -7.4609375,
            "text": "calcitonin gene-related peptide receptor occupancy",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.7421875,
            "end_logit": -7.53125,
            "text": "calcitonin gene-",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.7421875,
            "end_logit": -7.66796875,
            "text": "calcitonin gene-related peptide receptor occupancy by telcagepant in rhesus monkey and human brain using the positron emission tomography tracer [11C]MK-4232.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.56640625,
            "end_logit": 9.5546875,
            "text": "-related peptide receptor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.62890625,
            "end_logit": 9.5546875,
            "text": "related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": -7.7734375,
            "end_logit": 9.5546875,
            "text": "In vivo quantification of calcitonin gene-related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": -7.80859375,
            "end_logit": 9.5546875,
            "text": "peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": 9.7421875,
            "end_logit": -8.0234375,
            "text": "calcitonin gene-related peptide receptor occupancy by",
            "probability": 0.0
        },
        {
            "start_logit": 9.7421875,
            "end_logit": -8.0625,
            "text": "calcitonin gene-related peptide receptor occupancy by telcagepant in rhesus monkey and human brain using",
            "probability": 0.0
        },
        {
            "start_logit": 9.7421875,
            "end_logit": -8.0703125,
            "text": "calcitonin gene-related peptide receptor occupancy by telcagepant in rhesus monkey and human brain",
            "probability": 0.0
        },
        {
            "start_logit": 9.7421875,
            "end_logit": -8.125,
            "text": "calcitonin gene-related peptide receptor occupancy by telcagepant in rhesus monkey and",
            "probability": 0.0
        },
        {
            "start_logit": 9.7421875,
            "end_logit": -8.140625,
            "text": "calcitonin gene-related peptide receptor occupancy by telcagepant in rhesus monkey and human brain using the positron emission tomography tracer [11C",
            "probability": 0.0
        }
    ],
    "55032efde9bde69634000035_2": [
        {
            "start_logit": 8.2421875,
            "end_logit": 2.65625,
            "text": "calcitonin gene-related peptide",
            "probability": 0.794921875
        },
        {
            "start_logit": 8.2421875,
            "end_logit": 1.279296875,
            "text": "calcitonin gene-related peptide (CGRP) receptor",
            "probability": 0.2010498046875
        },
        {
            "start_logit": 8.2421875,
            "end_logit": -3.263671875,
            "text": "calcitonin gene-related peptide (CGRP",
            "probability": 0.0021305084228515625
        },
        {
            "start_logit": 8.2421875,
            "end_logit": -3.931640625,
            "text": "calcitonin",
            "probability": 0.0010967254638671875
        },
        {
            "start_logit": 8.2421875,
            "end_logit": -6.50390625,
            "text": "calcitonin gene",
            "probability": 8.392333984375e-05
        },
        {
            "start_logit": 8.2421875,
            "end_logit": -6.609375,
            "text": "calcitonin gene-related",
            "probability": 7.522106170654297e-05
        },
        {
            "start_logit": 8.2421875,
            "end_logit": -6.75390625,
            "text": "calcitonin gene-",
            "probability": 6.532669067382812e-05
        },
        {
            "start_logit": 8.2421875,
            "end_logit": -7.09765625,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist currently undergoing clinical trials for migraine (http://www.merck.com/research/pipeline/home.html).",
            "probability": 4.6372413635253906e-05
        },
        {
            "start_logit": 8.2421875,
            "end_logit": -7.1640625,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist currently",
            "probability": 4.32133674621582e-05
        },
        {
            "start_logit": 8.2421875,
            "end_logit": -7.37890625,
            "text": "calcitonin gene-related peptide (",
            "probability": 3.49879264831543e-05
        },
        {
            "start_logit": 8.2421875,
            "end_logit": -7.44921875,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist currently undergoing clinical trials for migraine (http://www.merck.com",
            "probability": 3.236532211303711e-05
        },
        {
            "start_logit": 8.2421875,
            "end_logit": -7.609375,
            "text": "calcitonin gene-related peptide (CGRP)",
            "probability": 2.765655517578125e-05
        },
        {
            "start_logit": 8.2421875,
            "end_logit": -7.71484375,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist currently undergoing clinical trials for migraine (http://www.merck.",
            "probability": 2.47955322265625e-05
        },
        {
            "start_logit": 8.2421875,
            "end_logit": -7.73828125,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist currently undergoing clinical trials for migraine (http://www.merck.com/research/pipeline",
            "probability": 2.4378299713134766e-05
        },
        {
            "start_logit": 8.2421875,
            "end_logit": -7.73828125,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist currently undergoing clinical trials for migraine (http://www.merck",
            "probability": 2.4378299713134766e-05
        },
        {
            "start_logit": 8.2421875,
            "end_logit": -7.76171875,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist currently undergoing clinical trials for migraine (http://www.merck.com/research/pipeline/home.ht",
            "probability": 2.372264862060547e-05
        },
        {
            "start_logit": 8.2421875,
            "end_logit": -7.81640625,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist currently undergoing clinical trials for migraine (http://www.merck.com/research/pipeline/home.html",
            "probability": 2.2590160369873047e-05
        },
        {
            "start_logit": -2.537109375,
            "end_logit": 2.65625,
            "text": "novel calcitonin gene-related peptide",
            "probability": 1.6510486602783203e-05
        },
        {
            "start_logit": -2.16796875,
            "end_logit": 1.279296875,
            "text": "CGRP) receptor",
            "probability": 6.020069122314453e-06
        },
        {
            "start_logit": -2.537109375,
            "end_logit": 1.279296875,
            "text": "novel calcitonin gene-related peptide (CGRP) receptor",
            "probability": 4.172325134277344e-06
        }
    ],
    "55032efde9bde69634000035_3": [
        {
            "start_logit": 9.1328125,
            "end_logit": 3.62890625,
            "text": "calcitonin gene-related peptide (CGRP) receptor",
            "probability": 0.9892578125
        },
        {
            "start_logit": 9.1328125,
            "end_logit": -1.119140625,
            "text": "calcitonin gene-related peptide",
            "probability": 0.0085601806640625
        },
        {
            "start_logit": 9.1328125,
            "end_logit": -2.833984375,
            "text": "calcitonin",
            "probability": 0.0015354156494140625
        },
        {
            "start_logit": 9.1328125,
            "end_logit": -5.3515625,
            "text": "calcitonin gene-related peptide (CGRP",
            "probability": 0.00012409687042236328
        },
        {
            "start_logit": 9.1328125,
            "end_logit": -6.2890625,
            "text": "calcitonin gene",
            "probability": 4.857778549194336e-05
        },
        {
            "start_logit": 9.1328125,
            "end_logit": -6.41796875,
            "text": "calcitonin gene-related",
            "probability": 4.285573959350586e-05
        },
        {
            "start_logit": 9.1328125,
            "end_logit": -6.46875,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist being evaluated for acute migraine treatment.",
            "probability": 4.0590763092041016e-05
        },
        {
            "start_logit": 9.1328125,
            "end_logit": -7.04296875,
            "text": "calcitonin gene-",
            "probability": 2.294778823852539e-05
        },
        {
            "start_logit": 9.1328125,
            "end_logit": -7.12890625,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist being",
            "probability": 2.086162567138672e-05
        },
        {
            "start_logit": 9.1328125,
            "end_logit": -7.4765625,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist being evaluated",
            "probability": 1.4781951904296875e-05
        },
        {
            "start_logit": 9.1328125,
            "end_logit": -7.94921875,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist being evaluated for acute migraine",
            "probability": 9.238719940185547e-06
        },
        {
            "start_logit": 9.1328125,
            "end_logit": -8.015625,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist being evaluated for",
            "probability": 8.64267349243164e-06
        },
        {
            "start_logit": 9.1328125,
            "end_logit": -8.1484375,
            "text": "calcitonin gene-related peptide (CGRP)",
            "probability": 7.569789886474609e-06
        },
        {
            "start_logit": 9.1328125,
            "end_logit": -8.1484375,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist",
            "probability": 7.569789886474609e-06
        },
        {
            "start_logit": 9.1328125,
            "end_logit": -8.15625,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist being evaluated for acute migraine treatment",
            "probability": 7.510185241699219e-06
        },
        {
            "start_logit": -3.25390625,
            "end_logit": 3.62890625,
            "text": "CGRP) receptor",
            "probability": 4.112720489501953e-06
        },
        {
            "start_logit": -6.65234375,
            "end_logit": 3.62890625,
            "text": "receptor",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.3125,
            "end_logit": 3.62890625,
            "text": ") receptor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.625,
            "end_logit": 3.62890625,
            "text": "(CGRP) receptor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.69921875,
            "end_logit": 3.62890625,
            "text": "Telcagepant is a calcitonin gene-related peptide (CGRP) receptor",
            "probability": 5.960464477539063e-08
        }
    ],
    "55032efde9bde69634000035_4": [
        {
            "start_logit": 9.546875,
            "end_logit": 9.375,
            "text": "Calcitonin gene-related peptide receptor",
            "probability": 1.0
        },
        {
            "start_logit": 9.546875,
            "end_logit": -2.162109375,
            "text": "Calcitonin",
            "probability": 9.715557098388672e-06
        },
        {
            "start_logit": -2.10546875,
            "end_logit": 9.375,
            "text": "receptor",
            "probability": 8.64267349243164e-06
        },
        {
            "start_logit": 9.546875,
            "end_logit": -6.15625,
            "text": "Calcitonin gene-related peptide",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.546875,
            "end_logit": -7.00390625,
            "text": "Calcitonin gene-related",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.546875,
            "end_logit": -7.02734375,
            "text": "Calcitonin gene",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.546875,
            "end_logit": -7.0390625,
            "text": "Calcitonin gene-related peptide receptor antagonists, such as telcagepant, may be useful for acute migraine treatment in patients with cardiovascular disease, a population for whom triptans are contraindicated.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5078125,
            "end_logit": 9.375,
            "text": "gene-related peptide receptor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.546875,
            "end_logit": -7.68359375,
            "text": "Calcitonin gene-related peptide receptor antagonists, such as telcagepant, may",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.546875,
            "end_logit": -7.88671875,
            "text": "Calcitonin gene-related peptide receptor antagonists, such as telcagepant, may be useful for acute migraine treatment in",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.734375,
            "end_logit": 9.375,
            "text": "-related peptide receptor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.546875,
            "end_logit": -7.91796875,
            "text": "Calcitonin gene-related peptide receptor antagonists, such as telcagepant, may be useful for acute migraine treatment in patients with cardiovascular disease",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.76953125,
            "end_logit": 9.375,
            "text": "related peptide receptor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.546875,
            "end_logit": -7.95703125,
            "text": "Calcitonin gene-related peptide receptor antagonists, such as telcagepant, may be useful for acute migraine treatment in patients with cardiovascular disease, a population for whom triptans",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.546875,
            "end_logit": -7.9765625,
            "text": "Calcitonin gene-related peptide receptor antagonists, such as telcagepant, may be useful for acute migraine treatment in patients with cardiovascular disease, a population for whom triptans are contraindicated",
            "probability": 0.0
        },
        {
            "start_logit": 9.546875,
            "end_logit": -7.9921875,
            "text": "Calcitonin gene-related peptide receptor antagonists, such as telcagepant, may be useful for acute migraine treatment in patients with cardiovascular disease, a population for whom triptan",
            "probability": 0.0
        },
        {
            "start_logit": 9.546875,
            "end_logit": -8.0078125,
            "text": "Calcitonin gene-related peptide receptor antagonists, such as telcagepant, may be useful for acute migraine treatment in patients",
            "probability": 0.0
        },
        {
            "start_logit": 9.546875,
            "end_logit": -8.015625,
            "text": "Calcitonin gene-related peptide receptor antagonists, such as telcagepant, may be useful for acute migraine treatment in patients with cardiovascular disease, a population for whom triptans are",
            "probability": 0.0
        },
        {
            "start_logit": 9.546875,
            "end_logit": -8.0234375,
            "text": "Calcitonin gene-related peptide receptor antagonists, such",
            "probability": 0.0
        },
        {
            "start_logit": 9.546875,
            "end_logit": -8.0234375,
            "text": "Calcitonin gene-related peptide receptor antagonists, such as telcagepant, may be useful for acute migraine treatment in patients with",
            "probability": 0.0
        }
    ],
    "55032efde9bde69634000035_5": [
        {
            "start_logit": 9.0390625,
            "end_logit": 5.16015625,
            "text": "calcitonin gene-related peptide (CGRP) receptor",
            "probability": 1.0
        },
        {
            "start_logit": 9.0390625,
            "end_logit": -2.951171875,
            "text": "calcitonin",
            "probability": 0.0002982616424560547
        },
        {
            "start_logit": 9.0390625,
            "end_logit": -4.015625,
            "text": "calcitonin gene-related peptide",
            "probability": 0.00010311603546142578
        },
        {
            "start_logit": 9.0390625,
            "end_logit": -5.0078125,
            "text": "calcitonin gene-related peptide (CGRP",
            "probability": 3.820657730102539e-05
        },
        {
            "start_logit": 9.0390625,
            "end_logit": -6.53515625,
            "text": "calcitonin gene",
            "probability": 8.285045623779297e-06
        },
        {
            "start_logit": 9.0390625,
            "end_logit": -7.13671875,
            "text": "calcitonin gene-related",
            "probability": 4.589557647705078e-06
        },
        {
            "start_logit": 9.0390625,
            "end_logit": -7.21875,
            "text": "calcitonin gene-",
            "probability": 4.172325134277344e-06
        },
        {
            "start_logit": 9.0390625,
            "end_logit": -7.37890625,
            "text": "calcitonin gene-related peptide (CGRP)",
            "probability": 3.5762786865234375e-06
        },
        {
            "start_logit": -3.892578125,
            "end_logit": 5.16015625,
            "text": "CGRP) receptor",
            "probability": 2.384185791015625e-06
        },
        {
            "start_logit": 9.0390625,
            "end_logit": -7.875,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonists (gepan",
            "probability": 2.1457672119140625e-06
        },
        {
            "start_logit": 9.0390625,
            "end_logit": -7.90234375,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonists (gepants",
            "probability": 2.1457672119140625e-06
        },
        {
            "start_logit": 9.0390625,
            "end_logit": -7.92578125,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonists",
            "probability": 2.086162567138672e-06
        },
        {
            "start_logit": 9.0390625,
            "end_logit": -8.0546875,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonists (gepants)-olcegepant (BIBN 4096 BS), telcagepant (MK-0974",
            "probability": 1.7881393432617188e-06
        },
        {
            "start_logit": 9.0390625,
            "end_logit": -8.0546875,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonists (gepants)-olcegepant (BIBN 4096",
            "probability": 1.7881393432617188e-06
        },
        {
            "start_logit": 9.0390625,
            "end_logit": -8.0546875,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonists (gepants)-olcegepant",
            "probability": 1.7881393432617188e-06
        },
        {
            "start_logit": 9.0390625,
            "end_logit": -8.0703125,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonists (gepants)-olcegepant (BIBN 4096 BS), telcagepant (MK-09",
            "probability": 1.7881393432617188e-06
        },
        {
            "start_logit": 9.0390625,
            "end_logit": -8.0703125,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonists (gepants)-olcegepant (BIBN 4096 BS)",
            "probability": 1.7881393432617188e-06
        },
        {
            "start_logit": -5.74609375,
            "end_logit": 5.16015625,
            "text": "receptor",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.796875,
            "end_logit": 5.16015625,
            "text": "(CGRP) receptor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.8984375,
            "end_logit": 5.16015625,
            "text": ") receptor",
            "probability": 5.960464477539063e-08
        }
    ],
    "55032efde9bde69634000035_6": [
        {
            "start_logit": 9.7265625,
            "end_logit": 9.515625,
            "text": "calcitonin gene-related peptide receptor",
            "probability": 1.0
        },
        {
            "start_logit": 9.7265625,
            "end_logit": -1.755859375,
            "text": "calcitonin",
            "probability": 1.2636184692382812e-05
        },
        {
            "start_logit": -1.84375,
            "end_logit": 9.515625,
            "text": "receptor",
            "probability": 9.357929229736328e-06
        },
        {
            "start_logit": 9.7265625,
            "end_logit": -6.5234375,
            "text": "calcitonin gene-related peptide",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.7265625,
            "end_logit": -7.0078125,
            "text": "calcitonin gene-related",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.7265625,
            "end_logit": -7.26171875,
            "text": "calcitonin gene-related peptide receptor antagonist, is being developed for the acute treatment of migraine.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.140625,
            "end_logit": 9.515625,
            "text": "gene-related peptide receptor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.7265625,
            "end_logit": -7.375,
            "text": "calcitonin gene",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.47265625,
            "end_logit": 9.515625,
            "text": "-related peptide receptor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.7265625,
            "end_logit": -7.734375,
            "text": "calcitonin gene-",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.56640625,
            "end_logit": 9.515625,
            "text": "related peptide receptor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.62890625,
            "end_logit": 9.515625,
            "text": "peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": 9.7265625,
            "end_logit": -7.953125,
            "text": "calcitonin gene-related peptide receptor antagonist, is",
            "probability": 0.0
        },
        {
            "start_logit": -7.765625,
            "end_logit": 9.515625,
            "text": "a calcitonin gene-related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": -7.828125,
            "end_logit": 9.515625,
            "text": "Telcagepant, a calcitonin gene-related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": 9.7265625,
            "end_logit": -8.0625,
            "text": "calcitonin gene-related peptide receptor antagonist, is being",
            "probability": 0.0
        },
        {
            "start_logit": -7.90234375,
            "end_logit": 9.515625,
            "text": ", a calcitonin gene-related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": -7.96875,
            "end_logit": 9.515625,
            "text": "cagepant, a calcitonin gene-related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": -1.84375,
            "end_logit": -7.26171875,
            "text": "receptor antagonist, is being developed for the acute treatment of migraine.",
            "probability": 0.0
        },
        {
            "start_logit": -7.765625,
            "end_logit": -1.755859375,
            "text": "a calcitonin",
            "probability": 0.0
        }
    ],
    "55032efde9bde69634000035_7": [
        {
            "start_logit": 9.640625,
            "end_logit": 9.3359375,
            "text": "calcitonin gene-related peptide receptor",
            "probability": 1.0
        },
        {
            "start_logit": 9.640625,
            "end_logit": -1.9541015625,
            "text": "calcitonin",
            "probability": 1.2636184692382812e-05
        },
        {
            "start_logit": -2.15234375,
            "end_logit": 9.3359375,
            "text": "receptor",
            "probability": 7.62939453125e-06
        },
        {
            "start_logit": 9.640625,
            "end_logit": -5.98828125,
            "text": "calcitonin gene-related peptide",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.640625,
            "end_logit": -6.89453125,
            "text": "calcitonin gene-related",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.640625,
            "end_logit": -7.08984375,
            "text": "calcitonin gene",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.640625,
            "end_logit": -7.47265625,
            "text": "calcitonin gene-",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.640625,
            "end_logit": -7.49609375,
            "text": "calcitonin gene-related peptide receptor antagonist, telcagepant, does not affect nitroglycerin-induced vasodilation in healthy men.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.23046875,
            "end_logit": 9.3359375,
            "text": "gene-related peptide receptor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.640625,
            "end_logit": -7.9609375,
            "text": "calcitonin gene-related peptide receptor antagonist, telcagepant, does not affect nitroglycerin-induced vasodilation in",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.69140625,
            "end_logit": 9.3359375,
            "text": "-related peptide receptor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.7421875,
            "end_logit": 9.3359375,
            "text": "related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": 9.640625,
            "end_logit": -8.1015625,
            "text": "calcitonin gene-related peptide receptor antagonist, telcagepant, does not affect nitroglycerin-induced",
            "probability": 0.0
        },
        {
            "start_logit": 9.640625,
            "end_logit": -8.1015625,
            "text": "calcitonin gene-related peptide receptor antagonist, telcagepant, does not affect",
            "probability": 0.0
        },
        {
            "start_logit": 9.640625,
            "end_logit": -8.125,
            "text": "calcitonin gene-related peptide receptor antagonist, telcagepant, does not",
            "probability": 0.0
        },
        {
            "start_logit": 9.640625,
            "end_logit": -8.125,
            "text": "calcitonin gene-related peptide receptor antagonist",
            "probability": 0.0
        },
        {
            "start_logit": -7.83203125,
            "end_logit": 9.3359375,
            "text": "peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": 9.640625,
            "end_logit": -8.1484375,
            "text": "calcitonin gene-related peptide receptor antagonist, telcagepant, does not affect nitroglycerin-induced vasodilation",
            "probability": 0.0
        },
        {
            "start_logit": 9.640625,
            "end_logit": -8.1484375,
            "text": "calcitonin gene-related peptide receptor antagonist, telcagepant, does not affect nitroglycerin-",
            "probability": 0.0
        },
        {
            "start_logit": 9.640625,
            "end_logit": -8.15625,
            "text": "calcitonin gene-related peptide receptor antagonist, telcagepant",
            "probability": 0.0
        }
    ],
    "55032efde9bde69634000035_8": [
        {
            "start_logit": 9.4921875,
            "end_logit": 8.40625,
            "text": "calcitonin gene-related peptide",
            "probability": 1.0
        },
        {
            "start_logit": 9.4921875,
            "end_logit": -2.234375,
            "text": "calcitonin gene-related peptide (CGRP) receptor",
            "probability": 2.372264862060547e-05
        },
        {
            "start_logit": 9.4921875,
            "end_logit": -2.267578125,
            "text": "calcitonin",
            "probability": 2.300739288330078e-05
        },
        {
            "start_logit": 9.4921875,
            "end_logit": -3.478515625,
            "text": "calcitonin gene-related peptide (CGRP",
            "probability": 6.854534149169922e-06
        },
        {
            "start_logit": -3.703125,
            "end_logit": 8.40625,
            "text": "peptide",
            "probability": 1.8477439880371094e-06
        },
        {
            "start_logit": 9.4921875,
            "end_logit": -7.07421875,
            "text": "calcitonin gene-related peptide (CGRP)",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.4921875,
            "end_logit": -7.15234375,
            "text": "calcitonin gene-related",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.4921875,
            "end_logit": -7.1796875,
            "text": "calcitonin gene",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.4921875,
            "end_logit": -7.23828125,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist, telcagepant, on the haemodynamic response to sublingual nitroglycerin (NTG).",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.4921875,
            "end_logit": -7.6015625,
            "text": "calcitonin gene-",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.4921875,
            "end_logit": -7.85546875,
            "text": "calcitonin gene-related peptide (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.4921875,
            "end_logit": -7.99609375,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist, telcagepant, on",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.4921875,
            "end_logit": -8.0390625,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.4921875,
            "end_logit": -8.0546875,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist, telcagepant, on the haemodynamic response to",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.4921875,
            "end_logit": -8.0703125,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist, telcagepant, on the haemodynamic response to sublingual nitroglycerin (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.4921875,
            "end_logit": -8.0703125,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist, telcagepant, on the haemodynamic response",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6796875,
            "end_logit": 8.40625,
            "text": "gene-related peptide",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.87109375,
            "end_logit": 8.40625,
            "text": "AIMS: To assess the effect of the calcitonin gene-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": -7.90625,
            "end_logit": 8.40625,
            "text": "-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": -7.97265625,
            "end_logit": 8.40625,
            "text": "related peptide",
            "probability": 0.0
        }
    ],
    "55032efde9bde69634000035_9": [
        {
            "start_logit": 9.78125,
            "end_logit": 9.5859375,
            "text": "calcitonin gene-related peptide receptor",
            "probability": 1.0
        },
        {
            "start_logit": 9.78125,
            "end_logit": -1.6416015625,
            "text": "calcitonin",
            "probability": 1.3232231140136719e-05
        },
        {
            "start_logit": -1.728515625,
            "end_logit": 9.5859375,
            "text": "receptor",
            "probability": 9.953975677490234e-06
        },
        {
            "start_logit": 9.78125,
            "end_logit": -6.3671875,
            "text": "calcitonin gene-related peptide",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.78125,
            "end_logit": -7.1953125,
            "text": "calcitonin gene-related peptide receptor antagonist which is being evaluated for the acute treatment of migraine.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.78125,
            "end_logit": -7.30859375,
            "text": "calcitonin gene-related",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.12109375,
            "end_logit": 9.5859375,
            "text": "gene-related peptide receptor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.78125,
            "end_logit": -7.4296875,
            "text": "calcitonin gene",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.24609375,
            "end_logit": 9.5859375,
            "text": "-related peptide receptor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.4140625,
            "end_logit": 9.5859375,
            "text": "related peptide receptor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.78125,
            "end_logit": -7.86328125,
            "text": "calcitonin gene-related peptide receptor antagonist which",
            "probability": 0.0
        },
        {
            "start_logit": 9.78125,
            "end_logit": -7.9140625,
            "text": "calcitonin gene-related peptide receptor antagonist which is being",
            "probability": 0.0
        },
        {
            "start_logit": -7.73046875,
            "end_logit": 9.5859375,
            "text": "peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": 9.78125,
            "end_logit": -7.96875,
            "text": "calcitonin gene-related peptide receptor antagonist which is being evaluated",
            "probability": 0.0
        },
        {
            "start_logit": 9.78125,
            "end_logit": -7.984375,
            "text": "calcitonin gene-related peptide receptor antagonist which is",
            "probability": 0.0
        },
        {
            "start_logit": 9.78125,
            "end_logit": -8.0078125,
            "text": "calcitonin gene-",
            "probability": 0.0
        },
        {
            "start_logit": 9.78125,
            "end_logit": -8.046875,
            "text": "calcitonin gene-related peptide receptor antagonist which is being evaluated for the",
            "probability": 0.0
        },
        {
            "start_logit": -7.86328125,
            "end_logit": 9.5859375,
            "text": "oral calcitonin gene-related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": 9.78125,
            "end_logit": -8.15625,
            "text": "calcitonin gene-related peptide receptor antagonist which is being evaluated for",
            "probability": 0.0
        },
        {
            "start_logit": -7.96484375,
            "end_logit": 9.5859375,
            "text": "BACKGROUND: Telcagepant is an oral calcitonin gene-related peptide receptor",
            "probability": 0.0
        }
    ],
    "55032efde9bde69634000035_10": [
        {
            "start_logit": 9.6015625,
            "end_logit": 7.078125,
            "text": "calcitonin gene-related peptide (CGRP) receptor",
            "probability": 1.0
        },
        {
            "start_logit": 9.6015625,
            "end_logit": -1.9970703125,
            "text": "calcitonin",
            "probability": 0.00011414289474487305
        },
        {
            "start_logit": 9.6015625,
            "end_logit": -3.537109375,
            "text": "calcitonin gene-related peptide",
            "probability": 2.4318695068359375e-05
        },
        {
            "start_logit": -3.580078125,
            "end_logit": 7.078125,
            "text": "CGRP) receptor",
            "probability": 1.8477439880371094e-06
        },
        {
            "start_logit": 9.6015625,
            "end_logit": -6.19140625,
            "text": "calcitonin gene-related peptide (CGRP",
            "probability": 1.7285346984863281e-06
        },
        {
            "start_logit": 9.6015625,
            "end_logit": -6.90234375,
            "text": "calcitonin gene",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": -4.5234375,
            "end_logit": 7.078125,
            "text": "receptor",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 9.6015625,
            "end_logit": -7.33203125,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonists olcegepant and telcagepant are very potent drugs.",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 9.6015625,
            "end_logit": -7.47265625,
            "text": "calcitonin gene-related",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 9.6015625,
            "end_logit": -7.82421875,
            "text": "calcitonin gene-",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 9.6015625,
            "end_logit": -7.96875,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonists",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.6015625,
            "end_logit": -8.1015625,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonists olce",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.6015625,
            "end_logit": -8.1171875,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonists olcegepant and telcagepant are very",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.6015625,
            "end_logit": -8.1328125,
            "text": "calcitonin gene-related peptide (",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.6015625,
            "end_logit": -8.140625,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonists olcegepant",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.6015625,
            "end_logit": -8.1484375,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonists ol",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.3359375,
            "end_logit": 7.078125,
            "text": ") receptor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.7265625,
            "end_logit": 7.078125,
            "text": "related peptide (CGRP) receptor",
            "probability": 0.0
        },
        {
            "start_logit": -7.734375,
            "end_logit": 7.078125,
            "text": "-related peptide (CGRP) receptor",
            "probability": 0.0
        },
        {
            "start_logit": -7.82421875,
            "end_logit": 7.078125,
            "text": "gene-related peptide (CGRP) receptor",
            "probability": 0.0
        }
    ],
    "55032efde9bde69634000035_11": [
        {
            "start_logit": 9.2734375,
            "end_logit": 5.3984375,
            "text": "Calcitonin gene-related peptide (CGRP) receptor",
            "probability": 1.0
        },
        {
            "start_logit": 9.2734375,
            "end_logit": -2.6171875,
            "text": "Calcitonin",
            "probability": 0.00033020973205566406
        },
        {
            "start_logit": 9.2734375,
            "end_logit": -4.43359375,
            "text": "Calcitonin gene-related peptide",
            "probability": 5.3942203521728516e-05
        },
        {
            "start_logit": 9.2734375,
            "end_logit": -5.23046875,
            "text": "Calcitonin gene-related peptide (CGRP",
            "probability": 2.4318695068359375e-05
        },
        {
            "start_logit": -1.60546875,
            "end_logit": 5.3984375,
            "text": "CGRP) receptor",
            "probability": 1.895427703857422e-05
        },
        {
            "start_logit": 9.2734375,
            "end_logit": -6.62109375,
            "text": "Calcitonin gene-related peptide (CGRP) receptor antagonists are another promising nonvasoconstrictor approach to treating acute migraine.",
            "probability": 6.020069122314453e-06
        },
        {
            "start_logit": 9.2734375,
            "end_logit": -6.8046875,
            "text": "Calcitonin gene",
            "probability": 5.0067901611328125e-06
        },
        {
            "start_logit": 9.2734375,
            "end_logit": -7.546875,
            "text": "Calcitonin gene-",
            "probability": 2.384185791015625e-06
        },
        {
            "start_logit": 9.2734375,
            "end_logit": -7.58203125,
            "text": "Calcitonin gene-related",
            "probability": 2.3245811462402344e-06
        },
        {
            "start_logit": 9.2734375,
            "end_logit": -7.61328125,
            "text": "Calcitonin gene-related peptide (CGRP) receptor antagonists are",
            "probability": 2.205371856689453e-06
        },
        {
            "start_logit": 9.2734375,
            "end_logit": -7.828125,
            "text": "Calcitonin gene-related peptide (CGRP) receptor antagonists are another",
            "probability": 1.7881393432617188e-06
        },
        {
            "start_logit": 9.2734375,
            "end_logit": -7.83984375,
            "text": "Calcitonin gene-related peptide (CGRP) receptor antagonists",
            "probability": 1.7881393432617188e-06
        },
        {
            "start_logit": 9.2734375,
            "end_logit": -7.8984375,
            "text": "Calcitonin gene-related peptide (CGRP) receptor antagonists are another promising nonvasoconstr",
            "probability": 1.6689300537109375e-06
        },
        {
            "start_logit": 9.2734375,
            "end_logit": -7.921875,
            "text": "Calcitonin gene-related peptide (CGRP) receptor antagonists are another promising nonvasoconstrictor approach to treating acute migraine. Olcegepant (BIBN4096",
            "probability": 1.6689300537109375e-06
        },
        {
            "start_logit": -5.57421875,
            "end_logit": 5.3984375,
            "text": "receptor",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.4140625,
            "end_logit": 5.3984375,
            "text": ") receptor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.69140625,
            "end_logit": 5.3984375,
            "text": "(CGRP) receptor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.8125,
            "end_logit": 5.3984375,
            "text": "related peptide (CGRP) receptor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.60546875,
            "end_logit": -5.23046875,
            "text": "CGRP",
            "probability": 0.0
        },
        {
            "start_logit": -1.60546875,
            "end_logit": -6.62109375,
            "text": "CGRP) receptor antagonists are another promising nonvasoconstrictor approach to treating acute migraine.",
            "probability": 0.0
        }
    ],
    "55032efde9bde69634000035_12": [
        {
            "start_logit": 9.40625,
            "end_logit": 2.083984375,
            "text": "calcitonin gene-related peptide (CGRP) receptor",
            "probability": 0.9482421875
        },
        {
            "start_logit": 9.40625,
            "end_logit": -1.080078125,
            "text": "calcitonin gene-related peptide",
            "probability": 0.040069580078125
        },
        {
            "start_logit": 9.40625,
            "end_logit": -2.404296875,
            "text": "calcitonin",
            "probability": 0.01061248779296875
        },
        {
            "start_logit": 9.40625,
            "end_logit": -5.7109375,
            "text": "calcitonin gene-related peptide (CGRP",
            "probability": 0.0003898143768310547
        },
        {
            "start_logit": 9.40625,
            "end_logit": -6.1796875,
            "text": "calcitonin gene",
            "probability": 0.00024390220642089844
        },
        {
            "start_logit": 9.40625,
            "end_logit": -6.69921875,
            "text": "calcitonin gene-related",
            "probability": 0.0001455545425415039
        },
        {
            "start_logit": 9.40625,
            "end_logit": -7.01171875,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist being investigated for the acute treatment of migraine.",
            "probability": 0.00010651350021362305
        },
        {
            "start_logit": 9.40625,
            "end_logit": -7.4140625,
            "text": "calcitonin gene-",
            "probability": 7.098913192749023e-05
        },
        {
            "start_logit": 9.40625,
            "end_logit": -7.4140625,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist being",
            "probability": 7.098913192749023e-05
        },
        {
            "start_logit": 9.40625,
            "end_logit": -7.8828125,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist being investigated",
            "probability": 4.4405460357666016e-05
        },
        {
            "start_logit": 9.40625,
            "end_logit": -8.0234375,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist being investigated for the",
            "probability": 3.8623809814453125e-05
        },
        {
            "start_logit": 9.40625,
            "end_logit": -8.0859375,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist being investigated for the acute treatment of migraine",
            "probability": 3.62396240234375e-05
        },
        {
            "start_logit": 9.40625,
            "end_logit": -8.1015625,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist being investigated for",
            "probability": 3.5643577575683594e-05
        },
        {
            "start_logit": 9.40625,
            "end_logit": -8.125,
            "text": "calcitonin gene-related peptide (",
            "probability": 3.4868717193603516e-05
        },
        {
            "start_logit": 9.40625,
            "end_logit": -8.140625,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist being investigated for the acute treatment of",
            "probability": 3.4332275390625e-05
        },
        {
            "start_logit": -3.142578125,
            "end_logit": 2.083984375,
            "text": "CGRP) receptor",
            "probability": 3.3974647521972656e-06
        },
        {
            "start_logit": -7.08984375,
            "end_logit": 2.083984375,
            "text": "receptor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.1171875,
            "end_logit": 2.083984375,
            "text": ") receptor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.8984375,
            "end_logit": 2.083984375,
            "text": "Background.- Telcagepant is a calcitonin gene-related peptide (CGRP) receptor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.91796875,
            "end_logit": 2.083984375,
            "text": "a calcitonin gene-related peptide (CGRP) receptor",
            "probability": 5.960464477539063e-08
        }
    ],
    "55032efde9bde69634000035_13": [
        {
            "start_logit": 9.7421875,
            "end_logit": 9.53125,
            "text": "calcitonin gene-related peptide",
            "probability": 1.0
        },
        {
            "start_logit": 9.7421875,
            "end_logit": -1.7109375,
            "text": "calcitonin",
            "probability": 1.2993812561035156e-05
        },
        {
            "start_logit": -1.849609375,
            "end_logit": 9.53125,
            "text": "peptide",
            "probability": 9.179115295410156e-06
        },
        {
            "start_logit": 9.7421875,
            "end_logit": -7.1484375,
            "text": "calcitonin gene",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.7421875,
            "end_logit": -7.1953125,
            "text": "calcitonin gene-related",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.7421875,
            "end_logit": -7.38671875,
            "text": "calcitonin gene-",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.26953125,
            "end_logit": 9.53125,
            "text": "gene-related peptide",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.7421875,
            "end_logit": -7.6328125,
            "text": "calcitonin gene-related peptide antagonist telcagepant 300 mg orally had an incidence of adverse events similar to placebo when used in the acute treatment of migraine.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.54296875,
            "end_logit": 9.53125,
            "text": "related peptide",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.62890625,
            "end_logit": 9.53125,
            "text": "-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": -7.75390625,
            "end_logit": 9.53125,
            "text": "3 randomized clinical trials (n = 1585) the calcitonin gene-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": -7.8203125,
            "end_logit": 9.53125,
            "text": "(n = 1585) the calcitonin gene-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": -7.8515625,
            "end_logit": 9.53125,
            "text": ") the calcitonin gene-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": -7.8671875,
            "end_logit": 9.53125,
            "text": "In 3 randomized clinical trials (n = 1585) the calcitonin gene-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": -7.87109375,
            "end_logit": 9.53125,
            "text": "the calcitonin gene-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": -7.87890625,
            "end_logit": 9.53125,
            "text": "n = 1585) the calcitonin gene-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": -7.8828125,
            "end_logit": 9.53125,
            "text": "trials (n = 1585) the calcitonin gene-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": -7.88671875,
            "end_logit": 9.53125,
            "text": "randomized clinical trials (n = 1585) the calcitonin gene-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": 9.7421875,
            "end_logit": -8.1484375,
            "text": "calcitonin gene-related peptide antagonist",
            "probability": 0.0
        },
        {
            "start_logit": 9.7421875,
            "end_logit": -8.234375,
            "text": "calcitonin gene-related peptide antagonist telcagepant 300 mg orally had",
            "probability": 0.0
        }
    ],
    "55032efde9bde69634000035_14": [
        {
            "start_logit": 9.75,
            "end_logit": 9.5703125,
            "text": "calcitonin gene-related peptide receptor",
            "probability": 1.0
        },
        {
            "start_logit": 9.75,
            "end_logit": -1.7236328125,
            "text": "calcitonin",
            "probability": 1.2516975402832031e-05
        },
        {
            "start_logit": -1.7578125,
            "end_logit": 9.5703125,
            "text": "receptor",
            "probability": 1.0132789611816406e-05
        },
        {
            "start_logit": 9.75,
            "end_logit": -6.4453125,
            "text": "calcitonin gene-related peptide",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.75,
            "end_logit": -7.265625,
            "text": "calcitonin gene-related",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.109375,
            "end_logit": 9.5703125,
            "text": "gene-related peptide receptor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.75,
            "end_logit": -7.40625,
            "text": "calcitonin gene",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.421875,
            "end_logit": 9.5703125,
            "text": "-related peptide receptor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.46484375,
            "end_logit": 9.5703125,
            "text": "related peptide receptor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.75,
            "end_logit": -7.8125,
            "text": "calcitonin gene-",
            "probability": 0.0
        },
        {
            "start_logit": -7.73828125,
            "end_logit": 9.5703125,
            "text": "peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": 9.75,
            "end_logit": -8.015625,
            "text": "calcitonin gene-related peptide receptor antagonist with",
            "probability": 0.0
        },
        {
            "start_logit": -7.8671875,
            "end_logit": 9.5703125,
            "text": "oral calcitonin gene-related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": -7.9609375,
            "end_logit": 9.5703125,
            "text": "BACKGROUND: Telcagepant is an oral calcitonin gene-related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": 9.75,
            "end_logit": -8.15625,
            "text": "calcitonin gene-related peptide receptor antagonist with acute antimigraine efficacy comparable",
            "probability": 0.0
        },
        {
            "start_logit": -7.98046875,
            "end_logit": 9.5703125,
            "text": "Telcagepant is an oral calcitonin gene-related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": 9.75,
            "end_logit": -8.171875,
            "text": "calcitonin gene-related peptide receptor antagonist with acute antimigraine efficacy comparable to",
            "probability": 0.0
        },
        {
            "start_logit": 9.75,
            "end_logit": -8.1953125,
            "text": "calcitonin gene-related peptide receptor antagonist",
            "probability": 0.0
        },
        {
            "start_logit": -8.015625,
            "end_logit": 9.5703125,
            "text": "cagepant is an oral calcitonin gene-related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": -8.03125,
            "end_logit": 9.5703125,
            "text": "gepant is an oral calcitonin gene-related peptide receptor",
            "probability": 0.0
        }
    ],
    "55032efde9bde69634000035_15": [
        {
            "start_logit": 8.9296875,
            "end_logit": 2.103515625,
            "text": "calcitonin gene-related peptide (CGRP) receptor",
            "probability": 0.62158203125
        },
        {
            "start_logit": 8.9296875,
            "end_logit": 1.591796875,
            "text": "calcitonin gene-related peptide",
            "probability": 0.3740234375
        },
        {
            "start_logit": 8.9296875,
            "end_logit": -3.1640625,
            "text": "calcitonin",
            "probability": 0.0032100677490234375
        },
        {
            "start_logit": 8.9296875,
            "end_logit": -4.59765625,
            "text": "calcitonin gene-related peptide (CGRP",
            "probability": 0.0007658004760742188
        },
        {
            "start_logit": 8.9296875,
            "end_logit": -6.15625,
            "text": "calcitonin gene",
            "probability": 0.00016105175018310547
        },
        {
            "start_logit": 8.9296875,
            "end_logit": -6.46875,
            "text": "calcitonin gene-related",
            "probability": 0.00011783838272094727
        },
        {
            "start_logit": 8.9296875,
            "end_logit": -7.1328125,
            "text": "calcitonin gene-",
            "probability": 6.0677528381347656e-05
        },
        {
            "start_logit": 8.9296875,
            "end_logit": -7.2421875,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist telcagepant (tablet formulation) for treatment of a migraine attack and across four attacks.",
            "probability": 5.435943603515625e-05
        },
        {
            "start_logit": 8.9296875,
            "end_logit": -7.80859375,
            "text": "calcitonin gene-related peptide (",
            "probability": 3.0994415283203125e-05
        },
        {
            "start_logit": 8.9296875,
            "end_logit": -7.81640625,
            "text": "calcitonin gene-related peptide (CGRP)",
            "probability": 3.0517578125e-05
        },
        {
            "start_logit": 8.9296875,
            "end_logit": -7.953125,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist telcagepant (tablet formulation) for treatment of a migraine attack and across four",
            "probability": 2.6702880859375e-05
        },
        {
            "start_logit": 8.9296875,
            "end_logit": -7.953125,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist",
            "probability": 2.6702880859375e-05
        },
        {
            "start_logit": 8.9296875,
            "end_logit": -8.03125,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist telcagepant (tablet formulation) for treatment of a migraine attack and across",
            "probability": 2.467632293701172e-05
        },
        {
            "start_logit": 8.9296875,
            "end_logit": -8.046875,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist telcagepant (tablet formulation) for treatment of a migraine attack and across four attacks",
            "probability": 2.4318695068359375e-05
        },
        {
            "start_logit": 8.9296875,
            "end_logit": -8.0625,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist telcagepant (tablet formulation) for",
            "probability": 2.390146255493164e-05
        },
        {
            "start_logit": 8.9296875,
            "end_logit": -8.0625,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist telcagepant (tablet formulation",
            "probability": 2.390146255493164e-05
        },
        {
            "start_logit": 8.9296875,
            "end_logit": -8.0703125,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist telcagepant (tablet formulation) for treatment of a migraine attack",
            "probability": 2.372264862060547e-05
        },
        {
            "start_logit": 8.9296875,
            "end_logit": -8.078125,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist telcagepant (",
            "probability": 2.3543834686279297e-05
        },
        {
            "start_logit": -3.92578125,
            "end_logit": 2.103515625,
            "text": "CGRP) receptor",
            "probability": 1.6093254089355469e-06
        },
        {
            "start_logit": -7.375,
            "end_logit": 2.103515625,
            "text": "receptor",
            "probability": 5.960464477539063e-08
        }
    ],
    "55032efde9bde69634000035_16": [
        {
            "start_logit": 9.5703125,
            "end_logit": 9.328125,
            "text": "calcitonin gene-related peptide",
            "probability": 1.0
        },
        {
            "start_logit": 9.5703125,
            "end_logit": -2.1171875,
            "text": "calcitonin",
            "probability": 1.0609626770019531e-05
        },
        {
            "start_logit": -2.28515625,
            "end_logit": 9.328125,
            "text": "peptide",
            "probability": 7.092952728271484e-06
        },
        {
            "start_logit": 9.5703125,
            "end_logit": -6.32421875,
            "text": "calcitonin gene-related peptide (CGRP) receptor",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.5703125,
            "end_logit": -6.73828125,
            "text": "calcitonin gene-related peptide (CGRP",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.5703125,
            "end_logit": -7.29296875,
            "text": "calcitonin gene",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.5703125,
            "end_logit": -7.4296875,
            "text": "calcitonin gene-related",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.5703125,
            "end_logit": -7.5390625,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist, telcagepant, and zolmitriptan in the acute treatment of migraine.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.5703125,
            "end_logit": -7.84765625,
            "text": "calcitonin gene-related peptide (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.65234375,
            "end_logit": 9.328125,
            "text": "gene-related peptide",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.5703125,
            "end_logit": -7.90234375,
            "text": "calcitonin gene-",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.5703125,
            "end_logit": -7.96875,
            "text": "calcitonin gene-related peptide (CGRP)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.78515625,
            "end_logit": 9.328125,
            "text": "the calcitonin gene-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": -7.84375,
            "end_logit": 9.328125,
            "text": "post-hoc analysis of patient-level data from a previous randomized, placebo-controlled trial of the calcitonin gene-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": -7.85546875,
            "end_logit": 9.328125,
            "text": "-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": 9.5703125,
            "end_logit": -8.109375,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist",
            "probability": 0.0
        },
        {
            "start_logit": -7.875,
            "end_logit": 9.328125,
            "text": "previous randomized, placebo-controlled trial of the calcitonin gene-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": -7.875,
            "end_logit": 9.328125,
            "text": "related peptide",
            "probability": 0.0
        },
        {
            "start_logit": -7.90625,
            "end_logit": 9.328125,
            "text": "trial of the calcitonin gene-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": -7.90625,
            "end_logit": 9.328125,
            "text": "of the calcitonin gene-related peptide",
            "probability": 0.0
        }
    ],
    "55032efde9bde69634000035_17": [
        {
            "start_logit": 9.2421875,
            "end_logit": 2.4765625,
            "text": "calcitonin gene-related peptide (CGRP) receptor",
            "probability": 0.84228515625
        },
        {
            "start_logit": 9.2421875,
            "end_logit": 0.734375,
            "text": "calcitonin gene-related peptide",
            "probability": 0.1474609375
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -2.6953125,
            "text": "calcitonin gene-related peptide (CGRP",
            "probability": 0.0047760009765625
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -2.712890625,
            "text": "calcitonin",
            "probability": 0.004703521728515625
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -6.625,
            "text": "calcitonin gene",
            "probability": 9.393692016601562e-05
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -6.97265625,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist telcagepant in human cranial arteries.",
            "probability": 6.604194641113281e-05
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -7.11328125,
            "text": "calcitonin gene-related",
            "probability": 5.739927291870117e-05
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -7.2734375,
            "text": "calcitonin gene-",
            "probability": 4.9114227294921875e-05
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -7.4140625,
            "text": "calcitonin gene-related peptide (CGRP)",
            "probability": 4.267692565917969e-05
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -7.70703125,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist telcagepant in",
            "probability": 3.165006637573242e-05
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -7.80859375,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist",
            "probability": 2.8848648071289062e-05
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -7.8125,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist telcagepant in human cranial arteries",
            "probability": 2.86102294921875e-05
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -8.0703125,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist telcagepant in human cranial",
            "probability": 2.2113323211669922e-05
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -8.09375,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist telcagepant",
            "probability": 2.1636486053466797e-05
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -8.09375,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist telca",
            "probability": 2.1636486053466797e-05
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -8.125,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist telcagepant in human",
            "probability": 2.092123031616211e-05
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -8.125,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist tel",
            "probability": 2.092123031616211e-05
        },
        {
            "start_logit": -2.94140625,
            "end_logit": 2.4765625,
            "text": "CGRP) receptor",
            "probability": 4.291534423828125e-06
        },
        {
            "start_logit": -6.9140625,
            "end_logit": 2.4765625,
            "text": "receptor",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.578125,
            "end_logit": 2.4765625,
            "text": ") receptor",
            "probability": 5.960464477539063e-08
        }
    ],
    "55032efde9bde69634000035_18": [
        {
            "start_logit": 9.734375,
            "end_logit": 9.5,
            "text": "calcitonin gene-related peptide receptor",
            "probability": 1.0
        },
        {
            "start_logit": 9.734375,
            "end_logit": -1.7451171875,
            "text": "calcitonin",
            "probability": 1.2993812561035156e-05
        },
        {
            "start_logit": -1.90234375,
            "end_logit": 9.5,
            "text": "receptor",
            "probability": 8.821487426757812e-06
        },
        {
            "start_logit": 9.734375,
            "end_logit": -6.40234375,
            "text": "calcitonin gene-related peptide",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.734375,
            "end_logit": -7.09765625,
            "text": "calcitonin gene-related",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.08984375,
            "end_logit": 9.5,
            "text": "gene-related peptide receptor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.734375,
            "end_logit": -7.34375,
            "text": "calcitonin gene",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.734375,
            "end_logit": -7.70703125,
            "text": "calcitonin gene-related peptide receptor antagonist telcagepant (MK-0974) in human isolated coronary arteries.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.484375,
            "end_logit": 9.5,
            "text": "-related peptide receptor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.734375,
            "end_logit": -7.7890625,
            "text": "calcitonin gene-",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.59765625,
            "end_logit": 9.5,
            "text": "related peptide receptor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.76953125,
            "end_logit": 9.5,
            "text": "peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": 9.734375,
            "end_logit": -8.0390625,
            "text": "calcitonin gene-related peptide receptor antagonist telcagepant (MK-0974) in",
            "probability": 0.0
        },
        {
            "start_logit": 9.734375,
            "end_logit": -8.09375,
            "text": "calcitonin gene-related peptide receptor antagonist",
            "probability": 0.0
        },
        {
            "start_logit": 9.734375,
            "end_logit": -8.1015625,
            "text": "calcitonin gene-related peptide receptor antagonist telcagepant (MK-0974) in human isolated coronary arteries",
            "probability": 0.0
        },
        {
            "start_logit": 9.734375,
            "end_logit": -8.109375,
            "text": "calcitonin gene-related peptide receptor antagonist telcagepant (MK-0974) in human isolated",
            "probability": 0.0
        },
        {
            "start_logit": -7.8984375,
            "end_logit": 9.5,
            "text": "Characterization of the calcitonin gene-related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": 9.734375,
            "end_logit": -8.1484375,
            "text": "calcitonin gene-related peptide receptor antagonist telcagepant (MK-0974) in human isolated coronary",
            "probability": 0.0
        },
        {
            "start_logit": -8.0625,
            "end_logit": 9.5,
            "text": "the calcitonin gene-related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": -1.90234375,
            "end_logit": -7.70703125,
            "text": "receptor antagonist telcagepant (MK-0974) in human isolated coronary arteries.",
            "probability": 0.0
        }
    ],
    "55032efde9bde69634000035_19": [
        {
            "start_logit": 9.7578125,
            "end_logit": 9.5,
            "text": "calcitonin gene-related peptide receptor",
            "probability": 1.0
        },
        {
            "start_logit": 9.7578125,
            "end_logit": -1.6748046875,
            "text": "calcitonin",
            "probability": 1.4185905456542969e-05
        },
        {
            "start_logit": -1.8564453125,
            "end_logit": 9.5,
            "text": "receptor",
            "probability": 9.059906005859375e-06
        },
        {
            "start_logit": 9.7578125,
            "end_logit": -5.9453125,
            "text": "calcitonin gene-related peptide",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.7578125,
            "end_logit": -6.96484375,
            "text": "calcitonin gene-related",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.7578125,
            "end_logit": -6.99609375,
            "text": "calcitonin gene",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.7578125,
            "end_logit": -7.39453125,
            "text": "calcitonin gene-",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.7578125,
            "end_logit": -7.5546875,
            "text": "calcitonin gene-related peptide receptor blockers.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.36328125,
            "end_logit": 9.5,
            "text": "gene-related peptide receptor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.49609375,
            "end_logit": 9.5,
            "text": "related peptide receptor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.609375,
            "end_logit": 9.5,
            "text": "peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": -7.67578125,
            "end_logit": 9.5,
            "text": "the calcitonin gene-related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": -7.6796875,
            "end_logit": 9.5,
            "text": "-related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": -7.90234375,
            "end_logit": 9.5,
            "text": "Telcagepant represents a new class of antimigraine drug-the calcitonin gene-related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": 9.7578125,
            "end_logit": -8.1875,
            "text": "calcitonin gene-related peptide receptor blockers",
            "probability": 0.0
        },
        {
            "start_logit": -7.94921875,
            "end_logit": 9.5,
            "text": "cagepant represents a new class of antimigraine drug-the calcitonin gene-related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": -7.94921875,
            "end_logit": 9.5,
            "text": "drug-the calcitonin gene-related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": -7.97265625,
            "end_logit": 9.5,
            "text": "t represents a new class of antimigraine drug-the calcitonin gene-related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": -7.98046875,
            "end_logit": 9.5,
            "text": "pant represents a new class of antimigraine drug-the calcitonin gene-related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": -7.98828125,
            "end_logit": 9.5,
            "text": "gepant represents a new class of antimigraine drug-the calcitonin gene-related peptide receptor",
            "probability": 0.0
        }
    ],
    "55032efde9bde69634000035_20": [
        {
            "start_logit": 9.640625,
            "end_logit": 9.453125,
            "text": "calcitonin gene-related peptide receptor",
            "probability": 1.0
        },
        {
            "start_logit": 9.640625,
            "end_logit": -1.9521484375,
            "text": "calcitonin",
            "probability": 1.1146068572998047e-05
        },
        {
            "start_logit": -1.9990234375,
            "end_logit": 9.453125,
            "text": "receptor",
            "probability": 8.821487426757812e-06
        },
        {
            "start_logit": 9.640625,
            "end_logit": -5.74609375,
            "text": "calcitonin gene-related peptide",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.640625,
            "end_logit": -7.3203125,
            "text": "calcitonin gene-related",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.640625,
            "end_logit": -7.37109375,
            "text": "calcitonin gene",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.640625,
            "end_logit": -7.3984375,
            "text": "calcitonin gene-",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.30859375,
            "end_logit": 9.453125,
            "text": "gene-related peptide receptor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.4140625,
            "end_logit": 9.453125,
            "text": "related peptide receptor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.4453125,
            "end_logit": 9.453125,
            "text": "oral calcitonin gene-related peptide receptor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.640625,
            "end_logit": -7.74609375,
            "text": "calcitonin gene-related peptide receptor antagonist, in adults.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.79296875,
            "end_logit": 9.453125,
            "text": "-related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": -7.8046875,
            "end_logit": 9.453125,
            "text": "an oral calcitonin gene-related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": -7.8203125,
            "end_logit": 9.453125,
            "text": "peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": 9.640625,
            "end_logit": -8.1640625,
            "text": "calcitonin gene-related peptide receptor antagonist",
            "probability": 0.0
        },
        {
            "start_logit": 9.640625,
            "end_logit": -8.1796875,
            "text": "calcitonin gene-related peptide receptor antagonist, in",
            "probability": 0.0
        },
        {
            "start_logit": -8.03125,
            "end_logit": 9.453125,
            "text": "telcagepant, an oral calcitonin gene-related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": -8.03125,
            "end_logit": 9.453125,
            "text": "cagepant, an oral calcitonin gene-related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": -8.0546875,
            "end_logit": 9.453125,
            "text": "pant, an oral calcitonin gene-related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": -8.0546875,
            "end_logit": 9.453125,
            "text": "gepant, an oral calcitonin gene-related peptide receptor",
            "probability": 0.0
        }
    ],
    "55032efde9bde69634000035_21": [
        {
            "start_logit": 9.75,
            "end_logit": 9.484375,
            "text": "calcitonin gene-related peptide receptor",
            "probability": 1.0
        },
        {
            "start_logit": 9.75,
            "end_logit": -1.7197265625,
            "text": "calcitonin",
            "probability": 1.3649463653564453e-05
        },
        {
            "start_logit": -1.9365234375,
            "end_logit": 9.484375,
            "text": "receptor",
            "probability": 8.404254913330078e-06
        },
        {
            "start_logit": 9.75,
            "end_logit": -6.6484375,
            "text": "calcitonin gene-related peptide",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.75,
            "end_logit": -6.95703125,
            "text": "calcitonin gene",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.75,
            "end_logit": -7.2578125,
            "text": "calcitonin gene-related",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.75,
            "end_logit": -7.45703125,
            "text": "calcitonin gene-related peptide receptor antagonist being developed for acute treatment of migraine with and without aura.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.75,
            "end_logit": -7.50390625,
            "text": "calcitonin gene-",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.34375,
            "end_logit": 9.484375,
            "text": "selective calcitonin gene-related peptide receptor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.359375,
            "end_logit": 9.484375,
            "text": "related peptide receptor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.37109375,
            "end_logit": 9.484375,
            "text": "peptide receptor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.57421875,
            "end_logit": 9.484375,
            "text": "gene-related peptide receptor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6015625,
            "end_logit": 9.484375,
            "text": "-related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": 9.75,
            "end_logit": -7.8984375,
            "text": "calcitonin gene-related peptide receptor antagonist being",
            "probability": 0.0
        },
        {
            "start_logit": -7.82421875,
            "end_logit": 9.484375,
            "text": ", and selective calcitonin gene-related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": -7.83984375,
            "end_logit": 9.484375,
            "text": "and selective calcitonin gene-related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": -7.859375,
            "end_logit": 9.484375,
            "text": ", orally active, and selective calcitonin gene-related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": 9.75,
            "end_logit": -8.1328125,
            "text": "calcitonin gene-related peptide receptor antagonist being developed for acute treatment of migraine with and",
            "probability": 0.0
        },
        {
            "start_logit": -7.8828125,
            "end_logit": 9.484375,
            "text": "Telcagepant is a novel, orally active, and selective calcitonin gene-related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": -7.91015625,
            "end_logit": 9.484375,
            "text": "novel, orally active, and selective calcitonin gene-related peptide receptor",
            "probability": 0.0
        }
    ],
    "55032efde9bde69634000035_22": [
        {
            "start_logit": 9.7734375,
            "end_logit": 9.3984375,
            "text": "calcitonin gene-related peptide",
            "probability": 1.0
        },
        {
            "start_logit": 9.7734375,
            "end_logit": -1.662109375,
            "text": "calcitonin",
            "probability": 1.5676021575927734e-05
        },
        {
            "start_logit": -2.134765625,
            "end_logit": 9.3984375,
            "text": "peptide",
            "probability": 6.735324859619141e-06
        },
        {
            "start_logit": 9.7734375,
            "end_logit": -3.8984375,
            "text": "calcitonin gene-related peptide (CGRP",
            "probability": 1.6689300537109375e-06
        },
        {
            "start_logit": 9.7734375,
            "end_logit": -5.203125,
            "text": "calcitonin gene-related peptide (CGRP) receptor",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 9.7734375,
            "end_logit": -7.23046875,
            "text": "calcitonin gene",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.7734375,
            "end_logit": -7.2890625,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist telcagepant and to compare its coronary vasoconstrictive potential to that of zolmitriptan.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.7734375,
            "end_logit": -7.3671875,
            "text": "calcitonin gene-related",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.7734375,
            "end_logit": -7.7421875,
            "text": "calcitonin gene-",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.7734375,
            "end_logit": -7.796875,
            "text": "calcitonin gene-related peptide (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.44140625,
            "end_logit": 9.3984375,
            "text": "gene-related peptide",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.7734375,
            "end_logit": -7.87890625,
            "text": "calcitonin gene-related peptide (CGRP)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5859375,
            "end_logit": 9.3984375,
            "text": "-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": 9.7734375,
            "end_logit": -8.0078125,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist telcagepant and to compare its coronary vasoconstrictive potential to",
            "probability": 0.0
        },
        {
            "start_logit": -7.6328125,
            "end_logit": 9.3984375,
            "text": "related peptide",
            "probability": 0.0
        },
        {
            "start_logit": 9.7734375,
            "end_logit": -8.03125,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist telcagepant and to compare its coronary vasoconstrictive potential to that",
            "probability": 0.0
        },
        {
            "start_logit": -7.66015625,
            "end_logit": 9.3984375,
            "text": "Studies were conducted in human isolated coronary arteries to explore the vascular effects of the calcitonin gene-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": 9.7734375,
            "end_logit": -8.046875,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist telcagepant and",
            "probability": 0.0
        },
        {
            "start_logit": -8.046875,
            "end_logit": 9.3984375,
            "text": "the calcitonin gene-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": -8.046875,
            "end_logit": 9.3984375,
            "text": "in human isolated coronary arteries to explore the vascular effects of the calcitonin gene-related peptide",
            "probability": 0.0
        }
    ],
    "55032efde9bde69634000035_23": [
        {
            "start_logit": 9.03125,
            "end_logit": 4.05859375,
            "text": "calcitonin gene-related peptide",
            "probability": 0.97314453125
        },
        {
            "start_logit": 9.03125,
            "end_logit": 0.394775390625,
            "text": "calcitonin gene-related peptide (CGRP) receptor",
            "probability": 0.0249481201171875
        },
        {
            "start_logit": 9.03125,
            "end_logit": -2.96484375,
            "text": "calcitonin",
            "probability": 0.0008635520935058594
        },
        {
            "start_logit": 9.03125,
            "end_logit": -3.7890625,
            "text": "calcitonin gene-related peptide (CGRP",
            "probability": 0.0003788471221923828
        },
        {
            "start_logit": 9.03125,
            "end_logit": -6.44921875,
            "text": "calcitonin gene-related",
            "probability": 2.6404857635498047e-05
        },
        {
            "start_logit": 9.03125,
            "end_logit": -6.61328125,
            "text": "calcitonin gene",
            "probability": 2.2590160369873047e-05
        },
        {
            "start_logit": 9.03125,
            "end_logit": -6.62890625,
            "text": "calcitonin gene-",
            "probability": 2.2232532501220703e-05
        },
        {
            "start_logit": 9.03125,
            "end_logit": -7.06640625,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist and is currently under clinical development.",
            "probability": 1.430511474609375e-05
        },
        {
            "start_logit": 9.03125,
            "end_logit": -7.4140625,
            "text": "calcitonin gene-related peptide (",
            "probability": 1.0073184967041016e-05
        },
        {
            "start_logit": 9.03125,
            "end_logit": -7.69921875,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist and is currently",
            "probability": 7.569789886474609e-06
        },
        {
            "start_logit": 9.03125,
            "end_logit": -7.8515625,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist and is currently under",
            "probability": 6.496906280517578e-06
        },
        {
            "start_logit": 9.03125,
            "end_logit": -7.90625,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist and is",
            "probability": 6.139278411865234e-06
        },
        {
            "start_logit": 9.03125,
            "end_logit": -8.015625,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist and",
            "probability": 5.4836273193359375e-06
        },
        {
            "start_logit": 9.03125,
            "end_logit": -8.015625,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist and is currently under clinical development",
            "probability": 5.4836273193359375e-06
        },
        {
            "start_logit": 9.03125,
            "end_logit": -8.046875,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist and is currently under clinical",
            "probability": 5.364418029785156e-06
        },
        {
            "start_logit": 9.03125,
            "end_logit": -8.078125,
            "text": "calcitonin gene-related peptide (CGRP)",
            "probability": 5.245208740234375e-06
        },
        {
            "start_logit": 9.03125,
            "end_logit": -8.125,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist",
            "probability": 4.947185516357422e-06
        },
        {
            "start_logit": -6.15625,
            "end_logit": 4.05859375,
            "text": "novel oral calcitonin gene-related peptide",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.36328125,
            "end_logit": 4.05859375,
            "text": "oral calcitonin gene-related peptide",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -2.837890625,
            "end_logit": 0.394775390625,
            "text": "CGRP) receptor",
            "probability": 1.7881393432617188e-07
        }
    ],
    "5c6ab4c17c78d6947100001d_1": [
        {
            "start_logit": 8.1953125,
            "end_logit": 9.671875,
            "text": "MATLAB environment",
            "probability": 1.0
        },
        {
            "start_logit": -1.2041015625,
            "end_logit": 9.671875,
            "text": "environment",
            "probability": 8.219480514526367e-05
        },
        {
            "start_logit": -1.3173828125,
            "end_logit": 9.671875,
            "text": "under the MATLAB environment",
            "probability": 7.31348991394043e-05
        },
        {
            "start_logit": 8.1953125,
            "end_logit": -4.03125,
            "text": "MAT",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": -6.20703125,
            "end_logit": 9.671875,
            "text": "LAB environment",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -6.2734375,
            "end_logit": 9.671875,
            "text": ".Availability and implementation: SELANSI runs under the MATLAB environment",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -6.2734375,
            "end_logit": 9.671875,
            "text": ". The tool offers total flexibility regarding network topology, kinetics and parameterization, as well as simulation options.Availability and implementation: SELANSI runs under the MATLAB environment",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -6.5234375,
            "end_logit": 9.671875,
            "text": "the MATLAB environment",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.1953125,
            "end_logit": -5.27734375,
            "text": "MATLAB environment,",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.1953125,
            "end_logit": -5.32421875,
            "text": "MATLAB environment, and is available under GPLv3 license at https://sites.google.com",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.1953125,
            "end_logit": -5.62890625,
            "text": "MATLAB",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.1953125,
            "end_logit": -6.31640625,
            "text": "MATLAB environment, and is available under GPLv3 license at https://sites.google.com/view",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.1953125,
            "end_logit": -6.44921875,
            "text": "MATLAB environment, and is available under GPLv3 license at https://sites.google.com/view/selansi.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.1953125,
            "end_logit": -7.2421875,
            "text": "MATLAB environment, and is available under GPLv3 license at https://sites.google",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -0.61181640625,
            "end_logit": -3.873046875,
            "text": "SEmi-LAgrangian SImulation of GRNs",
            "probability": 0.0
        },
        {
            "start_logit": -0.61181640625,
            "end_logit": -4.2890625,
            "text": "SEmi-LAgrangian SImulation of GRNs), a software toolbox for the simulation of stochastic multidimensional gene regulatory networks",
            "probability": 0.0
        },
        {
            "start_logit": -1.3173828125,
            "end_logit": -4.03125,
            "text": "under the MAT",
            "probability": 0.0
        },
        {
            "start_logit": -1.2041015625,
            "end_logit": -5.27734375,
            "text": "environment,",
            "probability": 0.0
        },
        {
            "start_logit": -1.2041015625,
            "end_logit": -5.32421875,
            "text": "environment, and is available under GPLv3 license at https://sites.google.com",
            "probability": 0.0
        },
        {
            "start_logit": -1.3173828125,
            "end_logit": -5.27734375,
            "text": "under the MATLAB environment,",
            "probability": 0.0
        }
    ],
    "5c6ab4c17c78d6947100001d_2": [
        {
            "start_logit": 9.5859375,
            "end_logit": 9.6640625,
            "text": "MATLAB environment",
            "probability": 1.0
        },
        {
            "start_logit": -1.279296875,
            "end_logit": 9.6640625,
            "text": "environment",
            "probability": 1.9073486328125e-05
        },
        {
            "start_logit": 9.5859375,
            "end_logit": -2.046875,
            "text": "MAT",
            "probability": 8.225440979003906e-06
        },
        {
            "start_logit": -6.36328125,
            "end_logit": 9.6640625,
            "text": "the MATLAB environment",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.5859375,
            "end_logit": -6.36328125,
            "text": "MATLAB",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.5390625,
            "end_logit": 9.6640625,
            "text": "under the MATLAB environment",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.8984375,
            "end_logit": 9.6640625,
            "text": "LAB environment",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.5859375,
            "end_logit": -7.22265625,
            "text": "MATLAB environment,",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.5859375,
            "end_logit": -7.24609375,
            "text": "MATLAB environment, and is available under GPLv3 license at https://sites.google.com/view/selansi.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.5859375,
            "end_logit": -7.3359375,
            "text": "MATLAB environment, and is available under GPLv3 license at https://sites.google.com",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.75390625,
            "end_logit": 9.6640625,
            "text": "Availability and implementation SELANSI runs under the MATLAB environment",
            "probability": 0.0
        },
        {
            "start_logit": -7.86328125,
            "end_logit": 9.6640625,
            "text": "implementation SELANSI runs under the MATLAB environment",
            "probability": 0.0
        },
        {
            "start_logit": 9.5859375,
            "end_logit": -7.8203125,
            "text": "MATLAB environment, and is available under GPLv3 license at https://sites.google.",
            "probability": 0.0
        },
        {
            "start_logit": 9.5859375,
            "end_logit": -7.84375,
            "text": "MATLAB environment, and is available under GPLv3 license at https://sites.google.com/view",
            "probability": 0.0
        },
        {
            "start_logit": -7.9296875,
            "end_logit": 9.6640625,
            "text": "SELANSI runs under the MATLAB environment",
            "probability": 0.0
        },
        {
            "start_logit": 9.5859375,
            "end_logit": -7.859375,
            "text": "MATLAB environment, and",
            "probability": 0.0
        },
        {
            "start_logit": -7.95703125,
            "end_logit": 9.6640625,
            "text": "runs under the MATLAB environment",
            "probability": 0.0
        },
        {
            "start_logit": 9.5859375,
            "end_logit": -7.9140625,
            "text": "MATLAB environment, and is available under GPLv3 license at https://sites.google",
            "probability": 0.0
        },
        {
            "start_logit": 9.5859375,
            "end_logit": -7.99609375,
            "text": "MATLAB environment, and is available under GPLv3 license at https:/",
            "probability": 0.0
        },
        {
            "start_logit": 9.5859375,
            "end_logit": -8.015625,
            "text": "MATLAB environment, and is available under GPLv3",
            "probability": 0.0
        }
    ],
    "5c6ab4c17c78d6947100001d_3": [
        {
            "start_logit": 8.921875,
            "end_logit": 9.5078125,
            "text": "MATLAB environment",
            "probability": 1.0
        },
        {
            "start_logit": -1.6435546875,
            "end_logit": 9.5078125,
            "text": "environment",
            "probability": 2.5451183319091797e-05
        },
        {
            "start_logit": 8.921875,
            "end_logit": -3.17578125,
            "text": "MAT",
            "probability": 3.0994415283203125e-06
        },
        {
            "start_logit": -6.0859375,
            "end_logit": 9.5078125,
            "text": "the MATLAB environment",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.328125,
            "end_logit": 9.5078125,
            "text": "under the MATLAB environment",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.921875,
            "end_logit": -5.796875,
            "text": "MATLAB",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.8203125,
            "end_logit": 9.5078125,
            "text": "LAB environment",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.76953125,
            "end_logit": 9.5078125,
            "text": "<br><b>Availability and implementation</b>: SELANSI runs under the MATLAB environment",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.76953125,
            "end_logit": 9.5078125,
            "text": "SELANSI runs under the MATLAB environment",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.79296875,
            "end_logit": 9.5078125,
            "text": ": SELANSI runs under the MATLAB environment",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.80078125,
            "end_logit": 9.5078125,
            "text": "Availability and implementation</b>: SELANSI runs under the MATLAB environment",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.8125,
            "end_logit": 9.5078125,
            "text": "runs under the MATLAB environment",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.8125,
            "end_logit": 9.5078125,
            "text": "I runs under the MATLAB environment",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.921875,
            "end_logit": -7.26953125,
            "text": "MATLAB environment, and is available under GPLv3 license at https://sites.google.com",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.921875,
            "end_logit": -7.8046875,
            "text": "MATLAB environment, and is available under GPLv3 license at https://sites.google.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.921875,
            "end_logit": -7.81640625,
            "text": "MATLAB environment,",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.921875,
            "end_logit": -7.87890625,
            "text": "MATLAB environment, and is available under GPLv3 license at https://sites.google",
            "probability": 0.0
        },
        {
            "start_logit": 8.921875,
            "end_logit": -7.9140625,
            "text": "MATLAB environment, and is available under GPLv3 licens",
            "probability": 0.0
        },
        {
            "start_logit": 8.921875,
            "end_logit": -7.94140625,
            "text": "MATLAB environment, and is available under GPLv3 license",
            "probability": 0.0
        },
        {
            "start_logit": 8.921875,
            "end_logit": -7.9765625,
            "text": "MATLAB environment, and is available under GPLv3 license at https:/",
            "probability": 0.0
        }
    ],
    "5c6ab4c17c78d6947100001d_4": [
        {
            "start_logit": 9.59375,
            "end_logit": 9.65625,
            "text": "MATLAB environment",
            "probability": 1.0
        },
        {
            "start_logit": -1.275390625,
            "end_logit": 9.65625,
            "text": "environment",
            "probability": 1.9073486328125e-05
        },
        {
            "start_logit": 9.59375,
            "end_logit": -2.013671875,
            "text": "MAT",
            "probability": 8.52346420288086e-06
        },
        {
            "start_logit": 9.59375,
            "end_logit": -6.375,
            "text": "MATLAB",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.83203125,
            "end_logit": 9.65625,
            "text": "the MATLAB environment",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.59375,
            "end_logit": -6.81640625,
            "text": "MATLAB environment,",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.94921875,
            "end_logit": 9.65625,
            "text": "LAB environment",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.03125,
            "end_logit": 9.65625,
            "text": "under the MATLAB environment",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.59375,
            "end_logit": -7.0859375,
            "text": "MATLAB environment, and is available under GPLv3 license at https://sites.google.com",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.59375,
            "end_logit": -7.21484375,
            "text": "MATLAB environment, and is available under GPLv3 license at https://sites.google.com/view/selansi.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.59375,
            "end_logit": -7.5703125,
            "text": "MATLAB environment, and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.59375,
            "end_logit": -7.69921875,
            "text": "MATLAB environment, and is available under GPLv3 license at https://sites.google.com/view",
            "probability": 0.0
        },
        {
            "start_logit": 9.59375,
            "end_logit": -7.703125,
            "text": "MATLAB environment, and is available under GPLv3 license at https://sites.google",
            "probability": 0.0
        },
        {
            "start_logit": -7.76953125,
            "end_logit": 9.65625,
            "text": "SELANSI runs under the MATLAB environment",
            "probability": 0.0
        },
        {
            "start_logit": 9.59375,
            "end_logit": -7.72265625,
            "text": "MATLAB environment, and is available under GPLv3 license at https://sites.google.",
            "probability": 0.0
        },
        {
            "start_logit": 9.59375,
            "end_logit": -7.8046875,
            "text": "MATLAB environment, and is",
            "probability": 0.0
        },
        {
            "start_logit": -7.92578125,
            "end_logit": 9.65625,
            "text": "runs under the MATLAB environment",
            "probability": 0.0
        },
        {
            "start_logit": 9.59375,
            "end_logit": -7.9296875,
            "text": "MATLAB environment, and is available",
            "probability": 0.0
        },
        {
            "start_logit": 9.59375,
            "end_logit": -7.95703125,
            "text": "MATLAB environment, and is available under",
            "probability": 0.0
        },
        {
            "start_logit": 9.59375,
            "end_logit": -7.96484375,
            "text": "MATLAB environment, and is available under GPLv3",
            "probability": 0.0
        }
    ],
    "5a992b371d1251d03b00000a_1": [
        {
            "start_logit": 8.5859375,
            "end_logit": 7.578125,
            "text": "Metagenomics of the Human Intestinal Tract",
            "probability": 1.0
        },
        {
            "start_logit": 8.5859375,
            "end_logit": -0.9609375,
            "text": "Metagenomics of the Human Intestinal Tract (MetaHIT) project are focusing mainly on the human microbiome.",
            "probability": 0.0001971721649169922
        },
        {
            "start_logit": 8.5859375,
            "end_logit": -3.392578125,
            "text": "Metagen",
            "probability": 1.7344951629638672e-05
        },
        {
            "start_logit": -4.140625,
            "end_logit": 7.578125,
            "text": "Tract",
            "probability": 2.9802322387695312e-06
        },
        {
            "start_logit": 8.5859375,
            "end_logit": -5.16796875,
            "text": "Metagenomics of the Human Intestinal Tract (MetaHIT) project",
            "probability": 2.9206275939941406e-06
        },
        {
            "start_logit": 8.5859375,
            "end_logit": -5.2578125,
            "text": "Metagenomics of the Human Intestinal Tract (",
            "probability": 2.682209014892578e-06
        },
        {
            "start_logit": 8.5859375,
            "end_logit": -5.91015625,
            "text": "Metagenomics",
            "probability": 1.3709068298339844e-06
        },
        {
            "start_logit": 8.5859375,
            "end_logit": -5.9296875,
            "text": "Metagenomics of the Human Intestinal Tract (MetaHIT) project are focusing mainly on the human microbiome",
            "probability": 1.3709068298339844e-06
        },
        {
            "start_logit": 8.5859375,
            "end_logit": -6.2890625,
            "text": "Metagenomics of the Human Intestinal",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": -5.453125,
            "end_logit": 7.578125,
            "text": "microbiome constituency is so relevant that several consortia like the Human Microbiome project (HMP) and Metagenomics of the Human Intestinal Tract",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": 8.5859375,
            "end_logit": -6.54296875,
            "text": "Metagenomics of",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 8.5859375,
            "end_logit": -6.65234375,
            "text": "Metagenomics of the Human Intestinal Tract (MetaHIT) project are",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -5.81640625,
            "end_logit": 7.578125,
            "text": "Human Intestinal Tract",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 8.5859375,
            "end_logit": -7.09765625,
            "text": "Metagenomics of the",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.5859375,
            "end_logit": -7.47265625,
            "text": "Metagenomics of the Human",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.79296875,
            "end_logit": 7.578125,
            "text": "and Metagenomics of the Human Intestinal Tract",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.0703125,
            "end_logit": 7.578125,
            "text": "the Human Intestinal Tract",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.296875,
            "end_logit": 7.578125,
            "text": "Intestinal Tract",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.625,
            "end_logit": 7.578125,
            "text": "Human Microbiome project (HMP) and Metagenomics of the Human Intestinal Tract",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.71484375,
            "end_logit": 7.578125,
            "text": "omics of the Human Intestinal Tract",
            "probability": 5.960464477539063e-08
        }
    ],
    "530c7f52970c65fa6b000010_1": [
        {
            "start_logit": -0.86669921875,
            "end_logit": 2.6171875,
            "text": "biofilm development of periodontal pathogens",
            "probability": 0.576171875
        },
        {
            "start_logit": -0.86669921875,
            "end_logit": 2.216796875,
            "text": "biofilm development",
            "probability": 0.3857421875
        },
        {
            "start_logit": -5.34375,
            "end_logit": 2.6171875,
            "text": "polymicrobial biofilm development of periodontal pathogens",
            "probability": 0.006549835205078125
        },
        {
            "start_logit": -5.578125,
            "end_logit": 2.6171875,
            "text": "disrupts polymicrobial biofilm development of periodontal pathogens",
            "probability": 0.00518035888671875
        },
        {
            "start_logit": -5.34375,
            "end_logit": 2.216796875,
            "text": "polymicrobial biofilm development",
            "probability": 0.00439453125
        },
        {
            "start_logit": -5.81640625,
            "end_logit": 2.6171875,
            "text": "periodontal pathogens",
            "probability": 0.00408172607421875
        },
        {
            "start_logit": -5.578125,
            "end_logit": 2.216796875,
            "text": "disrupts polymicrobial biofilm development",
            "probability": 0.0034770965576171875
        },
        {
            "start_logit": -6.0234375,
            "end_logit": 2.6171875,
            "text": "Oxantel disrupts polymicrobial biofilm development of periodontal pathogens",
            "probability": 0.00331878662109375
        },
        {
            "start_logit": -6.0234375,
            "end_logit": 2.216796875,
            "text": "Oxantel disrupts polymicrobial biofilm development",
            "probability": 0.0022296905517578125
        },
        {
            "start_logit": -6.99609375,
            "end_logit": 2.6171875,
            "text": "ial biofilm development of periodontal pathogens",
            "probability": 0.0012540817260742188
        },
        {
            "start_logit": -7.04296875,
            "end_logit": 2.6171875,
            "text": "icrobial biofilm development of periodontal pathogens",
            "probability": 0.00119781494140625
        },
        {
            "start_logit": -7.0625,
            "end_logit": 2.6171875,
            "text": "of periodontal pathogens",
            "probability": 0.0011739730834960938
        },
        {
            "start_logit": -7.27734375,
            "end_logit": 2.6171875,
            "text": "pathogens",
            "probability": 0.0009474754333496094
        },
        {
            "start_logit": -6.99609375,
            "end_logit": 2.216796875,
            "text": "ial biofilm development",
            "probability": 0.0008392333984375
        },
        {
            "start_logit": -7.04296875,
            "end_logit": 2.216796875,
            "text": "icrobial biofilm development",
            "probability": 0.0008006095886230469
        },
        {
            "start_logit": -7.45703125,
            "end_logit": 2.6171875,
            "text": "robial biofilm development of periodontal pathogens",
            "probability": 0.0007915496826171875
        },
        {
            "start_logit": -7.5859375,
            "end_logit": 2.6171875,
            "text": "development of periodontal pathogens",
            "probability": 0.0006957054138183594
        },
        {
            "start_logit": -7.45703125,
            "end_logit": 2.216796875,
            "text": "robial biofilm development",
            "probability": 0.0005292892456054688
        },
        {
            "start_logit": -7.5859375,
            "end_logit": 2.216796875,
            "text": "development",
            "probability": 0.00046706199645996094
        },
        {
            "start_logit": -0.86669921875,
            "end_logit": -6.75390625,
            "text": "biofilm development of periodontal",
            "probability": 4.887580871582031e-05
        }
    ],
    "5540fbce234c5a7c75000001_1": [
        {
            "start_logit": 9.828125,
            "end_logit": 9.6171875,
            "text": "Chaperone-mediated autophagy",
            "probability": 1.0
        },
        {
            "start_logit": 9.828125,
            "end_logit": -1.5009765625,
            "text": "Chaperone",
            "probability": 1.4960765838623047e-05
        },
        {
            "start_logit": -1.4990234375,
            "end_logit": 9.6171875,
            "text": "autophagy",
            "probability": 1.2099742889404297e-05
        },
        {
            "start_logit": 9.828125,
            "end_logit": -6.38671875,
            "text": "Chaperone-mediated autophagy (CMA) is a selective form of lysosomal degradation",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.828125,
            "end_logit": -6.66015625,
            "text": "Chaperone-mediated autophagy (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.828125,
            "end_logit": -6.6953125,
            "text": "Chaperone-mediated autophagy (CMA) is a selective form of lysosomal",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.828125,
            "end_logit": -7.11328125,
            "text": "Chaperone-mediated autophagy (CMA) is a selective form of lysosomal degradation targeting proteins carrying the KFERQ motif.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.828125,
            "end_logit": -7.26171875,
            "text": "Chaperone-mediated autophagy (CMA)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.828125,
            "end_logit": -7.28515625,
            "text": "Chaperone-mediated",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.16015625,
            "end_logit": 9.6171875,
            "text": "mediated autophagy",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.22265625,
            "end_logit": 9.6171875,
            "text": "-mediated autophagy",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.828125,
            "end_logit": -7.4375,
            "text": "Chaperone-mediated autophagy (CMA) is",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.828125,
            "end_logit": -7.5859375,
            "text": "Chaperone-",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.828125,
            "end_logit": -7.86328125,
            "text": "Chaperone-mediated autophagy (CMA",
            "probability": 0.0
        },
        {
            "start_logit": 9.828125,
            "end_logit": -7.8828125,
            "text": "Chaperone-mediated autophagy (CMA) is a",
            "probability": 0.0
        },
        {
            "start_logit": 9.828125,
            "end_logit": -8.1015625,
            "text": "Chaperone-mediated autophagy (CMA) is a selective form of lysosomal degradation targeting proteins carrying",
            "probability": 0.0
        },
        {
            "start_logit": -1.4990234375,
            "end_logit": -6.38671875,
            "text": "autophagy (CMA) is a selective form of lysosomal degradation",
            "probability": 0.0
        },
        {
            "start_logit": -1.4990234375,
            "end_logit": -6.66015625,
            "text": "autophagy (",
            "probability": 0.0
        },
        {
            "start_logit": -1.4990234375,
            "end_logit": -6.6953125,
            "text": "autophagy (CMA) is a selective form of lysosomal",
            "probability": 0.0
        },
        {
            "start_logit": -1.4990234375,
            "end_logit": -7.11328125,
            "text": "autophagy (CMA) is a selective form of lysosomal degradation targeting proteins carrying the KFERQ motif.",
            "probability": 0.0
        }
    ],
    "5540fbce234c5a7c75000001_2": [
        {
            "start_logit": 9.828125,
            "end_logit": 9.6171875,
            "text": "Chaperone-mediated autophagy",
            "probability": 1.0
        },
        {
            "start_logit": 9.828125,
            "end_logit": -1.5009765625,
            "text": "Chaperone",
            "probability": 1.4960765838623047e-05
        },
        {
            "start_logit": -1.4990234375,
            "end_logit": 9.6171875,
            "text": "autophagy",
            "probability": 1.2099742889404297e-05
        },
        {
            "start_logit": 9.828125,
            "end_logit": -6.38671875,
            "text": "Chaperone-mediated autophagy (CMA) is a selective form of lysosomal degradation",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.828125,
            "end_logit": -6.66015625,
            "text": "Chaperone-mediated autophagy (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.828125,
            "end_logit": -6.6953125,
            "text": "Chaperone-mediated autophagy (CMA) is a selective form of lysosomal",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.828125,
            "end_logit": -7.11328125,
            "text": "Chaperone-mediated autophagy (CMA) is a selective form of lysosomal degradation targeting proteins carrying the KFERQ motif.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.828125,
            "end_logit": -7.26171875,
            "text": "Chaperone-mediated autophagy (CMA)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.828125,
            "end_logit": -7.28515625,
            "text": "Chaperone-mediated",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.16015625,
            "end_logit": 9.6171875,
            "text": "mediated autophagy",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.22265625,
            "end_logit": 9.6171875,
            "text": "-mediated autophagy",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.828125,
            "end_logit": -7.4375,
            "text": "Chaperone-mediated autophagy (CMA) is",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.828125,
            "end_logit": -7.5859375,
            "text": "Chaperone-",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.828125,
            "end_logit": -7.86328125,
            "text": "Chaperone-mediated autophagy (CMA",
            "probability": 0.0
        },
        {
            "start_logit": 9.828125,
            "end_logit": -7.8828125,
            "text": "Chaperone-mediated autophagy (CMA) is a",
            "probability": 0.0
        },
        {
            "start_logit": 9.828125,
            "end_logit": -8.1015625,
            "text": "Chaperone-mediated autophagy (CMA) is a selective form of lysosomal degradation targeting proteins carrying",
            "probability": 0.0
        },
        {
            "start_logit": -1.4990234375,
            "end_logit": -6.38671875,
            "text": "autophagy (CMA) is a selective form of lysosomal degradation",
            "probability": 0.0
        },
        {
            "start_logit": -1.4990234375,
            "end_logit": -6.66015625,
            "text": "autophagy (",
            "probability": 0.0
        },
        {
            "start_logit": -1.4990234375,
            "end_logit": -6.6953125,
            "text": "autophagy (CMA) is a selective form of lysosomal",
            "probability": 0.0
        },
        {
            "start_logit": -1.4990234375,
            "end_logit": -7.11328125,
            "text": "autophagy (CMA) is a selective form of lysosomal degradation targeting proteins carrying the KFERQ motif.",
            "probability": 0.0
        }
    ],
    "5540fbce234c5a7c75000001_3": [
        {
            "start_logit": 9.8515625,
            "end_logit": 9.703125,
            "text": "Chaperone-mediated autophagy",
            "probability": 1.0
        },
        {
            "start_logit": 9.8515625,
            "end_logit": -1.4501953125,
            "text": "Chaperone",
            "probability": 1.4185905456542969e-05
        },
        {
            "start_logit": -1.3271484375,
            "end_logit": 9.703125,
            "text": "autophagy",
            "probability": 1.3828277587890625e-05
        },
        {
            "start_logit": 9.8515625,
            "end_logit": -6.98828125,
            "text": "Chaperone-mediated autophagy (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.0625,
            "end_logit": 9.703125,
            "text": "mediated autophagy",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8515625,
            "end_logit": -7.25,
            "text": "Chaperone-mediated",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.140625,
            "end_logit": 9.703125,
            "text": "-mediated autophagy",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8515625,
            "end_logit": -7.47265625,
            "text": "Chaperone-mediated autophagy (CMA) is a selective mechanism for the degradation of soluble cytosolic proteins bearing the sequence KFERQ.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8515625,
            "end_logit": -7.62890625,
            "text": "Chaperone-mediated autophagy (CMA) is",
            "probability": 0.0
        },
        {
            "start_logit": 9.8515625,
            "end_logit": -7.64453125,
            "text": "Chaperone-",
            "probability": 0.0
        },
        {
            "start_logit": 9.8515625,
            "end_logit": -7.671875,
            "text": "Chaperone-mediated autophagy (CMA)",
            "probability": 0.0
        },
        {
            "start_logit": 9.8515625,
            "end_logit": -7.96875,
            "text": "Chaperone-mediated autophagy (CMA) is a",
            "probability": 0.0
        },
        {
            "start_logit": 9.8515625,
            "end_logit": -8.046875,
            "text": "Chaperone-mediated autophagy (CMA",
            "probability": 0.0
        },
        {
            "start_logit": 9.8515625,
            "end_logit": -8.1328125,
            "text": "Chaperone-mediated autophagy (CMA) is a selective mechanism for the degradation of soluble cytosolic proteins bearing",
            "probability": 0.0
        },
        {
            "start_logit": -1.3271484375,
            "end_logit": -6.98828125,
            "text": "autophagy (",
            "probability": 0.0
        },
        {
            "start_logit": -1.3271484375,
            "end_logit": -7.47265625,
            "text": "autophagy (CMA) is a selective mechanism for the degradation of soluble cytosolic proteins bearing the sequence KFERQ.",
            "probability": 0.0
        },
        {
            "start_logit": -1.3271484375,
            "end_logit": -7.62890625,
            "text": "autophagy (CMA) is",
            "probability": 0.0
        },
        {
            "start_logit": -1.3271484375,
            "end_logit": -7.671875,
            "text": "autophagy (CMA)",
            "probability": 0.0
        },
        {
            "start_logit": -1.3271484375,
            "end_logit": -7.96875,
            "text": "autophagy (CMA) is a",
            "probability": 0.0
        },
        {
            "start_logit": -1.3271484375,
            "end_logit": -8.046875,
            "text": "autophagy (CMA",
            "probability": 0.0
        }
    ],
    "5540fbce234c5a7c75000001_4": [
        {
            "start_logit": 9.390625,
            "end_logit": 8.53125,
            "text": "chaperone-mediated autophagy",
            "probability": 1.0
        },
        {
            "start_logit": -0.28662109375,
            "end_logit": 8.53125,
            "text": "Macroautophagy is followed by chaperone-mediated autophagy",
            "probability": 6.252527236938477e-05
        },
        {
            "start_logit": 9.390625,
            "end_logit": -2.330078125,
            "text": "chaperone",
            "probability": 1.9252300262451172e-05
        },
        {
            "start_logit": -3.3125,
            "end_logit": 8.53125,
            "text": "autophagy",
            "probability": 3.039836883544922e-06
        },
        {
            "start_logit": 9.390625,
            "end_logit": -7.5234375,
            "text": "chaperone-mediated autophagy (",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.390625,
            "end_logit": -7.53125,
            "text": "chaperone-mediated",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.390625,
            "end_logit": -7.58203125,
            "text": "chaperone-mediated autophagy (CMA), in which Hsc70 (Heat shock cognate 70) selectively binds proteins with exposed KFERQ motifs and pushes them inside lysosomes",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.390625,
            "end_logit": -7.62890625,
            "text": "chaperone-mediated autophagy (CMA), in which Hsc70 (Heat shock cognate 70) selectively binds proteins with exposed KFERQ motifs and",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.390625,
            "end_logit": -7.7265625,
            "text": "chaperone-mediated autophagy (CMA),",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.390625,
            "end_logit": -7.75,
            "text": "chaperone-mediated autophagy (CMA), in which Hsc70 (Heat shock cognate 70) selectively binds proteins with exposed KFERQ motifs and pushes them inside lysosomes through",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.390625,
            "end_logit": -7.84375,
            "text": "chaperone-",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.390625,
            "end_logit": -7.86328125,
            "text": "chaperone-mediated autophagy (CMA), in which Hsc70 (Heat shock cognate 70) selectively binds proteins with exposed KFERQ motifs and pushes them inside lysosomes through the LAMP-2A",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.30859375,
            "end_logit": 8.53125,
            "text": "-mediated autophagy",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.32421875,
            "end_logit": 8.53125,
            "text": "mediated autophagy",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.59765625,
            "end_logit": 8.53125,
            "text": "by chaperone-mediated autophagy",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.8671875,
            "end_logit": 8.53125,
            "text": "ophagy is followed by chaperone-mediated autophagy",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.94140625,
            "end_logit": 8.53125,
            "text": "autophagy is followed by chaperone-mediated autophagy",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -0.28662109375,
            "end_logit": -2.330078125,
            "text": "Macroautophagy is followed by chaperone",
            "probability": 0.0
        },
        {
            "start_logit": -0.28662109375,
            "end_logit": -3.66796875,
            "text": "Macroautophagy",
            "probability": 0.0
        },
        {
            "start_logit": -0.28662109375,
            "end_logit": -7.5234375,
            "text": "Macroautophagy is followed by chaperone-mediated autophagy (",
            "probability": 0.0
        }
    ],
    "5540fbce234c5a7c75000001_5": [
        {
            "start_logit": 9.390625,
            "end_logit": 8.53125,
            "text": "chaperone-mediated autophagy",
            "probability": 1.0
        },
        {
            "start_logit": -0.28662109375,
            "end_logit": 8.53125,
            "text": "Macroautophagy is followed by chaperone-mediated autophagy",
            "probability": 6.252527236938477e-05
        },
        {
            "start_logit": 9.390625,
            "end_logit": -2.330078125,
            "text": "chaperone",
            "probability": 1.9252300262451172e-05
        },
        {
            "start_logit": -3.3125,
            "end_logit": 8.53125,
            "text": "autophagy",
            "probability": 3.039836883544922e-06
        },
        {
            "start_logit": 9.390625,
            "end_logit": -7.5234375,
            "text": "chaperone-mediated autophagy (",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.390625,
            "end_logit": -7.53125,
            "text": "chaperone-mediated",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.390625,
            "end_logit": -7.58203125,
            "text": "chaperone-mediated autophagy (CMA), in which Hsc70 (Heat shock cognate 70) selectively binds proteins with exposed KFERQ motifs and pushes them inside lysosomes",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.390625,
            "end_logit": -7.62890625,
            "text": "chaperone-mediated autophagy (CMA), in which Hsc70 (Heat shock cognate 70) selectively binds proteins with exposed KFERQ motifs and",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.390625,
            "end_logit": -7.7265625,
            "text": "chaperone-mediated autophagy (CMA),",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.390625,
            "end_logit": -7.75,
            "text": "chaperone-mediated autophagy (CMA), in which Hsc70 (Heat shock cognate 70) selectively binds proteins with exposed KFERQ motifs and pushes them inside lysosomes through",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.390625,
            "end_logit": -7.84375,
            "text": "chaperone-",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.390625,
            "end_logit": -7.86328125,
            "text": "chaperone-mediated autophagy (CMA), in which Hsc70 (Heat shock cognate 70) selectively binds proteins with exposed KFERQ motifs and pushes them inside lysosomes through the LAMP-2A",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.30859375,
            "end_logit": 8.53125,
            "text": "-mediated autophagy",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.32421875,
            "end_logit": 8.53125,
            "text": "mediated autophagy",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.59765625,
            "end_logit": 8.53125,
            "text": "by chaperone-mediated autophagy",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.8671875,
            "end_logit": 8.53125,
            "text": "ophagy is followed by chaperone-mediated autophagy",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.94140625,
            "end_logit": 8.53125,
            "text": "autophagy is followed by chaperone-mediated autophagy",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -0.28662109375,
            "end_logit": -2.330078125,
            "text": "Macroautophagy is followed by chaperone",
            "probability": 0.0
        },
        {
            "start_logit": -0.28662109375,
            "end_logit": -3.66796875,
            "text": "Macroautophagy",
            "probability": 0.0
        },
        {
            "start_logit": -0.28662109375,
            "end_logit": -7.5234375,
            "text": "Macroautophagy is followed by chaperone-mediated autophagy (",
            "probability": 0.0
        }
    ],
    "5540fbce234c5a7c75000001_6": [
        {
            "start_logit": 9.875,
            "end_logit": 9.734375,
            "text": "Chaperone-mediated autophagy",
            "probability": 1.0
        },
        {
            "start_logit": 9.875,
            "end_logit": -1.388671875,
            "text": "Chaperone",
            "probability": 1.4722347259521484e-05
        },
        {
            "start_logit": -1.2802734375,
            "end_logit": 9.734375,
            "text": "autophagy",
            "probability": 1.430511474609375e-05
        },
        {
            "start_logit": 9.875,
            "end_logit": -7.234375,
            "text": "Chaperone-mediated",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.10546875,
            "end_logit": 9.734375,
            "text": "mediated autophagy",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.203125,
            "end_logit": 9.734375,
            "text": "-mediated autophagy",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.875,
            "end_logit": -7.5390625,
            "text": "Chaperone-mediated autophagy (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.875,
            "end_logit": -7.63671875,
            "text": "Chaperone-mediated autophagy (CMA) is a selective mechanism for the degradation of soluble cytosolic proteins bearing the sequence KFERQ.",
            "probability": 0.0
        },
        {
            "start_logit": 9.875,
            "end_logit": -7.78515625,
            "text": "Chaperone-",
            "probability": 0.0
        },
        {
            "start_logit": 9.875,
            "end_logit": -7.83203125,
            "text": "Chaperone-mediated autophagy (CMA) is",
            "probability": 0.0
        },
        {
            "start_logit": 9.875,
            "end_logit": -8.0078125,
            "text": "Chaperone-mediated autophagy (CMA)",
            "probability": 0.0
        },
        {
            "start_logit": -7.9375,
            "end_logit": 9.734375,
            "text": "AIMS: Chaperone-mediated autophagy",
            "probability": 0.0
        },
        {
            "start_logit": 9.875,
            "end_logit": -8.140625,
            "text": "Chaperone-mediated autophagy (CMA) is a",
            "probability": 0.0
        },
        {
            "start_logit": 9.875,
            "end_logit": -8.140625,
            "text": "Chaperone-mediated autophagy (CMA) is a selective mechanism for the degradation of soluble cytosolic proteins bearing",
            "probability": 0.0
        },
        {
            "start_logit": -8.0390625,
            "end_logit": 9.734375,
            "text": ": Chaperone-mediated autophagy",
            "probability": 0.0
        },
        {
            "start_logit": -1.2802734375,
            "end_logit": -7.5390625,
            "text": "autophagy (",
            "probability": 0.0
        },
        {
            "start_logit": -1.2802734375,
            "end_logit": -7.63671875,
            "text": "autophagy (CMA) is a selective mechanism for the degradation of soluble cytosolic proteins bearing the sequence KFERQ.",
            "probability": 0.0
        },
        {
            "start_logit": -1.2802734375,
            "end_logit": -7.83203125,
            "text": "autophagy (CMA) is",
            "probability": 0.0
        },
        {
            "start_logit": -1.2802734375,
            "end_logit": -8.0078125,
            "text": "autophagy (CMA)",
            "probability": 0.0
        },
        {
            "start_logit": -7.9375,
            "end_logit": -1.388671875,
            "text": "AIMS: Chaperone",
            "probability": 0.0
        }
    ],
    "5540fbce234c5a7c75000001_7": [
        {
            "start_logit": 9.8046875,
            "end_logit": 9.71875,
            "text": "Chaperone-mediated autophagy",
            "probability": 1.0
        },
        {
            "start_logit": -1.2724609375,
            "end_logit": 9.71875,
            "text": "autophagy",
            "probability": 1.531839370727539e-05
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -1.5693359375,
            "text": "Chaperone",
            "probability": 1.239776611328125e-05
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -6.53125,
            "text": "Chaperone-mediated autophagy (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -7.21484375,
            "text": "Chaperone-mediated",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.19140625,
            "end_logit": 9.71875,
            "text": "mediated autophagy",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.2265625,
            "end_logit": 9.71875,
            "text": "-mediated autophagy",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -7.55859375,
            "text": "Chaperone-mediated autophagy (CMA)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -7.5625,
            "text": "Chaperone-",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -7.625,
            "text": "Chaperone-mediated autophagy (CMA) is",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -7.94921875,
            "text": "Chaperone-mediated autophagy (CMA) is a",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -8.0078125,
            "text": "Chaperone-mediated autophagy (CMA",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -8.0625,
            "text": "Chaperone-mediated autophagy (CMA) is a selective mechanism for the degradation of soluble cytosolic proteins bearing",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -8.1484375,
            "text": "Chaperone-mediated autophagy (CMA) is a selective mechanism for the degradation of soluble cytosolic proteins bearing the sequence KFERQ",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -8.1796875,
            "text": "Chaperone-mediated autophagy (CMA) is a selective mechanism for the degradation of soluble cytosolic proteins bearing the",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -8.1953125,
            "text": "Chaperone-mediated autophagy (CMA) is a selective mechanism for the degradation of soluble",
            "probability": 0.0
        },
        {
            "start_logit": -1.2724609375,
            "end_logit": -6.53125,
            "text": "autophagy (",
            "probability": 0.0
        },
        {
            "start_logit": -1.2724609375,
            "end_logit": -7.55859375,
            "text": "autophagy (CMA)",
            "probability": 0.0
        },
        {
            "start_logit": -1.2724609375,
            "end_logit": -7.625,
            "text": "autophagy (CMA) is",
            "probability": 0.0
        },
        {
            "start_logit": -1.2724609375,
            "end_logit": -7.94921875,
            "text": "autophagy (CMA) is a",
            "probability": 0.0
        }
    ],
    "5540fbce234c5a7c75000001_8": [
        {
            "start_logit": 9.2578125,
            "end_logit": 8.96875,
            "text": "chaperone-mediated autophagy",
            "probability": 1.0
        },
        {
            "start_logit": -1.466796875,
            "end_logit": 8.96875,
            "text": "Macroautophagy is followed by chaperone-mediated autophagy",
            "probability": 2.2113323211669922e-05
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -2.546875,
            "text": "chaperone",
            "probability": 1.0073184967041016e-05
        },
        {
            "start_logit": -2.671875,
            "end_logit": 8.96875,
            "text": "autophagy",
            "probability": 6.616115570068359e-06
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -7.43359375,
            "text": "chaperone-mediated autophagy (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -7.49609375,
            "text": "chaperone-mediated autophagy (CMA), in which Hsc70 (Heat shock cognate 70) selectively binds proteins with exposed KFERQ motifs and pushes them inside lysosomes",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -7.5390625,
            "text": "chaperone-mediated",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.2890625,
            "end_logit": 8.96875,
            "text": "-mediated autophagy",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.30859375,
            "end_logit": 8.96875,
            "text": "mediated autophagy",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -7.65234375,
            "text": "chaperone-mediated autophagy (CMA), in which Hsc70 (Heat shock cognate 70) selectively binds proteins with exposed KFERQ motifs and pushes them inside lysosomes through",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -7.6953125,
            "text": "chaperone-mediated autophagy (CMA),",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -7.703125,
            "text": "chaperone-mediated autophagy (CMA), in which Hsc70 (Heat shock cognate 70) selectively binds proteins with exposed KFERQ motifs and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -7.74609375,
            "text": "chaperone-mediated autophagy (CMA), in which Hsc70 (Heat shock cognate 70) selectively binds proteins with exposed KFERQ motifs and pushes them inside lysosomes through the LAMP-2A",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -7.85546875,
            "text": "chaperone-mediated autophagy (CMA), in which Hsc70 (Heat shock cognate 70) selectively binds proteins with exposed KFERQ motifs and pushes them inside lysosomes through the LAMP",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.66796875,
            "end_logit": 8.96875,
            "text": "by chaperone-mediated autophagy",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.81640625,
            "end_logit": 8.96875,
            "text": "ophagy is followed by chaperone-mediated autophagy",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.8984375,
            "end_logit": 8.96875,
            "text": "autophagy is followed by chaperone-mediated autophagy",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.466796875,
            "end_logit": -2.546875,
            "text": "Macroautophagy is followed by chaperone",
            "probability": 0.0
        },
        {
            "start_logit": -1.466796875,
            "end_logit": -4.03515625,
            "text": "Macroautophagy",
            "probability": 0.0
        },
        {
            "start_logit": -1.466796875,
            "end_logit": -7.43359375,
            "text": "Macroautophagy is followed by chaperone-mediated autophagy (",
            "probability": 0.0
        }
    ],
    "5ac138aa95d0062724000001_1": [
        {
            "start_logit": 9.46875,
            "end_logit": 9.4296875,
            "text": "N-arginine dibasic convertase",
            "probability": 1.0
        },
        {
            "start_logit": 9.46875,
            "end_logit": 0.5302734375,
            "text": "N-arginine dibasic convertase; Nrdc) is a metalloendopeptidase",
            "probability": 0.00013554096221923828
        },
        {
            "start_logit": -1.9345703125,
            "end_logit": 9.4296875,
            "text": "ase",
            "probability": 1.1146068572998047e-05
        },
        {
            "start_logit": 9.46875,
            "end_logit": -2.19140625,
            "text": "N",
            "probability": 8.940696716308594e-06
        },
        {
            "start_logit": 9.46875,
            "end_logit": -5.92578125,
            "text": "N-arginine dibasic convertase; Nrdc) is a metalloendopeptidase of the M16 family that promotes ectodomain shedding of the precursor forms of various growth factors and cytokines by",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.46875,
            "end_logit": -6.60546875,
            "text": "N-arginine dibasic convertase;",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.78515625,
            "end_logit": 9.4296875,
            "text": "arginine dibasic convertase",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.86328125,
            "end_logit": 9.4296875,
            "text": "convertase",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.8671875,
            "end_logit": 9.4296875,
            "text": "-arginine dibasic convertase",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.46875,
            "end_logit": -7.23046875,
            "text": "N-arginine dibasic convert",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.22265625,
            "end_logit": 9.4296875,
            "text": "dibasic convertase",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.46875,
            "end_logit": -7.265625,
            "text": "N-arginine dibasic convertase; Nrdc) is a metalloendopeptidase of the M16 family that",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.46875,
            "end_logit": -7.26953125,
            "text": "N-arginine dibasic convertase; Nrdc) is a metalloendopeptidase of the M16 family that promotes ectodomain shedding of the precursor forms of various growth factors and cytokines by enhancing",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.28515625,
            "end_logit": 9.4296875,
            "text": "asic convertase",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.29296875,
            "end_logit": 9.4296875,
            "text": "Nardilysin (N-arginine dibasic convertase",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.46875,
            "end_logit": -7.48046875,
            "text": "N-arginine dibasic convertase; Nrdc) is a metalloendopeptidase of the M16 family that promotes",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.46875,
            "end_logit": -7.5390625,
            "text": "N-arginine dibasic",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.46875,
            "end_logit": -7.66015625,
            "text": "N-arginine dib",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.9345703125,
            "end_logit": 0.5302734375,
            "text": "ase; Nrdc) is a metalloendopeptidase",
            "probability": 0.0
        },
        {
            "start_logit": -1.9619140625,
            "end_logit": 0.5302734375,
            "text": "metalloendopeptidase",
            "probability": 0.0
        }
    ],
    "5708a845cf1c32585100000f_1": [
        {
            "start_logit": 7.5,
            "end_logit": 7.9765625,
            "text": "Wnt",
            "probability": 1.0
        },
        {
            "start_logit": 7.5,
            "end_logit": -7.1875,
            "text": "Wnt signaling is known to be important for diverse embryonic and post-natal cellular events and be regulated by the proteins Dishevelled and Axin.",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.5,
            "end_logit": -7.45703125,
            "text": "Wnt signaling",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.5,
            "end_logit": -8.03125,
            "text": "Wnt signaling is",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.5,
            "end_logit": -8.0703125,
            "text": "Wnt signaling is known to be important for diverse embryonic and post-natal cellular events",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.5,
            "end_logit": -8.0703125,
            "text": "Wnt signaling is known to",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.5,
            "end_logit": -8.1015625,
            "text": "Wnt signaling is known to be important for diverse embryonic and post-natal cellular events and",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.5,
            "end_logit": -8.125,
            "text": "Wnt signaling is known to be important for diverse embryonic",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.71484375,
            "end_logit": -7.1875,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -6.71484375,
            "end_logit": -7.1875,
            "text": ". Although Dishevelled is activated by Wnt and involved in signal transduction, it is not clear how Dishevelled-mediated signaling is turned off.",
            "probability": 0.0
        },
        {
            "start_logit": -6.71484375,
            "end_logit": -7.1875,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -6.71484375,
            "end_logit": -7.73046875,
            "text": ". Although Dishevelled is activated by Wnt and involved in signal transduction, it is not clear how Dishevelled-mediated signaling is turned off",
            "probability": 0.0
        },
        {
            "start_logit": -6.71484375,
            "end_logit": -7.875,
            "text": ". Although Dishevelled is activated by Wnt and involved in signal transduction, it is not clear",
            "probability": 0.0
        },
        {
            "start_logit": -6.71484375,
            "end_logit": -7.921875,
            "text": ". Although Dishevelled is activated by Wnt and involved in signal transduction, it is not clear how Dishevelled-mediated signaling is turned",
            "probability": 0.0
        },
        {
            "start_logit": -6.71484375,
            "end_logit": -8.1171875,
            "text": ". Although Dishevelled is activated by Wnt and involved in signal transduction, it is not clear how Dishevelled-mediated signaling is",
            "probability": 0.0
        },
        {
            "start_logit": -7.80078125,
            "end_logit": -7.1875,
            "text": "signal transduction, it is not clear how Dishevelled-mediated signaling is turned off.",
            "probability": 0.0
        },
        {
            "start_logit": -7.8203125,
            "end_logit": -7.1875,
            "text": "turned off.",
            "probability": 0.0
        },
        {
            "start_logit": -7.86328125,
            "end_logit": -7.1875,
            "text": "in signal transduction, it is not clear how Dishevelled-mediated signaling is turned off.",
            "probability": 0.0
        },
        {
            "start_logit": -7.890625,
            "end_logit": -7.1875,
            "text": "by Wnt and involved in signal transduction, it is not clear how Dishevelled-mediated signaling is turned off.",
            "probability": 0.0
        },
        {
            "start_logit": -7.90625,
            "end_logit": -7.1875,
            "text": ", it is not clear how Dishevelled-mediated signaling is turned off.",
            "probability": 0.0
        }
    ],
    "5708a845cf1c32585100000f_2": [
        {
            "start_logit": 8.796875,
            "end_logit": 5.25390625,
            "text": "Wnt signaling",
            "probability": 0.9970703125
        },
        {
            "start_logit": 8.796875,
            "end_logit": -0.53125,
            "text": "Wnt",
            "probability": 0.00307464599609375
        },
        {
            "start_logit": -4.41796875,
            "end_logit": 5.25390625,
            "text": "canonical Wnt signaling",
            "probability": 1.8477439880371094e-06
        },
        {
            "start_logit": 8.796875,
            "end_logit": -8.1484375,
            "text": "Wnt signaling,",
            "probability": 1.4901161193847656e-06
        },
        {
            "start_logit": -6.2265625,
            "end_logit": 5.25390625,
            "text": "signaling",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.703125,
            "end_logit": 5.25390625,
            "text": "via canonical Wnt signaling",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.8046875,
            "end_logit": 5.25390625,
            "text": ". Intriguingly, within the same tissues where Xenopus Dishevelled (Xdsh) controls cell fate via canonical Wnt signaling",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.78125,
            "end_logit": 5.25390625,
            "text": "where Xenopus Dishevelled (Xdsh) controls cell fate via canonical Wnt signaling",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.8046875,
            "end_logit": 5.25390625,
            "text": ") controls cell fate via canonical Wnt signaling",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.83203125,
            "end_logit": 5.25390625,
            "text": "cell fate via canonical Wnt signaling",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.86328125,
            "end_logit": 5.25390625,
            "text": "Dishevelled (Xdsh) controls cell fate via canonical Wnt signaling",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.87109375,
            "end_logit": 5.25390625,
            "text": "controls cell fate via canonical Wnt signaling",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.8984375,
            "end_logit": 5.25390625,
            "text": "Dishevelled protein mediates several diverse biological processes. Intriguingly, within the same tissues where Xenopus Dishevelled (Xdsh) controls cell fate via canonical Wnt signaling",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.91796875,
            "end_logit": 5.25390625,
            "text": "(Xdsh) controls cell fate via canonical Wnt signaling",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.921875,
            "end_logit": 5.25390625,
            "text": "The Dishevelled protein mediates several diverse biological processes. Intriguingly, within the same tissues where Xenopus Dishevelled (Xdsh) controls cell fate via canonical Wnt signaling",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.92578125,
            "end_logit": 5.25390625,
            "text": ", within the same tissues where Xenopus Dishevelled (Xdsh) controls cell fate via canonical Wnt signaling",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.9375,
            "end_logit": 5.25390625,
            "text": "Xenopus Dishevelled (Xdsh) controls cell fate via canonical Wnt signaling",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.953125,
            "end_logit": 5.25390625,
            "text": "evelled (Xdsh) controls cell fate via canonical Wnt signaling",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.97265625,
            "end_logit": 5.25390625,
            "text": "dsh) controls cell fate via canonical Wnt signaling",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -4.41796875,
            "end_logit": -0.53125,
            "text": "canonical Wnt",
            "probability": 0.0
        }
    ],
    "5708a845cf1c32585100000f_3": [
        {
            "start_logit": 8.0078125,
            "end_logit": 8.171875,
            "text": "Wnt",
            "probability": 1.0
        },
        {
            "start_logit": -7.7265625,
            "end_logit": 8.171875,
            "text": ", are highly conserved components of canonical and noncanonical Wnt",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.77734375,
            "end_logit": 8.171875,
            "text": "components of canonical and noncanonical Wnt",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.7890625,
            "end_logit": 8.171875,
            "text": "canonical and noncanonical Wnt",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.0078125,
            "end_logit": -7.640625,
            "text": "Wnt signaling pathways.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.8125,
            "end_logit": 8.171875,
            "text": "humans, are highly conserved components of canonical and noncanonical Wnt",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.82421875,
            "end_logit": 8.171875,
            "text": "been identified in humans, are highly conserved components of canonical and noncanonical Wnt",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.828125,
            "end_logit": 8.171875,
            "text": "have been identified in humans, are highly conserved components of canonical and noncanonical Wnt",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.86328125,
            "end_logit": 8.171875,
            "text": "noncanonical Wnt",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.86328125,
            "end_logit": 8.171875,
            "text": "Dishevelled (DVL) proteins, three of which have been identified in humans, are highly conserved components of canonical and noncanonical Wnt",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.875,
            "end_logit": 8.171875,
            "text": "three of which have been identified in humans, are highly conserved components of canonical and noncanonical Wnt",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.8828125,
            "end_logit": 8.171875,
            "text": "al Wnt",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.89453125,
            "end_logit": 8.171875,
            "text": "which have been identified in humans, are highly conserved components of canonical and noncanonical Wnt",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.8984375,
            "end_logit": 8.171875,
            "text": "of canonical and noncanonical Wnt",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.0078125,
            "end_logit": -7.73828125,
            "text": "Wnt signaling pathways",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.90234375,
            "end_logit": 8.171875,
            "text": "are highly conserved components of canonical and noncanonical Wnt",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.9140625,
            "end_logit": 8.171875,
            "text": "of which have been identified in humans, are highly conserved components of canonical and noncanonical Wnt",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.91796875,
            "end_logit": 8.171875,
            "text": "and noncanonical Wnt",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.0078125,
            "end_logit": -7.953125,
            "text": "Wnt signaling",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.83203125,
            "end_logit": -7.640625,
            "text": ".",
            "probability": 0.0
        }
    ],
    "5acf74460340b9f058000013_1": [
        {
            "start_logit": 9.78125,
            "end_logit": 9.6953125,
            "text": "ABCC11",
            "probability": 1.0
        },
        {
            "start_logit": -1.546875,
            "end_logit": 9.6953125,
            "text": "1",
            "probability": 1.2099742889404297e-05
        },
        {
            "start_logit": 9.78125,
            "end_logit": -1.6455078125,
            "text": "ABC",
            "probability": 1.1920928955078125e-05
        },
        {
            "start_logit": -6.609375,
            "end_logit": 9.6953125,
            "text": "C11",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.78125,
            "end_logit": -7.03125,
            "text": "ABCC1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.4296875,
            "end_logit": 9.6953125,
            "text": "in ABCC11",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.8828125,
            "end_logit": 9.6953125,
            "text": "A single nucleotide polymorphism (SNP) in ABCC11",
            "probability": 0.0
        },
        {
            "start_logit": 9.78125,
            "end_logit": -8.015625,
            "text": "ABCC11 affects the cerumen VOC profiles of",
            "probability": 0.0
        },
        {
            "start_logit": 9.78125,
            "end_logit": -8.0703125,
            "text": "ABCC11 affects the cerumen VOC profiles of individuals from",
            "probability": 0.0
        },
        {
            "start_logit": 9.78125,
            "end_logit": -8.1015625,
            "text": "ABCC11 affects the cerumen VOC profiles of individuals from African, Caucasian, and Asian descent",
            "probability": 0.0
        },
        {
            "start_logit": 9.78125,
            "end_logit": -8.1015625,
            "text": "ABCC11 affects the cerumen VOC profiles of individuals from African,",
            "probability": 0.0
        },
        {
            "start_logit": -8.015625,
            "end_logit": 9.6953125,
            "text": "SNP) in ABCC11",
            "probability": 0.0
        },
        {
            "start_logit": -8.0234375,
            "end_logit": 9.6953125,
            "text": ") in ABCC11",
            "probability": 0.0
        },
        {
            "start_logit": 9.78125,
            "end_logit": -8.1171875,
            "text": "ABCC11 affects",
            "probability": 0.0
        },
        {
            "start_logit": 9.78125,
            "end_logit": -8.1484375,
            "text": "ABCC11 affects the cerumen VOC profiles",
            "probability": 0.0
        },
        {
            "start_logit": -8.0703125,
            "end_logit": 9.6953125,
            "text": "single nucleotide polymorphism (SNP) in ABCC11",
            "probability": 0.0
        },
        {
            "start_logit": 9.78125,
            "end_logit": -8.171875,
            "text": "ABCC11 affects the cerumen VOC profiles of individuals",
            "probability": 0.0
        },
        {
            "start_logit": 9.78125,
            "end_logit": -8.171875,
            "text": "ABCC11 affects the",
            "probability": 0.0
        },
        {
            "start_logit": 9.78125,
            "end_logit": -8.171875,
            "text": "ABCC11 affects the cerumen VOC profiles of individuals from African, Caucasian, and",
            "probability": 0.0
        },
        {
            "start_logit": 9.78125,
            "end_logit": -8.1796875,
            "text": "ABCC11 affects the cerumen VOC profiles of individuals from African, Caucasian, and Asian",
            "probability": 0.0
        }
    ],
    "5acf74460340b9f058000013_2": [
        {
            "start_logit": 9.8984375,
            "end_logit": 9.78125,
            "text": "ABCC11",
            "probability": 1.0
        },
        {
            "start_logit": 9.8984375,
            "end_logit": -1.3349609375,
            "text": "ABC",
            "probability": 1.4722347259521484e-05
        },
        {
            "start_logit": -1.2822265625,
            "end_logit": 9.78125,
            "text": "1",
            "probability": 1.3828277587890625e-05
        },
        {
            "start_logit": -6.35546875,
            "end_logit": 9.78125,
            "text": "C11",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8984375,
            "end_logit": -6.953125,
            "text": "ABCC1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8984375,
            "end_logit": -7.80078125,
            "text": "ABCC11 genotype alone does not predict the type and relative levels of volatiles found in human cerumen, and suggest that other biochemical pathways must",
            "probability": 0.0
        },
        {
            "start_logit": -7.73828125,
            "end_logit": 9.78125,
            "text": "that ABCC11",
            "probability": 0.0
        },
        {
            "start_logit": 9.8984375,
            "end_logit": -7.90234375,
            "text": "ABCC11 genotype alone does not predict the type and relative levels of volatiles found in human cerumen, and",
            "probability": 0.0
        },
        {
            "start_logit": 9.8984375,
            "end_logit": -7.90234375,
            "text": "ABCC11 genotype alone does not predict the type and relative levels of volatiles found in human cerumen, and suggest",
            "probability": 0.0
        },
        {
            "start_logit": -7.7890625,
            "end_logit": 9.78125,
            "text": "Our findings also reveal that ABCC11",
            "probability": 0.0
        },
        {
            "start_logit": 9.8984375,
            "end_logit": -7.91796875,
            "text": "ABCC11 genotype alone does not predict the type and relative levels of volatiles found in human cerumen, and suggest that other",
            "probability": 0.0
        },
        {
            "start_logit": 9.8984375,
            "end_logit": -7.91796875,
            "text": "ABCC11 genotype alone does not predict the type and relative levels of volatiles found in human cerumen, and suggest that other biochemical pathways must be",
            "probability": 0.0
        },
        {
            "start_logit": 9.8984375,
            "end_logit": -7.93359375,
            "text": "ABCC11 genotype alone does not predict the type and relative levels of volatiles found in human cerumen, and suggest that other biochemical pathways must be involved",
            "probability": 0.0
        },
        {
            "start_logit": 9.8984375,
            "end_logit": -7.95703125,
            "text": "ABCC11 genotype alone does",
            "probability": 0.0
        },
        {
            "start_logit": 9.8984375,
            "end_logit": -7.98046875,
            "text": "ABCC11 genotype alone does not predict the type and relative levels of volatiles found in human cerumen, and suggest that other biochemical pathways",
            "probability": 0.0
        },
        {
            "start_logit": 9.8984375,
            "end_logit": -7.99609375,
            "text": "ABCC11 genotype alone",
            "probability": 0.0
        },
        {
            "start_logit": 9.8984375,
            "end_logit": -8.015625,
            "text": "ABCC11 genotype alone does not predict the type and relative levels of volatiles found in human cerumen, and suggest that",
            "probability": 0.0
        },
        {
            "start_logit": 9.8984375,
            "end_logit": -8.0234375,
            "text": "ABCC11 genotype alone does not predict",
            "probability": 0.0
        },
        {
            "start_logit": 9.8984375,
            "end_logit": -8.0625,
            "text": "ABCC11 genotype alone does not predict the type and relative levels of volatiles found in human cerumen,",
            "probability": 0.0
        },
        {
            "start_logit": -7.94921875,
            "end_logit": 9.78125,
            "text": "findings also reveal that ABCC11",
            "probability": 0.0
        }
    ],
    "5acf74460340b9f058000013_3": [
        {
            "start_logit": 9.8828125,
            "end_logit": 9.7421875,
            "text": "ABCC11",
            "probability": 1.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -1.3916015625,
            "text": "ABC",
            "probability": 1.4603137969970703e-05
        },
        {
            "start_logit": -1.3818359375,
            "end_logit": 9.7421875,
            "text": "1",
            "probability": 1.2814998626708984e-05
        },
        {
            "start_logit": -6.375,
            "end_logit": 9.7421875,
            "text": "C11",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -7.1015625,
            "text": "ABCC1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -7.66015625,
            "text": "ABCC11 encodes an ATP-driven efflux pump protein that plays an important function in ceruminous apocrine glands of the auditory canal and the secretion of axillary odor precursors.",
            "probability": 0.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -8.0546875,
            "text": "ABCC11 encodes",
            "probability": 0.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -8.125,
            "text": "ABCC11 encodes an ATP-driven efflux pump protein that plays an important function in ceruminous apocrine glands of",
            "probability": 0.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -8.140625,
            "text": "ABCC11 encodes an ATP-driven efflux pump protein that plays an",
            "probability": 0.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -8.140625,
            "text": "ABCC11 encodes an",
            "probability": 0.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -8.15625,
            "text": "ABCC11 encodes an ATP-driven efflux pump protein that plays",
            "probability": 0.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -8.1796875,
            "text": "ABCC11 encodes an ATP-driven efflux pump protein that plays an important",
            "probability": 0.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -8.1796875,
            "text": "ABCC11 encodes an ATP-driven efflux pump protein that",
            "probability": 0.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -8.1796875,
            "text": "ABCC11 encodes an ATP-driven efflux pump protein that plays an important function in ceruminous apocrine glands of the",
            "probability": 0.0
        },
        {
            "start_logit": -1.3818359375,
            "end_logit": -7.66015625,
            "text": "1 encodes an ATP-driven efflux pump protein that plays an important function in ceruminous apocrine glands of the auditory canal and the secretion of axillary odor precursors.",
            "probability": 0.0
        },
        {
            "start_logit": -1.3818359375,
            "end_logit": -8.0546875,
            "text": "1 encodes",
            "probability": 0.0
        },
        {
            "start_logit": -1.3818359375,
            "end_logit": -8.125,
            "text": "1 encodes an ATP-driven efflux pump protein that plays an important function in ceruminous apocrine glands of",
            "probability": 0.0
        },
        {
            "start_logit": -1.3818359375,
            "end_logit": -8.140625,
            "text": "1 encodes an ATP-driven efflux pump protein that plays an",
            "probability": 0.0
        },
        {
            "start_logit": -1.3818359375,
            "end_logit": -8.140625,
            "text": "1 encodes an",
            "probability": 0.0
        },
        {
            "start_logit": -1.3818359375,
            "end_logit": -8.15625,
            "text": "1 encodes an ATP-driven efflux pump protein that plays",
            "probability": 0.0
        }
    ],
    "5acf74460340b9f058000013_4": [
        {
            "start_logit": 9.734375,
            "end_logit": 9.7578125,
            "text": "ABCC11",
            "probability": 1.0
        },
        {
            "start_logit": -1.3369140625,
            "end_logit": 9.7578125,
            "text": "1",
            "probability": 1.5437602996826172e-05
        },
        {
            "start_logit": 9.734375,
            "end_logit": -1.6669921875,
            "text": "ABC",
            "probability": 1.0848045349121094e-05
        },
        {
            "start_logit": -6.7109375,
            "end_logit": 9.7578125,
            "text": "C11",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.734375,
            "end_logit": -7.015625,
            "text": "ABCC1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.15625,
            "end_logit": 9.7578125,
            "text": "the adenosine triphosphate (ATP) binding cassette, sub-family C, member 11 gene (ABCC11",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.62109375,
            "end_logit": 9.7578125,
            "text": "(ABCC11",
            "probability": 0.0
        },
        {
            "start_logit": 9.734375,
            "end_logit": -7.60546875,
            "text": "ABCC11)",
            "probability": 0.0
        },
        {
            "start_logit": -7.6953125,
            "end_logit": 9.7578125,
            "text": "in the adenosine triphosphate (ATP) binding cassette, sub-family C, member 11 gene (ABCC11",
            "probability": 0.0
        },
        {
            "start_logit": -7.72265625,
            "end_logit": 9.7578125,
            "text": "Recent studies link a single nucleotide polymorphism (SNP) in the adenosine triphosphate (ATP) binding cassette, sub-family C, member 11 gene (ABCC11",
            "probability": 0.0
        },
        {
            "start_logit": 9.734375,
            "end_logit": -7.80078125,
            "text": "ABCC11) to",
            "probability": 0.0
        },
        {
            "start_logit": -7.875,
            "end_logit": 9.7578125,
            "text": "adenosine triphosphate (ATP) binding cassette, sub-family C, member 11 gene (ABCC11",
            "probability": 0.0
        },
        {
            "start_logit": -7.89453125,
            "end_logit": 9.7578125,
            "text": "link a single nucleotide polymorphism (SNP) in the adenosine triphosphate (ATP) binding cassette, sub-family C, member 11 gene (ABCC11",
            "probability": 0.0
        },
        {
            "start_logit": -7.93359375,
            "end_logit": 9.7578125,
            "text": "a single nucleotide polymorphism (SNP) in the adenosine triphosphate (ATP) binding cassette, sub-family C, member 11 gene (ABCC11",
            "probability": 0.0
        },
        {
            "start_logit": 9.734375,
            "end_logit": -7.9375,
            "text": "ABCC11) to the production of different types of axillary odorants",
            "probability": 0.0
        },
        {
            "start_logit": 9.734375,
            "end_logit": -7.94140625,
            "text": "ABCC11) to the production of different types of axillary odorants and",
            "probability": 0.0
        },
        {
            "start_logit": 9.734375,
            "end_logit": -7.9453125,
            "text": "ABCC11) to the production",
            "probability": 0.0
        },
        {
            "start_logit": -7.98046875,
            "end_logit": 9.7578125,
            "text": "single nucleotide polymorphism (SNP) in the adenosine triphosphate (ATP) binding cassette, sub-family C, member 11 gene (ABCC11",
            "probability": 0.0
        },
        {
            "start_logit": -7.99609375,
            "end_logit": 9.7578125,
            "text": ") binding cassette, sub-family C, member 11 gene (ABCC11",
            "probability": 0.0
        },
        {
            "start_logit": -8.0625,
            "end_logit": 9.7578125,
            "text": "(ATP) binding cassette, sub-family C, member 11 gene (ABCC11",
            "probability": 0.0
        }
    ],
    "62265b4a3a8413c653000083_1": [
        {
            "start_logit": 9.09375,
            "end_logit": 5.16015625,
            "text": "Runt-related transcription factor 1 (RUNX1T1) isoforms are involved in adipogenesis.",
            "probability": 0.9990234375
        },
        {
            "start_logit": 9.09375,
            "end_logit": -2.537109375,
            "text": "Run",
            "probability": 0.0004544258117675781
        },
        {
            "start_logit": 0.4970703125,
            "end_logit": 5.16015625,
            "text": ".",
            "probability": 0.0001850128173828125
        },
        {
            "start_logit": 9.09375,
            "end_logit": -4.4765625,
            "text": "Runt-related transcription factor 1",
            "probability": 6.55055046081543e-05
        },
        {
            "start_logit": 9.09375,
            "end_logit": -5.02734375,
            "text": "Runt-related transcription factor 1 (RUNX1T1) isoforms",
            "probability": 3.7550926208496094e-05
        },
        {
            "start_logit": 9.09375,
            "end_logit": -5.74609375,
            "text": "Runt-related transcription factor 1 (RUNX1T1) isoforms are involved in adipogenesis",
            "probability": 1.8358230590820312e-05
        },
        {
            "start_logit": 9.09375,
            "end_logit": -5.87890625,
            "text": "Runt-related transcription factor",
            "probability": 1.621246337890625e-05
        },
        {
            "start_logit": 9.09375,
            "end_logit": -6.0703125,
            "text": "Runt-related transcription factor 1 (",
            "probability": 1.329183578491211e-05
        },
        {
            "start_logit": 9.09375,
            "end_logit": -6.2890625,
            "text": "Runt-related transcription factor 1 (RUNX1T1) isoforms are",
            "probability": 1.0728836059570312e-05
        },
        {
            "start_logit": 9.09375,
            "end_logit": -7.08984375,
            "text": "Runt-related transcription factor 1 (RUNX1T1) isoforms are involved",
            "probability": 4.76837158203125e-06
        },
        {
            "start_logit": 9.09375,
            "end_logit": -7.1484375,
            "text": "Runt-related transcription",
            "probability": 4.5299530029296875e-06
        },
        {
            "start_logit": 9.09375,
            "end_logit": -7.26171875,
            "text": "Runt-related transcription factor 1 (RUNX1T1)",
            "probability": 4.0531158447265625e-06
        },
        {
            "start_logit": 9.09375,
            "end_logit": -7.4296875,
            "text": "Runt-",
            "probability": 3.3974647521972656e-06
        },
        {
            "start_logit": 9.09375,
            "end_logit": -7.53125,
            "text": "Runt",
            "probability": 3.0994415283203125e-06
        },
        {
            "start_logit": 9.09375,
            "end_logit": -7.578125,
            "text": "Runt-related",
            "probability": 2.9206275939941406e-06
        },
        {
            "start_logit": 9.09375,
            "end_logit": -7.578125,
            "text": "Runt-related transcription factor 1 (RUNX1T1) isoforms are involved in",
            "probability": 2.9206275939941406e-06
        },
        {
            "start_logit": -6.54296875,
            "end_logit": 5.16015625,
            "text": "related transcription factor 1 (RUNX1T1) isoforms are involved in adipogenesis.",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.8046875,
            "end_logit": 5.16015625,
            "text": "t-related transcription factor 1 (RUNX1T1) isoforms are involved in adipogenesis.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.19921875,
            "end_logit": 5.16015625,
            "text": "-related transcription factor 1 (RUNX1T1) isoforms are involved in adipogenesis.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.33984375,
            "end_logit": 5.16015625,
            "text": "in adipogenesis.",
            "probability": 5.960464477539063e-08
        }
    ],
    "54e8c7220fc566b149000002_1": [
        {
            "start_logit": -3.642578125,
            "end_logit": 7.61328125,
            "text": "the nucleus",
            "probability": 0.46630859375
        },
        {
            "start_logit": -3.724609375,
            "end_logit": 7.61328125,
            "text": "nucleus",
            "probability": 0.4296875
        },
        {
            "start_logit": -6.35546875,
            "end_logit": 7.61328125,
            "text": "p53 in the nucleus",
            "probability": 0.0309295654296875
        },
        {
            "start_logit": -6.4765625,
            "end_logit": 7.61328125,
            "text": "S100A4 interacts with p53 in the nucleus",
            "probability": 0.02740478515625
        },
        {
            "start_logit": -6.9375,
            "end_logit": 7.61328125,
            "text": "with p53 in the nucleus",
            "probability": 0.0172882080078125
        },
        {
            "start_logit": -7.06640625,
            "end_logit": 7.61328125,
            "text": "in the nucleus",
            "probability": 0.01519775390625
        },
        {
            "start_logit": -7.7265625,
            "end_logit": 7.61328125,
            "text": "4 interacts with p53 in the nucleus",
            "probability": 0.00783538818359375
        },
        {
            "start_logit": -8.0546875,
            "end_logit": 7.61328125,
            "text": "interacts with p53 in the nucleus",
            "probability": 0.005645751953125
        },
        {
            "start_logit": -6.35546875,
            "end_logit": -7.3828125,
            "text": "p53 in",
            "probability": 0.0
        },
        {
            "start_logit": -6.4765625,
            "end_logit": -7.3828125,
            "text": "S100A4 interacts with p53 in",
            "probability": 0.0
        },
        {
            "start_logit": -6.9375,
            "end_logit": -7.3828125,
            "text": "with p53 in",
            "probability": 0.0
        },
        {
            "start_logit": -7.06640625,
            "end_logit": -7.3828125,
            "text": "in",
            "probability": 0.0
        },
        {
            "start_logit": -7.7265625,
            "end_logit": -7.3828125,
            "text": "4 interacts with p53 in",
            "probability": 0.0
        },
        {
            "start_logit": -8.0546875,
            "end_logit": -7.3828125,
            "text": "interacts with p53 in",
            "probability": 0.0
        }
    ],
    "54e8c7220fc566b149000002_2": [
        {
            "start_logit": 1.1201171875,
            "end_logit": 9.2265625,
            "text": "nucleus",
            "probability": 0.96337890625
        },
        {
            "start_logit": -2.38671875,
            "end_logit": 9.2265625,
            "text": "cell nucleus",
            "probability": 0.0289764404296875
        },
        {
            "start_logit": -5.0546875,
            "end_logit": 9.2265625,
            "text": "proximity ligation assay, we show that the interaction takes place in the cell nucleus",
            "probability": 0.002010345458984375
        },
        {
            "start_logit": -5.08984375,
            "end_logit": 9.2265625,
            "text": "the cell nucleus",
            "probability": 0.001941680908203125
        },
        {
            "start_logit": -5.78125,
            "end_logit": 9.2265625,
            "text": "interaction takes place in the cell nucleus",
            "probability": 0.0009717941284179688
        },
        {
            "start_logit": -6.44921875,
            "end_logit": 9.2265625,
            "text": "in the cell nucleus",
            "probability": 0.0004982948303222656
        },
        {
            "start_logit": -6.48828125,
            "end_logit": 9.2265625,
            "text": "the interaction takes place in the cell nucleus",
            "probability": 0.0004794597625732422
        },
        {
            "start_logit": -7.1171875,
            "end_logit": 9.2265625,
            "text": "using proximity ligation assay, we show that the interaction takes place in the cell nucleus",
            "probability": 0.000255584716796875
        },
        {
            "start_logit": -7.1875,
            "end_logit": 9.2265625,
            "text": "that the interaction takes place in the cell nucleus",
            "probability": 0.00023818016052246094
        },
        {
            "start_logit": -7.29296875,
            "end_logit": 9.2265625,
            "text": ", we show that the interaction takes place in the cell nucleus",
            "probability": 0.00021529197692871094
        },
        {
            "start_logit": -7.51953125,
            "end_logit": 9.2265625,
            "text": "we show that the interaction takes place in the cell nucleus",
            "probability": 0.0001703500747680664
        },
        {
            "start_logit": -7.53125,
            "end_logit": 9.2265625,
            "text": "place in the cell nucleus",
            "probability": 0.00016891956329345703
        },
        {
            "start_logit": -7.83984375,
            "end_logit": 9.2265625,
            "text": "ligation assay, we show that the interaction takes place in the cell nucleus",
            "probability": 0.0001245737075805664
        },
        {
            "start_logit": -7.9296875,
            "end_logit": 9.2265625,
            "text": "show that the interaction takes place in the cell nucleus",
            "probability": 0.00011348724365234375
        },
        {
            "start_logit": -7.95703125,
            "end_logit": 9.2265625,
            "text": "takes place in the cell nucleus",
            "probability": 0.0001099705696105957
        },
        {
            "start_logit": 1.1201171875,
            "end_logit": -1.9619140625,
            "text": "nucleus.",
            "probability": 1.329183578491211e-05
        },
        {
            "start_logit": -2.38671875,
            "end_logit": -1.9619140625,
            "text": "cell nucleus.",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -3.916015625,
            "end_logit": -1.9619140625,
            "text": ".",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -5.0546875,
            "end_logit": -1.9619140625,
            "text": "proximity ligation assay, we show that the interaction takes place in the cell nucleus.",
            "probability": 0.0
        },
        {
            "start_logit": -5.08984375,
            "end_logit": -1.9619140625,
            "text": "the cell nucleus.",
            "probability": 0.0
        }
    ],
    "58f0b0c070f9fc6f0f000006_1": [
        {
            "start_logit": 9.7890625,
            "end_logit": 9.6484375,
            "text": "tardive dyskinesia",
            "probability": 1.0
        },
        {
            "start_logit": 9.7890625,
            "end_logit": -1.630859375,
            "text": "tard",
            "probability": 1.2636184692382812e-05
        },
        {
            "start_logit": -1.6357421875,
            "end_logit": 9.6484375,
            "text": "dyskinesia",
            "probability": 1.0967254638671875e-05
        },
        {
            "start_logit": -6.3828125,
            "end_logit": 9.6484375,
            "text": "ive dyskinesia",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.7890625,
            "end_logit": -7.33984375,
            "text": "tardive",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.61328125,
            "end_logit": 9.6484375,
            "text": "treating tardive dyskinesia",
            "probability": 0.0
        },
        {
            "start_logit": -7.875,
            "end_logit": 9.6484375,
            "text": "drug status for treating tardive dyskinesia",
            "probability": 0.0
        },
        {
            "start_logit": -7.92578125,
            "end_logit": 9.6484375,
            "text": "Valbenazine granted breakthrough drug status for treating tardive dyskinesia",
            "probability": 0.0
        },
        {
            "start_logit": -8.03125,
            "end_logit": 9.6484375,
            "text": "status for treating tardive dyskinesia",
            "probability": 0.0
        },
        {
            "start_logit": -8.0390625,
            "end_logit": 9.6484375,
            "text": "ine granted breakthrough drug status for treating tardive dyskinesia",
            "probability": 0.0
        },
        {
            "start_logit": -8.0390625,
            "end_logit": 9.6484375,
            "text": "benazine granted breakthrough drug status for treating tardive dyskinesia",
            "probability": 0.0
        },
        {
            "start_logit": -8.046875,
            "end_logit": 9.6484375,
            "text": "breakthrough drug status for treating tardive dyskinesia",
            "probability": 0.0
        },
        {
            "start_logit": -8.0546875,
            "end_logit": 9.6484375,
            "text": "for treating tardive dyskinesia",
            "probability": 0.0
        },
        {
            "start_logit": -8.0625,
            "end_logit": 9.6484375,
            "text": "nazine granted breakthrough drug status for treating tardive dyskinesia",
            "probability": 0.0
        },
        {
            "start_logit": -8.0859375,
            "end_logit": 9.6484375,
            "text": "zine granted breakthrough drug status for treating tardive dyskinesia",
            "probability": 0.0
        },
        {
            "start_logit": -8.1171875,
            "end_logit": 9.6484375,
            "text": "granted breakthrough drug status for treating tardive dyskinesia",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": 9.6484375,
            "text": "ed breakthrough drug status for treating tardive dyskinesia",
            "probability": 0.0
        },
        {
            "start_logit": -7.61328125,
            "end_logit": -1.630859375,
            "text": "treating tard",
            "probability": 0.0
        },
        {
            "start_logit": -7.875,
            "end_logit": -1.630859375,
            "text": "drug status for treating tard",
            "probability": 0.0
        },
        {
            "start_logit": -7.92578125,
            "end_logit": -1.630859375,
            "text": "Valbenazine granted breakthrough drug status for treating tard",
            "probability": 0.0
        }
    ],
    "5aae6499fcf456587200000c_1": [
        {
            "start_logit": 7.04296875,
            "end_logit": 1.408203125,
            "text": "oxacillin-resistant Staphylococcus aureus",
            "probability": 0.9921875
        },
        {
            "start_logit": 7.04296875,
            "end_logit": -3.814453125,
            "text": "oxacillin-resistant",
            "probability": 0.005329132080078125
        },
        {
            "start_logit": 7.04296875,
            "end_logit": -5.09375,
            "text": "oxa",
            "probability": 0.0014858245849609375
        },
        {
            "start_logit": 7.04296875,
            "end_logit": -6.6171875,
            "text": "oxacillin-resistant Staphylococcus aureus (",
            "probability": 0.00032258033752441406
        },
        {
            "start_logit": 7.04296875,
            "end_logit": -6.796875,
            "text": "oxacillin",
            "probability": 0.0002715587615966797
        },
        {
            "start_logit": -1.64453125,
            "end_logit": 1.408203125,
            "text": "Borderline oxacillin-resistant Staphylococcus aureus",
            "probability": 0.00016736984252929688
        },
        {
            "start_logit": 7.04296875,
            "end_logit": -7.44140625,
            "text": "oxacillin-resistant Staphylococcus aureus (BORSA)",
            "probability": 0.00014209747314453125
        },
        {
            "start_logit": 7.04296875,
            "end_logit": -7.44921875,
            "text": "oxacillin-",
            "probability": 0.00014102458953857422
        },
        {
            "start_logit": 7.04296875,
            "end_logit": -7.78515625,
            "text": "oxacillin-resistant Staphylococcus",
            "probability": 0.00010073184967041016
        },
        {
            "start_logit": 7.04296875,
            "end_logit": -7.94921875,
            "text": "oxacillin-resistant Staphylococcus aureus (BORSA",
            "probability": 8.547306060791016e-05
        },
        {
            "start_logit": -6.671875,
            "end_logit": 1.408203125,
            "text": "cillin-resistant Staphylococcus aureus",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": -1.64453125,
            "end_logit": -3.814453125,
            "text": "Borderline oxacillin-resistant",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": -7.26171875,
            "end_logit": 1.408203125,
            "text": "lin-resistant Staphylococcus aureus",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -7.96484375,
            "end_logit": 1.408203125,
            "text": "-resistant Staphylococcus aureus",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -8.03125,
            "end_logit": 1.408203125,
            "text": "Staphylococcus aureus",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -1.64453125,
            "end_logit": -5.09375,
            "text": "Borderline oxa",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -1.64453125,
            "end_logit": -6.6171875,
            "text": "Borderline oxacillin-resistant Staphylococcus aureus (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.64453125,
            "end_logit": -6.796875,
            "text": "Borderline oxacillin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.64453125,
            "end_logit": -7.44140625,
            "text": "Borderline oxacillin-resistant Staphylococcus aureus (BORSA)",
            "probability": 0.0
        },
        {
            "start_logit": -1.64453125,
            "end_logit": -7.44921875,
            "text": "Borderline oxacillin-",
            "probability": 0.0
        }
    ],
    "5aae6499fcf456587200000c_2": [
        {
            "start_logit": 8.0625,
            "end_logit": 8.125,
            "text": "MRSA",
            "probability": 1.0
        },
        {
            "start_logit": -2.69140625,
            "end_logit": 8.125,
            "text": "oxacillin-resistant Staphylococcus aureus (BORSA) may be misidentified as intrinsically methicillin-resistant Staphylococcus aureus (MRSA",
            "probability": 2.1457672119140625e-05
        },
        {
            "start_logit": 8.0625,
            "end_logit": -4.69921875,
            "text": "MRSA) in the clinical laboratory.",
            "probability": 2.682209014892578e-06
        },
        {
            "start_logit": 8.0625,
            "end_logit": -6.609375,
            "text": "MRSA) in",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -6.90234375,
            "end_logit": 8.125,
            "text": "Borderline oxacillin-resistant Staphylococcus aureus (BORSA) may be misidentified as intrinsically methicillin-resistant Staphylococcus aureus (MRSA",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.171875,
            "end_logit": 8.125,
            "text": "cillin-resistant Staphylococcus aureus (BORSA) may be misidentified as intrinsically methicillin-resistant Staphylococcus aureus (MRSA",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.56640625,
            "end_logit": 8.125,
            "text": "misidentified as intrinsically methicillin-resistant Staphylococcus aureus (MRSA",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.0625,
            "end_logit": -7.7578125,
            "text": "MRSA)",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.0625,
            "end_logit": -7.76953125,
            "text": "MRSA) in the",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.90625,
            "end_logit": 8.125,
            "text": "identified as intrinsically methicillin-resistant Staphylococcus aureus (MRSA",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.0625,
            "end_logit": -7.875,
            "text": "MRSA) in the clinical laboratory",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.9453125,
            "end_logit": 8.125,
            "text": "lin-resistant Staphylococcus aureus (BORSA) may be misidentified as intrinsically methicillin-resistant Staphylococcus aureus (MRSA",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.015625,
            "end_logit": 8.125,
            "text": "Staphylococcus aureus (BORSA) may be misidentified as intrinsically methicillin-resistant Staphylococcus aureus (MRSA",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.046875,
            "end_logit": 8.125,
            "text": "methicillin-resistant Staphylococcus aureus (MRSA",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.0546875,
            "end_logit": 8.125,
            "text": "ified as intrinsically methicillin-resistant Staphylococcus aureus (MRSA",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.0703125,
            "end_logit": 8.125,
            "text": "BORSA) may be misidentified as intrinsically methicillin-resistant Staphylococcus aureus (MRSA",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.09375,
            "end_logit": 8.125,
            "text": "(MRSA",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.1484375,
            "end_logit": 8.125,
            "text": "be misidentified as intrinsically methicillin-resistant Staphylococcus aureus (MRSA",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.1640625,
            "end_logit": 8.125,
            "text": "intrinsically methicillin-resistant Staphylococcus aureus (MRSA",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -2.69140625,
            "end_logit": -4.69921875,
            "text": "oxacillin-resistant Staphylococcus aureus (BORSA) may be misidentified as intrinsically methicillin-resistant Staphylococcus aureus (MRSA) in the clinical laboratory.",
            "probability": 0.0
        }
    ],
    "5aae6499fcf456587200000c_3": [
        {
            "start_logit": 3.751953125,
            "end_logit": -3.6796875,
            "text": "oxacillin-resistant Staphylococcus aureus",
            "probability": 0.6103515625
        },
        {
            "start_logit": 3.751953125,
            "end_logit": -4.921875,
            "text": "oxacillin-resistant",
            "probability": 0.17626953125
        },
        {
            "start_logit": 3.751953125,
            "end_logit": -6.51171875,
            "text": "oxacillin-resistant Staphylococcus aureus (BORSA",
            "probability": 0.03594970703125
        },
        {
            "start_logit": 3.751953125,
            "end_logit": -7.09765625,
            "text": "oxacillin",
            "probability": 0.0200042724609375
        },
        {
            "start_logit": 3.751953125,
            "end_logit": -7.10546875,
            "text": "oxa",
            "probability": 0.0198516845703125
        },
        {
            "start_logit": 3.751953125,
            "end_logit": -7.140625,
            "text": "oxacillin-resistant Staphylococcus aureus (BORSA)",
            "probability": 0.0191650390625
        },
        {
            "start_logit": 3.751953125,
            "end_logit": -7.43359375,
            "text": "oxacillin-resistant Staphylococcus aureus (BORSA) with oxacillin MICs \u22654 mg/L, the in vitro bactericidal activity and pharmacodynamic effect of oxacillin",
            "probability": 0.01428985595703125
        },
        {
            "start_logit": 3.751953125,
            "end_logit": -7.44140625,
            "text": "oxacillin-resistant Staphylococcus aureus (BOR",
            "probability": 0.01418304443359375
        },
        {
            "start_logit": 3.751953125,
            "end_logit": -7.5625,
            "text": "oxacillin-resistant Staphylococcus aureus (BORSA) with oxacillin MICs \u22654 mg/L, the in vitro bactericidal activity and pharmacodynamic effect of oxacillin against clinical BORSA isolates",
            "probability": 0.0125732421875
        },
        {
            "start_logit": 3.751953125,
            "end_logit": -7.56640625,
            "text": "oxacillin-",
            "probability": 0.01251220703125
        },
        {
            "start_logit": 3.751953125,
            "end_logit": -7.62109375,
            "text": "oxacillin-resistant Staphylococcus aureus (BORSA) with oxacillin MICs \u22654 mg/L, the in vitro bactericidal activity and pharmacodynamic effect of oxacillin against",
            "probability": 0.0118560791015625
        },
        {
            "start_logit": 3.751953125,
            "end_logit": -7.66015625,
            "text": "oxacillin-resistant Staphylococcus aureus (BORSA) with oxacillin MICs \u22654 mg/L",
            "probability": 0.0113983154296875
        },
        {
            "start_logit": 3.751953125,
            "end_logit": -7.6796875,
            "text": "oxacillin-resistant Staphylococcus aureus (BORSA) with oxacillin MICs \u22654 mg/L, the in vitro bactericidal activity and pharmacodynamic effect of oxacillin against clinical BORSA isolates was",
            "probability": 0.01117706298828125
        },
        {
            "start_logit": 3.751953125,
            "end_logit": -7.75390625,
            "text": "oxacillin-resistant Staphylococcus aureus (BORSA) with oxacillin MICs \u22654 mg/L,",
            "probability": 0.0104217529296875
        },
        {
            "start_logit": 3.751953125,
            "end_logit": -7.79296875,
            "text": "oxacillin-resistant Staphylococcus aureus (BORSA) with",
            "probability": 0.01001739501953125
        },
        {
            "start_logit": 3.751953125,
            "end_logit": -7.83203125,
            "text": "oxacillin-resistant Staphylococcus aureus (BORSA) with oxacillin MICs \u2265",
            "probability": 0.00963592529296875
        },
        {
            "start_logit": -4.87890625,
            "end_logit": -3.6796875,
            "text": "borderline oxacillin-resistant Staphylococcus aureus",
            "probability": 0.00010877847671508789
        },
        {
            "start_logit": -4.6484375,
            "end_logit": -4.59765625,
            "text": "BORSA) with oxacillin MICs \u22654 mg/L, the in vitro bactericidal activity and pharmacodynamic effect of oxacillin against clinical BORSA isolates was evaluated.",
            "probability": 5.46574592590332e-05
        },
        {
            "start_logit": -4.87890625,
            "end_logit": -4.921875,
            "text": "borderline oxacillin-resistant",
            "probability": 3.165006637573242e-05
        },
        {
            "start_logit": -5.65625,
            "end_logit": -4.59765625,
            "text": ".",
            "probability": 2.008676528930664e-05
        }
    ],
    "5aae6499fcf456587200000c_4": [
        {
            "start_logit": 9.109375,
            "end_logit": 2.2578125,
            "text": "Borderline oxacillin-resistant Staphylococcus aureus",
            "probability": 0.986328125
        },
        {
            "start_logit": 9.109375,
            "end_logit": -2.541015625,
            "text": "Borderline",
            "probability": 0.00814056396484375
        },
        {
            "start_logit": 9.109375,
            "end_logit": -3.921875,
            "text": "Borderline oxacillin-resistant",
            "probability": 0.0020427703857421875
        },
        {
            "start_logit": 9.109375,
            "end_logit": -3.92578125,
            "text": "Borderline oxacillin-resistant Staphylococcus aureus (BORSA) represents a quite poorly understood and inadequately defined phenotype of methicillin resistance.",
            "probability": 0.0020351409912109375
        },
        {
            "start_logit": 9.109375,
            "end_logit": -5.88671875,
            "text": "Borderline oxacillin",
            "probability": 0.0002875328063964844
        },
        {
            "start_logit": 9.109375,
            "end_logit": -6.16796875,
            "text": "Borderline oxacillin-resistant Staphylococcus aureus (BORSA) represents",
            "probability": 0.00021708011627197266
        },
        {
            "start_logit": 0.400634765625,
            "end_logit": 2.2578125,
            "text": "oxacillin-resistant Staphylococcus aureus",
            "probability": 0.00016248226165771484
        },
        {
            "start_logit": 9.109375,
            "end_logit": -7.0703125,
            "text": "Borderline oxacillin-",
            "probability": 8.767843246459961e-05
        },
        {
            "start_logit": 9.109375,
            "end_logit": -7.31640625,
            "text": "Borderline oxacillin-resistant Staphylococcus aureus (",
            "probability": 6.824731826782227e-05
        },
        {
            "start_logit": 9.109375,
            "end_logit": -7.53515625,
            "text": "Borderline oxacillin-resistant Staphylococcus aureus (BORSA) represents a quite poorly understood and inadequately defined phenotype of methicillin resistance",
            "probability": 5.4836273193359375e-05
        },
        {
            "start_logit": 9.109375,
            "end_logit": -7.546875,
            "text": "Borderline oxacillin-resistant Staphylococcus aureus (BORSA) represents a",
            "probability": 5.447864532470703e-05
        },
        {
            "start_logit": 9.109375,
            "end_logit": -7.59375,
            "text": "Borderline oxacillin-resistant Staphylococcus",
            "probability": 5.1975250244140625e-05
        },
        {
            "start_logit": 9.109375,
            "end_logit": -7.6640625,
            "text": "Borderline oxacillin-resistant Staphylococcus aureus (BORSA)",
            "probability": 4.845857620239258e-05
        },
        {
            "start_logit": 9.109375,
            "end_logit": -7.6875,
            "text": "Borderline oxacillin-resistant Staphylococcus aureus (BORSA) represents a quite",
            "probability": 4.7266483306884766e-05
        },
        {
            "start_logit": 9.109375,
            "end_logit": -7.828125,
            "text": "Borderline oxacillin-resistant Staphylococcus aureus (BORSA) represents a quite poorly understood and inadequate",
            "probability": 4.112720489501953e-05
        },
        {
            "start_logit": 9.109375,
            "end_logit": -7.83984375,
            "text": "Borderline oxacil",
            "probability": 4.082918167114258e-05
        },
        {
            "start_logit": 9.109375,
            "end_logit": -7.87109375,
            "text": "Borderline oxacillin-resistant Staphylococcus aureus (BORSA) represents a quite poorly",
            "probability": 3.9517879486083984e-05
        },
        {
            "start_logit": 0.400634765625,
            "end_logit": -3.921875,
            "text": "oxacillin-resistant",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 0.400634765625,
            "end_logit": -3.92578125,
            "text": "oxacillin-resistant Staphylococcus aureus (BORSA) represents a quite poorly understood and inadequately defined phenotype of methicillin resistance.",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -6.64453125,
            "end_logit": 2.2578125,
            "text": "cillin-resistant Staphylococcus aureus",
            "probability": 1.1920928955078125e-07
        }
    ],
    "5aae6499fcf456587200000c_5": [
        {
            "start_logit": 8.5546875,
            "end_logit": -1.7197265625,
            "text": "Borderline",
            "probability": 0.5146484375
        },
        {
            "start_logit": 8.5546875,
            "end_logit": -2.267578125,
            "text": "Borderline oxacillin-resistant Staphylococcus aureus",
            "probability": 0.2978515625
        },
        {
            "start_logit": 8.5546875,
            "end_logit": -3.689453125,
            "text": "Borderline oxacillin-resistant Staphylococcus aureus (BORSA) exhibit",
            "probability": 0.07183837890625
        },
        {
            "start_logit": -0.15283203125,
            "end_logit": 4.3203125,
            "text": ".",
            "probability": 0.03570556640625
        },
        {
            "start_logit": 8.5546875,
            "end_logit": -4.71875,
            "text": "Borderline oxacillin-resistant",
            "probability": 0.0256195068359375
        },
        {
            "start_logit": 8.5546875,
            "end_logit": -5.66796875,
            "text": "Borderline oxacillin-resistant Staphylococcus aureus (BORSA) exhibit oxacillin MIC values of 1-8 microg ml(-1), but lack mecA",
            "probability": 0.009918212890625
        },
        {
            "start_logit": 8.5546875,
            "end_logit": -6.23046875,
            "text": "Borderline oxacillin-resistant Staphylococcus aureus (BORSA) exhibit oxacillin MIC values of 1-8 microg ml(-1)",
            "probability": 0.005649566650390625
        },
        {
            "start_logit": 8.5546875,
            "end_logit": -6.25390625,
            "text": "Borderline oxacillin-resistant Staphylococcus aureus (BORSA) exhibit oxacillin MIC values of 1-8 microg ml(-1),",
            "probability": 0.005519866943359375
        },
        {
            "start_logit": 8.5546875,
            "end_logit": -6.390625,
            "text": "Borderline oxacillin-resistant Staphylococcus aureus (BORSA) exhibit oxacillin MIC values of 1-8 microg ml(-1), but",
            "probability": 0.00481414794921875
        },
        {
            "start_logit": 8.5546875,
            "end_logit": -6.40625,
            "text": "Borderline oxacillin-resistant Staphylococcus aureus (",
            "probability": 0.00473785400390625
        },
        {
            "start_logit": 8.5546875,
            "end_logit": -6.47265625,
            "text": "Borderline oxacillin-resistant Staphylococcus aureus (BORSA)",
            "probability": 0.004436492919921875
        },
        {
            "start_logit": 8.5546875,
            "end_logit": -6.49609375,
            "text": "Borderline oxacillin-resistant Staphylococcus aureus (BORSA) exhibit oxacillin MIC values of 1-8 microg ml(-1), but lack mecA,",
            "probability": 0.004329681396484375
        },
        {
            "start_logit": 8.5546875,
            "end_logit": -6.8203125,
            "text": "Borderline oxacillin",
            "probability": 0.0031337738037109375
        },
        {
            "start_logit": 8.5546875,
            "end_logit": -6.8671875,
            "text": "Borderline oxacillin-resistant Staphylococcus aureus (BORSA) exhibit oxacillin MIC values of 1-8 microg ml(-1), but lack",
            "probability": 0.0029888153076171875
        },
        {
            "start_logit": 8.5546875,
            "end_logit": -6.93359375,
            "text": "Borderline oxacillin-",
            "probability": 0.0027980804443359375
        },
        {
            "start_logit": 8.5546875,
            "end_logit": -7.01953125,
            "text": "Borderline oxacillin-resistant Staphylococcus aureus (BORSA) exhibit oxacillin MIC values of 1",
            "probability": 0.0025653839111328125
        },
        {
            "start_logit": 8.5546875,
            "end_logit": -7.0625,
            "text": "Borderline oxacillin-resistant Staphylococcus",
            "probability": 0.002460479736328125
        },
        {
            "start_logit": -3.611328125,
            "end_logit": 4.3203125,
            "text": "mecA, which encodes the low-affinity penicillin-binding protein (PBP)2a.",
            "probability": 0.001125335693359375
        },
        {
            "start_logit": -5.87109375,
            "end_logit": 4.3203125,
            "text": "lack mecA, which encodes the low-affinity penicillin-binding protein (PBP)2a.",
            "probability": 0.00011676549911499023
        },
        {
            "start_logit": -6.359375,
            "end_logit": 4.3203125,
            "text": "oxacillin MIC values of 1-8 microg ml(-1), but lack mecA, which encodes the low-affinity penicillin-binding protein (PBP)2a.",
            "probability": 7.194280624389648e-05
        }
    ],
    "5aae6499fcf456587200000c_6": [
        {
            "start_logit": 7.61328125,
            "end_logit": 5.1015625,
            "text": "borderline oxacillin resistant Staphylococcus aureus",
            "probability": 0.9990234375
        },
        {
            "start_logit": 0.83837890625,
            "end_logit": 5.1015625,
            "text": "oxacillin resistant Staphylococcus aureus",
            "probability": 0.0011386871337890625
        },
        {
            "start_logit": 7.61328125,
            "end_logit": -4.0625,
            "text": "borderline oxacillin resistant",
            "probability": 0.00010383129119873047
        },
        {
            "start_logit": 7.61328125,
            "end_logit": -4.2578125,
            "text": "borderline",
            "probability": 8.606910705566406e-05
        },
        {
            "start_logit": 7.61328125,
            "end_logit": -5.2578125,
            "text": "borderline oxacillin",
            "probability": 3.165006637573242e-05
        },
        {
            "start_logit": 7.61328125,
            "end_logit": -6.578125,
            "text": "borderline oxacillin resistant Staphylococcus aureus (",
            "probability": 8.404254913330078e-06
        },
        {
            "start_logit": 7.61328125,
            "end_logit": -7.34765625,
            "text": "borderline oxacillin resistant Staphylococcus aureus (BORSA)",
            "probability": 3.933906555175781e-06
        },
        {
            "start_logit": 7.61328125,
            "end_logit": -7.796875,
            "text": "borderline oxacillin resistant Staphylococcus",
            "probability": 2.5033950805664062e-06
        },
        {
            "start_logit": -6.5703125,
            "end_logit": 5.1015625,
            "text": "aureus",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -6.74609375,
            "end_logit": 5.1015625,
            "text": "cillin resistant Staphylococcus aureus",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -7.62890625,
            "end_logit": 5.1015625,
            "text": "lin resistant Staphylococcus aureus",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.98046875,
            "end_logit": 5.1015625,
            "text": "Staphylococcus aureus",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 0.83837890625,
            "end_logit": -4.0625,
            "text": "oxacillin resistant",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 0.83837890625,
            "end_logit": -5.2578125,
            "text": "oxacillin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 0.83837890625,
            "end_logit": -6.578125,
            "text": "oxacillin resistant Staphylococcus aureus (",
            "probability": 0.0
        },
        {
            "start_logit": 0.83837890625,
            "end_logit": -7.34765625,
            "text": "oxacillin resistant Staphylococcus aureus (BORSA)",
            "probability": 0.0
        },
        {
            "start_logit": 0.83837890625,
            "end_logit": -7.796875,
            "text": "oxacillin resistant Staphylococcus",
            "probability": 0.0
        },
        {
            "start_logit": -6.74609375,
            "end_logit": -4.0625,
            "text": "cillin resistant",
            "probability": 0.0
        },
        {
            "start_logit": -7.62890625,
            "end_logit": -4.0625,
            "text": "lin resistant",
            "probability": 0.0
        },
        {
            "start_logit": -6.74609375,
            "end_logit": -5.2578125,
            "text": "cillin",
            "probability": 0.0
        }
    ],
    "5aae6499fcf456587200000c_7": [
        {
            "start_logit": 7.04296875,
            "end_logit": 1.408203125,
            "text": "oxacillin-resistant Staphylococcus aureus",
            "probability": 0.9921875
        },
        {
            "start_logit": 7.04296875,
            "end_logit": -3.814453125,
            "text": "oxacillin-resistant",
            "probability": 0.005329132080078125
        },
        {
            "start_logit": 7.04296875,
            "end_logit": -5.09375,
            "text": "oxa",
            "probability": 0.0014858245849609375
        },
        {
            "start_logit": 7.04296875,
            "end_logit": -6.6171875,
            "text": "oxacillin-resistant Staphylococcus aureus (",
            "probability": 0.00032258033752441406
        },
        {
            "start_logit": 7.04296875,
            "end_logit": -6.796875,
            "text": "oxacillin",
            "probability": 0.0002715587615966797
        },
        {
            "start_logit": -1.64453125,
            "end_logit": 1.408203125,
            "text": "borderline oxacillin-resistant Staphylococcus aureus",
            "probability": 0.00016736984252929688
        },
        {
            "start_logit": 7.04296875,
            "end_logit": -7.44140625,
            "text": "oxacillin-resistant Staphylococcus aureus (BORSA)",
            "probability": 0.00014209747314453125
        },
        {
            "start_logit": 7.04296875,
            "end_logit": -7.44921875,
            "text": "oxacillin-",
            "probability": 0.00014102458953857422
        },
        {
            "start_logit": 7.04296875,
            "end_logit": -7.78515625,
            "text": "oxacillin-resistant Staphylococcus",
            "probability": 0.00010073184967041016
        },
        {
            "start_logit": 7.04296875,
            "end_logit": -7.94921875,
            "text": "oxacillin-resistant Staphylococcus aureus (BORSA",
            "probability": 8.547306060791016e-05
        },
        {
            "start_logit": -6.671875,
            "end_logit": 1.408203125,
            "text": "cillin-resistant Staphylococcus aureus",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": -1.64453125,
            "end_logit": -3.814453125,
            "text": "borderline oxacillin-resistant",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": -7.26171875,
            "end_logit": 1.408203125,
            "text": "lin-resistant Staphylococcus aureus",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -7.96484375,
            "end_logit": 1.408203125,
            "text": "-resistant Staphylococcus aureus",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -8.03125,
            "end_logit": 1.408203125,
            "text": "Staphylococcus aureus",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -1.64453125,
            "end_logit": -5.09375,
            "text": "borderline oxa",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -1.64453125,
            "end_logit": -6.6171875,
            "text": "borderline oxacillin-resistant Staphylococcus aureus (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.64453125,
            "end_logit": -6.796875,
            "text": "borderline oxacillin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.64453125,
            "end_logit": -7.44140625,
            "text": "borderline oxacillin-resistant Staphylococcus aureus (BORSA)",
            "probability": 0.0
        },
        {
            "start_logit": -1.64453125,
            "end_logit": -7.44921875,
            "text": "borderline oxacillin-",
            "probability": 0.0
        }
    ],
    "5aae6499fcf456587200000c_8": [
        {
            "start_logit": 5.2890625,
            "end_logit": 5.99609375,
            "text": "borderline oxacillin-resistant Staphylococcus aureus",
            "probability": 0.919921875
        },
        {
            "start_logit": 2.841796875,
            "end_logit": 5.99609375,
            "text": "oxacillin-resistant Staphylococcus aureus",
            "probability": 0.0797119140625
        },
        {
            "start_logit": 5.2890625,
            "end_logit": -3.81640625,
            "text": "borderline oxacillin-resistant Staphylococcus aureus (",
            "probability": 5.042552947998047e-05
        },
        {
            "start_logit": -6.03515625,
            "end_logit": 5.99609375,
            "text": "aureus",
            "probability": 1.1146068572998047e-05
        },
        {
            "start_logit": 5.2890625,
            "end_logit": -5.4453125,
            "text": "borderline",
            "probability": 9.953975677490234e-06
        },
        {
            "start_logit": 5.2890625,
            "end_logit": -5.66015625,
            "text": "borderline oxacillin-resistant",
            "probability": 7.927417755126953e-06
        },
        {
            "start_logit": -6.5546875,
            "end_logit": 5.99609375,
            "text": "cillin-resistant Staphylococcus aureus",
            "probability": 6.616115570068359e-06
        },
        {
            "start_logit": 5.2890625,
            "end_logit": -5.9375,
            "text": "borderline oxacillin",
            "probability": 6.079673767089844e-06
        },
        {
            "start_logit": 2.841796875,
            "end_logit": -3.81640625,
            "text": "oxacillin-resistant Staphylococcus aureus (",
            "probability": 4.410743713378906e-06
        },
        {
            "start_logit": -7.6015625,
            "end_logit": 5.99609375,
            "text": "lin-resistant Staphylococcus aureus",
            "probability": 2.3245811462402344e-06
        },
        {
            "start_logit": 5.2890625,
            "end_logit": -7.08984375,
            "text": "borderline oxacillin-",
            "probability": 1.9073486328125e-06
        },
        {
            "start_logit": -7.98046875,
            "end_logit": 5.99609375,
            "text": "Staphylococcus aureus",
            "probability": 1.6093254089355469e-06
        },
        {
            "start_logit": -8.0859375,
            "end_logit": 5.99609375,
            "text": "-resistant Staphylococcus aureus",
            "probability": 1.430511474609375e-06
        },
        {
            "start_logit": -8.203125,
            "end_logit": 5.99609375,
            "text": "resistant Staphylococcus aureus",
            "probability": 1.2516975402832031e-06
        },
        {
            "start_logit": 5.2890625,
            "end_logit": -7.55859375,
            "text": "borderline oxacillin-resistant Staphylococcus",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": 5.2890625,
            "end_logit": -7.67578125,
            "text": "borderline oxa",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": 5.2890625,
            "end_logit": -7.796875,
            "text": "borderline oxacillin-resistant Staphylococcus aureus (BORSA",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": 2.841796875,
            "end_logit": -5.66015625,
            "text": "oxacillin-resistant",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 2.841796875,
            "end_logit": -5.9375,
            "text": "oxacillin",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 2.841796875,
            "end_logit": -7.08984375,
            "text": "oxacillin-",
            "probability": 1.7881393432617188e-07
        }
    ],
    "5e46eb7a3f5415952900000d_1": [
        {
            "start_logit": 9.5390625,
            "end_logit": 9.53125,
            "text": "Parkinson's Disease",
            "probability": 1.0
        },
        {
            "start_logit": -1.892578125,
            "end_logit": 9.53125,
            "text": "Disease",
            "probability": 1.0967254638671875e-05
        },
        {
            "start_logit": 9.5390625,
            "end_logit": -2.1015625,
            "text": "Parkinson",
            "probability": 8.940696716308594e-06
        },
        {
            "start_logit": 9.5390625,
            "end_logit": -5.1796875,
            "text": "Parkinson's Disease Rating Scale, and the Quality of Life for Essential Tremor",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -6.59765625,
            "end_logit": 9.53125,
            "text": "'s Disease",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.5390625,
            "end_logit": -7.12109375,
            "text": "Parkinson's",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.1484375,
            "end_logit": 9.53125,
            "text": "s Disease",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.5390625,
            "end_logit": -7.43359375,
            "text": "Parkinson's Disease Rating Scale, and the Quality of Life for Essential Tremor Questionnaire (QUEST) were administered along with kinematic assessment of the treated limb.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.5390625,
            "end_logit": -7.67578125,
            "text": "Parkinson's Disease Rating",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.5390625,
            "end_logit": -7.70703125,
            "text": "Parkinson'",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.78125,
            "end_logit": 9.53125,
            "text": "Unified Parkinson's Disease",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.5390625,
            "end_logit": -7.87109375,
            "text": "Parkinson's Disease Rating Scale",
            "probability": 0.0
        },
        {
            "start_logit": 9.5390625,
            "end_logit": -7.9921875,
            "text": "Parkinson's Disease Rating Scale, and the Quality of Life for Essential Tremor Questionnaire",
            "probability": 0.0
        },
        {
            "start_logit": 9.5390625,
            "end_logit": -8.0078125,
            "text": "Parkinson's Disease Rating Scale, and the Quality of Life for Essential Tremor Questionnaire (QUEST) were administered along",
            "probability": 0.0
        },
        {
            "start_logit": 9.5390625,
            "end_logit": -8.015625,
            "text": "Parkinson's Disease Rating Scale, and the Quality of Life for Essential Tremor Questionnaire (QUEST) were administered along with kinematic assessment of the treated limb",
            "probability": 0.0
        },
        {
            "start_logit": 9.5390625,
            "end_logit": -8.03125,
            "text": "Parkinson's Disease Rating Scale, and the Quality of Life for Essential Tremor Questionnaire (QUEST",
            "probability": 0.0
        },
        {
            "start_logit": 9.5390625,
            "end_logit": -8.03125,
            "text": "Parkinson's Disease Rating Scale, and the Quality of Life for Essential Tremor Questionnaire (QUEST) were",
            "probability": 0.0
        },
        {
            "start_logit": 9.5390625,
            "end_logit": -8.0546875,
            "text": "Parkinson's Disease Rating Scale, and the Quality of Life for Essential Tremor Questionnaire (QUEST) were administered along with",
            "probability": 0.0
        },
        {
            "start_logit": 9.5390625,
            "end_logit": -8.0625,
            "text": "Parkinson's Disease Rating Scale, and",
            "probability": 0.0
        },
        {
            "start_logit": 9.5390625,
            "end_logit": -8.0703125,
            "text": "Parkinson's Disease Rating Scale, and the Quality of Life for Essential Tremor Questionnaire (QUEST) were administered along with kinematic assessment of",
            "probability": 0.0
        }
    ],
    "5e46eb7a3f5415952900000d_2": [
        {
            "start_logit": 9.5625,
            "end_logit": 9.46875,
            "text": "essential tremor",
            "probability": 1.0
        },
        {
            "start_logit": 9.5625,
            "end_logit": -2.11328125,
            "text": "essential",
            "probability": 9.357929229736328e-06
        },
        {
            "start_logit": -2.072265625,
            "end_logit": 9.46875,
            "text": "tremor",
            "probability": 8.881092071533203e-06
        },
        {
            "start_logit": -7.0546875,
            "end_logit": 9.46875,
            "text": "Tremor (FTM) has been used in large trials for essential tremor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.58984375,
            "end_logit": 9.46875,
            "text": "for essential tremor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.77734375,
            "end_logit": 9.46875,
            "text": "for Tremor (FTM) has been used in large trials for essential tremor",
            "probability": 0.0
        },
        {
            "start_logit": -7.78125,
            "end_logit": 9.46875,
            "text": "Clinical Rating Scale for Tremor (FTM) has been used in large trials for essential tremor",
            "probability": 0.0
        },
        {
            "start_logit": -7.828125,
            "end_logit": 9.46875,
            "text": "Scale for Tremor (FTM) has been used in large trials for essential tremor",
            "probability": 0.0
        },
        {
            "start_logit": -7.84765625,
            "end_logit": 9.46875,
            "text": "Rating Scale for Tremor (FTM) has been used in large trials for essential tremor",
            "probability": 0.0
        },
        {
            "start_logit": -7.8515625,
            "end_logit": 9.46875,
            "text": "Fahn-Tolosa-Marin Clinical Rating Scale for Tremor (FTM) has been used in large trials for essential tremor",
            "probability": 0.0
        },
        {
            "start_logit": -7.85546875,
            "end_logit": 9.46875,
            "text": "The Fahn-Tolosa-Marin Clinical Rating Scale for Tremor (FTM) has been used in large trials for essential tremor",
            "probability": 0.0
        },
        {
            "start_logit": -7.859375,
            "end_logit": 9.46875,
            "text": "been used in large trials for essential tremor",
            "probability": 0.0
        },
        {
            "start_logit": -7.86328125,
            "end_logit": 9.46875,
            "text": "Background: The Fahn-Tolosa-Marin Clinical Rating Scale for Tremor (FTM) has been used in large trials for essential tremor",
            "probability": 0.0
        },
        {
            "start_logit": -7.87890625,
            "end_logit": 9.46875,
            "text": "large trials for essential tremor",
            "probability": 0.0
        },
        {
            "start_logit": 9.5625,
            "end_logit": -8.1484375,
            "text": "essential tremor (ET), but its anchors for ratings from 0 to",
            "probability": 0.0
        },
        {
            "start_logit": 9.5625,
            "end_logit": -8.1796875,
            "text": "essential tremor (ET), but its anchors for ratings from 0 to 4 of upper limb tremor are",
            "probability": 0.0
        },
        {
            "start_logit": 9.5625,
            "end_logit": -8.1953125,
            "text": "essential tremor (ET",
            "probability": 0.0
        },
        {
            "start_logit": 9.5625,
            "end_logit": -8.2109375,
            "text": "essential tremor (ET), but its anchors for ratings from 0 to 4 of upper limb tremor",
            "probability": 0.0
        },
        {
            "start_logit": 9.5625,
            "end_logit": -8.2109375,
            "text": "essential tremor (ET), but its anchors for ratings from 0 to 4 of upper limb",
            "probability": 0.0
        },
        {
            "start_logit": 9.5625,
            "end_logit": -8.2109375,
            "text": "essential tremor (ET), but its anchors for ratings from 0 to 4 of upper limb tremor are probably too low",
            "probability": 0.0
        }
    ],
    "5e46eb7a3f5415952900000d_3": [
        {
            "start_logit": 5.33984375,
            "end_logit": 7.8671875,
            "text": "Essential Tremor",
            "probability": 0.98828125
        },
        {
            "start_logit": 0.86181640625,
            "end_logit": 7.8671875,
            "text": "Tremor Rating Scale, the Bain and Findley Clinical Tremor Rating Scale, the Bain and Findley Spirography Scale, the Washington Heights-Inwood Genetic Study of Essential Tremor",
            "probability": 0.0112457275390625
        },
        {
            "start_logit": -4.140625,
            "end_logit": 7.8671875,
            "text": "Tremor",
            "probability": 7.575750350952148e-05
        },
        {
            "start_logit": -7.6171875,
            "end_logit": 7.8671875,
            "text": "Clinical Tremor Rating Scale, the Bain and Findley Spirography Scale, the Washington Heights-Inwood Genetic Study of Essential Tremor",
            "probability": 2.384185791015625e-06
        },
        {
            "start_logit": 0.86181640625,
            "end_logit": -0.76171875,
            "text": "Tremor",
            "probability": 2.0265579223632812e-06
        },
        {
            "start_logit": 0.7900390625,
            "end_logit": -0.76171875,
            "text": "tremor severity scales (the Fahn-Tolosa-Marin Tremor",
            "probability": 1.9073486328125e-06
        },
        {
            "start_logit": 5.33984375,
            "end_logit": -5.6171875,
            "text": "Essential Tremor Rating Scale, and the Tremor Research Group Essential Tremor",
            "probability": 1.3709068298339844e-06
        },
        {
            "start_logit": 5.33984375,
            "end_logit": -6.09375,
            "text": "Essential",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": 0.7900390625,
            "end_logit": -2.306640625,
            "text": "tremor",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 5.33984375,
            "end_logit": -7.66796875,
            "text": "Essential Tremor Rating Scale, and the Tremor Research",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 5.33984375,
            "end_logit": -7.69140625,
            "text": "Essential Tremor Rating Scale, and the Tremor Research Group Essential Tremor Rating Assessment Scale",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 5.33984375,
            "end_logit": -7.796875,
            "text": "Essential Tremor Rating Scale, and the Tremor Research Group Essential Tremor Rating Assessment Scale), one ADL/disability scale (the Bain and Findley Tremor ADL Scale",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 5.33984375,
            "end_logit": -7.81640625,
            "text": "Essential Tremor Rating Scale, and the Tremor Research Group Essential Tremor Rating",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 5.33984375,
            "end_logit": -7.828125,
            "text": "Essential Tremor Rating Scale, and the Tremor Research Group Essential Tremor Rating Assessment Scale)",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 0.7900390625,
            "end_logit": -5.01953125,
            "text": "tremor severity",
            "probability": 0.0
        },
        {
            "start_logit": 0.86181640625,
            "end_logit": -6.09375,
            "text": "Tremor Rating Scale, the Bain and Findley Clinical Tremor Rating Scale, the Bain and Findley Spirography Scale, the Washington Heights-Inwood Genetic Study of Essential",
            "probability": 0.0
        },
        {
            "start_logit": 0.86181640625,
            "end_logit": -6.859375,
            "text": "Tremor Rating Scale, the Bain and Findley Clinical Tremor",
            "probability": 0.0
        },
        {
            "start_logit": 0.7900390625,
            "end_logit": -6.859375,
            "text": "tremor severity scales (the Fahn-Tolosa-Marin Tremor Rating Scale, the Bain and Findley Clinical Tremor",
            "probability": 0.0
        },
        {
            "start_logit": 0.86181640625,
            "end_logit": -7.5703125,
            "text": "Tremor Rating Scale, the Bain and Findley Clinical Tremor Rating Scale",
            "probability": 0.0
        },
        {
            "start_logit": 0.7900390625,
            "end_logit": -7.51953125,
            "text": "tremor severity scales",
            "probability": 0.0
        }
    ],
    "5e46eb7a3f5415952900000d_4": [
        {
            "start_logit": 9.5078125,
            "end_logit": 9.375,
            "text": "essential tremor",
            "probability": 1.0
        },
        {
            "start_logit": 9.5078125,
            "end_logit": -2.220703125,
            "text": "essential",
            "probability": 9.298324584960938e-06
        },
        {
            "start_logit": -2.25390625,
            "end_logit": 9.375,
            "text": "tremor",
            "probability": 7.867813110351562e-06
        },
        {
            "start_logit": -5.046875,
            "end_logit": 9.375,
            "text": "Tremor Rating Scale (TRS) in essential tremor",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 9.5078125,
            "end_logit": -7.6875,
            "text": "essential tremor (ET",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.5078125,
            "end_logit": -7.80859375,
            "text": "essential tremor (ET).",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.75,
            "end_logit": 9.375,
            "text": "in essential tremor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.796875,
            "end_logit": 9.375,
            "text": "The purpose of this study was to evaluate interrater and intrarater reliability of the Fahn-Tolosa-Marin Tremor Rating Scale (TRS) in essential tremor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.8203125,
            "end_logit": 9.375,
            "text": "this study was to evaluate interrater and intrarater reliability of the Fahn-Tolosa-Marin Tremor Rating Scale (TRS) in essential tremor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.84375,
            "end_logit": 9.375,
            "text": "study was to evaluate interrater and intrarater reliability of the Fahn-Tolosa-Marin Tremor Rating Scale (TRS) in essential tremor",
            "probability": 0.0
        },
        {
            "start_logit": 9.5078125,
            "end_logit": -8.015625,
            "text": "essential tremor (ET)",
            "probability": 0.0
        },
        {
            "start_logit": 9.5078125,
            "end_logit": -8.015625,
            "text": "essential tremor (",
            "probability": 0.0
        },
        {
            "start_logit": -7.984375,
            "end_logit": 9.375,
            "text": "purpose of this study was to evaluate interrater and intrarater reliability of the Fahn-Tolosa-Marin Tremor Rating Scale (TRS) in essential tremor",
            "probability": 0.0
        },
        {
            "start_logit": -8.0078125,
            "end_logit": 9.375,
            "text": "the Fahn-Tolosa-Marin Tremor Rating Scale (TRS) in essential tremor",
            "probability": 0.0
        },
        {
            "start_logit": -8.015625,
            "end_logit": 9.375,
            "text": "Fahn-Tolosa-Marin Tremor Rating Scale (TRS) in essential tremor",
            "probability": 0.0
        },
        {
            "start_logit": -8.0703125,
            "end_logit": 9.375,
            "text": "interrater and intrarater reliability of the Fahn-Tolosa-Marin Tremor Rating Scale (TRS) in essential tremor",
            "probability": 0.0
        },
        {
            "start_logit": -8.1015625,
            "end_logit": 9.375,
            "text": "S) in essential tremor",
            "probability": 0.0
        },
        {
            "start_logit": -8.1171875,
            "end_logit": 9.375,
            "text": "(TRS) in essential tremor",
            "probability": 0.0
        },
        {
            "start_logit": -8.125,
            "end_logit": 9.375,
            "text": ") in essential tremor",
            "probability": 0.0
        },
        {
            "start_logit": -8.140625,
            "end_logit": 9.375,
            "text": "Tolosa-Marin Tremor Rating Scale (TRS) in essential tremor",
            "probability": 0.0
        }
    ],
    "5e46eb7a3f5415952900000d_5": [
        {
            "start_logit": 8.7421875,
            "end_logit": 8.9296875,
            "text": "essential tremor",
            "probability": 1.0
        },
        {
            "start_logit": -2.376953125,
            "end_logit": 8.9296875,
            "text": "Tremor Rating Scale in essential tremor",
            "probability": 1.4841556549072266e-05
        },
        {
            "start_logit": -3.03515625,
            "end_logit": 8.9296875,
            "text": "tremor",
            "probability": 7.62939453125e-06
        },
        {
            "start_logit": 8.7421875,
            "end_logit": -3.400390625,
            "text": "essential",
            "probability": 4.410743713378906e-06
        },
        {
            "start_logit": -6.9609375,
            "end_logit": 8.9296875,
            "text": "in essential tremor",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.90625,
            "end_logit": 8.9296875,
            "text": "Assessment of interrater and intrarater reliability of the Fahn-Tolosa-Marin Tremor Rating Scale in essential tremor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.7421875,
            "end_logit": -7.75,
            "text": "essential tremor.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.96875,
            "end_logit": 8.9296875,
            "text": "interrater and intrarater reliability of the Fahn-Tolosa-Marin Tremor Rating Scale in essential tremor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0859375,
            "end_logit": 8.9296875,
            "text": "the Fahn-Tolosa-Marin Tremor Rating Scale in essential tremor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.125,
            "end_logit": 8.9296875,
            "text": "Fahn-Tolosa-Marin Tremor Rating Scale in essential tremor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.140625,
            "end_logit": 8.9296875,
            "text": "Scale in essential tremor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.140625,
            "end_logit": 8.9296875,
            "text": "and intrarater reliability of the Fahn-Tolosa-Marin Tremor Rating Scale in essential tremor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.21875,
            "end_logit": 8.9296875,
            "text": "Tolosa-Marin Tremor Rating Scale in essential tremor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.21875,
            "end_logit": 8.9296875,
            "text": "of interrater and intrarater reliability of the Fahn-Tolosa-Marin Tremor Rating Scale in essential tremor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.376953125,
            "end_logit": -1.046875,
            "text": "Tremor",
            "probability": 0.0
        },
        {
            "start_logit": -2.376953125,
            "end_logit": -3.400390625,
            "text": "Tremor Rating Scale in essential",
            "probability": 0.0
        },
        {
            "start_logit": -7.90625,
            "end_logit": -1.046875,
            "text": "Assessment of interrater and intrarater reliability of the Fahn-Tolosa-Marin Tremor",
            "probability": 0.0
        },
        {
            "start_logit": -7.96875,
            "end_logit": -1.046875,
            "text": "interrater and intrarater reliability of the Fahn-Tolosa-Marin Tremor",
            "probability": 0.0
        },
        {
            "start_logit": -8.0859375,
            "end_logit": -1.046875,
            "text": "the Fahn-Tolosa-Marin Tremor",
            "probability": 0.0
        },
        {
            "start_logit": -8.125,
            "end_logit": -1.046875,
            "text": "Fahn-Tolosa-Marin Tremor",
            "probability": 0.0
        }
    ],
    "5e46eb7a3f5415952900000d_6": [
        {
            "start_logit": 9.6796875,
            "end_logit": 9.46875,
            "text": "Essential Tremor",
            "probability": 1.0
        },
        {
            "start_logit": 9.6796875,
            "end_logit": -1.8759765625,
            "text": "Essential",
            "probability": 1.1742115020751953e-05
        },
        {
            "start_logit": -2.06640625,
            "end_logit": 9.46875,
            "text": "Tremor",
            "probability": 7.867813110351562e-06
        },
        {
            "start_logit": -7.828125,
            "end_logit": 9.46875,
            "text": "the Essential Tremor",
            "probability": 0.0
        },
        {
            "start_logit": 9.6796875,
            "end_logit": -8.09375,
            "text": "Essential Tremor Rating Assessment Scale.",
            "probability": 0.0
        },
        {
            "start_logit": -8.015625,
            "end_logit": 9.46875,
            "text": "Clinical Rating Scale and the Essential Tremor",
            "probability": 0.0
        },
        {
            "start_logit": -8.0234375,
            "end_logit": 9.46875,
            "text": "Comparison of the Fahn-Tolosa-Marin Clinical Rating Scale and the Essential Tremor",
            "probability": 0.0
        },
        {
            "start_logit": -8.0625,
            "end_logit": 9.46875,
            "text": "and the Essential Tremor",
            "probability": 0.0
        },
        {
            "start_logit": -8.0859375,
            "end_logit": 9.46875,
            "text": "Rating Scale and the Essential Tremor",
            "probability": 0.0
        },
        {
            "start_logit": -8.1015625,
            "end_logit": 9.46875,
            "text": "Fahn-Tolosa-Marin Clinical Rating Scale and the Essential Tremor",
            "probability": 0.0
        },
        {
            "start_logit": -8.109375,
            "end_logit": 9.46875,
            "text": "the Fahn-Tolosa-Marin Clinical Rating Scale and the Essential Tremor",
            "probability": 0.0
        },
        {
            "start_logit": -8.1171875,
            "end_logit": 9.46875,
            "text": "Scale and the Essential Tremor",
            "probability": 0.0
        },
        {
            "start_logit": -8.1328125,
            "end_logit": 9.46875,
            "text": "hn-Tolosa-Marin Clinical Rating Scale and the Essential Tremor",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": 9.46875,
            "text": "Tolosa-Marin Clinical Rating Scale and the Essential Tremor",
            "probability": 0.0
        },
        {
            "start_logit": -8.171875,
            "end_logit": 9.46875,
            "text": "Marin Clinical Rating Scale and the Essential Tremor",
            "probability": 0.0
        },
        {
            "start_logit": -7.828125,
            "end_logit": -1.8759765625,
            "text": "the Essential",
            "probability": 0.0
        },
        {
            "start_logit": -8.015625,
            "end_logit": -1.8759765625,
            "text": "Clinical Rating Scale and the Essential",
            "probability": 0.0
        },
        {
            "start_logit": -8.0234375,
            "end_logit": -1.8759765625,
            "text": "Comparison of the Fahn-Tolosa-Marin Clinical Rating Scale and the Essential",
            "probability": 0.0
        },
        {
            "start_logit": -8.0625,
            "end_logit": -1.8759765625,
            "text": "and the Essential",
            "probability": 0.0
        },
        {
            "start_logit": -8.0859375,
            "end_logit": -1.8759765625,
            "text": "Rating Scale and the Essential",
            "probability": 0.0
        }
    ],
    "58f4b1a170f9fc6f0f000010_1": [
        {
            "start_logit": -7.46484375,
            "end_logit": -6.69921875,
            "text": "Amanita phalloides",
            "probability": 0.10601806640625
        },
        {
            "start_logit": -7.50390625,
            "end_logit": -6.69921875,
            "text": "in Amanita phalloides",
            "probability": 0.10198974609375
        },
        {
            "start_logit": -7.46484375,
            "end_logit": -7.3046875,
            "text": "Amanita phalloides poisoning",
            "probability": 0.05810546875
        },
        {
            "start_logit": -8.0625,
            "end_logit": -6.69921875,
            "text": "liver transplantation improves patients' short-term post liver transplantation survival in Amanita phalloides",
            "probability": 0.05810546875
        },
        {
            "start_logit": -7.50390625,
            "end_logit": -7.3046875,
            "text": "in Amanita phalloides poisoning",
            "probability": 0.055450439453125
        },
        {
            "start_logit": -7.46484375,
            "end_logit": -7.41015625,
            "text": "Amanita phal",
            "probability": 0.052093505859375
        },
        {
            "start_logit": -8.171875,
            "end_logit": -6.69921875,
            "text": "liver transplantation survival in Amanita phalloides",
            "probability": 0.052093505859375
        },
        {
            "start_logit": -7.50390625,
            "end_logit": -7.41015625,
            "text": "in Amanita phal",
            "probability": 0.05010986328125
        },
        {
            "start_logit": -8.2265625,
            "end_logit": -6.69921875,
            "text": "anita phalloides",
            "probability": 0.049713134765625
        },
        {
            "start_logit": -8.2421875,
            "end_logit": -6.69921875,
            "text": "patients' short-term post liver transplantation survival in Amanita phalloides",
            "probability": 0.048919677734375
        },
        {
            "start_logit": -8.265625,
            "end_logit": -6.69921875,
            "text": "term post liver transplantation survival in Amanita phalloides",
            "probability": 0.04742431640625
        },
        {
            "start_logit": -8.2734375,
            "end_logit": -6.69921875,
            "text": "transplantation survival in Amanita phalloides",
            "probability": 0.04742431640625
        },
        {
            "start_logit": -7.46484375,
            "end_logit": -7.6953125,
            "text": "Amanita phallo",
            "probability": 0.039337158203125
        },
        {
            "start_logit": -7.50390625,
            "end_logit": -7.6953125,
            "text": "in Amanita phallo",
            "probability": 0.037506103515625
        },
        {
            "start_logit": -7.46484375,
            "end_logit": -7.80859375,
            "text": "Amanita",
            "probability": 0.03497314453125
        },
        {
            "start_logit": -7.46484375,
            "end_logit": -7.84375,
            "text": "Amani",
            "probability": 0.03363037109375
        },
        {
            "start_logit": -7.50390625,
            "end_logit": -7.80859375,
            "text": "in Amanita",
            "probability": 0.03363037109375
        },
        {
            "start_logit": -7.50390625,
            "end_logit": -7.84375,
            "text": "in Amani",
            "probability": 0.0325927734375
        },
        {
            "start_logit": -8.0625,
            "end_logit": -7.3046875,
            "text": "liver transplantation improves patients' short-term post liver transplantation survival in Amanita phalloides poisoning",
            "probability": 0.0318603515625
        },
        {
            "start_logit": -8.0625,
            "end_logit": -7.41015625,
            "text": "liver transplantation improves patients' short-term post liver transplantation survival in Amanita phal",
            "probability": 0.0287628173828125
        }
    ],
    "58aa0c6f396a458e50000008_1": [
        {
            "start_logit": 8.46875,
            "end_logit": 7.96484375,
            "text": "oxytocin",
            "probability": 1.0
        },
        {
            "start_logit": 8.46875,
            "end_logit": -7.5078125,
            "text": "oxytocin (OXT) and its receptor (OXTR) have critical roles in the regulation of pro-social behaviors, including social recognition, pair bonding, parental behavior, and stress-related responses.",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.46875,
            "end_logit": -7.98828125,
            "text": "oxytocin (OXT) and its receptor (OXTR) have critical roles in the regulation of pro-social behaviors, including social recognition, pair bonding",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.46875,
            "end_logit": -8.0078125,
            "text": "oxytocin (OXT) and",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.46875,
            "end_logit": -8.109375,
            "text": "oxytocin (OXT) and its receptor (OXTR) have",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.46875,
            "end_logit": -8.1328125,
            "text": "oxytocin (OXT) and its receptor (OXTR) have critical roles in the regulation",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.46875,
            "end_logit": -8.140625,
            "text": "oxytocin (OXT",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.46875,
            "end_logit": -8.140625,
            "text": "oxytocin (OXT) and its receptor (OXTR",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.46875,
            "end_logit": -8.140625,
            "text": "oxytocin (OXT) and its receptor (OXTR) have critical roles in the regulation of pro-social behaviors, including social recognition, pair bonding, parental behavior, and stress-related responses",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.46875,
            "end_logit": -8.1484375,
            "text": "oxytocin (OXT) and its receptor (OXTR) have critical roles in the regulation of",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.46875,
            "end_logit": -8.1484375,
            "text": "oxytocin (OXT) and its receptor (OXTR) have critical roles in the regulation of pro-social behaviors",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.46875,
            "end_logit": -8.15625,
            "text": "oxytocin (OXT)",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.46875,
            "end_logit": -8.15625,
            "text": "oxytocin (OXT) and its receptor (OXTR) have critical roles in the regulation of pro-social behaviors, including social recognition",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.46875,
            "end_logit": -8.15625,
            "text": "oxytocin (OXT) and its receptor (OXTR) have critical roles",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.46875,
            "end_logit": -8.15625,
            "text": "oxytocin (OXT) and its receptor (OXTR) have critical roles in the regulation of pro-social behaviors, including",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.46875,
            "end_logit": -8.1640625,
            "text": "oxytocin (OXT) and its receptor (OXTR) have critical roles in the regulation of pro-social behaviors, including social recognition, pair bonding,",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.46875,
            "end_logit": -8.171875,
            "text": "oxytocin (OXT) and its receptor (OXTR) have critical roles in the regulation of pro-social behaviors, including social recognition, pair bonding, parental behavior, and stress-related",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.89453125,
            "end_logit": 7.96484375,
            "text": "The neurohypophysial hormone oxytocin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.8984375,
            "end_logit": 7.96484375,
            "text": "hormone oxytocin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.921875,
            "end_logit": 7.96484375,
            "text": "neurohypophysial hormone oxytocin",
            "probability": 5.960464477539063e-08
        }
    ],
    "58aa0c6f396a458e50000008_2": [
        {
            "start_logit": 8.359375,
            "end_logit": 8.09375,
            "text": "oxytocin",
            "probability": 1.0
        },
        {
            "start_logit": 8.359375,
            "end_logit": -7.625,
            "text": "oxytocin has roles in social bonding, energy metabolism, and wound healing contributing to good physical, mental and social health.",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.359375,
            "end_logit": -7.984375,
            "text": "oxytocin has roles in social bonding, energy metabolism, and wound healing",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.359375,
            "end_logit": -8.03125,
            "text": "oxytocin has roles in social bonding, energy metabolism, and wound healing contributing",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.359375,
            "end_logit": -8.0390625,
            "text": "oxytocin has",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.359375,
            "end_logit": -8.0625,
            "text": "oxytocin has roles",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.359375,
            "end_logit": -8.0703125,
            "text": "oxytocin has roles in social bonding, energy metabolism, and",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.359375,
            "end_logit": -8.0703125,
            "text": "oxytocin has roles in social bonding,",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.359375,
            "end_logit": -8.078125,
            "text": "oxytocin has roles in social bonding, energy metabolism, and wound healing contributing to",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.359375,
            "end_logit": -8.09375,
            "text": "oxytocin has roles in",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.359375,
            "end_logit": -8.1015625,
            "text": "oxytocin has roles in social bonding, energy metabolism",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.359375,
            "end_logit": -8.109375,
            "text": "oxytocin has roles in social bonding",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.9453125,
            "end_logit": 8.09375,
            "text": "hormone oxytocin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.97265625,
            "end_logit": 8.09375,
            "text": "Neuropeptide hormone oxytocin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.94140625,
            "end_logit": -7.625,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.765625,
            "end_logit": -7.625,
            "text": "social bonding, energy metabolism, and wound healing contributing to good physical, mental and social health.",
            "probability": 0.0
        },
        {
            "start_logit": -7.9453125,
            "end_logit": -7.625,
            "text": "hormone oxytocin has roles in social bonding, energy metabolism, and wound healing contributing to good physical, mental and social health.",
            "probability": 0.0
        },
        {
            "start_logit": -7.97265625,
            "end_logit": -7.625,
            "text": "Neuropeptide hormone oxytocin has roles in social bonding, energy metabolism, and wound healing contributing to good physical, mental and social health.",
            "probability": 0.0
        },
        {
            "start_logit": -8.0390625,
            "end_logit": -7.625,
            "text": "mental and social health.",
            "probability": 0.0
        },
        {
            "start_logit": -8.046875,
            "end_logit": -7.625,
            "text": ", and wound healing contributing to good physical, mental and social health.",
            "probability": 0.0
        }
    ],
    "58aa0c6f396a458e50000008_3": [
        {
            "start_logit": 8.3359375,
            "end_logit": 8.09375,
            "text": "Oxytocin",
            "probability": 1.0
        },
        {
            "start_logit": 8.3359375,
            "end_logit": -5.85546875,
            "text": "Oxytocin is known as the 'love hormone' due its role in promoting mother-child and pair bonding.",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": 8.3359375,
            "end_logit": -7.82421875,
            "text": "Oxytocin is known as the 'love hormone' due",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.3359375,
            "end_logit": -7.92578125,
            "text": "Oxytocin is known",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.3359375,
            "end_logit": -8.0234375,
            "text": "Oxytocin is known as the 'love hormone",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.3359375,
            "end_logit": -8.0234375,
            "text": "Oxytocin is known as the 'love hormone' due its role in promoting mother-child and",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.3359375,
            "end_logit": -8.0546875,
            "text": "Oxytocin is known as the 'love hormone' due its",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.2890625,
            "end_logit": -5.85546875,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.56640625,
            "end_logit": -5.85546875,
            "text": "mother-child and pair bonding.",
            "probability": 0.0
        },
        {
            "start_logit": -7.69921875,
            "end_logit": -5.85546875,
            "text": "'love hormone' due its role in promoting mother-child and pair bonding.",
            "probability": 0.0
        },
        {
            "start_logit": -7.7734375,
            "end_logit": -5.85546875,
            "text": "known as the 'love hormone' due its role in promoting mother-child and pair bonding.",
            "probability": 0.0
        },
        {
            "start_logit": -7.78125,
            "end_logit": -5.85546875,
            "text": "role in promoting mother-child and pair bonding.",
            "probability": 0.0
        },
        {
            "start_logit": -7.78515625,
            "end_logit": -5.85546875,
            "text": "the 'love hormone' due its role in promoting mother-child and pair bonding.",
            "probability": 0.0
        },
        {
            "start_logit": -7.8125,
            "end_logit": -5.85546875,
            "text": "is known as the 'love hormone' due its role in promoting mother-child and pair bonding.",
            "probability": 0.0
        },
        {
            "start_logit": -7.83203125,
            "end_logit": -5.85546875,
            "text": "promoting mother-child and pair bonding.",
            "probability": 0.0
        },
        {
            "start_logit": -7.86328125,
            "end_logit": -5.85546875,
            "text": "love hormone' due its role in promoting mother-child and pair bonding.",
            "probability": 0.0
        },
        {
            "start_logit": -7.8984375,
            "end_logit": -5.85546875,
            "text": "as the 'love hormone' due its role in promoting mother-child and pair bonding.",
            "probability": 0.0
        },
        {
            "start_logit": -7.96875,
            "end_logit": -5.85546875,
            "text": "pair bonding.",
            "probability": 0.0
        },
        {
            "start_logit": -7.98828125,
            "end_logit": -5.85546875,
            "text": "in promoting mother-child and pair bonding.",
            "probability": 0.0
        },
        {
            "start_logit": -8.015625,
            "end_logit": -5.85546875,
            "text": "' due its role in promoting mother-child and pair bonding.",
            "probability": 0.0
        }
    ],
    "58aa0c6f396a458e50000008_4": [
        {
            "start_logit": 8.359375,
            "end_logit": 8.0234375,
            "text": "oxytocin",
            "probability": 1.0
        },
        {
            "start_logit": 8.359375,
            "end_logit": -6.875,
            "text": "oxytocin (OT) hormone pathway is involved in numerous physiological processes, and one of its receptor genes (OXTR) has been implicated in pair bonding behavior in mammalian lineages.",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.359375,
            "end_logit": -7.796875,
            "text": "oxytocin (OT) hormone pathway is involved in numerous physiological processes, and one of its receptor genes (OXTR",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.359375,
            "end_logit": -7.8359375,
            "text": "oxytocin (OT",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.359375,
            "end_logit": -7.88671875,
            "text": "oxytocin (OT) hormone pathway is involved in numerous physiological processes, and one of its receptor genes (OXTR) has been implicated in pair",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.359375,
            "end_logit": -7.9296875,
            "text": "oxytocin (OT) hormone pathway is involved in numerous physiological processes, and one of its receptor genes (OXTR) has been implicated in pair bonding behavior",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.359375,
            "end_logit": -7.96484375,
            "text": "oxytocin (OT)",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.359375,
            "end_logit": -8.0390625,
            "text": "oxytocin (",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.359375,
            "end_logit": -8.046875,
            "text": "oxytocin (OT) hormone",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.359375,
            "end_logit": -8.0546875,
            "text": "oxytocin (OT) hormone pathway is involved in numerous physiological processes, and",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.359375,
            "end_logit": -8.0625,
            "text": "oxytocin (OT) hormone pathway is involved in numerous physiological processes, and one of its receptor genes (OXTR) has been implicated in pair bonding behavior in mammalian lineages",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.359375,
            "end_logit": -8.0625,
            "text": "oxytocin (OT) hormone pathway is involved in numerous physiological processes, and one",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.359375,
            "end_logit": -8.0703125,
            "text": "oxytocin (OT) hormone pathway is involved in numerous physiological processes, and one of its receptor genes (OXTR) has been implicated in pair bonding behavior in",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.359375,
            "end_logit": -8.0703125,
            "text": "oxytocin (OT) hormone pathway is involved in numerous physiological processes, and one of its receptor genes (OXTR) has been implicated in pair bonding behavior in mammalian",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.359375,
            "end_logit": -8.09375,
            "text": "oxytocin (OT) hormone pathway is",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.359375,
            "end_logit": -8.1015625,
            "text": "oxytocin (OT) hormone pathway is involved in numerous physiological processes, and one of its receptor genes (OXTR) has been implicated in pair bonding",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.359375,
            "end_logit": -8.109375,
            "text": "oxytocin (OT) hormone pathway is involved in numerous physiological processes,",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.359375,
            "end_logit": -8.109375,
            "text": "oxytocin (OT) hormone pathway is involved in numerous physiological processes, and one of",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.8828125,
            "end_logit": 8.0234375,
            "text": "The oxytocin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.53125,
            "end_logit": -6.875,
            "text": ".",
            "probability": 0.0
        }
    ],
    "58aa0c6f396a458e50000008_5": [
        {
            "start_logit": 8.109375,
            "end_logit": 8.3203125,
            "text": "oxytocin",
            "probability": 1.0
        },
        {
            "start_logit": 8.109375,
            "end_logit": -7.984375,
            "text": "oxytocin, a hormone involved in parent-offspring",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.109375,
            "end_logit": -8.046875,
            "text": "oxytocin, a hormone involved in parent-",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.109375,
            "end_logit": -8.0625,
            "text": "oxytocin, a hormone involved in parent-offspring bonding",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.109375,
            "end_logit": -8.0859375,
            "text": "oxytocin, a",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.109375,
            "end_logit": -8.09375,
            "text": "oxytocin, a hormone involved in parent",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.828125,
            "end_logit": -7.984375,
            "text": "in parent-offspring",
            "probability": 0.0
        },
        {
            "start_logit": -7.8828125,
            "end_logit": -7.984375,
            "text": "parent-offspring",
            "probability": 0.0
        },
        {
            "start_logit": -7.828125,
            "end_logit": -8.046875,
            "text": "in parent-",
            "probability": 0.0
        },
        {
            "start_logit": -7.828125,
            "end_logit": -8.0625,
            "text": "in parent-offspring bonding",
            "probability": 0.0
        },
        {
            "start_logit": -7.828125,
            "end_logit": -8.09375,
            "text": "in parent",
            "probability": 0.0
        },
        {
            "start_logit": -7.8828125,
            "end_logit": -8.046875,
            "text": "parent-",
            "probability": 0.0
        },
        {
            "start_logit": -7.8828125,
            "end_logit": -8.0625,
            "text": "parent-offspring bonding",
            "probability": 0.0
        },
        {
            "start_logit": -7.8828125,
            "end_logit": -8.09375,
            "text": "parent",
            "probability": 0.0
        },
        {
            "start_logit": -8.0234375,
            "end_logit": -7.984375,
            "text": "hormone involved in parent-offspring",
            "probability": 0.0
        },
        {
            "start_logit": -8.0234375,
            "end_logit": -8.046875,
            "text": "hormone involved in parent-",
            "probability": 0.0
        },
        {
            "start_logit": -8.0859375,
            "end_logit": -7.984375,
            "text": "involved in parent-offspring",
            "probability": 0.0
        },
        {
            "start_logit": -8.0234375,
            "end_logit": -8.0625,
            "text": "hormone involved in parent-offspring bonding",
            "probability": 0.0
        },
        {
            "start_logit": -8.1015625,
            "end_logit": -7.984375,
            "text": ", a hormone involved in parent-offspring",
            "probability": 0.0
        },
        {
            "start_logit": -8.0234375,
            "end_logit": -8.09375,
            "text": "hormone involved in parent",
            "probability": 0.0
        }
    ],
    "58a5b1fe60087bc10a000024_1": [
        {
            "start_logit": 0.037567138671875,
            "end_logit": 4.69140625,
            "text": "small ubiquitin-like modifier (SUMO) pathway in eukaryotes is an essential post-translational modification required for a variety of cellular processes, development and organelle biogenesis.",
            "probability": 0.20849609375
        },
        {
            "start_logit": 0.0298919677734375,
            "end_logit": 4.69140625,
            "text": ".",
            "probability": 0.206787109375
        },
        {
            "start_logit": 0.029815673828125,
            "end_logit": 4.69140625,
            "text": ". SUMO-conjugating enzyme (Ubc9) is an important conjunction enzyme in the SUMO pathway.",
            "probability": 0.206787109375
        },
        {
            "start_logit": 0.029815673828125,
            "end_logit": 4.69140625,
            "text": ".",
            "probability": 0.206787109375
        },
        {
            "start_logit": -0.40673828125,
            "end_logit": 4.69140625,
            "text": "SUMO-conjugating enzyme (Ubc9) is an important conjunction enzyme in the SUMO pathway.",
            "probability": 0.133544921875
        },
        {
            "start_logit": -1.75,
            "end_logit": 4.69140625,
            "text": "The small ubiquitin-like modifier (SUMO) pathway in eukaryotes is an essential post-translational modification required for a variety of cellular processes, development and organelle biogenesis.",
            "probability": 0.03485107421875
        },
        {
            "start_logit": -6.83203125,
            "end_logit": 4.69140625,
            "text": "in eukaryotes is an essential post-translational modification required for a variety of cellular processes, development and organelle biogenesis.",
            "probability": 0.00021636486053466797
        },
        {
            "start_logit": -6.97265625,
            "end_logit": 4.69140625,
            "text": "important conjunction enzyme in the SUMO pathway.",
            "probability": 0.00018787384033203125
        },
        {
            "start_logit": -7.0,
            "end_logit": 4.69140625,
            "text": "of cellular processes, development and organelle biogenesis. SUMO-conjugating enzyme (Ubc9) is an important conjunction enzyme in the SUMO pathway.",
            "probability": 0.00018274784088134766
        },
        {
            "start_logit": -7.0,
            "end_logit": 4.69140625,
            "text": "of cellular processes, development and organelle biogenesis.",
            "probability": 0.00018274784088134766
        },
        {
            "start_logit": -7.1171875,
            "end_logit": 4.69140625,
            "text": "ubiquitin-like modifier (SUMO) pathway in eukaryotes is an essential post-translational modification required for a variety of cellular processes, development and organelle biogenesis.",
            "probability": 0.00016260147094726562
        },
        {
            "start_logit": -7.17578125,
            "end_logit": 4.69140625,
            "text": "eukaryotes is an essential post-translational modification required for a variety of cellular processes, development and organelle biogenesis.",
            "probability": 0.00015342235565185547
        },
        {
            "start_logit": -7.18359375,
            "end_logit": 4.69140625,
            "text": "a variety of cellular processes, development and organelle biogenesis. SUMO-conjugating enzyme (Ubc9) is an important conjunction enzyme in the SUMO pathway.",
            "probability": 0.00015223026275634766
        },
        {
            "start_logit": -7.18359375,
            "end_logit": 4.69140625,
            "text": "a variety of cellular processes, development and organelle biogenesis.",
            "probability": 0.00015223026275634766
        },
        {
            "start_logit": -7.203125,
            "end_logit": 4.69140625,
            "text": "modification required for a variety of cellular processes, development and organelle biogenesis. SUMO-conjugating enzyme (Ubc9) is an important conjunction enzyme in the SUMO pathway.",
            "probability": 0.00014925003051757812
        },
        {
            "start_logit": -7.203125,
            "end_logit": 4.69140625,
            "text": "modification required for a variety of cellular processes, development and organelle biogenesis.",
            "probability": 0.00014925003051757812
        },
        {
            "start_logit": -7.26953125,
            "end_logit": 4.69140625,
            "text": "for a variety of cellular processes, development and organelle biogenesis. SUMO-conjugating enzyme (Ubc9) is an important conjunction enzyme in the SUMO pathway.",
            "probability": 0.00013971328735351562
        },
        {
            "start_logit": -7.26953125,
            "end_logit": 4.69140625,
            "text": "for a variety of cellular processes, development and organelle biogenesis.",
            "probability": 0.00013971328735351562
        },
        {
            "start_logit": -7.28515625,
            "end_logit": 4.69140625,
            "text": "the SUMO pathway.",
            "probability": 0.00013744831085205078
        },
        {
            "start_logit": -7.31640625,
            "end_logit": 4.69140625,
            "text": "SUMO) pathway in eukaryotes is an essential post-translational modification required for a variety of cellular processes, development and organelle biogenesis.",
            "probability": 0.00013315677642822266
        }
    ],
    "58a5b1fe60087bc10a000024_2": [
        {
            "start_logit": 0.58642578125,
            "end_logit": 5.06640625,
            "text": ".",
            "probability": 0.83935546875
        },
        {
            "start_logit": -1.8076171875,
            "end_logit": 5.06640625,
            "text": "SUMO-conjugating enzyme UBC9 and is a novel target for sumoylation.",
            "probability": 0.0765380859375
        },
        {
            "start_logit": -2.56640625,
            "end_logit": 5.06640625,
            "text": "RAP80 interacts with the SUMO-conjugating enzyme UBC9 and is a novel target for sumoylation.",
            "probability": 0.035888671875
        },
        {
            "start_logit": -2.634765625,
            "end_logit": 5.06640625,
            "text": "UBC9 and is a novel target for sumoylation.",
            "probability": 0.03350830078125
        },
        {
            "start_logit": -4.30078125,
            "end_logit": 5.06640625,
            "text": "sumoylation.",
            "probability": 0.0063323974609375
        },
        {
            "start_logit": -5.8671875,
            "end_logit": 5.06640625,
            "text": "a novel target for sumoylation.",
            "probability": 0.0013227462768554688
        },
        {
            "start_logit": -5.95703125,
            "end_logit": 5.06640625,
            "text": "novel target for sumoylation.",
            "probability": 0.0012083053588867188
        },
        {
            "start_logit": -6.2578125,
            "end_logit": 5.06640625,
            "text": "target for sumoylation.",
            "probability": 0.0008950233459472656
        },
        {
            "start_logit": -6.2734375,
            "end_logit": 5.06640625,
            "text": "C9 and is a novel target for sumoylation.",
            "probability": 0.000881195068359375
        },
        {
            "start_logit": -6.34375,
            "end_logit": 5.06640625,
            "text": "9 and is a novel target for sumoylation.",
            "probability": 0.0008211135864257812
        },
        {
            "start_logit": -6.6171875,
            "end_logit": 5.06640625,
            "text": "ylation.",
            "probability": 0.0006246566772460938
        },
        {
            "start_logit": -6.65625,
            "end_logit": 5.06640625,
            "text": "the SUMO-conjugating enzyme UBC9 and is a novel target for sumoylation.",
            "probability": 0.0006008148193359375
        },
        {
            "start_logit": -6.7421875,
            "end_logit": 5.06640625,
            "text": "conjugating enzyme UBC9 and is a novel target for sumoylation.",
            "probability": 0.0005512237548828125
        },
        {
            "start_logit": -6.8359375,
            "end_logit": 5.06640625,
            "text": "and is a novel target for sumoylation.",
            "probability": 0.0005021095275878906
        },
        {
            "start_logit": -6.84375,
            "end_logit": 5.06640625,
            "text": "for sumoylation.",
            "probability": 0.0004978179931640625
        },
        {
            "start_logit": -6.93359375,
            "end_logit": 5.06640625,
            "text": "80 interacts with the SUMO-conjugating enzyme UBC9 and is a novel target for sumoylation.",
            "probability": 0.0004551410675048828
        },
        {
            "start_logit": -6.99609375,
            "end_logit": 5.06640625,
            "text": "enzyme UBC9 and is a novel target for sumoylation.",
            "probability": 0.0004279613494873047
        },
        {
            "start_logit": -1.8076171875,
            "end_logit": -5.671875,
            "text": "SUMO-conjugating enzyme UBC9 and",
            "probability": 1.6689300537109375e-06
        },
        {
            "start_logit": -2.56640625,
            "end_logit": -5.671875,
            "text": "RAP80 interacts with the SUMO-conjugating enzyme UBC9 and",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": -2.634765625,
            "end_logit": -5.671875,
            "text": "UBC9 and",
            "probability": 7.748603820800781e-07
        }
    ],
    "58a5b1fe60087bc10a000024_3": [
        {
            "start_logit": -3.783203125,
            "end_logit": -4.70703125,
            "text": "E2 SUMO-conjugating enzyme",
            "probability": 0.34375
        },
        {
            "start_logit": -3.783203125,
            "end_logit": -6.1640625,
            "text": "E2 SUMO-conjugating enzyme Ubc9 and a E3 SUMO ligase, PIASy, can enhance",
            "probability": 0.0804443359375
        },
        {
            "start_logit": -3.783203125,
            "end_logit": -6.1953125,
            "text": "E2 SUMO-conjugating enzyme Ubc9 and a E3 SUMO ligase, PIASy, can enhance Ets-1 sumoylation",
            "probability": 0.07794189453125
        },
        {
            "start_logit": -5.29296875,
            "end_logit": -4.70703125,
            "text": "SUMO-conjugating enzyme",
            "probability": 0.076171875
        },
        {
            "start_logit": -3.783203125,
            "end_logit": -6.59765625,
            "text": "E2 SUMO-conjugating enzyme Ubc9 and",
            "probability": 0.051910400390625
        },
        {
            "start_logit": -3.783203125,
            "end_logit": -6.6484375,
            "text": "E2 SUMO-conjugating enzyme Ubc9 and a E3 SUMO ligase, PIASy, can",
            "probability": 0.049530029296875
        },
        {
            "start_logit": -3.783203125,
            "end_logit": -6.671875,
            "text": "E2 SUMO-conjug",
            "probability": 0.04840087890625
        },
        {
            "start_logit": -3.783203125,
            "end_logit": -6.890625,
            "text": "E2 SUMO-conjugating enzyme Ubc9 and a E3 SUMO ligase, PIASy, can enhance Ets-1 sumoylation,",
            "probability": 0.03887939453125
        },
        {
            "start_logit": -3.783203125,
            "end_logit": -7.03515625,
            "text": "E2 SUMO-conjugating enzyme Ubc9 and a",
            "probability": 0.03350830078125
        },
        {
            "start_logit": -3.783203125,
            "end_logit": -7.03515625,
            "text": "E2 SUMO-conjugating",
            "probability": 0.03350830078125
        },
        {
            "start_logit": -3.783203125,
            "end_logit": -7.15234375,
            "text": "E2 SUMO-conjugating enzyme Ubc9 and a E3 SUMO ligase, PIASy, can enhance Ets-1 sumoylation, while",
            "probability": 0.0298004150390625
        },
        {
            "start_logit": -3.783203125,
            "end_logit": -7.15234375,
            "text": "E2 SUMO-conjugating enzyme Ubc9 and a E3 SUMO ligase, PIASy, can enhance Ets-1 sumoylation, while a SUMO protease, SENP1",
            "probability": 0.0298004150390625
        },
        {
            "start_logit": -5.29296875,
            "end_logit": -6.1640625,
            "text": "SUMO-conjugating enzyme Ubc9 and a E3 SUMO ligase, PIASy, can enhance",
            "probability": 0.017791748046875
        },
        {
            "start_logit": -5.29296875,
            "end_logit": -6.1953125,
            "text": "SUMO-conjugating enzyme Ubc9 and a E3 SUMO ligase, PIASy, can enhance Ets-1 sumoylation",
            "probability": 0.0172576904296875
        },
        {
            "start_logit": -6.890625,
            "end_logit": -4.70703125,
            "text": "that the E2 SUMO-conjugating enzyme",
            "probability": 0.01546478271484375
        },
        {
            "start_logit": -7.00390625,
            "end_logit": -4.70703125,
            "text": "sumoylation deficient version (Ets-1 K15R/K227R), as well as WT or mutant proteins of the SUMO pathway, we further demonstrated that the E2 SUMO-conjugating enzyme",
            "probability": 0.01375579833984375
        },
        {
            "start_logit": -5.29296875,
            "end_logit": -6.59765625,
            "text": "SUMO-conjugating enzyme Ubc9 and",
            "probability": 0.0114898681640625
        },
        {
            "start_logit": -5.29296875,
            "end_logit": -6.6484375,
            "text": "SUMO-conjugating enzyme Ubc9 and a E3 SUMO ligase, PIASy, can",
            "probability": 0.01096343994140625
        },
        {
            "start_logit": -5.29296875,
            "end_logit": -6.671875,
            "text": "SUMO-conjug",
            "probability": 0.01062774658203125
        },
        {
            "start_logit": -7.4140625,
            "end_logit": -4.70703125,
            "text": "demonstrated that the E2 SUMO-conjugating enzyme",
            "probability": 0.00909423828125
        }
    ],
    "58a5b1fe60087bc10a000024_4": [
        {
            "start_logit": -5.0234375,
            "end_logit": -2.11328125,
            "text": "E2 SUMO-conjugating enzyme",
            "probability": 0.258544921875
        },
        {
            "start_logit": -2.6484375,
            "end_logit": -5.21484375,
            "text": "SUMO modification is required for stimuli-induced p100 phosphorylation and that",
            "probability": 0.125
        },
        {
            "start_logit": -6.109375,
            "end_logit": -2.11328125,
            "text": "blocking SUMOylation of p100, either by site-directed mutation or by short interfering RNA-targeted diminution of E2 SUMO-conjugating enzyme",
            "probability": 0.08758544921875
        },
        {
            "start_logit": -2.6484375,
            "end_logit": -5.59375,
            "text": "SUMO modification is required for stimuli-induced p100 phosphorylation and",
            "probability": 0.0855712890625
        },
        {
            "start_logit": -6.484375,
            "end_logit": -2.11328125,
            "text": "SUMOylation of p100, either by site-directed mutation or by short interfering RNA-targeted diminution of E2 SUMO-conjugating enzyme",
            "probability": 0.060211181640625
        },
        {
            "start_logit": -2.6484375,
            "end_logit": -6.1953125,
            "text": "SUMO modification is required for stimuli-induced p100 phosphorylation and that blocking SUMOylation of p100,",
            "probability": 0.046875
        },
        {
            "start_logit": -6.828125,
            "end_logit": -2.11328125,
            "text": "SUMO-conjugating enzyme",
            "probability": 0.042694091796875
        },
        {
            "start_logit": -7.0859375,
            "end_logit": -2.11328125,
            "text": "that blocking SUMOylation of p100, either by site-directed mutation or by short interfering RNA-targeted diminution of E2 SUMO-conjugating enzyme",
            "probability": 0.03271484375
        },
        {
            "start_logit": -7.140625,
            "end_logit": -2.11328125,
            "text": "and that blocking SUMOylation of p100, either by site-directed mutation or by short interfering RNA-targeted diminution of E2 SUMO-conjugating enzyme",
            "probability": 0.0312347412109375
        },
        {
            "start_logit": -7.28515625,
            "end_logit": -2.11328125,
            "text": "p100 phosphorylation and that blocking SUMOylation of p100, either by site-directed mutation or by short interfering RNA-targeted diminution of E2 SUMO-conjugating enzyme",
            "probability": 0.0269317626953125
        },
        {
            "start_logit": -7.34765625,
            "end_logit": -2.11328125,
            "text": "of E2 SUMO-conjugating enzyme",
            "probability": 0.0252838134765625
        },
        {
            "start_logit": -7.5234375,
            "end_logit": -2.11328125,
            "text": "stimuli-induced p100 phosphorylation and that blocking SUMOylation of p100, either by site-directed mutation or by short interfering RNA-targeted diminution of E2 SUMO-conjugating enzyme",
            "probability": 0.0211334228515625
        },
        {
            "start_logit": -2.6484375,
            "end_logit": -7.01171875,
            "text": "SUMO modification is required",
            "probability": 0.02081298828125
        },
        {
            "start_logit": -7.546875,
            "end_logit": -2.11328125,
            "text": "conjugating enzyme",
            "probability": 0.02081298828125
        },
        {
            "start_logit": -7.5625,
            "end_logit": -2.11328125,
            "text": "diminution of E2 SUMO-conjugating enzyme",
            "probability": 0.020477294921875
        },
        {
            "start_logit": -2.6484375,
            "end_logit": -7.0625,
            "text": "SUMO modification is required for stimuli-induced p100 phosphorylation and that blocking",
            "probability": 0.0196990966796875
        },
        {
            "start_logit": -2.6484375,
            "end_logit": -7.0859375,
            "text": "SUMO modification is required for stimuli-induced p100 phosphorylation and that blocking SUMOylation of p100, either",
            "probability": 0.0192413330078125
        },
        {
            "start_logit": -2.6484375,
            "end_logit": -7.09375,
            "text": "SUMO modification is",
            "probability": 0.0190887451171875
        },
        {
            "start_logit": -2.6484375,
            "end_logit": -7.1015625,
            "text": "SUMO modification is required for stimuli-induced p100 phosphorylation and that blocking SUMOylation of p100, either by site-directed mutation or by short interfering RNA-targeted diminution of E2 SUMO-conjug",
            "probability": 0.018951416015625
        },
        {
            "start_logit": -2.6484375,
            "end_logit": -7.19921875,
            "text": "SUMO modification is required for stimuli-induced p100 phosphorylation and that blocking SUMOylation",
            "probability": 0.017242431640625
        }
    ],
    "58a5b1fe60087bc10a000024_5": [
        {
            "start_logit": 5.10546875,
            "end_logit": 6.0078125,
            "text": "SUMO-conjugating enzyme E2 UBC9 mediates viral immediate-early protein SUMOylation in crayfish to facilitate reproduction of white spot syndrome virus.",
            "probability": 0.98095703125
        },
        {
            "start_logit": 1.10546875,
            "end_logit": 6.0078125,
            "text": ".",
            "probability": 0.018035888671875
        },
        {
            "start_logit": 5.10546875,
            "end_logit": -2.416015625,
            "text": "SUMO-conjugating enzyme E2",
            "probability": 0.00021588802337646484
        },
        {
            "start_logit": -3.63671875,
            "end_logit": 6.0078125,
            "text": "SUMOylation in crayfish to facilitate reproduction of white spot syndrome virus.",
            "probability": 0.00015783309936523438
        },
        {
            "start_logit": -3.869140625,
            "end_logit": 6.0078125,
            "text": "protein SUMOylation in crayfish to facilitate reproduction of white spot syndrome virus.",
            "probability": 0.00012493133544921875
        },
        {
            "start_logit": -4.84765625,
            "end_logit": 6.0078125,
            "text": "viral immediate-early protein SUMOylation in crayfish to facilitate reproduction of white spot syndrome virus.",
            "probability": 4.667043685913086e-05
        },
        {
            "start_logit": -5.1640625,
            "end_logit": 6.0078125,
            "text": "facilitate reproduction of white spot syndrome virus.",
            "probability": 3.415346145629883e-05
        },
        {
            "start_logit": 5.10546875,
            "end_logit": -4.6640625,
            "text": "SUMO-conjugating enzyme E2 UBC9 mediates viral immediate-early protein SUMOylation in",
            "probability": 2.276897430419922e-05
        },
        {
            "start_logit": -5.75390625,
            "end_logit": 6.0078125,
            "text": "of white spot syndrome virus.",
            "probability": 1.8894672393798828e-05
        },
        {
            "start_logit": -5.8671875,
            "end_logit": 6.0078125,
            "text": "in crayfish to facilitate reproduction of white spot syndrome virus.",
            "probability": 1.6868114471435547e-05
        },
        {
            "start_logit": -6.1171875,
            "end_logit": 6.0078125,
            "text": "mediates viral immediate-early protein SUMOylation in crayfish to facilitate reproduction of white spot syndrome virus.",
            "probability": 1.3172626495361328e-05
        },
        {
            "start_logit": -6.25390625,
            "end_logit": 6.0078125,
            "text": "ylation in crayfish to facilitate reproduction of white spot syndrome virus.",
            "probability": 1.1444091796875e-05
        },
        {
            "start_logit": 5.10546875,
            "end_logit": -5.3671875,
            "text": "SUMO-conjugating enzyme E2 UBC9 mediates viral immediate-early protein SUMOylation in crayfish",
            "probability": 1.1265277862548828e-05
        },
        {
            "start_logit": 5.10546875,
            "end_logit": -5.59765625,
            "text": "SUMO",
            "probability": 9.000301361083984e-06
        },
        {
            "start_logit": -6.5078125,
            "end_logit": 6.0078125,
            "text": "immediate-early protein SUMOylation in crayfish to facilitate reproduction of white spot syndrome virus.",
            "probability": 8.881092071533203e-06
        },
        {
            "start_logit": -6.6796875,
            "end_logit": 6.0078125,
            "text": "reproduction of white spot syndrome virus.",
            "probability": 7.510185241699219e-06
        },
        {
            "start_logit": -6.69921875,
            "end_logit": 6.0078125,
            "text": "UBC9 mediates viral immediate-early protein SUMOylation in crayfish to facilitate reproduction of white spot syndrome virus.",
            "probability": 7.3909759521484375e-06
        },
        {
            "start_logit": -6.8515625,
            "end_logit": 6.0078125,
            "text": "early protein SUMOylation in crayfish to facilitate reproduction of white spot syndrome virus.",
            "probability": 6.318092346191406e-06
        },
        {
            "start_logit": -6.8671875,
            "end_logit": 6.0078125,
            "text": "to facilitate reproduction of white spot syndrome virus.",
            "probability": 6.198883056640625e-06
        },
        {
            "start_logit": -6.87109375,
            "end_logit": 6.0078125,
            "text": "fish to facilitate reproduction of white spot syndrome virus.",
            "probability": 6.198883056640625e-06
        }
    ],
    "58a5b1fe60087bc10a000024_6": [
        {
            "start_logit": 0.428955078125,
            "end_logit": 0.62890625,
            "text": "E2 SUMO-conjugating enzyme.",
            "probability": 0.5537109375
        },
        {
            "start_logit": 0.428955078125,
            "end_logit": 0.1903076171875,
            "text": "E2 SUMO-conjugating enzyme",
            "probability": 0.35693359375
        },
        {
            "start_logit": -2.396484375,
            "end_logit": 0.62890625,
            "text": ".",
            "probability": 0.032867431640625
        },
        {
            "start_logit": -2.693359375,
            "end_logit": 0.62890625,
            "text": "unique E2 SUMO-conjugating enzyme.",
            "probability": 0.0244140625
        },
        {
            "start_logit": -2.693359375,
            "end_logit": 0.1903076171875,
            "text": "unique E2 SUMO-conjugating enzyme",
            "probability": 0.0157012939453125
        },
        {
            "start_logit": -4.29296875,
            "end_logit": 0.62890625,
            "text": "Tax SUMOylation using a strategy based on the targeting of Ubc9, the unique E2 SUMO-conjugating enzyme.",
            "probability": 0.00492095947265625
        },
        {
            "start_logit": -4.29296875,
            "end_logit": 0.1903076171875,
            "text": "Tax SUMOylation using a strategy based on the targeting of Ubc9, the unique E2 SUMO-conjugating enzyme",
            "probability": 0.003177642822265625
        },
        {
            "start_logit": -4.953125,
            "end_logit": 0.62890625,
            "text": "SUMO-conjugating enzyme.",
            "probability": 0.002544403076171875
        },
        {
            "start_logit": -4.953125,
            "end_logit": 0.1903076171875,
            "text": "SUMO-conjugating enzyme",
            "probability": 0.0016412734985351562
        },
        {
            "start_logit": -6.1171875,
            "end_logit": 0.62890625,
            "text": "SUMOylation using a strategy based on the targeting of Ubc9, the unique E2 SUMO-conjugating enzyme.",
            "probability": 0.0007939338684082031
        },
        {
            "start_logit": -6.1171875,
            "end_logit": 0.1903076171875,
            "text": "SUMOylation using a strategy based on the targeting of Ubc9, the unique E2 SUMO-conjugating enzyme",
            "probability": 0.0005125999450683594
        },
        {
            "start_logit": 0.428955078125,
            "end_logit": -6.4296875,
            "text": "E2 SUMO-conjug",
            "probability": 0.0004761219024658203
        },
        {
            "start_logit": 0.428955078125,
            "end_logit": -6.4453125,
            "text": "E2 SUMO-conjugating",
            "probability": 0.0004687309265136719
        },
        {
            "start_logit": -7.10546875,
            "end_logit": 0.62890625,
            "text": "we revisited the role of Tax SUMOylation using a strategy based on the targeting of Ubc9, the unique E2 SUMO-conjugating enzyme.",
            "probability": 0.0002956390380859375
        },
        {
            "start_logit": -7.16796875,
            "end_logit": 0.62890625,
            "text": "study, we revisited the role of Tax SUMOylation using a strategy based on the targeting of Ubc9, the unique E2 SUMO-conjugating enzyme.",
            "probability": 0.0002777576446533203
        },
        {
            "start_logit": -7.19140625,
            "end_logit": 0.62890625,
            "text": "targeting of Ubc9, the unique E2 SUMO-conjugating enzyme.",
            "probability": 0.0002713203430175781
        },
        {
            "start_logit": -7.26953125,
            "end_logit": 0.62890625,
            "text": "on the targeting of Ubc9, the unique E2 SUMO-conjugating enzyme.",
            "probability": 0.00025081634521484375
        },
        {
            "start_logit": -7.28125,
            "end_logit": 0.62890625,
            "text": ", we revisited the role of Tax SUMOylation using a strategy based on the targeting of Ubc9, the unique E2 SUMO-conjugating enzyme.",
            "probability": 0.000247955322265625
        },
        {
            "start_logit": -7.29296875,
            "end_logit": 0.62890625,
            "text": "the role of Tax SUMOylation using a strategy based on the targeting of Ubc9, the unique E2 SUMO-conjugating enzyme.",
            "probability": 0.00024509429931640625
        },
        {
            "start_logit": -7.33203125,
            "end_logit": 0.62890625,
            "text": "role of Tax SUMOylation using a strategy based on the targeting of Ubc9, the unique E2 SUMO-conjugating enzyme.",
            "probability": 0.00023567676544189453
        }
    ],
    "5c011057133db5eb78000025_1": [
        {
            "start_logit": 9.1015625,
            "end_logit": 9.046875,
            "text": "phase II",
            "probability": 1.0
        },
        {
            "start_logit": -2.11328125,
            "end_logit": 9.046875,
            "text": "II",
            "probability": 1.341104507446289e-05
        },
        {
            "start_logit": 9.1015625,
            "end_logit": -2.703125,
            "text": "phase",
            "probability": 7.808208465576172e-06
        },
        {
            "start_logit": 9.1015625,
            "end_logit": -7.171875,
            "text": "phase II clinical trials",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1015625,
            "end_logit": -7.32421875,
            "text": "phase II clinical trials.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.78515625,
            "end_logit": 9.046875,
            "text": "in phase II",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.84765625,
            "end_logit": 9.046875,
            "text": "been evaluated in phase II",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.8671875,
            "end_logit": 9.046875,
            "text": ") have been evaluated in phase II",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.890625,
            "end_logit": 9.046875,
            "text": "have been evaluated in phase II",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.93359375,
            "end_logit": 9.046875,
            "text": "evaluated in phase II",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.93359375,
            "end_logit": 9.046875,
            "text": "treatment of drug-resistant tuberculosis, while several other novel compounds (AZD5847, PA-824, SQ109 and sutezolid) have been evaluated in phase II",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.93359375,
            "end_logit": 9.046875,
            "text": "the treatment of drug-resistant tuberculosis, while several other novel compounds (AZD5847, PA-824, SQ109 and sutezolid) have been evaluated in phase II",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.97265625,
            "end_logit": 9.046875,
            "text": "(AZD5847, PA-824, SQ109 and sutezolid) have been evaluated in phase II",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0078125,
            "end_logit": 9.046875,
            "text": "novel compounds (AZD5847, PA-824, SQ109 and sutezolid) have been evaluated in phase II",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0078125,
            "end_logit": 9.046875,
            "text": "several other novel compounds (AZD5847, PA-824, SQ109 and sutezolid) have been evaluated in phase II",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.11328125,
            "end_logit": -7.171875,
            "text": "II clinical trials",
            "probability": 0.0
        },
        {
            "start_logit": -2.11328125,
            "end_logit": -7.32421875,
            "text": "II clinical trials.",
            "probability": 0.0
        },
        {
            "start_logit": -7.78515625,
            "end_logit": -2.703125,
            "text": "in phase",
            "probability": 0.0
        },
        {
            "start_logit": -7.84765625,
            "end_logit": -2.703125,
            "text": "been evaluated in phase",
            "probability": 0.0
        },
        {
            "start_logit": -7.8671875,
            "end_logit": -2.703125,
            "text": ") have been evaluated in phase",
            "probability": 0.0
        }
    ],
    "601bfa531cb411341a000008_1": [
        {
            "start_logit": 9.875,
            "end_logit": 9.796875,
            "text": "primary microcephaly",
            "probability": 1.0
        },
        {
            "start_logit": -1.17578125,
            "end_logit": 9.796875,
            "text": "y",
            "probability": 1.5914440155029297e-05
        },
        {
            "start_logit": 9.875,
            "end_logit": -1.3779296875,
            "text": "primary",
            "probability": 1.4066696166992188e-05
        },
        {
            "start_logit": 9.875,
            "end_logit": -2.361328125,
            "text": "primary microcephaly and define a novel laminopathy.",
            "probability": 5.245208740234375e-06
        },
        {
            "start_logit": -6.65234375,
            "end_logit": 9.796875,
            "text": "microcephaly",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.875,
            "end_logit": -6.98828125,
            "text": "primary microcephaly and define a novel laminopathy",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.91015625,
            "end_logit": 9.796875,
            "text": "ephaly",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.875,
            "end_logit": -7.14453125,
            "text": "primary microcephal",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.15625,
            "end_logit": 9.796875,
            "text": "Heterozygous lamin B1 and lamin B2 variants cause primary microcephaly",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.875,
            "end_logit": -7.27734375,
            "text": "primary microcephaly and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5234375,
            "end_logit": 9.796875,
            "text": "lamin B1 and lamin B2 variants cause primary microcephaly",
            "probability": 0.0
        },
        {
            "start_logit": -7.58984375,
            "end_logit": 9.796875,
            "text": "cause primary microcephaly",
            "probability": 0.0
        },
        {
            "start_logit": 9.875,
            "end_logit": -7.703125,
            "text": "primary microc",
            "probability": 0.0
        },
        {
            "start_logit": 9.875,
            "end_logit": -7.8515625,
            "text": "primary microcephaly and define a",
            "probability": 0.0
        },
        {
            "start_logit": -7.80859375,
            "end_logit": 9.796875,
            "text": "variants cause primary microcephaly",
            "probability": 0.0
        },
        {
            "start_logit": -7.81640625,
            "end_logit": 9.796875,
            "text": "B1 and lamin B2 variants cause primary microcephaly",
            "probability": 0.0
        },
        {
            "start_logit": -7.82421875,
            "end_logit": 9.796875,
            "text": "and lamin B2 variants cause primary microcephaly",
            "probability": 0.0
        },
        {
            "start_logit": 9.875,
            "end_logit": -7.921875,
            "text": "primary microcephaly and define a novel lamin",
            "probability": 0.0
        },
        {
            "start_logit": 9.875,
            "end_logit": -7.95703125,
            "text": "primary microcephaly and define",
            "probability": 0.0
        },
        {
            "start_logit": -1.17578125,
            "end_logit": -2.361328125,
            "text": "y and define a novel laminopathy.",
            "probability": 0.0
        }
    ],
    "601bfa531cb411341a000008_2": [
        {
            "start_logit": 8.6015625,
            "end_logit": 8.3671875,
            "text": "primary microcephaly",
            "probability": 0.998046875
        },
        {
            "start_logit": 8.6015625,
            "end_logit": 2.01953125,
            "text": "primary microcephaly, implicating a major structural component of the nuclear envelope in its etiology and defining a new form of laminopathy",
            "probability": 0.0017538070678710938
        },
        {
            "start_logit": 5.38671875,
            "end_logit": 2.01953125,
            "text": "laminopathy",
            "probability": 7.021427154541016e-05
        },
        {
            "start_logit": 4.4453125,
            "end_logit": 2.66796875,
            "text": "lamin \u0251-helical rod domain",
            "probability": 5.21540641784668e-05
        },
        {
            "start_logit": 8.6015625,
            "end_logit": -3.35546875,
            "text": "primary",
            "probability": 8.165836334228516e-06
        },
        {
            "start_logit": -3.57421875,
            "end_logit": 8.3671875,
            "text": "y",
            "probability": 5.185604095458984e-06
        },
        {
            "start_logit": 8.6015625,
            "end_logit": -4.87890625,
            "text": "primary microcephaly, implicating a major structural component of the nuclear envelope in its etiology and defining a new form of lamin",
            "probability": 1.7881393432617188e-06
        },
        {
            "start_logit": 8.6015625,
            "end_logit": -5.5,
            "text": "primary microcephaly, implicating a major structural component of the nuclear envelope in its etiology and defining a new form of laminopathy.",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": -5.71875,
            "end_logit": 8.3671875,
            "text": ".CONCLUSION: We identify dominant pathogenic variants in LMNB1 and LMNB2 as a genetic cause of primary microcephaly",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -6.7734375,
            "end_logit": 8.3671875,
            "text": "microcephaly",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.6015625,
            "end_logit": -7.18359375,
            "text": "primary microcephal",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.6015625,
            "end_logit": -7.28515625,
            "text": "primary microcephaly, implicating a major structural component of the nuclear envelope in its etiology and defining a new",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 5.38671875,
            "end_logit": -4.87890625,
            "text": "lamin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 5.38671875,
            "end_logit": -5.5,
            "text": "laminopathy. The distinct nature of this lamin B-associated phenotype highlights the strikingly different developmental requirements for lamin paralogs and suggests a novel mechanism for primary microcephaly warranting future investigation.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 5.38671875,
            "end_logit": -5.5,
            "text": "laminopathy.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 4.4453125,
            "end_logit": -4.90625,
            "text": "lamin",
            "probability": 0.0
        },
        {
            "start_logit": 4.4453125,
            "end_logit": -5.5,
            "text": "lamin \u0251-helical rod domain, likely disrupting interactions required for higher-order assembly of lamin filaments.",
            "probability": 0.0
        },
        {
            "start_logit": 4.4453125,
            "end_logit": -5.80859375,
            "text": "lamin \u0251-helical rod",
            "probability": 0.0
        },
        {
            "start_logit": -3.57421875,
            "end_logit": 2.01953125,
            "text": "y, implicating a major structural component of the nuclear envelope in its etiology and defining a new form of laminopathy",
            "probability": 0.0
        },
        {
            "start_logit": -4.69921875,
            "end_logit": 2.01953125,
            "text": "new form of laminopathy",
            "probability": 0.0
        }
    ],
    "601bfa531cb411341a000008_3": [
        {
            "start_logit": 9.8046875,
            "end_logit": 9.78125,
            "text": "primary microcephaly",
            "probability": 1.0
        },
        {
            "start_logit": -1.20703125,
            "end_logit": 9.78125,
            "text": "y",
            "probability": 1.6450881958007812e-05
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -1.5439453125,
            "text": "primary",
            "probability": 1.1920928955078125e-05
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -6.03125,
            "text": "primary microcephaly and define a novel laminopathy",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.87109375,
            "end_logit": 9.78125,
            "text": "microcephaly",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -6.97265625,
            "text": "primary microcephaly and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -7.08203125,
            "text": "primary microcephal",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.09765625,
            "end_logit": 9.78125,
            "text": "ephaly",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.4453125,
            "end_logit": 9.78125,
            "text": "Heterozygous lamin B1 and lamin B2 variants cause primary microcephaly",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -7.55078125,
            "text": "primary microcephaly and define a novel lamin",
            "probability": 0.0
        },
        {
            "start_logit": -7.6015625,
            "end_logit": 9.78125,
            "text": "cause primary microcephaly",
            "probability": 0.0
        },
        {
            "start_logit": -7.61328125,
            "end_logit": 9.78125,
            "text": "lamin B1 and lamin B2 variants cause primary microcephaly",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -7.6796875,
            "text": "primary microc",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -7.71484375,
            "text": "primary microcephaly and define a",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -7.74609375,
            "text": "primary microcephaly and define",
            "probability": 0.0
        },
        {
            "start_logit": -7.875,
            "end_logit": 9.78125,
            "text": "variants cause primary microcephaly",
            "probability": 0.0
        },
        {
            "start_logit": -7.875,
            "end_logit": 9.78125,
            "text": "B1 and lamin B2 variants cause primary microcephaly",
            "probability": 0.0
        },
        {
            "start_logit": -7.93359375,
            "end_logit": 9.78125,
            "text": "and lamin B2 variants cause primary microcephaly",
            "probability": 0.0
        },
        {
            "start_logit": -7.98828125,
            "end_logit": 9.78125,
            "text": "lamin B2 variants cause primary microcephaly",
            "probability": 0.0
        },
        {
            "start_logit": -8.046875,
            "end_logit": 9.78125,
            "text": "B2 variants cause primary microcephaly",
            "probability": 0.0
        }
    ],
    "601bfa531cb411341a000008_4": [
        {
            "start_logit": 9.40625,
            "end_logit": 9.625,
            "text": "primary microcephaly",
            "probability": 0.94921875
        },
        {
            "start_logit": 9.40625,
            "end_logit": 6.70703125,
            "text": "primary microcephaly, implicating a major structural component of the nuclear envelope in its etiology and defining a new form of laminopathy",
            "probability": 0.05108642578125
        },
        {
            "start_logit": -1.5576171875,
            "end_logit": 9.625,
            "text": "y",
            "probability": 1.6450881958007812e-05
        },
        {
            "start_logit": 1.2216796875,
            "end_logit": 6.70703125,
            "text": "laminopathy",
            "probability": 1.430511474609375e-05
        },
        {
            "start_logit": 9.40625,
            "end_logit": -2.2890625,
            "text": "primary",
            "probability": 6.318092346191406e-06
        },
        {
            "start_logit": -1.5576171875,
            "end_logit": 6.70703125,
            "text": "y, implicating a major structural component of the nuclear envelope in its etiology and defining a new form of laminopathy",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": -2.845703125,
            "end_logit": 6.70703125,
            "text": "a new form of laminopathy",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.62109375,
            "end_logit": 9.625,
            "text": "microcephaly",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.203125,
            "end_logit": 9.625,
            "text": "of primary microcephaly",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.23046875,
            "end_logit": 9.625,
            "text": "ephaly",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.25,
            "end_logit": 9.625,
            "text": "genetic cause of primary microcephaly",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.40625,
            "end_logit": -7.390625,
            "text": "primary microcephal",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.62890625,
            "end_logit": 9.625,
            "text": "LMNB1 and LMNB2 as a genetic cause of primary microcephaly",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.40625,
            "end_logit": -7.4453125,
            "text": "primary microcephaly, implicating a major structural component of the nuclear envelope",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.7421875,
            "end_logit": 9.625,
            "text": "in LMNB1 and LMNB2 as a genetic cause of primary microcephaly",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.40625,
            "end_logit": -7.5546875,
            "text": "primary microcephaly, implicating a major structural component of the nuclear envelope in",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.40625,
            "end_logit": -7.703125,
            "text": "primary microcephaly,",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.40625,
            "end_logit": -7.7734375,
            "text": "primary microc",
            "probability": 0.0
        },
        {
            "start_logit": 9.40625,
            "end_logit": -7.81640625,
            "text": "primary microcephaly, implicating a major structural component of the nuclear envelope in its etiology and defining a new",
            "probability": 0.0
        },
        {
            "start_logit": -5.12109375,
            "end_logit": 6.70703125,
            "text": "opathy",
            "probability": 0.0
        }
    ],
    "61f7d745882a024a10000038_1": [
        {
            "start_logit": 8.4765625,
            "end_logit": 7.88671875,
            "text": "malaria",
            "probability": 1.0
        },
        {
            "start_logit": -4.32421875,
            "end_logit": 7.88671875,
            "text": "100% protection against controlled human malaria",
            "probability": 2.7418136596679688e-06
        },
        {
            "start_logit": 8.4765625,
            "end_logit": -7.3984375,
            "text": "malaria infection (CHMI) using homologous parasites (same P. falciparum strain as in the vaccine).",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.34765625,
            "end_logit": 7.88671875,
            "text": "Plasmodium falciparum sporozoite (SPZ) vaccine (PfSPZ Vaccine) has shown up to 100% protection against controlled human malaria",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.4765625,
            "end_logit": -8.0078125,
            "text": "malaria infection",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.4765625,
            "end_logit": -8.03125,
            "text": "malaria infection (CHMI) using homologous parasites (same P. falciparum strain as",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.4765625,
            "end_logit": -8.0625,
            "text": "malaria infection (CHMI) using homologous parasites (same P. falciparum",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.4765625,
            "end_logit": -8.09375,
            "text": "malaria infection (",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.4765625,
            "end_logit": -8.1171875,
            "text": "malaria infection (CHMI) using",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.4765625,
            "end_logit": -8.125,
            "text": "malaria infection (CH",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.4765625,
            "end_logit": -8.1484375,
            "text": "malaria infection (CHMI",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.8671875,
            "end_logit": 7.88671875,
            "text": "human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.89453125,
            "end_logit": 7.88671875,
            "text": "BACKGROUND: A live-attenuated Plasmodium falciparum sporozoite (SPZ) vaccine (PfSPZ Vaccine) has shown up to 100% protection against controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.9609375,
            "end_logit": 7.88671875,
            "text": ") has shown up to 100% protection against controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.96875,
            "end_logit": 7.88671875,
            "text": "against controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.97265625,
            "end_logit": 7.88671875,
            "text": "(PfSPZ Vaccine) has shown up to 100% protection against controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.98046875,
            "end_logit": 7.88671875,
            "text": "A live-attenuated Plasmodium falciparum sporozoite (SPZ) vaccine (PfSPZ Vaccine) has shown up to 100% protection against controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.98828125,
            "end_logit": 7.88671875,
            "text": "protection against controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.015625,
            "end_logit": 7.88671875,
            "text": "shown up to 100% protection against controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.015625,
            "end_logit": 7.88671875,
            "text": "Vaccine) has shown up to 100% protection against controlled human malaria",
            "probability": 5.960464477539063e-08
        }
    ],
    "61f7d745882a024a10000038_2": [
        {
            "start_logit": 8.5703125,
            "end_logit": 7.43359375,
            "text": "malaria",
            "probability": 0.9990234375
        },
        {
            "start_logit": 1.7021484375,
            "end_logit": 7.43359375,
            "text": "100% against homologous controlled human malaria",
            "probability": 0.0010404586791992188
        },
        {
            "start_logit": 8.5703125,
            "end_logit": -7.3828125,
            "text": "malaria infection (CHMI) in nonimmune adults.",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 1.7021484375,
            "end_logit": -0.71435546875,
            "text": "100%",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.5703125,
            "end_logit": -7.79296875,
            "text": "malaria infection (CHMI) in",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.5703125,
            "end_logit": -8.015625,
            "text": "malaria infection",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.44921875,
            "end_logit": 7.43359375,
            "text": "vaccine efficacies (VEs) of 100% against homologous controlled human malaria",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.84375,
            "end_logit": 7.43359375,
            "text": "of 100% against homologous controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.8671875,
            "end_logit": 7.43359375,
            "text": "human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.87109375,
            "end_logit": 7.43359375,
            "text": "infectious, aseptic, purified, cryopreserved PfSPZ administered to subjects taking weekly chloroquine chemoprophylaxis) have shown vaccine efficacies (VEs) of 100% against homologous controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.875,
            "end_logit": 7.43359375,
            "text": "(infectious, aseptic, purified, cryopreserved PfSPZ administered to subjects taking weekly chloroquine chemoprophylaxis) have shown vaccine efficacies (VEs) of 100% against homologous controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.87890625,
            "end_logit": 7.43359375,
            "text": "VEs) of 100% against homologous controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.94921875,
            "end_logit": 7.43359375,
            "text": "chloroquine chemoprophylaxis) have shown vaccine efficacies (VEs) of 100% against homologous controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.99609375,
            "end_logit": 7.43359375,
            "text": "efficacies (VEs) of 100% against homologous controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 1.7021484375,
            "end_logit": -6.33203125,
            "text": "100",
            "probability": 0.0
        },
        {
            "start_logit": 1.7021484375,
            "end_logit": -7.3828125,
            "text": "100% against homologous controlled human malaria infection (CHMI) in nonimmune adults.",
            "probability": 0.0
        },
        {
            "start_logit": 1.7021484375,
            "end_logit": -7.79296875,
            "text": "100% against homologous controlled human malaria infection (CHMI) in",
            "probability": 0.0
        },
        {
            "start_logit": 1.7021484375,
            "end_logit": -8.015625,
            "text": "100% against homologous controlled human malaria infection",
            "probability": 0.0
        },
        {
            "start_logit": 1.7021484375,
            "end_logit": -8.03125,
            "text": "100% against",
            "probability": 0.0
        },
        {
            "start_logit": -7.44921875,
            "end_logit": -0.71435546875,
            "text": "vaccine efficacies (VEs) of 100%",
            "probability": 0.0
        }
    ],
    "61f7d745882a024a10000038_3": [
        {
            "start_logit": 8.578125,
            "end_logit": 7.83203125,
            "text": "malaria",
            "probability": 1.0
        },
        {
            "start_logit": 8.578125,
            "end_logit": -7.83984375,
            "text": "malaria vaccine, PfSPZ Vaccine, protected 6 of 6 subjects (100%",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.578125,
            "end_logit": -7.8984375,
            "text": "malaria vaccine, PfSPZ Vaccine, protected 6 of 6 subjects (100%) against homologous Pf (same strain as in the vaccine) controlled human malaria infection (CHMI) 3 weeks",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.578125,
            "end_logit": -7.95703125,
            "text": "malaria vaccine, PfSPZ Vaccine, protected 6 of 6 subjects (100%) against homologous Pf (same strain as in the vaccine) controlled human malaria",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.578125,
            "end_logit": -8.046875,
            "text": "malaria vaccine, PfSPZ Vaccine, protected 6 of 6 subjects (100%) against homologous Pf (same strain as in the vaccine) controlled human malaria infection (CHMI) 3 weeks after",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.578125,
            "end_logit": -8.0625,
            "text": "malaria vaccine, PfSPZ Vaccine, protected 6 of 6 subjects (100",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.578125,
            "end_logit": -8.140625,
            "text": "malaria vaccine, PfSPZ Vaccine, protected 6 of",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.578125,
            "end_logit": -8.140625,
            "text": "malaria vaccine, PfSPZ Vaccine, protected 6 of 6 subjects (100%) against homologous Pf (same strain as",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.578125,
            "end_logit": -8.171875,
            "text": "malaria vaccine, PfSPZ Vaccine, protected 6 of 6 subjects (100%) against homologous Pf (same strain as in the vaccine) controlled human malaria infection (CHMI) 3",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.578125,
            "end_logit": -8.171875,
            "text": "malaria vaccine, PfSPZ Vaccine, protected 6 of 6 subjects (100%) against homologous Pf (same strain as in the vaccine) controlled human malaria infection",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.578125,
            "end_logit": -8.1953125,
            "text": "malaria vaccine, PfSPZ Vaccine, protected 6 of 6 subjects (100%) against homologous Pf (same strain as in the vaccine) controlled human malaria infection (CHMI",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.93359375,
            "end_logit": 7.83203125,
            "text": "BACKGROUND: A radiation-attenuated Plasmodium falciparum (Pf) sporozoite (SPZ) malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.99609375,
            "end_logit": 7.83203125,
            "text": "A radiation-attenuated Plasmodium falciparum (Pf) sporozoite (SPZ) malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.82421875,
            "end_logit": -7.6640625,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.8828125,
            "end_logit": -7.6640625,
            "text": "100%) against homologous Pf (same strain as in the vaccine) controlled human malaria infection (CHMI) 3 weeks after 5 doses administered intravenously.",
            "probability": 0.0
        },
        {
            "start_logit": -7.8984375,
            "end_logit": -7.6640625,
            "text": "the vaccine) controlled human malaria infection (CHMI) 3 weeks after 5 doses administered intravenously.",
            "probability": 0.0
        },
        {
            "start_logit": -7.9765625,
            "end_logit": -7.6640625,
            "text": "human malaria infection (CHMI) 3 weeks after 5 doses administered intravenously.",
            "probability": 0.0
        },
        {
            "start_logit": -7.9921875,
            "end_logit": -7.6640625,
            "text": "6 of 6 subjects (100%) against homologous Pf (same strain as in the vaccine) controlled human malaria infection (CHMI) 3 weeks after 5 doses administered intravenously.",
            "probability": 0.0
        },
        {
            "start_logit": -7.99609375,
            "end_logit": -7.6640625,
            "text": "malaria infection (CHMI) 3 weeks after 5 doses administered intravenously.",
            "probability": 0.0
        },
        {
            "start_logit": -8.0078125,
            "end_logit": -7.6640625,
            "text": "vaccine) controlled human malaria infection (CHMI) 3 weeks after 5 doses administered intravenously.",
            "probability": 0.0
        }
    ],
    "61f7d745882a024a10000038_4": [
        {
            "start_logit": 8.4609375,
            "end_logit": 7.94921875,
            "text": "malaria",
            "probability": 1.0
        },
        {
            "start_logit": 8.4609375,
            "end_logit": -8.1015625,
            "text": "malaria vaccines, (1) a recombinant protein with adjuvant vaccine aimed at Plasmodium falciparum",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.4609375,
            "end_logit": -8.1328125,
            "text": "malaria vaccines, (1) a recombinant protein with adjuvant vaccine aimed at Plasmodium falciparum (Pf) pre-erythrocytic stages",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.4609375,
            "end_logit": -8.140625,
            "text": "malaria vaccines, (1) a recombinant protein with adjuvant vaccine aimed at Plasmodium falciparum (Pf) pre-erythrocytic stages of the parasite cycle",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.4609375,
            "end_logit": -8.1640625,
            "text": "malaria vaccines, (1) a recombinant protein with adjuvant vaccine aimed at Plasmodium falciparum (Pf) pre-erythrocyt",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.4609375,
            "end_logit": -8.1640625,
            "text": "malaria vaccines, (1) a recombinant protein with adjuvant vaccine aimed at Plasmodium falciparum (",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.4609375,
            "end_logit": -8.171875,
            "text": "malaria vaccines, (1) a recombinant protein with adjuvant vaccine aimed at Plasmodium falciparum (Pf) pre-erythrocytic stages of",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.4609375,
            "end_logit": -8.1796875,
            "text": "malaria vaccines, (1) a recombinant protein with adjuvant vaccine aimed at Plasmodium falciparum (Pf",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.765625,
            "end_logit": 7.94921875,
            "text": "we focus on four approaches to malaria",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.81640625,
            "end_logit": 7.94921875,
            "text": "review, we focus on four approaches to malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.8046875,
            "end_logit": -7.546875,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.62109375,
            "end_logit": -7.72265625,
            "text": "whole sporozoite",
            "probability": 0.0
        },
        {
            "start_logit": -7.8046875,
            "end_logit": -7.546875,
            "text": "vaccines aimed at Pf and Plasmodium vivax sexual erythrocytic and mosquito stages.",
            "probability": 0.0
        },
        {
            "start_logit": -7.8046875,
            "end_logit": -7.546875,
            "text": "recombinant protein with adjuvant vaccines aimed at Pf and Plasmodium vivax sexual erythrocytic and mosquito stages.",
            "probability": 0.0
        },
        {
            "start_logit": -7.81640625,
            "end_logit": -7.546875,
            "text": ") recombinant protein with adjuvant vaccines aimed at Pf and Plasmodium vivax sexual erythrocytic and mosquito stages.",
            "probability": 0.0
        },
        {
            "start_logit": -7.81640625,
            "end_logit": -7.546875,
            "text": "(4) recombinant protein with adjuvant vaccines aimed at Pf and Plasmodium vivax sexual erythrocytic and mosquito stages.",
            "probability": 0.0
        },
        {
            "start_logit": -7.65625,
            "end_logit": -7.72265625,
            "text": "(2) whole sporozoite",
            "probability": 0.0
        },
        {
            "start_logit": -7.8203125,
            "end_logit": -7.72265625,
            "text": ") whole sporozoite",
            "probability": 0.0
        },
        {
            "start_logit": -7.82421875,
            "end_logit": -7.72265625,
            "text": "recombinant protein with adjuvant vaccine aimed at Plasmodium falciparum (Pf) pre-erythrocytic stages of the parasite cycle (RTS,S/AS01), (2) whole sporozoite",
            "probability": 0.0
        },
        {
            "start_logit": -7.62109375,
            "end_logit": -8.0625,
            "text": "whole spor",
            "probability": 0.0
        }
    ],
    "61f7d745882a024a10000038_5": [
        {
            "start_logit": 8.4609375,
            "end_logit": 7.94921875,
            "text": "malaria",
            "probability": 1.0
        },
        {
            "start_logit": 8.4609375,
            "end_logit": -8.1015625,
            "text": "malaria vaccines, (1) a recombinant protein with adjuvant vaccine aimed at Plasmodium falciparum",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.4609375,
            "end_logit": -8.1328125,
            "text": "malaria vaccines, (1) a recombinant protein with adjuvant vaccine aimed at Plasmodium falciparum (Pf) pre-erythrocytic stages",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.4609375,
            "end_logit": -8.140625,
            "text": "malaria vaccines, (1) a recombinant protein with adjuvant vaccine aimed at Plasmodium falciparum (Pf) pre-erythrocytic stages of the parasite cycle",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.4609375,
            "end_logit": -8.1640625,
            "text": "malaria vaccines, (1) a recombinant protein with adjuvant vaccine aimed at Plasmodium falciparum (Pf) pre-erythrocyt",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.4609375,
            "end_logit": -8.1640625,
            "text": "malaria vaccines, (1) a recombinant protein with adjuvant vaccine aimed at Plasmodium falciparum (",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.4609375,
            "end_logit": -8.171875,
            "text": "malaria vaccines, (1) a recombinant protein with adjuvant vaccine aimed at Plasmodium falciparum (Pf) pre-erythrocytic stages of",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.4609375,
            "end_logit": -8.1796875,
            "text": "malaria vaccines, (1) a recombinant protein with adjuvant vaccine aimed at Plasmodium falciparum (Pf",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.765625,
            "end_logit": 7.94921875,
            "text": "we focus on four approaches to malaria",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.81640625,
            "end_logit": 7.94921875,
            "text": "review, we focus on four approaches to malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.8046875,
            "end_logit": -7.546875,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.62109375,
            "end_logit": -7.72265625,
            "text": "whole sporozoite",
            "probability": 0.0
        },
        {
            "start_logit": -7.8046875,
            "end_logit": -7.546875,
            "text": "vaccines aimed at Pf and Plasmodium vivax sexual erythrocytic and mosquito stages.",
            "probability": 0.0
        },
        {
            "start_logit": -7.8046875,
            "end_logit": -7.546875,
            "text": "recombinant protein with adjuvant vaccines aimed at Pf and Plasmodium vivax sexual erythrocytic and mosquito stages.",
            "probability": 0.0
        },
        {
            "start_logit": -7.81640625,
            "end_logit": -7.546875,
            "text": ") recombinant protein with adjuvant vaccines aimed at Pf and Plasmodium vivax sexual erythrocytic and mosquito stages.",
            "probability": 0.0
        },
        {
            "start_logit": -7.81640625,
            "end_logit": -7.546875,
            "text": "(4) recombinant protein with adjuvant vaccines aimed at Pf and Plasmodium vivax sexual erythrocytic and mosquito stages.",
            "probability": 0.0
        },
        {
            "start_logit": -7.65625,
            "end_logit": -7.72265625,
            "text": "(2) whole sporozoite",
            "probability": 0.0
        },
        {
            "start_logit": -7.8203125,
            "end_logit": -7.72265625,
            "text": ") whole sporozoite",
            "probability": 0.0
        },
        {
            "start_logit": -7.82421875,
            "end_logit": -7.72265625,
            "text": "recombinant protein with adjuvant vaccine aimed at Plasmodium falciparum (Pf) pre-erythrocytic stages of the parasite cycle (RTS,S/AS01), (2) whole sporozoite",
            "probability": 0.0
        },
        {
            "start_logit": -7.62109375,
            "end_logit": -8.0625,
            "text": "whole spor",
            "probability": 0.0
        }
    ],
    "61f7d745882a024a10000038_6": [
        {
            "start_logit": 8.8984375,
            "end_logit": 7.44921875,
            "text": "malaria",
            "probability": 1.0
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -7.2890625,
            "text": "malaria vaccine, Plasmodium falciparum sporozoite vaccine (PfSPZ Vaccine), confers sterile protection against controlled human malaria infection (CHMI) with Plasmodium falciparum (Pf) parasites homologous to the vaccine strain up",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -7.890625,
            "text": "malaria vaccine, Plasmodium falciparum sporozoite",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -7.921875,
            "text": "malaria vaccine, Plasmodium falciparum sporozoite vaccine (PfSPZ Vaccine), confers sterile protection against controlled human malaria",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -7.96484375,
            "text": "malaria vaccine, Plasmodium falciparum sporozoite vaccine",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -8.0703125,
            "text": "malaria vaccine, Plasmodium falciparum",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.796875,
            "end_logit": 7.44921875,
            "text": "A live-attenuated malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.8984375,
            "end_logit": 7.44921875,
            "text": "live-attenuated malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.93359375,
            "end_logit": 7.44921875,
            "text": "attenuated malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.7109375,
            "end_logit": -7.2265625,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -6.7109375,
            "end_logit": -7.60546875,
            "text": ". No injectable malaria vaccine has demonstrated",
            "probability": 0.0
        },
        {
            "start_logit": -6.7109375,
            "end_logit": -7.82421875,
            "text": ". No injectable malaria vaccine",
            "probability": 0.0
        },
        {
            "start_logit": -6.7109375,
            "end_logit": -7.8359375,
            "text": ". No injectable malaria",
            "probability": 0.0
        },
        {
            "start_logit": -6.7109375,
            "end_logit": -7.83984375,
            "text": ". No injectable malaria vaccine has",
            "probability": 0.0
        },
        {
            "start_logit": -6.7109375,
            "end_logit": -7.9453125,
            "text": ". No",
            "probability": 0.0
        },
        {
            "start_logit": -7.73828125,
            "end_logit": -6.98828125,
            "text": "Plasmodium falciparum sporozoite vaccine (PfSPZ Vaccine), confers sterile protection against controlled human malaria infection (CHMI) with Plasmodium falciparum (Pf) parasites homologous to the vaccine strain up to 14 mo",
            "probability": 0.0
        },
        {
            "start_logit": -6.7109375,
            "end_logit": -8.0390625,
            "text": ". No injectable malaria vaccine has demonstrated long",
            "probability": 0.0
        },
        {
            "start_logit": -6.7109375,
            "end_logit": -8.0625,
            "text": ". No injectable",
            "probability": 0.0
        },
        {
            "start_logit": -7.8671875,
            "end_logit": -6.98828125,
            "text": "malaria infection (CHMI) with Plasmodium falciparum (Pf) parasites homologous to the vaccine strain up to 14 mo",
            "probability": 0.0
        },
        {
            "start_logit": -7.90625,
            "end_logit": -6.98828125,
            "text": ", confers sterile protection against controlled human malaria infection (CHMI) with Plasmodium falciparum (Pf) parasites homologous to the vaccine strain up to 14 mo",
            "probability": 0.0
        }
    ],
    "61f7d745882a024a10000038_7": [
        {
            "start_logit": 8.53125,
            "end_logit": 7.80859375,
            "text": "malaria",
            "probability": 1.0
        },
        {
            "start_logit": 8.53125,
            "end_logit": -7.4765625,
            "text": "malaria, but the features of the antibody response induced by this treatment remain unclear.",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.53125,
            "end_logit": -7.9765625,
            "text": "malaria, but the features of the antibody response induced",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.53125,
            "end_logit": -8.0078125,
            "text": "malaria, but the features of the antibody response induced by this treatment remain",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.53125,
            "end_logit": -8.046875,
            "text": "malaria, but the features of the antibody response induced by this treatment remain unclear",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.34375,
            "end_logit": 7.80859375,
            "text": "against malaria",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.53125,
            "end_logit": -8.078125,
            "text": "malaria,",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.53125,
            "end_logit": -8.1328125,
            "text": "malaria, but the features of the antibody response",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.53125,
            "end_logit": -8.140625,
            "text": "malaria, but",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.53125,
            "end_logit": -8.15625,
            "text": "malaria, but the features of the antibody response induced by",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.53125,
            "end_logit": -8.1640625,
            "text": "malaria, but the features of",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.703125,
            "end_logit": 7.80859375,
            "text": "Plasmodium falciparum sporozoites (PfSPZs) has been shown to be protective against malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.70703125,
            "end_logit": 7.80859375,
            "text": "Immunization with attenuated Plasmodium falciparum sporozoites (PfSPZs) has been shown to be protective against malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.80859375,
            "end_logit": 7.80859375,
            "text": "attenuated Plasmodium falciparum sporozoites (PfSPZs) has been shown to be protective against malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.8203125,
            "end_logit": 7.80859375,
            "text": "with attenuated Plasmodium falciparum sporozoites (PfSPZs) has been shown to be protective against malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.828125,
            "end_logit": 7.80859375,
            "text": "protective against malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.85546875,
            "end_logit": 7.80859375,
            "text": "been shown to be protective against malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.9140625,
            "end_logit": 7.80859375,
            "text": "sporozoites (PfSPZs) has been shown to be protective against malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.921875,
            "end_logit": 7.80859375,
            "text": "(PfSPZs) has been shown to be protective against malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.92578125,
            "end_logit": 7.80859375,
            "text": "be protective against malaria",
            "probability": 5.960464477539063e-08
        }
    ],
    "61f7d745882a024a10000038_8": [
        {
            "start_logit": 8.4375,
            "end_logit": 7.9921875,
            "text": "malaria",
            "probability": 1.0
        },
        {
            "start_logit": 8.4375,
            "end_logit": -7.08984375,
            "text": "malaria vaccines, which is based on human malaria sporozoites and called PfSPZ Vaccine, has been shown to protect a significant proportion of vaccine recipients from getting malaria.",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.4375,
            "end_logit": -7.796875,
            "text": "malaria vaccines, which is based on human malaria sporozoites and",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.4375,
            "end_logit": -7.875,
            "text": "malaria vaccines, which is based on human malaria sporozoites and called PfSPZ Vaccine, has been shown to protect a significant proportion of vaccine recipients from getting malaria",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.4375,
            "end_logit": -8.015625,
            "text": "malaria vaccines, which is based on human malaria sporozoites and called PfSPZ Vaccine, has been shown to protect a significant proportion of vaccine recipients from",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.4375,
            "end_logit": -8.109375,
            "text": "malaria vaccines, which is based on human malaria",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.4375,
            "end_logit": -8.1171875,
            "text": "malaria vaccines, which is based on human malaria sporozoites",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.4375,
            "end_logit": -8.1484375,
            "text": "malaria vaccines",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.4375,
            "end_logit": -8.1484375,
            "text": "malaria vaccines, which is based on human malaria sporozoites and called PfSPZ Vaccine, has been shown to protect a significant proportion of vaccine recipients",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.4375,
            "end_logit": -8.1484375,
            "text": "malaria vaccines, which is based on human malaria sporozoites and called PfSPZ Vaccine,",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.4375,
            "end_logit": -8.1484375,
            "text": "malaria vaccines, which is based on human malaria sporozoites and called PfSPZ",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.4375,
            "end_logit": -8.15625,
            "text": "malaria vaccines, which is based on human malaria spor",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.4375,
            "end_logit": -8.15625,
            "text": "malaria vaccines, which is based on human malaria sporozoites and called PfSPZ Vaccine, has been shown",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.4375,
            "end_logit": -8.15625,
            "text": "malaria vaccines,",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.4375,
            "end_logit": -8.1640625,
            "text": "malaria vaccines, which is based on human malaria sporozoites and called PfSPZ Vaccine, has been shown to",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.94921875,
            "end_logit": 7.9921875,
            "text": "human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.71484375,
            "end_logit": -7.08984375,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.765625,
            "end_logit": -7.08984375,
            "text": "malaria sporozoites and called PfSPZ Vaccine, has been shown to protect a significant proportion of vaccine recipients from getting malaria.",
            "probability": 0.0
        },
        {
            "start_logit": -7.86328125,
            "end_logit": -7.08984375,
            "text": "called PfSPZ Vaccine, has been shown to protect a significant proportion of vaccine recipients from getting malaria.",
            "probability": 0.0
        },
        {
            "start_logit": -7.87109375,
            "end_logit": -7.08984375,
            "text": "protect a significant proportion of vaccine recipients from getting malaria.",
            "probability": 0.0
        }
    ],
    "61f7d745882a024a10000038_9": [
        {
            "start_logit": 8.234375,
            "end_logit": 8.0390625,
            "text": "malaria",
            "probability": 1.0
        },
        {
            "start_logit": -3.669921875,
            "end_logit": 8.0390625,
            "text": "100% protection against controlled human malaria",
            "probability": 6.67572021484375e-06
        },
        {
            "start_logit": -6.8203125,
            "end_logit": 8.0390625,
            "text": "Plasmodium falciparum sporozoite (SPZ) vaccine (PfSPZ Vaccine) has shown up to 100% protection against controlled human malaria",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.234375,
            "end_logit": -7.546875,
            "text": "malaria infection (CHMI) using homologous parasites",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.234375,
            "end_logit": -7.83984375,
            "text": "malaria infection",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.234375,
            "end_logit": -7.88671875,
            "text": "malaria infection (CHMI) using homologous parasites (sa",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.234375,
            "end_logit": -7.89453125,
            "text": "malaria infection (CHMI) using homologous",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.234375,
            "end_logit": -7.9609375,
            "text": "malaria infection (",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.234375,
            "end_logit": -7.9765625,
            "text": "malaria infection (CHMI) using",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.84765625,
            "end_logit": 8.0390625,
            "text": "BACKGROUND: A live-attenuated Plasmodium falciparum sporozoite (SPZ) vaccine (PfSPZ Vaccine) has shown up to 100% protection against controlled human malaria",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.234375,
            "end_logit": -8.046875,
            "text": "malaria infection (CH",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.91015625,
            "end_logit": 8.0390625,
            "text": "(PfSPZ Vaccine) has shown up to 100% protection against controlled human malaria",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.9140625,
            "end_logit": 8.0390625,
            "text": "against controlled human malaria",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.9296875,
            "end_logit": 8.0390625,
            "text": ") has shown up to 100% protection against controlled human malaria",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.953125,
            "end_logit": 8.0390625,
            "text": "human malaria",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.984375,
            "end_logit": 8.0390625,
            "text": "A live-attenuated Plasmodium falciparum sporozoite (SPZ) vaccine (PfSPZ Vaccine) has shown up to 100% protection against controlled human malaria",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.99609375,
            "end_logit": 8.0390625,
            "text": "live-attenuated Plasmodium falciparum sporozoite (SPZ) vaccine (PfSPZ Vaccine) has shown up to 100% protection against controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0078125,
            "end_logit": 8.0390625,
            "text": "Vaccine) has shown up to 100% protection against controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.015625,
            "end_logit": 8.0390625,
            "text": "shown up to 100% protection against controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -3.669921875,
            "end_logit": -6.359375,
            "text": "100%",
            "probability": 0.0
        }
    ],
    "61f7d745882a024a10000038_10": [
        {
            "start_logit": 8.4921875,
            "end_logit": 7.875,
            "text": "malaria",
            "probability": 1.0
        },
        {
            "start_logit": 8.4921875,
            "end_logit": -7.6015625,
            "text": "malaria infection (CHMI) 3 weeks after immunization, but the durability of protection is unknown.",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.4921875,
            "end_logit": -7.89453125,
            "text": "malaria infection (CHMI) 3 weeks",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.4921875,
            "end_logit": -7.9609375,
            "text": "malaria infection (CHMI) 3 weeks after immunization, but the durability of protection is unknown",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.4921875,
            "end_logit": -8.046875,
            "text": "malaria infection (CHMI) 3",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.4921875,
            "end_logit": -8.0703125,
            "text": "malaria infection",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.4921875,
            "end_logit": -8.1171875,
            "text": "malaria infection (CHMI) 3 weeks after",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.4921875,
            "end_logit": -8.140625,
            "text": "malaria infection (CHMI) 3 weeks after immunization, but the durability of protection is",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.4921875,
            "end_logit": -8.140625,
            "text": "malaria infection (CHMI) 3 weeks after immunization, but the durability of protection",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.77734375,
            "end_logit": 7.875,
            "text": "human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.9296875,
            "end_logit": 7.875,
            "text": ", is highly protective against controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.95703125,
            "end_logit": 7.875,
            "text": "against controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.97265625,
            "end_logit": 7.875,
            "text": "highly protective against controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.9765625,
            "end_logit": 7.875,
            "text": "An attenuated Plasmodium falciparum (Pf) sporozoite (SPZ) vaccine, PfSPZ Vaccine, is highly protective against controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0390625,
            "end_logit": 7.875,
            "text": "controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.82421875,
            "end_logit": -7.6015625,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.77734375,
            "end_logit": -7.6015625,
            "text": "human malaria infection (CHMI) 3 weeks after immunization, but the durability of protection is unknown.",
            "probability": 0.0
        },
        {
            "start_logit": -7.9296875,
            "end_logit": -7.6015625,
            "text": ", is highly protective against controlled human malaria infection (CHMI) 3 weeks after immunization, but the durability of protection is unknown.",
            "probability": 0.0
        },
        {
            "start_logit": -7.95703125,
            "end_logit": -7.6015625,
            "text": "against controlled human malaria infection (CHMI) 3 weeks after immunization, but the durability of protection is unknown.",
            "probability": 0.0
        },
        {
            "start_logit": -7.96484375,
            "end_logit": -7.6015625,
            "text": "durability of protection is unknown.",
            "probability": 0.0
        }
    ],
    "61f7d745882a024a10000038_11": [
        {
            "start_logit": 8.3125,
            "end_logit": 7.27734375,
            "text": "malaria",
            "probability": 0.787109375
        },
        {
            "start_logit": 8.3125,
            "end_logit": 5.90234375,
            "text": "malaria sporozoite vaccine that has been reported to be safe and protective against P falciparum controlled human malaria",
            "probability": 0.1990966796875
        },
        {
            "start_logit": 5.6484375,
            "end_logit": 5.90234375,
            "text": "malaria",
            "probability": 0.0137481689453125
        },
        {
            "start_logit": -4.38671875,
            "end_logit": 7.27734375,
            "text": "Plasmodium falciparum sporozite (PfSPZ) Vaccine is a metabolically active, non-replicating, whole malaria",
            "probability": 2.384185791015625e-06
        },
        {
            "start_logit": -4.38671875,
            "end_logit": 5.90234375,
            "text": "Plasmodium falciparum sporozite (PfSPZ) Vaccine is a metabolically active, non-replicating, whole malaria sporozoite vaccine that has been reported to be safe and protective against P falciparum controlled human malaria",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 8.3125,
            "end_logit": -6.95703125,
            "text": "malaria sporozoite vaccine that has been reported to be safe and protective against P falciparum controlled human malaria infection in malaria-naive",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 8.3125,
            "end_logit": -7.18359375,
            "text": "malaria sporozoite vaccine that has been reported to be safe and protective against P falciparum controlled human malaria infection in",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.3125,
            "end_logit": -7.19921875,
            "text": "malaria sporozoite vaccine that has been reported to be safe and protective against P falciparum controlled human malaria infection",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.3125,
            "end_logit": -7.4921875,
            "text": "malaria sporozoite",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.3125,
            "end_logit": -7.5,
            "text": "malaria sporozoite vaccine that has been reported to be safe and protective against P falciparum controlled human malaria infection in malaria",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.3125,
            "end_logit": -7.51953125,
            "text": "malaria spor",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.3125,
            "end_logit": -7.546875,
            "text": "malaria sporozoite vaccine that has been reported to be safe and protective against P falciparum controlled human malaria infection in malaria-",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.3125,
            "end_logit": -7.6328125,
            "text": "malaria sporozoite vaccine that has been reported to be safe and protective against P falciparum controlled human malaria infection in malaria-naive ind",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.3125,
            "end_logit": -7.69921875,
            "text": "malaria sporozoite vaccine that has been reported to be safe and protective against P falciparum",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.3125,
            "end_logit": -7.7109375,
            "text": "malaria sporozoite vaccine that has been reported to be safe and protective against P falciparum controlled",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.3125,
            "end_logit": -7.84765625,
            "text": "malaria sporozoite vaccine that has been reported to",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.3125,
            "end_logit": -7.86328125,
            "text": "malaria sporozoite vaccine that has been",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.46875,
            "end_logit": 7.27734375,
            "text": "whole malaria",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.58984375,
            "end_logit": 7.27734375,
            "text": ", whole malaria",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.875,
            "end_logit": 7.27734375,
            "text": ", non-replicating, whole malaria",
            "probability": 1.1920928955078125e-07
        }
    ],
    "61f7d745882a024a10000038_12": [
        {
            "start_logit": 8.1484375,
            "end_logit": 8.2421875,
            "text": "malaria",
            "probability": 1.0
        },
        {
            "start_logit": -7.66015625,
            "end_logit": 8.2421875,
            "text": "Sterile protection against human malaria",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.71484375,
            "end_logit": 8.2421875,
            "text": "human malaria",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.76171875,
            "end_logit": 8.2421875,
            "text": "protection against human malaria",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.92578125,
            "end_logit": 8.2421875,
            "text": "against human malaria",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.1484375,
            "end_logit": -8.0390625,
            "text": "malaria by",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.1484375,
            "end_logit": -8.0625,
            "text": "malaria by chemoattenuated",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.1484375,
            "end_logit": -8.09375,
            "text": "malaria by chemoatten",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.1484375,
            "end_logit": -8.140625,
            "text": "malaria by chemoattenuated PfSPZ vaccine",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.1484375,
            "end_logit": -8.15625,
            "text": "malaria by chemoattenuated PfSPZ",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.1484375,
            "end_logit": -8.1796875,
            "text": "malaria by chemoattenuated PfSP",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.1484375,
            "end_logit": -8.1875,
            "text": "malaria by chemoattenuated PfS",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.1484375,
            "end_logit": -8.2265625,
            "text": "malaria by chemoat",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.66015625,
            "end_logit": -8.0390625,
            "text": "Sterile protection against human malaria by",
            "probability": 0.0
        },
        {
            "start_logit": -7.66015625,
            "end_logit": -8.0625,
            "text": "Sterile protection against human malaria by chemoattenuated",
            "probability": 0.0
        },
        {
            "start_logit": -7.66015625,
            "end_logit": -8.09375,
            "text": "Sterile protection against human malaria by chemoatten",
            "probability": 0.0
        },
        {
            "start_logit": -7.71484375,
            "end_logit": -8.0390625,
            "text": "human malaria by",
            "probability": 0.0
        },
        {
            "start_logit": -7.71484375,
            "end_logit": -8.0625,
            "text": "human malaria by chemoattenuated",
            "probability": 0.0
        },
        {
            "start_logit": -7.66015625,
            "end_logit": -8.140625,
            "text": "Sterile protection against human malaria by chemoattenuated PfSPZ vaccine",
            "probability": 0.0
        },
        {
            "start_logit": -7.76171875,
            "end_logit": -8.0390625,
            "text": "protection against human malaria by",
            "probability": 0.0
        }
    ],
    "61f7d745882a024a10000038_13": [
        {
            "start_logit": 8.5234375,
            "end_logit": 7.859375,
            "text": "malaria",
            "probability": 1.0
        },
        {
            "start_logit": 8.5234375,
            "end_logit": -8.2265625,
            "text": "malaria. A",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.7421875,
            "end_logit": 7.859375,
            "text": "Plasmodium falciparum sporozoites, is administered by direct venous inoculation (DVI) for maximal efficacy against malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.83203125,
            "end_logit": 7.859375,
            "text": "against malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.91796875,
            "end_logit": 7.859375,
            "text": "PfSPZ Vaccine, composed of radiation-attenuated, aseptic, purified, cryopreserved Plasmodium falciparum sporozoites, is administered by direct venous inoculation (DVI) for maximal efficacy against malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.92578125,
            "end_logit": 7.859375,
            "text": ", cryopreserved Plasmodium falciparum sporozoites, is administered by direct venous inoculation (DVI) for maximal efficacy against malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.94921875,
            "end_logit": 7.859375,
            "text": "attenuated, aseptic, purified, cryopreserved Plasmodium falciparum sporozoites, is administered by direct venous inoculation (DVI) for maximal efficacy against malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.95703125,
            "end_logit": 7.859375,
            "text": "of radiation-attenuated, aseptic, purified, cryopreserved Plasmodium falciparum sporozoites, is administered by direct venous inoculation (DVI) for maximal efficacy against malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.96484375,
            "end_logit": 7.859375,
            "text": ", purified, cryopreserved Plasmodium falciparum sporozoites, is administered by direct venous inoculation (DVI) for maximal efficacy against malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.96875,
            "end_logit": 7.859375,
            "text": ", aseptic, purified, cryopreserved Plasmodium falciparum sporozoites, is administered by direct venous inoculation (DVI) for maximal efficacy against malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.96875,
            "end_logit": 7.859375,
            "text": "radiation-attenuated, aseptic, purified, cryopreserved Plasmodium falciparum sporozoites, is administered by direct venous inoculation (DVI) for maximal efficacy against malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.9765625,
            "end_logit": 7.859375,
            "text": "direct venous inoculation (DVI) for maximal efficacy against malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.9765625,
            "end_logit": 7.859375,
            "text": "cryopreserved Plasmodium falciparum sporozoites, is administered by direct venous inoculation (DVI) for maximal efficacy against malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.98046875,
            "end_logit": 7.859375,
            "text": "(DVI) for maximal efficacy against malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.7421875,
            "end_logit": -7.65234375,
            "text": "Plasmodium falciparum",
            "probability": 0.0
        },
        {
            "start_logit": -7.91796875,
            "end_logit": -7.65234375,
            "text": "PfSPZ Vaccine, composed of radiation-attenuated, aseptic, purified, cryopreserved Plasmodium falciparum",
            "probability": 0.0
        },
        {
            "start_logit": -7.92578125,
            "end_logit": -7.65234375,
            "text": ", cryopreserved Plasmodium falciparum",
            "probability": 0.0
        },
        {
            "start_logit": -7.94921875,
            "end_logit": -7.65234375,
            "text": "attenuated, aseptic, purified, cryopreserved Plasmodium falciparum",
            "probability": 0.0
        },
        {
            "start_logit": -7.95703125,
            "end_logit": -7.65234375,
            "text": "of radiation-attenuated, aseptic, purified, cryopreserved Plasmodium falciparum",
            "probability": 0.0
        },
        {
            "start_logit": -7.96484375,
            "end_logit": -7.65234375,
            "text": ", purified, cryopreserved Plasmodium falciparum",
            "probability": 0.0
        }
    ],
    "61f7d745882a024a10000038_14": [
        {
            "start_logit": 8.4453125,
            "end_logit": 7.9765625,
            "text": "malaria",
            "probability": 1.0
        },
        {
            "start_logit": 8.4453125,
            "end_logit": -7.94921875,
            "text": "malaria vaccines because",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.4453125,
            "end_logit": -8.03125,
            "text": "malaria vaccines because of",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.4453125,
            "end_logit": -8.109375,
            "text": "malaria vaccines because of its unparall",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.78515625,
            "end_logit": 7.9765625,
            "text": "for malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.859375,
            "end_logit": 7.9765625,
            "text": "considered the gold standard for malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.91796875,
            "end_logit": 7.9765625,
            "text": "gold standard for malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.9609375,
            "end_logit": 7.9765625,
            "text": "radiation attenuated sporozoite (PfSPZ) vaccine has been considered the gold standard for malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.96484375,
            "end_logit": 7.9765625,
            "text": "The radiation attenuated sporozoite (PfSPZ) vaccine has been considered the gold standard for malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.97265625,
            "end_logit": 7.9765625,
            "text": "been considered the gold standard for malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0078125,
            "end_logit": 7.9765625,
            "text": "the gold standard for malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.03125,
            "end_logit": 7.9765625,
            "text": "has been considered the gold standard for malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0625,
            "end_logit": 7.9765625,
            "text": "nfections. The radiation attenuated sporozoite (PfSPZ) vaccine has been considered the gold standard for malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.078125,
            "end_logit": 7.9765625,
            "text": "vaccine has been considered the gold standard for malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.09375,
            "end_logit": 7.9765625,
            "text": "PfSPZ) vaccine has been considered the gold standard for malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.09375,
            "end_logit": 7.9765625,
            "text": "(PfSPZ) vaccine has been considered the gold standard for malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.109375,
            "end_logit": 7.9765625,
            "text": ") vaccine has been considered the gold standard for malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1171875,
            "end_logit": 7.9765625,
            "text": "attenuated sporozoite (PfSPZ) vaccine has been considered the gold standard for malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.78515625,
            "end_logit": -7.94921875,
            "text": "for malaria vaccines because",
            "probability": 0.0
        },
        {
            "start_logit": -7.78515625,
            "end_logit": -8.03125,
            "text": "for malaria vaccines because of",
            "probability": 0.0
        }
    ],
    "61f7d745882a024a10000038_15": [
        {
            "start_logit": 8.65625,
            "end_logit": 7.74609375,
            "text": "malaria",
            "probability": 1.0
        },
        {
            "start_logit": 8.65625,
            "end_logit": -7.90625,
            "text": "malaria vaccine, PfSPZ Vaccine, protected 6 of 6 subjects (100%",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.65625,
            "end_logit": -7.98046875,
            "text": "malaria vaccine, PfSPZ Vaccine, protected 6 of 6 subjects (100%) against homologous Pf (same strain as in the vaccine) controlled human malaria infection (CHMI) 3 weeks",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.65625,
            "end_logit": -8.046875,
            "text": "malaria vaccine, PfSPZ Vaccine, protected 6 of 6 subjects (100%) against homologous Pf (same strain as in the vaccine) controlled human malaria",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.65625,
            "end_logit": -8.109375,
            "text": "malaria vaccine, PfSPZ Vaccine, protected 6 of 6 subjects (100%) against homologous Pf (same strain as in the vaccine) controlled human malaria infection (CHMI) 3 weeks after",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.65625,
            "end_logit": -8.125,
            "text": "malaria vaccine, PfSPZ Vaccine, protected 6 of 6 subjects (100",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.65625,
            "end_logit": -8.1640625,
            "text": "malaria vaccine, PfSPZ Vaccine, protected 6 of 6 subjects (100%) against homologous Pf (same strain as",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.65625,
            "end_logit": -8.1953125,
            "text": "malaria vaccine, PfSPZ Vaccine, protected 6 of",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.65625,
            "end_logit": -8.203125,
            "text": "malaria vaccine, PfSPZ Vaccine, protected 6 of 6 subjects (100%) against homologous Pf (same strain as in the vaccine) controlled human malaria infection",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.65625,
            "end_logit": -8.2109375,
            "text": "malaria vaccine, PfSPZ Vaccine, protected 6 of 6 subjects (100%) against homologous Pf (same strain as in the vaccine) controlled human malaria infection (CHMI",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.65625,
            "end_logit": -8.2421875,
            "text": "malaria vaccine, PfSPZ Vaccine, protected 6 of 6 subjects (100%) against homologous Pf (same strain as in the vaccine) controlled human malaria infection (",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.65625,
            "end_logit": -8.2421875,
            "text": "malaria vaccine, PfSPZ Vaccine, protected 6 of 6 subjects (100%) against homologous Pf",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.65625,
            "end_logit": -8.2421875,
            "text": "malaria vaccine, PfSPZ Vaccine, protected 6 of 6 subjects (100%) against homologous Pf (same strain as in the vaccine) controlled human malaria infection (CHMI) 3",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.65625,
            "end_logit": -8.25,
            "text": "malaria vaccine, PfSPZ Vaccine, protected 6 of 6 subjects (100%) against homologous Pf (same strain as in the vaccine) controlled human malaria infection (CH",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.65625,
            "end_logit": -8.25,
            "text": "malaria vaccine, PfSPZ Vaccine, protected 6 of 6 subjects (100%) against homologous Pf (same strain as in",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.91015625,
            "end_logit": 7.74609375,
            "text": "CKGROUND: A radiation-attenuated Plasmodium falciparum (Pf) sporozoite (SPZ) malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.93359375,
            "end_logit": 7.74609375,
            "text": ") malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.9375,
            "end_logit": 7.74609375,
            "text": "Plasmodium falciparum (Pf) sporozoite (SPZ) malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.9453125,
            "end_logit": 7.74609375,
            "text": "attenuated Plasmodium falciparum (Pf) sporozoite (SPZ) malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.94921875,
            "end_logit": 7.74609375,
            "text": "radiation-attenuated Plasmodium falciparum (Pf) sporozoite (SPZ) malaria",
            "probability": 5.960464477539063e-08
        }
    ],
    "61f7d745882a024a10000038_16": [
        {
            "start_logit": 8.9140625,
            "end_logit": 7.40234375,
            "text": "malaria",
            "probability": 1.0
        },
        {
            "start_logit": 8.9140625,
            "end_logit": -7.390625,
            "text": "malaria chemoprophylaxis.",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.9140625,
            "end_logit": -7.97265625,
            "text": "malaria chemoprophylaxis",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.9140625,
            "end_logit": -8.015625,
            "text": "malaria chemo",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.9140625,
            "end_logit": -8.078125,
            "text": "malaria chemoprop",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.9140625,
            "end_logit": -8.078125,
            "text": "malaria chemoprophylax",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.9140625,
            "end_logit": -8.0859375,
            "text": "malaria chemoprophy",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.9140625,
            "end_logit": -8.1015625,
            "text": "malaria chemoprophyla",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.9140625,
            "end_logit": -8.1328125,
            "text": "malaria chemoprophylaxis. These",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.9140625,
            "end_logit": -8.1484375,
            "text": "malaria chemoprophylaxis. These advance",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.60546875,
            "end_logit": 7.40234375,
            "text": "on malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.73046875,
            "end_logit": 7.40234375,
            "text": "otective efficacy has been demonstrated in a small number of volunteers after intravenous (IV) inoculation of radiation-attenuated PfSPZ or in those who were exposed to live PfSPZ while on malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.8671875,
            "end_logit": 7.40234375,
            "text": "ective efficacy has been demonstrated in a small number of volunteers after intravenous (IV) inoculation of radiation-attenuated PfSPZ or in those who were exposed to live PfSPZ while on malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.9375,
            "end_logit": 7.40234375,
            "text": "those who were exposed to live PfSPZ while on malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.9453125,
            "end_logit": 7.40234375,
            "text": "who were exposed to live PfSPZ while on malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.94921875,
            "end_logit": 7.40234375,
            "text": "exposed to live PfSPZ while on malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.953125,
            "end_logit": 7.40234375,
            "text": "in those who were exposed to live PfSPZ while on malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.98828125,
            "end_logit": 7.40234375,
            "text": "efficacy has been demonstrated in a small number of volunteers after intravenous (IV) inoculation of radiation-attenuated PfSPZ or in those who were exposed to live PfSPZ while on malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.03125,
            "end_logit": 7.40234375,
            "text": "while on malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.03125,
            "end_logit": 7.40234375,
            "text": ") inoculation of radiation-attenuated PfSPZ or in those who were exposed to live PfSPZ while on malaria",
            "probability": 5.960464477539063e-08
        }
    ],
    "61f7d745882a024a10000038_17": [
        {
            "start_logit": 8.765625,
            "end_logit": 7.5234375,
            "text": "malaria",
            "probability": 1.0
        },
        {
            "start_logit": 8.765625,
            "end_logit": -8.1484375,
            "text": "malaria (mAbs 580 and 663). RTS,S mA",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.765625,
            "end_logit": -8.1875,
            "text": "malaria (",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.53515625,
            "end_logit": 7.5234375,
            "text": "AS01 (mAbs 317 and 311); an irradiated whole sporozoite vaccine PfSPZ (mAbs CIS43 and MGG4); or individuals exposed to malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6953125,
            "end_logit": 7.5234375,
            "text": "RTS,S/AS01 (mAbs 317 and 311); an irradiated whole sporozoite vaccine PfSPZ (mAbs CIS43 and MGG4); or individuals exposed to malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.71875,
            "end_logit": 7.5234375,
            "text": "whole sporozoite vaccine PfSPZ (mAbs CIS43 and MGG4); or individuals exposed to malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.7734375,
            "end_logit": 7.5234375,
            "text": "to malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.77734375,
            "end_logit": 7.5234375,
            "text": "mAbs CIS43 and MGG4); or individuals exposed to malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.7890625,
            "end_logit": 7.5234375,
            "text": "/AS01 (mAbs 317 and 311); an irradiated whole sporozoite vaccine PfSPZ (mAbs CIS43 and MGG4); or individuals exposed to malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.8046875,
            "end_logit": 7.5234375,
            "text": "irradiated whole sporozoite vaccine PfSPZ (mAbs CIS43 and MGG4); or individuals exposed to malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.84765625,
            "end_logit": 7.5234375,
            "text": "vaccine RTS,S/AS01 (mAbs 317 and 311); an irradiated whole sporozoite vaccine PfSPZ (mAbs CIS43 and MGG4); or individuals exposed to malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.87109375,
            "end_logit": 7.5234375,
            "text": "); or individuals exposed to malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.8984375,
            "end_logit": 7.5234375,
            "text": "); an irradiated whole sporozoite vaccine PfSPZ (mAbs CIS43 and MGG4); or individuals exposed to malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.8984375,
            "end_logit": 7.5234375,
            "text": "CSP vaccine RTS,S/AS01 (mAbs 317 and 311); an irradiated whole sporozoite vaccine PfSPZ (mAbs CIS43 and MGG4); or individuals exposed to malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.90625,
            "end_logit": 7.5234375,
            "text": "; or individuals exposed to malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.91796875,
            "end_logit": 7.5234375,
            "text": "an irradiated whole sporozoite vaccine PfSPZ (mAbs CIS43 and MGG4); or individuals exposed to malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.9296875,
            "end_logit": 7.5234375,
            "text": "mAbs 317 and 311); an irradiated whole sporozoite vaccine PfSPZ (mAbs CIS43 and MGG4); or individuals exposed to malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.53515625,
            "end_logit": -7.671875,
            "text": "AS01",
            "probability": 0.0
        },
        {
            "start_logit": -7.6953125,
            "end_logit": -7.671875,
            "text": "RTS,S/AS01",
            "probability": 0.0
        },
        {
            "start_logit": -7.7890625,
            "end_logit": -7.671875,
            "text": "/AS01",
            "probability": 0.0
        }
    ],
    "61f7d745882a024a10000038_18": [
        {
            "start_logit": 8.7265625,
            "end_logit": 7.671875,
            "text": "malaria",
            "probability": 1.0
        },
        {
            "start_logit": 8.7265625,
            "end_logit": -7.7109375,
            "text": "malaria by a simple chemoattenuated PfSPZ vaccine regimen in a randomized trial.",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.7265625,
            "end_logit": -7.87109375,
            "text": "malaria by a simple chemoattenuated PfSPZ vaccine regimen in",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.7265625,
            "end_logit": -8.03125,
            "text": "malaria by a simple chemoattenuated",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.7265625,
            "end_logit": -8.046875,
            "text": "malaria by",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.7265625,
            "end_logit": -8.1484375,
            "text": "malaria by a",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.7265625,
            "end_logit": -8.1484375,
            "text": "malaria by a simple chemoattenuated PfSPZ vaccine regimen",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.7265625,
            "end_logit": -8.15625,
            "text": "malaria by a simple chemoattenuated PfSPZ vaccine regimen in a",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.7265625,
            "end_logit": -8.15625,
            "text": "malaria by a simple chemoattenuated PfSPZ",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.7265625,
            "end_logit": -8.171875,
            "text": "malaria by a simple chemoattenuated PfSP",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.7265625,
            "end_logit": -8.1796875,
            "text": "malaria by a simple chemoatten",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.7265625,
            "end_logit": -8.2109375,
            "text": "malaria by a simple chemoattenuated PfSPZ vaccine",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.7265625,
            "end_logit": -8.2109375,
            "text": "malaria by a simple chemoattenuated PfS",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.796875,
            "end_logit": 7.671875,
            "text": "Heterologous protection against malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.88671875,
            "end_logit": 7.671875,
            "text": "against malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.94140625,
            "end_logit": 7.671875,
            "text": "protection against malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.89453125,
            "end_logit": -7.7109375,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.796875,
            "end_logit": -7.7109375,
            "text": "Heterologous protection against malaria by a simple chemoattenuated PfSPZ vaccine regimen in a randomized trial.",
            "probability": 0.0
        },
        {
            "start_logit": -7.8125,
            "end_logit": -7.7109375,
            "text": "randomized trial.",
            "probability": 0.0
        },
        {
            "start_logit": -7.88671875,
            "end_logit": -7.7109375,
            "text": "against malaria by a simple chemoattenuated PfSPZ vaccine regimen in a randomized trial.",
            "probability": 0.0
        }
    ],
    "61f7d745882a024a10000038_19": [
        {
            "start_logit": 8.7265625,
            "end_logit": 7.6796875,
            "text": "malaria",
            "probability": 1.0
        },
        {
            "start_logit": 8.7265625,
            "end_logit": -7.9140625,
            "text": "malaria at 1 year",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.7265625,
            "end_logit": -8.0078125,
            "text": "malaria at 1 year and immune correlates following PfSPZ vaccination.",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.7265625,
            "end_logit": -8.015625,
            "text": "malaria at",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.7265625,
            "end_logit": -8.1015625,
            "text": "malaria at 1",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.7265625,
            "end_logit": -8.125,
            "text": "malaria at 1 year and",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.7265625,
            "end_logit": -8.15625,
            "text": "malaria at 1 year and immune correlates",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.9375,
            "end_logit": 7.6796875,
            "text": "Protection against malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0078125,
            "end_logit": 7.6796875,
            "text": "against malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.98046875,
            "end_logit": -8.0078125,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.9375,
            "end_logit": -7.9140625,
            "text": "Protection against malaria at 1 year",
            "probability": 0.0
        },
        {
            "start_logit": -8.0078125,
            "end_logit": -7.9140625,
            "text": "against malaria at 1 year",
            "probability": 0.0
        },
        {
            "start_logit": -7.9375,
            "end_logit": -8.0078125,
            "text": "Protection against malaria at 1 year and immune correlates following PfSPZ vaccination.",
            "probability": 0.0
        },
        {
            "start_logit": -7.9375,
            "end_logit": -8.015625,
            "text": "Protection against malaria at",
            "probability": 0.0
        },
        {
            "start_logit": -8.0078125,
            "end_logit": -8.0078125,
            "text": "against malaria at 1 year and immune correlates following PfSPZ vaccination.",
            "probability": 0.0
        },
        {
            "start_logit": -7.9375,
            "end_logit": -8.1015625,
            "text": "Protection against malaria at 1",
            "probability": 0.0
        },
        {
            "start_logit": -8.0078125,
            "end_logit": -8.015625,
            "text": "against malaria at",
            "probability": 0.0
        },
        {
            "start_logit": -7.9375,
            "end_logit": -8.125,
            "text": "Protection against malaria at 1 year and",
            "probability": 0.0
        },
        {
            "start_logit": -8.0703125,
            "end_logit": -8.0078125,
            "text": "immune correlates following PfSPZ vaccination.",
            "probability": 0.0
        },
        {
            "start_logit": -7.9375,
            "end_logit": -8.15625,
            "text": "Protection against malaria at 1 year and immune correlates",
            "probability": 0.0
        }
    ],
    "61f7d745882a024a10000038_20": [
        {
            "start_logit": 8.65625,
            "end_logit": 7.74609375,
            "text": "malaria",
            "probability": 1.0
        },
        {
            "start_logit": 8.65625,
            "end_logit": -7.73046875,
            "text": "malaria infection.",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.65625,
            "end_logit": -7.8984375,
            "text": "malaria infection",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.82421875,
            "end_logit": 7.74609375,
            "text": "human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.88671875,
            "end_logit": 7.74609375,
            "text": "Attenuated PfSPZ Vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.9140625,
            "end_logit": 7.74609375,
            "text": "protection against heterologous controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.9453125,
            "end_logit": 7.74609375,
            "text": "strain-transcending T cells and durable protection against heterologous controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.03125,
            "end_logit": 7.74609375,
            "text": "T cells and durable protection against heterologous controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0390625,
            "end_logit": 7.74609375,
            "text": "PfSPZ Vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0546875,
            "end_logit": 7.74609375,
            "text": "Vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0625,
            "end_logit": 7.74609375,
            "text": "against heterologous controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0625,
            "end_logit": 7.74609375,
            "text": "controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0625,
            "end_logit": 7.74609375,
            "text": "and durable protection against heterologous controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0703125,
            "end_logit": 7.74609375,
            "text": "ending T cells and durable protection against heterologous controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.078125,
            "end_logit": 7.74609375,
            "text": "transcending T cells and durable protection against heterologous controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0859375,
            "end_logit": 7.74609375,
            "text": "PZ Vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.09375,
            "end_logit": 7.74609375,
            "text": "durable protection against heterologous controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.921875,
            "end_logit": -7.73046875,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.82421875,
            "end_logit": -7.73046875,
            "text": "human malaria infection.",
            "probability": 0.0
        },
        {
            "start_logit": -7.88671875,
            "end_logit": -7.73046875,
            "text": "Attenuated PfSPZ Vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria infection.",
            "probability": 0.0
        }
    ],
    "61f7d745882a024a10000038_21": [
        {
            "start_logit": 7.859375,
            "end_logit": 8.53125,
            "text": "malaria",
            "probability": 1.0
        },
        {
            "start_logit": -5.19921875,
            "end_logit": 8.53125,
            "text": "Plasmodium falciparum malaria",
            "probability": 2.1457672119140625e-06
        },
        {
            "start_logit": -7.0546875,
            "end_logit": 8.53125,
            "text": "falciparum malaria",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.50390625,
            "end_logit": 8.53125,
            "text": "Protection against Plasmodium falciparum malaria",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.79296875,
            "end_logit": 8.53125,
            "text": "against Plasmodium falciparum malaria",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.859375,
            "end_logit": -7.734375,
            "text": "malaria by PfSPZ Vaccine.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.859375,
            "end_logit": -7.94921875,
            "text": "malaria by",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -5.19921875,
            "end_logit": -7.734375,
            "text": "Plasmodium falciparum malaria by PfSPZ Vaccine.",
            "probability": 0.0
        },
        {
            "start_logit": -5.19921875,
            "end_logit": -7.94921875,
            "text": "Plasmodium falciparum malaria by",
            "probability": 0.0
        },
        {
            "start_logit": -5.19921875,
            "end_logit": -8.046875,
            "text": "Plasmodium falciparum",
            "probability": 0.0
        },
        {
            "start_logit": -6.89453125,
            "end_logit": -7.734375,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.0546875,
            "end_logit": -7.734375,
            "text": "falciparum malaria by PfSPZ Vaccine.",
            "probability": 0.0
        },
        {
            "start_logit": -7.0546875,
            "end_logit": -7.94921875,
            "text": "falciparum malaria by",
            "probability": 0.0
        },
        {
            "start_logit": -7.0546875,
            "end_logit": -8.046875,
            "text": "falciparum",
            "probability": 0.0
        },
        {
            "start_logit": -7.50390625,
            "end_logit": -7.734375,
            "text": "Protection against Plasmodium falciparum malaria by PfSPZ Vaccine.",
            "probability": 0.0
        },
        {
            "start_logit": -7.50390625,
            "end_logit": -7.94921875,
            "text": "Protection against Plasmodium falciparum malaria by",
            "probability": 0.0
        },
        {
            "start_logit": -7.79296875,
            "end_logit": -7.734375,
            "text": "against Plasmodium falciparum malaria by PfSPZ Vaccine.",
            "probability": 0.0
        },
        {
            "start_logit": -7.50390625,
            "end_logit": -8.046875,
            "text": "Protection against Plasmodium falciparum",
            "probability": 0.0
        },
        {
            "start_logit": -7.79296875,
            "end_logit": -7.94921875,
            "text": "against Plasmodium falciparum malaria by",
            "probability": 0.0
        },
        {
            "start_logit": -8.0546875,
            "end_logit": -7.734375,
            "text": "PfSPZ Vaccine.",
            "probability": 0.0
        }
    ],
    "61f7d745882a024a10000038_22": [
        {
            "start_logit": 8.4140625,
            "end_logit": 8.0078125,
            "text": "malaria",
            "probability": 1.0
        },
        {
            "start_logit": 8.4140625,
            "end_logit": -7.86328125,
            "text": "malaria by chemoattenuated PfSPZ vaccine.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.578125,
            "end_logit": 8.0078125,
            "text": "Sterile protection against human malaria",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.4140625,
            "end_logit": -8.0390625,
            "text": "malaria by chemoattenuated",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.4140625,
            "end_logit": -8.046875,
            "text": "malaria by",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.4140625,
            "end_logit": -8.0546875,
            "text": "malaria by chemoatten",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.4140625,
            "end_logit": -8.1171875,
            "text": "malaria by chemoattenuated PfSPZ",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.73828125,
            "end_logit": 8.0078125,
            "text": "protection against human malaria",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.4140625,
            "end_logit": -8.1484375,
            "text": "malaria by chemoattenuated PfSP",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.4140625,
            "end_logit": -8.15625,
            "text": "malaria by chemoattenuated PfSPZ vaccine",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.75390625,
            "end_logit": 8.0078125,
            "text": "human malaria",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.4140625,
            "end_logit": -8.171875,
            "text": "malaria by chemoattenuated PfS",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.98828125,
            "end_logit": 8.0078125,
            "text": "against human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.86328125,
            "end_logit": -7.86328125,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.578125,
            "end_logit": -7.86328125,
            "text": "Sterile protection against human malaria by chemoattenuated PfSPZ vaccine.",
            "probability": 0.0
        },
        {
            "start_logit": -7.73828125,
            "end_logit": -7.86328125,
            "text": "protection against human malaria by chemoattenuated PfSPZ vaccine.",
            "probability": 0.0
        },
        {
            "start_logit": -7.578125,
            "end_logit": -8.0390625,
            "text": "Sterile protection against human malaria by chemoattenuated",
            "probability": 0.0
        },
        {
            "start_logit": -7.75390625,
            "end_logit": -7.86328125,
            "text": "human malaria by chemoattenuated PfSPZ vaccine.",
            "probability": 0.0
        },
        {
            "start_logit": -7.578125,
            "end_logit": -8.046875,
            "text": "Sterile protection against human malaria by",
            "probability": 0.0
        },
        {
            "start_logit": -7.578125,
            "end_logit": -8.0546875,
            "text": "Sterile protection against human malaria by chemoatten",
            "probability": 0.0
        }
    ],
    "61f7d745882a024a10000038_23": [
        {
            "start_logit": 8.7109375,
            "end_logit": 7.6796875,
            "text": "malaria",
            "probability": 1.0
        },
        {
            "start_logit": 8.7109375,
            "end_logit": -7.8671875,
            "text": "malaria in infants in western Kenya: a double-blind, randomized, placebo-controlled phase 2 trial.",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.7109375,
            "end_logit": -8.03125,
            "text": "malaria in",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.7109375,
            "end_logit": -8.1015625,
            "text": "malaria in infants in",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.7109375,
            "end_logit": -8.1328125,
            "text": "malaria in infants in western Kenya",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.7109375,
            "end_logit": -8.1640625,
            "text": "malaria in infants",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.7109375,
            "end_logit": -8.1640625,
            "text": "malaria in infants in western Kenya: a double-blind",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.7109375,
            "end_logit": -8.1796875,
            "text": "malaria in infants in western",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.7109375,
            "end_logit": -8.1796875,
            "text": "malaria in infants in western Kenya:",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.7109375,
            "end_logit": -8.1796875,
            "text": "malaria in infants in western Kenya: a double-blind, randomized, placebo-controlled",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.94140625,
            "end_logit": 7.6796875,
            "text": "against malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0234375,
            "end_logit": 7.6796875,
            "text": "PfSPZ Vaccine against malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.03125,
            "end_logit": 7.6796875,
            "text": "Safety, immunogenicity and efficacy of PfSPZ Vaccine against malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0703125,
            "end_logit": 7.6796875,
            "text": "PZ Vaccine against malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.05859375,
            "end_logit": -7.8671875,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.81640625,
            "end_logit": -7.8671875,
            "text": "trial.",
            "probability": 0.0
        },
        {
            "start_logit": -7.859375,
            "end_logit": -7.8671875,
            "text": "phase 2 trial.",
            "probability": 0.0
        },
        {
            "start_logit": -7.91796875,
            "end_logit": -7.8671875,
            "text": "a double-blind, randomized, placebo-controlled phase 2 trial.",
            "probability": 0.0
        },
        {
            "start_logit": -7.94140625,
            "end_logit": -7.8671875,
            "text": "against malaria in infants in western Kenya: a double-blind, randomized, placebo-controlled phase 2 trial.",
            "probability": 0.0
        },
        {
            "start_logit": -7.9609375,
            "end_logit": -7.8671875,
            "text": "randomized, placebo-controlled phase 2 trial.",
            "probability": 0.0
        }
    ],
    "61f7d745882a024a10000038_24": [
        {
            "start_logit": 8.65625,
            "end_logit": 7.77734375,
            "text": "malaria",
            "probability": 1.0
        },
        {
            "start_logit": 8.65625,
            "end_logit": -8.09375,
            "text": "malaria infection (CHMI) by direct venous inoculation (DVI) of cryopreserved, infectious Plasmodium falciparum (Pf) sporozoites (",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.65625,
            "end_logit": -8.09375,
            "text": "malaria infection (CHMI) by direct venous inoculation (DVI) of cryopreserved, infectious Plasmodium falciparum",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.65625,
            "end_logit": -8.109375,
            "text": "malaria infection (CHMI) by direct venous inoculation (DVI) of cryopreserved, infectious Plasmodium falciparum (Pf) sporozoites",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.65625,
            "end_logit": -8.109375,
            "text": "malaria infection (CHMI) by",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.65625,
            "end_logit": -8.140625,
            "text": "malaria infection (CHMI) by direct venous inoculation (DVI) of cryopreserved, infectious Plasmodium falciparum (Pf) sporozoites (SPZ",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.65625,
            "end_logit": -8.15625,
            "text": "malaria infection (CHMI) by direct venous inoculation (DVI) of cryopreserved, infectious Plasmodium falciparum (Pf) sporozoites (SP",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.65625,
            "end_logit": -8.15625,
            "text": "malaria infection (CHMI) by direct venous inoculation (DVI) of cryopreserved, infectious Plasmodium falciparum (Pf) sporozoites (SPZ) (PfSPZ Challenge) to",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.65625,
            "end_logit": -8.1875,
            "text": "malaria infection (CHMI) by direct venous inoculation (DVI) of cryopreserved, infectious Plasmodium falciparum (Pf) sporozoites (SPZ)",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.65625,
            "end_logit": -8.1875,
            "text": "malaria infection (CHMI) by direct venous inoculation (DVI) of cryopreserved, infectious Plasmodium falciparum (Pf) spor",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.65625,
            "end_logit": -8.1953125,
            "text": "malaria infection (CHMI) by direct venous inoculation (DVI) of cryopreserved, infectious Plasmodium falciparum (Pf",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.65625,
            "end_logit": -8.203125,
            "text": "malaria infection (CHMI) by direct venous inoculation (",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.91796875,
            "end_logit": 7.77734375,
            "text": "We are using controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.94140625,
            "end_logit": 7.77734375,
            "text": "human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.98828125,
            "end_logit": 7.77734375,
            "text": "controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.84765625,
            "end_logit": -7.8671875,
            "text": ", infectious Plasmodium falciparum (Pf) sporozoites (SPZ) (PfSPZ Challenge) to try to reduce time and costs of developing PfSPZ Vaccine to prevent malaria in Africa",
            "probability": 0.0
        },
        {
            "start_logit": -7.9140625,
            "end_logit": -7.8671875,
            "text": "PfSPZ Challenge) to try to reduce time and costs of developing PfSPZ Vaccine to prevent malaria in Africa",
            "probability": 0.0
        },
        {
            "start_logit": -7.921875,
            "end_logit": -7.8671875,
            "text": "try to reduce time and costs of developing PfSPZ Vaccine to prevent malaria in Africa",
            "probability": 0.0
        },
        {
            "start_logit": -7.9609375,
            "end_logit": -7.8671875,
            "text": "PZ Challenge) to try to reduce time and costs of developing PfSPZ Vaccine to prevent malaria in Africa",
            "probability": 0.0
        },
        {
            "start_logit": -7.984375,
            "end_logit": -7.8671875,
            "text": "(PfSPZ Challenge) to try to reduce time and costs of developing PfSPZ Vaccine to prevent malaria in Africa",
            "probability": 0.0
        }
    ],
    "61f7d745882a024a10000038_25": [
        {
            "start_logit": 8.5390625,
            "end_logit": 7.828125,
            "text": "malaria",
            "probability": 1.0
        },
        {
            "start_logit": 8.5390625,
            "end_logit": -7.6328125,
            "text": "malaria infection (CHMI) 3 weeks after immunization, but the durability of protection is unknown.",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.5390625,
            "end_logit": -7.875,
            "text": "malaria infection (CHMI) 3 weeks",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.5390625,
            "end_logit": -7.98046875,
            "text": "malaria infection (CHMI) 3 weeks after immunization, but the durability of protection is unknown",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.5390625,
            "end_logit": -8.015625,
            "text": "malaria infection (CHMI) 3",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.5390625,
            "end_logit": -8.09375,
            "text": "malaria infection (CHMI) 3 weeks after",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.5390625,
            "end_logit": -8.09375,
            "text": "malaria infection",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.5390625,
            "end_logit": -8.1640625,
            "text": "malaria infection (CHMI) 3 weeks after immunization, but the durability of protection",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.7578125,
            "end_logit": 7.828125,
            "text": "human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.890625,
            "end_logit": 7.828125,
            "text": ", is highly protective against controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.92578125,
            "end_logit": 7.828125,
            "text": "An attenuated Plasmodium falciparum (Pf) sporozoite (SPZ) vaccine, PfSPZ Vaccine, is highly protective against controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.9453125,
            "end_logit": 7.828125,
            "text": "against controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.9453125,
            "end_logit": 7.828125,
            "text": "highly protective against controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0234375,
            "end_logit": 7.828125,
            "text": "controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0390625,
            "end_logit": 7.828125,
            "text": "Plasmodium falciparum (Pf) sporozoite (SPZ) vaccine, PfSPZ Vaccine, is highly protective against controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0546875,
            "end_logit": 7.828125,
            "text": "attenuated Plasmodium falciparum (Pf) sporozoite (SPZ) vaccine, PfSPZ Vaccine, is highly protective against controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0625,
            "end_logit": 7.828125,
            "text": ", PfSPZ Vaccine, is highly protective against controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.82421875,
            "end_logit": -7.6328125,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.7578125,
            "end_logit": -7.6328125,
            "text": "human malaria infection (CHMI) 3 weeks after immunization, but the durability of protection is unknown.",
            "probability": 0.0
        },
        {
            "start_logit": -7.890625,
            "end_logit": -7.6328125,
            "text": ", is highly protective against controlled human malaria infection (CHMI) 3 weeks after immunization, but the durability of protection is unknown.",
            "probability": 0.0
        }
    ],
    "61f7d745882a024a10000038_26": [
        {
            "start_logit": 8.78125,
            "end_logit": 7.5703125,
            "text": "malaria",
            "probability": 1.0
        },
        {
            "start_logit": 8.78125,
            "end_logit": -7.48046875,
            "text": "malaria through long-lived tissue-resident T cells and that administration of higher doses may further enhance protection.",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.78125,
            "end_logit": -7.921875,
            "text": "malaria through long-lived tissue-resident T cells and that administration of higher doses may",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.78125,
            "end_logit": -8.015625,
            "text": "malaria through",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.78125,
            "end_logit": -8.09375,
            "text": "malaria through long-lived tissue-resident T cells and",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.78125,
            "end_logit": -8.1171875,
            "text": "malaria through long-lived tissue-resident T cells and that administration of higher doses may further",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.78125,
            "end_logit": -8.1328125,
            "text": "malaria through long",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.78125,
            "end_logit": -8.140625,
            "text": "malaria through long-",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.78125,
            "end_logit": -8.140625,
            "text": "malaria through long-lived tissue-resident T cells and that administration of",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.78125,
            "end_logit": -8.1640625,
            "text": "malaria through long-lived tissue-resident T cells and that administration of higher doses may further enhance",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.78125,
            "end_logit": -8.171875,
            "text": "malaria through long-lived",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.78125,
            "end_logit": -8.1875,
            "text": "malaria through long-lived tissue-resident T cells and that",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.6640625,
            "end_logit": 7.5703125,
            "text": "Our findings suggest that PfSPZ Vaccine conferred durable protection to malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.8046875,
            "end_logit": 7.5703125,
            "text": "to malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.8984375,
            "end_logit": 7.5703125,
            "text": "findings suggest that PfSPZ Vaccine conferred durable protection to malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.9375,
            "end_logit": 7.5703125,
            "text": "protection to malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.96484375,
            "end_logit": 7.5703125,
            "text": "durable protection to malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.03125,
            "end_logit": 7.5703125,
            "text": "PfSPZ Vaccine conferred durable protection to malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0546875,
            "end_logit": 7.5703125,
            "text": "conferred durable protection to malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0625,
            "end_logit": 7.5703125,
            "text": "that PfSPZ Vaccine conferred durable protection to malaria",
            "probability": 5.960464477539063e-08
        }
    ],
    "61f7d745882a024a10000038_27": [
        {
            "start_logit": 8.8203125,
            "end_logit": 7.5546875,
            "text": "malaria",
            "probability": 1.0
        },
        {
            "start_logit": 8.8203125,
            "end_logit": -7.23828125,
            "text": "malaria vaccine, Plasmodium falciparum sporozoite vaccine (PfSPZ Vaccine), confers sterile protection against controlled human malaria infection (CHMI) with Plasmodium falciparum (Pf) parasites homologous to the vaccine strain up",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.8203125,
            "end_logit": -7.76171875,
            "text": "malaria vaccine, Plasmodium falciparum sporozoite",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.8203125,
            "end_logit": -7.80078125,
            "text": "malaria vaccine, Plasmodium falciparum sporozoite vaccine (PfSPZ Vaccine), confers sterile protection against controlled human malaria",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.8203125,
            "end_logit": -7.93359375,
            "text": "malaria vaccine, Plasmodium falciparum",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.8203125,
            "end_logit": -7.953125,
            "text": "malaria vaccine, Plasmodium falciparum sporozoite vaccine",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.8203125,
            "end_logit": -8.046875,
            "text": "malaria vaccine, Plasmodium falciparum spor",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.8203125,
            "end_logit": -8.0625,
            "text": "malaria vaccine, Plasmodium falciparum sporozoite vaccine (PfSPZ Vaccine), confers sterile protection against controlled human malaria infection (CHMI) with Plasmodium falciparum",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.8203125,
            "end_logit": -8.078125,
            "text": "malaria vaccine, Plasmodium falciparum sporozoite vaccine (PfSPZ Vaccine), confers sterile protection against controlled human malaria infection (CHMI) with Plasmodium falciparum (Pf) parasites homologous to",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.8203125,
            "end_logit": -8.1015625,
            "text": "malaria vaccine, Plasmodium falciparum sporozoite vaccine (PfSPZ Vaccine), confers sterile protection against controlled human malaria infection (CHMI) with Plasmodium falciparum (Pf) parasites homologous",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.8203125,
            "end_logit": -8.1015625,
            "text": "malaria vaccine, Plasmodium falciparum sporozoite vaccine (PfSPZ Vaccine), confers sterile protection against",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.8203125,
            "end_logit": -8.1015625,
            "text": "malaria vaccine, Plasmodium falciparum sporozoite vaccine (PfSPZ Vaccine), confers sterile protection against controlled human malaria infection (CHMI) with Plasmodium falciparum (Pf",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.8203125,
            "end_logit": -8.1015625,
            "text": "malaria vaccine, Plasmodium falciparum sporozoite vaccine (PfSPZ Vaccine), confers sterile protection against controlled human malaria infection",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.84375,
            "end_logit": 7.5546875,
            "text": "A live-attenuated malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.890625,
            "end_logit": 7.5546875,
            "text": "attenuated malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.90625,
            "end_logit": 7.5546875,
            "text": "live-attenuated malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.78515625,
            "end_logit": -7.3671875,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.69140625,
            "end_logit": -7.23828125,
            "text": "Plasmodium falciparum sporozoite vaccine (PfSPZ Vaccine), confers sterile protection against controlled human malaria infection (CHMI) with Plasmodium falciparum (Pf) parasites homologous to the vaccine strain up",
            "probability": 0.0
        },
        {
            "start_logit": -7.69140625,
            "end_logit": -7.3203125,
            "text": "Plasmodium falciparum sporozoite vaccine (PfSPZ Vaccine), confers sterile protection against controlled human malaria infection (CHMI) with Plasmodium falciparum (Pf) parasites homologous to the vaccine strain up to 14 mo",
            "probability": 0.0
        },
        {
            "start_logit": -7.81640625,
            "end_logit": -7.23828125,
            "text": "malaria infection (CHMI) with Plasmodium falciparum (Pf) parasites homologous to the vaccine strain up",
            "probability": 0.0
        }
    ],
    "61f7d745882a024a10000038_28": [
        {
            "start_logit": 8.6484375,
            "end_logit": 7.69140625,
            "text": "malaria",
            "probability": 1.0
        },
        {
            "start_logit": 8.6484375,
            "end_logit": -7.328125,
            "text": "malaria season.",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.69140625,
            "end_logit": 7.69140625,
            "text": ". PfSPZ Vaccine showed significant protection in African adults against P falciparum infection throughout an entire malaria",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.6484375,
            "end_logit": -7.86328125,
            "text": "malaria season.FUNDING: US National",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.6484375,
            "end_logit": -7.86328125,
            "text": "malaria season",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.6484375,
            "end_logit": -8.1640625,
            "text": "malaria season.FUNDING: US National In",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.60546875,
            "end_logit": 7.69140625,
            "text": "P falciparum infection throughout an entire malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.859375,
            "end_logit": 7.69140625,
            "text": "ON: PfSPZ Vaccine was well tolerated and safe. PfSPZ Vaccine showed significant protection in African adults against P falciparum infection throughout an entire malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.93359375,
            "end_logit": 7.69140625,
            "text": "significant protection in African adults against P falciparum infection throughout an entire malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.98828125,
            "end_logit": 7.69140625,
            "text": "PfSPZ Vaccine showed significant protection in African adults against P falciparum infection throughout an entire malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.99609375,
            "end_logit": 7.69140625,
            "text": "protection in African adults against P falciparum infection throughout an entire malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.99609375,
            "end_logit": 7.69140625,
            "text": "African adults against P falciparum infection throughout an entire malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.99609375,
            "end_logit": 7.69140625,
            "text": "well tolerated and safe. PfSPZ Vaccine showed significant protection in African adults against P falciparum infection throughout an entire malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0390625,
            "end_logit": 7.69140625,
            "text": "against P falciparum infection throughout an entire malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.69140625,
            "end_logit": -5.88671875,
            "text": ". PfSPZ Vaccine showed significant protection in African adults against P falciparum",
            "probability": 0.0
        },
        {
            "start_logit": -7.60546875,
            "end_logit": -5.88671875,
            "text": "P falciparum",
            "probability": 0.0
        },
        {
            "start_logit": -7.859375,
            "end_logit": -5.88671875,
            "text": "ON: PfSPZ Vaccine was well tolerated and safe. PfSPZ Vaccine showed significant protection in African adults against P falciparum",
            "probability": 0.0
        },
        {
            "start_logit": -7.93359375,
            "end_logit": -5.88671875,
            "text": "significant protection in African adults against P falciparum",
            "probability": 0.0
        },
        {
            "start_logit": -7.98828125,
            "end_logit": -5.88671875,
            "text": "PfSPZ Vaccine showed significant protection in African adults against P falciparum",
            "probability": 0.0
        },
        {
            "start_logit": -7.99609375,
            "end_logit": -5.88671875,
            "text": "protection in African adults against P falciparum",
            "probability": 0.0
        }
    ],
    "61f7d745882a024a10000038_29": [
        {
            "start_logit": 8.7265625,
            "end_logit": 7.6640625,
            "text": "malaria",
            "probability": 1.0
        },
        {
            "start_logit": 8.7265625,
            "end_logit": -7.84765625,
            "text": "malaria vaccine, PfSPZ Vaccine, protected 6 of 6 subjects (100%",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.7265625,
            "end_logit": -7.93359375,
            "text": "malaria vaccine, PfSPZ Vaccine, protected 6 of 6 subjects (100%) against homologous Pf (same strain as in the vaccine) controlled human malaria infection (CHMI) 3 weeks",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.7265625,
            "end_logit": -7.97265625,
            "text": "malaria vaccine, PfSPZ Vaccine, protected 6 of 6 subjects (100",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.7265625,
            "end_logit": -7.98046875,
            "text": "malaria vaccine, PfSPZ Vaccine, protected 6 of 6 subjects (100%) against homologous Pf (same strain as in the vaccine) controlled human malaria",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.7265625,
            "end_logit": -8.0390625,
            "text": "malaria vaccine, PfSPZ Vaccine, protected 6 of 6 subjects (100%) against homologous Pf (same strain as in the vaccine) controlled human malaria infection (CHMI) 3 weeks after",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.7265625,
            "end_logit": -8.1171875,
            "text": "malaria vaccine, PfSPZ Vaccine, protected 6 of 6 subjects (100%) against homologous Pf (same strain as",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.7265625,
            "end_logit": -8.1328125,
            "text": "malaria vaccine, PfSPZ Vaccine, protected 6 of",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.7265625,
            "end_logit": -8.15625,
            "text": "malaria vaccine, PfSPZ Vaccine, protected 6 of 6 subjects (100%) against homologous Pf (same strain as in the vaccine) controlled human malaria infection (CHMI) 3",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.7265625,
            "end_logit": -8.171875,
            "text": "malaria vaccine, PfSPZ Vaccine, protected 6 of 6 subjects (100%) against homologous Pf (same strain as in the vaccine) controlled human malaria infection",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.7265625,
            "end_logit": -8.1875,
            "text": "malaria vaccine, PfSPZ Vaccine, protected 6 of 6 subjects (100%) against homologous Pf (same strain as in the vaccine) controlled human malaria infection (CHMI",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.7265625,
            "end_logit": -8.203125,
            "text": "malaria vaccine, PfSPZ Vaccine, protected 6 of 6 subjects (100%) against homologous Pf (same",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.953125,
            "end_logit": 7.6640625,
            "text": "BACKGROUND: A radiation-attenuated Plasmodium falciparum (Pf) sporozoite (SPZ) malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.98046875,
            "end_logit": 7.6640625,
            "text": "A radiation-attenuated Plasmodium falciparum (Pf) sporozoite (SPZ) malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0078125,
            "end_logit": 7.6640625,
            "text": "Plasmodium falciparum (Pf) sporozoite (SPZ) malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0234375,
            "end_logit": 7.6640625,
            "text": "radiation-attenuated Plasmodium falciparum (Pf) sporozoite (SPZ) malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.8359375,
            "end_logit": -7.72265625,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.890625,
            "end_logit": -7.72265625,
            "text": "100%) against homologous Pf (same strain as in the vaccine) controlled human malaria infection (CHMI) 3 weeks after 5 doses administered intravenously.",
            "probability": 0.0
        },
        {
            "start_logit": -7.9140625,
            "end_logit": -7.72265625,
            "text": "the vaccine) controlled human malaria infection (CHMI) 3 weeks after 5 doses administered intravenously.",
            "probability": 0.0
        },
        {
            "start_logit": -7.9765625,
            "end_logit": -7.72265625,
            "text": "human malaria infection (CHMI) 3 weeks after 5 doses administered intravenously.",
            "probability": 0.0
        }
    ],
    "61f7d745882a024a10000038_30": [
        {
            "start_logit": 7.56640625,
            "end_logit": 7.01953125,
            "text": "malaria",
            "probability": 0.669921875
        },
        {
            "start_logit": 6.640625,
            "end_logit": 7.01953125,
            "text": "malaria sporozoite vaccine that has been reported to be safe and protective against P falciparum controlled human malaria",
            "probability": 0.264404296875
        },
        {
            "start_logit": 6.640625,
            "end_logit": 5.62109375,
            "text": "malaria",
            "probability": 0.0657958984375
        },
        {
            "start_logit": -4.3046875,
            "end_logit": 7.01953125,
            "text": "Plasmodium falciparum sporozite (PfSPZ) Vaccine is a metabolically active, non-replicating, whole malaria sporozoite vaccine that has been reported to be safe and protective against P falciparum controlled human malaria",
            "probability": 4.649162292480469e-06
        },
        {
            "start_logit": -4.3046875,
            "end_logit": 5.62109375,
            "text": "Plasmodium falciparum sporozite (PfSPZ) Vaccine is a metabolically active, non-replicating, whole malaria",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": 7.56640625,
            "end_logit": -7.265625,
            "text": "malaria infection in",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 7.56640625,
            "end_logit": -7.44140625,
            "text": "malaria infection in malaria-naive",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.56640625,
            "end_logit": -7.453125,
            "text": "malaria infection",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.56640625,
            "end_logit": -7.6796875,
            "text": "malaria infection in malaria",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.56640625,
            "end_logit": -7.7578125,
            "text": "malaria infection in malaria-",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.5703125,
            "end_logit": 7.01953125,
            "text": ", whole malaria sporozoite vaccine that has been reported to be safe and protective against P falciparum controlled human malaria",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.609375,
            "end_logit": 7.01953125,
            "text": "whole malaria sporozoite vaccine that has been reported to be safe and protective against P falciparum controlled human malaria",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 6.640625,
            "end_logit": -7.265625,
            "text": "malaria sporozoite vaccine that has been reported to be safe and protective against P falciparum controlled human malaria infection in",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 6.640625,
            "end_logit": -7.44140625,
            "text": "malaria sporozoite vaccine that has been reported to be safe and protective against P falciparum controlled human malaria infection in malaria-naive",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 6.640625,
            "end_logit": -7.453125,
            "text": "malaria sporozoite vaccine that has been reported to be safe and protective against P falciparum controlled human malaria infection",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.87109375,
            "end_logit": 7.01953125,
            "text": ", non-replicating, whole malaria sporozoite vaccine that has been reported to be safe and protective against P falciparum controlled human malaria",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 6.640625,
            "end_logit": -7.5390625,
            "text": "malaria sporozoite",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.94140625,
            "end_logit": 7.01953125,
            "text": "human malaria",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 6.640625,
            "end_logit": -7.5703125,
            "text": "malaria spor",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.0078125,
            "end_logit": 7.01953125,
            "text": "reported to be safe and protective against P falciparum controlled human malaria",
            "probability": 1.1920928955078125e-07
        }
    ],
    "61f7d745882a024a10000038_31": [
        {
            "start_logit": 8.5390625,
            "end_logit": 7.8828125,
            "text": "malaria",
            "probability": 1.0
        },
        {
            "start_logit": 8.5390625,
            "end_logit": -7.4609375,
            "text": "malaria infection ten weeks after the last dose (group III).",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.5390625,
            "end_logit": -7.9609375,
            "text": "malaria infection ten weeks after the last dose (group III",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.5390625,
            "end_logit": -7.98828125,
            "text": "malaria infection ten weeks",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.5390625,
            "end_logit": -8.0703125,
            "text": "malaria infection",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.5390625,
            "end_logit": -8.109375,
            "text": "malaria infection ten",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.5390625,
            "end_logit": -8.1328125,
            "text": "malaria infection ten weeks after",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.5390625,
            "end_logit": -8.15625,
            "text": "malaria infection ten weeks after the last",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.79296875,
            "end_logit": 7.8828125,
            "text": "human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.875,
            "end_logit": 7.8828125,
            "text": ") volunteers who underwent controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.87890625,
            "end_logit": 7.8828125,
            "text": "in 9 out of 9 (100%) volunteers who underwent controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.90234375,
            "end_logit": 7.8828125,
            "text": "controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.92578125,
            "end_logit": 7.8828125,
            "text": "infection in 9 out of 9 (100%) volunteers who underwent controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.9375,
            "end_logit": 7.8828125,
            "text": "100%) volunteers who underwent controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.94140625,
            "end_logit": 7.8828125,
            "text": "volunteers who underwent controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.95703125,
            "end_logit": 7.8828125,
            "text": "who underwent controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.96484375,
            "end_logit": 7.8828125,
            "text": "underwent controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.98046875,
            "end_logit": 7.8828125,
            "text": "prevented infection in 9 out of 9 (100%) volunteers who underwent controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.98046875,
            "end_logit": 7.8828125,
            "text": "safe, and prevented infection in 9 out of 9 (100%) volunteers who underwent controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.703125,
            "end_logit": -7.4609375,
            "text": ".",
            "probability": 0.0
        }
    ],
    "622d1ed13a8413c6530000a3_1": [
        {
            "start_logit": 10.09375,
            "end_logit": 6.52734375,
            "text": "The daughterless (da) gene in Drosophila encodes a broadly expressed transcriptional regulator whose specific functions in the control of sex determination and neurogenesis have been extensively examined.",
            "probability": 0.9931640625
        },
        {
            "start_logit": 4.66015625,
            "end_logit": 6.52734375,
            "text": "daughterless (da) gene in Drosophila encodes a broadly expressed transcriptional regulator whose specific functions in the control of sex determination and neurogenesis have been extensively examined.",
            "probability": 0.0043182373046875
        },
        {
            "start_logit": 10.09375,
            "end_logit": 0.0506591796875,
            "text": "The",
            "probability": 0.0015163421630859375
        },
        {
            "start_logit": 1.498046875,
            "end_logit": 6.52734375,
            "text": ".",
            "probability": 0.00018262863159179688
        },
        {
            "start_logit": 10.09375,
            "end_logit": -2.509765625,
            "text": "The daughterless (da) gene in",
            "probability": 0.00011783838272094727
        },
        {
            "start_logit": 10.09375,
            "end_logit": -3.3828125,
            "text": "The daughterless (da) gene in Drosophila",
            "probability": 4.9114227294921875e-05
        },
        {
            "start_logit": 10.09375,
            "end_logit": -3.80859375,
            "text": "The daughterless (da) gene in Drosophila encodes a broadly expressed transcriptional regulator",
            "probability": 3.1948089599609375e-05
        },
        {
            "start_logit": 10.09375,
            "end_logit": -4.00390625,
            "text": "The daughterless (da) gene in Drosophila encodes a broadly expressed transcriptional regulator whose",
            "probability": 2.6524066925048828e-05
        },
        {
            "start_logit": 10.09375,
            "end_logit": -4.78515625,
            "text": "The daughterless (da",
            "probability": 1.2159347534179688e-05
        },
        {
            "start_logit": 10.09375,
            "end_logit": -4.87890625,
            "text": "The daughterless (da) gene",
            "probability": 1.1086463928222656e-05
        },
        {
            "start_logit": 10.09375,
            "end_logit": -5.07421875,
            "text": "The daughterless (da) gene in Drosophila encodes a",
            "probability": 9.000301361083984e-06
        },
        {
            "start_logit": 10.09375,
            "end_logit": -5.1015625,
            "text": "The daughter",
            "probability": 8.821487426757812e-06
        },
        {
            "start_logit": 10.09375,
            "end_logit": -5.3515625,
            "text": "The daughterless (da) gene in Drosophila encodes a broadly",
            "probability": 6.854534149169922e-06
        },
        {
            "start_logit": 10.09375,
            "end_logit": -5.8203125,
            "text": "The daughterless (da)",
            "probability": 4.351139068603516e-06
        },
        {
            "start_logit": 10.09375,
            "end_logit": -5.859375,
            "text": "The daughterless (da) gene in Drosophila encodes a broadly expressed",
            "probability": 4.172325134277344e-06
        },
        {
            "start_logit": 10.09375,
            "end_logit": -6.140625,
            "text": "The daughterless (da) gene in Drosophila encodes",
            "probability": 3.159046173095703e-06
        },
        {
            "start_logit": 10.09375,
            "end_logit": -6.1875,
            "text": "The daughterless (da) gene in Drosophila encodes a broadly expressed transcriptional",
            "probability": 2.9802322387695312e-06
        },
        {
            "start_logit": 10.09375,
            "end_logit": -6.21484375,
            "text": "The daughterless (da) gene in Drosophila encodes a broadly expressed transcriptional regulator whose specific functions in the control of sex determination",
            "probability": 2.9206275939941406e-06
        },
        {
            "start_logit": 10.09375,
            "end_logit": -6.33984375,
            "text": "The daughterless (",
            "probability": 2.562999725341797e-06
        },
        {
            "start_logit": 10.09375,
            "end_logit": -6.515625,
            "text": "The daughterless (da) gene in Drosophila encodes a broadly expressed transcriptional regulator whose specific",
            "probability": 2.1457672119140625e-06
        }
    ],
    "56bc9268ac7ad1001900001b_1": [
        {
            "start_logit": 9.9140625,
            "end_logit": 9.8359375,
            "text": "interleukin-17",
            "probability": 1.0
        },
        {
            "start_logit": -1.0517578125,
            "end_logit": 9.8359375,
            "text": "17",
            "probability": 1.722574234008789e-05
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -1.24609375,
            "text": "interleukin",
            "probability": 1.5437602996826172e-05
        },
        {
            "start_logit": -6.03515625,
            "end_logit": 9.8359375,
            "text": "-17",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -7.8046875,
            "text": "interleukin-17 receptor A monoclonal antibody brodalumab has efficacy in the treatment of psoriasis.",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -7.9140625,
            "text": "interleukin-",
            "probability": 0.0
        },
        {
            "start_logit": -7.89453125,
            "end_logit": 9.8359375,
            "text": "BACKGROUND: Early clinical studies suggested that the anti-interleukin-17",
            "probability": 0.0
        },
        {
            "start_logit": -7.9765625,
            "end_logit": 9.8359375,
            "text": "Early clinical studies suggested that the anti-interleukin-17",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.0859375,
            "text": "interleukin-17 receptor",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.09375,
            "text": "interleukin-17 receptor A",
            "probability": 0.0
        },
        {
            "start_logit": -8.015625,
            "end_logit": 9.8359375,
            "text": "anti-interleukin-17",
            "probability": 0.0
        },
        {
            "start_logit": -8.0234375,
            "end_logit": 9.8359375,
            "text": "-interleukin-17",
            "probability": 0.0
        },
        {
            "start_logit": -8.03125,
            "end_logit": 9.8359375,
            "text": "the anti-interleukin-17",
            "probability": 0.0
        },
        {
            "start_logit": -8.03125,
            "end_logit": 9.8359375,
            "text": "clinical studies suggested that the anti-interleukin-17",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.1953125,
            "text": "interleukin-17 receptor A monoclonal antibody brodalumab has efficacy in the treatment of psoriasis",
            "probability": 0.0
        },
        {
            "start_logit": -1.0517578125,
            "end_logit": -7.8046875,
            "text": "17 receptor A monoclonal antibody brodalumab has efficacy in the treatment of psoriasis.",
            "probability": 0.0
        },
        {
            "start_logit": -1.0517578125,
            "end_logit": -8.0859375,
            "text": "17 receptor",
            "probability": 0.0
        },
        {
            "start_logit": -7.89453125,
            "end_logit": -1.24609375,
            "text": "BACKGROUND: Early clinical studies suggested that the anti-interleukin",
            "probability": 0.0
        },
        {
            "start_logit": -1.0517578125,
            "end_logit": -8.09375,
            "text": "17 receptor A",
            "probability": 0.0
        },
        {
            "start_logit": -7.9765625,
            "end_logit": -1.24609375,
            "text": "Early clinical studies suggested that the anti-interleukin",
            "probability": 0.0
        }
    ],
    "56bc9268ac7ad1001900001b_2": [
        {
            "start_logit": 9.890625,
            "end_logit": 9.796875,
            "text": "interleukin-17",
            "probability": 1.0
        },
        {
            "start_logit": -1.1767578125,
            "end_logit": 9.796875,
            "text": "17",
            "probability": 1.5556812286376953e-05
        },
        {
            "start_logit": 9.890625,
            "end_logit": -1.3330078125,
            "text": "interleukin",
            "probability": 1.4603137969970703e-05
        },
        {
            "start_logit": -6.19140625,
            "end_logit": 9.796875,
            "text": "-17",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.890625,
            "end_logit": -7.8515625,
            "text": "interleukin-",
            "probability": 0.0
        },
        {
            "start_logit": -7.80859375,
            "end_logit": 9.796875,
            "text": "Brodalumab, an anti-interleukin-17",
            "probability": 0.0
        },
        {
            "start_logit": -7.828125,
            "end_logit": 9.796875,
            "text": "-interleukin-17",
            "probability": 0.0
        },
        {
            "start_logit": -7.83203125,
            "end_logit": 9.796875,
            "text": "anti-interleukin-17",
            "probability": 0.0
        },
        {
            "start_logit": -7.89453125,
            "end_logit": 9.796875,
            "text": "dalumab, an anti-interleukin-17",
            "probability": 0.0
        },
        {
            "start_logit": -7.91796875,
            "end_logit": 9.796875,
            "text": "an anti-interleukin-17",
            "probability": 0.0
        },
        {
            "start_logit": -7.9296875,
            "end_logit": 9.796875,
            "text": ", an anti-interleukin-17",
            "probability": 0.0
        },
        {
            "start_logit": -7.9453125,
            "end_logit": 9.796875,
            "text": "lumab, an anti-interleukin-17",
            "probability": 0.0
        },
        {
            "start_logit": 9.890625,
            "end_logit": -8.046875,
            "text": "interleukin-17-receptor antibody for psoriasis.",
            "probability": 0.0
        },
        {
            "start_logit": -7.97265625,
            "end_logit": 9.796875,
            "text": "b, an anti-interleukin-17",
            "probability": 0.0
        },
        {
            "start_logit": -7.80859375,
            "end_logit": -1.3330078125,
            "text": "Brodalumab, an anti-interleukin",
            "probability": 0.0
        },
        {
            "start_logit": -7.828125,
            "end_logit": -1.3330078125,
            "text": "-interleukin",
            "probability": 0.0
        },
        {
            "start_logit": -7.83203125,
            "end_logit": -1.3330078125,
            "text": "anti-interleukin",
            "probability": 0.0
        },
        {
            "start_logit": -1.1767578125,
            "end_logit": -8.046875,
            "text": "17-receptor antibody for psoriasis.",
            "probability": 0.0
        },
        {
            "start_logit": -7.89453125,
            "end_logit": -1.3330078125,
            "text": "dalumab, an anti-interleukin",
            "probability": 0.0
        },
        {
            "start_logit": -7.91796875,
            "end_logit": -1.3330078125,
            "text": "an anti-interleukin",
            "probability": 0.0
        }
    ],
    "56c3184050c68dd416000003_1": [
        {
            "start_logit": 4.1953125,
            "end_logit": 4.50390625,
            "text": "essential hypertension",
            "probability": 0.998046875
        },
        {
            "start_logit": 1.5673828125,
            "end_logit": 0.7763671875,
            "text": "antihypertensive",
            "probability": 0.0017271041870117188
        },
        {
            "start_logit": -4.9609375,
            "end_logit": 4.50390625,
            "text": "hypertension",
            "probability": 0.00010538101196289062
        },
        {
            "start_logit": 4.1953125,
            "end_logit": -6.99609375,
            "text": "essential",
            "probability": 1.0132789611816406e-05
        },
        {
            "start_logit": -7.37109375,
            "end_logit": 4.50390625,
            "text": "with essential hypertension",
            "probability": 9.417533874511719e-06
        },
        {
            "start_logit": -7.625,
            "end_logit": 4.50390625,
            "text": "patients with essential hypertension",
            "probability": 7.271766662597656e-06
        },
        {
            "start_logit": 4.1953125,
            "end_logit": -7.34765625,
            "text": "essential hypertension (WHO classification I or II).",
            "probability": 7.092952728271484e-06
        },
        {
            "start_logit": -7.65625,
            "end_logit": 4.50390625,
            "text": "to patients with essential hypertension",
            "probability": 7.092952728271484e-06
        },
        {
            "start_logit": -7.76953125,
            "end_logit": 4.50390625,
            "text": ") administered for 3 years to patients with essential hypertension",
            "probability": 6.318092346191406e-06
        },
        {
            "start_logit": 1.5673828125,
            "end_logit": -7.984375,
            "text": "antihypertensive treatment with isradipine as",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 1.5673828125,
            "end_logit": -8.0625,
            "text": "antihypertensive treatment with isradipine as monotherapy (dose, 4.55 +/- 0.56 mg twice daily; n = 11) or isradipine (7.5 +/- 0",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 1.5673828125,
            "end_logit": -8.078125,
            "text": "antihypertensive treatment with isradipine as monotherapy (dose, 4.55 +/- 0.56 mg twice daily; n = 11",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 1.5673828125,
            "end_logit": -8.09375,
            "text": "antihypertensive treatment with isradipine as monotherapy (dose, 4.55 +/-",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 1.5673828125,
            "end_logit": -8.1015625,
            "text": "antihypertensive treatment",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 1.5673828125,
            "end_logit": -8.1171875,
            "text": "antihypertensive treatment with isradipine as monotherapy (dose, 4.55 +/- 0.56 mg twice daily; n = 11) or isradipine (7",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.84765625,
            "end_logit": 0.7763671875,
            "text": "preliminary data of an open multicenter trial of antihypertensive",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.88671875,
            "end_logit": 0.7763671875,
            "text": "data of an open multicenter trial of antihypertensive",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -4.9609375,
            "end_logit": -7.34765625,
            "text": "hypertension (WHO classification I or II).",
            "probability": 0.0
        },
        {
            "start_logit": -6.46875,
            "end_logit": -7.34765625,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.37109375,
            "end_logit": -6.99609375,
            "text": "with essential",
            "probability": 0.0
        }
    ],
    "56c3184050c68dd416000003_2": [
        {
            "start_logit": 2.63671875,
            "end_logit": 8.453125,
            "text": "antihypertensive drug in blacks with essential hypertension",
            "probability": 0.94140625
        },
        {
            "start_logit": -0.1463623046875,
            "end_logit": 8.453125,
            "text": "hypertension",
            "probability": 0.057861328125
        },
        {
            "start_logit": -5.60546875,
            "end_logit": 8.453125,
            "text": "essential hypertension",
            "probability": 0.0002460479736328125
        },
        {
            "start_logit": -6.54296875,
            "end_logit": 8.453125,
            "text": "in blacks with essential hypertension",
            "probability": 9.626150131225586e-05
        },
        {
            "start_logit": -6.97265625,
            "end_logit": 8.453125,
            "text": "Isradipine monotherapy was an effective antihypertensive drug in blacks with essential hypertension",
            "probability": 6.318092346191406e-05
        },
        {
            "start_logit": -7.15625,
            "end_logit": 8.453125,
            "text": "with essential hypertension",
            "probability": 5.233287811279297e-05
        },
        {
            "start_logit": 2.63671875,
            "end_logit": -1.3857421875,
            "text": "antihypertensive",
            "probability": 4.9948692321777344e-05
        },
        {
            "start_logit": -7.58984375,
            "end_logit": 8.453125,
            "text": "blacks with essential hypertension",
            "probability": 3.3855438232421875e-05
        },
        {
            "start_logit": -7.625,
            "end_logit": 8.453125,
            "text": "effective antihypertensive drug in blacks with essential hypertension",
            "probability": 3.2782554626464844e-05
        },
        {
            "start_logit": 2.63671875,
            "end_logit": -2.83984375,
            "text": "antihypertensive drug in blacks with essential hypertension, resulting in regression of left ventricular wall thickness and mass and augmentation of fractional shortening per 100 g left ventricular mass.",
            "probability": 1.1682510375976562e-05
        },
        {
            "start_logit": -0.1463623046875,
            "end_logit": -2.83984375,
            "text": "hypertension, resulting in regression of left ventricular wall thickness and mass and augmentation of fractional shortening per 100 g left ventricular mass.",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 2.63671875,
            "end_logit": -7.55078125,
            "text": "antihypertensive drug in blacks with essential hypertension, resulting in regression of left ventricular wall thickness and mass and augmentation of fractional shortening per 100 g left ventricular",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 2.63671875,
            "end_logit": -7.68359375,
            "text": "antihypertensive drug in blacks with essential hypertension, resulting in regression of left ventricular",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 2.63671875,
            "end_logit": -7.69921875,
            "text": "antihypertensive drug in blacks with essential hypertension,",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 2.63671875,
            "end_logit": -7.71875,
            "text": "antihypertensive drug in blacks with essential hypertension, resulting in regression of left ventricular wall thickness and mass and augmentation of fractional shortening per",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 2.63671875,
            "end_logit": -7.7734375,
            "text": "antihypertensive drug in blacks with essential hypertension, resulting in regression of left ventricular wall thickness and mass and augmentation of fractional shortening per 100 g left ventricular mass",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 2.63671875,
            "end_logit": -7.77734375,
            "text": "antihypertensive drug in",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 2.63671875,
            "end_logit": -7.84765625,
            "text": "antihypertensive drug in blacks with essential hypertension, resulting in regression of left ventricular wall thickness and mass and augmentation of fractional shortening per 100 g",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 2.63671875,
            "end_logit": -7.859375,
            "text": "antihypertensive drug in blacks with essential hypertension, resulting in regression of left ventricular wall thickness and mass and augmentation of fractional shortening per 100",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -4.4765625,
            "end_logit": -2.83984375,
            "text": ".",
            "probability": 0.0
        }
    ],
    "56c3184050c68dd416000003_3": [
        {
            "start_logit": 4.1953125,
            "end_logit": 4.50390625,
            "text": "essential hypertension",
            "probability": 0.998046875
        },
        {
            "start_logit": 1.5673828125,
            "end_logit": 0.7763671875,
            "text": "antihypertensive",
            "probability": 0.0017271041870117188
        },
        {
            "start_logit": -4.9609375,
            "end_logit": 4.50390625,
            "text": "hypertension",
            "probability": 0.00010538101196289062
        },
        {
            "start_logit": 4.1953125,
            "end_logit": -6.99609375,
            "text": "essential",
            "probability": 1.0132789611816406e-05
        },
        {
            "start_logit": -7.37109375,
            "end_logit": 4.50390625,
            "text": "with essential hypertension",
            "probability": 9.417533874511719e-06
        },
        {
            "start_logit": -7.625,
            "end_logit": 4.50390625,
            "text": "patients with essential hypertension",
            "probability": 7.271766662597656e-06
        },
        {
            "start_logit": 4.1953125,
            "end_logit": -7.34765625,
            "text": "essential hypertension (WHO classification I or II).",
            "probability": 7.092952728271484e-06
        },
        {
            "start_logit": -7.65625,
            "end_logit": 4.50390625,
            "text": "to patients with essential hypertension",
            "probability": 7.092952728271484e-06
        },
        {
            "start_logit": -7.76953125,
            "end_logit": 4.50390625,
            "text": ") administered for 3 years to patients with essential hypertension",
            "probability": 6.318092346191406e-06
        },
        {
            "start_logit": 1.5673828125,
            "end_logit": -7.984375,
            "text": "antihypertensive treatment with isradipine as",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 1.5673828125,
            "end_logit": -8.0625,
            "text": "antihypertensive treatment with isradipine as monotherapy (dose, 4.55 +/- 0.56 mg twice daily; n = 11) or isradipine (7.5 +/- 0",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 1.5673828125,
            "end_logit": -8.078125,
            "text": "antihypertensive treatment with isradipine as monotherapy (dose, 4.55 +/- 0.56 mg twice daily; n = 11",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 1.5673828125,
            "end_logit": -8.09375,
            "text": "antihypertensive treatment with isradipine as monotherapy (dose, 4.55 +/-",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 1.5673828125,
            "end_logit": -8.1015625,
            "text": "antihypertensive treatment",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 1.5673828125,
            "end_logit": -8.1171875,
            "text": "antihypertensive treatment with isradipine as monotherapy (dose, 4.55 +/- 0.56 mg twice daily; n = 11) or isradipine (7",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.84765625,
            "end_logit": 0.7763671875,
            "text": "preliminary data of an open multicenter trial of antihypertensive",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.88671875,
            "end_logit": 0.7763671875,
            "text": "data of an open multicenter trial of antihypertensive",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -4.9609375,
            "end_logit": -7.34765625,
            "text": "hypertension (WHO classification I or II).",
            "probability": 0.0
        },
        {
            "start_logit": -6.46875,
            "end_logit": -7.34765625,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.37109375,
            "end_logit": -6.99609375,
            "text": "with essential",
            "probability": 0.0
        }
    ],
    "56c3184050c68dd416000003_4": [
        {
            "start_logit": 7.4921875,
            "end_logit": 8.5703125,
            "text": "hypertension",
            "probability": 1.0
        },
        {
            "start_logit": -1.3076171875,
            "end_logit": 8.5703125,
            "text": "antihypertensive effect of isradipine was studied in 45 patients with mild-to-moderate hypertension",
            "probability": 0.00015115737915039062
        },
        {
            "start_logit": -7.79296875,
            "end_logit": 8.5703125,
            "text": "The antihypertensive effect of isradipine was studied in 45 patients with mild-to-moderate hypertension",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.828125,
            "end_logit": 8.5703125,
            "text": "patients with mild-to-moderate hypertension",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.890625,
            "end_logit": 8.5703125,
            "text": "with mild-to-moderate hypertension",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.90234375,
            "end_logit": 8.5703125,
            "text": "isradipine was studied in 45 patients with mild-to-moderate hypertension",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.9140625,
            "end_logit": 8.5703125,
            "text": "moderate hypertension",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.97265625,
            "end_logit": 8.5703125,
            "text": "45 patients with mild-to-moderate hypertension",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.984375,
            "end_logit": 8.5703125,
            "text": "in 45 patients with mild-to-moderate hypertension",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.98828125,
            "end_logit": 8.5703125,
            "text": "mild-to-moderate hypertension",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -8.046875,
            "end_logit": 8.5703125,
            "text": "of isradipine was studied in 45 patients with mild-to-moderate hypertension",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.4921875,
            "end_logit": -7.16015625,
            "text": "hypertension (mean age 59 years) using casual and ambulatory 24-h blood pressure measurement.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.4921875,
            "end_logit": -7.30078125,
            "text": "hypertension (mean age 59 years) using casual and ambulatory 24-h blood pressure",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.4921875,
            "end_logit": -7.859375,
            "text": "hypertension (mean age 59 years) using",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.4921875,
            "end_logit": -7.91796875,
            "text": "hypertension (mean age 59 years) using casual and ambulatory 24-h blood pressure measurement",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.4921875,
            "end_logit": -7.94921875,
            "text": "hypertension (mean age 59 years",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.4921875,
            "end_logit": -8.0390625,
            "text": "hypertension (mean age 59 years) using casual and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.4921875,
            "end_logit": -8.0390625,
            "text": "hypertension (mean age 59",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.4921875,
            "end_logit": -8.046875,
            "text": "hypertension (mean age 59 years) using casual and ambulatory 24",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.3076171875,
            "end_logit": -1.3583984375,
            "text": "antihypertensive",
            "probability": 0.0
        }
    ],
    "56c3184050c68dd416000003_5": [
        {
            "start_logit": 3.07421875,
            "end_logit": 8.046875,
            "text": "hypertension",
            "probability": 0.9873046875
        },
        {
            "start_logit": -1.3232421875,
            "end_logit": 8.046875,
            "text": "coronary flow reserve in patients with arterial hypertension",
            "probability": 0.01209259033203125
        },
        {
            "start_logit": -5.0,
            "end_logit": 8.046875,
            "text": "arterial hypertension",
            "probability": 0.0003063678741455078
        },
        {
            "start_logit": -5.1875,
            "end_logit": 8.046875,
            "text": "antihypertensive therapy with isradipine. Improvement of coronary flow reserve in patients with arterial hypertension",
            "probability": 0.00025391578674316406
        },
        {
            "start_logit": -5.75390625,
            "end_logit": 8.046875,
            "text": "Improvement of coronary flow reserve in patients with arterial hypertension",
            "probability": 0.00014472007751464844
        },
        {
            "start_logit": -6.94921875,
            "end_logit": 8.046875,
            "text": "with arterial hypertension",
            "probability": 4.3451786041259766e-05
        },
        {
            "start_logit": -7.41796875,
            "end_logit": 8.046875,
            "text": "in patients with arterial hypertension",
            "probability": 2.7179718017578125e-05
        },
        {
            "start_logit": -7.5546875,
            "end_logit": 8.046875,
            "text": "patients with arterial hypertension",
            "probability": 2.384185791015625e-05
        },
        {
            "start_logit": -7.8046875,
            "end_logit": 8.046875,
            "text": "term antihypertensive therapy with isradipine. Improvement of coronary flow reserve in patients with arterial hypertension",
            "probability": 1.8537044525146484e-05
        },
        {
            "start_logit": -7.828125,
            "end_logit": 8.046875,
            "text": "[Long-term antihypertensive therapy with isradipine. Improvement of coronary flow reserve in patients with arterial hypertension",
            "probability": 1.811981201171875e-05
        },
        {
            "start_logit": -7.875,
            "end_logit": 8.046875,
            "text": "Long-term antihypertensive therapy with isradipine. Improvement of coronary flow reserve in patients with arterial hypertension",
            "probability": 1.728534698486328e-05
        },
        {
            "start_logit": -7.99609375,
            "end_logit": 8.046875,
            "text": ". Improvement of coronary flow reserve in patients with arterial hypertension",
            "probability": 1.52587890625e-05
        },
        {
            "start_logit": -8.0234375,
            "end_logit": 8.046875,
            "text": "isradipine. Improvement of coronary flow reserve in patients with arterial hypertension",
            "probability": 1.4901161193847656e-05
        },
        {
            "start_logit": -8.046875,
            "end_logit": 8.046875,
            "text": "with isradipine. Improvement of coronary flow reserve in patients with arterial hypertension",
            "probability": 1.4543533325195312e-05
        },
        {
            "start_logit": -8.0859375,
            "end_logit": 8.046875,
            "text": "of coronary flow reserve in patients with arterial hypertension",
            "probability": 1.4007091522216797e-05
        },
        {
            "start_logit": -8.1484375,
            "end_logit": 8.046875,
            "text": "-term antihypertensive therapy with isradipine. Improvement of coronary flow reserve in patients with arterial hypertension",
            "probability": 1.3113021850585938e-05
        },
        {
            "start_logit": 3.07421875,
            "end_logit": -6.2734375,
            "text": "hypertension and microvascular angina].",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 3.07421875,
            "end_logit": -7.2734375,
            "text": "hypertension and",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 3.07421875,
            "end_logit": -7.3125,
            "text": "hypertension and microvascular angina]",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 3.07421875,
            "end_logit": -7.41015625,
            "text": "hypertension and microvascular angina",
            "probability": 1.7881393432617188e-07
        }
    ],
    "56c3184050c68dd416000003_6": [
        {
            "start_logit": 6.8046875,
            "end_logit": 6.23828125,
            "text": "arterial hypertension",
            "probability": 1.0
        },
        {
            "start_logit": -4.01171875,
            "end_logit": 6.23828125,
            "text": "hypertension",
            "probability": 1.996755599975586e-05
        },
        {
            "start_logit": 6.8046875,
            "end_logit": -5.08203125,
            "text": "arterial",
            "probability": 1.2040138244628906e-05
        },
        {
            "start_logit": 6.8046875,
            "end_logit": -7.359375,
            "text": "arterial hypertension in motor vehicle drivers",
            "probability": 1.2516975402832031e-06
        },
        {
            "start_logit": 6.8046875,
            "end_logit": -7.36328125,
            "text": "arterial hypertension in motor vehicle",
            "probability": 1.2516975402832031e-06
        },
        {
            "start_logit": 6.8046875,
            "end_logit": -7.515625,
            "text": "arterial hypertension in motor vehicle drivers].",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": 6.8046875,
            "end_logit": -7.67578125,
            "text": "arterial hypertension in motor vehicle drivers]",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": -7.23828125,
            "end_logit": 6.23828125,
            "text": "in arterial hypertension",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 6.8046875,
            "end_logit": -7.9375,
            "text": "arterial hypertension in",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 6.8046875,
            "end_logit": -7.953125,
            "text": "arterial hypertension in motor",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -7.5546875,
            "end_logit": 6.23828125,
            "text": "Isradipine in arterial hypertension",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -7.671875,
            "end_logit": 6.23828125,
            "text": "[Isradipine in arterial hypertension",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -7.9375,
            "end_logit": 6.23828125,
            "text": "dipine in arterial hypertension",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -7.94140625,
            "end_logit": 6.23828125,
            "text": "pine in arterial hypertension",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -4.01171875,
            "end_logit": -7.359375,
            "text": "hypertension in motor vehicle drivers",
            "probability": 0.0
        },
        {
            "start_logit": -4.01171875,
            "end_logit": -7.36328125,
            "text": "hypertension in motor vehicle",
            "probability": 0.0
        },
        {
            "start_logit": -4.01171875,
            "end_logit": -7.515625,
            "text": "hypertension in motor vehicle drivers].",
            "probability": 0.0
        },
        {
            "start_logit": -4.01171875,
            "end_logit": -7.67578125,
            "text": "hypertension in motor vehicle drivers]",
            "probability": 0.0
        },
        {
            "start_logit": -4.01171875,
            "end_logit": -7.9375,
            "text": "hypertension in",
            "probability": 0.0
        },
        {
            "start_logit": -4.01171875,
            "end_logit": -7.953125,
            "text": "hypertension in motor",
            "probability": 0.0
        }
    ],
    "56c3184050c68dd416000003_7": [
        {
            "start_logit": 2.234375,
            "end_logit": 9.03125,
            "text": "hypertension",
            "probability": 0.97314453125
        },
        {
            "start_logit": -1.400390625,
            "end_logit": 9.03125,
            "text": "essential hypertension",
            "probability": 0.0257415771484375
        },
        {
            "start_logit": -7.375,
            "end_logit": 9.03125,
            "text": "Evaluation of the safety and efficacy of isradipine in elderly patients with essential hypertension",
            "probability": 6.532669067382812e-05
        },
        {
            "start_logit": -7.50390625,
            "end_logit": 9.03125,
            "text": "elderly patients with essential hypertension",
            "probability": 5.7637691497802734e-05
        },
        {
            "start_logit": -7.625,
            "end_logit": 9.03125,
            "text": "with essential hypertension",
            "probability": 5.0902366638183594e-05
        },
        {
            "start_logit": -7.796875,
            "end_logit": 9.03125,
            "text": "isradipine in elderly patients with essential hypertension",
            "probability": 4.279613494873047e-05
        },
        {
            "start_logit": -7.83984375,
            "end_logit": 9.03125,
            "text": "in elderly patients with essential hypertension",
            "probability": 4.082918167114258e-05
        },
        {
            "start_logit": -7.84765625,
            "end_logit": 9.03125,
            "text": "patients with essential hypertension",
            "probability": 4.082918167114258e-05
        },
        {
            "start_logit": -7.953125,
            "end_logit": 9.03125,
            "text": "safety and efficacy of isradipine in elderly patients with essential hypertension",
            "probability": 3.6597251892089844e-05
        },
        {
            "start_logit": -7.984375,
            "end_logit": 9.03125,
            "text": "of isradipine in elderly patients with essential hypertension",
            "probability": 3.552436828613281e-05
        },
        {
            "start_logit": -7.984375,
            "end_logit": 9.03125,
            "text": "pine in elderly patients with essential hypertension",
            "probability": 3.552436828613281e-05
        },
        {
            "start_logit": -7.98828125,
            "end_logit": 9.03125,
            "text": "the safety and efficacy of isradipine in elderly patients with essential hypertension",
            "probability": 3.552436828613281e-05
        },
        {
            "start_logit": -8.0234375,
            "end_logit": 9.03125,
            "text": "dipine in elderly patients with essential hypertension",
            "probability": 3.415346145629883e-05
        },
        {
            "start_logit": -8.109375,
            "end_logit": 9.03125,
            "text": "of the safety and efficacy of isradipine in elderly patients with essential hypertension",
            "probability": 3.135204315185547e-05
        },
        {
            "start_logit": -8.109375,
            "end_logit": 9.03125,
            "text": "efficacy of isradipine in elderly patients with essential hypertension",
            "probability": 3.135204315185547e-05
        },
        {
            "start_logit": 2.234375,
            "end_logit": -7.16015625,
            "text": "hypertension.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -1.400390625,
            "end_logit": -7.16015625,
            "text": "essential hypertension.",
            "probability": 0.0
        },
        {
            "start_logit": -6.484375,
            "end_logit": -7.16015625,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.375,
            "end_logit": -7.16015625,
            "text": "Evaluation of the safety and efficacy of isradipine in elderly patients with essential hypertension.",
            "probability": 0.0
        },
        {
            "start_logit": -7.50390625,
            "end_logit": -7.16015625,
            "text": "elderly patients with essential hypertension.",
            "probability": 0.0
        }
    ],
    "56c3184050c68dd416000003_8": [
        {
            "start_logit": 7.03125,
            "end_logit": 9.015625,
            "text": "hypertension",
            "probability": 1.0
        },
        {
            "start_logit": -6.96875,
            "end_logit": 9.015625,
            "text": "treatment of hypertension",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": -7.36328125,
            "end_logit": 9.015625,
            "text": "of hypertension",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -7.66015625,
            "end_logit": 9.015625,
            "text": "A multicenter evaluation of the safety and efficacy of isradipine and atenolol in the treatment of hypertension",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -7.73046875,
            "end_logit": 9.015625,
            "text": "the treatment of hypertension",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.74609375,
            "end_logit": 9.015625,
            "text": "multicenter evaluation of the safety and efficacy of isradipine and atenolol in the treatment of hypertension",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.76171875,
            "end_logit": 9.015625,
            "text": "evaluation of the safety and efficacy of isradipine and atenolol in the treatment of hypertension",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.8046875,
            "end_logit": 9.015625,
            "text": "isradipine and atenolol in the treatment of hypertension",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.84375,
            "end_logit": 9.015625,
            "text": "in the treatment of hypertension",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.921875,
            "end_logit": 9.015625,
            "text": "safety and efficacy of isradipine and atenolol in the treatment of hypertension",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.92578125,
            "end_logit": 9.015625,
            "text": "the safety and efficacy of isradipine and atenolol in the treatment of hypertension",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.9296875,
            "end_logit": 9.015625,
            "text": "and atenolol in the treatment of hypertension",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.9375,
            "end_logit": 9.015625,
            "text": "of isradipine and atenolol in the treatment of hypertension",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.94921875,
            "end_logit": 9.015625,
            "text": "pine and atenolol in the treatment of hypertension",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.953125,
            "end_logit": 9.015625,
            "text": "dipine and atenolol in the treatment of hypertension",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.9921875,
            "end_logit": 9.015625,
            "text": "of the safety and efficacy of isradipine and atenolol in the treatment of hypertension",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.03125,
            "end_logit": -7.79296875,
            "text": "hypertension.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.73046875,
            "end_logit": -7.79296875,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -6.96875,
            "end_logit": -7.79296875,
            "text": "treatment of hypertension.",
            "probability": 0.0
        },
        {
            "start_logit": -7.36328125,
            "end_logit": -7.79296875,
            "text": "of hypertension.",
            "probability": 0.0
        }
    ],
    "56c3184050c68dd416000003_9": [
        {
            "start_logit": 7.6328125,
            "end_logit": 8.640625,
            "text": "hypertension",
            "probability": 1.0
        },
        {
            "start_logit": -7.796875,
            "end_logit": 8.640625,
            "text": "it is advisable to be very careful in the use of isradipine as a therapy for hypertension",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.8203125,
            "end_logit": 8.640625,
            "text": "for hypertension",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.8203125,
            "end_logit": 8.640625,
            "text": "isradipine as a therapy for hypertension",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.8828125,
            "end_logit": 8.640625,
            "text": "use of isradipine as a therapy for hypertension",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.91796875,
            "end_logit": 8.640625,
            "text": "therapy for hypertension",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.92578125,
            "end_logit": 8.640625,
            "text": "the use of isradipine as a therapy for hypertension",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.9453125,
            "end_logit": 8.640625,
            "text": "of isradipine as a therapy for hypertension",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.95703125,
            "end_logit": 8.640625,
            "text": "careful in the use of isradipine as a therapy for hypertension",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.95703125,
            "end_logit": 8.640625,
            "text": "is advisable to be very careful in the use of isradipine as a therapy for hypertension",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.98046875,
            "end_logit": 8.640625,
            "text": "pine as a therapy for hypertension",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.9921875,
            "end_logit": 8.640625,
            "text": "dipine as a therapy for hypertension",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.9921875,
            "end_logit": 8.640625,
            "text": "in the use of isradipine as a therapy for hypertension",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.99609375,
            "end_logit": 8.640625,
            "text": "be very careful in the use of isradipine as a therapy for hypertension",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.6328125,
            "end_logit": -7.171875,
            "text": "hypertension and other indications.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.5,
            "end_logit": -7.171875,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.796875,
            "end_logit": -7.171875,
            "text": "it is advisable to be very careful in the use of isradipine as a therapy for hypertension and other indications.",
            "probability": 0.0
        },
        {
            "start_logit": -7.8203125,
            "end_logit": -7.171875,
            "text": "for hypertension and other indications.",
            "probability": 0.0
        },
        {
            "start_logit": -7.8203125,
            "end_logit": -7.171875,
            "text": "isradipine as a therapy for hypertension and other indications.",
            "probability": 0.0
        },
        {
            "start_logit": -7.8515625,
            "end_logit": -7.171875,
            "text": "other indications.",
            "probability": 0.0
        }
    ],
    "56ffd08bcf1c325851000009_1": [
        {
            "start_logit": 8.765625,
            "end_logit": 8.1875,
            "text": "the 7SL RNA gene",
            "probability": 1.0
        },
        {
            "start_logit": 8.765625,
            "end_logit": 0.2998046875,
            "text": "the 7SL RNA gene.",
            "probability": 0.0003743171691894531
        },
        {
            "start_logit": 8.765625,
            "end_logit": -2.634765625,
            "text": "the",
            "probability": 1.996755599975586e-05
        },
        {
            "start_logit": -3.4609375,
            "end_logit": 8.1875,
            "text": "gene",
            "probability": 4.887580871582031e-06
        },
        {
            "start_logit": -4.40625,
            "end_logit": 8.1875,
            "text": "from the 7SL RNA gene",
            "probability": 1.9073486328125e-06
        },
        {
            "start_logit": -5.31640625,
            "end_logit": 8.1875,
            "text": "7SL RNA gene",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": -5.3828125,
            "end_logit": 8.1875,
            "text": "Alu elements are each a dimer of similar, but not identical, fragments of total size about 300 bp, and originate from the 7SL RNA gene",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 8.765625,
            "end_logit": -6.796875,
            "text": "the 7SL RNA",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.47265625,
            "end_logit": 8.1875,
            "text": "SL RNA gene",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.765625,
            "end_logit": -7.296875,
            "text": "the 7S",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.765625,
            "end_logit": -7.33984375,
            "text": "the 7SL",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.7890625,
            "end_logit": 8.1875,
            "text": "L RNA gene",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.96484375,
            "end_logit": 8.1875,
            "text": "300 bp, and originate from the 7SL RNA gene",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.765625,
            "end_logit": -7.6875,
            "text": "the 7",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.19140625,
            "end_logit": 8.1875,
            "text": "RNA gene",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.29296875,
            "end_logit": 8.1875,
            "text": "size about 300 bp, and originate from the 7SL RNA gene",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.3359375,
            "end_logit": 8.1875,
            "text": "originate from the 7SL RNA gene",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.3671875,
            "end_logit": 8.1875,
            "text": "about 300 bp, and originate from the 7SL RNA gene",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.79296875,
            "end_logit": 8.1875,
            "text": ", but not identical, fragments of total size about 300 bp, and originate from the 7SL RNA gene",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.79296875,
            "end_logit": 8.1875,
            "text": ", fragments of total size about 300 bp, and originate from the 7SL RNA gene",
            "probability": 5.960464477539063e-08
        }
    ],
    "58cf5c5a8acda34529000003_1": [
        {
            "start_logit": 0.78759765625,
            "end_logit": 2.1953125,
            "text": "\u03b2-D-glucosyl-hydroxymethyluracil",
            "probability": 0.9697265625
        },
        {
            "start_logit": -2.708984375,
            "end_logit": 0.8525390625,
            "text": ".",
            "probability": 0.007671356201171875
        },
        {
            "start_logit": -3.044921875,
            "end_logit": 0.8525390625,
            "text": "in telomeric repeats (99%) and in regions where transcription starts and stops.",
            "probability": 0.00550079345703125
        },
        {
            "start_logit": -3.388671875,
            "end_logit": 0.8525390625,
            "text": "T in the Leishmania genome and is only found in telomeric repeats (99%) and in regions where transcription starts and stops.",
            "probability": 0.003902435302734375
        },
        {
            "start_logit": -5.34765625,
            "end_logit": 2.1953125,
            "text": "-D-glucosyl-hydroxymethyluracil",
            "probability": 0.002105712890625
        },
        {
            "start_logit": -4.09765625,
            "end_logit": 0.8525390625,
            "text": "1% of T in the Leishmania genome and is only found in telomeric repeats (99%) and in regions where transcription starts and stops.",
            "probability": 0.0019159317016601562
        },
        {
            "start_logit": -5.515625,
            "end_logit": 2.1953125,
            "text": "(\u03b2-D-glucosyl-hydroxymethyluracil",
            "probability": 0.0017728805541992188
        },
        {
            "start_logit": 0.78759765625,
            "end_logit": -4.32421875,
            "text": "\u03b2-D-glucosyl-hydroxymethyluracil) replaces 1% of T in the Leishmania genome and is only found in telomeric repeats (99",
            "probability": 0.0014295578002929688
        },
        {
            "start_logit": -6.1484375,
            "end_logit": 2.1953125,
            "text": "-glucosyl-hydroxymethyluracil",
            "probability": 0.0009412765502929688
        },
        {
            "start_logit": -6.1875,
            "end_logit": 2.1953125,
            "text": "glucosyl-hydroxymethyluracil",
            "probability": 0.0009055137634277344
        },
        {
            "start_logit": -6.55859375,
            "end_logit": 2.1953125,
            "text": "D-glucosyl-hydroxymethyluracil",
            "probability": 0.0006270408630371094
        },
        {
            "start_logit": -6.640625,
            "end_logit": 2.1953125,
            "text": "osyl-hydroxymethyluracil",
            "probability": 0.0005750656127929688
        },
        {
            "start_logit": -6.7890625,
            "end_logit": 2.1953125,
            "text": "Base J (\u03b2-D-glucosyl-hydroxymethyluracil",
            "probability": 0.00049591064453125
        },
        {
            "start_logit": -6.8203125,
            "end_logit": 2.1953125,
            "text": "hydroxymethyluracil",
            "probability": 0.00048089027404785156
        },
        {
            "start_logit": -5.54296875,
            "end_logit": 0.8525390625,
            "text": "replaces 1% of T in the Leishmania genome and is only found in telomeric repeats (99%) and in regions where transcription starts and stops.",
            "probability": 0.0004515647888183594
        },
        {
            "start_logit": 0.78759765625,
            "end_logit": -5.52734375,
            "text": "\u03b2-D-glucosyl-hydroxymethyluracil) replaces 1% of T",
            "probability": 0.000431060791015625
        },
        {
            "start_logit": -6.93359375,
            "end_logit": 2.1953125,
            "text": "-hydroxymethyluracil",
            "probability": 0.000431060791015625
        },
        {
            "start_logit": -7.0546875,
            "end_logit": 2.1953125,
            "text": "uracil",
            "probability": 0.0003802776336669922
        },
        {
            "start_logit": 0.78759765625,
            "end_logit": -5.83203125,
            "text": "\u03b2-D-glucosyl-hydroxymethyluracil) replaces 1% of T in the Leishmania genome and is only found in telomeric repeats (99%",
            "probability": 0.00031757354736328125
        },
        {
            "start_logit": 0.78759765625,
            "end_logit": -6.0625,
            "text": "\u03b2-D-glucosyl-hydroxymethyluracil) replaces 1% of T in the Leishmania genome and",
            "probability": 0.0002512931823730469
        }
    ],
    "58cf5c5a8acda34529000003_2": [
        {
            "start_logit": -0.11322021484375,
            "end_logit": 2.84765625,
            "text": "\u03b2-D-glucosyl-hydroxymethyluracil",
            "probability": 0.98193359375
        },
        {
            "start_logit": -5.71484375,
            "end_logit": 2.84765625,
            "text": "-D-glucosyl-hydroxymethyluracil",
            "probability": 0.0036258697509765625
        },
        {
            "start_logit": -5.9375,
            "end_logit": 2.84765625,
            "text": "(\u03b2-D-glucosyl-hydroxymethyluracil",
            "probability": 0.0029010772705078125
        },
        {
            "start_logit": -6.4296875,
            "end_logit": 2.84765625,
            "text": "glucosyl-hydroxymethyluracil",
            "probability": 0.0017728805541992188
        },
        {
            "start_logit": -6.44921875,
            "end_logit": 2.84765625,
            "text": "-glucosyl-hydroxymethyluracil",
            "probability": 0.001739501953125
        },
        {
            "start_logit": -6.70703125,
            "end_logit": 2.84765625,
            "text": "D-glucosyl-hydroxymethyluracil",
            "probability": 0.0013437271118164062
        },
        {
            "start_logit": -6.8359375,
            "end_logit": 2.84765625,
            "text": "hydroxymethyluracil",
            "probability": 0.0011816024780273438
        },
        {
            "start_logit": -6.8359375,
            "end_logit": 2.84765625,
            "text": "osyl-hydroxymethyluracil",
            "probability": 0.0011816024780273438
        },
        {
            "start_logit": -6.8515625,
            "end_logit": 2.84765625,
            "text": "cil",
            "probability": 0.0011625289916992188
        },
        {
            "start_logit": -7.07421875,
            "end_logit": 2.84765625,
            "text": "uracil",
            "probability": 0.0009312629699707031
        },
        {
            "start_logit": -7.1328125,
            "end_logit": 2.84765625,
            "text": "-hydroxymethyluracil",
            "probability": 0.0008778572082519531
        },
        {
            "start_logit": -0.11322021484375,
            "end_logit": -4.46875,
            "text": "\u03b2-D-glucosyl-hydroxymethyluracil) replaces 1% of T in the Leishmania genome and is only found in telomeric repeats (99",
            "probability": 0.0006527900695800781
        },
        {
            "start_logit": -0.11322021484375,
            "end_logit": -5.859375,
            "text": "\u03b2-D-glucosyl-hydroxymethyluracil) replaces 1% of T in the Leishmania genome and is only found in telomeric repeats (99%",
            "probability": 0.00016307830810546875
        },
        {
            "start_logit": -0.11322021484375,
            "end_logit": -5.953125,
            "text": "\u03b2-D-glucosyl-hydroxymethyluracil) replaces 1% of T in the Leishmania genome and is only found in telomeric repeats",
            "probability": 0.00014841556549072266
        },
        {
            "start_logit": -0.11322021484375,
            "end_logit": -5.99609375,
            "text": "\u03b2-D-glucosyl-hydroxymethyluracil) replaces 1% of T in the Leishmania genome and",
            "probability": 0.00014162063598632812
        },
        {
            "start_logit": -0.11322021484375,
            "end_logit": -6.3984375,
            "text": "\u03b2-D-glucosyl-hydroxymethyluracil) replaces 1% of T",
            "probability": 9.435415267944336e-05
        },
        {
            "start_logit": -0.11322021484375,
            "end_logit": -6.4453125,
            "text": "\u03b2-D-glucosyl-hydroxymethyluracil) replaces 1%",
            "probability": 9.006261825561523e-05
        },
        {
            "start_logit": -0.11322021484375,
            "end_logit": -6.83984375,
            "text": "\u03b2-D-glucosyl-hydroxymethyluracil) replaces 1% of T in the Leishmania genome and is only",
            "probability": 6.091594696044922e-05
        },
        {
            "start_logit": -0.11322021484375,
            "end_logit": -6.94921875,
            "text": "\u03b2-D-glucosyl-hydroxymethyluracil) replaces 1% of T in",
            "probability": 5.459785461425781e-05
        },
        {
            "start_logit": -0.11322021484375,
            "end_logit": -7.0078125,
            "text": "\u03b2-D-glucosyl-hydroxymethyluracil) replaces 1% of T in the Leishmania genome and is only found in telomeric",
            "probability": 5.131959915161133e-05
        }
    ],
    "61f86c03882a024a10000044_1": [
        {
            "start_logit": -0.466552734375,
            "end_logit": 9.1328125,
            "text": "recessive hereditary motor neuropathy",
            "probability": 0.6845703125
        },
        {
            "start_logit": -2.142578125,
            "end_logit": 9.1328125,
            "text": "An ancestral 10-bp repeat expansion in VWA1 causes recessive hereditary motor neuropathy",
            "probability": 0.1285400390625
        },
        {
            "start_logit": -2.634765625,
            "end_logit": 9.1328125,
            "text": "neuropathy",
            "probability": 0.07861328125
        },
        {
            "start_logit": -3.04296875,
            "end_logit": 9.1328125,
            "text": "motor neuropathy",
            "probability": 0.05218505859375
        },
        {
            "start_logit": -3.09375,
            "end_logit": 9.1328125,
            "text": "hereditary motor neuropathy",
            "probability": 0.049591064453125
        },
        {
            "start_logit": -7.0859375,
            "end_logit": 9.1328125,
            "text": "ancestral 10-bp repeat expansion in VWA1 causes recessive hereditary motor neuropathy",
            "probability": 0.0009150505065917969
        },
        {
            "start_logit": -7.25,
            "end_logit": 9.1328125,
            "text": "10-bp repeat expansion in VWA1 causes recessive hereditary motor neuropathy",
            "probability": 0.0007767677307128906
        },
        {
            "start_logit": -7.34375,
            "end_logit": 9.1328125,
            "text": "causes recessive hereditary motor neuropathy",
            "probability": 0.0007071495056152344
        },
        {
            "start_logit": -7.3515625,
            "end_logit": 9.1328125,
            "text": "VWA1 causes recessive hereditary motor neuropathy",
            "probability": 0.000701904296875
        },
        {
            "start_logit": -7.421875,
            "end_logit": 9.1328125,
            "text": "in VWA1 causes recessive hereditary motor neuropathy",
            "probability": 0.0006542205810546875
        },
        {
            "start_logit": -7.49609375,
            "end_logit": 9.1328125,
            "text": "A1 causes recessive hereditary motor neuropathy",
            "probability": 0.0006074905395507812
        },
        {
            "start_logit": -7.59375,
            "end_logit": 9.1328125,
            "text": "expansion in VWA1 causes recessive hereditary motor neuropathy",
            "probability": 0.0005507469177246094
        },
        {
            "start_logit": -7.640625,
            "end_logit": 9.1328125,
            "text": "bp repeat expansion in VWA1 causes recessive hereditary motor neuropathy",
            "probability": 0.0005254745483398438
        },
        {
            "start_logit": -7.69140625,
            "end_logit": 9.1328125,
            "text": "repeat expansion in VWA1 causes recessive hereditary motor neuropathy",
            "probability": 0.000499725341796875
        },
        {
            "start_logit": -7.9609375,
            "end_logit": 9.1328125,
            "text": "-bp repeat expansion in VWA1 causes recessive hereditary motor neuropathy",
            "probability": 0.0003814697265625
        },
        {
            "start_logit": -0.466552734375,
            "end_logit": -4.59765625,
            "text": "recessive hereditary motor neuropathy.",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -2.142578125,
            "end_logit": -4.59765625,
            "text": "An ancestral 10-bp repeat expansion in VWA1 causes recessive hereditary motor neuropathy.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -2.634765625,
            "end_logit": -4.59765625,
            "text": "neuropathy.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -3.04296875,
            "end_logit": -4.59765625,
            "text": "motor neuropathy.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -3.09375,
            "end_logit": -4.59765625,
            "text": "hereditary motor neuropathy.",
            "probability": 5.960464477539063e-08
        }
    ],
    "5c6e16eb7c78d6947100004e_1": [
        {
            "start_logit": 9.4296875,
            "end_logit": 9.3828125,
            "text": "cystic fibrosis",
            "probability": 1.0
        },
        {
            "start_logit": -2.22265625,
            "end_logit": 9.3828125,
            "text": "fibrosis",
            "probability": 8.64267349243164e-06
        },
        {
            "start_logit": 9.4296875,
            "end_logit": -2.373046875,
            "text": "cystic",
            "probability": 7.808208465576172e-06
        },
        {
            "start_logit": -7.32421875,
            "end_logit": 9.3828125,
            "text": "diagnosis of cystic fibrosis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.4296875,
            "end_logit": -7.58984375,
            "text": "cystic fibrosis (CF) involves sweat induction, collection and handling, and measurement in an analytical lab.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.4296875,
            "end_logit": -7.7890625,
            "text": "cystic fibrosis (CF)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.4296875,
            "end_logit": -7.85546875,
            "text": "cystic fibrosis (CF) involves",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.4296875,
            "end_logit": -7.87109375,
            "text": "cystic fibrosis (CF",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.4296875,
            "end_logit": -7.87890625,
            "text": "cystic fibrosis (CF) involves sweat induction",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.4296875,
            "end_logit": -7.9375,
            "text": "cystic fibrosis (CF) involves sweat induction, collection",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.4296875,
            "end_logit": -7.96484375,
            "text": "cystic fibrosis (CF) involves sweat induction,",
            "probability": 0.0
        },
        {
            "start_logit": 9.4296875,
            "end_logit": -8.0390625,
            "text": "cystic fibrosis (CF) involves sweat induction, collection and handling, and measurement in an",
            "probability": 0.0
        },
        {
            "start_logit": 9.4296875,
            "end_logit": -8.046875,
            "text": "cystic fibrosis (CF) involves sweat induction, collection and",
            "probability": 0.0
        },
        {
            "start_logit": -8.0234375,
            "end_logit": 9.3828125,
            "text": "of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": 9.4296875,
            "end_logit": -8.078125,
            "text": "cystic fibrosis (CF) involves sweat induction, collection and handling",
            "probability": 0.0
        },
        {
            "start_logit": -8.0390625,
            "end_logit": 9.3828125,
            "text": "BACKGROUND: Sweat chloride testing for diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.046875,
            "end_logit": 9.3828125,
            "text": "for diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.0625,
            "end_logit": 9.3828125,
            "text": "Sweat chloride testing for diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": 9.4296875,
            "end_logit": -8.1171875,
            "text": "cystic fibrosis (CF) involves sweat induction, collection and handling, and measurement in an analytical lab",
            "probability": 0.0
        },
        {
            "start_logit": 9.4296875,
            "end_logit": -8.125,
            "text": "cystic fibrosis (CF) involves sweat induction, collection and handling, and measurement in",
            "probability": 0.0
        }
    ],
    "5c6e16eb7c78d6947100004e_2": [
        {
            "start_logit": 9.53125,
            "end_logit": 8.828125,
            "text": "cystic fibrosis",
            "probability": 1.0
        },
        {
            "start_logit": 9.53125,
            "end_logit": -2.212890625,
            "text": "cystic",
            "probability": 1.6033649444580078e-05
        },
        {
            "start_logit": -3.236328125,
            "end_logit": 8.828125,
            "text": "fibrosis",
            "probability": 2.86102294921875e-06
        },
        {
            "start_logit": 9.53125,
            "end_logit": -7.65234375,
            "text": "cystic fibrosis transmembrane conductance regulator) mutations and reasons to indicate the ST, as well as correlating sweat sodium and sweat chloride concentrations in subjects.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.53125,
            "end_logit": -7.76953125,
            "text": "cystic fibrosis transmembrane",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.53125,
            "end_logit": -7.82421875,
            "text": "cystic fibrosis transmembrane conductance",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.53125,
            "end_logit": -7.8984375,
            "text": "cystic fibrosis transmembrane conductance regulator",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.53125,
            "end_logit": -7.96875,
            "text": "cystic fibrosis transmembrane conductance regulator) mutations and reasons to",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.53125,
            "end_logit": -8.0078125,
            "text": "cystic fibrosis transmembrane conductance regulator) mutations and reasons to indicate the ST, as well as correlating sweat sodium and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.53125,
            "end_logit": -8.0078125,
            "text": "cystic fibrosis transmembrane conductance regulator) mutations and reasons to indicate the ST, as well as",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.53125,
            "end_logit": -8.0234375,
            "text": "cystic fibrosis transmembrane conductance regulator) mutations and reasons to indicate the ST, as well",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.53125,
            "end_logit": -8.0390625,
            "text": "cystic fibrosis transmembrane conductance regulator) mutations and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.53125,
            "end_logit": -8.0703125,
            "text": "cystic fibrosis transmembrane conductance regulator) mutations and reasons to indicate the ST, as well as correlating sweat sodium and sweat chloride concentrations",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.53125,
            "end_logit": -8.078125,
            "text": "cystic fibrosis transmembrane conductance regulator) mutations and reasons to indicate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.94921875,
            "end_logit": 8.828125,
            "text": "Objective: To conduct a descriptive analysis of the sweat test (ST), associating ST results with epidemiological data, CFTR (cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -7.984375,
            "end_logit": 8.828125,
            "text": "(cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.0703125,
            "end_logit": 8.828125,
            "text": "sweat test (ST), associating ST results with epidemiological data, CFTR (cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.1171875,
            "end_logit": 8.828125,
            "text": "To conduct a descriptive analysis of the sweat test (ST), associating ST results with epidemiological data, CFTR (cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.125,
            "end_logit": 8.828125,
            "text": "ST results with epidemiological data, CFTR (cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.15625,
            "end_logit": 8.828125,
            "text": "test (ST), associating ST results with epidemiological data, CFTR (cystic fibrosis",
            "probability": 0.0
        }
    ],
    "5c6e16eb7c78d6947100004e_3": [
        {
            "start_logit": 9.5,
            "end_logit": 9.515625,
            "text": "Cystic Fibrosis",
            "probability": 1.0
        },
        {
            "start_logit": -1.837890625,
            "end_logit": 9.515625,
            "text": "Fibrosis",
            "probability": 1.1920928955078125e-05
        },
        {
            "start_logit": 9.5,
            "end_logit": -2.234375,
            "text": "Cystic",
            "probability": 7.867813110351562e-06
        },
        {
            "start_logit": 9.5,
            "end_logit": -7.21875,
            "text": "Cystic Fibrosis Infants: Revealing Mechanisms beyond Impaired Chloride Transport.The sweat chloride test remains the gold standard for confirmatory diagnosis of cystic fibrosis (CF) in support of universal newborn screening programs.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.5,
            "end_logit": -7.21875,
            "text": "Cystic Fibrosis Infants: Revealing Mechanisms beyond Impaired Chloride Transport.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.5,
            "end_logit": -7.53125,
            "text": "Cystic Fibrosis Infants: Revealing Mechanisms beyond Impaired Chloride Transport.The sweat chloride test remains the gold standard",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.5,
            "end_logit": -7.61328125,
            "text": "Cystic Fibrosis Infants: Revealing Mechanisms beyond Impaired Chloride Transport.The sweat chloride test remains the gold standard for confirmatory diagnosis of cystic fibrosis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.5,
            "end_logit": -7.72265625,
            "text": "Cystic Fibrosis Infants: Revealing Mechanisms beyond Impaired Chloride Transport.The sweat chloride test remains the gold standard for confirmatory diagnosis of cystic fibrosis (CF) in",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.5,
            "end_logit": -7.80078125,
            "text": "Cystic Fibrosis Infants: Revealing Mechanisms beyond Impaired Chloride Transport.The sweat chloride test remains the gold standard for confirmatory diagnosis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.5,
            "end_logit": -7.8046875,
            "text": "Cystic Fibrosis Infants: Revealing Mechanisms beyond Impaired Chloride Transport.The sweat chloride test remains the gold standard for confirmatory diagnosis of cystic fibrosis (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.5,
            "end_logit": -7.8515625,
            "text": "Cystic Fibrosis Infants: Revealing Mechanisms beyond Impaired Chloride Transport.The sweat chloride test remains the gold standard for confirmatory diagnosis of cystic fibrosis (CF) in support",
            "probability": 0.0
        },
        {
            "start_logit": 9.5,
            "end_logit": -7.87109375,
            "text": "Cystic Fibrosis Infants: Revealing Mechanisms beyond Impaired Chloride Transport.The sweat chloride test remains the gold standard for confirmatory diagnosis of cystic fibrosis (CF",
            "probability": 0.0
        },
        {
            "start_logit": 9.5,
            "end_logit": -7.8984375,
            "text": "Cystic Fibrosis Infants",
            "probability": 0.0
        },
        {
            "start_logit": 9.5,
            "end_logit": -7.90625,
            "text": "Cystic Fibrosis Infants: Revealing Mechanisms beyond Impaired Chloride Transport.The sweat chloride test remains the gold standard for confirmatory diagnosis of cystic fibrosis (CF) in support of",
            "probability": 0.0
        },
        {
            "start_logit": 9.5,
            "end_logit": -7.91015625,
            "text": "Cystic Fibrosis Infants:",
            "probability": 0.0
        },
        {
            "start_logit": 9.5,
            "end_logit": -7.91796875,
            "text": "Cystic Fibrosis Infants: Revealing Mechanisms beyond Impaired Chloride Transport.The sweat chloride test remains the gold standard for confirmatory diagnosis of cystic fibrosis (CF) in support of universal newborn screening programs",
            "probability": 0.0
        },
        {
            "start_logit": 9.5,
            "end_logit": -7.91796875,
            "text": "Cystic Fibrosis Infants: Revealing Mechanisms beyond Impaired Chloride Transport.The sweat chloride test remains the gold standard for confirmatory diagnosis of cystic fibrosis (CF) in support of universal newborn screening",
            "probability": 0.0
        },
        {
            "start_logit": 9.5,
            "end_logit": -7.921875,
            "text": "Cystic Fibrosis Infants: Revealing Mechanisms beyond Impaired Chloride Transport",
            "probability": 0.0
        },
        {
            "start_logit": -8.140625,
            "end_logit": 9.515625,
            "text": "Sweat Metabolome of Screen-Positive Cystic Fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.1796875,
            "end_logit": 9.515625,
            "text": "The Sweat Metabolome of Screen-Positive Cystic Fibrosis",
            "probability": 0.0
        }
    ],
    "5c6e16eb7c78d6947100004e_4": [
        {
            "start_logit": 9.4609375,
            "end_logit": 9.453125,
            "text": "Cystic Fibrosis",
            "probability": 1.0
        },
        {
            "start_logit": -2.11328125,
            "end_logit": 9.453125,
            "text": "Fibrosis",
            "probability": 9.5367431640625e-06
        },
        {
            "start_logit": 9.4609375,
            "end_logit": -2.3125,
            "text": "Cystic",
            "probability": 7.808208465576172e-06
        },
        {
            "start_logit": 9.4609375,
            "end_logit": -7.43359375,
            "text": "Cystic Fibrosis Patients.The diagnosis is often delayed and the disease is advanced in most patients at the time of diagnosis.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.4609375,
            "end_logit": -7.43359375,
            "text": "Cystic Fibrosis Patients.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.4609375,
            "end_logit": -7.578125,
            "text": "Cystic Fibrosis Patients.The diagnosis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.4609375,
            "end_logit": -7.875,
            "text": "Cystic Fibrosis Patients.The diagnosis is often delayed and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.4609375,
            "end_logit": -7.9296875,
            "text": "Cystic Fibrosis Patients",
            "probability": 0.0
        },
        {
            "start_logit": 9.4609375,
            "end_logit": -7.9375,
            "text": "Cystic Fibrosis Patients.The diagnosis is often delayed and the disease is advanced in most patients at",
            "probability": 0.0
        },
        {
            "start_logit": 9.4609375,
            "end_logit": -7.9765625,
            "text": "Cystic Fibrosis Patients.The diagnosis is",
            "probability": 0.0
        },
        {
            "start_logit": 9.4609375,
            "end_logit": -7.99609375,
            "text": "Cystic Fibrosis Patients.The diagnosis is often delayed and the disease is advanced in",
            "probability": 0.0
        },
        {
            "start_logit": 9.4609375,
            "end_logit": -8.015625,
            "text": "Cystic Fibrosis Patients.The diagnosis is often delayed and the disease is advanced in most patients at the time of",
            "probability": 0.0
        },
        {
            "start_logit": 9.4609375,
            "end_logit": -8.0234375,
            "text": "Cystic Fibrosis Patients.The diagnosis is often delayed and the disease is",
            "probability": 0.0
        },
        {
            "start_logit": 9.4609375,
            "end_logit": -8.03125,
            "text": "Cystic Fibrosis Patients.The diagnosis is often",
            "probability": 0.0
        },
        {
            "start_logit": 9.4609375,
            "end_logit": -8.03125,
            "text": "Cystic Fibrosis Patients.The diagnosis is often delayed",
            "probability": 0.0
        },
        {
            "start_logit": -8.0234375,
            "end_logit": 9.453125,
            "text": "Assessment of Correlation between Sweat Chloride Levels and Clinical Features of Cystic Fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": 9.4609375,
            "end_logit": -8.046875,
            "text": "Cystic Fibrosis Patients.The diagnosis is often delayed and the disease is advanced in most patients at the",
            "probability": 0.0
        },
        {
            "start_logit": -8.1484375,
            "end_logit": 9.453125,
            "text": "of Cystic Fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -2.11328125,
            "end_logit": -7.43359375,
            "text": "Fibrosis Patients.The diagnosis is often delayed and the disease is advanced in most patients at the time of diagnosis.",
            "probability": 0.0
        },
        {
            "start_logit": -2.11328125,
            "end_logit": -7.43359375,
            "text": "Fibrosis Patients.",
            "probability": 0.0
        }
    ],
    "5c6e16eb7c78d6947100004e_5": [
        {
            "start_logit": 9.390625,
            "end_logit": 9.2890625,
            "text": "cystic fibrosis",
            "probability": 1.0
        },
        {
            "start_logit": 9.390625,
            "end_logit": -2.447265625,
            "text": "cystic",
            "probability": 7.927417755126953e-06
        },
        {
            "start_logit": -2.41015625,
            "end_logit": 9.2890625,
            "text": "fibrosis",
            "probability": 7.3909759521484375e-06
        },
        {
            "start_logit": -6.27734375,
            "end_logit": 9.2890625,
            "text": "In cystic fibrosis",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.390625,
            "end_logit": -6.84375,
            "text": "cystic fibrosis (CF), sweat chloride concentration has been proposed as an index of CFTR function for testing systemic drugs designed to activate mutant CFTR.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.390625,
            "end_logit": -7.84765625,
            "text": "cystic fibrosis (CF)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.390625,
            "end_logit": -7.86328125,
            "text": "cystic fibrosis (CF), sweat chloride concentration has been proposed as an index of CFTR function for",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.390625,
            "end_logit": -7.90625,
            "text": "cystic fibrosis (CF), sweat chloride concentration has",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.390625,
            "end_logit": -7.90625,
            "text": "cystic fibrosis (CF), sweat chloride concentration has been proposed as an index of CFTR function",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.390625,
            "end_logit": -7.91796875,
            "text": "cystic fibrosis (CF), sweat chloride concentration has been",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.390625,
            "end_logit": -7.94921875,
            "text": "cystic fibrosis (CF",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.390625,
            "end_logit": -7.98046875,
            "text": "cystic fibrosis (CF), sweat chloride concentration has been proposed as",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.390625,
            "end_logit": -7.9921875,
            "text": "cystic fibrosis (CF), sweat chloride concentration has been proposed",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.390625,
            "end_logit": -8.0078125,
            "text": "cystic fibrosis (CF), sweat chloride concentration has been proposed as an index of CFTR function for testing systemic drugs designed to activate mutant CFTR",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.390625,
            "end_logit": -8.0078125,
            "text": "cystic fibrosis (CF), sweat chloride concentration has been proposed as an index of CFTR function for testing systemic drugs designed",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.390625,
            "end_logit": -8.015625,
            "text": "cystic fibrosis (CF), sweat chloride concentration has been proposed as an index of CFTR function for testing systemic drugs designed to",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.390625,
            "end_logit": -8.046875,
            "text": "cystic fibrosis (CF), sweat chloride concentration has been proposed as an index of CFTR function for testing systemic drugs designed to activate mutant",
            "probability": 0.0
        },
        {
            "start_logit": 9.390625,
            "end_logit": -8.0546875,
            "text": "cystic fibrosis (CF), sweat chloride concentration has been proposed as an index of CFTR function for testing systemic drugs designed to activate",
            "probability": 0.0
        },
        {
            "start_logit": -6.27734375,
            "end_logit": -2.447265625,
            "text": "In cystic",
            "probability": 0.0
        },
        {
            "start_logit": -2.41015625,
            "end_logit": -6.84375,
            "text": "fibrosis (CF), sweat chloride concentration has been proposed as an index of CFTR function for testing systemic drugs designed to activate mutant CFTR.",
            "probability": 0.0
        }
    ],
    "5c6e16eb7c78d6947100004e_6": [
        {
            "start_logit": 9.4140625,
            "end_logit": 9.3203125,
            "text": "cystic fibrosis",
            "probability": 1.0
        },
        {
            "start_logit": 9.4140625,
            "end_logit": -2.408203125,
            "text": "cystic",
            "probability": 8.046627044677734e-06
        },
        {
            "start_logit": -2.3359375,
            "end_logit": 9.3203125,
            "text": "fibrosis",
            "probability": 7.867813110351562e-06
        },
        {
            "start_logit": -7.29296875,
            "end_logit": 9.3203125,
            "text": "diagnosis of cystic fibrosis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.4140625,
            "end_logit": -7.421875,
            "text": "cystic fibrosis (CF) involves sweat induction, collection and handling, and measurement in an analytical lab.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.4140625,
            "end_logit": -7.765625,
            "text": "cystic fibrosis (CF",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.4140625,
            "end_logit": -7.78515625,
            "text": "cystic fibrosis (CF)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.69921875,
            "end_logit": 9.3203125,
            "text": "BACKGROUND Sweat chloride testing for diagnosis of cystic fibrosis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.4140625,
            "end_logit": -7.8203125,
            "text": "cystic fibrosis (CF) involves",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.4140625,
            "end_logit": -7.8515625,
            "text": "cystic fibrosis (CF) involves sweat induction",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.4140625,
            "end_logit": -7.8671875,
            "text": "cystic fibrosis (CF) involves sweat induction, collection",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.4140625,
            "end_logit": -7.91015625,
            "text": "cystic fibrosis (CF) involves sweat induction,",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.84765625,
            "end_logit": 9.3203125,
            "text": "of cystic fibrosis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.4140625,
            "end_logit": -7.953125,
            "text": "cystic fibrosis (CF) involves sweat induction, collection and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.4140625,
            "end_logit": -8.015625,
            "text": "cystic fibrosis (CF) involves sweat induction, collection and handling, and measurement in an",
            "probability": 0.0
        },
        {
            "start_logit": 9.4140625,
            "end_logit": -8.046875,
            "text": "cystic fibrosis (CF) involves sweat induction, collection and handling",
            "probability": 0.0
        },
        {
            "start_logit": 9.4140625,
            "end_logit": -8.1015625,
            "text": "cystic fibrosis (CF) involves sweat induction, collection and handling, and measurement in an analytical lab",
            "probability": 0.0
        },
        {
            "start_logit": 9.4140625,
            "end_logit": -8.1015625,
            "text": "cystic fibrosis (CF) involves sweat induction, collection and handling, and measurement in",
            "probability": 0.0
        },
        {
            "start_logit": -8.015625,
            "end_logit": 9.3203125,
            "text": "for diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": 9.4140625,
            "end_logit": -8.1171875,
            "text": "cystic fibrosis (CF) involves sweat induction, collection and handling, and",
            "probability": 0.0
        }
    ],
    "5c6e16eb7c78d6947100004e_7": [
        {
            "start_logit": 9.453125,
            "end_logit": 9.375,
            "text": "cystic fibrosis",
            "probability": 1.0
        },
        {
            "start_logit": -2.271484375,
            "end_logit": 9.375,
            "text": "fibrosis",
            "probability": 8.046627044677734e-06
        },
        {
            "start_logit": 9.453125,
            "end_logit": -2.357421875,
            "text": "cystic",
            "probability": 7.987022399902344e-06
        },
        {
            "start_logit": -6.640625,
            "end_logit": 9.375,
            "text": "diagnosis of cystic fibrosis",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.46484375,
            "end_logit": 9.375,
            "text": "of cystic fibrosis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.453125,
            "end_logit": -7.60546875,
            "text": "cystic fibrosis (CF).",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.453125,
            "end_logit": -7.859375,
            "text": "cystic fibrosis (CF",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.453125,
            "end_logit": -7.875,
            "text": "cystic fibrosis (CF)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.9453125,
            "end_logit": 9.375,
            "text": "for diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -7.9609375,
            "end_logit": 9.375,
            "text": "OBJECTIVES Sweat chloride testing is the gold standard for diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.0859375,
            "end_logit": 9.375,
            "text": "Sweat chloride testing is the gold standard for diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.109375,
            "end_logit": 9.375,
            "text": "gold standard for diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": 9.375,
            "text": "the gold standard for diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": 9.375,
            "text": "chloride testing is the gold standard for diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.234375,
            "end_logit": 9.375,
            "text": "testing is the gold standard for diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -6.640625,
            "end_logit": -2.357421875,
            "text": "diagnosis of cystic",
            "probability": 0.0
        },
        {
            "start_logit": -7.46484375,
            "end_logit": -2.357421875,
            "text": "of cystic",
            "probability": 0.0
        },
        {
            "start_logit": -2.271484375,
            "end_logit": -7.60546875,
            "text": "fibrosis (CF).",
            "probability": 0.0
        },
        {
            "start_logit": -2.271484375,
            "end_logit": -7.859375,
            "text": "fibrosis (CF",
            "probability": 0.0
        },
        {
            "start_logit": -2.271484375,
            "end_logit": -7.875,
            "text": "fibrosis (CF)",
            "probability": 0.0
        }
    ],
    "5c6e16eb7c78d6947100004e_8": [
        {
            "start_logit": 9.4921875,
            "end_logit": 9.4609375,
            "text": "cystic fibrosis",
            "probability": 1.0
        },
        {
            "start_logit": -2.0703125,
            "end_logit": 9.4609375,
            "text": "fibrosis",
            "probability": 9.5367431640625e-06
        },
        {
            "start_logit": 9.4921875,
            "end_logit": -2.265625,
            "text": "cystic",
            "probability": 8.046627044677734e-06
        },
        {
            "start_logit": 9.4921875,
            "end_logit": -7.57421875,
            "text": "cystic fibrosis (CF) in support of universal newborn screening programs.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.4921875,
            "end_logit": -7.6875,
            "text": "cystic fibrosis (CF) in",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.67578125,
            "end_logit": 9.4609375,
            "text": "diagnosis of cystic fibrosis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6875,
            "end_logit": 9.4609375,
            "text": "of cystic fibrosis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.71875,
            "end_logit": 9.4609375,
            "text": "The sweat chloride test remains the gold standard for confirmatory diagnosis of cystic fibrosis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.8359375,
            "end_logit": 9.4609375,
            "text": "confirmatory diagnosis of cystic fibrosis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.921875,
            "end_logit": 9.4609375,
            "text": "sweat chloride test remains the gold standard for confirmatory diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": 9.4921875,
            "end_logit": -7.98828125,
            "text": "cystic fibrosis (CF",
            "probability": 0.0
        },
        {
            "start_logit": 9.4921875,
            "end_logit": -7.9921875,
            "text": "cystic fibrosis (CF) in support",
            "probability": 0.0
        },
        {
            "start_logit": 9.4921875,
            "end_logit": -8.015625,
            "text": "cystic fibrosis (CF)",
            "probability": 0.0
        },
        {
            "start_logit": 9.4921875,
            "end_logit": -8.03125,
            "text": "cystic fibrosis (CF) in support of",
            "probability": 0.0
        },
        {
            "start_logit": -8.0078125,
            "end_logit": 9.4609375,
            "text": "gold standard for confirmatory diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.0546875,
            "end_logit": 9.4609375,
            "text": "chloride test remains the gold standard for confirmatory diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": 9.4921875,
            "end_logit": -8.09375,
            "text": "cystic fibrosis (",
            "probability": 0.0
        },
        {
            "start_logit": -8.0703125,
            "end_logit": 9.4609375,
            "text": "test remains the gold standard for confirmatory diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.09375,
            "end_logit": 9.4609375,
            "text": "the gold standard for confirmatory diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.109375,
            "end_logit": 9.4609375,
            "text": "remains the gold standard for confirmatory diagnosis of cystic fibrosis",
            "probability": 0.0
        }
    ],
    "5c6e16eb7c78d6947100004e_9": [
        {
            "start_logit": 9.5078125,
            "end_logit": 9.53125,
            "text": "cystic fibrosis",
            "probability": 1.0
        },
        {
            "start_logit": -1.9189453125,
            "end_logit": 9.53125,
            "text": "fibrosis",
            "probability": 1.0967254638671875e-05
        },
        {
            "start_logit": 9.5078125,
            "end_logit": -2.205078125,
            "text": "cystic",
            "probability": 8.046627044677734e-06
        },
        {
            "start_logit": 9.5078125,
            "end_logit": -7.8671875,
            "text": "cystic fibrosis, electrolyte metabolism disorders, electrolyte balance, and electrolyte loss during exercise.",
            "probability": 0.0
        },
        {
            "start_logit": -8.046875,
            "end_logit": 9.53125,
            "text": "biomarker for cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.0546875,
            "end_logit": 9.53125,
            "text": "Sweat chloride is of interest as a biomarker for cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.0859375,
            "end_logit": 9.53125,
            "text": "for cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": 9.5078125,
            "end_logit": -8.1015625,
            "text": "cystic fibrosis, electrolyte metabolism disorders, electrolyte balance, and electrolyte loss during",
            "probability": 0.0
        },
        {
            "start_logit": 9.5078125,
            "end_logit": -8.109375,
            "text": "cystic fibrosis,",
            "probability": 0.0
        },
        {
            "start_logit": 9.5078125,
            "end_logit": -8.109375,
            "text": "cystic fibrosis, electrolyte metabolism disorders",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": 9.53125,
            "text": "chloride is of interest as a biomarker for cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -1.9189453125,
            "end_logit": -7.8671875,
            "text": "fibrosis, electrolyte metabolism disorders, electrolyte balance, and electrolyte loss during exercise.",
            "probability": 0.0
        },
        {
            "start_logit": -1.9189453125,
            "end_logit": -8.1015625,
            "text": "fibrosis, electrolyte metabolism disorders, electrolyte balance, and electrolyte loss during",
            "probability": 0.0
        },
        {
            "start_logit": -1.9189453125,
            "end_logit": -8.109375,
            "text": "fibrosis,",
            "probability": 0.0
        },
        {
            "start_logit": -1.9189453125,
            "end_logit": -8.109375,
            "text": "fibrosis, electrolyte metabolism disorders",
            "probability": 0.0
        },
        {
            "start_logit": -8.046875,
            "end_logit": -2.205078125,
            "text": "biomarker for cystic",
            "probability": 0.0
        },
        {
            "start_logit": -8.0546875,
            "end_logit": -2.205078125,
            "text": "Sweat chloride is of interest as a biomarker for cystic",
            "probability": 0.0
        },
        {
            "start_logit": -8.0859375,
            "end_logit": -2.205078125,
            "text": "for cystic",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": -2.205078125,
            "text": "chloride is of interest as a biomarker for cystic",
            "probability": 0.0
        },
        {
            "start_logit": -6.75390625,
            "end_logit": -7.8671875,
            "text": ".",
            "probability": 0.0
        }
    ],
    "5c6e16eb7c78d6947100004e_10": [
        {
            "start_logit": 9.453125,
            "end_logit": 9.375,
            "text": "cystic fibrosis",
            "probability": 1.0
        },
        {
            "start_logit": -2.271484375,
            "end_logit": 9.375,
            "text": "fibrosis",
            "probability": 8.046627044677734e-06
        },
        {
            "start_logit": 9.453125,
            "end_logit": -2.357421875,
            "text": "cystic",
            "probability": 7.987022399902344e-06
        },
        {
            "start_logit": -6.640625,
            "end_logit": 9.375,
            "text": "diagnosis of cystic fibrosis",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.46484375,
            "end_logit": 9.375,
            "text": "of cystic fibrosis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.453125,
            "end_logit": -7.60546875,
            "text": "cystic fibrosis (CF).",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.453125,
            "end_logit": -7.859375,
            "text": "cystic fibrosis (CF",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.453125,
            "end_logit": -7.875,
            "text": "cystic fibrosis (CF)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.9453125,
            "end_logit": 9.375,
            "text": "for diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -7.9609375,
            "end_logit": 9.375,
            "text": "OBJECTIVES Sweat chloride testing is the gold standard for diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.0859375,
            "end_logit": 9.375,
            "text": "Sweat chloride testing is the gold standard for diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.109375,
            "end_logit": 9.375,
            "text": "gold standard for diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": 9.375,
            "text": "the gold standard for diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": 9.375,
            "text": "chloride testing is the gold standard for diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.234375,
            "end_logit": 9.375,
            "text": "testing is the gold standard for diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -6.640625,
            "end_logit": -2.357421875,
            "text": "diagnosis of cystic",
            "probability": 0.0
        },
        {
            "start_logit": -7.46484375,
            "end_logit": -2.357421875,
            "text": "of cystic",
            "probability": 0.0
        },
        {
            "start_logit": -2.271484375,
            "end_logit": -7.60546875,
            "text": "fibrosis (CF).",
            "probability": 0.0
        },
        {
            "start_logit": -2.271484375,
            "end_logit": -7.859375,
            "text": "fibrosis (CF",
            "probability": 0.0
        },
        {
            "start_logit": -2.271484375,
            "end_logit": -7.875,
            "text": "fibrosis (CF)",
            "probability": 0.0
        }
    ],
    "5c6e16eb7c78d6947100004e_11": [
        {
            "start_logit": 9.4140625,
            "end_logit": 9.3203125,
            "text": "cystic fibrosis",
            "probability": 1.0
        },
        {
            "start_logit": 9.4140625,
            "end_logit": -2.408203125,
            "text": "cystic",
            "probability": 8.046627044677734e-06
        },
        {
            "start_logit": -2.3359375,
            "end_logit": 9.3203125,
            "text": "fibrosis",
            "probability": 7.867813110351562e-06
        },
        {
            "start_logit": -7.29296875,
            "end_logit": 9.3203125,
            "text": "diagnosis of cystic fibrosis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.4140625,
            "end_logit": -7.421875,
            "text": "cystic fibrosis (CF) involves sweat induction, collection and handling, and measurement in an analytical lab.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.4140625,
            "end_logit": -7.765625,
            "text": "cystic fibrosis (CF",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.4140625,
            "end_logit": -7.78515625,
            "text": "cystic fibrosis (CF)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.69921875,
            "end_logit": 9.3203125,
            "text": "BACKGROUND Sweat chloride testing for diagnosis of cystic fibrosis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.4140625,
            "end_logit": -7.8203125,
            "text": "cystic fibrosis (CF) involves",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.4140625,
            "end_logit": -7.8515625,
            "text": "cystic fibrosis (CF) involves sweat induction",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.4140625,
            "end_logit": -7.8671875,
            "text": "cystic fibrosis (CF) involves sweat induction, collection",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.4140625,
            "end_logit": -7.91015625,
            "text": "cystic fibrosis (CF) involves sweat induction,",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.84765625,
            "end_logit": 9.3203125,
            "text": "of cystic fibrosis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.4140625,
            "end_logit": -7.953125,
            "text": "cystic fibrosis (CF) involves sweat induction, collection and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.4140625,
            "end_logit": -8.015625,
            "text": "cystic fibrosis (CF) involves sweat induction, collection and handling, and measurement in an",
            "probability": 0.0
        },
        {
            "start_logit": 9.4140625,
            "end_logit": -8.046875,
            "text": "cystic fibrosis (CF) involves sweat induction, collection and handling",
            "probability": 0.0
        },
        {
            "start_logit": 9.4140625,
            "end_logit": -8.1015625,
            "text": "cystic fibrosis (CF) involves sweat induction, collection and handling, and measurement in an analytical lab",
            "probability": 0.0
        },
        {
            "start_logit": 9.4140625,
            "end_logit": -8.1015625,
            "text": "cystic fibrosis (CF) involves sweat induction, collection and handling, and measurement in",
            "probability": 0.0
        },
        {
            "start_logit": -8.015625,
            "end_logit": 9.3203125,
            "text": "for diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": 9.4140625,
            "end_logit": -8.1171875,
            "text": "cystic fibrosis (CF) involves sweat induction, collection and handling, and",
            "probability": 0.0
        }
    ],
    "5c6e16eb7c78d6947100004e_12": [
        {
            "start_logit": 9.5234375,
            "end_logit": 9.484375,
            "text": "cystic fibrosis",
            "probability": 1.0
        },
        {
            "start_logit": -2.021484375,
            "end_logit": 9.484375,
            "text": "fibrosis",
            "probability": 9.715557098388672e-06
        },
        {
            "start_logit": 9.5234375,
            "end_logit": -2.201171875,
            "text": "cystic",
            "probability": 8.463859558105469e-06
        },
        {
            "start_logit": 9.5234375,
            "end_logit": -7.78125,
            "text": "cystic fibrosis (CF) diagnosis.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.5234375,
            "end_logit": -7.82421875,
            "text": "cystic fibrosis (CF",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.5234375,
            "end_logit": -7.8671875,
            "text": "cystic fibrosis (CF) diagnosis",
            "probability": 0.0
        },
        {
            "start_logit": -7.8671875,
            "end_logit": 9.484375,
            "text": "for cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -7.90234375,
            "end_logit": 9.484375,
            "text": "BACKGROUND Sweat chloride test is the gold standard test for cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": 9.5234375,
            "end_logit": -8.0859375,
            "text": "cystic fibrosis (CF)",
            "probability": 0.0
        },
        {
            "start_logit": -8.1015625,
            "end_logit": 9.484375,
            "text": "gold standard test for cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.1328125,
            "end_logit": 9.484375,
            "text": "Sweat chloride test is the gold standard test for cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.140625,
            "end_logit": 9.484375,
            "text": "test for cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.140625,
            "end_logit": 9.484375,
            "text": "the gold standard test for cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": 9.484375,
            "text": "chloride test is the gold standard test for cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -2.021484375,
            "end_logit": -7.78125,
            "text": "fibrosis (CF) diagnosis.",
            "probability": 0.0
        },
        {
            "start_logit": -2.021484375,
            "end_logit": -7.82421875,
            "text": "fibrosis (CF",
            "probability": 0.0
        },
        {
            "start_logit": -2.021484375,
            "end_logit": -7.8671875,
            "text": "fibrosis (CF) diagnosis",
            "probability": 0.0
        },
        {
            "start_logit": -7.8671875,
            "end_logit": -2.201171875,
            "text": "for cystic",
            "probability": 0.0
        },
        {
            "start_logit": -7.90234375,
            "end_logit": -2.201171875,
            "text": "BACKGROUND Sweat chloride test is the gold standard test for cystic",
            "probability": 0.0
        },
        {
            "start_logit": -2.021484375,
            "end_logit": -8.0859375,
            "text": "fibrosis (CF)",
            "probability": 0.0
        }
    ],
    "5c6e16eb7c78d6947100004e_13": [
        {
            "start_logit": 9.3046875,
            "end_logit": 9.328125,
            "text": "cystic fibrosis",
            "probability": 1.0
        },
        {
            "start_logit": -2.396484375,
            "end_logit": 9.328125,
            "text": "fibrosis",
            "probability": 8.344650268554688e-06
        },
        {
            "start_logit": 9.3046875,
            "end_logit": -2.626953125,
            "text": "cystic",
            "probability": 6.496906280517578e-06
        },
        {
            "start_logit": 9.3046875,
            "end_logit": -7.078125,
            "text": "cystic fibrosis due to the fact that electrolyte levels in sweat are elevated in patients.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3046875,
            "end_logit": -7.4453125,
            "text": "cystic fibrosis due",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5390625,
            "end_logit": 9.328125,
            "text": "screening test for the cystic fibrosis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3046875,
            "end_logit": -7.70703125,
            "text": "cystic fibrosis due to",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.8984375,
            "end_logit": 9.328125,
            "text": "the cystic fibrosis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3046875,
            "end_logit": -7.90625,
            "text": "cystic fibrosis due to the fact",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.9765625,
            "end_logit": 9.328125,
            "text": "Sweat chloride test is known to be a screening test for the cystic fibrosis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3046875,
            "end_logit": -7.99609375,
            "text": "cystic fibrosis due to the",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3046875,
            "end_logit": -7.99609375,
            "text": "cystic fibrosis due to the fact that electrolyte levels in sweat are",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3046875,
            "end_logit": -8.0078125,
            "text": "cystic fibrosis due to the fact that",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3046875,
            "end_logit": -8.0234375,
            "text": "cystic fibrosis due to the fact that electrolyte levels",
            "probability": 0.0
        },
        {
            "start_logit": 9.3046875,
            "end_logit": -8.0234375,
            "text": "cystic fibrosis due to the fact that electrolyte levels in sweat",
            "probability": 0.0
        },
        {
            "start_logit": 9.3046875,
            "end_logit": -8.03125,
            "text": "cystic fibrosis due to the fact that electrolyte levels in sweat are elevated",
            "probability": 0.0
        },
        {
            "start_logit": -8.1015625,
            "end_logit": 9.328125,
            "text": "for the cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.109375,
            "end_logit": 9.328125,
            "text": "chloride test is known to be a screening test for the cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.1328125,
            "end_logit": 9.328125,
            "text": "a screening test for the cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.1328125,
            "end_logit": 9.328125,
            "text": "known to be a screening test for the cystic fibrosis",
            "probability": 0.0
        }
    ],
    "5c6e16eb7c78d6947100004e_14": [
        {
            "start_logit": 9.5,
            "end_logit": 9.34375,
            "text": "cystic fibrosis",
            "probability": 1.0
        },
        {
            "start_logit": 9.5,
            "end_logit": -2.25,
            "text": "cystic",
            "probability": 9.238719940185547e-06
        },
        {
            "start_logit": -2.296875,
            "end_logit": 9.34375,
            "text": "fibrosis",
            "probability": 7.510185241699219e-06
        },
        {
            "start_logit": 9.5,
            "end_logit": -7.484375,
            "text": "cystic fibrosis (CF).",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.43359375,
            "end_logit": 9.34375,
            "text": "for cystic fibrosis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.5,
            "end_logit": -7.85546875,
            "text": "cystic fibrosis (CF)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.5,
            "end_logit": -7.859375,
            "text": "cystic fibrosis (CF",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.76171875,
            "end_logit": 9.34375,
            "text": "OBJECTIVE Sweat chloride measurement is considered a standard diagnostic tool for cystic fibrosis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.96484375,
            "end_logit": 9.34375,
            "text": "Sweat chloride measurement is considered a standard diagnostic tool for cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.03125,
            "end_logit": 9.34375,
            "text": "diagnostic tool for cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.0859375,
            "end_logit": 9.34375,
            "text": "standard diagnostic tool for cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.109375,
            "end_logit": 9.34375,
            "text": "considered a standard diagnostic tool for cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.140625,
            "end_logit": 9.34375,
            "text": "chloride measurement is considered a standard diagnostic tool for cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": 9.34375,
            "text": "tool for cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -7.43359375,
            "end_logit": -2.25,
            "text": "for cystic",
            "probability": 0.0
        },
        {
            "start_logit": -2.296875,
            "end_logit": -7.484375,
            "text": "fibrosis (CF).",
            "probability": 0.0
        },
        {
            "start_logit": -7.76171875,
            "end_logit": -2.25,
            "text": "OBJECTIVE Sweat chloride measurement is considered a standard diagnostic tool for cystic",
            "probability": 0.0
        },
        {
            "start_logit": -2.296875,
            "end_logit": -7.85546875,
            "text": "fibrosis (CF)",
            "probability": 0.0
        },
        {
            "start_logit": -2.296875,
            "end_logit": -7.859375,
            "text": "fibrosis (CF",
            "probability": 0.0
        },
        {
            "start_logit": -7.96484375,
            "end_logit": -2.25,
            "text": "Sweat chloride measurement is considered a standard diagnostic tool for cystic",
            "probability": 0.0
        }
    ],
    "5c6e16eb7c78d6947100004e_15": [
        {
            "start_logit": 9.4296875,
            "end_logit": 9.34375,
            "text": "cystic fibrosis",
            "probability": 1.0
        },
        {
            "start_logit": 9.4296875,
            "end_logit": -2.37890625,
            "text": "cystic",
            "probability": 7.987022399902344e-06
        },
        {
            "start_logit": -2.302734375,
            "end_logit": 9.34375,
            "text": "fibrosis",
            "probability": 7.927417755126953e-06
        },
        {
            "start_logit": -7.26953125,
            "end_logit": 9.34375,
            "text": "diagnosis of cystic fibrosis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.4296875,
            "end_logit": -7.4453125,
            "text": "cystic fibrosis (CF) involves sweat induction, collection and handling, and measurement in an analytical lab.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.4296875,
            "end_logit": -7.85546875,
            "text": "cystic fibrosis (CF",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.4296875,
            "end_logit": -7.87109375,
            "text": "cystic fibrosis (CF) involves sweat induction",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.4296875,
            "end_logit": -7.87109375,
            "text": "cystic fibrosis (CF)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.4296875,
            "end_logit": -7.875,
            "text": "cystic fibrosis (CF) involves sweat induction, collection",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.4296875,
            "end_logit": -7.890625,
            "text": "cystic fibrosis (CF) involves",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.4296875,
            "end_logit": -7.9140625,
            "text": "cystic fibrosis (CF) involves sweat induction,",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.83203125,
            "end_logit": 9.34375,
            "text": "of cystic fibrosis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.4296875,
            "end_logit": -7.95703125,
            "text": "cystic fibrosis (CF) involves sweat induction, collection and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.89453125,
            "end_logit": 9.34375,
            "text": "Sweat chloride testing for diagnosis of cystic fibrosis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.4296875,
            "end_logit": -8.0234375,
            "text": "cystic fibrosis (CF) involves sweat induction, collection and handling",
            "probability": 0.0
        },
        {
            "start_logit": -7.94921875,
            "end_logit": 9.34375,
            "text": "for diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": 9.4296875,
            "end_logit": -8.0390625,
            "text": "cystic fibrosis (CF) involves sweat induction, collection and handling, and measurement in an",
            "probability": 0.0
        },
        {
            "start_logit": 9.4296875,
            "end_logit": -8.109375,
            "text": "cystic fibrosis (CF) involves sweat induction, collection and handling, and",
            "probability": 0.0
        },
        {
            "start_logit": 9.4296875,
            "end_logit": -8.1171875,
            "text": "cystic fibrosis (CF) involves sweat induction, collection and handling, and measurement in an analytical lab",
            "probability": 0.0
        },
        {
            "start_logit": -8.0625,
            "end_logit": 9.34375,
            "text": "chloride testing for diagnosis of cystic fibrosis",
            "probability": 0.0
        }
    ],
    "60292d191cb411341a00010e_1": [
        {
            "start_logit": 8.8125,
            "end_logit": 9.734375,
            "text": "bladder cancer",
            "probability": 1.0
        },
        {
            "start_logit": -0.9638671875,
            "end_logit": 9.734375,
            "text": "cancer",
            "probability": 5.692243576049805e-05
        },
        {
            "start_logit": 8.8125,
            "end_logit": -3.048828125,
            "text": "bladder",
            "probability": 2.8014183044433594e-06
        },
        {
            "start_logit": -7.71875,
            "end_logit": 9.734375,
            "text": "Bacillus Calmette-Gu\u00e9rin immunotherapy for bladder cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.71875,
            "end_logit": 9.734375,
            "text": "for bladder cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.84765625,
            "end_logit": 9.734375,
            "text": "Calmette-Gu\u00e9rin immunotherapy for bladder cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.953125,
            "end_logit": 9.734375,
            "text": "immunotherapy for bladder cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.98046875,
            "end_logit": 9.734375,
            "text": "ette-Gu\u00e9rin immunotherapy for bladder cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.984375,
            "end_logit": 9.734375,
            "text": "\u00e9rin immunotherapy for bladder cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.8125,
            "end_logit": -7.9609375,
            "text": "bladder cancer:",
            "probability": 0.0
        },
        {
            "start_logit": 8.8125,
            "end_logit": -8.15625,
            "text": "bladder cancer: a review of immunological aspects, clinical effects and BCG infections.",
            "probability": 0.0
        },
        {
            "start_logit": -0.9638671875,
            "end_logit": -7.9609375,
            "text": "cancer:",
            "probability": 0.0
        },
        {
            "start_logit": -0.9638671875,
            "end_logit": -8.15625,
            "text": "cancer: a review of immunological aspects, clinical effects and BCG infections.",
            "probability": 0.0
        },
        {
            "start_logit": -7.71875,
            "end_logit": -3.048828125,
            "text": "Bacillus Calmette-Gu\u00e9rin immunotherapy for bladder",
            "probability": 0.0
        },
        {
            "start_logit": -7.71875,
            "end_logit": -3.048828125,
            "text": "for bladder",
            "probability": 0.0
        },
        {
            "start_logit": -7.84765625,
            "end_logit": -3.048828125,
            "text": "Calmette-Gu\u00e9rin immunotherapy for bladder",
            "probability": 0.0
        },
        {
            "start_logit": -7.953125,
            "end_logit": -3.048828125,
            "text": "immunotherapy for bladder",
            "probability": 0.0
        },
        {
            "start_logit": -7.98046875,
            "end_logit": -3.048828125,
            "text": "ette-Gu\u00e9rin immunotherapy for bladder",
            "probability": 0.0
        },
        {
            "start_logit": -7.984375,
            "end_logit": -3.048828125,
            "text": "\u00e9rin immunotherapy for bladder",
            "probability": 0.0
        },
        {
            "start_logit": -6.71875,
            "end_logit": -8.15625,
            "text": ".",
            "probability": 0.0
        }
    ],
    "60292d191cb411341a00010e_2": [
        {
            "start_logit": 6.12890625,
            "end_logit": 9.546875,
            "text": "cancer",
            "probability": 0.80810546875
        },
        {
            "start_logit": 4.69140625,
            "end_logit": 9.546875,
            "text": "bladder cancer",
            "probability": 0.1920166015625
        },
        {
            "start_logit": -7.546875,
            "end_logit": 9.546875,
            "text": "Bacillus Calmette-Gu\u00e9rin (BCG) immunotherapy for bladder cancer",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": -7.63671875,
            "end_logit": 9.546875,
            "text": "for bladder cancer",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": -7.82421875,
            "end_logit": 9.546875,
            "text": "Calmette-Gu\u00e9rin (BCG) immunotherapy for bladder cancer",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -7.9140625,
            "end_logit": 9.546875,
            "text": "BCG) immunotherapy for bladder cancer",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -7.9609375,
            "end_logit": 9.546875,
            "text": "(BCG) immunotherapy for bladder cancer",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -7.96875,
            "end_logit": 9.546875,
            "text": "immunotherapy for bladder cancer",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -7.984375,
            "end_logit": 9.546875,
            "text": "ette-Gu\u00e9rin (BCG) immunotherapy for bladder cancer",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -8.015625,
            "end_logit": 9.546875,
            "text": ") immunotherapy for bladder cancer",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 6.12890625,
            "end_logit": -7.5546875,
            "text": "cancer has been used since 1976 when the first evidence of its ability to lower recurrence and progression rates was published.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 4.69140625,
            "end_logit": -6.23828125,
            "text": "bladder",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 6.12890625,
            "end_logit": -7.71484375,
            "text": "cancer has",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 6.12890625,
            "end_logit": -7.91796875,
            "text": "cancer has been used since",
            "probability": 0.0
        },
        {
            "start_logit": 6.12890625,
            "end_logit": -8.0390625,
            "text": "cancer has been",
            "probability": 0.0
        },
        {
            "start_logit": 6.12890625,
            "end_logit": -8.109375,
            "text": "cancer has been used since 1976",
            "probability": 0.0
        },
        {
            "start_logit": 6.12890625,
            "end_logit": -8.1640625,
            "text": "cancer has been used since 1976 when",
            "probability": 0.0
        },
        {
            "start_logit": 4.69140625,
            "end_logit": -7.5546875,
            "text": "bladder cancer has been used since 1976 when the first evidence of its ability to lower recurrence and progression rates was published.",
            "probability": 0.0
        },
        {
            "start_logit": 4.69140625,
            "end_logit": -7.71484375,
            "text": "bladder cancer has",
            "probability": 0.0
        },
        {
            "start_logit": 4.69140625,
            "end_logit": -7.91796875,
            "text": "bladder cancer has been used since",
            "probability": 0.0
        }
    ],
    "60292d191cb411341a00010e_3": [
        {
            "start_logit": 8.09375,
            "end_logit": 8.34375,
            "text": "cancer",
            "probability": 1.0
        },
        {
            "start_logit": -3.55078125,
            "end_logit": 8.34375,
            "text": "bladder cancer",
            "probability": 8.821487426757812e-06
        },
        {
            "start_logit": -7.4765625,
            "end_logit": 8.34375,
            "text": "non-muscle invasive bladder cancer",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.6015625,
            "end_logit": 8.34375,
            "text": "grade non-muscle invasive bladder cancer",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.6015625,
            "end_logit": 8.34375,
            "text": "high-grade non-muscle invasive bladder cancer",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.609375,
            "end_logit": 8.34375,
            "text": "for high-grade non-muscle invasive bladder cancer",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.66796875,
            "end_logit": 8.34375,
            "text": "BCG immunotherapy is the choice of care for high-grade non-muscle invasive bladder cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.09375,
            "end_logit": -7.55078125,
            "text": "cancer (NMIBC) after transurethral resection.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.8125,
            "end_logit": 8.34375,
            "text": "is the choice of care for high-grade non-muscle invasive bladder cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.8203125,
            "end_logit": 8.34375,
            "text": "muscle invasive bladder cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.84375,
            "end_logit": 8.34375,
            "text": "immunotherapy is the choice of care for high-grade non-muscle invasive bladder cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.859375,
            "end_logit": 8.34375,
            "text": "-muscle invasive bladder cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.8671875,
            "end_logit": 8.34375,
            "text": "the choice of care for high-grade non-muscle invasive bladder cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.87890625,
            "end_logit": 8.34375,
            "text": "care for high-grade non-muscle invasive bladder cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.89453125,
            "end_logit": 8.34375,
            "text": "choice of care for high-grade non-muscle invasive bladder cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.91015625,
            "end_logit": 8.34375,
            "text": "-grade non-muscle invasive bladder cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.09375,
            "end_logit": -7.95703125,
            "text": "cancer (NMIBC) after",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.09375,
            "end_logit": -8.1328125,
            "text": "cancer (NMIBC) after transurethral resection",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -3.55078125,
            "end_logit": -7.55078125,
            "text": "bladder cancer (NMIBC) after transurethral resection.",
            "probability": 0.0
        },
        {
            "start_logit": -3.55078125,
            "end_logit": -7.95703125,
            "text": "bladder cancer (NMIBC) after",
            "probability": 0.0
        }
    ],
    "60292d191cb411341a00010e_4": [
        {
            "start_logit": 8.3359375,
            "end_logit": 8.1484375,
            "text": "Tuberculosis",
            "probability": 1.0
        },
        {
            "start_logit": 8.3359375,
            "end_logit": -1.734375,
            "text": "Tuberculosis Following Intravesical Bacillus Calmette-Gu\u00e9rin (BCG) Immunotherapy for the Treatment of Bladder Cancer",
            "probability": 5.1021575927734375e-05
        },
        {
            "start_logit": 8.3359375,
            "end_logit": -7.64453125,
            "text": "Tuberculosis Following Intravesical Bacillus Calmette-Gu\u00e9rin (BCG) Immunotherapy for the Treatment of Bladder Cancer.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.55859375,
            "end_logit": 8.1484375,
            "text": "Renal Tuberculosis",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.3359375,
            "end_logit": -8.0390625,
            "text": "Tuberculosis Following",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.3359375,
            "end_logit": -8.1484375,
            "text": "Tuberculosis Following Intravesical Bacillus Calmette-",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.3359375,
            "end_logit": -8.15625,
            "text": "Tuberculosis Following Intravesical Bacillus Calmette-Gu",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -3.828125,
            "end_logit": -1.734375,
            "text": "Bladder Cancer",
            "probability": 0.0
        },
        {
            "start_logit": -4.6171875,
            "end_logit": -1.734375,
            "text": "Cancer",
            "probability": 0.0
        },
        {
            "start_logit": -7.55859375,
            "end_logit": -1.734375,
            "text": "Renal Tuberculosis Following Intravesical Bacillus Calmette-Gu\u00e9rin (BCG) Immunotherapy for the Treatment of Bladder Cancer",
            "probability": 0.0
        },
        {
            "start_logit": -7.734375,
            "end_logit": -1.734375,
            "text": "Treatment of Bladder Cancer",
            "probability": 0.0
        },
        {
            "start_logit": -7.7734375,
            "end_logit": -1.734375,
            "text": "the Treatment of Bladder Cancer",
            "probability": 0.0
        },
        {
            "start_logit": -7.79296875,
            "end_logit": -1.734375,
            "text": "of Bladder Cancer",
            "probability": 0.0
        },
        {
            "start_logit": -7.89453125,
            "end_logit": -1.734375,
            "text": "Bacillus Calmette-Gu\u00e9rin (BCG) Immunotherapy for the Treatment of Bladder Cancer",
            "probability": 0.0
        },
        {
            "start_logit": -7.91796875,
            "end_logit": -1.734375,
            "text": "for the Treatment of Bladder Cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.015625,
            "end_logit": -1.734375,
            "text": "BCG) Immunotherapy for the Treatment of Bladder Cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.03125,
            "end_logit": -1.734375,
            "text": "Calmette-Gu\u00e9rin (BCG) Immunotherapy for the Treatment of Bladder Cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.0546875,
            "end_logit": -1.734375,
            "text": "Intravesical Bacillus Calmette-Gu\u00e9rin (BCG) Immunotherapy for the Treatment of Bladder Cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.0546875,
            "end_logit": -1.734375,
            "text": "(BCG) Immunotherapy for the Treatment of Bladder Cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.078125,
            "end_logit": -1.734375,
            "text": ") Immunotherapy for the Treatment of Bladder Cancer",
            "probability": 0.0
        }
    ],
    "60292d191cb411341a00010e_5": [
        {
            "start_logit": 7.8828125,
            "end_logit": 10.21875,
            "text": "bladder cancer",
            "probability": 0.99609375
        },
        {
            "start_logit": 2.26953125,
            "end_logit": 10.21875,
            "text": "cancer",
            "probability": 0.003650665283203125
        },
        {
            "start_logit": 7.8828125,
            "end_logit": -4.02734375,
            "text": "bladder",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -6.56640625,
            "end_logit": 10.21875,
            "text": "superficial bladder cancer",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -7.6015625,
            "end_logit": 10.21875,
            "text": "nearly 40 years since Bacillus Calmette-Gu\u00e9rin (BCG) was first used as an immunotherapy to treat superficial bladder cancer",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.609375,
            "end_logit": 10.21875,
            "text": "Bacillus Calmette-Gu\u00e9rin (BCG) was first used as an immunotherapy to treat superficial bladder cancer",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.609375,
            "end_logit": 10.21875,
            "text": "40 years since Bacillus Calmette-Gu\u00e9rin (BCG) was first used as an immunotherapy to treat superficial bladder cancer",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.63671875,
            "end_logit": 10.21875,
            "text": "treat superficial bladder cancer",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.76953125,
            "end_logit": 10.21875,
            "text": "years since Bacillus Calmette-Gu\u00e9rin (BCG) was first used as an immunotherapy to treat superficial bladder cancer",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.80078125,
            "end_logit": 10.21875,
            "text": "It is nearly 40 years since Bacillus Calmette-Gu\u00e9rin (BCG) was first used as an immunotherapy to treat superficial bladder cancer",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.8125,
            "end_logit": 10.21875,
            "text": "since Bacillus Calmette-Gu\u00e9rin (BCG) was first used as an immunotherapy to treat superficial bladder cancer",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.875,
            "end_logit": 10.21875,
            "text": "immunotherapy to treat superficial bladder cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.87890625,
            "end_logit": 10.21875,
            "text": "an immunotherapy to treat superficial bladder cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.8828125,
            "end_logit": 10.21875,
            "text": "(BCG) was first used as an immunotherapy to treat superficial bladder cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.8828125,
            "end_logit": 10.21875,
            "text": "used as an immunotherapy to treat superficial bladder cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.8828125,
            "end_logit": 10.21875,
            "text": "Calmette-Gu\u00e9rin (BCG) was first used as an immunotherapy to treat superficial bladder cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.90234375,
            "end_logit": 10.21875,
            "text": "first used as an immunotherapy to treat superficial bladder cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.8828125,
            "end_logit": -7.33203125,
            "text": "bladder cancer.",
            "probability": 0.0
        },
        {
            "start_logit": 2.26953125,
            "end_logit": -7.33203125,
            "text": "cancer.",
            "probability": 0.0
        },
        {
            "start_logit": -6.56640625,
            "end_logit": -4.02734375,
            "text": "superficial bladder",
            "probability": 0.0
        }
    ],
    "60292d191cb411341a00010e_6": [
        {
            "start_logit": 8.203125,
            "end_logit": 8.2578125,
            "text": "cancer",
            "probability": 1.0
        },
        {
            "start_logit": -4.6875,
            "end_logit": 8.2578125,
            "text": "bladder cancer",
            "probability": 2.5033950805664062e-06
        },
        {
            "start_logit": 8.203125,
            "end_logit": -7.55078125,
            "text": "cancer can be effectively treated with BCG intravesical immunotherapy-it has demonstrated a reduction in tumor recurrence rates, but has had no positive impact on disease progression or prolongation of survival.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.6796875,
            "end_logit": 8.2578125,
            "text": "with bladder cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.203125,
            "end_logit": -7.921875,
            "text": "cancer can",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.9765625,
            "end_logit": 8.2578125,
            "text": "Prostatic urethral mucosal involvement with bladder cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.0078125,
            "end_logit": 8.2578125,
            "text": "mucosal involvement with bladder cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.03125,
            "end_logit": 8.2578125,
            "text": "urethral mucosal involvement with bladder cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.203125,
            "end_logit": -8.0546875,
            "text": "cancer can be effectively treated with BCG intravesical immunotherapy-it has demonstrated a reduction in tumor recurrence",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.203125,
            "end_logit": -8.125,
            "text": "cancer can be effectively treated with BCG intravesical immunotherapy-it has demonstrated a reduction in tumor recurrence rates",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.203125,
            "end_logit": -8.1328125,
            "text": "cancer can be effectively treated with BCG intravesical immunotherapy-it has demonstrated a reduction in tumor recurrence rates, but has had no positive impact on disease progression or",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.203125,
            "end_logit": -8.1484375,
            "text": "cancer can be effectively treated with BCG intravesical immunotherapy-it has demonstrated a reduction in tumor recurrence rates, but",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.203125,
            "end_logit": -8.1484375,
            "text": "cancer can be effectively treated with BCG intravesical immunotherapy-it has demonstrated a",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.203125,
            "end_logit": -8.15625,
            "text": "cancer can be effectively treated with BCG intravesical immunotherapy-it has demonstrated a reduction in tumor recurrence rates,",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.203125,
            "end_logit": -8.15625,
            "text": "cancer can be effectively treated with BCG intravesical immunotherapy-it has demonstrated",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.203125,
            "end_logit": -8.15625,
            "text": "cancer can be effectively treated with BCG intravesical immunotherapy-it has",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.203125,
            "end_logit": -8.1796875,
            "text": "cancer can be effectively treated with BCG intravesical immunotherapy-",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.203125,
            "end_logit": -8.1875,
            "text": "cancer can be",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.203125,
            "end_logit": -8.1953125,
            "text": "cancer can be effectively treated with BCG intravesical immunotherapy-it has demonstrated a reduction in tumor recurrence rates, but has had no positive impact on disease progression",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -4.6875,
            "end_logit": -7.55078125,
            "text": "bladder cancer can be effectively treated with BCG intravesical immunotherapy-it has demonstrated a reduction in tumor recurrence rates, but has had no positive impact on disease progression or prolongation of survival.",
            "probability": 0.0
        }
    ],
    "60292d191cb411341a00010e_7": [
        {
            "start_logit": 5.76953125,
            "end_logit": 10.1328125,
            "text": "bladder cancer",
            "probability": 0.96533203125
        },
        {
            "start_logit": 2.462890625,
            "end_logit": 10.1328125,
            "text": "cancer",
            "probability": 0.03515625
        },
        {
            "start_logit": -6.96875,
            "end_logit": 10.1328125,
            "text": "nonmuscle invasive bladder cancer",
            "probability": 2.8014183044433594e-06
        },
        {
            "start_logit": -7.375,
            "end_logit": 10.1328125,
            "text": "in nonmuscle invasive bladder cancer",
            "probability": 1.9073486328125e-06
        },
        {
            "start_logit": -7.55859375,
            "end_logit": 10.1328125,
            "text": "invasive bladder cancer",
            "probability": 1.5497207641601562e-06
        },
        {
            "start_logit": -7.89453125,
            "end_logit": 10.1328125,
            "text": "Mycobacterium bovis BCG for immunotherapy in nonmuscle invasive bladder cancer",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": -7.90625,
            "end_logit": 10.1328125,
            "text": "uscle invasive bladder cancer",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": -7.94921875,
            "end_logit": 10.1328125,
            "text": "immunotherapy in nonmuscle invasive bladder cancer",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": -7.96484375,
            "end_logit": 10.1328125,
            "text": "Recombinant Mycobacterium bovis BCG for immunotherapy in nonmuscle invasive bladder cancer",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": -7.9765625,
            "end_logit": 10.1328125,
            "text": "for immunotherapy in nonmuscle invasive bladder cancer",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": -7.9765625,
            "end_logit": 10.1328125,
            "text": "BCG for immunotherapy in nonmuscle invasive bladder cancer",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": -8.015625,
            "end_logit": 10.1328125,
            "text": "le invasive bladder cancer",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": -8.046875,
            "end_logit": 10.1328125,
            "text": "bovis BCG for immunotherapy in nonmuscle invasive bladder cancer",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": 5.76953125,
            "end_logit": -5.6171875,
            "text": "bladder",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 5.76953125,
            "end_logit": -7.8671875,
            "text": "bladder cancer.",
            "probability": 0.0
        },
        {
            "start_logit": 2.462890625,
            "end_logit": -7.8671875,
            "text": "cancer.",
            "probability": 0.0
        },
        {
            "start_logit": -6.96875,
            "end_logit": -5.6171875,
            "text": "nonmuscle invasive bladder",
            "probability": 0.0
        },
        {
            "start_logit": -7.375,
            "end_logit": -5.6171875,
            "text": "in nonmuscle invasive bladder",
            "probability": 0.0
        },
        {
            "start_logit": -7.55859375,
            "end_logit": -5.6171875,
            "text": "invasive bladder",
            "probability": 0.0
        },
        {
            "start_logit": -7.89453125,
            "end_logit": -5.6171875,
            "text": "Mycobacterium bovis BCG for immunotherapy in nonmuscle invasive bladder",
            "probability": 0.0
        }
    ],
    "60292d191cb411341a00010e_8": [
        {
            "start_logit": 6.38671875,
            "end_logit": 9.40625,
            "text": "cancer",
            "probability": 0.998046875
        },
        {
            "start_logit": 0.34619140625,
            "end_logit": 9.40625,
            "text": "bladder cancer",
            "probability": 0.002361297607421875
        },
        {
            "start_logit": -7.2421875,
            "end_logit": 9.40625,
            "text": "superficial bladder cancer",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": -7.78125,
            "end_logit": 9.40625,
            "text": "The advantage of BCG immunotherapy over intravesical chemotherapy in superficial bladder cancer",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -7.79296875,
            "end_logit": 9.40625,
            "text": "in superficial bladder cancer",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -7.83203125,
            "end_logit": 9.40625,
            "text": "BCG immunotherapy over intravesical chemotherapy in superficial bladder cancer",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -7.89453125,
            "end_logit": 9.40625,
            "text": "advantage of BCG immunotherapy over intravesical chemotherapy in superficial bladder cancer",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -7.9375,
            "end_logit": 9.40625,
            "text": "of BCG immunotherapy over intravesical chemotherapy in superficial bladder cancer",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 6.38671875,
            "end_logit": -7.85546875,
            "text": "cancer has been most apparent in patients with carcinoma in situ",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 6.38671875,
            "end_logit": -7.96484375,
            "text": "cancer has been most apparent in patients with carcinoma in situ (CIS), where complete response is increased from 50% to more than 70% and the proportion of patients remaining disease free for 5 years",
            "probability": 0.0
        },
        {
            "start_logit": 6.38671875,
            "end_logit": -8.0546875,
            "text": "cancer has been most apparent in patients with carcinoma in situ (CIS), where complete response is increased from 50% to more than 70%",
            "probability": 0.0
        },
        {
            "start_logit": 6.38671875,
            "end_logit": -8.0703125,
            "text": "cancer has been most apparent in patients with carcinoma in situ (CIS), where complete response is increased from 50% to more than 70% and the proportion of patients remaining disease free",
            "probability": 0.0
        },
        {
            "start_logit": 6.38671875,
            "end_logit": -8.0703125,
            "text": "cancer has been most apparent in patients with carcinoma in situ (CIS),",
            "probability": 0.0
        },
        {
            "start_logit": 6.38671875,
            "end_logit": -8.0703125,
            "text": "cancer has",
            "probability": 0.0
        },
        {
            "start_logit": 6.38671875,
            "end_logit": -8.0703125,
            "text": "cancer has been most apparent in patients with carcinoma in situ (CIS), where complete response is increased from 50%",
            "probability": 0.0
        },
        {
            "start_logit": 6.38671875,
            "end_logit": -8.09375,
            "text": "cancer has been most apparent in patients with carcinoma in situ (CIS), where complete response is increased from 50% to",
            "probability": 0.0
        },
        {
            "start_logit": 6.38671875,
            "end_logit": -8.09375,
            "text": "cancer has been most apparent in patients with carcinoma in situ (CIS",
            "probability": 0.0
        },
        {
            "start_logit": 6.38671875,
            "end_logit": -8.1015625,
            "text": "cancer has been most apparent in patients with carcinoma in situ (CIS), where complete response is increased from 50% to more than 70% and the proportion of patients remaining disease free for 5",
            "probability": 0.0
        },
        {
            "start_logit": 6.38671875,
            "end_logit": -8.109375,
            "text": "cancer has been most apparent in patients with carcinoma in situ (CIS), where complete response is increased from 50% to more than 70",
            "probability": 0.0
        },
        {
            "start_logit": 6.38671875,
            "end_logit": -8.1171875,
            "text": "cancer has been most apparent",
            "probability": 0.0
        }
    ],
    "60292d191cb411341a00010e_9": [
        {
            "start_logit": 8.1484375,
            "end_logit": 8.28125,
            "text": "cancer",
            "probability": 1.0
        },
        {
            "start_logit": -1.3974609375,
            "end_logit": 8.28125,
            "text": "bladder cancer",
            "probability": 7.086992263793945e-05
        },
        {
            "start_logit": 8.1484375,
            "end_logit": -7.59765625,
            "text": "cancer (NMIBC) and carcinoma in-situ (CIS) in terms of prevention of recurrence and progression.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.80078125,
            "end_logit": 8.28125,
            "text": "for high-grade non-muscle invasive bladder cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.83203125,
            "end_logit": 8.28125,
            "text": "standard of care for high-grade non-muscle invasive bladder cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.84375,
            "end_logit": 8.28125,
            "text": "high-grade non-muscle invasive bladder cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.84765625,
            "end_logit": 8.28125,
            "text": "has become the standard of care for high-grade non-muscle invasive bladder cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.890625,
            "end_logit": 8.28125,
            "text": "Bacillus Calmette-Gu\u00e9rin (BCG) immunotherapy has become the standard of care for high-grade non-muscle invasive bladder cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.91796875,
            "end_logit": 8.28125,
            "text": "invasive bladder cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.921875,
            "end_logit": 8.28125,
            "text": "grade non-muscle invasive bladder cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.9296875,
            "end_logit": 8.28125,
            "text": "the standard of care for high-grade non-muscle invasive bladder cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.953125,
            "end_logit": 8.28125,
            "text": "dministration of Bacillus Calmette-Gu\u00e9rin (BCG) immunotherapy has become the standard of care for high-grade non-muscle invasive bladder cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.953125,
            "end_logit": 8.28125,
            "text": "muscle invasive bladder cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.97265625,
            "end_logit": 8.28125,
            "text": "-grade non-muscle invasive bladder cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.1484375,
            "end_logit": -7.9375,
            "text": "cancer (NMIBC) and carcinoma in-situ (CIS) in",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.1484375,
            "end_logit": -7.9921875,
            "text": "cancer (NMIBC) and carcinoma in-situ (CIS) in terms",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.1484375,
            "end_logit": -8.0390625,
            "text": "cancer (NMIBC) and carcinoma in-situ (CIS) in terms of prevention of recurrence and progression. While most a",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.1484375,
            "end_logit": -8.0546875,
            "text": "cancer (NMIBC) and carcinoma in-situ (CIS) in terms of prevention of recurrence and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.1484375,
            "end_logit": -8.078125,
            "text": "cancer (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.1484375,
            "end_logit": -8.109375,
            "text": "cancer (NMIBC) and carcinoma in-situ (CIS) in terms of prevention of recurrence",
            "probability": 5.960464477539063e-08
        }
    ],
    "60292d191cb411341a00010e_10": [
        {
            "start_logit": 8.109375,
            "end_logit": 9.96875,
            "text": "bladder cancer",
            "probability": 1.0
        },
        {
            "start_logit": 0.1661376953125,
            "end_logit": 9.96875,
            "text": "cancer",
            "probability": 0.0003542900085449219
        },
        {
            "start_logit": 8.109375,
            "end_logit": -3.763671875,
            "text": "bladder",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": -7.81640625,
            "end_logit": 9.96875,
            "text": ") bladder cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.828125,
            "end_logit": 9.96875,
            "text": "for stage T1 grade 3 (T1G3) bladder cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.8515625,
            "end_logit": 9.96875,
            "text": "treatment of choice for stage T1 grade 3 (T1G3) bladder cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.8515625,
            "end_logit": 9.96875,
            "text": "current treatment of choice for stage T1 grade 3 (T1G3) bladder cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.86328125,
            "end_logit": 9.96875,
            "text": "Bacillus Calmette-Gu\u00e9rin (BCG) immunotherapy is regarded as the current treatment of choice for stage T1 grade 3 (T1G3) bladder cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.875,
            "end_logit": 9.96875,
            "text": "OBJECTIVES: Bacillus Calmette-Gu\u00e9rin (BCG) immunotherapy is regarded as the current treatment of choice for stage T1 grade 3 (T1G3) bladder cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.87890625,
            "end_logit": 9.96875,
            "text": "stage T1 grade 3 (T1G3) bladder cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.921875,
            "end_logit": 9.96875,
            "text": "is regarded as the current treatment of choice for stage T1 grade 3 (T1G3) bladder cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.94140625,
            "end_logit": 9.96875,
            "text": "(T1G3) bladder cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.9609375,
            "end_logit": 9.96875,
            "text": "regarded as the current treatment of choice for stage T1 grade 3 (T1G3) bladder cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.96484375,
            "end_logit": 9.96875,
            "text": ": Bacillus Calmette-Gu\u00e9rin (BCG) immunotherapy is regarded as the current treatment of choice for stage T1 grade 3 (T1G3) bladder cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.98046875,
            "end_logit": 9.96875,
            "text": "Calmette-Gu\u00e9rin (BCG) immunotherapy is regarded as the current treatment of choice for stage T1 grade 3 (T1G3) bladder cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.984375,
            "end_logit": 9.96875,
            "text": "grade 3 (T1G3) bladder cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.984375,
            "end_logit": 9.96875,
            "text": "BCG) immunotherapy is regarded as the current treatment of choice for stage T1 grade 3 (T1G3) bladder cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.98828125,
            "end_logit": 9.96875,
            "text": "the current treatment of choice for stage T1 grade 3 (T1G3) bladder cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.109375,
            "end_logit": -8.1484375,
            "text": "bladder cancer (BC), though its efficacy is limited by high recurrence and progression",
            "probability": 0.0
        },
        {
            "start_logit": 8.109375,
            "end_logit": -8.1484375,
            "text": "bladder cancer (BC), though its efficacy is limited by high recurrence and",
            "probability": 0.0
        }
    ],
    "60292d191cb411341a00010e_11": [
        {
            "start_logit": 8.25,
            "end_logit": 8.203125,
            "text": "cancer",
            "probability": 1.0
        },
        {
            "start_logit": -6.921875,
            "end_logit": 8.203125,
            "text": "bladder cancer",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.6640625,
            "end_logit": 8.203125,
            "text": "non-muscle-invasive bladder cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.6796875,
            "end_logit": 8.203125,
            "text": "The standard of care for most patients with non-muscle-invasive bladder cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.71484375,
            "end_logit": 8.203125,
            "text": "standard of care for most patients with non-muscle-invasive bladder cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.80859375,
            "end_logit": 8.203125,
            "text": "with non-muscle-invasive bladder cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.81640625,
            "end_logit": 8.203125,
            "text": "muscle-invasive bladder cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.828125,
            "end_logit": 8.203125,
            "text": "patients with non-muscle-invasive bladder cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.86328125,
            "end_logit": 8.203125,
            "text": "-muscle-invasive bladder cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.86328125,
            "end_logit": 8.203125,
            "text": "for most patients with non-muscle-invasive bladder cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.87890625,
            "end_logit": 8.203125,
            "text": "most patients with non-muscle-invasive bladder cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.25,
            "end_logit": -8.1953125,
            "text": "cancer (NMIBC) is immunotherapy with intravesical Bacillus Calmette-Gu\u00e9rin (BCG), which activates the immune system to recognize and destroy malignant cells and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.25,
            "end_logit": -8.21875,
            "text": "cancer (NMIBC) is immunotherapy with intravesical Bacillus Calmette-Gu\u00e9rin (BCG),",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.25,
            "end_logit": -8.21875,
            "text": "cancer (NMIBC)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.921875,
            "end_logit": -8.1953125,
            "text": "bladder cancer (NMIBC) is immunotherapy with intravesical Bacillus Calmette-Gu\u00e9rin (BCG), which activates the immune system to recognize and destroy malignant cells and",
            "probability": 0.0
        },
        {
            "start_logit": -6.921875,
            "end_logit": -8.21875,
            "text": "bladder cancer (NMIBC) is immunotherapy with intravesical Bacillus Calmette-Gu\u00e9rin (BCG),",
            "probability": 0.0
        },
        {
            "start_logit": -6.921875,
            "end_logit": -8.21875,
            "text": "bladder cancer (NMIBC)",
            "probability": 0.0
        },
        {
            "start_logit": -7.6640625,
            "end_logit": -8.140625,
            "text": "non-muscle-invasive",
            "probability": 0.0
        },
        {
            "start_logit": -7.6796875,
            "end_logit": -8.140625,
            "text": "The standard of care for most patients with non-muscle-invasive",
            "probability": 0.0
        },
        {
            "start_logit": -7.6640625,
            "end_logit": -8.1953125,
            "text": "non-muscle-invasive bladder cancer (NMIBC) is immunotherapy with intravesical Bacillus Calmette-Gu\u00e9rin (BCG), which activates the immune system to recognize and destroy malignant cells and",
            "probability": 0.0
        }
    ],
    "60292d191cb411341a00010e_12": [
        {
            "start_logit": 7.296875,
            "end_logit": 10.1953125,
            "text": "bladder cancer",
            "probability": 0.99609375
        },
        {
            "start_logit": 1.6220703125,
            "end_logit": 10.1953125,
            "text": "cancer",
            "probability": 0.0034008026123046875
        },
        {
            "start_logit": -6.625,
            "end_logit": 10.1953125,
            "text": "superficial bladder cancer",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": 7.296875,
            "end_logit": -4.6640625,
            "text": "bladder",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.63671875,
            "end_logit": 10.1953125,
            "text": "treat superficial bladder cancer",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.66796875,
            "end_logit": 10.1953125,
            "text": "Bacillus Calmette-Gu\u00e9rin (BCG) was first used as an immunotherapy to treat superficial bladder cancer",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.6875,
            "end_logit": 10.1953125,
            "text": "nearly 40 years since Bacillus Calmette-Gu\u00e9rin (BCG) was first used as an immunotherapy to treat superficial bladder cancer",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.73828125,
            "end_logit": 10.1953125,
            "text": "40 years since Bacillus Calmette-Gu\u00e9rin (BCG) was first used as an immunotherapy to treat superficial bladder cancer",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.80078125,
            "end_logit": 10.1953125,
            "text": "It is nearly 40 years since Bacillus Calmette-Gu\u00e9rin (BCG) was first used as an immunotherapy to treat superficial bladder cancer",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.828125,
            "end_logit": 10.1953125,
            "text": "immunotherapy to treat superficial bladder cancer",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.84375,
            "end_logit": 10.1953125,
            "text": "used as an immunotherapy to treat superficial bladder cancer",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.859375,
            "end_logit": 10.1953125,
            "text": "(BCG) was first used as an immunotherapy to treat superficial bladder cancer",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.86328125,
            "end_logit": 10.1953125,
            "text": "since Bacillus Calmette-Gu\u00e9rin (BCG) was first used as an immunotherapy to treat superficial bladder cancer",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.8671875,
            "end_logit": 10.1953125,
            "text": "an immunotherapy to treat superficial bladder cancer",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.87109375,
            "end_logit": 10.1953125,
            "text": "BCG) was first used as an immunotherapy to treat superficial bladder cancer",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.875,
            "end_logit": 10.1953125,
            "text": "first used as an immunotherapy to treat superficial bladder cancer",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.875,
            "end_logit": 10.1953125,
            "text": "Calmette-Gu\u00e9rin (BCG) was first used as an immunotherapy to treat superficial bladder cancer",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.625,
            "end_logit": -4.6640625,
            "text": "superficial bladder",
            "probability": 0.0
        },
        {
            "start_logit": -7.63671875,
            "end_logit": -4.6640625,
            "text": "treat superficial bladder",
            "probability": 0.0
        },
        {
            "start_logit": -7.66796875,
            "end_logit": -4.6640625,
            "text": "Bacillus Calmette-Gu\u00e9rin (BCG) was first used as an immunotherapy to treat superficial bladder",
            "probability": 0.0
        }
    ],
    "60292d191cb411341a00010e_13": [
        {
            "start_logit": 8.5,
            "end_logit": 7.96484375,
            "text": "cancer",
            "probability": 1.0
        },
        {
            "start_logit": -6.64453125,
            "end_logit": 7.96484375,
            "text": "bladder cancer",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.5,
            "end_logit": -7.59765625,
            "text": "cancer (NMIBC), with proven effects on reducing recurrence, progression, and death from NMIBC.",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.5,
            "end_logit": -8.09375,
            "text": "cancer (NMIBC), with",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.5,
            "end_logit": -8.1171875,
            "text": "cancer (NMIBC)",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.5,
            "end_logit": -8.125,
            "text": "cancer (NMIBC),",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.5,
            "end_logit": -8.125,
            "text": "cancer (NMIBC), with proven effects on reducing recurrence, progression, and death from NMIBC. However",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.5,
            "end_logit": -8.125,
            "text": "cancer (NM",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.5,
            "end_logit": -8.140625,
            "text": "cancer (NMIBC), with proven effects on reducing recurrence, progression, and death",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.5,
            "end_logit": -8.140625,
            "text": "cancer (",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.5,
            "end_logit": -8.15625,
            "text": "cancer (NMIBC), with proven effects on reducing recurrence",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.5,
            "end_logit": -8.15625,
            "text": "cancer (NMIBC), with proven effects on",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.5,
            "end_logit": -8.1640625,
            "text": "cancer (NMIBC), with proven effects on reducing recurrence, progression, and",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.8359375,
            "end_logit": 7.96484375,
            "text": "non-muscle-invasive bladder cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.8671875,
            "end_logit": 7.96484375,
            "text": "for non-muscle-invasive bladder cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.875,
            "end_logit": 7.96484375,
            "text": "Intravesical immunotherapy with bacille Calmette-Gu\u00e9rin (BCG) vaccine is the main treatment for non-muscle-invasive bladder cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.90625,
            "end_logit": 7.96484375,
            "text": "bacille Calmette-Gu\u00e9rin (BCG) vaccine is the main treatment for non-muscle-invasive bladder cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.92578125,
            "end_logit": 7.96484375,
            "text": "treatment for non-muscle-invasive bladder cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.953125,
            "end_logit": 7.96484375,
            "text": "-muscle-invasive bladder cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.9609375,
            "end_logit": 7.96484375,
            "text": "ille Calmette-Gu\u00e9rin (BCG) vaccine is the main treatment for non-muscle-invasive bladder cancer",
            "probability": 5.960464477539063e-08
        }
    ],
    "60292d191cb411341a00010e_14": [
        {
            "start_logit": 7.62890625,
            "end_logit": 9.8828125,
            "text": "bladder cancer",
            "probability": 1.0
        },
        {
            "start_logit": -0.2017822265625,
            "end_logit": 9.8828125,
            "text": "cancer",
            "probability": 0.0003952980041503906
        },
        {
            "start_logit": 7.62890625,
            "end_logit": -4.3828125,
            "text": "bladder",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -7.546875,
            "end_logit": 9.8828125,
            "text": "for intermediate to high-risk non-muscle invasive bladder cancer",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.65234375,
            "end_logit": 9.8828125,
            "text": "invasive bladder cancer",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.70703125,
            "end_logit": 9.8828125,
            "text": "first line therapy for intermediate to high-risk non-muscle invasive bladder cancer",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.7265625,
            "end_logit": 9.8828125,
            "text": "risk non-muscle invasive bladder cancer",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.76953125,
            "end_logit": 9.8828125,
            "text": "a first line therapy for intermediate to high-risk non-muscle invasive bladder cancer",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.796875,
            "end_logit": 9.8828125,
            "text": "therapy for intermediate to high-risk non-muscle invasive bladder cancer",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.84375,
            "end_logit": 9.8828125,
            "text": "intermediate to high-risk non-muscle invasive bladder cancer",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.8671875,
            "end_logit": 9.8828125,
            "text": "Bacille-Calmette-Guerin (BCG) immunotherapy was approved many decades ago as a first line therapy for intermediate to high-risk non-muscle invasive bladder cancer",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.890625,
            "end_logit": 9.8828125,
            "text": "as a first line therapy for intermediate to high-risk non-muscle invasive bladder cancer",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.890625,
            "end_logit": 9.8828125,
            "text": "approved many decades ago as a first line therapy for intermediate to high-risk non-muscle invasive bladder cancer",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.890625,
            "end_logit": 9.8828125,
            "text": "intravesical instillation of Bacille-Calmette-Guerin (BCG) immunotherapy was approved many decades ago as a first line therapy for intermediate to high-risk non-muscle invasive bladder cancer",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.890625,
            "end_logit": 9.8828125,
            "text": "muscle invasive bladder cancer",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.89453125,
            "end_logit": 9.8828125,
            "text": "non-muscle invasive bladder cancer",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.62890625,
            "end_logit": -7.5078125,
            "text": "bladder cancer, its long-term efficacy is still arguable as a proportion of up to 30-40% of patients will develop recurrence or progression of their disease.",
            "probability": 0.0
        },
        {
            "start_logit": 7.62890625,
            "end_logit": -8.078125,
            "text": "bladder cancer, its long-term efficacy is still arguable as a proportion of up to 30-40%",
            "probability": 0.0
        },
        {
            "start_logit": 7.62890625,
            "end_logit": -8.125,
            "text": "bladder cancer, its long-term efficacy is still arguable as a proportion of up to 30-40",
            "probability": 0.0
        },
        {
            "start_logit": 7.62890625,
            "end_logit": -8.140625,
            "text": "bladder cancer, its long-term efficacy is still arguable as",
            "probability": 0.0
        }
    ],
    "60292d191cb411341a00010e_15": [
        {
            "start_logit": 8.421875,
            "end_logit": 7.984375,
            "text": "cancer",
            "probability": 1.0
        },
        {
            "start_logit": -7.08984375,
            "end_logit": 7.984375,
            "text": "bladder cancer",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.421875,
            "end_logit": -7.67578125,
            "text": "cancer and urothelial CIS and platin-based systemic chemotherapy to improve postcystectomy disease-specific survival are examples of therapy-related atypia seen in the urinary tract.",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.51171875,
            "end_logit": 7.984375,
            "text": "treat high-risk non-muscle-invasive bladder cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.54296875,
            "end_logit": 7.984375,
            "text": "high-risk non-muscle-invasive bladder cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.421875,
            "end_logit": -8.140625,
            "text": "cancer and",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.421875,
            "end_logit": -8.1640625,
            "text": "cancer and urothelial",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.421875,
            "end_logit": -8.171875,
            "text": "cancer and urothelial CIS and platin-based systemic chemotherapy to improve postcystectomy disease-specific",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.421875,
            "end_logit": -8.171875,
            "text": "cancer and urothelial CIS and platin-based systemic chemotherapy to improve postcystectomy disease-",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.421875,
            "end_logit": -8.1953125,
            "text": "cancer and urothelial CIS",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.421875,
            "end_logit": -8.1953125,
            "text": "cancer and urothelial CIS and platin-based systemic chemotherapy to improve postcystectomy",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.80859375,
            "end_logit": 7.984375,
            "text": "intravesical immunotherapy to treat high-risk non-muscle-invasive bladder cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.83203125,
            "end_logit": 7.984375,
            "text": "risk non-muscle-invasive bladder cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.90625,
            "end_logit": 7.984375,
            "text": "bacillus Calmette-Gu\u00e9rin (BCG) intravesical immunotherapy to treat high-risk non-muscle-invasive bladder cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.94140625,
            "end_logit": 7.984375,
            "text": "to treat high-risk non-muscle-invasive bladder cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.953125,
            "end_logit": 7.984375,
            "text": "bladder tumour to reduce recurrences, bacillus Calmette-Gu\u00e9rin (BCG) intravesical immunotherapy to treat high-risk non-muscle-invasive bladder cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.9609375,
            "end_logit": 7.984375,
            "text": "Drugs such as mitomycin C used after transurethral resection of bladder tumour to reduce recurrences, bacillus Calmette-Gu\u00e9rin (BCG) intravesical immunotherapy to treat high-risk non-muscle-invasive bladder cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.015625,
            "end_logit": 7.984375,
            "text": "non-muscle-invasive bladder cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.015625,
            "end_logit": 7.984375,
            "text": "-risk non-muscle-invasive bladder cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0234375,
            "end_logit": 7.984375,
            "text": ", bacillus Calmette-Gu\u00e9rin (BCG) intravesical immunotherapy to treat high-risk non-muscle-invasive bladder cancer",
            "probability": 5.960464477539063e-08
        }
    ],
    "60292d191cb411341a00010e_16": [
        {
            "start_logit": 8.484375,
            "end_logit": 7.9375,
            "text": "cancer",
            "probability": 1.0
        },
        {
            "start_logit": -3.498046875,
            "end_logit": 7.9375,
            "text": "bladder cancer",
            "probability": 6.258487701416016e-06
        },
        {
            "start_logit": -6.87109375,
            "end_logit": 7.9375,
            "text": "high risk non-muscle invasive bladder cancer",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.484375,
            "end_logit": -7.51171875,
            "text": "cancer and urothelial carcinoma in situ, and platinum-based systemic chemotherapy to improve post-cystectomy disease-specific survival some of the causes of therapy related atypia in urinary bladder.",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.25390625,
            "end_logit": 7.9375,
            "text": "risk non-muscle invasive bladder cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.41796875,
            "end_logit": 7.9375,
            "text": "treat high risk non-muscle invasive bladder cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.484375,
            "end_logit": -7.97265625,
            "text": "cancer and urothelial carcinoma in situ",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.484375,
            "end_logit": -8.0390625,
            "text": "cancer and urothelial carcinoma in",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.484375,
            "end_logit": -8.0546875,
            "text": "cancer and urothelial carcinoma in situ, and platinum-based systemic chemotherapy to improve post-cystectomy disease-specific survival some of the causes of therapy related atypia in urinary bladder",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.484375,
            "end_logit": -8.0703125,
            "text": "cancer and urothelial carcinoma in situ, and platinum-based systemic chemotherapy to improve post-cystectomy disease-specific survival some",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.484375,
            "end_logit": -8.078125,
            "text": "cancer and urothelial carcinoma in situ, and platinum-based systemic chemotherapy to improve post-cystectomy disease-specific",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.484375,
            "end_logit": -8.09375,
            "text": "cancer and urothelial carcinoma",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.484375,
            "end_logit": -8.09375,
            "text": "cancer and urothelial carcinoma in situ, and platinum-based systemic chemotherapy to improve post-cystectomy disease-",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.484375,
            "end_logit": -8.1015625,
            "text": "cancer and urothelial carcinoma in situ, and platinum-based systemic chemotherapy to improve post-cystectomy disease-specific survival some of the causes of therapy related atypia in urinary",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.484375,
            "end_logit": -8.109375,
            "text": "cancer and",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.56640625,
            "end_logit": 7.9375,
            "text": "non-muscle invasive bladder cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.484375,
            "end_logit": -8.1171875,
            "text": "cancer and urothelial carcinoma in situ, and platinum-based systemic chemotherapy to",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.484375,
            "end_logit": -8.1171875,
            "text": "cancer and urothelial carcinoma in situ, and platinum-based systemic chemotherapy to improve post-cystectomy disease-specific survival some of the causes of therapy related",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.484375,
            "end_logit": -8.1171875,
            "text": "cancer and urothelial carcinoma in situ, and platinum-based systemic chemotherapy to improve post-cystectomy disease-specific survival",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.484375,
            "end_logit": -8.125,
            "text": "cancer and urothelial carcinoma in situ, and platinum-based systemic chemotherapy to improve post-cystectomy",
            "probability": 1.1920928955078125e-07
        }
    ],
    "60292d191cb411341a00010e_17": [
        {
            "start_logit": 7.99609375,
            "end_logit": 8.3984375,
            "text": "cancer",
            "probability": 1.0
        },
        {
            "start_logit": -2.736328125,
            "end_logit": 8.3984375,
            "text": "bladder cancer",
            "probability": 2.193450927734375e-05
        },
        {
            "start_logit": -7.5859375,
            "end_logit": 8.3984375,
            "text": "intravesical therapy of bladder cancer",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.61328125,
            "end_logit": 8.3984375,
            "text": "of bladder cancer",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.64453125,
            "end_logit": 8.3984375,
            "text": "This comprehensive review highlights recent developments in intravesical therapy of bladder cancer",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.69921875,
            "end_logit": 8.3984375,
            "text": "review highlights recent developments in intravesical therapy of bladder cancer",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.80859375,
            "end_logit": 8.3984375,
            "text": "comprehensive review highlights recent developments in intravesical therapy of bladder cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.83984375,
            "end_logit": 8.3984375,
            "text": "therapy of bladder cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.859375,
            "end_logit": 8.3984375,
            "text": "in intravesical therapy of bladder cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.99609375,
            "end_logit": -7.74609375,
            "text": "cancer and summarizes the mechanisms of action of BCG, and the important role of intravesical BCG immunotherapy and other immunotherapeutic agents in the therapy and prophylaxis of superficial TCC of the urinary bladder",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.99609375,
            "end_logit": -7.796875,
            "text": "cancer and summarizes the mechanisms of action of BCG, and the important role of intravesical BCG immunotherapy and other immunotherapeutic agents in the therapy and prophylaxis of superficial TCC of the urinary bladder.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.99609375,
            "end_logit": -7.9765625,
            "text": "cancer and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.99609375,
            "end_logit": -8.125,
            "text": "cancer and summarizes the mechanisms of action of BCG, and the important role of intravesical BCG immunotherapy and other immunotherapeutic agents in the therapy and prophylaxis of superficial TCC of",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.99609375,
            "end_logit": -8.1484375,
            "text": "cancer and summarizes the mechanisms of action of BCG, and the important role of intravesical BCG immunotherapy and other immunotherapeutic agents in the therapy and prophylaxis of superficial TCC of the urinary",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.99609375,
            "end_logit": -8.1640625,
            "text": "cancer and summarizes the mechanisms of action of BCG, and the important role of intravesical BCG immunotherapy and other immunotherapeutic agents in the therapy and prophylaxis of superficial TCC of the",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.99609375,
            "end_logit": -8.203125,
            "text": "cancer and summarizes the mechanisms of",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.99609375,
            "end_logit": -8.2265625,
            "text": "cancer and summarizes the mechanisms of action of BCG, and the important role of intravesical BCG immunotherapy and other immunotherapeutic agents in",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.736328125,
            "end_logit": -7.74609375,
            "text": "bladder cancer and summarizes the mechanisms of action of BCG, and the important role of intravesical BCG immunotherapy and other immunotherapeutic agents in the therapy and prophylaxis of superficial TCC of the urinary bladder",
            "probability": 0.0
        },
        {
            "start_logit": -2.736328125,
            "end_logit": -7.796875,
            "text": "bladder cancer and summarizes the mechanisms of action of BCG, and the important role of intravesical BCG immunotherapy and other immunotherapeutic agents in the therapy and prophylaxis of superficial TCC of the urinary bladder.",
            "probability": 0.0
        },
        {
            "start_logit": -2.736328125,
            "end_logit": -7.9765625,
            "text": "bladder cancer and",
            "probability": 0.0
        }
    ],
    "60292d191cb411341a00010e_18": [
        {
            "start_logit": 8.4375,
            "end_logit": 8.015625,
            "text": "cancer",
            "probability": 1.0
        },
        {
            "start_logit": 8.4375,
            "end_logit": -7.3046875,
            "text": "cancer treatment, appraises current optimal application of BCG immunotherapy in bladder cancer",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.6484375,
            "end_logit": 8.015625,
            "text": "This review summarises the history and development of BCG as a modern cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.4375,
            "end_logit": -8.125,
            "text": "cancer treatment, appraises current optimal application of BCG immunotherapy in bladder cancer, discusses",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.4375,
            "end_logit": -8.1328125,
            "text": "cancer treatment, appraises current optimal application of BCG immunotherapy in bladder cancer, discusses promising new therapies closely related to BCG, and",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.4375,
            "end_logit": -8.1328125,
            "text": "cancer treatment, appraises current optimal application of BCG immunotherapy in bladder cancer, discusses promising new therapies closely related to BCG, and briefly explores the possibility that BCG or related treatments may",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.77734375,
            "end_logit": 8.015625,
            "text": "review summarises the history and development of BCG as a modern cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.85546875,
            "end_logit": 8.015625,
            "text": "modern cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.9453125,
            "end_logit": 8.015625,
            "text": "BCG as a modern cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.30859375,
            "end_logit": -7.3046875,
            "text": "bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -6.30859375,
            "end_logit": -7.6171875,
            "text": "bladder cancer, discusses promising new therapies closely related to BCG, and briefly explores the possibility that BCG or related treatments may have an application in other urological malignancies.",
            "probability": 0.0
        },
        {
            "start_logit": -6.78515625,
            "end_logit": -7.6171875,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -6.30859375,
            "end_logit": -8.1171875,
            "text": "bladder cancer, discusses promising new therapies closely related to BCG, and briefly explores the possibility that BCG or related treatments may have an application in other urological malignancies",
            "probability": 0.0
        },
        {
            "start_logit": -6.30859375,
            "end_logit": -8.125,
            "text": "bladder cancer, discusses",
            "probability": 0.0
        },
        {
            "start_logit": -6.30859375,
            "end_logit": -8.1328125,
            "text": "bladder cancer, discusses promising new therapies closely related to BCG, and",
            "probability": 0.0
        },
        {
            "start_logit": -6.30859375,
            "end_logit": -8.1328125,
            "text": "bladder cancer, discusses promising new therapies closely related to BCG, and briefly explores the possibility that BCG or related treatments may",
            "probability": 0.0
        },
        {
            "start_logit": -7.6484375,
            "end_logit": -7.3046875,
            "text": "This review summarises the history and development of BCG as a modern cancer treatment, appraises current optimal application of BCG immunotherapy in bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -7.77734375,
            "end_logit": -7.3046875,
            "text": "review summarises the history and development of BCG as a modern cancer treatment, appraises current optimal application of BCG immunotherapy in bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -7.85546875,
            "end_logit": -7.3046875,
            "text": "modern cancer treatment, appraises current optimal application of BCG immunotherapy in bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -7.91015625,
            "end_logit": -7.3046875,
            "text": "in bladder cancer",
            "probability": 0.0
        }
    ],
    "60292d191cb411341a00010e_19": [
        {
            "start_logit": 6.8359375,
            "end_logit": 9.203125,
            "text": "cancer",
            "probability": 0.96875
        },
        {
            "start_logit": 3.39453125,
            "end_logit": 9.203125,
            "text": "bladder cancer",
            "probability": 0.0311279296875
        },
        {
            "start_logit": -7.66015625,
            "end_logit": 9.203125,
            "text": "prevent the recurrence of superficial bladder cancer",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -7.66796875,
            "end_logit": 9.203125,
            "text": "superficial bladder cancer",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -7.703125,
            "end_logit": 9.203125,
            "text": "Bacillus Calmette-Gu\u00e9rin (BCG) is used to treat and prevent the recurrence of superficial bladder cancer",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -7.75390625,
            "end_logit": 9.203125,
            "text": "Immunotherapy by intravesicular delivery of Bacillus Calmette-Gu\u00e9rin (BCG) is used to treat and prevent the recurrence of superficial bladder cancer",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -7.76953125,
            "end_logit": 9.203125,
            "text": "treat and prevent the recurrence of superficial bladder cancer",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -7.796875,
            "end_logit": 9.203125,
            "text": "and prevent the recurrence of superficial bladder cancer",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -7.80078125,
            "end_logit": 9.203125,
            "text": "of superficial bladder cancer",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -7.8359375,
            "end_logit": 9.203125,
            "text": "the recurrence of superficial bladder cancer",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -7.8671875,
            "end_logit": 9.203125,
            "text": "Calmette-Gu\u00e9rin (BCG) is used to treat and prevent the recurrence of superficial bladder cancer",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -7.89453125,
            "end_logit": 9.203125,
            "text": "is used to treat and prevent the recurrence of superficial bladder cancer",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -7.8984375,
            "end_logit": 9.203125,
            "text": "(BCG) is used to treat and prevent the recurrence of superficial bladder cancer",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -7.8984375,
            "end_logit": 9.203125,
            "text": ") is used to treat and prevent the recurrence of superficial bladder cancer",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -7.90234375,
            "end_logit": 9.203125,
            "text": "BCG) is used to treat and prevent the recurrence of superficial bladder cancer",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -7.9140625,
            "end_logit": 9.203125,
            "text": "to treat and prevent the recurrence of superficial bladder cancer",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 6.8359375,
            "end_logit": -7.70703125,
            "text": "cancer.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 3.39453125,
            "end_logit": -6.85546875,
            "text": "bladder",
            "probability": 0.0
        },
        {
            "start_logit": 3.39453125,
            "end_logit": -7.70703125,
            "text": "bladder cancer.",
            "probability": 0.0
        },
        {
            "start_logit": -6.76953125,
            "end_logit": -7.70703125,
            "text": ".",
            "probability": 0.0
        }
    ],
    "60292d191cb411341a00010e_20": [
        {
            "start_logit": 8.0546875,
            "end_logit": 8.390625,
            "text": "cancer",
            "probability": 1.0
        },
        {
            "start_logit": -3.955078125,
            "end_logit": 8.390625,
            "text": "bladder cancer",
            "probability": 6.139278411865234e-06
        },
        {
            "start_logit": -7.73828125,
            "end_logit": 8.390625,
            "text": "Bacillus Calmette-Gu\u00e9rin (BCG) immunotherapy is currently the most effective treatment of non-muscle invasive bladder cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.76171875,
            "end_logit": 8.390625,
            "text": "invasive bladder cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.82421875,
            "end_logit": 8.390625,
            "text": "muscle invasive bladder cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.91015625,
            "end_logit": 8.390625,
            "text": "non-muscle invasive bladder cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.9296875,
            "end_logit": 8.390625,
            "text": "-muscle invasive bladder cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.93359375,
            "end_logit": 8.390625,
            "text": "Calmette-Gu\u00e9rin (BCG) immunotherapy is currently the most effective treatment of non-muscle invasive bladder cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.95703125,
            "end_logit": 8.390625,
            "text": "BCG) immunotherapy is currently the most effective treatment of non-muscle invasive bladder cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.9609375,
            "end_logit": 8.390625,
            "text": "the most effective treatment of non-muscle invasive bladder cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.98828125,
            "end_logit": 8.390625,
            "text": "treatment of non-muscle invasive bladder cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.99609375,
            "end_logit": 8.390625,
            "text": "of non-muscle invasive bladder cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.015625,
            "end_logit": 8.390625,
            "text": "immunotherapy is currently the most effective treatment of non-muscle invasive bladder cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.0546875,
            "end_logit": -7.703125,
            "text": "cancer and one of the most successful applications of immunotherapy to the treatment of cancer.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.0546875,
            "end_logit": -8.0078125,
            "text": "cancer and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.0546875,
            "end_logit": -8.0703125,
            "text": "cancer and one of the most successful applications of immunotherapy to the treatment of cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.0546875,
            "end_logit": -8.109375,
            "text": "cancer and one of",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.0546875,
            "end_logit": -8.1171875,
            "text": "cancer and one",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.0546875,
            "end_logit": -8.140625,
            "text": "cancer and one of the most successful applications of immunotherapy to the treatment of",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.0546875,
            "end_logit": -8.140625,
            "text": "cancer and one of the most",
            "probability": 5.960464477539063e-08
        }
    ],
    "60292d191cb411341a00010e_21": [
        {
            "start_logit": 8.234375,
            "end_logit": 8.1953125,
            "text": "cancer",
            "probability": 1.0
        },
        {
            "start_logit": -3.294921875,
            "end_logit": 8.1953125,
            "text": "bladder cancer",
            "probability": 9.715557098388672e-06
        },
        {
            "start_logit": 8.234375,
            "end_logit": -7.58984375,
            "text": "cancer (NMIBC) and carcinoma in-situ (CIS) in terms of prevention of recurrence and progression.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.77734375,
            "end_logit": 8.1953125,
            "text": "for high-grade non-muscle invasive bladder cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.234375,
            "end_logit": -7.9140625,
            "text": "cancer (NMIBC) and carcinoma in-situ (CIS) in",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.87890625,
            "end_logit": 8.1953125,
            "text": "high-grade non-muscle invasive bladder cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.88671875,
            "end_logit": 8.1953125,
            "text": "has become the standard of care for high-grade non-muscle invasive bladder cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.890625,
            "end_logit": 8.1953125,
            "text": "Bacillus Calmette-Gu\u00e9rin (BCG) immunotherapy has become the standard of care for high-grade non-muscle invasive bladder cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.890625,
            "end_logit": 8.1953125,
            "text": "standard of care for high-grade non-muscle invasive bladder cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.90625,
            "end_logit": 8.1953125,
            "text": "The administration of Bacillus Calmette-Gu\u00e9rin (BCG) immunotherapy has become the standard of care for high-grade non-muscle invasive bladder cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.234375,
            "end_logit": -7.98046875,
            "text": "cancer (NMIBC) and carcinoma in-situ (CIS) in terms",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.953125,
            "end_logit": 8.1953125,
            "text": "grade non-muscle invasive bladder cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.96484375,
            "end_logit": 8.1953125,
            "text": ": The administration of Bacillus Calmette-Gu\u00e9rin (BCG) immunotherapy has become the standard of care for high-grade non-muscle invasive bladder cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.96875,
            "end_logit": 8.1953125,
            "text": "the standard of care for high-grade non-muscle invasive bladder cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.9921875,
            "end_logit": 8.1953125,
            "text": "non-muscle invasive bladder cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.99609375,
            "end_logit": 8.1953125,
            "text": "care for high-grade non-muscle invasive bladder cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.234375,
            "end_logit": -8.046875,
            "text": "cancer (NMIBC) and carcinoma in-situ (CIS) in terms of prevention of recurrence and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.015625,
            "end_logit": 8.1953125,
            "text": "muscle invasive bladder cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.234375,
            "end_logit": -8.0703125,
            "text": "cancer (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.234375,
            "end_logit": -8.09375,
            "text": "cancer (NMIBC) and carcinoma in-situ (CIS) in terms of prevention of recurrence",
            "probability": 5.960464477539063e-08
        }
    ],
    "60292d191cb411341a00010e_22": [
        {
            "start_logit": 8.046875,
            "end_logit": 8.34375,
            "text": "cancer",
            "probability": 1.0
        },
        {
            "start_logit": -5.078125,
            "end_logit": 8.34375,
            "text": "bladder cancer",
            "probability": 1.9669532775878906e-06
        },
        {
            "start_logit": -7.8515625,
            "end_logit": 8.34375,
            "text": "invasive bladder cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.875,
            "end_logit": 8.34375,
            "text": "When T1 high-grade non-muscle-invasive bladder cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.92578125,
            "end_logit": 8.34375,
            "text": "SUMMARY: When T1 high-grade non-muscle-invasive bladder cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.9453125,
            "end_logit": 8.34375,
            "text": "grade non-muscle-invasive bladder cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.9765625,
            "end_logit": 8.34375,
            "text": ": When T1 high-grade non-muscle-invasive bladder cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.98046875,
            "end_logit": 8.34375,
            "text": "T1 high-grade non-muscle-invasive bladder cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.046875,
            "end_logit": -8.0625,
            "text": "cancer is",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.046875,
            "end_logit": -8.078125,
            "text": "cancer is persistent or recurs",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.046875,
            "end_logit": -8.09375,
            "text": "cancer is persistent or",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.046875,
            "end_logit": -8.1171875,
            "text": "cancer is persistent or recurs shortly after a full course of bacille Calmette-Gu\u00e9rin (BCG) plus maintenance, further BCG is not likely to work",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.046875,
            "end_logit": -8.125,
            "text": "cancer is persistent or recurs shortly after a full course of bacille Calmette-Gu",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.046875,
            "end_logit": -8.140625,
            "text": "cancer is persistent or recurs shortly after a full course of bacille Calmette-Gu\u00e9rin (BCG) plus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.046875,
            "end_logit": -8.1484375,
            "text": "cancer is persistent or recurs shortly after a full course of bacille Calmette-",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.046875,
            "end_logit": -8.15625,
            "text": "cancer is persistent",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.046875,
            "end_logit": -8.1640625,
            "text": "cancer is persistent or recurs shortly after a full course of bacille Calmette-Gu\u00e9rin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.046875,
            "end_logit": -8.1640625,
            "text": "cancer is persistent or recurs shortly after a full course of bacille Calmette-Gu\u00e9rin (BCG) plus maintenance, further BCG is not likely to",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -5.078125,
            "end_logit": -8.0625,
            "text": "bladder cancer is",
            "probability": 0.0
        },
        {
            "start_logit": -5.078125,
            "end_logit": -8.078125,
            "text": "bladder cancer is persistent or recurs",
            "probability": 0.0
        }
    ],
    "60292d191cb411341a00010e_23": [
        {
            "start_logit": 5.69921875,
            "end_logit": 9.7578125,
            "text": "bladder cancer",
            "probability": 0.57763671875
        },
        {
            "start_logit": 5.3828125,
            "end_logit": 9.7578125,
            "text": "cancer",
            "probability": 0.42236328125
        },
        {
            "start_logit": -7.765625,
            "end_logit": 9.7578125,
            "text": "invasive bladder cancer",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": -7.79296875,
            "end_logit": 9.7578125,
            "text": "muscle-invasive bladder cancer",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": -7.85546875,
            "end_logit": 9.7578125,
            "text": "grade non-muscle-invasive bladder cancer",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": -7.859375,
            "end_logit": 9.7578125,
            "text": "primary high-grade non-muscle-invasive bladder cancer",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": -7.90625,
            "end_logit": 9.7578125,
            "text": "Prognostic significance of pre- and post-treatment PD-L1 expression in patients with primary high-grade non-muscle-invasive bladder cancer",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -7.9140625,
            "end_logit": 9.7578125,
            "text": "high-grade non-muscle-invasive bladder cancer",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -7.91796875,
            "end_logit": 9.7578125,
            "text": "treatment PD-L1 expression in patients with primary high-grade non-muscle-invasive bladder cancer",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -7.92578125,
            "end_logit": 9.7578125,
            "text": "PD-L1 expression in patients with primary high-grade non-muscle-invasive bladder cancer",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -7.9296875,
            "end_logit": 9.7578125,
            "text": "patients with primary high-grade non-muscle-invasive bladder cancer",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -7.94140625,
            "end_logit": 9.7578125,
            "text": "non-muscle-invasive bladder cancer",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -7.9609375,
            "end_logit": 9.7578125,
            "text": "-muscle-invasive bladder cancer",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 5.69921875,
            "end_logit": -5.47265625,
            "text": "bladder",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 5.69921875,
            "end_logit": -7.80859375,
            "text": "bladder cancer treated with BCG immunotherapy.",
            "probability": 0.0
        },
        {
            "start_logit": 5.3828125,
            "end_logit": -7.80859375,
            "text": "cancer treated with BCG immunotherapy.",
            "probability": 0.0
        },
        {
            "start_logit": -7.765625,
            "end_logit": -5.47265625,
            "text": "invasive bladder",
            "probability": 0.0
        },
        {
            "start_logit": -7.79296875,
            "end_logit": -5.47265625,
            "text": "muscle-invasive bladder",
            "probability": 0.0
        },
        {
            "start_logit": -7.85546875,
            "end_logit": -5.47265625,
            "text": "grade non-muscle-invasive bladder",
            "probability": 0.0
        },
        {
            "start_logit": -7.859375,
            "end_logit": -5.47265625,
            "text": "primary high-grade non-muscle-invasive bladder",
            "probability": 0.0
        }
    ],
    "60292d191cb411341a00010e_24": [
        {
            "start_logit": 6.4609375,
            "end_logit": 9.390625,
            "text": "cancer",
            "probability": 0.998046875
        },
        {
            "start_logit": 0.126708984375,
            "end_logit": 9.390625,
            "text": "bladder cancer",
            "probability": 0.0017681121826171875
        },
        {
            "start_logit": -7.7421875,
            "end_logit": 9.390625,
            "text": "treating bladder cancer",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -7.7734375,
            "end_logit": 9.390625,
            "text": "intravesical instillation of Mycobacterium bovis bacille Calmette-Gu\u00e9rin (BCG) has been used for treating bladder cancer",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -7.78515625,
            "end_logit": 9.390625,
            "text": ", intravesical instillation of Mycobacterium bovis bacille Calmette-Gu\u00e9rin (BCG) has been used for treating bladder cancer",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -7.79296875,
            "end_logit": 9.390625,
            "text": "bacille Calmette-Gu\u00e9rin (BCG) has been used for treating bladder cancer",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -7.83203125,
            "end_logit": 9.390625,
            "text": "Mycobacterium bovis bacille Calmette-Gu\u00e9rin (BCG) has been used for treating bladder cancer",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -7.8359375,
            "end_logit": 9.390625,
            "text": "BCG) has been used for treating bladder cancer",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -7.85546875,
            "end_logit": 9.390625,
            "text": "ille Calmette-Gu\u00e9rin (BCG) has been used for treating bladder cancer",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -7.86328125,
            "end_logit": 9.390625,
            "text": "(BCG) has been used for treating bladder cancer",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -7.875,
            "end_logit": 9.390625,
            "text": ") has been used for treating bladder cancer",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -7.88671875,
            "end_logit": 9.390625,
            "text": "used for treating bladder cancer",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -7.89453125,
            "end_logit": 9.390625,
            "text": "Calmette-Gu\u00e9rin (BCG) has been used for treating bladder cancer",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 6.4609375,
            "end_logit": -7.6640625,
            "text": "cancer and it still remains at the forefront of immunotherapy for cancer patients.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 6.4609375,
            "end_logit": -8.1015625,
            "text": "cancer and",
            "probability": 0.0
        },
        {
            "start_logit": 0.126708984375,
            "end_logit": -7.6640625,
            "text": "bladder cancer and it still remains at the forefront of immunotherapy for cancer patients.",
            "probability": 0.0
        },
        {
            "start_logit": 0.126708984375,
            "end_logit": -7.88671875,
            "text": "bladder",
            "probability": 0.0
        },
        {
            "start_logit": 0.126708984375,
            "end_logit": -8.1015625,
            "text": "bladder cancer and",
            "probability": 0.0
        },
        {
            "start_logit": -6.80078125,
            "end_logit": -7.6640625,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.7421875,
            "end_logit": -7.6640625,
            "text": "treating bladder cancer and it still remains at the forefront of immunotherapy for cancer patients.",
            "probability": 0.0
        }
    ],
    "60292d191cb411341a00010e_25": [
        {
            "start_logit": 8.359375,
            "end_logit": 9.8828125,
            "text": "bladder cancer",
            "probability": 1.0
        },
        {
            "start_logit": -0.281005859375,
            "end_logit": 9.8828125,
            "text": "cancer",
            "probability": 0.00017535686492919922
        },
        {
            "start_logit": 8.359375,
            "end_logit": -3.65234375,
            "text": "bladder",
            "probability": 1.3113021850585938e-06
        },
        {
            "start_logit": -7.484375,
            "end_logit": 9.8828125,
            "text": "invasive bladder cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.640625,
            "end_logit": 9.8828125,
            "text": "muscle invasive bladder cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.85546875,
            "end_logit": 9.8828125,
            "text": "into muscle invasive bladder cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.859375,
            "end_logit": 9.8828125,
            "text": "agent known to reduce progression into muscle invasive bladder cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.87109375,
            "end_logit": 9.8828125,
            "text": "BCG-based therapy is the most effective intravesical therapy for this kind of tumor and represents the only agent known to reduce progression into muscle invasive bladder cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.9140625,
            "end_logit": 9.8828125,
            "text": "only agent known to reduce progression into muscle invasive bladder cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.9296875,
            "end_logit": 9.8828125,
            "text": "progression into muscle invasive bladder cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.9375,
            "end_logit": 9.8828125,
            "text": "tumor and represents the only agent known to reduce progression into muscle invasive bladder cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.9453125,
            "end_logit": 9.8828125,
            "text": "the only agent known to reduce progression into muscle invasive bladder cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.9453125,
            "end_logit": 9.8828125,
            "text": "most effective intravesical therapy for this kind of tumor and represents the only agent known to reduce progression into muscle invasive bladder cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.94921875,
            "end_logit": 9.8828125,
            "text": "the most effective intravesical therapy for this kind of tumor and represents the only agent known to reduce progression into muscle invasive bladder cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.359375,
            "end_logit": -7.484375,
            "text": "bladder cancer, BCG is ineffective in approximately 30-40 % of cases and disease recurs in up to 50 % of patients.",
            "probability": 0.0
        },
        {
            "start_logit": 8.359375,
            "end_logit": -7.96484375,
            "text": "bladder cancer, BCG is ineffective in approximately 30-40 %",
            "probability": 0.0
        },
        {
            "start_logit": 8.359375,
            "end_logit": -8.0703125,
            "text": "bladder cancer, BCG is ineffective in approximately 30-40 % of cases and disease recurs in up to 50 %",
            "probability": 0.0
        },
        {
            "start_logit": 8.359375,
            "end_logit": -8.078125,
            "text": "bladder cancer, BCG is ineffective in approximately 30-40",
            "probability": 0.0
        },
        {
            "start_logit": 8.359375,
            "end_logit": -8.1328125,
            "text": "bladder cancer, BCG is ineffective in approximately 30-40 % of cases and",
            "probability": 0.0
        },
        {
            "start_logit": 8.359375,
            "end_logit": -8.1328125,
            "text": "bladder cancer, BCG is ineffective in approximately 30-",
            "probability": 0.0
        }
    ],
    "60292d191cb411341a00010e_26": [
        {
            "start_logit": 6.3828125,
            "end_logit": 9.4453125,
            "text": "cancer",
            "probability": 1.0
        },
        {
            "start_logit": -3.255859375,
            "end_logit": 9.4453125,
            "text": "bladder cancer",
            "probability": 6.502866744995117e-05
        },
        {
            "start_logit": -7.8046875,
            "end_logit": 9.4453125,
            "text": "for bladder cancer",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -7.80859375,
            "end_logit": 9.4453125,
            "text": "the search for less toxic and more potent therapeutic agents for bladder cancer",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -7.81640625,
            "end_logit": 9.4453125,
            "text": "search for less toxic and more potent therapeutic agents for bladder cancer",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -7.8515625,
            "end_logit": 9.4453125,
            "text": "BCG is considered an effective vehicle for delivery of antigens due to its unique characteristics, the genetic manipulation of these mycobacteria has been appealing in the search for less toxic and more potent therapeutic agents for bladder cancer",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -7.86328125,
            "end_logit": 9.4453125,
            "text": "agents for bladder cancer",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -7.875,
            "end_logit": 9.4453125,
            "text": "less toxic and more potent therapeutic agents for bladder cancer",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -7.890625,
            "end_logit": 9.4453125,
            "text": "genetic manipulation of these mycobacteria has been appealing in the search for less toxic and more potent therapeutic agents for bladder cancer",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -7.890625,
            "end_logit": 9.4453125,
            "text": "therapeutic agents for bladder cancer",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -7.8984375,
            "end_logit": 9.4453125,
            "text": "for less toxic and more potent therapeutic agents for bladder cancer",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -7.90234375,
            "end_logit": 9.4453125,
            "text": "antigens due to its unique characteristics, the genetic manipulation of these mycobacteria has been appealing in the search for less toxic and more potent therapeutic agents for bladder cancer",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -7.9296875,
            "end_logit": 9.4453125,
            "text": "the genetic manipulation of these mycobacteria has been appealing in the search for less toxic and more potent therapeutic agents for bladder cancer",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -7.94921875,
            "end_logit": 9.4453125,
            "text": "toxic and more potent therapeutic agents for bladder cancer",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -7.9609375,
            "end_logit": 9.4453125,
            "text": "potent therapeutic agents for bladder cancer",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -7.96484375,
            "end_logit": 9.4453125,
            "text": "mycobacteria has been appealing in the search for less toxic and more potent therapeutic agents for bladder cancer",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 6.3828125,
            "end_logit": -7.62890625,
            "text": "cancer immunotherapy.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -3.255859375,
            "end_logit": -7.62890625,
            "text": "bladder cancer immunotherapy.",
            "probability": 0.0
        },
        {
            "start_logit": -6.88671875,
            "end_logit": -7.62890625,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.8046875,
            "end_logit": -7.62890625,
            "text": "for bladder cancer immunotherapy.",
            "probability": 0.0
        }
    ],
    "60292d191cb411341a00010e_27": [
        {
            "start_logit": 6.1875,
            "end_logit": 9.5078125,
            "text": "cancer",
            "probability": 0.98291015625
        },
        {
            "start_logit": 2.123046875,
            "end_logit": 9.5078125,
            "text": "bladder cancer",
            "probability": 0.0169219970703125
        },
        {
            "start_logit": -7.71875,
            "end_logit": 9.5078125,
            "text": "of bladder cancer",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": -7.73828125,
            "end_logit": 9.5078125,
            "text": "BCG immunotherapy of bladder cancer",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": -7.8984375,
            "end_logit": 9.5078125,
            "text": "immunotherapy of bladder cancer",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 6.1875,
            "end_logit": -7.8515625,
            "text": "cancer: inhibition of tumor recurrence",
            "probability": 0.0
        },
        {
            "start_logit": 6.1875,
            "end_logit": -7.87890625,
            "text": "cancer: inhibition of tumor recurrence and associated immune responses.",
            "probability": 0.0
        },
        {
            "start_logit": 6.1875,
            "end_logit": -8.1484375,
            "text": "cancer: inhibition of tumor recurrence and",
            "probability": 0.0
        },
        {
            "start_logit": 2.123046875,
            "end_logit": -6.953125,
            "text": "bladder",
            "probability": 0.0
        },
        {
            "start_logit": 2.123046875,
            "end_logit": -7.8515625,
            "text": "bladder cancer: inhibition of tumor recurrence",
            "probability": 0.0
        },
        {
            "start_logit": 2.123046875,
            "end_logit": -7.87890625,
            "text": "bladder cancer: inhibition of tumor recurrence and associated immune responses.",
            "probability": 0.0
        },
        {
            "start_logit": 2.123046875,
            "end_logit": -8.1484375,
            "text": "bladder cancer: inhibition of tumor recurrence and",
            "probability": 0.0
        },
        {
            "start_logit": -6.61328125,
            "end_logit": -7.87890625,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.71875,
            "end_logit": -6.953125,
            "text": "of bladder",
            "probability": 0.0
        },
        {
            "start_logit": -7.73828125,
            "end_logit": -6.953125,
            "text": "BCG immunotherapy of bladder",
            "probability": 0.0
        },
        {
            "start_logit": -7.8984375,
            "end_logit": -6.953125,
            "text": "immunotherapy of bladder",
            "probability": 0.0
        },
        {
            "start_logit": -7.390625,
            "end_logit": -7.8515625,
            "text": "tumor recurrence",
            "probability": 0.0
        },
        {
            "start_logit": -7.390625,
            "end_logit": -7.87890625,
            "text": "tumor recurrence and associated immune responses.",
            "probability": 0.0
        },
        {
            "start_logit": -7.51953125,
            "end_logit": -7.8515625,
            "text": "inhibition of tumor recurrence",
            "probability": 0.0
        },
        {
            "start_logit": -7.51953125,
            "end_logit": -7.87890625,
            "text": "inhibition of tumor recurrence and associated immune responses.",
            "probability": 0.0
        }
    ],
    "5e776db8835f4e4777000011_1": [
        {
            "start_logit": 9.3046875,
            "end_logit": 9.3671875,
            "text": "Sanofi",
            "probability": 0.92822265625
        },
        {
            "start_logit": 8.6484375,
            "end_logit": 7.46484375,
            "text": "MannKind Corporation",
            "probability": 0.07159423828125
        },
        {
            "start_logit": -1.9521484375,
            "end_logit": 9.3671875,
            "text": "i",
            "probability": 1.1980533599853516e-05
        },
        {
            "start_logit": 9.3046875,
            "end_logit": -2.103515625,
            "text": "San",
            "probability": 9.655952453613281e-06
        },
        {
            "start_logit": 8.6484375,
            "end_logit": -3.423828125,
            "text": "Mann",
            "probability": 1.3113021850585938e-06
        },
        {
            "start_logit": -4.40234375,
            "end_logit": 9.3671875,
            "text": "by Sanofi",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": -4.32421875,
            "end_logit": 7.46484375,
            "text": "tion",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.48828125,
            "end_logit": 9.3671875,
            "text": ". Afrezza has been marketed since February, 2015 by Sanofi",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.3046875,
            "end_logit": -6.81640625,
            "text": "Sanof",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.3046875,
            "end_logit": -6.91015625,
            "text": "Sanofi after",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.0234375,
            "end_logit": 9.3671875,
            "text": "ofi",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.6484375,
            "end_logit": -6.33984375,
            "text": "MannKind Corpora",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3046875,
            "end_logit": -7.015625,
            "text": "Sanofi after getting FDA approval in June 2014.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3046875,
            "end_logit": -7.46484375,
            "text": "Sanofi after getting FDA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.6484375,
            "end_logit": -6.96875,
            "text": "MannKind Corporation started",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.6484375,
            "end_logit": -7.015625,
            "text": "MannKind Corporation started developing its ultra-rapid-acting insulin Afrezza in a bold bid, probably by managing the issues in which Exubera was not successful.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.79296875,
            "end_logit": 9.3671875,
            "text": ", 2015 by Sanofi",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3046875,
            "end_logit": -7.79296875,
            "text": "Sanofi after getting FDA approval in June 2014",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3046875,
            "end_logit": -7.82421875,
            "text": "Sanofi after getting FDA approval",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3046875,
            "end_logit": -7.859375,
            "text": "Sanofi after getting FDA approval in",
            "probability": 5.960464477539063e-08
        }
    ],
    "58a5a51060087bc10a000021_1": [
        {
            "start_logit": 9.78125,
            "end_logit": 9.453125,
            "text": "Nox1",
            "probability": 1.0
        },
        {
            "start_logit": 9.78125,
            "end_logit": -1.5498046875,
            "text": "Nox",
            "probability": 1.6689300537109375e-05
        },
        {
            "start_logit": -1.9130859375,
            "end_logit": 9.453125,
            "text": "1",
            "probability": 8.344650268554688e-06
        },
        {
            "start_logit": 9.78125,
            "end_logit": -7.0,
            "text": "Nox1 oxidase",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.78125,
            "end_logit": -7.40234375,
            "text": "Nox1 oxidase, functions as either a canonical or hybrid system using Nox organizing subunit 1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.78125,
            "end_logit": -7.58984375,
            "text": "Nox1 oxidase, functions as either a canonical or hybrid system using Nox organizing subunit",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.78125,
            "end_logit": -7.65234375,
            "text": "Nox1 oxidase, functions as either a canonical or hybrid system using Nox organizing subunit 1 (NoxO1) or p47",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.78125,
            "end_logit": -7.65625,
            "text": "Nox1 oxidase, functions as either a canonical or hybrid system using Nox organizing subunit 1 (NoxO1) or p47(phox",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.78125,
            "end_logit": -7.65625,
            "text": "Nox1 oxidase, functions as either a canonical or hybrid system using Nox organizing subunit 1 (NoxO1)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.359375,
            "end_logit": 9.453125,
            "text": ", Nox1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.78125,
            "end_logit": -7.73828125,
            "text": "Nox1 oxidase, functions as either a canonical or hybrid system using Nox organizing subunit 1 (NoxO1) or p47(phox), respectively",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.78125,
            "end_logit": -7.77734375,
            "text": "Nox1 oxidase, functions as either a canonical or hybrid system using Nox",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.78125,
            "end_logit": -7.80859375,
            "text": "Nox1 oxidase, functions as either",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.78125,
            "end_logit": -7.8125,
            "text": "Nox1 oxidase,",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.78125,
            "end_logit": -7.8203125,
            "text": "Nox1 oxidase, functions as either a canonical or hybrid system using Nox organizing subunit 1 (NoxO1) or",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.78125,
            "end_logit": -7.828125,
            "text": "Nox1 oxidase, functions as either a canonical or hybrid system using Nox organizing subunit 1 (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.78125,
            "end_logit": -7.83203125,
            "text": "Nox1 oxidase, functions",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.78125,
            "end_logit": -7.85546875,
            "text": "Nox1 oxidase, functions as either a canonical or hybrid system using Nox organizing subunit 1 (NoxO1) or p47(phox)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.55078125,
            "end_logit": 9.453125,
            "text": "family, Nox1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0078125,
            "end_logit": 9.453125,
            "text": "member of this family, Nox1",
            "probability": 0.0
        }
    ],
    "58a5a51060087bc10a000021_2": [
        {
            "start_logit": 8.90625,
            "end_logit": 3.615234375,
            "text": "Nox1",
            "probability": 0.98291015625
        },
        {
            "start_logit": 8.90625,
            "end_logit": -0.6025390625,
            "text": "Nox1.",
            "probability": 0.01446533203125
        },
        {
            "start_logit": 8.90625,
            "end_logit": -2.34375,
            "text": "Nox",
            "probability": 0.002532958984375
        },
        {
            "start_logit": 0.8310546875,
            "end_logit": 3.615234375,
            "text": "Noxa1 and the superoxide-producing activity of Nox1",
            "probability": 0.00030493736267089844
        },
        {
            "start_logit": 0.8310546875,
            "end_logit": -0.6025390625,
            "text": "Noxa1 and the superoxide-producing activity of Nox1.",
            "probability": 4.5299530029296875e-06
        },
        {
            "start_logit": 0.8310546875,
            "end_logit": -1.2548828125,
            "text": "Noxa1",
            "probability": 2.3245811462402344e-06
        },
        {
            "start_logit": -4.66015625,
            "end_logit": 3.615234375,
            "text": "superoxide-producing activity of Nox1",
            "probability": 1.2516975402832031e-06
        },
        {
            "start_logit": 0.8310546875,
            "end_logit": -2.34375,
            "text": "Noxa1 and the superoxide-producing activity of Nox",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": -5.1640625,
            "end_logit": 3.615234375,
            "text": "of Nox1",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": -6.953125,
            "end_logit": 3.615234375,
            "text": "Noxo1 at threonine 341 regulates its interaction with Noxa1 and the superoxide-producing activity of Nox1",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.01953125,
            "end_logit": 3.615234375,
            "text": "Phosphorylation of Noxo1 at threonine 341 regulates its interaction with Noxa1 and the superoxide-producing activity of Nox1",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.1171875,
            "end_logit": 3.615234375,
            "text": "1",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.16796875,
            "end_logit": 3.615234375,
            "text": "with Noxa1 and the superoxide-producing activity of Nox1",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.3203125,
            "end_logit": 3.615234375,
            "text": "interaction with Noxa1 and the superoxide-producing activity of Nox1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -3.203125,
            "end_logit": -0.6025390625,
            "text": ".",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.64453125,
            "end_logit": 3.615234375,
            "text": "at threonine 341 regulates its interaction with Noxa1 and the superoxide-producing activity of Nox1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.671875,
            "end_logit": 3.615234375,
            "text": "threonine 341 regulates its interaction with Noxa1 and the superoxide-producing activity of Nox1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.82421875,
            "end_logit": 3.615234375,
            "text": "its interaction with Noxa1 and the superoxide-producing activity of Nox1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.9453125,
            "end_logit": 3.615234375,
            "text": "the superoxide-producing activity of Nox1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.96875,
            "end_logit": 3.615234375,
            "text": "of Noxo1 at threonine 341 regulates its interaction with Noxa1 and the superoxide-producing activity of Nox1",
            "probability": 5.960464477539063e-08
        }
    ],
    "58a5a51060087bc10a000021_3": [
        {
            "start_logit": 9.796875,
            "end_logit": 9.265625,
            "text": "Nox1",
            "probability": 1.0
        },
        {
            "start_logit": 9.796875,
            "end_logit": -1.3623046875,
            "text": "Nox",
            "probability": 2.4318695068359375e-05
        },
        {
            "start_logit": -2.111328125,
            "end_logit": 9.265625,
            "text": "1",
            "probability": 6.735324859619141e-06
        },
        {
            "start_logit": 9.796875,
            "end_logit": -5.12109375,
            "text": "Nox1, a member of the Nox family",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 9.796875,
            "end_logit": -6.29296875,
            "text": "Nox1, a member of the Nox",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.796875,
            "end_logit": -6.89453125,
            "text": "Nox1, a member of the Nox family NAPDH oxidase",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.796875,
            "end_logit": -7.1953125,
            "text": "Nox1, a member of the Nox family NAPDH oxidases, requires expression of its regulatory soluble proteins Noxo1 (Nox organizer 1) and Noxa1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.796875,
            "end_logit": -7.36328125,
            "text": "Nox1, a member of the Nox family NAPDH oxidases, requires expression of its regulatory soluble proteins Noxo1 (Nox organizer 1) and Nox",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.8515625,
            "end_logit": 9.265625,
            "text": "Superoxide production by Nox1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.796875,
            "end_logit": -7.4375,
            "text": "Nox1, a member of the Nox family NAP",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.796875,
            "end_logit": -7.48046875,
            "text": "Nox1, a member of the Nox family NAPDH oxidases",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.796875,
            "end_logit": -7.51171875,
            "text": "Nox1, a member of the Nox family NAPDH oxidases, requires expression of its regulatory soluble proteins Noxo1 (Nox organizer 1)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.796875,
            "end_logit": -7.53125,
            "text": "Nox1, a member of the Nox family NAPDH oxidases, requires expression of its regulatory soluble proteins Noxo1 (Nox organizer 1) and Noxa1 (Nox activator 1) and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.796875,
            "end_logit": -7.6015625,
            "text": "Nox1, a member of the Nox family NAPDH oxidases,",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.796875,
            "end_logit": -7.609375,
            "text": "Nox1, a member of the Nox family NAPDH",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.796875,
            "end_logit": -7.6171875,
            "text": "Nox1, a member",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.796875,
            "end_logit": -7.625,
            "text": "Nox1, a member of the Nox family NAPDH oxidases, requires expression of its regulatory soluble proteins Noxo1 (Nox organizer 1) and Noxa1 (Nox activator 1)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.12890625,
            "end_logit": 9.265625,
            "text": "by Nox1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.111328125,
            "end_logit": -5.12109375,
            "text": "1, a member of the Nox family",
            "probability": 0.0
        },
        {
            "start_logit": -6.8515625,
            "end_logit": -1.3623046875,
            "text": "Superoxide production by Nox",
            "probability": 0.0
        }
    ],
    "58a5a51060087bc10a000021_4": [
        {
            "start_logit": 9.09375,
            "end_logit": 5.8984375,
            "text": "Noxa1",
            "probability": 0.92236328125
        },
        {
            "start_logit": 9.09375,
            "end_logit": 3.251953125,
            "text": "Noxa1, an interaction that participates in Nox1",
            "probability": 0.06524658203125
        },
        {
            "start_logit": 7.359375,
            "end_logit": 3.251953125,
            "text": "Nox1",
            "probability": 0.0115203857421875
        },
        {
            "start_logit": 9.09375,
            "end_logit": -1.9130859375,
            "text": "Nox",
            "probability": 0.0003733634948730469
        },
        {
            "start_logit": 9.09375,
            "end_logit": -3.23046875,
            "text": "Noxa1, an interaction that participates in Nox",
            "probability": 0.0001004338264465332
        },
        {
            "start_logit": 9.09375,
            "end_logit": -3.890625,
            "text": "Noxa1, an interaction that participates in Nox1 activation.",
            "probability": 5.173683166503906e-05
        },
        {
            "start_logit": 7.359375,
            "end_logit": -3.23046875,
            "text": "Nox",
            "probability": 1.7762184143066406e-05
        },
        {
            "start_logit": 7.359375,
            "end_logit": -3.890625,
            "text": "Nox1 activation.",
            "probability": 9.119510650634766e-06
        },
        {
            "start_logit": 9.09375,
            "end_logit": -6.890625,
            "text": "Noxa1, an interaction that participates in Nox1 activation. Thus phosphorylation of Noxo1 at Thr341 appears to play a crucial role in PMA-elicited activation of Nox1,",
            "probability": 2.562999725341797e-06
        },
        {
            "start_logit": 9.09375,
            "end_logit": -7.02734375,
            "text": "Noxa1, an interaction that participates in Nox1 activation. Thus phosphorylation of Noxo1 at Thr341 appears",
            "probability": 2.2649765014648438e-06
        },
        {
            "start_logit": 9.09375,
            "end_logit": -7.1171875,
            "text": "Noxa1, an interaction that participates in Nox1 activation. Thus phosphorylation of Noxo1 at Thr341 appears to play a crucial role in PMA-elicited activation of Nox1",
            "probability": 2.0265579223632812e-06
        },
        {
            "start_logit": 9.09375,
            "end_logit": -7.296875,
            "text": "Noxa1, an interaction that participates in Nox1 activation. Thus phosphorylation of Noxo1 at Thr341 appears to",
            "probability": 1.7285346984863281e-06
        },
        {
            "start_logit": 7.359375,
            "end_logit": -6.73828125,
            "text": "Nox1 activation. Thus phosphorylation of Noxo1 at Thr341 appears to play a crucial role in PMA-elicited activation of Nox1, providing a molecular link between PKC",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -5.3359375,
            "end_logit": 5.8984375,
            "text": "a1",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -5.38671875,
            "end_logit": 5.8984375,
            "text": "Phosphorylation of Thr341 allows Noxo1 to sufficiently interact with Noxa1",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 7.359375,
            "end_logit": -6.890625,
            "text": "Nox1 activation. Thus phosphorylation of Noxo1 at Thr341 appears to play a crucial role in PMA-elicited activation of Nox1,",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 7.359375,
            "end_logit": -7.02734375,
            "text": "Nox1 activation. Thus phosphorylation of Noxo1 at Thr341 appears",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.359375,
            "end_logit": -7.1171875,
            "text": "Nox1 activation. Thus phosphorylation of Noxo1 at Thr341 appears to play a crucial role in PMA-elicited activation of Nox1",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.359375,
            "end_logit": -7.296875,
            "text": "Nox1 activation. Thus phosphorylation of Noxo1 at Thr341 appears to",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -6.3046875,
            "end_logit": 5.8984375,
            "text": "interact with Noxa1",
            "probability": 1.7881393432617188e-07
        }
    ],
    "58a5a51060087bc10a000021_5": [
        {
            "start_logit": 9.859375,
            "end_logit": 9.2890625,
            "text": "Nox1",
            "probability": 1.0
        },
        {
            "start_logit": 9.859375,
            "end_logit": -1.3017578125,
            "text": "Nox",
            "probability": 2.485513687133789e-05
        },
        {
            "start_logit": -2.189453125,
            "end_logit": 9.2890625,
            "text": "1",
            "probability": 5.841255187988281e-06
        },
        {
            "start_logit": 9.859375,
            "end_logit": -5.9453125,
            "text": "Nox1 activity in different manners.",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.859375,
            "end_logit": -7.125,
            "text": "Nox1 activity",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.859375,
            "end_logit": -7.39453125,
            "text": "Nox1 activity in",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.859375,
            "end_logit": -7.5546875,
            "text": "Nox1 activity in different",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.66015625,
            "end_logit": 9.2890625,
            "text": "Thus phosphorylation of Noxo1 at Thr341 and at Ser154 appears to regulate Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -7.9375,
            "end_logit": 9.2890625,
            "text": "regulate Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -7.98046875,
            "end_logit": 9.2890625,
            "text": "4 appears to regulate Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -7.99609375,
            "end_logit": 9.2890625,
            "text": "Noxo1 at Thr341 and at Ser154 appears to regulate Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -8.09375,
            "end_logit": 9.2890625,
            "text": "341 and at Ser154 appears to regulate Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -8.1171875,
            "end_logit": 9.2890625,
            "text": "of Noxo1 at Thr341 and at Ser154 appears to regulate Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -8.125,
            "end_logit": 9.2890625,
            "text": "to regulate Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -8.1328125,
            "end_logit": 9.2890625,
            "text": "Ser154 appears to regulate Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -8.1484375,
            "end_logit": 9.2890625,
            "text": "phosphorylation of Noxo1 at Thr341 and at Ser154 appears to regulate Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -8.1484375,
            "end_logit": 9.2890625,
            "text": "appears to regulate Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -8.15625,
            "end_logit": 9.2890625,
            "text": "Thr341 and at Ser154 appears to regulate Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -8.15625,
            "end_logit": 9.2890625,
            "text": "154 appears to regulate Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -2.189453125,
            "end_logit": -5.9453125,
            "text": "1 activity in different manners.",
            "probability": 0.0
        }
    ],
    "58a5a51060087bc10a000021_6": [
        {
            "start_logit": 1.197265625,
            "end_logit": -3.5390625,
            "text": "Nox",
            "probability": 0.5185546875
        },
        {
            "start_logit": 1.197265625,
            "end_logit": -4.89453125,
            "text": "Nox1 is known to absolutely require both an organizer protein (p47",
            "probability": 0.1336669921875
        },
        {
            "start_logit": 1.197265625,
            "end_logit": -5.234375,
            "text": "Nox1",
            "probability": 0.094970703125
        },
        {
            "start_logit": 1.197265625,
            "end_logit": -5.8671875,
            "text": "Nox1 is known to absolutely require both an organizer protein (p47(phox)",
            "probability": 0.050445556640625
        },
        {
            "start_logit": 1.197265625,
            "end_logit": -6.09375,
            "text": "Nox1 is known to absolutely require both an organizer protein (p4",
            "probability": 0.04022216796875
        },
        {
            "start_logit": 1.197265625,
            "end_logit": -6.625,
            "text": "Nox1 is known to",
            "probability": 0.0236358642578125
        },
        {
            "start_logit": 1.197265625,
            "end_logit": -6.64453125,
            "text": "Nox1 is known to absolutely require both an organizer protein (p47(phox) or Noxo1) andanactivatorprotein (p67",
            "probability": 0.0232696533203125
        },
        {
            "start_logit": 1.197265625,
            "end_logit": -6.765625,
            "text": "Nox1 is known to absolutely require both an organizer protein (p47(phox) or Noxo1) andanactivatorprotein (p67(phox)",
            "probability": 0.020538330078125
        },
        {
            "start_logit": 1.197265625,
            "end_logit": -6.79296875,
            "text": "Nox1 is known to absolutely require both an organizer protein (p47(phox) or Noxo1) andanactivatorprotein (p67(phox) or Noxa1)",
            "probability": 0.0200653076171875
        },
        {
            "start_logit": 1.197265625,
            "end_logit": -6.875,
            "text": "Nox1 is known to absolutely require both an organizer protein (p47(phox) or Noxo1)",
            "probability": 0.0184173583984375
        },
        {
            "start_logit": 1.197265625,
            "end_logit": -6.91015625,
            "text": "Nox1 is known",
            "probability": 0.017852783203125
        },
        {
            "start_logit": 1.197265625,
            "end_logit": -7.00390625,
            "text": "Nox1 is known to absolutely require both",
            "probability": 0.0162506103515625
        },
        {
            "start_logit": 1.197265625,
            "end_logit": -7.04296875,
            "text": "Nox1 is known to absolutely require both an organizer protein (p47(phox) or Noxo1) andanactivatorprotein (p67(phox) or Noxa1",
            "probability": 0.015625
        },
        {
            "start_logit": -4.4453125,
            "end_logit": -3.5390625,
            "text": "Nox enzymes such as gp91(phox)/Nox2 and Nox",
            "probability": 0.0018415451049804688
        },
        {
            "start_logit": -3.552734375,
            "end_logit": -4.89453125,
            "text": "p47",
            "probability": 0.0011606216430664062
        },
        {
            "start_logit": -4.7890625,
            "end_logit": -3.669921875,
            "text": ".",
            "probability": 0.0011434555053710938
        },
        {
            "start_logit": -5.2890625,
            "end_logit": -3.5390625,
            "text": "gp91(phox)/Nox2 and Nox",
            "probability": 0.0007915496826171875
        },
        {
            "start_logit": -4.4453125,
            "end_logit": -4.58203125,
            "text": "Nox enzymes such as gp91(phox)",
            "probability": 0.0006461143493652344
        },
        {
            "start_logit": -4.4453125,
            "end_logit": -4.74609375,
            "text": "Nox",
            "probability": 0.0005526542663574219
        },
        {
            "start_logit": -5.7109375,
            "end_logit": -3.5390625,
            "text": "and Nox",
            "probability": 0.0005192756652832031
        }
    ],
    "58a5a51060087bc10a000021_7": [
        {
            "start_logit": 9.8046875,
            "end_logit": 9.5078125,
            "text": "NOX1",
            "probability": 1.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -1.482421875,
            "text": "NOX",
            "probability": 1.6808509826660156e-05
        },
        {
            "start_logit": -1.82421875,
            "end_logit": 9.5078125,
            "text": "1",
            "probability": 8.940696716308594e-06
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -6.5,
            "text": "NOX1 was absolutely required for activation with NOXO1 and NOXA1 and that this activity required interaction of the putative NADPH-binding region of this domain with NOXA1.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.78125,
            "end_logit": 9.5078125,
            "text": "of NOX1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.34765625,
            "end_logit": 9.5078125,
            "text": "Studies of cytosolic co-factors showed that the C-terminal cytoplasmic domain of NOX1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -7.73828125,
            "text": "NOX1 was",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -7.7421875,
            "text": "NOX1 was absolutely required for activation with NOXO1 and NOXA1 and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -7.8046875,
            "text": "NOX1 was absolutely required for activation with NOXO1 and NOXA1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -7.81640625,
            "text": "NOX1 was absolutely required for activation with NOXO1 and NOXA1 and that this activity required interaction of the putative NADPH-binding region of this domain with NOXA1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -7.83203125,
            "text": "NOX1 was absolutely required for activation with NOXO1 and NOX",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -7.859375,
            "text": "NOX1 was absolutely required for activation with NOXO1 and NOXA1 and that this activity required interaction of the putative NADPH-binding region of this domain with NOX",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -7.8671875,
            "text": "NOX1 was absolutely required for activation with NOXO1 and NOXA1 and that this activity required interaction of the putative NADPH-binding region of this domain with",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -7.89453125,
            "text": "NOX1 was absolutely required for activation with NOXO1 and NOXA1 and that this activity required interaction of the putative NADPH",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -7.9140625,
            "text": "NOX1 was absolutely required for activation with NOXO1 and NOXA1 and that this activity required interaction of the putative NADPH-binding region of",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -7.92578125,
            "text": "NOX1 was absolutely required for activation",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -7.9296875,
            "text": "NOX1 was absolutely required for activation with NOXO1 and NOXA1 and that this activity required",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -7.9375,
            "text": "NOX1 was absolutely required for activation with NOXO1 and NOXA1 and that this activity required interaction of the putative NADPH-binding region of this domain",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -7.9765625,
            "text": "NOX1 was absolutely required for activation with NOXO1 and NOXA1 and that this activity required interaction of the putative NADPH-",
            "probability": 0.0
        },
        {
            "start_logit": -7.90234375,
            "end_logit": 9.5078125,
            "text": "domain of NOX1",
            "probability": 0.0
        }
    ],
    "58a5a51060087bc10a000021_8": [
        {
            "start_logit": 8.96875,
            "end_logit": 6.5625,
            "text": "Nox1",
            "probability": 0.9990234375
        },
        {
            "start_logit": 8.96875,
            "end_logit": -0.481201171875,
            "text": "Nox1.",
            "probability": 0.0008692741394042969
        },
        {
            "start_logit": 8.96875,
            "end_logit": -2.4453125,
            "text": "Nox",
            "probability": 0.00012230873107910156
        },
        {
            "start_logit": -5.33203125,
            "end_logit": 6.5625,
            "text": "1",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -5.51953125,
            "end_logit": 6.5625,
            "text": "NADPH oxidase Organizer 1 (NoxO1) is shown to interact with the NADPH-binding region of Nox1",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -6.3203125,
            "end_logit": 6.5625,
            "text": "of Nox1",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.125,
            "end_logit": 6.5625,
            "text": "shown to interact with the NADPH-binding region of Nox1",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.41796875,
            "end_logit": 6.5625,
            "text": "Additionally, NADPH oxidase Organizer 1 (NoxO1) is shown to interact with the NADPH-binding region of Nox1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.42578125,
            "end_logit": 6.5625,
            "text": ", NADPH oxidase Organizer 1 (NoxO1) is shown to interact with the NADPH-binding region of Nox1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.55078125,
            "end_logit": 6.5625,
            "text": "NADPH-binding region of Nox1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.578125,
            "end_logit": 6.5625,
            "text": "the NADPH-binding region of Nox1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.61328125,
            "end_logit": 6.5625,
            "text": "NoxO1) is shown to interact with the NADPH-binding region of Nox1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.65625,
            "end_logit": 6.5625,
            "text": "region of Nox1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.67578125,
            "end_logit": 6.5625,
            "text": "(NoxO1) is shown to interact with the NADPH-binding region of Nox1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.75,
            "end_logit": 6.5625,
            "text": "interact with the NADPH-binding region of Nox1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.75390625,
            "end_logit": 6.5625,
            "text": "r 1 (NoxO1) is shown to interact with the NADPH-binding region of Nox1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.77734375,
            "end_logit": 6.5625,
            "text": "with the NADPH-binding region of Nox1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -3.22265625,
            "end_logit": -0.481201171875,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -5.33203125,
            "end_logit": -0.481201171875,
            "text": "1.",
            "probability": 0.0
        },
        {
            "start_logit": -5.51953125,
            "end_logit": -0.481201171875,
            "text": "NADPH oxidase Organizer 1 (NoxO1) is shown to interact with the NADPH-binding region of Nox1.",
            "probability": 0.0
        }
    ],
    "58a5a51060087bc10a000021_9": [
        {
            "start_logit": 9.9140625,
            "end_logit": 9.5859375,
            "text": "Nox1",
            "probability": 1.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -1.197265625,
            "text": "Nox",
            "probability": 2.0802021026611328e-05
        },
        {
            "start_logit": -1.5986328125,
            "end_logit": 9.5859375,
            "text": "1",
            "probability": 9.953975677490234e-06
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -5.95703125,
            "text": "Nox1, complexed with p22(phox) at the membrane, requires its regulatory soluble proteins Noxo1 and Noxa1.",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -6.734375,
            "text": "Nox1,",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -7.5078125,
            "text": "Nox1, complexed with p22(phox",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -7.546875,
            "text": "Nox1, complexed with p22(phox) at",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -7.66015625,
            "text": "Nox1, complexed with p22(phox) at the membrane, requires its regulatory soluble proteins Noxo1 and Noxa1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -7.703125,
            "text": "Nox1, complexed with p22",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -7.77734375,
            "text": "Nox1, complexed",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -7.81640625,
            "text": "Nox1, complexed with p22(phox)",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -7.828125,
            "text": "Nox1, complexed with p22(phox) at the membrane, requires",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -7.83203125,
            "text": "Nox1, complexed with",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -7.8359375,
            "text": "Nox1, complexed with p22(phox) at the membrane,",
            "probability": 0.0
        },
        {
            "start_logit": -7.51953125,
            "end_logit": 9.5859375,
            "text": "oxidase Nox1",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -7.89453125,
            "text": "Nox1, complexed with p22(phox) at the membrane, requires its regulatory soluble proteins Noxo1 and Nox",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -7.8984375,
            "text": "Nox1, complexed with p22(phox) at the",
            "probability": 0.0
        },
        {
            "start_logit": -7.65234375,
            "end_logit": 9.5859375,
            "text": "NADPH oxidase Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -7.89453125,
            "end_logit": 9.5859375,
            "text": "producing NADPH oxidase Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -7.921875,
            "end_logit": 9.5859375,
            "text": "Activation of the non-phagocytic superoxide-producing NADPH oxidase Nox1",
            "probability": 0.0
        }
    ],
    "58a5a51060087bc10a000021_10": [
        {
            "start_logit": 7.73828125,
            "end_logit": 9.046875,
            "text": "NADPH oxidase 1",
            "probability": 1.0
        },
        {
            "start_logit": 7.73828125,
            "end_logit": 1.109375,
            "text": "NADPH oxidase 1 assembly and activation.",
            "probability": 0.0003571510314941406
        },
        {
            "start_logit": -2.5,
            "end_logit": 9.046875,
            "text": "1",
            "probability": 3.594160079956055e-05
        },
        {
            "start_logit": -4.71484375,
            "end_logit": 9.046875,
            "text": "NOXO1 phosphorylation on serine 154 is critical for optimal NADPH oxidase 1",
            "probability": 3.933906555175781e-06
        },
        {
            "start_logit": 7.73828125,
            "end_logit": -4.34765625,
            "text": "NADPH",
            "probability": 1.5497207641601562e-06
        },
        {
            "start_logit": -6.5,
            "end_logit": 9.046875,
            "text": "optimal NADPH oxidase 1",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -6.828125,
            "end_logit": 9.046875,
            "text": "serine 154 is critical for optimal NADPH oxidase 1",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -7.1953125,
            "end_logit": 9.046875,
            "text": "phosphorylation on serine 154 is critical for optimal NADPH oxidase 1",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.19921875,
            "end_logit": 9.046875,
            "text": "on serine 154 is critical for optimal NADPH oxidase 1",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.73828125,
            "end_logit": -6.01953125,
            "text": "NADPH oxidase",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.45703125,
            "end_logit": 9.046875,
            "text": "oxidase 1",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.6328125,
            "end_logit": 9.046875,
            "text": "for optimal NADPH oxidase 1",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.6953125,
            "end_logit": 9.046875,
            "text": "critical for optimal NADPH oxidase 1",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.96484375,
            "end_logit": 9.046875,
            "text": "is critical for optimal NADPH oxidase 1",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -8.046875,
            "end_logit": 9.046875,
            "text": "O1 phosphorylation on serine 154 is critical for optimal NADPH oxidase 1",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.73828125,
            "end_logit": -7.703125,
            "text": "NADPH oxidase 1 assembly and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.73828125,
            "end_logit": -7.72265625,
            "text": "NADPH oxidase 1 assembly",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.73828125,
            "end_logit": -7.73828125,
            "text": "NADPH oxidase 1 assembly and activation",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.095703125,
            "end_logit": 1.109375,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -2.5,
            "end_logit": 1.109375,
            "text": "1 assembly and activation.",
            "probability": 0.0
        }
    ],
    "58a5a51060087bc10a000021_11": [
        {
            "start_logit": 9.8359375,
            "end_logit": 9.546875,
            "text": "Nox1",
            "probability": 1.0
        },
        {
            "start_logit": 9.8359375,
            "end_logit": -1.4619140625,
            "text": "Nox",
            "probability": 1.6689300537109375e-05
        },
        {
            "start_logit": -1.771484375,
            "end_logit": 9.546875,
            "text": "1",
            "probability": 9.179115295410156e-06
        },
        {
            "start_logit": 9.8359375,
            "end_logit": -5.60546875,
            "text": "Nox1 requires both the organizer protein Noxo1 and the activator protein Noxa1.",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.8359375,
            "end_logit": -7.23828125,
            "text": "Nox1 requires both",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.0078125,
            "end_logit": 9.546875,
            "text": "oxidase Nox1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8359375,
            "end_logit": -7.3671875,
            "text": "Nox1 requires",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8359375,
            "end_logit": -7.61328125,
            "text": "Nox1 requires both the organizer protein Noxo1 and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.328125,
            "end_logit": 9.546875,
            "text": "Activation of the superoxide-producing NADPH oxidase Nox1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.46875,
            "end_logit": 9.546875,
            "text": "NADPH oxidase Nox1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8359375,
            "end_logit": -7.77734375,
            "text": "Nox1 requires both the organizer protein Noxo1 and the activator protein Noxa1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.546875,
            "end_logit": 9.546875,
            "text": "superoxide-producing NADPH oxidase Nox1",
            "probability": 0.0
        },
        {
            "start_logit": 9.8359375,
            "end_logit": -7.8828125,
            "text": "Nox1 requires both the organizer protein Noxo1 and the",
            "probability": 0.0
        },
        {
            "start_logit": 9.8359375,
            "end_logit": -7.890625,
            "text": "Nox1 requires both the",
            "probability": 0.0
        },
        {
            "start_logit": 9.8359375,
            "end_logit": -7.97265625,
            "text": "Nox1 requires both the organizer",
            "probability": 0.0
        },
        {
            "start_logit": -7.71484375,
            "end_logit": 9.546875,
            "text": "the superoxide-producing NADPH oxidase Nox1",
            "probability": 0.0
        },
        {
            "start_logit": 9.8359375,
            "end_logit": -8.0078125,
            "text": "Nox1 requires both the organizer protein Noxo1 and the activator protein Nox",
            "probability": 0.0
        },
        {
            "start_logit": -7.83203125,
            "end_logit": 9.546875,
            "text": "producing NADPH oxidase Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -8.125,
            "end_logit": 9.546875,
            "text": "of the superoxide-producing NADPH oxidase Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -1.771484375,
            "end_logit": -5.60546875,
            "text": "1 requires both the organizer protein Noxo1 and the activator protein Noxa1.",
            "probability": 0.0
        }
    ],
    "58a5a51060087bc10a000021_12": [
        {
            "start_logit": 9.8828125,
            "end_logit": 9.1875,
            "text": "NOX1",
            "probability": 1.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -1.185546875,
            "text": "NOX",
            "probability": 3.147125244140625e-05
        },
        {
            "start_logit": -2.271484375,
            "end_logit": 9.1875,
            "text": "1",
            "probability": 5.304813385009766e-06
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -6.38671875,
            "text": "NOX1, an NADPH oxidase homologue that is most abundantly expressed in colon epithelial cells, requires the regulatory subunits NOXO1 (NOX organizing protein 1) and NOXA1",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -6.62890625,
            "text": "NOX1, an NADPH oxidase homologue that is most abundantly expressed in colon epithelial cells, requires the regulatory subunits NOXO1 (NOX organizing protein 1)",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -6.71875,
            "text": "NOX1, an NADPH oxidase homologue that is most abundantly expressed in colon epithelial cells, requires the regulatory subunits NOXO1 (NOX organizing protein 1) and NOX",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -6.82421875,
            "text": "NOX1, an NADPH oxidase homologue that is most abundantly expressed in colon epithelial cells, requires the regulatory subunits NOXO1 (NOX organizing protein 1",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -7.0078125,
            "text": "NOX1, an NADPH oxidase homologue that is most abundantly expressed in colon epithelial cells, requires the regulatory subunits NOXO1 (NOX organizing protein 1) and NOXA1 (NOX activating",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -7.0625,
            "text": "NOX1, an NADPH oxidase homologue that is most abundantly expressed in colon epithelial cells, requires the regulatory subunits NOXO1 (NOX organizing protein 1) and NOXA1 (NOX activating protein 1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -7.09375,
            "text": "NOX1, an NADPH oxidase homologue that is most abundantly expressed in colon epithelial cells, requires the regulatory subunits NOXO1 (NOX organizing protein 1) and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -7.15625,
            "text": "NOX1, an NADPH oxidase homologue that is most abundantly expressed in colon epithelial cells, requires the regulatory subunits NOXO1 (NOX organizing protein 1) and NOXA1 (NOX",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -7.1953125,
            "text": "NOX1, an NADPH oxidase homologue that is most abundantly expressed in colon epithelial cells, requires the regulatory subunits NOXO1 (NOX organizing protein 1) and NOXA1 (NOX activating protein 1),",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -7.20703125,
            "text": "NOX1, an NADPH oxidase homologue that is most abundantly expressed in colon epithelial cells, requires the regulatory subunits NOXO1 (NOX organizing protein 1) and NOXA1 (NOX activating protein",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -7.265625,
            "text": "NOX1, an NADPH oxidase homologue that is most abundantly expressed in colon epithelial cells, requires the regulatory subunits",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -7.28515625,
            "text": "NOX1, an NADPH oxidase homologue that is most abundantly expressed in colon epithelial cells, requires the regulatory",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -7.2890625,
            "text": "NOX1, an NADPH oxidase homologue that is most abundantly expressed in colon epithelial cells, requires the regulatory subunits NOXO1 (NOX",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.271484375,
            "end_logit": -6.38671875,
            "text": "1, an NADPH oxidase homologue that is most abundantly expressed in colon epithelial cells, requires the regulatory subunits NOXO1 (NOX organizing protein 1) and NOXA1",
            "probability": 0.0
        },
        {
            "start_logit": -2.271484375,
            "end_logit": -6.62890625,
            "text": "1, an NADPH oxidase homologue that is most abundantly expressed in colon epithelial cells, requires the regulatory subunits NOXO1 (NOX organizing protein 1)",
            "probability": 0.0
        },
        {
            "start_logit": -2.271484375,
            "end_logit": -6.71875,
            "text": "1, an NADPH oxidase homologue that is most abundantly expressed in colon epithelial cells, requires the regulatory subunits NOXO1 (NOX organizing protein 1) and NOX",
            "probability": 0.0
        },
        {
            "start_logit": -2.271484375,
            "end_logit": -6.82421875,
            "text": "1, an NADPH oxidase homologue that is most abundantly expressed in colon epithelial cells, requires the regulatory subunits NOXO1 (NOX organizing protein 1",
            "probability": 0.0
        }
    ],
    "58a5a51060087bc10a000021_13": [
        {
            "start_logit": 9.78125,
            "end_logit": 9.375,
            "text": "Nox1",
            "probability": 1.0
        },
        {
            "start_logit": 9.78125,
            "end_logit": -1.4072265625,
            "text": "Nox",
            "probability": 2.0802021026611328e-05
        },
        {
            "start_logit": -1.896484375,
            "end_logit": 9.375,
            "text": "1",
            "probability": 8.463859558105469e-06
        },
        {
            "start_logit": 9.78125,
            "end_logit": -3.0390625,
            "text": "Nox1, an oxidase that is likely involved in host defence at the colon, requires novel proteins homologous to p47phox and p67phox, designated Noxo1 and Noxa1",
            "probability": 4.0531158447265625e-06
        },
        {
            "start_logit": 9.78125,
            "end_logit": -4.83203125,
            "text": "Nox1, an oxidase that is likely involved in host defence at the colon, requires novel proteins homologous to p47phox and p67phox, designated Noxo1 and Noxa1, respectively.",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 9.78125,
            "end_logit": -6.2734375,
            "text": "Nox1, an oxidase that is likely involved in host defence at the colon, requires novel proteins homologous to p47phox and p67phox, designated Noxo1 and Nox",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.78125,
            "end_logit": -6.5234375,
            "text": "Nox1, an oxidase that is likely involved in host defence at the colon, requires novel proteins homologous to p47phox and p67phox",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.28515625,
            "end_logit": 9.375,
            "text": "Activation of Nox1",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.78125,
            "end_logit": -6.734375,
            "text": "Nox1, an oxidase that is likely involved in host defence at the colon, requires novel proteins homologous to p47phox and p67",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.78125,
            "end_logit": -6.7734375,
            "text": "Nox1, an oxidase that is likely involved in host defence at the colon, requires novel proteins homologous to p47phox",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.78125,
            "end_logit": -6.84375,
            "text": "Nox1, an oxidase that is likely involved in host defence at the colon, requires novel proteins homologous to p47phox and p67phox, designated Noxo1 and Noxa1, respectively",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.78125,
            "end_logit": -6.90234375,
            "text": "Nox1, an oxidase that",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.78125,
            "end_logit": -6.99609375,
            "text": "Nox1, an oxidase",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.78125,
            "end_logit": -7.015625,
            "text": "Nox1, an oxidase that is likely involved in host defence at the colon, requires novel proteins homologous to p47phox and p67phox,",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.78125,
            "end_logit": -7.01953125,
            "text": "Nox1, an oxidase that is likely involved in host defence at the colon, requires novel proteins homologous to p47",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.78125,
            "end_logit": -7.328125,
            "text": "Nox1, an oxidase that is likely involved in host defence at the colon, requires novel proteins homologous to p47phox and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.78125,
            "end_logit": -7.43359375,
            "text": "Nox1, an oxidase that is likely involved in host defence at the colon, requires novel proteins homologous to p47phox and p67phox, designated Noxo1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.78125,
            "end_logit": -7.47265625,
            "text": "Nox1, an",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.78125,
            "end_logit": -7.48828125,
            "text": "Nox1, an oxidase that is likely involved in host defence at the colon, requires novel proteins homologous to p47phox and p",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.4765625,
            "end_logit": 9.375,
            "text": "of Nox1",
            "probability": 5.960464477539063e-08
        }
    ],
    "58a5a51060087bc10a000021_14": [
        {
            "start_logit": 0.430908203125,
            "end_logit": 2.12109375,
            "text": "NADPH oxidase 1 with betaPix and Nox Organizer 1.",
            "probability": 0.8427734375
        },
        {
            "start_logit": -1.48828125,
            "end_logit": 2.12109375,
            "text": ".",
            "probability": 0.12353515625
        },
        {
            "start_logit": -2.947265625,
            "end_logit": 2.12109375,
            "text": "Nox Organizer 1.",
            "probability": 0.0287322998046875
        },
        {
            "start_logit": -6.79296875,
            "end_logit": 2.12109375,
            "text": "betaPix and Nox Organizer 1.",
            "probability": 0.0006127357482910156
        },
        {
            "start_logit": -6.83203125,
            "end_logit": 2.12109375,
            "text": "1 with betaPix and Nox Organizer 1.",
            "probability": 0.0005893707275390625
        },
        {
            "start_logit": -7.0,
            "end_logit": 2.12109375,
            "text": "Pix and Nox Organizer 1.",
            "probability": 0.000499725341796875
        },
        {
            "start_logit": -7.0625,
            "end_logit": 2.12109375,
            "text": "and Nox Organizer 1.",
            "probability": 0.0004696846008300781
        },
        {
            "start_logit": 0.430908203125,
            "end_logit": -5.48828125,
            "text": "NADPH oxidase 1 with betaPix",
            "probability": 0.00041794776916503906
        },
        {
            "start_logit": -7.40625,
            "end_logit": 2.12109375,
            "text": "of NADPH oxidase 1 with betaPix and Nox Organizer 1.",
            "probability": 0.0003330707550048828
        },
        {
            "start_logit": -7.40625,
            "end_logit": 2.12109375,
            "text": "with betaPix and Nox Organizer 1.",
            "probability": 0.0003330707550048828
        },
        {
            "start_logit": -7.59375,
            "end_logit": 2.12109375,
            "text": "Molecular interaction of NADPH oxidase 1 with betaPix and Nox Organizer 1.",
            "probability": 0.0002760887145996094
        },
        {
            "start_logit": 0.430908203125,
            "end_logit": -5.9140625,
            "text": "NADPH oxidase 1 with betaPix and Nox Organizer 1",
            "probability": 0.00027179718017578125
        },
        {
            "start_logit": -7.69921875,
            "end_logit": 2.12109375,
            "text": "oxidase 1 with betaPix and Nox Organizer 1.",
            "probability": 0.0002474784851074219
        },
        {
            "start_logit": 0.430908203125,
            "end_logit": -6.07421875,
            "text": "NADPH oxidase 1 with betaPix and Nox",
            "probability": 0.00023245811462402344
        },
        {
            "start_logit": -7.76953125,
            "end_logit": 2.12109375,
            "text": "interaction of NADPH oxidase 1 with betaPix and Nox Organizer 1.",
            "probability": 0.00023066997528076172
        },
        {
            "start_logit": -7.81640625,
            "end_logit": 2.12109375,
            "text": "x and Nox Organizer 1.",
            "probability": 0.00022017955780029297
        },
        {
            "start_logit": -7.8203125,
            "end_logit": 2.12109375,
            "text": "r 1.",
            "probability": 0.00022017955780029297
        },
        {
            "start_logit": 0.430908203125,
            "end_logit": -7.28515625,
            "text": "NADPH oxidase 1",
            "probability": 6.92605972290039e-05
        },
        {
            "start_logit": 0.430908203125,
            "end_logit": -7.33984375,
            "text": "NADPH oxidase 1 with betaPix and Nox Organize",
            "probability": 6.562471389770508e-05
        },
        {
            "start_logit": 0.430908203125,
            "end_logit": -7.34375,
            "text": "NADPH oxidase",
            "probability": 6.508827209472656e-05
        }
    ],
    "58a5a51060087bc10a000021_15": [
        {
            "start_logit": 9.1875,
            "end_logit": 8.203125,
            "text": "NOX1",
            "probability": 0.9990234375
        },
        {
            "start_logit": 9.1875,
            "end_logit": 1.6064453125,
            "text": "NOX1)",
            "probability": 0.0013675689697265625
        },
        {
            "start_logit": 9.1875,
            "end_logit": -1.7080078125,
            "text": "NOX",
            "probability": 4.982948303222656e-05
        },
        {
            "start_logit": -3.15625,
            "end_logit": 8.203125,
            "text": "1",
            "probability": 4.351139068603516e-06
        },
        {
            "start_logit": -5.765625,
            "end_logit": 8.203125,
            "text": "by NADPH oxidase 1 (NOX1",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.1875,
            "end_logit": -7.16015625,
            "text": "NOX1), which is mainly expressed in colon epithelial cells, requires the membrane-bound component p22(PHOX",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.31640625,
            "end_logit": 8.203125,
            "text": "NADPH oxidase 1 (NOX1",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.1875,
            "end_logit": -7.328125,
            "text": "NOX1), which is mainly expressed in colon epithelial cells, requires the membrane-bound component p22(PHOX)",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.1875,
            "end_logit": -7.39453125,
            "text": "NOX1), which is mainly expressed in colon epithelial cells, requires the membrane-bound component p22",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.1875,
            "end_logit": -7.42578125,
            "text": "NOX1), which is mainly expressed in colon epithelial cells, requires the membrane-bound component p22(PHOX) and",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.1875,
            "end_logit": -7.52734375,
            "text": "NOX1),",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1875,
            "end_logit": -7.59765625,
            "text": "NOX1), which is mainly expressed in colon epithelial cells, requires the membrane-bound component p22(",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1875,
            "end_logit": -7.66015625,
            "text": "NOX1), which",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1875,
            "end_logit": -7.68359375,
            "text": "NOX1), which is mainly expressed in colon epithelial cells, requires the membrane-bound component p22(PHOX) and the cytosolic partners NOX organizer 1 (NOXO1), NOX activator",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1875,
            "end_logit": -7.6875,
            "text": "NOX1), which is mainly expressed in colon epithelial cells, requires the membrane-bound component p22(PHOX) and the cytosolic partners NOX organizer 1 (NOXO1)",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.87890625,
            "end_logit": 8.203125,
            "text": "(NOX1",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.53125,
            "end_logit": 8.203125,
            "text": "Reactive oxygen species (ROS) production by NADPH oxidase 1 (NOX1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -3.15625,
            "end_logit": 1.6064453125,
            "text": "1)",
            "probability": 0.0
        },
        {
            "start_logit": -5.765625,
            "end_logit": 1.6064453125,
            "text": "by NADPH oxidase 1 (NOX1)",
            "probability": 0.0
        },
        {
            "start_logit": -6.31640625,
            "end_logit": 1.6064453125,
            "text": "NADPH oxidase 1 (NOX1)",
            "probability": 0.0
        }
    ],
    "58a5a51060087bc10a000021_16": [
        {
            "start_logit": 9.7265625,
            "end_logit": 9.1171875,
            "text": "NOX1",
            "probability": 1.0
        },
        {
            "start_logit": 9.7265625,
            "end_logit": -1.5205078125,
            "text": "NOX",
            "probability": 2.390146255493164e-05
        },
        {
            "start_logit": -2.384765625,
            "end_logit": 9.1171875,
            "text": "1",
            "probability": 5.4836273193359375e-06
        },
        {
            "start_logit": 9.7265625,
            "end_logit": -6.6640625,
            "text": "NOX1, an NADPH oxidase homologue that is most abundantly expressed in colon epithelial cells, requires the regulatory subunits NOXO1 (NOX organizing protein 1) and NOXA1",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.7265625,
            "end_logit": -6.734375,
            "text": "NOX1, an NADPH oxidase homologue that is most abundantly expressed in colon epithelial cells, requires the regulatory subunits NOXO1 (NOX organizing protein 1)",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.7265625,
            "end_logit": -6.796875,
            "text": "NOX1, an NADPH oxidase homologue that is most abundantly expressed in colon epithelial cells, requires the regulatory subunits NOXO1 (NOX organizing protein 1",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.7265625,
            "end_logit": -7.078125,
            "text": "NOX1, an NADPH oxidase homologue that is most abundantly expressed in colon epithelial cells, requires the regulatory subunits NOXO1 (NOX organizing protein 1) and NOX",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.7265625,
            "end_logit": -7.09765625,
            "text": "NOX1, an NADPH oxidase homologue that is most abundantly expressed in colon epithelial cells, requires the regulatory subunits NOXO1 (NOX organizing protein 1) and",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.7265625,
            "end_logit": -7.14453125,
            "text": "NOX1, an NADPH oxidase homologue that is most abundantly expressed in colon epithelial cells, requires the regulatory subunits NOXO1 (NOX organizing protein 1) and NOXA1 (NOX activating",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.7265625,
            "end_logit": -7.1640625,
            "text": "NOX1, an NADPH oxidase homologue that is most abundantly expressed in colon epithelial cells, requires the regulatory subunits NOXO1 (NOX organizing protein 1) and NOXA1 (NOX activating protein 1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.7265625,
            "end_logit": -7.25390625,
            "text": "NOX1, an NADPH oxidase homologue that is most abundantly expressed in colon epithelial cells, requires the regulatory subunits NOXO1 (NOX organizing protein 1) and NOXA1 (NOX activating protein",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.7265625,
            "end_logit": -7.265625,
            "text": "NOX1, an NADPH oxidase homologue that is most abundantly expressed in colon epithelial cells, requires the regulatory subunits",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.7265625,
            "end_logit": -7.2734375,
            "text": "NOX1, an NADPH oxidase homologue that is most abundantly expressed in colon epithelial cells, requires the regulatory subunits NOXO1 (NOX organizing protein 1) and NOXA1 (NOX activating protein 1)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.7265625,
            "end_logit": -7.29296875,
            "text": "NOX1, an NADPH oxidase homologue that is most abundantly expressed in colon epithelial cells, requires the regulatory subunits NOXO1 (NOX organizing protein 1) and NOXA1 (NOX activating protein 1),",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.7265625,
            "end_logit": -7.328125,
            "text": "NOX1, an NADPH oxidase homologue that is most abundantly expressed in colon epithelial cells, requires the regulatory subunits NOXO1 (NOX organizing protein 1) and NOXA1 (NOX",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.7265625,
            "end_logit": -7.35546875,
            "text": "NOX1, an NADPH oxidase homologue that is most abundantly expressed in colon epithelial cells, requires the regulatory subunits NOXO1 (NOX",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.7265625,
            "end_logit": -7.359375,
            "text": "NOX1, an NADPH oxidase homologue that is most abundantly expressed in colon epithelial cells, requires the regulatory subunits NOXO1 (NOX organizing protein",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.7265625,
            "end_logit": -7.4296875,
            "text": "NOX1, an NADPH oxidase homologue that is most abundantly expressed in colon epithelial cells, requires the regulatory subunits NOXO1 (NOX organizing",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.384765625,
            "end_logit": -6.6640625,
            "text": "1, an NADPH oxidase homologue that is most abundantly expressed in colon epithelial cells, requires the regulatory subunits NOXO1 (NOX organizing protein 1) and NOXA1",
            "probability": 0.0
        },
        {
            "start_logit": -2.384765625,
            "end_logit": -6.734375,
            "text": "1, an NADPH oxidase homologue that is most abundantly expressed in colon epithelial cells, requires the regulatory subunits NOXO1 (NOX organizing protein 1)",
            "probability": 0.0
        }
    ],
    "58a5a51060087bc10a000021_17": [
        {
            "start_logit": 9.765625,
            "end_logit": 9.4375,
            "text": "Nox1",
            "probability": 1.0
        },
        {
            "start_logit": 9.765625,
            "end_logit": -1.5732421875,
            "text": "Nox",
            "probability": 1.6570091247558594e-05
        },
        {
            "start_logit": -1.9384765625,
            "end_logit": 9.4375,
            "text": "1",
            "probability": 8.285045623779297e-06
        },
        {
            "start_logit": 9.765625,
            "end_logit": -6.9296875,
            "text": "Nox1 requires both",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.765625,
            "end_logit": -7.08984375,
            "text": "Nox1 requires both the organizer protein Noxo1 and the activator protein Noxa1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.765625,
            "end_logit": -7.359375,
            "text": "Nox1 requires",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.765625,
            "end_logit": -7.390625,
            "text": "Nox1 requires both the organizer protein Noxo1 and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.11328125,
            "end_logit": 9.4375,
            "text": "oxidase Nox1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.390625,
            "end_logit": 9.4375,
            "text": "NADPH oxidase Nox1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.40625,
            "end_logit": 9.4375,
            "text": "superoxide-producing NADPH oxidase Nox1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.765625,
            "end_logit": -7.7734375,
            "text": "Nox1 requires both the organizer protein Noxo1 and the",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.765625,
            "end_logit": -7.83203125,
            "text": "Nox1 requires both the",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.51953125,
            "end_logit": 9.4375,
            "text": "Activation of the superoxide-producing NADPH oxidase Nox1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.765625,
            "end_logit": -7.86328125,
            "text": "Nox1 requires both the organizer protein Noxo1 and the activator protein Nox",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.765625,
            "end_logit": -7.99609375,
            "text": "Nox1 requires both the organizer protein Noxo1 and the activator",
            "probability": 0.0
        },
        {
            "start_logit": 9.765625,
            "end_logit": -8.0234375,
            "text": "Nox1 requires both the organizer",
            "probability": 0.0
        },
        {
            "start_logit": -7.72265625,
            "end_logit": 9.4375,
            "text": "the superoxide-producing NADPH oxidase Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -7.78125,
            "end_logit": 9.4375,
            "text": "producing NADPH oxidase Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -8.1328125,
            "end_logit": 9.4375,
            "text": "of the superoxide-producing NADPH oxidase Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -7.11328125,
            "end_logit": -1.5732421875,
            "text": "oxidase Nox",
            "probability": 0.0
        }
    ],
    "58a5a51060087bc10a000021_18": [
        {
            "start_logit": 9.890625,
            "end_logit": 9.46875,
            "text": "Nox1",
            "probability": 1.0
        },
        {
            "start_logit": 9.890625,
            "end_logit": -1.1640625,
            "text": "Nox",
            "probability": 2.4139881134033203e-05
        },
        {
            "start_logit": -1.806640625,
            "end_logit": 9.46875,
            "text": "1",
            "probability": 8.344650268554688e-06
        },
        {
            "start_logit": 9.890625,
            "end_logit": -6.52734375,
            "text": "Nox1,",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.890625,
            "end_logit": -7.171875,
            "text": "Nox1, complexed with p22(phox) at the membrane, requires its regulatory soluble proteins Noxo1 and Noxa1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.890625,
            "end_logit": -7.53125,
            "text": "Nox1, complexed with p22(phox",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.890625,
            "end_logit": -7.578125,
            "text": "Nox1, complexed with p22(phox) at",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.890625,
            "end_logit": -7.7421875,
            "text": "Nox1, complexed with p22",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.890625,
            "end_logit": -7.765625,
            "text": "Nox1, complexed with p22(phox) at the membrane, requires its regulatory soluble proteins Noxo1 and Nox",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.37109375,
            "end_logit": 9.46875,
            "text": "oxidase Nox1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.890625,
            "end_logit": -7.796875,
            "text": "Nox1, complexed with p22(phox) at the membrane, requires",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.890625,
            "end_logit": -7.80078125,
            "text": "Nox1, complexed with p22(phox) at the membrane,",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.890625,
            "end_logit": -7.8203125,
            "text": "Nox1, complexed with",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.890625,
            "end_logit": -7.83984375,
            "text": "Nox1, complexed with p22(phox) at the membrane, requires its regulatory soluble proteins Noxo1 and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.890625,
            "end_logit": -7.875,
            "text": "Nox1, complexed",
            "probability": 0.0
        },
        {
            "start_logit": 9.890625,
            "end_logit": -7.875,
            "text": "Nox1, complexed with p22(phox)",
            "probability": 0.0
        },
        {
            "start_logit": 9.890625,
            "end_logit": -7.87890625,
            "text": "Nox1, complexed with p22(phox) at the",
            "probability": 0.0
        },
        {
            "start_logit": -7.55859375,
            "end_logit": 9.46875,
            "text": "NADPH oxidase Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -7.86328125,
            "end_logit": 9.46875,
            "text": "Activation of the non-phagocytic superoxide-producing NADPH oxidase Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -7.87109375,
            "end_logit": 9.46875,
            "text": "producing NADPH oxidase Nox1",
            "probability": 0.0
        }
    ],
    "58a5a51060087bc10a000021_19": [
        {
            "start_logit": 9.84375,
            "end_logit": 9.578125,
            "text": "Nox1",
            "probability": 1.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -1.2685546875,
            "text": "Nox",
            "probability": 1.9550323486328125e-05
        },
        {
            "start_logit": -1.5400390625,
            "end_logit": 9.578125,
            "text": "1",
            "probability": 1.138448715209961e-05
        },
        {
            "start_logit": -7.2734375,
            "end_logit": 9.578125,
            "text": "(Nox1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.84375,
            "end_logit": -7.5625,
            "text": "Nox1) is a",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.34375,
            "end_logit": 9.578125,
            "text": "NADPH oxidase 1 (Nox1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.84375,
            "end_logit": -7.67578125,
            "text": "Nox1) is",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.84375,
            "end_logit": -7.71484375,
            "text": "Nox1) is a multicomponent enzyme consisting of p22(phox), Nox organizer 1 (NOXO1), Nox1 activator 1, and Rac1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.84375,
            "end_logit": -7.77734375,
            "text": "Nox1) is a multicomponent enzyme consisting of p22",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -7.8203125,
            "text": "Nox1)",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -7.82421875,
            "text": "Nox1) is a multicomponent enzyme consisting",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -7.87109375,
            "text": "Nox1) is a multicomponent enzyme consisting of p22(phox)",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -7.89453125,
            "text": "Nox1) is a multicomponent enzyme consisting of p22(phox",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -7.921875,
            "text": "Nox1) is a multicomponent enzyme consisting of p22(",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -7.93359375,
            "text": "Nox1) is a multicomponent enzyme consisting of p22(phox), Nox organizer 1 (NOXO1)",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -7.94921875,
            "text": "Nox1) is a multicomponent enzyme consisting of p22(phox), Nox organizer 1 (NOXO1",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -7.95703125,
            "text": "Nox1) is a multicomponent enzyme consisting of p22(phox), Nox organizer 1 (NOXO1), Nox",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -7.9609375,
            "text": "Nox1) is a multicomponent enzyme consisting of p22(phox), Nox organizer 1 (NOXO1), Nox1 activator",
            "probability": 0.0
        },
        {
            "start_logit": -7.2734375,
            "end_logit": -1.2685546875,
            "text": "(Nox",
            "probability": 0.0
        },
        {
            "start_logit": -7.34375,
            "end_logit": -1.2685546875,
            "text": "NADPH oxidase 1 (Nox",
            "probability": 0.0
        }
    ],
    "58a5a51060087bc10a000021_20": [
        {
            "start_logit": 9.796875,
            "end_logit": 9.546875,
            "text": "Nox1",
            "probability": 1.0
        },
        {
            "start_logit": 9.796875,
            "end_logit": -1.4775390625,
            "text": "Nox",
            "probability": 1.633167266845703e-05
        },
        {
            "start_logit": -1.73046875,
            "end_logit": 9.546875,
            "text": "1",
            "probability": 9.834766387939453e-06
        },
        {
            "start_logit": -4.9609375,
            "end_logit": 9.546875,
            "text": "Superoxide production by Nox1",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 9.796875,
            "end_logit": -5.9140625,
            "text": "Nox1, a member of the Nox family",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.796875,
            "end_logit": -6.12890625,
            "text": "Nox1, a member of the Nox",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.99609375,
            "end_logit": 9.546875,
            "text": "by Nox1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.796875,
            "end_logit": -7.26171875,
            "text": "Nox1, a member of the Nox family NAPDH oxidase",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.796875,
            "end_logit": -7.56640625,
            "text": "Nox1, a member of the Nox family NAPDH oxidases, requires expression of its regulatory soluble proteins Noxo1 (Nox organizer 1) and Noxa1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.796875,
            "end_logit": -7.578125,
            "text": "Nox1, a member of the Nox family NAPDH oxidases, requires expression of its regulatory soluble proteins Noxo1 (Nox organizer 1) and Nox",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.796875,
            "end_logit": -7.6328125,
            "text": "Nox1, a member",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.796875,
            "end_logit": -7.7109375,
            "text": "Nox1, a member of the Nox family NAP",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.796875,
            "end_logit": -7.7265625,
            "text": "Nox1, a member of the Nox family NAPDH oxidases, requires expression of its regulatory soluble proteins Noxo1 (Nox organizer 1) and Noxa1 (Nox activator 1) and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.796875,
            "end_logit": -7.76171875,
            "text": "Nox1, a member of the Nox family NAPDH oxidases, requires expression of its regulatory soluble proteins Noxo1 (Nox organizer 1)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.796875,
            "end_logit": -7.78515625,
            "text": "Nox1, a member of the Nox family NAPDH oxidases, requires expression of its regulatory soluble proteins Noxo1 (Nox organizer 1) and Noxa1 (Nox activator",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.796875,
            "end_logit": -7.80859375,
            "text": "Nox1, a member of",
            "probability": 0.0
        },
        {
            "start_logit": 9.796875,
            "end_logit": -7.82421875,
            "text": "Nox1, a member of the Nox family NAPDH oxidases",
            "probability": 0.0
        },
        {
            "start_logit": -8.0546875,
            "end_logit": 9.546875,
            "text": "UNLABELLED: Superoxide production by Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -4.9609375,
            "end_logit": -1.4775390625,
            "text": "Superoxide production by Nox",
            "probability": 0.0
        },
        {
            "start_logit": -1.73046875,
            "end_logit": -5.9140625,
            "text": "1, a member of the Nox family",
            "probability": 0.0
        }
    ],
    "58a5a51060087bc10a000021_21": [
        {
            "start_logit": 8.515625,
            "end_logit": 8.859375,
            "text": "NOX1",
            "probability": 1.0
        },
        {
            "start_logit": 8.515625,
            "end_logit": -1.0849609375,
            "text": "NOX",
            "probability": 4.792213439941406e-05
        },
        {
            "start_logit": -1.6015625,
            "end_logit": 8.859375,
            "text": "of NADPH oxidase 1 (NOX1",
            "probability": 4.035234451293945e-05
        },
        {
            "start_logit": -2.16015625,
            "end_logit": 8.859375,
            "text": "1",
            "probability": 2.3186206817626953e-05
        },
        {
            "start_logit": 8.515625,
            "end_logit": -3.529296875,
            "text": "NOX1) mediates endothelial nitric oxide synthase (eNOS) uncoupling and endothelial dysfunction in a streptozotocin-induced murine model of diabetes.",
            "probability": 4.172325134277344e-06
        },
        {
            "start_logit": -5.7109375,
            "end_logit": 8.859375,
            "text": "activation of NADPH oxidase 1 (NOX1",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 8.515625,
            "end_logit": -5.79296875,
            "text": "NOX1)",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -6.9296875,
            "end_logit": 8.859375,
            "text": "dependent activation of NADPH oxidase 1 (NOX1",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.08203125,
            "end_logit": 8.859375,
            "text": "NADPH oxidase 1 (NOX1",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.41015625,
            "end_logit": 8.859375,
            "text": "p47phox- and NADPH oxidase organiser 1 (NOXO1)-dependent activation of NADPH oxidase 1 (NOX1",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.515625,
            "end_logit": -7.109375,
            "text": "NOX1) mediates endothelial nitric oxide synthase (eNOS) uncoupling and endothelial dysfunction in",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.4921875,
            "end_logit": 8.859375,
            "text": "NADPH oxidase organiser 1 (NOXO1)-dependent activation of NADPH oxidase 1 (NOX1",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.5625,
            "end_logit": 8.859375,
            "text": "and NADPH oxidase organiser 1 (NOXO1)-dependent activation of NADPH oxidase 1 (NOX1",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.515625,
            "end_logit": -7.24609375,
            "text": "NOX1) mediates endothelial nitric oxide synthase (eNOS) uncoupling",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.515625,
            "end_logit": -7.36328125,
            "text": "NOX1) mediates endothelial nitric oxide synthase (eNOS) uncoupling and endothelial dysfunction in a",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.515625,
            "end_logit": -7.40625,
            "text": "NOX1) mediates endothelial nitric oxide synthase (eNOS",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.8046875,
            "end_logit": 8.859375,
            "text": "(NOX1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.515625,
            "end_logit": -7.4921875,
            "text": "NOX1) mediates",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.515625,
            "end_logit": -7.51953125,
            "text": "NOX1) mediates endothelial nitric oxide synthase (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.515625,
            "end_logit": -7.546875,
            "text": "NOX1) mediates endothelial nitric oxide synthase",
            "probability": 5.960464477539063e-08
        }
    ],
    "58a5a51060087bc10a000021_22": [
        {
            "start_logit": 9.8046875,
            "end_logit": 9.5078125,
            "text": "NOX1",
            "probability": 1.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -1.482421875,
            "text": "NOX",
            "probability": 1.6808509826660156e-05
        },
        {
            "start_logit": -1.82421875,
            "end_logit": 9.5078125,
            "text": "1",
            "probability": 8.940696716308594e-06
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -6.5,
            "text": "NOX1 was absolutely required for activation with NOXO1 and NOXA1 and that this activity required interaction of the putative NADPH-binding region of this domain with NOXA1.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.78125,
            "end_logit": 9.5078125,
            "text": "of NOX1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.34765625,
            "end_logit": 9.5078125,
            "text": "Studies of cytosolic co-factors showed that the C-terminal cytoplasmic domain of NOX1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -7.73828125,
            "text": "NOX1 was",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -7.7421875,
            "text": "NOX1 was absolutely required for activation with NOXO1 and NOXA1 and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -7.8046875,
            "text": "NOX1 was absolutely required for activation with NOXO1 and NOXA1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -7.81640625,
            "text": "NOX1 was absolutely required for activation with NOXO1 and NOXA1 and that this activity required interaction of the putative NADPH-binding region of this domain with NOXA1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -7.83203125,
            "text": "NOX1 was absolutely required for activation with NOXO1 and NOX",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -7.859375,
            "text": "NOX1 was absolutely required for activation with NOXO1 and NOXA1 and that this activity required interaction of the putative NADPH-binding region of this domain with NOX",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -7.8671875,
            "text": "NOX1 was absolutely required for activation with NOXO1 and NOXA1 and that this activity required interaction of the putative NADPH-binding region of this domain with",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -7.89453125,
            "text": "NOX1 was absolutely required for activation with NOXO1 and NOXA1 and that this activity required interaction of the putative NADPH",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -7.9140625,
            "text": "NOX1 was absolutely required for activation with NOXO1 and NOXA1 and that this activity required interaction of the putative NADPH-binding region of",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -7.92578125,
            "text": "NOX1 was absolutely required for activation",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -7.9296875,
            "text": "NOX1 was absolutely required for activation with NOXO1 and NOXA1 and that this activity required",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -7.9375,
            "text": "NOX1 was absolutely required for activation with NOXO1 and NOXA1 and that this activity required interaction of the putative NADPH-binding region of this domain",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -7.9765625,
            "text": "NOX1 was absolutely required for activation with NOXO1 and NOXA1 and that this activity required interaction of the putative NADPH-",
            "probability": 0.0
        },
        {
            "start_logit": -7.90234375,
            "end_logit": 9.5078125,
            "text": "domain of NOX1",
            "probability": 0.0
        }
    ],
    "58a5a51060087bc10a000021_23": [
        {
            "start_logit": 2.359375,
            "end_logit": -2.138671875,
            "text": "p67(phox) that acts in conjunction with Nox organizer 1 (NoxO1) to regulate reactive oxygen species (ROS) production by the NADPH oxidase Nox1.",
            "probability": 0.4599609375
        },
        {
            "start_logit": 2.359375,
            "end_logit": -2.25,
            "text": "p67(phox) that acts in conjunction with Nox organizer 1 (NoxO1) to regulate reactive oxygen species (ROS) production by the NADPH oxidase Nox1",
            "probability": 0.41162109375
        },
        {
            "start_logit": 2.359375,
            "end_logit": -4.01953125,
            "text": "p67(phox)",
            "probability": 0.07012939453125
        },
        {
            "start_logit": 2.359375,
            "end_logit": -5.8203125,
            "text": "p67",
            "probability": 0.0115814208984375
        },
        {
            "start_logit": 2.359375,
            "end_logit": -5.93359375,
            "text": "p67(phox",
            "probability": 0.010345458984375
        },
        {
            "start_logit": 2.359375,
            "end_logit": -5.97265625,
            "text": "p67(phox) that acts in conjunction with Nox organizer 1 (NoxO1) to regulate reactive oxygen species (ROS) production by the NADPH oxidase Nox",
            "probability": 0.00994873046875
        },
        {
            "start_logit": 2.359375,
            "end_logit": -6.7265625,
            "text": "p67(",
            "probability": 0.004688262939453125
        },
        {
            "start_logit": 2.359375,
            "end_logit": -6.76171875,
            "text": "p67(phox) that acts in conjunction with Nox organizer 1 (NoxO1) to regulate reactive oxygen species (ROS) production by the NADPH oxidase",
            "probability": 0.00450897216796875
        },
        {
            "start_logit": 2.359375,
            "end_logit": -7.20703125,
            "text": "p67(phox) that",
            "probability": 0.002887725830078125
        },
        {
            "start_logit": 2.359375,
            "end_logit": -7.4609375,
            "text": "p67(phox) that acts in conjunction with Nox organizer 1 (NoxO1) to regulate reactive oxygen species (ROS) production",
            "probability": 0.0022487640380859375
        },
        {
            "start_logit": 2.359375,
            "end_logit": -7.46484375,
            "text": "p",
            "probability": 0.002231597900390625
        },
        {
            "start_logit": 2.359375,
            "end_logit": -7.65234375,
            "text": "p67(phox) that acts in conjunction with Nox organizer 1 (NoxO1) to regulate reactive oxygen species",
            "probability": 0.0018510818481445312
        },
        {
            "start_logit": 2.359375,
            "end_logit": -7.66015625,
            "text": "p67(phox) that acts in conjunction with Nox organizer 1 (NoxO1) to regulate reactive oxygen species (ROS",
            "probability": 0.0018377304077148438
        },
        {
            "start_logit": 2.359375,
            "end_logit": -7.70703125,
            "text": "p67(phox) that acts in conjunction with Nox organizer 1 (",
            "probability": 0.0017518997192382812
        },
        {
            "start_logit": 2.359375,
            "end_logit": -7.7109375,
            "text": "p67(phox) that acts in conjunction with Nox organize",
            "probability": 0.0017518997192382812
        },
        {
            "start_logit": 2.359375,
            "end_logit": -7.734375,
            "text": "p67(phox) that acts in conjunction with Nox organizer 1 (NoxO1)",
            "probability": 0.0017118453979492188
        },
        {
            "start_logit": -4.4296875,
            "end_logit": -2.138671875,
            "text": ".",
            "probability": 0.0005183219909667969
        },
        {
            "start_logit": -5.40234375,
            "end_logit": -2.138671875,
            "text": "regulate reactive oxygen species (ROS) production by the NADPH oxidase Nox1.",
            "probability": 0.00019669532775878906
        },
        {
            "start_logit": -5.40234375,
            "end_logit": -2.25,
            "text": "regulate reactive oxygen species (ROS) production by the NADPH oxidase Nox1",
            "probability": 0.0001748800277709961
        },
        {
            "start_logit": -6.41015625,
            "end_logit": -2.138671875,
            "text": "Nox1.",
            "probability": 7.176399230957031e-05
        }
    ],
    "58a5a51060087bc10a000021_24": [
        {
            "start_logit": 9.8359375,
            "end_logit": 9.375,
            "text": "Nox1",
            "probability": 1.0
        },
        {
            "start_logit": 9.8359375,
            "end_logit": -1.431640625,
            "text": "Nox",
            "probability": 2.014636993408203e-05
        },
        {
            "start_logit": -2.087890625,
            "end_logit": 9.375,
            "text": "1",
            "probability": 6.616115570068359e-06
        },
        {
            "start_logit": 9.8359375,
            "end_logit": -6.984375,
            "text": "Nox1 is highly expressed in the colon, and requires two cytosolic regulators, the organizer subunit NoxO1 and the activator subunit NoxA1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8359375,
            "end_logit": -7.078125,
            "text": "Nox1 is highly expressed in the colon, and requires two cytosolic regulators, the organizer subunit NoxO1 and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8359375,
            "end_logit": -7.171875,
            "text": "Nox1 is highly expressed in the colon, and requires two cytosolic regulators, the organizer subunit NoxO1 and the activator subunit Nox",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8359375,
            "end_logit": -7.56640625,
            "text": "Nox1 is highly expressed in the colon, and requires two cytosolic regulators, the organizer subunit NoxO1 and the",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8359375,
            "end_logit": -7.59765625,
            "text": "Nox1 is highly expressed in the colon, and requires two cytosolic regulators, the organizer subunit NoxO1 and the activator",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8359375,
            "end_logit": -7.70703125,
            "text": "Nox1 is highly expressed in the colon, and requires two cytosolic regulators, the organizer subunit NoxO1 and the activator subunit NoxA1, as well",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8359375,
            "end_logit": -7.71875,
            "text": "Nox1 is highly expressed in the colon, and requires two cytosolic regulators, the organizer subunit NoxO1 and the activator subunit NoxA1, as well as the binding of Rac1 GTPase,",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8359375,
            "end_logit": -7.71875,
            "text": "Nox1 is highly expressed in the colon, and requires two cytosolic regulators, the organizer subunit NoxO1 and the activator subunit NoxA1, as well as",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8359375,
            "end_logit": -7.74609375,
            "text": "Nox1 is highly expressed in the colon, and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8359375,
            "end_logit": -7.7578125,
            "text": "Nox1 is highly expressed in the colon, and requires two cytosolic regulators",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8359375,
            "end_logit": -7.7578125,
            "text": "Nox1 is highly expressed in the colon, and requires two cytosolic regulators, the organizer subunit NoxO1 and the activator subunit NoxA1, as well as the binding of Rac1 GTPase",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8359375,
            "end_logit": -7.765625,
            "text": "Nox1 is highly expressed in the colon, and requires two cytosolic regulators, the organizer subunit NoxO1 and the activator subunit",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8359375,
            "end_logit": -7.78125,
            "text": "Nox1 is highly expressed in the colon, and requires two cytosolic regulators, the",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8359375,
            "end_logit": -7.8125,
            "text": "Nox1 is highly expressed in the colon, and requires two cytosolic regulators, the organizer subunit",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.087890625,
            "end_logit": -6.1953125,
            "text": "1 is highly expressed in the colon, and requires two cytosolic regulators, the organizer subunit NoxO1 and the activator subunit NoxA1, as well as the binding of Rac1 GTPase, for its activity.",
            "probability": 0.0
        },
        {
            "start_logit": -2.087890625,
            "end_logit": -6.984375,
            "text": "1 is highly expressed in the colon, and requires two cytosolic regulators, the organizer subunit NoxO1 and the activator subunit NoxA1",
            "probability": 0.0
        },
        {
            "start_logit": -2.087890625,
            "end_logit": -7.078125,
            "text": "1 is highly expressed in the colon, and requires two cytosolic regulators, the organizer subunit NoxO1 and",
            "probability": 0.0
        }
    ],
    "58a5a51060087bc10a000021_25": [
        {
            "start_logit": 9.8671875,
            "end_logit": 9.359375,
            "text": "Nox1",
            "probability": 1.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -1.341796875,
            "text": "Nox",
            "probability": 2.2649765014648438e-05
        },
        {
            "start_logit": -2.083984375,
            "end_logit": 9.359375,
            "text": "1",
            "probability": 6.496906280517578e-06
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -6.078125,
            "text": "Nox1 is highly expressed in the colon, and it requires two cytosolic regulators, NoxO1 and NoxA1, as well as the binding of Rac1 GTPase, for its activity.",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -7.33203125,
            "text": "Nox1 is highly expressed in the colon, and it requires two",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -7.55078125,
            "text": "Nox1 is highly expressed in the colon, and it requires two cytosolic regulators, NoxO1 and NoxA1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -7.57421875,
            "text": "Nox1 is highly expressed in the colon, and it requires two cytosolic regulators, NoxO1 and NoxA1, as well",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -7.671875,
            "text": "Nox1 is highly expressed in the colon, and it requires two cytosolic regulators, NoxO1 and NoxA1, as well as",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -7.7109375,
            "text": "Nox1 is highly expressed in the colon, and it requires two cytosolic regulators, NoxO1 and NoxA1, as well as the binding of Rac1 GTPase,",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -7.7265625,
            "text": "Nox1 is highly expressed in the colon, and it requires two cytosolic regulators",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -7.78515625,
            "text": "Nox1 is",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -7.78515625,
            "text": "Nox1 is highly expressed in the colon, and it requires two cytosolic regulators, NoxO1 and NoxA1, as",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -7.79296875,
            "text": "Nox1 is highly expressed in the colon, and it requires two cytosolic regulators, NoxO1 and NoxA1, as well as the binding of Rac1 GTPase",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -7.80078125,
            "text": "Nox1 is highly expressed in the colon, and it requires",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -7.8125,
            "text": "Nox1 is highly expressed in the colon, and it requires two cytosolic regulators, NoxO1 and NoxA1,",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -7.81640625,
            "text": "Nox1 is highly expressed in the colon, and it requires two cytosolic regulators, NoxO1 and NoxA1, as well as the binding of Rac1 GTPase, for",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -7.83203125,
            "text": "Nox1 is highly expressed in the colon, and it requires two cytosolic regulators, NoxO1 and NoxA1, as well as the binding of Rac1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.083984375,
            "end_logit": -6.078125,
            "text": "1 is highly expressed in the colon, and it requires two cytosolic regulators, NoxO1 and NoxA1, as well as the binding of Rac1 GTPase, for its activity.",
            "probability": 0.0
        },
        {
            "start_logit": -2.083984375,
            "end_logit": -7.33203125,
            "text": "1 is highly expressed in the colon, and it requires two",
            "probability": 0.0
        },
        {
            "start_logit": -2.083984375,
            "end_logit": -7.55078125,
            "text": "1 is highly expressed in the colon, and it requires two cytosolic regulators, NoxO1 and NoxA1",
            "probability": 0.0
        }
    ],
    "58a5a51060087bc10a000021_26": [
        {
            "start_logit": 9.8671875,
            "end_logit": 8.9453125,
            "text": "NOX1",
            "probability": 1.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -0.7119140625,
            "text": "NOX",
            "probability": 6.401538848876953e-05
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -1.994140625,
            "text": "NOX1)",
            "probability": 1.7762184143066406e-05
        },
        {
            "start_logit": -2.27734375,
            "end_logit": 8.9453125,
            "text": "1",
            "probability": 5.364418029785156e-06
        },
        {
            "start_logit": -5.9609375,
            "end_logit": 8.9453125,
            "text": "by NADPH oxidase 1 (NOX1",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.1953125,
            "end_logit": 8.9453125,
            "text": "NADPH oxidase 1 (NOX1",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -7.1640625,
            "text": "NOX1), which is mainly expressed in colon epithelial cells, requires the membrane-bound component p22(PHOX",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -7.23046875,
            "text": "NOX1), which is mainly expressed in colon epithelial cells, requires the membrane-bound component p22(PHOX) and",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -7.3125,
            "text": "NOX1), which is mainly expressed in colon epithelial cells, requires the membrane-bound component p22",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -7.31640625,
            "text": "NOX1), which is mainly expressed in colon epithelial cells, requires the membrane-bound component p22(PHOX)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -7.42578125,
            "text": "NOX1),",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -7.48046875,
            "text": "NOX1), which is mainly expressed in colon epithelial cells, requires the membrane-bound component p22(PHOX) and the cytosolic partners NOX organizer 1 (NOXO1)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -7.4921875,
            "text": "NOX1), which",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -7.546875,
            "text": "NOX1), which is mainly expressed in colon epithelial cells, requires the membrane-bound component p22(PHOX) and the cytosolic partners NOX organizer 1 (NOXO1), NOX activator",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -7.55078125,
            "text": "NOX1), which is mainly expressed in colon epithelial cells, requires the membrane-bound component p22(",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.90625,
            "end_logit": 8.9453125,
            "text": "(NOX1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.66015625,
            "end_logit": 8.9453125,
            "text": "Reactive oxygen species (ROS) production by NADPH oxidase 1 (NOX1",
            "probability": 0.0
        },
        {
            "start_logit": -2.27734375,
            "end_logit": -1.994140625,
            "text": "1)",
            "probability": 0.0
        },
        {
            "start_logit": -5.9609375,
            "end_logit": -0.7119140625,
            "text": "by NADPH oxidase 1 (NOX",
            "probability": 0.0
        },
        {
            "start_logit": -6.1953125,
            "end_logit": -0.7119140625,
            "text": "NADPH oxidase 1 (NOX",
            "probability": 0.0
        }
    ],
    "58a5a51060087bc10a000021_27": [
        {
            "start_logit": 9.796875,
            "end_logit": 9.265625,
            "text": "Nox1",
            "probability": 1.0
        },
        {
            "start_logit": 9.796875,
            "end_logit": -1.3623046875,
            "text": "Nox",
            "probability": 2.4318695068359375e-05
        },
        {
            "start_logit": -2.111328125,
            "end_logit": 9.265625,
            "text": "1",
            "probability": 6.735324859619141e-06
        },
        {
            "start_logit": 9.796875,
            "end_logit": -5.12109375,
            "text": "Nox1, a member of the Nox family",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 9.796875,
            "end_logit": -6.29296875,
            "text": "Nox1, a member of the Nox",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.796875,
            "end_logit": -6.89453125,
            "text": "Nox1, a member of the Nox family NAPDH oxidase",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.796875,
            "end_logit": -7.1953125,
            "text": "Nox1, a member of the Nox family NAPDH oxidases, requires expression of its regulatory soluble proteins Noxo1 (Nox organizer 1) and Noxa1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.796875,
            "end_logit": -7.36328125,
            "text": "Nox1, a member of the Nox family NAPDH oxidases, requires expression of its regulatory soluble proteins Noxo1 (Nox organizer 1) and Nox",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.8515625,
            "end_logit": 9.265625,
            "text": "Superoxide production by Nox1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.796875,
            "end_logit": -7.4375,
            "text": "Nox1, a member of the Nox family NAP",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.796875,
            "end_logit": -7.48046875,
            "text": "Nox1, a member of the Nox family NAPDH oxidases",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.796875,
            "end_logit": -7.51171875,
            "text": "Nox1, a member of the Nox family NAPDH oxidases, requires expression of its regulatory soluble proteins Noxo1 (Nox organizer 1)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.796875,
            "end_logit": -7.53125,
            "text": "Nox1, a member of the Nox family NAPDH oxidases, requires expression of its regulatory soluble proteins Noxo1 (Nox organizer 1) and Noxa1 (Nox activator 1) and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.796875,
            "end_logit": -7.6015625,
            "text": "Nox1, a member of the Nox family NAPDH oxidases,",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.796875,
            "end_logit": -7.609375,
            "text": "Nox1, a member of the Nox family NAPDH",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.796875,
            "end_logit": -7.6171875,
            "text": "Nox1, a member",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.796875,
            "end_logit": -7.625,
            "text": "Nox1, a member of the Nox family NAPDH oxidases, requires expression of its regulatory soluble proteins Noxo1 (Nox organizer 1) and Noxa1 (Nox activator 1)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.12890625,
            "end_logit": 9.265625,
            "text": "by Nox1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.111328125,
            "end_logit": -5.12109375,
            "text": "1, a member of the Nox family",
            "probability": 0.0
        },
        {
            "start_logit": -6.8515625,
            "end_logit": -1.3623046875,
            "text": "Superoxide production by Nox",
            "probability": 0.0
        }
    ],
    "58e7902b3e8b6dc87c000007_1": [
        {
            "start_logit": 9.734375,
            "end_logit": 9.6171875,
            "text": "IFN signature",
            "probability": 1.0
        },
        {
            "start_logit": 9.734375,
            "end_logit": -1.68359375,
            "text": "IFN",
            "probability": 1.239776611328125e-05
        },
        {
            "start_logit": -1.6689453125,
            "end_logit": 9.6171875,
            "text": "signature",
            "probability": 1.1324882507324219e-05
        },
        {
            "start_logit": -7.76171875,
            "end_logit": 9.6171875,
            "text": "I IFN signature",
            "probability": 0.0
        },
        {
            "start_logit": -7.875,
            "end_logit": 9.6171875,
            "text": "A five gene type I IFN signature",
            "probability": 0.0
        },
        {
            "start_logit": -7.91015625,
            "end_logit": 9.6171875,
            "text": "gene type I IFN signature",
            "probability": 0.0
        },
        {
            "start_logit": -7.9609375,
            "end_logit": 9.6171875,
            "text": "type I IFN signature",
            "probability": 0.0
        },
        {
            "start_logit": -7.98046875,
            "end_logit": 9.6171875,
            "text": "five gene type I IFN signature",
            "probability": 0.0
        },
        {
            "start_logit": 9.734375,
            "end_logit": -8.1171875,
            "text": "IFN signature was assessed in these subjects to",
            "probability": 0.0
        },
        {
            "start_logit": 9.734375,
            "end_logit": -8.125,
            "text": "IFN signature was",
            "probability": 0.0
        },
        {
            "start_logit": 9.734375,
            "end_logit": -8.140625,
            "text": "IFN signature was assessed in these subjects to identify subpopulations showing both activation and concordance of the type I IFN pathway in the peripheral blood and disease-affected tissues of each disease and",
            "probability": 0.0
        },
        {
            "start_logit": 9.734375,
            "end_logit": -8.1640625,
            "text": "IFN signature was assessed in these subjects to identify subpopulations showing",
            "probability": 0.0
        },
        {
            "start_logit": 9.734375,
            "end_logit": -8.171875,
            "text": "IFN signature was assessed in these subjects to identify subpopulations showing both activation and concordance of the type I IFN pathway in",
            "probability": 0.0
        },
        {
            "start_logit": 9.734375,
            "end_logit": -8.1796875,
            "text": "IFN signature was assessed in these subjects to identify subpopulations showing both activation and concordance of the type I IFN pathway in the peripheral blood and",
            "probability": 0.0
        },
        {
            "start_logit": 9.734375,
            "end_logit": -8.1875,
            "text": "IFN signature was assessed in these subjects to identify subpopulations showing both activation and concordance of the type I IFN pathway in the peripheral blood",
            "probability": 0.0
        },
        {
            "start_logit": -7.76171875,
            "end_logit": -1.68359375,
            "text": "I IFN",
            "probability": 0.0
        },
        {
            "start_logit": -7.875,
            "end_logit": -1.68359375,
            "text": "A five gene type I IFN",
            "probability": 0.0
        },
        {
            "start_logit": -7.91015625,
            "end_logit": -1.68359375,
            "text": "gene type I IFN",
            "probability": 0.0
        },
        {
            "start_logit": -7.9609375,
            "end_logit": -1.68359375,
            "text": "type I IFN",
            "probability": 0.0
        },
        {
            "start_logit": -7.98046875,
            "end_logit": -1.68359375,
            "text": "five gene type I IFN",
            "probability": 0.0
        }
    ],
    "58e7902b3e8b6dc87c000007_2": [
        {
            "start_logit": 9.7265625,
            "end_logit": 9.609375,
            "text": "interferon signature",
            "probability": 1.0
        },
        {
            "start_logit": 9.7265625,
            "end_logit": -1.7177734375,
            "text": "interferon",
            "probability": 1.1920928955078125e-05
        },
        {
            "start_logit": -1.703125,
            "end_logit": 9.609375,
            "text": "signature",
            "probability": 1.0788440704345703e-05
        },
        {
            "start_logit": 9.7265625,
            "end_logit": -7.53125,
            "text": "interferon signature similar to but less intense than that seen in patients with lupus.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.60546875,
            "end_logit": 9.609375,
            "text": "an interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": -7.75390625,
            "end_logit": 9.609375,
            "text": "Gene expression analysis of peripheral blood cells from patients with rheumatoid arthritis and multiple sclerosis demonstrate an interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": -7.85546875,
            "end_logit": 9.609375,
            "text": "patients with rheumatoid arthritis and multiple sclerosis demonstrate an interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": -7.8828125,
            "end_logit": 9.609375,
            "text": "cells from patients with rheumatoid arthritis and multiple sclerosis demonstrate an interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": -7.890625,
            "end_logit": 9.609375,
            "text": "with rheumatoid arthritis and multiple sclerosis demonstrate an interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": -7.89453125,
            "end_logit": 9.609375,
            "text": "demonstrate an interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": -7.92578125,
            "end_logit": 9.609375,
            "text": "from patients with rheumatoid arthritis and multiple sclerosis demonstrate an interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": -7.94921875,
            "end_logit": 9.609375,
            "text": "peripheral blood cells from patients with rheumatoid arthritis and multiple sclerosis demonstrate an interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": 9.7265625,
            "end_logit": -8.0703125,
            "text": "interferon signature similar",
            "probability": 0.0
        },
        {
            "start_logit": -7.95703125,
            "end_logit": 9.609375,
            "text": "multiple sclerosis demonstrate an interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": -7.95703125,
            "end_logit": 9.609375,
            "text": "rheumatoid arthritis and multiple sclerosis demonstrate an interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": -7.9609375,
            "end_logit": 9.609375,
            "text": "and multiple sclerosis demonstrate an interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": 9.7265625,
            "end_logit": -8.1953125,
            "text": "interferon signature similar to but less",
            "probability": 0.0
        },
        {
            "start_logit": -1.703125,
            "end_logit": -7.53125,
            "text": "signature similar to but less intense than that seen in patients with lupus.",
            "probability": 0.0
        },
        {
            "start_logit": -7.60546875,
            "end_logit": -1.7177734375,
            "text": "an interferon",
            "probability": 0.0
        },
        {
            "start_logit": -7.75390625,
            "end_logit": -1.7177734375,
            "text": "Gene expression analysis of peripheral blood cells from patients with rheumatoid arthritis and multiple sclerosis demonstrate an interferon",
            "probability": 0.0
        }
    ],
    "58e7902b3e8b6dc87c000007_3": [
        {
            "start_logit": 9.5859375,
            "end_logit": 9.546875,
            "text": "interferon signature",
            "probability": 1.0
        },
        {
            "start_logit": -1.8525390625,
            "end_logit": 9.546875,
            "text": "signature",
            "probability": 1.0848045349121094e-05
        },
        {
            "start_logit": 9.5859375,
            "end_logit": -2.07421875,
            "text": "interferon",
            "probability": 9.059906005859375e-06
        },
        {
            "start_logit": -3.904296875,
            "end_logit": 9.546875,
            "text": "the interferon signature",
            "probability": 1.3709068298339844e-06
        },
        {
            "start_logit": -6.6796875,
            "end_logit": 9.546875,
            "text": "termed the interferon signature",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.5859375,
            "end_logit": -7.45703125,
            "text": "interferon signature.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.80078125,
            "end_logit": 9.546875,
            "text": ", and a fraction of patients with rheumatoid arthritis display a specific expression pattern of interferon-dependent genes in their leukocytes, termed the interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": -7.8359375,
            "end_logit": 9.546875,
            "text": "interferon-dependent genes in their leukocytes, termed the interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": -7.87890625,
            "end_logit": 9.546875,
            "text": "of interferon-dependent genes in their leukocytes, termed the interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": -7.88671875,
            "end_logit": 9.546875,
            "text": "patients with rheumatoid arthritis display a specific expression pattern of interferon-dependent genes in their leukocytes, termed the interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": -7.94921875,
            "end_logit": 9.546875,
            "text": "with rheumatoid arthritis display a specific expression pattern of interferon-dependent genes in their leukocytes, termed the interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": -7.96484375,
            "end_logit": 9.546875,
            "text": "specific expression pattern of interferon-dependent genes in their leukocytes, termed the interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": -7.96484375,
            "end_logit": 9.546875,
            "text": "rheumatoid arthritis display a specific expression pattern of interferon-dependent genes in their leukocytes, termed the interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": -7.96484375,
            "end_logit": 9.546875,
            "text": ", psoriasis, and a fraction of patients with rheumatoid arthritis display a specific expression pattern of interferon-dependent genes in their leukocytes, termed the interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": -7.9765625,
            "end_logit": 9.546875,
            "text": "and a fraction of patients with rheumatoid arthritis display a specific expression pattern of interferon-dependent genes in their leukocytes, termed the interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": -7.984375,
            "end_logit": 9.546875,
            "text": "a specific expression pattern of interferon-dependent genes in their leukocytes, termed the interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": -7.984375,
            "end_logit": 9.546875,
            "text": "of patients with rheumatoid arthritis display a specific expression pattern of interferon-dependent genes in their leukocytes, termed the interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": -3.904296875,
            "end_logit": -2.07421875,
            "text": "the interferon",
            "probability": 0.0
        },
        {
            "start_logit": -6.6796875,
            "end_logit": -2.07421875,
            "text": "termed the interferon",
            "probability": 0.0
        },
        {
            "start_logit": -1.8525390625,
            "end_logit": -7.45703125,
            "text": "signature.",
            "probability": 0.0
        }
    ],
    "58e7902b3e8b6dc87c000007_4": [
        {
            "start_logit": 9.015625,
            "end_logit": 9.296875,
            "text": "interferon signature",
            "probability": 1.0
        },
        {
            "start_logit": -2.3359375,
            "end_logit": 9.296875,
            "text": "signature",
            "probability": 1.1742115020751953e-05
        },
        {
            "start_logit": 9.015625,
            "end_logit": -3.03515625,
            "text": "interferon",
            "probability": 4.410743713378906e-06
        },
        {
            "start_logit": 9.015625,
            "end_logit": -6.703125,
            "text": "interferon signature in lupus).",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.9921875,
            "end_logit": 9.296875,
            "text": ". interferon signature",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.29296875,
            "end_logit": 9.296875,
            "text": "gene signatures associated with the activation of specific pathways in these diseases (e.g. interferon signature",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.36328125,
            "end_logit": 9.296875,
            "text": "autoimmune disorders, have led to the identification of gene signatures associated with the activation of specific pathways in these diseases (e.g. interferon signature",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5390625,
            "end_logit": 9.296875,
            "text": "differential gene expression studies performed on selected tissues from patients with autoimmune disorders, have led to the identification of gene signatures associated with the activation of specific pathways in these diseases (e.g. interferon signature",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.58984375,
            "end_logit": 9.296875,
            "text": "gene expression studies performed on selected tissues from patients with autoimmune disorders, have led to the identification of gene signatures associated with the activation of specific pathways in these diseases (e.g. interferon signature",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.59765625,
            "end_logit": 9.296875,
            "text": "with autoimmune disorders, have led to the identification of gene signatures associated with the activation of specific pathways in these diseases (e.g. interferon signature",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.60546875,
            "end_logit": 9.296875,
            "text": "studies performed on selected tissues from patients with autoimmune disorders, have led to the identification of gene signatures associated with the activation of specific pathways in these diseases (e.g. interferon signature",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.64453125,
            "end_logit": 9.296875,
            "text": "disorders, have led to the identification of gene signatures associated with the activation of specific pathways in these diseases (e.g. interferon signature",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.65625,
            "end_logit": 9.296875,
            "text": "scale differential gene expression studies performed on selected tissues from patients with autoimmune disorders, have led to the identification of gene signatures associated with the activation of specific pathways in these diseases (e.g. interferon signature",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.69140625,
            "end_logit": 9.296875,
            "text": "patients with autoimmune disorders, have led to the identification of gene signatures associated with the activation of specific pathways in these diseases (e.g. interferon signature",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.70703125,
            "end_logit": 9.296875,
            "text": "identification of gene signatures associated with the activation of specific pathways in these diseases (e.g. interferon signature",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.015625,
            "end_logit": -7.95703125,
            "text": "interferon signature in lupus)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.015625,
            "end_logit": -7.9921875,
            "text": "interferon signature in",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.3359375,
            "end_logit": -6.703125,
            "text": "signature in lupus).",
            "probability": 0.0
        },
        {
            "start_logit": -6.9921875,
            "end_logit": -3.03515625,
            "text": ". interferon",
            "probability": 0.0
        },
        {
            "start_logit": -2.3359375,
            "end_logit": -7.95703125,
            "text": "signature in lupus)",
            "probability": 0.0
        }
    ],
    "58e7902b3e8b6dc87c000007_5": [
        {
            "start_logit": 9.671875,
            "end_logit": 9.6875,
            "text": "interferon signature",
            "probability": 1.0
        },
        {
            "start_logit": -1.5107421875,
            "end_logit": 9.6875,
            "text": "signature",
            "probability": 1.3947486877441406e-05
        },
        {
            "start_logit": 9.671875,
            "end_logit": -1.857421875,
            "text": "interferon",
            "probability": 9.655952453613281e-06
        },
        {
            "start_logit": -7.77734375,
            "end_logit": 9.6875,
            "text": "type I interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": -7.9609375,
            "end_logit": 9.6875,
            "text": "I interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": 9.671875,
            "end_logit": -7.96875,
            "text": "interferon signature and",
            "probability": 0.0
        },
        {
            "start_logit": 9.671875,
            "end_logit": -7.98046875,
            "text": "interferon signature and the response to rituximab in rheumatoid arthritis patients.",
            "probability": 0.0
        },
        {
            "start_logit": -7.99609375,
            "end_logit": 9.6875,
            "text": "Relationship between the type I interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": -8.0078125,
            "end_logit": 9.6875,
            "text": "the type I interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": 9.671875,
            "end_logit": -8.109375,
            "text": "interferon signature and the response to",
            "probability": 0.0
        },
        {
            "start_logit": 9.671875,
            "end_logit": -8.125,
            "text": "interferon signature and the response to rituximab in",
            "probability": 0.0
        },
        {
            "start_logit": 9.671875,
            "end_logit": -8.125,
            "text": "interferon signature and the",
            "probability": 0.0
        },
        {
            "start_logit": 9.671875,
            "end_logit": -8.1328125,
            "text": "interferon signature and the response to rituximab",
            "probability": 0.0
        },
        {
            "start_logit": -1.5107421875,
            "end_logit": -7.96875,
            "text": "signature and",
            "probability": 0.0
        },
        {
            "start_logit": -1.5107421875,
            "end_logit": -7.98046875,
            "text": "signature and the response to rituximab in rheumatoid arthritis patients.",
            "probability": 0.0
        },
        {
            "start_logit": -1.5107421875,
            "end_logit": -8.109375,
            "text": "signature and the response to",
            "probability": 0.0
        },
        {
            "start_logit": -1.5107421875,
            "end_logit": -8.125,
            "text": "signature and the response to rituximab in",
            "probability": 0.0
        },
        {
            "start_logit": -1.5107421875,
            "end_logit": -8.125,
            "text": "signature and the",
            "probability": 0.0
        },
        {
            "start_logit": -7.77734375,
            "end_logit": -1.857421875,
            "text": "type I interferon",
            "probability": 0.0
        },
        {
            "start_logit": -1.5107421875,
            "end_logit": -8.1328125,
            "text": "signature and the response to rituximab",
            "probability": 0.0
        }
    ],
    "58e7902b3e8b6dc87c000007_6": [
        {
            "start_logit": 9.7578125,
            "end_logit": 9.6953125,
            "text": "interferon signature",
            "probability": 1.0
        },
        {
            "start_logit": -1.466796875,
            "end_logit": 9.6953125,
            "text": "signature",
            "probability": 1.329183578491211e-05
        },
        {
            "start_logit": 9.7578125,
            "end_logit": -1.6513671875,
            "text": "interferon",
            "probability": 1.1861324310302734e-05
        },
        {
            "start_logit": -7.2890625,
            "end_logit": 9.6953125,
            "text": "I interferon signature",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.40234375,
            "end_logit": 9.6953125,
            "text": "type I interferon signature",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.734375,
            "end_logit": 9.6953125,
            "text": "the type I interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": -7.94140625,
            "end_logit": 9.6953125,
            "text": "Importance of correlation between gene expression levels: application to the type I interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": -7.97265625,
            "end_logit": 9.6953125,
            "text": "application to the type I interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": 9.7578125,
            "end_logit": -8.0625,
            "text": "interferon signature in rheumatoid arthritis.",
            "probability": 0.0
        },
        {
            "start_logit": -8.015625,
            "end_logit": 9.6953125,
            "text": "to the type I interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": -8.0859375,
            "end_logit": 9.6953125,
            "text": "gene expression levels: application to the type I interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": -8.109375,
            "end_logit": 9.6953125,
            "text": "of correlation between gene expression levels: application to the type I interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": -8.1171875,
            "end_logit": 9.6953125,
            "text": "correlation between gene expression levels: application to the type I interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": -7.2890625,
            "end_logit": -1.6513671875,
            "text": "I interferon",
            "probability": 0.0
        },
        {
            "start_logit": -7.40234375,
            "end_logit": -1.6513671875,
            "text": "type I interferon",
            "probability": 0.0
        },
        {
            "start_logit": -7.734375,
            "end_logit": -1.6513671875,
            "text": "the type I interferon",
            "probability": 0.0
        },
        {
            "start_logit": -1.466796875,
            "end_logit": -8.0625,
            "text": "signature in rheumatoid arthritis.",
            "probability": 0.0
        },
        {
            "start_logit": -7.94140625,
            "end_logit": -1.6513671875,
            "text": "Importance of correlation between gene expression levels: application to the type I interferon",
            "probability": 0.0
        },
        {
            "start_logit": -7.97265625,
            "end_logit": -1.6513671875,
            "text": "application to the type I interferon",
            "probability": 0.0
        },
        {
            "start_logit": -8.015625,
            "end_logit": -1.6513671875,
            "text": "to the type I interferon",
            "probability": 0.0
        }
    ],
    "517170c48ed59a060a00000d_1": [
        {
            "start_logit": 8.7109375,
            "end_logit": 7.49609375,
            "text": "25",
            "probability": 1.0
        },
        {
            "start_logit": 8.7109375,
            "end_logit": -6.6484375,
            "text": "25 selenoproteins",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 8.7109375,
            "end_logit": -6.8671875,
            "text": "25 selenoproteins.",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -7.21484375,
            "end_logit": 7.49609375,
            "text": "The human selenoproteome consists of 25",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.328125,
            "end_logit": 7.49609375,
            "text": "of 25",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.38671875,
            "end_logit": 7.49609375,
            "text": "selenoproteome consists of 25",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.796875,
            "end_logit": 7.49609375,
            "text": "human selenoproteome consists of 25",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.94921875,
            "end_logit": 7.49609375,
            "text": "consists of 25",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.9765625,
            "end_logit": 7.49609375,
            "text": "ome consists of 25",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0625,
            "end_logit": 7.49609375,
            "text": "oproteome consists of 25",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.5625,
            "end_logit": -6.8671875,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -6.9453125,
            "end_logit": -6.6484375,
            "text": "selenoproteins",
            "probability": 0.0
        },
        {
            "start_logit": -6.9453125,
            "end_logit": -6.8671875,
            "text": "selenoproteins.",
            "probability": 0.0
        },
        {
            "start_logit": -7.21484375,
            "end_logit": -6.6484375,
            "text": "The human selenoproteome consists of 25 selenoproteins",
            "probability": 0.0
        },
        {
            "start_logit": -7.328125,
            "end_logit": -6.6484375,
            "text": "of 25 selenoproteins",
            "probability": 0.0
        },
        {
            "start_logit": -7.38671875,
            "end_logit": -6.6484375,
            "text": "selenoproteome consists of 25 selenoproteins",
            "probability": 0.0
        },
        {
            "start_logit": -7.21484375,
            "end_logit": -6.8671875,
            "text": "The human selenoproteome consists of 25 selenoproteins.",
            "probability": 0.0
        },
        {
            "start_logit": -7.328125,
            "end_logit": -6.8671875,
            "text": "of 25 selenoproteins.",
            "probability": 0.0
        },
        {
            "start_logit": -7.38671875,
            "end_logit": -6.8671875,
            "text": "selenoproteome consists of 25 selenoproteins.",
            "probability": 0.0
        },
        {
            "start_logit": -7.796875,
            "end_logit": -6.6484375,
            "text": "human selenoproteome consists of 25 selenoproteins",
            "probability": 0.0
        }
    ],
    "5e669e0e1af46fc130000019_1": [
        {
            "start_logit": 9.6328125,
            "end_logit": 9.703125,
            "text": "XXY",
            "probability": 1.0
        },
        {
            "start_logit": -1.400390625,
            "end_logit": 9.703125,
            "text": "Y",
            "probability": 1.6033649444580078e-05
        },
        {
            "start_logit": 9.6328125,
            "end_logit": -1.921875,
            "text": "XX",
            "probability": 8.881092071533203e-06
        },
        {
            "start_logit": -7.52734375,
            "end_logit": 9.703125,
            "text": "Klinefelter syndrome (XXY",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.67578125,
            "end_logit": 9.703125,
            "text": "(XXY",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.86328125,
            "end_logit": 9.703125,
            "text": "inefelter syndrome (XXY",
            "probability": 0.0
        },
        {
            "start_logit": -7.9609375,
            "end_logit": 9.703125,
            "text": "felter syndrome (XXY",
            "probability": 0.0
        },
        {
            "start_logit": -8.015625,
            "end_logit": 9.703125,
            "text": "syndrome (XXY",
            "probability": 0.0
        },
        {
            "start_logit": -8.0234375,
            "end_logit": 9.703125,
            "text": "lter syndrome (XXY",
            "probability": 0.0
        },
        {
            "start_logit": 9.6328125,
            "end_logit": -7.97265625,
            "text": "XXY)",
            "probability": 0.0
        },
        {
            "start_logit": -8.0546875,
            "end_logit": 9.703125,
            "text": "er syndrome (XXY",
            "probability": 0.0
        },
        {
            "start_logit": -1.400390625,
            "end_logit": -7.97265625,
            "text": "Y)",
            "probability": 0.0
        },
        {
            "start_logit": -7.52734375,
            "end_logit": -1.921875,
            "text": "Klinefelter syndrome (XX",
            "probability": 0.0
        },
        {
            "start_logit": -7.67578125,
            "end_logit": -1.921875,
            "text": "(XX",
            "probability": 0.0
        },
        {
            "start_logit": -7.86328125,
            "end_logit": -1.921875,
            "text": "inefelter syndrome (XX",
            "probability": 0.0
        },
        {
            "start_logit": -7.9609375,
            "end_logit": -1.921875,
            "text": "felter syndrome (XX",
            "probability": 0.0
        },
        {
            "start_logit": -8.015625,
            "end_logit": -1.921875,
            "text": "syndrome (XX",
            "probability": 0.0
        },
        {
            "start_logit": -8.0234375,
            "end_logit": -1.921875,
            "text": "lter syndrome (XX",
            "probability": 0.0
        },
        {
            "start_logit": -8.0546875,
            "end_logit": -1.921875,
            "text": "er syndrome (XX",
            "probability": 0.0
        },
        {
            "start_logit": -7.52734375,
            "end_logit": -7.97265625,
            "text": "Klinefelter syndrome (XXY)",
            "probability": 0.0
        }
    ],
    "5e669e0e1af46fc130000019_2": [
        {
            "start_logit": 7.484375,
            "end_logit": 8.7734375,
            "text": "X",
            "probability": 1.0
        },
        {
            "start_logit": -4.87890625,
            "end_logit": 8.7734375,
            "text": "extra X",
            "probability": 4.291534423828125e-06
        },
        {
            "start_logit": 7.484375,
            "end_logit": -6.09765625,
            "text": "X chromosome (47,XXY",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.6875,
            "end_logit": 8.7734375,
            "text": "an extra X",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.7421875,
            "end_logit": 8.7734375,
            "text": "About 1 in 650 boys are born with an extra X",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.796875,
            "end_logit": 8.7734375,
            "text": "with an extra X",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.8984375,
            "end_logit": 8.7734375,
            "text": "1 in 650 boys are born with an extra X",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.91796875,
            "end_logit": 8.7734375,
            "text": "born with an extra X",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.94140625,
            "end_logit": 8.7734375,
            "text": "boys are born with an extra X",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.484375,
            "end_logit": -7.8515625,
            "text": "X chromosome (47,XX",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.484375,
            "end_logit": -8.0078125,
            "text": "X chromosome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.484375,
            "end_logit": -8.125,
            "text": "X chromosome (47,XXY or Klinefelter syndrome). 47,XX",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.484375,
            "end_logit": -8.1640625,
            "text": "X chromosome (47,XXY or Klinefelter syndrome)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.484375,
            "end_logit": -8.1953125,
            "text": "X chromosome (47,XXY or Klinefelter syndrome). 47,XXY",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.484375,
            "end_logit": -8.21875,
            "text": "X chromosome (47,XXY or Klinefelt",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -4.87890625,
            "end_logit": -6.09765625,
            "text": "extra X chromosome (47,XXY",
            "probability": 0.0
        },
        {
            "start_logit": -5.91796875,
            "end_logit": -6.09765625,
            "text": "47,XXY",
            "probability": 0.0
        },
        {
            "start_logit": -4.87890625,
            "end_logit": -7.8515625,
            "text": "extra X chromosome (47,XX",
            "probability": 0.0
        },
        {
            "start_logit": -4.87890625,
            "end_logit": -8.0078125,
            "text": "extra X chromosome",
            "probability": 0.0
        },
        {
            "start_logit": -4.87890625,
            "end_logit": -8.125,
            "text": "extra X chromosome (47,XXY or Klinefelter syndrome). 47,XX",
            "probability": 0.0
        }
    ],
    "5e669e0e1af46fc130000019_3": [
        {
            "start_logit": 3.8515625,
            "end_logit": 9.9453125,
            "text": "additional X",
            "probability": 0.81982421875
        },
        {
            "start_logit": 2.337890625,
            "end_logit": 9.9453125,
            "text": "X",
            "probability": 0.18017578125
        },
        {
            "start_logit": -4.69140625,
            "end_logit": 9.9453125,
            "text": "an additional X",
            "probability": 0.00015926361083984375
        },
        {
            "start_logit": -6.64453125,
            "end_logit": 9.9453125,
            "text": "by an additional X",
            "probability": 2.2590160369873047e-05
        },
        {
            "start_logit": -7.5546875,
            "end_logit": 9.9453125,
            "text": "well recognized chromosomal abnormality caused by an additional X",
            "probability": 9.119510650634766e-06
        },
        {
            "start_logit": -7.703125,
            "end_logit": 9.9453125,
            "text": "caused by an additional X",
            "probability": 7.867813110351562e-06
        },
        {
            "start_logit": -7.75,
            "end_logit": 9.9453125,
            "text": "chromosomal abnormality caused by an additional X",
            "probability": 7.510185241699219e-06
        },
        {
            "start_logit": -7.76171875,
            "end_logit": 9.9453125,
            "text": "abnormality caused by an additional X",
            "probability": 7.450580596923828e-06
        },
        {
            "start_logit": -7.765625,
            "end_logit": 9.9453125,
            "text": "Klinefelter syndrome is well recognized chromosomal abnormality caused by an additional X",
            "probability": 7.3909759521484375e-06
        },
        {
            "start_logit": -7.765625,
            "end_logit": 9.9453125,
            "text": ", Klinefelter syndrome is well recognized chromosomal abnormality caused by an additional X",
            "probability": 7.3909759521484375e-06
        },
        {
            "start_logit": -7.8046875,
            "end_logit": 9.9453125,
            "text": "recognized chromosomal abnormality caused by an additional X",
            "probability": 7.092952728271484e-06
        },
        {
            "start_logit": -7.91796875,
            "end_logit": 9.9453125,
            "text": "On the other hand, Klinefelter syndrome is well recognized chromosomal abnormality caused by an additional X",
            "probability": 6.377696990966797e-06
        },
        {
            "start_logit": -7.96484375,
            "end_logit": 9.9453125,
            "text": "inefelter syndrome is well recognized chromosomal abnormality caused by an additional X",
            "probability": 6.079673767089844e-06
        },
        {
            "start_logit": 3.8515625,
            "end_logit": -5.01171875,
            "text": "additional X chromosome",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 3.8515625,
            "end_logit": -5.8984375,
            "text": "additional X chromosome in",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 2.337890625,
            "end_logit": -5.01171875,
            "text": "X chromosome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 3.8515625,
            "end_logit": -7.03515625,
            "text": "additional X chromosome in males (47,XXY), and the characteristic clinical findings include tall stature, immaturity of external genitalia, testicular dysfunction.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 3.8515625,
            "end_logit": -7.140625,
            "text": "additional",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 2.337890625,
            "end_logit": -5.8984375,
            "text": "X chromosome in",
            "probability": 0.0
        },
        {
            "start_logit": 3.8515625,
            "end_logit": -7.5,
            "text": "additional X chromosome in males",
            "probability": 0.0
        }
    ],
    "5e669e0e1af46fc130000019_4": [
        {
            "start_logit": 9.6796875,
            "end_logit": 9.6796875,
            "text": "47, XXY",
            "probability": 1.0
        },
        {
            "start_logit": -1.2421875,
            "end_logit": 9.6796875,
            "text": "Y",
            "probability": 1.806020736694336e-05
        },
        {
            "start_logit": 9.6796875,
            "end_logit": -1.6728515625,
            "text": "47",
            "probability": 1.1742115020751953e-05
        },
        {
            "start_logit": 9.6796875,
            "end_logit": -5.3515625,
            "text": "47, XXY; the extra sex chromosome is due to meiotic chromosomal nondisjunction.",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.6796875,
            "end_logit": -5.4296875,
            "text": "47, XXY; the extra sex chromosome",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.6796875,
            "end_logit": -6.54296875,
            "text": "47, XX",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.0234375,
            "end_logit": 9.6796875,
            "text": ", XXY",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.078125,
            "end_logit": 9.6796875,
            "text": "XXY",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.6796875,
            "end_logit": -7.2109375,
            "text": "47,",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.6796875,
            "end_logit": -7.63671875,
            "text": "47, XXY; the extra sex chromosome is due to meiotic chromosomal nondisjunction",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.671875,
            "end_logit": 9.6796875,
            "text": "is 47, XXY",
            "probability": 0.0
        },
        {
            "start_logit": 9.6796875,
            "end_logit": -7.73828125,
            "text": "47, XXY; the extra sex chromosome is",
            "probability": 0.0
        },
        {
            "start_logit": 9.6796875,
            "end_logit": -7.75,
            "text": "47, XXY; the extra sex",
            "probability": 0.0
        },
        {
            "start_logit": -7.8046875,
            "end_logit": 9.6796875,
            "text": "The formal cytogenetic designation for Klinefelter syndrome is 47, XXY",
            "probability": 0.0
        },
        {
            "start_logit": -7.84375,
            "end_logit": 9.6796875,
            "text": "Klinefelter syndrome is 47, XXY",
            "probability": 0.0
        },
        {
            "start_logit": 9.6796875,
            "end_logit": -7.95703125,
            "text": "47, XXY; the extra sex chromosome is due",
            "probability": 0.0
        },
        {
            "start_logit": -1.2421875,
            "end_logit": -5.3515625,
            "text": "Y; the extra sex chromosome is due to meiotic chromosomal nondisjunction.",
            "probability": 0.0
        },
        {
            "start_logit": -1.2421875,
            "end_logit": -5.4296875,
            "text": "Y; the extra sex chromosome",
            "probability": 0.0
        },
        {
            "start_logit": -1.2421875,
            "end_logit": -7.63671875,
            "text": "Y; the extra sex chromosome is due to meiotic chromosomal nondisjunction",
            "probability": 0.0
        },
        {
            "start_logit": -1.2421875,
            "end_logit": -7.73828125,
            "text": "Y; the extra sex chromosome is",
            "probability": 0.0
        }
    ],
    "5e669e0e1af46fc130000019_5": [
        {
            "start_logit": 8.359375,
            "end_logit": 8.015625,
            "text": "X",
            "probability": 1.0
        },
        {
            "start_logit": -4.703125,
            "end_logit": 8.015625,
            "text": "additional X",
            "probability": 2.1457672119140625e-06
        },
        {
            "start_logit": 8.359375,
            "end_logit": -6.90234375,
            "text": "X chromosome in males leading to a karyotype of 47,XXY.",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -6.81640625,
            "end_logit": 8.015625,
            "text": "an additional X",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.359375,
            "end_logit": -7.72265625,
            "text": "X chromosome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.359375,
            "end_logit": -7.828125,
            "text": "X chromosome in",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.359375,
            "end_logit": -7.953125,
            "text": "X chromosome in males leading",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.65234375,
            "end_logit": 8.015625,
            "text": "Klinefelter syndrome (KS) is characterized by an additional X",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.359375,
            "end_logit": -8.0078125,
            "text": "X chromosome in males leading to",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.359375,
            "end_logit": -8.0703125,
            "text": "X chromosome in males",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.359375,
            "end_logit": -8.109375,
            "text": "X chromosome in males leading to a",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.359375,
            "end_logit": -8.109375,
            "text": "X chromosome in males leading to a karyotype of 47,XX",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.87109375,
            "end_logit": 8.015625,
            "text": "by an additional X",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.91015625,
            "end_logit": 8.015625,
            "text": "inefelter syndrome (KS) is characterized by an additional X",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.99609375,
            "end_logit": 8.015625,
            "text": "characterized by an additional X",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0078125,
            "end_logit": 8.015625,
            "text": "(KS) is characterized by an additional X",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0546875,
            "end_logit": 8.015625,
            "text": "felter syndrome (KS) is characterized by an additional X",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -4.703125,
            "end_logit": -6.90234375,
            "text": "additional X chromosome in males leading to a karyotype of 47,XXY.",
            "probability": 0.0
        },
        {
            "start_logit": -4.703125,
            "end_logit": -7.72265625,
            "text": "additional X chromosome",
            "probability": 0.0
        },
        {
            "start_logit": -4.703125,
            "end_logit": -7.828125,
            "text": "additional X chromosome in",
            "probability": 0.0
        }
    ],
    "5e669e0e1af46fc130000019_6": [
        {
            "start_logit": 9.4765625,
            "end_logit": 9.84375,
            "text": "47,XXY",
            "probability": 1.0
        },
        {
            "start_logit": -0.921875,
            "end_logit": 9.84375,
            "text": "Y",
            "probability": 3.069639205932617e-05
        },
        {
            "start_logit": 9.4765625,
            "end_logit": -2.12890625,
            "text": "47",
            "probability": 6.318092346191406e-06
        },
        {
            "start_logit": -5.4296875,
            "end_logit": 9.84375,
            "text": "a 47,XXY",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 9.4765625,
            "end_logit": -5.3203125,
            "text": "47,XXY chromosomal abnormality, has been shown to be associated with a number of malignancies, but has not been linked to acute leukemias to date.",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.4765625,
            "end_logit": -5.4140625,
            "text": "47,XX",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -5.80859375,
            "end_logit": 9.84375,
            "text": ",XXY",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.40625,
            "end_logit": 9.84375,
            "text": "XXY",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.546875,
            "end_logit": 9.84375,
            "text": "Klinefelter syndrome (KS), a 47,XXY",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.83984375,
            "end_logit": 9.84375,
            "text": "inefelter syndrome (KS), a 47,XXY",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.4765625,
            "end_logit": -7.890625,
            "text": "47,XXY chromosomal abnormality,",
            "probability": 0.0
        },
        {
            "start_logit": 9.4765625,
            "end_logit": -7.91796875,
            "text": "47,XXY chromosomal abnormality, has been shown to be associated with a number of malignancies, but",
            "probability": 0.0
        },
        {
            "start_logit": 9.4765625,
            "end_logit": -7.92578125,
            "text": "47,XXY chromosomal abnormality, has been shown to be associated with a number",
            "probability": 0.0
        },
        {
            "start_logit": 9.4765625,
            "end_logit": -7.9296875,
            "text": "47,XXY chromosomal abnormality, has been shown to be associated with a number of malignancies, but has not been linked to acute leukemias to",
            "probability": 0.0
        },
        {
            "start_logit": 9.4765625,
            "end_logit": -7.95703125,
            "text": "47,XXY chromosomal abnormality, has been shown to be associated with a number of malignancies, but has not been linked to acute leukemias to date",
            "probability": 0.0
        },
        {
            "start_logit": 9.4765625,
            "end_logit": -7.9609375,
            "text": "47,XXY chromosomal abnormality, has been shown to be associated with a number of malignancies, but has not been linked to acute leukemias to date. We p",
            "probability": 0.0
        },
        {
            "start_logit": 9.4765625,
            "end_logit": -7.9765625,
            "text": "47,",
            "probability": 0.0
        },
        {
            "start_logit": 9.4765625,
            "end_logit": -7.98828125,
            "text": "47,XXY chromosomal abnormality, has been shown to be associated with a number of malignancies, but has not",
            "probability": 0.0
        },
        {
            "start_logit": 9.4765625,
            "end_logit": -7.98828125,
            "text": "47,XXY chromosomal abnormality, has been",
            "probability": 0.0
        },
        {
            "start_logit": 9.4765625,
            "end_logit": -8.03125,
            "text": "47,XXY chromosomal abnormality, has been shown to",
            "probability": 0.0
        }
    ],
    "5e669e0e1af46fc130000019_7": [
        {
            "start_logit": 9.328125,
            "end_logit": 9.484375,
            "text": "47, XXY",
            "probability": 1.0
        },
        {
            "start_logit": -1.583984375,
            "end_logit": 9.484375,
            "text": "Y",
            "probability": 1.817941665649414e-05
        },
        {
            "start_logit": 9.328125,
            "end_logit": -2.1796875,
            "text": "47",
            "probability": 8.58306884765625e-06
        },
        {
            "start_logit": 9.328125,
            "end_logit": -2.20703125,
            "text": "47, XXY; the extra sex chromosome",
            "probability": 8.404254913330078e-06
        },
        {
            "start_logit": 9.328125,
            "end_logit": -4.9765625,
            "text": "47, XXY; the extra sex chromosome is due to meiotic chromosomal nondisjunction.",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 9.328125,
            "end_logit": -6.68359375,
            "text": "47, XX",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.0078125,
            "end_logit": 9.484375,
            "text": "XXY",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.21484375,
            "end_logit": 9.484375,
            "text": ", XXY",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.328125,
            "end_logit": -7.234375,
            "text": "47,",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.328125,
            "end_logit": -7.4375,
            "text": "47, XXY; the extra sex",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.328125,
            "end_logit": -7.48828125,
            "text": "47, XXY; the extra sex chromosome is due to meiotic chromosomal nondisjunction",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.328125,
            "end_logit": -7.57421875,
            "text": "47, XXY; the extra sex chromosome is",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.73828125,
            "end_logit": 9.484375,
            "text": "is 47, XXY",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.78515625,
            "end_logit": 9.484375,
            "text": "Klinefelter syndrome is 47, XXY",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.828125,
            "end_logit": 9.484375,
            "text": "formal cytogenetic designation for Klinefelter syndrome is 47, XXY",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.83984375,
            "end_logit": 9.484375,
            "text": "cytogenetic designation for Klinefelter syndrome is 47, XXY",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.328125,
            "end_logit": -7.87109375,
            "text": "47, XXY; the extra sex chromosome is due to meiotic chromosomal nondisjunction. In",
            "probability": 0.0
        },
        {
            "start_logit": 9.328125,
            "end_logit": -7.90234375,
            "text": "47, XXY; the extra sex chromosome is due",
            "probability": 0.0
        },
        {
            "start_logit": -1.583984375,
            "end_logit": -2.20703125,
            "text": "Y; the extra sex chromosome",
            "probability": 0.0
        },
        {
            "start_logit": -3.68359375,
            "end_logit": -2.20703125,
            "text": "extra sex chromosome",
            "probability": 0.0
        }
    ],
    "5e669e0e1af46fc130000019_8": [
        {
            "start_logit": 9.90625,
            "end_logit": 9.78125,
            "text": "XXY",
            "probability": 1.0
        },
        {
            "start_logit": 9.90625,
            "end_logit": -1.201171875,
            "text": "XX",
            "probability": 1.6987323760986328e-05
        },
        {
            "start_logit": -1.1015625,
            "end_logit": 9.78125,
            "text": "Y",
            "probability": 1.6570091247558594e-05
        },
        {
            "start_logit": 9.90625,
            "end_logit": -7.05859375,
            "text": "XXY chromosomal abnormality may be more than coincidental.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.90625,
            "end_logit": -7.64453125,
            "text": "XXY chromosomal abnormality may",
            "probability": 0.0
        },
        {
            "start_logit": -7.734375,
            "end_logit": 9.78125,
            "text": "the XXY",
            "probability": 0.0
        },
        {
            "start_logit": 9.90625,
            "end_logit": -8.0390625,
            "text": "XXY chromosomal abnormality",
            "probability": 0.0
        },
        {
            "start_logit": 9.90625,
            "end_logit": -8.0390625,
            "text": "XXY chromosomal abnormality may be more than coincidental",
            "probability": 0.0
        },
        {
            "start_logit": -7.93359375,
            "end_logit": 9.78125,
            "text": "teratocarcinoma is reported suggesting that the association of a gonadotropin-secreting tumor with the XXY",
            "probability": 0.0
        },
        {
            "start_logit": -7.94140625,
            "end_logit": 9.78125,
            "text": "association of a gonadotropin-secreting tumor with the XXY",
            "probability": 0.0
        },
        {
            "start_logit": -7.96484375,
            "end_logit": 9.78125,
            "text": "a mediastinal teratocarcinoma is reported suggesting that the association of a gonadotropin-secreting tumor with the XXY",
            "probability": 0.0
        },
        {
            "start_logit": -7.96484375,
            "end_logit": 9.78125,
            "text": "the association of a gonadotropin-secreting tumor with the XXY",
            "probability": 0.0
        },
        {
            "start_logit": -7.97265625,
            "end_logit": 9.78125,
            "text": "Klinefelter's syndrome with the development of a mediastinal teratocarcinoma is reported suggesting that the association of a gonadotropin-secreting tumor with the XXY",
            "probability": 0.0
        },
        {
            "start_logit": 9.90625,
            "end_logit": -8.109375,
            "text": "XXY chromosomal abnormality may be",
            "probability": 0.0
        },
        {
            "start_logit": -7.99609375,
            "end_logit": 9.78125,
            "text": "case of Klinefelter's syndrome with the development of a mediastinal teratocarcinoma is reported suggesting that the association of a gonadotropin-secreting tumor with the XXY",
            "probability": 0.0
        },
        {
            "start_logit": -8.0078125,
            "end_logit": 9.78125,
            "text": "A case of Klinefelter's syndrome with the development of a mediastinal teratocarcinoma is reported suggesting that the association of a gonadotropin-secreting tumor with the XXY",
            "probability": 0.0
        },
        {
            "start_logit": -8.0234375,
            "end_logit": 9.78125,
            "text": "of Klinefelter's syndrome with the development of a mediastinal teratocarcinoma is reported suggesting that the association of a gonadotropin-secreting tumor with the XXY",
            "probability": 0.0
        },
        {
            "start_logit": -8.03125,
            "end_logit": 9.78125,
            "text": "tumor with the XXY",
            "probability": 0.0
        },
        {
            "start_logit": -8.0390625,
            "end_logit": 9.78125,
            "text": "inefelter's syndrome with the development of a mediastinal teratocarcinoma is reported suggesting that the association of a gonadotropin-secreting tumor with the XXY",
            "probability": 0.0
        },
        {
            "start_logit": -8.0390625,
            "end_logit": 9.78125,
            "text": "the development of a mediastinal teratocarcinoma is reported suggesting that the association of a gonadotropin-secreting tumor with the XXY",
            "probability": 0.0
        }
    ],
    "5e669e0e1af46fc130000019_9": [
        {
            "start_logit": 4.9375,
            "end_logit": 2.150390625,
            "text": "a 47, XXY",
            "probability": 0.87353515625
        },
        {
            "start_logit": 2.96484375,
            "end_logit": 2.150390625,
            "text": "Klinefelter syndrome (KS) is a chromosomal abnormality characterised by a 47, XXY",
            "probability": 0.12200927734375
        },
        {
            "start_logit": 4.9375,
            "end_logit": -4.34375,
            "text": "a 47, XXY karyotype associated with hypogonadism",
            "probability": 0.001323699951171875
        },
        {
            "start_logit": 4.9375,
            "end_logit": -4.78125,
            "text": "a 47, XX",
            "probability": 0.0008549690246582031
        },
        {
            "start_logit": 4.9375,
            "end_logit": -5.50390625,
            "text": "a",
            "probability": 0.00041484832763671875
        },
        {
            "start_logit": 4.9375,
            "end_logit": -5.5859375,
            "text": "a 47, XXY karyotype",
            "probability": 0.0003821849822998047
        },
        {
            "start_logit": 2.96484375,
            "end_logit": -4.34375,
            "text": "Klinefelter syndrome (KS) is a chromosomal abnormality characterised by a 47, XXY karyotype associated with hypogonadism",
            "probability": 0.00018346309661865234
        },
        {
            "start_logit": 2.96484375,
            "end_logit": -4.78125,
            "text": "Klinefelter syndrome (KS) is a chromosomal abnormality characterised by a 47, XX",
            "probability": 0.00011843442916870117
        },
        {
            "start_logit": 4.9375,
            "end_logit": -6.76171875,
            "text": "a 47, XXY karyotype associated",
            "probability": 0.00011843442916870117
        },
        {
            "start_logit": 4.9375,
            "end_logit": -6.953125,
            "text": "a 47, XXY karyotype associated with hypogonadism and infertility",
            "probability": 9.745359420776367e-05
        },
        {
            "start_logit": 4.9375,
            "end_logit": -6.9765625,
            "text": "a 47,",
            "probability": 9.512901306152344e-05
        },
        {
            "start_logit": 4.9375,
            "end_logit": -7.33203125,
            "text": "a 47, XXY karyotype associated with",
            "probability": 6.645917892456055e-05
        },
        {
            "start_logit": 2.96484375,
            "end_logit": -5.50390625,
            "text": "Klinefelter syndrome (KS) is a chromosomal abnormality characterised by a",
            "probability": 5.7697296142578125e-05
        },
        {
            "start_logit": 2.96484375,
            "end_logit": -5.5859375,
            "text": "Klinefelter syndrome (KS) is a chromosomal abnormality characterised by a 47, XXY karyotype",
            "probability": 5.340576171875e-05
        },
        {
            "start_logit": 4.9375,
            "end_logit": -7.5703125,
            "text": "a 47, XXY karyotype associated with hypogonadism and infertility. W",
            "probability": 5.257129669189453e-05
        },
        {
            "start_logit": 4.9375,
            "end_logit": -7.69140625,
            "text": "a 47, XXY karyotype associated with hypogonadism and infertility.",
            "probability": 4.6372413635253906e-05
        },
        {
            "start_logit": -4.91796875,
            "end_logit": 2.150390625,
            "text": "47, XXY",
            "probability": 4.601478576660156e-05
        },
        {
            "start_logit": 4.9375,
            "end_logit": -7.734375,
            "text": "a 47, XXY karyotype associated with hypogonadism and",
            "probability": 4.458427429199219e-05
        },
        {
            "start_logit": 2.96484375,
            "end_logit": -6.76171875,
            "text": "Klinefelter syndrome (KS) is a chromosomal abnormality characterised by a 47, XXY karyotype associated",
            "probability": 1.6391277313232422e-05
        },
        {
            "start_logit": 2.96484375,
            "end_logit": -6.953125,
            "text": "Klinefelter syndrome (KS) is a chromosomal abnormality characterised by a 47, XXY karyotype associated with hypogonadism and infertility",
            "probability": 1.3470649719238281e-05
        }
    ],
    "5e669e0e1af46fc130000019_10": [
        {
            "start_logit": 9.015625,
            "end_logit": 7.04296875,
            "text": "Y",
            "probability": 1.0
        },
        {
            "start_logit": 9.015625,
            "end_logit": -5.76953125,
            "text": "Y chromosome microdeletions",
            "probability": 2.7418136596679688e-06
        },
        {
            "start_logit": 9.015625,
            "end_logit": -6.25390625,
            "text": "Y chromosome microdeletions.",
            "probability": 1.6689300537109375e-06
        },
        {
            "start_logit": 9.015625,
            "end_logit": -7.5703125,
            "text": "Y chromosome microdelet",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 9.015625,
            "end_logit": -7.93359375,
            "text": "Y chromosome microd",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.58984375,
            "end_logit": 7.04296875,
            "text": "and Y",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.21484375,
            "end_logit": 7.04296875,
            "text": "nonobstructive azoospermia are numerical and structural chromosome abnormalities, including Klinefelter syndrome (47,XXY) and Y",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.3046875,
            "end_logit": 7.04296875,
            "text": "47,XXY) and Y",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5078125,
            "end_logit": 7.04296875,
            "text": ",XXY) and Y",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.56640625,
            "end_logit": 7.04296875,
            "text": "ive azoospermia are numerical and structural chromosome abnormalities, including Klinefelter syndrome (47,XXY) and Y",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.625,
            "end_logit": 7.04296875,
            "text": "including Klinefelter syndrome (47,XXY) and Y",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.65234375,
            "end_logit": 7.04296875,
            "text": "defects associated with nonobstructive azoospermia are numerical and structural chromosome abnormalities, including Klinefelter syndrome (47,XXY) and Y",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.67578125,
            "end_logit": 7.04296875,
            "text": "numerical and structural chromosome abnormalities, including Klinefelter syndrome (47,XXY) and Y",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.72265625,
            "end_logit": 7.04296875,
            "text": "XXY) and Y",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.734375,
            "end_logit": 7.04296875,
            "text": "The most common cytogenetic defects associated with nonobstructive azoospermia are numerical and structural chromosome abnormalities, including Klinefelter syndrome (47,XXY) and Y",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.75390625,
            "end_logit": 7.04296875,
            "text": "with nonobstructive azoospermia are numerical and structural chromosome abnormalities, including Klinefelter syndrome (47,XXY) and Y",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.7734375,
            "end_logit": 7.04296875,
            "text": "tructive azoospermia are numerical and structural chromosome abnormalities, including Klinefelter syndrome (47,XXY) and Y",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.58984375,
            "end_logit": -5.76953125,
            "text": "and Y chromosome microdeletions",
            "probability": 0.0
        },
        {
            "start_logit": -6.33984375,
            "end_logit": -6.25390625,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -6.58984375,
            "end_logit": -6.25390625,
            "text": "and Y chromosome microdeletions.",
            "probability": 0.0
        }
    ],
    "5e669e0e1af46fc130000019_11": [
        {
            "start_logit": 4.078125,
            "end_logit": 9.7265625,
            "text": "additional X",
            "probability": 0.96240234375
        },
        {
            "start_logit": 0.81982421875,
            "end_logit": 9.7265625,
            "text": "X",
            "probability": 0.03704833984375
        },
        {
            "start_logit": -3.259765625,
            "end_logit": 9.7265625,
            "text": "an additional X",
            "probability": 0.0006275177001953125
        },
        {
            "start_logit": -6.55859375,
            "end_logit": 9.7265625,
            "text": "by an additional X",
            "probability": 2.300739288330078e-05
        },
        {
            "start_logit": -7.65625,
            "end_logit": 9.7265625,
            "text": "well recognized chromosomal abnormality caused by an additional X",
            "probability": 7.68899917602539e-06
        },
        {
            "start_logit": -7.76171875,
            "end_logit": 9.7265625,
            "text": "Klinefelter syndrome is well recognized chromosomal abnormality caused by an additional X",
            "probability": 6.9141387939453125e-06
        },
        {
            "start_logit": -7.76953125,
            "end_logit": 9.7265625,
            "text": "chromosomal abnormality caused by an additional X",
            "probability": 6.9141387939453125e-06
        },
        {
            "start_logit": -7.7890625,
            "end_logit": 9.7265625,
            "text": "caused by an additional X",
            "probability": 6.794929504394531e-06
        },
        {
            "start_logit": -7.8203125,
            "end_logit": 9.7265625,
            "text": "abnormality caused by an additional X",
            "probability": 6.556510925292969e-06
        },
        {
            "start_logit": -7.8359375,
            "end_logit": 9.7265625,
            "text": ", Klinefelter syndrome is well recognized chromosomal abnormality caused by an additional X",
            "probability": 6.4373016357421875e-06
        },
        {
            "start_logit": -7.87890625,
            "end_logit": 9.7265625,
            "text": "recognized chromosomal abnormality caused by an additional X",
            "probability": 6.198883056640625e-06
        },
        {
            "start_logit": -7.9375,
            "end_logit": 9.7265625,
            "text": "the other hand, Klinefelter syndrome is well recognized chromosomal abnormality caused by an additional X",
            "probability": 5.781650543212891e-06
        },
        {
            "start_logit": -7.98046875,
            "end_logit": 9.7265625,
            "text": "inefelter syndrome is well recognized chromosomal abnormality caused by an additional X",
            "probability": 5.543231964111328e-06
        },
        {
            "start_logit": 4.078125,
            "end_logit": -4.9609375,
            "text": "additional X chromosome",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 4.078125,
            "end_logit": -5.70703125,
            "text": "additional X chromosome in",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 4.078125,
            "end_logit": -6.94921875,
            "text": "additional X chromosome in males (47,XXY), and the characteristic clinical findings include tall stature, immaturity of external genitalia, testicular dysfunction.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 4.078125,
            "end_logit": -7.1171875,
            "text": "additional",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 4.078125,
            "end_logit": -7.50390625,
            "text": "additional X chromosome in males",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 4.078125,
            "end_logit": -7.671875,
            "text": "additional X chromosome in males (47,XXY",
            "probability": 0.0
        },
        {
            "start_logit": 4.078125,
            "end_logit": -7.75390625,
            "text": "additional X chromosome in males (47,XXY)",
            "probability": 0.0
        }
    ],
    "5e669e0e1af46fc130000019_12": [
        {
            "start_logit": 8.75,
            "end_logit": 9.6953125,
            "text": "47, XXY",
            "probability": 1.0
        },
        {
            "start_logit": -1.3427734375,
            "end_logit": 9.6953125,
            "text": "Y",
            "probability": 4.166364669799805e-05
        },
        {
            "start_logit": 8.75,
            "end_logit": -3.1796875,
            "text": "47",
            "probability": 2.562999725341797e-06
        },
        {
            "start_logit": -5.89453125,
            "end_logit": 9.6953125,
            "text": "XXY",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -6.44921875,
            "end_logit": 9.6953125,
            "text": ", XXY",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.09375,
            "end_logit": 9.6953125,
            "text": "(47, XXY",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.1484375,
            "end_logit": 9.6953125,
            "text": "which Klinefelter's syndrome (47, XXY",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.26171875,
            "end_logit": 9.6953125,
            "text": "Klinefelter's syndrome (47, XXY",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.75,
            "end_logit": -6.34375,
            "text": "47, XX",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.74609375,
            "end_logit": 9.6953125,
            "text": "chromosomal abnormalities in which Klinefelter's syndrome (47, XXY",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.765625,
            "end_logit": 9.6953125,
            "text": "have chromosomal abnormalities in which Klinefelter's syndrome (47, XXY",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.79296875,
            "end_logit": 9.6953125,
            "text": "8 patients, 39(10.9%) were found to have chromosomal abnormalities in which Klinefelter's syndrome (47, XXY",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.8515625,
            "end_logit": 9.6953125,
            "text": "39(10.9%) were found to have chromosomal abnormalities in which Klinefelter's syndrome (47, XXY",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.87890625,
            "end_logit": 9.6953125,
            "text": "patients, 39(10.9%) were found to have chromosomal abnormalities in which Klinefelter's syndrome (47, XXY",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.91015625,
            "end_logit": 9.6953125,
            "text": "10.9%) were found to have chromosomal abnormalities in which Klinefelter's syndrome (47, XXY",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.9140625,
            "end_logit": 9.6953125,
            "text": ") were found to have chromosomal abnormalities in which Klinefelter's syndrome (47, XXY",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.91796875,
            "end_logit": 9.6953125,
            "text": "(10.9%) were found to have chromosomal abnormalities in which Klinefelter's syndrome (47, XXY",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.75,
            "end_logit": -7.2578125,
            "text": "47, XXY) was",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.75,
            "end_logit": -7.625,
            "text": "47, XXY)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.75,
            "end_logit": -7.69140625,
            "text": "47, XXY) was the most",
            "probability": 0.0
        }
    ],
    "5e669e0e1af46fc130000019_13": [
        {
            "start_logit": 8.3046875,
            "end_logit": 5.23828125,
            "text": "Klinefelter syndrome (KS) is a chromosome abnormality characterized by a 47, XXY karyotype associated with hypogonadism and infertility.",
            "probability": 0.88134765625
        },
        {
            "start_logit": 6.25390625,
            "end_logit": 5.23828125,
            "text": "a 47, XXY karyotype associated with hypogonadism and infertility.",
            "probability": 0.11297607421875
        },
        {
            "start_logit": 8.3046875,
            "end_logit": -0.0286102294921875,
            "text": "Klinefelter syndrome (KS) is a chromosome abnormality characterized by a 47, XXY",
            "probability": 0.0045166015625
        },
        {
            "start_logit": 6.25390625,
            "end_logit": -0.0286102294921875,
            "text": "a 47, XXY",
            "probability": 0.0005831718444824219
        },
        {
            "start_logit": 0.60595703125,
            "end_logit": 5.23828125,
            "text": ".",
            "probability": 0.00039768218994140625
        },
        {
            "start_logit": 8.3046875,
            "end_logit": -3.1328125,
            "text": "Kl",
            "probability": 0.00020313262939453125
        },
        {
            "start_logit": 8.3046875,
            "end_logit": -4.18359375,
            "text": "Klinefelter syndrome (KS) is a chromosome abnormality characterized by a",
            "probability": 7.134675979614258e-05
        },
        {
            "start_logit": 8.3046875,
            "end_logit": -4.6640625,
            "text": "Klinefelter syndrome (KS) is a chromosome abnormality characterized by a 47, XX",
            "probability": 4.398822784423828e-05
        },
        {
            "start_logit": 8.3046875,
            "end_logit": -6.04296875,
            "text": "Klinefelter syndrome (KS) is a chromosome abnormality characterized by a 47, XXY karyotype",
            "probability": 1.1146068572998047e-05
        },
        {
            "start_logit": 8.3046875,
            "end_logit": -6.05078125,
            "text": "Klinefelter syndrome (KS) is a chromosome abnormality characterized by a 47, XXY karyotype associated with hypogonadism",
            "probability": 1.0907649993896484e-05
        },
        {
            "start_logit": 6.25390625,
            "end_logit": -4.18359375,
            "text": "a",
            "probability": 9.119510650634766e-06
        },
        {
            "start_logit": 6.25390625,
            "end_logit": -4.6640625,
            "text": "a 47, XX",
            "probability": 5.662441253662109e-06
        },
        {
            "start_logit": 8.3046875,
            "end_logit": -6.73828125,
            "text": "Klinefelter syndrome (KS) is a chromosome abnormality characterized by a 47, XXY karyotype associated",
            "probability": 5.543231964111328e-06
        },
        {
            "start_logit": 8.3046875,
            "end_logit": -6.74609375,
            "text": "Klinefelter syndrome (KS) is a chromosome abnormality characterized by a 47,",
            "probability": 5.543231964111328e-06
        },
        {
            "start_logit": 8.3046875,
            "end_logit": -6.82421875,
            "text": "Klinefelter syndrome (KS) is a chromosome abnormality characterized",
            "probability": 5.066394805908203e-06
        },
        {
            "start_logit": 8.3046875,
            "end_logit": -6.8515625,
            "text": "Klinefelter syndrome (KS) is",
            "probability": 4.947185516357422e-06
        },
        {
            "start_logit": 8.3046875,
            "end_logit": -6.96484375,
            "text": "Klinefelter syndrome (KS) is a chromosome abnormality characterized by a 47, XXY karyotype associated with hypogonadism and infertility",
            "probability": 4.410743713378906e-06
        },
        {
            "start_logit": 8.3046875,
            "end_logit": -7.171875,
            "text": "Klinefelter syndrome (KS) is a chromosome abnormality characterized by",
            "probability": 3.5762786865234375e-06
        },
        {
            "start_logit": 8.3046875,
            "end_logit": -7.2109375,
            "text": "Klinefelter syndrome (KS) is a chromosome abnormality characterized by a 47, XXY karyotype associated with",
            "probability": 3.4570693969726562e-06
        },
        {
            "start_logit": 8.3046875,
            "end_logit": -7.4140625,
            "text": "Klinefelter syndrome (",
            "probability": 2.8014183044433594e-06
        }
    ],
    "5e669e0e1af46fc130000019_14": [
        {
            "start_logit": 7.33203125,
            "end_logit": 2.73828125,
            "text": "sex chromosome anomalies including XXY, XXYY, XXXY and XXXXY.",
            "probability": 0.71875
        },
        {
            "start_logit": 7.33203125,
            "end_logit": 1.7890625,
            "text": "sex chromosome anomalies",
            "probability": 0.279296875
        },
        {
            "start_logit": 7.33203125,
            "end_logit": -3.55078125,
            "text": "sex",
            "probability": 0.0013341903686523438
        },
        {
            "start_logit": 7.33203125,
            "end_logit": -5.69140625,
            "text": "sex chromosome anomalies including",
            "probability": 0.00015687942504882812
        },
        {
            "start_logit": -1.140625,
            "end_logit": 2.73828125,
            "text": ".",
            "probability": 0.00015079975128173828
        },
        {
            "start_logit": 7.33203125,
            "end_logit": -5.9453125,
            "text": "sex chromosome anomalies including XX",
            "probability": 0.00012123584747314453
        },
        {
            "start_logit": 7.33203125,
            "end_logit": -5.9453125,
            "text": "sex chromosome anomalies including XXY",
            "probability": 0.00012123584747314453
        },
        {
            "start_logit": 7.33203125,
            "end_logit": -6.6328125,
            "text": "sex chromosome",
            "probability": 6.097555160522461e-05
        },
        {
            "start_logit": 7.33203125,
            "end_logit": -7.109375,
            "text": "sex chromosome anomalies including XXY, XXYY, XXXY",
            "probability": 3.814697265625e-05
        },
        {
            "start_logit": 7.33203125,
            "end_logit": -7.20703125,
            "text": "sex chromosome anomalies including XXY, XX",
            "probability": 3.445148468017578e-05
        },
        {
            "start_logit": 7.33203125,
            "end_logit": -7.37890625,
            "text": "sex chromosome anomalies including XXY, XXYY, XXXY and XXXXY",
            "probability": 2.8967857360839844e-05
        },
        {
            "start_logit": 7.33203125,
            "end_logit": -7.44140625,
            "text": "sex chromosome anomalies including XXY, XXYY, XXXY and XX",
            "probability": 2.7239322662353516e-05
        },
        {
            "start_logit": 7.33203125,
            "end_logit": -7.54296875,
            "text": "sex chromosome anomalies including XXY, XXYY, XX",
            "probability": 2.4616718292236328e-05
        },
        {
            "start_logit": -5.54296875,
            "end_logit": 2.73828125,
            "text": "Klinefelter's syndrome may be associated with a variety of different sex chromosome anomalies including XXY, XXYY, XXXY and XXXXY.",
            "probability": 1.8477439880371094e-06
        },
        {
            "start_logit": -5.54296875,
            "end_logit": 1.7890625,
            "text": "Klinefelter's syndrome may be associated with a variety of different sex chromosome anomalies",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -6.95703125,
            "end_logit": 2.73828125,
            "text": "XXY, XXYY, XXXY and XXXXY.",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -7.2890625,
            "end_logit": 2.73828125,
            "text": "chromosome anomalies including XXY, XXYY, XXXY and XXXXY.",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.41796875,
            "end_logit": 2.73828125,
            "text": "different sex chromosome anomalies including XXY, XXYY, XXXY and XXXXY.",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.421875,
            "end_logit": 2.73828125,
            "text": "variety of different sex chromosome anomalies including XXY, XXYY, XXXY and XXXXY.",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.4375,
            "end_logit": 2.73828125,
            "text": "anomalies including XXY, XXYY, XXXY and XXXXY.",
            "probability": 2.384185791015625e-07
        }
    ],
    "5e669e0e1af46fc130000019_15": [
        {
            "start_logit": 8.0,
            "end_logit": 9.78125,
            "text": "47,XXY",
            "probability": 1.0
        },
        {
            "start_logit": -0.98583984375,
            "end_logit": 9.78125,
            "text": "Y",
            "probability": 0.00012540817260742188
        },
        {
            "start_logit": 8.0,
            "end_logit": -1.8994140625,
            "text": "47,XXY chromosomal pattern, has largely been associated with physical abnormalities.",
            "probability": 8.463859558105469e-06
        },
        {
            "start_logit": -4.7109375,
            "end_logit": 9.78125,
            "text": "a 47,XXY",
            "probability": 3.039836883544922e-06
        },
        {
            "start_logit": -5.69140625,
            "end_logit": 9.78125,
            "text": "XXY",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": 8.0,
            "end_logit": -4.07421875,
            "text": "47",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": -6.62109375,
            "end_logit": 9.78125,
            "text": "Klinefelter's syndrome, characterised by a 47,XXY",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -6.7265625,
            "end_logit": 9.78125,
            "text": ",XXY",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -7.1953125,
            "end_logit": 9.78125,
            "text": "characterised by a 47,XXY",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.23828125,
            "end_logit": 9.78125,
            "text": "by a 47,XXY",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.0,
            "end_logit": -6.41015625,
            "text": "47,XX",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.0,
            "end_logit": -7.5859375,
            "text": "47,XXY chromosomal pattern",
            "probability": 0.0
        },
        {
            "start_logit": 8.0,
            "end_logit": -7.625,
            "text": "47,",
            "probability": 0.0
        },
        {
            "start_logit": 8.0,
            "end_logit": -7.80859375,
            "text": "47,XXY chromosomal pattern,",
            "probability": 0.0
        },
        {
            "start_logit": -0.98583984375,
            "end_logit": -1.8994140625,
            "text": "Y chromosomal pattern, has largely been associated with physical abnormalities.",
            "probability": 0.0
        },
        {
            "start_logit": -3.927734375,
            "end_logit": -1.8994140625,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -4.7109375,
            "end_logit": -1.8994140625,
            "text": "a 47,XXY chromosomal pattern, has largely been associated with physical abnormalities.",
            "probability": 0.0
        },
        {
            "start_logit": -5.69140625,
            "end_logit": -1.8994140625,
            "text": "XXY chromosomal pattern, has largely been associated with physical abnormalities.",
            "probability": 0.0
        },
        {
            "start_logit": -6.62109375,
            "end_logit": -1.8994140625,
            "text": "Klinefelter's syndrome, characterised by a 47,XXY chromosomal pattern, has largely been associated with physical abnormalities.",
            "probability": 0.0
        },
        {
            "start_logit": -0.98583984375,
            "end_logit": -7.5859375,
            "text": "Y chromosomal pattern",
            "probability": 0.0
        }
    ],
    "5e669e0e1af46fc130000019_16": [
        {
            "start_logit": 8.65625,
            "end_logit": 7.07421875,
            "text": "t(13q;14q)",
            "probability": 1.0
        },
        {
            "start_logit": 8.65625,
            "end_logit": -1.5234375,
            "text": "t(13q;14q).",
            "probability": 0.0001838207244873047
        },
        {
            "start_logit": 8.65625,
            "end_logit": -2.7265625,
            "text": "t",
            "probability": 5.519390106201172e-05
        },
        {
            "start_logit": 8.65625,
            "end_logit": -5.58203125,
            "text": "t(13q;14q",
            "probability": 3.159046173095703e-06
        },
        {
            "start_logit": -4.3515625,
            "end_logit": 7.07421875,
            "text": ")",
            "probability": 2.205371856689453e-06
        },
        {
            "start_logit": 8.65625,
            "end_logit": -6.04296875,
            "text": "t(13q",
            "probability": 1.9669532775878906e-06
        },
        {
            "start_logit": 8.65625,
            "end_logit": -6.3671875,
            "text": "t(13q;14",
            "probability": 1.430511474609375e-06
        },
        {
            "start_logit": 8.65625,
            "end_logit": -6.4453125,
            "text": "t(13",
            "probability": 1.3113021850585938e-06
        },
        {
            "start_logit": -5.36328125,
            "end_logit": 7.07421875,
            "text": ",t(13q;14q)",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": 8.65625,
            "end_logit": -7.02734375,
            "text": "t(13q;",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": -5.6875,
            "end_logit": 7.07421875,
            "text": "abnormality 46,XXY,t(13q;14q)",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -5.72265625,
            "end_logit": 7.07421875,
            "text": "translocation abnormality 46,XXY,t(13q;14q)",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 8.65625,
            "end_logit": -7.38671875,
            "text": "t(",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -6.59765625,
            "end_logit": 7.07421875,
            "text": "(13q;14q)",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.7265625,
            "end_logit": 7.07421875,
            "text": "13q;14q)",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.85546875,
            "end_logit": 7.07421875,
            "text": ";14q)",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.05859375,
            "end_logit": 7.07421875,
            "text": "13/14 translocation abnormality 46,XXY,t(13q;14q)",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.25,
            "end_logit": 7.07421875,
            "text": "14q)",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.3046875,
            "end_logit": 7.07421875,
            "text": "with 13/14 translocation abnormality 46,XXY,t(13q;14q)",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.3125,
            "end_logit": 7.07421875,
            "text": "46,XXY,t(13q;14q)",
            "probability": 1.1920928955078125e-07
        }
    ],
    "56c8f4615795f9a73e00001a_1": [
        {
            "start_logit": 9.8828125,
            "end_logit": 9.7578125,
            "text": "GBshape",
            "probability": 1.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -1.373046875,
            "text": "GBs",
            "probability": 1.4603137969970703e-05
        },
        {
            "start_logit": -1.333984375,
            "end_logit": 9.7578125,
            "text": "e",
            "probability": 1.341104507446289e-05
        },
        {
            "start_logit": -5.52734375,
            "end_logit": 9.7578125,
            "text": "hape",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -7.05859375,
            "text": "GBshap",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -8.0390625,
            "text": "GBshape:",
            "probability": 0.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -8.125,
            "text": "GBshape: a genome browser database for DNA shape annotations.",
            "probability": 0.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -8.1953125,
            "text": "GBshape: a",
            "probability": 0.0
        },
        {
            "start_logit": -1.333984375,
            "end_logit": -8.0390625,
            "text": "e:",
            "probability": 0.0
        },
        {
            "start_logit": -1.333984375,
            "end_logit": -8.125,
            "text": "e: a genome browser database for DNA shape annotations.",
            "probability": 0.0
        },
        {
            "start_logit": -1.333984375,
            "end_logit": -8.1953125,
            "text": "e: a",
            "probability": 0.0
        },
        {
            "start_logit": -5.52734375,
            "end_logit": -7.05859375,
            "text": "hap",
            "probability": 0.0
        },
        {
            "start_logit": -5.52734375,
            "end_logit": -8.0390625,
            "text": "hape:",
            "probability": 0.0
        },
        {
            "start_logit": -5.52734375,
            "end_logit": -8.125,
            "text": "hape: a genome browser database for DNA shape annotations.",
            "probability": 0.0
        },
        {
            "start_logit": -5.52734375,
            "end_logit": -8.1953125,
            "text": "hape: a",
            "probability": 0.0
        },
        {
            "start_logit": -6.85546875,
            "end_logit": -8.125,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.8359375,
            "end_logit": -8.125,
            "text": "genome browser database for DNA shape annotations.",
            "probability": 0.0
        },
        {
            "start_logit": -7.8828125,
            "end_logit": -8.125,
            "text": "DNA shape annotations.",
            "probability": 0.0
        },
        {
            "start_logit": -7.94140625,
            "end_logit": -8.125,
            "text": "shape annotations.",
            "probability": 0.0
        },
        {
            "start_logit": -7.9765625,
            "end_logit": -8.125,
            "text": "database for DNA shape annotations.",
            "probability": 0.0
        }
    ],
    "56c8f4615795f9a73e00001a_2": [
        {
            "start_logit": 9.6015625,
            "end_logit": 9.8046875,
            "text": "GBshape",
            "probability": 1.0
        },
        {
            "start_logit": -1.134765625,
            "end_logit": 9.8046875,
            "text": "e",
            "probability": 2.1755695343017578e-05
        },
        {
            "start_logit": 9.6015625,
            "end_logit": -1.8984375,
            "text": "GBs",
            "probability": 8.285045623779297e-06
        },
        {
            "start_logit": -5.33984375,
            "end_logit": 9.8046875,
            "text": "hape",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.6015625,
            "end_logit": -6.87109375,
            "text": "GBshape; freely available at http://rohslab.cmb.usc.edu",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.16015625,
            "end_logit": 9.8046875,
            "text": "Our Genome Browser for DNA shape annotations (GBshape",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.6015625,
            "end_logit": -6.9609375,
            "text": "GBshap",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.24609375,
            "end_logit": 9.8046875,
            "text": "Genome Browser for DNA shape annotations (GBshape",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.3125,
            "end_logit": 9.8046875,
            "text": "(GBshape",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.6015625,
            "end_logit": -7.34375,
            "text": "GBshape; freely available at http://rohslab.cmb.us",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.6015625,
            "end_logit": -7.4609375,
            "text": "GBshape; freely available at http://rohslab.cmb.usc.edu/GBshape/",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.6015625,
            "end_logit": -7.5546875,
            "text": "GBshape; freely available at http://rohslab",
            "probability": 0.0
        },
        {
            "start_logit": 9.6015625,
            "end_logit": -7.5703125,
            "text": "GBshape; freely available at http://rohslab.cmb.",
            "probability": 0.0
        },
        {
            "start_logit": 9.6015625,
            "end_logit": -7.578125,
            "text": "GBshape; freely available at http://rohslab.cmb.usc",
            "probability": 0.0
        },
        {
            "start_logit": 9.6015625,
            "end_logit": -7.578125,
            "text": "GBshape; freely available at http://rohslab.cmb.usc.",
            "probability": 0.0
        },
        {
            "start_logit": 9.6015625,
            "end_logit": -7.67578125,
            "text": "GBshape; freely available at http://rohslab.cmb",
            "probability": 0.0
        },
        {
            "start_logit": 9.6015625,
            "end_logit": -7.6953125,
            "text": "GBshape; freely available at http://rohslab.cmb.usc.edu/",
            "probability": 0.0
        },
        {
            "start_logit": 9.6015625,
            "end_logit": -7.7109375,
            "text": "GBshape; freely available at http://rohslab.",
            "probability": 0.0
        },
        {
            "start_logit": 9.6015625,
            "end_logit": -7.7890625,
            "text": "GBshape; freely available at http://rohslab.cm",
            "probability": 0.0
        },
        {
            "start_logit": -1.134765625,
            "end_logit": -6.87109375,
            "text": "e; freely available at http://rohslab.cmb.usc.edu",
            "probability": 0.0
        }
    ],
    "56c8f4615795f9a73e00001a_3": [
        {
            "start_logit": 9.8046875,
            "end_logit": 9.734375,
            "text": "GBshape",
            "probability": 1.0
        },
        {
            "start_logit": -1.408203125,
            "end_logit": 9.734375,
            "text": "e",
            "probability": 1.3649463653564453e-05
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -1.564453125,
            "text": "GBs",
            "probability": 1.2516975402832031e-05
        },
        {
            "start_logit": -5.90234375,
            "end_logit": 9.734375,
            "text": "hape",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -7.31640625,
            "text": "GBshap",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -7.7578125,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as a function of genomic position at nucleotide resolution.",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -8.0390625,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as a function of genomic position at",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -8.0546875,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as a",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -8.0625,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -8.09375,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format,",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -8.09375,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -8.109375,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -8.125,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as a function",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -8.1328125,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as a function of genomic position at nucleotide resolution",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -8.1484375,
            "text": "GBshape can",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -8.1484375,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome brow",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -8.15625,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as a function of",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -8.15625,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -8.171875,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as a function of genomic position",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -8.1875,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as a function of genomic position at nucleotide",
            "probability": 0.0
        }
    ],
    "56c8f4615795f9a73e00001a_4": [
        {
            "start_logit": 9.5234375,
            "end_logit": 9.7734375,
            "text": "GBshape",
            "probability": 1.0
        },
        {
            "start_logit": -1.2578125,
            "end_logit": 9.7734375,
            "text": "e",
            "probability": 2.0802021026611328e-05
        },
        {
            "start_logit": 9.5234375,
            "end_logit": -2.0859375,
            "text": "GBs",
            "probability": 7.092952728271484e-06
        },
        {
            "start_logit": -5.72265625,
            "end_logit": 9.7734375,
            "text": "hape",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.5234375,
            "end_logit": -6.54296875,
            "text": "GBshape; freely available at http://rohslab.cmb.usc.edu",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.21875,
            "end_logit": 9.7734375,
            "text": "Our Genome Browser for DNA shape annotations (GBshape",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.5234375,
            "end_logit": -6.9765625,
            "text": "GBshape; freely available at http://rohslab",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.3828125,
            "end_logit": 9.7734375,
            "text": "(GBshape",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.5234375,
            "end_logit": -7.1796875,
            "text": "GBshape; freely available at http://rohslab.cmb.us",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.5234375,
            "end_logit": -7.18359375,
            "text": "GBshape; freely available at http://rohslab.cmb.usc.edu/GBshape/",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.46484375,
            "end_logit": 9.7734375,
            "text": "Genome Browser for DNA shape annotations (GBshape",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.5234375,
            "end_logit": -7.328125,
            "text": "GBshap",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.5234375,
            "end_logit": -7.34375,
            "text": "GBshape; freely available at http://rohslab.cmb.usc",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.5234375,
            "end_logit": -7.453125,
            "text": "GBshape; freely available at http://rohslab.cmb.usc.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.5234375,
            "end_logit": -7.453125,
            "text": "GBshape; freely available at http://rohslab.cmb",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.5234375,
            "end_logit": -7.48828125,
            "text": "GBshape; freely available at http://rohslab.cmb.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.5234375,
            "end_logit": -7.5703125,
            "text": "GBshape; freely available at http://rohslab.",
            "probability": 0.0
        },
        {
            "start_logit": 9.5234375,
            "end_logit": -7.6015625,
            "text": "GBshape; freely available at http://rohslab.cmb.usc.edu/",
            "probability": 0.0
        },
        {
            "start_logit": 9.5234375,
            "end_logit": -7.60546875,
            "text": "GBshape;",
            "probability": 0.0
        },
        {
            "start_logit": -7.86328125,
            "end_logit": 9.7734375,
            "text": "DNA shape annotations (GBshape",
            "probability": 0.0
        }
    ],
    "56c8f4615795f9a73e00001a_5": [
        {
            "start_logit": 9.8046875,
            "end_logit": 9.734375,
            "text": "GBshape",
            "probability": 1.0
        },
        {
            "start_logit": -1.408203125,
            "end_logit": 9.734375,
            "text": "e",
            "probability": 1.3649463653564453e-05
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -1.564453125,
            "text": "GBs",
            "probability": 1.2516975402832031e-05
        },
        {
            "start_logit": -5.90234375,
            "end_logit": 9.734375,
            "text": "hape",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -7.31640625,
            "text": "GBshap",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -7.7578125,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as a function of genomic position at nucleotide resolution.",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -8.0390625,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as a function of genomic position at",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -8.0546875,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as a",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -8.0625,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -8.09375,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format,",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -8.09375,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -8.109375,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -8.125,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as a function",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -8.1328125,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as a function of genomic position at nucleotide resolution",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -8.1484375,
            "text": "GBshape can",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -8.1484375,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome brow",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -8.15625,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as a function of",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -8.15625,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -8.171875,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as a function of genomic position",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -8.1875,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as a function of genomic position at nucleotide",
            "probability": 0.0
        }
    ],
    "56c8f4615795f9a73e00001a_6": [
        {
            "start_logit": 9.796875,
            "end_logit": 9.765625,
            "text": "GBshape",
            "probability": 1.0
        },
        {
            "start_logit": -1.318359375,
            "end_logit": 9.765625,
            "text": "e",
            "probability": 1.4841556549072266e-05
        },
        {
            "start_logit": 9.796875,
            "end_logit": -1.5908203125,
            "text": "GBs",
            "probability": 1.1682510375976562e-05
        },
        {
            "start_logit": -5.6875,
            "end_logit": 9.765625,
            "text": "hape",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.796875,
            "end_logit": -7.25390625,
            "text": "GBshap",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.796875,
            "end_logit": -7.71484375,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as a function of genomic position at nucleotide resolution.",
            "probability": 0.0
        },
        {
            "start_logit": 9.796875,
            "end_logit": -8.0859375,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as a function of genomic position at",
            "probability": 0.0
        },
        {
            "start_logit": 9.796875,
            "end_logit": -8.09375,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as",
            "probability": 0.0
        },
        {
            "start_logit": 9.796875,
            "end_logit": -8.1015625,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as a",
            "probability": 0.0
        },
        {
            "start_logit": 9.796875,
            "end_logit": -8.1484375,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and",
            "probability": 0.0
        },
        {
            "start_logit": 9.796875,
            "end_logit": -8.15625,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in",
            "probability": 0.0
        },
        {
            "start_logit": 9.796875,
            "end_logit": -8.15625,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format,",
            "probability": 0.0
        },
        {
            "start_logit": 9.796875,
            "end_logit": -8.171875,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as a function",
            "probability": 0.0
        },
        {
            "start_logit": 9.796875,
            "end_logit": -8.1796875,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as a function of",
            "probability": 0.0
        },
        {
            "start_logit": 9.796875,
            "end_logit": -8.1875,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome brow",
            "probability": 0.0
        },
        {
            "start_logit": 9.796875,
            "end_logit": -8.1953125,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as a function of genomic position at nucleotide resolution",
            "probability": 0.0
        },
        {
            "start_logit": 9.796875,
            "end_logit": -8.203125,
            "text": "GBshape can",
            "probability": 0.0
        },
        {
            "start_logit": 9.796875,
            "end_logit": -8.203125,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format",
            "probability": 0.0
        },
        {
            "start_logit": -1.318359375,
            "end_logit": -7.71484375,
            "text": "e can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as a function of genomic position at nucleotide resolution.",
            "probability": 0.0
        },
        {
            "start_logit": -1.318359375,
            "end_logit": -8.0859375,
            "text": "e can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as a function of genomic position at",
            "probability": 0.0
        }
    ],
    "56c8f4615795f9a73e00001a_7": [
        {
            "start_logit": 9.578125,
            "end_logit": 9.8203125,
            "text": "GBshape",
            "probability": 1.0
        },
        {
            "start_logit": -0.99658203125,
            "end_logit": 9.8203125,
            "text": "e",
            "probability": 2.5272369384765625e-05
        },
        {
            "start_logit": 9.578125,
            "end_logit": -1.888671875,
            "text": "GBs",
            "probability": 8.165836334228516e-06
        },
        {
            "start_logit": -5.6640625,
            "end_logit": 9.8203125,
            "text": "hape",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.578125,
            "end_logit": -6.07421875,
            "text": "GBshap",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.578125,
            "end_logit": -6.10546875,
            "text": "GBshape; freely available at http://rohslab.cmb.usc.edu",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.37109375,
            "end_logit": 9.8203125,
            "text": "(GBshape",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.640625,
            "end_logit": 9.8203125,
            "text": ". Our Genome Browser for DNA shape annotations (GBshape",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.671875,
            "end_logit": 9.8203125,
            "text": "Our Genome Browser for DNA shape annotations (GBshape",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.578125,
            "end_logit": -6.93359375,
            "text": "GBshape; freely available at http://rohslab.cmb.us",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.578125,
            "end_logit": -7.12109375,
            "text": "GBshape; freely available at http://rohslab.cmb.usc",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.578125,
            "end_logit": -7.2421875,
            "text": "GBshape; freely available at http://rohslab",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.578125,
            "end_logit": -7.33203125,
            "text": "GBshape; freely available at http://rohslab.cmb",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.578125,
            "end_logit": -7.3515625,
            "text": "GBshape; freely available at http://rohslab.cmb.usc.edu/GBshape/",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.640625,
            "end_logit": 9.8203125,
            "text": "Genome Browser for DNA shape annotations (GBshape",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.578125,
            "end_logit": -7.41796875,
            "text": "GBshape; freely available at http://rohslab.cmb.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.578125,
            "end_logit": -7.44140625,
            "text": "GBshape;",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.578125,
            "end_logit": -7.48828125,
            "text": "GBshape; freely available at http://rohslab.cmb.usc.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.73828125,
            "end_logit": 9.8203125,
            "text": "DNA shape annotations (GBshape",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.578125,
            "end_logit": -7.6484375,
            "text": "GBshape; freely available at http://rohslab.cm",
            "probability": 0.0
        }
    ],
    "56c8f4615795f9a73e00001a_8": [
        {
            "start_logit": 9.8125,
            "end_logit": 9.84375,
            "text": "GBshape",
            "probability": 1.0
        },
        {
            "start_logit": -1.021484375,
            "end_logit": 9.84375,
            "text": "e",
            "probability": 1.9669532775878906e-05
        },
        {
            "start_logit": 9.8125,
            "end_logit": -1.494140625,
            "text": "GBs",
            "probability": 1.1920928955078125e-05
        },
        {
            "start_logit": -5.1015625,
            "end_logit": 9.84375,
            "text": "hape",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 9.8125,
            "end_logit": -6.71875,
            "text": "GBshape framework.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8125,
            "end_logit": -7.12109375,
            "text": "GBshap",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8125,
            "end_logit": -7.41796875,
            "text": "GBshape framework. GBshape",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8125,
            "end_logit": -7.43359375,
            "text": "GBshape framework. GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8125,
            "end_logit": -7.515625,
            "text": "GBshape framework. GBshape can",
            "probability": 0.0
        },
        {
            "start_logit": 9.8125,
            "end_logit": -7.59765625,
            "text": "GBshape framework. GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format,",
            "probability": 0.0
        },
        {
            "start_logit": 9.8125,
            "end_logit": -7.69140625,
            "text": "GBshape framework. GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as a",
            "probability": 0.0
        },
        {
            "start_logit": 9.8125,
            "end_logit": -7.73828125,
            "text": "GBshape framework. GBshape can be used to visualize DNA shape annotations qualitatively in a genome brow",
            "probability": 0.0
        },
        {
            "start_logit": 9.8125,
            "end_logit": -7.7421875,
            "text": "GBshape framework. GBshape can be",
            "probability": 0.0
        },
        {
            "start_logit": 9.8125,
            "end_logit": -7.75390625,
            "text": "GBshape framework. GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as",
            "probability": 0.0
        },
        {
            "start_logit": 9.8125,
            "end_logit": -7.76171875,
            "text": "GBshape framework. GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and",
            "probability": 0.0
        },
        {
            "start_logit": 9.8125,
            "end_logit": -7.76953125,
            "text": "GBshape framework. GBshape can be used to visualize DNA shape annotations qualitatively in",
            "probability": 0.0
        },
        {
            "start_logit": 9.8125,
            "end_logit": -7.79296875,
            "text": "GBshape framework. GBshape can be used to visualize DNA shape annotations qualitatively in a",
            "probability": 0.0
        },
        {
            "start_logit": -7.8671875,
            "end_logit": 9.84375,
            "text": "the GBshape",
            "probability": 0.0
        },
        {
            "start_logit": -7.90234375,
            "end_logit": 9.84375,
            "text": "genomes can easily be added using the GBshape",
            "probability": 0.0
        },
        {
            "start_logit": -7.96484375,
            "end_logit": 9.84375,
            "text": "Additional genomes can easily be added using the GBshape",
            "probability": 0.0
        }
    ],
    "56c8f4615795f9a73e00001a_9": [
        {
            "start_logit": 9.7109375,
            "end_logit": 9.8046875,
            "text": "GBshape",
            "probability": 1.0
        },
        {
            "start_logit": -1.154296875,
            "end_logit": 9.8046875,
            "text": "e",
            "probability": 1.9073486328125e-05
        },
        {
            "start_logit": 9.7109375,
            "end_logit": -1.72265625,
            "text": "GBs",
            "probability": 9.834766387939453e-06
        },
        {
            "start_logit": -5.6171875,
            "end_logit": 9.8046875,
            "text": "hape",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.7109375,
            "end_logit": -6.671875,
            "text": "GBshape; freely available at http://rohslab.cmb.usc.edu",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.7109375,
            "end_logit": -6.7421875,
            "text": "GBshap",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.21484375,
            "end_logit": 9.8046875,
            "text": "(GBshape",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.25390625,
            "end_logit": 9.8046875,
            "text": "Our Genome Browser for DNA shape annotations (GBshape",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.7109375,
            "end_logit": -7.23046875,
            "text": "GBshape; freely available at http://rohslab.cmb.us",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.7109375,
            "end_logit": -7.234375,
            "text": "GBshape; freely available at http://rohslab.cmb.usc.edu/GBshape/",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.7109375,
            "end_logit": -7.25390625,
            "text": "GBshape; freely available at http://rohslab",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.4140625,
            "end_logit": 9.8046875,
            "text": "Genome Browser for DNA shape annotations (GBshape",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.7109375,
            "end_logit": -7.421875,
            "text": "GBshape; freely available at http://rohslab.cmb.usc",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.7109375,
            "end_logit": -7.5078125,
            "text": "GBshape; freely available at http://rohslab.cmb.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.7109375,
            "end_logit": -7.5078125,
            "text": "GBshape; freely available at http://rohslab.cmb.usc.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.7109375,
            "end_logit": -7.53125,
            "text": "GBshape; freely available at http://rohslab.cmb",
            "probability": 0.0
        },
        {
            "start_logit": 9.7109375,
            "end_logit": -7.57421875,
            "text": "GBshape; freely available at http://rohslab.cmb.usc.edu/",
            "probability": 0.0
        },
        {
            "start_logit": 9.7109375,
            "end_logit": -7.62890625,
            "text": "GBshape; freely available at http://rohslab.",
            "probability": 0.0
        },
        {
            "start_logit": 9.7109375,
            "end_logit": -7.65234375,
            "text": "GBshape; freely available at http://rohslab.cm",
            "probability": 0.0
        },
        {
            "start_logit": 9.7109375,
            "end_logit": -7.6796875,
            "text": "GBshape; freely available at http:/",
            "probability": 0.0
        }
    ],
    "56c8f4615795f9a73e00001a_10": [
        {
            "start_logit": 9.8046875,
            "end_logit": 9.734375,
            "text": "GBshape",
            "probability": 1.0
        },
        {
            "start_logit": -1.408203125,
            "end_logit": 9.734375,
            "text": "e",
            "probability": 1.3649463653564453e-05
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -1.564453125,
            "text": "GBs",
            "probability": 1.2516975402832031e-05
        },
        {
            "start_logit": -5.90234375,
            "end_logit": 9.734375,
            "text": "hape",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -7.31640625,
            "text": "GBshap",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -7.7578125,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as a function of genomic position at nucleotide resolution.",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -8.0390625,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as a function of genomic position at",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -8.0546875,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as a",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -8.0625,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -8.09375,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format,",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -8.09375,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -8.109375,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -8.125,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as a function",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -8.1328125,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as a function of genomic position at nucleotide resolution",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -8.1484375,
            "text": "GBshape can",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -8.1484375,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome brow",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -8.15625,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as a function of",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -8.15625,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -8.171875,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as a function of genomic position",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -8.1875,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as a function of genomic position at nucleotide",
            "probability": 0.0
        }
    ],
    "56c8f4615795f9a73e00001a_11": [
        {
            "start_logit": 9.5234375,
            "end_logit": 9.7734375,
            "text": "GBshape",
            "probability": 1.0
        },
        {
            "start_logit": -1.2578125,
            "end_logit": 9.7734375,
            "text": "e",
            "probability": 2.0802021026611328e-05
        },
        {
            "start_logit": 9.5234375,
            "end_logit": -2.0859375,
            "text": "GBs",
            "probability": 7.092952728271484e-06
        },
        {
            "start_logit": -5.72265625,
            "end_logit": 9.7734375,
            "text": "hape",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.5234375,
            "end_logit": -6.54296875,
            "text": "GBshape; freely available at http://rohslab.cmb.usc.edu",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.21875,
            "end_logit": 9.7734375,
            "text": "Our Genome Browser for DNA shape annotations (GBshape",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.5234375,
            "end_logit": -6.9765625,
            "text": "GBshape; freely available at http://rohslab",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.3828125,
            "end_logit": 9.7734375,
            "text": "(GBshape",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.5234375,
            "end_logit": -7.1796875,
            "text": "GBshape; freely available at http://rohslab.cmb.us",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.5234375,
            "end_logit": -7.18359375,
            "text": "GBshape; freely available at http://rohslab.cmb.usc.edu/GBshape/",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.46484375,
            "end_logit": 9.7734375,
            "text": "Genome Browser for DNA shape annotations (GBshape",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.5234375,
            "end_logit": -7.328125,
            "text": "GBshap",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.5234375,
            "end_logit": -7.34375,
            "text": "GBshape; freely available at http://rohslab.cmb.usc",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.5234375,
            "end_logit": -7.453125,
            "text": "GBshape; freely available at http://rohslab.cmb.usc.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.5234375,
            "end_logit": -7.453125,
            "text": "GBshape; freely available at http://rohslab.cmb",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.5234375,
            "end_logit": -7.48828125,
            "text": "GBshape; freely available at http://rohslab.cmb.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.5234375,
            "end_logit": -7.5703125,
            "text": "GBshape; freely available at http://rohslab.",
            "probability": 0.0
        },
        {
            "start_logit": 9.5234375,
            "end_logit": -7.6015625,
            "text": "GBshape; freely available at http://rohslab.cmb.usc.edu/",
            "probability": 0.0
        },
        {
            "start_logit": 9.5234375,
            "end_logit": -7.60546875,
            "text": "GBshape;",
            "probability": 0.0
        },
        {
            "start_logit": -7.86328125,
            "end_logit": 9.7734375,
            "text": "DNA shape annotations (GBshape",
            "probability": 0.0
        }
    ],
    "5e36cf8eb5b409ea53000007_1": [
        {
            "start_logit": 8.3359375,
            "end_logit": 5.5859375,
            "text": "melanocyte",
            "probability": 1.0
        },
        {
            "start_logit": 8.3359375,
            "end_logit": -3.072265625,
            "text": "melan",
            "probability": 0.00017404556274414062
        },
        {
            "start_logit": 8.3359375,
            "end_logit": -5.84765625,
            "text": "melanocyte umbrella above the kidney marrow protects HSPCs against ultraviolet light in zebrafish.",
            "probability": 1.0788440704345703e-05
        },
        {
            "start_logit": 8.3359375,
            "end_logit": -6.8828125,
            "text": "melanocyte umbrella above the kidney marrow protects HSPCs",
            "probability": 3.874301910400391e-06
        },
        {
            "start_logit": 8.3359375,
            "end_logit": -6.93359375,
            "text": "melanocyte umbrella above the kidney marrow",
            "probability": 3.6954879760742188e-06
        },
        {
            "start_logit": 8.3359375,
            "end_logit": -7.05078125,
            "text": "melanocyte umbrella above the kidney marrow protects HSPCs against ultraviolet light in zebrafish. Because mutants that lack melanocytes have normal steady-state haematopoiesis under standard laboratory conditions, we hypothesized that melanocytes",
            "probability": 3.2186508178710938e-06
        },
        {
            "start_logit": -5.9453125,
            "end_logit": 5.5859375,
            "text": ". Here we show that a melanocyte",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -6.03125,
            "end_logit": 5.5859375,
            "text": "ocyte",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -5.9453125,
            "end_logit": -3.072265625,
            "text": ". Here we show that a melan",
            "probability": 0.0
        },
        {
            "start_logit": -5.94140625,
            "end_logit": -5.84375,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -5.94140625,
            "end_logit": -5.84765625,
            "text": ". During the transition from an aquatic to a terrestrial environment, HSPCs relocated into the bone marrow, which is protected from ultraviolet light by the cortical bone around the marrow.",
            "probability": 0.0
        },
        {
            "start_logit": -5.9453125,
            "end_logit": -5.84375,
            "text": ". The umbrella of melanocytes associated with the haematopoietic niche is highly evolutionarily conserved in aquatic animals, including the sea lamprey, a basal vertebrate.",
            "probability": 0.0
        },
        {
            "start_logit": -5.16796875,
            "end_logit": -6.625,
            "text": "melanocytes",
            "probability": 0.0
        },
        {
            "start_logit": -5.9453125,
            "end_logit": -5.84765625,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -5.9453125,
            "end_logit": -5.84765625,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -5.9453125,
            "end_logit": -5.84765625,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -5.9453125,
            "end_logit": -5.84765625,
            "text": ". Because mutants that lack melanocytes have normal steady-state haematopoiesis under standard laboratory conditions, we hypothesized that melanocytes above the stem cell niche protect HSPCs against ultraviolet-light-induced DNA damage.",
            "probability": 0.0
        },
        {
            "start_logit": -5.9453125,
            "end_logit": -5.84765625,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -5.9453125,
            "end_logit": -5.84765625,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -5.9453125,
            "end_logit": -5.84765625,
            "text": ".",
            "probability": 0.0
        }
    ],
    "54ff45966ad7dcbc12000010_1": [
        {
            "start_logit": 2.099609375,
            "end_logit": 3.056640625,
            "text": "SPINK5",
            "probability": 0.984375
        },
        {
            "start_logit": -2.603515625,
            "end_logit": 3.056640625,
            "text": "Netherton syndrome (NS) is a serious inherited skin disorder caused by mutations in the gene SPINK5",
            "probability": 0.0089263916015625
        },
        {
            "start_logit": 2.099609375,
            "end_logit": -3.2578125,
            "text": "SPINK5 (serine protease inhibitor Kazal type 5) which encodes for a serine protease inhibitor LEKTI",
            "probability": 0.0017862319946289062
        },
        {
            "start_logit": 2.099609375,
            "end_logit": -3.65625,
            "text": "SPINK5 (serine protease inhibitor Kazal type 5) which",
            "probability": 0.0011987686157226562
        },
        {
            "start_logit": -5.0,
            "end_logit": 3.056640625,
            "text": "gene SPINK5",
            "probability": 0.0008111000061035156
        },
        {
            "start_logit": 2.099609375,
            "end_logit": -4.26171875,
            "text": "SPINK5 (serine protease inhibitor Kazal type 5) which encodes for a serine protease inhibitor LEKTI (lymphoepithelial Kazal type-related inhibitor)",
            "probability": 0.0006518363952636719
        },
        {
            "start_logit": 2.099609375,
            "end_logit": -5.0546875,
            "text": "SPINK5 (serine protease inhibitor Kazal type 5) which encodes for a serine protease inhibitor LEKTI (lymphoepithelial Kazal type-related inhibitor",
            "probability": 0.0002961158752441406
        },
        {
            "start_logit": 2.099609375,
            "end_logit": -5.171875,
            "text": "SPINK5 (serine protease inhibitor Kazal type 5)",
            "probability": 0.00026345252990722656
        },
        {
            "start_logit": -6.21875,
            "end_logit": 3.056640625,
            "text": "mutations in the gene SPINK5",
            "probability": 0.00023984909057617188
        },
        {
            "start_logit": -6.421875,
            "end_logit": 3.056640625,
            "text": "by mutations in the gene SPINK5",
            "probability": 0.00019562244415283203
        },
        {
            "start_logit": -7.0234375,
            "end_logit": 3.056640625,
            "text": "K5",
            "probability": 0.00010722875595092773
        },
        {
            "start_logit": -0.9150390625,
            "end_logit": -3.2578125,
            "text": "a serine protease inhibitor LEKTI",
            "probability": 8.749961853027344e-05
        },
        {
            "start_logit": -7.26171875,
            "end_logit": 3.056640625,
            "text": "the gene SPINK5",
            "probability": 8.481740951538086e-05
        },
        {
            "start_logit": -7.28125,
            "end_logit": 3.056640625,
            "text": "disorder caused by mutations in the gene SPINK5",
            "probability": 8.285045623779297e-05
        },
        {
            "start_logit": -7.328125,
            "end_logit": 3.056640625,
            "text": "5",
            "probability": 7.903575897216797e-05
        },
        {
            "start_logit": 2.099609375,
            "end_logit": -6.48828125,
            "text": "SPINK5 (serine protease inhibitor Kazal type 5) which encodes for a serine protease",
            "probability": 7.033348083496094e-05
        },
        {
            "start_logit": 2.099609375,
            "end_logit": -6.62890625,
            "text": "SPINK5 (serine protease inhibitor Kazal type 5) which encodes for a serine protease inhibitor",
            "probability": 6.109476089477539e-05
        },
        {
            "start_logit": 2.099609375,
            "end_logit": -6.67578125,
            "text": "SPINK5 (serine protease inhibitor Kazal type 5) which encodes for a serine protease inhibitor LEKT",
            "probability": 5.829334259033203e-05
        },
        {
            "start_logit": 2.099609375,
            "end_logit": -6.85546875,
            "text": "SPINK",
            "probability": 4.869699478149414e-05
        },
        {
            "start_logit": 2.099609375,
            "end_logit": -7.04296875,
            "text": "SPINK5 (serine protease inhibitor Kazal type 5",
            "probability": 4.035234451293945e-05
        }
    ],
    "54ff45966ad7dcbc12000010_2": [
        {
            "start_logit": 4.0546875,
            "end_logit": 3.349609375,
            "text": "serine protease inhibitor Kazal type 5 (SPINK5",
            "probability": 0.93115234375
        },
        {
            "start_logit": 4.0546875,
            "end_logit": 0.53125,
            "text": "serine protease inhibitor Kazal type 5 (SPINK5)",
            "probability": 0.05548095703125
        },
        {
            "start_logit": 4.0546875,
            "end_logit": -1.5390625,
            "text": "serine protease inhibitor Kazal type 5 (SPINK5) gene leading to lymphoepithelial Kazal-type-related inhibitor (LEKTI) deficiency cause NS.",
            "probability": 0.00699615478515625
        },
        {
            "start_logit": -1.5576171875,
            "end_logit": 3.349609375,
            "text": "SPINK5",
            "probability": 0.0033969879150390625
        },
        {
            "start_logit": 4.0546875,
            "end_logit": -3.41796875,
            "text": "serine protease inhibitor Kazal type 5 (SPINK5) gene leading to lymphoepithelial Kazal-type-related inhibitor (LEKTI",
            "probability": 0.0010690689086914062
        },
        {
            "start_logit": -2.873046875,
            "end_logit": 3.349609375,
            "text": "(SPINK5",
            "probability": 0.0009107589721679688
        },
        {
            "start_logit": -1.5576171875,
            "end_logit": 0.53125,
            "text": "SPINK5)",
            "probability": 0.00020313262939453125
        },
        {
            "start_logit": 4.0546875,
            "end_logit": -5.3515625,
            "text": "serine protease inhibitor Kazal type 5 (SPINK",
            "probability": 0.00015461444854736328
        },
        {
            "start_logit": -4.90234375,
            "end_logit": 3.349609375,
            "text": "Mutations in the serine protease inhibitor Kazal type 5 (SPINK5",
            "probability": 0.00011938810348510742
        },
        {
            "start_logit": 4.0546875,
            "end_logit": -6.0546875,
            "text": "serine protease inhibitor",
            "probability": 7.653236389160156e-05
        },
        {
            "start_logit": 4.0546875,
            "end_logit": -6.25,
            "text": "serine protease",
            "probability": 6.300210952758789e-05
        },
        {
            "start_logit": 4.0546875,
            "end_logit": -6.39453125,
            "text": "serine protease inhibitor Kazal type 5 (SPINK5) gene leading to lymphoepithelial Kazal-type-related inhibitor (LEKTI)",
            "probability": 5.424022674560547e-05
        },
        {
            "start_logit": -2.873046875,
            "end_logit": 0.53125,
            "text": "(SPINK5)",
            "probability": 5.424022674560547e-05
        },
        {
            "start_logit": 4.0546875,
            "end_logit": -6.46875,
            "text": "serine",
            "probability": 5.060434341430664e-05
        },
        {
            "start_logit": 4.0546875,
            "end_logit": -6.83203125,
            "text": "serine protease inhibitor Kazal type 5",
            "probability": 3.49879264831543e-05
        },
        {
            "start_logit": 4.0546875,
            "end_logit": -6.87109375,
            "text": "serine protease inhibitor Kazal type 5 (SPINK5) gene",
            "probability": 3.3974647521972656e-05
        },
        {
            "start_logit": -1.5576171875,
            "end_logit": -1.5390625,
            "text": "SPINK5) gene leading to lymphoepithelial Kazal-type-related inhibitor (LEKTI) deficiency cause NS.",
            "probability": 2.562999725341797e-05
        },
        {
            "start_logit": -6.62890625,
            "end_logit": 3.349609375,
            "text": "the serine protease inhibitor Kazal type 5 (SPINK5",
            "probability": 2.1278858184814453e-05
        },
        {
            "start_logit": -6.66015625,
            "end_logit": 3.349609375,
            "text": "inhibitor Kazal type 5 (SPINK5",
            "probability": 2.0563602447509766e-05
        },
        {
            "start_logit": 4.0546875,
            "end_logit": -7.45703125,
            "text": "serine protease inhibitor Kazal type 5 (SPINK5) gene leading to lymphoepithelial Kazal-type-related inhibitor (LEKT",
            "probability": 1.8775463104248047e-05
        }
    ],
    "54ff45966ad7dcbc12000010_3": [
        {
            "start_logit": 9.328125,
            "end_logit": 9.078125,
            "text": "LEKTI",
            "probability": 0.68115234375
        },
        {
            "start_logit": 7.8515625,
            "end_logit": 9.1171875,
            "text": "SPINK5",
            "probability": 0.161865234375
        },
        {
            "start_logit": 7.8515625,
            "end_logit": 9.078125,
            "text": "SPINK5 gene and to the consequent lack of expression of its encoded protein LEKTI",
            "probability": 0.1568603515625
        },
        {
            "start_logit": 9.328125,
            "end_logit": -2.5234375,
            "text": "LE",
            "probability": 6.258487701416016e-06
        },
        {
            "start_logit": -2.681640625,
            "end_logit": 9.078125,
            "text": "protein LEKTI",
            "probability": 4.112720489501953e-06
        },
        {
            "start_logit": -2.736328125,
            "end_logit": 9.1171875,
            "text": "5",
            "probability": 4.112720489501953e-06
        },
        {
            "start_logit": -2.736328125,
            "end_logit": 9.078125,
            "text": "5 gene and to the consequent lack of expression of its encoded protein LEKTI",
            "probability": 3.933906555175781e-06
        },
        {
            "start_logit": -2.8515625,
            "end_logit": 9.078125,
            "text": "I",
            "probability": 3.516674041748047e-06
        },
        {
            "start_logit": 7.8515625,
            "end_logit": -2.5234375,
            "text": "SPINK5 gene and to the consequent lack of expression of its encoded protein LE",
            "probability": 1.430511474609375e-06
        },
        {
            "start_logit": 7.8515625,
            "end_logit": -4.40234375,
            "text": "SPIN",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.328125,
            "end_logit": -6.86328125,
            "text": "LEKTI in the skin and all stratified epithelial tissues.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.68359375,
            "end_logit": 9.078125,
            "text": "KTI",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.140625,
            "end_logit": 9.1171875,
            "text": "K5",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.140625,
            "end_logit": 9.078125,
            "text": "K5 gene and to the consequent lack of expression of its encoded protein LEKTI",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.328125,
            "end_logit": -7.52734375,
            "text": "LEKT",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.8515625,
            "end_logit": -6.1875,
            "text": "SPINK5 gene and to the consequent lack of expression of its encoded protein",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.328125,
            "end_logit": -7.67578125,
            "text": "LEKTI in",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.71484375,
            "end_logit": 9.1171875,
            "text": "the SPINK5",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.71484375,
            "end_logit": 9.078125,
            "text": "the SPINK5 gene and to the consequent lack of expression of its encoded protein LEKTI",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.796875,
            "end_logit": 9.1171875,
            "text": "NS is due to loss-of-function mutations in the SPINK5",
            "probability": 5.960464477539063e-08
        }
    ],
    "54ff45966ad7dcbc12000010_4": [
        {
            "start_logit": 9.6875,
            "end_logit": 9.6953125,
            "text": "LEKTI",
            "probability": 1.0
        },
        {
            "start_logit": -1.365234375,
            "end_logit": 9.6953125,
            "text": "I",
            "probability": 1.5914440155029297e-05
        },
        {
            "start_logit": 9.6875,
            "end_logit": -1.80078125,
            "text": "LE",
            "probability": 1.0311603546142578e-05
        },
        {
            "start_logit": -5.19921875,
            "end_logit": 9.6953125,
            "text": "Lympho-epithelial Kazal-type-related inhibitor (LEKTI",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -5.234375,
            "end_logit": 9.6953125,
            "text": "(LEKTI",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -5.265625,
            "end_logit": 9.6953125,
            "text": "KTI",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.6875,
            "end_logit": -5.640625,
            "text": "LEKT",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.6875,
            "end_logit": -5.9296875,
            "text": "LEKTI)",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.6875,
            "end_logit": -6.375,
            "text": "LEKTI) is the defective protein of the ichthyosiform condition Netherton syndrome (NS).",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.6875,
            "end_logit": -7.61328125,
            "text": "LEKTI) is",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.7421875,
            "end_logit": 9.6953125,
            "text": "-epithelial Kazal-type-related inhibitor (LEKTI",
            "probability": 0.0
        },
        {
            "start_logit": -7.87109375,
            "end_logit": 9.6953125,
            "text": "epithelial Kazal-type-related inhibitor (LEKTI",
            "probability": 0.0
        },
        {
            "start_logit": -7.9765625,
            "end_logit": 9.6953125,
            "text": "inhibitor (LEKTI",
            "probability": 0.0
        },
        {
            "start_logit": -8.015625,
            "end_logit": 9.6953125,
            "text": "related inhibitor (LEKTI",
            "probability": 0.0
        },
        {
            "start_logit": 9.6875,
            "end_logit": -8.0546875,
            "text": "LEKTI) is the defective protein of",
            "probability": 0.0
        },
        {
            "start_logit": -5.19921875,
            "end_logit": -1.80078125,
            "text": "Lympho-epithelial Kazal-type-related inhibitor (LE",
            "probability": 0.0
        },
        {
            "start_logit": -5.234375,
            "end_logit": -1.80078125,
            "text": "(LE",
            "probability": 0.0
        },
        {
            "start_logit": -1.365234375,
            "end_logit": -5.9296875,
            "text": "I)",
            "probability": 0.0
        },
        {
            "start_logit": -1.365234375,
            "end_logit": -6.375,
            "text": "I) is the defective protein of the ichthyosiform condition Netherton syndrome (NS).",
            "probability": 0.0
        },
        {
            "start_logit": -1.365234375,
            "end_logit": -7.61328125,
            "text": "I) is",
            "probability": 0.0
        }
    ],
    "54ff45966ad7dcbc12000010_5": [
        {
            "start_logit": 9.828125,
            "end_logit": 9.703125,
            "text": "LEKTI",
            "probability": 1.0
        },
        {
            "start_logit": 9.828125,
            "end_logit": -1.5400390625,
            "text": "LE",
            "probability": 1.3113021850585938e-05
        },
        {
            "start_logit": -1.4716796875,
            "end_logit": 9.703125,
            "text": "I",
            "probability": 1.239776611328125e-05
        },
        {
            "start_logit": -6.0,
            "end_logit": 9.703125,
            "text": "KTI",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.203125,
            "end_logit": 9.703125,
            "text": "serine protease inhibitor LEKTI",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.828125,
            "end_logit": -7.09765625,
            "text": "LEKTI is the etiological origin of Netherton syndrome, which causes detachment of the stratum corneum and chronic inflammation.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.0234375,
            "end_logit": 9.703125,
            "text": "inhibitor LEKTI",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.828125,
            "end_logit": -7.51171875,
            "text": "LEKT",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6328125,
            "end_logit": 9.703125,
            "text": "protease inhibitor LEKTI",
            "probability": 0.0
        },
        {
            "start_logit": -7.71875,
            "end_logit": 9.703125,
            "text": "the serine protease inhibitor LEKTI",
            "probability": 0.0
        },
        {
            "start_logit": -7.78125,
            "end_logit": 9.703125,
            "text": "Deficiency in the serine protease inhibitor LEKTI",
            "probability": 0.0
        },
        {
            "start_logit": 9.828125,
            "end_logit": -8.0625,
            "text": "LEKTI is the etiological origin of Netherton syndrome, which causes detachment of the stratum corneum",
            "probability": 0.0
        },
        {
            "start_logit": -7.97265625,
            "end_logit": 9.703125,
            "text": "in the serine protease inhibitor LEKTI",
            "probability": 0.0
        },
        {
            "start_logit": 9.828125,
            "end_logit": -8.125,
            "text": "LEKTI is the etiological origin of Netherton syndrome, which",
            "probability": 0.0
        },
        {
            "start_logit": 9.828125,
            "end_logit": -8.125,
            "text": "LEKTI is",
            "probability": 0.0
        },
        {
            "start_logit": 9.828125,
            "end_logit": -8.1484375,
            "text": "LEKTI is the etiological origin of Netherton syndrome, which causes detachment of the stratum corneum and",
            "probability": 0.0
        },
        {
            "start_logit": 9.828125,
            "end_logit": -8.1484375,
            "text": "LEKTI is the etiological origin of Netherton syndrome,",
            "probability": 0.0
        },
        {
            "start_logit": 9.828125,
            "end_logit": -8.15625,
            "text": "LEKTI is the etiological origin of Netherton syndrome, which causes detachment of the",
            "probability": 0.0
        },
        {
            "start_logit": -6.203125,
            "end_logit": -1.5400390625,
            "text": "serine protease inhibitor LE",
            "probability": 0.0
        },
        {
            "start_logit": -7.0234375,
            "end_logit": -1.5400390625,
            "text": "inhibitor LE",
            "probability": 0.0
        }
    ],
    "53175e9fb166e2b80600000a_1": [
        {
            "start_logit": 2.9609375,
            "end_logit": 6.55859375,
            "text": "Recent functional genetic studies have pointed out that LKB1 plays a physiological role in controlling the Wnt-signaling pathway",
            "probability": 0.91162109375
        },
        {
            "start_logit": 0.1937255859375,
            "end_logit": 6.55859375,
            "text": "controlling the Wnt-signaling pathway",
            "probability": 0.0576171875
        },
        {
            "start_logit": -1.03125,
            "end_logit": 6.55859375,
            "text": "Wnt-signaling pathway",
            "probability": 0.0168914794921875
        },
        {
            "start_logit": 0.1937255859375,
            "end_logit": 4.1875,
            "text": "controlling the Wnt-signaling pathway and activation of the pathway as a consequence of LKB1 haploinsufficiency might be responsible for the development of harmatomatous polyps.",
            "probability": 0.005382537841796875
        },
        {
            "start_logit": -0.08203125,
            "end_logit": 4.1875,
            "text": ".",
            "probability": 0.004077911376953125
        },
        {
            "start_logit": -1.03125,
            "end_logit": 4.1875,
            "text": "Wnt-signaling pathway and activation of the pathway as a consequence of LKB1 haploinsufficiency might be responsible for the development of harmatomatous polyps.",
            "probability": 0.0015783309936523438
        },
        {
            "start_logit": -3.44921875,
            "end_logit": 6.55859375,
            "text": "the Wnt-signaling pathway",
            "probability": 0.0015048980712890625
        },
        {
            "start_logit": 2.9609375,
            "end_logit": -1.3486328125,
            "text": "Recent functional genetic studies have pointed out that LKB1 plays a physiological role in controlling the Wnt-signaling pathway and",
            "probability": 0.0003371238708496094
        },
        {
            "start_logit": -5.02734375,
            "end_logit": 6.55859375,
            "text": "pathway",
            "probability": 0.00031065940856933594
        },
        {
            "start_logit": -5.5859375,
            "end_logit": 6.55859375,
            "text": "LKB1 plays a physiological role in controlling the Wnt-signaling pathway",
            "probability": 0.00017702579498291016
        },
        {
            "start_logit": -3.44921875,
            "end_logit": 4.1875,
            "text": "the Wnt-signaling pathway and activation of the pathway as a consequence of LKB1 haploinsufficiency might be responsible for the development of harmatomatous polyps.",
            "probability": 0.0001399517059326172
        },
        {
            "start_logit": -6.10546875,
            "end_logit": 6.55859375,
            "text": "in controlling the Wnt-signaling pathway",
            "probability": 0.00010573863983154297
        },
        {
            "start_logit": -6.34375,
            "end_logit": 6.55859375,
            "text": "physiological role in controlling the Wnt-signaling pathway",
            "probability": 8.362531661987305e-05
        },
        {
            "start_logit": -6.59375,
            "end_logit": 6.55859375,
            "text": "studies have pointed out that LKB1 plays a physiological role in controlling the Wnt-signaling pathway",
            "probability": 6.508827209472656e-05
        },
        {
            "start_logit": -6.68359375,
            "end_logit": 6.55859375,
            "text": "functional genetic studies have pointed out that LKB1 plays a physiological role in controlling the Wnt-signaling pathway",
            "probability": 5.930662155151367e-05
        },
        {
            "start_logit": -6.75,
            "end_logit": 6.55859375,
            "text": "that LKB1 plays a physiological role in controlling the Wnt-signaling pathway",
            "probability": 5.5730342864990234e-05
        },
        {
            "start_logit": -6.80078125,
            "end_logit": 6.55859375,
            "text": "signaling pathway",
            "probability": 5.269050598144531e-05
        },
        {
            "start_logit": -6.81640625,
            "end_logit": 6.55859375,
            "text": "-signaling pathway",
            "probability": 5.1915645599365234e-05
        },
        {
            "start_logit": -6.91796875,
            "end_logit": 6.55859375,
            "text": "role in controlling the Wnt-signaling pathway",
            "probability": 4.690885543823242e-05
        },
        {
            "start_logit": -6.96875,
            "end_logit": 6.55859375,
            "text": "genetic studies have pointed out that LKB1 plays a physiological role in controlling the Wnt-signaling pathway",
            "probability": 4.476308822631836e-05
        }
    ],
    "5a9d31711d1251d03b00001c_1": [
        {
            "start_logit": 9.8203125,
            "end_logit": 9.609375,
            "text": "100 nm",
            "probability": 1.0
        },
        {
            "start_logit": 9.8203125,
            "end_logit": -1.37890625,
            "text": "100",
            "probability": 1.6689300537109375e-05
        },
        {
            "start_logit": -1.6357421875,
            "end_logit": 9.609375,
            "text": "nm",
            "probability": 1.043081283569336e-05
        },
        {
            "start_logit": 9.8203125,
            "end_logit": -5.78125,
            "text": "100 nm.",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.46875,
            "end_logit": 9.609375,
            "text": "diamtere of 100 nm",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.234375,
            "end_logit": 9.609375,
            "text": "maximum diamtere of 100 nm",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.625,
            "end_logit": 9.609375,
            "text": "of 100 nm",
            "probability": 0.0
        },
        {
            "start_logit": -7.66015625,
            "end_logit": 9.609375,
            "text": "their maximum diamtere of 100 nm",
            "probability": 0.0
        },
        {
            "start_logit": -7.7265625,
            "end_logit": 9.609375,
            "text": "they attained their maximum diamtere of 100 nm",
            "probability": 0.0
        },
        {
            "start_logit": -7.91015625,
            "end_logit": 9.609375,
            "text": "tere of 100 nm",
            "probability": 0.0
        },
        {
            "start_logit": -7.98046875,
            "end_logit": 9.609375,
            "text": "attained their maximum diamtere of 100 nm",
            "probability": 0.0
        },
        {
            "start_logit": -8.0546875,
            "end_logit": 9.609375,
            "text": "vesicles increased until they attained their maximum diamtere of 100 nm",
            "probability": 0.0
        },
        {
            "start_logit": -8.078125,
            "end_logit": 9.609375,
            "text": "number remained relatively constant while the size of the vesicles increased until they attained their maximum diamtere of 100 nm",
            "probability": 0.0
        },
        {
            "start_logit": -8.0859375,
            "end_logit": 9.609375,
            "text": "the vesicles increased until they attained their maximum diamtere of 100 nm",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": 9.609375,
            "text": "e of 100 nm",
            "probability": 0.0
        },
        {
            "start_logit": -8.21875,
            "end_logit": 9.609375,
            "text": "until they attained their maximum diamtere of 100 nm",
            "probability": 0.0
        },
        {
            "start_logit": -1.6357421875,
            "end_logit": -5.78125,
            "text": "nm.",
            "probability": 0.0
        },
        {
            "start_logit": -6.46875,
            "end_logit": -1.37890625,
            "text": "diamtere of 100",
            "probability": 0.0
        },
        {
            "start_logit": -7.234375,
            "end_logit": -1.37890625,
            "text": "maximum diamtere of 100",
            "probability": 0.0
        },
        {
            "start_logit": -7.625,
            "end_logit": -1.37890625,
            "text": "of 100",
            "probability": 0.0
        }
    ],
    "5a7346662dc08e987e00001a_1": [
        {
            "start_logit": 3.619140625,
            "end_logit": 7.28125,
            "text": "drug abuse",
            "probability": 0.998046875
        },
        {
            "start_logit": -3.6484375,
            "end_logit": 7.28125,
            "text": "intravenous drug abuse",
            "probability": 0.0006976127624511719
        },
        {
            "start_logit": -4.88671875,
            "end_logit": 7.28125,
            "text": "abuse",
            "probability": 0.00020313262939453125
        },
        {
            "start_logit": -4.890625,
            "end_logit": 7.28125,
            "text": "Puffy hand syndrome is an unrecognized complication of intravenous drug abuse",
            "probability": 0.0002015829086303711
        },
        {
            "start_logit": -4.9140625,
            "end_logit": 7.28125,
            "text": "of intravenous drug abuse",
            "probability": 0.00019681453704833984
        },
        {
            "start_logit": 3.619140625,
            "end_logit": -2.123046875,
            "text": "drug abuse.",
            "probability": 8.20159912109375e-05
        },
        {
            "start_logit": -6.15625,
            "end_logit": 7.28125,
            "text": "complication of intravenous drug abuse",
            "probability": 5.6803226470947266e-05
        },
        {
            "start_logit": -6.953125,
            "end_logit": 7.28125,
            "text": "unrecognized complication of intravenous drug abuse",
            "probability": 2.562999725341797e-05
        },
        {
            "start_logit": -7.28515625,
            "end_logit": 7.28125,
            "text": "an unrecognized complication of intravenous drug abuse",
            "probability": 1.8298625946044922e-05
        },
        {
            "start_logit": -7.625,
            "end_logit": 7.28125,
            "text": "y hand syndrome is an unrecognized complication of intravenous drug abuse",
            "probability": 1.3113021850585938e-05
        },
        {
            "start_logit": -7.63671875,
            "end_logit": 7.28125,
            "text": "hand syndrome is an unrecognized complication of intravenous drug abuse",
            "probability": 1.2993812561035156e-05
        },
        {
            "start_logit": -7.72265625,
            "end_logit": 7.28125,
            "text": "syndrome is an unrecognized complication of intravenous drug abuse",
            "probability": 1.1861324310302734e-05
        },
        {
            "start_logit": -7.78125,
            "end_logit": 7.28125,
            "text": "is an unrecognized complication of intravenous drug abuse",
            "probability": 1.1205673217773438e-05
        },
        {
            "start_logit": 3.619140625,
            "end_logit": -6.84375,
            "text": "drug",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -3.6484375,
            "end_logit": -2.123046875,
            "text": "intravenous drug abuse.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -3.974609375,
            "end_logit": -2.123046875,
            "text": ".",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -4.88671875,
            "end_logit": -2.123046875,
            "text": "abuse.",
            "probability": 0.0
        },
        {
            "start_logit": -4.890625,
            "end_logit": -2.123046875,
            "text": "Puffy hand syndrome is an unrecognized complication of intravenous drug abuse.",
            "probability": 0.0
        },
        {
            "start_logit": -4.9140625,
            "end_logit": -2.123046875,
            "text": "of intravenous drug abuse.",
            "probability": 0.0
        },
        {
            "start_logit": -6.15625,
            "end_logit": -2.123046875,
            "text": "complication of intravenous drug abuse.",
            "probability": 0.0
        }
    ],
    "5a7346662dc08e987e00001a_2": [
        {
            "start_logit": 4.484375,
            "end_logit": 8.7265625,
            "text": "drug abuse",
            "probability": 0.9990234375
        },
        {
            "start_logit": -3.181640625,
            "end_logit": 8.7265625,
            "text": "abuse",
            "probability": 0.00046896934509277344
        },
        {
            "start_logit": -4.86328125,
            "end_logit": 8.7265625,
            "text": "intravenous drug abuse",
            "probability": 8.744001388549805e-05
        },
        {
            "start_logit": -5.703125,
            "end_logit": 8.7265625,
            "text": "complication of intravenous drug abuse",
            "probability": 3.7550926208496094e-05
        },
        {
            "start_logit": -5.8828125,
            "end_logit": 8.7265625,
            "text": "of intravenous drug abuse",
            "probability": 3.141164779663086e-05
        },
        {
            "start_logit": -7.49609375,
            "end_logit": 8.7265625,
            "text": "Puffy hand syndrome is a complication of intravenous drug abuse",
            "probability": 6.258487701416016e-06
        },
        {
            "start_logit": -7.859375,
            "end_logit": 8.7265625,
            "text": "BACKGROUND: Puffy hand syndrome is a complication of intravenous drug abuse",
            "probability": 4.351139068603516e-06
        },
        {
            "start_logit": -7.98828125,
            "end_logit": 8.7265625,
            "text": "y hand syndrome is a complication of intravenous drug abuse",
            "probability": 3.874301910400391e-06
        },
        {
            "start_logit": -8.0234375,
            "end_logit": 8.7265625,
            "text": "hand syndrome is a complication of intravenous drug abuse",
            "probability": 3.6954879760742188e-06
        },
        {
            "start_logit": -8.03125,
            "end_logit": 8.7265625,
            "text": "a complication of intravenous drug abuse",
            "probability": 3.6954879760742188e-06
        },
        {
            "start_logit": -8.0546875,
            "end_logit": 8.7265625,
            "text": ": Puffy hand syndrome is a complication of intravenous drug abuse",
            "probability": 3.5762786865234375e-06
        },
        {
            "start_logit": -8.0625,
            "end_logit": 8.7265625,
            "text": "syndrome is a complication of intravenous drug abuse",
            "probability": 3.5762786865234375e-06
        },
        {
            "start_logit": 4.484375,
            "end_logit": -3.95703125,
            "text": "drug abuse, which has no current available treatment.",
            "probability": 3.0994415283203125e-06
        },
        {
            "start_logit": 4.484375,
            "end_logit": -6.62890625,
            "text": "drug",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 4.484375,
            "end_logit": -7.9921875,
            "text": "drug abuse,",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 4.484375,
            "end_logit": -8.03125,
            "text": "drug abuse, which",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 4.484375,
            "end_logit": -8.0390625,
            "text": "drug abuse, which has no",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -3.181640625,
            "end_logit": -3.95703125,
            "text": "abuse, which has no current available treatment.",
            "probability": 0.0
        },
        {
            "start_logit": -4.86328125,
            "end_logit": -3.95703125,
            "text": "intravenous drug abuse, which has no current available treatment.",
            "probability": 0.0
        },
        {
            "start_logit": -5.12890625,
            "end_logit": -3.95703125,
            "text": ".",
            "probability": 0.0
        }
    ],
    "5a7346662dc08e987e00001a_3": [
        {
            "start_logit": 4.19140625,
            "end_logit": 7.42578125,
            "text": "drug abuse",
            "probability": 0.9990234375
        },
        {
            "start_logit": -4.640625,
            "end_logit": 7.42578125,
            "text": "intravenous drug abuse",
            "probability": 0.00014638900756835938
        },
        {
            "start_logit": -4.71484375,
            "end_logit": 7.42578125,
            "text": "abuse",
            "probability": 0.0001354217529296875
        },
        {
            "start_logit": -4.73046875,
            "end_logit": 7.42578125,
            "text": "Puffy hand syndrome is a complication of intravenous drug abuse",
            "probability": 0.00013327598571777344
        },
        {
            "start_logit": 4.19140625,
            "end_logit": -1.9306640625,
            "text": "drug abuse, which has no current available treatment.",
            "probability": 8.606910705566406e-05
        },
        {
            "start_logit": -5.7421875,
            "end_logit": 7.42578125,
            "text": "of intravenous drug abuse",
            "probability": 4.8279762268066406e-05
        },
        {
            "start_logit": -6.2421875,
            "end_logit": 7.42578125,
            "text": "complication of intravenous drug abuse",
            "probability": 2.9325485229492188e-05
        },
        {
            "start_logit": -7.625,
            "end_logit": 7.42578125,
            "text": "y hand syndrome is a complication of intravenous drug abuse",
            "probability": 7.3909759521484375e-06
        },
        {
            "start_logit": -7.71484375,
            "end_logit": 7.42578125,
            "text": "hand syndrome is a complication of intravenous drug abuse",
            "probability": 6.735324859619141e-06
        },
        {
            "start_logit": -7.71875,
            "end_logit": 7.42578125,
            "text": "syndrome is a complication of intravenous drug abuse",
            "probability": 6.735324859619141e-06
        },
        {
            "start_logit": -7.80078125,
            "end_logit": 7.42578125,
            "text": "a complication of intravenous drug abuse",
            "probability": 6.198883056640625e-06
        },
        {
            "start_logit": -7.98828125,
            "end_logit": 7.42578125,
            "text": "is a complication of intravenous drug abuse",
            "probability": 5.125999450683594e-06
        },
        {
            "start_logit": 4.19140625,
            "end_logit": -6.7421875,
            "text": "drug",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 4.19140625,
            "end_logit": -7.953125,
            "text": "drug abuse, which",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 4.19140625,
            "end_logit": -7.98046875,
            "text": "drug abuse, which has no",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -4.078125,
            "end_logit": -1.9306640625,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -4.640625,
            "end_logit": -1.9306640625,
            "text": "intravenous drug abuse, which has no current available treatment.",
            "probability": 0.0
        },
        {
            "start_logit": -4.71484375,
            "end_logit": -1.9306640625,
            "text": "abuse, which has no current available treatment.",
            "probability": 0.0
        },
        {
            "start_logit": -4.73046875,
            "end_logit": -1.9306640625,
            "text": "Puffy hand syndrome is a complication of intravenous drug abuse, which has no current available treatment.",
            "probability": 0.0
        },
        {
            "start_logit": -5.7421875,
            "end_logit": -1.9306640625,
            "text": "of intravenous drug abuse, which has no current available treatment.",
            "probability": 0.0
        }
    ],
    "5a7346662dc08e987e00001a_4": [
        {
            "start_logit": 3.619140625,
            "end_logit": 7.28125,
            "text": "drug abuse",
            "probability": 0.998046875
        },
        {
            "start_logit": -3.6484375,
            "end_logit": 7.28125,
            "text": "intravenous drug abuse",
            "probability": 0.0006976127624511719
        },
        {
            "start_logit": -4.88671875,
            "end_logit": 7.28125,
            "text": "abuse",
            "probability": 0.00020313262939453125
        },
        {
            "start_logit": -4.890625,
            "end_logit": 7.28125,
            "text": "Puffy hand syndrome is an unrecognized complication of intravenous drug abuse",
            "probability": 0.0002015829086303711
        },
        {
            "start_logit": -4.9140625,
            "end_logit": 7.28125,
            "text": "of intravenous drug abuse",
            "probability": 0.00019681453704833984
        },
        {
            "start_logit": 3.619140625,
            "end_logit": -2.123046875,
            "text": "drug abuse.",
            "probability": 8.20159912109375e-05
        },
        {
            "start_logit": -6.15625,
            "end_logit": 7.28125,
            "text": "complication of intravenous drug abuse",
            "probability": 5.6803226470947266e-05
        },
        {
            "start_logit": -6.953125,
            "end_logit": 7.28125,
            "text": "unrecognized complication of intravenous drug abuse",
            "probability": 2.562999725341797e-05
        },
        {
            "start_logit": -7.28515625,
            "end_logit": 7.28125,
            "text": "an unrecognized complication of intravenous drug abuse",
            "probability": 1.8298625946044922e-05
        },
        {
            "start_logit": -7.625,
            "end_logit": 7.28125,
            "text": "y hand syndrome is an unrecognized complication of intravenous drug abuse",
            "probability": 1.3113021850585938e-05
        },
        {
            "start_logit": -7.63671875,
            "end_logit": 7.28125,
            "text": "hand syndrome is an unrecognized complication of intravenous drug abuse",
            "probability": 1.2993812561035156e-05
        },
        {
            "start_logit": -7.72265625,
            "end_logit": 7.28125,
            "text": "syndrome is an unrecognized complication of intravenous drug abuse",
            "probability": 1.1861324310302734e-05
        },
        {
            "start_logit": -7.78125,
            "end_logit": 7.28125,
            "text": "is an unrecognized complication of intravenous drug abuse",
            "probability": 1.1205673217773438e-05
        },
        {
            "start_logit": 3.619140625,
            "end_logit": -6.84375,
            "text": "drug",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -3.6484375,
            "end_logit": -2.123046875,
            "text": "intravenous drug abuse.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -3.974609375,
            "end_logit": -2.123046875,
            "text": ".",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -4.88671875,
            "end_logit": -2.123046875,
            "text": "abuse.",
            "probability": 0.0
        },
        {
            "start_logit": -4.890625,
            "end_logit": -2.123046875,
            "text": "Puffy hand syndrome is an unrecognized complication of intravenous drug abuse.",
            "probability": 0.0
        },
        {
            "start_logit": -4.9140625,
            "end_logit": -2.123046875,
            "text": "of intravenous drug abuse.",
            "probability": 0.0
        },
        {
            "start_logit": -6.15625,
            "end_logit": -2.123046875,
            "text": "complication of intravenous drug abuse.",
            "probability": 0.0
        }
    ],
    "5a7346662dc08e987e00001a_5": [
        {
            "start_logit": 5.3203125,
            "end_logit": 7.5390625,
            "text": "drug abuse",
            "probability": 1.0
        },
        {
            "start_logit": -4.4609375,
            "end_logit": 7.5390625,
            "text": "abuse",
            "probability": 5.650520324707031e-05
        },
        {
            "start_logit": -7.3125,
            "end_logit": 7.5390625,
            "text": "intravenous drug abuse",
            "probability": 3.2782554626464844e-06
        },
        {
            "start_logit": 5.3203125,
            "end_logit": -5.14453125,
            "text": "drug",
            "probability": 3.0994415283203125e-06
        },
        {
            "start_logit": -7.72265625,
            "end_logit": 7.5390625,
            "text": "complication of intravenous drug abuse",
            "probability": 2.1457672119140625e-06
        },
        {
            "start_logit": -7.734375,
            "end_logit": 7.5390625,
            "text": "of intravenous drug abuse",
            "probability": 2.1457672119140625e-06
        },
        {
            "start_logit": -7.734375,
            "end_logit": 7.5390625,
            "text": "puffy hand syndrome is an unrecognized complication of intravenous drug abuse",
            "probability": 2.1457672119140625e-06
        },
        {
            "start_logit": 5.3203125,
            "end_logit": -7.1015625,
            "text": "drug abuse this painless syndrome appears during or after a long period of drug addiction it involves the hands and sometimes the forearms and may cause functional aesthetic and social disturbances when the hand volume",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 5.3203125,
            "end_logit": -7.1171875,
            "text": "drug abuse this painless syndrome appears during or after a long period of drug addiction it involves the hands and sometimes the forearms and",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 5.3203125,
            "end_logit": -7.28515625,
            "text": "drug abuse this painless syndrome appears during or after a long period of drug addiction it involves the hands and sometimes the forearms and may cause functional aesthetic and social disturbances when the hand",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 5.3203125,
            "end_logit": -7.3203125,
            "text": "drug abuse this",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 5.3203125,
            "end_logit": -7.36328125,
            "text": "drug abuse this painless syndrome appears during or after a long period of drug addiction it involves the hands and sometimes the forearms and may cause functional aesthetic and social disturbances when the hand volume is",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 5.3203125,
            "end_logit": -7.390625,
            "text": "drug abuse this painless syndrome appears during or after a long period of drug addiction it involves the hands and sometimes the forearms and may",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 5.3203125,
            "end_logit": -7.48828125,
            "text": "drug abuse this painless syndrome appears during or after a long period of drug addiction it involves the hands",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 5.3203125,
            "end_logit": -7.49609375,
            "text": "drug abuse this painless syndrome appears during or after a long period of drug addiction it involves the hands and sometimes the forearms and may cause functional aesthetic and social disturbances when the hand volume is important",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 5.3203125,
            "end_logit": -7.5078125,
            "text": "drug abuse this painless syndrome appears during or after a long period of drug addiction it involves the hands and",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 5.3203125,
            "end_logit": -7.5078125,
            "text": "drug abuse this painless syndrome appears during or after a long period of drug addiction",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 5.3203125,
            "end_logit": -7.60546875,
            "text": "drug abuse this painless syndrome appears during or after a long period of drug addiction it involves the hands and sometimes",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 5.3203125,
            "end_logit": -7.6796875,
            "text": "drug abuse this painless syndrome appears during or after a long period of drug addiction it involves the hands and sometimes the forearms and may cause functional aesthetic and social disturbances when",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -5.2890625,
            "end_logit": -4.96875,
            "text": ".",
            "probability": 0.0
        }
    ],
    "5a7346662dc08e987e00001a_6": [
        {
            "start_logit": -4.74609375,
            "end_logit": 1.9697265625,
            "text": "drug abuse",
            "probability": 0.85595703125
        },
        {
            "start_logit": -6.96484375,
            "end_logit": 1.9697265625,
            "text": "intravenous drug abuse",
            "probability": 0.0931396484375
        },
        {
            "start_logit": -7.6953125,
            "end_logit": 1.9697265625,
            "text": "abuse",
            "probability": 0.044830322265625
        },
        {
            "start_logit": -4.3984375,
            "end_logit": -3.91796875,
            "text": ".",
            "probability": 0.0033779144287109375
        },
        {
            "start_logit": -5.36328125,
            "end_logit": -3.91796875,
            "text": "low stretch bandaging and wearing elastic garments which is effective in decreasing the volume of puffy hand syndrome.",
            "probability": 0.00128173828125
        },
        {
            "start_logit": -4.74609375,
            "end_logit": -6.5703125,
            "text": "drug abuse which has no current available treatment arm and forearm edema are voluminous and cause functional and aesthetic disturbances we report two cases successfully treated by low stretch bandages",
            "probability": 0.00016880035400390625
        },
        {
            "start_logit": -7.58984375,
            "end_logit": -3.91796875,
            "text": "currently consists of low stretch bandaging and wearing elastic garments which is effective in decreasing the volume of puffy hand syndrome.",
            "probability": 0.00013780593872070312
        },
        {
            "start_logit": -7.62109375,
            "end_logit": -3.91796875,
            "text": "of low stretch bandaging and wearing elastic garments which is effective in decreasing the volume of puffy hand syndrome.",
            "probability": 0.00013363361358642578
        },
        {
            "start_logit": -7.79296875,
            "end_logit": -3.91796875,
            "text": "consists of low stretch bandaging and wearing elastic garments which is effective in decreasing the volume of puffy hand syndrome.",
            "probability": 0.00011247396469116211
        },
        {
            "start_logit": -4.74609375,
            "end_logit": -6.984375,
            "text": "drug abuse which",
            "probability": 0.00011074542999267578
        },
        {
            "start_logit": -7.83984375,
            "end_logit": -3.91796875,
            "text": "stretch bandaging and wearing elastic garments which is effective in decreasing the volume of puffy hand syndrome.",
            "probability": 0.00010734796524047852
        },
        {
            "start_logit": -5.36328125,
            "end_logit": -6.84375,
            "text": "low stretch bandaging",
            "probability": 6.93202018737793e-05
        },
        {
            "start_logit": -7.16015625,
            "end_logit": -6.00390625,
            "text": "low stretch bandages a 40 year old man and a 34 year old woman both intravenous drug users",
            "probability": 2.6285648345947266e-05
        },
        {
            "start_logit": -7.16015625,
            "end_logit": -6.01953125,
            "text": "low stretch bandages a 40 year old man and a 34 year old woman both intravenous drug users with puffy hand syndrome were hospitalized for 11 days treatment included daily multilayer bandaging",
            "probability": 2.586841583251953e-05
        },
        {
            "start_logit": -7.73046875,
            "end_logit": -5.53515625,
            "text": "the pathogenesis of this edema is probably multifactorial venous lymphatic insufficiency and the direct toxicity of injected drugs",
            "probability": 2.396106719970703e-05
        },
        {
            "start_logit": -7.41796875,
            "end_logit": -6.01953125,
            "text": "multilayer bandaging",
            "probability": 2.014636993408203e-05
        },
        {
            "start_logit": -6.96484375,
            "end_logit": -6.5703125,
            "text": "intravenous drug abuse which has no current available treatment arm and forearm edema are voluminous and cause functional and aesthetic disturbances we report two cases successfully treated by low stretch bandages",
            "probability": 1.8358230590820312e-05
        },
        {
            "start_logit": -7.6640625,
            "end_logit": -6.01953125,
            "text": "daily multilayer bandaging",
            "probability": 1.5735626220703125e-05
        },
        {
            "start_logit": -7.16015625,
            "end_logit": -6.5703125,
            "text": "low stretch bandages",
            "probability": 1.5020370483398438e-05
        },
        {
            "start_logit": -7.85546875,
            "end_logit": -6.01953125,
            "text": "included daily multilayer bandaging",
            "probability": 1.2993812561035156e-05
        }
    ],
    "56cf236f3975bb303a000002_1": [
        {
            "start_logit": 9.171875,
            "end_logit": 5.43359375,
            "text": "T-type calcium channels",
            "probability": 0.9990234375
        },
        {
            "start_logit": 9.171875,
            "end_logit": -2.388671875,
            "text": "T-type",
            "probability": 0.0003979206085205078
        },
        {
            "start_logit": 9.171875,
            "end_logit": -2.697265625,
            "text": "T",
            "probability": 0.00029349327087402344
        },
        {
            "start_logit": 9.171875,
            "end_logit": -6.9375,
            "text": "T-",
            "probability": 4.231929779052734e-06
        },
        {
            "start_logit": 9.171875,
            "end_logit": -7.9296875,
            "text": "T-type calcium channels, we examined if more selective T-type calcium channel blockers and also inhibitors of cystathionine-\u03b3-lyase (CSE), a",
            "probability": 1.5497207641601562e-06
        },
        {
            "start_logit": 9.171875,
            "end_logit": -8.0703125,
            "text": "T-type calcium channels, we examined",
            "probability": 1.3709068298339844e-06
        },
        {
            "start_logit": 9.171875,
            "end_logit": -8.0703125,
            "text": "T-type calcium channels, we examined if more selective T-type calcium channel",
            "probability": 1.3709068298339844e-06
        },
        {
            "start_logit": 9.171875,
            "end_logit": -8.0859375,
            "text": "T-type calcium channels, we examined if more selective T-type calcium channel blockers and also inhibitors of cystathionine-\u03b3-lyase",
            "probability": 1.3113021850585938e-06
        },
        {
            "start_logit": 9.171875,
            "end_logit": -8.09375,
            "text": "T-type calcium channels, we examined if more selective T-type calcium channel blockers and also inhibitors of cystathionine-\u03b3-lyase (CSE)",
            "probability": 1.3113021850585938e-06
        },
        {
            "start_logit": 9.171875,
            "end_logit": -8.09375,
            "text": "T-type calcium channels, we examined if more selective T-type calcium channel blockers and also inhibitors of cystathionine-\u03b3-lyase (CSE),",
            "probability": 1.3113021850585938e-06
        },
        {
            "start_logit": 9.171875,
            "end_logit": -8.09375,
            "text": "T-type calcium channels, we examined if more selective T-type calcium channel blockers and also inhibitors of cystathionine-\u03b3-lyase (CSE), a major",
            "probability": 1.3113021850585938e-06
        },
        {
            "start_logit": 9.171875,
            "end_logit": -8.1015625,
            "text": "T-type calcium channels, we examined if more selective T-type calcium channel blockers and",
            "probability": 1.3113021850585938e-06
        },
        {
            "start_logit": 9.171875,
            "end_logit": -8.1328125,
            "text": "T-type calcium channels, we examined if more selective T-type calcium channel blockers and also inhibitors of cystathionine-\u03b3",
            "probability": 1.2516975402832031e-06
        },
        {
            "start_logit": -5.53125,
            "end_logit": 5.43359375,
            "text": "block T-type calcium channels",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -5.84765625,
            "end_logit": 5.43359375,
            "text": "channels",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.46484375,
            "end_logit": 5.43359375,
            "text": "type calcium channels",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.51171875,
            "end_logit": 5.43359375,
            "text": "calcium channels",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.70703125,
            "end_logit": 5.43359375,
            "text": "-type calcium channels",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.8125,
            "end_logit": 5.43359375,
            "text": "known to block T-type calcium channels",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.87109375,
            "end_logit": 5.43359375,
            "text": "Given evidence that chemotherapy-induced neuropathic pain is blocked by ethosuximide, known to block T-type calcium channels",
            "probability": 5.960464477539063e-08
        }
    ],
    "6026ed981cb411341a0000d2_1": [
        {
            "start_logit": -5.1171875,
            "end_logit": -4.3359375,
            "text": ".",
            "probability": 0.56689453125
        },
        {
            "start_logit": -7.30078125,
            "end_logit": -4.3359375,
            "text": "galcanezumab) and TEV48125 (fremanezumab)] have been published recently, and phase 3 trials are in process.",
            "probability": 0.0635986328125
        },
        {
            "start_logit": -7.64453125,
            "end_logit": -4.3359375,
            "text": "LY2951742 (galcanezumab) and TEV48125 (fremanezumab)] have been published recently, and phase 3 trials are in process.",
            "probability": 0.04510498046875
        },
        {
            "start_logit": -7.6640625,
            "end_logit": -4.3359375,
            "text": "erenumab), LY2951742 (galcanezumab) and TEV48125 (fremanezumab)] have been published recently, and phase 3 trials are in process.",
            "probability": 0.04437255859375
        },
        {
            "start_logit": -7.69921875,
            "end_logit": -4.3359375,
            "text": "recently, and phase 3 trials are in process.",
            "probability": 0.04302978515625
        },
        {
            "start_logit": -7.703125,
            "end_logit": -4.3359375,
            "text": "fremanezumab)] have been published recently, and phase 3 trials are in process.",
            "probability": 0.042694091796875
        },
        {
            "start_logit": -7.7890625,
            "end_logit": -4.3359375,
            "text": "(galcanezumab) and TEV48125 (fremanezumab)] have been published recently, and phase 3 trials are in process.",
            "probability": 0.0391845703125
        },
        {
            "start_logit": -7.80859375,
            "end_logit": -4.3359375,
            "text": "process.",
            "probability": 0.03857421875
        },
        {
            "start_logit": -7.81640625,
            "end_logit": -4.3359375,
            "text": "and phase 3 trials are in process.",
            "probability": 0.0379638671875
        },
        {
            "start_logit": -7.8203125,
            "end_logit": -4.3359375,
            "text": "TEV48125 (fremanezumab)] have been published recently, and phase 3 trials are in process.",
            "probability": 0.0379638671875
        },
        {
            "start_logit": -7.11328125,
            "end_logit": -7.078125,
            "text": "calcitonin gene-related peptide (CGRP) pathway [ALD403 (eptinezumab)",
            "probability": 0.00498199462890625
        },
        {
            "start_logit": -7.13671875,
            "end_logit": -7.078125,
            "text": "eptinezumab)",
            "probability": 0.004825592041015625
        },
        {
            "start_logit": -7.2265625,
            "end_logit": -7.078125,
            "text": "the calcitonin gene-related peptide (CGRP) pathway [ALD403 (eptinezumab)",
            "probability": 0.004428863525390625
        },
        {
            "start_logit": -7.11328125,
            "end_logit": -7.28125,
            "text": "calcitonin gene-related peptide (CGRP) pathway [ALD403 (eptinezumab), AMG334 (erenumab)",
            "probability": 0.004062652587890625
        },
        {
            "start_logit": -7.11328125,
            "end_logit": -7.296875,
            "text": "calcitonin gene-related peptide (",
            "probability": 0.004001617431640625
        },
        {
            "start_logit": -7.13671875,
            "end_logit": -7.28125,
            "text": "eptinezumab), AMG334 (erenumab)",
            "probability": 0.003940582275390625
        },
        {
            "start_logit": -7.13671875,
            "end_logit": -7.328125,
            "text": "eptinezumab), AMG334 (erenumab), LY2951742 (galcanezumab) and TEV48125 (fremanezumab)]",
            "probability": 0.0037593841552734375
        },
        {
            "start_logit": -7.2265625,
            "end_logit": -7.28125,
            "text": "the calcitonin gene-related peptide (CGRP) pathway [ALD403 (eptinezumab), AMG334 (erenumab)",
            "probability": 0.0036144256591796875
        },
        {
            "start_logit": -7.2265625,
            "end_logit": -7.296875,
            "text": "the calcitonin gene-related peptide (",
            "probability": 0.003559112548828125
        },
        {
            "start_logit": -7.11328125,
            "end_logit": -7.4375,
            "text": "calcitonin gene-related peptide (CGRP)",
            "probability": 0.003475189208984375
        }
    ],
    "587e0116ae05ffb474000002_1": [
        {
            "start_logit": 9.78125,
            "end_logit": 9.703125,
            "text": "CisMapper",
            "probability": 1.0
        },
        {
            "start_logit": -1.470703125,
            "end_logit": 9.703125,
            "text": "per",
            "probability": 1.2993812561035156e-05
        },
        {
            "start_logit": 9.78125,
            "end_logit": -1.62890625,
            "text": "Cis",
            "probability": 1.2040138244628906e-05
        },
        {
            "start_logit": -6.453125,
            "end_logit": 9.703125,
            "text": "Mapper",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.78125,
            "end_logit": -7.01953125,
            "text": "CisMap",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.78125,
            "end_logit": -8.0703125,
            "text": "CisMapper: predicting regulatory interactions from transcription factor",
            "probability": 0.0
        },
        {
            "start_logit": 9.78125,
            "end_logit": -8.0859375,
            "text": "CisMapper: predicting regulatory interactions from transcription factor ChIP-seq data",
            "probability": 0.0
        },
        {
            "start_logit": 9.78125,
            "end_logit": -8.0859375,
            "text": "CisMapper: predicting regulatory interactions from transcription",
            "probability": 0.0
        },
        {
            "start_logit": 9.78125,
            "end_logit": -8.09375,
            "text": "CisMapper:",
            "probability": 0.0
        },
        {
            "start_logit": 9.78125,
            "end_logit": -8.140625,
            "text": "CisMapper: predicting regulatory interactions from",
            "probability": 0.0
        },
        {
            "start_logit": 9.78125,
            "end_logit": -8.1484375,
            "text": "CisMapper: predicting regulatory interactions from transcription factor ChIP-",
            "probability": 0.0
        },
        {
            "start_logit": 9.78125,
            "end_logit": -8.1640625,
            "text": "CisMapper: predicting regulatory interactions from transcription factor ChIP-seq",
            "probability": 0.0
        },
        {
            "start_logit": 9.78125,
            "end_logit": -8.1640625,
            "text": "CisMapper: predicting regulatory",
            "probability": 0.0
        },
        {
            "start_logit": 9.78125,
            "end_logit": -8.171875,
            "text": "CisMapper: predicting regulatory interactions from transcription factor ChIP",
            "probability": 0.0
        },
        {
            "start_logit": 9.78125,
            "end_logit": -8.1796875,
            "text": "CisMapper: predicting regulatory interactions",
            "probability": 0.0
        },
        {
            "start_logit": -1.470703125,
            "end_logit": -8.0703125,
            "text": "per: predicting regulatory interactions from transcription factor",
            "probability": 0.0
        },
        {
            "start_logit": -1.470703125,
            "end_logit": -8.0859375,
            "text": "per: predicting regulatory interactions from transcription factor ChIP-seq data",
            "probability": 0.0
        },
        {
            "start_logit": -1.470703125,
            "end_logit": -8.0859375,
            "text": "per: predicting regulatory interactions from transcription",
            "probability": 0.0
        },
        {
            "start_logit": -1.470703125,
            "end_logit": -8.09375,
            "text": "per:",
            "probability": 0.0
        },
        {
            "start_logit": -1.470703125,
            "end_logit": -8.140625,
            "text": "per: predicting regulatory interactions from",
            "probability": 0.0
        }
    ],
    "587e0116ae05ffb474000002_2": [
        {
            "start_logit": 9.828125,
            "end_logit": 9.6953125,
            "text": "CisMapper",
            "probability": 1.0
        },
        {
            "start_logit": 9.828125,
            "end_logit": -1.533203125,
            "text": "Cis",
            "probability": 1.3232231140136719e-05
        },
        {
            "start_logit": -1.509765625,
            "end_logit": 9.6953125,
            "text": "per",
            "probability": 1.1861324310302734e-05
        },
        {
            "start_logit": -6.48828125,
            "end_logit": 9.6953125,
            "text": "Mapper",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.828125,
            "end_logit": -7.26953125,
            "text": "CisMap",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.828125,
            "end_logit": -7.49609375,
            "text": "CisMapper, which predicts the regulatory targets of a TF using the correlation between a histone mark at the TF's bound sites and the expression of each gene across a panel of tissues.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.828125,
            "end_logit": -7.828125,
            "text": "CisMapper, which",
            "probability": 0.0
        },
        {
            "start_logit": 9.828125,
            "end_logit": -7.90625,
            "text": "CisMapper, which predicts the regulatory targets of a TF using the correlation between a histone mark at the TF's bound sites and the expression of each gene across a",
            "probability": 0.0
        },
        {
            "start_logit": 9.828125,
            "end_logit": -7.91015625,
            "text": "CisMapper, which predicts the regulatory targets of a TF using the correlation between a histone mark at the TF's bound sites and the expression of each gene across",
            "probability": 0.0
        },
        {
            "start_logit": 9.828125,
            "end_logit": -7.9453125,
            "text": "CisMapper, which predicts the regulatory targets of a TF using the correlation between a histone mark at the TF's bound sites and the expression",
            "probability": 0.0
        },
        {
            "start_logit": 9.828125,
            "end_logit": -7.95703125,
            "text": "CisMapper, which predicts the regulatory targets of a TF using the correlation between a histone mark at",
            "probability": 0.0
        },
        {
            "start_logit": 9.828125,
            "end_logit": -7.9609375,
            "text": "CisMapper, which predicts the regulatory targets of a TF using the correlation between a histone mark at the TF's bound sites and the expression of each gene",
            "probability": 0.0
        },
        {
            "start_logit": 9.828125,
            "end_logit": -7.9609375,
            "text": "CisMapper, which predicts the regulatory targets of",
            "probability": 0.0
        },
        {
            "start_logit": 9.828125,
            "end_logit": -7.97265625,
            "text": "CisMapper, which predicts the regulatory targets of a TF using the correlation between a histone mark at the TF's bound sites and the expression of",
            "probability": 0.0
        },
        {
            "start_logit": 9.828125,
            "end_logit": -7.98046875,
            "text": "CisMapper,",
            "probability": 0.0
        },
        {
            "start_logit": 9.828125,
            "end_logit": -7.98828125,
            "text": "CisMapper, which predicts the regulatory targets of a TF using",
            "probability": 0.0
        },
        {
            "start_logit": 9.828125,
            "end_logit": -7.98828125,
            "text": "CisMapper, which predicts the regulatory targets of a TF using the correlation between a histone mark at the TF's bound sites and",
            "probability": 0.0
        },
        {
            "start_logit": 9.828125,
            "end_logit": -8.0078125,
            "text": "CisMapper, which predicts the regulatory targets of a TF using the correlation between a histone mark at the TF's bound sites and the expression of each gene across a panel of",
            "probability": 0.0
        },
        {
            "start_logit": -7.875,
            "end_logit": 9.6953125,
            "text": "present CisMapper",
            "probability": 0.0
        },
        {
            "start_logit": 9.828125,
            "end_logit": -8.015625,
            "text": "CisMapper, which predicts the regulatory targets of a TF using the correlation between a histone mark at the",
            "probability": 0.0
        }
    ],
    "587e0116ae05ffb474000002_3": [
        {
            "start_logit": 9.8125,
            "end_logit": 9.7109375,
            "text": "CisMapper",
            "probability": 1.0
        },
        {
            "start_logit": -1.4375,
            "end_logit": 9.7109375,
            "text": "per",
            "probability": 1.2934207916259766e-05
        },
        {
            "start_logit": 9.8125,
            "end_logit": -1.564453125,
            "text": "Cis",
            "probability": 1.2636184692382812e-05
        },
        {
            "start_logit": -6.453125,
            "end_logit": 9.7109375,
            "text": "Mapper",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8125,
            "end_logit": -7.3125,
            "text": "CisMap",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.60546875,
            "end_logit": 9.7109375,
            "text": "that CisMapper",
            "probability": 0.0
        },
        {
            "start_logit": 9.8125,
            "end_logit": -7.83984375,
            "text": "CisMapper is more accurate at predicting the target genes of a TF than the distance-based approaches currently",
            "probability": 0.0
        },
        {
            "start_logit": 9.8125,
            "end_logit": -7.9453125,
            "text": "CisMapper is",
            "probability": 0.0
        },
        {
            "start_logit": 9.8125,
            "end_logit": -7.97265625,
            "text": "CisMapper is more accurate at predicting the target genes of a TF than",
            "probability": 0.0
        },
        {
            "start_logit": 9.8125,
            "end_logit": -8.0078125,
            "text": "CisMapper is more",
            "probability": 0.0
        },
        {
            "start_logit": 9.8125,
            "end_logit": -8.015625,
            "text": "CisMapper is more accurate at predicting the target genes of a TF than the distance-based approaches currently used, and is particularly advantageous for predicting the long-range regulatory interactions typical",
            "probability": 0.0
        },
        {
            "start_logit": -7.92578125,
            "end_logit": 9.7109375,
            "text": "chromatin conformation capture and differential expression data, we show that CisMapper",
            "probability": 0.0
        },
        {
            "start_logit": 9.8125,
            "end_logit": -8.03125,
            "text": "CisMapper is more accurate at predicting the target genes of a TF than the distance-based approaches currently used",
            "probability": 0.0
        },
        {
            "start_logit": 9.8125,
            "end_logit": -8.0390625,
            "text": "CisMapper is more accurate at",
            "probability": 0.0
        },
        {
            "start_logit": -7.9375,
            "end_logit": 9.7109375,
            "text": "Using both chromatin conformation capture and differential expression data, we show that CisMapper",
            "probability": 0.0
        },
        {
            "start_logit": -7.94140625,
            "end_logit": 9.7109375,
            "text": "we show that CisMapper",
            "probability": 0.0
        },
        {
            "start_logit": -7.94921875,
            "end_logit": 9.7109375,
            "text": "both chromatin conformation capture and differential expression data, we show that CisMapper",
            "probability": 0.0
        },
        {
            "start_logit": -7.953125,
            "end_logit": 9.7109375,
            "text": ", we show that CisMapper",
            "probability": 0.0
        },
        {
            "start_logit": 9.8125,
            "end_logit": -8.078125,
            "text": "CisMapper is more accurate at predicting the target genes of a TF than the distance-based approaches currently used,",
            "probability": 0.0
        },
        {
            "start_logit": 9.8125,
            "end_logit": -8.0859375,
            "text": "CisMapper is more accurate at predicting the target genes of a TF than the distance-based approaches currently used, and is particularly advantageous for predicting the long-range regulatory interactions typical of tissue",
            "probability": 0.0
        }
    ],
    "587e0116ae05ffb474000002_4": [
        {
            "start_logit": 9.8828125,
            "end_logit": 9.7421875,
            "text": "CisMapper",
            "probability": 1.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -1.3681640625,
            "text": "Cis",
            "probability": 1.4960765838623047e-05
        },
        {
            "start_logit": -1.3525390625,
            "end_logit": 9.7421875,
            "text": "per",
            "probability": 1.3232231140136719e-05
        },
        {
            "start_logit": -5.890625,
            "end_logit": 9.7421875,
            "text": "Mapper",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -6.78515625,
            "text": "CisMap",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -7.19140625,
            "text": "CisMapper also predicts which TF binding sites regulate a given gene more accurately than using genomic distance.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -7.7421875,
            "text": "CisMapper also predicts which TF binding sites",
            "probability": 0.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -7.75,
            "text": "CisMapper also predicts which TF binding sites regulate a given gene more accurately than using genomic distance. Unlike distance-based methods, CisMapper",
            "probability": 0.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -7.7578125,
            "text": "CisMapper also predicts which TF binding sites regulate",
            "probability": 0.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -7.87109375,
            "text": "CisMapper also predicts which TF binding sites regulate a given gene more",
            "probability": 0.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -7.875,
            "text": "CisMapper also predicts which TF binding sites regulate a given gene more accurately than using genomic distance. Unlike distance-based methods, CisMapper can predict which transcription start site of a gene is regulated",
            "probability": 0.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -7.8828125,
            "text": "CisMapper also predicts which TF binding sites regulate a given gene more accurately than using genomic distance. Unlike distance-based methods, CisMapper can predict which transcription start site",
            "probability": 0.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -7.88671875,
            "text": "CisMapper also predicts which TF binding sites regulate a",
            "probability": 0.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -7.91015625,
            "text": "CisMapper also predicts which TF binding sites regulate a given gene more accurately than using genomic distance. Unlike distance-based methods, CisMapper can predict which transcription start site of a gene",
            "probability": 0.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -7.9296875,
            "text": "CisMapper also predicts which TF binding sites regulate a given gene more accurately than using genomic distance. Unlike distance-based methods, CisMap",
            "probability": 0.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -7.9453125,
            "text": "CisMapper also predicts which TF binding sites regulate a given gene more accurately than using genomic distance. Unlike distance-based methods, CisMapper can",
            "probability": 0.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -7.96484375,
            "text": "CisMapper also predicts which TF binding sites regulate a given gene more accurately",
            "probability": 0.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -7.96875,
            "text": "CisMapper also predicts",
            "probability": 0.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -7.97265625,
            "text": "CisMapper also predicts which TF binding sites regulate a given gene more accurately than",
            "probability": 0.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -7.97265625,
            "text": "CisMapper also predicts which TF binding sites regulate a given gene more accurately than using genomic distance. Unlike distance-based methods, CisMapper can predict which transcription start",
            "probability": 0.0
        }
    ],
    "587e0116ae05ffb474000002_5": [
        {
            "start_logit": 9.84375,
            "end_logit": 9.71875,
            "text": "CisMapper",
            "probability": 1.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -1.4833984375,
            "text": "Cis",
            "probability": 1.3649463653564453e-05
        },
        {
            "start_logit": -1.4453125,
            "end_logit": 9.71875,
            "text": "per",
            "probability": 1.2516975402832031e-05
        },
        {
            "start_logit": -6.2890625,
            "end_logit": 9.71875,
            "text": "Mapper",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.84375,
            "end_logit": -7.12890625,
            "text": "CisMap",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.84375,
            "end_logit": -7.96484375,
            "text": "CisMapper: predicting regulatory interactions from transcription factor ChIP-seq data.",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.046875,
            "text": "CisMapper:",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.0703125,
            "text": "CisMapper: predicting regulatory interactions from transcription factor",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.0859375,
            "text": "CisMapper: predicting regulatory interactions from transcription",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.109375,
            "text": "CisMapper: predicting regulatory interactions from transcription factor ChIP-seq data",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.140625,
            "text": "CisMapper: predicting regulatory interactions from transcription factor ChIP-",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.1484375,
            "text": "CisMapper: predicting regulatory interactions from transcription factor ChIP-seq",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.15625,
            "text": "CisMapper: predicting regulatory interactions from",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.1640625,
            "text": "CisMapper: predicting regulatory interactions from transcription factor ChIP",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.171875,
            "text": "CisMapper: predicting regulatory",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.1796875,
            "text": "CisMapper: predicting regulatory interactions",
            "probability": 0.0
        },
        {
            "start_logit": -1.4453125,
            "end_logit": -7.96484375,
            "text": "per: predicting regulatory interactions from transcription factor ChIP-seq data.",
            "probability": 0.0
        },
        {
            "start_logit": -1.4453125,
            "end_logit": -8.046875,
            "text": "per:",
            "probability": 0.0
        },
        {
            "start_logit": -1.4453125,
            "end_logit": -8.0703125,
            "text": "per: predicting regulatory interactions from transcription factor",
            "probability": 0.0
        },
        {
            "start_logit": -1.4453125,
            "end_logit": -8.0859375,
            "text": "per: predicting regulatory interactions from transcription",
            "probability": 0.0
        }
    ],
    "587e0116ae05ffb474000002_6": [
        {
            "start_logit": 9.84375,
            "end_logit": 9.71875,
            "text": "CisMapper",
            "probability": 1.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -1.4833984375,
            "text": "Cis",
            "probability": 1.3649463653564453e-05
        },
        {
            "start_logit": -1.4453125,
            "end_logit": 9.71875,
            "text": "per",
            "probability": 1.2516975402832031e-05
        },
        {
            "start_logit": -6.2890625,
            "end_logit": 9.71875,
            "text": "Mapper",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.84375,
            "end_logit": -7.12890625,
            "text": "CisMap",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.84375,
            "end_logit": -7.96484375,
            "text": "CisMapper: predicting regulatory interactions from transcription factor ChIP-seq data.",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.046875,
            "text": "CisMapper:",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.0703125,
            "text": "CisMapper: predicting regulatory interactions from transcription factor",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.0859375,
            "text": "CisMapper: predicting regulatory interactions from transcription",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.109375,
            "text": "CisMapper: predicting regulatory interactions from transcription factor ChIP-seq data",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.140625,
            "text": "CisMapper: predicting regulatory interactions from transcription factor ChIP-",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.1484375,
            "text": "CisMapper: predicting regulatory interactions from transcription factor ChIP-seq",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.15625,
            "text": "CisMapper: predicting regulatory interactions from",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.1640625,
            "text": "CisMapper: predicting regulatory interactions from transcription factor ChIP",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.171875,
            "text": "CisMapper: predicting regulatory",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.1796875,
            "text": "CisMapper: predicting regulatory interactions",
            "probability": 0.0
        },
        {
            "start_logit": -1.4453125,
            "end_logit": -7.96484375,
            "text": "per: predicting regulatory interactions from transcription factor ChIP-seq data.",
            "probability": 0.0
        },
        {
            "start_logit": -1.4453125,
            "end_logit": -8.046875,
            "text": "per:",
            "probability": 0.0
        },
        {
            "start_logit": -1.4453125,
            "end_logit": -8.0703125,
            "text": "per: predicting regulatory interactions from transcription factor",
            "probability": 0.0
        },
        {
            "start_logit": -1.4453125,
            "end_logit": -8.0859375,
            "text": "per: predicting regulatory interactions from transcription",
            "probability": 0.0
        }
    ],
    "587e0116ae05ffb474000002_7": [
        {
            "start_logit": 9.859375,
            "end_logit": 9.734375,
            "text": "CisMapper",
            "probability": 1.0
        },
        {
            "start_logit": 9.859375,
            "end_logit": -1.4609375,
            "text": "Cis",
            "probability": 1.3709068298339844e-05
        },
        {
            "start_logit": -1.3642578125,
            "end_logit": 9.734375,
            "text": "per",
            "probability": 1.329183578491211e-05
        },
        {
            "start_logit": -6.25,
            "end_logit": 9.734375,
            "text": "Mapper",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.859375,
            "end_logit": -7.359375,
            "text": "CisMap",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5625,
            "end_logit": 9.734375,
            "text": "that CisMapper",
            "probability": 0.0
        },
        {
            "start_logit": 9.859375,
            "end_logit": -7.76171875,
            "text": "CisMapper is more accurate at predicting the target genes of a TF than the distance-based approaches currently",
            "probability": 0.0
        },
        {
            "start_logit": 9.859375,
            "end_logit": -7.83984375,
            "text": "CisMapper is",
            "probability": 0.0
        },
        {
            "start_logit": 9.859375,
            "end_logit": -7.91015625,
            "text": "CisMapper is more accurate at predicting the target genes of a TF than",
            "probability": 0.0
        },
        {
            "start_logit": 9.859375,
            "end_logit": -7.91796875,
            "text": "CisMapper is more",
            "probability": 0.0
        },
        {
            "start_logit": 9.859375,
            "end_logit": -7.953125,
            "text": "CisMapper is more accurate at predicting the target genes of a TF than the distance-based approaches currently used, and is particularly advantageous for predicting the long-range regulatory interactions typical",
            "probability": 0.0
        },
        {
            "start_logit": 9.859375,
            "end_logit": -7.98046875,
            "text": "CisMapper is more accurate at",
            "probability": 0.0
        },
        {
            "start_logit": 9.859375,
            "end_logit": -7.9921875,
            "text": "CisMapper is more accurate at predicting the target genes of a TF than the distance-based approaches currently used",
            "probability": 0.0
        },
        {
            "start_logit": 9.859375,
            "end_logit": -8.0390625,
            "text": "CisMapper is more accurate at predicting the target genes of a TF than the distance-based approaches currently used, and is particularly advantageous for predicting the long-range regulatory interactions typical of tissue",
            "probability": 0.0
        },
        {
            "start_logit": 9.859375,
            "end_logit": -8.0390625,
            "text": "CisMapper is more accurate at predicting the target genes",
            "probability": 0.0
        },
        {
            "start_logit": 9.859375,
            "end_logit": -8.0390625,
            "text": "CisMapper is more accurate at predicting the target genes of a TF than the distance-based approaches currently used,",
            "probability": 0.0
        },
        {
            "start_logit": 9.859375,
            "end_logit": -8.0390625,
            "text": "CisMapper is more accurate at predicting the target genes of a TF than the distance-based approaches currently used, and",
            "probability": 0.0
        },
        {
            "start_logit": 9.859375,
            "end_logit": -8.0546875,
            "text": "CisMapper is more accurate at predicting the target genes of a TF than the",
            "probability": 0.0
        },
        {
            "start_logit": 9.859375,
            "end_logit": -8.0703125,
            "text": "CisMapper is more accurate at predicting the target genes of a TF than the distance-based approaches currently used, and is particularly",
            "probability": 0.0
        },
        {
            "start_logit": -7.953125,
            "end_logit": 9.734375,
            "text": "we show that CisMapper",
            "probability": 0.0
        }
    ],
    "60314c361cb411341a00012e_1": [
        {
            "start_logit": 9.3515625,
            "end_logit": 9.8203125,
            "text": "inflammation of the aorta",
            "probability": 1.0
        },
        {
            "start_logit": -0.63427734375,
            "end_logit": 9.8203125,
            "text": "aorta",
            "probability": 4.6133995056152344e-05
        },
        {
            "start_logit": 9.3515625,
            "end_logit": -1.212890625,
            "text": "inflammation of the aorta due to various causes.",
            "probability": 1.621246337890625e-05
        },
        {
            "start_logit": 9.3515625,
            "end_logit": -2.15234375,
            "text": "inflammation",
            "probability": 6.318092346191406e-06
        },
        {
            "start_logit": -5.86328125,
            "end_logit": 9.8203125,
            "text": "the aorta",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.27734375,
            "end_logit": 9.8203125,
            "text": "the inflammation of the aorta",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.4765625,
            "end_logit": 9.8203125,
            "text": "Aortitis is the inflammation of the aorta",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.17578125,
            "end_logit": 9.8203125,
            "text": "of the aorta",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.8203125,
            "end_logit": 9.8203125,
            "text": "itis is the inflammation of the aorta",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0625,
            "end_logit": 9.8203125,
            "text": "is the inflammation of the aorta",
            "probability": 0.0
        },
        {
            "start_logit": 9.3515625,
            "end_logit": -7.65625,
            "text": "inflammation of the aorta due",
            "probability": 0.0
        },
        {
            "start_logit": 9.3515625,
            "end_logit": -7.66796875,
            "text": "inflammation of the aorta due to various causes",
            "probability": 0.0
        },
        {
            "start_logit": 9.3515625,
            "end_logit": -7.81640625,
            "text": "inflammation of the aorta due to various",
            "probability": 0.0
        },
        {
            "start_logit": 9.3515625,
            "end_logit": -7.86328125,
            "text": "inflammation of the aorta due to",
            "probability": 0.0
        },
        {
            "start_logit": -0.63427734375,
            "end_logit": -1.212890625,
            "text": "aorta due to various causes.",
            "probability": 0.0
        },
        {
            "start_logit": -4.00390625,
            "end_logit": -1.212890625,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -5.86328125,
            "end_logit": -1.212890625,
            "text": "the aorta due to various causes.",
            "probability": 0.0
        },
        {
            "start_logit": -6.27734375,
            "end_logit": -1.212890625,
            "text": "the inflammation of the aorta due to various causes.",
            "probability": 0.0
        },
        {
            "start_logit": -6.4765625,
            "end_logit": -1.212890625,
            "text": "Aortitis is the inflammation of the aorta due to various causes.",
            "probability": 0.0
        },
        {
            "start_logit": -0.63427734375,
            "end_logit": -7.65625,
            "text": "aorta due",
            "probability": 0.0
        }
    ],
    "60314c361cb411341a00012e_2": [
        {
            "start_logit": 8.28125,
            "end_logit": 9.7421875,
            "text": "inflammation of the aorta",
            "probability": 1.0
        },
        {
            "start_logit": -1.0859375,
            "end_logit": 9.7421875,
            "text": "aorta",
            "probability": 8.481740951538086e-05
        },
        {
            "start_logit": 8.28125,
            "end_logit": -3.353515625,
            "text": "inflammation",
            "probability": 2.0265579223632812e-06
        },
        {
            "start_logit": -6.13671875,
            "end_logit": 9.7421875,
            "text": "the aorta",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -7.375,
            "end_logit": 9.7421875,
            "text": "of the aorta",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.625,
            "end_logit": 9.7421875,
            "text": "the inflammation of the aorta",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.62890625,
            "end_logit": 9.7421875,
            "text": "Aortitis is the inflammation of the aorta",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.890625,
            "end_logit": 9.7421875,
            "text": "PURPOSE OF REVIEW: Aortitis is the inflammation of the aorta",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.95703125,
            "end_logit": 9.7421875,
            "text": ": Aortitis is the inflammation of the aorta",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.078125,
            "end_logit": 9.7421875,
            "text": "REVIEW: Aortitis is the inflammation of the aorta",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1796875,
            "end_logit": 9.7421875,
            "text": "itis is the inflammation of the aorta",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1875,
            "end_logit": 9.7421875,
            "text": "OF REVIEW: Aortitis is the inflammation of the aorta",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.28125,
            "end_logit": -7.16796875,
            "text": "inflammation of the aorta due",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.0859375,
            "end_logit": -7.16796875,
            "text": "aorta due",
            "probability": 0.0
        },
        {
            "start_logit": -7.625,
            "end_logit": -3.353515625,
            "text": "the inflammation",
            "probability": 0.0
        },
        {
            "start_logit": -7.62890625,
            "end_logit": -3.353515625,
            "text": "Aortitis is the inflammation",
            "probability": 0.0
        },
        {
            "start_logit": -7.890625,
            "end_logit": -3.353515625,
            "text": "PURPOSE OF REVIEW: Aortitis is the inflammation",
            "probability": 0.0
        },
        {
            "start_logit": -7.95703125,
            "end_logit": -3.353515625,
            "text": ": Aortitis is the inflammation",
            "probability": 0.0
        },
        {
            "start_logit": -8.078125,
            "end_logit": -3.353515625,
            "text": "REVIEW: Aortitis is the inflammation",
            "probability": 0.0
        },
        {
            "start_logit": -8.1796875,
            "end_logit": -3.353515625,
            "text": "itis is the inflammation",
            "probability": 0.0
        }
    ],
    "60314c361cb411341a00012e_3": [
        {
            "start_logit": 8.7265625,
            "end_logit": 9.6484375,
            "text": "inflammation of the aorta",
            "probability": 0.9990234375
        },
        {
            "start_logit": 1.669921875,
            "end_logit": 9.6484375,
            "text": "Aortitis is the all-encompassing pathological term ascribed to inflammation of the aorta",
            "probability": 0.0008625984191894531
        },
        {
            "start_logit": 8.7265625,
            "end_logit": 1.3193359375,
            "text": "inflammation of the aorta.",
            "probability": 0.00024139881134033203
        },
        {
            "start_logit": -1.1552734375,
            "end_logit": 9.6484375,
            "text": "aorta",
            "probability": 5.0961971282958984e-05
        },
        {
            "start_logit": 8.7265625,
            "end_logit": -2.86328125,
            "text": "inflammation",
            "probability": 3.6954879760742188e-06
        },
        {
            "start_logit": -4.96875,
            "end_logit": 9.6484375,
            "text": "to inflammation of the aorta",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": -5.59375,
            "end_logit": 9.6484375,
            "text": "the all-encompassing pathological term ascribed to inflammation of the aorta",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -6.125,
            "end_logit": 9.6484375,
            "text": "term ascribed to inflammation of the aorta",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -6.37109375,
            "end_logit": 9.6484375,
            "text": "all-encompassing pathological term ascribed to inflammation of the aorta",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.4296875,
            "end_logit": 9.6484375,
            "text": "the aorta",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 1.669921875,
            "end_logit": 1.3193359375,
            "text": "Aortitis is the all-encompassing pathological term ascribed to inflammation of the aorta.",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.75390625,
            "end_logit": 9.6484375,
            "text": "ascribed to inflammation of the aorta",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.8828125,
            "end_logit": 9.6484375,
            "text": "pathological term ascribed to inflammation of the aorta",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.265625,
            "end_logit": 9.6484375,
            "text": "encompassing pathological term ascribed to inflammation of the aorta",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.2890625,
            "end_logit": 9.6484375,
            "text": "is the all-encompassing pathological term ascribed to inflammation of the aorta",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.359375,
            "end_logit": 9.6484375,
            "text": "itis is the all-encompassing pathological term ascribed to inflammation of the aorta",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.37890625,
            "end_logit": 9.6484375,
            "text": "of the aorta",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.4609375,
            "end_logit": 9.6484375,
            "text": "-encompassing pathological term ascribed to inflammation of the aorta",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.7265625,
            "end_logit": -7.78125,
            "text": "inflammation of the",
            "probability": 0.0
        },
        {
            "start_logit": -1.1552734375,
            "end_logit": 1.3193359375,
            "text": "aorta.",
            "probability": 0.0
        }
    ],
    "5891c90949702f2e01000001_1": [
        {
            "start_logit": 9.6328125,
            "end_logit": 9.5234375,
            "text": "INCA",
            "probability": 1.0
        },
        {
            "start_logit": 9.6328125,
            "end_logit": -1.9482421875,
            "text": "INC",
            "probability": 1.043081283569336e-05
        },
        {
            "start_logit": -1.8935546875,
            "end_logit": 9.5234375,
            "text": "A",
            "probability": 9.834766387939453e-06
        },
        {
            "start_logit": 9.6328125,
            "end_logit": -8.09375,
            "text": "INCA: synonymous codon usage analysis and clustering by",
            "probability": 0.0
        },
        {
            "start_logit": 9.6328125,
            "end_logit": -8.1015625,
            "text": "INCA: synonymous codon usage analysis and clustering by means",
            "probability": 0.0
        },
        {
            "start_logit": 9.6328125,
            "end_logit": -8.125,
            "text": "INCA: synonymous codon usage analysis and",
            "probability": 0.0
        },
        {
            "start_logit": 9.6328125,
            "end_logit": -8.140625,
            "text": "INCA: synonymous codon usage analysis and clustering by means of self-organizing map.",
            "probability": 0.0
        },
        {
            "start_logit": 9.6328125,
            "end_logit": -8.15625,
            "text": "INCA: synonymous codon usage analysis and clustering by means of",
            "probability": 0.0
        },
        {
            "start_logit": 9.6328125,
            "end_logit": -8.1640625,
            "text": "INCA: synonymous codon usage analysis and clustering",
            "probability": 0.0
        },
        {
            "start_logit": 9.6328125,
            "end_logit": -8.1796875,
            "text": "INCA: synonymous codon usage analysis",
            "probability": 0.0
        },
        {
            "start_logit": 9.6328125,
            "end_logit": -8.1796875,
            "text": "INCA: synonymous codon usage analysis and clustering by means of self-organizing",
            "probability": 0.0
        },
        {
            "start_logit": 9.6328125,
            "end_logit": -8.1953125,
            "text": "INCA:",
            "probability": 0.0
        },
        {
            "start_logit": -1.8935546875,
            "end_logit": -8.09375,
            "text": "A: synonymous codon usage analysis and clustering by",
            "probability": 0.0
        },
        {
            "start_logit": -1.8935546875,
            "end_logit": -8.1015625,
            "text": "A: synonymous codon usage analysis and clustering by means",
            "probability": 0.0
        },
        {
            "start_logit": -1.8935546875,
            "end_logit": -8.125,
            "text": "A: synonymous codon usage analysis and",
            "probability": 0.0
        },
        {
            "start_logit": -1.8935546875,
            "end_logit": -8.140625,
            "text": "A: synonymous codon usage analysis and clustering by means of self-organizing map.",
            "probability": 0.0
        },
        {
            "start_logit": -1.8935546875,
            "end_logit": -8.15625,
            "text": "A: synonymous codon usage analysis and clustering by means of",
            "probability": 0.0
        },
        {
            "start_logit": -1.8935546875,
            "end_logit": -8.1640625,
            "text": "A: synonymous codon usage analysis and clustering",
            "probability": 0.0
        },
        {
            "start_logit": -1.8935546875,
            "end_logit": -8.1796875,
            "text": "A: synonymous codon usage analysis",
            "probability": 0.0
        },
        {
            "start_logit": -1.8935546875,
            "end_logit": -8.1796875,
            "text": "A: synonymous codon usage analysis and clustering by means of self-organizing",
            "probability": 0.0
        }
    ],
    "5891c90949702f2e01000001_2": [
        {
            "start_logit": 9.7734375,
            "end_logit": 9.3125,
            "text": "INCA",
            "probability": 1.0
        },
        {
            "start_logit": 9.7734375,
            "end_logit": -1.4541015625,
            "text": "INC",
            "probability": 2.092123031616211e-05
        },
        {
            "start_logit": -2.09375,
            "end_logit": 9.3125,
            "text": "A",
            "probability": 6.973743438720703e-06
        },
        {
            "start_logit": -4.8515625,
            "end_logit": 9.3125,
            "text": "INteractive Codon usage Analysis (INCA",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 9.7734375,
            "end_logit": -6.62109375,
            "text": "INCA) provides an array of features useful in analysis of synonymous codon usage in whole genomes.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.7734375,
            "end_logit": -7.515625,
            "text": "INCA) provides an array of features useful in analysis of synonymous codon usage in whole genomes. In addition to computing codon frequencies and several usage indices, such as 'codon bias",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.1328125,
            "end_logit": 9.3125,
            "text": "Codon usage Analysis (INCA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.53125,
            "end_logit": 9.3125,
            "text": "(INCA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -4.8515625,
            "end_logit": -1.4541015625,
            "text": "INteractive Codon usage Analysis (INC",
            "probability": 0.0
        },
        {
            "start_logit": -3.150390625,
            "end_logit": -3.828125,
            "text": "the self-organizing map",
            "probability": 0.0
        },
        {
            "start_logit": -7.1328125,
            "end_logit": -1.4541015625,
            "text": "Codon usage Analysis (INC",
            "probability": 0.0
        },
        {
            "start_logit": -2.09375,
            "end_logit": -6.62109375,
            "text": "A) provides an array of features useful in analysis of synonymous codon usage in whole genomes.",
            "probability": 0.0
        },
        {
            "start_logit": -7.53125,
            "end_logit": -1.4541015625,
            "text": "(INC",
            "probability": 0.0
        },
        {
            "start_logit": -2.09375,
            "end_logit": -7.515625,
            "text": "A) provides an array of features useful in analysis of synonymous codon usage in whole genomes. In addition to computing codon frequencies and several usage indices, such as 'codon bias",
            "probability": 0.0
        },
        {
            "start_logit": -3.150390625,
            "end_logit": -6.62109375,
            "text": "the self-organizing map, used for gene clustering according to the preferred utilization of codons.",
            "probability": 0.0
        },
        {
            "start_logit": -6.109375,
            "end_logit": -3.828125,
            "text": ". Finally, INCA includes a specific unsupervised neural network algorithm, the self-organizing map",
            "probability": 0.0
        },
        {
            "start_logit": -3.150390625,
            "end_logit": -7.44140625,
            "text": "the self-organizing map, used for gene clustering",
            "probability": 0.0
        },
        {
            "start_logit": -3.150390625,
            "end_logit": -7.4453125,
            "text": "the self-organizing map,",
            "probability": 0.0
        },
        {
            "start_logit": -7.390625,
            "end_logit": -3.828125,
            "text": "INCA includes a specific unsupervised neural network algorithm, the self-organizing map",
            "probability": 0.0
        },
        {
            "start_logit": -7.48828125,
            "end_logit": -3.828125,
            "text": "interactive graphical display of calculated values, thus allowing visual detection of various trends in codon usage. Finally, INCA includes a specific unsupervised neural network algorithm, the self-organizing map",
            "probability": 0.0
        }
    ],
    "5891c90949702f2e01000001_3": [
        {
            "start_logit": 9.28125,
            "end_logit": 9.1484375,
            "text": "INCA",
            "probability": 1.0
        },
        {
            "start_logit": -1.5625,
            "end_logit": 9.1484375,
            "text": "INteractive Codon usage Analysis (INCA",
            "probability": 1.9371509552001953e-05
        },
        {
            "start_logit": 9.28125,
            "end_logit": -2.08984375,
            "text": "INC",
            "probability": 1.2993812561035156e-05
        },
        {
            "start_logit": -2.275390625,
            "end_logit": 9.1484375,
            "text": "A",
            "probability": 9.5367431640625e-06
        },
        {
            "start_logit": 9.28125,
            "end_logit": -5.74609375,
            "text": "INCA)",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -5.86328125,
            "end_logit": 9.1484375,
            "text": "UNLABELLED: INteractive Codon usage Analysis (INCA",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.28125,
            "end_logit": -6.54296875,
            "text": "INCA) provides an array of features useful in analysis of synonymous codon usage in whole genomes.",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.28125,
            "end_logit": -7.30859375,
            "text": "INCA) provides",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.32421875,
            "end_logit": 9.1484375,
            "text": "Codon usage Analysis (INCA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.484375,
            "end_logit": 9.1484375,
            "text": ": INteractive Codon usage Analysis (INCA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.28125,
            "end_logit": -7.6640625,
            "text": "INCA) provides an",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.64453125,
            "end_logit": 9.1484375,
            "text": "(INCA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.28125,
            "end_logit": -7.87109375,
            "text": "INCA) provides an array of features useful",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.28125,
            "end_logit": -7.8828125,
            "text": "INCA) provides an array of features useful in analysis of synonymous codon usage in whole genomes",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.28125,
            "end_logit": -7.91796875,
            "text": "INCA) provides an array of features useful in analysis of synonymous codon usage in",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.28125,
            "end_logit": -7.953125,
            "text": "INCA) provides an array of",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.28125,
            "end_logit": -7.99609375,
            "text": "INCA) provides an array",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.95703125,
            "end_logit": 9.1484375,
            "text": "usage Analysis (INCA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.5625,
            "end_logit": -2.08984375,
            "text": "INteractive Codon usage Analysis (INC",
            "probability": 0.0
        },
        {
            "start_logit": -1.5625,
            "end_logit": -5.74609375,
            "text": "INteractive Codon usage Analysis (INCA)",
            "probability": 0.0
        }
    ],
    "5891c90949702f2e01000001_4": [
        {
            "start_logit": 9.609375,
            "end_logit": 9.5234375,
            "text": "INCA",
            "probability": 1.0
        },
        {
            "start_logit": -1.892578125,
            "end_logit": 9.5234375,
            "text": "A",
            "probability": 1.0192394256591797e-05
        },
        {
            "start_logit": 9.609375,
            "end_logit": -1.9951171875,
            "text": "INC",
            "probability": 9.953975677490234e-06
        },
        {
            "start_logit": 9.609375,
            "end_logit": -8.0625,
            "text": "INCA: synonymous codon usage analysis and clustering by means",
            "probability": 0.0
        },
        {
            "start_logit": 9.609375,
            "end_logit": -8.078125,
            "text": "INCA: synonymous codon usage analysis and clustering by",
            "probability": 0.0
        },
        {
            "start_logit": 9.609375,
            "end_logit": -8.1171875,
            "text": "INCA: synonymous codon usage analysis and",
            "probability": 0.0
        },
        {
            "start_logit": 9.609375,
            "end_logit": -8.140625,
            "text": "INCA: synonymous codon usage analysis and clustering by means of",
            "probability": 0.0
        },
        {
            "start_logit": 9.609375,
            "end_logit": -8.1640625,
            "text": "INCA: synonymous codon usage analysis and clustering",
            "probability": 0.0
        },
        {
            "start_logit": 9.609375,
            "end_logit": -8.171875,
            "text": "INCA: synonymous codon usage analysis and clustering by means of self-organizing map",
            "probability": 0.0
        },
        {
            "start_logit": 9.609375,
            "end_logit": -8.1796875,
            "text": "INCA: synonymous codon usage analysis and clustering by means of self-organizing",
            "probability": 0.0
        },
        {
            "start_logit": 9.609375,
            "end_logit": -8.203125,
            "text": "INCA: synonymous codon usage analysis",
            "probability": 0.0
        },
        {
            "start_logit": 9.609375,
            "end_logit": -8.234375,
            "text": "INCA:",
            "probability": 0.0
        },
        {
            "start_logit": -1.892578125,
            "end_logit": -8.0625,
            "text": "A: synonymous codon usage analysis and clustering by means",
            "probability": 0.0
        },
        {
            "start_logit": -1.892578125,
            "end_logit": -8.078125,
            "text": "A: synonymous codon usage analysis and clustering by",
            "probability": 0.0
        },
        {
            "start_logit": -1.892578125,
            "end_logit": -8.1171875,
            "text": "A: synonymous codon usage analysis and",
            "probability": 0.0
        },
        {
            "start_logit": -1.892578125,
            "end_logit": -8.140625,
            "text": "A: synonymous codon usage analysis and clustering by means of",
            "probability": 0.0
        },
        {
            "start_logit": -1.892578125,
            "end_logit": -8.1640625,
            "text": "A: synonymous codon usage analysis and clustering",
            "probability": 0.0
        },
        {
            "start_logit": -1.892578125,
            "end_logit": -8.171875,
            "text": "A: synonymous codon usage analysis and clustering by means of self-organizing map",
            "probability": 0.0
        },
        {
            "start_logit": -1.892578125,
            "end_logit": -8.1796875,
            "text": "A: synonymous codon usage analysis and clustering by means of self-organizing",
            "probability": 0.0
        },
        {
            "start_logit": -1.892578125,
            "end_logit": -8.203125,
            "text": "A: synonymous codon usage analysis",
            "probability": 0.0
        }
    ],
    "5891c90949702f2e01000001_5": [
        {
            "start_logit": 9.546875,
            "end_logit": 9.4140625,
            "text": "INCA",
            "probability": 1.0
        },
        {
            "start_logit": 9.546875,
            "end_logit": -1.8818359375,
            "text": "INC",
            "probability": 1.233816146850586e-05
        },
        {
            "start_logit": -1.8564453125,
            "end_logit": 9.4140625,
            "text": "A",
            "probability": 1.1146068572998047e-05
        },
        {
            "start_logit": -4.41796875,
            "end_logit": 9.4140625,
            "text": "INteractive Codon usage Analysis (INCA",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": 9.546875,
            "end_logit": -6.1015625,
            "text": "INCA)",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.546875,
            "end_logit": -7.59375,
            "text": "INCA) provides",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5390625,
            "end_logit": 9.4140625,
            "text": "Codon usage Analysis (INCA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.546875,
            "end_logit": -7.734375,
            "text": "INCA) provides an array of features useful in analysis of synonymous codon usage in whole genomes",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.546875,
            "end_logit": -7.80078125,
            "text": "INCA) provides an",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.546875,
            "end_logit": -7.8203125,
            "text": "INCA) provides an array of features useful",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.546875,
            "end_logit": -7.83984375,
            "text": "INCA) provides an array of features useful in analysis of synonymous codon usage in",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.546875,
            "end_logit": -7.91015625,
            "text": "INCA) provides an array of features useful in analysis of synonymous codon usage in whole",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.546875,
            "end_logit": -7.94140625,
            "text": "INCA) provides an array of",
            "probability": 0.0
        },
        {
            "start_logit": 9.546875,
            "end_logit": -7.99609375,
            "text": "INCA) provides an array",
            "probability": 0.0
        },
        {
            "start_logit": 9.546875,
            "end_logit": -8.015625,
            "text": "INCA) provides an array of features useful in",
            "probability": 0.0
        },
        {
            "start_logit": 9.546875,
            "end_logit": -8.03125,
            "text": "INCA) provides an array of features useful in analysis",
            "probability": 0.0
        },
        {
            "start_logit": 9.546875,
            "end_logit": -8.0703125,
            "text": "INCA) provides an array of features useful in analysis of synonymous codon usage",
            "probability": 0.0
        },
        {
            "start_logit": -7.94921875,
            "end_logit": 9.4140625,
            "text": "(INCA",
            "probability": 0.0
        },
        {
            "start_logit": -8.09375,
            "end_logit": 9.4140625,
            "text": "usage Analysis (INCA",
            "probability": 0.0
        },
        {
            "start_logit": -4.41796875,
            "end_logit": -1.8818359375,
            "text": "INteractive Codon usage Analysis (INC",
            "probability": 0.0
        }
    ],
    "5891c90949702f2e01000001_6": [
        {
            "start_logit": 9.6171875,
            "end_logit": 9.46875,
            "text": "INCA",
            "probability": 1.0
        },
        {
            "start_logit": 9.6171875,
            "end_logit": -1.859375,
            "text": "INC",
            "probability": 1.1920928955078125e-05
        },
        {
            "start_logit": -1.85546875,
            "end_logit": 9.46875,
            "text": "A",
            "probability": 1.0311603546142578e-05
        },
        {
            "start_logit": -5.23046875,
            "end_logit": 9.46875,
            "text": "INteractive Codon usage Analysis (INCA",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 9.6171875,
            "end_logit": -7.14453125,
            "text": "INCA) provides an array of features useful in analysis of synonymous codon usage in whole genomes.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.6171875,
            "end_logit": -7.296875,
            "text": "INCA)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.6171875,
            "end_logit": -7.62890625,
            "text": "INCA) provides",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5390625,
            "end_logit": 9.46875,
            "text": "Codon usage Analysis (INCA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.6171875,
            "end_logit": -7.8984375,
            "text": "INCA) provides an",
            "probability": 0.0
        },
        {
            "start_logit": 9.6171875,
            "end_logit": -7.9453125,
            "text": "INCA) provides an array of features useful",
            "probability": 0.0
        },
        {
            "start_logit": 9.6171875,
            "end_logit": -7.97265625,
            "text": "INCA) provides an array of",
            "probability": 0.0
        },
        {
            "start_logit": 9.6171875,
            "end_logit": -7.9921875,
            "text": "INCA) provides an array of features useful in analysis of synonymous codon usage in",
            "probability": 0.0
        },
        {
            "start_logit": 9.6171875,
            "end_logit": -8.03125,
            "text": "INCA) provides an array of features useful in analysis of synonymous codon usage in whole genomes",
            "probability": 0.0
        },
        {
            "start_logit": -7.89453125,
            "end_logit": 9.46875,
            "text": "(INCA",
            "probability": 0.0
        },
        {
            "start_logit": 9.6171875,
            "end_logit": -8.0625,
            "text": "INCA) provides an array",
            "probability": 0.0
        },
        {
            "start_logit": -8.0859375,
            "end_logit": 9.46875,
            "text": "usage Analysis (INCA",
            "probability": 0.0
        },
        {
            "start_logit": -5.23046875,
            "end_logit": -1.859375,
            "text": "INteractive Codon usage Analysis (INC",
            "probability": 0.0
        },
        {
            "start_logit": -1.85546875,
            "end_logit": -7.14453125,
            "text": "A) provides an array of features useful in analysis of synonymous codon usage in whole genomes.",
            "probability": 0.0
        },
        {
            "start_logit": -1.85546875,
            "end_logit": -7.296875,
            "text": "A)",
            "probability": 0.0
        },
        {
            "start_logit": -7.5390625,
            "end_logit": -1.859375,
            "text": "Codon usage Analysis (INC",
            "probability": 0.0
        }
    ],
    "5891c90949702f2e01000001_7": [
        {
            "start_logit": 9.515625,
            "end_logit": 9.078125,
            "text": "INCA",
            "probability": 0.9990234375
        },
        {
            "start_logit": 2.580078125,
            "end_logit": 9.078125,
            "text": "INteractive Codon usage Analysis (INCA",
            "probability": 0.0009698867797851562
        },
        {
            "start_logit": 9.515625,
            "end_logit": -1.7099609375,
            "text": "INC",
            "probability": 2.0623207092285156e-05
        },
        {
            "start_logit": -2.3671875,
            "end_logit": 9.078125,
            "text": "A",
            "probability": 6.9141387939453125e-06
        },
        {
            "start_logit": 9.515625,
            "end_logit": -5.09375,
            "text": "INCA)",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 9.515625,
            "end_logit": -6.13671875,
            "text": "INCA) provides an array of features useful in analysis of synonymous codon usage in whole genomes.",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.39453125,
            "end_logit": 9.078125,
            "text": "(INCA",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.78515625,
            "end_logit": 9.078125,
            "text": "Codon usage Analysis (INCA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.515625,
            "end_logit": -7.3515625,
            "text": "INCA) provides an array of features useful in analysis of synonymous codon usage in whole genomes. In addition to computing codon frequencies and several usage indices, such as 'codon bias",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 2.580078125,
            "end_logit": -1.7099609375,
            "text": "INteractive Codon usage Analysis (INC",
            "probability": 0.0
        },
        {
            "start_logit": 2.580078125,
            "end_logit": -5.09375,
            "text": "INteractive Codon usage Analysis (INCA)",
            "probability": 0.0
        },
        {
            "start_logit": 2.580078125,
            "end_logit": -5.37109375,
            "text": "INteractive Codon usage Analysis",
            "probability": 0.0
        },
        {
            "start_logit": 2.580078125,
            "end_logit": -6.13671875,
            "text": "INteractive Codon usage Analysis (INCA) provides an array of features useful in analysis of synonymous codon usage in whole genomes.",
            "probability": 0.0
        },
        {
            "start_logit": -1.6943359375,
            "end_logit": -2.556640625,
            "text": "the self-organizing map",
            "probability": 0.0
        },
        {
            "start_logit": 2.580078125,
            "end_logit": -7.2578125,
            "text": "INteractive Codon usage",
            "probability": 0.0
        },
        {
            "start_logit": 2.580078125,
            "end_logit": -7.3515625,
            "text": "INteractive Codon usage Analysis (INCA) provides an array of features useful in analysis of synonymous codon usage in whole genomes. In addition to computing codon frequencies and several usage indices, such as 'codon bias",
            "probability": 0.0
        },
        {
            "start_logit": 2.580078125,
            "end_logit": -7.44921875,
            "text": "INteractive",
            "probability": 0.0
        },
        {
            "start_logit": -2.3671875,
            "end_logit": -5.09375,
            "text": "A)",
            "probability": 0.0
        },
        {
            "start_logit": -1.6943359375,
            "end_logit": -6.13671875,
            "text": "the self-organizing map, used for gene clustering according to the preferred utilization of codons.AVAILABILITY: INCA is available for the Win32 platform and is free of charge for academic use.",
            "probability": 0.0
        },
        {
            "start_logit": -1.6943359375,
            "end_logit": -6.13671875,
            "text": "the self-organizing map, used for gene clustering according to the preferred utilization of codons.",
            "probability": 0.0
        }
    ],
    "5891c90949702f2e01000001_8": [
        {
            "start_logit": 9.6875,
            "end_logit": 9.3203125,
            "text": "INCA",
            "probability": 1.0
        },
        {
            "start_logit": 0.262451171875,
            "end_logit": 9.3203125,
            "text": "INteractive Codon usage Analysis (INCA",
            "probability": 8.153915405273438e-05
        },
        {
            "start_logit": 9.6875,
            "end_logit": -1.4501953125,
            "text": "INC",
            "probability": 2.110004425048828e-05
        },
        {
            "start_logit": -2.029296875,
            "end_logit": 9.3203125,
            "text": "A",
            "probability": 8.225440979003906e-06
        },
        {
            "start_logit": 9.6875,
            "end_logit": -5.52734375,
            "text": "INCA)",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 9.6875,
            "end_logit": -6.43359375,
            "text": "INCA) provides an array of features useful in analysis of synonymous codon usage in whole genomes.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.36328125,
            "end_logit": 9.3203125,
            "text": "UNLABELLED: INteractive Codon usage Analysis (INCA",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.859375,
            "end_logit": 9.3203125,
            "text": "(INCA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.6875,
            "end_logit": -7.48046875,
            "text": "INCA) provides an array of features useful in analysis of synonymous codon usage in whole genomes. In addition to computing codon frequencies and several usage indices, such as 'codon bias",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.6875,
            "end_logit": -7.55859375,
            "text": "INCA) provides",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.23828125,
            "end_logit": 9.3203125,
            "text": "Codon usage Analysis (INCA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.6875,
            "end_logit": -7.77734375,
            "text": "INCA) provides an",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.6875,
            "end_logit": -7.8125,
            "text": "INCA) provides an array of features useful in analysis of synonymous codon usage in whole genomes. In addition",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.8359375,
            "end_logit": 9.3203125,
            "text": ": INteractive Codon usage Analysis (INCA",
            "probability": 0.0
        },
        {
            "start_logit": 0.262451171875,
            "end_logit": -1.4501953125,
            "text": "INteractive Codon usage Analysis (INC",
            "probability": 0.0
        },
        {
            "start_logit": 0.262451171875,
            "end_logit": -5.48046875,
            "text": "INteractive Codon usage Analysis",
            "probability": 0.0
        },
        {
            "start_logit": 0.262451171875,
            "end_logit": -5.52734375,
            "text": "INteractive Codon usage Analysis (INCA)",
            "probability": 0.0
        },
        {
            "start_logit": 0.262451171875,
            "end_logit": -6.43359375,
            "text": "INteractive Codon usage Analysis (INCA) provides an array of features useful in analysis of synonymous codon usage in whole genomes.",
            "probability": 0.0
        },
        {
            "start_logit": 0.262451171875,
            "end_logit": -7.35546875,
            "text": "INteractive Codon usage",
            "probability": 0.0
        },
        {
            "start_logit": 0.262451171875,
            "end_logit": -7.48046875,
            "text": "INteractive Codon usage Analysis (INCA) provides an array of features useful in analysis of synonymous codon usage in whole genomes. In addition to computing codon frequencies and several usage indices, such as 'codon bias",
            "probability": 0.0
        }
    ],
    "5891c90949702f2e01000001_9": [
        {
            "start_logit": 9.6796875,
            "end_logit": 9.1953125,
            "text": "INCA",
            "probability": 1.0
        },
        {
            "start_logit": 9.6796875,
            "end_logit": -1.8095703125,
            "text": "INC",
            "probability": 1.6689300537109375e-05
        },
        {
            "start_logit": -2.443359375,
            "end_logit": 9.1953125,
            "text": "A",
            "probability": 5.424022674560547e-06
        },
        {
            "start_logit": 9.6796875,
            "end_logit": -6.74609375,
            "text": "INCA has numerous options for the interactive graphical display of calculated values, thus allowing visual detection of various trends in codon usage.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.6796875,
            "end_logit": -6.921875,
            "text": "INCA has numerous options for the interactive graphical display of calculated values, thus allowing visual detection of various trends in codon usage. Finally, INCA includes a specific unsupervised neural network",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.6796875,
            "end_logit": -7.32421875,
            "text": "INCA has",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.6796875,
            "end_logit": -7.390625,
            "text": "INCA has numerous options for the interactive graphical display of calculated values, thus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.6796875,
            "end_logit": -7.4296875,
            "text": "INCA has numerous options for the interactive graphical display of calculated values, thus allowing",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.94921875,
            "end_logit": 9.1953125,
            "text": "of INCA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.6796875,
            "end_logit": -7.76171875,
            "text": "INCA has numerous options for the interactive graphical display of calculated values, thus allowing visual detection of various trends in codon usage",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.6796875,
            "end_logit": -7.76171875,
            "text": "INCA has numerous",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.59765625,
            "end_logit": 9.1953125,
            "text": "codon bias', effective Nc and CAI, the primary strength of INCA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.84765625,
            "end_logit": 9.1953125,
            "text": "codon frequencies and several usage indices, such as 'codon bias', effective Nc and CAI, the primary strength of INCA",
            "probability": 0.0
        },
        {
            "start_logit": -6.94921875,
            "end_logit": -1.8095703125,
            "text": "of INC",
            "probability": 0.0
        },
        {
            "start_logit": -2.443359375,
            "end_logit": -6.74609375,
            "text": "A has numerous options for the interactive graphical display of calculated values, thus allowing visual detection of various trends in codon usage.",
            "probability": 0.0
        },
        {
            "start_logit": -2.443359375,
            "end_logit": -6.921875,
            "text": "A has numerous options for the interactive graphical display of calculated values, thus allowing visual detection of various trends in codon usage. Finally, INCA includes a specific unsupervised neural network",
            "probability": 0.0
        },
        {
            "start_logit": -7.59765625,
            "end_logit": -1.8095703125,
            "text": "codon bias', effective Nc and CAI, the primary strength of INC",
            "probability": 0.0
        },
        {
            "start_logit": -7.84765625,
            "end_logit": -1.8095703125,
            "text": "codon frequencies and several usage indices, such as 'codon bias', effective Nc and CAI, the primary strength of INC",
            "probability": 0.0
        },
        {
            "start_logit": -2.443359375,
            "end_logit": -7.32421875,
            "text": "A has",
            "probability": 0.0
        },
        {
            "start_logit": -2.443359375,
            "end_logit": -7.390625,
            "text": "A has numerous options for the interactive graphical display of calculated values, thus",
            "probability": 0.0
        }
    ],
    "5891c90949702f2e01000001_10": [
        {
            "start_logit": 9.65625,
            "end_logit": 9.484375,
            "text": "INCA",
            "probability": 1.0
        },
        {
            "start_logit": 9.65625,
            "end_logit": -1.89453125,
            "text": "INC",
            "probability": 1.150369644165039e-05
        },
        {
            "start_logit": -1.966796875,
            "end_logit": 9.484375,
            "text": "A",
            "probability": 8.940696716308594e-06
        },
        {
            "start_logit": 9.65625,
            "end_logit": -7.5703125,
            "text": "INCA includes a specific unsupervised neural network algorithm, the self-organizing map, used for gene clustering according to the preferred utilization of codons.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.65625,
            "end_logit": -7.609375,
            "text": "INCA includes a specific unsupervised neural network",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.65625,
            "end_logit": -7.828125,
            "text": "INCA includes a specific unsupervised neural network algorithm, the self-organizing map",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.65625,
            "end_logit": -7.84375,
            "text": "INCA includes",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.65625,
            "end_logit": -7.86328125,
            "text": "INCA includes a specific unsupervised neural network algorithm, the self-organizing map,",
            "probability": 0.0
        },
        {
            "start_logit": 9.65625,
            "end_logit": -7.91015625,
            "text": "INCA includes a specific unsupervised neural network algorithm, the self-organizing map, used",
            "probability": 0.0
        },
        {
            "start_logit": 9.65625,
            "end_logit": -7.921875,
            "text": "INCA includes a specific unsupervised neural network algorithm, the self-organizing map, used for gene clustering",
            "probability": 0.0
        },
        {
            "start_logit": 9.65625,
            "end_logit": -8.0078125,
            "text": "INCA includes a specific unsupervised neural network algorithm, the self-organizing map, used for gene clustering according to the preferred utilization of codons.AVAILABILITY: INCA is available",
            "probability": 0.0
        },
        {
            "start_logit": 9.65625,
            "end_logit": -8.0078125,
            "text": "INCA includes a specific unsupervised neural network algorithm, the self-organizing",
            "probability": 0.0
        },
        {
            "start_logit": 9.65625,
            "end_logit": -8.015625,
            "text": "INCA includes a",
            "probability": 0.0
        },
        {
            "start_logit": 9.65625,
            "end_logit": -8.0390625,
            "text": "INCA includes a specific unsupervised neural network algorithm, the self-",
            "probability": 0.0
        },
        {
            "start_logit": 9.65625,
            "end_logit": -8.046875,
            "text": "INCA includes a specific unsupervised neural network algorithm, the self-organizing map, used for gene clustering according",
            "probability": 0.0
        },
        {
            "start_logit": -7.88671875,
            "end_logit": 9.484375,
            "text": ", INCA",
            "probability": 0.0
        },
        {
            "start_logit": 9.65625,
            "end_logit": -8.0625,
            "text": "INCA includes a specific unsupervised neural network algorithm,",
            "probability": 0.0
        },
        {
            "start_logit": 9.65625,
            "end_logit": -8.0625,
            "text": "INCA includes a specific unsupervised neural network algorithm, the self-organizing map, used for gene clustering according to the preferred utilization of codons.AVAILABILITY: INCA is available for the Win32 platform and",
            "probability": 0.0
        },
        {
            "start_logit": 9.65625,
            "end_logit": -8.0625,
            "text": "INCA includes a specific unsupervised neural network algorithm, the self-organizing map, used for gene clustering according to",
            "probability": 0.0
        },
        {
            "start_logit": -1.966796875,
            "end_logit": -7.5703125,
            "text": "A includes a specific unsupervised neural network algorithm, the self-organizing map, used for gene clustering according to the preferred utilization of codons.",
            "probability": 0.0
        }
    ],
    "5891c90949702f2e01000001_11": [
        {
            "start_logit": 9.6328125,
            "end_logit": 9.5234375,
            "text": "INCA",
            "probability": 1.0
        },
        {
            "start_logit": 9.6328125,
            "end_logit": -1.9482421875,
            "text": "INC",
            "probability": 1.043081283569336e-05
        },
        {
            "start_logit": -1.8935546875,
            "end_logit": 9.5234375,
            "text": "A",
            "probability": 9.834766387939453e-06
        },
        {
            "start_logit": 9.6328125,
            "end_logit": -8.09375,
            "text": "INCA: synonymous codon usage analysis and clustering by",
            "probability": 0.0
        },
        {
            "start_logit": 9.6328125,
            "end_logit": -8.1015625,
            "text": "INCA: synonymous codon usage analysis and clustering by means",
            "probability": 0.0
        },
        {
            "start_logit": 9.6328125,
            "end_logit": -8.125,
            "text": "INCA: synonymous codon usage analysis and",
            "probability": 0.0
        },
        {
            "start_logit": 9.6328125,
            "end_logit": -8.140625,
            "text": "INCA: synonymous codon usage analysis and clustering by means of self-organizing map.",
            "probability": 0.0
        },
        {
            "start_logit": 9.6328125,
            "end_logit": -8.15625,
            "text": "INCA: synonymous codon usage analysis and clustering by means of",
            "probability": 0.0
        },
        {
            "start_logit": 9.6328125,
            "end_logit": -8.1640625,
            "text": "INCA: synonymous codon usage analysis and clustering",
            "probability": 0.0
        },
        {
            "start_logit": 9.6328125,
            "end_logit": -8.1796875,
            "text": "INCA: synonymous codon usage analysis",
            "probability": 0.0
        },
        {
            "start_logit": 9.6328125,
            "end_logit": -8.1796875,
            "text": "INCA: synonymous codon usage analysis and clustering by means of self-organizing",
            "probability": 0.0
        },
        {
            "start_logit": 9.6328125,
            "end_logit": -8.1953125,
            "text": "INCA:",
            "probability": 0.0
        },
        {
            "start_logit": -1.8935546875,
            "end_logit": -8.09375,
            "text": "A: synonymous codon usage analysis and clustering by",
            "probability": 0.0
        },
        {
            "start_logit": -1.8935546875,
            "end_logit": -8.1015625,
            "text": "A: synonymous codon usage analysis and clustering by means",
            "probability": 0.0
        },
        {
            "start_logit": -1.8935546875,
            "end_logit": -8.125,
            "text": "A: synonymous codon usage analysis and",
            "probability": 0.0
        },
        {
            "start_logit": -1.8935546875,
            "end_logit": -8.140625,
            "text": "A: synonymous codon usage analysis and clustering by means of self-organizing map.",
            "probability": 0.0
        },
        {
            "start_logit": -1.8935546875,
            "end_logit": -8.15625,
            "text": "A: synonymous codon usage analysis and clustering by means of",
            "probability": 0.0
        },
        {
            "start_logit": -1.8935546875,
            "end_logit": -8.1640625,
            "text": "A: synonymous codon usage analysis and clustering",
            "probability": 0.0
        },
        {
            "start_logit": -1.8935546875,
            "end_logit": -8.1796875,
            "text": "A: synonymous codon usage analysis",
            "probability": 0.0
        },
        {
            "start_logit": -1.8935546875,
            "end_logit": -8.1796875,
            "text": "A: synonymous codon usage analysis and clustering by means of self-organizing",
            "probability": 0.0
        }
    ],
    "6277e4ee56bf9aee6f000008_1": [
        {
            "start_logit": 5.71484375,
            "end_logit": 1.892578125,
            "text": "acetaminophen",
            "probability": 0.9990234375
        },
        {
            "start_logit": 5.71484375,
            "end_logit": -6.0859375,
            "text": "acetaminophen for controlling fever and inflammation and be cautious about using NSAIDs in management of COVID-19 patients until there are enough evidence.",
            "probability": 0.0003418922424316406
        },
        {
            "start_logit": 5.71484375,
            "end_logit": -6.4765625,
            "text": "acetaminophen for controlling fever and inflammation and be cautious about using NSAIDs",
            "probability": 0.00023031234741210938
        },
        {
            "start_logit": 5.71484375,
            "end_logit": -7.33984375,
            "text": "acetaminophen for controlling fever and inflammation",
            "probability": 9.751319885253906e-05
        },
        {
            "start_logit": 5.71484375,
            "end_logit": -7.609375,
            "text": "acetaminophen for",
            "probability": 7.480382919311523e-05
        },
        {
            "start_logit": 5.71484375,
            "end_logit": -7.640625,
            "text": "acetaminophen for controlling fever and inflammation and be cautious about",
            "probability": 7.2479248046875e-05
        },
        {
            "start_logit": -5.99609375,
            "end_logit": 1.892578125,
            "text": "substitutes such as acetaminophen",
            "probability": 8.225440979003906e-06
        },
        {
            "start_logit": -6.35546875,
            "end_logit": 1.892578125,
            "text": "as acetaminophen",
            "probability": 5.7220458984375e-06
        },
        {
            "start_logit": -2.404296875,
            "end_logit": -2.509765625,
            "text": "NSAIDs",
            "probability": 3.635883331298828e-06
        },
        {
            "start_logit": -7.8984375,
            "end_logit": 1.892578125,
            "text": "use substitutes such as acetaminophen",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": -2.404296875,
            "end_logit": -7.5703125,
            "text": "NSAIDs have",
            "probability": 0.0
        },
        {
            "start_logit": -2.404296875,
            "end_logit": -7.67578125,
            "text": "NSAIDs have been effective in treating respiratory infections caused by influenza and rhinovirus, since there is no clinical trial on COVID-19 and case-reports and clinical experiences are indicative of elongation of treatment duration",
            "probability": 0.0
        },
        {
            "start_logit": -7.9921875,
            "end_logit": -2.509765625,
            "text": ", NSAIDs",
            "probability": 0.0
        },
        {
            "start_logit": -5.99609375,
            "end_logit": -6.0859375,
            "text": "substitutes such as acetaminophen for controlling fever and inflammation and be cautious about using NSAIDs in management of COVID-19 patients until there are enough evidence.",
            "probability": 0.0
        },
        {
            "start_logit": -6.16015625,
            "end_logit": -6.0859375,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -6.35546875,
            "end_logit": -6.0859375,
            "text": "as acetaminophen for controlling fever and inflammation and be cautious about using NSAIDs in management of COVID-19 patients until there are enough evidence.",
            "probability": 0.0
        },
        {
            "start_logit": -5.99609375,
            "end_logit": -6.4765625,
            "text": "substitutes such as acetaminophen for controlling fever and inflammation and be cautious about using NSAIDs",
            "probability": 0.0
        },
        {
            "start_logit": -5.99609375,
            "end_logit": -6.671875,
            "text": "substitutes",
            "probability": 0.0
        },
        {
            "start_logit": -6.35546875,
            "end_logit": -6.4765625,
            "text": "as acetaminophen for controlling fever and inflammation and be cautious about using NSAIDs",
            "probability": 0.0
        },
        {
            "start_logit": -6.91796875,
            "end_logit": -6.0859375,
            "text": "NSAIDs in management of COVID-19 patients until there are enough evidence.",
            "probability": 0.0
        }
    ],
    "6277e4ee56bf9aee6f000008_2": [
        {
            "start_logit": 1.845703125,
            "end_logit": 3.07421875,
            "text": "pain",
            "probability": 0.9873046875
        },
        {
            "start_logit": -2.921875,
            "end_logit": 3.07421875,
            "text": "ibuprofen can be safely administered for pain",
            "probability": 0.0083770751953125
        },
        {
            "start_logit": -4.79296875,
            "end_logit": 3.07421875,
            "text": ". As per the current strength of evidence, acetaminophen and ibuprofen can be safely administered for pain",
            "probability": 0.0012903213500976562
        },
        {
            "start_logit": 1.845703125,
            "end_logit": -3.908203125,
            "text": "pain management in children with COVID-19.",
            "probability": 0.0009145736694335938
        },
        {
            "start_logit": -5.94921875,
            "end_logit": 3.07421875,
            "text": "NSAIDS, spasmolytics etc. can be used if non-pharmacological therapy is inadequate. As per the current strength of evidence, acetaminophen and ibuprofen can be safely administered for pain",
            "probability": 0.0004057884216308594
        },
        {
            "start_logit": -2.921875,
            "end_logit": -0.51025390625,
            "text": "ibuprofen",
            "probability": 0.00023305416107177734
        },
        {
            "start_logit": -6.9453125,
            "end_logit": 3.07421875,
            "text": ", acetaminophen and ibuprofen can be safely administered for pain",
            "probability": 0.00014925003051757812
        },
        {
            "start_logit": 1.845703125,
            "end_logit": -5.73046875,
            "text": "pain management",
            "probability": 0.0001481771469116211
        },
        {
            "start_logit": -7.06640625,
            "end_logit": 3.07421875,
            "text": "acetaminophen and ibuprofen can be safely administered for pain",
            "probability": 0.0001327991485595703
        },
        {
            "start_logit": -7.11328125,
            "end_logit": 3.07421875,
            "text": "Pharmacological approaches like acetaminophen, NSAIDS, spasmolytics etc. can be used if non-pharmacological therapy is inadequate. As per the current strength of evidence, acetaminophen and ibuprofen can be safely administered for pain",
            "probability": 0.00012671947479248047
        },
        {
            "start_logit": -7.3984375,
            "end_logit": 3.07421875,
            "text": "and ibuprofen can be safely administered for pain",
            "probability": 9.489059448242188e-05
        },
        {
            "start_logit": -7.4765625,
            "end_logit": 3.07421875,
            "text": "current strength of evidence, acetaminophen and ibuprofen can be safely administered for pain",
            "probability": 8.7738037109375e-05
        },
        {
            "start_logit": -7.51953125,
            "end_logit": 3.07421875,
            "text": "for pain",
            "probability": 8.440017700195312e-05
        },
        {
            "start_logit": -7.65625,
            "end_logit": 3.07421875,
            "text": "like acetaminophen, NSAIDS, spasmolytics etc. can be used if non-pharmacological therapy is inadequate. As per the current strength of evidence, acetaminophen and ibuprofen can be safely administered for pain",
            "probability": 7.390975952148438e-05
        },
        {
            "start_logit": -7.78125,
            "end_logit": 3.07421875,
            "text": ", NSAIDS, spasmolytics etc. can be used if non-pharmacological therapy is inadequate. As per the current strength of evidence, acetaminophen and ibuprofen can be safely administered for pain",
            "probability": 6.520748138427734e-05
        },
        {
            "start_logit": -7.79296875,
            "end_logit": 3.07421875,
            "text": "spasmolytics etc. can be used if non-pharmacological therapy is inadequate. As per the current strength of evidence, acetaminophen and ibuprofen can be safely administered for pain",
            "probability": 6.41942024230957e-05
        },
        {
            "start_logit": -7.828125,
            "end_logit": 3.07421875,
            "text": "evidence, acetaminophen and ibuprofen can be safely administered for pain",
            "probability": 6.222724914550781e-05
        },
        {
            "start_logit": -7.8515625,
            "end_logit": 3.07421875,
            "text": "safely administered for pain",
            "probability": 6.031990051269531e-05
        },
        {
            "start_logit": 1.845703125,
            "end_logit": -6.70703125,
            "text": "pain management in",
            "probability": 5.5789947509765625e-05
        },
        {
            "start_logit": 1.845703125,
            "end_logit": -6.77734375,
            "text": "pain management in children",
            "probability": 5.2034854888916016e-05
        }
    ],
    "6277e4ee56bf9aee6f000008_3": [
        {
            "start_logit": 4.421875,
            "end_logit": 5.640625,
            "text": "Paracetamol",
            "probability": 1.0
        },
        {
            "start_logit": 4.421875,
            "end_logit": -3.63671875,
            "text": "Paracetamol (acetaminophen) has been proposed as an alternative to NSAIDs but there are issues with liver toxicity at high doses.",
            "probability": 9.316205978393555e-05
        },
        {
            "start_logit": 4.421875,
            "end_logit": -4.171875,
            "text": "Paracetamol (acetaminophen) has been proposed as an alternative to NSAIDs",
            "probability": 5.4776668548583984e-05
        },
        {
            "start_logit": 4.421875,
            "end_logit": -5.48046875,
            "text": "Paracetamol (acetaminophen) has been proposed as an alternative to NSAIDs but there are issues with liver toxicity at high doses. There are clearly COVID-19 cases where NSAIDs",
            "probability": 1.4722347259521484e-05
        },
        {
            "start_logit": 4.421875,
            "end_logit": -6.359375,
            "text": "Paracetamol (acetaminophen) has been proposed as an alternative to NSAIDs but there are issues with liver toxicity at high doses. There are clearly COVID-19 cases where NSAIDs should not",
            "probability": 6.139278411865234e-06
        },
        {
            "start_logit": 4.421875,
            "end_logit": -7.015625,
            "text": "Paracetamol (acetaminophen) has been proposed as an alternative to NSAIDs but there are issues with liver toxicity at high doses. There are clearly COVID-19 cases where NSAIDs should",
            "probability": 3.159046173095703e-06
        },
        {
            "start_logit": 4.421875,
            "end_logit": -7.0703125,
            "text": "Paracetamol (acetaminophen) has been proposed as an alternative to NSAIDs but there are issues with liver toxicity at high doses. There are clearly COVID-19 cases where NSAIDs should not be",
            "probability": 3.039836883544922e-06
        },
        {
            "start_logit": 4.421875,
            "end_logit": -7.21484375,
            "text": "Paracetamol (acetaminophen) has been proposed as an alternative to NSAIDs but there are issues with liver toxicity at high doses. There are clearly COVID-19 cases where NSAIDs should not be used",
            "probability": 2.6226043701171875e-06
        },
        {
            "start_logit": 4.421875,
            "end_logit": -7.34375,
            "text": "Paracetamol (acetaminophen) has",
            "probability": 2.3245811462402344e-06
        },
        {
            "start_logit": 4.421875,
            "end_logit": -7.4140625,
            "text": "Paracetamol (acetaminophen) has been proposed as an alternative to NSAIDs but",
            "probability": 2.1457672119140625e-06
        },
        {
            "start_logit": 4.421875,
            "end_logit": -7.5234375,
            "text": "Paracetamol (acetaminophen) has been proposed",
            "probability": 1.9073486328125e-06
        },
        {
            "start_logit": -4.125,
            "end_logit": -3.634765625,
            "text": "NSAIDs should not be used, but there is no strong evidence that NSAIDs must be avoided in all patients with COVID-19; clinicians must weigh these choices on an individual basis.",
            "probability": 0.0
        },
        {
            "start_logit": -4.546875,
            "end_logit": -3.63671875,
            "text": "NSAIDs but there are issues with liver toxicity at high doses.",
            "probability": 0.0
        },
        {
            "start_logit": -4.80859375,
            "end_logit": -3.63671875,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -4.80859375,
            "end_logit": -3.634765625,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -4.546875,
            "end_logit": -4.171875,
            "text": "NSAIDs",
            "probability": 0.0
        },
        {
            "start_logit": -4.125,
            "end_logit": -5.48046875,
            "text": "NSAIDs",
            "probability": 0.0
        },
        {
            "start_logit": -4.546875,
            "end_logit": -5.48046875,
            "text": "NSAIDs but there are issues with liver toxicity at high doses. There are clearly COVID-19 cases where NSAIDs",
            "probability": 0.0
        },
        {
            "start_logit": -4.80859375,
            "end_logit": -5.48046875,
            "text": ". There are clearly COVID-19 cases where NSAIDs",
            "probability": 0.0
        },
        {
            "start_logit": -4.125,
            "end_logit": -6.359375,
            "text": "NSAIDs should not",
            "probability": 0.0
        }
    ],
    "6277e4ee56bf9aee6f000008_4": [
        {
            "start_logit": 2.400390625,
            "end_logit": 2.46875,
            "text": "paracetamol",
            "probability": 0.3671875
        },
        {
            "start_logit": 2.6171875,
            "end_logit": 2.201171875,
            "text": "pain",
            "probability": 0.350341796875
        },
        {
            "start_logit": 2.400390625,
            "end_logit": 2.201171875,
            "text": "paracetamol can be listed as the first option in these patients, and then NSAIDs can also be reliably used for pain",
            "probability": 0.281494140625
        },
        {
            "start_logit": 2.6171875,
            "end_logit": -6.26953125,
            "text": "pain management",
            "probability": 7.355213165283203e-05
        },
        {
            "start_logit": 2.6171875,
            "end_logit": -6.28515625,
            "text": "pain management in patients with COVID-19 if there are no absolute contraindications such as kidney failure or gastric bleeding.",
            "probability": 7.241964340209961e-05
        },
        {
            "start_logit": 2.400390625,
            "end_logit": -6.26953125,
            "text": "paracetamol can be listed as the first option in these patients, and then NSAIDs can also be reliably used for pain management",
            "probability": 5.91278076171875e-05
        },
        {
            "start_logit": 2.400390625,
            "end_logit": -7.1328125,
            "text": "paracetamol can be listed as the first option in these patients, and then NSAIDs",
            "probability": 2.485513687133789e-05
        },
        {
            "start_logit": 2.400390625,
            "end_logit": -7.2890625,
            "text": "paracetamol can be listed as the first option in these patients, and then NSAIDs can",
            "probability": 2.1219253540039062e-05
        },
        {
            "start_logit": 2.6171875,
            "end_logit": -7.58984375,
            "text": "pain management in patients with COVID-19 if there are no absolute contraindications such",
            "probability": 1.9490718841552734e-05
        },
        {
            "start_logit": 2.400390625,
            "end_logit": -7.45703125,
            "text": "paracetamol can",
            "probability": 1.806020736694336e-05
        },
        {
            "start_logit": -7.57421875,
            "end_logit": 2.46875,
            "text": "analgesia, paracetamol",
            "probability": 1.722574234008789e-05
        },
        {
            "start_logit": 2.6171875,
            "end_logit": -7.74609375,
            "text": "pain management in patients with COVID-19 if there are",
            "probability": 1.6689300537109375e-05
        },
        {
            "start_logit": 2.6171875,
            "end_logit": -7.75390625,
            "text": "pain management in patients with COVID-19 if there are no absolute contraindications such as kidney failure",
            "probability": 1.6689300537109375e-05
        },
        {
            "start_logit": 2.400390625,
            "end_logit": -7.5703125,
            "text": "paracetamol can be listed as the first option in these patients, and then NSAIDs can also",
            "probability": 1.6033649444580078e-05
        },
        {
            "start_logit": 2.400390625,
            "end_logit": -7.58984375,
            "text": "paracetamol can be listed as the first option in these patients, and then NSAIDs can also be reliably used for pain management in patients with COVID-19 if there are no absolute contraindications such",
            "probability": 1.5795230865478516e-05
        },
        {
            "start_logit": 2.400390625,
            "end_logit": -7.7265625,
            "text": "paracetamol can be listed as the first option in these patients, and then NSAIDs can also be reliably used",
            "probability": 1.3709068298339844e-05
        },
        {
            "start_logit": 2.400390625,
            "end_logit": -7.74609375,
            "text": "paracetamol can be listed as the first option in these patients, and then NSAIDs can also be reliably used for pain management in patients with COVID-19 if there are",
            "probability": 1.3530254364013672e-05
        },
        {
            "start_logit": 2.400390625,
            "end_logit": -7.75390625,
            "text": "paracetamol can be listed as the first option in these patients, and then NSAIDs can also be reliably used for pain management in patients with COVID-19 if there are no absolute contraindications such as kidney failure",
            "probability": 1.341104507446289e-05
        },
        {
            "start_logit": -7.57421875,
            "end_logit": 2.201171875,
            "text": "analgesia, paracetamol can be listed as the first option in these patients, and then NSAIDs can also be reliably used for pain",
            "probability": 1.3113021850585938e-05
        },
        {
            "start_logit": 2.400390625,
            "end_logit": -7.7890625,
            "text": "paracetamol can be",
            "probability": 1.2874603271484375e-05
        }
    ],
    "6277e4ee56bf9aee6f000008_5": [
        {
            "start_logit": 7.6015625,
            "end_logit": 8.6171875,
            "text": "Paracetamol",
            "probability": 1.0
        },
        {
            "start_logit": 7.6015625,
            "end_logit": -6.6796875,
            "text": "Paracetamol (acetaminophen) has",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.6015625,
            "end_logit": -6.78515625,
            "text": "Paracetamol (acetaminophen) has been proposed",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.6015625,
            "end_logit": -7.12890625,
            "text": "Paracetamol (acetaminophen) has been proposed as an alternative",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.6015625,
            "end_logit": -7.20703125,
            "text": "Paracetamol (acetaminophen) has been",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.6015625,
            "end_logit": -7.546875,
            "text": "Paracetamol (acetaminophen) has been proposed as an alternative to NSAIDs but there are issues with liver toxicity",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.6015625,
            "end_logit": -7.5703125,
            "text": "Paracetamol (acetaminophen) has been proposed as an alternative to NSAIDs but",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.6015625,
            "end_logit": -7.62890625,
            "text": "Paracetamol (acetaminophen) has been proposed as an alternative to NSAIDs",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.6015625,
            "end_logit": -7.6953125,
            "text": "Paracetamol (acetaminophen) has been proposed as",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.6015625,
            "end_logit": -7.75,
            "text": "Paracetamol (acetaminophen) has been proposed as an alternative to NSAIDs but there are issues with liver toxicity at high doses",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.6015625,
            "end_logit": -7.80859375,
            "text": "Paracetamol (acetaminophen) has been proposed as an",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.6015625,
            "end_logit": -7.8359375,
            "text": "Paracetamol (acetaminophen) has been proposed as an alternative to NSAIDs but there are issues with liver toxicity at",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.6015625,
            "end_logit": -7.875,
            "text": "Paracetamol (acetaminophen) has been proposed as an alternative to",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.6015625,
            "end_logit": -7.9140625,
            "text": "Paracetamol (acetaminophen)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.6015625,
            "end_logit": -7.91796875,
            "text": "Paracetamol (acetaminophen) has been proposed as an alternative to NSAIDs but there are issues with liver",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.80078125,
            "end_logit": -6.6796875,
            "text": "(acetaminophen) has",
            "probability": 0.0
        },
        {
            "start_logit": -7.80078125,
            "end_logit": -6.78515625,
            "text": "(acetaminophen) has been proposed",
            "probability": 0.0
        },
        {
            "start_logit": -7.8515625,
            "end_logit": -6.78515625,
            "text": "proposed",
            "probability": 0.0
        },
        {
            "start_logit": -8.09375,
            "end_logit": -6.6796875,
            "text": "acetaminophen) has",
            "probability": 0.0
        },
        {
            "start_logit": -7.6953125,
            "end_logit": -7.12890625,
            "text": "alternative",
            "probability": 0.0
        }
    ],
    "589a247078275d0c4a000035_1": [
        {
            "start_logit": 7.67578125,
            "end_logit": 8.7109375,
            "text": "neuroblastoma",
            "probability": 1.0
        },
        {
            "start_logit": -7.8046875,
            "end_logit": 8.7109375,
            "text": "for high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.88671875,
            "end_logit": 8.7109375,
            "text": "risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.94140625,
            "end_logit": 8.7109375,
            "text": "part of post-consolidation therapy for high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.97265625,
            "end_logit": 8.7109375,
            "text": "Unituxin\u2122; ch14.18), a monoclonal antibody against disialoganglioside, improved survival as part of post-consolidation therapy for high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.9921875,
            "end_logit": 8.7109375,
            "text": "high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.99609375,
            "end_logit": 8.7109375,
            "text": "; ch14.18), a monoclonal antibody against disialoganglioside, improved survival as part of post-consolidation therapy for high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.99609375,
            "end_logit": 8.7109375,
            "text": "Dinutuximab (Unituxin\u2122; ch14.18), a monoclonal antibody against disialoganglioside, improved survival as part of post-consolidation therapy for high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -8.0078125,
            "end_logit": 8.7109375,
            "text": "therapy for high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -8.03125,
            "end_logit": 8.7109375,
            "text": "antibody against disialoganglioside, improved survival as part of post-consolidation therapy for high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -8.03125,
            "end_logit": 8.7109375,
            "text": "monoclonal antibody against disialoganglioside, improved survival as part of post-consolidation therapy for high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -8.03125,
            "end_logit": 8.7109375,
            "text": "a monoclonal antibody against disialoganglioside, improved survival as part of post-consolidation therapy for high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -8.0390625,
            "end_logit": 8.7109375,
            "text": "), a monoclonal antibody against disialoganglioside, improved survival as part of post-consolidation therapy for high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -8.0390625,
            "end_logit": 8.7109375,
            "text": "in\u2122; ch14.18), a monoclonal antibody against disialoganglioside, improved survival as part of post-consolidation therapy for high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -8.046875,
            "end_logit": 8.7109375,
            "text": "post-consolidation therapy for high-risk neuroblastoma",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.67578125,
            "end_logit": -7.92578125,
            "text": "neuroblastoma.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.921875,
            "end_logit": -7.92578125,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.8046875,
            "end_logit": -7.92578125,
            "text": "for high-risk neuroblastoma.",
            "probability": 0.0
        },
        {
            "start_logit": -7.88671875,
            "end_logit": -7.92578125,
            "text": "risk neuroblastoma.",
            "probability": 0.0
        },
        {
            "start_logit": -7.94140625,
            "end_logit": -7.92578125,
            "text": "part of post-consolidation therapy for high-risk neuroblastoma.",
            "probability": 0.0
        }
    ],
    "589a247078275d0c4a000035_2": [
        {
            "start_logit": 7.56640625,
            "end_logit": 8.78125,
            "text": "Neuroblastoma",
            "probability": 1.0
        },
        {
            "start_logit": -7.73828125,
            "end_logit": 8.78125,
            "text": "Risk Neuroblastoma",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.76953125,
            "end_logit": 8.78125,
            "text": "in High-Risk Neuroblastoma",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.92578125,
            "end_logit": 8.78125,
            "text": "Dinutuximab: A Review in High-Risk Neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.93359375,
            "end_logit": 8.78125,
            "text": "A Review in High-Risk Neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.94921875,
            "end_logit": 8.78125,
            "text": "High-Risk Neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -8.0078125,
            "end_logit": 8.78125,
            "text": "utuximab: A Review in High-Risk Neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -8.0234375,
            "end_logit": 8.78125,
            "text": "uximab: A Review in High-Risk Neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -8.046875,
            "end_logit": 8.78125,
            "text": "Review in High-Risk Neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -8.0625,
            "end_logit": 8.78125,
            "text": "-Risk Neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -8.0703125,
            "end_logit": 8.78125,
            "text": ": A Review in High-Risk Neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.56640625,
            "end_logit": -8.109375,
            "text": "Neuroblastoma.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.8671875,
            "end_logit": -8.109375,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.73828125,
            "end_logit": -8.109375,
            "text": "Risk Neuroblastoma.",
            "probability": 0.0
        },
        {
            "start_logit": -7.76953125,
            "end_logit": -8.109375,
            "text": "in High-Risk Neuroblastoma.",
            "probability": 0.0
        },
        {
            "start_logit": -7.92578125,
            "end_logit": -8.109375,
            "text": "Dinutuximab: A Review in High-Risk Neuroblastoma.",
            "probability": 0.0
        },
        {
            "start_logit": -7.93359375,
            "end_logit": -8.109375,
            "text": "A Review in High-Risk Neuroblastoma.",
            "probability": 0.0
        },
        {
            "start_logit": -7.94921875,
            "end_logit": -8.109375,
            "text": "High-Risk Neuroblastoma.",
            "probability": 0.0
        },
        {
            "start_logit": -8.0078125,
            "end_logit": -8.109375,
            "text": "utuximab: A Review in High-Risk Neuroblastoma.",
            "probability": 0.0
        },
        {
            "start_logit": -8.0234375,
            "end_logit": -8.109375,
            "text": "uximab: A Review in High-Risk Neuroblastoma.",
            "probability": 0.0
        }
    ],
    "589a247078275d0c4a000035_3": [
        {
            "start_logit": 7.66015625,
            "end_logit": 8.6875,
            "text": "neuroblastoma",
            "probability": 1.0
        },
        {
            "start_logit": -7.77734375,
            "end_logit": 8.6875,
            "text": "Unituxin\u2122) is a chimeric human-mouse monoclonal antibody that binds to the glycolipid antigen disialoganglioside, which is highly expressed on the surface of neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.83203125,
            "end_logit": 8.6875,
            "text": "; Unituxin\u2122) is a chimeric human-mouse monoclonal antibody that binds to the glycolipid antigen disialoganglioside, which is highly expressed on the surface of neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.875,
            "end_logit": 8.6875,
            "text": "uxin\u2122) is a chimeric human-mouse monoclonal antibody that binds to the glycolipid antigen disialoganglioside, which is highly expressed on the surface of neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.88671875,
            "end_logit": 8.6875,
            "text": "of neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.66015625,
            "end_logit": -7.67578125,
            "text": "neuroblastoma cells.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.66015625,
            "end_logit": -8.171875,
            "text": "neuroblastoma cells. This intravenous drug is approved in the EU",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.66015625,
            "end_logit": -8.203125,
            "text": "neuroblastoma cells. This intravenous drug is approved in the EU and USA as combination therapy with granulocyte-macrophage colony-stimulating factor (GM-CSF",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.66015625,
            "end_logit": -8.203125,
            "text": "neuroblastoma cells. This intravenous drug is approved in the EU and USA as combination therapy with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin (IL",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.66015625,
            "end_logit": -8.2265625,
            "text": "neuroblastoma cells. This intravenous drug is approved in the EU and USA as combination therapy with granulocyte-macrophage",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.66015625,
            "end_logit": -8.2265625,
            "text": "neuroblastoma cells. This intravenous drug is approved in the EU and USA as combination therapy with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin (IL)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.66015625,
            "end_logit": -8.2265625,
            "text": "neuroblastoma cells. This intravenous drug is approved in the EU and USA as combination therapy with granulocyte-macrophage colony-stimulating factor (GM",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.66015625,
            "end_logit": -8.234375,
            "text": "neuroblastoma cells. This intravenous drug is approved in the EU and USA as combination therapy with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin (IL)-2 and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.66015625,
            "end_logit": -8.234375,
            "text": "neuroblastoma cells. This intravenous drug is approved in the EU and USA as combination therapy with granulocyte-macrophage colony-",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.66015625,
            "end_logit": -8.234375,
            "text": "neuroblastoma cells. This intravenous drug is approved in the EU and USA as combination therapy with granulocyte-macrophage colony-stimulating",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.66015625,
            "end_logit": -8.234375,
            "text": "neuroblastoma cells. This intravenous drug is approved in the EU and USA as combination therapy with granulocyte-macrophage colony-stimulating factor (GM-CSF)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.84765625,
            "end_logit": -7.67578125,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -6.84765625,
            "end_logit": -7.67578125,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -6.84765625,
            "end_logit": -8.171875,
            "text": ". This intravenous drug is approved in the EU",
            "probability": 0.0
        },
        {
            "start_logit": -6.84765625,
            "end_logit": -8.203125,
            "text": ". This intravenous drug is approved in the EU and USA as combination therapy with granulocyte-macrophage colony-stimulating factor (GM-CSF",
            "probability": 0.0
        }
    ],
    "589a247078275d0c4a000035_4": [
        {
            "start_logit": 7.44921875,
            "end_logit": 8.8359375,
            "text": "neuroblastoma",
            "probability": 1.0
        },
        {
            "start_logit": -7.85546875,
            "end_logit": 8.8359375,
            "text": "the postconsolidation treatment of patients with high-risk neuroblastoma",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.86328125,
            "end_logit": 8.8359375,
            "text": "postconsolidation treatment of patients with high-risk neuroblastoma",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.87109375,
            "end_logit": 8.8359375,
            "text": "risk neuroblastoma",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.89453125,
            "end_logit": 8.8359375,
            "text": "tion treatment of patients with high-risk neuroblastoma",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.91015625,
            "end_logit": 8.8359375,
            "text": "treatment of patients with high-risk neuroblastoma",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.9140625,
            "end_logit": 8.8359375,
            "text": "patients with high-risk neuroblastoma",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.91796875,
            "end_logit": 8.8359375,
            "text": "with high-risk neuroblastoma",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.94140625,
            "end_logit": 8.8359375,
            "text": "Dinutuximab administered in combination with GM-CSF, IL-2 and isotretinoin represents an important advance in the postconsolidation treatment of patients with high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.95703125,
            "end_logit": 8.8359375,
            "text": "of patients with high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.96484375,
            "end_logit": 8.8359375,
            "text": "advance in the postconsolidation treatment of patients with high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.99609375,
            "end_logit": 8.8359375,
            "text": "in the postconsolidation treatment of patients with high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -8.0078125,
            "end_logit": 8.8359375,
            "text": "solidation treatment of patients with high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -8.015625,
            "end_logit": 8.8359375,
            "text": "dation treatment of patients with high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -8.015625,
            "end_logit": 8.8359375,
            "text": "important advance in the postconsolidation treatment of patients with high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.44921875,
            "end_logit": -7.46484375,
            "text": "neuroblastoma, with its benefits outweighing its risks in a patient population with a poor prognosis and limited therapeutic options.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.44921875,
            "end_logit": -8.0390625,
            "text": "neuroblastoma, with its benefits outweighing",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.44921875,
            "end_logit": -8.0703125,
            "text": "neuroblastoma, with its benefits outweigh",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.44921875,
            "end_logit": -8.0859375,
            "text": "neuroblastoma, with its benefits outweighing its risks in a patient population with a poor prognosis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.44921875,
            "end_logit": -8.09375,
            "text": "neuroblastoma, with its benefits outweighing its risks in a",
            "probability": 5.960464477539063e-08
        }
    ],
    "589a247078275d0c4a000035_5": [
        {
            "start_logit": 7.52734375,
            "end_logit": 8.8203125,
            "text": "neuroblastoma",
            "probability": 1.0
        },
        {
            "start_logit": -7.82421875,
            "end_logit": 8.8203125,
            "text": "risk neuroblastoma",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.84375,
            "end_logit": 8.8203125,
            "text": "treatment of pediatric patients with high-risk neuroblastoma",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.8515625,
            "end_logit": 8.8203125,
            "text": "Dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.9375,
            "end_logit": 8.8203125,
            "text": "the treatment of pediatric patients with high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.94140625,
            "end_logit": 8.8203125,
            "text": "with high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.94140625,
            "end_logit": 8.8203125,
            "text": "patients with high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.97265625,
            "end_logit": 8.8203125,
            "text": "utuximab for the treatment of pediatric patients with high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.98046875,
            "end_logit": 8.8203125,
            "text": "uximab for the treatment of pediatric patients with high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.9921875,
            "end_logit": 8.8203125,
            "text": "pediatric patients with high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.99609375,
            "end_logit": 8.8203125,
            "text": "high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -8.0234375,
            "end_logit": 8.8203125,
            "text": "for the treatment of pediatric patients with high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -8.0390625,
            "end_logit": 8.8203125,
            "text": "of pediatric patients with high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.52734375,
            "end_logit": -7.8671875,
            "text": "neuroblastoma.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.90234375,
            "end_logit": -7.8671875,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.82421875,
            "end_logit": -7.8671875,
            "text": "risk neuroblastoma.",
            "probability": 0.0
        },
        {
            "start_logit": -7.84375,
            "end_logit": -7.8671875,
            "text": "treatment of pediatric patients with high-risk neuroblastoma.",
            "probability": 0.0
        },
        {
            "start_logit": -7.8515625,
            "end_logit": -7.8671875,
            "text": "Dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma.",
            "probability": 0.0
        },
        {
            "start_logit": -7.9375,
            "end_logit": -7.8671875,
            "text": "the treatment of pediatric patients with high-risk neuroblastoma.",
            "probability": 0.0
        },
        {
            "start_logit": -7.94140625,
            "end_logit": -7.8671875,
            "text": "with high-risk neuroblastoma.",
            "probability": 0.0
        }
    ],
    "589a247078275d0c4a000035_6": [
        {
            "start_logit": 7.2734375,
            "end_logit": 8.921875,
            "text": "neuroblastoma",
            "probability": 1.0
        },
        {
            "start_logit": -7.484375,
            "end_logit": 8.921875,
            "text": "GD2 monoclonal antibody approved in combination with GM-CSF, IL-2, and RA for maintenance treatment of pediatric patients with high-risk neuroblastoma",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -7.5625,
            "end_logit": 8.921875,
            "text": "risk neuroblastoma",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.79296875,
            "end_logit": 8.921875,
            "text": "with high-risk neuroblastoma",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.828125,
            "end_logit": 8.921875,
            "text": "first anti-GD2 monoclonal antibody approved in combination with GM-CSF, IL-2, and RA for maintenance treatment of pediatric patients with high-risk neuroblastoma",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.84375,
            "end_logit": 8.921875,
            "text": "maintenance treatment of pediatric patients with high-risk neuroblastoma",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.87890625,
            "end_logit": 8.921875,
            "text": "treatment of pediatric patients with high-risk neuroblastoma",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.9296875,
            "end_logit": 8.921875,
            "text": "Dinutuximab is the first anti-GD2 monoclonal antibody approved in combination with GM-CSF, IL-2, and RA for maintenance treatment of pediatric patients with high-risk neuroblastoma",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.9453125,
            "end_logit": 8.921875,
            "text": "patients with high-risk neuroblastoma",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.9453125,
            "end_logit": 8.921875,
            "text": "the first anti-GD2 monoclonal antibody approved in combination with GM-CSF, IL-2, and RA for maintenance treatment of pediatric patients with high-risk neuroblastoma",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.9609375,
            "end_logit": 8.921875,
            "text": "for maintenance treatment of pediatric patients with high-risk neuroblastoma",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.2734375,
            "end_logit": -7.4296875,
            "text": "neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.2734375,
            "end_logit": -7.6171875,
            "text": "neuroblastoma who",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.2734375,
            "end_logit": -7.9453125,
            "text": "neuroblastoma who achieve",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.2734375,
            "end_logit": -7.99609375,
            "text": "neuroblastoma who achieve at least",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.2734375,
            "end_logit": -8.0234375,
            "text": "neuroblastoma who achieve at",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.2734375,
            "end_logit": -8.0234375,
            "text": "neuroblastoma who achieve at least a",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.2734375,
            "end_logit": -8.046875,
            "text": "neuroblastoma who achieve at least a partial response to",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.2734375,
            "end_logit": -8.0625,
            "text": "neuroblastoma who achieve at least a partial",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.2734375,
            "end_logit": -8.078125,
            "text": "neuroblastoma who achieve at least a partial response",
            "probability": 5.960464477539063e-08
        }
    ],
    "589a247078275d0c4a000035_7": [
        {
            "start_logit": 7.2421875,
            "end_logit": 8.9140625,
            "text": "neuroblastoma",
            "probability": 1.0
        },
        {
            "start_logit": -7.72265625,
            "end_logit": 8.9140625,
            "text": "risk neuroblastoma",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.75390625,
            "end_logit": 8.9140625,
            "text": "with high-risk neuroblastoma",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.94140625,
            "end_logit": 8.9140625,
            "text": "treatment of pediatric patients with high-risk neuroblastoma",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.9453125,
            "end_logit": 8.9140625,
            "text": "maintenance treatment of pediatric patients with high-risk neuroblastoma",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.9765625,
            "end_logit": 8.9140625,
            "text": "for maintenance treatment of pediatric patients with high-risk neuroblastoma",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.9921875,
            "end_logit": 8.9140625,
            "text": "patients with high-risk neuroblastoma",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -8.0078125,
            "end_logit": 8.9140625,
            "text": "(interleukin-2 [IL-2]), and isotretinoin (13-cis-retinoic acid [RA]) for maintenance treatment of pediatric patients with high-risk neuroblastoma",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.2421875,
            "end_logit": -7.4296875,
            "text": "neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.2421875,
            "end_logit": -7.6171875,
            "text": "neuroblastoma who",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.2421875,
            "end_logit": -7.890625,
            "text": "neuroblastoma who achieve",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.2421875,
            "end_logit": -8.0703125,
            "text": "neuroblastoma who achieve at least",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.2421875,
            "end_logit": -8.078125,
            "text": "neuroblastoma who achieve at least a partial response to",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.2421875,
            "end_logit": -8.078125,
            "text": "neuroblastoma who achieve at least a partial response",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.2421875,
            "end_logit": -8.0859375,
            "text": "neuroblastoma who achieve at",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.2421875,
            "end_logit": -8.0859375,
            "text": "neuroblastoma who achieve at least a partial",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.2421875,
            "end_logit": -8.1015625,
            "text": "neuroblastoma who achieve at least a",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.7578125,
            "end_logit": -7.4296875,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.72265625,
            "end_logit": -7.4296875,
            "text": "risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.",
            "probability": 0.0
        },
        {
            "start_logit": -7.75390625,
            "end_logit": -7.4296875,
            "text": "with high-risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.",
            "probability": 0.0
        }
    ],
    "589a247078275d0c4a000035_8": [
        {
            "start_logit": 7.26953125,
            "end_logit": 8.921875,
            "text": "neuroblastoma",
            "probability": 1.0
        },
        {
            "start_logit": -7.80078125,
            "end_logit": 8.921875,
            "text": "with high-risk neuroblastoma",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.80078125,
            "end_logit": 8.921875,
            "text": "risk neuroblastoma",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.83203125,
            "end_logit": 8.921875,
            "text": "Dinutuximab is a novel monoclonal antibody that is efficacious as part of combination immunotherapy in pediatric patients with high-risk neuroblastoma",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.89453125,
            "end_logit": 8.921875,
            "text": "CONCLUSION</b>: Dinutuximab is a novel monoclonal antibody that is efficacious as part of combination immunotherapy in pediatric patients with high-risk neuroblastoma",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.90625,
            "end_logit": 8.921875,
            "text": "5 mg/m<br><b>CONCLUSION</b>: Dinutuximab is a novel monoclonal antibody that is efficacious as part of combination immunotherapy in pediatric patients with high-risk neuroblastoma",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.9140625,
            "end_logit": 8.921875,
            "text": "part of combination immunotherapy in pediatric patients with high-risk neuroblastoma",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.9140625,
            "end_logit": 8.921875,
            "text": "combination immunotherapy in pediatric patients with high-risk neuroblastoma",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.92578125,
            "end_logit": 8.921875,
            "text": "is efficacious as part of combination immunotherapy in pediatric patients with high-risk neuroblastoma",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.92578125,
            "end_logit": 8.921875,
            "text": ": Dinutuximab is a novel monoclonal antibody that is efficacious as part of combination immunotherapy in pediatric patients with high-risk neuroblastoma",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.9296875,
            "end_logit": 8.921875,
            "text": "patients with high-risk neuroblastoma",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.9375,
            "end_logit": 8.921875,
            "text": "in pediatric patients with high-risk neuroblastoma",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.94921875,
            "end_logit": 8.921875,
            "text": "uximab is a novel monoclonal antibody that is efficacious as part of combination immunotherapy in pediatric patients with high-risk neuroblastoma",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.95703125,
            "end_logit": 8.921875,
            "text": "as part of combination immunotherapy in pediatric patients with high-risk neuroblastoma",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.26953125,
            "end_logit": -8.2109375,
            "text": "neuroblastoma.<br",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.26953125,
            "end_logit": -8.21875,
            "text": "neuroblastoma.<br>",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.7890625,
            "end_logit": -8.2109375,
            "text": "<br",
            "probability": 0.0
        },
        {
            "start_logit": -7.7890625,
            "end_logit": -8.21875,
            "text": "<br>",
            "probability": 0.0
        },
        {
            "start_logit": -7.90234375,
            "end_logit": -8.1015625,
            "text": "dinutuximab is 17.5 mg/",
            "probability": 0.0
        },
        {
            "start_logit": -7.90625,
            "end_logit": -8.1015625,
            "text": "5 mg/",
            "probability": 0.0
        }
    ],
    "589a247078275d0c4a000035_9": [
        {
            "start_logit": 7.38671875,
            "end_logit": 8.8984375,
            "text": "neuroblastoma",
            "probability": 1.0
        },
        {
            "start_logit": -7.78125,
            "end_logit": 8.8984375,
            "text": "risk neuroblastoma",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.84765625,
            "end_logit": 8.8984375,
            "text": "treatment of pediatric high-risk neuroblastoma",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.8671875,
            "end_logit": 8.8984375,
            "text": "the treatment of pediatric high-risk neuroblastoma",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.8828125,
            "end_logit": 8.8984375,
            "text": ", represents an important therapeutic advance in the treatment of pediatric high-risk neuroblastoma",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.94140625,
            "end_logit": 8.8984375,
            "text": "therapeutic advance in the treatment of pediatric high-risk neuroblastoma",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.9453125,
            "end_logit": 8.8984375,
            "text": "Immunotherapy with the anti-GD2 monoclonal antibody ch14.18, or dinutuximab, represents an important therapeutic advance in the treatment of pediatric high-risk neuroblastoma",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.94921875,
            "end_logit": 8.8984375,
            "text": "in the treatment of pediatric high-risk neuroblastoma",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.9609375,
            "end_logit": 8.8984375,
            "text": "important therapeutic advance in the treatment of pediatric high-risk neuroblastoma",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.98046875,
            "end_logit": 8.8984375,
            "text": "pediatric high-risk neuroblastoma",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.38671875,
            "end_logit": -7.7421875,
            "text": "neuroblastoma and is now considered part of standard of care in this patient population.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.38671875,
            "end_logit": -8.0859375,
            "text": "neuroblastoma and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.38671875,
            "end_logit": -8.2109375,
            "text": "neuroblastoma and is now",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.8515625,
            "end_logit": -7.7421875,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.75,
            "end_logit": -7.7421875,
            "text": "considered part of standard of care in this patient population.",
            "probability": 0.0
        },
        {
            "start_logit": -7.78125,
            "end_logit": -7.7421875,
            "text": "risk neuroblastoma and is now considered part of standard of care in this patient population.",
            "probability": 0.0
        },
        {
            "start_logit": -7.83984375,
            "end_logit": -7.7421875,
            "text": "now considered part of standard of care in this patient population.",
            "probability": 0.0
        },
        {
            "start_logit": -7.84765625,
            "end_logit": -7.7421875,
            "text": "treatment of pediatric high-risk neuroblastoma and is now considered part of standard of care in this patient population.",
            "probability": 0.0
        },
        {
            "start_logit": -7.8671875,
            "end_logit": -7.7421875,
            "text": "the treatment of pediatric high-risk neuroblastoma and is now considered part of standard of care in this patient population.",
            "probability": 0.0
        },
        {
            "start_logit": -7.8828125,
            "end_logit": -7.7421875,
            "text": ", represents an important therapeutic advance in the treatment of pediatric high-risk neuroblastoma and is now considered part of standard of care in this patient population.",
            "probability": 0.0
        }
    ],
    "589a247078275d0c4a000035_10": [
        {
            "start_logit": 7.44921875,
            "end_logit": 8.8515625,
            "text": "neuroblastoma",
            "probability": 1.0
        },
        {
            "start_logit": -7.734375,
            "end_logit": 8.8515625,
            "text": "<b>PURPOSE</b>: The pharmacology, clinical efficacy, safety, dosage and administration, and role in therapy of dinutuximab for the treatment of high-risk pediatric neuroblastoma",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.85546875,
            "end_logit": 8.8515625,
            "text": "the treatment of high-risk pediatric neuroblastoma",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.87109375,
            "end_logit": 8.8515625,
            "text": "treatment of high-risk pediatric neuroblastoma",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.875,
            "end_logit": 8.8515625,
            "text": "role in therapy of dinutuximab for the treatment of high-risk pediatric neuroblastoma",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.87890625,
            "end_logit": 8.8515625,
            "text": "dinutuximab for the treatment of high-risk pediatric neuroblastoma",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.44921875,
            "end_logit": -7.6484375,
            "text": "neuroblastoma are reviewed.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.44921875,
            "end_logit": -8.125,
            "text": "neuroblastoma are reviewed.<br>",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.44921875,
            "end_logit": -8.140625,
            "text": "neuroblastoma are reviewed.<br><b>SUMMARY</b>",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.44921875,
            "end_logit": -8.1640625,
            "text": "neuroblastoma are reviewed.<br><b>",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.44921875,
            "end_logit": -8.171875,
            "text": "neuroblastoma are reviewed.<br><b>SUMMARY</",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.44921875,
            "end_logit": -8.1796875,
            "text": "neuroblastoma are",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.44921875,
            "end_logit": -8.1875,
            "text": "neuroblastoma are reviewed.<br><b>SUMMARY</b",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.44921875,
            "end_logit": -8.1953125,
            "text": "neuroblastoma are reviewed.<br><b>SUMMARY<",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.81640625,
            "end_logit": -7.6484375,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -6.81640625,
            "end_logit": -7.6484375,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -6.81640625,
            "end_logit": -8.125,
            "text": ".<br>",
            "probability": 0.0
        },
        {
            "start_logit": -6.81640625,
            "end_logit": -8.140625,
            "text": ".<br><b>SUMMARY</b>",
            "probability": 0.0
        },
        {
            "start_logit": -6.81640625,
            "end_logit": -8.1640625,
            "text": ".<br><b>",
            "probability": 0.0
        },
        {
            "start_logit": -6.81640625,
            "end_logit": -8.171875,
            "text": ".<br><b>SUMMARY</",
            "probability": 0.0
        }
    ],
    "589a247078275d0c4a000035_11": [
        {
            "start_logit": 7.12109375,
            "end_logit": 9.0859375,
            "text": "neuroblastoma",
            "probability": 1.0
        },
        {
            "start_logit": -7.8203125,
            "end_logit": 9.0859375,
            "text": "risk neuroblastoma",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.8359375,
            "end_logit": 9.0859375,
            "text": "with high-risk neuroblastoma",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.84765625,
            "end_logit": 9.0859375,
            "text": "use (in combination with granulocyte macrophage colony-stimulating factor, interleukin-2 and 13-cis retinoic acid) in the treatment of paediatric patients with high-risk neuroblastoma",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.85546875,
            "end_logit": 9.0859375,
            "text": "first approval for use (in combination with granulocyte macrophage colony-stimulating factor, interleukin-2 and 13-cis retinoic acid) in the treatment of paediatric patients with high-risk neuroblastoma",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.890625,
            "end_logit": 9.0859375,
            "text": "this first approval for use (in combination with granulocyte macrophage colony-stimulating factor, interleukin-2 and 13-cis retinoic acid) in the treatment of paediatric patients with high-risk neuroblastoma",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.89453125,
            "end_logit": 9.0859375,
            "text": "treatment of paediatric patients with high-risk neuroblastoma",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.9140625,
            "end_logit": 9.0859375,
            "text": "the treatment of paediatric patients with high-risk neuroblastoma",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.91796875,
            "end_logit": 9.0859375,
            "text": "patients with high-risk neuroblastoma",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.12109375,
            "end_logit": -8.0703125,
            "text": "neuroblastoma who",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.12109375,
            "end_logit": -8.125,
            "text": "neuroblastoma who achieve at",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.12109375,
            "end_logit": -8.125,
            "text": "neuroblastoma who achieve at least",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.12109375,
            "end_logit": -8.1484375,
            "text": "neuroblastoma who achieve",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.12109375,
            "end_logit": -8.1875,
            "text": "neuroblastoma who achieve at least partial response to",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.12109375,
            "end_logit": -8.1953125,
            "text": "neuroblastoma who achieve at least partial response to prior",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.12109375,
            "end_logit": -8.203125,
            "text": "neuroblastoma who achieve at least partial",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.12109375,
            "end_logit": -8.25,
            "text": "neuroblastoma who achieve at least partial response",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.12109375,
            "end_logit": -8.2578125,
            "text": "neuroblastoma who achieve at least partial response to prior first-line multiagent, multimodality therapy.<br>",
            "probability": 0.0
        },
        {
            "start_logit": -7.8203125,
            "end_logit": -8.0703125,
            "text": "risk neuroblastoma who",
            "probability": 0.0
        },
        {
            "start_logit": -7.8359375,
            "end_logit": -8.0703125,
            "text": "with high-risk neuroblastoma who",
            "probability": 0.0
        }
    ],
    "589a247078275d0c4a000035_12": [
        {
            "start_logit": 7.69140625,
            "end_logit": 8.703125,
            "text": "neuroblastoma",
            "probability": 1.0
        },
        {
            "start_logit": -7.77734375,
            "end_logit": 8.703125,
            "text": "The US FDA has recently approved the use of dinutuximab combination therapy for the treatment of high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.8203125,
            "end_logit": 8.703125,
            "text": "risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.8359375,
            "end_logit": 8.703125,
            "text": "treatment of high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.85546875,
            "end_logit": 8.703125,
            "text": "recently approved the use of dinutuximab combination therapy for the treatment of high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.87890625,
            "end_logit": 8.703125,
            "text": "use of dinutuximab combination therapy for the treatment of high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.89453125,
            "end_logit": 8.703125,
            "text": "the treatment of high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.8984375,
            "end_logit": 8.703125,
            "text": "dinutuximab combination therapy for the treatment of high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.9453125,
            "end_logit": 8.703125,
            "text": "high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.94921875,
            "end_logit": 8.703125,
            "text": "for the treatment of high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.95703125,
            "end_logit": 8.703125,
            "text": "of high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.95703125,
            "end_logit": 8.703125,
            "text": "has recently approved the use of dinutuximab combination therapy for the treatment of high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.96484375,
            "end_logit": 8.703125,
            "text": "FDA has recently approved the use of dinutuximab combination therapy for the treatment of high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.96875,
            "end_logit": 8.703125,
            "text": "of dinutuximab combination therapy for the treatment of high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.97265625,
            "end_logit": 8.703125,
            "text": "the use of dinutuximab combination therapy for the treatment of high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.97265625,
            "end_logit": 8.703125,
            "text": "utuximab combination therapy for the treatment of high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.69140625,
            "end_logit": -7.6875,
            "text": "neuroblastoma in paediatric patients.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.69140625,
            "end_logit": -8.0078125,
            "text": "neuroblastoma in",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.859375,
            "end_logit": -7.6875,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.77734375,
            "end_logit": -7.6875,
            "text": "The US FDA has recently approved the use of dinutuximab combination therapy for the treatment of high-risk neuroblastoma in paediatric patients.",
            "probability": 0.0
        }
    ],
    "589a247078275d0c4a000035_13": [
        {
            "start_logit": 7.25,
            "end_logit": 8.9765625,
            "text": "neuroblastoma",
            "probability": 1.0
        },
        {
            "start_logit": -7.78125,
            "end_logit": 8.9765625,
            "text": "National Cancer Institute are developing dinutuximab (Unituxin\u2122; ch14.18), a monoclonal antibody targeting GD2, for the treatment of neuroblastoma",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.79296875,
            "end_logit": 8.9765625,
            "text": "Unituxin\u2122; ch14.18), a monoclonal antibody targeting GD2, for the treatment of neuroblastoma",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.8359375,
            "end_logit": 8.9765625,
            "text": "; ch14.18), a monoclonal antibody targeting GD2, for the treatment of neuroblastoma",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.84375,
            "end_logit": 8.9765625,
            "text": "of neuroblastoma",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.859375,
            "end_logit": 8.9765625,
            "text": "treatment of neuroblastoma",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.8671875,
            "end_logit": 8.9765625,
            "text": "the treatment of neuroblastoma",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.8984375,
            "end_logit": 8.9765625,
            "text": "developing dinutuximab (Unituxin\u2122; ch14.18), a monoclonal antibody targeting GD2, for the treatment of neuroblastoma",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.91796875,
            "end_logit": 8.9765625,
            "text": ", a monoclonal antibody targeting GD2, for the treatment of neuroblastoma",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.94140625,
            "end_logit": 8.9765625,
            "text": "United Therapeutics Corporation and the National Cancer Institute are developing dinutuximab (Unituxin\u2122; ch14.18), a monoclonal antibody targeting GD2, for the treatment of neuroblastoma",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.9453125,
            "end_logit": 8.9765625,
            "text": "Cancer Institute are developing dinutuximab (Unituxin\u2122; ch14.18), a monoclonal antibody targeting GD2, for the treatment of neuroblastoma",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.9453125,
            "end_logit": 8.9765625,
            "text": "the National Cancer Institute are developing dinutuximab (Unituxin\u2122; ch14.18), a monoclonal antibody targeting GD2, for the treatment of neuroblastoma",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.953125,
            "end_logit": 8.9765625,
            "text": "for the treatment of neuroblastoma",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.953125,
            "end_logit": 8.9765625,
            "text": "in\u2122; ch14.18), a monoclonal antibody targeting GD2, for the treatment of neuroblastoma",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.95703125,
            "end_logit": 8.9765625,
            "text": "ch14.18), a monoclonal antibody targeting GD2, for the treatment of neuroblastoma",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.95703125,
            "end_logit": 8.9765625,
            "text": "uxin\u2122; ch14.18), a monoclonal antibody targeting GD2, for the treatment of neuroblastoma",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.25,
            "end_logit": -7.74609375,
            "text": "neuroblastoma.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.84765625,
            "end_logit": -7.74609375,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.78125,
            "end_logit": -7.74609375,
            "text": "National Cancer Institute are developing dinutuximab (Unituxin\u2122; ch14.18), a monoclonal antibody targeting GD2, for the treatment of neuroblastoma.",
            "probability": 0.0
        },
        {
            "start_logit": -7.79296875,
            "end_logit": -7.74609375,
            "text": "Unituxin\u2122; ch14.18), a monoclonal antibody targeting GD2, for the treatment of neuroblastoma.",
            "probability": 0.0
        }
    ],
    "589a247078275d0c4a000035_14": [
        {
            "start_logit": 7.35546875,
            "end_logit": 8.9296875,
            "text": "neuroblastoma",
            "probability": 1.0
        },
        {
            "start_logit": -7.796875,
            "end_logit": 8.9296875,
            "text": "risk neuroblastoma",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.95703125,
            "end_logit": 8.9296875,
            "text": "Immunotherapy of high-risk neuroblastoma",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.9609375,
            "end_logit": 8.9296875,
            "text": "PURPOSE: Immunotherapy of high-risk neuroblastoma",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.98828125,
            "end_logit": 8.9296875,
            "text": "high-risk neuroblastoma",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -8.0859375,
            "end_logit": 8.9296875,
            "text": "of high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.35546875,
            "end_logit": -7.9453125,
            "text": "neuroblastoma using the anti-GD2 antibody dinutuximab induces antibody-dependent cell-mediated cytotoxicity (ADCC).",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.35546875,
            "end_logit": -8.171875,
            "text": "neuroblastoma using the anti-GD2 antibody dinutuximab induces antibody-dependent cell-",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.35546875,
            "end_logit": -8.171875,
            "text": "neuroblastoma using the anti-GD2 antibody dinutuximab induces antibody-dependent cell-mediated",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.35546875,
            "end_logit": -8.1796875,
            "text": "neuroblastoma using the anti-GD2 antibody dinutuximab induces antibody-dependent cell-mediated cytotoxicity",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.921875,
            "end_logit": -7.9453125,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.796875,
            "end_logit": -7.9453125,
            "text": "risk neuroblastoma using the anti-GD2 antibody dinutuximab induces antibody-dependent cell-mediated cytotoxicity (ADCC).",
            "probability": 0.0
        },
        {
            "start_logit": -7.91796875,
            "end_logit": -7.9453125,
            "text": "antibody-dependent cell-mediated cytotoxicity (ADCC).",
            "probability": 0.0
        },
        {
            "start_logit": -7.95703125,
            "end_logit": -7.9453125,
            "text": "Immunotherapy of high-risk neuroblastoma using the anti-GD2 antibody dinutuximab induces antibody-dependent cell-mediated cytotoxicity (ADCC).",
            "probability": 0.0
        },
        {
            "start_logit": -7.9609375,
            "end_logit": -7.9453125,
            "text": "PURPOSE: Immunotherapy of high-risk neuroblastoma using the anti-GD2 antibody dinutuximab induces antibody-dependent cell-mediated cytotoxicity (ADCC).",
            "probability": 0.0
        },
        {
            "start_logit": -7.9609375,
            "end_logit": -7.9453125,
            "text": "GD2 antibody dinutuximab induces antibody-dependent cell-mediated cytotoxicity (ADCC).",
            "probability": 0.0
        },
        {
            "start_logit": -7.98828125,
            "end_logit": -7.9453125,
            "text": "high-risk neuroblastoma using the anti-GD2 antibody dinutuximab induces antibody-dependent cell-mediated cytotoxicity (ADCC).",
            "probability": 0.0
        },
        {
            "start_logit": -7.796875,
            "end_logit": -8.171875,
            "text": "risk neuroblastoma using the anti-GD2 antibody dinutuximab induces antibody-dependent cell-",
            "probability": 0.0
        },
        {
            "start_logit": -7.796875,
            "end_logit": -8.171875,
            "text": "risk neuroblastoma using the anti-GD2 antibody dinutuximab induces antibody-dependent cell-mediated",
            "probability": 0.0
        },
        {
            "start_logit": -8.0234375,
            "end_logit": -7.9453125,
            "text": "anti-GD2 antibody dinutuximab induces antibody-dependent cell-mediated cytotoxicity (ADCC).",
            "probability": 0.0
        }
    ],
    "589a247078275d0c4a000035_15": [
        {
            "start_logit": 7.2421875,
            "end_logit": 8.9140625,
            "text": "neuroblastoma",
            "probability": 1.0
        },
        {
            "start_logit": -7.72265625,
            "end_logit": 8.9140625,
            "text": "risk neuroblastoma",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.75390625,
            "end_logit": 8.9140625,
            "text": "with high-risk neuroblastoma",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.94140625,
            "end_logit": 8.9140625,
            "text": "treatment of pediatric patients with high-risk neuroblastoma",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.9453125,
            "end_logit": 8.9140625,
            "text": "maintenance treatment of pediatric patients with high-risk neuroblastoma",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.9765625,
            "end_logit": 8.9140625,
            "text": "for maintenance treatment of pediatric patients with high-risk neuroblastoma",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.9921875,
            "end_logit": 8.9140625,
            "text": "patients with high-risk neuroblastoma",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -8.0078125,
            "end_logit": 8.9140625,
            "text": "(interleukin-2 [IL-2]), and isotretinoin (13-cis-retinoic acid [RA]) for maintenance treatment of pediatric patients with high-risk neuroblastoma",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.2421875,
            "end_logit": -7.4296875,
            "text": "neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.2421875,
            "end_logit": -7.6171875,
            "text": "neuroblastoma who",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.2421875,
            "end_logit": -7.890625,
            "text": "neuroblastoma who achieve",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.2421875,
            "end_logit": -8.0703125,
            "text": "neuroblastoma who achieve at least",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.2421875,
            "end_logit": -8.078125,
            "text": "neuroblastoma who achieve at least a partial response to",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.2421875,
            "end_logit": -8.078125,
            "text": "neuroblastoma who achieve at least a partial response",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.2421875,
            "end_logit": -8.0859375,
            "text": "neuroblastoma who achieve at",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.2421875,
            "end_logit": -8.0859375,
            "text": "neuroblastoma who achieve at least a partial",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.2421875,
            "end_logit": -8.1015625,
            "text": "neuroblastoma who achieve at least a",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.7578125,
            "end_logit": -7.4296875,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.72265625,
            "end_logit": -7.4296875,
            "text": "risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.",
            "probability": 0.0
        },
        {
            "start_logit": -7.75390625,
            "end_logit": -7.4296875,
            "text": "with high-risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.",
            "probability": 0.0
        }
    ],
    "589a247078275d0c4a000035_16": [
        {
            "start_logit": 7.6171875,
            "end_logit": 8.734375,
            "text": "neuroblastoma",
            "probability": 1.0
        },
        {
            "start_logit": -7.76171875,
            "end_logit": 8.734375,
            "text": "with high-risk neuroblastoma",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.82421875,
            "end_logit": 8.734375,
            "text": "risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.92578125,
            "end_logit": 8.734375,
            "text": "treatment of pediatric patients with high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.93359375,
            "end_logit": 8.734375,
            "text": "maintenance treatment of pediatric patients with high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.93359375,
            "end_logit": 8.734375,
            "text": "first anti-GD2 monoclonal antibody approved in combination with GM-CSF, IL-2, and RA for maintenance treatment of pediatric patients with high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.94140625,
            "end_logit": 8.734375,
            "text": "Dinutuximab is the first anti-GD2 monoclonal antibody approved in combination with GM-CSF, IL-2, and RA for maintenance treatment of pediatric patients with high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.953125,
            "end_logit": 8.734375,
            "text": "for maintenance treatment of pediatric patients with high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.97265625,
            "end_logit": 8.734375,
            "text": "patients with high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.98046875,
            "end_logit": 8.734375,
            "text": "CONCLUSIONS Dinutuximab is the first anti-GD2 monoclonal antibody approved in combination with GM-CSF, IL-2, and RA for maintenance treatment of pediatric patients with high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.98046875,
            "end_logit": 8.734375,
            "text": "of pediatric patients with high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.9921875,
            "end_logit": 8.734375,
            "text": ", and RA for maintenance treatment of pediatric patients with high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -8.015625,
            "end_logit": 8.734375,
            "text": "the first anti-GD2 monoclonal antibody approved in combination with GM-CSF, IL-2, and RA for maintenance treatment of pediatric patients with high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -8.0234375,
            "end_logit": 8.734375,
            "text": "in combination with GM-CSF, IL-2, and RA for maintenance treatment of pediatric patients with high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -8.0234375,
            "end_logit": 8.734375,
            "text": "is the first anti-GD2 monoclonal antibody approved in combination with GM-CSF, IL-2, and RA for maintenance treatment of pediatric patients with high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.6171875,
            "end_logit": -7.71875,
            "text": "neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.6171875,
            "end_logit": -7.84765625,
            "text": "neuroblastoma who",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.6171875,
            "end_logit": -8.046875,
            "text": "neuroblastoma who achieve",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.6171875,
            "end_logit": -8.0859375,
            "text": "neuroblastoma who achieve at least a partial response to",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.6171875,
            "end_logit": -8.09375,
            "text": "neuroblastoma who achieve at least",
            "probability": 5.960464477539063e-08
        }
    ],
    "589a247078275d0c4a000035_17": [
        {
            "start_logit": 7.25,
            "end_logit": 8.9765625,
            "text": "neuroblastoma",
            "probability": 1.0
        },
        {
            "start_logit": -7.78125,
            "end_logit": 8.9765625,
            "text": "National Cancer Institute are developing dinutuximab (Unituxin\u2122; ch14.18), a monoclonal antibody targeting GD2, for the treatment of neuroblastoma",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.79296875,
            "end_logit": 8.9765625,
            "text": "Unituxin\u2122; ch14.18), a monoclonal antibody targeting GD2, for the treatment of neuroblastoma",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.8359375,
            "end_logit": 8.9765625,
            "text": "; ch14.18), a monoclonal antibody targeting GD2, for the treatment of neuroblastoma",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.84375,
            "end_logit": 8.9765625,
            "text": "of neuroblastoma",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.859375,
            "end_logit": 8.9765625,
            "text": "treatment of neuroblastoma",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.8671875,
            "end_logit": 8.9765625,
            "text": "the treatment of neuroblastoma",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.8984375,
            "end_logit": 8.9765625,
            "text": "developing dinutuximab (Unituxin\u2122; ch14.18), a monoclonal antibody targeting GD2, for the treatment of neuroblastoma",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.91796875,
            "end_logit": 8.9765625,
            "text": ", a monoclonal antibody targeting GD2, for the treatment of neuroblastoma",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.94140625,
            "end_logit": 8.9765625,
            "text": "United Therapeutics Corporation and the National Cancer Institute are developing dinutuximab (Unituxin\u2122; ch14.18), a monoclonal antibody targeting GD2, for the treatment of neuroblastoma",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.9453125,
            "end_logit": 8.9765625,
            "text": "Cancer Institute are developing dinutuximab (Unituxin\u2122; ch14.18), a monoclonal antibody targeting GD2, for the treatment of neuroblastoma",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.9453125,
            "end_logit": 8.9765625,
            "text": "the National Cancer Institute are developing dinutuximab (Unituxin\u2122; ch14.18), a monoclonal antibody targeting GD2, for the treatment of neuroblastoma",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.953125,
            "end_logit": 8.9765625,
            "text": "for the treatment of neuroblastoma",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.953125,
            "end_logit": 8.9765625,
            "text": "in\u2122; ch14.18), a monoclonal antibody targeting GD2, for the treatment of neuroblastoma",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.95703125,
            "end_logit": 8.9765625,
            "text": "ch14.18), a monoclonal antibody targeting GD2, for the treatment of neuroblastoma",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.95703125,
            "end_logit": 8.9765625,
            "text": "uxin\u2122; ch14.18), a monoclonal antibody targeting GD2, for the treatment of neuroblastoma",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.25,
            "end_logit": -7.74609375,
            "text": "neuroblastoma.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.84765625,
            "end_logit": -7.74609375,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.78125,
            "end_logit": -7.74609375,
            "text": "National Cancer Institute are developing dinutuximab (Unituxin\u2122; ch14.18), a monoclonal antibody targeting GD2, for the treatment of neuroblastoma.",
            "probability": 0.0
        },
        {
            "start_logit": -7.79296875,
            "end_logit": -7.74609375,
            "text": "Unituxin\u2122; ch14.18), a monoclonal antibody targeting GD2, for the treatment of neuroblastoma.",
            "probability": 0.0
        }
    ],
    "589a247078275d0c4a000035_18": [
        {
            "start_logit": 7.4375,
            "end_logit": 8.8828125,
            "text": "neuroblastoma",
            "probability": 1.0
        },
        {
            "start_logit": -7.734375,
            "end_logit": 8.8828125,
            "text": "with high-risk neuroblastoma",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.8515625,
            "end_logit": 8.8828125,
            "text": "risk neuroblastoma",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.87890625,
            "end_logit": 8.8828125,
            "text": "the treatment of pediatric patients with high-risk neuroblastoma",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.890625,
            "end_logit": 8.8828125,
            "text": "treatment of pediatric patients with high-risk neuroblastoma",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.9140625,
            "end_logit": 8.8828125,
            "text": "recently approved for use in combination with granulocyte- macrophage colony-stimulating factor, interleukin-2, and isotretinoin for the treatment of pediatric patients with high-risk neuroblastoma",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.95703125,
            "end_logit": 8.8828125,
            "text": "for the treatment of pediatric patients with high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.96484375,
            "end_logit": 8.8828125,
            "text": "of pediatric patients with high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.96484375,
            "end_logit": 8.8828125,
            "text": "patients with high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.984375,
            "end_logit": 8.8828125,
            "text": "novel monoclonal antibody recently approved for use in combination with granulocyte- macrophage colony-stimulating factor, interleukin-2, and isotretinoin for the treatment of pediatric patients with high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.98828125,
            "end_logit": 8.8828125,
            "text": "use in combination with granulocyte- macrophage colony-stimulating factor, interleukin-2, and isotretinoin for the treatment of pediatric patients with high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.9921875,
            "end_logit": 8.8828125,
            "text": ", and isotretinoin for the treatment of pediatric patients with high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -8.0078125,
            "end_logit": 8.8828125,
            "text": "for use in combination with granulocyte- macrophage colony-stimulating factor, interleukin-2, and isotretinoin for the treatment of pediatric patients with high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -8.0078125,
            "end_logit": 8.8828125,
            "text": ") is a novel monoclonal antibody recently approved for use in combination with granulocyte- macrophage colony-stimulating factor, interleukin-2, and isotretinoin for the treatment of pediatric patients with high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.4375,
            "end_logit": -7.79296875,
            "text": "neuroblastoma.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.89453125,
            "end_logit": -7.79296875,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.734375,
            "end_logit": -7.79296875,
            "text": "with high-risk neuroblastoma.",
            "probability": 0.0
        },
        {
            "start_logit": -7.8515625,
            "end_logit": -7.79296875,
            "text": "risk neuroblastoma.",
            "probability": 0.0
        },
        {
            "start_logit": -7.87890625,
            "end_logit": -7.79296875,
            "text": "the treatment of pediatric patients with high-risk neuroblastoma.",
            "probability": 0.0
        },
        {
            "start_logit": -7.890625,
            "end_logit": -7.79296875,
            "text": "treatment of pediatric patients with high-risk neuroblastoma.",
            "probability": 0.0
        }
    ],
    "589a247078275d0c4a000035_19": [
        {
            "start_logit": 7.68359375,
            "end_logit": 8.703125,
            "text": "neuroblastoma",
            "probability": 1.0
        },
        {
            "start_logit": -7.90625,
            "end_logit": 8.703125,
            "text": "part of combination immunotherapy in pediatric patients with high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.91015625,
            "end_logit": 8.703125,
            "text": "risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.9140625,
            "end_logit": 8.703125,
            "text": "with high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.9140625,
            "end_logit": 8.703125,
            "text": "patients with high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.91796875,
            "end_logit": 8.703125,
            "text": "in pediatric patients with high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.97265625,
            "end_logit": 8.703125,
            "text": "is efficacious as part of combination immunotherapy in pediatric patients with high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.99609375,
            "end_logit": 8.703125,
            "text": "Dinutuximab is a novel monoclonal antibody that is efficacious as part of combination immunotherapy in pediatric patients with high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -8.0078125,
            "end_logit": 8.703125,
            "text": "combination immunotherapy in pediatric patients with high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -8.015625,
            "end_logit": 8.703125,
            "text": "CONCLUSION Dinutuximab is a novel monoclonal antibody that is efficacious as part of combination immunotherapy in pediatric patients with high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -8.0234375,
            "end_logit": 8.703125,
            "text": "novel monoclonal antibody that is efficacious as part of combination immunotherapy in pediatric patients with high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -8.03125,
            "end_logit": 8.703125,
            "text": "pediatric patients with high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -8.03125,
            "end_logit": 8.703125,
            "text": "that is efficacious as part of combination immunotherapy in pediatric patients with high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -8.046875,
            "end_logit": 8.703125,
            "text": "high-risk neuroblastoma",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.0546875,
            "end_logit": 8.703125,
            "text": "as part of combination immunotherapy in pediatric patients with high-risk neuroblastoma",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.0625,
            "end_logit": 8.703125,
            "text": "immunotherapy in pediatric patients with high-risk neuroblastoma",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.68359375,
            "end_logit": -7.8125,
            "text": "neuroblastoma.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.91796875,
            "end_logit": -7.8125,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.90625,
            "end_logit": -7.8125,
            "text": "part of combination immunotherapy in pediatric patients with high-risk neuroblastoma.",
            "probability": 0.0
        },
        {
            "start_logit": -7.91015625,
            "end_logit": -7.8125,
            "text": "risk neuroblastoma.",
            "probability": 0.0
        }
    ],
    "589a247078275d0c4a000035_20": [
        {
            "start_logit": 7.66796875,
            "end_logit": 8.703125,
            "text": "neuroblastoma",
            "probability": 1.0
        },
        {
            "start_logit": -7.85546875,
            "end_logit": 8.703125,
            "text": "formerly called ch14.18), a monoclonal antibody targeting the disialoganglioside GD2, has been shown to significantly improve survival rates in patients with high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.859375,
            "end_logit": 8.703125,
            "text": "with high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.875,
            "end_logit": 8.703125,
            "text": "risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.87890625,
            "end_logit": 8.703125,
            "text": "patients with high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.8828125,
            "end_logit": 8.703125,
            "text": "Dinutuximab (formerly called ch14.18), a monoclonal antibody targeting the disialoganglioside GD2, has been shown to significantly improve survival rates in patients with high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.90625,
            "end_logit": 8.703125,
            "text": "called ch14.18), a monoclonal antibody targeting the disialoganglioside GD2, has been shown to significantly improve survival rates in patients with high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.90625,
            "end_logit": 8.703125,
            "text": "in patients with high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.921875,
            "end_logit": 8.703125,
            "text": "been shown to significantly improve survival rates in patients with high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.9453125,
            "end_logit": 8.703125,
            "text": ", a monoclonal antibody targeting the disialoganglioside GD2, has been shown to significantly improve survival rates in patients with high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.94921875,
            "end_logit": 8.703125,
            "text": ", has been shown to significantly improve survival rates in patients with high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.97265625,
            "end_logit": 8.703125,
            "text": "has been shown to significantly improve survival rates in patients with high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.97265625,
            "end_logit": 8.703125,
            "text": "monoclonal antibody targeting the disialoganglioside GD2, has been shown to significantly improve survival rates in patients with high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.98046875,
            "end_logit": 8.703125,
            "text": "(formerly called ch14.18), a monoclonal antibody targeting the disialoganglioside GD2, has been shown to significantly improve survival rates in patients with high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.99609375,
            "end_logit": 8.703125,
            "text": "antibody targeting the disialoganglioside GD2, has been shown to significantly improve survival rates in patients with high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -8.0078125,
            "end_logit": 8.703125,
            "text": "uximab (formerly called ch14.18), a monoclonal antibody targeting the disialoganglioside GD2, has been shown to significantly improve survival rates in patients with high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.66796875,
            "end_logit": -7.71484375,
            "text": "neuroblastoma.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.8984375,
            "end_logit": -7.71484375,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.85546875,
            "end_logit": -7.71484375,
            "text": "formerly called ch14.18), a monoclonal antibody targeting the disialoganglioside GD2, has been shown to significantly improve survival rates in patients with high-risk neuroblastoma.",
            "probability": 0.0
        },
        {
            "start_logit": -7.859375,
            "end_logit": -7.71484375,
            "text": "with high-risk neuroblastoma.",
            "probability": 0.0
        }
    ],
    "589a247078275d0c4a000035_21": [
        {
            "start_logit": 7.46875,
            "end_logit": 8.828125,
            "text": "neuroblastoma",
            "probability": 1.0
        },
        {
            "start_logit": -7.71875,
            "end_logit": 8.828125,
            "text": "of neuroblastoma",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.82421875,
            "end_logit": 8.828125,
            "text": "Unituxin\u2122) is a chimeric human-mouse monoclonal antibody that binds to the glycolipid antigen disialoganglioside, which is highly expressed on the surface of neuroblastoma",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.86328125,
            "end_logit": 8.828125,
            "text": "; Unituxin\u2122) is a chimeric human-mouse monoclonal antibody that binds to the glycolipid antigen disialoganglioside, which is highly expressed on the surface of neuroblastoma",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.9609375,
            "end_logit": 8.828125,
            "text": "in\u2122) is a chimeric human-mouse monoclonal antibody that binds to the glycolipid antigen disialoganglioside, which is highly expressed on the surface of neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.9609375,
            "end_logit": 8.828125,
            "text": "uxin\u2122) is a chimeric human-mouse monoclonal antibody that binds to the glycolipid antigen disialoganglioside, which is highly expressed on the surface of neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.9765625,
            "end_logit": 8.828125,
            "text": "binds to the glycolipid antigen disialoganglioside, which is highly expressed on the surface of neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.98046875,
            "end_logit": 8.828125,
            "text": "the surface of neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.9921875,
            "end_logit": 8.828125,
            "text": "antigen disialoganglioside, which is highly expressed on the surface of neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.9921875,
            "end_logit": 8.828125,
            "text": "surface of neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.9921875,
            "end_logit": 8.828125,
            "text": "on the surface of neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -8.0234375,
            "end_logit": 8.828125,
            "text": "human-mouse monoclonal antibody that binds to the glycolipid antigen disialoganglioside, which is highly expressed on the surface of neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -8.0234375,
            "end_logit": 8.828125,
            "text": ") is a chimeric human-mouse monoclonal antibody that binds to the glycolipid antigen disialoganglioside, which is highly expressed on the surface of neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.46875,
            "end_logit": -7.8828125,
            "text": "neuroblastoma cells.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.46875,
            "end_logit": -8.1875,
            "text": "neuroblastoma cells",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.91015625,
            "end_logit": -7.8828125,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.71875,
            "end_logit": -7.8828125,
            "text": "of neuroblastoma cells.",
            "probability": 0.0
        },
        {
            "start_logit": -7.82421875,
            "end_logit": -7.8828125,
            "text": "Unituxin\u2122) is a chimeric human-mouse monoclonal antibody that binds to the glycolipid antigen disialoganglioside, which is highly expressed on the surface of neuroblastoma cells.",
            "probability": 0.0
        },
        {
            "start_logit": -7.86328125,
            "end_logit": -7.8828125,
            "text": "; Unituxin\u2122) is a chimeric human-mouse monoclonal antibody that binds to the glycolipid antigen disialoganglioside, which is highly expressed on the surface of neuroblastoma cells.",
            "probability": 0.0
        },
        {
            "start_logit": -7.9609375,
            "end_logit": -7.8828125,
            "text": "in\u2122) is a chimeric human-mouse monoclonal antibody that binds to the glycolipid antigen disialoganglioside, which is highly expressed on the surface of neuroblastoma cells.",
            "probability": 0.0
        }
    ],
    "589a247078275d0c4a000035_22": [
        {
            "start_logit": 7.69140625,
            "end_logit": 8.703125,
            "text": "neuroblastoma",
            "probability": 1.0
        },
        {
            "start_logit": -7.77734375,
            "end_logit": 8.703125,
            "text": "The US FDA has recently approved the use of dinutuximab combination therapy for the treatment of high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.8203125,
            "end_logit": 8.703125,
            "text": "risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.8359375,
            "end_logit": 8.703125,
            "text": "treatment of high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.85546875,
            "end_logit": 8.703125,
            "text": "recently approved the use of dinutuximab combination therapy for the treatment of high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.87890625,
            "end_logit": 8.703125,
            "text": "use of dinutuximab combination therapy for the treatment of high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.89453125,
            "end_logit": 8.703125,
            "text": "the treatment of high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.8984375,
            "end_logit": 8.703125,
            "text": "dinutuximab combination therapy for the treatment of high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.9453125,
            "end_logit": 8.703125,
            "text": "high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.94921875,
            "end_logit": 8.703125,
            "text": "for the treatment of high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.95703125,
            "end_logit": 8.703125,
            "text": "of high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.95703125,
            "end_logit": 8.703125,
            "text": "has recently approved the use of dinutuximab combination therapy for the treatment of high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.96484375,
            "end_logit": 8.703125,
            "text": "FDA has recently approved the use of dinutuximab combination therapy for the treatment of high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.96875,
            "end_logit": 8.703125,
            "text": "of dinutuximab combination therapy for the treatment of high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.97265625,
            "end_logit": 8.703125,
            "text": "the use of dinutuximab combination therapy for the treatment of high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.97265625,
            "end_logit": 8.703125,
            "text": "utuximab combination therapy for the treatment of high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.69140625,
            "end_logit": -7.6875,
            "text": "neuroblastoma in paediatric patients.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.69140625,
            "end_logit": -8.0078125,
            "text": "neuroblastoma in",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.859375,
            "end_logit": -7.6875,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.77734375,
            "end_logit": -7.6875,
            "text": "The US FDA has recently approved the use of dinutuximab combination therapy for the treatment of high-risk neuroblastoma in paediatric patients.",
            "probability": 0.0
        }
    ],
    "589a247078275d0c4a000035_23": [
        {
            "start_logit": 7.52734375,
            "end_logit": 8.8203125,
            "text": "neuroblastoma",
            "probability": 1.0
        },
        {
            "start_logit": -7.82421875,
            "end_logit": 8.8203125,
            "text": "risk neuroblastoma",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.84375,
            "end_logit": 8.8203125,
            "text": "treatment of pediatric patients with high-risk neuroblastoma",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.8515625,
            "end_logit": 8.8203125,
            "text": "Dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.9375,
            "end_logit": 8.8203125,
            "text": "the treatment of pediatric patients with high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.94140625,
            "end_logit": 8.8203125,
            "text": "with high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.94140625,
            "end_logit": 8.8203125,
            "text": "patients with high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.97265625,
            "end_logit": 8.8203125,
            "text": "utuximab for the treatment of pediatric patients with high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.98046875,
            "end_logit": 8.8203125,
            "text": "uximab for the treatment of pediatric patients with high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.9921875,
            "end_logit": 8.8203125,
            "text": "pediatric patients with high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.99609375,
            "end_logit": 8.8203125,
            "text": "high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -8.0234375,
            "end_logit": 8.8203125,
            "text": "for the treatment of pediatric patients with high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -8.0390625,
            "end_logit": 8.8203125,
            "text": "of pediatric patients with high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.52734375,
            "end_logit": -7.8671875,
            "text": "neuroblastoma.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.90234375,
            "end_logit": -7.8671875,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.82421875,
            "end_logit": -7.8671875,
            "text": "risk neuroblastoma.",
            "probability": 0.0
        },
        {
            "start_logit": -7.84375,
            "end_logit": -7.8671875,
            "text": "treatment of pediatric patients with high-risk neuroblastoma.",
            "probability": 0.0
        },
        {
            "start_logit": -7.8515625,
            "end_logit": -7.8671875,
            "text": "Dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma.",
            "probability": 0.0
        },
        {
            "start_logit": -7.9375,
            "end_logit": -7.8671875,
            "text": "the treatment of pediatric patients with high-risk neuroblastoma.",
            "probability": 0.0
        },
        {
            "start_logit": -7.94140625,
            "end_logit": -7.8671875,
            "text": "with high-risk neuroblastoma.",
            "probability": 0.0
        }
    ],
    "589a247078275d0c4a000035_24": [
        {
            "start_logit": 7.6171875,
            "end_logit": 8.7421875,
            "text": "neuroblastoma",
            "probability": 1.0
        },
        {
            "start_logit": -7.90234375,
            "end_logit": 8.7421875,
            "text": "risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.95703125,
            "end_logit": 8.7421875,
            "text": "with high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.98046875,
            "end_logit": 8.7421875,
            "text": "patients with high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.99609375,
            "end_logit": 8.7421875,
            "text": "dinutuximab in pediatric patients with high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -8.0078125,
            "end_logit": 8.7421875,
            "text": "Transverse myelitis as an unexpected complication following treatment with dinutuximab in pediatric patients with high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -8.046875,
            "end_logit": 8.7421875,
            "text": "treatment with dinutuximab in pediatric patients with high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -8.046875,
            "end_logit": 8.7421875,
            "text": "complication following treatment with dinutuximab in pediatric patients with high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -8.0546875,
            "end_logit": 8.7421875,
            "text": "uximab in pediatric patients with high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -8.0546875,
            "end_logit": 8.7421875,
            "text": "myelitis as an unexpected complication following treatment with dinutuximab in pediatric patients with high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -8.0546875,
            "end_logit": 8.7421875,
            "text": "utuximab in pediatric patients with high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.6171875,
            "end_logit": -7.828125,
            "text": "neuroblastoma: A case series.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.6171875,
            "end_logit": -8.125,
            "text": "neuroblastoma: A case series",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.6171875,
            "end_logit": -8.15625,
            "text": "neuroblastoma:",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.9375,
            "end_logit": -7.828125,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.90234375,
            "end_logit": -7.828125,
            "text": "risk neuroblastoma: A case series.",
            "probability": 0.0
        },
        {
            "start_logit": -7.94921875,
            "end_logit": -7.828125,
            "text": "case series.",
            "probability": 0.0
        },
        {
            "start_logit": -7.95703125,
            "end_logit": -7.828125,
            "text": "with high-risk neuroblastoma: A case series.",
            "probability": 0.0
        },
        {
            "start_logit": -7.98046875,
            "end_logit": -7.828125,
            "text": "patients with high-risk neuroblastoma: A case series.",
            "probability": 0.0
        },
        {
            "start_logit": -7.99609375,
            "end_logit": -7.828125,
            "text": "dinutuximab in pediatric patients with high-risk neuroblastoma: A case series.",
            "probability": 0.0
        }
    ],
    "589a247078275d0c4a000035_25": [
        {
            "start_logit": 7.7734375,
            "end_logit": 8.640625,
            "text": "neuroblastoma",
            "probability": 1.0
        },
        {
            "start_logit": -7.76171875,
            "end_logit": 8.640625,
            "text": "Findings of the randomized phase III study (ANBL0032) led to the approval of dinutuximab for the treatment of children with high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.81640625,
            "end_logit": 8.640625,
            "text": "ANBL0032) led to the approval of dinutuximab for the treatment of children with high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.81640625,
            "end_logit": 8.640625,
            "text": "study (ANBL0032) led to the approval of dinutuximab for the treatment of children with high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.83203125,
            "end_logit": 8.640625,
            "text": "approval of dinutuximab for the treatment of children with high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.83984375,
            "end_logit": 8.640625,
            "text": "dinutuximab for the treatment of children with high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.84375,
            "end_logit": 8.640625,
            "text": "the treatment of children with high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.84765625,
            "end_logit": 8.640625,
            "text": "treatment of children with high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.859375,
            "end_logit": 8.640625,
            "text": ") led to the approval of dinutuximab for the treatment of children with high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.87109375,
            "end_logit": 8.640625,
            "text": "the randomized phase III study (ANBL0032) led to the approval of dinutuximab for the treatment of children with high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.87890625,
            "end_logit": 8.640625,
            "text": "of dinutuximab for the treatment of children with high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.87890625,
            "end_logit": 8.640625,
            "text": "the approval of dinutuximab for the treatment of children with high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.88671875,
            "end_logit": 8.640625,
            "text": "risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.90234375,
            "end_logit": 8.640625,
            "text": "with high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.91796875,
            "end_logit": 8.640625,
            "text": "(ANBL0032) led to the approval of dinutuximab for the treatment of children with high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.921875,
            "end_logit": 8.640625,
            "text": "phase III study (ANBL0032) led to the approval of dinutuximab for the treatment of children with high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.7734375,
            "end_logit": -7.76953125,
            "text": "neuroblastoma.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.921875,
            "end_logit": -7.76953125,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.76171875,
            "end_logit": -7.76953125,
            "text": "Findings of the randomized phase III study (ANBL0032) led to the approval of dinutuximab for the treatment of children with high-risk neuroblastoma.",
            "probability": 0.0
        },
        {
            "start_logit": -7.81640625,
            "end_logit": -7.76953125,
            "text": "ANBL0032) led to the approval of dinutuximab for the treatment of children with high-risk neuroblastoma.",
            "probability": 0.0
        }
    ],
    "5c8cd26a0101eac870000003_1": [
        {
            "start_logit": 6.6953125,
            "end_logit": 5.390625,
            "text": "secreted protein content (exoproteome) revealed that many enzymes involved in carbohydrate hydrolysis were regulated by VdSec22 or VdSso1.",
            "probability": 0.9931640625
        },
        {
            "start_logit": 1.294921875,
            "end_logit": 5.390625,
            "text": "Comparative analyses of the secreted protein content (exoproteome) revealed that many enzymes involved in carbohydrate hydrolysis were regulated by VdSec22 or VdSso1.",
            "probability": 0.00449371337890625
        },
        {
            "start_logit": 0.40234375,
            "end_logit": 5.390625,
            "text": ".",
            "probability": 0.0018367767333984375
        },
        {
            "start_logit": 6.6953125,
            "end_logit": -3.24609375,
            "text": "secreted protein content (exoproteome) revealed",
            "probability": 0.00017559528350830078
        },
        {
            "start_logit": 6.6953125,
            "end_logit": -3.6328125,
            "text": "secreted protein content",
            "probability": 0.00011974573135375977
        },
        {
            "start_logit": 6.6953125,
            "end_logit": -4.43359375,
            "text": "secreted",
            "probability": 5.358457565307617e-05
        },
        {
            "start_logit": 6.6953125,
            "end_logit": -5.390625,
            "text": "secreted protein",
            "probability": 2.0682811737060547e-05
        },
        {
            "start_logit": 6.6953125,
            "end_logit": -6.0234375,
            "text": "secreted protein content (exoproteome)",
            "probability": 1.0967254638671875e-05
        },
        {
            "start_logit": 6.6953125,
            "end_logit": -6.5390625,
            "text": "secreted protein content (exoproteome) revealed that many enzymes involved in carbohydrate hydrolysis",
            "probability": 6.556510925292969e-06
        },
        {
            "start_logit": 6.6953125,
            "end_logit": -6.80859375,
            "text": "secreted protein content (exoproteome) revealed that",
            "probability": 4.947185516357422e-06
        },
        {
            "start_logit": 6.6953125,
            "end_logit": -6.86328125,
            "text": "secreted protein content (exoproteome) revealed that many enzymes involved in carbohydrate hydrolysis were",
            "probability": 4.708766937255859e-06
        },
        {
            "start_logit": 6.6953125,
            "end_logit": -6.92578125,
            "text": "secreted protein content (exoproteome) revealed that many",
            "probability": 4.410743713378906e-06
        },
        {
            "start_logit": 6.6953125,
            "end_logit": -6.93359375,
            "text": "secreted protein content (",
            "probability": 4.351139068603516e-06
        },
        {
            "start_logit": 6.6953125,
            "end_logit": -7.296875,
            "text": "secreted protein content (exoproteome) revealed that many enzymes",
            "probability": 3.0994415283203125e-06
        },
        {
            "start_logit": 6.6953125,
            "end_logit": -7.3984375,
            "text": "secreted protein content (exoproteome) revealed that many enzymes involved in",
            "probability": 2.8014183044433594e-06
        },
        {
            "start_logit": 6.6953125,
            "end_logit": -7.53515625,
            "text": "secreted protein content (exoproteome) revealed that many enzymes involved in carbohydrate hydrolysis were regulated by VdSec22",
            "probability": 2.4437904357910156e-06
        },
        {
            "start_logit": 6.6953125,
            "end_logit": -7.5546875,
            "text": "secreted protein content (exoproteome",
            "probability": 2.384185791015625e-06
        },
        {
            "start_logit": -6.43359375,
            "end_logit": 5.390625,
            "text": "many enzymes involved in carbohydrate hydrolysis were regulated by VdSec22 or VdSso1.",
            "probability": 1.9669532775878906e-06
        },
        {
            "start_logit": -6.62890625,
            "end_logit": 5.390625,
            "text": "(exoproteome) revealed that many enzymes involved in carbohydrate hydrolysis were regulated by VdSec22 or VdSso1.",
            "probability": 1.6093254089355469e-06
        },
        {
            "start_logit": -6.640625,
            "end_logit": 5.390625,
            "text": "the secreted protein content (exoproteome) revealed that many enzymes involved in carbohydrate hydrolysis were regulated by VdSec22 or VdSso1.",
            "probability": 1.6093254089355469e-06
        }
    ],
    "5cb0e4a6ecadf2e73f00005b_1": [
        {
            "start_logit": 5.8828125,
            "end_logit": 8.3359375,
            "text": "surfaceome",
            "probability": 1.0
        },
        {
            "start_logit": -3.236328125,
            "end_logit": 8.3359375,
            "text": "ome",
            "probability": 0.00010979175567626953
        },
        {
            "start_logit": 5.8828125,
            "end_logit": -2.291015625,
            "text": "surfaceome, we developed the surfaceome predictor SURFY, based on machine learning.",
            "probability": 2.4318695068359375e-05
        },
        {
            "start_logit": 5.8828125,
            "end_logit": -2.759765625,
            "text": "surfaceome, we developed the surfaceome",
            "probability": 1.519918441772461e-05
        },
        {
            "start_logit": -6.7578125,
            "end_logit": 8.3359375,
            "text": "analysis of the human surfaceome",
            "probability": 3.2186508178710938e-06
        },
        {
            "start_logit": -6.8671875,
            "end_logit": 8.3359375,
            "text": "o enable analysis of the human surfaceome",
            "probability": 2.9206275939941406e-06
        },
        {
            "start_logit": -6.8984375,
            "end_logit": 8.3359375,
            "text": "the human surfaceome",
            "probability": 2.8014183044433594e-06
        },
        {
            "start_logit": -6.98046875,
            "end_logit": 8.3359375,
            "text": "enable analysis of the human surfaceome",
            "probability": 2.6226043701171875e-06
        },
        {
            "start_logit": -7.05078125,
            "end_logit": 8.3359375,
            "text": "human surfaceome",
            "probability": 2.384185791015625e-06
        },
        {
            "start_logit": -7.68359375,
            "end_logit": 8.3359375,
            "text": "of the human surfaceome",
            "probability": 1.3113021850585938e-06
        },
        {
            "start_logit": 5.8828125,
            "end_logit": -5.33984375,
            "text": "surface",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": 2.8125,
            "end_logit": -2.291015625,
            "text": "surfaceome predictor SURFY, based on machine learning.",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": 5.8828125,
            "end_logit": -5.50390625,
            "text": "surfaceome, we developed the surfaceome predictor",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": 2.8125,
            "end_logit": -2.759765625,
            "text": "surfaceome",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 5.8828125,
            "end_logit": -6.6953125,
            "text": "surfaceome, we developed the surface",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 5.8828125,
            "end_logit": -6.81640625,
            "text": "surfaceome, we developed the surfaceome predictor SURFY, based on machine learning",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 5.8828125,
            "end_logit": -7.0625,
            "text": "surfaceome,",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 5.8828125,
            "end_logit": -7.08203125,
            "text": "surfaceome, we developed the surfaceome predictor SURFY,",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 5.8828125,
            "end_logit": -7.25,
            "text": "surfaceome, we",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 5.8828125,
            "end_logit": -7.50390625,
            "text": "surfaceome, we developed",
            "probability": 1.1920928955078125e-07
        }
    ],
    "550618f58e1671127b000007_1": [
        {
            "start_logit": 5.39453125,
            "end_logit": 1.9208984375,
            "text": "protein phosphatase inhibitor-1 (PPI-1)",
            "probability": 0.87890625
        },
        {
            "start_logit": 3.15234375,
            "end_logit": 1.9208984375,
            "text": ", protein phosphatase inhibitor-1 (PPI-1)",
            "probability": 0.09332275390625
        },
        {
            "start_logit": 5.39453125,
            "end_logit": -1.865234375,
            "text": "protein phosphatase inhibitor-1 (PPI-1",
            "probability": 0.0199127197265625
        },
        {
            "start_logit": 3.15234375,
            "end_logit": -1.865234375,
            "text": ", protein phosphatase inhibitor-1 (PPI-1",
            "probability": 0.00211334228515625
        },
        {
            "start_logit": 5.39453125,
            "end_logit": -4.14453125,
            "text": "protein phosphatase inhibitor-1 (PPI",
            "probability": 0.0020389556884765625
        },
        {
            "start_logit": 5.39453125,
            "end_logit": -5.3125,
            "text": "protein",
            "probability": 0.0006341934204101562
        },
        {
            "start_logit": 5.39453125,
            "end_logit": -5.421875,
            "text": "protein phosphatase inhibitor-1 (",
            "probability": 0.000568389892578125
        },
        {
            "start_logit": 5.39453125,
            "end_logit": -5.63671875,
            "text": "protein phosphatase inhibitor-1",
            "probability": 0.0004584789276123047
        },
        {
            "start_logit": 3.15234375,
            "end_logit": -3.498046875,
            "text": ",",
            "probability": 0.0004127025604248047
        },
        {
            "start_logit": 5.39453125,
            "end_logit": -5.98828125,
            "text": "protein phosphatase inhibitor-1 (PPI-",
            "probability": 0.00032258033752441406
        },
        {
            "start_logit": 5.39453125,
            "end_logit": -6.171875,
            "text": "protein phosphatase inhibitor",
            "probability": 0.0002684593200683594
        },
        {
            "start_logit": 3.15234375,
            "end_logit": -4.14453125,
            "text": ", protein phosphatase inhibitor-1 (PPI",
            "probability": 0.00021564960479736328
        },
        {
            "start_logit": 5.39453125,
            "end_logit": -6.90625,
            "text": "protein phosphatase inhibitor-",
            "probability": 0.00012874603271484375
        },
        {
            "start_logit": 5.39453125,
            "end_logit": -7.44140625,
            "text": "protein phosphatase",
            "probability": 7.56978988647461e-05
        },
        {
            "start_logit": 3.15234375,
            "end_logit": -5.3125,
            "text": ", protein",
            "probability": 6.73532485961914e-05
        },
        {
            "start_logit": 3.15234375,
            "end_logit": -5.421875,
            "text": ", protein phosphatase inhibitor-1 (",
            "probability": 6.03795051574707e-05
        },
        {
            "start_logit": 3.15234375,
            "end_logit": -5.63671875,
            "text": ", protein phosphatase inhibitor-1",
            "probability": 4.887580871582031e-05
        },
        {
            "start_logit": 3.15234375,
            "end_logit": -5.98828125,
            "text": ", protein phosphatase inhibitor-1 (PPI-",
            "probability": 3.415346145629883e-05
        },
        {
            "start_logit": 3.15234375,
            "end_logit": -6.171875,
            "text": ", protein phosphatase inhibitor",
            "probability": 2.849102020263672e-05
        },
        {
            "start_logit": 3.15234375,
            "end_logit": -6.90625,
            "text": ", protein phosphatase inhibitor-",
            "probability": 1.3649463653564453e-05
        }
    ],
    "550618f58e1671127b000007_2": [
        {
            "start_logit": 9.8828125,
            "end_logit": 4.734375,
            "text": "Inhibitor 1 (I-1)",
            "probability": 0.98388671875
        },
        {
            "start_logit": 9.8828125,
            "end_logit": 0.3828125,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase 1 (PP1), a major eukaryotic Ser/Thr phosphatase.",
            "probability": 0.01267242431640625
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -0.826171875,
            "text": "Inhibitor",
            "probability": 0.00377655029296875
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -5.4921875,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase 1 (",
            "probability": 3.55839729309082e-05
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -5.515625,
            "text": "Inhibitor 1",
            "probability": 3.4749507904052734e-05
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -5.52734375,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase 1 (PP1),",
            "probability": 3.421306610107422e-05
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -5.59765625,
            "text": "Inhibitor 1 (I-1) is",
            "probability": 3.218650817871094e-05
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -6.35546875,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase 1 (PP1), a",
            "probability": 1.4960765838623047e-05
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -6.6875,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase 1 (PP1)",
            "probability": 1.0788440704345703e-05
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -6.71875,
            "text": "Inhibitor 1 (I-",
            "probability": 1.043081283569336e-05
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -6.75,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase 1 (PP",
            "probability": 1.0132789611816406e-05
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -6.76953125,
            "text": "Inhibitor 1 (I-1",
            "probability": 9.953975677490234e-06
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -6.90234375,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase 1 (PP1), a major eukaryotic Ser/Thr phosphatase",
            "probability": 8.702278137207031e-06
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -6.953125,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase 1",
            "probability": 8.285045623779297e-06
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -7.1015625,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase 1 (PP1",
            "probability": 7.092952728271484e-06
        },
        {
            "start_logit": -3.84765625,
            "end_logit": 4.734375,
            "text": "(I-1)",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": -6.05078125,
            "end_logit": 4.734375,
            "text": ")",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -2.5625,
            "end_logit": 0.3828125,
            "text": ". Nonphosphorylated I-1 is inactive, whereas phosphorylated I-1 is a potent PP1 inhibitor.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.5625,
            "end_logit": 0.3828125,
            "text": ".",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.564453125,
            "end_logit": 0.3828125,
            "text": ".",
            "probability": 5.960464477539063e-08
        }
    ],
    "550618f58e1671127b000007_3": [
        {
            "start_logit": 8.09375,
            "end_logit": 1.82421875,
            "text": "Ser67-phosphorylated inhibitor 1 is a potent protein phosphatase 1 inhibitor.",
            "probability": 0.91015625
        },
        {
            "start_logit": 8.09375,
            "end_logit": -0.64111328125,
            "text": "Ser67-phosphorylated inhibitor 1",
            "probability": 0.07708740234375
        },
        {
            "start_logit": 8.09375,
            "end_logit": -3.267578125,
            "text": "Ser67-phosphorylated inhibitor 1 is",
            "probability": 0.005584716796875
        },
        {
            "start_logit": 8.09375,
            "end_logit": -3.427734375,
            "text": "Ser",
            "probability": 0.00473785400390625
        },
        {
            "start_logit": 8.09375,
            "end_logit": -4.625,
            "text": "Ser67",
            "probability": 0.001434326171875
        },
        {
            "start_logit": 8.09375,
            "end_logit": -6.890625,
            "text": "Ser67-phosphorylated",
            "probability": 0.000148773193359375
        },
        {
            "start_logit": 8.09375,
            "end_logit": -6.94921875,
            "text": "Ser67-",
            "probability": 0.00013971328735351562
        },
        {
            "start_logit": 8.09375,
            "end_logit": -7.0546875,
            "text": "Ser67-phosphorylated inhibitor",
            "probability": 0.00012624263763427734
        },
        {
            "start_logit": 8.09375,
            "end_logit": -7.78125,
            "text": "Ser67-phosphorylated inhibitor 1 is a",
            "probability": 6.109476089477539e-05
        },
        {
            "start_logit": 8.09375,
            "end_logit": -7.94140625,
            "text": "Ser67-phosphorylated inhibitor 1 is a potent protein phosphatase 1",
            "probability": 5.227327346801758e-05
        },
        {
            "start_logit": 8.09375,
            "end_logit": -8.015625,
            "text": "Ser67-phosphorylated inhibitor 1 is a potent",
            "probability": 4.8279762268066406e-05
        },
        {
            "start_logit": -1.955078125,
            "end_logit": 1.82421875,
            "text": ".",
            "probability": 3.910064697265625e-05
        },
        {
            "start_logit": -4.8828125,
            "end_logit": 1.82421875,
            "text": "inhibitor 1 is a potent protein phosphatase 1 inhibitor.",
            "probability": 2.086162567138672e-06
        },
        {
            "start_logit": -6.2265625,
            "end_logit": 1.82421875,
            "text": "phosphorylated inhibitor 1 is a potent protein phosphatase 1 inhibitor.",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -7.07421875,
            "end_logit": 1.82421875,
            "text": "protein phosphatase 1 inhibitor.",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.1328125,
            "end_logit": 1.82421875,
            "text": "67-phosphorylated inhibitor 1 is a potent protein phosphatase 1 inhibitor.",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.25390625,
            "end_logit": 1.82421875,
            "text": "potent protein phosphatase 1 inhibitor.",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.33984375,
            "end_logit": 1.82421875,
            "text": "-phosphorylated inhibitor 1 is a potent protein phosphatase 1 inhibitor.",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -4.8828125,
            "end_logit": -0.64111328125,
            "text": "inhibitor 1",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.77734375,
            "end_logit": 1.82421875,
            "text": "a potent protein phosphatase 1 inhibitor.",
            "probability": 1.1920928955078125e-07
        }
    ],
    "550618f58e1671127b000007_4": [
        {
            "start_logit": 9.9453125,
            "end_logit": 8.4453125,
            "text": "Inhibitor 1 (I-1)",
            "probability": 1.0
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -0.892578125,
            "text": "Inhibitor",
            "probability": 8.821487426757812e-05
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -1.80859375,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase 1 (PP1), the predominating Ser/Thr phosphatase in the heart.",
            "probability": 3.534555435180664e-05
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -1.88671875,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase 1 (PP1), the predominating Ser/Thr phosphatase in the heart",
            "probability": 3.272294998168945e-05
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -3.810546875,
            "text": "Inhibitor 1 (I-1) is",
            "probability": 4.76837158203125e-06
        },
        {
            "start_logit": -3.095703125,
            "end_logit": 8.4453125,
            "text": ")",
            "probability": 2.1457672119140625e-06
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -6.52734375,
            "text": "Inhibitor 1",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -5.2734375,
            "end_logit": 8.4453125,
            "text": "(I-1)",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -6.83984375,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase 1 (",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -6.890625,
            "text": "Inhibitor 1 (I-1",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -7.08203125,
            "text": "Inhibitor 1 (I",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -7.1875,
            "text": "Inhibitor 1 (I-",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -7.2578125,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase 1 (PP1), the predominating Ser/Thr phosphatase in the",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -7.2890625,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase 1 (PP1),",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -7.32421875,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase 1 (PP1)",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -7.40625,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase 1 (PP",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -7.484375,
            "text": "Inhibitor 1 (I-1) is a",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -7.5,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase 1",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -7.52734375,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase 1 (PP1",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -7.55859375,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase 1 (PP1), the predominating Ser/Thr phosphatase in",
            "probability": 1.1920928955078125e-07
        }
    ],
    "550618f58e1671127b000007_5": [
        {
            "start_logit": 9.8671875,
            "end_logit": 7.59375,
            "text": "Inhibitor 1 (I-1)",
            "probability": 0.9990234375
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -0.42138671875,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase 1 (PP1), a major eukaryotic Ser/Thr phosphatase.",
            "probability": 0.0003273487091064453
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -0.93310546875,
            "text": "Inhibitor",
            "probability": 0.00019693374633789062
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -3.5703125,
            "text": "Inhibitor 1 (I-1) is",
            "probability": 1.4066696166992188e-05
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -5.65625,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase 1 (",
            "probability": 1.7285346984863281e-06
        },
        {
            "start_logit": -3.96484375,
            "end_logit": 7.59375,
            "text": ")",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -6.26953125,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase 1 (PP1),",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -6.40625,
            "text": "Inhibitor 1",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -6.8671875,
            "text": "Inhibitor 1 (I-1",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -6.96875,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase 1 (PP1)",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -7.03515625,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase 1 (PP",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -7.0703125,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase 1 (PP1), a",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -7.1328125,
            "text": "Inhibitor 1 (I",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -7.17578125,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase 1",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -7.19921875,
            "text": "Inhibitor 1 (I-",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -7.265625,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase 1 (PP1), a major eukaryotic Ser/Thr phosphatase",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -7.41796875,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase 1 (PP1",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -7.58984375,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -7.66015625,
            "text": "Inhibitor 1 (I-1) is a",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -5.79296875,
            "end_logit": 7.59375,
            "text": "(I-1)",
            "probability": 1.7881393432617188e-07
        }
    ],
    "550618f58e1671127b000007_6": [
        {
            "start_logit": 9.8046875,
            "end_logit": 8.703125,
            "text": "Inhibitor 1 (I-1)",
            "probability": 1.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -1.1630859375,
            "text": "Inhibitor",
            "probability": 5.227327346801758e-05
        },
        {
            "start_logit": -2.73046875,
            "end_logit": 8.703125,
            "text": ")",
            "probability": 3.635883331298828e-06
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -5.6328125,
            "text": "Inhibitor 1 (I-1) is",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -5.6953125,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase 1 (PP1), the predominating Ser/Thr phosphatase in the heart",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -6.51171875,
            "text": "Inhibitor 1",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -5.61328125,
            "end_logit": 8.703125,
            "text": "(I-1)",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -6.9375,
            "text": "Inhibitor 1 (I-1",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -6.9609375,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase 1 (",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -7.0546875,
            "text": "Inhibitor 1 (I",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -7.10546875,
            "text": "Inhibitor 1 (I-",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -7.40625,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase 1 (PP1), the predominating Ser/Thr phosphatase in the",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -7.546875,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase 1 (PP1)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -7.609375,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase 1 (PP",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -7.62890625,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase 1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -7.6328125,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase 1 (PP1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -7.640625,
            "text": "Inhibitor 1 (I-1) is a",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -7.66015625,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase 1 (PP1),",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -7.67578125,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase 1 (PP1), the predominating Ser/Thr phosphatase in",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -7.73828125,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase 1 (PP1), the predominating Ser/Thr phosphatase",
            "probability": 5.960464477539063e-08
        }
    ],
    "5881f9b65bf093691f000001_1": [
        {
            "start_logit": 9.46875,
            "end_logit": 9.375,
            "text": "Parasympathetic neurons",
            "probability": 1.0
        },
        {
            "start_logit": -1.91015625,
            "end_logit": 9.375,
            "text": "neurons",
            "probability": 1.150369644165039e-05
        },
        {
            "start_logit": 9.46875,
            "end_logit": -2.23046875,
            "text": "Parasympathetic",
            "probability": 9.059906005859375e-06
        },
        {
            "start_logit": 9.46875,
            "end_logit": -3.693359375,
            "text": "Parasympathetic neurons originate from nerve-associated peripheral glial progenitors.",
            "probability": 2.086162567138672e-06
        },
        {
            "start_logit": 9.46875,
            "end_logit": -6.796875,
            "text": "Parasympathetic neurons originate",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -1.91015625,
            "end_logit": -3.693359375,
            "text": "neurons originate from nerve-associated peripheral glial progenitors.",
            "probability": 0.0
        },
        {
            "start_logit": -4.7578125,
            "end_logit": -3.693359375,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -1.91015625,
            "end_logit": -6.796875,
            "text": "neurons originate",
            "probability": 0.0
        },
        {
            "start_logit": -7.28125,
            "end_logit": -3.693359375,
            "text": "from nerve-associated peripheral glial progenitors.",
            "probability": 0.0
        },
        {
            "start_logit": -7.3828125,
            "end_logit": -3.693359375,
            "text": "glial progenitors.",
            "probability": 0.0
        },
        {
            "start_logit": -7.49609375,
            "end_logit": -3.693359375,
            "text": "progenitors.",
            "probability": 0.0
        },
        {
            "start_logit": -7.58984375,
            "end_logit": -3.693359375,
            "text": "peripheral glial progenitors.",
            "probability": 0.0
        },
        {
            "start_logit": -7.88671875,
            "end_logit": -3.693359375,
            "text": "originate from nerve-associated peripheral glial progenitors.",
            "probability": 0.0
        },
        {
            "start_logit": -7.89453125,
            "end_logit": -3.693359375,
            "text": "nerve-associated peripheral glial progenitors.",
            "probability": 0.0
        },
        {
            "start_logit": -7.96875,
            "end_logit": -3.693359375,
            "text": "associated peripheral glial progenitors.",
            "probability": 0.0
        },
        {
            "start_logit": -8.046875,
            "end_logit": -3.693359375,
            "text": "-associated peripheral glial progenitors.",
            "probability": 0.0
        },
        {
            "start_logit": -7.88671875,
            "end_logit": -6.796875,
            "text": "originate",
            "probability": 0.0
        }
    ],
    "5881f9b65bf093691f000001_2": [
        {
            "start_logit": 8.609375,
            "end_logit": 9.328125,
            "text": "Parasympathetic neurons",
            "probability": 1.0
        },
        {
            "start_logit": -1.78515625,
            "end_logit": 9.328125,
            "text": "neurons",
            "probability": 3.069639205932617e-05
        },
        {
            "start_logit": 8.609375,
            "end_logit": -3.3125,
            "text": "Parasympathetic",
            "probability": 3.2186508178710938e-06
        },
        {
            "start_logit": 8.609375,
            "end_logit": -6.07421875,
            "text": "Parasympathetic neurons originate from nerve-associated peripheral glial progenitors.",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.375,
            "end_logit": 9.328125,
            "text": ". Parasympathetic neurons",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.1171875,
            "end_logit": 9.328125,
            "text": "Neurodevelopment. Parasympathetic neurons",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.609375,
            "end_logit": -7.83984375,
            "text": "Parasympathetic neurons originate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.78515625,
            "end_logit": -6.07421875,
            "text": "neurons originate from nerve-associated peripheral glial progenitors.",
            "probability": 0.0
        },
        {
            "start_logit": -1.78515625,
            "end_logit": -7.83984375,
            "text": "neurons originate",
            "probability": 0.0
        },
        {
            "start_logit": -7.375,
            "end_logit": -3.3125,
            "text": ". Parasympathetic",
            "probability": 0.0
        },
        {
            "start_logit": -8.1171875,
            "end_logit": -3.3125,
            "text": "Neurodevelopment. Parasympathetic",
            "probability": 0.0
        },
        {
            "start_logit": -5.8046875,
            "end_logit": -6.07421875,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.0,
            "end_logit": -6.07421875,
            "text": "from nerve-associated peripheral glial progenitors.",
            "probability": 0.0
        },
        {
            "start_logit": -7.375,
            "end_logit": -6.07421875,
            "text": ". Parasympathetic neurons originate from nerve-associated peripheral glial progenitors.",
            "probability": 0.0
        },
        {
            "start_logit": -7.55078125,
            "end_logit": -6.07421875,
            "text": "glial progenitors.",
            "probability": 0.0
        },
        {
            "start_logit": -7.55078125,
            "end_logit": -6.07421875,
            "text": "originate from nerve-associated peripheral glial progenitors.",
            "probability": 0.0
        },
        {
            "start_logit": -7.63671875,
            "end_logit": -6.07421875,
            "text": "peripheral glial progenitors.",
            "probability": 0.0
        },
        {
            "start_logit": -7.7421875,
            "end_logit": -6.07421875,
            "text": "nerve-associated peripheral glial progenitors.",
            "probability": 0.0
        },
        {
            "start_logit": -7.7890625,
            "end_logit": -6.07421875,
            "text": "associated peripheral glial progenitors.",
            "probability": 0.0
        },
        {
            "start_logit": -7.79296875,
            "end_logit": -6.07421875,
            "text": "progenitors.",
            "probability": 0.0
        }
    ],
    "5881f9b65bf093691f000001_3": [
        {
            "start_logit": 9.15625,
            "end_logit": 9.421875,
            "text": "Parasympathetic neurons",
            "probability": 1.0
        },
        {
            "start_logit": -1.8330078125,
            "end_logit": 9.421875,
            "text": "neurons",
            "probability": 1.6987323760986328e-05
        },
        {
            "start_logit": 9.15625,
            "end_logit": -2.677734375,
            "text": "Parasympathetic",
            "probability": 5.543231964111328e-06
        },
        {
            "start_logit": 9.15625,
            "end_logit": -7.29296875,
            "text": "Parasympathetic neurons originate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.15625,
            "end_logit": -7.85546875,
            "text": "Parasympathetic neurons originate from nerve-associated peripheral glial progenitors",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.8330078125,
            "end_logit": -7.29296875,
            "text": "neurons originate",
            "probability": 0.0
        },
        {
            "start_logit": -1.8330078125,
            "end_logit": -7.85546875,
            "text": "neurons originate from nerve-associated peripheral glial progenitors",
            "probability": 0.0
        },
        {
            "start_logit": -7.3828125,
            "end_logit": -7.85546875,
            "text": "from nerve-associated peripheral glial progenitors",
            "probability": 0.0
        },
        {
            "start_logit": -7.53515625,
            "end_logit": -7.85546875,
            "text": "glial progenitors",
            "probability": 0.0
        },
        {
            "start_logit": -8.234375,
            "end_logit": -7.29296875,
            "text": "originate",
            "probability": 0.0
        },
        {
            "start_logit": -7.68359375,
            "end_logit": -7.85546875,
            "text": "peripheral glial progenitors",
            "probability": 0.0
        },
        {
            "start_logit": -7.96875,
            "end_logit": -7.85546875,
            "text": "associated peripheral glial progenitors",
            "probability": 0.0
        },
        {
            "start_logit": -7.9765625,
            "end_logit": -7.85546875,
            "text": "nerve-associated peripheral glial progenitors",
            "probability": 0.0
        },
        {
            "start_logit": -8.09375,
            "end_logit": -7.85546875,
            "text": "-associated peripheral glial progenitors",
            "probability": 0.0
        },
        {
            "start_logit": -8.21875,
            "end_logit": -7.85546875,
            "text": "progenitors",
            "probability": 0.0
        },
        {
            "start_logit": -8.234375,
            "end_logit": -7.85546875,
            "text": "originate from nerve-associated peripheral glial progenitors",
            "probability": 0.0
        }
    ],
    "5881f9b65bf093691f000001_4": [
        {
            "start_logit": 8.609375,
            "end_logit": 9.328125,
            "text": "Parasympathetic neurons",
            "probability": 1.0
        },
        {
            "start_logit": -1.78515625,
            "end_logit": 9.328125,
            "text": "neurons",
            "probability": 3.069639205932617e-05
        },
        {
            "start_logit": 8.609375,
            "end_logit": -3.3125,
            "text": "Parasympathetic",
            "probability": 3.2186508178710938e-06
        },
        {
            "start_logit": 8.609375,
            "end_logit": -6.07421875,
            "text": "Parasympathetic neurons originate from nerve-associated peripheral glial progenitors.",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.375,
            "end_logit": 9.328125,
            "text": ". Parasympathetic neurons",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.1171875,
            "end_logit": 9.328125,
            "text": "Neurodevelopment. Parasympathetic neurons",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.609375,
            "end_logit": -7.83984375,
            "text": "Parasympathetic neurons originate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.78515625,
            "end_logit": -6.07421875,
            "text": "neurons originate from nerve-associated peripheral glial progenitors.",
            "probability": 0.0
        },
        {
            "start_logit": -1.78515625,
            "end_logit": -7.83984375,
            "text": "neurons originate",
            "probability": 0.0
        },
        {
            "start_logit": -7.375,
            "end_logit": -3.3125,
            "text": ". Parasympathetic",
            "probability": 0.0
        },
        {
            "start_logit": -8.1171875,
            "end_logit": -3.3125,
            "text": "Neurodevelopment. Parasympathetic",
            "probability": 0.0
        },
        {
            "start_logit": -5.8046875,
            "end_logit": -6.07421875,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.0,
            "end_logit": -6.07421875,
            "text": "from nerve-associated peripheral glial progenitors.",
            "probability": 0.0
        },
        {
            "start_logit": -7.375,
            "end_logit": -6.07421875,
            "text": ". Parasympathetic neurons originate from nerve-associated peripheral glial progenitors.",
            "probability": 0.0
        },
        {
            "start_logit": -7.55078125,
            "end_logit": -6.07421875,
            "text": "glial progenitors.",
            "probability": 0.0
        },
        {
            "start_logit": -7.55078125,
            "end_logit": -6.07421875,
            "text": "originate from nerve-associated peripheral glial progenitors.",
            "probability": 0.0
        },
        {
            "start_logit": -7.63671875,
            "end_logit": -6.07421875,
            "text": "peripheral glial progenitors.",
            "probability": 0.0
        },
        {
            "start_logit": -7.7421875,
            "end_logit": -6.07421875,
            "text": "nerve-associated peripheral glial progenitors.",
            "probability": 0.0
        },
        {
            "start_logit": -7.7890625,
            "end_logit": -6.07421875,
            "text": "associated peripheral glial progenitors.",
            "probability": 0.0
        },
        {
            "start_logit": -7.79296875,
            "end_logit": -6.07421875,
            "text": "progenitors.",
            "probability": 0.0
        }
    ],
    "5c71d6d27c78d6947100006a_1": [
        {
            "start_logit": 9.6953125,
            "end_logit": 9.6015625,
            "text": "Clostridium difficile",
            "probability": 1.0
        },
        {
            "start_logit": -1.7392578125,
            "end_logit": 9.6015625,
            "text": "difficile",
            "probability": 1.0788440704345703e-05
        },
        {
            "start_logit": 9.6953125,
            "end_logit": -1.849609375,
            "text": "Clostridium",
            "probability": 1.0609626770019531e-05
        },
        {
            "start_logit": -7.69140625,
            "end_logit": 9.6015625,
            "text": "Fecal microbiota transplantation is a highly effective intervention for patients suffering from recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": 9.6953125,
            "end_logit": -8.046875,
            "text": "Clostridium difficile,",
            "probability": 0.0
        },
        {
            "start_logit": -7.98828125,
            "end_logit": 9.6015625,
            "text": "from recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -7.9921875,
            "end_logit": 9.6015625,
            "text": "microbiota transplantation is a highly effective intervention for patients suffering from recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": 9.6953125,
            "end_logit": -8.1171875,
            "text": "Clostridium difficile, a",
            "probability": 0.0
        },
        {
            "start_logit": -8.03125,
            "end_logit": 9.6015625,
            "text": "recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.046875,
            "end_logit": 9.6015625,
            "text": "patients suffering from recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.0625,
            "end_logit": 9.6015625,
            "text": "intervention for patients suffering from recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.09375,
            "end_logit": 9.6015625,
            "text": "suffering from recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.09375,
            "end_logit": 9.6015625,
            "text": "for patients suffering from recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -7.69140625,
            "end_logit": -1.849609375,
            "text": "Fecal microbiota transplantation is a highly effective intervention for patients suffering from recurrent Clostridium",
            "probability": 0.0
        },
        {
            "start_logit": -1.7392578125,
            "end_logit": -8.046875,
            "text": "difficile,",
            "probability": 0.0
        },
        {
            "start_logit": -7.98828125,
            "end_logit": -1.849609375,
            "text": "from recurrent Clostridium",
            "probability": 0.0
        },
        {
            "start_logit": -7.9921875,
            "end_logit": -1.849609375,
            "text": "microbiota transplantation is a highly effective intervention for patients suffering from recurrent Clostridium",
            "probability": 0.0
        },
        {
            "start_logit": -1.7392578125,
            "end_logit": -8.1171875,
            "text": "difficile, a",
            "probability": 0.0
        },
        {
            "start_logit": -8.03125,
            "end_logit": -1.849609375,
            "text": "recurrent Clostridium",
            "probability": 0.0
        },
        {
            "start_logit": -8.046875,
            "end_logit": -1.849609375,
            "text": "patients suffering from recurrent Clostridium",
            "probability": 0.0
        }
    ],
    "5c71d6d27c78d6947100006a_2": [
        {
            "start_logit": 9.7421875,
            "end_logit": 9.5546875,
            "text": "Clostridium difficile",
            "probability": 1.0
        },
        {
            "start_logit": 9.7421875,
            "end_logit": -1.7412109375,
            "text": "Clostridium",
            "probability": 1.239776611328125e-05
        },
        {
            "start_logit": -1.85546875,
            "end_logit": 9.5546875,
            "text": "difficile",
            "probability": 9.238719940185547e-06
        },
        {
            "start_logit": 9.7421875,
            "end_logit": -7.8828125,
            "text": "Clostridium difficile Proctitis Following",
            "probability": 0.0
        },
        {
            "start_logit": 9.7421875,
            "end_logit": -7.88671875,
            "text": "Clostridium difficile Proctitis Following Total Colectomy.",
            "probability": 0.0
        },
        {
            "start_logit": 9.7421875,
            "end_logit": -7.98046875,
            "text": "Clostridium difficile Proctitis Following Total Colectomy",
            "probability": 0.0
        },
        {
            "start_logit": 9.7421875,
            "end_logit": -7.98828125,
            "text": "Clostridium difficile Proctitis",
            "probability": 0.0
        },
        {
            "start_logit": 9.7421875,
            "end_logit": -7.99609375,
            "text": "Clostridium difficile Proct",
            "probability": 0.0
        },
        {
            "start_logit": -7.8671875,
            "end_logit": 9.5546875,
            "text": "Fecal Microbiota Transplantation for Treatment of Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": 9.7421875,
            "end_logit": -8.0859375,
            "text": "Clostridium difficile Proctitis Following Total",
            "probability": 0.0
        },
        {
            "start_logit": -7.8984375,
            "end_logit": 9.5546875,
            "text": "of Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -7.8984375,
            "end_logit": 9.5546875,
            "text": "Treatment of Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -7.921875,
            "end_logit": 9.5546875,
            "text": "Mini-Fecal Microbiota Transplantation for Treatment of Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.0234375,
            "end_logit": 9.5546875,
            "text": "-Fecal Microbiota Transplantation for Treatment of Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.1171875,
            "end_logit": 9.5546875,
            "text": "for Treatment of Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.1484375,
            "end_logit": 9.5546875,
            "text": "Microbiota Transplantation for Treatment of Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -7.8671875,
            "end_logit": -1.7412109375,
            "text": "Fecal Microbiota Transplantation for Treatment of Clostridium",
            "probability": 0.0
        },
        {
            "start_logit": -7.8984375,
            "end_logit": -1.7412109375,
            "text": "of Clostridium",
            "probability": 0.0
        },
        {
            "start_logit": -7.8984375,
            "end_logit": -1.7412109375,
            "text": "Treatment of Clostridium",
            "probability": 0.0
        },
        {
            "start_logit": -7.921875,
            "end_logit": -1.7412109375,
            "text": "Mini-Fecal Microbiota Transplantation for Treatment of Clostridium",
            "probability": 0.0
        }
    ],
    "5c71d6d27c78d6947100006a_3": [
        {
            "start_logit": 9.7265625,
            "end_logit": 9.5625,
            "text": "Clostridium difficile",
            "probability": 1.0
        },
        {
            "start_logit": 9.7265625,
            "end_logit": -1.76953125,
            "text": "Clostridium",
            "probability": 1.2040138244628906e-05
        },
        {
            "start_logit": -1.83203125,
            "end_logit": 9.5625,
            "text": "difficile",
            "probability": 9.655952453613281e-06
        },
        {
            "start_logit": 9.7265625,
            "end_logit": -7.9609375,
            "text": "Clostridium difficile carriage",
            "probability": 0.0
        },
        {
            "start_logit": 9.7265625,
            "end_logit": -8.03125,
            "text": "Clostridium difficile carriage rates following fecal microbiota transplantation",
            "probability": 0.0
        },
        {
            "start_logit": 9.7265625,
            "end_logit": -8.0703125,
            "text": "Clostridium difficile carriage rates following",
            "probability": 0.0
        },
        {
            "start_logit": 9.7265625,
            "end_logit": -8.125,
            "text": "Clostridium difficile carriage rates following fecal microbiota",
            "probability": 0.0
        },
        {
            "start_logit": 9.7265625,
            "end_logit": -8.125,
            "text": "Clostridium difficile carriage rates",
            "probability": 0.0
        },
        {
            "start_logit": -8.0703125,
            "end_logit": 9.5625,
            "text": "We aimed to assess the asymptomatic Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.0859375,
            "end_logit": 9.5625,
            "text": "asymptomatic Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.15625,
            "end_logit": 9.5625,
            "text": "the asymptomatic Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -1.83203125,
            "end_logit": -7.9609375,
            "text": "difficile carriage",
            "probability": 0.0
        },
        {
            "start_logit": -8.0703125,
            "end_logit": -1.76953125,
            "text": "We aimed to assess the asymptomatic Clostridium",
            "probability": 0.0
        },
        {
            "start_logit": -1.83203125,
            "end_logit": -8.03125,
            "text": "difficile carriage rates following fecal microbiota transplantation",
            "probability": 0.0
        },
        {
            "start_logit": -8.0859375,
            "end_logit": -1.76953125,
            "text": "asymptomatic Clostridium",
            "probability": 0.0
        },
        {
            "start_logit": -1.83203125,
            "end_logit": -8.0703125,
            "text": "difficile carriage rates following",
            "probability": 0.0
        },
        {
            "start_logit": -8.15625,
            "end_logit": -1.76953125,
            "text": "the asymptomatic Clostridium",
            "probability": 0.0
        },
        {
            "start_logit": -1.83203125,
            "end_logit": -8.125,
            "text": "difficile carriage rates following fecal microbiota",
            "probability": 0.0
        },
        {
            "start_logit": -1.83203125,
            "end_logit": -8.125,
            "text": "difficile carriage rates",
            "probability": 0.0
        },
        {
            "start_logit": -8.0703125,
            "end_logit": -7.9609375,
            "text": "We aimed to assess the asymptomatic Clostridium difficile carriage",
            "probability": 0.0
        }
    ],
    "5c71d6d27c78d6947100006a_4": [
        {
            "start_logit": 9.765625,
            "end_logit": 9.5625,
            "text": "Clostridium difficile",
            "probability": 1.0
        },
        {
            "start_logit": 9.765625,
            "end_logit": -1.662109375,
            "text": "Clostridium",
            "probability": 1.329183578491211e-05
        },
        {
            "start_logit": -1.83203125,
            "end_logit": 9.5625,
            "text": "difficile",
            "probability": 9.238719940185547e-06
        },
        {
            "start_logit": 9.765625,
            "end_logit": -7.60546875,
            "text": "Clostridium difficile infection, and case reports document its use in the successful treatment of constipation, diarrhea, and abdominal pain.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.84765625,
            "end_logit": 9.5625,
            "text": "the infusion of donor feces into a recipient's intestinal tract, has been used for decades to treat recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -7.85546875,
            "end_logit": 9.5625,
            "text": "treat recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -7.87890625,
            "end_logit": 9.5625,
            "text": "infusion of donor feces into a recipient's intestinal tract, has been used for decades to treat recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -7.890625,
            "end_logit": 9.5625,
            "text": "Fecal transplantation, the infusion of donor feces into a recipient's intestinal tract, has been used for decades to treat recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -7.93359375,
            "end_logit": 9.5625,
            "text": "used for decades to treat recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -7.93359375,
            "end_logit": 9.5625,
            "text": "recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": 9.765625,
            "end_logit": -8.171875,
            "text": "Clostridium difficile infection, and case reports document",
            "probability": 0.0
        },
        {
            "start_logit": -7.96875,
            "end_logit": 9.5625,
            "text": "been used for decades to treat recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -7.97265625,
            "end_logit": 9.5625,
            "text": "has been used for decades to treat recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -7.9921875,
            "end_logit": 9.5625,
            "text": ", has been used for decades to treat recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": 9.765625,
            "end_logit": -8.2109375,
            "text": "Clostridium difficile infection,",
            "probability": 0.0
        },
        {
            "start_logit": 9.765625,
            "end_logit": -8.2109375,
            "text": "Clostridium difficile infection",
            "probability": 0.0
        },
        {
            "start_logit": -1.83203125,
            "end_logit": -7.60546875,
            "text": "difficile infection, and case reports document its use in the successful treatment of constipation, diarrhea, and abdominal pain.",
            "probability": 0.0
        },
        {
            "start_logit": -7.84765625,
            "end_logit": -1.662109375,
            "text": "the infusion of donor feces into a recipient's intestinal tract, has been used for decades to treat recurrent Clostridium",
            "probability": 0.0
        },
        {
            "start_logit": -7.85546875,
            "end_logit": -1.662109375,
            "text": "treat recurrent Clostridium",
            "probability": 0.0
        },
        {
            "start_logit": -7.87890625,
            "end_logit": -1.662109375,
            "text": "infusion of donor feces into a recipient's intestinal tract, has been used for decades to treat recurrent Clostridium",
            "probability": 0.0
        }
    ],
    "5c71d6d27c78d6947100006a_5": [
        {
            "start_logit": 9.796875,
            "end_logit": 9.546875,
            "text": "Clostridium difficile",
            "probability": 1.0
        },
        {
            "start_logit": 9.796875,
            "end_logit": -1.5986328125,
            "text": "Clostridium",
            "probability": 1.4424324035644531e-05
        },
        {
            "start_logit": -1.8701171875,
            "end_logit": 9.546875,
            "text": "difficile",
            "probability": 8.52346420288086e-06
        },
        {
            "start_logit": 9.796875,
            "end_logit": -7.484375,
            "text": "Clostridium difficile Infection in Two English Hospitals: A Review.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.796875,
            "end_logit": -7.6484375,
            "text": "Clostridium difficile Infection in Two English Hospitals: A Review.Fecal microbiota transplant (FMT) has emerged as a highly efficacious treatment for difficult cases of refractory and/or recurrent Clostridium difficile",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.796875,
            "end_logit": -7.875,
            "text": "Clostridium difficile Infection in Two English Hospitals: A Review.Fecal microbiota transplant (FMT) has emerged",
            "probability": 0.0
        },
        {
            "start_logit": 9.796875,
            "end_logit": -7.9296875,
            "text": "Clostridium difficile Infection in",
            "probability": 0.0
        },
        {
            "start_logit": 9.796875,
            "end_logit": -7.9375,
            "text": "Clostridium difficile Infection in Two English Hospitals: A Review.Fecal microbiota",
            "probability": 0.0
        },
        {
            "start_logit": 9.796875,
            "end_logit": -7.953125,
            "text": "Clostridium difficile Infection in Two English Hospitals: A Review.Fecal microbiota transplant (FMT) has emerged as a highly efficacious treatment for difficult cases of refractory and/or recurrent Clostridium difficile infection (CDI",
            "probability": 0.0
        },
        {
            "start_logit": 9.796875,
            "end_logit": -7.9765625,
            "text": "Clostridium difficile Infection in Two English Hospitals: A Review.Fecal microbiota transplant (FMT)",
            "probability": 0.0
        },
        {
            "start_logit": 9.796875,
            "end_logit": -7.98046875,
            "text": "Clostridium difficile Infection in Two English Hospitals: A Review.Fecal microbiota transplant (FMT) has emerged as a highly efficacious treatment for difficult cases of refractory and/or recurrent Clostridium difficile infection (CDI)",
            "probability": 0.0
        },
        {
            "start_logit": 9.796875,
            "end_logit": -7.99609375,
            "text": "Clostridium difficile Infection in Two English Hospitals: A Review.Fecal microbiota transplant (",
            "probability": 0.0
        },
        {
            "start_logit": 9.796875,
            "end_logit": -8.0078125,
            "text": "Clostridium difficile Infection in Two English Hospitals: A Review.Fecal microbiota transplant",
            "probability": 0.0
        },
        {
            "start_logit": 9.796875,
            "end_logit": -8.015625,
            "text": "Clostridium difficile Infection in Two English Hospitals: A Review.Fecal microbiota transplant (FMT) has emerged as",
            "probability": 0.0
        },
        {
            "start_logit": 9.796875,
            "end_logit": -8.0234375,
            "text": "Clostridium difficile Infection in Two English Hospitals: A Review.Fecal microbiota transplant (FMT) has emerged as a highly efficacious treatment for difficult cases of refractory and/",
            "probability": 0.0
        },
        {
            "start_logit": 9.796875,
            "end_logit": -8.0234375,
            "text": "Clostridium difficile Infection in Two English Hospitals: A Review.Fecal microbiota transplant (FMT",
            "probability": 0.0
        },
        {
            "start_logit": 9.796875,
            "end_logit": -8.03125,
            "text": "Clostridium difficile Infection in Two English Hospitals: A Review.Fecal microbiota transplant (FMT) has emerged as a highly efficacious treatment for difficult cases of refractory and/or recurrent Clostridium difficile infection",
            "probability": 0.0
        },
        {
            "start_logit": -7.84765625,
            "end_logit": 9.546875,
            "text": "Comparison of Different Strategies for Providing Fecal Microbiota Transplantation to Treat Patients with Recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -7.93359375,
            "end_logit": 9.546875,
            "text": "Fecal Microbiota Transplantation to Treat Patients with Recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.0390625,
            "end_logit": 9.546875,
            "text": "Patients with Recurrent Clostridium difficile",
            "probability": 0.0
        }
    ],
    "5c71d6d27c78d6947100006a_6": [
        {
            "start_logit": 9.7578125,
            "end_logit": 9.59375,
            "text": "Clostridium difficile",
            "probability": 1.0
        },
        {
            "start_logit": 9.7578125,
            "end_logit": -1.6875,
            "text": "Clostridium",
            "probability": 1.2695789337158203e-05
        },
        {
            "start_logit": -1.7646484375,
            "end_logit": 9.59375,
            "text": "difficile",
            "probability": 9.953975677490234e-06
        },
        {
            "start_logit": 9.7578125,
            "end_logit": -7.96875,
            "text": "Clostridium difficile Infection following Fecal Microbiota Transplantation.",
            "probability": 0.0
        },
        {
            "start_logit": -7.93359375,
            "end_logit": 9.59375,
            "text": "Complete Microbiota Engraftment Is Not Essential for Recovery from Recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": 9.7578125,
            "end_logit": -8.109375,
            "text": "Clostridium difficile Infection following Fecal Microbiota Transplantation",
            "probability": 0.0
        },
        {
            "start_logit": 9.7578125,
            "end_logit": -8.109375,
            "text": "Clostridium difficile Infection following Fecal Microbiota",
            "probability": 0.0
        },
        {
            "start_logit": 9.7578125,
            "end_logit": -8.125,
            "text": "Clostridium difficile Infection following",
            "probability": 0.0
        },
        {
            "start_logit": -8.015625,
            "end_logit": 9.59375,
            "text": "Microbiota Engraftment Is Not Essential for Recovery from Recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.125,
            "end_logit": 9.59375,
            "text": "Recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.125,
            "end_logit": 9.59375,
            "text": "from Recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.15625,
            "end_logit": 9.59375,
            "text": "Recovery from Recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -7.93359375,
            "end_logit": -1.6875,
            "text": "Complete Microbiota Engraftment Is Not Essential for Recovery from Recurrent Clostridium",
            "probability": 0.0
        },
        {
            "start_logit": -8.015625,
            "end_logit": -1.6875,
            "text": "Microbiota Engraftment Is Not Essential for Recovery from Recurrent Clostridium",
            "probability": 0.0
        },
        {
            "start_logit": -1.7646484375,
            "end_logit": -7.96875,
            "text": "difficile Infection following Fecal Microbiota Transplantation.",
            "probability": 0.0
        },
        {
            "start_logit": -8.125,
            "end_logit": -1.6875,
            "text": "Recurrent Clostridium",
            "probability": 0.0
        },
        {
            "start_logit": -8.125,
            "end_logit": -1.6875,
            "text": "from Recurrent Clostridium",
            "probability": 0.0
        },
        {
            "start_logit": -8.15625,
            "end_logit": -1.6875,
            "text": "Recovery from Recurrent Clostridium",
            "probability": 0.0
        },
        {
            "start_logit": -1.7646484375,
            "end_logit": -8.109375,
            "text": "difficile Infection following Fecal Microbiota Transplantation",
            "probability": 0.0
        },
        {
            "start_logit": -1.7646484375,
            "end_logit": -8.109375,
            "text": "difficile Infection following Fecal Microbiota",
            "probability": 0.0
        }
    ],
    "5c71d6d27c78d6947100006a_7": [
        {
            "start_logit": 9.765625,
            "end_logit": 9.5625,
            "text": "Clostridium difficile",
            "probability": 1.0
        },
        {
            "start_logit": 9.765625,
            "end_logit": -1.662109375,
            "text": "Clostridium",
            "probability": 1.329183578491211e-05
        },
        {
            "start_logit": -1.83203125,
            "end_logit": 9.5625,
            "text": "difficile",
            "probability": 9.238719940185547e-06
        },
        {
            "start_logit": 9.765625,
            "end_logit": -7.60546875,
            "text": "Clostridium difficile infection, and case reports document its use in the successful treatment of constipation, diarrhea, and abdominal pain.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.84765625,
            "end_logit": 9.5625,
            "text": "the infusion of donor feces into a recipient's intestinal tract, has been used for decades to treat recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -7.85546875,
            "end_logit": 9.5625,
            "text": "treat recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -7.87890625,
            "end_logit": 9.5625,
            "text": "infusion of donor feces into a recipient's intestinal tract, has been used for decades to treat recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -7.890625,
            "end_logit": 9.5625,
            "text": "Fecal transplantation, the infusion of donor feces into a recipient's intestinal tract, has been used for decades to treat recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -7.93359375,
            "end_logit": 9.5625,
            "text": "used for decades to treat recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -7.93359375,
            "end_logit": 9.5625,
            "text": "recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": 9.765625,
            "end_logit": -8.171875,
            "text": "Clostridium difficile infection, and case reports document",
            "probability": 0.0
        },
        {
            "start_logit": -7.96875,
            "end_logit": 9.5625,
            "text": "been used for decades to treat recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -7.97265625,
            "end_logit": 9.5625,
            "text": "has been used for decades to treat recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -7.9921875,
            "end_logit": 9.5625,
            "text": ", has been used for decades to treat recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": 9.765625,
            "end_logit": -8.2109375,
            "text": "Clostridium difficile infection,",
            "probability": 0.0
        },
        {
            "start_logit": 9.765625,
            "end_logit": -8.2109375,
            "text": "Clostridium difficile infection",
            "probability": 0.0
        },
        {
            "start_logit": -1.83203125,
            "end_logit": -7.60546875,
            "text": "difficile infection, and case reports document its use in the successful treatment of constipation, diarrhea, and abdominal pain.",
            "probability": 0.0
        },
        {
            "start_logit": -7.84765625,
            "end_logit": -1.662109375,
            "text": "the infusion of donor feces into a recipient's intestinal tract, has been used for decades to treat recurrent Clostridium",
            "probability": 0.0
        },
        {
            "start_logit": -7.85546875,
            "end_logit": -1.662109375,
            "text": "treat recurrent Clostridium",
            "probability": 0.0
        },
        {
            "start_logit": -7.87890625,
            "end_logit": -1.662109375,
            "text": "infusion of donor feces into a recipient's intestinal tract, has been used for decades to treat recurrent Clostridium",
            "probability": 0.0
        }
    ],
    "5c71d6d27c78d6947100006a_8": [
        {
            "start_logit": 9.78125,
            "end_logit": 9.6171875,
            "text": "Clostridium difficile",
            "probability": 1.0
        },
        {
            "start_logit": 9.78125,
            "end_logit": -1.64453125,
            "text": "Clostridium",
            "probability": 1.2814998626708984e-05
        },
        {
            "start_logit": -1.7080078125,
            "end_logit": 9.6171875,
            "text": "difficile",
            "probability": 1.0132789611816406e-05
        },
        {
            "start_logit": 9.78125,
            "end_logit": -7.859375,
            "text": "Clostridium difficile infection, with near 90% of success.",
            "probability": 0.0
        },
        {
            "start_logit": -7.765625,
            "end_logit": 9.6171875,
            "text": "Fecal microbiota transplantation (FMT) has an incomparable efficacy to treat recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": 9.78125,
            "end_logit": -8.015625,
            "text": "Clostridium difficile infection, with near 90",
            "probability": 0.0
        },
        {
            "start_logit": 9.78125,
            "end_logit": -8.0234375,
            "text": "Clostridium difficile infection, with near 90%",
            "probability": 0.0
        },
        {
            "start_logit": 9.78125,
            "end_logit": -8.140625,
            "text": "Clostridium difficile infection, with",
            "probability": 0.0
        },
        {
            "start_logit": 9.78125,
            "end_logit": -8.140625,
            "text": "Clostridium difficile infection",
            "probability": 0.0
        },
        {
            "start_logit": 9.78125,
            "end_logit": -8.171875,
            "text": "Clostridium difficile infection, with near",
            "probability": 0.0
        },
        {
            "start_logit": -8.0078125,
            "end_logit": 9.6171875,
            "text": "treat recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.03125,
            "end_logit": 9.6171875,
            "text": "recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.0390625,
            "end_logit": 9.6171875,
            "text": "incomparable efficacy to treat recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.0546875,
            "end_logit": 9.6171875,
            "text": "T) has an incomparable efficacy to treat recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.0703125,
            "end_logit": 9.6171875,
            "text": "FMT) has an incomparable efficacy to treat recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.0859375,
            "end_logit": 9.6171875,
            "text": "arable efficacy to treat recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.09375,
            "end_logit": 9.6171875,
            "text": ") has an incomparable efficacy to treat recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.1015625,
            "end_logit": 9.6171875,
            "text": "(FMT) has an incomparable efficacy to treat recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -7.765625,
            "end_logit": -1.64453125,
            "text": "Fecal microbiota transplantation (FMT) has an incomparable efficacy to treat recurrent Clostridium",
            "probability": 0.0
        },
        {
            "start_logit": -1.7080078125,
            "end_logit": -7.859375,
            "text": "difficile infection, with near 90% of success.",
            "probability": 0.0
        }
    ],
    "5c71d6d27c78d6947100006a_9": [
        {
            "start_logit": 9.7578125,
            "end_logit": 9.6328125,
            "text": "Clostridium difficile",
            "probability": 1.0
        },
        {
            "start_logit": 9.7578125,
            "end_logit": -1.6796875,
            "text": "Clostridium",
            "probability": 1.2218952178955078e-05
        },
        {
            "start_logit": -1.654296875,
            "end_logit": 9.6328125,
            "text": "difficile",
            "probability": 1.1026859283447266e-05
        },
        {
            "start_logit": 9.7578125,
            "end_logit": -7.9140625,
            "text": "Clostridium difficile infection, has emerged as a promising therapy for intestinal MDR bacterial decolonization.",
            "probability": 0.0
        },
        {
            "start_logit": -7.80859375,
            "end_logit": 9.6328125,
            "text": "Fecal microbiota transplantation (FMT), a highly effective treatment for recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": 9.7578125,
            "end_logit": -8.03125,
            "text": "Clostridium difficile infection, has emerged as a promising therapy for intestinal MDR bacterial decolonization",
            "probability": 0.0
        },
        {
            "start_logit": 9.7578125,
            "end_logit": -8.0625,
            "text": "Clostridium difficile infection, has emerged as a promising therapy for intestinal MDR bacterial decolon",
            "probability": 0.0
        },
        {
            "start_logit": 9.7578125,
            "end_logit": -8.0859375,
            "text": "Clostridium difficile infection, has emerged as a promising therapy for intestinal MDR bacterial dec",
            "probability": 0.0
        },
        {
            "start_logit": -7.96484375,
            "end_logit": 9.6328125,
            "text": "for recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -7.96875,
            "end_logit": 9.6328125,
            "text": "treatment for recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": 9.7578125,
            "end_logit": -8.1171875,
            "text": "Clostridium difficile infection, has emerged",
            "probability": 0.0
        },
        {
            "start_logit": 9.7578125,
            "end_logit": -8.140625,
            "text": "Clostridium difficile infection, has emerged as",
            "probability": 0.0
        },
        {
            "start_logit": -8.015625,
            "end_logit": 9.6328125,
            "text": "recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": 9.7578125,
            "end_logit": -8.1484375,
            "text": "Clostridium difficile infection, has",
            "probability": 0.0
        },
        {
            "start_logit": 9.7578125,
            "end_logit": -8.171875,
            "text": "Clostridium difficile infection,",
            "probability": 0.0
        },
        {
            "start_logit": -8.046875,
            "end_logit": 9.6328125,
            "text": "highly effective treatment for recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": 9.7578125,
            "end_logit": -8.1796875,
            "text": "Clostridium difficile infection",
            "probability": 0.0
        },
        {
            "start_logit": -8.0703125,
            "end_logit": 9.6328125,
            "text": ", a highly effective treatment for recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -7.80859375,
            "end_logit": -1.6796875,
            "text": "Fecal microbiota transplantation (FMT), a highly effective treatment for recurrent Clostridium",
            "probability": 0.0
        },
        {
            "start_logit": -1.654296875,
            "end_logit": -7.9140625,
            "text": "difficile infection, has emerged as a promising therapy for intestinal MDR bacterial decolonization.",
            "probability": 0.0
        }
    ],
    "5c71d6d27c78d6947100006a_10": [
        {
            "start_logit": 9.796875,
            "end_logit": 9.625,
            "text": "Clostridium difficile",
            "probability": 1.0
        },
        {
            "start_logit": 9.796875,
            "end_logit": -1.5869140625,
            "text": "Clostridium",
            "probability": 1.3530254364013672e-05
        },
        {
            "start_logit": -1.67578125,
            "end_logit": 9.625,
            "text": "difficile",
            "probability": 1.043081283569336e-05
        },
        {
            "start_logit": 9.796875,
            "end_logit": -7.75390625,
            "text": "Clostridium difficile infection (R-CDI) that cannot be cured with antibiotics alone.",
            "probability": 0.0
        },
        {
            "start_logit": 9.796875,
            "end_logit": -7.94921875,
            "text": "Clostridium difficile infection (R-CDI) that cannot be",
            "probability": 0.0
        },
        {
            "start_logit": 9.796875,
            "end_logit": -8.0390625,
            "text": "Clostridium difficile infection (R-CDI) that cannot",
            "probability": 0.0
        },
        {
            "start_logit": 9.796875,
            "end_logit": -8.0625,
            "text": "Clostridium difficile infection",
            "probability": 0.0
        },
        {
            "start_logit": 9.796875,
            "end_logit": -8.0625,
            "text": "Clostridium difficile infection (R-CDI) that cannot be cured with antibiotics alone",
            "probability": 0.0
        },
        {
            "start_logit": -7.921875,
            "end_logit": 9.625,
            "text": "OBJECTIVES Fecal microbiota transplantation (FMT) is increasingly being used for treatment of recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": 9.796875,
            "end_logit": -8.1015625,
            "text": "Clostridium difficile infection (R-CDI) that",
            "probability": 0.0
        },
        {
            "start_logit": 9.796875,
            "end_logit": -8.109375,
            "text": "Clostridium difficile infection (R-CDI) that cann",
            "probability": 0.0
        },
        {
            "start_logit": 9.796875,
            "end_logit": -8.125,
            "text": "Clostridium difficile infection (R-CDI) that cannot be cured",
            "probability": 0.0
        },
        {
            "start_logit": -7.96875,
            "end_logit": 9.625,
            "text": "Fecal microbiota transplantation (FMT) is increasingly being used for treatment of recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.046875,
            "end_logit": 9.625,
            "text": "treatment of recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.1171875,
            "end_logit": 9.625,
            "text": "recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.1328125,
            "end_logit": 9.625,
            "text": "FMT) is increasingly being used for treatment of recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": 9.625,
            "text": "of recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -1.67578125,
            "end_logit": -7.75390625,
            "text": "difficile infection (R-CDI) that cannot be cured with antibiotics alone.",
            "probability": 0.0
        },
        {
            "start_logit": -7.921875,
            "end_logit": -1.5869140625,
            "text": "OBJECTIVES Fecal microbiota transplantation (FMT) is increasingly being used for treatment of recurrent Clostridium",
            "probability": 0.0
        },
        {
            "start_logit": -7.96875,
            "end_logit": -1.5869140625,
            "text": "Fecal microbiota transplantation (FMT) is increasingly being used for treatment of recurrent Clostridium",
            "probability": 0.0
        }
    ],
    "5c71d6d27c78d6947100006a_11": [
        {
            "start_logit": 9.7421875,
            "end_logit": 9.53125,
            "text": "Clostridium difficile",
            "probability": 1.0
        },
        {
            "start_logit": 9.7421875,
            "end_logit": -1.7255859375,
            "text": "Clostridium",
            "probability": 1.2814998626708984e-05
        },
        {
            "start_logit": -1.904296875,
            "end_logit": 9.53125,
            "text": "difficile",
            "probability": 8.64267349243164e-06
        },
        {
            "start_logit": 9.7421875,
            "end_logit": -7.5234375,
            "text": "Clostridium difficile infection (CDI).",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.7421875,
            "end_logit": -7.9609375,
            "text": "Clostridium difficile infection (",
            "probability": 0.0
        },
        {
            "start_logit": -7.7578125,
            "end_logit": 9.53125,
            "text": "Fecal microbiota transplantation (FMT) restores a diverse bacterial profile to the gastrointestinal tract and may effectively treat patients with Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": 9.7421875,
            "end_logit": -7.99609375,
            "text": "Clostridium difficile infection (CDI",
            "probability": 0.0
        },
        {
            "start_logit": 9.7421875,
            "end_logit": -8.03125,
            "text": "Clostridium difficile infection",
            "probability": 0.0
        },
        {
            "start_logit": 9.7421875,
            "end_logit": -8.046875,
            "text": "Clostridium difficile infection (CDI)",
            "probability": 0.0
        },
        {
            "start_logit": -7.88671875,
            "end_logit": 9.53125,
            "text": "with Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -7.92578125,
            "end_logit": 9.53125,
            "text": "BACKGROUND Fecal microbiota transplantation (FMT) restores a diverse bacterial profile to the gastrointestinal tract and may effectively treat patients with Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -7.953125,
            "end_logit": 9.53125,
            "text": "treat patients with Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.015625,
            "end_logit": 9.53125,
            "text": "patients with Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.078125,
            "end_logit": 9.53125,
            "text": "may effectively treat patients with Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.0859375,
            "end_logit": 9.53125,
            "text": "restores a diverse bacterial profile to the gastrointestinal tract and may effectively treat patients with Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.1015625,
            "end_logit": 9.53125,
            "text": "diverse bacterial profile to the gastrointestinal tract and may effectively treat patients with Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.1015625,
            "end_logit": 9.53125,
            "text": "FMT) restores a diverse bacterial profile to the gastrointestinal tract and may effectively treat patients with Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.109375,
            "end_logit": 9.53125,
            "text": "bacterial profile to the gastrointestinal tract and may effectively treat patients with Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.109375,
            "end_logit": 9.53125,
            "text": "effectively treat patients with Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.1171875,
            "end_logit": 9.53125,
            "text": "a diverse bacterial profile to the gastrointestinal tract and may effectively treat patients with Clostridium difficile",
            "probability": 0.0
        }
    ],
    "5c71d6d27c78d6947100006a_12": [
        {
            "start_logit": 9.734375,
            "end_logit": 9.5703125,
            "text": "Clostridium difficile",
            "probability": 1.0
        },
        {
            "start_logit": 9.734375,
            "end_logit": -1.724609375,
            "text": "Clostridium",
            "probability": 1.233816146850586e-05
        },
        {
            "start_logit": -1.814453125,
            "end_logit": 9.5703125,
            "text": "difficile",
            "probability": 9.59634780883789e-06
        },
        {
            "start_logit": 9.734375,
            "end_logit": -7.890625,
            "text": "Clostridium difficile infection (rCDI) by fecal microbiota transplantation (FMT), using either heterologous donor stool samples or autologous stool samples, were characterized by Illumina next-generation sequencing.",
            "probability": 0.0
        },
        {
            "start_logit": 9.734375,
            "end_logit": -7.984375,
            "text": "Clostridium difficile infection (rCDI) by fecal microbiota transplantation",
            "probability": 0.0
        },
        {
            "start_logit": 9.734375,
            "end_logit": -7.99609375,
            "text": "Clostridium difficile infection (rCDI) by fecal microbiota",
            "probability": 0.0
        },
        {
            "start_logit": -7.90234375,
            "end_logit": 9.5703125,
            "text": "Bacterial communities from subjects treated for recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": 9.734375,
            "end_logit": -8.125,
            "text": "Clostridium difficile infection (rCDI) by fecal microbiota transplantation (",
            "probability": 0.0
        },
        {
            "start_logit": -7.98046875,
            "end_logit": 9.5703125,
            "text": "subjects treated for recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": 9.734375,
            "end_logit": -8.15625,
            "text": "Clostridium difficile infection (rCDI) by fecal microbiota transplantation (FMT), using either heterologous donor stool samples or",
            "probability": 0.0
        },
        {
            "start_logit": -7.9921875,
            "end_logit": 9.5703125,
            "text": "recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": 9.734375,
            "end_logit": -8.1640625,
            "text": "Clostridium difficile infection (rCDI) by fecal microbiota transplantation (FMT",
            "probability": 0.0
        },
        {
            "start_logit": 9.734375,
            "end_logit": -8.1640625,
            "text": "Clostridium difficile infection",
            "probability": 0.0
        },
        {
            "start_logit": 9.734375,
            "end_logit": -8.171875,
            "text": "Clostridium difficile infection (rCDI) by fecal microbiota transplantation (FMT), using either",
            "probability": 0.0
        },
        {
            "start_logit": 9.734375,
            "end_logit": -8.1796875,
            "text": "Clostridium difficile infection (rCDI) by fecal microbiota transplantation (FMT), using either heterologous donor stool samples or autologous stool samples, were characterized by Illumina next-generation sequencing",
            "probability": 0.0
        },
        {
            "start_logit": -8.0234375,
            "end_logit": 9.5703125,
            "text": "communities from subjects treated for recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.0390625,
            "end_logit": 9.5703125,
            "text": "for recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.046875,
            "end_logit": 9.5703125,
            "text": "treated for recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -7.90234375,
            "end_logit": -1.724609375,
            "text": "Bacterial communities from subjects treated for recurrent Clostridium",
            "probability": 0.0
        },
        {
            "start_logit": -1.814453125,
            "end_logit": -7.890625,
            "text": "difficile infection (rCDI) by fecal microbiota transplantation (FMT), using either heterologous donor stool samples or autologous stool samples, were characterized by Illumina next-generation sequencing.",
            "probability": 0.0
        }
    ],
    "5c71d6d27c78d6947100006a_13": [
        {
            "start_logit": 9.734375,
            "end_logit": 9.5859375,
            "text": "Clostridium difficile",
            "probability": 1.0
        },
        {
            "start_logit": 9.734375,
            "end_logit": -1.7509765625,
            "text": "Clostridium",
            "probability": 1.2040138244628906e-05
        },
        {
            "start_logit": -1.7841796875,
            "end_logit": 9.5859375,
            "text": "difficile",
            "probability": 9.953975677490234e-06
        },
        {
            "start_logit": 9.734375,
            "end_logit": -7.92578125,
            "text": "Clostridium difficile infections, with potential applications against other diseases associated with changes in gut microbiota.",
            "probability": 0.0
        },
        {
            "start_logit": -7.8125,
            "end_logit": 9.5859375,
            "text": "Fecal microbiota transplantation is a compelling treatment for recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": 9.734375,
            "end_logit": -8.0234375,
            "text": "Clostridium difficile infections, with potential",
            "probability": 0.0
        },
        {
            "start_logit": 9.734375,
            "end_logit": -8.09375,
            "text": "Clostridium difficile infections, with",
            "probability": 0.0
        },
        {
            "start_logit": 9.734375,
            "end_logit": -8.125,
            "text": "Clostridium difficile infections, with potential applications against other diseases associated with changes in gut microbiota",
            "probability": 0.0
        },
        {
            "start_logit": 9.734375,
            "end_logit": -8.1328125,
            "text": "Clostridium difficile infections,",
            "probability": 0.0
        },
        {
            "start_logit": -7.98828125,
            "end_logit": 9.5859375,
            "text": "recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -7.99609375,
            "end_logit": 9.5859375,
            "text": "treatment for recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": 9.734375,
            "end_logit": -8.1484375,
            "text": "Clostridium difficile infections, with potential applications against other diseases associated",
            "probability": 0.0
        },
        {
            "start_logit": 9.734375,
            "end_logit": -8.15625,
            "text": "Clostridium difficile infections",
            "probability": 0.0
        },
        {
            "start_logit": 9.734375,
            "end_logit": -8.15625,
            "text": "Clostridium difficile infections, with potential applications against other diseases associated with changes",
            "probability": 0.0
        },
        {
            "start_logit": 9.734375,
            "end_logit": -8.1640625,
            "text": "Clostridium difficile infections, with potential applications against other diseases associated with changes in gut",
            "probability": 0.0
        },
        {
            "start_logit": 9.734375,
            "end_logit": -8.1640625,
            "text": "Clostridium difficile infections, with potential applications",
            "probability": 0.0
        },
        {
            "start_logit": -8.0625,
            "end_logit": 9.5859375,
            "text": "microbiota transplantation is a compelling treatment for recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.078125,
            "end_logit": 9.5859375,
            "text": "for recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.0859375,
            "end_logit": 9.5859375,
            "text": "is a compelling treatment for recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.1015625,
            "end_logit": 9.5859375,
            "text": "compelling treatment for recurrent Clostridium difficile",
            "probability": 0.0
        }
    ],
    "5c71d6d27c78d6947100006a_14": [
        {
            "start_logit": 9.7578125,
            "end_logit": 9.5625,
            "text": "Clostridium difficile",
            "probability": 1.0
        },
        {
            "start_logit": 9.7578125,
            "end_logit": -1.7021484375,
            "text": "Clostridium",
            "probability": 1.2934207916259766e-05
        },
        {
            "start_logit": -1.83203125,
            "end_logit": 9.5625,
            "text": "difficile",
            "probability": 9.357929229736328e-06
        },
        {
            "start_logit": 9.7578125,
            "end_logit": -7.703125,
            "text": "Clostridium difficile infection, but well-designed, randomized-controlled trials and Long-term follow-up registries are stilt required.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.73046875,
            "end_logit": 9.5625,
            "text": "Fecal microbiota transplantation (FMT) holds considerable promise as a therapy for recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": 9.7578125,
            "end_logit": -8.0546875,
            "text": "Clostridium difficile infection, but well-designed, randomized-controlled trials and",
            "probability": 0.0
        },
        {
            "start_logit": 9.7578125,
            "end_logit": -8.09375,
            "text": "Clostridium difficile infection, but well-designed, randomized-controlled trials and Long-term follow-up registries are",
            "probability": 0.0
        },
        {
            "start_logit": 9.7578125,
            "end_logit": -8.1015625,
            "text": "Clostridium difficile infection",
            "probability": 0.0
        },
        {
            "start_logit": 9.7578125,
            "end_logit": -8.109375,
            "text": "Clostridium difficile infection, but well-designed, randomized-controlled trials and Long-term follow-up registries are stilt required",
            "probability": 0.0
        },
        {
            "start_logit": 9.7578125,
            "end_logit": -8.1171875,
            "text": "Clostridium difficile infection, but well-designed, randomized-controlled trials and Long-term",
            "probability": 0.0
        },
        {
            "start_logit": 9.7578125,
            "end_logit": -8.1484375,
            "text": "Clostridium difficile infection, but well-designed, randomized-controlled trials and Long-term follow-up",
            "probability": 0.0
        },
        {
            "start_logit": 9.7578125,
            "end_logit": -8.15625,
            "text": "Clostridium difficile infection, but well-designed, randomized-controlled trials and Long-term follow-",
            "probability": 0.0
        },
        {
            "start_logit": 9.7578125,
            "end_logit": -8.15625,
            "text": "Clostridium difficile infection, but well-designed, randomized-controlled trials and Long-term follow",
            "probability": 0.0
        },
        {
            "start_logit": 9.7578125,
            "end_logit": -8.1640625,
            "text": "Clostridium difficile infection, but well-designed, randomized-controlled trials and Long",
            "probability": 0.0
        },
        {
            "start_logit": 9.7578125,
            "end_logit": -8.1640625,
            "text": "Clostridium difficile infection, but well-designed",
            "probability": 0.0
        },
        {
            "start_logit": 9.7578125,
            "end_logit": -8.1640625,
            "text": "Clostridium difficile infection, but well-designed, randomized-controlled",
            "probability": 0.0
        },
        {
            "start_logit": -8.0546875,
            "end_logit": 9.5625,
            "text": "therapy for recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.0546875,
            "end_logit": 9.5625,
            "text": "FMT) holds considerable promise as a therapy for recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.0625,
            "end_logit": 9.5625,
            "text": "recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.0625,
            "end_logit": 9.5625,
            "text": ") holds considerable promise as a therapy for recurrent Clostridium difficile",
            "probability": 0.0
        }
    ],
    "5c71d6d27c78d6947100006a_15": [
        {
            "start_logit": 9.78125,
            "end_logit": 9.6015625,
            "text": "Clostridium difficile",
            "probability": 1.0
        },
        {
            "start_logit": 9.78125,
            "end_logit": -1.6279296875,
            "text": "Clostridium",
            "probability": 1.341104507446289e-05
        },
        {
            "start_logit": -1.7275390625,
            "end_logit": 9.6015625,
            "text": "difficile",
            "probability": 1.0132789611816406e-05
        },
        {
            "start_logit": 9.78125,
            "end_logit": -7.73828125,
            "text": "Clostridium difficile infection (CDI) and is considered as a treatment for other gastrointestinal (GI) diseases.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.609375,
            "end_logit": 9.6015625,
            "text": "Fecal microbiota transplantation (FMT) is an effective treatment for recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": 9.78125,
            "end_logit": -7.91015625,
            "text": "Clostridium difficile infection (CDI) and",
            "probability": 0.0
        },
        {
            "start_logit": 9.78125,
            "end_logit": -7.921875,
            "text": "Clostridium difficile infection (CDI",
            "probability": 0.0
        },
        {
            "start_logit": 9.78125,
            "end_logit": -7.96875,
            "text": "Clostridium difficile infection",
            "probability": 0.0
        },
        {
            "start_logit": 9.78125,
            "end_logit": -8.0078125,
            "text": "Clostridium difficile infection (CDI)",
            "probability": 0.0
        },
        {
            "start_logit": 9.78125,
            "end_logit": -8.046875,
            "text": "Clostridium difficile infection (",
            "probability": 0.0
        },
        {
            "start_logit": 9.78125,
            "end_logit": -8.046875,
            "text": "Clostridium difficile infection (CDI) and is",
            "probability": 0.0
        },
        {
            "start_logit": 9.78125,
            "end_logit": -8.0546875,
            "text": "Clostridium difficile infection (CDI) and is considered as",
            "probability": 0.0
        },
        {
            "start_logit": 9.78125,
            "end_logit": -8.078125,
            "text": "Clostridium difficile infection (CDI) and is considered",
            "probability": 0.0
        },
        {
            "start_logit": 9.78125,
            "end_logit": -8.078125,
            "text": "Clostridium difficile infection (CDI) and is considered as a treatment for other gastrointestinal (GI",
            "probability": 0.0
        },
        {
            "start_logit": 9.78125,
            "end_logit": -8.109375,
            "text": "Clostridium difficile infection (CDI) and is considered as a",
            "probability": 0.0
        },
        {
            "start_logit": -8.0234375,
            "end_logit": 9.6015625,
            "text": "treatment for recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.1015625,
            "end_logit": 9.6015625,
            "text": "recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.1484375,
            "end_logit": 9.6015625,
            "text": "FMT) is an effective treatment for recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.1484375,
            "end_logit": 9.6015625,
            "text": "microbiota transplantation (FMT) is an effective treatment for recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -7.609375,
            "end_logit": -1.6279296875,
            "text": "Fecal microbiota transplantation (FMT) is an effective treatment for recurrent Clostridium",
            "probability": 0.0
        }
    ],
    "5c71d6d27c78d6947100006a_16": [
        {
            "start_logit": 9.7734375,
            "end_logit": 9.5859375,
            "text": "Clostridium difficile",
            "probability": 1.0
        },
        {
            "start_logit": 9.7734375,
            "end_logit": -1.6435546875,
            "text": "Clostridium",
            "probability": 1.329183578491211e-05
        },
        {
            "start_logit": -1.78125,
            "end_logit": 9.5859375,
            "text": "difficile",
            "probability": 9.59634780883789e-06
        },
        {
            "start_logit": 9.7734375,
            "end_logit": -7.86328125,
            "text": "Clostridium difficile infection with ulcerative pancolitis, as an alternative in case of antibiotic therapy failure.",
            "probability": 0.0
        },
        {
            "start_logit": -7.87109375,
            "end_logit": 9.5859375,
            "text": "Fecal microbiota transplantation is relatively simple to perform, well-tolerated, safe and effective in recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": 9.7734375,
            "end_logit": -8.0703125,
            "text": "Clostridium difficile infection with ulcerative pancolitis, as an alternative in case of",
            "probability": 0.0
        },
        {
            "start_logit": 9.7734375,
            "end_logit": -8.0703125,
            "text": "Clostridium difficile infection with ulcerative pancolitis, as an alternative in case of antibiotic therapy failure",
            "probability": 0.0
        },
        {
            "start_logit": 9.7734375,
            "end_logit": -8.09375,
            "text": "Clostridium difficile infection with ulcerative pancolitis, as",
            "probability": 0.0
        },
        {
            "start_logit": 9.7734375,
            "end_logit": -8.109375,
            "text": "Clostridium difficile infection with ulcerative pancolitis, as an alternative in case of antibiotic therapy",
            "probability": 0.0
        },
        {
            "start_logit": 9.7734375,
            "end_logit": -8.109375,
            "text": "Clostridium difficile infection with ulcerative pancolitis, as an alternative in case",
            "probability": 0.0
        },
        {
            "start_logit": 9.7734375,
            "end_logit": -8.125,
            "text": "Clostridium difficile infection with ulcerative pancolitis, as an",
            "probability": 0.0
        },
        {
            "start_logit": 9.7734375,
            "end_logit": -8.125,
            "text": "Clostridium difficile infection",
            "probability": 0.0
        },
        {
            "start_logit": 9.7734375,
            "end_logit": -8.1328125,
            "text": "Clostridium difficile infection with ulcerative pancolitis, as an alternative in",
            "probability": 0.0
        },
        {
            "start_logit": 9.7734375,
            "end_logit": -8.1328125,
            "text": "Clostridium difficile infection with",
            "probability": 0.0
        },
        {
            "start_logit": 9.7734375,
            "end_logit": -8.171875,
            "text": "Clostridium difficile infection with ulcerative pancolitis,",
            "probability": 0.0
        },
        {
            "start_logit": 9.7734375,
            "end_logit": -8.1796875,
            "text": "Clostridium difficile infection with ulcerative pancolitis",
            "probability": 0.0
        },
        {
            "start_logit": 9.7734375,
            "end_logit": -8.1796875,
            "text": "Clostridium difficile infection with ulcerative pancolitis, as an alternative in case of antibiotic",
            "probability": 0.0
        },
        {
            "start_logit": -8.0078125,
            "end_logit": 9.5859375,
            "text": "recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.0625,
            "end_logit": 9.5859375,
            "text": "in recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.0625,
            "end_logit": 9.5859375,
            "text": ", well-tolerated, safe and effective in recurrent Clostridium difficile",
            "probability": 0.0
        }
    ],
    "5c71d6d27c78d6947100006a_17": [
        {
            "start_logit": 9.75,
            "end_logit": 9.59375,
            "text": "Clostridium difficile",
            "probability": 1.0
        },
        {
            "start_logit": 9.75,
            "end_logit": -1.701171875,
            "text": "Clostridium",
            "probability": 1.239776611328125e-05
        },
        {
            "start_logit": -1.7587890625,
            "end_logit": 9.59375,
            "text": "difficile",
            "probability": 1.0073184967041016e-05
        },
        {
            "start_logit": 9.75,
            "end_logit": -7.953125,
            "text": "Clostridium difficile infection and coexistent inflammatory bowel disease remains unclear.",
            "probability": 0.0
        },
        {
            "start_logit": 9.75,
            "end_logit": -8.03125,
            "text": "Clostridium difficile infection and",
            "probability": 0.0
        },
        {
            "start_logit": 9.75,
            "end_logit": -8.0703125,
            "text": "Clostridium difficile infection",
            "probability": 0.0
        },
        {
            "start_logit": 9.75,
            "end_logit": -8.0859375,
            "text": "Clostridium difficile infection and coexistent inflammatory bowel",
            "probability": 0.0
        },
        {
            "start_logit": 9.75,
            "end_logit": -8.0859375,
            "text": "Clostridium difficile infection and coexist",
            "probability": 0.0
        },
        {
            "start_logit": 9.75,
            "end_logit": -8.1328125,
            "text": "Clostridium difficile infection and coexistent inflammatory bowel disease",
            "probability": 0.0
        },
        {
            "start_logit": 9.75,
            "end_logit": -8.140625,
            "text": "Clostridium difficile infection and coexistent inflammatory bowel disease remains unclear",
            "probability": 0.0
        },
        {
            "start_logit": 9.75,
            "end_logit": -8.1484375,
            "text": "Clostridium difficile infection and coexistent",
            "probability": 0.0
        },
        {
            "start_logit": 9.75,
            "end_logit": -8.15625,
            "text": "Clostridium difficile infection and coexistent inflammatory",
            "probability": 0.0
        },
        {
            "start_logit": -8.0078125,
            "end_logit": 9.59375,
            "text": "fecal microbiota transplantation in recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.03125,
            "end_logit": 9.59375,
            "text": "The use of fecal microbiota transplantation in recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.0625,
            "end_logit": 9.59375,
            "text": "recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.1171875,
            "end_logit": 9.59375,
            "text": "microbiota transplantation in recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.1328125,
            "end_logit": 9.59375,
            "text": "use of fecal microbiota transplantation in recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.1484375,
            "end_logit": 9.59375,
            "text": "of fecal microbiota transplantation in recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -1.7587890625,
            "end_logit": -7.953125,
            "text": "difficile infection and coexistent inflammatory bowel disease remains unclear.",
            "probability": 0.0
        },
        {
            "start_logit": -8.0078125,
            "end_logit": -1.701171875,
            "text": "fecal microbiota transplantation in recurrent Clostridium",
            "probability": 0.0
        }
    ],
    "589630f378275d0c4a000007_1": [
        {
            "start_logit": 8.1953125,
            "end_logit": 8.0078125,
            "text": "proteasome",
            "probability": 1.0
        },
        {
            "start_logit": 8.1953125,
            "end_logit": -7.05078125,
            "text": "proteasome inhibitors (bortezomib, carfilzomib, and ixazomib), monoclonal antibodies (daratumumab and elotuzumab), histone deacetylase",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.421875,
            "end_logit": 8.0078125,
            "text": "MM therapy is significantly improved by the introduction of novel therapeutics such as immunomodulatory agents (thalidomide, lenalidomide, and pomalidomide), proteasome",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.1953125,
            "end_logit": -7.69921875,
            "text": "proteasome inhibitors",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.1953125,
            "end_logit": -7.7265625,
            "text": "proteasome inhibitors (bortezomib, carfilzomib, and ixazomib), monoclonal antibodies (daratumumab and elotuzumab), histone deacetylase (HDAC",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.1953125,
            "end_logit": -7.765625,
            "text": "proteasome inhibitors (bortezomib",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.1953125,
            "end_logit": -7.78125,
            "text": "proteasome inhibitors (bortezomib, carfilzomib",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.1953125,
            "end_logit": -7.96875,
            "text": "proteasome inhibitors (bortezomib, carfilzomib, and ixazomib)",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.1953125,
            "end_logit": -8.0078125,
            "text": "proteasome inhibitors (bortezomib, carfilzomib, and ixazomib), monoclonal antibodies (daratumumab and elotuzumab)",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.86328125,
            "end_logit": 8.0078125,
            "text": "Over the past decade, MM therapy is significantly improved by the introduction of novel therapeutics such as immunomodulatory agents (thalidomide, lenalidomide, and pomalidomide), proteasome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.9375,
            "end_logit": 8.0078125,
            "text": ", proteasome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.9609375,
            "end_logit": 8.0078125,
            "text": ", MM therapy is significantly improved by the introduction of novel therapeutics such as immunomodulatory agents (thalidomide, lenalidomide, and pomalidomide), proteasome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.99609375,
            "end_logit": 8.0078125,
            "text": "novel therapeutics such as immunomodulatory agents (thalidomide, lenalidomide, and pomalidomide), proteasome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.44140625,
            "end_logit": -6.91796875,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.34375,
            "end_logit": -6.91796875,
            "text": "histone deacetylase (HDAC) inhibitors (Panobinostat).",
            "probability": 0.0
        },
        {
            "start_logit": -7.34375,
            "end_logit": -7.05078125,
            "text": "histone deacetylase",
            "probability": 0.0
        },
        {
            "start_logit": -7.69140625,
            "end_logit": -6.91796875,
            "text": "HDAC) inhibitors (Panobinostat).",
            "probability": 0.0
        },
        {
            "start_logit": -7.8515625,
            "end_logit": -6.91796875,
            "text": "bortezomib, carfilzomib, and ixazomib), monoclonal antibodies (daratumumab and elotuzumab), histone deacetylase (HDAC) inhibitors (Panobinostat).",
            "probability": 0.0
        },
        {
            "start_logit": -7.8984375,
            "end_logit": -6.91796875,
            "text": ", histone deacetylase (HDAC) inhibitors (Panobinostat).",
            "probability": 0.0
        },
        {
            "start_logit": -7.9453125,
            "end_logit": -6.91796875,
            "text": ").",
            "probability": 0.0
        }
    ],
    "589630f378275d0c4a000007_2": [
        {
            "start_logit": 7.8828125,
            "end_logit": 8.3828125,
            "text": "proteasome",
            "probability": 1.0
        },
        {
            "start_logit": -6.94921875,
            "end_logit": 8.3828125,
            "text": "generation proteasome",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.8359375,
            "end_logit": 8.3828125,
            "text": "the second-generation proteasome",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.87890625,
            "end_logit": 8.3828125,
            "text": "Ixazomib (MLN9708-MLN2238), the second-generation proteasome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.91796875,
            "end_logit": 8.3828125,
            "text": "second-generation proteasome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.953125,
            "end_logit": 8.3828125,
            "text": ", the second-generation proteasome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.96484375,
            "end_logit": 8.3828125,
            "text": "azomib (MLN9708-MLN2238), the second-generation proteasome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.98828125,
            "end_logit": 8.3828125,
            "text": "-generation proteasome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.98828125,
            "end_logit": 8.3828125,
            "text": "b (MLN9708-MLN2238), the second-generation proteasome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.8828125,
            "end_logit": -7.78125,
            "text": "proteasome inhibitor, selectivity and potency were similar to that of bortezomib, is currently being investigated in phase I studies.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.8828125,
            "end_logit": -8.1328125,
            "text": "proteasome inhibitor, selectivity and potency were similar to that",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.8828125,
            "end_logit": -8.1484375,
            "text": "proteasome inhibitor, selectivity and potency were",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.8828125,
            "end_logit": -8.1484375,
            "text": "proteasome inhibitor, selectivity and potency were similar to",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.8828125,
            "end_logit": -8.15625,
            "text": "proteasome inhibitor, selectivity and potency were similar to that of bortezomib",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.8828125,
            "end_logit": -8.1640625,
            "text": "proteasome inhibitor, selectivity and potency were similar to that of bortezomib, is currently",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.8828125,
            "end_logit": -8.171875,
            "text": "proteasome inhibitor, selectivity and potency were similar to that of bortezomib,",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.8828125,
            "end_logit": -8.1796875,
            "text": "proteasome inhibitor, selectivity and potency were similar to that of",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.8828125,
            "end_logit": -8.1875,
            "text": "proteasome inhibitor, selectivity and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.76953125,
            "end_logit": -7.78125,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -6.94921875,
            "end_logit": -7.78125,
            "text": "generation proteasome inhibitor, selectivity and potency were similar to that of bortezomib, is currently being investigated in phase I studies.",
            "probability": 0.0
        }
    ],
    "589630f378275d0c4a000007_3": [
        {
            "start_logit": 7.46484375,
            "end_logit": 8.53125,
            "text": "proteasome",
            "probability": 1.0
        },
        {
            "start_logit": 7.46484375,
            "end_logit": -0.8623046875,
            "text": "proteasome inhibitor; and daratumumab and elotuzumab, two monoclonal antibodies that target CD38",
            "probability": 8.285045623779297e-05
        },
        {
            "start_logit": -6.37890625,
            "end_logit": 8.53125,
            "text": "first oral proteasome",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": -6.76953125,
            "end_logit": 8.53125,
            "text": "oral proteasome",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 7.46484375,
            "end_logit": -6.3046875,
            "text": "proteasome inhibitor; and daratumumab and elotuzumab, two monoclonal antibodies that target CD38 and SLAMF7, respectively.",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.41015625,
            "end_logit": 8.53125,
            "text": "FDA approved three new therapies for multiple myeloma: ixazomib, the first oral proteasome",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.4765625,
            "end_logit": 8.53125,
            "text": "In the last few weeks, the FDA approved three new therapies for multiple myeloma: ixazomib, the first oral proteasome",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.4921875,
            "end_logit": 8.53125,
            "text": "the first oral proteasome",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.6484375,
            "end_logit": 8.53125,
            "text": "the FDA approved three new therapies for multiple myeloma: ixazomib, the first oral proteasome",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.96875,
            "end_logit": 8.53125,
            "text": "new therapies for multiple myeloma: ixazomib, the first oral proteasome",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.9921875,
            "end_logit": 8.53125,
            "text": ", the first oral proteasome",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -8.015625,
            "end_logit": 8.53125,
            "text": ": ixazomib, the first oral proteasome",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -8.0234375,
            "end_logit": 8.53125,
            "text": ", the FDA approved three new therapies for multiple myeloma: ixazomib, the first oral proteasome",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -8.046875,
            "end_logit": 8.53125,
            "text": "three new therapies for multiple myeloma: ixazomib, the first oral proteasome",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.46484375,
            "end_logit": -7.71875,
            "text": "proteasome inhibitor; and daratumumab and elotuzumab, two monoclonal antibodies that target CD38 and SLAMF7, respectively",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.46484375,
            "end_logit": -7.75,
            "text": "proteasome inhibitor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.46484375,
            "end_logit": -7.8515625,
            "text": "proteasome inhibitor; and daratumumab and elotuzumab, two monoclonal antibodies that target CD38 and SLAMF7",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.46484375,
            "end_logit": -7.8515625,
            "text": "proteasome inhibitor;",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.46484375,
            "end_logit": -7.953125,
            "text": "proteasome inhibitor; and daratumumab and elotuzumab, two monoclonal antibodies that target CD38 and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.46484375,
            "end_logit": -7.98046875,
            "text": "proteasome inhibitor; and daratumumab and elotuzumab, two monoclonal antibodies that target CD38 and SLAMF",
            "probability": 5.960464477539063e-08
        }
    ],
    "589630f378275d0c4a000007_4": [
        {
            "start_logit": 8.015625,
            "end_logit": 8.09375,
            "text": "proteasome",
            "probability": 1.0
        },
        {
            "start_logit": -7.43359375,
            "end_logit": 8.09375,
            "text": "first oral proteasome",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.015625,
            "end_logit": -7.37890625,
            "text": "proteasome inhibitor to be evaluated in multiple myeloma, exerts substantial anti-myeloma activity as a single agent and particularly in combination with immunomodulatory drugs and it may be an attractive option for maintenance therapy.",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.71484375,
            "end_logit": 8.09375,
            "text": "oral proteasome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.75390625,
            "end_logit": 8.09375,
            "text": "the first oral proteasome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.875,
            "end_logit": 8.09375,
            "text": ", the first oral proteasome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.90234375,
            "end_logit": 8.09375,
            "text": "Ixazomib, the first oral proteasome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.9921875,
            "end_logit": 8.09375,
            "text": "azomib, the first oral proteasome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.015625,
            "end_logit": -7.9453125,
            "text": "proteasome inhibitor to be evaluated in multiple myeloma",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.015625,
            "end_logit": -7.9609375,
            "text": "proteasome inhibitor to",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.015625,
            "end_logit": -8.0078125,
            "text": "proteasome inhibitor to be evaluated in multiple myeloma, exerts substantial anti-myeloma activity as a single agent and particularly in combination with immunomodulatory drugs and it may",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.015625,
            "end_logit": -8.046875,
            "text": "proteasome inhibitor to be evaluated in multiple myeloma, exerts substantial anti-myeloma activity as a single agent and particularly in combination with immunomodulatory drugs and",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.015625,
            "end_logit": -8.078125,
            "text": "proteasome inhibitor to be evaluated in multiple myeloma,",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.015625,
            "end_logit": -8.0859375,
            "text": "proteasome inhibitor to be evaluated in multiple myeloma, exerts substantial anti-myeloma activity as",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.015625,
            "end_logit": -8.1015625,
            "text": "proteasome inhibitor to be evaluated in multiple myeloma, exerts substantial anti-myeloma activity as a single agent and particularly",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.015625,
            "end_logit": -8.1328125,
            "text": "proteasome inhibitor to be evaluated",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.76171875,
            "end_logit": -7.37890625,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.43359375,
            "end_logit": -7.37890625,
            "text": "first oral proteasome inhibitor to be evaluated in multiple myeloma, exerts substantial anti-myeloma activity as a single agent and particularly in combination with immunomodulatory drugs and it may be an attractive option for maintenance therapy.",
            "probability": 0.0
        },
        {
            "start_logit": -7.71484375,
            "end_logit": -7.37890625,
            "text": "oral proteasome inhibitor to be evaluated in multiple myeloma, exerts substantial anti-myeloma activity as a single agent and particularly in combination with immunomodulatory drugs and it may be an attractive option for maintenance therapy.",
            "probability": 0.0
        },
        {
            "start_logit": -7.75390625,
            "end_logit": -7.37890625,
            "text": "the first oral proteasome inhibitor to be evaluated in multiple myeloma, exerts substantial anti-myeloma activity as a single agent and particularly in combination with immunomodulatory drugs and it may be an attractive option for maintenance therapy.",
            "probability": 0.0
        }
    ],
    "589630f378275d0c4a000007_5": [
        {
            "start_logit": 8.125,
            "end_logit": 5.62890625,
            "text": "proteasome",
            "probability": 1.0
        },
        {
            "start_logit": 8.125,
            "end_logit": -5.75,
            "text": "proteasome inhibitors have also been used clinically, including carfilzomib, oprozomib, ixazomib, and delanzomib.",
            "probability": 1.150369644165039e-05
        },
        {
            "start_logit": 8.125,
            "end_logit": -7.45703125,
            "text": "proteasome inhibitors",
            "probability": 2.086162567138672e-06
        },
        {
            "start_logit": 8.125,
            "end_logit": -7.5390625,
            "text": "proteasome inhibitors have",
            "probability": 1.9073486328125e-06
        },
        {
            "start_logit": 8.125,
            "end_logit": -7.54296875,
            "text": "proteasome inhibitors have also been used clinically, including carfilzomib, oprozomib",
            "probability": 1.9073486328125e-06
        },
        {
            "start_logit": -5.09765625,
            "end_logit": 5.62890625,
            "text": "generation proteasome",
            "probability": 1.7881393432617188e-06
        },
        {
            "start_logit": 8.125,
            "end_logit": -7.61328125,
            "text": "proteasome inhibitors have also been used clinically, including carfilzomib",
            "probability": 1.7881393432617188e-06
        },
        {
            "start_logit": 8.125,
            "end_logit": -7.62109375,
            "text": "proteasome inhibitors have also",
            "probability": 1.7881393432617188e-06
        },
        {
            "start_logit": 8.125,
            "end_logit": -7.7734375,
            "text": "proteasome inhibitors have also been",
            "probability": 1.4901161193847656e-06
        },
        {
            "start_logit": 8.125,
            "end_logit": -7.8828125,
            "text": "proteasome inhibitors have also been used",
            "probability": 1.3709068298339844e-06
        },
        {
            "start_logit": 8.125,
            "end_logit": -7.9140625,
            "text": "proteasome inhibitors have also been used clinically",
            "probability": 1.3113021850585938e-06
        },
        {
            "start_logit": 8.125,
            "end_logit": -8.0546875,
            "text": "proteasome inhibitors have also been used clinically, including carfil",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": 8.125,
            "end_logit": -8.0625,
            "text": "proteasome inhibitors have also been used clinically,",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": 8.125,
            "end_logit": -8.0703125,
            "text": "proteasome inhibitors have also been used clinically, including carfilzomib,",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": -7.37109375,
            "end_logit": 5.62890625,
            "text": "next-generation proteasome",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.59375,
            "end_logit": 5.62890625,
            "text": "bortezomib in 2003, several next-generation proteasome",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.6640625,
            "end_logit": 5.62890625,
            "text": "2003, several next-generation proteasome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.6875,
            "end_logit": 5.62890625,
            "text": "introduction of bortezomib in 2003, several next-generation proteasome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.71484375,
            "end_logit": 5.62890625,
            "text": "several next-generation proteasome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.7265625,
            "end_logit": 5.62890625,
            "text": "Since the introduction of bortezomib in 2003, several next-generation proteasome",
            "probability": 1.1920928955078125e-07
        }
    ],
    "589630f378275d0c4a000007_6": [
        {
            "start_logit": 8.1015625,
            "end_logit": 8.265625,
            "text": "proteasome",
            "probability": 1.0
        },
        {
            "start_logit": -7.796875,
            "end_logit": 8.265625,
            "text": "AIM: The aim of the present study was to characterize the pharmacokinetics of the oral proteasome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.8125,
            "end_logit": 8.265625,
            "text": "study was to characterize the pharmacokinetics of the oral proteasome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.8984375,
            "end_logit": 8.265625,
            "text": "present study was to characterize the pharmacokinetics of the oral proteasome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.9375,
            "end_logit": 8.265625,
            "text": "aim of the present study was to characterize the pharmacokinetics of the oral proteasome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.9453125,
            "end_logit": 8.265625,
            "text": "oral proteasome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.953125,
            "end_logit": 8.265625,
            "text": "the present study was to characterize the pharmacokinetics of the oral proteasome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.97265625,
            "end_logit": 8.265625,
            "text": "The aim of the present study was to characterize the pharmacokinetics of the oral proteasome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.1015625,
            "end_logit": -7.859375,
            "text": "proteasome inhibitor, ixazomib, in patients with solid tumours and moderate or severe hepatic impairment, to provide posology recommendations.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.1015625,
            "end_logit": -8.15625,
            "text": "proteasome inhibitor, ixazomib, in",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.87890625,
            "end_logit": -7.859375,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.8125,
            "end_logit": -7.859375,
            "text": "study was to characterize the pharmacokinetics of the oral proteasome inhibitor, ixazomib, in patients with solid tumours and moderate or severe hepatic impairment, to provide posology recommendations.",
            "probability": 0.0
        },
        {
            "start_logit": -7.83203125,
            "end_logit": -7.859375,
            "text": "posology recommendations.",
            "probability": 0.0
        },
        {
            "start_logit": -7.88671875,
            "end_logit": -7.859375,
            "text": ", ixazomib, in patients with solid tumours and moderate or severe hepatic impairment, to provide posology recommendations.",
            "probability": 0.0
        },
        {
            "start_logit": -7.8984375,
            "end_logit": -7.859375,
            "text": "present study was to characterize the pharmacokinetics of the oral proteasome inhibitor, ixazomib, in patients with solid tumours and moderate or severe hepatic impairment, to provide posology recommendations.",
            "probability": 0.0
        },
        {
            "start_logit": -7.9375,
            "end_logit": -7.859375,
            "text": "aim of the present study was to characterize the pharmacokinetics of the oral proteasome inhibitor, ixazomib, in patients with solid tumours and moderate or severe hepatic impairment, to provide posology recommendations.",
            "probability": 0.0
        },
        {
            "start_logit": -7.9453125,
            "end_logit": -7.859375,
            "text": "oral proteasome inhibitor, ixazomib, in patients with solid tumours and moderate or severe hepatic impairment, to provide posology recommendations.",
            "probability": 0.0
        },
        {
            "start_logit": -7.953125,
            "end_logit": -7.859375,
            "text": "the present study was to characterize the pharmacokinetics of the oral proteasome inhibitor, ixazomib, in patients with solid tumours and moderate or severe hepatic impairment, to provide posology recommendations.",
            "probability": 0.0
        },
        {
            "start_logit": -7.97265625,
            "end_logit": -7.859375,
            "text": "recommendations.",
            "probability": 0.0
        },
        {
            "start_logit": -7.97265625,
            "end_logit": -7.859375,
            "text": "The aim of the present study was to characterize the pharmacokinetics of the oral proteasome inhibitor, ixazomib, in patients with solid tumours and moderate or severe hepatic impairment, to provide posology recommendations.",
            "probability": 0.0
        }
    ],
    "589630f378275d0c4a000007_7": [
        {
            "start_logit": 8.046875,
            "end_logit": 8.1484375,
            "text": "proteasome",
            "probability": 1.0
        },
        {
            "start_logit": -7.73828125,
            "end_logit": 8.1484375,
            "text": "oral proteasome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.8984375,
            "end_logit": 8.1484375,
            "text": "ixazomib, an oral proteasome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.046875,
            "end_logit": -7.8515625,
            "text": "proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairment.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.953125,
            "end_logit": 8.1484375,
            "text": "azomib, an oral proteasome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.96484375,
            "end_logit": 8.1484375,
            "text": "b, an oral proteasome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.97265625,
            "end_logit": 8.1484375,
            "text": "Pharmacokinetics of ixazomib, an oral proteasome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.98828125,
            "end_logit": 8.1484375,
            "text": "an oral proteasome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.99609375,
            "end_logit": 8.1484375,
            "text": ", an oral proteasome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.0078125,
            "end_logit": 8.1484375,
            "text": "mib, an oral proteasome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.046875,
            "end_logit": -7.9453125,
            "text": "proteasome inhibitor, in",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.046875,
            "end_logit": -8.125,
            "text": "proteasome inhibitor, in solid",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.046875,
            "end_logit": -8.1328125,
            "text": "proteasome inhibitor, in solid tumour patients",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.046875,
            "end_logit": -8.1328125,
            "text": "proteasome inhibitor, in solid tumour patients with",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.046875,
            "end_logit": -8.15625,
            "text": "proteasome inhibitor, in solid tumour",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.046875,
            "end_logit": -8.15625,
            "text": "proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairment",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.8515625,
            "end_logit": -7.8515625,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.73828125,
            "end_logit": -7.8515625,
            "text": "oral proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairment.",
            "probability": 0.0
        },
        {
            "start_logit": -7.73828125,
            "end_logit": -7.9453125,
            "text": "oral proteasome inhibitor, in",
            "probability": 0.0
        },
        {
            "start_logit": -7.85546875,
            "end_logit": -7.8515625,
            "text": "hepatic impairment.",
            "probability": 0.0
        }
    ],
    "589630f378275d0c4a000007_8": [
        {
            "start_logit": 8.1953125,
            "end_logit": 7.96875,
            "text": "proteasome",
            "probability": 1.0
        },
        {
            "start_logit": -7.328125,
            "end_logit": 7.96875,
            "text": ", proteasome",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.1953125,
            "end_logit": -7.765625,
            "text": "proteasome inhibitor to reach phase III trials.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.62890625,
            "end_logit": 7.96875,
            "text": "Ixazomib is the first oral, proteasome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.6328125,
            "end_logit": 7.96875,
            "text": "first oral, proteasome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.78515625,
            "end_logit": 7.96875,
            "text": "the first oral, proteasome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.7890625,
            "end_logit": 7.96875,
            "text": "b is the first oral, proteasome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.80859375,
            "end_logit": 7.96875,
            "text": "azomib is the first oral, proteasome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.8203125,
            "end_logit": 7.96875,
            "text": "is the first oral, proteasome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.82421875,
            "end_logit": 7.96875,
            "text": "oral, proteasome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.84765625,
            "end_logit": 7.96875,
            "text": "mib is the first oral, proteasome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.1953125,
            "end_logit": -8.078125,
            "text": "proteasome inhibitor to",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.1953125,
            "end_logit": -8.1875,
            "text": "proteasome inhibitor to reach",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.8515625,
            "end_logit": -7.765625,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.328125,
            "end_logit": -7.765625,
            "text": ", proteasome inhibitor to reach phase III trials.",
            "probability": 0.0
        },
        {
            "start_logit": -7.62890625,
            "end_logit": -7.765625,
            "text": "Ixazomib is the first oral, proteasome inhibitor to reach phase III trials.",
            "probability": 0.0
        },
        {
            "start_logit": -7.6328125,
            "end_logit": -7.765625,
            "text": "first oral, proteasome inhibitor to reach phase III trials.",
            "probability": 0.0
        },
        {
            "start_logit": -7.328125,
            "end_logit": -8.078125,
            "text": ", proteasome inhibitor to",
            "probability": 0.0
        },
        {
            "start_logit": -7.328125,
            "end_logit": -8.1875,
            "text": ", proteasome inhibitor to reach",
            "probability": 0.0
        },
        {
            "start_logit": -7.78125,
            "end_logit": -7.765625,
            "text": "phase III trials.",
            "probability": 0.0
        }
    ],
    "589630f378275d0c4a000007_9": [
        {
            "start_logit": 8.1484375,
            "end_logit": 8.1015625,
            "text": "proteasome",
            "probability": 1.0
        },
        {
            "start_logit": 8.1484375,
            "end_logit": -7.37890625,
            "text": "proteasome inhibitor, has improved pharmacotherapeutic parameters compared to bortezomib.",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.53515625,
            "end_logit": 8.1015625,
            "text": "oral proteasome",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.6328125,
            "end_logit": 8.1015625,
            "text": "MLN2238 (ixazomib), an oral proteasome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.85546875,
            "end_logit": 8.1015625,
            "text": ", an oral proteasome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.92578125,
            "end_logit": 8.1015625,
            "text": "(ixazomib), an oral proteasome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.9296875,
            "end_logit": 8.1015625,
            "text": "an oral proteasome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.953125,
            "end_logit": 8.1015625,
            "text": "), an oral proteasome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.9765625,
            "end_logit": 8.1015625,
            "text": "ixazomib), an oral proteasome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.1484375,
            "end_logit": -8.03125,
            "text": "proteasome inhibitor, has",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.9921875,
            "end_logit": 8.1015625,
            "text": "238 (ixazomib), an oral proteasome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.6796875,
            "end_logit": -7.37890625,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.53515625,
            "end_logit": -7.37890625,
            "text": "oral proteasome inhibitor, has improved pharmacotherapeutic parameters compared to bortezomib.",
            "probability": 0.0
        },
        {
            "start_logit": -7.6328125,
            "end_logit": -7.37890625,
            "text": "MLN2238 (ixazomib), an oral proteasome inhibitor, has improved pharmacotherapeutic parameters compared to bortezomib.",
            "probability": 0.0
        },
        {
            "start_logit": -7.85546875,
            "end_logit": -7.37890625,
            "text": ", an oral proteasome inhibitor, has improved pharmacotherapeutic parameters compared to bortezomib.",
            "probability": 0.0
        },
        {
            "start_logit": -7.8671875,
            "end_logit": -7.37890625,
            "text": ", has improved pharmacotherapeutic parameters compared to bortezomib.",
            "probability": 0.0
        },
        {
            "start_logit": -7.87109375,
            "end_logit": -7.37890625,
            "text": "bortezomib.",
            "probability": 0.0
        },
        {
            "start_logit": -7.90234375,
            "end_logit": -7.37890625,
            "text": "pharmacotherapeutic parameters compared to bortezomib.",
            "probability": 0.0
        },
        {
            "start_logit": -7.92578125,
            "end_logit": -7.37890625,
            "text": "(ixazomib), an oral proteasome inhibitor, has improved pharmacotherapeutic parameters compared to bortezomib.",
            "probability": 0.0
        },
        {
            "start_logit": -7.9296875,
            "end_logit": -7.37890625,
            "text": "an oral proteasome inhibitor, has improved pharmacotherapeutic parameters compared to bortezomib.",
            "probability": 0.0
        }
    ],
    "589630f378275d0c4a000007_10": [
        {
            "start_logit": 7.953125,
            "end_logit": 8.265625,
            "text": "proteasome",
            "probability": 1.0
        },
        {
            "start_logit": -7.68359375,
            "end_logit": 8.265625,
            "text": "population pharmacokinetic analysis of the investigational oral proteasome",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.796875,
            "end_logit": 8.265625,
            "text": "This population pharmacokinetic analysis of the investigational oral proteasome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.953125,
            "end_logit": -7.48828125,
            "text": "proteasome inhibitor ixazomib assessed the feasibility of switching from body surface area (BSA)-based to fixed dosing, and the impact of baseline covariates on ixazomib pharmacokinetics.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.98046875,
            "end_logit": 8.265625,
            "text": "oral proteasome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.0859375,
            "end_logit": 8.265625,
            "text": "investigational oral proteasome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.953125,
            "end_logit": -7.90625,
            "text": "proteasome inhibitor ixazomib assessed the feasibility of switching from body surface area (BSA)-based to fixed dosing, and the impact of baseline covariates on ixazomib pharmacokinetics",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.953125,
            "end_logit": -7.95703125,
            "text": "proteasome inhibitor ixazomib assessed",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.953125,
            "end_logit": -7.9921875,
            "text": "proteasome inhibitor ixazomib assessed the feasibility of switching from body surface area (BSA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.953125,
            "end_logit": -8.015625,
            "text": "proteasome inhibitor ixazomib assessed the feasibility of switching from body surface area (BSA)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.953125,
            "end_logit": -8.03125,
            "text": "proteasome inhibitor ixazomib assessed the feasibility of switching from body surface area",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.953125,
            "end_logit": -8.0546875,
            "text": "proteasome inhibitor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.953125,
            "end_logit": -8.0625,
            "text": "proteasome inhibitor ixazomib assessed the feasibility of",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.953125,
            "end_logit": -8.0625,
            "text": "proteasome inhibitor ixazomib assessed the feasibility of switching from body surface area (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.953125,
            "end_logit": -8.0625,
            "text": "proteasome inhibitor ixazomib assessed the feasibility of switching from body surface area (BSA)-based to fixed dosing, and the impact of",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.953125,
            "end_logit": -8.0703125,
            "text": "proteasome inhibitor ixazomib assessed the feasibility of switching from body surface area (BSA)-based to fixed dosing, and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.953125,
            "end_logit": -8.078125,
            "text": "proteasome inhibitor ixazomib assessed the feasibility of switching from body surface",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.953125,
            "end_logit": -8.078125,
            "text": "proteasome inhibitor ixazomib assessed the feasibility of switching from body surface area (BSA)-based to fixed dosing, and the impact of baseline covariates on",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.953125,
            "end_logit": -8.078125,
            "text": "proteasome inhibitor ixazomib assessed the feasibility of switching from body surface area (BSA)-based to fixed dosing, and the impact of baseline covariates",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.953125,
            "end_logit": -8.078125,
            "text": "proteasome inhibitor ixazomib assessed the feasibility of switching from body surface area (BSA)-",
            "probability": 5.960464477539063e-08
        }
    ],
    "55201a316b348bb82c000019_1": [
        {
            "start_logit": 9.9140625,
            "end_logit": 9.5078125,
            "text": "55 S",
            "probability": 1.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -0.662109375,
            "text": "55",
            "probability": 3.820657730102539e-05
        },
        {
            "start_logit": -1.5791015625,
            "end_logit": 9.5078125,
            "text": "S",
            "probability": 1.0192394256591797e-05
        },
        {
            "start_logit": -5.16796875,
            "end_logit": 9.5078125,
            "text": "small sedimentation coefficient of 55 S",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -6.74609375,
            "text": "55 S, consisting of 39 S large and 28 S small subunits.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.0703125,
            "end_logit": 9.5078125,
            "text": "a small sedimentation coefficient of 55 S",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -7.55078125,
            "text": "55 S,",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -7.84765625,
            "text": "55 S, consisting",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -7.94921875,
            "text": "55 S, consisting of 39 S large and 28",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -7.95703125,
            "text": "55 S, consisting of 39 S large and",
            "probability": 0.0
        },
        {
            "start_logit": -7.7109375,
            "end_logit": 9.5078125,
            "text": "mitochondrial ribosome (mitoribosome) has a highly protein-rich composition with a small sedimentation coefficient of 55 S",
            "probability": 0.0
        },
        {
            "start_logit": -7.76953125,
            "end_logit": 9.5078125,
            "text": "The mammalian mitochondrial ribosome (mitoribosome) has a highly protein-rich composition with a small sedimentation coefficient of 55 S",
            "probability": 0.0
        },
        {
            "start_logit": -7.828125,
            "end_logit": 9.5078125,
            "text": "with a small sedimentation coefficient of 55 S",
            "probability": 0.0
        },
        {
            "start_logit": -7.83984375,
            "end_logit": 9.5078125,
            "text": "sedimentation coefficient of 55 S",
            "probability": 0.0
        },
        {
            "start_logit": -7.95703125,
            "end_logit": 9.5078125,
            "text": "mammalian mitochondrial ribosome (mitoribosome) has a highly protein-rich composition with a small sedimentation coefficient of 55 S",
            "probability": 0.0
        },
        {
            "start_logit": -8.046875,
            "end_logit": 9.5078125,
            "text": "protein-rich composition with a small sedimentation coefficient of 55 S",
            "probability": 0.0
        },
        {
            "start_logit": -8.046875,
            "end_logit": 9.5078125,
            "text": "highly protein-rich composition with a small sedimentation coefficient of 55 S",
            "probability": 0.0
        },
        {
            "start_logit": -5.16796875,
            "end_logit": -0.662109375,
            "text": "small sedimentation coefficient of 55",
            "probability": 0.0
        },
        {
            "start_logit": -7.0703125,
            "end_logit": -0.662109375,
            "text": "a small sedimentation coefficient of 55",
            "probability": 0.0
        },
        {
            "start_logit": -1.5791015625,
            "end_logit": -6.74609375,
            "text": "S, consisting of 39 S large and 28 S small subunits.",
            "probability": 0.0
        }
    ],
    "55201a316b348bb82c000019_2": [
        {
            "start_logit": 9.8984375,
            "end_logit": 9.34375,
            "text": "55 S",
            "probability": 1.0
        },
        {
            "start_logit": 9.8984375,
            "end_logit": -0.6123046875,
            "text": "55",
            "probability": 4.7206878662109375e-05
        },
        {
            "start_logit": -1.6494140625,
            "end_logit": 9.34375,
            "text": "S",
            "probability": 9.59634780883789e-06
        },
        {
            "start_logit": 9.8984375,
            "end_logit": -6.01171875,
            "text": "55 S mammalian mitochondrial ribosome (referred to hereafter as \"mitoribosome\") is protein-rich, containing nearly twice as much protein as the Escherichia coli ribosome.",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.8984375,
            "end_logit": -7.33203125,
            "text": "55 S mammalian mitochondrial ribosome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8984375,
            "end_logit": -7.67578125,
            "text": "55 S mammalian mitochondrial ribosome (referred to hereafter as \"mitoribosome\") is protein-rich, containing nearly twice as much protein as the Escherichia coli ribosome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8984375,
            "end_logit": -7.7265625,
            "text": "55 S mammalian mitochondrial ribosome (referred to hereafter as \"mitoribosome\") is",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8984375,
            "end_logit": -7.80078125,
            "text": "55 S mammalian mitochondrial ribosome (referred to hereafter as \"mitoribosome\")",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8984375,
            "end_logit": -7.82421875,
            "text": "55 S mammalian mitochondrial ribosome (referred to hereafter as \"mitoribosome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8984375,
            "end_logit": -7.8359375,
            "text": "55 S mammalian mitochondrial ribosome (referred to hereafter as \"mitoribos",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8984375,
            "end_logit": -7.8671875,
            "text": "55 S mammalian mitochondrial ribosome (referred to hereafter as \"mitori",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8984375,
            "end_logit": -7.89453125,
            "text": "55 S mammalian mitochondrial ribosome (referred to hereafter as \"mitoribosome\"",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.94140625,
            "end_logit": 9.34375,
            "text": "The 55 S",
            "probability": 0.0
        },
        {
            "start_logit": -1.6494140625,
            "end_logit": -6.01171875,
            "text": "S mammalian mitochondrial ribosome (referred to hereafter as \"mitoribosome\") is protein-rich, containing nearly twice as much protein as the Escherichia coli ribosome.",
            "probability": 0.0
        },
        {
            "start_logit": -7.94140625,
            "end_logit": -0.6123046875,
            "text": "The 55",
            "probability": 0.0
        },
        {
            "start_logit": -1.6494140625,
            "end_logit": -7.33203125,
            "text": "S mammalian mitochondrial ribosome",
            "probability": 0.0
        },
        {
            "start_logit": -1.6494140625,
            "end_logit": -7.67578125,
            "text": "S mammalian mitochondrial ribosome (referred to hereafter as \"mitoribosome\") is protein-rich, containing nearly twice as much protein as the Escherichia coli ribosome",
            "probability": 0.0
        },
        {
            "start_logit": -1.6494140625,
            "end_logit": -7.7265625,
            "text": "S mammalian mitochondrial ribosome (referred to hereafter as \"mitoribosome\") is",
            "probability": 0.0
        },
        {
            "start_logit": -1.6494140625,
            "end_logit": -7.80078125,
            "text": "S mammalian mitochondrial ribosome (referred to hereafter as \"mitoribosome\")",
            "probability": 0.0
        },
        {
            "start_logit": -1.6494140625,
            "end_logit": -7.82421875,
            "text": "S mammalian mitochondrial ribosome (referred to hereafter as \"mitoribosome",
            "probability": 0.0
        }
    ],
    "55201a316b348bb82c000019_3": [
        {
            "start_logit": 9.296875,
            "end_logit": 9.4921875,
            "text": "55 S",
            "probability": 1.0
        },
        {
            "start_logit": -1.6162109375,
            "end_logit": 9.4921875,
            "text": "S",
            "probability": 1.8358230590820312e-05
        },
        {
            "start_logit": 9.296875,
            "end_logit": -2.083984375,
            "text": "55",
            "probability": 9.417533874511719e-06
        },
        {
            "start_logit": -7.37109375,
            "end_logit": 9.4921875,
            "text": "The sedimentation coefficient of the intact monosome was about 55 S",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.4609375,
            "end_logit": 9.4921875,
            "text": "about 55 S",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.296875,
            "end_logit": -7.34765625,
            "text": "55 S.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.55078125,
            "end_logit": 9.4921875,
            "text": "intact monosome was about 55 S",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.82421875,
            "end_logit": 9.4921875,
            "text": "monosome was about 55 S",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.8515625,
            "end_logit": 9.4921875,
            "text": "the intact monosome was about 55 S",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.859375,
            "end_logit": 9.4921875,
            "text": "ome was about 55 S",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0078125,
            "end_logit": 9.4921875,
            "text": "sedimentation coefficient of the intact monosome was about 55 S",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.6162109375,
            "end_logit": -7.34765625,
            "text": "S.",
            "probability": 0.0
        },
        {
            "start_logit": -7.37109375,
            "end_logit": -2.083984375,
            "text": "The sedimentation coefficient of the intact monosome was about 55",
            "probability": 0.0
        },
        {
            "start_logit": -7.4609375,
            "end_logit": -2.083984375,
            "text": "about 55",
            "probability": 0.0
        },
        {
            "start_logit": -7.55078125,
            "end_logit": -2.083984375,
            "text": "intact monosome was about 55",
            "probability": 0.0
        },
        {
            "start_logit": -7.82421875,
            "end_logit": -2.083984375,
            "text": "monosome was about 55",
            "probability": 0.0
        },
        {
            "start_logit": -7.8515625,
            "end_logit": -2.083984375,
            "text": "the intact monosome was about 55",
            "probability": 0.0
        },
        {
            "start_logit": -7.859375,
            "end_logit": -2.083984375,
            "text": "ome was about 55",
            "probability": 0.0
        },
        {
            "start_logit": -8.0078125,
            "end_logit": -2.083984375,
            "text": "sedimentation coefficient of the intact monosome was about 55",
            "probability": 0.0
        },
        {
            "start_logit": -6.3515625,
            "end_logit": -7.34765625,
            "text": ".",
            "probability": 0.0
        }
    ],
    "5e2a1096aa19d7443100000e_1": [
        {
            "start_logit": 9.625,
            "end_logit": 6.7734375,
            "text": "vascular endothelial growth factor A",
            "probability": 1.0
        },
        {
            "start_logit": 9.625,
            "end_logit": -1.9501953125,
            "text": "vascular",
            "probability": 0.0001609325408935547
        },
        {
            "start_logit": 9.625,
            "end_logit": -2.1640625,
            "text": "vascular endothelial growth factor A (VEGF-A)",
            "probability": 0.0001302957534790039
        },
        {
            "start_logit": 9.625,
            "end_logit": -3.462890625,
            "text": "vascular endothelial growth factor A (VEGF-A",
            "probability": 3.5643577575683594e-05
        },
        {
            "start_logit": 9.625,
            "end_logit": -3.83984375,
            "text": "vascular endothelial growth factor",
            "probability": 2.4318695068359375e-05
        },
        {
            "start_logit": 9.625,
            "end_logit": -5.953125,
            "text": "vascular endothelial growth factor A (VEGF",
            "probability": 2.9206275939941406e-06
        },
        {
            "start_logit": 9.625,
            "end_logit": -6.4609375,
            "text": "vascular endothelial growth factor A (VEGF-A), in vivo.",
            "probability": 1.7881393432617188e-06
        },
        {
            "start_logit": 9.625,
            "end_logit": -7.1171875,
            "text": "vascular endothelial growth",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": 9.625,
            "end_logit": -7.22265625,
            "text": "vascular endothelial",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": 9.625,
            "end_logit": -7.23046875,
            "text": "vascular endothelial growth factor A (VEGF-",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": 9.625,
            "end_logit": -7.30859375,
            "text": "vascular endothelial growth factor A (VEGF-A),",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 9.625,
            "end_logit": -7.37109375,
            "text": "vascular endothelial growth factor A (",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 9.625,
            "end_logit": -7.890625,
            "text": "vascular endothelial growth factor A (VEGF-A), in vivo",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -5.09375,
            "end_logit": 6.7734375,
            "text": "modified mRNA encoding vascular endothelial growth factor A",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -5.203125,
            "end_logit": 6.7734375,
            "text": "A",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -6.15625,
            "end_logit": 6.7734375,
            "text": "encoding vascular endothelial growth factor A",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.54296875,
            "end_logit": 6.7734375,
            "text": "endothelial growth factor A",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.88671875,
            "end_logit": 6.7734375,
            "text": "a modified mRNA encoding vascular endothelial growth factor A",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.12890625,
            "end_logit": 6.7734375,
            "text": "mRNA encoding vascular endothelial growth factor A",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.2265625,
            "end_logit": 6.7734375,
            "text": "growth factor A",
            "probability": 5.960464477539063e-08
        }
    ],
    "5caa0247ecadf2e73f000055_1": [
        {
            "start_logit": 2.751953125,
            "end_logit": 3.6953125,
            "text": "moesin",
            "probability": 0.998046875
        },
        {
            "start_logit": 2.751953125,
            "end_logit": -3.55078125,
            "text": "moesin (Moe)",
            "probability": 0.0007143020629882812
        },
        {
            "start_logit": 2.751953125,
            "end_logit": -3.70703125,
            "text": "moesin (Moe).",
            "probability": 0.0006108283996582031
        },
        {
            "start_logit": -5.53125,
            "end_logit": 3.6953125,
            "text": "epidermal growth factor receptor (Egfr) pathway, is required for tracheal cell apical constriction and for organising an actomyosin complex, which we propose is mediated by Crb recruitment of moesin",
            "probability": 0.00025272369384765625
        },
        {
            "start_logit": -6.62890625,
            "end_logit": 3.6953125,
            "text": "esin",
            "probability": 8.463859558105469e-05
        },
        {
            "start_logit": -7.06640625,
            "end_logit": 3.6953125,
            "text": "of moesin",
            "probability": 5.46574592590332e-05
        },
        {
            "start_logit": 2.751953125,
            "end_logit": -6.2890625,
            "text": "moesin (Moe",
            "probability": 4.601478576660156e-05
        },
        {
            "start_logit": 2.751953125,
            "end_logit": -6.41015625,
            "text": "moesin (",
            "probability": 4.094839096069336e-05
        },
        {
            "start_logit": -7.44921875,
            "end_logit": 3.6953125,
            "text": "by Crb recruitment of moesin",
            "probability": 3.701448440551758e-05
        },
        {
            "start_logit": 2.751953125,
            "end_logit": -6.55078125,
            "text": "moesin (Mo",
            "probability": 3.55839729309082e-05
        },
        {
            "start_logit": -7.578125,
            "end_logit": 3.6953125,
            "text": "we propose is mediated by Crb recruitment of moesin",
            "probability": 3.266334533691406e-05
        },
        {
            "start_logit": -7.58984375,
            "end_logit": 3.6953125,
            "text": "recruitment of moesin",
            "probability": 3.212690353393555e-05
        },
        {
            "start_logit": -7.62890625,
            "end_logit": 3.6953125,
            "text": "propose is mediated by Crb recruitment of moesin",
            "probability": 3.1113624572753906e-05
        },
        {
            "start_logit": -7.6328125,
            "end_logit": 3.6953125,
            "text": "(Egfr) pathway, is required for tracheal cell apical constriction and for organising an actomyosin complex, which we propose is mediated by Crb recruitment of moesin",
            "probability": 3.0875205993652344e-05
        },
        {
            "start_logit": -7.64453125,
            "end_logit": 3.6953125,
            "text": "Crb recruitment of moesin",
            "probability": 3.063678741455078e-05
        },
        {
            "start_logit": -7.7265625,
            "end_logit": 3.6953125,
            "text": "parallel with the epidermal growth factor receptor (Egfr) pathway, is required for tracheal cell apical constriction and for organising an actomyosin complex, which we propose is mediated by Crb recruitment of moesin",
            "probability": 2.8133392333984375e-05
        },
        {
            "start_logit": -7.74609375,
            "end_logit": 3.6953125,
            "text": "is mediated by Crb recruitment of moesin",
            "probability": 2.7477741241455078e-05
        },
        {
            "start_logit": 2.751953125,
            "end_logit": -6.81640625,
            "text": "mo",
            "probability": 2.7239322662353516e-05
        },
        {
            "start_logit": -4.96484375,
            "end_logit": -3.70703125,
            "text": ".",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.62890625,
            "end_logit": -3.55078125,
            "text": "esin (Moe)",
            "probability": 5.960464477539063e-08
        }
    ],
    "5e4604d83f54159529000003_1": [
        {
            "start_logit": 3.08203125,
            "end_logit": 9.578125,
            "text": "carotid and vertebral artery dissection",
            "probability": 0.80078125
        },
        {
            "start_logit": 1.5888671875,
            "end_logit": 9.578125,
            "text": "acute (within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 0.1800537109375
        },
        {
            "start_logit": -0.7373046875,
            "end_logit": 9.578125,
            "text": "dissection",
            "probability": 0.0176849365234375
        },
        {
            "start_logit": -3.052734375,
            "end_logit": 9.578125,
            "text": "artery dissection",
            "probability": 0.0017375946044921875
        },
        {
            "start_logit": -6.640625,
            "end_logit": 9.578125,
            "text": ") carotid and vertebral artery dissection",
            "probability": 4.8160552978515625e-05
        },
        {
            "start_logit": -7.68359375,
            "end_logit": 9.578125,
            "text": "in acute (within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 1.6868114471435547e-05
        },
        {
            "start_logit": -7.76171875,
            "end_logit": 9.578125,
            "text": "AIMS: CADISS is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 1.5676021575927734e-05
        },
        {
            "start_logit": -7.76953125,
            "end_logit": 9.578125,
            "text": "vertebral artery dissection",
            "probability": 1.5676021575927734e-05
        },
        {
            "start_logit": -7.8046875,
            "end_logit": 9.578125,
            "text": "and vertebral artery dissection",
            "probability": 1.5020370483398438e-05
        },
        {
            "start_logit": -7.80859375,
            "end_logit": 9.578125,
            "text": "(within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 1.4960765838623047e-05
        },
        {
            "start_logit": -7.83203125,
            "end_logit": 9.578125,
            "text": "prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 1.4722347259521484e-05
        },
        {
            "start_logit": -7.875,
            "end_logit": 9.578125,
            "text": "multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 1.4007091522216797e-05
        },
        {
            "start_logit": -7.9140625,
            "end_logit": 9.578125,
            "text": "randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 1.3470649719238281e-05
        },
        {
            "start_logit": -7.95703125,
            "end_logit": 9.578125,
            "text": "within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 1.2993812561035156e-05
        },
        {
            "start_logit": -7.97265625,
            "end_logit": 9.578125,
            "text": "CADISS is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 1.2755393981933594e-05
        },
        {
            "start_logit": -7.97265625,
            "end_logit": 9.578125,
            "text": "trial in acute (within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 1.2755393981933594e-05
        },
        {
            "start_logit": 3.08203125,
            "end_logit": -7.0390625,
            "text": "carotid",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 3.08203125,
            "end_logit": -7.15625,
            "text": "carotid and vertebral artery dissection.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 1.5888671875,
            "end_logit": -6.0703125,
            "text": "acute",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 1.5888671875,
            "end_logit": -7.0390625,
            "text": "acute (within 7 days of onset) carotid",
            "probability": 0.0
        }
    ],
    "5e4604d83f54159529000003_2": [
        {
            "start_logit": 3.44921875,
            "end_logit": 9.4453125,
            "text": "carotid and vertebral artery dissection",
            "probability": 0.8798828125
        },
        {
            "start_logit": 1.3154296875,
            "end_logit": 9.4453125,
            "text": "acute (within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 0.104248046875
        },
        {
            "start_logit": -0.65966796875,
            "end_logit": 9.4453125,
            "text": "dissection",
            "probability": 0.01454925537109375
        },
        {
            "start_logit": -2.888671875,
            "end_logit": 9.4453125,
            "text": "artery dissection",
            "probability": 0.0015592575073242188
        },
        {
            "start_logit": -6.58984375,
            "end_logit": 9.4453125,
            "text": ") carotid and vertebral artery dissection",
            "probability": 3.8683414459228516e-05
        },
        {
            "start_logit": -7.37109375,
            "end_logit": 9.4453125,
            "text": "and vertebral artery dissection",
            "probability": 1.7702579498291016e-05
        },
        {
            "start_logit": -7.49609375,
            "end_logit": 9.4453125,
            "text": "vertebral artery dissection",
            "probability": 1.5616416931152344e-05
        },
        {
            "start_logit": -7.640625,
            "end_logit": 9.4453125,
            "text": "in acute (within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 1.3470649719238281e-05
        },
        {
            "start_logit": -7.64453125,
            "end_logit": 9.4453125,
            "text": "AIMS  CADISS is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 1.33514404296875e-05
        },
        {
            "start_logit": -7.83203125,
            "end_logit": 9.4453125,
            "text": "(within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 1.1146068572998047e-05
        },
        {
            "start_logit": -7.84375,
            "end_logit": 9.4453125,
            "text": "prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 1.1026859283447266e-05
        },
        {
            "start_logit": -7.875,
            "end_logit": 9.4453125,
            "text": "multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 1.0669231414794922e-05
        },
        {
            "start_logit": -7.88671875,
            "end_logit": 9.4453125,
            "text": "randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 1.0609626770019531e-05
        },
        {
            "start_logit": -7.9453125,
            "end_logit": 9.4453125,
            "text": "CADISS is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 9.953975677490234e-06
        },
        {
            "start_logit": -7.9453125,
            "end_logit": 9.4453125,
            "text": "within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 9.953975677490234e-06
        },
        {
            "start_logit": -7.9765625,
            "end_logit": 9.4453125,
            "text": "trial in acute (within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 9.655952453613281e-06
        },
        {
            "start_logit": 3.44921875,
            "end_logit": -6.7890625,
            "text": "carotid",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 3.44921875,
            "end_logit": -6.9609375,
            "text": "carotid and vertebral artery dissection.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 1.3154296875,
            "end_logit": -6.1484375,
            "text": "acute",
            "probability": 0.0
        },
        {
            "start_logit": 1.3154296875,
            "end_logit": -6.7890625,
            "text": "acute (within 7 days of onset) carotid",
            "probability": 0.0
        }
    ],
    "5e4604d83f54159529000003_3": [
        {
            "start_logit": 3.44921875,
            "end_logit": 9.4453125,
            "text": "carotid and vertebral artery dissection",
            "probability": 0.8798828125
        },
        {
            "start_logit": 1.3154296875,
            "end_logit": 9.4453125,
            "text": "acute (within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 0.104248046875
        },
        {
            "start_logit": -0.65966796875,
            "end_logit": 9.4453125,
            "text": "dissection",
            "probability": 0.01454925537109375
        },
        {
            "start_logit": -2.888671875,
            "end_logit": 9.4453125,
            "text": "artery dissection",
            "probability": 0.0015592575073242188
        },
        {
            "start_logit": -6.58984375,
            "end_logit": 9.4453125,
            "text": ") carotid and vertebral artery dissection",
            "probability": 3.8683414459228516e-05
        },
        {
            "start_logit": -7.37109375,
            "end_logit": 9.4453125,
            "text": "and vertebral artery dissection",
            "probability": 1.7702579498291016e-05
        },
        {
            "start_logit": -7.49609375,
            "end_logit": 9.4453125,
            "text": "vertebral artery dissection",
            "probability": 1.5616416931152344e-05
        },
        {
            "start_logit": -7.640625,
            "end_logit": 9.4453125,
            "text": "in acute (within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 1.3470649719238281e-05
        },
        {
            "start_logit": -7.64453125,
            "end_logit": 9.4453125,
            "text": "AIMS CADISS is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 1.33514404296875e-05
        },
        {
            "start_logit": -7.83203125,
            "end_logit": 9.4453125,
            "text": "(within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 1.1146068572998047e-05
        },
        {
            "start_logit": -7.84375,
            "end_logit": 9.4453125,
            "text": "prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 1.1026859283447266e-05
        },
        {
            "start_logit": -7.875,
            "end_logit": 9.4453125,
            "text": "multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 1.0669231414794922e-05
        },
        {
            "start_logit": -7.88671875,
            "end_logit": 9.4453125,
            "text": "randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 1.0609626770019531e-05
        },
        {
            "start_logit": -7.9453125,
            "end_logit": 9.4453125,
            "text": "CADISS is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 9.953975677490234e-06
        },
        {
            "start_logit": -7.9453125,
            "end_logit": 9.4453125,
            "text": "within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 9.953975677490234e-06
        },
        {
            "start_logit": -7.9765625,
            "end_logit": 9.4453125,
            "text": "trial in acute (within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 9.655952453613281e-06
        },
        {
            "start_logit": 3.44921875,
            "end_logit": -6.7890625,
            "text": "carotid",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 3.44921875,
            "end_logit": -6.9609375,
            "text": "carotid and vertebral artery dissection.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 1.3154296875,
            "end_logit": -6.1484375,
            "text": "acute",
            "probability": 0.0
        },
        {
            "start_logit": 1.3154296875,
            "end_logit": -6.7890625,
            "text": "acute (within 7 days of onset) carotid",
            "probability": 0.0
        }
    ],
    "5e4604d83f54159529000003_4": [
        {
            "start_logit": 3.44921875,
            "end_logit": 9.4453125,
            "text": "carotid and vertebral artery dissection",
            "probability": 0.8798828125
        },
        {
            "start_logit": 1.3154296875,
            "end_logit": 9.4453125,
            "text": "acute (within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 0.104248046875
        },
        {
            "start_logit": -0.65966796875,
            "end_logit": 9.4453125,
            "text": "dissection",
            "probability": 0.01454925537109375
        },
        {
            "start_logit": -2.888671875,
            "end_logit": 9.4453125,
            "text": "artery dissection",
            "probability": 0.0015592575073242188
        },
        {
            "start_logit": -6.58984375,
            "end_logit": 9.4453125,
            "text": ") carotid and vertebral artery dissection",
            "probability": 3.8683414459228516e-05
        },
        {
            "start_logit": -7.37109375,
            "end_logit": 9.4453125,
            "text": "and vertebral artery dissection",
            "probability": 1.7702579498291016e-05
        },
        {
            "start_logit": -7.49609375,
            "end_logit": 9.4453125,
            "text": "vertebral artery dissection",
            "probability": 1.5616416931152344e-05
        },
        {
            "start_logit": -7.640625,
            "end_logit": 9.4453125,
            "text": "in acute (within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 1.3470649719238281e-05
        },
        {
            "start_logit": -7.64453125,
            "end_logit": 9.4453125,
            "text": "AIMS CADISS is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 1.33514404296875e-05
        },
        {
            "start_logit": -7.83203125,
            "end_logit": 9.4453125,
            "text": "(within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 1.1146068572998047e-05
        },
        {
            "start_logit": -7.84375,
            "end_logit": 9.4453125,
            "text": "prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 1.1026859283447266e-05
        },
        {
            "start_logit": -7.875,
            "end_logit": 9.4453125,
            "text": "multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 1.0669231414794922e-05
        },
        {
            "start_logit": -7.88671875,
            "end_logit": 9.4453125,
            "text": "randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 1.0609626770019531e-05
        },
        {
            "start_logit": -7.9453125,
            "end_logit": 9.4453125,
            "text": "CADISS is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 9.953975677490234e-06
        },
        {
            "start_logit": -7.9453125,
            "end_logit": 9.4453125,
            "text": "within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 9.953975677490234e-06
        },
        {
            "start_logit": -7.9765625,
            "end_logit": 9.4453125,
            "text": "trial in acute (within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 9.655952453613281e-06
        },
        {
            "start_logit": 3.44921875,
            "end_logit": -6.7890625,
            "text": "carotid",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 3.44921875,
            "end_logit": -6.9609375,
            "text": "carotid and vertebral artery dissection.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 1.3154296875,
            "end_logit": -6.1484375,
            "text": "acute",
            "probability": 0.0
        },
        {
            "start_logit": 1.3154296875,
            "end_logit": -6.7890625,
            "text": "acute (within 7 days of onset) carotid",
            "probability": 0.0
        }
    ],
    "5e4604d83f54159529000003_5": [
        {
            "start_logit": 3.328125,
            "end_logit": 9.0703125,
            "text": "carotid and vertebral artery dissection",
            "probability": 0.94287109375
        },
        {
            "start_logit": 0.268798828125,
            "end_logit": 9.0703125,
            "text": "acute (within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 0.044097900390625
        },
        {
            "start_logit": -1.5048828125,
            "end_logit": 9.0703125,
            "text": "dissection",
            "probability": 0.007518768310546875
        },
        {
            "start_logit": -1.853515625,
            "end_logit": 9.0703125,
            "text": "artery dissection",
            "probability": 0.00531005859375
        },
        {
            "start_logit": -6.46484375,
            "end_logit": 9.0703125,
            "text": ") carotid and vertebral artery dissection",
            "probability": 5.245208740234375e-05
        },
        {
            "start_logit": -7.01953125,
            "end_logit": 9.0703125,
            "text": "vertebral artery dissection",
            "probability": 3.0338764190673828e-05
        },
        {
            "start_logit": -7.07421875,
            "end_logit": 9.0703125,
            "text": "and vertebral artery dissection",
            "probability": 2.849102020263672e-05
        },
        {
            "start_logit": -7.50390625,
            "end_logit": 9.0703125,
            "text": "in acute (within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 1.8715858459472656e-05
        },
        {
            "start_logit": -7.72265625,
            "end_logit": 9.0703125,
            "text": "CADISS is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 1.5020370483398438e-05
        },
        {
            "start_logit": -7.765625,
            "end_logit": 9.0703125,
            "text": "prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 1.430511474609375e-05
        },
        {
            "start_logit": -7.7734375,
            "end_logit": 9.0703125,
            "text": "(within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 1.424551010131836e-05
        },
        {
            "start_logit": -7.83203125,
            "end_logit": 9.0703125,
            "text": "multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 1.3470649719238281e-05
        },
        {
            "start_logit": -7.8515625,
            "end_logit": 9.0703125,
            "text": "randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 1.3172626495361328e-05
        },
        {
            "start_logit": -7.90625,
            "end_logit": 9.0703125,
            "text": "within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 1.245737075805664e-05
        },
        {
            "start_logit": -7.93359375,
            "end_logit": 9.0703125,
            "text": "trial in acute (within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 1.2099742889404297e-05
        },
        {
            "start_logit": -7.9609375,
            "end_logit": 9.0703125,
            "text": "controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 1.1801719665527344e-05
        },
        {
            "start_logit": 3.328125,
            "end_logit": -6.703125,
            "text": "carotid and vertebral artery dissection.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 3.328125,
            "end_logit": -6.80859375,
            "text": "carotid",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 0.268798828125,
            "end_logit": -6.703125,
            "text": "acute (within 7 days of onset) carotid and vertebral artery dissection.",
            "probability": 0.0
        },
        {
            "start_logit": 0.268798828125,
            "end_logit": -6.734375,
            "text": "acute",
            "probability": 0.0
        }
    ],
    "56c073fcef6e394741000020_1": [
        {
            "start_logit": 8.3125,
            "end_logit": 6.83203125,
            "text": "Spermidine protects against \u03b1-synuclein neurotoxicity.",
            "probability": 0.9990234375
        },
        {
            "start_logit": 1.4189453125,
            "end_logit": 6.83203125,
            "text": ".",
            "probability": 0.0010166168212890625
        },
        {
            "start_logit": 8.3125,
            "end_logit": -3.1875,
            "text": "Spermidine",
            "probability": 4.464387893676758e-05
        },
        {
            "start_logit": 8.3125,
            "end_logit": -5.4375,
            "text": "Spermidine protects",
            "probability": 4.708766937255859e-06
        },
        {
            "start_logit": 8.3125,
            "end_logit": -6.8203125,
            "text": "Spermidine protects against \u03b1-synuclein neurotoxicity",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": 8.3125,
            "end_logit": -6.83203125,
            "text": "Spermidine protects against",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": 8.3125,
            "end_logit": -7.375,
            "text": "Spermidine protects against \u03b1-synuclein",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -6.66015625,
            "end_logit": 6.83203125,
            "text": "synuclein neurotoxicity.",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.85546875,
            "end_logit": 6.83203125,
            "text": "\u03b1-synuclein neurotoxicity.",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.93359375,
            "end_logit": 6.83203125,
            "text": "against \u03b1-synuclein neurotoxicity.",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.0390625,
            "end_logit": 6.83203125,
            "text": "protects against \u03b1-synuclein neurotoxicity.",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.09375,
            "end_logit": 6.83203125,
            "text": "neurotoxicity.",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.31640625,
            "end_logit": 6.83203125,
            "text": "-synuclein neurotoxicity.",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.0390625,
            "end_logit": -5.4375,
            "text": "protects",
            "probability": 0.0
        },
        {
            "start_logit": -6.66015625,
            "end_logit": -6.8203125,
            "text": "synuclein neurotoxicity",
            "probability": 0.0
        },
        {
            "start_logit": -6.85546875,
            "end_logit": -6.8203125,
            "text": "\u03b1-synuclein neurotoxicity",
            "probability": 0.0
        },
        {
            "start_logit": -6.93359375,
            "end_logit": -6.8203125,
            "text": "against \u03b1-synuclein neurotoxicity",
            "probability": 0.0
        },
        {
            "start_logit": -6.93359375,
            "end_logit": -6.83203125,
            "text": "against",
            "probability": 0.0
        },
        {
            "start_logit": -7.0390625,
            "end_logit": -6.8203125,
            "text": "protects against \u03b1-synuclein neurotoxicity",
            "probability": 0.0
        },
        {
            "start_logit": -7.0390625,
            "end_logit": -6.83203125,
            "text": "protects against",
            "probability": 0.0
        }
    ],
    "56c073fcef6e394741000020_2": [
        {
            "start_logit": 3.34375,
            "end_logit": -1.748046875,
            "text": "Spermidine protects against \u03b1-synuclein neurotoxicity",
            "probability": 0.96875
        },
        {
            "start_logit": 3.34375,
            "end_logit": -5.75,
            "text": "Spermidine protects",
            "probability": 0.0177459716796875
        },
        {
            "start_logit": 3.34375,
            "end_logit": -6.625,
            "text": "Spermidine",
            "probability": 0.007396697998046875
        },
        {
            "start_logit": 3.34375,
            "end_logit": -7.453125,
            "text": "Spermidine protects against",
            "probability": 0.003231048583984375
        },
        {
            "start_logit": 3.34375,
            "end_logit": -7.5859375,
            "text": "Spermidine protects against \u03b1-synuclein",
            "probability": 0.0028285980224609375
        },
        {
            "start_logit": -6.58984375,
            "end_logit": -1.748046875,
            "text": "against \u03b1-synuclein neurotoxicity",
            "probability": 4.7147274017333984e-05
        },
        {
            "start_logit": -6.61328125,
            "end_logit": -1.748046875,
            "text": "synuclein neurotoxicity",
            "probability": 4.607439041137695e-05
        },
        {
            "start_logit": -6.640625,
            "end_logit": -1.748046875,
            "text": "protects against \u03b1-synuclein neurotoxicity",
            "probability": 4.470348358154297e-05
        },
        {
            "start_logit": -6.6953125,
            "end_logit": -1.748046875,
            "text": "\u03b1-synuclein neurotoxicity",
            "probability": 4.2319297790527344e-05
        },
        {
            "start_logit": -7.13671875,
            "end_logit": -1.748046875,
            "text": "-synuclein neurotoxicity",
            "probability": 2.7298927307128906e-05
        },
        {
            "start_logit": -8.1796875,
            "end_logit": -1.748046875,
            "text": "neurotoxicity",
            "probability": 9.59634780883789e-06
        },
        {
            "start_logit": -6.640625,
            "end_logit": -5.75,
            "text": "protects",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": -6.58984375,
            "end_logit": -7.453125,
            "text": "against",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.640625,
            "end_logit": -7.453125,
            "text": "protects against",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.58984375,
            "end_logit": -7.5859375,
            "text": "against \u03b1-synuclein",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.61328125,
            "end_logit": -7.5859375,
            "text": "synuclein",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.640625,
            "end_logit": -7.5859375,
            "text": "protects against \u03b1-synuclein",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.6953125,
            "end_logit": -7.5859375,
            "text": "\u03b1-synuclein",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.13671875,
            "end_logit": -7.5859375,
            "text": "-synuclein",
            "probability": 5.960464477539063e-08
        }
    ],
    "606074ab94d57fd87900003e_1": [
        {
            "start_logit": 9.9375,
            "end_logit": 9.734375,
            "text": "Rtpca",
            "probability": 1.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -1.2177734375,
            "text": "Rt",
            "probability": 1.7523765563964844e-05
        },
        {
            "start_logit": -1.3486328125,
            "end_logit": 9.734375,
            "text": "a",
            "probability": 1.2516975402832031e-05
        },
        {
            "start_logit": -5.7734375,
            "end_logit": 9.734375,
            "text": "pca",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.9375,
            "end_logit": -6.58984375,
            "text": "Rtpc",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.9375,
            "end_logit": -7.9609375,
            "text": "Rtpca: an R package for differential thermal proximity coaggregation analysis.",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -8.0390625,
            "text": "Rtpca:",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -8.0703125,
            "text": "Rtpca: an",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -8.078125,
            "text": "Rtpca: an R package",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -8.109375,
            "text": "Rtpca: an R",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -8.1484375,
            "text": "Rtpca: an R package for differential thermal proximity coaggregation analysis",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -8.171875,
            "text": "Rtpca: an R package for differential thermal proximity coaggr",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -8.171875,
            "text": "Rtpca: an R package for differential thermal proximity coaggreg",
            "probability": 0.0
        },
        {
            "start_logit": -1.3486328125,
            "end_logit": -7.9609375,
            "text": "a: an R package for differential thermal proximity coaggregation analysis.",
            "probability": 0.0
        },
        {
            "start_logit": -1.3486328125,
            "end_logit": -8.0390625,
            "text": "a:",
            "probability": 0.0
        },
        {
            "start_logit": -1.3486328125,
            "end_logit": -8.0703125,
            "text": "a: an",
            "probability": 0.0
        },
        {
            "start_logit": -1.3486328125,
            "end_logit": -8.078125,
            "text": "a: an R package",
            "probability": 0.0
        },
        {
            "start_logit": -1.3486328125,
            "end_logit": -8.109375,
            "text": "a: an R",
            "probability": 0.0
        },
        {
            "start_logit": -1.3486328125,
            "end_logit": -8.1484375,
            "text": "a: an R package for differential thermal proximity coaggregation analysis",
            "probability": 0.0
        },
        {
            "start_logit": -1.3486328125,
            "end_logit": -8.171875,
            "text": "a: an R package for differential thermal proximity coaggr",
            "probability": 0.0
        }
    ],
    "606074ab94d57fd87900003e_2": [
        {
            "start_logit": 9.9296875,
            "end_logit": 9.7734375,
            "text": "Rtpca",
            "probability": 1.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -1.23046875,
            "text": "Rt",
            "probability": 1.6689300537109375e-05
        },
        {
            "start_logit": -1.1943359375,
            "end_logit": 9.7734375,
            "text": "a",
            "probability": 1.4722347259521484e-05
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -6.14453125,
            "text": "Rtpc",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.06640625,
            "end_logit": 9.7734375,
            "text": "pca",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -7.5,
            "text": "Rtpca is",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -7.93359375,
            "text": "Rtpca is an R package",
            "probability": 0.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -7.98046875,
            "text": "Rtpca is an R package implementing methods for inferring protein-protein interactions based on thermal proteome profiling experiments of a single condition or in a",
            "probability": 0.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -8.0078125,
            "text": "Rtpca is an R package implementing methods for inferring protein-protein interactions based on thermal proteome profiling experiments of a single condition or in",
            "probability": 0.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -8.0390625,
            "text": "Rtpca is an R package implementing methods for inferring protein-protein interactions based on thermal proteome profiling experiments of",
            "probability": 0.0
        },
        {
            "start_logit": -1.1943359375,
            "end_logit": -7.5,
            "text": "a is",
            "probability": 0.0
        },
        {
            "start_logit": -1.1943359375,
            "end_logit": -7.93359375,
            "text": "a is an R package",
            "probability": 0.0
        },
        {
            "start_logit": -1.1943359375,
            "end_logit": -7.98046875,
            "text": "a is an R package implementing methods for inferring protein-protein interactions based on thermal proteome profiling experiments of a single condition or in a",
            "probability": 0.0
        },
        {
            "start_logit": -1.1943359375,
            "end_logit": -8.0078125,
            "text": "a is an R package implementing methods for inferring protein-protein interactions based on thermal proteome profiling experiments of a single condition or in",
            "probability": 0.0
        },
        {
            "start_logit": -1.1943359375,
            "end_logit": -8.0390625,
            "text": "a is an R package implementing methods for inferring protein-protein interactions based on thermal proteome profiling experiments of",
            "probability": 0.0
        },
        {
            "start_logit": -6.06640625,
            "end_logit": -6.14453125,
            "text": "pc",
            "probability": 0.0
        },
        {
            "start_logit": -6.06640625,
            "end_logit": -7.5,
            "text": "pca is",
            "probability": 0.0
        },
        {
            "start_logit": -6.06640625,
            "end_logit": -7.93359375,
            "text": "pca is an R package",
            "probability": 0.0
        },
        {
            "start_logit": -6.06640625,
            "end_logit": -7.98046875,
            "text": "pca is an R package implementing methods for inferring protein-protein interactions based on thermal proteome profiling experiments of a single condition or in a",
            "probability": 0.0
        },
        {
            "start_logit": -6.06640625,
            "end_logit": -8.0078125,
            "text": "pca is an R package implementing methods for inferring protein-protein interactions based on thermal proteome profiling experiments of a single condition or in",
            "probability": 0.0
        }
    ],
    "513ce494bee46bd34c000009_1": [
        {
            "start_logit": 9.7578125,
            "end_logit": 9.703125,
            "text": "polycystic kidney disease",
            "probability": 1.0
        },
        {
            "start_logit": -1.37890625,
            "end_logit": 9.703125,
            "text": "disease",
            "probability": 1.4483928680419922e-05
        },
        {
            "start_logit": 9.7578125,
            "end_logit": -1.6591796875,
            "text": "polycystic",
            "probability": 1.1563301086425781e-05
        },
        {
            "start_logit": 9.7578125,
            "end_logit": -5.24609375,
            "text": "polycystic kidney disease (PKD",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.76171875,
            "end_logit": 9.703125,
            "text": "recessive polycystic kidney disease",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.7578125,
            "end_logit": -6.875,
            "text": "polycystic kidney",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.94140625,
            "end_logit": 9.703125,
            "text": "kidney disease",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.09375,
            "end_logit": 9.703125,
            "text": "autosomal recessive polycystic kidney disease",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.7578125,
            "end_logit": -7.25390625,
            "text": "polycystic kidney disease (PKD)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.22265625,
            "end_logit": 9.703125,
            "text": "of autosomal recessive polycystic kidney disease",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.7578125,
            "end_logit": -7.3359375,
            "text": "polycystic kidney disease (PK",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.7578125,
            "end_logit": -7.421875,
            "text": "polycystic kidney disease (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6328125,
            "end_logit": 9.703125,
            "text": "development of autosomal recessive polycystic kidney disease",
            "probability": 0.0
        },
        {
            "start_logit": -7.87890625,
            "end_logit": 9.703125,
            "text": "is accompanied by development of autosomal recessive polycystic kidney disease",
            "probability": 0.0
        },
        {
            "start_logit": -7.94921875,
            "end_logit": 9.703125,
            "text": "accompanied by development of autosomal recessive polycystic kidney disease",
            "probability": 0.0
        },
        {
            "start_logit": -7.96484375,
            "end_logit": 9.703125,
            "text": "malformation of primary cilia, and in the collecting ducts of kidney tubules this is accompanied by development of autosomal recessive polycystic kidney disease",
            "probability": 0.0
        },
        {
            "start_logit": -7.984375,
            "end_logit": 9.703125,
            "text": "kidney tubules this is accompanied by development of autosomal recessive polycystic kidney disease",
            "probability": 0.0
        },
        {
            "start_logit": -7.9921875,
            "end_logit": 9.703125,
            "text": "by development of autosomal recessive polycystic kidney disease",
            "probability": 0.0
        },
        {
            "start_logit": -8.015625,
            "end_logit": 9.703125,
            "text": "primary cilia, and in the collecting ducts of kidney tubules this is accompanied by development of autosomal recessive polycystic kidney disease",
            "probability": 0.0
        },
        {
            "start_logit": -8.0859375,
            "end_logit": 9.703125,
            "text": "tubules this is accompanied by development of autosomal recessive polycystic kidney disease",
            "probability": 0.0
        }
    ],
    "5a885daa61bb38fb24000018_1": [
        {
            "start_logit": 4.12890625,
            "end_logit": 0.59716796875,
            "text": "Asp(D)-Glu-(E)-Ala(A)-Asp(D) which is part of a more extended motif",
            "probability": 0.422119140625
        },
        {
            "start_logit": 4.12890625,
            "end_logit": 0.39990234375,
            "text": "Asp(D)-Glu-(E)-Ala(A)-Asp(D) which is part of a more extended motif.",
            "probability": 0.345947265625
        },
        {
            "start_logit": 3.0703125,
            "end_logit": 0.400146484375,
            "text": "RNA helicases that have been implicated in cellular processes involving alteration of RNA secondary structure, such as translation initiation and splicing.",
            "probability": 0.1202392578125
        },
        {
            "start_logit": 4.12890625,
            "end_logit": -1.5400390625,
            "text": "Asp(D)-Glu-(E)-Ala(A)-Asp(D)",
            "probability": 0.049835205078125
        },
        {
            "start_logit": 3.0703125,
            "end_logit": -0.97998046875,
            "text": "RNA helicase",
            "probability": 0.03021240234375
        },
        {
            "start_logit": 4.12890625,
            "end_logit": -2.724609375,
            "text": "Asp(D)-Glu-(E)-Ala(A)-Asp(D) which",
            "probability": 0.015228271484375
        },
        {
            "start_logit": 4.12890625,
            "end_logit": -4.1640625,
            "text": "Asp(D)-Glu-(E)-Ala(A)-Asp",
            "probability": 0.0036106109619140625
        },
        {
            "start_logit": 4.12890625,
            "end_logit": -4.33984375,
            "text": "Asp",
            "probability": 0.0030269622802734375
        },
        {
            "start_logit": 3.0703125,
            "end_logit": -3.845703125,
            "text": "RNA helicases that have been implicated in cellular processes involving alteration of RNA secondary structure, such as translation initiation and splicing. These proteins share eight conserved amino acid motifs",
            "probability": 0.0017242431640625
        },
        {
            "start_logit": 3.0703125,
            "end_logit": -4.00390625,
            "text": "RNA helicases that have been implicated in cellular processes involving alteration of RNA secondary structure, such as translation initiation and splicing. These proteins share",
            "probability": 0.0014696121215820312
        },
        {
            "start_logit": 4.12890625,
            "end_logit": -5.09765625,
            "text": "Asp(D)-Glu-(E)-Ala(A)-Asp(D",
            "probability": 0.0014181137084960938
        },
        {
            "start_logit": 3.0703125,
            "end_logit": -4.33984375,
            "text": "RNA helicases that have been implicated in cellular processes involving alteration of RNA secondary structure, such as translation initiation and splicing. These proteins share eight conserved amino acid motifs, including Asp",
            "probability": 0.0010509490966796875
        },
        {
            "start_logit": -1.9111328125,
            "end_logit": 0.400146484375,
            "text": "DEAD box proteins are putative RNA helicases that have been implicated in cellular processes involving alteration of RNA secondary structure, such as translation initiation and splicing.",
            "probability": 0.0008244514465332031
        },
        {
            "start_logit": -2.57421875,
            "end_logit": 0.59716796875,
            "text": ". These proteins share eight conserved amino acid motifs, including Asp(D)-Glu-(E)-Ala(A)-Asp(D) which is part of a more extended motif",
            "probability": 0.0005178451538085938
        },
        {
            "start_logit": 4.12890625,
            "end_logit": -6.234375,
            "text": "Asp(D)-Glu-(E)-Ala(A)-Asp(",
            "probability": 0.0004553794860839844
        },
        {
            "start_logit": 3.0703125,
            "end_logit": -5.20703125,
            "text": "RNA helicases that have been implicated in cellular processes involving alteration of RNA secondary structure, such as translation initiation and splicing. These proteins share eight",
            "probability": 0.0004410743713378906
        },
        {
            "start_logit": -2.57421875,
            "end_logit": 0.400146484375,
            "text": ".",
            "probability": 0.0004258155822753906
        },
        {
            "start_logit": -2.57421875,
            "end_logit": 0.39990234375,
            "text": ". These proteins share eight conserved amino acid motifs, including Asp(D)-Glu-(E)-Ala(A)-Asp(D) which is part of a more extended motif.",
            "probability": 0.0004258155822753906
        },
        {
            "start_logit": -2.57421875,
            "end_logit": 0.39990234375,
            "text": ".",
            "probability": 0.0004258155822753906
        },
        {
            "start_logit": -3.013671875,
            "end_logit": 0.59716796875,
            "text": "including Asp(D)-Glu-(E)-Ala(A)-Asp(D) which is part of a more extended motif",
            "probability": 0.0003342628479003906
        }
    ],
    "52b2e409f828ad283c00000e_1": [
        {
            "start_logit": 7.96484375,
            "end_logit": 8.4375,
            "text": "schizophrenia",
            "probability": 1.0
        },
        {
            "start_logit": -7.68359375,
            "end_logit": 8.4375,
            "text": "with schizophrenia",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.94921875,
            "end_logit": 8.4375,
            "text": "To describe the frequency and trends in the use of antipsychotics for adults with schizophrenia",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.95703125,
            "end_logit": 8.4375,
            "text": "use of antipsychotics for adults with schizophrenia",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.96875,
            "end_logit": 8.4375,
            "text": "the use of antipsychotics for adults with schizophrenia",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.97265625,
            "end_logit": 8.4375,
            "text": "antipsychotics for adults with schizophrenia",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.9921875,
            "end_logit": 8.4375,
            "text": "of antipsychotics for adults with schizophrenia",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.015625,
            "end_logit": 8.4375,
            "text": "the frequency and trends in the use of antipsychotics for adults with schizophrenia",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.03125,
            "end_logit": 8.4375,
            "text": "in the use of antipsychotics for adults with schizophrenia",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.03125,
            "end_logit": 8.4375,
            "text": "frequency and trends in the use of antipsychotics for adults with schizophrenia",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.0390625,
            "end_logit": 8.4375,
            "text": "for adults with schizophrenia",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.0546875,
            "end_logit": 8.4375,
            "text": "adults with schizophrenia",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.0546875,
            "end_logit": 8.4375,
            "text": "describe the frequency and trends in the use of antipsychotics for adults with schizophrenia",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.96484375,
            "end_logit": -7.81640625,
            "text": "schizophrenia in Canada from 2005 to 2009.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.96484375,
            "end_logit": -8.0078125,
            "text": "schizophrenia in Canada from",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.96484375,
            "end_logit": -8.015625,
            "text": "schizophrenia in",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.96484375,
            "end_logit": -8.0625,
            "text": "schizophrenia in Canada",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.87109375,
            "end_logit": -7.81640625,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.68359375,
            "end_logit": -7.81640625,
            "text": "with schizophrenia in Canada from 2005 to 2009.",
            "probability": 0.0
        },
        {
            "start_logit": -7.68359375,
            "end_logit": -8.0078125,
            "text": "with schizophrenia in Canada from",
            "probability": 0.0
        }
    ],
    "52b2e409f828ad283c00000e_2": [
        {
            "start_logit": 8.28125,
            "end_logit": 8.0859375,
            "text": "schizophrenia",
            "probability": 1.0
        },
        {
            "start_logit": 8.28125,
            "end_logit": -7.45703125,
            "text": "schizophrenia was listed as the indication. RESULTS: First-generation antipsychotic (FGA) recommendations for adults with schizophrenia increased by 38% between 2005 and 2009, from 329 380 to 454 960 recommendations.",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.28125,
            "end_logit": -7.45703125,
            "text": "schizophrenia was listed as the indication.",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.28125,
            "end_logit": -7.6015625,
            "text": "schizophrenia was listed as the indication. RESULTS: First-generation antipsychotic (FGA) recommendations for adults with schizophrenia increased by 38",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.28125,
            "end_logit": -7.6953125,
            "text": "schizophrenia was listed as the indication. RESULTS: First-generation antipsychotic (FGA) recommendations for adults with schizophrenia increased by 38% between 2005 and 2009, from 329 380 to 454 96",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.28125,
            "end_logit": -7.703125,
            "text": "schizophrenia was listed as the indication. RESULTS: First-generation antipsychotic (FGA) recommendations for adults with schizophrenia increased by 38%",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.28125,
            "end_logit": -7.74609375,
            "text": "schizophrenia was listed as the indication. RESULTS: First-generation antipsychotic (FGA) recommendations for adults with schizophrenia increased by 38% between 2005 and 2009, from 329 380 to",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.28125,
            "end_logit": -7.84375,
            "text": "schizophrenia was listed as the indication. RESULTS: First-generation antipsychotic (FGA) recommendations for adults with schizophrenia increased by",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.28125,
            "end_logit": -7.8671875,
            "text": "schizophrenia was listed as the indication. RESULTS: First-generation antipsychotic (FGA) recommendations for adults with schizophrenia increased by 38% between 2005 and 2009, from 329 380 to 454",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.28125,
            "end_logit": -7.90625,
            "text": "schizophrenia was listed as",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.28125,
            "end_logit": -7.9140625,
            "text": "schizophrenia was listed as the indication. RESULTS: First-generation antipsychotic (FGA) recommendations for adults with schizophrenia",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.28125,
            "end_logit": -7.9609375,
            "text": "schizophrenia was listed as the indication. RESULTS: First-generation antipsychotic (FGA) recommendations for adults with schizophrenia increased",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.28125,
            "end_logit": -7.96484375,
            "text": "schizophrenia was listed as the indication. RESULTS: First-generation antipsychotic (FGA) recommendations for adults with schizophrenia increased by 38% between 2005 and 2009, from 329 380 to 454 960",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.28125,
            "end_logit": -8.015625,
            "text": "schizophrenia was listed as the indication. RESULTS: First-generation antipsychotic (FGA) recommendations for adults with schizophrenia increased by 38% between 2005 and 2009",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.28125,
            "end_logit": -8.0234375,
            "text": "schizophrenia was listed as the indication. RESULTS: First-generation antipsychotic (FGA) recommendations for adults with schizophrenia increased by 38% between 2005 and 2009, from 329 380",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.28125,
            "end_logit": -8.03125,
            "text": "schizophrenia was",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.84375,
            "end_logit": 8.0859375,
            "text": "which schizophrenia",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.28125,
            "end_logit": -8.046875,
            "text": "schizophrenia was listed as the indication. RESULTS: First-generation antipsychotic (FGA) recommendations for adults with schizophrenia increased by 38% between 2005 and",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.94921875,
            "end_logit": 8.0859375,
            "text": "Antipsychotic recommendations were estimated using CDTI data in which schizophrenia",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.6640625,
            "end_logit": -7.45703125,
            "text": ". RESULTS: First-generation antipsychotic (FGA) recommendations for adults with schizophrenia increased by 38% between 2005 and 2009, from 329 380 to 454 960 recommendations.",
            "probability": 0.0
        }
    ],
    "52b2e409f828ad283c00000e_3": [
        {
            "start_logit": 7.9921875,
            "end_logit": 8.3046875,
            "text": "schizophrenia",
            "probability": 1.0
        },
        {
            "start_logit": -6.80859375,
            "end_logit": 8.3046875,
            "text": ". Its best indication seems to be paranoid schizophrenia",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.390625,
            "end_logit": 8.3046875,
            "text": "oid schizophrenia",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.8828125,
            "end_logit": 8.3046875,
            "text": "paranoid schizophrenia",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.9921875,
            "end_logit": -7.6328125,
            "text": "schizophrenia, although some data suggest bipolar action.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.984375,
            "end_logit": 8.3046875,
            "text": "be paranoid schizophrenia",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.98828125,
            "end_logit": 8.3046875,
            "text": "Its best indication seems to be paranoid schizophrenia",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.03125,
            "end_logit": 8.3046875,
            "text": "indication seems to be paranoid schizophrenia",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.9921875,
            "end_logit": -8.03125,
            "text": "schizophrenia, although",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.9921875,
            "end_logit": -8.0625,
            "text": "schizophrenia, although some data suggest",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.9921875,
            "end_logit": -8.0703125,
            "text": "schizophrenia, although some",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.9921875,
            "end_logit": -8.078125,
            "text": "schizophrenia,",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.9921875,
            "end_logit": -8.0859375,
            "text": "schizophrenia, although some data",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.80859375,
            "end_logit": -7.6328125,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -6.80859375,
            "end_logit": -7.6328125,
            "text": ". Its pharmacological profile is close to that of clozapine: it has dopamine (D2), histamine (H1), serotonin (5-HT2) and adrenergic (alpha 1)-blocking activities.",
            "probability": 0.0
        },
        {
            "start_logit": -6.80859375,
            "end_logit": -7.6328125,
            "text": ". Its best indication seems to be paranoid schizophrenia, although some data suggest bipolar action.",
            "probability": 0.0
        },
        {
            "start_logit": -6.80859375,
            "end_logit": -7.6328125,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -6.80859375,
            "end_logit": -7.6328125,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -6.80859375,
            "end_logit": -8.03125,
            "text": ". Its best indication seems to be paranoid schizophrenia, although",
            "probability": 0.0
        },
        {
            "start_logit": -6.80859375,
            "end_logit": -8.0703125,
            "text": ". Its pharmacological profile is close to",
            "probability": 0.0
        }
    ],
    "6252f496e764a53204000020_1": [
        {
            "start_logit": 9.8671875,
            "end_logit": 6.5625,
            "text": "ABCG1 is an ATP binding cassette (ABC) transporter that removes excess cholesterol from peripheral tissues.",
            "probability": 0.8759765625
        },
        {
            "start_logit": 9.8671875,
            "end_logit": 4.609375,
            "text": "ABCG1 is an ATP binding cassette (ABC) transporter",
            "probability": 0.123291015625
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -1.2451171875,
            "text": "ABC",
            "probability": 0.00035452842712402344
        },
        {
            "start_logit": 1.15625,
            "end_logit": 6.5625,
            "text": ".",
            "probability": 0.00014317035675048828
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -6.1015625,
            "text": "ABCG1 is an ATP binding cassette (ABC",
            "probability": 2.7418136596679688e-06
        },
        {
            "start_logit": -2.96484375,
            "end_logit": 6.5625,
            "text": "transporter that removes excess cholesterol from peripheral tissues.",
            "probability": 2.3245811462402344e-06
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -6.296875,
            "text": "ABCG1 is an ATP binding cassette",
            "probability": 2.2649765014648438e-06
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -6.625,
            "text": "ABCG1 is an ATP binding cassette (ABC) transporter that",
            "probability": 1.6093254089355469e-06
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -6.64453125,
            "text": "ABCG1 is",
            "probability": 1.5497207641601562e-06
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -6.9296875,
            "text": "ABCG1 is an ATP binding cassette (ABC) transporter that removes excess cholesterol",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -7.0546875,
            "text": "ABCG1 is an ATP binding cassette (ABC) transporter that removes excess cholesterol from peripheral tissues",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -7.08984375,
            "text": "ABCG1 is an",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -7.15234375,
            "text": "ABCG1",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -7.21484375,
            "text": "ABCG1 is an ATP binding cassette (",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -7.24609375,
            "text": "ABCG1 is an ATP binding cassette (ABC) transporter that removes",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -7.2890625,
            "text": "ABCG1 is an ATP binding cassette (ABC) transporter that removes excess cholesterol from",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -7.30078125,
            "text": "ABCG1 is an ATP binding cassette (ABC)",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -7.390625,
            "text": "ABCG1 is an ATP binding",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -7.4296875,
            "text": "ABCG1 is an ATP binding cassette (ABC) transporter that removes excess",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -2.96484375,
            "end_logit": 4.609375,
            "text": "transporter",
            "probability": 2.980232238769531e-07
        }
    ],
    "601ee4c61cb411341a000066_1": [
        {
            "start_logit": 9.8125,
            "end_logit": 9.7421875,
            "text": "1967",
            "probability": 1.0
        },
        {
            "start_logit": -1.1953125,
            "end_logit": 9.7421875,
            "text": "7",
            "probability": 1.6450881958007812e-05
        },
        {
            "start_logit": 9.8125,
            "end_logit": -1.4287109375,
            "text": "196",
            "probability": 1.3947486877441406e-05
        },
        {
            "start_logit": -6.72265625,
            "end_logit": 9.7421875,
            "text": "in 1967",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6484375,
            "end_logit": 9.7421875,
            "text": "the first human heart transplant in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -7.90625,
            "end_logit": 9.7421875,
            "text": "first human heart transplant in 1967",
            "probability": 0.0
        },
        {
            "start_logit": 9.8125,
            "end_logit": -7.984375,
            "text": "1967 was",
            "probability": 0.0
        },
        {
            "start_logit": 9.8125,
            "end_logit": -8.046875,
            "text": "1967 was performed using a deceased donor heart,",
            "probability": 0.0
        },
        {
            "start_logit": -7.98046875,
            "end_logit": 9.7421875,
            "text": "human heart transplant in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.015625,
            "end_logit": 9.7421875,
            "text": "heart transplant in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.0625,
            "end_logit": 9.7421875,
            "text": "transplant in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -6.72265625,
            "end_logit": -1.4287109375,
            "text": "in 196",
            "probability": 0.0
        },
        {
            "start_logit": -7.6484375,
            "end_logit": -1.4287109375,
            "text": "the first human heart transplant in 196",
            "probability": 0.0
        },
        {
            "start_logit": -1.1953125,
            "end_logit": -7.984375,
            "text": "7 was",
            "probability": 0.0
        },
        {
            "start_logit": -1.1953125,
            "end_logit": -8.046875,
            "text": "7 was performed using a deceased donor heart,",
            "probability": 0.0
        },
        {
            "start_logit": -7.90625,
            "end_logit": -1.4287109375,
            "text": "first human heart transplant in 196",
            "probability": 0.0
        },
        {
            "start_logit": -7.98046875,
            "end_logit": -1.4287109375,
            "text": "human heart transplant in 196",
            "probability": 0.0
        },
        {
            "start_logit": -8.015625,
            "end_logit": -1.4287109375,
            "text": "heart transplant in 196",
            "probability": 0.0
        },
        {
            "start_logit": -8.0625,
            "end_logit": -1.4287109375,
            "text": "transplant in 196",
            "probability": 0.0
        },
        {
            "start_logit": -6.72265625,
            "end_logit": -7.984375,
            "text": "in 1967 was",
            "probability": 0.0
        }
    ],
    "601ee4c61cb411341a000066_2": [
        {
            "start_logit": 7.22265625,
            "end_logit": 9.6953125,
            "text": "1967",
            "probability": 0.9697265625
        },
        {
            "start_logit": 3.76171875,
            "end_logit": 9.6953125,
            "text": "In 1967",
            "probability": 0.03021240234375
        },
        {
            "start_logit": -1.25,
            "end_logit": 9.6953125,
            "text": "7",
            "probability": 0.00020194053649902344
        },
        {
            "start_logit": 7.22265625,
            "end_logit": -3.666015625,
            "text": "1967, Christian Barnard performed the first successful human-to-human heart transplant.",
            "probability": 1.4901161193847656e-06
        },
        {
            "start_logit": 7.22265625,
            "end_logit": -4.41015625,
            "text": "196",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 7.22265625,
            "end_logit": -5.75,
            "text": "1967, Christian Barnard",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 3.76171875,
            "end_logit": -3.666015625,
            "text": "In 1967, Christian Barnard performed the first successful human-to-human heart transplant.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.22265625,
            "end_logit": -7.546875,
            "text": "1967, Christian Barnard performed",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 3.76171875,
            "end_logit": -4.41015625,
            "text": "In 196",
            "probability": 0.0
        },
        {
            "start_logit": 7.22265625,
            "end_logit": -7.92578125,
            "text": "1967, Christian Barnar",
            "probability": 0.0
        },
        {
            "start_logit": 7.22265625,
            "end_logit": -7.92578125,
            "text": "1967, Christian Barnard performed the",
            "probability": 0.0
        },
        {
            "start_logit": 7.22265625,
            "end_logit": -7.9609375,
            "text": "1967, Christian Barnard performed the first successful human-to",
            "probability": 0.0
        },
        {
            "start_logit": 3.76171875,
            "end_logit": -5.75,
            "text": "In 1967, Christian Barnard",
            "probability": 0.0
        },
        {
            "start_logit": 3.76171875,
            "end_logit": -5.78125,
            "text": "In",
            "probability": 0.0
        },
        {
            "start_logit": 3.76171875,
            "end_logit": -7.546875,
            "text": "In 1967, Christian Barnard performed",
            "probability": 0.0
        },
        {
            "start_logit": 3.76171875,
            "end_logit": -7.92578125,
            "text": "In 1967, Christian Barnar",
            "probability": 0.0
        },
        {
            "start_logit": 3.76171875,
            "end_logit": -7.92578125,
            "text": "In 1967, Christian Barnard performed the",
            "probability": 0.0
        },
        {
            "start_logit": 3.76171875,
            "end_logit": -7.9609375,
            "text": "In 1967, Christian Barnard performed the first successful human-to",
            "probability": 0.0
        },
        {
            "start_logit": -1.25,
            "end_logit": -3.666015625,
            "text": "7, Christian Barnard performed the first successful human-to-human heart transplant.",
            "probability": 0.0
        },
        {
            "start_logit": -2.197265625,
            "end_logit": -3.666015625,
            "text": "Christian Barnard performed the first successful human-to-human heart transplant.",
            "probability": 0.0
        }
    ],
    "601ee4c61cb411341a000066_3": [
        {
            "start_logit": 9.9296875,
            "end_logit": 9.734375,
            "text": "1967",
            "probability": 1.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -1.0556640625,
            "text": "196",
            "probability": 2.0802021026611328e-05
        },
        {
            "start_logit": -1.1669921875,
            "end_logit": 9.734375,
            "text": "7",
            "probability": 1.531839370727539e-05
        },
        {
            "start_logit": -3.224609375,
            "end_logit": 9.734375,
            "text": "Christiaan Barnard in 1967",
            "probability": 1.9669532775878906e-06
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -6.07421875,
            "text": "1967, there has been substantial progress in the field of heart transplantation, especially over the last several decades.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.2265625,
            "end_logit": 9.734375,
            "text": "in 1967",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.8046875,
            "end_logit": 9.734375,
            "text": "by Christiaan Barnard in 1967",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -7.63671875,
            "text": "1967, there has been substantial progress in the field of heart transplantation, especially over the last several decades",
            "probability": 0.0
        },
        {
            "start_logit": -7.4453125,
            "end_logit": 9.734375,
            "text": "n Barnard in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -7.5,
            "end_logit": 9.734375,
            "text": "Since the first successful human heart transplant performed by Christiaan Barnard in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -7.50390625,
            "end_logit": 9.734375,
            "text": "Barnard in 1967",
            "probability": 0.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -7.828125,
            "text": "1967, there has been substantial progress in the field of heart transplantation, especially over the last several",
            "probability": 0.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -7.86328125,
            "text": "1967, there has been substantial progress in the field of heart transplantation, especially over the last",
            "probability": 0.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -7.9140625,
            "text": "1967, there has been substantial progress in the field of heart transplantation,",
            "probability": 0.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -7.92578125,
            "text": "1967, there has been",
            "probability": 0.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -7.93359375,
            "text": "1967,",
            "probability": 0.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -7.9453125,
            "text": "1967, there has been substantial progress in the field of heart transplantation, especially over the",
            "probability": 0.0
        },
        {
            "start_logit": -7.75390625,
            "end_logit": 9.734375,
            "text": "nard in 1967",
            "probability": 0.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -7.96484375,
            "text": "1967, there has been substantial",
            "probability": 0.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -7.96484375,
            "text": "1967, there has been substantial progress in the field of heart transplantation, especially",
            "probability": 0.0
        }
    ],
    "601ee4c61cb411341a000066_4": [
        {
            "start_logit": 7.4453125,
            "end_logit": 9.359375,
            "text": "1967",
            "probability": 0.96240234375
        },
        {
            "start_logit": 4.20703125,
            "end_logit": 9.359375,
            "text": "December 3rd, 1967",
            "probability": 0.037322998046875
        },
        {
            "start_logit": -1.78515625,
            "end_logit": 9.359375,
            "text": "7",
            "probability": 9.393692016601562e-05
        },
        {
            "start_logit": -6.08984375,
            "end_logit": 9.359375,
            "text": "on December 3rd, 1967",
            "probability": 1.2516975402832031e-06
        },
        {
            "start_logit": -6.2265625,
            "end_logit": 9.359375,
            "text": ", 1967",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": 7.4453125,
            "end_logit": -4.36328125,
            "text": "196",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": 7.4453125,
            "end_logit": -4.6640625,
            "text": "1967.",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": -6.75390625,
            "end_logit": 9.359375,
            "text": "Christiaan ('Chris') Barnard at Groote Schuur Hospital in Cape Town on December 3rd, 1967",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -6.92578125,
            "end_logit": 9.359375,
            "text": ", Christiaan ('Chris') Barnard at Groote Schuur Hospital in Cape Town on December 3rd, 1967",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -7.33984375,
            "end_logit": 9.359375,
            "text": "at Groote Schuur Hospital in Cape Town on December 3rd, 1967",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.37890625,
            "end_logit": 9.359375,
            "text": "by the South African surgeon, Christiaan ('Chris') Barnard at Groote Schuur Hospital in Cape Town on December 3rd, 1967",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.68359375,
            "end_logit": 9.359375,
            "text": "Chris') Barnard at Groote Schuur Hospital in Cape Town on December 3rd, 1967",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 4.20703125,
            "end_logit": -4.36328125,
            "text": "December 3rd, 196",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 4.20703125,
            "end_logit": -4.55078125,
            "text": "December",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 4.20703125,
            "end_logit": -4.6640625,
            "text": "December 3rd, 1967.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 4.20703125,
            "end_logit": -6.296875,
            "text": "December 3rd",
            "probability": 0.0
        },
        {
            "start_logit": -1.78515625,
            "end_logit": -4.6640625,
            "text": "7.",
            "probability": 0.0
        },
        {
            "start_logit": -1.9580078125,
            "end_logit": -5.3203125,
            "text": "50th anniversary",
            "probability": 0.0
        },
        {
            "start_logit": -1.9580078125,
            "end_logit": -7.3828125,
            "text": "50th",
            "probability": 0.0
        },
        {
            "start_logit": -1.9580078125,
            "end_logit": -7.58984375,
            "text": "50th anniversary of the first human heart transplant that had",
            "probability": 0.0
        }
    ],
    "601ee4c61cb411341a000066_5": [
        {
            "start_logit": 7.39453125,
            "end_logit": 9.5234375,
            "text": "1967",
            "probability": 0.990234375
        },
        {
            "start_logit": 2.796875,
            "end_logit": 9.5234375,
            "text": "December 1967",
            "probability": 0.0099334716796875
        },
        {
            "start_logit": -1.6875,
            "end_logit": 9.5234375,
            "text": "7",
            "probability": 0.00011217594146728516
        },
        {
            "start_logit": -6.33984375,
            "end_logit": 9.5234375,
            "text": "Christiaan Barnard in December 1967",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": 7.39453125,
            "end_logit": -4.34765625,
            "text": "196",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": -7.02734375,
            "end_logit": 9.5234375,
            "text": "in December 1967",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -7.19140625,
            "end_logit": 9.5234375,
            "text": "by Christiaan Barnard in December 1967",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -7.6171875,
            "end_logit": 9.5234375,
            "text": "n Barnard in December 1967",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.65234375,
            "end_logit": 9.5234375,
            "text": "istiaan Barnard in December 1967",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.70703125,
            "end_logit": 9.5234375,
            "text": "d in December 1967",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.7265625,
            "end_logit": 9.5234375,
            "text": "It has been 40 years since the first human-to-human heart transplant performed in South Africa by Christiaan Barnard in December 1967",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.74609375,
            "end_logit": 9.5234375,
            "text": "Barnard in December 1967",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.8203125,
            "end_logit": 9.5234375,
            "text": "in South Africa by Christiaan Barnard in December 1967",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.82421875,
            "end_logit": 9.5234375,
            "text": "South Africa by Christiaan Barnard in December 1967",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.84765625,
            "end_logit": 9.5234375,
            "text": "iaan Barnard in December 1967",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.859375,
            "end_logit": 9.5234375,
            "text": "first human-to-human heart transplant performed in South Africa by Christiaan Barnard in December 1967",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.87890625,
            "end_logit": 9.5234375,
            "text": "Africa by Christiaan Barnard in December 1967",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.88671875,
            "end_logit": 9.5234375,
            "text": "nard in December 1967",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 2.796875,
            "end_logit": -4.34765625,
            "text": "December 196",
            "probability": 0.0
        },
        {
            "start_logit": 2.796875,
            "end_logit": -6.15234375,
            "text": "December",
            "probability": 0.0
        }
    ],
    "601ee4c61cb411341a000066_6": [
        {
            "start_logit": 9.984375,
            "end_logit": 9.75,
            "text": "1967",
            "probability": 1.0
        },
        {
            "start_logit": 9.984375,
            "end_logit": -0.875,
            "text": "196",
            "probability": 2.4318695068359375e-05
        },
        {
            "start_logit": -1.130859375,
            "end_logit": 9.75,
            "text": "7",
            "probability": 1.4841556549072266e-05
        },
        {
            "start_logit": -4.7421875,
            "end_logit": 9.75,
            "text": "Christiaan Barnard in 1967",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 9.984375,
            "end_logit": -6.28515625,
            "text": "1967, there has been substantial progress in the field of heart transplantation, especially over the last several decades.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.42578125,
            "end_logit": 9.75,
            "text": "in 1967",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.87890625,
            "end_logit": 9.75,
            "text": "by Christiaan Barnard in 1967",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.4140625,
            "end_logit": 9.75,
            "text": "n Barnard in 1967",
            "probability": 0.0
        },
        {
            "start_logit": 9.984375,
            "end_logit": -7.65234375,
            "text": "1967, there has been substantial progress in the field of heart transplantation, especially over the last several decades",
            "probability": 0.0
        },
        {
            "start_logit": -7.6328125,
            "end_logit": 9.75,
            "text": "Barnard in 1967",
            "probability": 0.0
        },
        {
            "start_logit": 9.984375,
            "end_logit": -7.9453125,
            "text": "1967, there has been substantial progress in the field of heart transplantation, especially over the last several",
            "probability": 0.0
        },
        {
            "start_logit": -7.71484375,
            "end_logit": 9.75,
            "text": "istiaan Barnard in 1967",
            "probability": 0.0
        },
        {
            "start_logit": 9.984375,
            "end_logit": -7.9609375,
            "text": "1967, there has been substantial progress in the field of heart transplantation, especially over the last",
            "probability": 0.0
        },
        {
            "start_logit": 9.984375,
            "end_logit": -7.96875,
            "text": "1967, there has been substantial progress in the field of heart transplantation,",
            "probability": 0.0
        },
        {
            "start_logit": 9.984375,
            "end_logit": -7.9765625,
            "text": "1967, there has been substantial progress in the field of heart transplantation, especially",
            "probability": 0.0
        },
        {
            "start_logit": 9.984375,
            "end_logit": -7.9921875,
            "text": "1967, there has been substantial progress in the field of heart transplantation, especially over the",
            "probability": 0.0
        },
        {
            "start_logit": 9.984375,
            "end_logit": -7.9921875,
            "text": "1967, there has been substantial progress in the field of heart transplantation, especially over",
            "probability": 0.0
        },
        {
            "start_logit": 9.984375,
            "end_logit": -8.0234375,
            "text": "1967, there",
            "probability": 0.0
        },
        {
            "start_logit": 9.984375,
            "end_logit": -8.0234375,
            "text": "1967,",
            "probability": 0.0
        },
        {
            "start_logit": -7.8125,
            "end_logit": 9.75,
            "text": "iaan Barnard in 1967",
            "probability": 0.0
        }
    ],
    "601ee4c61cb411341a000066_7": [
        {
            "start_logit": 9.8984375,
            "end_logit": 9.7578125,
            "text": "1967",
            "probability": 1.0
        },
        {
            "start_logit": 9.8984375,
            "end_logit": -1.173828125,
            "text": "196",
            "probability": 1.7940998077392578e-05
        },
        {
            "start_logit": -1.154296875,
            "end_logit": 9.7578125,
            "text": "7",
            "probability": 1.5795230865478516e-05
        },
        {
            "start_logit": -6.35546875,
            "end_logit": 9.7578125,
            "text": "in 1967",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8984375,
            "end_logit": -7.20703125,
            "text": "1967, the field of heart transplantation has advanced to the point where survival and acceptable quality of life are commonplace.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.0859375,
            "end_logit": 9.7578125,
            "text": "Since the first human heart transplantation was performed in 1967",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.7109375,
            "end_logit": 9.7578125,
            "text": "the first human heart transplantation was performed in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -7.796875,
            "end_logit": 9.7578125,
            "text": "first human heart transplantation was performed in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -7.82421875,
            "end_logit": 9.7578125,
            "text": "human heart transplantation was performed in 1967",
            "probability": 0.0
        },
        {
            "start_logit": 9.8984375,
            "end_logit": -7.9765625,
            "text": "1967, the field of heart transplantation has advanced",
            "probability": 0.0
        },
        {
            "start_logit": 9.8984375,
            "end_logit": -7.99609375,
            "text": "1967, the field of heart transplantation has",
            "probability": 0.0
        },
        {
            "start_logit": -7.91015625,
            "end_logit": 9.7578125,
            "text": "heart transplantation was performed in 1967",
            "probability": 0.0
        },
        {
            "start_logit": 9.8984375,
            "end_logit": -8.0546875,
            "text": "1967, the field of heart transplantation has advanced to",
            "probability": 0.0
        },
        {
            "start_logit": 9.8984375,
            "end_logit": -8.0625,
            "text": "1967,",
            "probability": 0.0
        },
        {
            "start_logit": -6.35546875,
            "end_logit": -1.173828125,
            "text": "in 196",
            "probability": 0.0
        },
        {
            "start_logit": -7.0859375,
            "end_logit": -1.173828125,
            "text": "Since the first human heart transplantation was performed in 196",
            "probability": 0.0
        },
        {
            "start_logit": -1.154296875,
            "end_logit": -7.20703125,
            "text": "7, the field of heart transplantation has advanced to the point where survival and acceptable quality of life are commonplace.",
            "probability": 0.0
        },
        {
            "start_logit": -7.7109375,
            "end_logit": -1.173828125,
            "text": "the first human heart transplantation was performed in 196",
            "probability": 0.0
        },
        {
            "start_logit": -7.796875,
            "end_logit": -1.173828125,
            "text": "first human heart transplantation was performed in 196",
            "probability": 0.0
        },
        {
            "start_logit": -7.82421875,
            "end_logit": -1.173828125,
            "text": "human heart transplantation was performed in 196",
            "probability": 0.0
        }
    ],
    "601ee4c61cb411341a000066_8": [
        {
            "start_logit": 9.8046875,
            "end_logit": 9.65625,
            "text": "1967",
            "probability": 1.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -1.44140625,
            "text": "196",
            "probability": 1.4960765838623047e-05
        },
        {
            "start_logit": -1.5126953125,
            "end_logit": 9.65625,
            "text": "7",
            "probability": 1.2040138244628906e-05
        },
        {
            "start_logit": -7.1640625,
            "end_logit": 9.65625,
            "text": "in 1967",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.65625,
            "end_logit": 9.65625,
            "text": "The first human-to-human heart transplant was performed 50 years ago in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -7.80078125,
            "end_logit": 9.65625,
            "text": "50 years ago in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -7.8046875,
            "end_logit": 9.65625,
            "text": "first human-to-human heart transplant was performed 50 years ago in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -7.890625,
            "end_logit": 9.65625,
            "text": "human-to-human heart transplant was performed 50 years ago in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -7.91796875,
            "end_logit": 9.65625,
            "text": "human heart transplant was performed 50 years ago in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -7.95703125,
            "end_logit": 9.65625,
            "text": "performed 50 years ago in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -7.96484375,
            "end_logit": 9.65625,
            "text": "heart transplant was performed 50 years ago in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -7.9765625,
            "end_logit": 9.65625,
            "text": "years ago in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -7.99609375,
            "end_logit": 9.65625,
            "text": "-to-human heart transplant was performed 50 years ago in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.015625,
            "end_logit": 9.65625,
            "text": "-human heart transplant was performed 50 years ago in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.0234375,
            "end_logit": 9.65625,
            "text": "transplant was performed 50 years ago in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.0546875,
            "end_logit": 9.65625,
            "text": "ago in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.0703125,
            "end_logit": 9.65625,
            "text": "was performed 50 years ago in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.078125,
            "end_logit": 9.65625,
            "text": "to-human heart transplant was performed 50 years ago in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -7.1640625,
            "end_logit": -1.44140625,
            "text": "in 196",
            "probability": 0.0
        },
        {
            "start_logit": -7.65625,
            "end_logit": -1.44140625,
            "text": "The first human-to-human heart transplant was performed 50 years ago in 196",
            "probability": 0.0
        }
    ],
    "601ee4c61cb411341a000066_9": [
        {
            "start_logit": 9.765625,
            "end_logit": 9.6796875,
            "text": "1967",
            "probability": 1.0
        },
        {
            "start_logit": -1.41015625,
            "end_logit": 9.6796875,
            "text": "7",
            "probability": 1.4066696166992188e-05
        },
        {
            "start_logit": 9.765625,
            "end_logit": -1.5380859375,
            "text": "196",
            "probability": 1.3530254364013672e-05
        },
        {
            "start_logit": -6.36328125,
            "end_logit": 9.6796875,
            "text": "in 1967",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.6015625,
            "end_logit": 9.6796875,
            "text": "Since the first human-to-human heart transplantation, performed in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -7.83984375,
            "end_logit": 9.6796875,
            "text": "performed in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -7.890625,
            "end_logit": 9.6796875,
            "text": "human-to-human heart transplantation, performed in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -7.94921875,
            "end_logit": 9.6796875,
            "text": "the first human-to-human heart transplantation, performed in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -7.95703125,
            "end_logit": 9.6796875,
            "text": "first human-to-human heart transplantation, performed in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -7.9765625,
            "end_logit": 9.6796875,
            "text": ", performed in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -7.98046875,
            "end_logit": 9.6796875,
            "text": "human heart transplantation, performed in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -6.36328125,
            "end_logit": -1.5380859375,
            "text": "in 196",
            "probability": 0.0
        },
        {
            "start_logit": -1.41015625,
            "end_logit": -7.59765625,
            "text": "7, advances in organ donation, surgical techniques, organ preservation, perioperative care, immunologic risk assessment, immunosuppression agents, monitoring of graft function and surveillance of long-term complications have drastically increased recipient survival.",
            "probability": 0.0
        },
        {
            "start_logit": -7.6015625,
            "end_logit": -1.5380859375,
            "text": "Since the first human-to-human heart transplantation, performed in 196",
            "probability": 0.0
        },
        {
            "start_logit": -7.83984375,
            "end_logit": -1.5380859375,
            "text": "performed in 196",
            "probability": 0.0
        },
        {
            "start_logit": -7.890625,
            "end_logit": -1.5380859375,
            "text": "human-to-human heart transplantation, performed in 196",
            "probability": 0.0
        },
        {
            "start_logit": -7.94921875,
            "end_logit": -1.5380859375,
            "text": "the first human-to-human heart transplantation, performed in 196",
            "probability": 0.0
        },
        {
            "start_logit": -7.95703125,
            "end_logit": -1.5380859375,
            "text": "first human-to-human heart transplantation, performed in 196",
            "probability": 0.0
        },
        {
            "start_logit": -7.9765625,
            "end_logit": -1.5380859375,
            "text": ", performed in 196",
            "probability": 0.0
        },
        {
            "start_logit": -7.98046875,
            "end_logit": -1.5380859375,
            "text": "human heart transplantation, performed in 196",
            "probability": 0.0
        }
    ],
    "601ee4c61cb411341a000066_10": [
        {
            "start_logit": 9.8671875,
            "end_logit": 9.7890625,
            "text": "1967",
            "probability": 1.0
        },
        {
            "start_logit": -1.0498046875,
            "end_logit": 9.7890625,
            "text": "7",
            "probability": 1.817941665649414e-05
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -1.2646484375,
            "text": "196",
            "probability": 1.5795230865478516e-05
        },
        {
            "start_logit": -6.38671875,
            "end_logit": 9.7890625,
            "text": "in 1967",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -6.80078125,
            "text": "1967 was performed using a deceased donor heart, the advent of brain death criteria and the ability to avoid long warm ischemic times led donation after cardiac death (DCD) transplantation to fall out of favor.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -7.55859375,
            "text": "1967 was",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -7.6796875,
            "text": "1967 was performed using a deceased donor heart, the advent of brain death criteria and the ability to avoid long warm ischemic times led donation after cardiac death",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -7.7734375,
            "text": "1967 was performed using a deceased donor heart, the advent of brain death criteria and",
            "probability": 0.0
        },
        {
            "start_logit": -7.7578125,
            "end_logit": 9.7890625,
            "text": "the first human heart transplant in 1967",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -7.859375,
            "text": "1967 was performed using a deceased donor heart,",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -7.90234375,
            "text": "1967 was performed using a deceased donor heart, the advent of brain death criteria and the ability to avoid long warm ischemic times led donation after cardiac death (DCD) transplantation to",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -7.953125,
            "text": "1967 was performed using a deceased donor heart, the advent of brain death criteria and the ability to avoid long warm ischemic times led donation after cardiac death (",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -7.96484375,
            "text": "1967 was performed using a deceased donor heart, the advent of brain death criteria and the ability to avoid long warm ischemic times led donation after cardiac",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -7.98828125,
            "text": "1967 was performed using a deceased donor",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.0078125,
            "text": "1967 was performed using a deceased donor heart, the advent of brain death criteria and the ability to",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.0078125,
            "text": "1967 was performed using a deceased donor heart, the advent of brain death criteria",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.015625,
            "text": "1967 was performed using a deceased donor heart, the advent of brain death",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.0234375,
            "text": "1967 was performed using a deceased donor heart, the advent of brain death criteria and the ability to avoid long warm ischemic times led",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.046875,
            "text": "1967 was performed using a deceased donor heart, the advent of brain death criteria and the",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.0546875,
            "text": "1967 was performed using a deceased donor heart, the advent of brain death criteria and the ability to avoid long warm ischemic times led donation after cardiac death (DCD)",
            "probability": 0.0
        }
    ],
    "601ee4c61cb411341a000066_11": [
        {
            "start_logit": 6.4453125,
            "end_logit": 9.5703125,
            "text": "1967",
            "probability": 0.9091796875
        },
        {
            "start_logit": 4.1328125,
            "end_logit": 9.5703125,
            "text": "December 1967",
            "probability": 0.09002685546875
        },
        {
            "start_logit": -1.6123046875,
            "end_logit": 9.5703125,
            "text": "7",
            "probability": 0.0002865791320800781
        },
        {
            "start_logit": -7.4453125,
            "end_logit": 9.5703125,
            "text": "in December 1967",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": -7.51171875,
            "end_logit": 9.5703125,
            "text": "Christiaan Barnard and his team in December 1967",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": -7.59375,
            "end_logit": 9.5703125,
            "text": "Professor Christiaan Barnard and his team in December 1967",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -7.625,
            "end_logit": 9.5703125,
            "text": "The Human Tissue Act of 1983 had its origin in the first successful heart transplant operation performed by Professor Christiaan Barnard and his team in December 1967",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -7.66015625,
            "end_logit": 9.5703125,
            "text": "or Christiaan Barnard and his team in December 1967",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -7.78125,
            "end_logit": 9.5703125,
            "text": "by Professor Christiaan Barnard and his team in December 1967",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -7.84765625,
            "end_logit": 9.5703125,
            "text": "Human Tissue Act of 1983 had its origin in the first successful heart transplant operation performed by Professor Christiaan Barnard and his team in December 1967",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -7.95703125,
            "end_logit": 9.5703125,
            "text": "first successful heart transplant operation performed by Professor Christiaan Barnard and his team in December 1967",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -7.98046875,
            "end_logit": 9.5703125,
            "text": "successful heart transplant operation performed by Professor Christiaan Barnard and his team in December 1967",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -7.984375,
            "end_logit": 9.5703125,
            "text": "n Barnard and his team in December 1967",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -7.984375,
            "end_logit": 9.5703125,
            "text": "operation performed by Professor Christiaan Barnard and his team in December 1967",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -7.9921875,
            "end_logit": 9.5703125,
            "text": "heart transplant operation performed by Professor Christiaan Barnard and his team in December 1967",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -8.0078125,
            "end_logit": 9.5703125,
            "text": "istiaan Barnard and his team in December 1967",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -8.0078125,
            "end_logit": 9.5703125,
            "text": "Tissue Act of 1983 had its origin in the first successful heart transplant operation performed by Professor Christiaan Barnard and his team in December 1967",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 6.4453125,
            "end_logit": -5.0859375,
            "text": "196",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 4.1328125,
            "end_logit": -5.0859375,
            "text": "December 196",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 4.1328125,
            "end_logit": -5.93359375,
            "text": "December",
            "probability": 0.0
        }
    ],
    "601ee4c61cb411341a000066_12": [
        {
            "start_logit": 8.4765625,
            "end_logit": 9.640625,
            "text": "1967",
            "probability": 0.998046875
        },
        {
            "start_logit": 2.33984375,
            "end_logit": 9.640625,
            "text": "December 1967",
            "probability": 0.0021495819091796875
        },
        {
            "start_logit": -1.3662109375,
            "end_logit": 9.640625,
            "text": "7",
            "probability": 5.257129669189453e-05
        },
        {
            "start_logit": 8.4765625,
            "end_logit": -3.248046875,
            "text": "196",
            "probability": 2.5033950805664062e-06
        },
        {
            "start_logit": -5.80078125,
            "end_logit": 9.640625,
            "text": "Christiaan Barnard performed the first human-to-human heart transplant in December 1967",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -6.9609375,
            "end_logit": 9.640625,
            "text": "Dr. Christiaan Barnard performed the first human-to-human heart transplant in December 1967",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.26953125,
            "end_logit": 9.640625,
            "text": ". Christiaan Barnard performed the first human-to-human heart transplant in December 1967",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.28125,
            "end_logit": 9.640625,
            "text": "n Barnard performed the first human-to-human heart transplant in December 1967",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.42578125,
            "end_logit": 9.640625,
            "text": "Barnard performed the first human-to-human heart transplant in December 1967",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.44140625,
            "end_logit": 9.640625,
            "text": "istiaan Barnard performed the first human-to-human heart transplant in December 1967",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.46484375,
            "end_logit": 9.640625,
            "text": "iaan Barnard performed the first human-to-human heart transplant in December 1967",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.66015625,
            "end_logit": 9.640625,
            "text": "nard performed the first human-to-human heart transplant in December 1967",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.7578125,
            "end_logit": 9.640625,
            "text": "in December 1967",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.8203125,
            "end_logit": 9.640625,
            "text": "since Dr. Christiaan Barnard performed the first human-to-human heart transplant in December 1967",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.91015625,
            "end_logit": 9.640625,
            "text": "It has been 50 years since Dr. Christiaan Barnard performed the first human-to-human heart transplant in December 1967",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.9453125,
            "end_logit": 9.640625,
            "text": "d performed the first human-to-human heart transplant in December 1967",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.953125,
            "end_logit": 9.640625,
            "text": "first human-to-human heart transplant in December 1967",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.953125,
            "end_logit": 9.640625,
            "text": "human-to-human heart transplant in December 1967",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.4765625,
            "end_logit": -7.38671875,
            "text": "1967 in",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.4765625,
            "end_logit": -7.4921875,
            "text": "1967 in South Africa",
            "probability": 5.960464477539063e-08
        }
    ],
    "601ee4c61cb411341a000066_13": [
        {
            "start_logit": 9.3359375,
            "end_logit": 9.7109375,
            "text": "1967",
            "probability": 1.0
        },
        {
            "start_logit": -1.294921875,
            "end_logit": 9.7109375,
            "text": "7",
            "probability": 2.4139881134033203e-05
        },
        {
            "start_logit": -2.416015625,
            "end_logit": 9.7109375,
            "text": "3 December 1967",
            "probability": 7.867813110351562e-06
        },
        {
            "start_logit": 9.3359375,
            "end_logit": -2.142578125,
            "text": "196",
            "probability": 7.152557373046875e-06
        },
        {
            "start_logit": -6.625,
            "end_logit": 9.7109375,
            "text": "December 1967",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.3359375,
            "end_logit": -6.54296875,
            "text": "1967, by Christiaan Barnard in South Africa.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.30859375,
            "end_logit": 9.7109375,
            "text": "on 3 December 1967",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.328125,
            "end_logit": 9.7109375,
            "text": "The first successful human heart transplantation was reported on 3 December 1967",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.52734375,
            "end_logit": 9.7109375,
            "text": "reported on 3 December 1967",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.80078125,
            "end_logit": 9.7109375,
            "text": "first successful human heart transplantation was reported on 3 December 1967",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3359375,
            "end_logit": -7.984375,
            "text": "1967,",
            "probability": 0.0
        },
        {
            "start_logit": -2.416015625,
            "end_logit": -2.142578125,
            "text": "3 December 196",
            "probability": 0.0
        },
        {
            "start_logit": -1.294921875,
            "end_logit": -6.54296875,
            "text": "7, by Christiaan Barnard in South Africa.",
            "probability": 0.0
        },
        {
            "start_logit": -6.625,
            "end_logit": -2.142578125,
            "text": "December 196",
            "probability": 0.0
        },
        {
            "start_logit": -2.416015625,
            "end_logit": -6.54296875,
            "text": "3 December 1967, by Christiaan Barnard in South Africa.",
            "probability": 0.0
        },
        {
            "start_logit": -1.294921875,
            "end_logit": -7.984375,
            "text": "7,",
            "probability": 0.0
        },
        {
            "start_logit": -7.30859375,
            "end_logit": -2.142578125,
            "text": "on 3 December 196",
            "probability": 0.0
        },
        {
            "start_logit": -7.328125,
            "end_logit": -2.142578125,
            "text": "The first successful human heart transplantation was reported on 3 December 196",
            "probability": 0.0
        },
        {
            "start_logit": -7.52734375,
            "end_logit": -2.142578125,
            "text": "reported on 3 December 196",
            "probability": 0.0
        },
        {
            "start_logit": -2.416015625,
            "end_logit": -7.4609375,
            "text": "3 December",
            "probability": 0.0
        }
    ],
    "601ee4c61cb411341a000066_14": [
        {
            "start_logit": 9.734375,
            "end_logit": 9.6328125,
            "text": "1967",
            "probability": 1.0
        },
        {
            "start_logit": 9.734375,
            "end_logit": -1.57421875,
            "text": "196",
            "probability": 1.341104507446289e-05
        },
        {
            "start_logit": -1.4755859375,
            "end_logit": 9.6328125,
            "text": "7",
            "probability": 1.341104507446289e-05
        },
        {
            "start_logit": -5.265625,
            "end_logit": 9.6328125,
            "text": "December 1967",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.734375,
            "end_logit": -6.578125,
            "text": "1967.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.60546875,
            "end_logit": 9.6328125,
            "text": "2nd December 1967",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.078125,
            "end_logit": 9.6328125,
            "text": "Groote Schuur Hospital on the 2nd December 1967",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.3125,
            "end_logit": 9.6328125,
            "text": "at Groote Schuur Hospital on the 2nd December 1967",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.4453125,
            "end_logit": 9.6328125,
            "text": "Hospital on the 2nd December 1967",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.453125,
            "end_logit": 9.6328125,
            "text": "on the 2nd December 1967",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.48046875,
            "end_logit": 9.6328125,
            "text": "Schuur Hospital on the 2nd December 1967",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.4921875,
            "end_logit": 9.6328125,
            "text": "the 2nd December 1967",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.58203125,
            "end_logit": 9.6328125,
            "text": "ote Schuur Hospital on the 2nd December 1967",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.61328125,
            "end_logit": 9.6328125,
            "text": "The world's first human-to-human heart transplant was performed at Groote Schuur Hospital on the 2nd December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -7.6796875,
            "end_logit": 9.6328125,
            "text": "uur Hospital on the 2nd December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -7.75,
            "end_logit": 9.6328125,
            "text": "ur Hospital on the 2nd December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -7.7890625,
            "end_logit": 9.6328125,
            "text": "human-to-human heart transplant was performed at Groote Schuur Hospital on the 2nd December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -7.79296875,
            "end_logit": 9.6328125,
            "text": "human heart transplant was performed at Groote Schuur Hospital on the 2nd December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -5.265625,
            "end_logit": -1.57421875,
            "text": "December 196",
            "probability": 0.0
        },
        {
            "start_logit": -1.4755859375,
            "end_logit": -6.578125,
            "text": "7.",
            "probability": 0.0
        }
    ],
    "601ee4c61cb411341a000066_15": [
        {
            "start_logit": 9.78125,
            "end_logit": 9.6875,
            "text": "1967",
            "probability": 1.0
        },
        {
            "start_logit": -1.337890625,
            "end_logit": 9.6875,
            "text": "7",
            "probability": 1.4841556549072266e-05
        },
        {
            "start_logit": 9.78125,
            "end_logit": -1.44140625,
            "text": "196",
            "probability": 1.4722347259521484e-05
        },
        {
            "start_logit": -5.58203125,
            "end_logit": 9.6875,
            "text": "Christiaan Barnard in Cape Town December 3rd 1967",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -5.7578125,
            "end_logit": 9.6875,
            "text": "50 years have passed since the first human to human heart transplantation, performed by Christiaan Barnard in Cape Town December 3rd 1967",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.78125,
            "end_logit": -6.109375,
            "text": "1967.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.10546875,
            "end_logit": 9.6875,
            "text": "by Christiaan Barnard in Cape Town December 3rd 1967",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.125,
            "end_logit": 9.6875,
            "text": "December 3rd 1967",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.203125,
            "end_logit": 9.6875,
            "text": "3rd 1967",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.421875,
            "end_logit": 9.6875,
            "text": "Cape Town December 3rd 1967",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.4375,
            "end_logit": 9.6875,
            "text": "n Barnard in Cape Town December 3rd 1967",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.56640625,
            "end_logit": 9.6875,
            "text": "iaan Barnard in Cape Town December 3rd 1967",
            "probability": 0.0
        },
        {
            "start_logit": -7.59375,
            "end_logit": 9.6875,
            "text": "Barnard in Cape Town December 3rd 1967",
            "probability": 0.0
        },
        {
            "start_logit": -7.609375,
            "end_logit": 9.6875,
            "text": "in Cape Town December 3rd 1967",
            "probability": 0.0
        },
        {
            "start_logit": -7.609375,
            "end_logit": 9.6875,
            "text": "istiaan Barnard in Cape Town December 3rd 1967",
            "probability": 0.0
        },
        {
            "start_logit": -7.6328125,
            "end_logit": 9.6875,
            "text": "Town December 3rd 1967",
            "probability": 0.0
        },
        {
            "start_logit": -7.76171875,
            "end_logit": 9.6875,
            "text": "d in Cape Town December 3rd 1967",
            "probability": 0.0
        },
        {
            "start_logit": -7.8671875,
            "end_logit": 9.6875,
            "text": "nard in Cape Town December 3rd 1967",
            "probability": 0.0
        },
        {
            "start_logit": -5.58203125,
            "end_logit": -1.44140625,
            "text": "Christiaan Barnard in Cape Town December 3rd 196",
            "probability": 0.0
        },
        {
            "start_logit": -5.7578125,
            "end_logit": -1.44140625,
            "text": "50 years have passed since the first human to human heart transplantation, performed by Christiaan Barnard in Cape Town December 3rd 196",
            "probability": 0.0
        }
    ],
    "601ee4c61cb411341a000066_16": [
        {
            "start_logit": 9.484375,
            "end_logit": 9.7265625,
            "text": "1967",
            "probability": 1.0
        },
        {
            "start_logit": -1.212890625,
            "end_logit": 9.7265625,
            "text": "7",
            "probability": 2.2470951080322266e-05
        },
        {
            "start_logit": 9.484375,
            "end_logit": -1.958984375,
            "text": "196",
            "probability": 8.344650268554688e-06
        },
        {
            "start_logit": -3.35546875,
            "end_logit": 9.7265625,
            "text": "In 1967",
            "probability": 2.6226043701171875e-06
        },
        {
            "start_logit": 9.484375,
            "end_logit": -6.3984375,
            "text": "1967, he led the team that performed the world's first human-to-human heart transplant.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.484375,
            "end_logit": -7.3828125,
            "text": "1967, he led the team that performed the world",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.484375,
            "end_logit": -7.828125,
            "text": "1967, he led the team that performed the world'",
            "probability": 0.0
        },
        {
            "start_logit": 9.484375,
            "end_logit": -7.90625,
            "text": "1967, he led the team that performed the world's",
            "probability": 0.0
        },
        {
            "start_logit": -3.35546875,
            "end_logit": -1.958984375,
            "text": "In 196",
            "probability": 0.0
        },
        {
            "start_logit": -1.212890625,
            "end_logit": -6.3984375,
            "text": "7, he led the team that performed the world's first human-to-human heart transplant.",
            "probability": 0.0
        },
        {
            "start_logit": -1.212890625,
            "end_logit": -7.3828125,
            "text": "7, he led the team that performed the world",
            "probability": 0.0
        },
        {
            "start_logit": -1.212890625,
            "end_logit": -7.828125,
            "text": "7, he led the team that performed the world'",
            "probability": 0.0
        },
        {
            "start_logit": -1.212890625,
            "end_logit": -7.90625,
            "text": "7, he led the team that performed the world's",
            "probability": 0.0
        },
        {
            "start_logit": -3.35546875,
            "end_logit": -6.3984375,
            "text": "In 1967, he led the team that performed the world's first human-to-human heart transplant.",
            "probability": 0.0
        },
        {
            "start_logit": -3.35546875,
            "end_logit": -7.3828125,
            "text": "In 1967, he led the team that performed the world",
            "probability": 0.0
        },
        {
            "start_logit": -3.35546875,
            "end_logit": -7.734375,
            "text": "In",
            "probability": 0.0
        },
        {
            "start_logit": -3.35546875,
            "end_logit": -7.828125,
            "text": "In 1967, he led the team that performed the world'",
            "probability": 0.0
        },
        {
            "start_logit": -3.35546875,
            "end_logit": -7.90625,
            "text": "In 1967, he led the team that performed the world's",
            "probability": 0.0
        },
        {
            "start_logit": -6.2890625,
            "end_logit": -6.3984375,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.63671875,
            "end_logit": -6.3984375,
            "text": "the world's first human-to-human heart transplant.",
            "probability": 0.0
        }
    ],
    "601ee4c61cb411341a000066_17": [
        {
            "start_logit": 9.7421875,
            "end_logit": 9.7421875,
            "text": "1967",
            "probability": 1.0
        },
        {
            "start_logit": 0.384033203125,
            "end_logit": 9.7421875,
            "text": "1953, followed by the first successful heart transplant in 1967",
            "probability": 8.612871170043945e-05
        },
        {
            "start_logit": -0.923828125,
            "end_logit": 9.7421875,
            "text": "7",
            "probability": 2.3365020751953125e-05
        },
        {
            "start_logit": 9.7421875,
            "end_logit": -1.18359375,
            "text": "196",
            "probability": 1.806020736694336e-05
        },
        {
            "start_logit": -7.19140625,
            "end_logit": 9.7421875,
            "text": "in 1967",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.7421875,
            "end_logit": -7.421875,
            "text": "1967, and later to the first infusion of bone marrow-derived cells to the human myocardium in 2002, significant progress has been made",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.7421875,
            "end_logit": -7.5859375,
            "text": "1967, and later to the first infusion of bone marrow-derived cells to the human myocardium in 2002, significant progress has been made in",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.7421875,
            "end_logit": -7.640625,
            "text": "1967, and later to the first infusion of bone marrow-derived cells to the human myocardium in 2002, significant progress has been made in h",
            "probability": 0.0
        },
        {
            "start_logit": 9.7421875,
            "end_logit": -7.640625,
            "text": "1967, and later to the first infusion of bone marrow-derived cells to the human myocardium in 2002",
            "probability": 0.0
        },
        {
            "start_logit": 9.7421875,
            "end_logit": -7.75,
            "text": "1967, and later to the first infusion of bone marrow-derived cells to the human myocardium in 2002, significant progress has been",
            "probability": 0.0
        },
        {
            "start_logit": -7.75390625,
            "end_logit": 9.7421875,
            "text": "in 1953, followed by the first successful heart transplant in 1967",
            "probability": 0.0
        },
        {
            "start_logit": 9.7421875,
            "end_logit": -7.84375,
            "text": "1967, and later to the first infusion of bone marrow-derived cells to the",
            "probability": 0.0
        },
        {
            "start_logit": 9.7421875,
            "end_logit": -7.84375,
            "text": "1967,",
            "probability": 0.0
        },
        {
            "start_logit": 9.7421875,
            "end_logit": -7.8515625,
            "text": "1967, and later to the first infusion of bone marrow-derived cells to the human myocardium in",
            "probability": 0.0
        },
        {
            "start_logit": 9.7421875,
            "end_logit": -7.8671875,
            "text": "1967, and later to the first infusion of bone marrow-derived cells to the human myocardium in 2002, significant progress",
            "probability": 0.0
        },
        {
            "start_logit": -7.875,
            "end_logit": 9.7421875,
            "text": "From the repair of the first septal defect in 1953, followed by the first successful heart transplant in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -7.875,
            "end_logit": 9.7421875,
            "text": "first septal defect in 1953, followed by the first successful heart transplant in 1967",
            "probability": 0.0
        },
        {
            "start_logit": 9.7421875,
            "end_logit": -7.890625,
            "text": "1967, and later to the first infusion of bone marrow-derived cells to the human myocardium",
            "probability": 0.0
        },
        {
            "start_logit": -7.8984375,
            "end_logit": 9.7421875,
            "text": "first successful heart transplant in 1967",
            "probability": 0.0
        },
        {
            "start_logit": 9.7421875,
            "end_logit": -7.90625,
            "text": "1967, and later to the first infusion of bone marrow-derived cells to the human myocardium in 2002, significant progress has",
            "probability": 0.0
        }
    ],
    "601ee4c61cb411341a000066_18": [
        {
            "start_logit": 9.609375,
            "end_logit": 9.6328125,
            "text": "1967",
            "probability": 1.0
        },
        {
            "start_logit": -1.44921875,
            "end_logit": 9.6328125,
            "text": "7",
            "probability": 1.5676021575927734e-05
        },
        {
            "start_logit": 9.609375,
            "end_logit": -1.7900390625,
            "text": "196",
            "probability": 1.0848045349121094e-05
        },
        {
            "start_logit": -3.142578125,
            "end_logit": 9.6328125,
            "text": "3 December 1967",
            "probability": 2.86102294921875e-06
        },
        {
            "start_logit": -6.01953125,
            "end_logit": 9.6328125,
            "text": "December 1967",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.375,
            "end_logit": 9.6328125,
            "text": "on 3 December 1967",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.609375,
            "end_logit": -6.74609375,
            "text": "1967.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.7890625,
            "end_logit": 9.6328125,
            "text": "at Groote Schuur Hospital, Cape Town, on 3 December 1967",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.41796875,
            "end_logit": 9.6328125,
            "text": "Article on the first heart transplant, performed at Groote Schuur Hospital, Cape Town, on 3 December 1967",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.515625,
            "end_logit": 9.6328125,
            "text": ", on 3 December 1967",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.515625,
            "end_logit": 9.6328125,
            "text": "Cape Town, on 3 December 1967",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.55859375,
            "end_logit": 9.6328125,
            "text": "Groote Schuur Hospital, Cape Town, on 3 December 1967",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6875,
            "end_logit": 9.6328125,
            "text": "Town, on 3 December 1967",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.765625,
            "end_logit": 9.6328125,
            "text": "Hospital, Cape Town, on 3 December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -7.796875,
            "end_logit": 9.6328125,
            "text": "ote Schuur Hospital, Cape Town, on 3 December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -7.80078125,
            "end_logit": 9.6328125,
            "text": ", Cape Town, on 3 December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -7.8515625,
            "end_logit": 9.6328125,
            "text": "Schuur Hospital, Cape Town, on 3 December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -7.859375,
            "end_logit": 9.6328125,
            "text": "performed at Groote Schuur Hospital, Cape Town, on 3 December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -3.142578125,
            "end_logit": -1.7900390625,
            "text": "3 December 196",
            "probability": 0.0
        },
        {
            "start_logit": -6.01953125,
            "end_logit": -1.7900390625,
            "text": "December 196",
            "probability": 0.0
        }
    ],
    "601ee4c61cb411341a000066_19": [
        {
            "start_logit": 5.71484375,
            "end_logit": 9.65625,
            "text": "December 3, 1967",
            "probability": 0.9697265625
        },
        {
            "start_logit": 2.2109375,
            "end_logit": 9.65625,
            "text": "1967",
            "probability": 0.029052734375
        },
        {
            "start_logit": -1.1318359375,
            "end_logit": 9.65625,
            "text": "7",
            "probability": 0.0010251998901367188
        },
        {
            "start_logit": -1.9951171875,
            "end_logit": 9.65625,
            "text": "On December 3, 1967",
            "probability": 0.0004324913024902344
        },
        {
            "start_logit": 5.71484375,
            "end_logit": -1.234375,
            "text": "December 3, 1967, in Cape Town, South Africa, Dr. Christian Barnard revolutionized organ transplantation with the first successful human heart transplant.",
            "probability": 1.811981201171875e-05
        },
        {
            "start_logit": -7.12890625,
            "end_logit": 9.65625,
            "text": ", 1967",
            "probability": 2.562999725341797e-06
        },
        {
            "start_logit": 2.2109375,
            "end_logit": -1.234375,
            "text": "1967, in Cape Town, South Africa, Dr. Christian Barnard revolutionized organ transplantation with the first successful human heart transplant.",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 5.71484375,
            "end_logit": -4.92578125,
            "text": "December",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 5.71484375,
            "end_logit": -6.3515625,
            "text": "December 3, 1967, in Cape Town, South Africa, Dr. Christian Barnard",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 0.466064453125,
            "end_logit": -1.234375,
            "text": "Christian Barnard revolutionized organ transplantation with the first successful human heart transplant.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 5.71484375,
            "end_logit": -6.91015625,
            "text": "December 3, 1967, in Cape Town, South Africa, Dr. Christian Barnard revolution",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 5.71484375,
            "end_logit": -7.11328125,
            "text": "December 3",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 5.71484375,
            "end_logit": -7.1640625,
            "text": "December 3, 1967, in Cape Town, South Africa, Dr. Christian Barnard revolutionized organ transplantation with",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 5.71484375,
            "end_logit": -7.28515625,
            "text": "December 3, 1967, in Cape Town, South Africa, Dr",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 5.71484375,
            "end_logit": -7.296875,
            "text": "December 3, 1967, in Cape Town, South Africa",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 5.71484375,
            "end_logit": -7.5390625,
            "text": "December 3, 1967, in Cape Town, South Africa, Dr. Christian Barnard revolutionized organ transplantation",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 5.71484375,
            "end_logit": -7.56640625,
            "text": "December 3,",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 5.71484375,
            "end_logit": -7.65625,
            "text": "December 3, 1967, in Cape Town, South Africa, Dr. Christian Barnard revolutionized",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 5.71484375,
            "end_logit": -7.66015625,
            "text": "December 3, 1967, in Cape Town",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 5.71484375,
            "end_logit": -7.71484375,
            "text": "December 3, 196",
            "probability": 0.0
        }
    ],
    "601ee4c61cb411341a000066_20": [
        {
            "start_logit": 9.640625,
            "end_logit": 9.578125,
            "text": "1967",
            "probability": 1.0
        },
        {
            "start_logit": -1.5595703125,
            "end_logit": 9.578125,
            "text": "7",
            "probability": 1.3649463653564453e-05
        },
        {
            "start_logit": 9.640625,
            "end_logit": -1.767578125,
            "text": "196",
            "probability": 1.1861324310302734e-05
        },
        {
            "start_logit": 9.640625,
            "end_logit": -6.65234375,
            "text": "1967 and followed this by introducing the technique of heterotopic heart transplantation in 1974.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.8359375,
            "end_logit": 9.578125,
            "text": "Barnard performed the 1st human-to-human orthotopic heart transplantation in 1967",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.8359375,
            "end_logit": 9.578125,
            "text": "in 1967",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.640625,
            "end_logit": -7.10546875,
            "text": "1967 and followed this by introducing the technique of heterotopic heart transplantation in 1974",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.640625,
            "end_logit": -7.7265625,
            "text": "1967 and followed this by introducing the technique of heterotopic heart transplantation in",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.640625,
            "end_logit": -7.77734375,
            "text": "1967 and",
            "probability": 0.0
        },
        {
            "start_logit": 9.640625,
            "end_logit": -7.93359375,
            "text": "1967 and followed this by",
            "probability": 0.0
        },
        {
            "start_logit": 9.640625,
            "end_logit": -7.96875,
            "text": "1967 and followed this by introducing the",
            "probability": 0.0
        },
        {
            "start_logit": 9.640625,
            "end_logit": -7.96875,
            "text": "1967 and followed",
            "probability": 0.0
        },
        {
            "start_logit": -7.94140625,
            "end_logit": 9.578125,
            "text": "nard performed the 1st human-to-human orthotopic heart transplantation in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.0078125,
            "end_logit": 9.578125,
            "text": "human-to-human orthotopic heart transplantation in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.0234375,
            "end_logit": 9.578125,
            "text": "orthotopic heart transplantation in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.046875,
            "end_logit": 9.578125,
            "text": "1st human-to-human orthotopic heart transplantation in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -1.5595703125,
            "end_logit": -6.65234375,
            "text": "7 and followed this by introducing the technique of heterotopic heart transplantation in 1974.",
            "probability": 0.0
        },
        {
            "start_logit": -6.8359375,
            "end_logit": -1.767578125,
            "text": "Barnard performed the 1st human-to-human orthotopic heart transplantation in 196",
            "probability": 0.0
        },
        {
            "start_logit": -6.8359375,
            "end_logit": -1.767578125,
            "text": "in 196",
            "probability": 0.0
        },
        {
            "start_logit": -1.5595703125,
            "end_logit": -7.10546875,
            "text": "7 and followed this by introducing the technique of heterotopic heart transplantation in 1974",
            "probability": 0.0
        }
    ],
    "5fdb2e23a43ad3127800000a_1": [
        {
            "start_logit": 1.80859375,
            "end_logit": 3.244140625,
            "text": "cis-regulatory elements is central to understanding gene transcription. Hypersensitivity of cis-regulatory elements to digestion with DNaseI remains the gold-standard approach to locating such elements.",
            "probability": 0.44140625
        },
        {
            "start_logit": 1.80859375,
            "end_logit": 3.244140625,
            "text": "cis-regulatory elements is central to understanding gene transcription.",
            "probability": 0.44140625
        },
        {
            "start_logit": -0.71923828125,
            "end_logit": 3.244140625,
            "text": ". Hypersensitivity of cis-regulatory elements to digestion with DNaseI remains the gold-standard approach to locating such elements.",
            "probability": 0.035186767578125
        },
        {
            "start_logit": -0.71923828125,
            "end_logit": 3.244140625,
            "text": ".",
            "probability": 0.035186767578125
        },
        {
            "start_logit": -0.7197265625,
            "end_logit": 3.244140625,
            "text": ".",
            "probability": 0.035125732421875
        },
        {
            "start_logit": -3.130859375,
            "end_logit": 3.244140625,
            "text": "The identification of cis-regulatory elements is central to understanding gene transcription. Hypersensitivity of cis-regulatory elements to digestion with DNaseI remains the gold-standard approach to locating such elements.",
            "probability": 0.0031528472900390625
        },
        {
            "start_logit": -3.130859375,
            "end_logit": 3.244140625,
            "text": "The identification of cis-regulatory elements is central to understanding gene transcription.",
            "probability": 0.0031528472900390625
        },
        {
            "start_logit": -3.91796875,
            "end_logit": 3.244140625,
            "text": "gene transcription. Hypersensitivity of cis-regulatory elements to digestion with DNaseI remains the gold-standard approach to locating such elements.",
            "probability": 0.001438140869140625
        },
        {
            "start_logit": -3.91796875,
            "end_logit": 3.244140625,
            "text": "gene transcription.",
            "probability": 0.001438140869140625
        },
        {
            "start_logit": 1.80859375,
            "end_logit": -3.13671875,
            "text": "cis-regulatory elements",
            "probability": 0.0007457733154296875
        },
        {
            "start_logit": -5.5078125,
            "end_logit": 3.244140625,
            "text": "DNaseI remains the gold-standard approach to locating such elements.",
            "probability": 0.00029206275939941406
        },
        {
            "start_logit": -5.66015625,
            "end_logit": 3.244140625,
            "text": "identification of cis-regulatory elements is central to understanding gene transcription. Hypersensitivity of cis-regulatory elements to digestion with DNaseI remains the gold-standard approach to locating such elements.",
            "probability": 0.00025200843811035156
        },
        {
            "start_logit": -5.66015625,
            "end_logit": 3.244140625,
            "text": "identification of cis-regulatory elements is central to understanding gene transcription.",
            "probability": 0.00025200843811035156
        },
        {
            "start_logit": -5.8515625,
            "end_logit": 3.244140625,
            "text": "the gold-standard approach to locating such elements.",
            "probability": 0.0002071857452392578
        },
        {
            "start_logit": -5.86328125,
            "end_logit": 3.244140625,
            "text": "cis-regulatory elements to digestion with DNaseI remains the gold-standard approach to locating such elements.",
            "probability": 0.00020551681518554688
        },
        {
            "start_logit": -6.10546875,
            "end_logit": 3.244140625,
            "text": "Hypersensitivity of cis-regulatory elements to digestion with DNaseI remains the gold-standard approach to locating such elements.",
            "probability": 0.00016129016876220703
        },
        {
            "start_logit": -6.19140625,
            "end_logit": 3.244140625,
            "text": "central to understanding gene transcription. Hypersensitivity of cis-regulatory elements to digestion with DNaseI remains the gold-standard approach to locating such elements.",
            "probability": 0.0001480579376220703
        },
        {
            "start_logit": -6.19140625,
            "end_logit": 3.244140625,
            "text": "central to understanding gene transcription.",
            "probability": 0.0001480579376220703
        },
        {
            "start_logit": -6.28125,
            "end_logit": 3.244140625,
            "text": "locating such elements.",
            "probability": 0.0001348257064819336
        },
        {
            "start_logit": -6.31640625,
            "end_logit": 3.244140625,
            "text": "gold-standard approach to locating such elements.",
            "probability": 0.00013065338134765625
        }
    ],
    "5fdb2e23a43ad3127800000a_2": [
        {
            "start_logit": 4.49609375,
            "end_logit": 4.359375,
            "text": "Hypersensitivity of cis-regulatory elements to digestion with DNaseI remains the gold-standard approach to locating such elements.",
            "probability": 0.93359375
        },
        {
            "start_logit": 0.97998046875,
            "end_logit": 4.359375,
            "text": "cis-regulatory elements to digestion with DNaseI remains the gold-standard approach to locating such elements.",
            "probability": 0.02764892578125
        },
        {
            "start_logit": 4.49609375,
            "end_logit": 0.83251953125,
            "text": "Hypersensitivity of cis-regulatory elements",
            "probability": 0.027313232421875
        },
        {
            "start_logit": 0.0071868896484375,
            "end_logit": 4.359375,
            "text": ".",
            "probability": 0.01044464111328125
        },
        {
            "start_logit": 0.97998046875,
            "end_logit": 0.83251953125,
            "text": "cis-regulatory elements",
            "probability": 0.000812530517578125
        },
        {
            "start_logit": 4.49609375,
            "end_logit": -5.83984375,
            "text": "Hypersensitivity of cis-regulatory elements to",
            "probability": 3.463029861450195e-05
        },
        {
            "start_logit": 4.49609375,
            "end_logit": -5.86328125,
            "text": "Hypersensitivity",
            "probability": 3.3795833587646484e-05
        },
        {
            "start_logit": 4.49609375,
            "end_logit": -5.91796875,
            "text": "Hypersensitivity of cis-regulatory elements to digestion with DNaseI remains",
            "probability": 3.2007694244384766e-05
        },
        {
            "start_logit": -5.8359375,
            "end_logit": 4.359375,
            "text": "DNaseI remains the gold-standard approach to locating such elements.",
            "probability": 3.0279159545898438e-05
        },
        {
            "start_logit": -5.890625,
            "end_logit": 4.359375,
            "text": "locating such elements.",
            "probability": 2.866983413696289e-05
        },
        {
            "start_logit": -6.60546875,
            "end_logit": 4.359375,
            "text": "regulatory elements to digestion with DNaseI remains the gold-standard approach to locating such elements.",
            "probability": 1.3947486877441406e-05
        },
        {
            "start_logit": -6.7578125,
            "end_logit": 4.359375,
            "text": "elements to digestion with DNaseI remains the gold-standard approach to locating such elements.",
            "probability": 1.2099742889404297e-05
        },
        {
            "start_logit": -6.8203125,
            "end_logit": 4.359375,
            "text": "approach to locating such elements.",
            "probability": 1.1265277862548828e-05
        },
        {
            "start_logit": -6.86328125,
            "end_logit": 4.359375,
            "text": "with DNaseI remains the gold-standard approach to locating such elements.",
            "probability": 1.0907649993896484e-05
        },
        {
            "start_logit": -6.8984375,
            "end_logit": 4.359375,
            "text": "elements.",
            "probability": 1.043081283569336e-05
        },
        {
            "start_logit": -6.9296875,
            "end_logit": 4.359375,
            "text": "of cis-regulatory elements to digestion with DNaseI remains the gold-standard approach to locating such elements.",
            "probability": 1.0132789611816406e-05
        },
        {
            "start_logit": 4.49609375,
            "end_logit": -7.1015625,
            "text": "Hypersensitivity of cis-regulatory",
            "probability": 9.715557098388672e-06
        },
        {
            "start_logit": 4.49609375,
            "end_logit": -7.15234375,
            "text": "Hypersensitivity of cis-regulatory elements to digestion with DNaseI remains the gold-standard",
            "probability": 9.298324584960938e-06
        },
        {
            "start_logit": -7.015625,
            "end_logit": 4.359375,
            "text": "-regulatory elements to digestion with DNaseI remains the gold-standard approach to locating such elements.",
            "probability": 9.298324584960938e-06
        },
        {
            "start_logit": -7.02734375,
            "end_logit": 4.359375,
            "text": "I remains the gold-standard approach to locating such elements.",
            "probability": 9.179115295410156e-06
        }
    ],
    "5fdb2e23a43ad3127800000a_3": [
        {
            "start_logit": 2.984375,
            "end_logit": 5.5625,
            "text": "The identification of cis-regulatory elements is central to understanding gene transcription.",
            "probability": 0.90625
        },
        {
            "start_logit": 0.669921875,
            "end_logit": 5.5625,
            "text": ".",
            "probability": 0.0897216796875
        },
        {
            "start_logit": -2.76953125,
            "end_logit": 5.5625,
            "text": "gene transcription.",
            "probability": 0.002872467041015625
        },
        {
            "start_logit": -4.67578125,
            "end_logit": 5.5625,
            "text": "identification of cis-regulatory elements is central to understanding gene transcription.",
            "probability": 0.00042700767517089844
        },
        {
            "start_logit": -4.83984375,
            "end_logit": 5.5625,
            "text": "cis-regulatory elements is central to understanding gene transcription.",
            "probability": 0.000362396240234375
        },
        {
            "start_logit": -5.83984375,
            "end_logit": 5.5625,
            "text": "central to understanding gene transcription.",
            "probability": 0.0001327991485595703
        },
        {
            "start_logit": -5.86328125,
            "end_logit": 5.5625,
            "text": "of cis-regulatory elements is central to understanding gene transcription.",
            "probability": 0.00013065338134765625
        },
        {
            "start_logit": -5.93359375,
            "end_logit": 5.5625,
            "text": "elements is central to understanding gene transcription.",
            "probability": 0.00012087821960449219
        },
        {
            "start_logit": -6.06640625,
            "end_logit": 5.5625,
            "text": "understanding gene transcription.",
            "probability": 0.00010675191879272461
        },
        {
            "start_logit": -6.16796875,
            "end_logit": 5.5625,
            "text": "regulatory elements is central to understanding gene transcription.",
            "probability": 9.566545486450195e-05
        },
        {
            "start_logit": -6.75390625,
            "end_logit": 5.5625,
            "text": "-regulatory elements is central to understanding gene transcription.",
            "probability": 5.364418029785156e-05
        },
        {
            "start_logit": -6.91015625,
            "end_logit": 5.5625,
            "text": "is central to understanding gene transcription.",
            "probability": 4.589557647705078e-05
        },
        {
            "start_logit": 2.984375,
            "end_logit": -4.40234375,
            "text": "The",
            "probability": 4.2438507080078125e-05
        },
        {
            "start_logit": -7.0859375,
            "end_logit": 5.5625,
            "text": "to understanding gene transcription.",
            "probability": 3.832578659057617e-05
        },
        {
            "start_logit": -7.31640625,
            "end_logit": 5.5625,
            "text": "transcription.",
            "probability": 3.057718276977539e-05
        },
        {
            "start_logit": 2.984375,
            "end_logit": -5.98046875,
            "text": "The identification of cis-regulatory elements",
            "probability": 8.761882781982422e-06
        },
        {
            "start_logit": 2.984375,
            "end_logit": -6.71875,
            "text": "The identification of cis-regulatory elements is",
            "probability": 4.231929779052734e-06
        },
        {
            "start_logit": 2.984375,
            "end_logit": -6.94921875,
            "text": "The identification of cis-regulatory elements is central to understanding gene transcription",
            "probability": 3.337860107421875e-06
        },
        {
            "start_logit": 2.984375,
            "end_logit": -7.16015625,
            "text": "The identification of cis-regulatory elements is central",
            "probability": 2.682209014892578e-06
        },
        {
            "start_logit": 2.984375,
            "end_logit": -7.33984375,
            "text": "The identification of cis-regulatory",
            "probability": 2.2649765014648438e-06
        }
    ],
    "53318685d6d3ac6a3400003d_1": [
        {
            "start_logit": 9.71875,
            "end_logit": 9.4921875,
            "text": "autosomal dominant",
            "probability": 1.0
        },
        {
            "start_logit": 9.71875,
            "end_logit": -1.77734375,
            "text": "autosomal",
            "probability": 1.2636184692382812e-05
        },
        {
            "start_logit": -1.9580078125,
            "end_logit": 9.4921875,
            "text": "dominant",
            "probability": 8.404254913330078e-06
        },
        {
            "start_logit": 9.71875,
            "end_logit": -7.94921875,
            "text": "autosomal dominant mode of inheritance, distinct facial and skeleton features (a hoarse voice and internal notch of the femoral head).",
            "probability": 0.0
        },
        {
            "start_logit": 9.71875,
            "end_logit": -7.94921875,
            "text": "autosomal dominant mode",
            "probability": 0.0
        },
        {
            "start_logit": 9.71875,
            "end_logit": -8.0078125,
            "text": "autosomal dominant mode of",
            "probability": 0.0
        },
        {
            "start_logit": -8.0234375,
            "end_logit": 9.4921875,
            "text": "AD has an autosomal dominant",
            "probability": 0.0
        },
        {
            "start_logit": -8.1484375,
            "end_logit": 9.4921875,
            "text": "has an autosomal dominant",
            "probability": 0.0
        },
        {
            "start_logit": -8.1484375,
            "end_logit": 9.4921875,
            "text": "an autosomal dominant",
            "probability": 0.0
        },
        {
            "start_logit": -8.0234375,
            "end_logit": -1.77734375,
            "text": "AD has an autosomal",
            "probability": 0.0
        },
        {
            "start_logit": -1.9580078125,
            "end_logit": -7.94921875,
            "text": "dominant mode of inheritance, distinct facial and skeleton features (a hoarse voice and internal notch of the femoral head).",
            "probability": 0.0
        },
        {
            "start_logit": -1.9580078125,
            "end_logit": -7.94921875,
            "text": "dominant mode",
            "probability": 0.0
        },
        {
            "start_logit": -8.1484375,
            "end_logit": -1.77734375,
            "text": "has an autosomal",
            "probability": 0.0
        },
        {
            "start_logit": -8.1484375,
            "end_logit": -1.77734375,
            "text": "an autosomal",
            "probability": 0.0
        },
        {
            "start_logit": -1.9580078125,
            "end_logit": -8.0078125,
            "text": "dominant mode of",
            "probability": 0.0
        },
        {
            "start_logit": -6.63671875,
            "end_logit": -7.94921875,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -8.0234375,
            "end_logit": -7.94921875,
            "text": "AD has an autosomal dominant mode of inheritance, distinct facial and skeleton features (a hoarse voice and internal notch of the femoral head).",
            "probability": 0.0
        },
        {
            "start_logit": -8.0234375,
            "end_logit": -7.94921875,
            "text": "AD has an autosomal dominant mode",
            "probability": 0.0
        },
        {
            "start_logit": -8.0546875,
            "end_logit": -7.94921875,
            "text": ").",
            "probability": 0.0
        },
        {
            "start_logit": -8.0234375,
            "end_logit": -8.0078125,
            "text": "AD has an autosomal dominant mode of",
            "probability": 0.0
        }
    ],
    "53318685d6d3ac6a3400003d_2": [
        {
            "start_logit": 9.6484375,
            "end_logit": 9.390625,
            "text": "autosomal dominant",
            "probability": 1.0
        },
        {
            "start_logit": 9.6484375,
            "end_logit": -1.919921875,
            "text": "autosomal",
            "probability": 1.233816146850586e-05
        },
        {
            "start_logit": -2.09765625,
            "end_logit": 9.390625,
            "text": "dominant",
            "probability": 7.987022399902344e-06
        },
        {
            "start_logit": 9.6484375,
            "end_logit": -7.046875,
            "text": "autosomal dominant or",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.6484375,
            "end_logit": -7.046875,
            "text": "autosomal dominant or an autosomal recessive (AR) mode of inheritance, GD by an autosomal recessive mode of inheritance and AD by an autosomal dominant mode of inheritance.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.6484375,
            "end_logit": -7.30859375,
            "text": "autosomal dominant or an autosomal recessive (AR) mode of inheritance, GD by an autosomal recessive mode of inheritance and AD by an autosomal dominant",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.6484375,
            "end_logit": -7.57421875,
            "text": "autosomal dominant or an autosomal recessive",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.6484375,
            "end_logit": -7.59765625,
            "text": "autosomal dominant or an autosomal recessive (AR) mode of inheritance, GD by an autosomal recessive",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.6484375,
            "end_logit": -7.91796875,
            "text": "autosomal dominant or an autosomal recessive (AR) mode of inheritance, GD by an autosomal recessive mode of inheritance and AD by",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.6484375,
            "end_logit": -7.9375,
            "text": "autosomal dominant or an",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.6484375,
            "end_logit": -7.99609375,
            "text": "autosomal dominant or an autosomal recessive (AR) mode of inheritance, GD by",
            "probability": 0.0
        },
        {
            "start_logit": -7.74609375,
            "end_logit": 9.390625,
            "text": "WMS is transmitted either by an autosomal dominant",
            "probability": 0.0
        },
        {
            "start_logit": 9.6484375,
            "end_logit": -8.0078125,
            "text": "autosomal dominant or an autosomal recessive (AR) mode of inheritance, GD by an autosomal recessive mode of inheritance and AD by an autosomal dominant mode",
            "probability": 0.0
        },
        {
            "start_logit": 9.6484375,
            "end_logit": -8.0234375,
            "text": "autosomal dominant or an autosomal recessive (AR) mode of inheritance, GD by an autosomal recessive mode of inheritance and AD by an",
            "probability": 0.0
        },
        {
            "start_logit": 9.6484375,
            "end_logit": -8.03125,
            "text": "autosomal dominant or an autosomal",
            "probability": 0.0
        },
        {
            "start_logit": 9.6484375,
            "end_logit": -8.0390625,
            "text": "autosomal dominant or an autosomal recessive (AR) mode of inheritance, GD by an",
            "probability": 0.0
        },
        {
            "start_logit": -7.87109375,
            "end_logit": 9.390625,
            "text": "transmitted either by an autosomal dominant",
            "probability": 0.0
        },
        {
            "start_logit": -7.91015625,
            "end_logit": 9.390625,
            "text": ", WMS is transmitted either by an autosomal dominant",
            "probability": 0.0
        },
        {
            "start_logit": -7.95703125,
            "end_logit": 9.390625,
            "text": "an autosomal dominant",
            "probability": 0.0
        },
        {
            "start_logit": -7.9765625,
            "end_logit": 9.390625,
            "text": "S is transmitted either by an autosomal dominant",
            "probability": 0.0
        }
    ],
    "53318685d6d3ac6a3400003d_3": [
        {
            "start_logit": 9.765625,
            "end_logit": 9.5078125,
            "text": "autosomal dominant",
            "probability": 1.0
        },
        {
            "start_logit": 9.765625,
            "end_logit": -1.681640625,
            "text": "autosomal",
            "probability": 1.3709068298339844e-05
        },
        {
            "start_logit": -1.90234375,
            "end_logit": 9.5078125,
            "text": "dominant",
            "probability": 8.52346420288086e-06
        },
        {
            "start_logit": 9.765625,
            "end_logit": -6.7265625,
            "text": "autosomal dominant mode of inheritance.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.765625,
            "end_logit": -7.578125,
            "text": "autosomal dominant mode",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.765625,
            "end_logit": -7.8671875,
            "text": "autosomal dominant mode of",
            "probability": 0.0
        },
        {
            "start_logit": 9.765625,
            "end_logit": -8.046875,
            "text": "autosomal dominant mode of inheritance",
            "probability": 0.0
        },
        {
            "start_logit": -7.8203125,
            "end_logit": 9.5078125,
            "text": "The condition appeared to be sporadic in 16 cases but the observation of vertical transmission in three families was consistent with an autosomal dominant",
            "probability": 0.0
        },
        {
            "start_logit": -7.8359375,
            "end_logit": 9.5078125,
            "text": "the observation of vertical transmission in three families was consistent with an autosomal dominant",
            "probability": 0.0
        },
        {
            "start_logit": -7.83984375,
            "end_logit": 9.5078125,
            "text": "condition appeared to be sporadic in 16 cases but the observation of vertical transmission in three families was consistent with an autosomal dominant",
            "probability": 0.0
        },
        {
            "start_logit": -7.84765625,
            "end_logit": 9.5078125,
            "text": "three families was consistent with an autosomal dominant",
            "probability": 0.0
        },
        {
            "start_logit": -7.8515625,
            "end_logit": 9.5078125,
            "text": "consistent with an autosomal dominant",
            "probability": 0.0
        },
        {
            "start_logit": -7.87109375,
            "end_logit": 9.5078125,
            "text": "an autosomal dominant",
            "probability": 0.0
        },
        {
            "start_logit": -7.87109375,
            "end_logit": 9.5078125,
            "text": "vertical transmission in three families was consistent with an autosomal dominant",
            "probability": 0.0
        },
        {
            "start_logit": -7.9375,
            "end_logit": 9.5078125,
            "text": "families was consistent with an autosomal dominant",
            "probability": 0.0
        },
        {
            "start_logit": -7.97265625,
            "end_logit": 9.5078125,
            "text": "observation of vertical transmission in three families was consistent with an autosomal dominant",
            "probability": 0.0
        },
        {
            "start_logit": -7.9765625,
            "end_logit": 9.5078125,
            "text": "cases but the observation of vertical transmission in three families was consistent with an autosomal dominant",
            "probability": 0.0
        },
        {
            "start_logit": -7.98046875,
            "end_logit": 9.5078125,
            "text": "of vertical transmission in three families was consistent with an autosomal dominant",
            "probability": 0.0
        },
        {
            "start_logit": -7.99609375,
            "end_logit": 9.5078125,
            "text": "transmission in three families was consistent with an autosomal dominant",
            "probability": 0.0
        },
        {
            "start_logit": -8.015625,
            "end_logit": 9.5078125,
            "text": "was consistent with an autosomal dominant",
            "probability": 0.0
        }
    ],
    "5c5312097e3cb0e231000011_1": [
        {
            "start_logit": 9.40625,
            "end_logit": 9.421875,
            "text": "Ohio",
            "probability": 1.0
        },
        {
            "start_logit": -1.9736328125,
            "end_logit": 9.421875,
            "text": "io",
            "probability": 1.150369644165039e-05
        },
        {
            "start_logit": 9.40625,
            "end_logit": -2.26171875,
            "text": "Oh",
            "probability": 8.404254913330078e-06
        },
        {
            "start_logit": -6.4765625,
            "end_logit": 9.421875,
            "text": "in Ohio",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.40625,
            "end_logit": -7.0390625,
            "text": "Ohio,",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.84375,
            "end_logit": 9.421875,
            "text": "2014 measles outbreak in Ohio",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.9375,
            "end_logit": 9.421875,
            "text": "measles outbreak in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -7.9609375,
            "end_logit": 9.421875,
            "text": "Recent outbreaks in Amish communities include a 2014 measles outbreak in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -8.046875,
            "end_logit": 9.421875,
            "text": "outbreaks in Amish communities include a 2014 measles outbreak in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -8.0625,
            "end_logit": 9.421875,
            "text": "outbreak in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -8.0703125,
            "end_logit": 9.421875,
            "text": "a 2014 measles outbreak in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -8.09375,
            "end_logit": 9.421875,
            "text": "in Amish communities include a 2014 measles outbreak in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -8.109375,
            "end_logit": 9.421875,
            "text": "Amish communities include a 2014 measles outbreak in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -8.1484375,
            "end_logit": 9.421875,
            "text": "communities include a 2014 measles outbreak in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -6.4765625,
            "end_logit": -2.26171875,
            "text": "in Oh",
            "probability": 0.0
        },
        {
            "start_logit": -1.9736328125,
            "end_logit": -7.0390625,
            "text": "io,",
            "probability": 0.0
        },
        {
            "start_logit": -7.84375,
            "end_logit": -2.26171875,
            "text": "2014 measles outbreak in Oh",
            "probability": 0.0
        },
        {
            "start_logit": -7.9375,
            "end_logit": -2.26171875,
            "text": "measles outbreak in Oh",
            "probability": 0.0
        },
        {
            "start_logit": -7.9609375,
            "end_logit": -2.26171875,
            "text": "Recent outbreaks in Amish communities include a 2014 measles outbreak in Oh",
            "probability": 0.0
        },
        {
            "start_logit": -8.046875,
            "end_logit": -2.26171875,
            "text": "outbreaks in Amish communities include a 2014 measles outbreak in Oh",
            "probability": 0.0
        }
    ],
    "5c5312097e3cb0e231000011_2": [
        {
            "start_logit": 9.2109375,
            "end_logit": 9.109375,
            "text": "Ohio",
            "probability": 1.0
        },
        {
            "start_logit": 9.2109375,
            "end_logit": -2.462890625,
            "text": "Oh",
            "probability": 9.5367431640625e-06
        },
        {
            "start_logit": -2.564453125,
            "end_logit": 9.109375,
            "text": "io",
            "probability": 7.748603820800781e-06
        },
        {
            "start_logit": -7.52734375,
            "end_logit": 9.109375,
            "text": "in Ohio",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.64453125,
            "end_logit": 9.109375,
            "text": "2014 outbreak in Amish communities in Ohio",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.66796875,
            "end_logit": 9.109375,
            "text": "Measles outbreaks in the United States continue to occur in subpopulations with sufficient numbers of undervaccinated individuals, with a 2014 outbreak in Amish communities in Ohio",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.92578125,
            "end_logit": 9.109375,
            "text": "in the United States continue to occur in subpopulations with sufficient numbers of undervaccinated individuals, with a 2014 outbreak in Amish communities in Ohio",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.9296875,
            "end_logit": 9.109375,
            "text": "outbreaks in the United States continue to occur in subpopulations with sufficient numbers of undervaccinated individuals, with a 2014 outbreak in Amish communities in Ohio",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.9453125,
            "end_logit": 9.109375,
            "text": "outbreak in Amish communities in Ohio",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.96484375,
            "end_logit": 9.109375,
            "text": "in Amish communities in Ohio",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.98046875,
            "end_logit": 9.109375,
            "text": "the United States continue to occur in subpopulations with sufficient numbers of undervaccinated individuals, with a 2014 outbreak in Amish communities in Ohio",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.09375,
            "end_logit": 9.109375,
            "text": "Amish communities in Ohio",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1015625,
            "end_logit": 9.109375,
            "text": "United States continue to occur in subpopulations with sufficient numbers of undervaccinated individuals, with a 2014 outbreak in Amish communities in Ohio",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1015625,
            "end_logit": 9.109375,
            "text": "continue to occur in subpopulations with sufficient numbers of undervaccinated individuals, with a 2014 outbreak in Amish communities in Ohio",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1015625,
            "end_logit": 9.109375,
            "text": "a 2014 outbreak in Amish communities in Ohio",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1015625,
            "end_logit": 9.109375,
            "text": "to occur in subpopulations with sufficient numbers of undervaccinated individuals, with a 2014 outbreak in Amish communities in Ohio",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.52734375,
            "end_logit": -2.462890625,
            "text": "in Oh",
            "probability": 0.0
        },
        {
            "start_logit": -7.64453125,
            "end_logit": -2.462890625,
            "text": "2014 outbreak in Amish communities in Oh",
            "probability": 0.0
        },
        {
            "start_logit": -7.66796875,
            "end_logit": -2.462890625,
            "text": "Measles outbreaks in the United States continue to occur in subpopulations with sufficient numbers of undervaccinated individuals, with a 2014 outbreak in Amish communities in Oh",
            "probability": 0.0
        },
        {
            "start_logit": -7.92578125,
            "end_logit": -2.462890625,
            "text": "in the United States continue to occur in subpopulations with sufficient numbers of undervaccinated individuals, with a 2014 outbreak in Amish communities in Oh",
            "probability": 0.0
        }
    ],
    "5c5312097e3cb0e231000011_3": [
        {
            "start_logit": 9.546875,
            "end_logit": 9.453125,
            "text": "Ohio",
            "probability": 1.0
        },
        {
            "start_logit": 9.546875,
            "end_logit": -2.02734375,
            "text": "Oh",
            "probability": 1.0311603546142578e-05
        },
        {
            "start_logit": -1.9375,
            "end_logit": 9.453125,
            "text": "io",
            "probability": 1.0311603546142578e-05
        },
        {
            "start_logit": -7.56640625,
            "end_logit": 9.453125,
            "text": "in Ohio",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.546875,
            "end_logit": -7.75,
            "text": "Ohio were transmission primarily within households, the small proportion of Amish people affected, and the large number of people in the Amish community who sought vaccination.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.546875,
            "end_logit": -7.9453125,
            "text": "Ohio were",
            "probability": 0.0
        },
        {
            "start_logit": -7.8984375,
            "end_logit": 9.453125,
            "text": "CONCLUSIONS The key epidemiologic features of a measles outbreak in the Amish community in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": 9.546875,
            "end_logit": -8.0390625,
            "text": "Ohio were transmission primarily within households",
            "probability": 0.0
        },
        {
            "start_logit": 9.546875,
            "end_logit": -8.0546875,
            "text": "Ohio were transmission primarily within households, the small proportion of Amish people affected, and the large number of people in",
            "probability": 0.0
        },
        {
            "start_logit": 9.546875,
            "end_logit": -8.0625,
            "text": "Ohio were transmission primarily within households, the small proportion of Amish people affected, and the large number of people in the",
            "probability": 0.0
        },
        {
            "start_logit": -7.98828125,
            "end_logit": 9.453125,
            "text": "measles outbreak in the Amish community in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": 9.546875,
            "end_logit": -8.1171875,
            "text": "Ohio were transmission primarily within households, the small proportion of Amish people affected, and",
            "probability": 0.0
        },
        {
            "start_logit": -8.0390625,
            "end_logit": 9.453125,
            "text": "a measles outbreak in the Amish community in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -8.046875,
            "end_logit": 9.453125,
            "text": "Amish community in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -8.0703125,
            "end_logit": 9.453125,
            "text": "epidemiologic features of a measles outbreak in the Amish community in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -8.0703125,
            "end_logit": 9.453125,
            "text": "outbreak in the Amish community in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -8.0859375,
            "end_logit": 9.453125,
            "text": "the Amish community in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -7.56640625,
            "end_logit": -2.02734375,
            "text": "in Oh",
            "probability": 0.0
        },
        {
            "start_logit": -1.9375,
            "end_logit": -7.75,
            "text": "io were transmission primarily within households, the small proportion of Amish people affected, and the large number of people in the Amish community who sought vaccination.",
            "probability": 0.0
        },
        {
            "start_logit": -1.9375,
            "end_logit": -7.9453125,
            "text": "io were",
            "probability": 0.0
        }
    ],
    "5c5312097e3cb0e231000011_4": [
        {
            "start_logit": 9.59375,
            "end_logit": 9.2890625,
            "text": "Ohio",
            "probability": 1.0
        },
        {
            "start_logit": 9.59375,
            "end_logit": -1.8388671875,
            "text": "Oh",
            "probability": 1.4722347259521484e-05
        },
        {
            "start_logit": -2.181640625,
            "end_logit": 9.2890625,
            "text": "io",
            "probability": 7.748603820800781e-06
        },
        {
            "start_logit": 9.59375,
            "end_logit": -7.125,
            "text": "Ohio pushing the annual cases to the highest national number reported in the last 20 years.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.546875,
            "end_logit": 9.2890625,
            "text": "in Ohio",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.59375,
            "end_logit": -7.90234375,
            "text": "Ohio pushing the annual cases to the",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.59375,
            "end_logit": -7.921875,
            "text": "Ohio push",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.59375,
            "end_logit": -7.95703125,
            "text": "Ohio pushing the annual cases to",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.59375,
            "end_logit": -7.97265625,
            "text": "Ohio pushing the annual cases to the highest national number reported",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.59375,
            "end_logit": -7.97265625,
            "text": "Ohio pushing the annual cases to the highest national number reported in",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.59375,
            "end_logit": -7.97265625,
            "text": "Ohio pushing the annual cases to the highest national number reported in the last 20",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.59375,
            "end_logit": -7.984375,
            "text": "Ohio pushing the annual cases to the highest national number reported in the",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.59375,
            "end_logit": -7.99609375,
            "text": "Ohio pushing the annual cases to the highest",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.71484375,
            "end_logit": 9.2890625,
            "text": "2014 outbreak in Amish communities in Ohio",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.75390625,
            "end_logit": 9.2890625,
            "text": "Measles outbreaks in the United States continue to occur in subpopulations with sufficient numbers of undervaccinated individuals, with a 2014 outbreak in Amish communities in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -7.921875,
            "end_logit": 9.2890625,
            "text": "outbreak in Amish communities in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -7.984375,
            "end_logit": 9.2890625,
            "text": "in Amish communities in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -7.98828125,
            "end_logit": 9.2890625,
            "text": "outbreaks in the United States continue to occur in subpopulations with sufficient numbers of undervaccinated individuals, with a 2014 outbreak in Amish communities in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -7.98828125,
            "end_logit": 9.2890625,
            "text": "in the United States continue to occur in subpopulations with sufficient numbers of undervaccinated individuals, with a 2014 outbreak in Amish communities in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -8.0078125,
            "end_logit": 9.2890625,
            "text": "the United States continue to occur in subpopulations with sufficient numbers of undervaccinated individuals, with a 2014 outbreak in Amish communities in Ohio",
            "probability": 0.0
        }
    ],
    "5c5312097e3cb0e231000011_5": [
        {
            "start_logit": 9.6171875,
            "end_logit": 9.4375,
            "text": "Ohio",
            "probability": 1.0
        },
        {
            "start_logit": 9.6171875,
            "end_logit": -1.8818359375,
            "text": "Oh",
            "probability": 1.2040138244628906e-05
        },
        {
            "start_logit": -1.9599609375,
            "end_logit": 9.4375,
            "text": "io",
            "probability": 9.298324584960938e-06
        },
        {
            "start_logit": -7.20703125,
            "end_logit": 9.4375,
            "text": "in Ohio",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.6171875,
            "end_logit": -7.8125,
            "text": "Ohio, resulting in 368 cases reported.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.6171875,
            "end_logit": -7.98046875,
            "text": "Ohio,",
            "probability": 0.0
        },
        {
            "start_logit": 9.6171875,
            "end_logit": -7.99609375,
            "text": "Ohio, resulting in",
            "probability": 0.0
        },
        {
            "start_logit": 9.6171875,
            "end_logit": -8.0234375,
            "text": "Ohio, resulting",
            "probability": 0.0
        },
        {
            "start_logit": 9.6171875,
            "end_logit": -8.0703125,
            "text": "Ohio, resulting in 36",
            "probability": 0.0
        },
        {
            "start_logit": 9.6171875,
            "end_logit": -8.0859375,
            "text": "Ohio, resulting in 368 cases reported",
            "probability": 0.0
        },
        {
            "start_logit": 9.6171875,
            "end_logit": -8.0859375,
            "text": "Ohio, resulting in 368",
            "probability": 0.0
        },
        {
            "start_logit": -7.9453125,
            "end_logit": 9.4375,
            "text": "2014 measles outbreak in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -8.015625,
            "end_logit": 9.4375,
            "text": "measles outbreak in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -8.0703125,
            "end_logit": 9.4375,
            "text": "Recent outbreaks in Amish communities include a 2014 measles outbreak in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -8.1328125,
            "end_logit": 9.4375,
            "text": "outbreaks in Amish communities include a 2014 measles outbreak in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -8.1328125,
            "end_logit": 9.4375,
            "text": "outbreak in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": 9.4375,
            "text": "Amish communities include a 2014 measles outbreak in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -8.1796875,
            "end_logit": 9.4375,
            "text": "in Amish communities include a 2014 measles outbreak in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": 9.4375,
            "text": "a 2014 measles outbreak in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -7.20703125,
            "end_logit": -1.8818359375,
            "text": "in Oh",
            "probability": 0.0
        }
    ],
    "5c5312097e3cb0e231000011_6": [
        {
            "start_logit": 9.546875,
            "end_logit": 9.453125,
            "text": "Ohio",
            "probability": 1.0
        },
        {
            "start_logit": 9.546875,
            "end_logit": -2.02734375,
            "text": "Oh",
            "probability": 1.0311603546142578e-05
        },
        {
            "start_logit": -1.9375,
            "end_logit": 9.453125,
            "text": "io",
            "probability": 1.0311603546142578e-05
        },
        {
            "start_logit": -7.56640625,
            "end_logit": 9.453125,
            "text": "in Ohio",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.546875,
            "end_logit": -7.75,
            "text": "Ohio were transmission primarily within households, the small proportion of Amish people affected, and the large number of people in the Amish community who sought vaccination.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.546875,
            "end_logit": -7.9453125,
            "text": "Ohio were",
            "probability": 0.0
        },
        {
            "start_logit": -7.8984375,
            "end_logit": 9.453125,
            "text": "CONCLUSIONS The key epidemiologic features of a measles outbreak in the Amish community in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": 9.546875,
            "end_logit": -8.0390625,
            "text": "Ohio were transmission primarily within households",
            "probability": 0.0
        },
        {
            "start_logit": 9.546875,
            "end_logit": -8.0546875,
            "text": "Ohio were transmission primarily within households, the small proportion of Amish people affected, and the large number of people in",
            "probability": 0.0
        },
        {
            "start_logit": 9.546875,
            "end_logit": -8.0625,
            "text": "Ohio were transmission primarily within households, the small proportion of Amish people affected, and the large number of people in the",
            "probability": 0.0
        },
        {
            "start_logit": -7.98828125,
            "end_logit": 9.453125,
            "text": "measles outbreak in the Amish community in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": 9.546875,
            "end_logit": -8.1171875,
            "text": "Ohio were transmission primarily within households, the small proportion of Amish people affected, and",
            "probability": 0.0
        },
        {
            "start_logit": -8.0390625,
            "end_logit": 9.453125,
            "text": "a measles outbreak in the Amish community in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -8.046875,
            "end_logit": 9.453125,
            "text": "Amish community in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -8.0703125,
            "end_logit": 9.453125,
            "text": "epidemiologic features of a measles outbreak in the Amish community in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -8.0703125,
            "end_logit": 9.453125,
            "text": "outbreak in the Amish community in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -8.0859375,
            "end_logit": 9.453125,
            "text": "the Amish community in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -7.56640625,
            "end_logit": -2.02734375,
            "text": "in Oh",
            "probability": 0.0
        },
        {
            "start_logit": -1.9375,
            "end_logit": -7.75,
            "text": "io were transmission primarily within households, the small proportion of Amish people affected, and the large number of people in the Amish community who sought vaccination.",
            "probability": 0.0
        },
        {
            "start_logit": -1.9375,
            "end_logit": -7.9453125,
            "text": "io were",
            "probability": 0.0
        }
    ],
    "5c5312097e3cb0e231000011_7": [
        {
            "start_logit": 9.5703125,
            "end_logit": 9.328125,
            "text": "Ohio",
            "probability": 1.0
        },
        {
            "start_logit": 9.5703125,
            "end_logit": -1.9404296875,
            "text": "Oh",
            "probability": 1.2636184692382812e-05
        },
        {
            "start_logit": -2.1640625,
            "end_logit": 9.328125,
            "text": "io",
            "probability": 7.927417755126953e-06
        },
        {
            "start_logit": -6.84765625,
            "end_logit": 9.328125,
            "text": ".Measles outbreaks in the United States continue to occur in subpopulations with sufficient numbers of undervaccinated individuals, with a 2014 outbreak in Amish communities in Ohio",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.09375,
            "end_logit": 9.328125,
            "text": "in Ohio",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.5703125,
            "end_logit": -7.56640625,
            "text": "Ohio pushing the annual cases to the highest national number reported in the last 20 years.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.5703125,
            "end_logit": -7.8984375,
            "text": "Ohio push",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.796875,
            "end_logit": 9.328125,
            "text": "2014 outbreak in Amish communities in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": 9.5703125,
            "end_logit": -8.046875,
            "text": "Ohio pushing the annual cases to",
            "probability": 0.0
        },
        {
            "start_logit": 9.5703125,
            "end_logit": -8.1015625,
            "text": "Ohio pushing the annual cases to the highest national number reported in",
            "probability": 0.0
        },
        {
            "start_logit": 9.5703125,
            "end_logit": -8.109375,
            "text": "Ohio pushing the annual cases to the highest national number reported in the",
            "probability": 0.0
        },
        {
            "start_logit": -7.9140625,
            "end_logit": 9.328125,
            "text": "Measles outbreaks in the United States continue to occur in subpopulations with sufficient numbers of undervaccinated individuals, with a 2014 outbreak in Amish communities in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -7.96875,
            "end_logit": 9.328125,
            "text": "in Amish communities in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -7.96875,
            "end_logit": 9.328125,
            "text": "Outbreak Response.Measles outbreaks in the United States continue to occur in subpopulations with sufficient numbers of undervaccinated individuals, with a 2014 outbreak in Amish communities in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -7.9765625,
            "end_logit": 9.328125,
            "text": "outbreak in Amish communities in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -8.0234375,
            "end_logit": 9.328125,
            "text": "Options for Outbreak Response.Measles outbreaks in the United States continue to occur in subpopulations with sufficient numbers of undervaccinated individuals, with a 2014 outbreak in Amish communities in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -8.03125,
            "end_logit": 9.328125,
            "text": "Amish communities in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -8.046875,
            "end_logit": 9.328125,
            "text": "a 2014 outbreak in Amish communities in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -6.84765625,
            "end_logit": -1.9404296875,
            "text": ".Measles outbreaks in the United States continue to occur in subpopulations with sufficient numbers of undervaccinated individuals, with a 2014 outbreak in Amish communities in Oh",
            "probability": 0.0
        },
        {
            "start_logit": -7.09375,
            "end_logit": -1.9404296875,
            "text": "in Oh",
            "probability": 0.0
        }
    ],
    "61f95f9f882a024a1000004e_1": [
        {
            "start_logit": 9.7734375,
            "end_logit": 9.671875,
            "text": "Oguchi disease",
            "probability": 1.0
        },
        {
            "start_logit": 9.7734375,
            "end_logit": -1.623046875,
            "text": "Og",
            "probability": 1.2516975402832031e-05
        },
        {
            "start_logit": -1.521484375,
            "end_logit": 9.671875,
            "text": "disease",
            "probability": 1.2516975402832031e-05
        },
        {
            "start_logit": 9.7734375,
            "end_logit": -6.4296875,
            "text": "Oguchi",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.859375,
            "end_logit": 9.671875,
            "text": "uchi disease",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.7734375,
            "end_logit": -7.1171875,
            "text": "Oguch",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.7734375,
            "end_logit": -7.421875,
            "text": "Oguchi disease, a",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.7734375,
            "end_logit": -7.45703125,
            "text": "Oguchi disease, a rare subtype of congenital stationary night blindness (CSNB).",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.7734375,
            "end_logit": -7.46875,
            "text": "Oguchi disease,",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5234375,
            "end_logit": 9.671875,
            "text": "i disease",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.56640625,
            "end_logit": 9.671875,
            "text": "cause Oguchi disease",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.7734375,
            "end_logit": -7.8359375,
            "text": "Oguchi disease, a rare subtype of congenital stationary night blindness",
            "probability": 0.0
        },
        {
            "start_logit": 9.7734375,
            "end_logit": -7.93359375,
            "text": "Oguchi disease, a rare",
            "probability": 0.0
        },
        {
            "start_logit": 9.7734375,
            "end_logit": -7.97265625,
            "text": "Oguchi disease, a rare subtype of congenital stationary night blindness (CSNB",
            "probability": 0.0
        },
        {
            "start_logit": 9.7734375,
            "end_logit": -8.03125,
            "text": "Oguchi disease, a rare subtype of congenital stationary night blindness (",
            "probability": 0.0
        },
        {
            "start_logit": 9.7734375,
            "end_logit": -8.0703125,
            "text": "Oguchi disease, a rare subtype",
            "probability": 0.0
        },
        {
            "start_logit": 9.7734375,
            "end_logit": -8.09375,
            "text": "Oguchi disease, a rare subtype of congenital stationary night blindness (CS",
            "probability": 0.0
        },
        {
            "start_logit": 9.7734375,
            "end_logit": -8.1015625,
            "text": "Oguchi disease, a rare subtype of congenital stationary night blindness (CSNB)",
            "probability": 0.0
        },
        {
            "start_logit": 9.7734375,
            "end_logit": -8.1015625,
            "text": "Oguchi disease, a rare subtype of congenital stationary night",
            "probability": 0.0
        },
        {
            "start_logit": 9.7734375,
            "end_logit": -8.125,
            "text": "Oguchi disease, a rare subtype of congenital stationary",
            "probability": 0.0
        }
    ]
}
